FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Guerra, DL
   Airoldi, C
   Viana, RR
AF Guerra, Denis L.
   Airoldi, Claudio
   Viana, Rubia R.
TI RETRACTED: Modification of hectorite by organofunctionalization for use
   in removing U(VI) from aqueous media: thermodynamic approach (Retracted
   article. See vol. 102, pg. 648, 2011)
SO JOURNAL OF ENVIRONMENTAL RADIOACTIVITY
LA English
DT Article; Retracted Publication
DE Hectorite; Adsorption; Uranyl; Thermodynamic properties
ID MODIFIED MESOPOROUS SILICA; IONIC-STRENGTH; COBALT(II) COMPLEXES;
   ADSORPTION BEHAVIOR; URANYL ADSORPTION; ACID ACTIVATION; CATION REMOVAL;
   BINDING-SITES; HANFORD SITE; SORPTION
AB A Hectorite sample (H) has been chemically modified with N-propyldiethylenetrimethoxysilane and bis[3-(triethoxysilyl)propyl]tetrasulfide. The resulting materials (H-3TPT and H-NPTM) have been characterized through elemental analysis, X-ray diffractometry, carbon nuclear magnetic resonance in the solid state, textural analysis, and thermogravimetric analysis. The adsorption experiments were performed under batch process with pH, ionic strength, contact time, and uranyl concentration as variables. The attached basic centers adsorbed uranyl cation to give maxima adsorption capacity of 5.55 +/- 0.21, 14.86 +/- 0.05, and 18.99 +/- 0.05 x 10(-3) mmol g(-1) for H, H-3TPT, and H-NPTM, respectively. From calorimetric determinations the quantitative thermal effects for UO22+/center interactions gave exothermic enthalpy (Delta H-int = -6.90 to -7.88 kJ mol-1), negative Gibbs free energy (Delta(int)G = -22.34 to -24.56 kJ mol(-1)), and positive entropy (Delta S-int = 51.80-56.00J K-1 mol(-1)). These thermodynamic data confirmed the energetically favorable condition of such interaction solid/liquid for all systems. (C) 2009 Published by Elsevier Ltd.
C1 [Guerra, Denis L.; Viana, Rubia R.] Univ Fed Mato Grosso, Ctr Recursos Minerais, BR-78060900 Cuiaba, Mato Grosso, Brazil.
   [Airoldi, Claudio] Univ Estadual Campinas, Inst Chem, BR-13084971 Sao Paulo, Brazil.
RP Guerra, DL (reprint author), Univ Fed Mato Grosso, Ctr Recursos Minerais, BR-78060900 Cuiaba, Mato Grosso, Brazil.
EM dlguerra@pq.cnpq.br
FU CNPq [150060/2006-8]; FAPESP
FX The authors are indebted to CNPq (Proc. n. 150060/2006-8) for
   fellowships and FAPESP for financial support.
CR Alcantara EFC, 2007, J COLLOID INTERF SCI, V311, P1, DOI 10.1016/j.jcis.2007.02.075
   Arai Y, 2006, GEOCHIM COSMOCHIM AC, V70, P2492, DOI 10.1016/j.gca.2006.02.013
   Babel S, 2003, J HAZARD MATER, V97, P219, DOI 10.1016/S0304-3894(02)00263-7
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   Bhattacharyya KG, 2006, COLLOID SURFACE A, V277, P191, DOI 10.1016/j.colsurfa.2005.11.060
   BOROVEC Z, 1981, CHEM GEOL, V32, P45, DOI 10.1016/0009-2541(81)90127-3
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Catalano JG, 2005, GEOCHIM COSMOCHIM AC, V69, P2995, DOI 10.1016/j.gca.2005.01.025
   Cestaria AR, 2009, J HAZARD MATER, V161, P307, DOI 10.1016/j.jhazmat.2008.03.091
   Chen CL, 2007, APPL RADIAT ISOTOPES, V65, P155, DOI 10.1016/j.apradiso.2006.07.003
   Davies C. W., 1962, ION ASS, P37
   Dias NL, 1998, COLLOID SURFACE A, V144, P219, DOI 10.1016/S0927-7757(98)00569-X
   Donia AM, 2009, HYDROMETALLURGY, V95, P183, DOI 10.1016/j.hydromet.2008.05.037
   Evangelista SM, 2007, SURF SCI, V601, P2194, DOI 10.1016/j.susc.2007.03.020
   Fonseca MG, 2001, J COLLOID INTERF SCI, V240, P229, DOI 10.1006/jcis.2001.7581
   FONSECA MG, 1999, J CHEM SOC DA, V42, P3687
   Freundlich H, 1906, Z PHYS CHEM-STOCH VE, V57, P385
   Garcia-Diego C, 2008, CHEM ENG J, V143, P337, DOI 10.1016/j.cej.2008.06.022
   Guerra DL, 2008, J HAZARD MATER, V155, P230, DOI 10.1016/j.jhazmat.2007.11.054
   Guerra DL, 2008, INORG CHEM COMMUN, V11, P539, DOI 10.1016/j.inoche.2008.01.027
   Guerra DL, 2006, POLYHEDRON, V25, P2880, DOI 10.1016/j.poly.2006.04.015
   GUILLAUMONT R, 2003, UPDATE THERMODYNAMIC
   Guo ZJ, 2009, COLLOID SURFACE A, V336, P123, DOI 10.1016/j.colsurfa.2008.11.032
   HERBELIN AL, 1999, 9901 OR STAT U
   Ho YS, 1999, PROCESS BIOCHEM, V34, P451, DOI 10.1016/S0032-9592(98)00112-5
   HSI CKD, 1985, GEOCHIM COSMOCHIM AC, V49, P1931
   Huheey J. E, 1993, INORGANIC CHEM PRINC
   Janchen J, 2009, ICARUS, V200, P463, DOI 10.1016/j.icarus.2008.12.006
   Karadag D, 2007, J HAZARD MATER, V144, P432, DOI 10.1016/j.jhazmat.2006.10.055
   Lagergren S, 1898, KUNGLIGA SVENSKA VET, V24, P1, DOI DOI 10.1007/BF01501332
   LANGMUIR D, 1978, GEOCHIM COSMOCHIM AC, V42, P547, DOI 10.1016/0016-7037(78)90001-7
   Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004
   Lazarin AM, 2007, THERMOCHIM ACTA, V454, P43, DOI 10.1016/j.tca.2006.12.016
   Lee SY, 2009, APPL CLAY SCI, V44, P259, DOI 10.1016/j.clay.2009.03.002
   LOW KS, 1995, BIORESOURCE TECHNOL, V51, P227, DOI 10.1016/0960-8524(94)00123-I
   Macedo TR, 2007, CLAY CLAY MINER, V55, P151, DOI 10.1346/CCMN.2007.0550204
   Machado RSA, 2004, TALANTA, V63, P317, DOI 10.1016/j.talanta.2003.10.048
   Madhu NT, 2003, THERMOCHIM ACTA, V400, P29, DOI 10.1016/S0040-6031(02)00475-6
   NAKAYAMA FS, 1971, J INORG NUCL CHEM, V33, P1287, DOI 10.1016/0022-1902(71)80422-0
   Naseem R, 2001, WATER RES, V35, P3982, DOI 10.1016/S0043-1354(01)00130-0
   Niu ZW, 2009, APPL RADIAT ISOTOPES, V67, P1582, DOI 10.1016/j.apradiso.2009.03.113
   Ogawa M, 2003, APPL CLAY SCI, V22, P179, DOI 10.1016/S0169-1317(02)00157-6
   Payne TE, 2004, APPL CLAY SCI, V26, P151, DOI 10.1016/j.clay.2003.08.013
   Perez-Quintanilla D, 2006, J HAZARD MATER, V134, P245, DOI 10.1016/j.jhazmat.2005.11.004
   Perez-Quintanilla D, 2007, J COLLOID INTERF SCI, V313, P551, DOI 10.1016/j.jcis.2007.04.063
   Prado AGS, 2001, ANAL CHIM ACTA, V432, P201, DOI 10.1016/S0003-2670(00)01372-6
   Redden G, 2001, J COLLOID INTERF SCI, V244, P211, DOI 10.1006/jcis.2001.7996
   Ruiz VSO, 2006, J MATER CHEM, V16, P2338, DOI 10.1039/b515676a
   Ruiz VSO, 2004, THERMOCHIM ACTA, V420, P73, DOI 10.1016/j.tca.2003.10.029
   Salih B, 1998, TALANTA, V46, P1205, DOI 10.1016/S0039-9140(97)00362-7
   Shanmugharaj AM, 2006, J COLLOID INTERF SCI, V298, P854, DOI 10.1016/j.jcis.2005.12.049
   Sharma P, 2008, MICROPOR MESOPOR MAT, V116, P641, DOI 10.1016/j.micromeso.2008.05.036
   Sharma P, 2009, J COLLOID INTERF SCI, V332, P298, DOI 10.1016/j.jcis.2008.12.074
   Sheng GD, 2008, APPL RADIAT ISOTOPES, V66, P1313, DOI 10.1016/j.apradiso.2008.03.005
   SILVA OG, 2006, J COLLOID INTERF SCI, V302, P485
   SIPS R, 1948, J CHEM PHYS, V16, P490, DOI 10.1063/1.1746922
   STUMM W, 1992, GEOCHIM COSMOCHIM AC, V56, P3233, DOI 10.1016/0016-7037(92)90301-X
   Sylwester ER, 2000, GEOCHIM COSMOCHIM AC, V64, P2431, DOI 10.1016/S0016-7037(00)00376-8
   Tang XW, 2009, J HAZARD MATER, V161, P824, DOI 10.1016/j.jhazmat.2008.04.059
   TSUNASHIMA A, 1981, CLAY CLAY MINER, V29, P10, DOI 10.1346/CCMN.1981.0290102
   Um W, 2007, J CONTAM HYDROL, V93, P255, DOI 10.1016/j.jconhyd.2007.03.002
   Venaruzzo JL, 2002, MICROPOR MESOPOR MAT, V56, P73, DOI 10.1016/S1387-1811(02)00443-2
   Villaescusa I, 2000, J CHEM TECHNOL BIOT, V75, P812, DOI 10.1002/1097-4660(200009)75:9<812::AID-JCTB284>3.3.CO;2-2
   WEBER TW, 1974, AICHE J, V20, P228, DOI 10.1002/aic.690200204
   Xia K, 1997, GEOCHIM COSMOCHIM AC, V61, P2223, DOI 10.1016/S0016-7037(97)00080-X
   Xie SB, 2009, J ENVIRON RADIOACTIV, V100, P162, DOI 10.1016/j.jenvrad.2008.09.008
   XIUWEN X, 2007, J COLLOID INTERF SCI, V315, P555
   Zachara JM, 2002, GEOCHIM COSMOCHIM AC, V66, P193, DOI 10.1016/S0016-7037(01)00759-1
   ZACHARA JM, 1993, AQUAT SCI, V55, P250, DOI 10.1007/BF00877270
   Zhang HX, 2005, COLLOID SURFACE A, V252, P1, DOI 10.1016/j.colsurfa.2004.10.005
NR 70
TC 4
Z9 5
U1 1
U2 21
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0265-931X
EI 1879-1700
J9 J ENVIRON RADIOACTIV
JI J. Environ. Radioact.
PD FEB
PY 2010
VL 101
IS 2
BP 122
EP 133
DI 10.1016/j.jenvrad.2009.09.005
PG 12
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 555GH
UT WOS:000274496300005
PM 19828216
DA 2018-12-27
ER

PT J
AU Kumar, S
   Atray, D
   Paiwal, D
   Balasubramanyam, G
   Duraiswamy, P
   Kulkarni, S
AF Kumar, S.
   Atray, D.
   Paiwal, D.
   Balasubramanyam, G.
   Duraiswamy, P.
   Kulkarni, S.
TI RETRACTED: Dental unit waterlines: source of contamination and
   cross-infection (Retracted article. See vol. 78, pg. 340, 2011)
SO JOURNAL OF HOSPITAL INFECTION
LA English
DT Review; Retracted Publication
DE Dental unit waterlines; Dentist; Disinfection; Infection; Microbial
   contamination; Patient
ID MICROBIAL-CONTAMINATION; BACTERIAL-CONTAMINATION; LEGIONNAIRES-DISEASE;
   LEGIONELLA-PNEUMOPHILA; RISK-FACTORS; MYCOBACTERICIDAL ACTIVITY;
   PERACETIC-ACID; NU-CIDEX; SYSTEMS; BIOFILMS
AB Dental chair units (DCUs) are used in the treatment of many patients throughout each day and microbial contamination of specific component parts is an important potential source of cross-infection. The quality of dental unit water is of considerable importance since patients and dental staff are regularly exposed to water and aerosols generated from the dental unit. This water hosts a diverse microflora of bacteria, yeasts, fungi, viruses, protozoa, unicellular algae and nematodes which may be contaminated with micro-organisms found in the biofilm formed due to water stagnation in the narrow-bore dental unit waterline (DUWL) tubings. The water thus contaminated, when used for various treatment procedures through dental handpieces, air/water/three-in-one syringe, etc., produces aerosols that can cause infection. The present review emphasises the risks of infection from DUWL and various water treatment procedures available to disinfect the DUWLs. (C) 2009 The Hospital Infection Society. Published by Elsevier Ltd. All rights reserved.
C1 [Kumar, S.; Atray, D.; Paiwal, D.; Balasubramanyam, G.; Duraiswamy, P.; Kulkarni, S.] Darshan Dent Coll & Hosp, Dept Prevent & Community Dent, Udaipur 313001, India.
RP Kulkarni, S (reprint author), Darshan Dent Coll & Hosp, Dept Prevent & Community Dent, Ranakpur Rd, Udaipur 313001, India.
EM sanrescommunity@yahoo.com
CR al Shorman Hisham, 2002, Dent Update, V29, P292
   *AM DENT ASS, 1996, NY STAT DENT J, V62, P74
   American Dental Association, 1996, J AM DENT ASSOC, V127, P185
   ATLAS RM, 1995, APPL ENVIRON MICROB, V61, P1208
   Barbeau J, 1996, APPL ENVIRON MICROB, V62, P3954
   BARLETT CL, 1983, ZENTRALB BAKT MIKRO, V255, P64
   BATIK O, 1983, J ENVIRON HEALTH, V45, P227
   Beierle J W, 1993, J Calif Dent Assoc, V21, P13
   BLENKINSOPP SA, 1992, APPL ENVIRON MICROB, V58, P3770
   BROWN CA, 1985, TUBERCLE, V66, P251, DOI 10.1016/0041-3879(85)90062-5
   Chobot S, 1997, Cent Eur J Public Health, V5, P164
   CLARK A, 1974, P ROY SOC MED, V67, P1269
   Cleveland J, 1999, J AM DENT ASSOC, V130, P1653
   Kohn William G, 2003, MMWR Recomm Rep, V52, P1
   COSTERTON JW, 1984, DEV IND MICROBIOL, V25, P363
   COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251
   CTESCERI LS, 1998, STANDARD METHODS EXA
   DAVIES KJ, 1994, BRIT DENT J, V176, P262, DOI 10.1038/sj.bdj.4808430
   DAVIS DM, 1991, J CHEM SOC PERK T, V2, P15491
   de Saravia SG, 2005, WORLD J MICROB BIOT, V21, P1077, DOI 10.1007/s11274-004-8288-1
   DOUGLAS CWI, 1993, BRIT DENT J, V174, P167, DOI 10.1038/sj.bdj.4808114
   Dutil S, 2006, J APPL MICROBIOL, V100, P955, DOI 10.1111/j.1365-2672.2006.02845.x
   EDELSTEIN PH, 1986, J HOSP INFECT, V8, P109, DOI 10.1016/0195-6701(86)90037-X
   EXNER M, 1987, ZBL HYG UMWELTMED, V183, P549
   FIEHN NE, 1988, J DENT RES, V67, P1499, DOI 10.1177/00220345880670121101
   Fields BS, 2002, CLIN MICROBIOL REV, V15, P506, DOI 10.1128/CMR.15.3.506-526.2002
   Flemming HC, 2002, APPL MICROBIOL BIOT, V59, P629, DOI 10.1007/s00253-002-1066-9
   FURUHASHI M, 1985, J HOSP INFECT, V6, P81, DOI 10.1016/S0195-6701(85)80022-0
   Griffiths PA, 1999, J HOSP INFECT, V41, P111, DOI 10.1016/S0195-6701(99)90048-8
   HAMBLETON P, 1983, J HYG-CAMBRIDGE, V90, P451, DOI 10.1017/S0022172400029090
   HARPER D, 1985, J HOSP INFECT      S, V6, P81
   Harrel SK, 2004, J AM DENT ASSOC, V135, P429, DOI 10.14219/jada.archive.2004.0207
   *HLTH SAF COMM, 2000, LEG DIS CONTR LEG BA
   Kettering James D, 2002, J Contemp Dent Pract, V3, P1
   KING CH, 1988, APPL ENVIRON MICROB, V54, P3023
   KUSNETSOV JM, 1994, J APPL BACTERIOL, V77, P461, DOI 10.1111/j.1365-2672.1994.tb03450.x
   Landes DP, 1996, BRIT DENT J, V181, P73, DOI 10.1038/sj.bdj.4809162
   Leggat PA, 2001, INT DENT J, V51, P39, DOI 10.1002/j.1875-595X.2001.tb00816.x
   LEWIS DL, 1992, LANCET, V340, P1252, DOI 10.1016/0140-6736(92)92950-K
   LOHR DC, 1978, JAMA-J AM MED ASSOC, V239, P1528, DOI 10.1001/jama.239.15.1528
   LYNAM PA, 1995, J HOSP INFECT, V30, P237, DOI 10.1016/S0195-6701(95)90322-4
   MACKENZIE CD, 1994, FASEB J, V8, pA908
   MARSTON BJ, 1994, ARCH INTERN MED, V154, P2417, DOI 10.1001/archinte.154.21.2417
   MARTIN MV, 1987, BRIT DENT J, V163, P152, DOI 10.1038/sj.bdj.4806220
   Middleton AM, 1997, J HOSP INFECT, V37, P137, DOI 10.1016/S0195-6701(97)90183-3
   MILLS SE, 1986, J AM DENT ASSOC, V113, P280, DOI 10.14219/jada.archive.1986.0178
   Montebugnoli L, 2000, J DENT RES, V79, P199
   MONTECALVO MA, 1994, LANCET, V343, P1639, DOI 10.1016/S0140-6736(94)93093-7
   Morin P, 2000, J HOSP INFECT, V45, P218, DOI 10.1053/jhin.2000.0732
   MurdochKinch CA, 1997, J AM DENT ASSOC, V128, P1235, DOI 10.14219/jada.archive.1997.0400
   O'Donnell MJ, 2007, J DENT, V35, P438, DOI 10.1016/j.jdent.2007.01.001
   O'Donnell MJ, 2006, J DENT, V34, P648, DOI 10.1016/j.jdent.2005.12.006
   O'Donnell MJ, 2005, J HOSP INFECT, V59, P348, DOI 10.1016/j.jhin.2004.10.001
   ODONNELL MJ, 2006, CLIN TXB DENT HYGIEN, P181
   OMAHONY MC, 1990, EPIDEMIOL INFECT, V104, P361, DOI 10.1017/S0950268800047385
   OPPENHEIM BA, 1987, EPIDEMIOL INFECT, V99, P159, DOI 10.1017/S095026880006698X
   Pankhurst CL, 2007, J DENT, V35, P712, DOI 10.1016/j.jdent.2007.06.002
   Pankhurst Caroline L, 2005, Prim Dent Care, V12, P53, DOI 10.1308/1355761053695176
   Pankhurst Caroline L, 2003, Prim Dent Care, V10, P5, DOI 10.1308/135576103322504030
   PANKHURST CL, 1990, J HOSP INFECT, V16, P9, DOI 10.1016/0195-6701(90)90044-O
   Pankhurst CL, 1998, INT DENT J, V48, P359, DOI 10.1111/j.1875-595X.1998.tb00697.x
   Pankhurst CL, 2002, J DENT RES, V81, pA446
   Pankhurst CL, 1996, J HOSP INFECT, V32, P249, DOI 10.1016/S0195-6701(96)90035-3
   PANKHURST CL, 2000, BRIT DENT ASS FACT F
   Porteous NB, 2004, ORAL SURG ORAL MED O, V98, P40, DOI 10.1016/j.tripleo.2004.02.006
   Rangel-Frausto MS, 1999, INFECT CONT HOSP EP, V20, P793, DOI 10.1086/501586
   Rusin P A, 1997, Rev Environ Contam Toxicol, V152, P57
   Rutala WA, 1999, INFECT CONT HOSP EP, V20, P69, DOI 10.1086/501544
   Sattar S A, 1996, Can J Infect Control, V11, P51
   SCHEID R C, 1990, Clinical Preventive Dentistry, V12, P9
   SCHULZEROBBECKE R, 1995, TUBERCLE LUNG DIS, V76, P318, DOI 10.1016/S0962-8479(05)80030-9
   Siegel SC, 2002, J AM DENT ASSOC, V133, P184, DOI 10.14219/jada.archive.2002.0142
   STANLEY P, 1998, AM J INFECT CONTROL, V26, P185
   Stout JE, 1997, NEW ENGL J MED, V337, P682, DOI 10.1056/NEJM199709043371006
   Straus WL, 1996, ARCH INTERN MED, V156, P1685, DOI 10.1001/archinte.156.15.1685
   TALL BD, 1995, CAN J MICROBIOL, V41, P647, DOI 10.1139/m95-088
   Tuttlebee CM, 2002, J HOSP INFECT, V52, P192, DOI 10.1053/jhin.2002.1282
   WADOWSKY RM, 1995, APPL ENVIRON MICROB, V48, P1197
   Walker JT, 2004, EUR J ORAL SCI, V112, P412, DOI 10.1111/j.1600-0722.2004.00151.x
   Walker JT, 2000, APPL ENVIRON MICROB, V66, P3363, DOI 10.1128/AEM.66.8.3363-3367.2000
   Walker JT, 2004, INT BIODETER BIODEGR, V54, P87, DOI 10.1016/j.ibiod.2004.03.012
   Wallace R J Jr, 1987, Infect Dis Clin North Am, V1, P677
   WALLACE RJ, 1983, REV INFECT DIS, V5, P657
   WHITEHOUSE RLS, 1991, J DENT, V19, P290, DOI 10.1016/0300-5712(91)90075-A
   Williams HN, 1996, J AM DENT ASSOC, V127, P1188, DOI 10.14219/jada.archive.1996.0410
   WILLIAMS HN, 1994, CAN J MICROBIOL, V40, P127, DOI 10.1139/m94-020
   WILLIAMS HN, 1994, J AM DENT ASSOC, V125, P1205, DOI 10.14219/jada.archive.1994.0164
   Williams J F, 1996, Compend Contin Educ Dent, V17, P691
   Williams J F, 1996, Compend Contin Educ Dent, V17, P538
   WILLIAMS JF, 1993, J AM DENT ASSOC, V124, P59, DOI 10.14219/jada.archive.1993.0205
   WILSON LA, 1991, ARCH OPHTHALMOL-CHIC, V109, P1155, DOI 10.1001/archopht.1991.01080080115043
   PROTECTION POLLUTION
   1993, OFF J EUR COMMUNITY, V169, P1
NR 93
TC 18
Z9 26
U1 4
U2 36
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0195-6701
EI 1532-2939
J9 J HOSP INFECT
JI J. Hosp. Infect.
PD FEB
PY 2010
VL 74
IS 2
BP 99
EP 111
DI 10.1016/j.jhin.2009.03.027
PG 13
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 569JB
UT WOS:000275591300001
PM 20113847
DA 2018-12-27
ER

PT J
AU Zainazor, CT
   Hidayah, MSN
   Chai, LC
   Tunung, R
   Ghazali, FM
   Son, R
AF Zainazor, Tuan C.
   Hidayah, M. S. Noor
   Chai, L. C.
   Tunung, R.
   Ghazali, F. Mohamad
   Son, R.
TI RETRACTED: The Scenario of Norovirus Contamination in Food and Food
   Handlers (Retracted article. See vol. 21, pg. 665, 2011)
SO JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Review; Retracted Publication
DE Norovirus; food; food handlers
ID NORWALK-LIKE VIRUSES; HUMAN ENTERIC VIRUSES; HEPATITIS-A VIRUS;
   INFECTIOUS INTESTINAL DISEASE; REVERSE-TRANSCRIPTASE PCR; UNITED-STATES;
   VIRAL GASTROENTERITIS; FOODBORNE VIRUSES; RT-PCR; WATERBORNE OUTBREAK
AB Recently, many cases related to viral gastroenteritis outbreaks have been reported all over the world. Noroviruses are found to be leading as the major cause of outbreaks of acute gastroenteritis. Patients with acute gastroenteritis are normally found to be positive with norovirus when the stools and vomit are analyzed. This paper reviews various activities and previous reports that describe norovirus contamination in various food matrixes and the relationship between food handlers. Lately, a numbers of norovirus outbreaks have been reported that are involved with fresh produce (such as vegetables, fruits), shellfish, and prepared food. Food produce processed by infected food handlers may therefore become easily contaminated. In addition, foods that required much handling and had been eaten without heat treatment gave the high risk for getting foodborne illnesses. The standard method for detection of norovirus has already been available for stool samples. However, only a few methods for detection of norovirus in food samples have been developed until now.
C1 [Zainazor, Tuan C.] Minist Hlth Malaysia, Natl Publ Hlth Lab, Sungai Buloh 47000, Selangor, Malaysia.
   [Zainazor, Tuan C.; Hidayah, M. S. Noor; Chai, L. C.; Tunung, R.; Ghazali, F. Mohamad; Son, R.] Univ Putra Malaysia, Fac Food Sci & Technol, Natl Food Safety Res Ctr, Serdang 43400, Selangor, Malaysia.
RP Zainazor, CT (reprint author), Minist Hlth Malaysia, Natl Publ Hlth Lab, Lot 1853, Sungai Buloh 47000, Selangor, Malaysia.
EM zainazor@yahoo.com
CR Abbaszadegan M, 2003, J AM WATER WORKS ASS, V95, P107
   ADDISS DG, 1989, EPIDEMIOL INFECT, V103, P63, DOI 10.1017/S0950268800030363
   Amar CFL, 2007, EUR J CLIN MICROBIOL, V26, P311, DOI 10.1007/s10096-007-0290-8
   Amon JJ, 2005, J INFECT DIS, V192, P1323, DOI 10.1086/462425
   Anderson AD, 2003, J INFECT DIS, V187, P303, DOI 10.1086/346239
   Anderson AD, 2001, AM J EPIDEMIOL, V154, P1013, DOI 10.1093/aje/154.11.1013
   ANDO T, 2000, J INFECT DIS, V181, P336
   Arness MK, 2000, EMERG INFECT DIS, V6, P204
   Baert L, 2009, EPIDEMIOL INFECT, V137, P316, DOI 10.1017/S0950268808001830
   Beller M, 1997, JAMA-J AM MED ASSOC, V278, P563, DOI 10.1001/jama.278.7.563
   Bidawid S, 2004, J FOOD PROTECT, V67, P103, DOI 10.4315/0362-028X-67.1.103
   Bosch A, 2001, WATER SCI TECHNOL, V43, P61
   Boxman ILA, 2006, INT J FOOD MICROBIOL, V108, P391, DOI 10.1016/j.ijfoodmicro.2006.01.002
   Braham S, 2009, J VIROL METHODS, V158, P30, DOI 10.1016/j.jviromet.2009.01.006
   Bresee JS, 2002, CLIN INFECT DIS, V35, P748, DOI 10.1086/342386
   Bruggink L, 2008, ARCH VIROL, V153, P729, DOI 10.1007/s00705-008-0036-7
   Bull RA, 2006, J CLIN MICROBIOL, V44, P327, DOI 10.1128/JCM.44.2.327-333.2006
   Butot S, 2007, APPL ENVIRON MICROB, V73, P186, DOI [10.1128/AEM.01248-06, 10.1128/AEM.00450-07]
   Calder L, 2003, EPIDEMIOL INFECT, V131, P745, DOI 10.1017/S0950268803008586
   Carter MJ, 2005, J APPL MICROBIOL, V98, P1354, DOI 10.1111/j.1365-2672.2005.02635.x
   Chapin AR, 2005, J CLIN MICROBIOL, V43, P1112, DOI 10.1128/JCM.43.3.1112-1117.2005
   Cheesbrough JS, 2000, EPIDEMIOL INFECT, V125, P93, DOI 10.1017/S095026889900432X
   Cheng PKC, 2005, J MED VIROL, V76, P593, DOI 10.1002/jmv.20402
   CLIVER DO, 1995, TRENDS FOOD SCI TECH, V6, P353, DOI 10.1016/S0924-2244(00)89190-6
   Daniels NA, 2000, J INFECT DIS, V181, P1467, DOI 10.1086/315365
   Doyle A, 2004, Euro Surveill, V9, P24
   Drosten C, 2003, TRENDS MOL MED, V9, P325, DOI 10.1016/S1471-4914(03)00133-3
   Duizer E, 2004, J GEN VIROL, V85, P79, DOI 10.1099/vir.0.19478-0
   Estes MK, 2000, J INFECT DIS, V181, pS367, DOI 10.1086/315579
   [European Food Safety Authority European Food Safety Authority], 2007, EFSA J
   Fang Zhao-Yin, 2007, Chinese Journal of Virology, V23, P9
   Fankhauser RL, 2002, J INFECT DIS, V186, P1, DOI 10.1086/341085
   Fout GS, 2003, APPL ENVIRON MICROB, V69, P3158, DOI 10.1128/AEM.69.6.3158-3164.2003
   Fretz R, 2005, EUR J CLIN MICROBIOL, V24, P256, DOI 10.1007/s10096-005-1310-1
   Fumian TM, 2009, J VIROL METHODS, V155, P39, DOI 10.1016/j.jviromet.2008.09.026
   Gentry J, 2009, J VIROL METHODS, V156, P59, DOI 10.1016/j.jviromet.2008.11.001
   Gilpatrick SG, 2000, J VIROL METHODS, V90, P69, DOI 10.1016/S0166-0934(00)00220-2
   Green KY, 2000, J INFECT DIS, V181, pS322, DOI 10.1086/315591
   GREEN KY, 2007, FIELDS VIROLOGY, V1, P949
   Guevremont E, 2006, J VIROL METHODS, V134, P130, DOI 10.1016/j.jviromet.2005.12.009
   Gulati BR, 2001, J FOOD PROTECT, V64, P1430, DOI 10.4315/0362-028X-64.9.1430
   HERWALDT BL, 1994, J CLIN MICROBIOL, V32, P861
   HIERTQVIST M, 2006, EUROSURVEILLANCE, V11
   HILL S, 2003, INVESTIGATION FOOD R
   Hutin YJF, 1999, NEW ENGL J MED, V340, P595, DOI 10.1056/NEJM199902253400802
   Khamrin P, 2009, J VIROL METHODS, V157, P219, DOI 10.1016/j.jviromet.2008.12.012
   Kim HY, 2008, J VIROL METHODS, V153, P104, DOI 10.1016/j.jviromet.2008.07.022
   Kim JH, 2008, TUMOR BIOL, V29, P41, DOI 10.1159/000132570
   KONOWALCHUK BS, 1975, J MILK FOOD TECHNOL, V38, P600
   Koopmans M, 2004, INT J FOOD MICROBIOL, V90, P23, DOI 10.1016/S0168-1605(03)00169-7
   KURITSKY JN, 1984, ANN INTERN MED, V100, P519, DOI 10.7326/0003-4819-100-4-519
   Laverick MA, 2004, LETT APPL MICROBIOL, V39, P127, DOI 10.1111/j.1472-765X.2004.01534.x
   Le Guyader FS, 2006, EMERG INFECT DIS, V12, P931
   Le Guyader FS, 2004, INT J FOOD MICROBIOL, V97, P179, DOI 10.1016/j.ijfoodmicro.2004.04.018
   Le Guyader FS, 2004, J FOOD PROTECT, V67, P2315, DOI 10.4315/0362-028X-67.10.2315
   Leggitt PR, 2000, J FOOD PROTECT, V63, P1738, DOI 10.4315/0362-028X-63.12.1738
   LEGUYADER F, 1994, APPL ENVIRON MICROB, V60, P3665
   Lindesmith L, 2003, NAT MED, V9, P548, DOI 10.1038/nm860
   Lopman B, 2008, PLOS MED, V5, P187, DOI 10.1371/journal.pmed.0050042
   Marks PJ, 2000, EPIDEMIOL INFECT, V124, P481, DOI 10.1017/S0950268899003805
   MARSHALL JA, 2009, INT J INFECT DIS, V13, pE125
   Marvin HJP, 2009, FOOD CONTROL, V20, P345, DOI 10.1016/j.foodcont.2008.07.024
   Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502
   Meakins SM, 2003, J HOSP INFECT, V53, P1, DOI 10.1053/jhin.2002.1326
   Myrmel M, 2000, ARCH VIROL, V145, P711, DOI 10.1007/s007050050665
   Nishida T, 2003, APPL ENVIRON MICROB, V69, P5782, DOI 10.1128/AEM.69.10.5782-5786.2003
   Nishida T, 2007, MICROBIOL IMMUNOL, V51, P177, DOI 10.1111/j.1348-0421.2007.tb03899.x
   Okabayashi T, 2008, J CLIN MICROBIOL, V46, P1985, DOI 10.1128/JCM.00305-08
   Ozawa K, 2007, J CLIN MICROBIOL, V45, P3996, DOI 10.1128/JCM.01516-07
   Park Y, 2008, APPL ENVIRON MICROB, V74, P4226, DOI 10.1128/AEM.00013-08
   Parshionikar SU, 2003, APPL ENVIRON MICROB, V69, P5263, DOI 10.1128/AEM.69.9.5263-5268.2003
   Patel MM, 2008, EMERG INFECT DIS, V14, P1224, DOI 10.3201/eid1408.071114
   Patel MM, 2009, J CLIN VIROL, V44, P1, DOI 10.1016/j.jcv.2008.10.009
   Ponka A, 1999, EPIDEMIOL INFECT, V123, P469, DOI 10.1017/S0950268899003064
   Potasman I, 2002, CLIN INFECT DIS, V35, P921, DOI 10.1086/342330
   ROSENBLUM LS, 1990, AM J PUBLIC HEALTH, V80, P1075, DOI 10.2105/AJPH.80.9.1075
   Rutjes SA, 2006, J FOOD PROTECT, V69, P1949, DOI 10.4315/0362-028X-69.8.1949
   Sair AI, 2002, J VIROL METHODS, V100, P57, DOI 10.1016/S0166-0934(01)00397-4
   Saito Koichi, 2006, Kansenshogaku Zasshi, V80, P399
   Scherer K, 2009, FOOD ENVIRON VIROL, V1, P42, DOI 10.1007/s12560-008-9007-0
   Schultz AC, 2007, INT J FOOD MICROBIOL, V114, P352, DOI 10.1016/j.ijfoodmicro.2006.09.028
   Schwab KJ, 1996, APPL ENVIRON MICROB, V62, P2086
   Schwab KJ, 2003, APPL ENVIRON MICROB, V69, P5819, DOI 10.1128/AEM.69.10.5819-5825.2003
   Schwab KJ, 2000, APPL ENVIRON MICROB, V66, P213, DOI 10.1128/AEM.66.1.213-218.2000
   Seymour IJ, 2001, J APPL MICROBIOL, V91, P759, DOI 10.1046/j.1365-2672.2001.01427.x
   Straub TM, 2007, EMERG INFECT DIS, V13, P396, DOI 10.3201/eid1303.060549
   Teunis PFM, 2008, J MED VIROL, V80, P1468, DOI 10.1002/jmv.21237
   Uchino K, 2006, JPN J INFECT DIS, V59, P270
   Ueki Y, 2005, WATER RES, V39, P4271, DOI 10.1016/j.watres.2005.06.035
   Vanderpas J, 2009, J HOSP INFECT, V71, P214, DOI 10.1016/j.jhin.2008.11.024
   Verhoef L, 2008, EMERG INFECT DIS, V14, P238, DOI 10.3201/eid1402.061567
   Vivancos R, 2009, INT J INFECT DIS, V13, P629, DOI 10.1016/j.ijid.2008.09.023
   Widdowson MA, 2005, EMERG INFECT DIS, V11, P95, DOI 10.3201/eid1101.040426
   Zheng DP, 2006, VIROLOGY, V346, P312, DOI 10.1016/j.virol.2005.11.015
NR 94
TC 27
Z9 27
U1 4
U2 28
PU KOREAN SOC MICROBIOLOGY & BIOTECHNOLOGY
PI SEOUL
PA KOREA SCI TECHNOL CENTER #507,  635-4 YEOGSAM-DONG, KANGNAM-GU, SEOUL
   135-703, SOUTH KOREA
SN 1017-7825
J9 J MICROBIOL BIOTECHN
JI J. Microbiol. Biotechnol.
PD FEB
PY 2010
VL 20
IS 2
BP 229
EP 237
DI 10.4014/jmb.0906.06032
PG 9
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA 563CI
UT WOS:000275103400001
DA 2018-12-27
ER

PT J
AU MacLean, A
AF MacLean, Allan
TI RETRACTED: To peritonealise or not to peritonealise? A randomised trial
   at abdominal hysterectomy in Iran (Retracted Article)
SO JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Correction; Retracted Publication
CR Behtash N, 2001, J Obstet Gynaecol, V21, P520
NR 1
TC 0
Z9 0
U1 2
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0144-3615
EI 1364-6893
J9 J OBSTET GYNAECOL
JI J. Obstet. Gynaecol.
PD FEB
PY 2010
VL 30
IS 2
BP 221
EP 221
PG 1
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 560BZ
UT WOS:000274878100041
PM 20144002
OA Bronze
DA 2018-12-27
ER

PT J
AU Li, J
AF Li, J.
TI RETRACTED: Friction and Wear Properties of PA6-reinforced PTFE
   Composites (Retracted article. See vol. 29, pg. 3297, 2010)
SO JOURNAL OF REINFORCED PLASTICS AND COMPOSITES
LA English
DT Article; Retracted Publication
DE composition; tribological properties; worn
ID REINFORCED POLYETHERIMIDE COMPOSITES; TRIBOLOGICAL BEHAVIOR;
   PERFORMANCE; FILLER
AB Blending polytetrafluorothylene (PTFE) with PA6 in different compositions was carried out in a co-rotating twin-screw extruder where PTFE acts as the polymer matrix and PA6 as the dispersed phase. The effects of PA6 content on the tribological properties of the composites were investigated. The worn surface morphologies of neat PTFE and its composites were examined with scanning electron microscopy (SEM) and the wear mechanisms were discussed. The presence of PA6 particles dispersed in the PTFE continuous phase exhibited superior tribological characteristics to unfilled PTFE. The optimum wear reduction is obtained when the content of PA6 is 30 vol%.
C1 Shanghai Second Polytech Univ, Sch Mech & Elect Engn, Shanghai 201209, Peoples R China.
RP Li, J (reprint author), Shanghai Second Polytech Univ, Sch Mech & Elect Engn, Shanghai 201209, Peoples R China.
EM lijian2008d@sina.com
FU Shanghai Second Polytechnic University [JD208001]
FX The authors would like to thank the School Fund (Project No. JD208001),
   Shanghai Second Polytechnic University for their help.
CR BELYI VA, 1982, FRICTION WEAR POLYM, P235
   Bijwe J, 2007, TRIBOL INT, V40, P844, DOI 10.1016/j.triboint.2006.08.005
   Bijwe J, 2007, WEAR, V262, P749, DOI 10.1016/j.wear.2006.08.011
   Cartledge HCY, 1996, WEAR, V194, P178, DOI 10.1016/0043-1648(95)06839-2
   FRANKE R, 2001, P WTC 2001 VIENN, P3
   Li F, 2001, WEAR, V249, P877, DOI 10.1016/S0043-1648(01)00816-X
   Lin JC, 2007, COMPOS PART B-ENG, V38, P79, DOI 10.1016/j.compositesb.2006.03.012
   Shi YJ, 2007, TRIBOL INT, V40, P1195, DOI 10.1016/j.triboint.2006.12.006
   Su FH, 2008, WEAR, V264, P562, DOI 10.1016/j.wear.2007.04.007
   Su FH, 2007, COMPOS SCI TECHNOL, V67, P981, DOI 10.1016/j.compscitech.2006.06.010
   TANG W, 2000, TRIBOLOGY, V20, P10
   Wang YX, 2007, WEAR, V262, P876, DOI 10.1016/j.wear.2006.08.026
NR 12
TC 4
Z9 5
U1 5
U2 13
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0731-6844
EI 1530-7964
J9 J REINF PLAST COMP
JI J. Reinf. Plast. Compos.
PD FEB
PY 2010
VL 29
IS 4
BP 490
EP 496
DI 10.1177/0731684408099408
PG 7
WC Materials Science, Composites; Polymer Science
SC Materials Science; Polymer Science
GA 554OY
UT WOS:000274445500002
DA 2018-12-27
ER

PT J
AU Dai, SD
   Wang, Y
   Jiang, GY
   Zhang, PX
   Dong, XJ
   Wei, Q
   Xu, HT
   Li, QC
   Zhao, C
   Wang, EH
AF Dai, Shun-Dong
   Wang, Yan
   Jiang, Gui-Yang
   Zhang, Peng-Xin
   Dong, Xin-Jun
   Wei, Qiang
   Xu, Hong-Tao
   Li, Qing-Chang
   Zhao, Chen
   Wang, En-Hua
TI RETRACTED: Kaiso is expressed in lung cancer: Its expression and
   localization is affected by p120ctn (Retracted article. See vol. 102,
   pg. 141, 2010)
SO LUNG CANCER
LA English
DT Article; Retracted Publication
DE Lung cancer; Clinicopathological factors; Kaiso; p120ctn; Metastasis
ID MEDIATED TRANSCRIPTIONAL REPRESSION; PROTEIN INTERACTION MOTIF;
   RHO-FAMILY GTPASES; E-CADHERIN; TYROSINE PHOSPHORYLATION; BETA-CATENIN;
   NUCLEAR-LOCALIZATION; BINDING-PROTEIN; BTB/POZ DOMAIN; PARTNER KAISO
AB Background: Kaiso is a recently identified transcription factor that binds to p120-catenin (p120ctn), an Armadillo catenin and cell adhesion cofactor. However, clinical studies of human solid tumors have not been reported to investigate relationship between these proteins.
   Methods: Expression and localization of Kaiso and p120ctn were examined in 196 lung cancer specimens (including 55 cases of paired lymph node metastases and 80 cases with complete follow-up records) by immunohistochemistry. Three lung cancer cell lines, BE1, SPC, and A549 were used to establish p120ctn stably ablated or overexpressed cell lines. Co-immunoprecipitation was used to confirm p120ctn bind Kaiso in lung cancer tissue and cell lines. Localization and expression levels of Kaiso were detected via immunofluorescence, cytoplasmic vs. nuclear fractionation Western blot analysis and reverse transcription-polymerase chain reaction.
   Results: Cytoplasmic Kaiso expression was evident in 115 (58.7%), and abnormal p120ctn expression was noted in 168 (85.7%). Cytoplasmic Kaiso and abnormal p120ctn expressions were associated with higher degree of malignancy (high-stage and lymph node metastases, all P<0.05). Abnormal p120ctn and cytoplasmic Kaiso expressions were higher in matched autologous nodal metastases than in primary growths. The lung cancer-related 5-year survival rate was significantly lower in patients who were cytoplasmic Kaiso-positive (22.9%; P = 0.029) or abnormal p120ctn expression (20.6%; P = 0.001). Multivariate analysis showed abnormal p120ctn expression was an independent factor defining the clinicopathological characters of patients. Cytoplasmic Kaiso expression was correlated with cytoplasmic p120ctn, they formed Kaiso-p120ctn complex in lung cancer tissues and cell lines. In addition, p120ctn ablation and overexpression altered Kaiso subcellular localization and protein level. Although both isoforms can regulate subcellular localization and protein levels of Kaiso, we found that only p120ctn isoform 3, but not isoform 1, directly interacts with Kaiso.
   Conclusion: p120ctn and Kaiso might co-participate in the progression and lymph node metastasis of lung cancer. p120ctn regulates expression and localization of Kaiso in lung cancer cells. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Wang, En-Hua] China Med Univ, Dept Pathol, Coll Basic Med Sci, Shenyang 110001, Peoples R China.
   Affiliated Hosp 1, Dept Pathol, Shenyang 110001, Peoples R China.
RP Wang, EH (reprint author), China Med Univ, Dept Pathol, Coll Basic Med Sci, N 2nd Rd 92,Heping Ward, Shenyang 110001, Peoples R China.
EM wangeh@hotmail.com
FU National Natural Science Foundation of China [30470764, 30670917,
   30670888]
FX This study was supported by grants from the National Natural Science
   Foundation of China (No. 30470764, 30670917 to En-Hua Wang and No.
   30670888 to C. Zhao).
CR Aho S, 2002, J CELL SCI, V115, P1391
   ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193
   Anastasiadis PZ, 2000, J CELL SCI, V113, P1319
   Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637
   BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664
   BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5
   Dai SD, 2007, LUNG CANCER, V57, P54, DOI 10.1016/j.lungcan.2007.02.008
   Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398
   Daniel JM, 1999, MOL CELL BIOL, V19, P3614
   Daniel JM, 2007, BBA-MOL CELL RES, V1773, P59, DOI 10.1016/j.bbamcr.2006.08.052
   Davis MA, 2006, DEV CELL, V10, P21, DOI 10.1016/j.devcel.2005.12.004
   Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111
   DOWNING JR, 1991, ONCOGENE, V6, P607
   Grosheva I, 2001, J CELL SCI, V114, P695
   Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115
   KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713
   Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003
   Kelly KF, 2004, J CELL SCI, V117, P6143, DOI 10.1242/jcs.01541
   Kelly KF, 2004, J CELL SCI, V117, P2675, DOI 10.1242/jcs.01101
   Kim SW, 2004, NAT CELL BIOL, V6, P1212, DOI 10.1038/ncb1191
   Liu Y, 2007, APMIS, V115, P848, DOI 10.1111/j.1600-0463.2007.apm_673.x
   Liu Y, 2009, LUNG CANCER, V63, P375, DOI 10.1016/j.lungcan.2008.12.012
   Liu Y, 2009, EXP CELL RES, V315, P890, DOI 10.1016/j.yexcr.2008.12.016
   Liu Y, 2009, CANCER SCI, V100, P441, DOI 10.1111/j.1349-7006.2008.01067.x
   Lopes EC, 2008, CANCER RES, V68, P7258, DOI 10.1158/0008-5472.CAN-08-0344
   Maeda M, 2006, ONCOGENE, V25, P4595, DOI 10.1038/sj.onc.1209396
   Moreno-Bueno G, 2003, J PATHOL, V199, P471, DOI 10.1002/path.1310
   Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567
   Ogden SR, 2008, MOL BIOL CELL, V19, P4110, DOI 10.1091/mbc.E08-03-0283
   Park JI, 2006, DEV CELL, V11, P683, DOI 10.1016/j.devcel.2006.09.022
   Park JI, 2005, DEV CELL, V8, P843, DOI 10.1016/j.devcel.2005.04.010
   Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501
   Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161
   REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629
   Roczniak-Ferguson A, 2003, J CELL SCI, V116, P4201, DOI 10.1242/jcs.00724
   Ruzov A, 2004, DEVELOPMENT, V131, P6185, DOI 10.1242/dev.01549
   Sobin DHWC, 2002, INT UNION CANC UICC
   Soubry A, 2005, CANCER RES, V65, P2224, DOI 10.1158/0008-5472.CAN-04-2020
   Spring CM, 2005, EXP CELL RES, V305, P253, DOI 10.1016/j.yexcr.2005.01.007
   Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x
   van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980
   van Roy FM, 2005, NAT REV CANCER, V5, P956, DOI 10.1038/nrc1752
   Wang EH, 2006, HISTOL HISTOPATHOL, V21, P841, DOI 10.14670/HH-21.841
   Watanabe Yoh, 2003, Ann Thorac Cardiovasc Surg, V9, P343
   Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001
   Yanagisawa M, 2004, J BIOL CHEM, V279, P9512, DOI 10.1074/jbc.M310895200
   Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008
NR 47
TC 19
Z9 26
U1 1
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-5002
EI 1872-8332
J9 LUNG CANCER
JI Lung Cancer
PD FEB
PY 2010
VL 67
IS 2
BP 205
EP 215
DI 10.1016/j.lungcan.2009.06.013
PG 11
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 553PD
UT WOS:000274378400013
PM 19615783
DA 2018-12-27
ER

PT J
AU Liu, HW
AF Liu, Haiwen
TI RETRACTED: NEURAL MODELING FOR COMPACT COPLANAR WAVEGUIDE BANDPASS
   FILTER LOADED SPLIT RING RESONATOR (Retracted article. See vol. 52, pg.
   1681, 2010)
SO MICROWAVE AND OPTICAL TECHNOLOGY LETTERS
LA English
DT Article; Retracted Publication
DE neural modeling; coplanar waveguide; bandpass filter; split ring
   resonator
AB Compact coplanar waveguide (CPW) bandpass filter loaded split ring resonator is presented in this article. The proposed filter exhibits a quasi-elliptic function response and its circuit size occupies only 12 x 11.8 mm(2) (approximate to 0.21 lambda g x 0.20 lambda g). Also, a simple circuit model is given, and the parametric study of this filter is discussed. Then. with the aid of NeuroModeler software, a five-layer feed-forward perceptron neural networks model is built lip to optimize the proposed filter design fast and accurately. Finally, this newly CPW bandpass filter was fabricated and measured. A good agreement between simulations and measurement verifies the proposed left-handed filter and the validity of design methodology. (C) 2009 Wiley Periodicals, Inc. Microwave Opt Technol Lett 52: 344-347, 2010; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/mop.24925
C1 E China Jiaotong Univ, Sch Informat Engn, Nanchang 330013, Peoples R China.
RP Liu, HW (reprint author), E China Jiaotong Univ, Sch Informat Engn, Nanchang 330013, Peoples R China.
EM liuhaiwen@gmail.com
FU K.C. Wong Education Foundation, Hong Kong
FX This work is supported by in part by K.C. Wong Education Foundation,
   Hong Kong.
CR Baena JD, 2005, IEEE T MICROW THEORY, V53, P1451, DOI 10.1109/TMTT.2005.845211
   BATMANOV A, 2007, P AS PAC MICR C, V1, P1883
   Chen D, 2007, ELECTRON LETT, V43, P526, DOI 10.1049/el:20070422
   Dib N, 2005, INT J RF MICROW C E, V15, P551, DOI 10.1002/mmce.20099
   Falcone F, 2004, MICROW OPT TECHN LET, V40, P3, DOI 10.1002/mop.11269
   Martin F, 2003, IEEE MICROW WIREL CO, V13, P511, DOI 10.1109/LMWC.2003.819964
   Pendry JB, 1999, IEEE T MICROW THEORY, V47, P2075, DOI 10.1109/22.798002
   SANADA A, 2002, IEEE MTT S, V1, P385
   Simons R., 2001, COPLANAR WAVEGUIDE C
   VESELAGO VG, 1968, SOV PHYS USPEKHI, V10, P509, DOI 10.1070/PU1968v010n04ABEH003699
   Yildiz C, 2004, IEE P-MICROW ANTEN P, V151, P7, DOI 10.1049/ip-map:20040249
   Yildiz C, 2003, INT J RF MICROW C E, V13, P438, DOI 10.1002/mmce.10104
   Zhang QJ, 2003, IEEE T MICROW THEORY, V51, P1339, DOI 10.1109/TMTT.2003.809179
   ZHANG QJ, 2004, NEUROMODELER VERSION
NR 14
TC 1
Z9 1
U1 2
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0895-2477
EI 1098-2760
J9 MICROW OPT TECHN LET
JI Microw. Opt. Technol. Lett.
PD FEB
PY 2010
VL 52
IS 2
BP 344
EP 347
DI 10.1002/mop.24925
PG 4
WC Engineering, Electrical & Electronic; Optics
SC Engineering; Optics
GA 541SH
UT WOS:000273439900025
DA 2018-12-27
ER

PT J
AU Alcaide, M
   Lemus, JA
   Blanco, G
   Tella, JL
   Serrano, D
   Negro, JJ
   Rodriguez, A
   Garcia-Montijano, M
AF Alcaide, Miguel
   Lemus, Jesus A.
   Blanco, Guillermo
   Tella, Jose L.
   Serrano, David
   Negro, Juan J.
   Rodriguez, Airam
   Garcia-Montijano, Marino
TI RETRACTED: MHC diversity and differential exposure to pathogens in
   kestrels (Aves: Falconidae) (Retracted article. See vol. 22, pg. 1185,
   2013)
SO MOLECULAR ECOLOGY
LA English
DT Article; Retracted Publication
DE adaptive evolution; immunogenetics; infectious diseases; insularity;
   pathogen-mediated selection
ID MAJOR HISTOCOMPATIBILITY COMPLEX; POLYMERASE-CHAIN-REACTION; SNIPE
   GALLINAGO-MEDIA; HOST IMMUNE DEFENSE; WEST-NILE-VIRUS;
   INFECTIOUS-DISEASE; MATE CHOICE; GEOGRAPHICAL VARIATION; LABORATORY
   DIAGNOSIS; AVIAN POLYOMAVIRUS
AB Pathogen diversity is thought to drive major histocompatibility complex (MHC) polymorphism given that host's immune repertories are dependent on antigen recognition capabilities. Here, we surveyed an extensive community of pathogens (n = 35 taxa) and MHC diversity in mainland versus island subspecies of the Eurasian kestrel Falco tinnunculus and in a sympatric mainland population of the phylogenetically related lesser kestrel Falco naumanni. Insular subspecies are commonly exposed to impoverished pathogen communities whilst different species' ecologies and contrasting life-history traits may lead to different levels of pathogen exposure. Although specific host traits may explain differential particular infections, overall pathogen diversity, richness and prevalence were higher in the truly cosmopolitan, euriphagous and long-distance disperser Eurasian kestrel than in the estenophagous, steppe-specialist, philopatric but long-distance migratory lesser kestrel. Accordingly, the continental population of Eurasian kestrels displayed a higher number (64 vs. 49) as well as more divergent alleles at both MHC class I and class II loci. Detailed analyses of amino acid diversity revealed that significant differences between both species were exclusive to those functionally important codons comprising the antigen binding sites. The lowest pathogen burdens and the smallest but still quite divergent set of MHC alleles (n = 16) were found in island Eurasian kestrels, where the rates of allele fixation at MHC loci seem to have occurred faster than at neutral markers. The results presented in this study would therefore support the role of pathogen diversity and abundance in shaping patterns of genetic variation at evolutionary relevant MHC genes.
C1 [Alcaide, Miguel; Tella, Jose L.; Serrano, David; Negro, Juan J.; Rodriguez, Airam] CSIC, Estac Biol Donana, Seville 41013, Spain.
   [Lemus, Jesus A.; Blanco, Guillermo] CSIC, Dept Ecol & Evolut, Museo Ciencias Nat, E-28006 Madrid, Spain.
   [Alcaide, Miguel] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.
   [Garcia-Montijano, Marino] GIR Diagnost SL, Madrid 28180, Spain.
RP Alcaide, M (reprint author), CSIC, Estac Biol Donana, Avda Maria Luisa S-N, Seville 41013, Spain.
EM malcaide@oeb.harvard.edu
RI Tella, Jose/I-3707-2015; Blanco, Guillermo/L-3170-2014; Serrano,
   David/B-5352-2013; Negro, Juan/I-2653-2015; Alcaide, Miguel/A-1400-2012
OI Tella, Jose/0000-0002-3038-7424; Blanco, Guillermo/0000-0001-5742-4929;
   Serrano, David/0000-0001-6205-386X; Negro, Juan/0000-0002-8697-5647; 
FU Micinn [CGL2004-04120, CGL2007-61395/BOS]; CSIC
FX We thank JC Illera, the Associate Editor Staffan Bensch and three
   anonymous reviewers for helpful comments and suggestions to early drafts
   of this manuscript. JA Fargallo, J Potti, M de la Riva, M Jimenez and
   others kindly provided Eurasian kestrel samples for genetic analyses.
   This study was funded by the Micinn (formerly MCyT,
   http://www.micinn.es) of the Spanish Government (projects CGL2004-04120
   and CGL2007-61395/BOS) and the CSIC (http://www.csic.es), which also
   provided research grants to M Alcaide and A Rodriguez.
CR Acevedo-Whitehouse K, 2006, TRENDS ECOL EVOL, V21, P433, DOI 10.1016/j.tree.2006.05.010
   Aguilar A, 2004, P NATL ACAD SCI USA, V101, P3490, DOI 10.1073/pnas.0306582101
   Alcaide M, 2005, IBIS, V147, P608, DOI 10.1111/j.1474-919x.2005.00429.x
   ALCAIDE M, 2009, HEREDITY, V102, P90
   Alcaide M, 2008, MOL ECOL, V17, P2652, DOI 10.1111/j.1365-294X.2008.03791.x
   Alcaide M, 2007, J MOL EVOL, V65, P541, DOI 10.1007/s00239-007-9033-9
   Alcaide M, 2009, CONSERV GENET, V10, P1349, DOI 10.1007/s10592-008-9653-7
   Alcaide M, 2009, J ANIM ECOL, V78, P468, DOI 10.1111/j.1365-2656.2008.01493.x
   Aranaz A, 1997, SEMIN AVIAN EXOT PET, V6, P9, DOI 10.1016/S1055-937X(97)80036-9
   BEADELL JS, 2007, PLOS ONE, V9, pE896
   Bize P, 2004, J ANIM ECOL, V73, P1080, DOI 10.1111/j.0021-8790.2004.00880.x
   Blais J., 2007, PLOS ONE, V8, P1
   Blanco G, 2001, J AVIAN BIOL, V32, P271, DOI 10.1111/j.0908-8857.2001.320310.x
   Blanco G, 2007, ENVIRON MICROBIOL, V9, P1738, DOI 10.1111/j.1462-2920.2007.01291.x
   Bonneaud C, 2006, EVOLUTION, V60, P383, DOI 10.1554/05-409.1
   Bonneaud C, 2006, P R SOC B, V273, P1111, DOI 10.1098/rspb.2005.3325
   Cardoso M, 2005, VIRUS GENES, V30, P371, DOI 10.1007/s11262-005-6781-8
   CARRETE M, 2008, ECOL APPL, V19, P840
   Clarke A, 2006, P ROY SOC B-BIOL SCI, V273, P2257, DOI 10.1098/rspb.2006.3545
   Clifford DL, 2006, BIOL CONSERV, V131, P230, DOI 10.1016/j.biocon.2006.04.029
   CLYDE VL, 2001, MANUAL AVIAN MED SUR, P424
   Cosgrove CL, 2006, J PARASITOL, V92, P1362, DOI 10.1645/GE-879R.1
   Crowl TA, 2008, FRONT ECOL ENVIRON, V6, P238, DOI 10.1890/070151
   Daszak P, 2000, SCIENCE, V287, P443, DOI 10.1126/science.287.5452.443
   de Bellocq JG, 2008, J EVOLUTION BIOL, V21, P1144, DOI 10.1111/j.1420-9101.2008.01538.x
   Dionne M, 2007, EVOLUTION, V61, P2154, DOI 10.1111/j.1558-5646.2007.00178.x
   Dobson Andrew P., 1997, P155
   Ekblom R, 2004, MOL ECOL, V13, P3821, DOI 10.1111/j.1365-294X.2004.02361.x
   Ekblom R, 2007, MOL ECOL, V16, P1439, DOI 10.1111/j.1365-294X.2007.03281.x
   Farkas T, 2007, ZOONOSES PUBLIC HLTH, V54, P38, DOI 10.1111/j.1863-2378.2007.01005.x
   Fish KN, 1996, J VIROL, V70, P1855
   Forbes NA, 2005, VET REC, V156, P134, DOI 10.1136/vr.156.5.134
   Forero MG, 1996, BIOL CONSERV, V78, P289, DOI 10.1016/S0006-3207(96)00011-0
   FRIEND M, 1999, FIELD MANUAL WILDLIF
   Grabensteiner E, 2006, VET PARASITOL, V142, P223, DOI 10.1016/j.vetpar.2006.07.011
   Greiner Ellis C., 1994, P1007
   Groombridge JJ, 2002, MOL PHYLOGENET EVOL, V25, P267, DOI 10.1016/S1055-7903(02)00254-3
   Gutierrez-Espeleta GA, 2001, HEREDITY, V86, P439, DOI 10.1046/j.1365-2540.2001.00853.x
   Hall T. A., 1997, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Hambuch TM, 2002, EVOLUTION, V56, P841
   Hansson B, 2005, ANIM CONSERV, V8, P83, DOI 10.1017/S1367943004001878
   Hellgren O, 2004, J PARASITOL, V90, P797, DOI 10.1645/GE-184R1
   HOFLE U, 2007, VET MICROBIOL, V129, P171
   HOLMES AR, 1994, J CLIN MICROBIOL, V32, P228
   Hsu CM, 2006, AVIAN DIS, V50, P348, DOI 10.1637/7485-121105R.1
   Hubalek Z, 2004, J WILDLIFE DIS, V40, P639, DOI 10.7589/0090-3558-40.4.639
   HUGHES AL, 1992, NATURE, V355, P402, DOI 10.1038/355402b0
   Jarvi SI, 2004, MOL ECOL, V13, P2157, DOI 10.1111/j.1365-294X.2004.02228.x
   Johnston SP, 2006, J CLIN MICROBIOL, V44, P1087, DOI 10.1128/JCM.44.3.1087-1089.2006
   Jovani R, 2006, TRENDS PARASITOL, V22, P214, DOI 10.1016/j.pt.2006.02.011
   KHAN AA, 1994, APPL ENVIRON MICROB, V60, P3739
   Kiss I, 2006, ACTA VET HUNG, V54, P525, DOI 10.1556/AVet.54.2006.4.10
   Klein J., 1986, NATURAL HIST MAJOR H
   Korpimaki E, 1996, ANIM BEHAV, V51, P945, DOI 10.1006/anbe.1996.0098
   Loiseau C, 2008, ECOL LETT, V11, P258, DOI 10.1111/j.1461-0248.2007.01141.x
   Lopez G, 2008, VECTOR-BORNE ZOONOT, V8, P615, DOI 10.1089/vbz.2007.0200
   Lumeij J. T, 2000, RAPTOR BIOMEDICINE, VIII
   Malkinson M, 2002, CURR TOP MICROBIOL, V267, P309
   Matson KD, 2006, P ROY SOC B-BIOL SCI, V273, P2267, DOI 10.1098/rspb.2006.3590
   McCoy KD, 2005, MOL ECOL, V14, P2825, DOI 10.1111/j.1365-294X.2005.02631.x
   Mekkes DR, 2005, AVIAN PATHOL, V34, P348, DOI 10.1080/03079450500179954
   MEULMAN JJ, 2004, HDB QUANTITATIVE MET, P49, DOI DOI 10.4135/9781412986311
   Moller AP, 1996, EVOLUTION, V50, P2066, DOI 10.1111/j.1558-5646.1996.tb03592.x
   Moller AP, 1998, EVOL ECOL, V12, P945, DOI 10.1023/A:1006516222343
   Munster VJ, 2007, PLOS PATHOG, V3, P630, DOI 10.1371/journal.ppat.0030061
   Nguyen L, 2005, TRENDS CELL BIOL, V15, P269, DOI 10.1016/j.tcb.2005.03.009
   Olsen B, 2006, SCIENCE, V312, P384, DOI 10.1126/science.1122438
   Owen JP, 2008, IMMUNOGENETICS, V60, P621, DOI 10.1007/s00251-008-0314-2
   Petersen L, 2001, J APPL MICROBIOL, V91, P217, DOI 10.1046/j.1365-2672.2001.01383.x
   Piertney SB, 2006, HEREDITY, V96, P7, DOI 10.1038/sj.hdy.6800724
   Potti J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001276
   Prugnolle F, 2005, CURR BIOL, V15, P1022, DOI 10.1016/j.cub.2005.04.050
   Richardson DS, 2005, P ROY SOC B-BIOL SCI, V272, P759, DOI 10.1098/rspb.2004.3028
   Richardson DS, 2003, MOL ECOL, V12, P3523, DOI 10.1046/j.1365-294X.2003.02005.x
   Robinson J, 2003, NUCLEIC ACIDS RES, V31, P311, DOI 10.1093/nar/GKG070
   Rodi DJ, 2004, BIOINFORMATICS, V20, P3481, DOI 10.1093/bioinformatics/bth432
   Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359
   Saxena MK, 2006, VET RES COMMUN, V30, P851, DOI 10.1007/s11259-006-3321-5
   Schrenzel M, 2007, J VET DIAGN INVEST, V19, P479, DOI 10.1177/104063870701900504
   Simmons K, 1980, BIRDS W PALEARCTIC, V2
   Skarstein F, 2005, BEHAV ECOL SOCIOBIOL, V57, P374, DOI 10.1007/s00265-004-0860-z
   Smith KF, 2006, CONSERV BIOL, V20, P1349, DOI 10.1111/j.1523-1739.2006.00524.x
   Sommer Simone, 2005, Frontiers in Zoology, V2, P1, DOI 10.1186/1742-9994-2-16
   Stone EG, 2005, J ZOO WILDLIFE MED, V36, P245, DOI 10.1638/04-026.1
   Tadese T, 2003, J VET DIAGN INVEST, V15, P141, DOI 10.1177/104063870301500208
   Tella JL, 1997, BEHAV ECOL SOCIOBIOL, V40, P253, DOI 10.1007/s002650050340
   Tella JL, 2002, P ROY SOC B-BIOL SCI, V269, P1059, DOI 10.1098/rspb.2001.1951
   Tella JL, 2002, J EVOLUTION BIOL, V15, P32, DOI 10.1046/j.1420-9101.2002.00375.x
   Tella JL, 1996, AUK, V113, P253
   Tella JL, 1999, P NATL ACAD SCI USA, V96, P1785, DOI 10.1073/pnas.96.4.1785
   Tella JL, 2008, FRONT ECOL ENVIRON, V6, P11, DOI 10.1890/1540-9295(2008)6[11:BTROPI]2.0.CO;2
   Toro H, 2005, AVIAN DIS, V49, P92, DOI 10.1637/7268-083104R1
   Turcsanyi I, 2005, VET REC, V157, P235, DOI 10.1136/vr.157.8.235
   Valkiunas G, 2006, J PARASITOL, V92, P418, DOI 10.1645/GE-3547RN.1
   VANRIPER C, 1986, ECOL MONOGR, V56, P327, DOI 10.2307/1942550
   Visscher PM, 2001, NATURE, V409, P303, DOI 10.1038/35053160
   WAKELAND EK, 1990, IMMUNOL RES, V9, P115, DOI 10.1007/BF02918202
   Wikelski M, 2004, ECOL SOC, V9
   Zhang Y, 2006, ARCH VIROL, V151, P1525, DOI 10.1007/s00705-006-0731-1
NR 99
TC 47
Z9 48
U1 6
U2 45
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0962-1083
J9 MOL ECOL
JI Mol. Ecol.
PD FEB
PY 2010
VL 19
IS 4
BP 691
EP 705
DI 10.1111/j.1365-294X.2009.04507.x
PG 15
WC Biochemistry & Molecular Biology; Ecology; Evolutionary Biology
SC Biochemistry & Molecular Biology; Environmental Sciences & Ecology;
   Evolutionary Biology
GA 548IG
UT WOS:000273953400007
PM 20074317
DA 2018-12-27
ER

PT J
AU Dutta, T
   Jain, NK
   McMillan, NAJ
   Parekh, HS
AF Dutta, Tathagata
   Jain, Narendra K.
   McMillan, Nigel A. J.
   Parekh, Harendra S.
TI RETRACTED: Dendrimer nanocarriers as versatile vectors in gene delivery
   (Retracted Article. See vol 6, pg 815, 2010)
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Review; Retracted Publication
DE Dendrimer; Dendriplex; Gene delivery; Nonviral vectors
ID POLY PROPYLENEIMINE DENDRIMER; MURINE CARDIAC TRANSPLANTS; IN-VITRO;
   POLYAMIDOAMINE DENDRIMERS; POLY(PROPYLENEIMINE) DENDRIMERS; DNA
   DELIVERY; STARBURST DENDRIMERS; CATIONIC LIPOSOMES; PLASMID DNA;
   COMPLEXES
AB The successful delivery of nucleic acids to particular target sites is the challenge that is being addressed using a variety of viral and nonviral delivery systems, both of which have distinct advantages and disadvantages. Nonviral vectors offer the advantage of safety and flexibility over viral vectors, although they lack efficiency. Dendrimers are novel, three-dimensional polymers that have the ability to interact with various forms of nucleic acids such as plasmid DNA, antisense oligonucleotides, and RNA to form complexes that protect the nucleic acid from degradation. The interaction between the dendrimers and the nucleic acids is purely electrostatic where the cationic dendrimer condenses the anionic nucleic acids. Because cell membranes are negatively charged, the net positive charge of the dendrimer nucleic acid complex determines the transfection efficiency, although highly cationic systems are also cytotoxic. The nature of the dendrimer nucleic acid complex depends on various factors like stoichiometry, concentration of dendrimer-amines and nucleic acid-phosphates, as well as bulk solvent properties like pH, salt concentration, buffer strength, and dynamics of mixing. This article aims to review the role of dendrimers as novel gene delivery vectors both in vitro and in vivo. Dendrimer-based transfection reagents have become routine tools for in vitro transfection, but in vivo delivery of therapeutic nucleic acids remains a challenge.
   From the Clinical Editor: This review discusses the role of dendrimers as novel gene delivery vectors both in vitro and in vivo. Dendrimer based transfection reagents have become routine tools for in vitro transfection but in vivo delivery of therapeutic nucleic acids remains a challenge. (C) 2010 Published by Elsevier Inc.
C1 [Dutta, Tathagata; Parekh, Harendra S.] Univ Queensland, Sch Pharm, St Lucia, Qld, Australia.
   [Jain, Narendra K.] Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Sagar, India.
   [Dutta, Tathagata; McMillan, Nigel A. J.] Univ Queensland, Princess Alexandra Hosp, Diamantina Inst Canc Immunol & Metab Med, Brisbane, Qld 4072, Australia.
RP Parekh, HS (reprint author), Univ Queensland, Sch Pharm, St Lucia, Qld, Australia.
EM h.parekh@pharmacy.uq.edu.au
RI Parekh, Harendra/D-6846-2011
OI Parekh, Harendra/0000-0001-8792-4318; McMillan,
   Nigel/0000-0002-9471-1406
FU National Health and Medical Research Council of Australia
FX This work was supported by the National Health and Medical Research
   Council of Australia.
CR Agashe HB, 2006, J PHARM PHARMACOL, V58, P1491, DOI 10.1211/jpp.58.11.0010
   Behr JP, 1997, CHIMIA, V51, P34
   BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P382, DOI 10.1021/bc00029a002
   Bielinska A, 1996, NUCLEIC ACIDS RES, V24, P2176, DOI 10.1093/nar/24.11.2176
   Bielinska AU, 1997, BBA-GENE STRUCT EXPR, V1353, P180, DOI 10.1016/S0167-4781(97)00069-9
   Boris D, 1996, MACROMOLECULES, V29, P7251, DOI 10.1021/ma960397k
   Bosman AW, 1999, CHEM REV, V99, P1665, DOI 10.1021/cr970069y
   BRIGHAM KL, 1989, AM J MED SCI, V298, P278, DOI 10.1097/00000441-198910000-00013
   CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X
   CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39
   Chai MH, 2001, J AM CHEM SOC, V123, P4670, DOI 10.1021/ja002824m
   DeLong R, 1997, J PHARM SCI, V86, P762, DOI 10.1021/js960409f
   Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019
   Dutta T, 2008, NANOTOXICOLOGY, V2, P62, DOI 10.1080/17435390802105167
   Dutta T, 2008, VACCINE, V26, P3389, DOI 10.1016/j.vaccine.2008.04.058
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2006, J EXP NANOSCI, V1, P235, DOI 10.1080/17458080600647146
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Duxbury MS, 2003, BIOCHEM BIOPH RES CO, V311, P786, DOI 10.1016/j.bbrc.2003.10.060
   Finsinger D, 2000, GENE THER, V7, P1183, DOI 10.1038/sj.gt.3301227
   Gebhart CL, 2001, J CONTROL RELEASE, V73, P401, DOI 10.1016/S0168-3659(01)00357-1
   Gilmore Ian R., 2006, Current Drug Delivery, V3, P147, DOI 10.2174/156720106776359159
   Godbey WT, 1999, P NATL ACAD SCI USA, V96, P5177, DOI 10.1073/pnas.96.9.5177
   Goula D, 1998, GENE THER, V5, P1291, DOI 10.1038/sj.gt.3300717
   Goula D, 1998, GENE THER, V5, P712, DOI 10.1038/sj.gt.3300635
   Greelish JP, 1999, NAT MED, V5, P439
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   Huang YZ, 2003, J BIOL CHEM, V278, P1108, DOI 10.1074/jbc.M205413200
   Jaaskelainen I, 2000, EUR J PHARM SCI, V10, P187, DOI 10.1016/S0928-0987(00)00068-3
   Johnson PG, 1998, J INVEST DERMATOL, V111, P457, DOI 10.1046/j.1523-1747.1998.00301.x
   Jones JW, 2003, J ORG CHEM, V68, P2385, DOI 10.1021/jo0265784
   Kabanov VA, 1999, MACROMOLECULES, V32, P1904, DOI 10.1021/ma9716443
   Kabanov VA, 2000, MACROMOLECULES, V33, P9587, DOI 10.1021/ma000674u
   Kao GY, 1996, CANCER GENE THER, V3, P250
   Kihara F, 2003, BIOCONJUGATE CHEM, V14, P342, DOI 10.1021/bc025613a
   Kim T, 2004, BIOMACROMOLECULES, V5, P2487, DOI 10.1021/bm049563j
   KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0
   Kukowska-Latallo JF, 2000, HUM GENE THER, V11, P1385, DOI 10.1089/10430340050057468
   Ledley FD, 1996, PHARM RES-DORDR, V13, P1595, DOI 10.1023/A:1016420102549
   Li S, 1999, GENE THER, V6, P585, DOI 10.1038/sj.gt.3300865
   Li S, 1999, AM J PHYSIOL-LUNG C, V276, pL796, DOI 10.1152/ajplung.1999.276.5.L796
   Li S, 1998, GENE THER, V5, P930, DOI 10.1038/sj.gt.3300683
   Liu Y, 1997, NAT BIOTECHNOL, V15, P167, DOI 10.1038/nbt0297-167
   Maksimenko AV, 2003, J GENE MED, V5, P61, DOI 10.1002/jgm.319
   Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168-3659(99)00246-1
   Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
   Manunta M, 2004, NUCLEIC ACIDS RES, V32, P2730, DOI 10.1093/nar/gkh595
   Manunta M, 2006, J IMMUNOL METHODS, V314, P134, DOI 10.1016/j.jim.2006.06.007
   Marano RJ, 2004, EXP EYE RES, V79, P525, DOI 10.1016/j.exer.2004.06.023
   Maruyama-Tabata H, 2000, GENE THER, V7, P53, DOI 10.1038/sj.gt.3301044
   MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530
   NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307
   Nakanishi H, 2003, GENE THER, V10, P434, DOI 10.1038/sj.gt.3301912
   NISHIDA K, 1992, INT J PHARM, V80, P101, DOI 10.1016/0378-5173(92)90267-6
   Nishikawa M, 1996, ADV DRUG DELIVER REV, V21, P135, DOI 10.1016/S0169-409X(96)00403-6
   Nishikawa M, 2001, HUM GENE THER, V12, P861, DOI 10.1089/104303401750195836
   Norkin LC, 2001, EXP CELL RES, V266, P229, DOI 10.1006/excr.2001.5202
   ONO T, 1990, NEUROSCI LETT, V117, P259, DOI 10.1016/0304-3940(90)90673-W
   Parekh HS, 2007, CURR PHARM DESIGN, V13, P2837, DOI 10.2174/138161207781757024
   Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539
   PLAUTZ GE, 1993, P NATL ACAD SCI USA, V90, P4645, DOI 10.1073/pnas.90.10.4645
   Qin LH, 1998, HUM GENE THER, V9, P553, DOI 10.1089/hum.1998.9.4-553
   Rainov NG, 1999, HUM GENE THER, V10, P311, DOI 10.1089/10430349950019093
   RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519
   Rietveld IB, 2001, MACROMOLECULES, V34, P8380, DOI 10.1021/ma010363z
   Roberts JC, 1996, J BIOMED MATER RES, V30, P53, DOI 10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q
   Ruponen M, 2003, J CONTROL RELEASE, V93, P213, DOI 10.1016/j.jconrel.2003.08.004
   SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10670, DOI 10.1021/bi00499a014
   Sato N, 2001, CLIN CANCER RES, V7, P3606
   Shakthivel T, 2003, DRUG DELIV TECHNOL, V3, P73
   Silvius JR, 2003, BBA-BIOMEMBRANES, V1610, P174, DOI 10.1016/S0005-2736(03)00016-6
   Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200
   Takakura Y, 1996, PHARMACEUT RES, V13, P820, DOI 10.1023/A:1016084508097
   Tang MX, 1997, GENE THER, V4, P823, DOI 10.1038/sj.gt.3300454
   Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630
   Tomalia DA, 2004, ALDRICHIM ACTA, V37, P39
   Tousignant JD, 2000, HUM GENE THER, V11, P2493, DOI 10.1089/10430340050207984
   TRIPATHI PK, 2001, INDIAN J PHARM SCI, V65, P15
   Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117
   Turunen MP, 1999, GENE THER, V6, P6, DOI 10.1038/sj.gt.3300800
   Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563
   Vincent L, 2003, INT J CANCER, V105, P419, DOI 10.1002/ijc.11105
   Wang YN, 2001, AM J TRANSPLANT, V1, P334, DOI 10.1034/j.1600-6143.2001.10408.x
   Wang YO, 2000, MOL THER, V2, P602, DOI 10.1006/mthe.2000.0201
   Wilbur DS, 1998, BIOCONJUGATE CHEM, V9, P813, DOI 10.1021/bc980055e
   Yang JP, 1997, GENE THER, V4, P950, DOI 10.1038/sj.gt.3300485
   ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997
   ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3
   ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073
NR 90
TC 80
Z9 82
U1 2
U2 49
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD FEB
PY 2010
VL 6
IS 1
BP 25
EP 34
DI 10.1016/j.nano.2009.05.005
PG 10
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 552NN
UT WOS:000274299000003
PM 19450708
DA 2018-12-27
ER

PT J
AU Liu, XB
   Leung, S
   Wang, CX
   Tan, Z
   Wang, J
   Guo, TB
   Fang, L
   Zhao, YG
   Wan, B
   Qin, X
   Lu, LM
   Li, RS
   Pan, H
   Song, MJ
   Liu, AL
   Hong, J
   Lu, HT
   Zhang, JZ
AF Liu, Xuebin
   Leung, Stewart
   Wang, Chunxia
   Tan, Zhu
   Wang, Ji
   Guo, Taylor B.
   Fang, Lei
   Zhao, Yonggang
   Wan, Bing
   Qin, Xia
   Lu, Limin
   Li, Runsheng
   Pan, Heng
   Song, Mingjuan
   Liu, Ailian
   Hong, Jian
   Lu, Hongtao
   Zhang, Jingwu Z.
TI RETRACTED: Crucial role of interleukin-7 in T helper type 17 survival
   and expansion in autoimmune disease (Retracted article. See vol. 19, pg.
   1673, 2013)
SO NATURE MEDICINE
LA English
DT Article; Retracted Publication
ID CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA EXPRESSION; MULTIPLE-SCLEROSIS;
   T(H)17 CELLS; FAMILY CYTOKINES; DEFICIENT MICE; TH17 CELLS; TGF-BETA;
   RECEPTOR; ENCEPHALOMYELITIS
AB Interleukin-7 receptor (IL-7R) is genetically associated with susceptibility to multiple sclerosis. Here we describe that IL-7 is essential for survival and expansion of pathogenic T helper type 17 (T(H)17) cells in experimental autoimmune encephalomyelitis (EAE). IL-7 directly expanded effector T(H)17 cells in EAE and human T(H)17 cells from subjects with multiple sclerosis, whereas it was not required for T(H)17 differentiation. IL-7R antagonism rendered differentiated T(H)17 cells susceptible to apoptosis through the inhibition of Janus kinase-signal transducer and activator of transcription-5 (JAK-STAT5) pathway and altered expression of the prosurvival protein Bcl-2 and the proapoptotic protein Bax, leading to decreased severity of EAE. In contrast, T(H)1 and regulatory T (T-reg) cells were less susceptible to or not affected by IL-7R antagonism in vivo. The selectivity was attributable to minimal expression of IL-7R alpha in T-reg cells and correlated with a high level of Socs1 (encoding suppressor of cytokine signaling-1) expression in T(H)1 cells. The study reveals a unique, previously undescribed role of IL-7-IL-7R in T(H)17 cell survival and expansion and has implications in the treatment of autoimmune disease.
C1 [Liu, Xuebin; Leung, Stewart; Wang, Chunxia; Tan, Zhu; Wang, Ji; Guo, Taylor B.; Fang, Lei; Zhao, Yonggang; Wan, Bing; Qin, Xia; Lu, Limin; Li, Runsheng; Pan, Heng; Song, Mingjuan; Liu, Ailian; Lu, Hongtao; Zhang, Jingwu Z.] GlaxoSmithKline, Ctr Res & Dev, Dept Neuroimmunol, Shanghai, Peoples R China.
   [Hong, Jian] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
RP Zhang, JZ (reprint author), GlaxoSmithKline, Ctr Res & Dev, Dept Neuroimmunol, Shanghai, Peoples R China.
EM jingwu.z.zang@gsk.com
CR Akirav EM, 2009, J NEUROSCI RES, V87, P3511, DOI 10.1002/jnr.21981
   Amadi-Obi A, 2007, NAT MED, V13, P711, DOI 10.1038/nm1585
   Bettelli E, 2007, ANN NY ACAD SCI, V1103, P11, DOI 10.1196/annals.1394.021
   Betti M, 2006, ANN ONCOL, V17, P235
   Bielekova B, 1999, J NEUROIMMUNOL, V100, P115, DOI 10.1016/S0165-5728(99)00200-3
   Chen Y, 2006, J CLIN INVEST, V116, P1317, DOI 10.1172/JCI25308
   Cho ML, 2006, J IMMUNOL, V176, P5652, DOI 10.4049/jimmunol.176.9.5652
   Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355
   Egwuagu CE, 2009, CYTOKINE, V47, P149, DOI 10.1016/j.cyto.2009.07.003
   Elder JT, 2007, J INVEST DERMATOL, V127, P2495, DOI 10.1038/sj.jid.5700855
   Fry TJ, 2005, J IMMUNOL, V174, P6571, DOI 10.4049/jimmunol.174.11.6571
   Gregory SG, 2007, NAT GENET, V39, P1083, DOI 10.1038/ng2103
   Hafler DA, 2007, NEW ENGL J MED, V357, P851, DOI 10.1056/NEJMoa073493
   Isaksen DE, 2002, J IMMUNOL, V168, P3288, DOI 10.4049/jimmunol.168.7.3288
   ISSAZADEH S, 1995, J NEUROSCI RES, V40, P579, DOI 10.1002/jnr.490400503
   Jiang Q, 2005, CYTOKINE GROWTH F R, V16, P513, DOI 10.1016/j.cytogfr.2005.05.004
   Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566
   Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Kumar M, 2006, J NEUROIMMUNOL, V180, P178, DOI 10.1016/j.jneuroim.2006.08.003
   Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257
   Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009
   Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772
   Liu XB, 2008, J IMMUNOL, V180, P6070, DOI 10.4049/jimmunol.180.9.6070
   Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500
   Lu N, 2009, J EXP MED, V206, P2111, DOI 10.1084/jem.20090153
   Lundmark F, 2007, NAT GENET, V39, P1108, DOI 10.1038/ng2106
   Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1191/135245899678847275
   McFarland HF, 2007, NAT IMMUNOL, V8, P913, DOI 10.1038/ni1507
   McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698
   McGeachy MJ, 2005, J IMMUNOL, V175, P3025, DOI 10.4049/jimmunol.175.5.3025
   Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449
   O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8
   Palmer MJ, 2008, CELL MOL IMMUNOL, V5, P79, DOI 10.1038/cmi.2008.10
   Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261
   PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955
   Rochman Y, 2009, NAT REV IMMUNOL, V9, P480, DOI 10.1038/nri2580
   Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122
   Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468
   Seddon B, 2003, NAT IMMUNOL, V4, P680, DOI 10.1038/ni946
   Seki Y, 2007, J IMMUNOL, V178, P262, DOI 10.4049/jimmunol.178.1.262
   Serada S, 2008, P NATL ACAD SCI USA, V105, P9041, DOI 10.1073/pnas.0802218105
   Sospedra M, 2005, ANNU REV IMMUNOL, V23, P683, DOI 10.1146/annurev.immunol.23.021704.115707
   Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551
   Stritesky GL, 2008, J IMMUNOL, V181, P5948, DOI 10.4049/jimmunol.181.9.5948
   Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001
   Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098
   Tzartos JS, 2008, AM J PATHOL, V172, P146, DOI 10.2353/ajpath.2008.070690
   Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001
   Veldhoen M, 2009, J EXP MED, V206, P43, DOI 10.1084/jem.20081438
   Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579
   VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519
   Wang ZJ, 2006, J CLIN INVEST, V116, P2434, DOI 10.1172/JCI25826
   Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557
   Weiner HL, 2008, J NEUROL, V255, P3, DOI 10.1007/s00415-008-1002-8
   Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021
NR 56
TC 96
Z9 107
U1 3
U2 33
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD FEB
PY 2010
VL 16
IS 2
BP 191
EP U97
DI 10.1038/nm.2077
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 552MZ
UT WOS:000274297000040
PM 20062065
DA 2018-12-27
ER

PT J
AU Liu, SJ
   Chen, J
AF Liu, S. J.
   Chen, J.
TI RETRACTED: Fracture of thin-walled structure with SPH shell formulation
   (Retracted article. See vol. 49, pg. 795, 2011)
SO THIN-WALLED STRUCTURES
LA English
DT Article; Retracted Publication
DE SPH; Shell; Mechanics; Fracture; Thin-walled structure
ID SMOOTHED PARTICLE HYDRODYNAMICS; ARBITRARY EVOLVING CRACKS; CONFORMING
   NODAL INTEGRATION; FREE GALERKIN METHODS; MESHFREE METHODS;
   FINITE-ELEMENT; LARGE-DEFORMATION; DYNAMIC FRACTURE; MESHLESS METHODS;
   COHESIVE CRACKS
AB A meshless shell method for dynamic fracture problems based on normalized smoothed particle hydrodynamics (SPH) is presented. The SPH method is corrected by a normalization in order to fulfill completeness requirement. Instabilities are controlled by stress-point integration. The method is modified for Mindlin-Reissner shell analysis. Stress based fracture criterion is incorporated based on the visibility method. The method is applied to two dynamic fracture problems. Results are very promising. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Liu, S. J.; Chen, J.] Beijing Univ Technol, Dept Mech Engn, Beijing, Peoples R China.
RP Liu, SJ (reprint author), Beijing Univ Technol, Dept Mech Engn, Beijing, Peoples R China.
EM sajaliu@hotmail.com
CR Areias PMA, 2006, COMPUT METHOD APPL M, V195, P5343, DOI 10.1016/j.cma.2005.10.024
   BELYTSCHKO T, 1995, ENG FRACT MECH, V51, P295, DOI 10.1016/0013-7944(94)00153-9
   Belytschko T, 1996, INT J NUMER METH ENG, V39, P923, DOI 10.1002/(SICI)1097-0207(19960330)39:6<923::AID-NME887>3.3.CO;2-N
   Belytschko T, 1996, COMPUT METHOD APPL M, V139, P3, DOI 10.1016/S0045-7825(96)01078-X
   Bonet J, 2000, INT J NUMER METH ENG, V47, P1189, DOI 10.1002/(SICI)1097-0207(20000228)47:6<1189::AID-NME830>3.0.CO;2-I
   Campbell J, 2000, COMPUT METHOD APPL M, V184, P49, DOI 10.1016/S0045-7825(99)00442-9
   CHAO TW, 2004, THESIS CALTECH
   Chen JS, 2001, INT J NUMER METH ENG, V50, P435, DOI 10.1002/1097-0207(20010120)50:2<435::AID-NME32>3.0.CO;2-A
   Feldman J, 2007, INT J NUMER METH ENG, V72, P295, DOI 10.1002/nme.2010
   GINGOLD RA, 1977, MON NOT R ASTRON SOC, V181, P375, DOI 10.1093/mnras/181.3.375
   Hao S, 2004, INT J SOLIDS STRUCT, V41, P1773, DOI 10.1016/j.ijsolstr.2003.10.025
   Hao S, 2000, J APPL MECH-T ASME, V67, P803, DOI 10.1115/1.1325413
   Hao S, 2000, COMPUT METHOD APPL M, V187, P401, DOI 10.1016/S0045-7825(00)80003-1
   Hao S, 2006, COMPUT METHOD APPL M, V195, P6059, DOI 10.1016/j.cma.2005.10.030
   ILYUSHIN AA, 1956, PLASTICITE
   Javidruzi M, 2004, THIN WALL STRUCT, V42, P79, DOI 10.1016/S0263-8231(03)00125-3
   JOHNSON GR, 1996, COMPUTER METHODS APP, V39, P2127
   Khayyer A, 2008, COAST ENG, V55, P236, DOI 10.1016/j.coastateng.2007.10.001
   Krongauz Y, 1997, COMPUT METHOD APPL M, V146, P371, DOI 10.1016/S0045-7825(96)01234-0
   Krysl P, 1996, INT J SOLIDS STRUCT, V33, P3057, DOI 10.1016/0020-7683(95)00265-0
   LEITAO VMA, 2001, INT J NUMERICAL METH, V52, P1130
   Li S, 2000, COMPUT MECH, V25, P102, DOI 10.1007/s004660050463
   LIEW KM, 2004, INT J NUMERICAL METH, V60, P1877
   Liu WK, 1999, COMP MATER SCI, V16, P197, DOI 10.1016/S0927-0256(99)00062-2
   LIU WK, 1995, INT J NUMER METH FL, V20, P1081, DOI 10.1002/fld.1650200824
   MuscatFenech CM, 1997, INT J FRACTURE, V84, P297, DOI 10.1023/A:1007325719337
   Noguchi H, 2000, INT J NUMER METH ENG, V47, P1215, DOI 10.1002/(SICI)1097-0207(20000228)47:6<1215::AID-NME834>3.0.CO;2-M
   Osman MH, 1999, THIN WALL STRUCT, V35, P81, DOI 10.1016/S0263-8231(99)00025-7
   Rabczuk T, 2007, INT J NUMER METH ENG, V72, P524, DOI 10.1002/nme.2013
   Rabczuk T, 2007, COMPUT METHOD APPL M, V196, P2777, DOI 10.1016/j.cma.2006.06.020
   Rabczuk T, 2007, INT J NUMER METH ENG, V69, P993, DOI 10.1002/nme.1797
   Rabczuk T, 2006, INT J FRACTURE, V137, P19, DOI 10.1007/s10704-005-3075-z
   Rabczuk T, 2005, INT J NUMER METH ENG, V63, P1559, DOI 10.1002/nme.1326
   Rabczuk T, 2004, INT J NUMER METH ENG, V61, P2316, DOI 10.1002/nme.1151
   Rabczuk T, 2004, COMPUT METHOD APPL M, V193, P1035, DOI 10.1016/j.cma.2003.12.005
   Rabczuk T, 2003, INT J NUMER METH ENG, V56, P1421, DOI 10.1002/nme.617
   Rabczuk T, 2007, COMPUT MECH, V39, P743, DOI 10.1007/s00466-006-0067-4
   Rabczuk T, 2006, CMES-COMP MODEL ENG, V16, P115
   Randles P. W., 1997, INT J IMPACT ENG, V20, P525
   Randles PW, 2000, INT J NUMER METH ENG, V48, P1445, DOI 10.1002/1097-0207(20000810)48:10<1445::AID-NME831>3.0.CO;2-9
   Rodriguez-Paz M, 2005, COMPUT STRUCT, V83, P1396, DOI 10.1016/j.compstruc.2004.11.025
   SWEGLE JW, 1995, J COMPUT PHYS, V116, P123, DOI 10.1006/jcph.1995.1010
   Vafai A, 1999, THIN WALL STRUCT, V33, P211, DOI 10.1016/S0263-8231(98)00042-1
   Vaziri A, 2006, THIN WALL STRUCT, V44, P141, DOI 10.1016/j.tws.2006.02.004
   Vignjevic R, 2006, CMES-COMP MODEL ENG, V13, P35
   Vignjevic R, 2000, COMPUT METHOD APPL M, V184, P67, DOI 10.1016/S0045-7825(99)00441-7
   Vignjevic R, 2001, CMES-COMP MODEL ENG, V2, P319
   Vignjevic R, 1999, INT J IMPACT ENG, V23, P945, DOI 10.1016/S0734-743X(99)00137-2
   Vignjevic R, 2006, CMES-COMP MODEL ENG, V14, P181
   Wang DD, 2006, COMPUT MECH, V39, P83, DOI 10.1007/s00466-005-0010-0
   Zi G, 2007, COMPUT MECH, V40, P367, DOI 10.1007/s00466-006-0115-0
NR 51
TC 3
Z9 3
U1 2
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0263-8231
EI 1879-3223
J9 THIN WALL STRUCT
JI Thin-Walled Struct.
PD FEB
PY 2010
VL 48
IS 2
BP 118
EP 126
DI 10.1016/j.tws.2009.09.002
PG 9
WC Engineering, Civil
SC Engineering
GA 556LC
UT WOS:000274591500005
DA 2018-12-27
ER

PT J
AU Mayack, SR
   Shadrach, JL
   Kim, FS
   Wagers, AJ
AF Mayack, Shane R.
   Shadrach, Jennifer L.
   Kim, Francis S.
   Wagers, Amy J.
TI RETRACTED: Systemic signals regulate ageing and rejuvenation of blood
   stem cell niches (Retracted article. See vol. 467, pg. 872, 2010)
SO NATURE
LA English
DT Article; Retracted Publication
ID HEMATOPOIETIC-STEM; IGF-I; PROGENITOR CELLS; SKELETAL-MUSCLE; GROWTH;
   OSTEOBLASTS; PATHWAYS; BONE; IDENTIFICATION; REGENERATION
AB Ageing in multicellular organisms typically involves a progressive decline in cell replacement and repair processes, resulting in several physiological deficiencies, including inefficient muscle repair, reduced bone mass, and dysregulation of blood formation (haematopoiesis). Although defects in tissue-resident stem cells clearly contribute to these phenotypes, it is unclear to what extent they reflect stem cell intrinsic alterations or age-related changes in the stem cell supportive microenvironment, or niche. Here, using complementary in vivo and in vitro heterochronic models, we show that age-associated changes in stem cell supportive niche cells deregulate normal haematopoiesis by causing haematopoietic stem cell dysfunction. Furthermore, we find that age-dependent defects in niche cells are systemically regulated and can be reversed by exposure to a young circulation or by neutralization of the conserved longevity regulator, insulin-like growth factor-1, in the marrow microenvironment. Together, these results show a new and critical role for local and systemic factors in signalling age-related haematopoietic decline, and highlight a new model in which blood-borne factors in aged animals act through local niche cells to induce age-dependent disruption of stem cell function.
C1 [Mayack, Shane R.; Shadrach, Jennifer L.; Kim, Francis S.; Wagers, Amy J.] Harvard Univ, Howard Hughes Med Inst, Dept Stem Cell & Regenerat Biol, Harvard Stem Cell Inst,Joslin Diabet Ctr, Boston, MA 02115 USA.
RP Wagers, AJ (reprint author), Harvard Univ, Howard Hughes Med Inst, Dept Stem Cell & Regenerat Biol, Harvard Stem Cell Inst,Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02115 USA.
EM amy.wagers@joslin.harvard.edu
FU Burroughs-Welcome Fund; WM Keck Foundation; Glenn Foundation; National
   Institutes of Health (NIH) [1 DP2 OD004345-01, T32DK07260-29]; Iacocca
   Foundation; Joslin Diabetes Center DERC [P30DK036836]
FX This work was supported in part by funding from the Burroughs-Welcome
   Fund, WM Keck Foundation, Glenn Foundation, and National Institutes of
   Health (NIH) 1 DP2 OD004345-01 (to A. J. W.), by fellowships from the
   NIH (T32DK07260-29) and the Iacocca Foundation (to S. R. M.), and by the
   Joslin Diabetes Center DERC (P30DK036836). We thank J. LaVecchio and G.
   Buruzula for expert cell sorting, C. J. Luckey for anti-IGF-1 antibody,
   and L. Zon, R. Lee, D. Rossi, L. P. Kane, S. Lowe and C. Dall'Osso for
   helpful advice and critical reading of the manuscript. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the NIH.
CR Arai F, 2005, TRENDS CARDIOVAS MED, V15, P75, DOI 10.1016/j.tcm.2005.03.002
   Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460
   Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Caspari R, 2004, P NATL ACAD SCI USA, V101, P10895, DOI 10.1073/pnas.0402857101
   Cornish J, 2004, BIOCHEM BIOPH RES CO, V318, P240, DOI 10.1016/j.bbrc.2004.04.020
   DiGirolamo DJ, 2007, J BIOL CHEM, V282, P31666, DOI 10.1074/jbc.M705219200
   Eggan K, 2006, NATURE, V441, P1109, DOI 10.1038/nature04929
   Ema H, 2006, NAT PROTOC, V1, P2979, DOI 10.1038/nprot.2006.447
   Fisher MC, 2005, BONE, V37, P741, DOI 10.1016/j.bone.2005.07.024
   Fulzele K, 2007, J BIOL CHEM, V282, P25649, DOI 10.1074/jbc.M700651200
   GIBSON LF, 1993, BLOOD, V82, P3005
   Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700
   Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159
   Jones DL, 2008, NAT REV MOL CELL BIO, V9, P11, DOI 10.1038/nrm2319
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Kuro-O M, 2008, BIOL CHEM, V389, P233, DOI 10.1515/BC.2008.028
   Liang Y, 2005, BLOOD, V106, P1479, DOI 10.1182/blood-2004-11-4282
   Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578
   Mayack SR, 2008, BLOOD, V112, P519, DOI 10.1182/blood-2008-01-133710
   Morrison SJ, 1997, DEVELOPMENT, V124, P1929
   Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011
   Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839
   Nakasaki M, 2008, BONE, V43, P869, DOI 10.1016/j.bone.2008.07.241
   Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242
   Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036
   Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862
   Rossi DJ, 2005, P NATL ACAD SCI USA, V102, P9194, DOI 10.1073/pnas.0503280102
   Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021
   Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003
   Wagers AJ, 2005, CELL, V122, P659, DOI 10.1016/j.cell.2005.08.021
   Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807
   Wang YM, 2007, J BONE MINER RES, V22, P1329, DOI 10.1359/JBMR.070517
   Welniak LA, 2004, BIOL BLOOD MARROW TR, V10, P32, DOI 10.1016/j.bbmt.2003.09.008
   Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779
   Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 37
TC 89
Z9 97
U1 3
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JAN 28
PY 2010
VL 463
IS 7280
BP 495
EP U109
DI 10.1038/nature08749
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 548QK
UT WOS:000273981100041
PM 20110993
DA 2018-12-27
ER

PT J
AU Wei, J
   Barr, J
   Kong, LY
   Wang, YT
   Wu, A
   Sharma, AK
   Gumin, J
   Henry, V
   Colman, H
   Sawaya, R
   Lang, FF
   Heimberger, AB
AF Wei, Jun
   Barr, Jason
   Kong, Ling-Yuan
   Wang, Yongtao
   Wu, Adam
   Sharma, Amit K.
   Gumin, Joy
   Henry, Verlene
   Colman, Howard
   Sawaya, Raymond
   Lang, Frederick F.
   Heimberger, Amy B.
TI RETRACTED: Glioma-Associated Cancer-Initiating Cells Induce
   Immunosuppression (Retracted article. See vol. 21, pg. 2189, 2015)
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID MESENCHYMAL STEM-CELLS; REGULATORY T-CELLS; MALIGNANT GLIOMA; POTENTIAL
   MECHANISM; EXPRESSION; GROWTH; GLIOBLASTOMA; MODULATION; APOPTOSIS;
   THERAPY
AB Purpose: Glioblastoma multiforme is a lethal cancer that responds poorly to therapy. Glioblastoma multiforme cancer-initiating cells have been shown to mediate resistance to both chemotherapy and radiation; however, it is unknown to what extent these cells contribute to the profound immunosuppression in glioblastoma multiforme patients and if strategies that alter their differentiation state can reduce this immunosuppression.
   Experimental Design: We isolated a subpopulation of cells from glioblastoma multiforme that possessed the capacity for self-renewal, formed neurospheres in vitro, were capable of pluripotent differentiation, and could initiate tumors in vivo. The immune phenotype of these cells was characterized including the elaboration of immunosuppressive cytokines and chemokines by ELISA. Functional immunosuppressive properties were characterized based on the inhibition of T-cell proliferation and effector responses, triggering of T-cell apoptosis, and induction of FoxP3(+) regulatory T cells. On altering their differentiation state, the immunosuppressive phenotype and functional assays were reevaluated.
   Results: We found that the cancer-initiating cells markedly inhibited T-cell proliferation and activation, induced regulatory T cells, and triggered T-cell apoptosis that was mediated by B7-H1 and soluble Galectin-3. These immunosuppressive properties were diminished on altering the differentiation of the cancer-initiating cells.
   Conclusion: Cancer-initiating cells contribute to tumor evasion of the immunosurveillance and approaches that alter the differentiation state may have immunotherapeutic potential. Clin Cancer Res; 16 (2); 461-73. (C) 2010 AACR.
C1 [Wei, Jun; Barr, Jason; Kong, Ling-Yuan; Wang, Yongtao; Wu, Adam; Sharma, Amit K.; Gumin, Joy; Henry, Verlene; Sawaya, Raymond; Lang, Frederick F.; Heimberger, Amy B.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA.
   [Colman, Howard] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA.
RP Heimberger, AB (reprint author), POB 301402,Unit 442, Houston, TX 77230 USA.
EM aheimber@mdanderson.org
FU Anthony Bullock III Foundation; Dr. Marnie Rose Foundation; The
   University of Texas M.D. Anderson Cancer Center; NIH [CA120813-01]
FX Anthony Bullock III Foundation, Dr. Marnie Rose Foundation, The
   University of Texas M.D. Anderson Cancer Center, and NIH grant
   CA120813-01 (A.B. Heimberger). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   article.
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007
   COLMAN H, 2008, J CLIN ONCOL, V26, pS89
   Dey M, 2006, LETT DRUG DES DISCOV, V3, P443, DOI 10.2174/157018006778194844
   Dingli D, 2006, STEM CELLS, V24, P2603, DOI 10.1634/stemcells.2006-0136
   Djouad F, 2003, BLOOD, V102, P3837, DOI 10.1182/blood-2003-04-1193
   Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
   Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155
   Fecci PE, 2006, CANCER RES, V66, P3294, DOI 10.1158/0008-5472.CAN-05-3773
   Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364
   Ghods AJ, 2007, STEM CELLS, V25, P1645, DOI 10.1634/stemcells.2006-0624
   Gomez GG, 2006, GENE THER MOL BIOL, V10A, P133
   Hegardt P, 2000, CELL IMMUNOL, V200, P116, DOI 10.1006/cimm.2000.1625
   Heimberger AB, 2003, CLIN CANCER RES, V9, P4247
   Heimberger AB, 2008, CLIN CANCER RES, V14, P5166, DOI 10.1158/1078-0432.CCR-08-0320
   HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213
   Hussain SF, 2007, CANCER RES, V67, P9630, DOI 10.1158/0008-5472.CAN-07-1243
   Hwang KC, 2008, P NATL ACAD SCI USA, V105, P7467, DOI 10.1073/pnas.0802825105
   Kang SK, 2006, STEM CELLS DEV, V15, P423, DOI 10.1089/scd.2006.15.423
   Kim R, 2004, CANCER, V100, P2281, DOI 10.1002/cncr.20270
   Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361
   Kuklinski S, 2000, J NEUROSCI RES, V60, P45, DOI 10.1002/(SICI)1097-4547(20000401)60:1<45::AID-JNR5>3.0.CO;2-Y
   KURPAD SN, 1995, GLIA, V15, P244, DOI 10.1002/glia.440150306
   Le Blanc K, 2003, EXP HEMATOL, V31, P890, DOI 10.1016/S0301-472X(03)00110-3
   LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X
   Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473
   Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67
   Majumdar MK, 2003, J BIOMED SCI, V10, P228, DOI 10.1159/000068710
   Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164
   Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517
   Peng W, 2008, CANCER RES, V68, P7228, DOI 10.1158/0008-5472.CAN-08-1245
   Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349
   Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100
   ROSZMAN T, 1991, IMMUNOL TODAY, V12, P370, DOI 10.1016/0167-5699(91)90068-5
   Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666
   Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401
   Strik HM, 2007, ONCOL REP, V18, P483
   Sun YR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005498
   Tallman MS, 1996, LEUKEMIA, V10, P1262
   TILG H, 1994, BLOOD, V83, P113
   Vogel W, 2003, HAEMATOLOGICA, V88, P126
   Wei J, 2007, P NATL ACAD SCI USA, V104, P18169, DOI 10.1073/pnas.0703642104
   Wintterle S, 2003, CANCER RES, V63, P7462
NR 44
TC 156
Z9 162
U1 2
U2 20
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JAN 15
PY 2010
VL 16
IS 2
BP 461
EP 473
DI 10.1158/1078-0432.CCR-09-1983
PG 13
WC Oncology
SC Oncology
GA 607ZE
UT WOS:000278545000012
PM 20068105
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Takamatsu, R
   Teruya, H
   Takeshima, E
   Ishikawa, C
   Matsumoto, K
   Mukaida, N
   Li, JD
   Heuner, K
   Higa, F
   Fujita, J
   Mori, N
AF Takamatsu, Reika
   Teruya, Hiromitsu
   Takeshima, Eriko
   Ishikawa, Chie
   Matsumoto, Kunihiro
   Mukaida, Naofumi
   Li, Jian-Dong
   Heuner, Klaus
   Higa, Futoshi
   Fujita, Jiro
   Mori, Naoki
TI RETRACTED: Molecular characterization of Legionella pneumophila-induced
   interleukin-8 expression in T cells (Retracted article. See vol. 11,
   artn no. 127, 2011)
SO BMC MICROBIOLOGY
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; LUNG EPITHELIAL-CELLS; MAP KINASE;
   SIGNAL-TRANSDUCTION; TNF-ALPHA; C-JUN; PATHWAY; INFECTION;
   PHOSPHORYLATION
AB Background: Legionella pneumophila is the causative agent of human Legionnaire's disease. During infection, the bacterium invades macrophages and lung epithelial cells, and replicates intracellularly. However, little is known about its interaction with T cells. We investigated the ability of L. pneumophila to infect and stimulate the production of interleukin-8 (IL-8) in T cells. The objective of this study was to assess whether L. pneumophila interferes with the immune system by interacting and infecting T cells.
   Results: Wild-type L. pneumophila and flagellin-deficient Legionella, but not L. pneumophila lacking a functional type IV secretion system Dot/Icm, replicated in T cells. On the other hand, wild-type L. pneumophila and Dot/Icm-deficient Legionella, but not flagellin-deficient Legionella or heat-killed Legionella induced IL-8 expression. L. pneumophila activated an IL-8 promoter through the NF-kappa B and AP-1 binding regions. Wild-type L. pneumophila but not flagellin-deficient Legionella activated NF-kappa B, p38 mitogen-activated protein kinase (MAPK), Jun N-terminal kinase (JNK), and transforming growth factor beta-associated kinase 1 (TAK1). Transfection of dominant negative mutants of I kappa B alpha, I kappa B kinase, NF-kappa B-inducing kinase, TAK1, MyD88, and p38 MAPK inhibited L. pneumophila-induced IL-8 activation. Inhibitors of NF-kappa B, p38 MAPK, and JNK blocked L. pneumophila-induced IL-8 expression. In addition, c-Jun, JunD, cyclic AMP response element binding protein, and activating transcription factor 1, which are substrates of p38 MAPK and JNK, bound to the AP-1 site of the IL-8 promoter.
   Conclusions: Taken together, L. pneumophila induced a flagellin-dependent activation of TAK1, p38 MAPK, and JNK, as well as NF-kappa B and AP-1, which resulted in IL-8 production in human T cells, presumably contributing to the immune response in Legionnaire's disease.
C1 [Takamatsu, Reika; Teruya, Hiromitsu; Takeshima, Eriko; Ishikawa, Chie; Mori, Naoki] Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Okinawa 9030215, Japan.
   [Teruya, Hiromitsu; Takeshima, Eriko; Higa, Futoshi; Fujita, Jiro] Univ Ryukyus, Grad Sch Med, Div Control & Prevent Infect Dis, Okinawa 9030215, Japan.
   [Ishikawa, Chie] Univ Ryukyus, Transdisciplinary Res Org Subtrop & Isl Studies, Okinawa 9030215, Japan.
   [Matsumoto, Kunihiro] Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 4648602, Japan.
   [Mukaida, Naofumi] Kanazawa Univ, Div Mol Bioregulat, Canc Res Inst, Kanazawa, Ishikawa 9200934, Japan.
   [Li, Jian-Dong] Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA.
   [Heuner, Klaus] Robert Koch Inst, Project Grp Nosocomial Infect Elderly 26, D-13353 Berlin, Germany.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
RI Mukaida, Naofumi/D-7623-2011
OI Mukaida, Naofumi/0000-0002-4193-1851
FU Japan Society for the Promotion of Science [21591211]; Ministry of
   Education, Culture, Sports, Science and Technology [20012044]; Takeda
   Science Foundation
FX We thank D. W. Ballard for providing the I kappa B alpha dominant
   negative mutant; R. Geleziunas for providing the NIK, IKK alpha, and IKK
   beta dominant negative mutants; K.-T. Jeang for providing the IKK gamma
   dominant negative mutant; and M. Muzio for providing the MyD88 dominant
   negative mutant. This study was supported in part by Grants-in-Aid for
   Scientific Research ( C) 21591211 to N.M. from Japan Society for the
   Promotion of Science; Scientific Research on Priority Areas 20012044 to
   N.M. from the Ministry of Education, Culture, Sports, Science and
   Technology; and the Takeda Science Foundation.
CR Abu-Zant A, 2007, CELL MICROBIOL, V9, P246, DOI 10.1111/j.1462-5822.2006.00785.x
   Andrews HL, 1998, INFECT IMMUN, V66, P950
   Archer KA, 2006, INFECT IMMUN, V74, P3325, DOI 10.1128/IAI.02049-05
   Bartfeld S, 2009, CELL MICROBIOL, V11, P1638, DOI 10.1111/j.1462-5822.2009.01354.x
   BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809
   Chang B, 2004, MICROB PATHOGENESIS, V37, P295, DOI 10.1016/j.micpath.2004.10.002
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1
   Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426
   Dejardin E, 2006, BIOCHEM PHARMACOL, V72, P1161, DOI 10.1016/j.bcp.2006.08.007
   Dietrich C, 2001, INFECT IMMUN, V69, P2116, DOI 10.1128/IAI.69.4.2116-2122.2001
   Edelstein PH, 1999, P NATL ACAD SCI USA, V96, P8190, DOI 10.1073/pnas.96.14.8190
   Ge JN, 2009, P NATL ACAD SCI USA, V106, P13725, DOI 10.1073/pnas.0907200106
   Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157
   Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3
   Hawn TR, 2007, J IMMUNOL, V179, P6981, DOI 10.4049/jimmunol.179.10.6981
   Hawn TR, 2006, J INFECT DIS, V193, P1693, DOI 10.1086/504525
   Iha H, 2003, ONCOGENE, V22, P8912, DOI 10.1038/sj.onc.1207058
   Im J, 2009, MOL IMMUNOL, V47, P614, DOI 10.1016/j.molimm.2009.09.004
   Joshi AD, 2001, CELL MICROBIOL, V3, P99, DOI 10.1046/j.1462-5822.2001.00093.x
   Kagan JC, 2002, NAT CELL BIOL, V4, P945, DOI 10.1038/ncb883
   Liu HY, 2006, P NATL ACAD SCI USA, V103, P7048, DOI 10.1073/pnas.0601554103
   Losick VP, 2006, J EXP MED, V203, P2177, DOI 10.1084/jem.20060766
   Matsunaga K, 2003, INFECT IMMUN, V71, P6672, DOI 10.1128/IAI.71.11.6672-6675.2003
   McHugh SL, 2000, J LEUKOCYTE BIOL, V67, P863
   Miao EA, 2007, SEMIN IMMUNOPATHOL, V29, P275, DOI 10.1007/s00281-007-0078-z
   Molofsky AB, 2005, INFECT IMMUN, V73, P5720, DOI 10.1128/IAI.73.9.5720-5734.2005
   Mori N, 1999, BLOOD, V93, P2360
   Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612
   N'Guessan PD, 2007, AM J PHYSIOL-LUNG C, V292, pL267, DOI 10.1152/ajplung.00100.2006
   Neild AL, 2004, CELL MICROBIOL, V6, P1011, DOI 10.1111/j.1462-5822.2004.00450.x
   Neild AL, 2003, IMMUNITY, V18, P813, DOI 10.1016/S1074-7613(03)00140-7
   Newton C, 2000, INFECT IMMUN, V68, P5234, DOI 10.1128/IAI.68.9.5234-5240.2000
   Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465
   O'Neill LAJ, 2003, BIOCHEM SOC T, V31, P643, DOI 10.1042/bst0310643
   OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582
   Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096
   Schmeck B, 2007, EUR RESPIR J, V29, P25, DOI 10.1183/09031936.00141005
   Shin S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000220
   Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098
   Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439
   Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x
   Teruya H, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-102
   Vinciguerra M, 2004, J BIOL CHEM, V279, P9634, DOI 10.1074/jbc.M308721200
   Weissgerber P, 2003, FEMS MICROBIOL LETT, V219, P173, DOI 10.1016/S0378-1097(03)00051-X
   Welsh CT, 2004, INFECT IMMUN, V72, P1512, DOI 10.1128/IAI.72.3.1512-1518.2004
   Zanassi P, 2001, J BIOL CHEM, V276, P11487, DOI 10.1074/jbc.M007631200
NR 46
TC 5
Z9 6
U1 1
U2 20
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2180
J9 BMC MICROBIOL
JI BMC Microbiol.
PD JAN 5
PY 2010
VL 10
AR 1
DI 10.1186/1471-2180-10-1
PG 18
WC Microbiology
SC Microbiology
GA 557PO
UT WOS:000274681800001
PM 20051107
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Lagana, L
   Reger, SL
AF Lagana, Luciana
   Reger, Stacy L.
TI RETRACTED: A pilot study on perceived stress and PTSD symptomatology in
   relation to four dimensions of older women's physical health (Retracted
   article. See vol. 14, pg. 769, 2010)
SO AGING & MENTAL HEALTH
LA English
DT Article; Retracted Publication
DE physical functioning; posttraumatic stress disorder; distress; ethnic
   minorities
ID SELF-RATED HEALTH; POSTTRAUMATIC-STRESS; ALLOSTATIC LOAD;
   SOCIOECONOMIC-STATUS; PARTNER VIOLENCE; MENTAL-HEALTH; MINI-COG;
   DISORDER; LIFE; OUTCOMES
AB Objectives: The authors examined whether selected demographic and psychological factors would predict physical health dimensions in a sample of 53 cognitively high-functioning and ethnically diverse women (age 65-105 years). Method: Predictors encompassed posttraumatic stress disorder (PTSD) symptomatology and perceived stress (of a nontraumatic nature and beyond health status) in relation to four dimensions of physical health. Age and income, well-known correlates of health in the target population, were included as potential predictors. The authors first tested the relationship between potential predictors and health dimensions via a canonical correlation analysis, and then employed full multiple regression analyses to simultaneously test the predictors in each health dimension model. Results: Perceived stress was a significant predictor of lower levels of general health (GH), but not of physical role limitations or physical functioning (PF). Conversely, PTSD symptomatology predicted more limitations in role fulfillment (and, to a lesser extent, impairedPF), but not lower levels of GH. As expected, age and income were predictive of some physical health dimensions. The hypothesized predictors failed to account for a significant portion of variance in pain scores. Conclusion: PTSD symptomatology and perceived stress might influence older women's physical health dimensions differentially; additional research on larger samples is needed to corroborate these findings.
C1 [Lagana, Luciana] Calif State Univ Northridge, Dept Clin Psychol, Northridge, CA 91330 USA.
   [Reger, Stacy L.] Univ Nevada, Dept Clin Psychol, Las Vegas, NV 89154 USA.
RP Lagana, L (reprint author), Calif State Univ Northridge, Dept Clin Psychol, Northridge, CA 91330 USA.
EM luciana.lagana@csun.edu
FU NIH MBRS SCORE [2 S06 GM048680-12A1]; NIH NIGMS MARC [2T34 GM00835]
FX This research was supported by NIH MBRS SCORE grant # 2 S06
   GM048680-12A1 and NIH NIGMS MARC grant # 2T34 GM00835, Luciana Lagana,
   Principal Investigator. We thank Dr. Edward Kubany for offering us to
   use his PTSD screen in this research, as well as Dr. Andrew Ainsworth,
   this study's statistical consultant, for his careful input.
CR Abas M, 2002, BRIT J PSYCHIAT, V181, P123
   Amaya-Jackson L, 1999, J TRAUMA STRESS, V12, P709, DOI 10.1023/A:1024781504756
   American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   Andreski P, 1998, PSYCHIAT RES, V79, P131, DOI 10.1016/S0165-1781(98)00026-2
   Averill PM, 2000, J ANXIETY DISORD, V14, P133, DOI 10.1016/S0887-6185(99)00045-6
   Borson S, 2003, J AM GERIATR SOC, V51, P1451, DOI 10.1046/j.1532-5415.2003.51465.x
   Borson S, 2000, INT J GERIATR PSYCH, V15, P1021, DOI 10.1002/1099-1166(200011)15:11<1021::AID-GPS234>3.0.CO;2-6
   Charles ST, 2007, PSYCHOL AGING, V22, P331, DOI 10.1037/0882-7974.22.2.331
   DELONGIS A, 1988, J PERS SOC PSYCHOL, V54, P486, DOI 10.1037/0022-3514.54.3.486
   Dutton MA, 2006, J INTERPERS VIOLENCE, V21, P955, DOI 10.1177/0886260506289178
   Edwards RR, 2005, PAIN MED, V6, P88, DOI 10.1111/j.1526-4637.2005.05007.x
   ENGEL GL, 1980, AM J PSYCHIAT, V137, P535
   ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460
   Fillenbaum Gerda G, 2006, Am J Geriatr Pharmacother, V4, P93, DOI 10.1016/j.amjopharm.2006.06.005
   Fisher BS, 2006, GERONTOLOGIST, V46, P200, DOI 10.1093/geront/46.2.200
   Gama EV, 2000, AGE AGEING, V29, P267
   Ghaed SG, 2007, HEALTH PSYCHOL, V26, P668, DOI 10.1037/0278-6133.26.6.668
   Gonyea JG, 2005, FAM SOC, V86, P338, DOI 10.1606/1044-3894.3431
   Green CR, 2003, PAIN MED, V4, P277, DOI 10.1046/j.1526-4637.2003.03034.x
   Green CR, 2003, J PAIN, V4, P82, DOI 10.1054/jpai.2003.8
   HENNON CB, 1994, MID LIFE DIVORCE COU, P39
   HOCKING LB, 1995, INT J PSYCHIAT MED, V25, P221, DOI 10.2190/XRGV-FD1A-VWP5-RE9Q
   Hoeymans N, 1997, SOC SCI MED, V45, P1527, DOI 10.1016/S0277-9536(97)00089-0
   HYER L, 1995, PSYCHOTHERAPY, V32, P348, DOI 10.1037/0033-3204.32.2.348
   Jemal A, 2008, AM J PREV MED, V34, P1, DOI 10.1016/j.amepre.2007.09.017
   KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012
   KOENIG HG, 2002, LINK RELIG HLTH PSYC, P174
   Krause N, 2004, J GERONTOL B-PSYCHOL, V59, pS287, DOI 10.1093/geronb/59.5.S287
   Kubany ES, 2000, PSYCHOL ASSESSMENT, V12, P197, DOI 10.1037//1040-3590.12.2.197
   Kubiak SP, 2005, AM J ORTHOPSYCHIAT, V75, P451, DOI 10.1037/0002-9432.75.4.451
   LAGANA L, 2009, OLDER WOMENS P UNPUB
   Lagana L, 2009, EDUC GERONTOL, V35, P732, DOI 10.1080/03601270802708442
   Landerman LR, 1998, J GERONTOL B-PSYCHOL, V53, pS258, DOI 10.1093/geronb/53B.5.S258
   LAZARUS RS, 1985, AM PSYCHOL, V40, P770, DOI 10.1037//0003-066X.40.7.770
   Lee MA, 2007, RES AGING, V29, P457, DOI 10.1177/0164027507303171
   LYONS RA, 1994, AGE AGEING, V23, P182, DOI 10.1093/ageing/23.3.182
   McEwen BS, 2000, NEUROCHEM RES, V25, P1219, DOI 10.1023/A:1007687911139
   McEwen BS, 1999, ANN NY ACAD SCI, V896, P30, DOI 10.1111/j.1749-6632.1999.tb08103.x
   Mechanic MB, 2004, J INTERPERS VIOLENCE, V19, P1283, DOI 10.1177/0886260504270690
   Pearlin LI, 2005, J HEALTH SOC BEHAV, V46, P205, DOI 10.1177/002214650504600206
   PEARLIN LI, 1998, HDB AGING MENTAL HLT, P323
   Pico-Alfonso MA, 2006, J WOMENS HEALTH, V15, P599, DOI 10.1089/jwh.2006.15.599
   Pinquart M, 2003, PSYCHOL AGING, V18, P250, DOI 10.1037/0882-7974.18.2.250
   PRILUTSKY R, 2006, THESIS CALIFORNIA ST
   Ravenell JE, 2006, J NATL MED ASSOC, V98, P544
   Rohrer JE, 2008, CLIN REHABIL, V22, P38, DOI 10.1177/0269215507079095
   Rossi NE, 2007, DEATH STUD, V31, P863, DOI 10.1080/07481180701603246
   Seeman TE, 1997, ARCH INTERN MED, V157, P2259
   Seeman TE, 2001, P NATL ACAD SCI USA, V98, P4770, DOI 10.1073/pnas.081072698
   Shavers VL, 2007, J NATL MED ASSOC, V99, P1013
   Skinner MA, 2004, COGNITIVE THER RES, V28, P695, DOI 10.1023/B:COTR.0000045572.33750.6c
   Son J, 2007, J AGING HEALTH, V19, P871, DOI 10.1177/0898264307308568
   STAUDINGER UM, 1993, DEV PSYCHOPATHOL, V5, P541, DOI 10.1017/S0954579400006155
   Tabachnick B., 2007, USING MULTIVARIATE S
   Taylor MK, 2008, MIL MED, V173, P738, DOI 10.7205/MILMED.173.8.738
   Tyra P A, 1993, J Gerontol Nurs, V19, P7
   US Census Bureau, 2006, INC POV HLTH INS COV
   van Zelst WH, 2006, INT J GERIATR PSYCH, V21, P180, DOI 10.1002/gps.1448
   van Zelst WH, 2003, PSYCHOTHER PSYCHOSOM, V72, P333, DOI 10.1159/000073030
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Ware JE, 1994, SF 36 PHYS MENTAL HL
   Zautra AJ, 1999, ANN NY ACAD SCI, V876, P397, DOI 10.1111/j.1749-6632.1999.tb07664.x
   Zinzow HM, 2007, TRAUMA VIOLENCE ABUS, V8, P384, DOI 10.1177/1524838007307295
NR 63
TC 1
Z9 1
U1 2
U2 11
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1360-7863
EI 1364-6915
J9 AGING MENT HEALTH
JI Aging Ment. Health
PY 2010
VL 14
IS 4
BP 396
EP 404
AR PII 921978817
DI 10.1080/13607860903046578
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 593FT
UT WOS:000277438900003
PM 20455114
DA 2018-12-27
ER

PT J
AU Stanimirovic, Z
   Aleksic, N
   Kulic, M
   Maletic, M
AF Stanimirovic, Z.
   Aleksic, Nevenka
   Kulic, M.
   Maletic, M.
TI RETRACTED: FUMAGILLIN-INDUCED CHROMOSOME ABERRATIONS IN MOUSE
   BONE-MARROW CELLS (Retracted article. See vol. 67, pg. 747, 2015)
SO ARCHIVES OF BIOLOGICAL SCIENCES
LA English
DT Article; Retracted Publication
DE Fumagillin; genotoxicity; mitotic index; chromosome aberrations;
   insertions; BALB/c mice
ID PROLIFERATIVE KIDNEY-DISEASE; TROUT ONCORHYNCHUS-MYKISS; INTESTINAL
   MICROSPORIDIOSIS; METHIONINE AMINOPEPTIDASE; ASPERGILLUS-FUMIGATUS;
   MUS-MUSCULUS; NOSEMA-APIS; IN-VITRO; GENOTOXICITY; TESTS
AB The genotoxicity of fumagillin was evaluated assessing the mitotic index and chromosome aberrations in mouse bone-marrow cells. Mice were given fumagillin orally in doses 5, 10 and 20 mg/kg bw. All doses significantly (p<0.001) reduced the mitotic index. The medium and maximum doses led to significant (p<0.01 and p<0.001, respectively) increases in numeric aberrations. The highest dose induced both structural and numeric aberrations (p<0.001), and insertions on the first pair of autosomes that were amplified in the 1C and 1E regions. These results pointed to the genotoxic potential of fumagillin in the range of medium and maximum doses applied.
C1 [Stanimirovic, Z.; Aleksic, Nevenka; Maletic, M.] Univ Belgrade, Fac Vet Med, Belgrade 11000, Serbia.
   [Kulic, M.] Univ Sarajevo, Fac Med, E Sarajevo 73300, Bosnia & Herceg.
RP Stanimirovic, Z (reprint author), Univ Belgrade, Fac Vet Med, Belgrade 11000, Serbia.
OI Stanimirovic, Zoran/0000-0003-2657-8591
CR AGULNIK SI, 1990, GENETIKA+, V26, P664
   AGULNIK SI, 1988, TSITOLOGIYA+, V30, P773
   Albertini RJ, 2000, MUTAT RES-REV MUTAT, V463, P111, DOI 10.1016/S1383-5742(00)00049-1
   AMES BN, 1989, ENVIRON MOL MUTAGEN, V14, P66, DOI 10.1002/em.2850140614
   ANDERSON D, 1995, MUTAT RES-FUND MOL M, V330, P115, DOI 10.1016/0027-5107(95)00039-L
   ASSIL HI, 1991, J AGR FOOD CHEM, V39, P2206, DOI 10.1021/jf00012a021
   BAILEY L, 1953, NATURE, V171, P212, DOI 10.1038/171212a0
   *COMM STAND GEN NO, 1979, MOUSE NEWS LETT, V61, P4
   Conteas CN, 2000, AM J TROP MED HYG, V63, P121, DOI 10.4269/ajtmh.2000.63.121
   COWELL JK, 1984, CHROMOSOMA, V89, P294, DOI 10.1007/BF00292478
   ELMATBOULI M, 1991, DIS AQUAT ORGAN, V10, P109, DOI 10.3354/dao010109
   Fardis M, 2003, BIOORGAN MED CHEM, V11, P5051, DOI 10.1016/j.bmc.2003.08.031
   FURGALA B., 1962, JOUR APICULTURAL RES, V1, P35
   Golden MC, 1998, MYCOSES, V41, P97, DOI 10.1111/j.1439-0507.1998.tb00308.x
   Griffith EC, 1998, P NATL ACAD SCI USA, V95, P15183, DOI 10.1073/pnas.95.26.15183
   HEDRICK RP, 1988, DIS AQUAT ORGAN, V4, P165, DOI 10.3354/dao004165
   Heil J, 1996, MUTAT RES-GENET TOX, V368, P181, DOI 10.1016/S0165-1218(96)90060-9
   HSU TC, 1969, COMP MAMMALIAN CYTOG, P1
   INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0
   Karagouni E, 2005, VET PARASITOL, V134, P215, DOI 10.1016/j.vetpar.2005.07.020
   KATZNELSON H, 1952, SCIENCE, V115, P70, DOI 10.1126/science.115.2977.70
   KENT ML, 1994, DIS AQUAT ORGAN, V20, P231
   KULIC M, 2006, THESIS U BANJALUKA
   le Gouvello R, 1999, AQUACULTURE, V171, P27, DOI 10.1016/S0044-8486(98)00430-X
   Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324
   LIU TP, 1990, TISSUE CELL, V22, P511, DOI 10.1016/0040-8166(90)90078-N
   LIU TP, 1990, TISSUE CELL, V22, P523, DOI 10.1016/0040-8166(90)90080-S
   Mazzanti CM, 2004, GENOME RES, V14, P1585, DOI 10.1101/gr.2552804
   MLADJAN V, 2000, P 2 S AN CLIN PATH T, P211
   Molina JM, 2000, AIDS, V14, P1341, DOI 10.1097/00002030-200007070-00006
   Molina JM, 2002, NEW ENGL J MED, V346, P1963, DOI 10.1056/NEJMoa012924
   Morris DJ, 2003, AQUACULTURE, V221, P51, DOI 10.1016/S0044-8486(03)00024-3
   MORTELMANS K, 1986, ENVIRON MOL MUTAGEN, V8, P1, DOI 10.1002/em.2860080802
   Nieminen SM, 2002, MUTAT RES-GEN TOX EN, V520, P161, DOI 10.1016/S1383-5718(02)00202-4
   NORPPA H, 2003, TOXICOL LETT S1, V144, P25
   PURCHASE IFH, 1978, BRIT J CANCER, V37, P873, DOI 10.1038/bjc.1978.132
   Rada V, 1997, APIDOLOGIE, V28, P357, DOI 10.1051/apido:19970603
   RONNE M, 1991, GENET SEL EVOL, V23, pS49, DOI 10.1051/gse:19910703
   ROSBERGER DF, 1993, CORNEA, V12, P261, DOI 10.1097/00003226-199305000-00013
   Sabater-Vilar M, 2003, J FOOD PROTECT, V66, P2123, DOI 10.4315/0362-028X-66.11.2123
   SEABRIGH.M, 1971, LANCET, V2, P971
   Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099
   Stanimirovic Z, 2005, MUTAT RES-GEN TOX EN, V588, P152, DOI 10.1016/j.mrgentox.2005.10.003
   STANIMIROVIC Z, 1995, ACTA VET-BEOGRAD, V45, P155
   Stanimirovic Z, 1998, ACTA VET-BEOGRAD, V48, P255
   STANIMIROVIC Z, 2006, ACTA VET-BEOGRAD, V4, P353
   STANIMIROVIC Z, 1999, P 29 ANN M EUR ENV M, V85, P44
   Stanimirovic Z, 2007, MUTAT RES-GEN TOX EN, V628, P1, DOI 10.1016/j.mrgentox.2006.09.014
   STEVANOVIC J, 2000, P 2 S AN CLIN PATH T, P227
   Stevanovic J, 2008, ENVIRON MOL MUTAGEN, V49, P594, DOI 10.1002/em.20409
   Stevanovic J, 2006, ACTA VET-BEOGRAD, V56, P437, DOI 10.2298/AVB0606437S
   STOLTZ DR, 1970, SCIENCE, V167, P1501, DOI 10.1126/science.167.3924.1501
   Wang JY, 2000, J CELL BIOCHEM, V77, P465, DOI 10.1002/(SICI)1097-4644(20000601)77:3<465::AID-JCB11>3.3.CO;2-D
   WILKINS JH, 1994, EYE, V8, P703, DOI 10.1038/eye.1994.177
   ZIMONJIC DB, 1990, GENOTOXIC AGENTS EFF, P1
NR 55
TC 6
Z9 6
U1 2
U2 7
PU INST BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC
PI BEOGRAD
PA 29 NOVEMBRA 142, BEOGRAD, 11060, SERBIA
SN 0354-4664
EI 1821-4339
J9 ARCH BIOL SCI
JI Arch. Biol. Sci.
PY 2010
VL 62
IS 1
BP 47
EP 55
DI 10.2298/ABS1001047S
PG 9
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 595KT
UT WOS:000277610000007
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Noordewier, MK
   van Horen, F
   Ruys, KI
   Stapel, DA
AF Noordewier, Marret K.
   van Horen, Femke
   Ruys, Kirsten I.
   Stapel, Diederik A.
TI RETRACTED: What's in a Name? 361.708 Euros: The Effects of Marital Name
   Change (Retracted article. See vol. 34, pg. 192, 2012)
SO BASIC AND APPLIED SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
ID WOMENS SURNAMES; MARRIED-WOMEN; SELF-ESTEEM; ATTITUDES; MS; DECISIONS;
   PERCEPTIONS; STEREOTYPES; MEN
AB Marital name change is not without consequences. Women who took their partner's name appear to be different from women who kept their own name on a variety of demographics and beliefs, which are more or less associated with the female stereotype (Study 1). Subsequent studies show that women's surnames are used as a cue for judgment (Studies 2-4). A woman who took her partner's name or a hyphenated name was judged as more caring, more dependent, less intelligent, more emotional, less competent, and less ambitious in comparison with a woman who kept her own name. A woman with her own name, on the other hand, was judged as less caring, more independent, more ambitious, more intelligent, and more competent, which was similar to an unmarried woman living together or a man. Finally, a job applicant who took her partner's name, in comparison with one with her own name, was less likely to be hired for a job and her monthly salary was estimated 861,21 lower (calculated to a working life, 361.708,20).
C1 [Noordewier, Marret K.] Tilburg Univ, Tilburg Inst Behav Econ Res, Social Psychol Dept, NL-5000 LE Tilburg, Netherlands.
RP Noordewier, MK (reprint author), Tilburg Univ, Tilburg Inst Behav Econ Res, Social Psychol Dept, POB 90153, NL-5000 LE Tilburg, Netherlands.
EM m.k.noordewier@uvt.nl
CR BANAJI MR, 1993, J PERS SOC PSYCHOL, V65, P272, DOI 10.1037/0022-3514.65.2.272
   Bertrand M, 2004, AM ECON REV, V94, P991, DOI 10.1257/0002828042002561
   Blair IV, 2002, J PERS SOC PSYCHOL, V83, P5, DOI 10.1037//0022-3514.83.1.5
   Crawford M, 1998, PSYCHOL WOMEN QUART, V22, P197, DOI 10.1111/j.1471-6402.1998.tb00150.x
   DEAUX K, 1993, GENDER STEREOTYPES
   DION KL, 1990, SEX ROLES, V22, P569, DOI 10.1007/BF00288235
   DION KL, 1991, PSYCHOL WOMEN QUART, V15, P403, DOI 10.1111/j.1471-6402.1991.tb00416.x
   Dovidio JF, 2000, PSYCHOL SCI, V11, P315, DOI 10.1111/1467-9280.00262
   DYKSTRA P, 2005, 4 NKPS NETH INT DEM
   Etaugh CE, 1999, PSYCHOL WOMEN QUART, V23, P819, DOI 10.1111/j.1471-6402.1999.tb00400.x
   Forbes GB, 2002, SEX ROLES, V46, P167, DOI 10.1023/A:1019613819247
   Glick P, 2004, J PERS SOC PSYCHOL, V86, P713, DOI 10.1037/0022-3514.86.5.713
   Goldin C, 2004, J ECON PERSPECT, V18, P143, DOI 10.1257/0895330041371268
   GREENWALD AG, 1995, PSYCHOL REV, V102, P4, DOI 10.1037//0033-295X.102.1.4
   Hodson G, 2005, PERS SOC PSYCHOL B, V31, P1099, DOI 10.1177/0146167205274895
   Hoffnung M, 2006, SEX ROLES, V55, P817, DOI 10.1007/s11199-006-9133-9
   JOHNSON DR, 1995, J MARRIAGE FAM, V57, P724, DOI 10.2307/353926
   KITE ME, 2001, ENCY WOMEN GENDER, P561
   Kline SL, 1996, J SOC PERS RELAT, V13, P593, DOI 10.1177/0265407596134007
   Koole SL, 2001, J PERS SOC PSYCHOL, V80, P669, DOI 10.1037//0022-3514.80.4.669
   Lawton CA, 2003, PSYCHOL WOMEN QUART, V27, P215, DOI 10.1111/1471-6402.00101
   NUTTIN JM, 1985, EUR J SOC PSYCHOL, V15, P353, DOI 10.1002/ejsp.2420150309
   Pelham BW, 2002, J PERS SOC PSYCHOL, V82, P469, DOI 10.1037//0022-3514.82.4.469
   Rosenthal R, 1991, ESSENTIALS BEHAV RES
   SCHEUBLE L, 1993, J MARRIAGE FAM, V55, P747, DOI 10.2307/353354
   Scheuble LK, 2005, SEX ROLES, V53, P143, DOI 10.1007/s11199-005-4288-3
   STANNARD U, 1977, MAN
   Stapel DA, 1998, J EXP SOC PSYCHOL, V34, P136, DOI 10.1006/jesp.1997.1346
   STAPEL DA, 2001, PERSONALITY SOCIAL P, V8, P915, DOI DOI 10.1177/0146167201278001
   Twenge JM, 1997, PSYCHOL WOMEN QUART, V21, P417, DOI 10.1111/j.1471-6402.1997.tb00122.x
NR 30
TC 3
Z9 3
U1 1
U2 18
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0197-3533
EI 1532-4834
J9 BASIC APPL SOC PSYCH
JI Basic Appl Soc. Psychol.
PY 2010
VL 32
IS 1
BP 17
EP 25
AR PII 919477693
DI 10.1080/01973530903539812
PG 9
WC Psychology, Social
SC Psychology
GA 593NU
UT WOS:000277463900003
DA 2018-12-27
ER

PT J
AU Shweta
   Kumar, R
   Singh, BL
   Deepshikha, V
AF Shweta
   Kumar, Rahul
   Singh, B. L.
   Deepshikha, Verma
TI RETRACTED: Integrating Microbial Composting and Vermicomposting for
   Effective Utilization of By-products of Sugar Cane-Processing Industries
   (Retracted article. See vol. 15, pg. 68, 2011)
SO BIOREMEDIATION JOURNAL
LA English
DT Article; Retracted Publication
DE bioinoculants; Drawida willsi; integrated system of composting;
   microbial activity; sugar-cane industries; vermicompost
ID ENZYME-ACTIVITIES; ORGANIC-MATTER; EISENIA-FETIDA; WASTE; PAPER;
   NITROGEN; BIOMASS; SLUDGE; ANDREI; CARBON
AB In recent years integrated system of composting, with bioinoculants and subsequent vermicomposting, to overcome the problem of lignocellulosic waste degradation of different crop residues and waste industrial by-products is receiving worldwide attention of scientists. However, there appears no report available on the technical viability of the approach on waste by-products of sugar-cane industry. Therefore, in the present study, the waste by-products of sugar-cane industry viz. bagasse (b), press-mud (p), and trash (t) have been subjected to bioinoculation followed by vermicomposting with a view to shorten stabilization time, and improve the product quality. The substrate (press-mud alone and in combination of other by-products of sugar-processing industries) was predecomposed for 30 days by inoculating it with Pleurotus sajorcaju, Trichoderma viridae, Aspergillus niger, and Pseudomonas striatum in different combinations. This was followed by vermicomposting for 40 days using Drawida willsi species of the native earthworms. Results indicated that the combinations of both the systems reduced the overall time required for composting to 20 days and accelerated the degradation process of waste by-products of sugar-processing industry, thereby producing a nutrient-enriched compost product.
C1 [Shweta; Kumar, Rahul; Singh, B. L.; Deepshikha, Verma] Dr BRA Univ, Dharam Samaj Coll, Dept Zool, Vermiculture Res Stn, Aligarh 202001, Uttar Pradesh, India.
RP Shweta (reprint author), Dr BRA Univ, Dharam Samaj Coll, Dept Zool, Vermiculture Res Stn, Aligarh 202001, Uttar Pradesh, India.
EM kmshweta3@yahoo.com
FU Department of Biotechnology, Ministry of Science and Technology,
   Government of India, New Delhi
FX The authors are thankful to the Department of Biotechnology, Ministry of
   Science and Technology, Government of India, New Delhi, for financial
   assistance.
CR Atiyeh RM, 2002, BIORESOURCE TECHNOL, V81, P103, DOI 10.1016/S0960-8524(01)00122-5
   Beauchamp CJ, 2006, BIORESOURCE TECHNOL, V97, P1002, DOI 10.1016/j.biortech.2005.04.041
   Benitez E, 1999, BIORESOURCE TECHNOL, V67, P297, DOI 10.1016/S0960-8524(98)00117-5
   Benitez E, 2000, BIOL FERT SOILS, V31, P489, DOI 10.1007/s003740000197
   BERNAL M, 2006, BIOCYCLE, V6, P14
   BEYER L, 2005, SOIL BIOL BIOCHEM, V25, P587
   BUSWELL JA, 1994, BIOTECHNOL LETT, V16, P1317
   Curry JP, 2007, PEDOBIOLOGIA, V50, P463, DOI 10.1016/j.pedobi.2006.09.001
   DALE P, 2007, EKOLOGIA, V53, P11
   DATTA R, 1981, BIOTECHNOL BIOENG, V23, P2167, DOI 10.1002/bit.260230921
   Dominguez Jorge, 2004, P401
   Eiland F, 2001, MICROBIAL ECOL, V41, P272, DOI 10.1007/s002480000071
   Elvira C, 1998, BIORESOURCE TECHNOL, V63, P205, DOI 10.1016/S0960-8524(97)00145-4
   Fischer K, 1997, SOIL BIOL BIOCHEM, V29, P1149, DOI 10.1016/S0038-0717(96)00304-5
   GINTEROVA A, 1975, FOLIA MICROBIOL, V20, P246, DOI 10.1007/BF02876786
   HUNSA PK, 1999, SCI ASIA, V25, P133
   Komilis DP, 2006, WASTE MANAGE, V26, P62, DOI 10.1016/j.wasman.2004.12.020
   Kumar V, 1999, BIOL FERT SOILS, V28, P301, DOI 10.1007/s003740050497
   Maboeta MS, 2003, ECOTOX ENVIRON SAFE, V56, P265, DOI 10.1016/S0147-6513(02)00101-X
   MANNA MC, 2003, BIOL FERT SOILS, V24, P129
   Ndegwa PM, 2001, BIORESOURCE TECHNOL, V76, P107, DOI 10.1016/S0960-8524(00)00104-8
   Ndegwa PM, 2000, BIORESOURCE TECHNOL, V75, P7, DOI 10.1016/S0960-8524(00)00038-9
   Pramanik P, 2007, BIORESOURCE TECHNOL, V98, P2485, DOI 10.1016/j.biortech.2006.09.017
   RAO NSS, 2005, BIOFERTILIZER AGR, P70
   Singh A, 2002, BIORESOURCE TECHNOL, V85, P107, DOI 10.1016/S0960-8524(02)00095-0
   SINGH R, 1981, FORAGE EVALUATION SC, V23, P23
   Subler S, 1998, BIOL FERT SOILS, V26, P243, DOI 10.1007/s003740050374
   Valaskova V, 2006, MICROBIOL-SGM, V152, P3613, DOI 10.1099/mic.0.29149-0
   VinceslasAkpa M, 1997, SOIL BIOL BIOCHEM, V29, P751, DOI 10.1016/S0038-0717(96)00201-5
   Walkley A, 1934, SOIL SCI, V37, P29, DOI 10.1097/00010694-193401000-00003
   Zhang BG, 2000, SOIL BIOL BIOCHEM, V32, P2055, DOI 10.1016/S0038-0717(00)00111-5
NR 31
TC 3
Z9 4
U1 5
U2 19
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1088-9868
EI 1547-6529
J9 BIOREMEDIAT J
JI Bioremediat. J.
PY 2010
VL 14
IS 3
BP 158
EP 167
AR PII 924662542
DI 10.1080/10889868.2010.495365
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 630HQ
UT WOS:000280264300004
DA 2018-12-27
ER

PT J
AU Safarinejad, MR
AF Safarinejad, Mohammad Reza
TI RETRACTED: Analysis of association between the 5-HTTLPR and STin2
   polymorphisms in the serotonin-transporter gene and clinical response to
   a selective serotonin reuptake inhibitor (sertraline) in patients with
   premature ejaculation (Retracted article. See vol. 115, pg. E9, 2015)
SO BJU INTERNATIONAL
LA English
DT Article; Retracted Publication
DE premature ejaculation; polymorphisms; selective serotonin reuptake
   inhibitors; serotonin transporter; treatment outcome
ID DOUBLE-BLIND; PROMOTER-POLYMORPHISM; PAROXETINE TREATMENT; SEXUAL
   DYSFUNCTION; ALLELIC VARIATION; DEPRESSION; EFFICACY; DISORDERS;
   PHARMACOGENETICS; SYMPTOMATOLOGY
AB OBJECTIVE
   To test the hypothesis that polymorphism within the gene-linked polymorphic region (5-HTTLPR) and second intron of SLC6A4 gene (STin2) is associated with selective serotonin-reuptake inhibitors (SSRIs) response in subjects with premature ejaculation (PE).
   PATIENTS AND METHODS
   In all, 246 men with PE were recruited in this study. They were asked to take sertraline 50 mg daily for 2 weeks, and thereafter 100 mg daily, for a 12-week treatment period. Pretreatment evaluation included history and physical examination, intravaginal ejaculatory latency time (IELT), and International Index of Erectile Function (IIEF). The efficacy of treatment was assessed using responses to IIEF, and geometric mean IELT evaluation. 5-HTTLPR was genotyped using polymerase chain reaction techniques. A repeated-measures analysis of variance of geometric mean IELT was done to test a genotype effect on treatment outcome with SSRI (sertraline).
   RESULTS
   Of 227 participants who completed the study, 175 (77.1%) responded to sertraline (IELT > 1 min). Overall the patients had a 3.7-fold (95% confidence interval, CI, 1.72-5.46) increase of the geometric mean IELT (P = 0.001). The results showed that responses were significantly better for the L-A/L-A genotype of the 5-HTTLPR polymorphism than for S-allele carriers (P = 0.001). The STin2 12/12 genotype was found more often in those responding to sertraline than in those not responding (P = 0.001). The probability of patients responding sufficiently to sertraline with an L-A/L-A genotype was highest (odds ratio 4.66, 95% CI, 2.48-6.14).
   CONCLUSIONS
   These findings indicate that the genotype of 5-HTT contributes in unique ways to the variation in the outcome of PE treatment with SSRIs.
C1 [Safarinejad, Mohammad Reza] Shahid Beheshti Univ MC, Urol & Nephrol Res Ctr, Tehran, Iran.
RP Safarinejad, MR (reprint author), POB 19395-1849, Tehran, Iran.
EM safarinejad@unrc.ir
OI Safarinejad, Mohammad Reza/0000-0003-3055-5915
CR Abou-Sleiman PM, 2006, J NEUROL NEUROSUR PS, V77, P1302, DOI 10.1136/jnnp.2005.082024
   Arafa M, 2006, INT J IMPOT RES, V18, P534, DOI 10.1038/sj.ijir.3901469
   Arias B, 2003, J CLIN PSYCHOPHARM, V23, P563, DOI 10.1097/01.jcp.0000095350.32154.73
   Aschka C, 2001, J FAM PRACTICE, V50, P773
   Coolen LM, 1998, J COMP NEUROL, V397, P421, DOI 10.1002/(SICI)1096-9861(19980803)397:3<421::AID-CNE8>3.0.CO;2-4
   Fan JB, 2005, MOL PSYCHIATR, V10, P928, DOI 10.1038/sj.mp.4001690
   Fiskerstrand CE, 1999, FEBS LETT, V458, P171, DOI 10.1016/S0014-5793(99)01150-3
   Gelernter J, 1999, AM J MED GENET, V88, P61, DOI 10.1002/(SICI)1096-8628(19990205)88:1<61::AID-AJMG11>3.0.CO;2-K
   Gelernter J, 1997, HUM GENET, V101, P243, DOI 10.1007/s004390050624
   Gunthert KC, 2007, PSYCHOSOM MED, V69, P762, DOI 10.1097/PSY.0b013e318157ad42
   Hariri AR, 2002, SCIENCE, V297, P400, DOI 10.1126/science.1071829
   Heils A, 1996, J NEUROCHEM, V66, P2621
   HEYM J, 1988, J CLIN PSYCHIAT, V49, P40
   Johnson BA, 2008, PROG NEURO-PSYCHOPH, V32, P209, DOI 10.1016/j.pnpbp.2007.07.030
   Kaiser R, 2002, AM J MED GENET, V114, P323, DOI 10.1002/ajmg.10119
   Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537
   Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527
   Lesch KP, 2001, J AFFECT DISORDERS, V62, P57, DOI 10.1016/S0165-0327(00)00351-7
   Lesch KP, 1997, J NEURAL TRANSM, V104, P1259, DOI 10.1007/BF01294726
   McMahon CG, 1998, J UROLOGY, V159, P1935, DOI 10.1016/S0022-5347(01)63201-4
   Nakamura M, 2000, MOL PSYCHIATR, V5, P32, DOI 10.1038/sj.mp.4000698
   Ng CH, 2004, AUST NZ J PSYCHIAT, V38, P483, DOI 10.1111/j.1440-1614.2004.01400.x
   Pollock BG, 2000, NEUROPSYCHOPHARMACOL, V23, P587, DOI 10.1016/S0893-133X(00)00132-9
   Rausch JL, 2002, BIOL PSYCHIAT, V51, P723, DOI 10.1016/S0006-3223(01)01283-5
   Read S, 1997, J PUBLIC HEALTH MED, V19, P387, DOI 10.1093/oxfordjournals.pubmed.a024665
   Roblin D., 2000, INT J PHARM MED, V14, P313
   Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0
   Safarinejad MR, 2007, J CLIN PSYCHOPHARM, V27, P444, DOI 10.1097/jcp.0b013e31814b98d4
   Safarinejad MR, 2006, CLIN NEUROPHARMACOL, V29, P243, DOI 10.1097/01.WNF.0000228210.12194.46
   Safarinejad MR, 2006, INT J IMPOT RES, V18, P164, DOI 10.1039/sj.ijis.3901384
   SAFARINEJAD MR, 2009, UROLOGY, V181, P2656
   Serretti A, 2005, PROG NEURO-PSYCHOPH, V29, P1074, DOI 10.1016/j.pnpbp.2005.03.013
   Serretti A, 2004, PSYCHOPHARMACOLOGY, V174, P490, DOI 10.1007/s00213-004-1822-x
   Serretti A, 1999, MOL PSYCHIATR, V4, P280, DOI 10.1038/sj.mp.4000485
   Serretti A, 2006, PSYCHIAT RES, V145, P61, DOI 10.1016/j.psychres.2005.09.020
   Smeraldi E, 1998, MOL PSYCHIATR, V3, P508, DOI 10.1038/sj.mp.4000425
   Smits KM, 2004, MOL PSYCHIATR, V9, P433, DOI 10.1038/sj.mp.4001488
   Truitt WA, 2002, SCIENCE, V297, P1566, DOI 10.1126/science.1073885
   Waldinger MD, 2001, J CLIN PSYCHOPHARM, V21, P556, DOI 10.1097/00004714-200112000-00003
   WALDINGER MD, 1994, AM J PSYCHIAT, V151, P1377
   Yu YWY, 2002, MOL PSYCHIATR, V7, P1115, DOI 10.1038/sj.mp.4001141
   Zanardi R, 2000, J CLIN PSYCHOPHARM, V20, P105, DOI 10.1097/00004714-200002000-00021
NR 42
TC 23
Z9 29
U1 3
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-4096
EI 1464-410X
J9 BJU INT
JI BJU Int.
PD JAN
PY 2010
VL 105
IS 1
BP 73
EP 78
DI 10.1111/j.1464-410X.2009.08714.x
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 530DJ
UT WOS:000272568800014
PM 19549114
OA Bronze
DA 2018-12-27
ER

PT J
AU Ganguli, S
   Mazumder, M
   Basu, P
   Roy, P
   Mitra, S
   Datta, A
AF Ganguli, Sayak
   Mazumder, Manjita
   Basu, Protip
   Roy, Paushali
   Mitra, Sayani
   Datta, Abhijit
TI RETRACTED: In silico screening of herbal and nanoparticle lead compounds
   for effectivity against H5N1, H1N1 neuraminidase and telomerase
   (Retracted article. See vol. 11, art. no. 258, 2010)
SO BMC BIOINFORMATICS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 8th Asia Pacific Bioinformatics Conference
CY JAN 18-21, 2010
CL Bangalore, INDIA
ID CELL-LINES; BAICALEIN; INHIBITION; SIMILARITY
AB Background: Traditionally, drugs were discovered by testing compounds synthesized in time consuming multi-step processes against a battery of in vivo biological screens. Promising compounds were then further studied in development, where their pharmacokinetic properties, metabolism and potential toxicity were investigated.
   Methods: Here we present a study on the most talked about herbal lead compounds and their potential binding affinity to the effector molecules of major disease causing agents, H5N1 and H1N1(Neuraminidase). The work also encompasses the screening of the nanoparticle compound fullerene which have been reported to have anti HIV activity. Further studies were also performed with telomerase which has been the target of numerous anti cancer experiments.
   Results: The results revealed that most herbal lead compounds were effective targets against H5N1 neuraminidase, namely baicalein was found to be an effective target for inhibiting the neuraminidase of H1N1 virus. Telomerase was found to be effectively bound by curcumin at the RNA binding interface. The study with nanoparticle fullerene also showed that it has the potential of serving as an effective ligand for inhibiting H1N1 neuraminidase and telomerase.
   Conclusion: Our data demonstrate that the new in silico screening method is highly efficient for identifying potential lead compounds against major infectious disease.
C1 [Ganguli, Sayak; Mazumder, Manjita; Basu, Protip; Roy, Paushali; Mitra, Sayani; Datta, Abhijit] Presidency Coll, DBT Ctr Bioinformat, Kolkata, India.
RP Ganguli, S (reprint author), Presidency Coll, DBT Ctr Bioinformat, Kolkata, India.
EM sayakbif@yahoo.com; manjita_bonny@gmail.com; basuprotip@gmail.com;
   paushali.06@gmail.com; sayanimitra@gmail.com; abhijit_datta21@yahoo.com
CR Aristotle L, 2004, ANTICANCER RES, V24, P987
   Bakry R, 2007, INT J NANOMED, V2, P639
   Chen X, 2002, J CHEM INF COMP SCI, V42, P1407, DOI 10.1021/ci025531g
   Cui SX, 2006, INT J MOL MED, V18, P227
   Gao DY, 1996, BIOCHEM MOL BIOL INT, V39, P215
   Lipinski CA, 2000, J PHARMACOL TOXICOL, V44, P235, DOI 10.1016/S1056-8719(00)00107-6
   Matsuzaki Y, 1996, JPN J CANCER RES, V87, P170, DOI 10.1111/j.1349-7006.1996.tb03155.x
   SEKIYA K, 1982, BIOCHEM BIOPH RES CO, V105, P1090, DOI 10.1016/0006-291X(82)91081-6
   Thimm M, 2004, J CHEM INF COMP SCI, V44, P1816, DOI 10.1021/ci049920h
   Yim H, 1999, PLANTA MED, V65, P9, DOI 10.1055/s-1999-13953
   Youssef KM, 2005, ARCH PHARM, V338, P181, DOI 10.1002/ardp.200400939
NR 11
TC 1
Z9 1
U1 2
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PY 2010
VL 11
SU 1
AR S13
DI 10.1186/1471-2105-11-S1-S13
PG 5
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA 548NE
UT WOS:000273969500014
PM 20122184
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Xu, FG
   Dong, CQ
   Xie, C
   Ren, JC
AF Xu, Fagong
   Dong, Chaoqing
   Xie, Chao
   Ren, Jicun
TI RETRACTED: Ultrahighly Sensitive Homogeneous Detection of DNA and
   MicroRNA by Using Single-Silver-Nanoparticle Counting (Retracted
   article. See vol. 16, pg. 14225, 2010)
SO CHEMISTRY-A EUROPEAN JOURNAL
LA English
DT Article; Retracted Publication
DE DNA; homogeneous assays; nanoparticles; RNA; silver
ID FLUORESCENCE CORRELATION SPECTROSCOPY; RESONANCE ENERGY-TRANSFER;
   SCATTERING SUBMICROSCOPIC PARTICLES; NUCLEIC-ACID HYBRIDIZATION; DYNAMIC
   LIGHT-SCATTERING; GOLD NANOPARTICLES; BIOLOGICAL APPLICATIONS;
   COLORIMETRIC DETECTION; GENE-EXPRESSION; P53 MUTATIONS
AB DNA and RNA analysis is of high importance for clinical diagnoses, forensic analysis, and basic studies in the biological and biomedical fields. In this paper, we report the ultrahighly sensitive homogeneous detection of DNA and microRNA by using a novel single-silver-nanoparticle counting (SSNPC) technique. The principle of SSNPC is based on the photon-burst counting of single silver nanoparticles (Ag NPs) in a highly focused laser beam (about 0.5 fL detection volume) due to Brownian motion and the strong resonance Rayleigh scattering of single Ag NPs. We first investigated the performance of the SSNPC system and then developed an ultrasensitive homogeneous detection method for DNA and microRNA based on this single-nanoparticle technique. Sandwich nucleic acid hybridization models were utilized in the assays. In the hybridization process, when two Ag-NP-oligonucleotide conjugates were mixed in a sample containing DNA (or micro-RNA) targets, the binding of the targets caused the Ag NPs to form dimers (or oligomers), which led to a reduction in the photon-burst counts. The SSNPC method was used to measure the change in the photon-burst counts. The relationship between the change of the photon-burst counts and the target concentration showed a good linearity. This method was used for the assay of sequence-specific DNA fragments and microRNAs. The detection limits were at about the 1 fM level, which is 2-5 orders of magnitude more sensitive than current homogeneous methods.
C1 [Xu, Fagong; Dong, Chaoqing; Xie, Chao; Ren, Jicun] Shanghai Jiao Tong Univ, Coll Chem & Chem Engn, State Key Lab Met Matrix Composites, Shanghai 200240, Peoples R China.
RP Ren, JC (reprint author), Shanghai Jiao Tong Univ, Coll Chem & Chem Engn, State Key Lab Met Matrix Composites, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.
EM jicunren@sjtu.edu.cn
FU NSFC [20675052, 20727005, 20975067]; National Basic Research Program of
   China [2009CB930400]
FX This work was financially supported by the NSFC (grant ties.: 20675052,
   20727005, and 20975067) and the National Basic Research Program of China
   (2009CB930400).
CR Algar WR, 2009, ANAL CHEM, V81, P4113, DOI 10.1021/ac900421p
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   CARDULLO RA, 1988, P NATL ACAD SCI USA, V85, P8790, DOI 10.1073/pnas.85.23.8790
   Chen XD, 2008, J AM CHEM SOC, V130, P16947, DOI 10.1021/ja804628x
   Dai Q, 2008, J AM CHEM SOC, V130, P8138, DOI 10.1021/ja801947e
   Dong CQ, 2006, J PHYS CHEM B, V110, P11069, DOI 10.1021/jp060279r
   Du BA, 2006, ANGEW CHEM INT EDIT, V45, P8022, DOI 10.1002/anie.200603331
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Facher EA, 1997, CANCER, V79, P2424, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2424::AID-CNCR19>3.0.CO;2-T
   Franz O, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.11.e3
   GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357
   Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023
   Han MS, 2006, ANGEW CHEM INT EDIT, V45, P1807, DOI 10.1002/anie.200504277
   Jenison R, 2001, NAT BIOTECHNOL, V19, P62, DOI 10.1038/83530
   Jin RC, 2003, J AM CHEM SOC, V125, P1643, DOI 10.1021/ja021096v
   Kim SA, 2007, NAT METHODS, V4, P963, DOI 10.1038/NMETH1104
   KINJO M, 1995, NUCLEIC ACIDS RES, V23, P1795, DOI 10.1093/nar/23.10.1795
   Liu CH, 2006, ANAL CHEM, V78, P3738, DOI 10.1021/ac0522409
   Liu GL, 2007, NAT METHODS, V4, P1015, DOI 10.1038/nmeth1133
   Liu X, 2008, J AM CHEM SOC, V130, P2780, DOI 10.1021/ja711298b
   Masuko M, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e34
   Neely LA, 2006, NAT METHODS, V3, P41, DOI 10.1038/NMETH825
   Nelson PT, 2004, NAT METHODS, V1, P155, DOI 10.1038/NMETH717
   Politz JC, 1998, P NATL ACAD SCI USA, V95, P6043, DOI 10.1073/pnas.95.11.6043
   RAY PC, 2006, ANGEW CHEM, V118, P1169
   Reynolds RA, 2000, J AM CHEM SOC, V122, P3795, DOI 10.1021/ja000133k
   Rijiravanich P, 2008, ANAL CHEM, V80, P3904, DOI 10.1021/ac701867m
   Rodin SN, 1998, P NATL ACAD SCI USA, V95, P11927, DOI 10.1073/pnas.95.20.11927
   Shi WW, 2008, LAB CHIP, V8, P1432, DOI 10.1039/b808753a
   SIXOU S, 1994, NUCLEIC ACIDS RES, V22, P662, DOI 10.1093/nar/22.4.662
   Song H., 2006, ANGEW CHEM, V118, P7494
   Sonnichsen C, 2005, NAT BIOTECHNOL, V23, P741, DOI 10.1038/nbt1100
   Southern E, 2006, NAT PROTOC, V1, P518, DOI 10.1038/nprot.2006.73
   Storhoff JJ, 2004, NAT BIOTECHNOL, V22, P883, DOI 10.1038/nbt977
   Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i
   SUN YL, 1982, NUCLEIC ACIDS RES, V10, P5753, DOI 10.1093/nar/10.19.5753
   Sunters A, 1996, NUCLEIC ACIDS RES, V24, P2456, DOI 10.1093/nar/24.12.2456
   Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757
   Thompson DG, 2008, ANAL CHEM, V80, P2805, DOI 10.1021/ac702403w
   Tokareva I, 2004, J AM CHEM SOC, V126, P15784, DOI 10.1021/ja046779k
   vanKranen HJ, 1997, CANCER RES, V57, P1238
   Varallyay E, 2008, NAT PROTOC, V3, P190, DOI 10.1038/nprot.2007.528
   Vidal BC, 2005, NEW J CHEM, V29, P812, DOI 10.1039/b417683a
   Wang KL, 2007, CHEMBIOCHEM, V8, P1126, DOI 10.1002/cbic.200700174
   Wark AW, 2008, ANGEW CHEM INT EDIT, V47, P644, DOI 10.1002/anie.200702450
   Wu W, 2007, INT J CANCER, V120, P953, DOI 10.1002/ijc.22454
   Xie C, 2009, J AM CHEM SOC, V131, P12763, DOI 10.1021/ja903873n
   Xu XY, 2007, ANAL CHEM, V79, P6650, DOI 10.1021/ac070867g
   Yao G, 2003, CHEM-EUR J, V9, P5686, DOI 10.1002/chem.200304977
   Yea KH, 2006, CHEM COMMUN, P1509, DOI 10.1039/b516253j
   Yguerabide J, 2001, J CELL BIOCHEM, V84, P71, DOI 10.1002/jcb.10077
   Yguerabide J, 1998, ANAL BIOCHEM, V262, P137, DOI 10.1006/abio.1998.2759
   Yguerabide J, 1998, ANAL BIOCHEM, V262, P157, DOI 10.1006/abio.1998.2760
NR 53
TC 13
Z9 14
U1 7
U2 62
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0947-6539
EI 1521-3765
J9 CHEM-EUR J
JI Chem.-Eur. J.
PY 2010
VL 16
IS 3
BP 1010
EP 1016
DI 10.1002/chem.200902555
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA 556TQ
UT WOS:000274615700035
PM 19938021
DA 2018-12-27
ER

PT J
AU Gao, M
   Li, H
   Feng, WZ
AF Gao, Ming
   Li, Hang
   Feng, Wanzhong
TI RETRACTED: Flame Retardance and Thermal Degradation of Intumescent Flame
   Retardant Polypropylene with Microencapsulated TPMP (Retracted article.
   See vol. 184, pg. 2171, 2012)
SO COMBUSTION SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Degradation; Flame retardant; Microcapsules; Polypropylene; Synthesis
ID PHOSPHORUS-CONTAINING EPOXY; PHOSPHATE; RESINS
AB Tri (1-oxo-2,6,7-trioxa-1-phosphabicyclo[2,2,2] methylene-4) phosphate (TPMP) and microencapsulated TPMP (MC-TPMP) with a melamine resin shell, respectively, were synthesized. Their structures were characterized by IR, XPS, scanning electron microscopy (SEM), and thermogravimetry (TG) analysis. The flame retardance of TPMP and MC-TPMP combined with atactic polypropylene (APP) in polypropylene (PP) was characterized by limiting oxygen index (LOI) and UL-94 test. The authors found that the LOI values of PP/APP/MC-TPMP composites are higher than those of PP/APP/TPMP composites. They found that 30% of APP/MC-TPMP in PP gets 32.0% of LOI and UL 94V-0. The morphology of the char structure was studied by SEM. Thermal properties of the PP/APP/MC-TPMP and PP/APP/TPMP composites were investigated with TG and differential TG (DTG). The flame retardant mechanism has been discussed according to the results of TG, DTG, and SEM.
C1 [Gao, Ming] N China Inst Sci & Technol, Dept Environm Engn, Yanjiao Beijing 101601, Peoples R China.
   [Li, Hang] Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China.
   [Feng, Wanzhong] China Univ Geosci, Great Wall Coll, Baoding, Hebei, Peoples R China.
RP Gao, M (reprint author), N China Inst Sci & Technol, Dept Environm Engn, Box 206, Yanjiao Beijing 101601, Peoples R China.
EM gmscy@hotmail.com
CR Bourbigot S, 1996, J CHEM SOC FARADAY T, V92, P149, DOI 10.1039/ft9969200149
   Gao F, 2006, POLYM DEGRAD STABIL, V91, P1295, DOI 10.1016/j.polymdegradstab.2005.08.013
   GAO M, 2008, PMSE PREPRINTS, V98, P533
   Halpern Y, 1984, U. S. Patent, Patent No. [4,480,093, 4480093]
   HENDRICKSON L, 1995, POLYM ENG SCI, V35, P211, DOI 10.1002/pen.760350215
   Kandola BK, 1996, J MACROMOL SCI R M C, VC36, P721
   LI X, 2002, BEIJING LIGONG DAXUE, V22, P650
   LI X, 2003, GAOFENZI CAILIAO KEX, V19, P198
   LI X, 2008, Patent No. 101195642
   Liu YL, 2001, POLYMER, V42, P3445, DOI 10.1016/S0032-3861(00)00717-5
   Liu YL, 1996, J APPL POLYM SCI, V61, P613, DOI 10.1002/(SICI)1097-4628(19960725)61:4<613::AID-APP5>3.0.CO;2-O
   Ma ZL, 2006, J APPL POLYM SCI, V101, P739, DOI 10.1002/app.23973
   Shieh JY, 2001, POLYMER, V42, P7617, DOI 10.1016/S0032-3861(01)00257-9
   Wang CS, 1999, J POLYM SCI POL CHEM, V37, P3903, DOI 10.1002/(SICI)1099-0518(19991101)37:21<3903::AID-POLA4>3.0.CO;2-X
   Wu K, 2008, POLYM ADVAN TECHNOL, V19, P1118, DOI 10.1002/pat.1095
   Xing WY, 2009, POLYM ADVAN TECHNOL, V20, P696, DOI 10.1002/pat.1335
   Zhang LL, 2009, J APPL POLYM SCI, V111, P168, DOI 10.1002/app.29045
   Zhou S, 2008, FIRE MATER, V32, P307, DOI 10.1002/fam.969
NR 18
TC 7
Z9 7
U1 5
U2 32
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0010-2202
EI 1563-521X
J9 COMBUST SCI TECHNOL
JI Combust. Sci. Technol.
PY 2010
VL 182
IS 10
BP 1446
EP 1456
AR PII 927405347
DI 10.1080/00102200903490228
PG 11
WC Thermodynamics; Energy & Fuels; Engineering, Multidisciplinary;
   Engineering, Chemical
SC Thermodynamics; Energy & Fuels; Engineering
GA 659NO
UT WOS:000282573900005
DA 2018-12-27
ER

PT J
AU Gervini, D
AF Gervini, Daniel
TI RETRACTED: The functional singular value decomposition for bivariate
   stochastic processes (Retracted article. See vol. 54, pg. 2358, 2010)
SO COMPUTATIONAL STATISTICS & DATA ANALYSIS
LA English
DT Article; Retracted Publication
ID PRINCIPAL COMPONENT ANALYSIS; INFERENCE; SIGNALS; MODELS
AB In this article we present some statistical applications of the functional singular value decomposition (FSVD). This tool allows us to decompose the sample mean of a bivariate stochastic process into components that are functions of separate variables. These components are sometimes interpretable functions that summarize salient features of the data. The FSVD can be used to visually detect outliers, to estimate the mean of a stochastic process or to obtain individual smoothers of the sample surfaces. As estimators of the mean, we show by simulation that FSVD estimators are competitive with tensor-product splines in some situations. (C) 2009 Elsevier B.V. All rights reserved.
C1 Univ Wisconsin, Dept Math Sci, Milwaukee, WI 53201 USA.
RP Gervini, D (reprint author), Univ Wisconsin, Dept Math Sci, POB 413, Milwaukee, WI 53201 USA.
EM gervini@uwm.edu
RI Gervini, Daniel/E-6904-2014
OI Gervini, Daniel/0000-0003-2655-0337
CR Adler R. J., 2007, RANDOM FIELDS GEOMET
   AUBRY N, 1991, J STAT PHYS, V64, P683, DOI 10.1007/BF01048312
   de Boor C.A., 2001, PRACTICAL GUIDE SPLI
   Dente JA, 1996, SIGNAL PROCESS-IMAGE, V8, P131, DOI 10.1016/0923-5965(95)00041-0
   Ferraty F., 2006, NONPARAMETRIC FUNCTI
   Gasser T, 2004, METHODS HUMAN GROWTH, P179, DOI DOI 10.1017/CBO9780511542411.008
   Gervini D, 2006, J ROY STAT SOC B, V68, P671, DOI 10.1111/j.1467-9868.2006.00561.x
   Gohberg I., 2003, BASIC CLASSES LINEAR
   GU C, 2000, SMOOTHING REGRESSION, P329
   HARDLE W, 2000, SMOOTHING REGRESSION, P357
   HASTIE T., 2001, ELEMENTS STAT LEARNI
   Kneip A, 2001, J AM STAT ASSOC, V96, P519, DOI 10.1198/016214501753168235
   Morris JS, 2006, J ROY STAT SOC B, V68, P179, DOI 10.1111/j.1467-9868.2006.00539.x
   NYCHKA D, 2000, SMOOTHING REGRESSION, P393
   Ramsay J. O., 2005, FUNCTIONAL DATA ANAL
   RAMSAY J. O., 2002, APPL FUNCTIONAL DATA
   Silverman BW, 1996, ANN STAT, V24, P1
   Taylor JE, 2007, J AM STAT ASSOC, V102, P913, DOI 10.1198/016214507000000815
   TYLER DE, 1981, ANN STAT, V9, P725, DOI 10.1214/aos/1176345514
   Yao F, 2006, J ROY STAT SOC B, V68, P3, DOI 10.1111/j.1467-9868.2005.00530.x
NR 20
TC 4
Z9 4
U1 2
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-9473
EI 1872-7352
J9 COMPUT STAT DATA AN
JI Comput. Stat. Data Anal.
PD JAN 1
PY 2010
VL 54
IS 1
BP 163
EP 172
DI 10.1016/j.csda.2009.07.024
PG 10
WC Computer Science, Interdisciplinary Applications; Statistics &
   Probability
SC Computer Science; Mathematics
GA 536AW
UT WOS:000273015500015
DA 2018-12-27
ER

PT J
AU Sivasubramanian, M
   Kalimuthu, S
AF Sivasubramanian, M.
   Kalimuthu, S.
TI RETRACTED: A computer application in mathematics (Retracted article. See
   vol. 63, pg. 1424, 2012)
SO COMPUTERS & MATHEMATICS WITH APPLICATIONS
LA English
DT Article; Retracted Publication
DE Number theory; Algebra; Geometry; Euclidean postulates; Non-Euclidean
   geometries and physical applications to geometry
AB In this study, a computer application was used to solve a mathematical problem. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Sivasubramanian, M.] Dr Mahalingam Coll Engn & Technol, Dept Math, Pollachi 642003, Tamil Nadu, India.
RP Sivasubramanian, M (reprint author), Dr Mahalingam Coll Engn & Technol, Dept Math, Pollachi 642003, Tamil Nadu, India.
EM profpk49@yahoo.com; ohm@budweiser.com
CR SIVASUBRAMANIAN M, 2008, J MATH STAT, V4, P122
   SIVASUBRAMANIAN M, 2008, J MATH STAT, V4, P146
NR 2
TC 1
Z9 1
U1 3
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0898-1221
EI 1873-7668
J9 COMPUT MATH APPL
JI Comput. Math. Appl.
PD JAN
PY 2010
VL 59
IS 1
BP 296
EP 297
DI 10.1016/j.camwa.2009.07.048
PG 2
WC Mathematics, Applied
SC Mathematics
GA 548XW
UT WOS:000274004500030
OA Bronze
DA 2018-12-27
ER

PT J
AU Hua, S
   Antao, ST
   Corbett, A
   Witting, PK
AF Hua, S.
   Antao, S. T.
   Corbett, A.
   Witting, P. K.
TI RETRACTED: The Significance of Neuroglobin in the Brain (Retracted
   article. See vol. 17, pg. 2684, 2010)
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review; Retracted Publication
DE Neuroglobin; oxygen transport; antioxidant; neuroprotection; hypoxia;
   ischemia
ID NUCLEOTIDE DISSOCIATION INHIBITOR; HYPOXIA REOXYGENATION INJURY;
   VERTEBRATE GLOBIN FAMILY; LIGAND-BINDING; NITRIC-OXIDE; MOUSE
   NEUROGLOBIN; OXIDATIVE STRESS; IN-VIVO; PROTEIN-TRANSDUCTION;
   HEME-POCKET
AB Since its discovery in 2000, neuroglobin (Nb) has been demonstrated to have an essential and conserved function in vertebrates with the consequential discovery of a neuroprotective role. Nb is a member of the globin superfamily and is predominantly expressed in neurons of the central and peripheral nervous system. Thorough studies have been performed to elucidate the molecular structure of Nb and its ligand binding characteristics. The precise physiological function and mechanism of action of Nb is beginning to be established, with a number of hypotheses having been put forward. While Nb shares an intrinsic affinity for low-molecular weight diatomic gases similar to other globins, the relatively low level of Nb expression in cerebral neurons places limitations on its potential to function as a reservoir for oxygen, especially during periods of acute ischemia. In vitro studies have suggested that the neuroprotective role of Nb may be due to its ability to scavenge reactive oxygen (ROS) and nitrogen (RNS) species. However other studies have proposed Nb as being part of a signalling chain that transmits the redox state of the cell that is protective against oxidative stress or that inhibits apoptosis. This review is intended to summarize the structural, genomic and functional data on neuroglobin to date, thereby providing perspectives for future research on these molecules that may have substantial biomedical implications.
C1 [Antao, S. T.; Witting, P. K.] Univ Sydney, Discipline Pathol, Bosch Inst, Sydney Med Sch, Sydney, NSW 2006, Australia.
   [Hua, S.; Antao, S. T.; Witting, P. K.] Univ Sydney, Sydney Med Sch, Concord Repatriat Gen Hosp, Vasc Biol Grp,ANZAC Res Inst, Concord, NSW 2139, Australia.
   [Corbett, A.] Concord Repatriat Gen Hosp, Dept Neurosci, Concord, NSW 2139, Australia.
RP Witting, PK (reprint author), Univ Sydney, Discipline Pathol, Bosch Inst, Sydney Med Sch, Sydney, NSW 2006, Australia.
EM pwitting@med.usyd.edu.au
FU Australian Research Council; Diabetes Australia Research Trust; National
   Heart and Stroke Foundations of Australia
FX We acknowledge the following funding bodies for their support:
   Australian Research Council (Discovery Grant and Fellowship) and the
   Diabetes Australia Research Trust (2009 grant-in-aid) awarded to PKW;
   and the National Heart and Stroke Foundations of Australia (co-funded
   PhD stipend to STA).
CR Agam K, 2000, J NEUROSCI, V20, P5748
   Bentmann A, 2005, J BIOL CHEM, V280, P20660, DOI 10.1074/jbc.M501338200
   Brunori M, 2007, CELL MOL LIFE SCI, V64, P1259, DOI 10.1007/s00018-007-7090-2
   Brunori M, 2006, FASEB J, V20, P2192, DOI 10.1096/fj.06-6643rev
   Brunori M, 2005, P NATL ACAD SCI USA, V102, P8483, DOI 10.1073/pnas.0408766102
   Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096
   Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093
   Burmester T, 2004, NEWS PHYSIOL SCI, V19, P110, DOI 10.1152/nips.01513.2003
   Burmester T, 2009, J EXP BIOL, V212, P1423, DOI 10.1242/jeb.000729
   Burmester Thorsten, 2008, V9, P211
   Conley KE, 2000, ACTA PHYSIOL SCAND, V168, P623, DOI 10.1046/j.1365-201x.2000.00714.x
   Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200
   Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200
   Droge W, 2002, PHYSIOL REV, V82, P47
   Du WH, 2003, J AM CHEM SOC, V125, P8080, DOI 10.1021/ja034584r
   Duong TTH, 2008, BRAIN RES, V1219, P8, DOI 10.1016/j.brainres.2008.04.044
   Duong TTH, 2009, J NEUROCHEM, V108, P1143, DOI 10.1111/j.1471-4159.2008.05846.x
   Eliasson MJL, 1999, J NEUROSCI, V19, P5910, DOI 10.1523/JNEUROSCI.19-14-05910.1999
   Fago A, 2004, J BIOL CHEM, V279, P44417, DOI 10.1074/jbc.M407126200
   Fago A, 2004, IUBMB LIFE, V56, P689, DOI 10.1080/15216540500037299
   Fago A, 2008, IUBMB LIFE, V60, P398, DOI 10.1002/iub.35
   Fago A, 2006, FEBS LETT, V580, P4884, DOI 10.1016/j.febslet.2006.08.003
   Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298
   Flogel U, 2004, FASEB J, V18, P1156, DOI 10.1096/fj.03-1382fje
   Fordel E, 2007, FEBS J, V274, P1312, DOI 10.1111/j.1742-4658.2007.05679.x
   Fordel E, 2006, NEUROSCI LETT, V410, P146, DOI 10.1016/j.neulet.2006.09.027
   Fuchs C, 2006, CYTOGENET GENOME RES, V112, P296, DOI 10.1159/000089884
   Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378
   Geuens E, 2003, J BIOL CHEM, V278, P30417, DOI 10.1074/jbc.C300203200
   Godecke A, 2003, J BIOL CHEM, V278, P21761, DOI 10.1074/jbc.M302573200
   Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200
   Hamdane D, 2003, J BIOL CHEM, V278, P51713, DOI 10.1074/jbc.M309396200
   Hankeln T, 2005, J INORG BIOCHEM, V99, P110, DOI 10.1016/j.jinorgbio.2004.11.009
   Herold S, 2005, COMP BIOCHEM PHYS A, V142, P124, DOI 10.1016/j.cbpb.2005.06.009
   Herold S, 2004, J BIOL CHEM, V279, P22841, DOI 10.1074/jbc.M313732200
   Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7
   Hou SB, 2001, P NATL ACAD SCI USA, V98, P9353, DOI 10.1073/pnas.161185598
   Hundahl C, 2006, BRAIN RES, V1085, P19, DOI 10.1016/j.brainres.2006.02.040
   Hundahl C, 2005, NEUROPATH APPL NEURO, V31, P610, DOI 10.1111/j.1365-2990.2005.00657.x
   Hundahl CA, 2008, NEUROENDOCRINOLOGY, V88, P183, DOI 10.1159/000135617
   Hundahl CA, 2008, NEUROENDOCRINOLOGY, V88, P173, DOI 10.1159/000129698
   Itoh Y, 2003, P NATL ACAD SCI USA, V100, P4879, DOI 10.1073/pnas.0831078100
   Jin KL, 2008, NEUROSCI LETT, V430, P135, DOI 10.1016/j.neulet.2007.10.031
   Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029
   Khan AA, 2008, FASEB J, V22, P1737, DOI 10.1096/fj.07-100784
   Khan AA, 2007, P NATL ACAD SCI USA, V104, P19114, DOI 10.1073/pnas.0706167104
   Khan AA, 2006, P NATL ACAD SCI USA, V103, P17944, DOI 10.1073/pnas.0607497103
   Koder RL, 2009, NATURE, V458, P305, DOI 10.1038/nature07841
   Kriegl JM, 2002, P NATL ACAD SCI USA, V99, P7992, DOI 10.1073/pnas.082244399
   Kugelstadt D, 2004, BIOCHEM BIOPH RES CO, V325, P719, DOI 10.1016/j.bbrc.2004.10.080
   Kundu S, 2003, TRENDS PLANT SCI, V8, P387, DOI 10.1016/S1360-1385(03)00163-8
   Lardinois OM, 2008, BIOCHEMISTRY-US, V47, P10440, DOI 10.1021/bi800771k
   Li RC, 2008, NEUROBIOL AGING, V29, P1815, DOI 10.1016/j.neurobiolaging.2007.05.001
   Li RC, 2006, BRAIN RES, V1096, P173, DOI 10.1016/j.brainres.2006.04.063
   Lipton P, 1999, PHYSIOL REV, V79, P1431
   Liu JX, 2009, J NEUROSCI RES, V87, P164, DOI 10.1002/jnr.21826
   Mammen PPA, 2002, J HISTOCHEM CYTOCHEM, V50, P1591, DOI 10.1177/002215540205001203
   Mendoza V, 2005, TRANSPL P, V37, P237, DOI 10.1016/j.transproceed.2004.12.270
   Merx Marc W., 2001, FASEB Journal, V15, P1077
   Milani M, 2005, J INORG BIOCHEM, V99, P97, DOI 10.1016/j.jinorgbio.2004.10.035
   Milton SL, 2006, J BIOMED SCI, V13, P509, DOI 10.1007/s11373-006-9084-8
   Nienhaus K, 2004, J BIOL CHEM, V279, P22944, DOI 10.1074/jbc.M401561200
   Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9647, DOI 10.1021/bi034788k
   Nienhaus K, 2007, IUBMB LIFE, V59, P490, DOI 10.1080/15216540601188538
   Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622
   Palmer AE, 2009, CHEM REV, V109, P4533, DOI 10.1021/cr900293t
   Peroni D, 2007, NEUROSCI LETT, V421, P110, DOI 10.1016/j.neulet.2007.05.046
   Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7
   Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-repots/kvf248
   Petersen MG, 2008, J INORG BIOCHEM, V102, P1777, DOI 10.1016/j.jinorgbio.2008.05.008
   Powers JM, 2006, J NEUROPATH EXP NEUR, V65, P716, DOI 10.1097/01.jnen.0000228200.27539.19
   Rayner BS, 2009, BIOCHEM J, V423, P169, DOI 10.1042/BJ20090716
   Rayner BS, 2006, J NEUROCHEM, V97, P211, DOI 10.1111/j.1471-4159.2006.03726.x
   Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5
   Roesner A, 2005, MOL BIOL EVOL, V22, P12, DOI 10.1093/molbev/msh258
   Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200
   Schmidt-Kastner R, 2006, BRAIN RES, V1103, P173, DOI 10.1016/j.brainres.2006.05.047
   Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181
   Shang AJ, 2006, BRAIN RES, V1078, P219, DOI 10.1016/j.brainres.2006.01.064
   Sims NR, 2004, J BIOENERG BIOMEMBR, V36, P329, DOI 10.1023/B:JOBB.0000041763.63958.e7
   Sims NR, 2002, NEUROCHEM INT, V40, P511, DOI 10.1016/S0197-0186(01)00122-X
   SIMS NR, 2009, BIOCH BIOPH IN PRESS
   Sowa AW, 1998, P NATL ACAD SCI USA, V95, P10317, DOI 10.1073/pnas.95.17.10317
   Studer L, 2000, J NEUROSCI, V20, P7377
   Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698
   Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100
   TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002
   Trandafir F, 2004, BBA-PROTEINS PROTEOM, V1702, P153, DOI 10.1016/j.bbapap.2004.08.004
   Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200
   Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200
   Uno T, 2004, J BIOL CHEM, V279, P5886, DOI 10.1074/jbc.M311748200
   Vallone B, 2004, PROTEINS, V56, P85, DOI 10.1002/prot.20113
   Vallone B, 2004, P NATL ACAD SCI USA, V101, P17351, DOI 10.1073/pnas.0407633101
   Van Doorslaer S, 2003, J BIOL CHEM, V278, P4919, DOI 10.1074/jbc.M210617200
   Vinck E, 2006, J BIOL INORG CHEM, V11, P467, DOI 10.1007/s00775-006-0100-2
   Vinogradov SN, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-31
   Wakasugi K, 2005, BIOCHEMISTRY-US, V44, P2943, DOI 10.1021/bi0477539
   Wakasugi K, 2004, BIOCHEMISTRY-US, V43, P5119, DOI 10.1021/bi0495782
   Wakasugi K, 2004, BIOCHEM BIOPH RES CO, V318, P453, DOI 10.1016/j.bbrc.2004.04.045
   Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200
   Walker FA, 2006, J BIOL INORG CHEM, V11, P391, DOI 10.1007/s00775-006-0095-8
   Wang DH, 2008, CHINESE J PHYS, V46, P712
   Wang XY, 2008, STROKE, V39, P1869, DOI 10.1161/STROKEAHA.107.506022
   Watanabe S, 2008, BIOCHEM BIOPH RES CO, V369, P695, DOI 10.1016/j.bbrc.2008.02.089
   Weber RE, 2004, RESP PHYSIOL NEUROBI, V144, P141, DOI 10.1016/j.resp.2004.04.018
   Weber RE, 2001, PHYSIOL REV, V81, P569
   WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857
   Wittenberg J. B., 1992, ADV COMP ENV PHYSL, V13, P60
   Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243
   Witting PK, 2001, J BIOL CHEM, V276, P16540, DOI 10.1074/jbc.M011707200
   Wystub S, 2003, NEUROSCI LETT, V346, P114, DOI 10.1016/S0304-3940(03)00563-9
   Xu WL, 2003, ACTA BIOCH BIOPH SIN, V35, P823
   Zhou GY, 2008, BIOTECHNOL APPL BIOC, V49, P25, DOI 10.1042/BA20070061
   Zhu YH, 2002, BLOOD, V100, P2494, DOI 10.1182/blood-2002-01-0280
NR 114
TC 9
Z9 12
U1 5
U2 15
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD JAN
PY 2010
VL 17
IS 2
BP 160
EP 172
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 532OF
UT WOS:000272758600005
PM 19941472
DA 2018-12-27
ER

PT J
AU Shlien, A
   Malkin, D
AF Shlien, Adam
   Malkin, David
TI RETRACTED: Copy number variations and cancer susceptibility (Retracted
   article. See vol. 28, pg. 376, 2016)
SO CURRENT OPINION IN ONCOLOGY
LA English
DT Review; Retracted Publication
DE cancer genome; cancer susceptibility; copy number variation
ID FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-SUPPRESSOR GENE; MALIGNANT
   RHABDOID TUMOR; LARGE GERMLINE DELETION; LARGE GENOMIC DELETIONS;
   LI-FRAUMENI-SYNDROME; BREAST-CANCER; JUVENILE POLYPOSIS; HUMAN-DISEASE;
   REARRANGEMENTS
AB Purpose of review
   DNA copy number variations (CNVs) comprise a recently discovered element of genetic variation that affects a greater cumulative fraction of the genome than single-nucleotide polymorphisms (SNPs). This review discusses current understanding of the characteristics of Cl in the human genome and explores the emerging discoveries of both constitutional and somatic Cl in an ever-expanding variety of human cancers.
   Recent findings
   The advent of high-resolution SNP arrays has made it possible to identify Cl Characterization of widespread constitutional Cl offers insight into their role in disease susceptibility, whereas somatic CNVs identify regions of the genome involved in disease phenotype. The role of Cl in cancer has only emerged in the last 2 years, with constitutional Cl originally being observed in the Li-Fraumeni cancer susceptibility syndrome, and more recently in neuroblastoma.
   Summary
   It is not yet known how common or how functionally relevant Cl will be to the process of carcinogenesis. Nonetheless, the inherent instability and structural variability that characterize cancer cell genomes make this form of genetic variation particularly intriguing to the study of cancer.
C1 [Malkin, David] Univ Toronto, Div Hematol Oncol, Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
   [Shlien, Adam; Malkin, David] Univ Toronto, Dept Genet & Genome Biol, Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
   [Shlien, Adam; Malkin, David] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1X8, Canada.
   [Malkin, David] Univ Toronto, Dept Pediat, Toronto, ON M5G 1X8, Canada.
RP Malkin, D (reprint author), Univ Toronto, Div Hematol Oncol, Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM david.malkin@sickkids.ca
FU Canadian Cancer Society; SickKids Foundation; Canadian Institutes for
   Health Research; Canada Foundation for Innovation
FX The research was supported by a grant from the Canadian Cancer Society,
   SickKids Foundation, Canadian Institutes for Health Research and Canada
   Foundation for Innovation. A.S. is supported by the Frederick Banting
   and Charles Best Canada Graduate Scholarship from the Canadian
   Institutes for Health Research.
CR Aretz S, 2005, J MED GENET, V42, P185, DOI 10.1136/jmg.2004.022822
   Bausch B, 2006, NEW ENGL J MED, V354, P2729, DOI 10.1056/NEJMc066006
   Baysal BE, 2004, J MED GENET, V41, P703, DOI 10.1136/jmg.2004.019224
   Bittel Douglas C., 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009531
   Bougeard G, 2008, J MED GENET, V45, P535, DOI 10.1136/jmg.2008.057570
   Bougeard G, 2003, ONCOGENE, V22, P840, DOI 10.1038/sj.onc.1206155
   Bremner R, 1997, AM J HUM GENET, V61, P556, DOI 10.1086/515499
   Cascon A, 2006, GENE CHROMOSOME CANC, V45, P213, DOI 10.1002/gcc.20283
   Casilli F, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.040212
   Chan TL, 2001, ONCOGENE, V20, P2976, DOI 10.1038/sj.onc.1204376
   Charames GS, 2008, HUM GENET, V124, P535, DOI 10.1007/s00439-008-0579-4
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Cybulski C, 2006, J MED GENET, V43, P863, DOI 10.1136/jmg.2006.044974
   Cybulski C, 2007, BREAST CANCER RES TR, V102, P119, DOI 10.1007/s10549-006-9320-y
   Delnatte C, 2006, AM J HUM GENET, V78, P1066, DOI 10.1086/504301
   Diskin SJ, 2009, NATURE, V459, P987, DOI 10.1038/nature08035
   Elsea SH, 2008, EUR J HUM GENET, V16, P412, DOI 10.1038/sj.ejhg.5202009
   Feuk L, 2006, NAT REV GENET, V7, P85, DOI 10.1038/nrg1767
   Forbes S A, 2008, Curr Protoc Hum Genet, VChapter 10, DOI 10.1002/0471142905.hg1011s57
   Frank B, 2007, CARCINOGENESIS, V28, P1442, DOI 10.1093/carcin/bgm033
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Gault J, 2003, AM J MED GENET B, V123B, P39, DOI 10.1002/ajmg.b.20061
   Greenway SC, 2009, NAT GENET, V41, P931, DOI 10.1038/ng.415
   Guryev V, 2008, NAT GENET, V40, P538, DOI 10.1038/ng.141
   Henrichsen CN, 2009, NAT GENET, V41, P424, DOI 10.1038/ng.345
   Higgins ME, 2007, NUCLEIC ACIDS RES, V35, pD721, DOI 10.1093/nar/gkl811
   HODGSON SV, 1993, J MED GENET, V30, P369, DOI 10.1136/jmg.30.5.369
   Horvath A, 2008, CLIN CANCER RES, V14, P388, DOI 10.1158/1078-0432.CCR-07-1155
   HUFF V, 1991, AM J HUM GENET, V48, P997
   Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416
   Inoue K, 2002, ANNU REV GENOM HUM G, V3, P199, DOI 10.1146/annurev.genom.3.032802.120023
   Ionita-Laza I, 2009, GENOMICS, V93, P22, DOI 10.1016/j.ygeno.2008.08.012
   Jackson EM, 2007, HUM GENET, V122, P117, DOI 10.1007/s00439-007-0386-3
   Kishi M, 1998, JPN J CANCER RES, V89, P1
   Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833
   Kozlowski P, 2007, HUM GENET, V121, P389, DOI 10.1007/s00439-006-0308-9
   LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315
   Le Meur N, 2004, EUR J HUM GENET, V12, P415, DOI 10.1038/sj.ejhg.5201155
   Lesueur F, 2008, BRIT J CANCER, V99, P364, DOI 10.1038/sj.bjc.6604470
   Levran O, 2005, HUM MUTAT, V25, P142, DOI 10.1002/humu.20125
   Maher B, 2008, NATURE, V456, P18, DOI 10.1038/456018a
   McCarroll SA, 2008, NAT GENET, V40, P1166, DOI 10.1038/ng.238
   McCarroll SA, 2007, NAT GENET, V39, pS37, DOI 10.1038/ng2080
   McWhinney SR, 2004, J CLIN ENDOCR METAB, V89, P5694, DOI 10.1210/jc.2004-0769
   Mefford HC, 2008, NEW ENGL J MED, V359, P1685, DOI 10.1056/NEJMoa0805384
   Merla G, 2006, AM J HUM GENET, V79, P332, DOI 10.1086/506371
   Meyer-Lindenberg A, 2006, NAT REV NEUROSCI, V7, P380, DOI 10.1038/nrn1906
   Montagna M, 2003, HUM MOL GENET, V12, P1055, DOI 10.1093/hmg/ddg120
   Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690
   Nagy R, 2004, ONCOGENE, V23, P6445, DOI 10.1038/sj.onc.1207714
   NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203
   Perry GH, 2008, AM J HUM GENET, V82, P685, DOI 10.1016/j.ajhg.2007.12.010
   PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341
   Plaschke J, 2003, J MED GENET, V40, P597, DOI 10.1136/jmg.40.8.597
   Prasad SE, 2008, DEV DISABIL RES REV, V14, P26, DOI 10.1002/ddrr.5
   Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329
   RICHARDS FM, 1993, HUM MOL GENET, V2, P879, DOI 10.1093/hmg/2.7.879
   Riva P, 2000, AM J HUM GENET, V66, P100, DOI 10.1086/302709
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918
   Shimkets R, 1996, AM J HUM GENET, V59, P417
   Shlien A, 2008, P NATL ACAD SCI USA, V105, P11264, DOI 10.1073/pnas.0802970105
   Stefansson H, 2008, NATURE, V455, P232, DOI 10.1038/nature07229
   Stella A, 2007, CLIN GENET, V71, P130, DOI 10.1111/j.1399-0004.2007.00745.x
   Stone JL, 2008, NATURE, V455, P237, DOI 10.1038/nature07239
   Stranger BE, 2007, SCIENCE, V315, P848, DOI 10.1126/science.1136678
   Su LK, 2000, HUM GENET, V106, P101, DOI 10.1007/s004390051016
   Swensen JJ, 2009, J MED GENET, V46, P68, DOI 10.1136/jmg.2008.060152
   Thomas G, 2009, NAT GENET, V41, P579, DOI 10.1038/ng.353
   Traherne JA, 2008, INT J IMMUNOGENET, V35, P179, DOI 10.1111/j.1744-313X.2008.00765.x
   Tsilchorozidou T, 2004, J MED GENET, V41, P529, DOI 10.1136/jmg.2003.016774
   Turner DJ, 2008, NAT GENET, V40, P90, DOI 10.1038/ng.2007.40
   Van Hattem WA, 2008, GUT, V57, P623, DOI 10.1136/gut.2007.142927
   Vandepoele K, 2005, MOL BIOL EVOL, V22, P2265, DOI 10.1093/molbev/msi222
   Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358
NR 75
TC 43
Z9 43
U1 3
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8746
EI 1531-703X
J9 CURR OPIN ONCOL
JI Curr. Opin. Oncol.
PD JAN
PY 2010
VL 22
IS 1
BP 55
EP 63
DI 10.1097/CCO.0b013e328333dca4
PG 9
WC Oncology
SC Oncology
GA 537LP
UT WOS:000273114700009
PM 19952747
DA 2018-12-27
ER

PT J
AU Sanchez-Pardo, E
AF Sanchez-Pardo, Esther
TI RETRACTED: WHO WILL CARRY THE WORD? The threshold between unspeakability
   and silence in the Holocaust narratives of Charlotte Delbo and Jorge
   Semprun (Retracted article. See vol. 18, pg. 348, 2014)
SO EUROPEAN JOURNAL OF ENGLISH STUDIES
LA English
DT Article; Retracted Publication
DE Holocaust; Delbo; Semprun; memory; unspeakability; trauma
AB This article is an attempt to go beyond the heated debates over the aesthetics of Holocaust representation into a productive exploration of the politics of memory in the contemporary world. It also engages with current theory in the fields of memory studies, trauma, narratology and life writing, to elucidate what, in particular, the study of these disciplines may contribute to the understanding of the relationship between aesthetics, politics, loss and grief. My hope is that the treatment of memory, trauma and the simultaneity of past pain and its aftermath addressed in the following approaches to Charlotte Delbo - in her trilogy Auschwitz and After - and Jorge Semprun - in his memoir Literature or Life - will be applicable as 'lessons' beyond the Holocaust and towards other difficult moments in traumatic history.
C1 UCM, Depto F Inglesa II, Madrid 28040, Spain.
RP Sanchez-Pardo, E (reprint author), UCM, Depto F Inglesa II, Ciudad Univ S-N, Madrid 28040, Spain.
EM esanchez_pardo@filol.ucm.es
CR BAL M, 1991, STORYTELLING ESSAYS
   Bal Mieke, 1999, ACTS MEMORY CULTURAL
   CARUTH C, 1996, UNCLAIMED EXPERIENCE, pR7
   CORTANZE G, 1998, MAGAZINE LITTERAIRE, V364, P63
   DELBO C, 1982, THEATRE HOLOCAUST, P268
   DELBO C, 1995, DAYS MEMORY
   Delbo Charlotte, 1995, AUSCHWITZ
   HAIDU P, 1992, PROBING THE LIMITS OF REPRESENTATION, P277
   Horowitz Sara R, 1997, VOICING VOID MUTENES
   KOFMAN Sarah, 1987, PAROLES SUFFOQUEES
   Laub Dori, 1992, TESTIMONY CRISES WIT, P57
   Lyotard J.-F., 1988, HEIDEGGER JEWS
   Nora Pierre, 1996, REALMS MEMORY CONSTR
   SEMPRUN J, 1994, ECRITURE
   SEMPRUN J, 1994, MAGAZINE LIT, V317, P102
   SEMPRUN J, 1997, GRAND VOYAGE
   SIEGEL D, 1995, J PSYCHOTHERAPY PRAC, V4, P97
   SMOCK A, 1984, ESPRIT CREATEUR, V24, P5
   Young James E., 1993, TEXTURE MEMORY HOLOC
NR 19
TC 2
Z9 2
U1 1
U2 14
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1382-5577
EI 1744-4233
J9 EUR J ENGL STUD
JI Eur. J. Engl. Stud.
PY 2010
VL 14
IS 1
SI SI
BP 37
EP 48
DI 10.1080/13825571003588429
PG 12
WC Cultural Studies; Linguistics; Language & Linguistics; Literature
SC Cultural Studies; Linguistics; Literature
GA 795FF
UT WOS:000292958100004
DA 2018-12-27
ER

PT J
AU Fang, BJ
   Li, YF
   Song, Y
   Li, N
AF Fang, Baijun
   Li, Yufu
   Song, Yongping
   Li, Ning
TI RETRACTED: Isolation and characterization of multipotent progenitor
   cells from the human fetal aorta wall (Retracted article. See vol. 236,
   pg. 1360, 2011)
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article; Retracted Publication
DE mesenchymal stem cells; CD105; vascular progenitor cells; endothelial
   cells; smooth muscle cells
ID SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR-BETA; MESENCHYMAL STEM-CELLS;
   BONE-MARROW; ENDOTHELIAL-CELLS; IN-VITRO; HEMANGIOBLASTIC
   CHARACTERISTICS; ATHEROSCLEROSIS; MICE; DIFFERENTIATION
AB Recent evidence indicates that vascular progenitor cells may be the source of smooth muscle cells (SMCs) and endothelial cells (ECs). In the present study we isolated CD105(+), CD34(-) and fetal liver kinase(+) (Flk1(+)) cells from the human fetal arterial wall and demonstrated that they were vascular progenitors for both ECs and SMCs. In vitro, these cells cultured with vascular endothelial growth factor could differentiate into cells that expressed endothelial markers. Meanwhile, cells cultured with platelet-derived growth factor-BB could differentiate into cells that expressed smooth muscle markers. When transplanted into NOD/SCID mice, they contributed to neoangiogenesis in vivo during wound healing. These cells could also differentiate into osteogenic and adipogenic lineages in vitro. Hence multipotent vascular progenitor cells do exist in the arterial wall and they may have implications in the physical and pathological conditions of the vessel. Because these cells can be expanded in culture without obvious senescence for more than 30 population doublings, they may be an important source of ECs for cellular pro- or anti-angiogenic therapies.
C1 [Fang, Baijun; Li, Yufu; Song, Yongping; Li, Ning] Zhengzhou Univ, Henan Tumor Hosp, Henan Inst Haematol, Ctr Excellence Tissue Engn, Zhengzhou 450008, Peoples R China.
   [Fang, Baijun] Chinese Acad Med Sci, Ctr Excellence Tissue Engn, Beijing 100037, Peoples R China.
   [Fang, Baijun] Peking Union Med Coll, Beijing 100021, Peoples R China.
   [Li, Yufu] Zhengzhou Univ, Affiliated Hosp 1, Dept Gastroenterol, Zhengzhou 450008, Peoples R China.
RP Song, Y (reprint author), Zhengzhou Univ, Henan Tumor Hosp, Henan Inst Haematol, Ctr Excellence Tissue Engn, 127 Dongming Rd, Zhengzhou 450008, Peoples R China.
EM fdation@sina.com
FU Ministry of Science and Technology of P.R. China [2002AA205061]; Henan
   Outstanding Youth Foundation [0612000900]
FX We thank the staff at the Center of Excellence in Tissue Engineering,
   Institute of Basic Medical Science & School of Basic Medicine, Chinese
   Academy of Medical Science & Peking Union Medical College. This work was
   supported by grants from the '863 Projects' of Ministry of Science and
   Technology of P.R. China (No. 2002AA205061) and Henan Outstanding Youth
   Foundation (No. 0612000900).
CR ARCINIEGAS E, 1992, J CELL SCI, V103, P521
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413
   Braun M, 1999, CARDIOVASC RES, V41, P395, DOI 10.1016/S0008-6363(98)00302-2
   Canfield AE, 2000, FEBS LETT, V487, P267, DOI 10.1016/S0014-5793(00)02363-2
   CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027
   DEMER LL, 1995, CIRCULATION, V92, P2029, DOI 10.1161/01.CIR.92.8.2029
   DeRuiter MC, 1997, CIRC RES, V80, P444, DOI 10.1161/01.RES.80.4.444
   Fang BJ, 2005, BLOOD, V105, P2733, DOI 10.1182/blood-2004-07-2514
   Fang BJ, 2004, J LAB CLIN MED, V143, P230, DOI 10.1016/j.lab.2003.11.008
   Fang BJ, 2003, J HEMATOTH STEM CELL, V12, P603, DOI 10.1089/15258160360732632
   FITZGERALD PJ, 1992, CIRCULATION, V86, P64, DOI 10.1161/01.CIR.86.1.64
   Frid MG, 1997, CIRC RES, V81, P940
   Guo H, 2003, EXP HEMATOL, V31, P650, DOI 10.1016/S0301-472X(03)00087-0
   Hu YH, 2004, J CLIN INVEST, V113, P1258, DOI 10.1172/JCI200419628
   Jiang XB, 2000, DEVELOPMENT, V127, P1607
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071
   Ma XL, 2000, ARTERIOSCL THROM VAS, V20, P2546, DOI 10.1161/01.ATV.20.12.2546
   Mikawa T, 1996, DEV BIOL, V174, P221, DOI 10.1006/dbio.1996.0068
   MIRONOV AA, 1995, TISSUE CELL, V27, P31, DOI 10.1016/S0040-8166(95)80006-9
   Muraglia A, 2000, J CELL SCI, V113, P1161
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ross R, 1999, AM HEART J, V138, pS419, DOI 10.1016/S0002-8703(99)70266-8
   Sainz J, 2006, ARTERIOSCL THROM VAS, V26, P281, DOI 10.1161/01.ATV.0000197793.83391.91
   Schatteman GC, 2000, J CLIN INVEST, V106, P571, DOI 10.1172/JCI9087
   SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445
   Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121
   SHIOI A, 1995, ARTERIOSCL THROM VAS, V15, P2003, DOI 10.1161/01.ATV.15.11.2003
   Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070
   Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229
   YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489
   Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568
NR 34
TC 14
Z9 16
U1 4
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD JAN
PY 2010
VL 235
IS 1
BP 130
EP 138
DI 10.1258/ebm.2009.009178
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 555TK
UT WOS:000274538200017
PM 20404027
DA 2018-12-27
ER

PT J
AU Banumathi, E
   Sheikpranbabu, S
   Haribalaganesh, R
   Gurunathan, S
AF Banumathi, Elayapplan
   Sheikpranbabu, Sardarpasha
   Haribalaganesh, Ravinarayanan
   Gurunathan, Sangiliyandi
TI RETRACTED: PEDF prevents reactive oxygen species generation and retinal
   endothelial cell damage at high glucose levels (Retracted article. See
   vol. 94, pg. 203, 2012)
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article; Retracted Publication
DE pigment epithelium-derived factor; high glucose; oxidative stress;
   diabetic retinopathy; retinal endothelial cells
ID EPITHELIUM-DERIVED FACTOR; DIABETES-INDUCED ACTIVATION;
   PIGMENT-EPITHELIUM; OXIDATIVE STRESS; INDUCED APOPTOSIS; COMPLICATIONS;
   DYSFUNCTION; RETINOPATHY; INHIBITION; PERICYTES
AB Oxidative stress is associated with the development of retinopathy in diabetes; dietary supplementations of multi-antioxidants have no beneficial effects clinically. An antioxidant which could specifically target pathogenesis of diabetic retinopathy is the need of the hour. Pigment epithelium-derived factor is a potent, endogenously produced, multifunctional factor (neurotrophic, anti-angiogenic, anti-inflammatory etc.,) in the eye which recently was also shown to posses anti-oxidative action. However, its anti-oxidative effect against high glucose-induced oxidative stress in retinal endothelial cells has not been investigated. Here, we examined its anti-oxidative effect on cell morphology, survival, reactive oxygen species generation, lipid peroxidation, antioxidant status and caspase-3 activation under high glucose conditions in bovine retinal endothelial cells (BRECs). Cells grown at 33 mM glucose in the presence of PEDF at concentrations 10-50 nM did not exhibit shrinkage. Pigment epithelium-derived factor inhibited the high glucose-induced rise in reactive oxygen species generation and lipid peroxidation. In these cells, reduced glutathione levels and mitochondrial and superoxide dismutase activities increased markedly while reactive oxygen species generation decreased significantly in presence of PEDF as compared with cells grown in the absence of PEDF under high glucose conditions (10-20 nM, *p < 0.01&**p < 0.001; 30-50 nM, ***p < 0.0001). Our results suggest that pigment epithelium-derived factor has an anti-oxidant effect in bovine retinal endothelial cells at a high glucose level. The action of pigment epithelium-derived factor not only varies with the cell type but also depends on its concentration and environmental conditions. Therefore, further studies are required to determine if pigment epithelium-derived factor might constitute a preventive and/or a curative treatment for retinal neovascularization. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Banumathi, Elayapplan; Sheikpranbabu, Sardarpasha; Haribalaganesh, Ravinarayanan; Gurunathan, Sangiliyandi] Kalasalingam Univ, Kalasalingam Acad Res & Educ, Dept Biotechnol, Div Mol & Cellular Biol, Srivilliputhur 626190, Tamil Nadu, India.
RP Gurunathan, S (reprint author), Kalasalingam Univ, Kalasalingam Acad Res & Educ, Dept Biotechnol, Div Mol & Cellular Biol, Srivilliputhur 626190, Tamil Nadu, India.
EM lvsangs@yahoo.com
CR Amano S, 2005, MICROVASC RES, V69, P45, DOI 10.1016/j.mvr.2004.11.001
   ANDERSON RE, 1984, CURR EYE RES, V3, P223, DOI 10.3109/02713688408997203
   Banumathi E, 2009, MICROVASC RES, V77, P377, DOI 10.1016/j.mvr.2008.12.005
   BANUMATHI E, 2009, ANGIOGENESIS, DOI DOI 10.1007/S/10456-009-9153-5
   BAUMGARTNERPARZER SM, 1995, DIABETES, V44, P1323, DOI 10.2337/diabetes.44.11.1323
   Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1
   BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Buege J A, 1978, Methods Enzymol, V52, P302
   Cai J, 2006, J BIOL CHEM, V281, P3604, DOI 10.1074/jbc.M5074401200
   Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280
   Cao W, 1999, J NEUROSCI RES, V57, P789, DOI 10.1002/(SICI)1097-4547(19990915)57:6<789::AID-JNR4>3.3.CO;2-D
   Chen HB, 2008, BIOCHEM BIOPH RES CO, V369, P718, DOI 10.1016/j.bbrc.2008.02.100
   Christofides PD, 2004, INT J ROBUST NONLIN, V14, P87, DOI 10.1002/rnc.864
   Cui Y, 2006, EXP EYE RES, V83, P807, DOI 10.1016/j.exer.2006.03.024
   Cury-Boaventura MF, 2005, CLIN SCI, V108, P245, DOI 10.1042/CS20040281
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   De Vriese AS, 2000, BRIT J PHARMACOL, V130, P963, DOI 10.1038/sj.bjp.0703393
   Du YP, 2003, FREE RADICAL BIO MED, V35, P1491, DOI 10.1016/j.freeradbiomed.2003.08.018
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Fadeel B, 1998, BLOOD, V92, P4808
   GURUNATHAN S, 2005, PEDF INHIBITS VEGF A
   Hancock JT, 2001, FREE RADICAL BIO MED, V31, P697, DOI 10.1016/S0891-5849(01)00646-3
   Haskins K, 2003, ANN NY ACAD SCI, V1005, P43, DOI 10.1196/annals.1288.006
   Ho TC, 2006, BIOCHEM BIOPH RES CO, V342, P372, DOI 10.1016/j.bbre.2006.01.164
   Hutchings H, 2002, BIOCHEM BIOPH RES CO, V294, P764, DOI 10.1016/S0006-291X(02)00548-X
   KOHNER EM, 1970, AM J OPHTHALMOL, V69, P778, DOI 10.1016/0002-9394(70)93420-3
   KONO Y, 1978, ARCH BIOCHEM BIOPHYS, V186, P189, DOI 10.1016/0003-9861(78)90479-4
   Kowluru RA, 1997, FREE RADICAL BIO MED, V22, P587, DOI 10.1016/S0891-5849(96)00347-4
   Kowluru RA, 2003, FREE RADICAL RES, V37, P1169, DOI 10.1080/10715760310001604189
   Kowluru RA, 2003, DIABETES, V52, P818, DOI 10.2337/diabetes.52.3.818
   Kowluru RA, 2002, FREE RADICAL RES, V36, P993, DOI 10.1080/1071576021000006572
   Kowluru RA, 2001, DIABETES, V50, P1938, DOI 10.2337/diabetes.50.8.1938
   Lenaz G, 1998, BIOFACTORS, V8, P195, DOI 10.1002/biof.5520080305
   LORENZI M, 1991, DIABETES, V40, P653, DOI 10.2337/diabetes.40.6.653
   Marchioli R, 2001, LIPIDS, V36, pS53, DOI 10.1007/s11745-001-0683-y
   MERAJI S, 1987, DIABETES, V36, P978, DOI 10.2337/diabetes.36.8.978
   Mu H, 2009, MOL BIOL REP, V36, P2147, DOI 10.1007/s11033-008-9428-8
   MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3
   SELDAK J, 1968, ANAL BIOCHEM, V25, P192
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   TANIWAKI T, 1995, J NEUROCHEM, V64, P2509
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349
   Westermann G, 2000, TRACE ELEM ELECTROLY, V17, P180
   Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V296, P877, DOI 10.1016/S0006-291X(02)00940-3
   Yamagishi SI, 2004, J MOL CELL CARDIOL, V37, P497, DOI 10.1016/j.yjmcc.2004.04.007
NR 48
TC 25
Z9 27
U1 3
U2 22
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2010
VL 90
IS 1
BP 89
EP 96
DI 10.1016/j.exer.2009.09.014
PG 8
WC Ophthalmology
SC Ophthalmology
GA 542SW
UT WOS:000273516500013
PM 19837064
DA 2018-12-27
ER

PT J
AU Eliasova, I
   Mazura, I
   Smejtek, L
AF Eliasova, I.
   Mazura, I.
   Smejtek, L.
TI RETRACTED: DNA Analysis of Ancient Skeletal Remains (Retracted article.
   See vol. 59, pg. 138, 2013)
SO FOLIA BIOLOGICA
LA English
DT Article; Retracted Publication
DE ancient DNA; advanced-glycation end-products; amelogenin; STR analysis;
   settlement at Knezeves
ID PROTEIN CROSS-LINKS; AMPLIFICATION; EXTRACTION; SPECIMENS
AB Non-Governmental Organization Archaia (http://www.archaia.cz) carried out the rescue archaeological research at Knezeves near Prague in 1998. Most of dating objects in Knezeves come from the period of Late and Final Bronze Age. The approximately 3,000 years old set, which included 11 human remains from three settlement features, was collected for the study. First, gender was determined according to anthropological characteristics. Ancient DNA from bones was extracted by the phenol-chloroform procedure and N-phenacetylthiazolum bromide reagent. Polymerase chain reaction amplification of AMEL XY, part of amelogenin gene, with subsequent polyacrylamide gel electrophoresis and Short Tandem Repeats analysis followed. DNA profiles of skeletal remains were obtained by the fragmentation analysis of autosomal short tandem repeat markers. Genetic profiles showed us whether individuals from Knezeves were in mutual relationship (parent - descendant). The congruence of results in sex determination supported reliability of genetic methods, which are suitable for sex determination of fragmental and subadult skeletal remains.
C1 [Eliasova, I.; Mazura, I.] Charles Univ Prague, Fac Sci, Dept Anthropol & Human Genet, Prague, Czech Republic.
   [Smejtek, L.] Inst Archaeol Heritage Cent Bohemia, Prague, Czech Republic.
RP Eliasova, I (reprint author), V Podluzi 5, Prague 14000 4, Czech Republic.
EM i.eliasova@seznam.cz
CR *APPL BIOS AMPF ST, 2007, PCR AMPL KIT US MAN
   Cipollaro M, 1998, BIOCHEM BIOPH RES CO, V247, P901, DOI 10.1006/bbrc.1998.8881
   Evison MP, 1997, J FORENSIC SCI, V42, P1032
   Faerman M, 1995, GENE, V167, P327, DOI 10.1016/0378-1119(95)00697-4
   Haack K, 2000, Anthropol Anz, V58, P51
   Hofreiter M, 2001, NUCLEIC ACIDS RES, V29, P4793, DOI 10.1093/nar/29.23.4793
   KUBALEK P, 2007, BRONZE AGE SETTLEMEN
   LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0
   PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939
   Poinar HN, 1998, SCIENCE, V281, P402, DOI 10.1126/science.281.5375.402
   Rohland N, 2004, BIOTECHNIQUES, V36, P814, DOI 10.2144/04365ST05
   Sifis ME, 2002, J FORENSIC SCI, V47, P589
   Thornalley PJ, 1999, BIOCHEM PHARMACOL, V57, P303, DOI 10.1016/S0006-2952(98)00284-6
   TUROSS N, 1994, EXPERIENTIA, V50, P530, DOI 10.1007/BF01921721
   Vasan S, 1996, NATURE, V382, P275, DOI 10.1038/382275a0
NR 15
TC 2
Z9 2
U1 1
U2 12
PU CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE
PI PRAGUE 6
PA FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC
SN 0015-5500
J9 FOLIA BIOL-PRAGUE
JI Folia Biol.-Prague
PY 2010
VL 56
IS 2
BP 47
EP 50
PG 4
WC Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Oncology; Cell Biology
GA 595GS
UT WOS:000277599300002
PM 20492755
DA 2018-12-27
ER

PT J
AU Milgrom, J
AF Milgrom, J.
TI RETRACTED: Community HUGS: An assessment and intervention playgroup for
   women with postnatal depression and their infants, using a behavioural
   framework (Retracted Article)
SO INFANT MENTAL HEALTH JOURNAL
LA English
DT Meeting Abstract; Retracted Publication
C1 [Milgrom, J.] Univ Melbourne, Melbourne, Vic 3010, Australia.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0163-9641
EI 1097-0355
J9 INFANT MENT HEALTH J
JI Infant Ment. Health J.
PY 2010
VL 31
IS 3
SU S
BP 27
EP 27
PG 1
WC Psychology, Developmental
SC Psychology
GA V27KJ
UT WOS:000208611800075
DA 2018-12-27
ER

PT J
AU Hashemiparast, SM
   Fallahgoul, H
   Hosseyni, A
AF Hashemiparast, S. M.
   Fallahgoul, H.
   Hosseyni, A.
TI RETRACTED: Fourier series approximation for periodic solution of system
   of integral equations using Szego-Bernstein weights (Retracted article.
   See vol. 88, pg. 2666, 2011)
SO INTERNATIONAL JOURNAL OF COMPUTER MATHEMATICS
LA English
DT Article; Retracted Publication
DE periodic solution; system of integral equations; Gauss quadrature rules;
   Fourier series; Szego-Bernestein weights
AB A class of systems of integral equations having periodic solutions are considered, the infinite limits of integrals in the system of integral equations are reduced to the integrals on (-1, 1) with respect to Szego Bernstein weights, the Fourier series of unknown functions for separable kernels of the system of integral equations are applied and then the system of equations is solved to obtain the related unknown coefficient of the Fourier series expansions. Finally, numerical examples are presented to illustrate the very high accuracy of the method and related tables are given.
C1 [Hashemiparast, S. M.; Fallahgoul, H.; Hosseyni, A.] KN Toosi Univ Technol, Dept Math, Fac Sci, Tehran, Iran.
RP Hashemiparast, SM (reprint author), KN Toosi Univ Technol, Dept Math, Fac Sci, Tehran, Iran.
EM hashemiparast@kntu.ac.ir
CR ADOMIAN G, 1995, COMPUT MATH APPL, V29, P1, DOI 10.1016/0898-1221(94)00244-F
   Adomian G, 1994, SOLVING FRONTIER PRO
   Atkinson K., 1997, NUMERICAL SOLUTION I
   Debnath L, 1997, NONLINEAR PARTIAL DI
   Delves L.M., 1985, COMPUTATIONAL METHOD
   Evans DJ, 2002, INT J COMPUT MATH, V79, P817, DOI 10.1080/00207160290029246
   FISCHER B, 1992, J COMPUT APPL MATH, V43, P99, DOI 10.1016/0377-0427(92)90261-U
   Gautschi W., 1996, Acta Numerica, V5, P45, DOI 10.1017/S0962492900002622
   GOLUB GH, 1969, MATH COMPUT, V23, P221, DOI 10.2307/2004418
   Kress R, 1989, LINEAR INTEGRAL EQUA
   Logan JD, 1994, INTRO NONLINEAR PART
   LUBICH C, 1987, BIT, V27, P216, DOI 10.1007/BF01934186
   Mastroianni G., 1995, Numerical Algorithms, V10, P113, DOI 10.1007/BF02198298
   Mastroianni G, 2002, APPL MATH COMPUT, V128, P365, DOI 10.1016/S0096-3003(01)00080-7
   OREGAN D, 1999, J APPL MATH COMPUT, V105, P121
   Prudnikov A. P., 1981, INTEGRALS SERIES ELE
   Rashidinia J, 2007, J MATH ANAL APPL, V333, P1216, DOI 10.1016/j.jmaa.2006.12.016
   SZEGO G, 1975, AM MATH SOC C PUBL, V23
   VANDEWALLE S, 1991, APPL NUMER MATH, V8, P149, DOI 10.1016/0168-9274(91)90048-5
   Wazwaz A. M., 1997, 1 COURSE INTEGRAL EQ
   Wazwaz AM, 1999, APPL MATH COMPUT, V100, P13, DOI 10.1016/S0096-3003(98)00018-6
   Wazwaz AM, 2001, APPL MATH COMPUT, V123, P109, DOI 10.1016/S0096-3003(00)00064-3
   Wazwaz AM, 2002, PARTIAL DIFFERENTIAL
   Whitham G. B, 1974, LINEAR NONLINEAR WAV
NR 24
TC 2
Z9 2
U1 2
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0020-7160
EI 1029-0265
J9 INT J COMPUT MATH
JI Int. J. Comput. Math.
PY 2010
VL 87
IS 7
BP 1485
EP 1496
DI 10.1080/00207160802380934
PG 12
WC Mathematics, Applied
SC Mathematics
GA 605NB
UT WOS:000278353200005
DA 2018-12-27
ER

PT J
AU Herken, EN
   Erel, O
   Guzel, S
   Celik, H
   Ibanoglu, S
AF Herken, Emine Nur
   Erel, Ozcan
   Guzel, Salih
   Celik, Hakim
   Ibanoglu, Senol
TI RETRACTED: TOTAL ANTIOXIDANT, PHENOLIC COMPOUNDS, AND TOTAL OXIDANT
   STATUS OF CERTIFIED AND UNCERTIFIED TURKEY'S HONEYS (Retracted article.
   See vol. 13, pg. 945, 2010)
SO INTERNATIONAL JOURNAL OF FOOD PROPERTIES
LA English
DT Article; Retracted Publication
DE Honey; Total antioxidant capacity; Total oxidant status; Total phenols
ID ANTIBACTERIAL ACTIVITY; CHEMICAL-COMPOSITION; HYDROGEN-PEROXIDE;
   OXIDATIVE STRESS; FLORAL SOURCES; CAPACITY; ORIGIN; IDENTIFICATION;
   CHEMOMETRICS; COMPONENTS
AB In this study, total oxidant status (TOS), total antioxidant capacity (TAC) and total phenols (TP) of seventeen certified and eight uncertified honey samples were analyzed. The TAC and TOS of the samples were determined using novel methods. Uncertified honey samples had significantly lower values for their TP, TAC and TOS contents than those of certified honey samples. There was significant correlation between TOS and TP values (P < 0.01) and between TOS and TAC values (P < 0.05).
C1 [Herken, Emine Nur] Pamukkale Univ, Dept Food Engn, Fac Engn, TR-20020 Denizli, Turkey.
   [Erel, Ozcan; Guzel, Salih; Celik, Hakim] Harran Univ, Fac Med, Dept Clin Biochem, Sanliurfa, Turkey.
   [Ibanoglu, Senol] Gaziantep Univ, Dept Food Engn, Fac Engn, Gaziantep, Turkey.
RP Herken, EN (reprint author), Pamukkale Univ, Dept Food Engn, Fac Engn, Kinilki Campus, TR-20020 Denizli, Turkey.
EM nurherken@pau.edu.tr
CR Al-Mamary M, 2002, NUTR RES, V22, P1041, DOI 10.1016/S0271-5317(02)00406-2
   Al-Waili Noori S., 2003, Journal of Medicinal Food, V6, P135, DOI 10.1089/109662003322233549
   Aljadi AM, 2004, FOOD CHEM, V85, P513, DOI 10.1016/S0308-8146(02)00596-4
   Andrade P, 1997, FOOD CHEM, V60, P79, DOI 10.1016/S0308-8146(96)00313-5
   Anklam E, 1998, FOOD CHEM, V63, P549, DOI 10.1016/S0308-8146(98)00057-0
   Arvanitoyannis IS, 2005, CRIT REV FOOD SCI, V45, P193, DOI 10.1080/10408690590956369
   Beretta G, 2005, ANAL CHIM ACTA, V533, P185, DOI 10.1016/j.aca.2004.11.010
   Blasa M, 2006, FOOD CHEM, V97, P217, DOI 10.1016/j.foodchem.2005.03.039
   Dustmann JH, 1979, APIACTA, V14, P7
   Erel O, 2004, CLIN BIOCHEM, V37, P112, DOI 10.1016/j.clinbiochem.2003.10.014
   Erel O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/j.clinbiochem.2005.08.008
   Gheldof N, 2003, J AGR FOOD CHEM, V51, P1500, DOI 10.1021/jf025897t
   Gheldof N, 2002, J AGR FOOD CHEM, V50, P3050, DOI 10.1021/jf0114637
   Gheldof N, 2002, J AGR FOOD CHEM, V50, P5870, DOI 10.1021/jf0256135
   Guler A, 2007, FOOD CHEM, V105, P1119, DOI 10.1016/j.foodchem.2007.02.024
   Kosecik M, 2005, INT J CARDIOL, V100, P61, DOI 10.1016/j.ijcard.2004.05.069
   Kucuk M, 2007, FOOD CHEM, V100, P526, DOI 10.1016/j.foodchem.2005.10.010
   Lachman J, 2007, FOOD CHEM, V101, P973, DOI 10.1016/j.foodchem.2006.02.049
   MCCARTHY J, 1995, AM BEE J, V135, P341
   Meda A, 2005, FOOD CHEM, V91, P571, DOI [10.1016/j.foodchem.2004.10.006, 10.1016/j.foochem.2004.10.006]
   MOLAN PC, 1992, BEE WORLD, V73, P5, DOI 10.1080/0005772X.1992.11099109
   Mothershaw AS, 2004, INT J FOOD PROP, V7, P629, DOI [10.1081/JFP-200033062, 10.1081/JFP-120040215]
   *NAT HON BOARD, 2008, HON HLTH THER QUAL
   Niki E, 2000, IUBMB LIFE, V50, P323, DOI 10.1080/15216540051081119
   Pellegrini N, 2003, J NUTR, V133, P2812
   Perez Martin R. A., 2008, International Journal of Food Properties, V11, P727
   Schramm DD, 2003, J AGR FOOD CHEM, V51, P1732, DOI 10.1021/jf025928k
   Skerget M, 2005, FOOD CHEM, V89, P191, DOI 10.1016/j.foodchem.2004.02.025
   Sorkun K, 2001, Z NATURFORSCH C, V56, P666
   Subramanian R, 2007, INT J FOOD PROP, V10, P127, DOI 10.1080/10942910600981708
   Taormina PJ, 2001, INT J FOOD MICROBIOL, V69, P217, DOI 10.1016/S0168-1605(01)00505-0
   VINSON JA, 1995, J AGR FOOD CHEM, V43, P401, DOI 10.1021/jf00050a027
   Vit P, 1997, Z LEBENSM UNTERS F A, V204, P43, DOI 10.1007/s002170050034
   Weston RJ, 2000, FOOD CHEM, V71, P235, DOI 10.1016/S0308-8146(00)00162-X
   WHITE JW, 1963, BIOCHIM BIOPHYS ACTA, V73, P57
   Yanik M, 2004, ACTA NEUROPSYCHIATR, V16, P200, DOI 10.1111/j.0924-2708.2004.00090.x
NR 36
TC 3
Z9 3
U1 2
U2 26
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1094-2912
EI 1532-2386
J9 INT J FOOD PROP
JI Int. J. Food Prop.
PY 2010
VL 13
IS 3
BP 599
EP 607
DI 10.1080/10942910902716968
PG 9
WC Food Science & Technology
SC Food Science & Technology
GA 595DC
UT WOS:000277589900016
OA Bronze
DA 2018-12-27
ER

PT J
AU Shin, DH
AF Shin, Dong-Hee
TI RETRACTED: The Dynamic User Activities in Massive Multiplayer Online
   Role-Playing Games (Retracted article. See vol. 29, pg. 438, 2013)
SO INTERNATIONAL JOURNAL OF HUMAN-COMPUTER INTERACTION
LA English
DT Article; Retracted Publication
ID INFORMATION-TECHNOLOGY; PERCEIVED USEFULNESS; CONSUMER-BEHAVIOR;
   SOCIAL-INFLUENCE; FLOW EXPERIENCE; ACCEPTANCE; MODEL; SECURITY;
   ADOPTION; WORLD
AB Massive multiplayer online role-playing games (MMORPGs) have been popular for several years and have spawned a whole subculture. Although studies on online games have received more attention in the literature, MMORPGs have seldom been addressed. This study applies the theory of reasoned action and modifies the technology acceptance model to propose a research model. An empirical study was conducted to test this model. The goal of this study is to examine what perceived factors contribute to an online game user's behaviors. The results of this study indicate that users' attitudes and intentions are influenced by perceived security and perceived enjoyment. Subjective norm and flow are key behavioral antecedents to users' loyalty.
C1 Sungkyunkwan Univ, Dept Interact Sci, Seoul 110745, South Korea.
RP Shin, DH (reprint author), Sungkyunkwan Univ, Dept Interact Sci, 90322 Int Hall,53 Myeongnyun Dong 3 Ga, Seoul 110745, South Korea.
EM dshin@skku.edu
FU National Research Foundation of Korea; Ministry of Education, Science
   and Technology [R31-2008-000-10062-0]
FX This research was supported by World Class University program through
   the National Research Foundation of Korea funded by the Ministry of
   Education, Science and Technology (Grant No. R31-2008-000-10062-0).
CR *2 LIF, 2000, 4 QUART 2 LIF VIRT E
   Ahuja MK, 2005, MIS QUART, V29, P427
   AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Ajzen I, 1980, UNDERSTANDING ATTITU
   Aladwani AM, 2001, INT J INFORM MANAGE, V21, P213, DOI 10.1016/S0268-4012(01)00011-1
   AMORY A, 1998, P ED MEDIA ED TELECO, V1, P50
   Anderson R. E., 1995, MULTIVARIATE DATA AN
   Bagozzi R. P., 1988, J ACAD MARKET SCI, V16, P74, DOI DOI 10.1007/BF02723327
   BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238
   BREWARD M, 2007, 8 WORLD C MAN EBUSIN, P4
   Brown SA, 2005, MIS QUART, V29, P399
   Browne M. W., 1993, TESTING STRUCTURAL E, P136, DOI DOI 10.1177/0049124192021002001
   Chai S, 2006, Information Universe: Journal of Issues in Informing Science & Information Technology, V3, P127
   Chen LD, 2002, INFORM MANAGE-AMSTER, V39, P705, DOI 10.1016/S0378-7206(01)00127-6
   Childers TL, 2001, J RETAILING, V77, P511, DOI 10.1016/S0022-4359(01)00056-2
   Childress M.D., 2006, DISTANCE EDUC, V27, P187, DOI DOI 10.1080/01587910600789522
   CHIN WW, 1998, QUANT METH SER, P295, DOI DOI 10.1016/J.AAP.2008.12.010
   Chou TJ, 2003, CYBERPSYCHOL BEHAV, V6, P663, DOI 10.1089/109493103322725469
   Chuang YC, 2006, CYBERPSYCHOL BEHAV, V9, P451, DOI 10.1089/cpb.2006.9.451
   Cronbach L. J, 1971, ED MEASUREMENT, P443
   CSIKSZENTMIHALY.M, 1977, BOREDOM ANXIETY
   CSIKSZENTMIHALY.M, 1990, FLOW PSYCOLOGY OPTIM
   Cyr D, 2005, J GLOB INF MANAG, V13, P25, DOI 10.4018/jgim.2005100102
   Dabholkar PA, 2002, J ACAD MARKET SCI, V30, P184, DOI 10.1177/0092070302303001
   DAVIS FD, 1989, MIS QUART, V13, P319, DOI 10.2307/249008
   Ducheneaut N., 2006, GAMES CULTURE, V1, P281, DOI DOI 10.1177/1555412006292613
   EtezadiAmoli J, 1996, INFORM MANAGE, V30, P65, DOI 10.1016/0378-7206(95)00052-6
   FETSCHERIN M, 2007, USER ACCEPTANC UNPUB
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   Gao Y, 2005, ELECTRON LIBR, V23, P533, DOI 10.1108/02640470510631245
   Godwin J.U., 2001, INFORM MANAGEMENT CO, V9, P165, DOI DOI 10.1108/EUM0000000005808
   Ha I, 2007, INFORM MANAGE-AMSTER, V44, P276, DOI 10.1016/j.im.2007.01.001
   Hoffman DL, 1999, COMMUN ACM, V42, P80, DOI 10.1145/299157.299175
   Hsu CL, 2007, COMPUT HUM BEHAV, V23, P1642, DOI 10.1016/j.chb.2005.09.001
   Hsu CL, 2004, INFORM MANAGE-AMSTER, V41, P853, DOI 10.1016/j.im.2003.08.014
   Hung S.-Y., 2003, ELECTRON COMMER R A, V2, P42, DOI DOI 10.1016/S1567-4223(03)00008-5
   JOE S, 2008, QUAL QUANT, V2, P1
   Joreskog K. G., 1996, LISREL 8 USERS REFER
   Karahanna E, 1999, INFORM MANAGE-AMSTER, V35, P237, DOI 10.1016/S0378-7206(98)00096-2
   Koufaris M, 2002, INFORM SYST RES, V13, P205, DOI 10.1287/isre.13.2.205.83
   Lucas HC, 2000, INFORM MANAGE, V38, P119, DOI 10.1016/S0378-7206(00)00059-8
   MALONE TW, 1981, COGNITIVE SCI, V5, P333, DOI 10.1016/S0364-0213(81)80017-1
   McFarlane A., 2002, CAMB J EDUC, V32, P219, DOI [10.1080/03057640220147568, DOI 10.1080/03057640220147568]
   MCGRAW G, 2006, SOFTWARE SECURITY, P18
   McGraw G, 2007, IEEE SECUR PRIV, V5, P76, DOI 10.1109/MSP.2007.116
   Moon JW, 2001, INFORM MANAGE, V38, P217, DOI 10.1016/S0378-7206(00)00061-6
   Novak TP, 2000, MARKET SCI, V19, P22, DOI 10.1287/mksc.19.1.22.15184
   Nowak KL, 2003, PRESENCE-TELEOP VIRT, V12, P481, DOI 10.1162/105474603322761289
   Nysveen H, 2005, J SERV RES-US, V7, P257, DOI 10.1177/1094670504271151
   Papadopoulou Panagiota, 2007, Virtual Reality, V11, P107, DOI 10.1007/s10055-006-0059-x
   Pavlou PA, 2003, INT J ELECTRON COMM, V7, P101
   Rettie R, 2001, INTERNET RES, V11, P103, DOI 10.1108/10662240110695070
   Salisbury WD, 2001, IND MANAGE DATA SYST, V101, P165, DOI 10.1108/02635570110390071
   SATHYE M, 1999, INT J BANK MARK, V17, P324, DOI DOI 10.1108/02652329910305689
   Schwartz PM, 2000, WISC LAW REV, P743
   Shin D., 2007, INTERACTING COMPUTER, V19, P45
   SHIN DH, 2008, CYBERPSYCHOLOGY BEHA, V11, P12
   Smith HJ, 1996, MIS QUART, V20, P167, DOI 10.2307/249477
   Song JK, 2006, INFORM SYST FRONT, V8, P241, DOI 10.1007/s10796-006-8782-0
   SWEETSER P, 2005, ACM COMPUTERS ENTERT, V3, P1, DOI DOI 10.1145/1077246.1077253
   TAYLOR J, 2005, DIGITAL GAMEPLAY, P130
   TAYLOR S, 1995, INFORM SYST RES, V6, P144, DOI 10.1287/isre.6.2.144
   TREVINO LK, 1992, COMMUN RES, V19, P539, DOI 10.1177/009365092019005001
   van der Heijden H, 2004, MIS QUART, V28, P695
   van der Heijden H, 2003, INFORM MANAGE-AMSTER, V40, P541, DOI 10.1016/S0378-7206(02)00079-4
   Venkatesh V, 2000, MIS QUART, V24, P115, DOI 10.2307/3250981
   White H., 2004, J FINANCIAL SERVICES, V9, P49, DOI DOI 10.1057/PALGRAVE.FSM.4770140
   Williams D., 2006, GAMES CULTURE, V1, P338, DOI DOI 10.1177/1555412006292616
   Wu J., 2007, J ELECTRON COMMER RE, V8, P128
   YANG J, 2007, LECT NOTES COMPUTER, V4564, P375
   Yenisey MM, 2005, BEHAV INFORM TECHNOL, V24, P259, DOI 10.1080/0144929042000320992
NR 71
TC 20
Z9 20
U1 3
U2 27
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1044-7318
EI 1532-7590
J9 INT J HUM-COMPUT INT
JI Int. J. Hum.-Comput. Interact.
PY 2010
VL 26
IS 4
BP 317
EP 344
AR PII 920336784
DI 10.1080/10447310903575473
PG 28
WC Computer Science, Cybernetics; Ergonomics
SC Computer Science; Engineering
GA 593PC
UT WOS:000277470300002
DA 2018-12-27
ER

PT J
AU Shin, DH
AF Shin, Dong-Hee
TI RETRACTED: Modeling the Interaction of Users and Mobile Payment System:
   Conceptual Framework (Retracted article. See vol. 29, pg. 317, 2013)
SO INTERNATIONAL JOURNAL OF HUMAN-COMPUTER INTERACTION
LA English
DT Article; Retracted Publication
ID INFORMATION-TECHNOLOGY; CONSUMER-BEHAVIOR; E-COMMERCE; E-SERVICES;
   TRUST; ACCEPTANCE; ADOPTION; COMMUNITIES; PERSPECTIVE; BELIEFS
AB The growing interest in mobile commerce and the high penetration rate of mobile communication service are expected to provide mobile operators with a new and great business opportunity, the mobile payment. This study proposes a research model that examines the factors that determine consumer acceptance of mobile payment system. To achieve this goal, it employed the technology acceptance model (TAM), adding the concepts of security, trust, social influence, and computer-efficacy from Unified Theory of Acceptance and Use of Technology. The model is examined through an empirical study using structural equation modeling techniques. Although the model confirms the classical role of TAM factors, the results also show that users' attitudes and intentions are influenced by perceived risk and trust. Significant support for the model was found in the data collected from a survey of potential mobile payment system users. Based on the findings, this study proposes a conceptual framework of adoption enablers, drivers, and barriers with propositions to guide future research in mobile payment. Implications to practice and means to overcome the barriers are suggested.
C1 Sungkyunkwan Univ, Dept Interact Sci, WCU Funded Program, Seoul 110745, South Korea.
RP Shin, DH (reprint author), Sungkyunkwan Univ, Dept Interact Sci, WCU Funded Program, Int Hall,53 Myeongnyun Dong 3-Ga, Seoul 110745, South Korea.
EM dshin@skku.edu
FU Ministry of Education, Science and Technology [R31-2008-000-10062-0];
   Korean Government [NRF-2010-B00171]
FX This research was supported by WCU (World Class University) program
   through the National Research Foundation of Korea funded by the Ministry
   of Education, Science and Technology (Grant No. R31-2008-000-10062-0).
   This work was supported by the National Research Foundation of Korea
   Grant funded by the Korean Government (NRF-2010-B00171).
CR Agarwal R, 2000, MIS QUART, V24, P665, DOI 10.2307/3250951
   Ajzen I, 1980, UNDERSTANDING ATTITU
   ARBUCKLE JL, 2005, AMOS TM 6 0 USERS GU
   Au Y. A., 2007, ELECTRON COMMER R A, V7, P141
   Bagozzi R. P., 1988, J ACAD MARKET SCI, V16, P74, DOI DOI 10.1007/BF02723327
   Bandura A., 1997, SELF EFFICACY EXERCI
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238
   Brown SA, 2005, MIS QUART, V29, P399
   Byrne B., 2001, INT J TESTING, V1, P55, DOI DOI 10.1207/S15327574IJT0101_
   Chen LD, 2008, INT J MOB COMMUN, V6, P32, DOI 10.1504/IJMC.2008.015997
   CHEONG J, 2002, ITS 15 BIENN C, P11
   Chin W. W., 2001, PLS GRAPH USERS GUID
   Chin WW, 2003, INFORM SYST RES, V14, P189, DOI 10.1287/isre.14.2.189.16018
   Chou YT, 2004, J BUS RES, V57, P1423, DOI 10.1016/S0148-2693(02)00432-0
   Compeau D, 1999, MIS QUART, V23, P145, DOI 10.2307/249749
   DAHLBERG T, 2003, P INT C MOB BUS, P211
   Dahlberg T, 2007, 40 HAW INT C SYST SC
   Dahlberg T, 2008, ELECTRON COMMER R A, V7, P165, DOI 10.1016/j.elerap.2007.02.001
   DAVIS FD, 1989, MIS QUART, V13, P319, DOI 10.2307/249008
   Dewan S. G., 2005, J INFORM PRIVACY SEC, V1, P4, DOI DOI 10.1080/15536548.2005.10855765
   EtezadiAmoli J, 1996, INFORM MANAGE, V30, P65, DOI 10.1016/0378-7206(95)00052-6
   Fang JM, 2009, COMPUT HUM BEHAV, V25, P144, DOI 10.1016/j.chb.2008.08.002
   Featherman MS, 2003, INT J HUM-COMPUT ST, V59, P451, DOI 10.1016/S1071-5819(03)00111-3
   Fishbein M., 1975, BELIEF ATTITUDE INTE
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   *GARTN RES FIRM, 2009, MOB PAYM 2007 2012
   Gefen D, 2004, OMEGA-INT J MANAGE S, V32, P407, DOI 10.1016/j.omega.2004.01.006
   Gerpott Torsten J., 2009, International Journal of Electronic Finance, V3, P1, DOI 10.1504/IJEF.2009.024267
   Herzberg A, 2003, COMMUN ACM, V46, P53, DOI 10.1145/769800.769801
   Ho H, 2008, INT CONF E BUS ENG, P341, DOI 10.1109/ICEBE.2008.70
   Hsu CL, 2007, COMPUT HUM BEHAV, V23, P1642, DOI 10.1016/j.chb.2005.09.001
   Joreskog K. G., 1996, LISREL 8 USERS REFER
   Kelloway E. K, 1998, USING LISREL STRUCTU
   Lee MC, 2009, ELECTRON COMMER R A, V8, P130, DOI 10.1016/j.elerap.2008.11.006
   Linck K., 2006, P 14 EUR C INF SYST, pS1
   Liu C, 2005, INFORM MANAGE-AMSTER, V42, P289, DOI 10.1016/j.im.2004.01.003
   Loehlin J. C., 1998, LATENT VARIABLES MOD
   Lucas HC, 2000, INFORM MANAGE, V38, P119, DOI 10.1016/S0378-7206(00)00059-8
   Malhotra Y., 1999, P 32 HAW INT C SYST, P1
   Mallat N, 2004, COMMUN ACM, V47, P42, DOI 10.1145/986213.986236
   Mathieson K., 2001, Data Base for Advances in Information Systems, V32, P86
   McKnight DH, 2002, INFORM SYST RES, V13, P334, DOI 10.1287/isre.13.3.334.81
   Misra S. K., 2004, Electronic Commerce Research, V4, P359, DOI 10.1023/B:ELEC.0000037082.39182.3a
   Miyazaki AD, 2001, J CONSUM AFF, V35, P27, DOI 10.1111/j.1745-6606.2001.tb00101.x
   NIJITE D, 2005, J SERVICES RES, V5, P43
   Nunnally JC, 1978, PSYCHOMETRIC THEORY
   Nysveen H, 2005, J SERV RES-US, V7, P257, DOI 10.1177/1094670504271151
   Pavlou PA, 2004, INFORM SYST RES, V15, P37, DOI 10.1287/isre.1040.0015
   PETER JP, 1981, J MARKETING RES, V18, P133, DOI 10.2307/3150948
   Pousttchi K, 2003, P 2 INT C MOB BUS VI, P201
   Rubinstein R. Y., 2007, SIMULATION MONTE CAR
   SCHWARZER R, 1994, PSYCHOL HEALTH, V9, P161, DOI 10.1080/08870449408407475
   Shin D., 2007, INTERACTING COMPUTER, V19, P45
   SHIN DH, 2008, CYBERPSYCHOLOGY BEHA, V11, P12
   Shin DH, 2008, INTERACT COMPUT, V20, P433, DOI 10.1016/j.intcom.2008.04.001
   Siau K, 2003, COMMUN ACM, V46, P91, DOI 10.1145/641205.641211
   Teo E., 2005, P INT C MOB PAYM, P663
   Teo TSH, 2003, OMEGA-INT J MANAGE S, V31, P483, DOI 10.1016/j.omega.2003.08.005
   van de Kar E., 2004, P EUR WIND EN C, P1
   Venkatesh V, 2003, MIS QUART, V27, P425
   Venkatesh V, 2000, MIS QUART, V24, P115, DOI 10.2307/3250981
   Viehland D., 2007, 18 AUSTR C INF SYST
   Wu Y., 2007, IEEE INT C IND ENG E, V2, P199
   Zmijewska A., 2005, P INT C MOB BUS ICMB, P354
NR 65
TC 30
Z9 30
U1 4
U2 55
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 520 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1044-7318
EI 1532-7590
J9 INT J HUM-COMPUT INT
JI Int. J. Hum.-Comput. Interact.
PY 2010
VL 26
IS 10
BP 917
EP 940
AR PII 926893419
DI 10.1080/10447318.2010.502098
PG 24
WC Computer Science, Cybernetics; Ergonomics
SC Computer Science; Engineering
GA 650NF
UT WOS:000281855500002
DA 2018-12-27
ER

PT J
AU Mathur, N
   Singh, J
   Bohra, S
   Bohra, A
   Vyas, A
AF Mathur, Nishi
   Singh, Joginder
   Bohra, Sachendra
   Bohra, Avinash
   Vyas, Anil
TI RETRACTED: Removal of Chromium by Some Multipurpose Tree Seedlings of
   Indian Thar Desert (Retracted article. See vol. 13, pg. 316, 2011)
SO INTERNATIONAL JOURNAL OF PHYTOREMEDIATION
LA English
DT Article; Retracted Publication
DE chromium speciation; phytoremediation; organic acids; vesicular
   arbuscular mycorrhizal fungi
ID POLLUTED SOIL; PLANTS; PHYTOREMEDIATION; ACCUMULATION; SPECIATION; CROPS
AB An experiment was conducted to study the potential of chromium (Cr) phytoaccumulatory capabilities of four tree species viz., Anogeissus latifolia, Terminalia arjuna, Tecomella undulata, and Salvadora persica. Possibility of enhancement of Cr uptake by citric acid and vesicular arbuscular mycorrhizal fungi (VAM) amendments were also tried. Cr is a major pollutant of the environment. Chromium can exist in oxidation states from III to VI, but the most stable and common forms of Cr are trivalent and hexavalent species. Cr(VI) was more toxic to the tree growth in terms of collar diameter (CD) increment in all the tree species than Cr(III). Roots accumulated more Cr than shoots in all the tree species. There was more than 10 fold increase in root Cr content in comparison with shoot Cr content in all the trees at all the concentration of Cr and all sources of Cr. Citric acid significantly increased the Cr content in the tissues of roots in all the species under both speciation of Cr. The highest increase in Cr content brought by 20 mM citric acid addition was in A. latifolia. Results suggest that Anogeissus latifolia is a potential Cr accumulator with citric acid as soil amendment.
C1 [Mathur, Nishi; Singh, Joginder; Bohra, Sachendra; Vyas, Anil] Jai Narain Vyas Univ, Dept Bot, Microbial Biotechnol & Biofertilizer Lab, Jodhpur 342003, Rajasthan, India.
   [Bohra, Avinash] Mahila PG Mahavidhyalaya, Dept Biotechnol, Jodhpur, Rajasthan, India.
RP Vyas, A (reprint author), Jai Narain Vyas Univ, Dept Bot, Microbial Biotechnol & Biofertilizer Lab, Jodhpur 342003, Rajasthan, India.
EM dranilvyas@scientist.com
OI Singh, Joginder/0000-0001-6968-4912
FU Department of Science & Technology Fast Track Research SERC Scheme, New
   Delhi
FX This study was funded by a grant provided by Department of Science &
   Technology, Under Fast Track Research SERC Scheme, New Delhi.
CR BAKER AJM, 1994, RESOUR CONSERV RECY, V11, P41, DOI 10.1016/0921-3449(94)90077-9
   Cervantes C, 2001, FEMS MICROBIOL REV, V25, P335, DOI 10.1016/S0168-6445(01)00057-2
   Chandra P, 1997, ACS SYM SER, V664, P274, DOI 10.1145/264107.264209
   HUFFMAN EWD, 1973, PLANT PHYSIOL, V52, P72, DOI 10.1104/pp.52.1.72
   HUFFMAN EWD, 1973, J AGR FOOD CHEM, V21, P982, DOI 10.1021/jf60190a008
   Khan AG, 2001, ENVIRON INT, V26, P417, DOI 10.1016/S0160-4120(01)00022-8
   Krishnamurthy S., 1994, Northeastern Geology, V16, P14
   MATHUR N, 1995, PLANT CELL REP, V14, P735, DOI 10.1007/BF00232658
   Pulford ID, 2001, ENVIRON GEOCHEM HLTH, V23, P307, DOI 10.1023/A:1012243129773
   Shahandeh H, 2000, INT J PHYTOREMEDIAT, V2, P31, DOI 10.1080/15226510008500029
   Shanker AK, 2005, ENVIRON INT, V31, P739, DOI 10.1016/j.envint.2005.02.003
   Shanker AK, 2004, PLANT SCI, V166, P1035, DOI 10.1016/j.plantsci.2003.12.015
   Simon L, 2001, ENVIRON GEOCHEM HLTH, V23, P313, DOI 10.1023/A:1012295113844
   WILKINSON L, 1996, SYSTAT WINDOWS
   Wu LH, 2003, CHEMOSPHERE, V50, P819, DOI 10.1016/S0045-6535(02)00225-4
   Zayed A, 1998, PLANTA, V206, P293, DOI 10.1007/s004250050403
   Zayed AM, 2003, PLANT SOIL, V249, P139, DOI 10.1023/A:1022504826342
NR 17
TC 2
Z9 2
U1 3
U2 20
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1522-6514
EI 1549-7879
J9 INT J PHYTOREMEDIAT
JI Int. J. Phytoremediat.
PY 2010
VL 12
IS 8
BP 798
EP 804
AR PII 927731454
DI 10.1080/15226510903390494
PG 7
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 660ZT
UT WOS:000282691400006
PM 21166349
DA 2018-12-27
ER

PT J
AU Wang, F
   Lin, J
   Liu, XH
AF Wang, Feng
   Lin, Jie
   Liu, Xiaohua
TI RETRACTED: Three-dimensional model of customer order decoupling point
   position in mass customisation (Retracted article. See vol. 49, pg.
   4191, 2011)
SO INTERNATIONAL JOURNAL OF PRODUCTION RESEARCH
LA English
DT Article; Retracted Publication
DE mass customisation; customer order decoupling point (CODP); customer
   requirements
ID MANUFACTURING STRATEGY; SUPPLY CHAIN; POSTPONEMENT; LINKING
AB Traditionally the customer order decoupling point (CODP) has focused mainly on the engineering and production activities, defined a CODP for an enterprise (or supply chain) based on the integration of these two activities. As customer requirements for short lead-times in combination with customisations increase, uniform CODP for all products of enterprise (or supply chain) makes the traditional view of the CODP insufficient in these cases. The purpose of this paper is thus to provide a more general approach to define several CODP as a three-dimensional concept based on the integration of product, engineering and production activities. The extended CODP captures the complexity in terms of possible configurations, increases the flexibility of the manufacturing system, but also provides a framework for the issues that must be handled when positioning the CODPs in terms of products, engineering and production activities simultaneously. The three-dimensional CODP is an important extension to make the theory better reflecting reality and hence increase the scope and acceptance of both the concept CODP per se, and the analysis based on the CODP. We also provide a classification of products based on a combined engineering and production perspective where the efficient CODPs constitute a set providing the highest level of customer value and the minimum delivery lead time.
C1 [Wang, Feng; Lin, Jie; Liu, Xiaohua] Tongji Univ, Sch Econ & Management, Shanghai 200092, Peoples R China.
RP Wang, F (reprint author), Tongji Univ, Sch Econ & Management, Shanghai 200092, Peoples R China.
EM morning1231@163.com
FU CIMS, China [2007AA04Z151]; Program for New Century Excellent Talents in
   University, China [NCET-06-0377]; Shanghai Leading Academic Discipline
   Project, Project [B310]
FX The paper is supported by the National High-Tech. R&D Program for CIMS,
   China (No. 2007AA04Z151), Program for New Century Excellent Talents in
   University, China (No. NCET-06-0377), Shanghai Leading Academic
   Discipline Project, Project (No. B310).
CR Berry W.L., 1992, INT J OPER PROD MAN, V12, P3
   BHATTACHARYA AK, 1994, COMPUT INTEGR MANUF, V7, P134, DOI 10.1016/0951-5240(94)90007-8
   Browne J., 1996, PRODUCTION MANAGEMEN
   BUCKLIN LP, 1965, J MARKETING RES, V2, P26, DOI 10.2307/3149333
   Cox JF, 2002, APICS DICT
   Fogliatto FS, 2003, INT J PROD RES, V41, P1811, DOI 10.1080/1352816031000074991
   Giesberts P. M. J., 1992, Production Planning and Control, V3, P300, DOI 10.1080/09537289208919402
   Graman GA, 2002, PROD OPER MANAG, V11, P340
   Higgins P., 1996, MANUFACTURING PLANNI
   Hill T, 2000, MANUFACTURING STRATE
   HILL T., 1995, MANUFACTURING STRATE
   Hoekstra S., 1992, INTEGRATED LOGISTICS
   Lin G, 2004, J GEOPHYS ENG, V1, P63, DOI 10.1088/1742-2132/1/1/008)
   MASONJONES R, 1999, INT J LOGIST MANAG, V10, P13, DOI DOI 10.1108/09574099910805969
   MATHER H, 1999, PROFITABLY DELIGHT Y
   Naylor JB, 1999, INT J PROD ECON, V62, P107
   Olhager J, 2003, INT J PROD ECON, V85, P319, DOI 10.1016/S0925-5273(03)00119-1
   Olhager J, 2001, INT J PROD ECON, V69, P215, DOI 10.1016/S0925-5273(99)00098-5
   OLHAGER J, 1990, EUR J OPER RES, V45, P135, DOI 10.1016/0377-2217(90)90180-J
   OLHAGER J, 1994, P 1994 PAC C MAN JAK, P1093
   Raturi A.S., 1990, J OPERATIONS MANAGEM, V9, P230
   Rudberg M, 2004, PROD PLAN CONTROL, V15, P445, DOI 10.1080/095372804200238764
   Sackett P. J., 1997, Integrated Manufacturing Systems, V8, P359, DOI 10.1108/09576069710188779
   Shao XF, 2008, INT J PROD RES, V46, P153, DOI 10.1080/00207540600844027
   SHARMAN G, 1984, HARVARD BUS REV, V62, P71
   Shingo S., 1981, STUDY TOYOTA PRODUCT
   Song J-S., 2003, HDB OPERATIONS RES M
   Stadtler H., 2002, SUPPLY CHAIN MANAGEM
   STALK G, 1988, HARVARD BUS REV, V66, P41
   Swaminathan JM, 1998, MANAGE SCI, V44, pS161, DOI 10.1287/mnsc.44.12.S161
   van der Aalst WMP, 2001, INFORM SYST FRONT, V3, P297, DOI 10.1023/A:1011409408711
   Wemmerlov U., 1984, J OPERATIONS MANAGEM, V4, P347
   WIKNER J, 2005, INT J LOGIST-RES APP, V3, P211
   WIKNER J, 2001, WP284 LINK I TECHN D
   Wortmann J. C., 1997, CUSTOMER DRIVEN MANU
   Yang B, 2003, INT J PROD RES, V41, P2075, DOI 10.1080/00207544031000077284
NR 36
TC 12
Z9 12
U1 6
U2 40
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0020-7543
EI 1366-588X
J9 INT J PROD RES
JI Int. J. Prod. Res.
PY 2010
VL 48
IS 13
BP 3741
EP 3757
AR PII 912316845
DI 10.1080/00207540902865746
PG 17
WC Engineering, Industrial; Engineering, Manufacturing; Operations Research
   & Management Science
SC Engineering; Operations Research & Management Science
GA 596OH
UT WOS:000277694100002
DA 2018-12-27
ER

PT J
AU Taleghani, M
   Ansari, HR
   Jennings, P
AF Taleghani, Mohammad
   Ansari, Hamid Reza
   Jennings, Philip
TI RETRACTED: Renewable energy education for architects: lessons from
   developed and developing countries (Retracted article. See vol. 18, pg.
   563, 2011)
SO INTERNATIONAL JOURNAL OF SUSTAINABLE DEVELOPMENT AND WORLD ECOLOGY
LA English
DT Editorial Material; Retracted Publication
DE renewable energy; sustainable energy; sustainable architecture;
   sustainable development
AB Sustainability is a crucial issue for our times and architecture has an important role to play in sustainable development. Buildings are responsible for approximately 40% of the total world annual energy consumption. In addition, over the past decade, several new approaches have emerged for the incorporation of sustainability and renewable energy into architectural education. One way of reducing building energy consumption is to educate architects to design buildings that are powered by renewable forms of energy for heating, lighting, cooling, ventilation and hot water supply. A comparison of sustainable architectural education in economically developed and developing countries provides some insights about how to modernise the architectural curriculum to facilitate the process of sustainable development. The key findings of this research are to: (1) include principles of sustainable development in the core content of all architecture courses, including the role of renewable energy, energy efficiency and embodied energy; (2) offer design studio courses in architectural education that involve the practical use of renewable energy technology; (3) offer short courses and flexible courses, which are particularly attractive to busy professional architects who want to keep their knowledge base up to date; and (4) offer online courses to attract foreign students and that are also suitable for disabled students.
C1 [Taleghani, Mohammad; Ansari, Hamid Reza] Univ Tehran, Fac Architecture, Tehran, Iran.
   [Jennings, Philip] Murdoch Univ, Sch Engn & Energy, Perth, WA, Australia.
RP Taleghani, M (reprint author), Univ Tehran, Fac Architecture, Tehran, Iran.
EM taleghani@ut.ac.ir
CR Anthony K. H., 1991, DESIGN JURIES TRIAL, P9
   Blakers A., 2005, 9 MONTH INT C SEARCH
   *CSIRO, 2001, CLIM CHANG PROJ AUST
   GIDION S, 1974, SPACE TIME ARCHITECT
   Hes D., 2005, THESIS RMIT U MELBOU
   Jefferson W., 2005, SUSTAINABLE ENERGY C
   Jennings P, 2009, RENEW ENERG, V34, P435, DOI 10.1016/j.renene.2008.05.005
   JENNINGS PJ, 1997, P 35 ANZSES C CANB
   Keating M, 1993, EARTH SUMMITS AGENDA
   Kim J.-J., 1998, INTRO SUSTAINABLE AR
   Omer AM, 2007, RENEW SUST ENERG REV, V12, P2265
   Salama A. M., 2005, PARADIGMATIC TRENDS
   The World Conservation Union (IUCN) United Nations Environment Programme (UNEP) World Wide Fund for Nature (WWF), 1991, CAR EARTH STRAT SUST
   *UIA, 2008, UIA ARCH ED REFL REC
   UNCED (United Nations Conference on Environment and Development), 1992, 21 UNCED
   WCED, 1990, OUR COMM FUT BRUNDTL
   Whitford F., 1984, BAUHAUS, P30
   Wingler Hans, 1969, BAUHAUS
   World Commission on Environment and Development (WCED), 1987, OUR COMM FUT BRUNDTL
   *WORLD RES I, 1994, GUID GLOB ENV
NR 20
TC 4
Z9 4
U1 3
U2 15
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1350-4509
J9 INT J SUST DEV WORLD
JI Int. J. Sustain. Dev. World Ecol.
PY 2010
VL 17
IS 5
BP 444
EP 450
AR PII 928021996
DI 10.1080/13504509.2010.500797
PG 7
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Ecology
SC Science & Technology - Other Topics; Environmental Sciences & Ecology
GA 664OL
UT WOS:000282971500011
DA 2018-12-27
ER

PT J
AU Yamamoto, T
   Gotoh, M
   Hattori, R
   Toriyama, K
   Kamei, Y
   Iwaguro, H
   Matsukawa, Y
   Funahashi, Y
AF Yamamoto, Tokunori
   Gotoh, Momokazu
   Hattori, Ryohei
   Toriyama, Kazuhiro
   Kamei, Yuzuru
   Iwaguro, Hideki
   Matsukawa, Yoshihisa
   Funahashi, Yasuhito
TI RETRACTED: Periurethral injection of autologous adipose-derived stem
   cells for the treatment of stress urinary incontinence in patients
   undergoing radical prostatectomy: Report of two initial cases (Retracted
   article. See vol. 17, pg. 896, 2010)
SO INTERNATIONAL JOURNAL OF UROLOGY
LA English
DT Article; Retracted Publication
DE adipose-derived stem cells; injection; radical prostatectomy; stress
   urinary incontinence; urethra
ID BONE-MARROW-TRANSPLANTATION; STROMAL CELLS; MESENCHYMAL CELLS; TISSUE;
   THERAPY; GROWTH; MODEL; TRIAL
AB Objectives:
   To report a novel cell therapy using autologous adipose tissue-derived stem cells (ADSC) for stress urinary incontinence caused by urethral sphincteric deficiency and the outcomes in two initial cases undergoing periurethral injection of stem cells for the treatment of urinary incontinence after radical prostatectomy.
   Methods:
   Two patients with moderate stress incontinence after radical prostatectomy were enrolled. After liposuction of 250 mL of adipose tissue from the abdomen, we isolated ADSC from this tissue by using the Celution system. Subsequently, the isolated ADSC and a mixture of stem cells and adipose tissue were transurethrally injected into the rhabdosphincter and submucosal space of the urethra, respectively. Short-term outcomes during a 12-week follow-up were assessed by a 24-h pad test, a validated patient questionnaire, urethral pressure profile, transrectal ultrasonography, and magnetic resonance imaging.
   Results:
   Urinary incontinence progressively improved after 2 weeks of injection up to 12 weeks in terms of decreased leakage volume in a 24-h pad test, decreased frequency and amount of incontinence, and improved quality of life as per the questionnaire. In urethral pressure profile, both maximum urethral closing pressure and functional profile length increased. Ultrasonography and magnetic resonance imaging showed sustained presence of the injected adipose tissue. Enhanced ultrasonography showed a progressive increase in the blood flow to the injected area. No significant adverse events were observed peri- and postoperatively.
   Conclusion:
   This preliminary study showed that periurethral injection of the autologous ADSC is a safe and feasible treatment modality for stress urinary incontinence.
C1 [Yamamoto, Tokunori; Gotoh, Momokazu; Hattori, Ryohei; Matsukawa, Yoshihisa; Funahashi, Yasuhito] Nagoya Univ, Grad Sch Med, Dept Urol, Showa Ku, Nagoya, Aichi 466855, Japan.
   [Toriyama, Kazuhiro; Kamei, Yuzuru] Nagoya Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Nagoya, Aichi 466855, Japan.
   [Iwaguro, Hideki] Cytori Therapeut, San Diego, CA USA.
RP Gotoh, M (reprint author), Nagoya Univ, Grad Sch Med, Dept Urol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 466855, Japan.
EM gotoh@med.nagoya-u.ac.jp
RI KAMEI, Yuzuru/E-4432-2015; Gotoh, momokazu/I-7239-2014
CR Arai Y, 2009, INT J UROL, V16, P915, DOI 10.1111/j.1442-2042.2009.02385.x
   Avery K, 2004, NEUROUROL URODYNAM, V23, P322, DOI 10.1002/nau.20041
   BACIGALUPO A, 1992, BONE MARROW TRANSPL, V9, P467
   Banfi A, 2001, LEUKEMIA LYMPHOMA, V42, P863, DOI 10.3109/10428190109097705
   Banfi A, 2001, CANCER, V92, P2419, DOI 10.1002/1097-0142(20011101)92:9<2419::AID-CNCR1591>3.0.CO;2-K
   Carlson KV, 2001, UROL CLIN N AM, V28, P595, DOI 10.1016/S0094-0143(05)70165-8
   Carr LK, 2008, INT UROGYNECOL J, V19, P881, DOI 10.1007/s00192-007-0553-z
   Crivellaro S, 2008, INT J UROL, V15, P910, DOI 10.1111/j.1442-2042.2008.02161.x
   Dave DS, 2008, J UROLOGY, V179, P568, DOI 10.1016/S0022-5347(08)61672-9
   Fraser JK, 2006, TRENDS BIOTECHNOL, V24, P150, DOI 10.1016/j.tibtech.2006.01.010
   Garcia-Olmo D, 2005, DIS COLON RECTUM, V48, P1416, DOI 10.1007/s10350-0052-6
   GLUCKMAN E, 1992, BLOOD, V79, P269
   Gotoh M, 2009, INT J UROL, V16, P303, DOI 10.1111/j.1442-2042.2008.02237.x
   Hagen EK, 2001, ACTA RADIOL, V42, P225, DOI 10.1080/028418501127346530
   Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Jack GS, 2005, J UROLOGY, V174, P2041, DOI 10.1097/01.ju.0000176489.96993.84
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Lee PE, 2001, J UROLOGY, V165, P153, DOI 10.1097/00005392-200101000-00037
   Lin K, 2008, CYTOTHERAPY, V10, P417, DOI 10.1080/14653240801982979
   Nagaya N, 2005, CIRCULATION, V112, P1128, DOI 10.1161/CIRCULATIONAHA.104.500447
   Rangappa S, 2003, ANN THORAC SURG, V75, P775, DOI 10.1016/S0003-4975(02)04568-X
   Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1
   Safford KM, 2002, BIOCHEM BIOPH RES CO, V294, P371, DOI 10.1016/S0006-291X(02)00469-2
   WATANABE T, 2007, JPN J REGEN MED S, V6, P184
   Xu Y, 2005, CURR OPIN MOL THER, V7, P300
   YOSHIMURA K, 2005, INT FAT APPL TECHN S, P9
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 29
TC 51
Z9 62
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0919-8172
EI 1442-2042
J9 INT J UROL
JI Int. J. Urol.
PD JAN
PY 2010
VL 17
IS 1
BP 75
EP 82
DI 10.1111/j.1442-2042.2009.02429.x
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 535FU
UT WOS:000272953500014
PM 20002225
DA 2018-12-27
ER

PT J
AU Shen, Z
   Chen, L
   Hao, F
   Wang, G
   Fan, P
   Liu, Y
AF Shen, Z.
   Chen, L.
   Hao, F.
   Wang, G.
   Fan, P.
   Liu, Y.
TI RETRACTED: Intron-1 rs3761548 is related to the defective transcription
   of Foxp3 in psoriasis through abrogating E47/c-Myb binding (Retracted
   Article)
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article; Retracted Publication
DE Foxp3; regulatory T cell; transcription; single nucleotide polymorphism;
   transcription factor; E47; c-Myb
ID REGULATORY T-CELLS; LOOP-HELIX PROTEINS; C-MYB; LYMPHOCYTE DEVELOPMENT;
   DEPENDENT MECHANISM; AUTOIMMUNE-DISEASE; GENE-EXPRESSION; E2A; RECEPTOR;
   GROWTH
AB Foxp3 is a master transcription factor (TF) for development and function of CD4+CD25+Foxp3+ regulatory T cells (Treg cells) and is critical for the transcription of target genes. But the transcriptional regulation of Foxp3 itself has not been fully understood until now. Here, we aimed to demonstrate the hypothesis that upstream single nucleotide polymorphism(s) (SNPs) of Foxp3 was/were responsible for the defective transcription of Foxp3 in psoriasis and to explore the mechanism behind this hypothesis. In this study, SNP of large sample was investigated for risk analysis. Mature algorithms, electrophoretic mobility shift and chromatin immunoprecipitation assays were used to identify TF binding site variations. Loss-of-function and overexpression assays and cell cycle blocker assay were performed to identify when and what kind of possible roles the candidate factors play. Our results showed that intron-1 rs3761548 was correlated with a significant susceptibility to psoriasis. The rs3761548 contributed to the decreased resting Foxp3 transcription and impaired acceleration of Foxp3 transcription levels after stimulation in psoriatic patients with genotype AA. We analysed and demonstrated potent new E47/c-Myb -dependent regulation elements in rs3761548, oppositely controlling Foxp3 gene transcription at G1 and G2/M phases of Treg cells in psoriatic patients. For patients with rs3761548 AA, the polymorphism causes loss of bindings to the E47 and c-Myb factors, leading to defective transcription of Foxp3 gene. Further identification of the networks and molecular mechanisms underlying Foxp3 transcription may provide new insights into Foxp3 transcriptional regulation and alternative therapeutic strategies to improve characteristics of autoimmune disorders.
C1 [Shen, Z.; Hao, F.] Third Mil Med Univ, Southwest Hosp, Dept Dermatol, Chongqing 400038, Peoples R China.
   [Chen, L.] Third Mil Med Univ, Dept Dermatol, Inst Battle Surg, Daping Hosp, Chongqing 400038, Peoples R China.
   [Wang, G.; Fan, P.; Liu, Y.] Fourth Mil Med Univ, Dept Dermatol, Xijing Hosp, Xian 710032, Peoples R China.
RP Shen, Z (reprint author), Third Mil Med Univ, Southwest Hosp, Dept Dermatol, Chongqing 400038, Peoples R China.
EM shenzhuxa@gmail.com
RI Lauschner, Flavia/P-2457-2018
FU National Natural Science Foundation of China [30600558, 30572112];
   Innovation Project of Outstanding Young Scholar of Third Military
   Medical University [2007XG35]
FX We wish to thank all the patients and controls who have assisted with
   this study. This work was supported by National Natural Science
   Foundation of China (No. 30600558 and 30572112) and Innovation Project
   of Outstanding Young Scholar of Third Military Medical University (No.
   2007XG35).
CR Anderson MK, 2006, IMMUNOL REV, V209, P191, DOI 10.1111/j.0105-2896.2006.00352.x
   Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273
   Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782
   BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522
   Ban Y, 2007, J AUTOIMMUN, V28, P201, DOI 10.1016/j.jaut.2007.02.016
   Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737S94
   Bassuny WM, 2003, IMMUNOGENETICS, V55, P149, DOI 10.1007/s00251-003-0559-8
   Bender TP, 2004, NAT IMMUNOL, V5, P721, DOI 10.1038/ni1085
   Bennett CL, 2001, NAT GENET, V27, P20
   Boyman O, 2007, TRENDS IMMUNOL, V28, P51, DOI 10.1016/j.it.2006.12.005
   Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473
   Clarke SL, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000129
   Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590
   de Boer OJ, 2007, J HISTOCHEM CYTOCHEM, V55, P891, DOI 10.1369/jhc.6A7119.2007
   Dooley S, 1996, LEUKEMIA RES, V20, P429, DOI 10.1016/0145-2126(96)00012-4
   Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038
   GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077
   Ghosh D, 2000, NUCLEIC ACIDS RES, V28, P308, DOI 10.1093/nar/28.1.308
   Griffiths CEM, 2007, LANCET, V370, P263, DOI 10.1016/S0140-6736(07)61128-3
   Hu H, 2007, TRENDS IMMUNOL, V28, P329, DOI 10.1016/j.it.2007.06.006
   Huggins GS, 1999, J BIOL CHEM, V274, P28690, DOI 10.1074/jbc.274.40.28690
   Istrail S, 2005, P NATL ACAD SCI USA, V102, P4954, DOI 10.1073/pnas.0409624102
   Jin Y, 2007, NEW ENGL J MED, V356, P1216, DOI 10.1056/NEJMoa061592
   Kagen MH, 2006, E SCHERING RES FDN W, V56, P193
   Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014
   Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109
   Lazorchak A, 2005, TRENDS IMMUNOL, V26, P334, DOI 10.1016/j.it.2005.03.011
   Li MO, 2006, IMMUNITY, V25, P455, DOI 10.1016/j.immuni.2006.07.011
   Lieu YK, 2004, P NATL ACAD SCI USA, V101, P14853, DOI 10.1073/pnas.0405338101
   Mantel PY, 2006, J IMMUNOL, V176, P3593, DOI 10.4049/jimmunol.176.6.3593
   Mantel PY, 2007, PLOS BIOL, V5, P2847, DOI 10.1371/journal.pbio.0050329
   Marinescu VD, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-79
   Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000
   Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333
   Morgan ME, 2005, HUM IMMUNOL, V66, P13, DOI 10.1016/j.humimm.2004.05.016
   Murre C, 2005, NAT IMMUNOL, V6, P1079, DOI 10.1038/ni1260
   MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0
   Najarian DJ, 2003, J AM ACAD DERMATOL, V48, P805, DOI 10.1067/mjd.2003.540
   Nakata Y, 2007, MOL CELL BIOL, V27, P2048, DOI 10.1128/MCB.01100-06
   Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839
   Pardo J, 2003, INT IMMUNOL, V15, P1441, DOI 10.1093/intimm/dxg141
   Pyzik M, 2007, J LEUKOCYTE BIOL, V82, P335, DOI 10.1189/jlb.1006644
   Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880
   Rosenberg P, 2007, J HEPATOL, V46, P1111, DOI 10.1016/j.jhep.2007.01.024
   Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x
   SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419
   SCHUG J, 1997, CBILTR19971001V00 U
   Schwartz R, 2006, P NATL ACAD SCI USA, V103, P9976, DOI 10.1073/pnas.0603728103
   Shen Z, 2006, J AM ACAD DERMATOL, V54, P992, DOI 10.1016/j.jaad.2006.02.033
   Sugiyama H, 2005, J IMMUNOL, V174, P164, DOI 10.4049/jimmunol.174.1.164
   Tai P, 2008, J CELL PHYSIOL, V214, P456, DOI 10.1002/jcp.21221
   Tran DQ, 2007, BLOOD, V110, P2983, DOI 10.1182/blood-2007-06-094656
   Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437
   YAMAMOTO M, 2007, LEUKEMIA RES, V32, P651
   Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747
NR 55
TC 36
Z9 40
U1 3
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JAN-FEB
PY 2010
VL 14
IS 1-2
BP 226
EP 241
DI 10.1111/j.1582-4934.2008.00370.x
PG 16
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 569YV
UT WOS:000275639700020
PM 20414968
OA Bronze
DA 2018-12-27
ER

PT J
AU Hafner, M
   Stapel, DA
AF Hafner, Michael
   Stapel, Diederik A.
TI RETRACTED: Information to go: Fluency enhances the usability of primed
   information (Retracted article. See vol. 49, pg. 318, 2013)
SO JOURNAL OF EXPERIMENTAL SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
DE Processing fluency; Priming; Hedonic marking; (Judged) usability
ID PERCEPTUAL FLUENCY; MERE EXPOSURE; PROCESSING FLUENCY;
   IMPRESSION-FORMATION; JUDGMENTS; MEMORY; MOOD; APPLICABILITY;
   ACCESSIBILITY; JUDGEABILITY
AB We propose that over and above signaling a positive state of affairs, a fluency experience may be interpreted as a cue to the usability of the information at stake. Three experiments demonstrate this effect in a classic social psychological priming paradigm. Specifically, we show that when primed traits are processed fluently, they have effects independent of whether or not these traits are descriptively applicable to a Subsequent target description. In Experiment 1, fluency was manipulated by rhyming. In Experiment 2 letter size of the primes was manipulated. Experiment 3 investigated underlying processes and aimed to control for a possible alternative explanation. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Hafner, Michael] Univ Utrecht, Dept Social & Org Psychol, NL-3584 CS Utrecht, Netherlands.
   [Stapel, Diederik A.] Tilburg Univ, TIBER, NL-5000 LE Tilburg, Netherlands.
RP Hafner, M (reprint author), Univ Utrecht, Dept Social & Org Psychol, Heidelberglaan 1, NL-3584 CS Utrecht, Netherlands.
EM m.hafner@uu.nl; d.a.stapel@uvt.nl
CR Alter AL, 2008, PSYCHOL SCI, V19, P161, DOI 10.1111/j.1467-9280.2008.02062.x
   BORNSTEIN RF, 1994, SOC COGNITION, V12, P103, DOI 10.1521/soco.1994.12.2.103
   BOWER GH, 1981, AM PSYCHOL, V36, P129, DOI 10.1037/0003-066X.36.2.129
   BRICKMAN P, 1972, J EXP SOC PSYCHOL, V8, P31, DOI 10.1016/0022-1031(72)90059-5
   Brinol P, 2006, PSYCHOL SCI, V17, P200, DOI 10.1111/j.1467-9280.2006.01686.x
   Bruner JS, 1957, CONT APPROACHES COGN, P41
   CARVER CS, 1990, PSYCHOL REV, V97, P19, DOI 10.1037//0033-295X.97.1.19
   Corneille O, 1999, J PERS SOC PSYCHOL, V76, P377, DOI 10.1037/0022-3514.76.3.377
   Croizet JC, 2000, J EXP SOC PSYCHOL, V36, P155, DOI 10.1006/jesp.1999.1397
   DEVINE PG, 1989, J PERS SOC PSYCHOL, V56, P5, DOI 10.1037/0022-3514.56.5.680
   Fazendeiro T, 2005, MEM COGNITION, V33, P249, DOI 10.3758/BF03195314
   FIEDLER K, 1991, COGNITION EMOTION, V5, P363, DOI 10.1080/02699939108411048
   Hafner M, 2009, SOC COGNITION, V27, P615
   Harmon-Jones E, 2001, PERS SOC PSYCHOL B, V27, P889, DOI 10.1177/0146167201277011
   HIGGINS ET, 1995, J EXP SOC PSYCHOL, V31, P218, DOI 10.1006/jesp.1995.1011
   HIGGINS ET, 1977, J EXP SOC PSYCHOL, V13, P141
   Higgins ET, 1996, SOCIAL PSYCHOL HDB B, P133
   Huber DE, 2008, J EXP PSYCHOL LEARN, V34, P1305, DOI 10.1037/a0013370
   Jacoby L. L, 1989, VARIETIES MEMORY CON, P391, DOI DOI 10.1002/ACP.2350050509
   JACOBY LL, 1981, J EXP PSYCHOL GEN, V110, P306, DOI 10.1037/0096-3445.110.3.306
   Lee AY, 2004, J PERS SOC PSYCHOL, V86, P205, DOI 10.1037/0022-3514.86.2.205
   MANDLER G, 1987, J EXP PSYCHOL LEARN, V13, P646, DOI 10.1037//0278-7393.13.4.646
   MARTIN LL, 1986, J PERS SOC PSYCHOL, V51, P493, DOI 10.1037/0022-3514.51.3.493
   McGlone MS, 2000, PSYCHOL SCI, V11, P424, DOI 10.1111/1467-9280.00282
   Monahan JL, 2000, PSYCHOL SCI, V11, P462, DOI 10.1111/1467-9280.00289
   Reber R, 1998, PSYCHOL SCI, V9, P45, DOI 10.1111/1467-9280.00008
   Reber R, 2004, PERS SOC PSYCHOL REV, V8, P364, DOI 10.1207/s15327957pspr0804_3
   Reber R, 2004, CONSCIOUS COGN, V13, P47, DOI 10.1016/S1053-8100(03)00049-7
   Reber R, 1999, CONSCIOUS COGN, V8, P338, DOI 10.1006/ccog.1999.0386
   SCHWARZ N, 1983, J PERS SOC PSYCHOL, V45, P513, DOI 10.1037/0022-3514.45.3.513
   Schwarz N, 2003, PSYCHOL INQ, V14, P296, DOI 10.1207/S15327965PLI1403&4_20
   Srull T.K, 1989, MEMORY COGNITION ITS
   SRULL TK, 1979, J PERS SOC PSYCHOL, V37, P1660, DOI 10.1037//0022-3514.37.10.1660
   Stapel DA, 2000, J PERS SOC PSYCHOL, V78, P19, DOI 10.1037//0022-3514.78.1.19
   Stapel DA, 2005, SOC COGNITION, V23, P324, DOI 10.1521/soco.2005.23.4.324
   Stapel DA, 2007, ASSIMILATION AND CONTRAST IN SOCIAL PSYCHOLOGY, P1
   SWAP WC, 1977, PERS SOC PSYCHOL B, V3, P248, DOI 10.1177/014616727700300219
   Unkelbach C, 2006, PSYCHOL SCI, V17, P339, DOI 10.1111/j.1467-9280.2006.01708.x
   Unkelbach C, 2007, J EXP PSYCHOL LEARN, V33, P219, DOI 10.1037/0278-7393.33.1.219
   WHITTLESEA BWA, 1993, J EXP PSYCHOL LEARN, V19, P1235, DOI 10.1037//0278-7393.19.6.1235
   Winkielman P, 2003, PSYCHOLOGY OF EVALUATION, P189
   Winkielman P, 2001, J PERS SOC PSYCHOL, V81, P989, DOI 10.1037//0022-3514.81.6.989
   YZERBYT VY, 1994, J PERS SOC PSYCHOL, V66, P48, DOI 10.1037//0022-3514.66.1.48
   ZAJONC RB, 1974, J EXP SOC PSYCHOL, V10, P248, DOI 10.1016/0022-1031(74)90071-7
   ZAJONC RB, 1968, J PERS SOC PSYCHOL, V9, P1, DOI 10.1037/h0025848
   ZILLMANN D, 1974, J PERS SOC PSYCHOL, V30, P782, DOI 10.1037/h0037541
NR 46
TC 7
Z9 7
U1 2
U2 32
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-1031
EI 1096-0465
J9 J EXP SOC PSYCHOL
JI J. Exp. Soc. Psychol.
PD JAN
PY 2010
VL 46
IS 1
BP 73
EP 84
DI 10.1016/j.jesp.2009.10.001
PG 12
WC Psychology, Social
SC Psychology
GA 537ZH
UT WOS:000273152700008
DA 2018-12-27
ER

PT J
AU Casati, P
AF Casati, Paolo
TI RETRACTED: Irreducible SLn+1-Representations Remain Indecomposable
   Restricted to Some Abelian Subalgebras (Retracted article. See vol. 15,
   pg. 201, 2012)
SO JOURNAL OF LIE THEORY
LA English
DT Article; Retracted Publication
DE Simple Lie algebras; indecomponsable representations
ID LIE-ALGEBRAS; REPRESENTATIONS; BASES
AB In this paper we show that any irreducible finite dimensional representation of SLn+1 remains indecomposable if restricted to n-dimensional abelian subalgebras spanned by simple root vectors.
C1 Univ Milano Bicocca, Dipartimento Matemat & Applicaz, I-20125 Milan, Italy.
RP Casati, P (reprint author), Univ Milano Bicocca, Dipartimento Matemat & Applicaz, Via Cozzi 53, I-20125 Milan, Italy.
CR Bliem Thomas, 2008, Proceedings of the 2008 International Conference on Information Theory and Statistical Learning, P80
   Cagliero L, 2004, MANUSCRIPTA MATH, V115, P417, DOI 10.1007/s00229-004-0499-0
   Casati P, 2006, J GEOM PHYS, V56, P418, DOI 10.1016/j.geomphys.2005.02.010
   CASATI P, J MATH PHYS IN PRESS
   Douglas A, 2007, COMMUN ALGEBRA, V35, P1433, DOI 10.1080/00927870601168814
   Humphreys J. E., 1972, INTRO LIE ALGEBRAS R
   KNAPP AW, 2002, PROGR MATH, V140
   LI SP, 1986, J MATH PHYS, V27, P668, DOI 10.1063/1.527222
   LITTELMANN P, 1995, ANN MATH, V142, P499, DOI 10.2307/2118553
   Littelmann P, 1997, J PURE APPL ALGEBRA, V117, P447, DOI 10.1016/S0022-4049(97)00022-4
   LITTELMANN P, 1998, TRANSFORM GROUPS, V3, P145, DOI [10.1007/BF01236431, DOI 10.1007/BF01236431]
   MEDINA A, 1985, ANN SCI ECOLE NORM S, V18, P553
   Premat A., 2007, INDECOMPOSABLE REPRE
NR 13
TC 5
Z9 5
U1 2
U2 8
PU HELDERMANN VERLAG
PI LEMGO
PA LANGER GRABEN 17, 32657 LEMGO, GERMANY
SN 0949-5932
J9 J LIE THEORY
JI J. Lie Theory
PY 2010
VL 20
IS 2
BP 393
EP 407
PG 15
WC Mathematics
SC Mathematics
GA 641YU
UT WOS:000281170000009
DA 2018-12-27
ER

PT J
AU Carty, J
   Ahern, A
AF Carty, John
   Ahern, Aoife
TI RETRACTED: Mapping the relationship between transport energy consumption
   and urban form characteristics for the Greater Dublin Area (Retracted
   article. See vol. 8, pg. 197, 2012)
SO JOURNAL OF MAPS
LA English
DT Article; Retracted Publication
AB Energy consumption and emissions from the transport sector continue to rise, adding to growing concerns about the environmental impacts caused by transport systems and related land-use patterns. Transportation and land-use are a function of one another, therefore it is often hypothesized that changing urban form will result in changes in transport energy consumption.
   This paper intends to explore further the relationship between urban form and transport energy consumption. It is hypothesised in this research that more compact neighbourhoods result in more sustainable communities, with lower transport energy consumption. The theory is to an extent premised on urban containment, to provide a concentration of socially sustainable mixed uses, that will concentrate development and reduce the need to travel, thus reducing transport energy consumption.
   Using the Census of Population of Ireland 2006 Place of Work - Census of Anonymised Records ( POW-CAR) Dataset it is intended to examine urban form factors in terms of their influence on journey to work energy consumption. To examine the hypothesis, the transport energy consumption of different urban forms will be found, thus allowing the most sustainable urban forms in the Greater Dublin Area to be identified. The results of this research can then be used to assess the transport energy consumption of future development plans and therefore allow greater transport sustainability to be achieved through improved design of the location and form of major new development.
C1 [Carty, John; Ahern, Aoife] Univ Coll Dublin, Sch Architecture Landscape & Civil Engn, Dublin 4, Ireland.
RP Carty, J (reprint author), Univ Coll Dublin, Sch Architecture Landscape & Civil Engn, Newstead Bldg, Dublin 4, Ireland.
EM john.carty@ucd.ie
FU Environmental Protection Agency
FX This work was completed as part of the Urban Environment Project and
   supported by the Environmental Protection Agency. We would like to
   acknowledge the use of the Central Statistics Office - Census Place of
   Work Anonymised Microdata File, Government of Ireland.
CR Anderson WP, 1996, URBAN STUD, V33, P7, DOI 10.1080/00420989650012095
   Boarnet M. G., 2001, TRAVEL BY DESIGN
   Bourne L. S, 1982, INTERNAL STRUCTURE C
   Cervero R, 1996, TRANSPORT RES A-POL, V30, P361, DOI 10.1016/0965-8564(95)00033-X
   Frank L, 1995, TRANSPORT RES REC, V1466, P44
   FULFORD C, 1996, COMPACT CITY SUSTAIN
   Gordon P, 1997, J AM PLANN ASSOC, V63, P95, DOI 10.1080/01944369708975727
   *IR CENTR STAT OFF, 2002, POP CENS
   *IR CENTR STAT OFF, 1986, POP CENS
   *IR CENTR STAT OFF, 1996, POP CENS
   *IR CENTR STAT OFF, 1991, POP CENS
   *IR CENTR STAT OFF, 2006, POP CENS
   Newman Peter, 1989, CITIES AUTOMOBILE DE
NR 13
TC 6
Z9 6
U1 4
U2 21
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1744-5647
J9 J MAPS
JI J. Maps
PY 2010
VL 6
IS 1
BP 160
EP 168
DI 10.4113/jom.2010.1074
PG 9
WC Geography; Geography, Physical
SC Geography; Physical Geography
GA 613EV
UT WOS:000278961800005
DA 2018-12-27
ER

PT J
AU Field, K
   Beale, L
AF Field, Kenneth
   Beale, Linda
TI RETRACTED: Geo-Genealogy of Irish Surnames (Retracted article. See vol.
   8, pg. 196, 2012)
SO JOURNAL OF MAPS
LA English
DT Article; Retracted Publication
AB This paper outlines the design and production of the Geo-genealogy of Irish Surnames map. The large-format A0 print document uses classic Irish symbology and themes to create a visually striking representation of historic and numeric data relating to Irish surnames from the 1890 Irish census. Created using Esri ArcGIS, the map was designed to illustrate the flexibility and quality afforded by modern GIS for high quality cartographic design and production without recourse to alternative software.
C1 [Field, Kenneth] Kingston Univ London, Ctr GIS, Kingston Upon Thames KT1 2EE, Surrey, England.
   [Beale, Linda] Univ London Imperial Coll Sci Technol & Med, SAHSU, London W2 1PG, England.
RP Field, K (reprint author), Kingston Univ London, Ctr GIS, Penrhyn Rd, Kingston Upon Thames KT1 2EE, Surrey, England.
EM ken.field@kingston.ac.uk
CR DENT B., 2008, SERIES DEMOGRAPHIC M
   ESRI, 2009, CART REPR
   GROSS T., 2007, MAP COLORING 4 COLOR
   UNIVERSITY OF ESSEX, 2009, ONL HIST POP REP AR
NR 4
TC 2
Z9 2
U1 2
U2 16
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1744-5647
J9 J MAPS
JI J. Maps
PY 2010
VL 6
IS 1
BP 651
EP 656
DI 10.4113/jom.2010.1128
PG 6
WC Geography; Geography, Physical
SC Geography; Physical Geography
GA 700US
UT WOS:000285770400007
DA 2018-12-27
ER

PT J
AU Krishna, KM
AF Krishna, K. Muni
TI RETRACTED: Extreme oceanographic events recorded in the southwest coast
   of India during the 1998-1999 summer season (Retracted article. See vol.
   81, pg. 341, 2010)
SO JOURNAL OF MARINE SYSTEMS
LA English
DT Article; Retracted Publication
DE Chlorophyll-a; Sea surface temperature; Upwelling; Wind speed
ID ENSO; SYSTEMS
AB Two unusual oceanographic events occurred during the 1998-1999 summer season off the southwest coast of India. The first was strong and sustained warming that occurred in mid-May and lasted for 2 weeks. The second was an enhanced cooling that lasted from mid to late summer. These two events were the result of fluctuations of wind-induced upwelling. The spatial as well as the temporal extent of these conditions are analyzed and the corresponding atmospheric setting is described. Using climatological data, the 1998-99 summer season is placed in the log term context of the climatic variability in the region. The influence of those events on phytoplankton and anchovy recruitment may have contributed to a record high level of anchovy recruitment in 1999. (C) 2009 Elsevier B.V. All rights reserved.
C1 Andhra Univ, Dept Meteorol & Oceanog, Visakhapatnam 530003, Andhra Pradesh, India.
RP Krishna, KM (reprint author), Andhra Univ, Dept Meteorol & Oceanog, Visakhapatnam 530003, Andhra Pradesh, India.
EM kailasam15@yahoo.co.in
CR BANSE K, 1968, DEEP-SEA RES, V15, P45, DOI 10.1016/0011-7471(68)90028-4
   Banse K., 1959, J MAR BIOL ASSOC IND, V1, P33
   DARBYSHIRE M, 1967, DEEP-SEA RES, V14, P295, DOI 10.1016/0011-7471(67)90073-3
   Huang BH, 2007, J CLIMATE, V20, P2937, DOI 10.1175/JCLI4169.1
   Jensen TG, 2007, J CLIMATE, V20, P2978, DOI 10.1175/JCLI4150.1
   Johannessen O. M., 1981, FISKDIR SKR SER HAVU, V18, P247
   Klein SA, 1999, J CLIMATE, V12, P917, DOI 10.1175/1520-0442(1999)012<0917:RSSTVD>2.0.CO;2
   Korrubel JL, 1998, S AFR J MARINE SCI, V19, P415
   Krishna KM, 2008, ANN GEOPHYS-GERMANY, V26, P1331
   Krishna KM, 2008, J APPL REMOTE SENS, V2, DOI 10.1117/1.2837118
   Krishna KM, 2008, J APPL REMOTE SENS, V2, DOI 10.1117/1.3026540
   KRISHNA KM, 2007, THESIS ANDHRA U INDI
   LATHIPHA PN, 1985, INDIAN J MAR SCI, V14, P10
   LONGHURST AR, 1990, CAN J FISH AQUAT SCI, V47, P2407, DOI 10.1139/f90-268
   MAHESWARAN M, 2000, INDIAN J MAR SCI, V15, P20
   Meyers G, 2007, J CLIMATE, V20, P2872, DOI 10.1175/JCLI4152.1
   Rao A.D., 2004, P METOC 2004, P183
   REYNOLDS RW, 1993, J CLIMATE, V6, P114, DOI 10.1175/1520-0442(1993)006<0114:AIRTGS>2.0.CO;2
   Sharma G.S., 1978, INDIAN J MAR SCI, V17, P16
   Ward MN, 1996, J CLIMATE, V9, P1877, DOI 10.1175/1520-0442(1996)009<1877:NSWOTG>2.0.CO;2
   WEBSTER PJ, 1992, Q J ROY METEOR SOC, V118, P877, DOI 10.1002/qj.49711850705
   Webster PJ, 1999, NATURE, V401, P356, DOI 10.1038/43848
   Wolter K., 1993, P 17 CLIM DIAGN WORK, P52
   WOODRUFF SD, 1987, B AM METEOROL SOC, V68, P1239, DOI 10.1175/1520-0477(1987)068<1239:ACOADS>2.0.CO;2
   WOODRUFF SD, 1998, PHYS CHEM EARTH, V23, P517, DOI DOI 10.1016/S0079-1946(98)00064-0
   WORELY SJ, 2005, INT J CLIMATOL CLIMA, V25, P823
NR 26
TC 1
Z9 1
U1 2
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-7963
EI 1879-1573
J9 J MARINE SYST
JI J. Mar. Syst.
PD JAN
PY 2010
VL 79
IS 1-2
BP 44
EP 49
DI 10.1016/j.jmarsys.2009.07.003
PG 6
WC Geosciences, Multidisciplinary; Marine & Freshwater Biology;
   Oceanography
SC Geology; Marine & Freshwater Biology; Oceanography
GA 532PH
UT WOS:000272761400004
DA 2018-12-27
ER

PT J
AU Ismail, AA
   Aly, HM
AF Ismail, Ali A.
   Aly, H. M.
TI RETRACTED: Optimal planning of failure-step stress partially accelerated
   life tests under type-II censoring (Retracted article. See vol. 84, pg.
   2759, 2014)
SO JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION
LA English
DT Article; Retracted Publication
DE partially accelerated life test; failure-step stress test; Weibull
   lifetime distribution; type-II censoring; maximum likelihood method;
   Fisher-information matrix; generalized asymptotic variance; optimal
   design; D-optimality
ID OPTIMAL-DESIGN
AB This paper considers optimum plans for failure-step stress partially accelerated life tests with two stress levels under type-II censoring assuming Weibull distribution as a lifetime model. The optimum test plans determine the optimum proportion of test units failing at each stress according to a certain optimality criterion. The D-optimality criterion is considered. Some numerical illustrations are provided to illustrate the proposed procedure.
C1 [Ismail, Ali A.] King Saud Univ, Coll Sci, Dept Stat & Operat Res, Riyadh 11451, Saudi Arabia.
   [Aly, H. M.] Cairo Univ, Dept Stat, Fac Econ & Polit Sci, Giza, Egypt.
RP Ismail, AA (reprint author), King Saud Univ, Coll Sci, Dept Stat & Operat Res, POB 2455, Riyadh 11451, Saudi Arabia.
EM aismail100@yahoo.com
FU Research Center, College of Science at King Saud University
   [Stat/2009/14]
FX The authors would like to thank the Research Center, College of Science
   at King Saud University for supporting this paper under the project
   number Stat/2009/14.
CR ABDELGHALY AA, 2007, INTERSTAT ELECT 1102
   ABDELGHALY AA, 2008, INTERSTAT ELECT 0102
   ABDELGHALY AA, 1997, P 32 ANN C STAT COMP, P45
   ABDELGHANI MM, 1998, THESIS CAIRO U EGYPT
   Aly HM, 2008, FAR E J THEOR STAT, V24, P175
   ATTIA AF, 1996, P 31 ANN C STAT COMP, P128
   BAI DS, 1993, RELIAB ENG SYST SAFE, V40, P85, DOI 10.1016/0951-8320(93)90122-F
   BAI DS, 1992, IEEE T RELIAB, V41, P400, DOI 10.1109/24.159807
   BAI DS, 1989, IEEE T RELIAB, V38, P528, DOI 10.1109/24.46476
   BHATTACHARYYA GK, 1989, COMMUN STAT THEORY, V18, P1627, DOI 10.1080/03610928908829990
   DEGROOT MH, 1979, NAV RES LOG, V26, P223, DOI 10.1002/nav.3800260204
   Goel P. K., 1971, 50 CARN MELL U DEP S
   ISMAIL AA, 2004, THESIS CAIRO U EGYPT
   ISMAIL AA, 2006, INTERSTAT ELECT 0601
   Madi MT, 1997, MICROELECTRON RELIAB, V37, P1165, DOI 10.1016/S0026-2714(96)00292-2
   MILLER R, 1983, IEEE T RELIAB, V32, P59, DOI 10.1109/TR.1983.5221475
   Nelson W. B., 1990, ACCELERATED LIFE TES
NR 17
TC 20
Z9 20
U1 2
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0094-9655
EI 1563-5163
J9 J STAT COMPUT SIM
JI J. Stat. Comput. Simul.
PY 2010
VL 80
IS 12
BP 1335
EP 1348
AR PII 917531316
DI 10.1080/00949650903071096
PG 14
WC Computer Science, Interdisciplinary Applications; Statistics &
   Probability
SC Computer Science; Mathematics
GA 683LK
UT WOS:000284477100003
DA 2018-12-27
ER

PT J
AU Huang, YM
   Ma, QL
AF Huang, Yuan Ming
   Ma, Qing-Lan
TI RETRACTED: Synthesis and mesomorphic properties of
   three-benzene-ring-containing banana-shaped liquid crystals (Retracted
   article. See vol. 38, pg. 1079, 2011)
SO LIQUID CRYSTALS
LA English
DT Article; Retracted Publication
DE banana-shaped liquid crystal; three-benzene-ring; bent core; mesophase;
   phase transition temperature
ID ACHIRAL MOLECULES; END-GROUPS
AB A homologous series of three-benzene-ring-containing banana-shaped compounds, N,N-bis(4-alkylcarbonyloxybenzylidene)benzene-1,3-diamine, were synthesised by esterifying aliphatic acids with the three-benzene-ring bent core 1,3-phenylene-bis(4-hydroxybenzylideneamine). As the number of carbon atoms in the aliphatic acids increased from 1 to 12, 12 novel banana-shaped compounds resulted with increasing lengths in their terminal tails. The mesomorphic properties of this homologous series of three-benzene-ring-containing banana-shaped compounds were characterised by means of polarised optical microscopy, differential scanning calorimetry, X-ray diffraction and electro-optical studies. Our results have demonstrated that this series of banana-shaped compounds can form mesophases, although each of their bent cores contains only three benzene rings.
EM dongshanisland@126.com
FU Natural Science Foundation of China [10674091]; Education Ministry of
   China [2005-546, 206110]; 11th Young Scientist Program of Yunnan
   Province [2008PY058]; Natural Science Foundation of Yunnan Province
   [2008CD110]
FX This work was financially supported by the following funds: (1) the
   Natural Science Foundation of China (No. 10674091); (2) the Scientific
   Research Fund for Returned Overseas Chinese Scholar from Education
   Ministry of China (No. 2005-546); (3) Key Research Project of the
   Education Ministry of China (No. 206110); (4) the 11th Young Scientist
   Program of Yunnan Province (No. 2008PY058); and (5) the Natural Science
   Foundation of Yunnan Province (No. 2008CD110).
CR Achten R, 2004, LIQ CRYST, V31, P215, DOI 10.1080/02678290310001642531
   Coleman DA, 2003, SCIENCE, V301, P1204, DOI 10.1126/science.1084956
   Heppke G, 1998, SCIENCE, V279, P1872, DOI 10.1126/science.279.5358.1872
   Huang YM, 2009, MOL CRYST LIQ CRYST, V511, P1807, DOI 10.1080/15421400903054444
   Huang YM, 2009, MOL CRYST LIQ CRYST, V510, P214, DOI 10.1080/15421400903066349
   Huang YM, 2009, MOL CRYST LIQ CRYST, V510, P34, DOI 10.1080/15421400903057884
   [黄远明 Huang Yuanming], 2009, [光学学报, Acta Optica Sinica], V29, P1160
   Lee CK, 2003, LIQ CRYST, V30, P1401, DOI 10.1080/02678290310001621930
   Lee CK, 2002, LIQ CRYST, V29, P1007, DOI 10.1080/02678290210149540
   Lee CK, 2001, LIQ CRYST, V28, P1749, DOI 10.1080/02678290110078711
   Link DR, 1997, SCIENCE, V278, P1924, DOI 10.1126/science.278.5345.1924
   Niori T, 1996, J MATER CHEM, V6, P1231, DOI 10.1039/jm9960601231
   Pelzl G, 1999, ADV MATER, V11, P707, DOI 10.1002/(SICI)1521-4095(199906)11:9<707::AID-ADMA707>3.0.CO;2-D
   Reddy RA, 2000, LIQ CRYST, V27, P1613, DOI 10.1080/026782900750037176
   Shen D, 1998, CHEM COMMUN, P2573, DOI 10.1039/a807547f
   Shin ST, 2004, LIQ CRYST, V31, P935, DOI 10.1080/02678290410001709257
   Tang YH, 2005, CHINESE SCI BULL, V50, P1849, DOI 10.1360/982005-6
   Umadevi S, 2005, LIQ CRYST, V32, P287, DOI 10.1080/02678290500031814
   Walba DM, 2000, SCIENCE, V288, P2181, DOI 10.1126/science.288.5474.2181
NR 19
TC 5
Z9 5
U1 4
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0267-8292
J9 LIQ CRYST
JI Liq. Cryst.
PY 2010
VL 37
IS 9
BP 1119
EP 1126
DI 10.1080/02678292.2010.489156
PG 8
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA 648OB
UT WOS:000281702700002
DA 2018-12-27
ER

PT J
AU Dusan, D
   Vesna, KM
   Veselin, B
AF Dusan, D.
   Vesna, K. M.
   Veselin, B.
TI RETRACTED: Heating Cable Application in Solving Paraffin Deposition
   Problem in Tubing (Retracted article. See vol. 29, pg. 873, 2011)
SO PETROLEUM SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
DE deposition; heating cable; heavy oil; paraffin; tubing
ID FLOW
AB The exploitation process of paraffin-based crude is more complex than production of other oil types. The paraffin type of crude is characterized by a high pure point that can reach 46 degrees C, non-Newtonian flow characteristics in temperature range close to the pure point, and occurrence of paraffin deposition. During production of this oil type, paraffin deposition is evident, especially in the tubing's upper zone, ranging from 700 m depth upwards. In Serbia about 70% of oil production accounts for the heavy oil, out of which approximately 25% is represented by high paraffin oil. In this article, heating cable application for solving a paraffin deposition problem in tubing has been considered. It is solved by heating the upper part of the tubing at a temperature that exceeds the one when the paraffin deposition occurs, and at the same time the increased temperature causes a reduction in oil viscosity, resulting in improved oil flow rate. Uniform heat distribution can be achieved by tubing electric heating along whole heating zone. This article presents an original heating cable application that can be easily and quickly installed in the well. Application of this method and the results are exemplified by the flowing well B-8, where two different heating cables are used.
C1 [Dusan, D.; Vesna, K. M.; Veselin, B.] Univ Belgrade, Fac Min & Geol, Belgrade 11000, Serbia.
RP Dusan, D (reprint author), Univ Belgrade, Fac Min & Geol, Djusina 7, Belgrade 11000, Serbia.
EM danilovic@rgf.bg.ac.yu
CR DANILOVIC D, 2008, INTELLECT PROPERTY J, V4, P1
   DANILOVIC D, 2008, TERMOTEHNIKA, V3, P1
   *JAG CABL FACT, 2008, TECHN DOC JAG CABL F
   Kane M, 2003, FUEL, V82, P127, DOI 10.1016/S0016-2361(02)00222-3
   Roopa I, 2005, PETROL SCI TECHNOL, V23, P681, DOI 10.1081/LFT-200033014
   *SCHLUMB LOG INC, 2008, PIPESIM SOFTW
   SIERRA R, 2001, 69709 SPE, P1
   *THERM, 2004, TECHN DOC THERM CABL
   Venkatesan R, 2005, CHEM ENG SCI, V60, P3587, DOI 10.1016/j.ces.2005.02.045
   Wang XL, 2009, SPE PROD OPER, V24, P35, DOI 10.2118/103829-PA
NR 10
TC 1
Z9 2
U1 2
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1091-6466
EI 1532-2459
J9 PETROL SCI TECHNOL
JI Pet. Sci. Technol.
PY 2010
VL 28
IS 9
BP 969
EP 978
AR PII 921533061
DI 10.1080/10916460902937075
PG 10
WC Energy & Fuels; Engineering, Chemical; Engineering, Petroleum
SC Energy & Fuels; Engineering
GA 596GI
UT WOS:000277672700011
DA 2018-12-27
ER

PT J
AU Bergmann, N
   Bonhommeau, S
   Lange, KM
   Greil, SM
   Eisebitt, S
   de Groot, F
   Chergui, M
   Aziz, EF
AF Bergmann, Nora
   Bonhommeau, Sebastien
   Lange, Kathrin M.
   Greil, Stefanie M.
   Eisebitt, Stefan
   de Groot, Frank
   Chergui, Majed
   Aziz, Emad F.
TI RETRACTED: On the enzymatic activity of catalase: an iron L-edge X-ray
   absorption study of the active centre (Retracted article. See vol. 20,
   pg. 16294, 2018)
SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS
LA English
DT Article; Retracted Publication
ID FERRYL PROTONATION; SPECTROSCOPY; PEROXIDASE; RESOLUTION; ENZYMES;
   LIGAND
AB Catalase and methaemoglobin have very similar haem groups, which are both ferric, yet catalase decomposes hydrogen peroxide to water and oxygen very efficiently, while methaemoglobin does not. Structural studies have attributed this behaviour to their different distal environments. Here we present Fe L-2,L-3-edge X-ray absorption spectra of these proteins in physiological solutions, which reveal clear differences in their electronic structures, in that pi back-donation of the Fe atom occurs in catalase, which confers on it a partial ferryl (Fe4+) character, while this is not the case in methaemoglobin. The origin of the Fe4+ character stems from the proximal tyrosine residue. We also find that both systems are in a high spin state. Temperature effects influence the spectra of catalase only weakly, in agreement with previous studies of its chemical activity. We conclude that the high activity of catalase is not only determined by its distal environment but also by its partial ferryl character.
C1 [Chergui, Majed; Aziz, Emad F.] Ecole Polytech Fed Lausanne, Lab Spect Ultrarapide, Fac Sci Base, ISIC BSP, CH-1015 Lausanne, Switzerland.
   [Bergmann, Nora] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany.
   [Bonhommeau, Sebastien] Univ Bordeaux 1, Inst Mol Sci, CNRS, UMR 5255, F-33405 Talence, France.
   [Lange, Kathrin M.; Greil, Stefanie M.; Eisebitt, Stefan; Aziz, Emad F.] BESSY II, Helmholtz Zentrum Berlin Mat & Energie, D-12489 Berlin, Germany.
   [Eisebitt, Stefan] Tech Univ Berlin, Inst Opt & Atom Phys, D-10623 Berlin, Germany.
   [de Groot, Frank] Univ Utrecht, Dept Inorgan Chem & Catalysis, NL-3584 CA Utrecht, Netherlands.
RP Chergui, M (reprint author), Ecole Polytech Fed Lausanne, Lab Spect Ultrarapide, Fac Sci Base, ISIC BSP, CH-1015 Lausanne, Switzerland.
EM Majed.Chergui@epfl.ch; Emad.Aziz@helmholtz-berlin.de
RI de Groot, Frank/A-1918-2009; Institute (DINS), Debye/G-7730-2014; Aziz,
   Emad/A-4463-2017; BONHOMMEAU, SEBASTIEN/N-3155-2017
OI Aziz, Emad/0000-0003-1794-4350; BONHOMMEAU,
   SEBASTIEN/0000-0002-9213-7201
FU Swiss NSF [IZKOZ2-126024]; European Science Foundation
FX We thank Dr R. Pietri for useful discussions. E. F. A. thanks the Swiss
   NSF for the grant IZKOZ2-126024 during his stay in Lausanne and the
   European Science Foundation DYNA programme for financial support.
CR Arcovito A, 2007, P NATL ACAD SCI USA, V104, P6211, DOI 10.1073/pnas.0608411104
   Aziz EF, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.075120
   Aziz EF, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.068103
   Behan RK, 2006, J INORG BIOCHEM, V100, P448, DOI 10.1016/j.jinorgbio.2005.12.019
   Bonhommeau S, 2008, PHYS CHEM CHEM PHYS, V10, P5882, DOI 10.1039/b806783j
   Bragger JM, 2000, BBA-PROTEIN STRUCT M, V1480, P278, DOI 10.1016/S0167-4838(00)00081-9
   CHANCE B, 1985, FED PROC, V44, P676
   CHANCE M, 1986, BIOCHEMISTRY-US, V25, P1259, DOI 10.1021/bi00354a010
   de Groot F, 2005, COORDIN CHEM REV, V249, P31, DOI 10.1016/j.ccr.2004.03.018
   de Groot F, 2008, ADV CONDENS MAT SCI, V6, P1
   Everse J., 1991, PEROXIDASES CHEM BIO, V1
   Everse J., 1991, PEROXIDASES CHEM BIO, V2
   FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9
   HABER J, 1993, EUR J BIOCHEM, V217, P567, DOI 10.1111/j.1432-1033.1993.tb18278.x
   Hersleth HP, 2006, J INORG BIOCHEM, V100, P460, DOI 10.1016/j.jinorgbio.2006.01.018
   Hocking RK, 2007, J AM CHEM SOC, V129, P113, DOI 10.1021/ja065627h
   Hocking RK, 2006, J AM CHEM SOC, V128, P10442, DOI 10.1021/ja061802i
   Horner O, 2007, J BIOL INORG CHEM, V12, P509, DOI 10.1007/s00775-006-0203-9
   Lauermann I, 2009, CHEMPHYSCHEM, V10, P532, DOI 10.1002/cphc.200800788
   Lever ABP, 1984, INORGANIC ELECT SPEC
   Newcomb M, 2008, P NATL ACAD SCI USA, V105, P8179, DOI 10.1073/pnas.0708299105
   NEWTON MD, 1991, CHEM REV, V91, P767, DOI 10.1021/cr00005a007
   Nicholls P, 2001, ADV INORG CHEM, V51, P51
   POULOS TL, 1980, J BIOL CHEM, V255, P8199
   Powers L, 2001, BBA-PROTEIN STRUCT M, V1546, P44, DOI 10.1016/S0167-4838(00)00221-1
   Redaelli C, 2002, CHEMBIOCHEM, V3, P226, DOI 10.1002/1439-7633(20020301)3:2/3<226::AID-CBIC226>3.0.CO;2-7
   Shi XL, 2008, BIOTECHNOL LETT, V30, P181, DOI 10.1007/s10529-007-9510-7
   Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275
   TAKANO T, 1977, J MOL BIOL, V110, P569, DOI 10.1016/S0022-2836(77)80112-5
   THOLE BT, 1985, PHYS REV B, V32, P5107, DOI 10.1103/PhysRevB.32.5107
   Wasinger EC, 2003, J AM CHEM SOC, V125, P12894, DOI 10.1021/ja034634s
   Winter B, 2006, CHEM REV, V106, P1176, DOI 10.1021/cr040381p
NR 32
TC 27
Z9 27
U1 3
U2 3
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9076
EI 1463-9084
J9 PHYS CHEM CHEM PHYS
JI Phys. Chem. Chem. Phys.
PY 2010
VL 12
IS 18
BP 4827
EP 4832
DI 10.1039/b924245g
PG 6
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 589MU
UT WOS:000277153800035
PM 20428565
DA 2018-12-27
ER

PT J
AU He, TX
   Zhang, L
   Xin, HL
   Deng, WL
AF He, Tianxian
   Zhang, Li
   Xin, Hongliang
   Deng, Wenli
TI RETRACTED: Morphology and mechanics of the adhesive disc of liana
   Parthenocissus tricuspidata (Retracted article. See vol. 83, pg. 1341,
   2011)
SO PURE AND APPLIED CHEMISTRY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 13th International Biotechnology Symposium and Exhibition (IBS) of the
   Biotechnology-for-the-Sustainability-of-Human-Society
CY OCT 12-17, 2008
CL Dalian, PEOPLES R CHINA
SP Biotechnol Sustainabil Human Soc
DE adhesive disc; adhesive properties; microstructure; Parthenocissus
   tricuspidata; super-adhesion mechanism
ID GECKO FOOT-HAIR; DERIVATIVES; LIZARDS; SETAE
AB A single mature adhesive disc of Parthenocissus tricuspidata has an average mass of only about 0.0005 g, an average attached area of about 1.22 mm(2), and an adhesive force of about 13.7 N. On average, the disc can support a combined weight of stern, leaf, branchlet, and tendril which is 260 times greater than its own weight during the growth,and can sustain a maximum pulling force which is 2800000 times higher than that produced by its own weight. Experimental studies reveal that the adhesive disc of R tricuspidata has super-adhesive properties. Microscopic experiments show some new microstructures, and we propose a new hypothesis and model to elucidate the mechanism of adhesion.
C1 [He, Tianxian; Zhang, Li; Xin, Hongliang; Deng, Wenli] S China Univ Technol, Coll Mat Sci & Engn, Guangzhou 510640, Peoples R China.
RP Deng, WL (reprint author), S China Univ Technol, Coll Mat Sci & Engn, Guangzhou 510640, Peoples R China.
FU State Key Development Program for Basic Research of China
   [2009CB930604]; Natural Science Foundation of Guangdong Province, China
   [815 1064101000111]
FX This work was Supported financially by the State Key Development Program
   for Basic Research of China (Grant No. 2009CB930604) and the Natural
   Science Foundation of Guangdong Province, China (Grant No. 815
   1064101000111).
CR Autumn K, 2002, P NATL ACAD SCI USA, V99, P12252, DOI 10.1073/pnas.192252799
   Autumn K, 2000, NATURE, V405, P681
   Darwin C., 1875, MOVEMENT HABITS CLIM
   ENDRESS AG, 1977, CAN J BOT, V55, P918, DOI 10.1139/b77-112
   GADOW H., 1901, CAMBRIDGE NATURAL HI, V8
   Ge L, 2007, P NATL ACAD SCI USA, V104, P10792, DOI 10.1073/pnas.0703505104
   Geim AK, 2003, NAT MATER, V2, P461, DOI 10.1038/nmat917
   HILLER U, 1968, Zeitschrift fuer Morphologie der Tiere, V62, P307, DOI 10.1007/BF00401561
   Huber G, 2005, P NATL ACAD SCI USA, V102, P16293, DOI 10.1073/pnas.0506328102
   JUNKER S, 1976, NEW PHYTOL, V77, P741, DOI 10.1111/j.1469-8137.1976.tb04669.x
   MADERSON PF, 1964, NATURE, V203, P780, DOI 10.1038/203780a0
   MALPIGHI M, 1686, OPERA OMNIA ANATOMES
   RUIBAL R, 1965, J MORPHOL, V117, P271, DOI 10.1002/jmor.1051170302
   Schmidt H. R., 1904, JENA Z NATURW, V39, P551
   Son IH, 2007, PARASITOL RES, V101, P237, DOI 10.1007/s00436-006-0454-y
   STORK NE, 1980, J EXP BIOL, V88, P91
   Tanaka T, 1998, PHYTOCHEMISTRY, V48, P1241, DOI 10.1016/S0031-9422(97)00898-4
   Thoennessen Manfred, 2006, Umweltwissenschaften und Schadstoff-Forschung, V18, P5
   VERVOITTE V, 1984, BIOSCIENCE, V3, P14
   Zhao Y, 2006, J VAC SCI TECHNOL B, V24, P331, DOI 10.1116/1.2163891
NR 20
TC 2
Z9 3
U1 3
U2 21
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0033-4545
EI 1365-3075
J9 PURE APPL CHEM
JI Pure Appl. Chem.
PD JAN
PY 2010
VL 82
IS 1
BP 91
EP 96
DI 10.1351/PAC-CON-08-12-06
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA 557ZK
UT WOS:000274709300009
OA Bronze
DA 2018-12-27
ER

PT J
AU Sheikpranbabu, S
   Ravinarayanan, H
   Elayappan, B
   Jongsun, P
   Gurunathan, S
AF Sheikpranbabu, Sardarpasha
   Ravinarayanan, Haribalaganesh
   Elayappan, Banumathi
   Jongsun, Park
   Gurunathan, Sangiliyandi
TI RETRACTED: Pigment epithelium-derived factor inhibits vascular
   endothelial growth factor-and interleukin-1beta-induced vascular
   permeability and angiogenesis in retinal endothelial cells (Retracted
   article. See vol. 55, pg. 189, 2011)
SO VASCULAR PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE Pigment epithelium-derived factor; Vascular endothelial growth factor;
   Interleukin-1 beta; Permeability; Angiogenesis
ID DIABETIC-RETINOPATHY; BLOOD-VESSELS; SRC; NEOVASCULARIZATION; PEDF;
   BARRIER; VEGF; ACTIVATION; EXPRESSION; LEAKAGE
AB Increased vascular permeability associated with retinal vascular leakage is known to occur in patients with diabetes, and contributes to endothelial barrier dysfunction. The purpose of this study was to examine the effect of pigment epithelium-derived factor (PEDF) on signaling cascade in porcine retinal endothelial cells (PREC) related to permeability and angiogenesis induced by vascular endothelial growth factor (VEGF)-and interleukin-1 beta (IL-1 beta). PREC were exposed to VEGF, IL-1 beta and PEDF at different concentrations, and in vitro permeability was assessed by solute flux assay using 70-kDa RITC-dextran. Angiogenic assays such as proliferation, migration and tube formation were determined by MTT, wound-scratch method and on-gel assay system respectively. To explore the signaling pathways behind VEGF-and IL-1 beta-induced PREC permeability, an inhibitor assay was carried out using PP2, a Src kinase inhibitor. Further, Src activity was assessed by transient transfection assay using constitutively active (CA) and dominant negative (DN) Src mutants. We report that VEGF-and IL-1 beta-stimulates permeability, in a dose and time-dependent manner and PEDF inhibits the VEGF-and IL-1 beta-induced PREC permeability. In addition, PEDF inhibits the VEGF-and IL-1 beta-induced endothelial cell proliferation, migration and tube formation. In addition, overexpression of DN Src blocked both VEGF-and IL-1 beta-stimulation of permeability, proliferation and migration, while overexpression of CA Src overpowers the inhibitory action of PEDF on permeability, proliferation and migration. These results demonstrate that PEDF may inhibit the VEGF-and IL-1 beta-induced permeability and angiogenesis via Src-dependent pathway. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Sheikpranbabu, Sardarpasha; Ravinarayanan, Haribalaganesh; Elayappan, Banumathi; Gurunathan, Sangiliyandi] Kalasalingam Univ, Div Mol & Cellular Biol, Dept Biotechnol, Kalasalingam Acad Res & Educ, Krishnankoil 626190, Tamil Nadu, India.
   [Jongsun, Park] Chungnam Natl Univ, Coll Med, Dept Pharmacol, Canc Res Inst,Cell Signaling Lab, Taejon 301131, South Korea.
RP Gurunathan, S (reprint author), Kalasalingam Univ, Div Mol & Cellular Biol, Dept Biotechnol, Kalasalingam Acad Res & Educ, Anand Nagar, Krishnankoil 626190, Tamil Nadu, India.
EM lvsangs@yahoo.com
OI Park, Jongsun/0000-0002-4690-1854
FU Department of Biotechnology, Ministry of Science and Technology, New
   Delhi [BT/PR/7704/MED/14/1065/2006]; Indian Council of Medical Research
   [53/5/2006-BMS]; Department of Science and Technology
   [SR/FT/L-118/2006]; Korean Government, Ministry of 598 Science and
   Technology: Engineering Research Center [2009-599 0062916]; University
   Grants Commission, New Delhi [601 F.10-4/2005/SA-I]
FX Prof. G. Sangiliyandi was supported by a grants from Department of
   Biotechnology, Ministry of Science and Technology, New Delhi (Grant No.
   BT/PR/7704/MED/14/1065/2006), Indian Council of Medical Research (Grant
   No. 53/5/2006-BMS) and Department of Science and Technology (Grant No.
   SR/FT/L-118/2006). Prof. Jongsun 597 Parkwas supported by a grant from
   the Korean Government, Ministry of 598 Science and Technology:
   Engineering Research Center Program (2009-599 0062916). Mr. Sheikwas
   supported by the grant for Junior Research 600 Fellowship from
   University Grants Commission, New Delhi (Grant No. 601
   F.10-4/2005/SA-I). We thank Mr. V. Deepak and Mr. V. Ramanathan for 602
   the critical reading of this manuscript.
CR ABUELASRAR AM, 1993, AM J OPHTHALMOL, V114, P731
   Aiello LP, 1996, ARCH OPHTHALMOL-CHIC, V114, P1252, DOI 10.1001/archopht.1996.01100140452016
   Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473
   Aiello LP, 2000, KIDNEY INT, V58, pS113, DOI 10.1046/j.1523-1755.2000.07718.x
   al-Ramadi BK, 2001, J IMMUNOL, V167, P6827, DOI 10.4049/jimmunol.167.12.6827
   Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953
   Antonetti DA, 2002, J NEUROCHEM, V80, P667, DOI 10.1046/j.0022-3042.2001.00740.x
   Banumathi E, 2009, MICROVASC RES, V77, P377, DOI 10.1016/j.mvr.2008.12.005
   Behzadian MA, 2003, FASEB J, V17, P752, DOI 10.1096/fj.02-0484fje
   Boehm BO, 2003, DIABETOLOGIA, V46, P394, DOI 10.1007/s00125-003-1040-9
   Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6
   BROSNAN CF, 1989, J NEUROIMMUNOL, V25, P227, DOI 10.1016/0165-5728(89)90141-0
   Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8
   Carmo A, 1999, VISION RES, V39, P3817, DOI 10.1016/S0042-6989(99)00117-0
   CLAUDIO L, 1994, LAB INVEST, V70, P850
   Criscuoli ML, 2005, BLOOD, V105, P1508, DOI 10.1182/blood-2004-06-2246
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Dvorak HF, 2000, SEMIN PERINATOL, V24, P75, DOI 10.1016/S0146-0005(00)80061-0
   Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   FRANK RN, 1991, OPHTHALMOLOGY, V98, P586
   Funakoshi-Tago M, 2003, EUR J BIOCHEM, V270, P1257, DOI 10.1046/j.1432-1033.2003.03487.x
   Gao G, 2003, DIABETOLOGIA, V46, P689, DOI 10.1007/s00125-003-1085-9
   Gao GQ, 2002, DRUG DISCOV TODAY, V7, P171, DOI 10.1016/S1359-6446(01)02160-2
   Gao GQ, 2002, DIABETES, V51, P1218, DOI 10.2337/diabetes.51.4.1218
   Gao GQ, 2002, J BIOL CHEM, V277, P9492, DOI 10.1074/jbc.M108004200
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007
   HETIER E, 1988, J NEUROSCI RES, V21, P391, DOI 10.1002/jnr.490210230
   Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101
   Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050
   MARTINEY JA, 1990, AM J PATHOL, V137, P1411
   MARTINEY JA, 1992, J NEUROIMMUNOL, V41, P167, DOI 10.1016/0165-5728(92)90067-U
   McMullen M, 2004, ONCOGENE, V23, P1275, DOI 10.1038/sj.onc.1207243
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4
   Ogata N, 2001, AM J OPHTHALMOL, V132, P378, DOI 10.1016/S0002-9394(01)01008-X
   Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160
   PEER J, 1995, LAB INVEST, V72, P638
   PELZEK C, 2002, OPHTHALMOL CLIN N AM, V15, P1
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   ROBERGE FG, 1988, J IMMUNOL, V140, P2193
   Sheikpranbabu S, 2009, LIFE SCI, V85, P719, DOI 10.1016/j.lfs.2009.09.015
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Su XJ, 2003, MOL VIS, V9, P171
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511
   Tombran-Tink J, 2003, TRENDS MOL MED, V9, P244, DOI 10.1016/S1471-4914(03)00074-1
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349
   WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130
   Yang KJ, 2008, J BIOL CHEM, V283, P1480, DOI 10.1074/jbc.M706361200
   Yuuki T, 2001, J DIABETES COMPLICAT, V15, P257, DOI 10.1016/S1056-8727(01)00155-6
NR 57
TC 19
Z9 21
U1 2
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1537-1891
EI 1879-3649
J9 VASC PHARMACOL
JI Vasc. Pharmacol.
PD JAN-FEB
PY 2010
VL 52
IS 1-2
BP 84
EP 94
DI 10.1016/j.vph.2009.12.002
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 563TR
UT WOS:000275157900011
PM 20006737
DA 2018-12-27
ER

PT J
AU Schatzberg, SJ
AF Schatzberg, Scott J.
TI RETRACTED: Idiopathic Granulomatous and Necrotizing Inflammatory
   Disorders of the Canine Central Nervous System (Retracted article. See
   vol. 40, pg. XI, 2010)
SO VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE
LA English
DT Article; Retracted Publication
DE Central nervous system; Granulomatous meningoencephalomyelitis;
   Necrotizing meningoencephalitis
ID MAGNETIC-RESONANCE IMAGES; PUG DOG ENCEPHALITIS; ACIDIC PROTEIN GFAP;
   CYTOSINE-ARABINOSIDE; CEREBROSPINAL-FLUIDS; COMPUTED-TOMOGRAPHY;
   AUTOIMMUNE-DISEASE; YORKSHIRE TERRIERS; CLINICAL FINDINGS; UNKNOWN
   ETIOLOGY
AB Granulomatous meningoencephalomyelitis (GME), necrotizing meningoencephalitis (NME), and necrotizing leukoencephalitis (NLE) are common inflammatory conditions of the canine central nervous system (CNS). While each disease has unique histopathological features, these canine disorders collectively seem to be aberrant immune responses directed against the CNS. A review of the neurologic signs and general neurodiagnostic approach to canine meningoencephalitis (ME) is followed by an overview of the specific clinical and neuropathological features of GME, NME, and NLE. The etiopathogenesis of each disorder is explored, including potential genetic, immunologic, and environmental factors, along with the current and prospective immunomodulatory therapies for ME.
C1 Univ Georgia, Coll Vet Med, Dept Small Anim Med & Surg, Athens, GA 30602 USA.
RP Schatzberg, SJ (reprint author), Univ Georgia, Coll Vet Med, Dept Small Anim Med & Surg, 501 DW Brooks Dr, Athens, GA 30602 USA.
EM schatz13@uga.edu
CR Adamo FP, 2004, J AM VET MED ASSOC, V225, P1196
   Adamo FR, 2004, JAVMA-J AM VET MED A, V225, P1211, DOI 10.2460/javma.2004.225.1211
   Adamo PF, 2007, J SMALL ANIM PRACT, V48, P486, DOI 10.1111/j.1748-5827.2006.00303.x
   ADAMS J, 1984, GREENFIELDS NEUROPAT, P273
   Aresu L, 2007, J COMP PATHOL, V136, P279, DOI 10.1016/j.jcpa.2007.02.008
   BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x
   BENNETT WM, 1986, ANNU REV MED, V37, P215
   BRAUND KG, 1978, J AM VET MED ASSOC, V172, P1195
   BRAUND KG, 1985, J AM VET MED ASSOC, V186, P138
   Cantile C, 2001, VET PATHOL, V38, P119, DOI 10.1354/vp.38-1-119
   Cherubini GB, 2006, VET REC, V159, P110, DOI 10.1136/vr.159.4.110
   Cherubini GB, 2008, J SMALL ANIM PRACT, V49, P634, DOI 10.1111/j.1748-5827.2008.00628.x
   Chong AS, 2006, AM J TRANSPLANT, V6, P69, DOI 10.1111/j.1600-6143.2005.01152.x
   Coates JR, 2007, J VET INTERN MED, V21, P100, DOI 10.1892/0891-6640(2007)21[100:PAATFT]2.0.CO;2
   CORDY DR, 1989, VET PATHOL, V26, P191, DOI 10.1177/030098588902600301
   CORDY DR, 1979, VET PATHOL, V16, P325, DOI 10.1177/030098587901600306
   CUDDON PA, 1984, COMP CONT EDUC PRACT, V6, P23
   de Lahunta A, 2009, VET NEUROANATOMY CLI
   de Stefani A, 2007, 20 ANN S EUR COLL VE, P508
   Evans CF, 1996, J EXP MED, V184, P2371, DOI 10.1084/jem.184.6.2371
   Fankhauser R., 1972, Advances vet Sci comp Med, V16, P35
   Feliu-Pascual AL, 2007, 20 ANN S EUR COLL VE, P509
   FLEGEL T, 2007, 20 ANN S EUR COLL VE, P508
   Flegel T, 2008, VET RADIOL ULTRASOUN, V49, P419, DOI 10.1111/j.1740-8261.2008.00400.x
   GARCIACARBONERO R, 2001, CANC CHEMOTHERAPY BI, P265
   Greer KA, 2009, RES VET SCI, V86, P438, DOI 10.1016/j.rvsc.2008.10.002
   Gregory C. R., 2000, Kirk's current veterinary therapy XIII: small animal practice., P509
   Gregory CR, 1998, TRANSPLANT P, V30, P4143, DOI 10.1016/S0041-1345(98)01373-6
   GRIFFIN J, 1982, EXP HEMATOL, V10, P774
   Herrera B, 2007, MULT SCLER, V13, P856, DOI 10.1177/352458507076961
   Higgins RJ, 2007, 20 ANN S EUR COLL VE, P35
   Hoffman GE, 2001, EXP NEUROL, V171, P272, DOI 10.1006/exnr.2001.7783
   Kipar A, 1998, VET PATHOL, V35, P43, DOI 10.1177/030098589803500104
   Kitagawa M, 2004, J VET MED A, V51, P277, DOI 10.1111/j.1439-0442.2004.00636.x
   Kitagawa M, 2009, J VET MED SCI, V71, P233, DOI 10.1292/jvms.71.233
   Koblik PD, 1999, VET RADIOL ULTRASOUN, V40, P434, DOI 10.1111/j.1740-8261.1999.tb00371.x
   Koestner A, 1975, Acta Neuropathol Suppl, VSuppl 6, P85
   Kristal O, 2004, J VET INTERN MED, V18, P75, DOI 10.1892/0891-6640(2004)18<75:HAWCLC>2.0.CO;2
   KRUEGER N, 1994, VET REC, V135, P224, DOI 10.1136/vr.135.10.224
   Kuwamura M, 2002, J SMALL ANIM PRACT, V43, P459, DOI 10.1111/j.1748-5827.2002.tb00014.x
   Levine JM, 2008, J VET INTERN MED, V22, P961, DOI 10.1111/j.1939-1676.2008.0137.x
   Matsuki N, 2004, J VET MED SCI, V66, P295, DOI 10.1292/jvms.66.295
   Menaut P, 2008, VET REC, V162, P241, DOI 10.1136/vr.162.8.241
   Munana KR, 1996, VET CLIN N AM-SMALL, V26, P857
   Munana KR, 1998, J AM VET MED ASSOC, V212, P1902
   Neilson DE, 2009, AM J HUM GENET, V84, P44, DOI 10.1016/j.ajhg.2008.12.009
   Nuhsbaum MT, 2002, VET OPHTHALMOL, V5, P29, DOI 10.1046/j.1463-5224.2002.00215.x
   Okamoto M, 2002, J COMP PATHOL, V126, P312, DOI 10.1053/jcpa.2002.0550
   Oldstone MBA, 1998, FASEB J, V12, P1255
   PERCY DH, 1970, AM J VET RES, V31, P145
   PLUMMER SB, 1992, VET RADIOL ULTRASOUN, V33, P307, DOI 10.1111/j.1740-8261.1992.tb00148.x
   Porter BF, 2006, VET PATHOL, V43, P981, DOI 10.1354/vp.43-6-981
   Robson D, 2003, VET REC, V152, P739, DOI 10.1136/vr.152.24.739
   SCHATZBERG S, 2007, 20 ANN S EUR COLL VE, P63
   Schatzberg SJ, 2005, J VET INTERN MED, V19, P553, DOI 10.1892/0891-6640(2005)19[553:PCRSFD]2.0.CO;2
   Schwab S, 2007, J COMP PATHOL, V136, P96, DOI 10.1016/j.jcpa.2006.11.006
   SCOTTMONCRIEFF JCR, 1991, CANCER CHEMOTH PHARM, V29, P13, DOI 10.1007/BF00686329
   SHESHBERADARAN H, 1984, J VIROL, V52, P995
   Shibuya M, 2007, J VET MED SCI, V69, P241, DOI 10.1292/jvms.69.241
   Sorjonen D. C., 1989, Veterinary Medicine Report, V1, P399
   SORJONEN DC, 1990, J AM ANIM HOSP ASSOC, V26, P141
   SPECIALE J, 1992, J AM ANIM HOSP ASSOC, V28, P327
   STALIS IH, 1995, VET PATHOL, V32, P230, DOI 10.1177/030098589503200303
   Storch MK, 2006, J NEUROPATH EXP NEUR, V65, P1137, DOI 10.1097/01.jnen.0000248547.13176.9d
   Summers B. A., 1995, VET NEUROPATHOLOGY
   Suzuki M, 2003, J VET MED SCI, V65, P1319, DOI 10.1292/jvms.65.1319
   Suzuki M, 2003, J VET MED SCI, V65, P1233, DOI 10.1292/jvms.65.1233
   Theil DJ, 2001, J NEUROVIROL, V7, P220
   THOMAS JB, 1989, J SMALL ANIM PRACT, V30, P287, DOI 10.1111/j.1748-5827.1989.tb01558.x
   Thomas WB, 1998, CLIN TECH SMALL AN P, V13, P167, DOI 10.1016/S1096-2867(98)80038-8
   Timmann D, 2007, J SMALL ANIM PRACT, V48, P339, DOI 10.1111/j.1748-5827.2006.00239.x
   TIPOLD A, 1993, J SMALL ANIM PRACT, V34, P623, DOI 10.1111/j.1748-5827.1993.tb02598.x
   TIPOLD A, 1995, J VET INTERN MED, V9, P304, DOI 10.1111/j.1939-1676.1995.tb01089.x
   Toda Y, 2007, VET REC, V161, P261, DOI 10.1136/vr.161.8.261
   Uchida K, 1999, VET PATHOL, V36, P301, DOI 10.1354/vp.36-4-301
   Uriarte JL, 2007, 20 ANN S EUR COLL VE, P508
   VANDEVELDE M, 1981, VET PATHOL, V18, P577, DOI 10.1177/030098588101800502
   von Praun F, 2006, VET RADIOL ULTRASOUN, V47, P260, DOI 10.1111/j.1740-8261.2006.00137.x
   Weissenbock H, 1998, J CLIN MICROBIOL, V36, P2127
   Whitley RJ, 2002, LANCET, V359, P507, DOI 10.1016/S0140-6736(02)07681-X
   Young BD, 2009, J VET INTERN MED, V23, P527, DOI 10.1111/j.1939-1676.2009.0306.x
   Zarfoss M, 2006, J SMALL ANIM PRACT, V47, P588, DOI 10.1111/j.1748-5827.2006.00172.x
NR 82
TC 10
Z9 12
U1 1
U2 35
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0195-5616
EI 1878-1306
J9 VET CLIN N AM-SMALL
JI Vet. Clin. N. Am.-Small Anim. Pract.
PD JAN
PY 2010
VL 40
IS 1
BP 101
EP +
DI 10.1016/j.cvsm.2009.09.003
PG 21
WC Veterinary Sciences
SC Veterinary Sciences
GA 574QG
UT WOS:000276006100007
PM 19942059
DA 2018-12-27
ER

PT J
AU Haddad, JJ
AF Haddad, J. J.
TI RETRACTED: ENDOTOXIN-MEDIATED REGULATION OF NUCLEAR FACTOR-kappa B
   NUCLEAR TRANSLOCATION AND ACTIVATION IN THE HIPPOCAMPUS OF THE CENTRAL
   NERVOUS SYSTEM: MODULATION BY INTRACEREBROVENTRICULAR TREATMENT WITH
   THYMULIN AND THE IMMUNOMODULATORY ROLE OF THE I kappa B-alpha/pI kappa
   B-alpha PATHWAY (Retracted article. See vol. 169, pg. 558, 2010)
SO NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE anti-inflammatory; endotoxin/LPS; hippocampus; intracerebroventricular;
   NF-kappa B/I kappa B; thymulin
ID SERUM THYMIC-FACTOR; INFLAMMATORY HYPERALGESIA; INDUCED APOPTOSIS;
   CYTOKINE RELEASE; PEPTIDE; CELLS; PAIN; CAMP; HIF-1-ALPHA; INHIBITION
AB The transcription factor nuclear factor kappa B (NF-kappa B) is one member of a ubiquitously expressed family of Rel-related transcription factors that serve as critical regulators of many proinflammatory genes and immunomodulators. Nevertheless, the immunomodulatory potential of thymulin and its effect on NF-kappa B in vivo, and particularly in the central nervous system (CNS), is not well characterized. In this study, the role of endotoxin (ET/LPS) in regulating NF-kappa B was deciphered in various compartments of the CNS. Stereotaxic localization reverberated specific intracerebroventricular (ICV) injection of ET into the CNS, with or without pretreatment with ICV thymulin. Treatment with ET (1 mu g for 45 min; ICV) upregulated the expression and nuclear localization of NF-kappa B-1 (p50), NF-kappa B-2, (p52), RelA (p65), RelB (p68) and c-Rel (p75) in the hippocampus (HC), an effect abrogated, in a dose-dependent manner, by ICV pretreatment (30 min) with thymulin. Thymulin modulated the phosphorylation of I kappa B-alpha in the HC by upregulating the cytosolic accumulation of I kappa B-alpha and downregulating its phosphorylation (pI kappa B-alpha). Further analysis of the DNA-binding activity revealed an upregulated activity in the HC relative to saline-constitutive expression of the RelA (p65) subunit, the specificity Of which was determined by a mutant oligonucleotide of RelA and a cold, non-specific competitor. ET did not induce the DNA-binding activity of NF-kappa B in the diencephalon (DE) or substantia nigra (SN) at various time points, when compared with baseline levels of expression. Intraperitoneal (IP) injections of ET (25 mu g for 15 min) in vivo upregulated the expression of NF-kappa B subunits in the liver and reduced the cytosolic accumulation of I kappa B-alpha by inducing pI kappa B-alpha. Furthermore, IP pretreatment with thymulin followed by ICV injection of ET attenuated and reduced the DNA-binding activity of NF-kappa B in the HC. These results indicate that ICV injection of ET regulates the nuclear translocation and activation of NF-kappa B subunits within specific compartments in the brain, an effect particularly localized to the hippocampus. Additionally, thymulin attenuated the ET-induced response, with particular involvement of the transduction pathway implicating I kappa B-alpha, the major cytosolic inhibitor of NF-kappa B. The in vivo molecular regulation of thymulin via the NF-kappa B pathway is critical to understanding the alleviating anti-inflammatory role of this nonapeptide and paving the way to unraveling pathways associated with neuroimmune interactions mediating proinflammatory signals in the CNS. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Haddad, J. J.] Univ Dundee, Ninewells Hosp & Med Sch, Sch Med, Oxygen Signaling Res Grp, Dundee DD1 9SY, Scotland.
   [Haddad, J. J.] Amer Univ Beirut, Fac Med, Dept Human Morphol, Beirut, Lebanon.
RP Haddad, JJ (reprint author), Univ Balamand, Fac Hlth Sci, Dept Med Lab Sci, Beirut, Lebanon.
EM john.haddad@yahoo.co.uk
FU Anonymous Trust (Scotland); National Institute for Biological Standards
   and Control (England); Tenovus Trust (Scotland); UK Medical Research
   Council; National Institutes of Health (NIH); Wellcome Trust (London);
   Georges John Livanos
FX The author's work is, in part, supported by the Anonymous Trust
   (Scotland, to Dr. Stephen C. Land [SCL], University of Dundee), the
   National Institute for Biological Standards and Control (England, to
   Professor Bared Safieh-Garabedian), the Tenovus Trust (Scotland, to
   SCL), the UK Medical Research Council (MRC, London, to SCL), the
   National Institutes of Health (NIH) and the Wellcome Trust (London, to
   SCL). The author would like to sincerely thank Professors Nayef E. Saade
   (American University of Beirut, Lebanon) and Bared Safieh-Garabedian
   (Queen Mary University of London, UK, formerly at the American
   University of Beirut) for their technical support for this study and for
   providing samples for analysis. Parts of this work were undertaken while
   the author was a PhD candidate at the University of Dundee, in
   collaboration with the American University of Beirut, and were presented
   at the Neuroimmunology meeting in Edinburgh, Scotland, UK in 2001
   (Safieh-Garabedian et al., 2001). Dr. John J. Haddad, then a PhD
   candidate, held the distinguished Georges John Livanos fellowship at the
   University of Dundee, Scotland (London, UK) and the National Institutes
   of Health postdoctoral fellowship (NIH; UCSF, CA, USA).
CR BACH JF, 1977, NATURE, V266, P55, DOI 10.1038/266055a0
   Brown OA, 1999, NEUROENDOCRINOLOGY, V69, P20, DOI 10.1159/000054399
   Brown OA, 2000, J GERONTOL A-BIOL, V55, pB170, DOI 10.1093/gerona/55.4.B170
   DARDENNE M, 1980, EUR J IMMUNOL, V10, P83, DOI 10.1002/eji.1830100203
   Dardenne M, 1993, Prog Clin Biol Res, V380, P23
   Dardenne M, 1999, ANN MED, V31, P34
   Dardenne M, 2006, ANN NY ACAD SCI, V1088, P153, DOI 10.1196/annals.1366.006
   Haddad JJ, 2002, J NEUROIMMUNOL, V133, P1, DOI 10.1016/S0165-5728(02)00357-0
   HADDAD JJ, 2009, ENCY NEUROSCIENCE, P2527
   Haddad JJE, 2000, J BIOL CHEM, V275, P21130, DOI 10.1074/jbc.M000737200
   Haddad JJE, 2000, AM J PHYSIOL-LUNG C, V278, pL492
   Haddad JJE, 2000, BIOCHEM BIOPH RES CO, V274, P500, DOI 10.1006/bbrc.2000.3155
   Haddad JJ, 2007, BIOCHEM BIOPH RES CO, V353, P217, DOI 10.1016/j.bbrc.2006.12.032
   Hadley AJ, 1997, NEUROIMMUNOMODULAT, V4, P62, DOI 10.1159/000097322
   Henriques-Coelho T, 2008, ENDOCRINOLOGY, V149, P4367, DOI 10.1210/en.2008-0018
   Kanaan SA, 1996, PAIN, V66, P373, DOI 10.1016/0304-3959(96)03068-0
   MILLINGTON G, 1992, J ENDOCRINOL, V133, P163, DOI 10.1677/joe.0.1330163
   MUTCHNICK MG, 1982, J RHEUMATOL, V9, P627
   Prasad AS, 2008, EXP GERONTOL, V43, P370, DOI 10.1016/j.exger.2007.10.013
   Prasad AS, 2007, J NUTR, V137, P1345
   Qi XF, 2009, MOL IMMUNOL, V46, P1925, DOI 10.1016/j.molimm.2009.03.018
   Reggiani PC, 2009, ANN NY ACAD SCI, V1153, P98, DOI 10.1111/j.1749-6632.2008.03964.x
   RINALDIGARACI C, 1985, EUR J IMMUNOL, V15, P548, DOI 10.1002/eji.1830150604
   Saade NE, 2003, NEUROSCIENCE, V119, P155, DOI 10.1016/S0306-4522(03)00072-1
   Safieh-Garabedian B, 2003, NEUROSCIENCE, V121, P865, DOI 10.1016/S0306-4522(03)00500-1
   Safieh-Garabedian B, 2002, BRIT J PHARMACOL, V136, P947, DOI 10.1038/sj.bjp.0704793
   Safieh-Garabedian B, 2002, NEUROPHARMACOLOGY, V42, P864, DOI 10.1016/S0028-3908(02)00028-X
   SAFIEHGARABEDIA.B, 2001, J NEUROIMMUNOL, V118, P30
   SafiehGarabedian B, 1996, BRAIN RES, V717, P179, DOI 10.1016/0006-8993(95)01532-9
   SAFIEHGARABEDIAN B, 1993, INT ARCH ALLERGY IMM, V101, P126, DOI 10.1159/000236509
   Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074-7613(01)00104-2
   Wall EA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000202
   Welsh CJ, 2009, ANN NY ACAD SCI, V1153, P209, DOI 10.1111/j.1749-6632.2008.03984.x
   YANG JP, 1995, FEBS LETT, V361, P89, DOI 10.1016/0014-5793(95)00157-5
   Yasuda J, 2003, BIOCHEM BIOPH RES CO, V311, P501, DOI 10.1016/j.bbrc.2003.10.025
NR 35
TC 6
Z9 6
U1 4
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD DEC 29
PY 2009
VL 164
IS 4
BP 1509
EP 1520
DI 10.1016/j.neuroscience.2009.09.056
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 526WQ
UT WOS:000272327000012
PM 19782726
DA 2018-12-27
ER

PT J
AU Malek, F
AF Malek, Fareq
TI RETRACTED: Design and analytical modeling of folded waveguide traveling
   wave tube (Retracted article. See vol. 629, pg. 406, 2011)
SO NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS
   SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT
LA English
DT Article; Retracted Publication
DE Folded waveguide traveling wave tube; X-band; Spatial harmonic;
   Normalized dispersion
ID MILLIMETER-WAVE; SLOW-WAVE
AB We are developing a simple analytical model for the design of the folded waveguide traveling wave tube (FWTWT). Numerical software does exist for the design of FWTWT but requires large computer run time, is costly and does not provide the physical view for rapid design optimization of the FWTWT. In this paper, the design and analysis of the FWTWT using the spatial harmonics method of the TE10 mode of the EM wave are presented. An X-band FWTWT is used to verify this method. The normalized dispersion and beam line equations are used to simplify the design process so that the FWTWT can be designed to operate at any desired frequency. Both the S parameter-ABCD-S parameter conversion method and the equivalent circuit model method using Marcuvitz theorem are used for deriving the S parameters and for the analysis of dispersion curve of the 90 degrees sharp-cornered bend of the FWTWT. The analysis is developed by considering the straight and curved portions of the structure supporting the TE10 mode of the EM wave. (C) 2009 Elsevier B.V. All rights reserved.
C1 Univ Malaysia Perlis, Sch Comp & Commun Engn, Kuala Perlis 02000, Perlis, Malaysia.
RP Malek, F (reprint author), Univ Malaysia Perlis, Sch Comp & Commun Engn, 12 & 14 Jalan Satu,Taman Seberang Jaya Fasa 3, Kuala Perlis 02000, Perlis, Malaysia.
EM mfareq@unimap.edu.my
CR Bhattacharjee S, 2004, IEEE T PLASMA SCI, V32, P1002, DOI 10.1109/TPS.2004.828886
   Booske JH, 2005, IEEE T ELECTRON DEV, V52, P685, DOI 10.1109/TED.2005.845798
   Collin R. E., 1992, FDN MICROWAVE ENG
   DOHLER G, 1993, VAC ELECT ANN REV P, V5, P15
   Gittins J.F., 1964, POWER TRAVELLING WAV
   Han ST, 2003, MICROW OPT TECHN LET, V38, P161, DOI 10.1002/mop.11003
   Harvey A. F., 1960, IRE T MICROWAVE THEO, V8, P30
   Hutter RGE., 1960, BEAM WAVE ELECT MICR
   Kumar D, 2008, PROG ELECTROMAGN RES, V80, P409, DOI 10.2528/PIER07120302
   Liu SK, 2000, INT J INFRARED MILLI, V21, P655, DOI 10.1023/A:1006696106798
   Marcuvitz N., 1986, WAVEGUIDE HDB
   Mondal M, 2008, PROG ELECTROM RES LE, V3, P187, DOI 10.2528/PIERL08042204
   Nie Z, 2008, PROG ELECTROMAGN RES, V85, P83, DOI 10.2528/PIER08081905
   PANDA DK, 2008, ANAL PROG ELECTROMAG, V4, P91
   PIERCE JR, 1950, TRAVELING WAVE TUBES
   Pozar David M., 1998, MICROWAVE ENG
   Psarros I, 2008, PROG ELECTROMAGN RES, V87, P197, DOI 10.2528/PIER08102202
   Reutskiy SY, 2008, PROG ELECTROMAGN RES, V82, P203, DOI 10.2528/PIER08022701
   Rizzi PA., 1998, MICROWAVE ENG PASSIV
   Shahi AK, 2007, PROG ELECTROMAGN RES, V75, P51, DOI 10.2528/PIER07051601
   Singh G, 2008, Progress In Electromagnetics Research B, V4, P41, DOI 10.2528/PIERB08010402
   STUART RA, 2004, DESIGN FOLDED WAVEGU
   STUART RA, 2005, 2 EMRS DTC TECHN C E
   Su DY, 2008, PROG ELECTROMAGN RES, V80, P381, DOI 10.2528/PIER07120902
   Sumathy M, 2009, J INFRARED MILLIM TE, V30, P151, DOI 10.1007/s10762-008-9431-0
   Vaish A, 2008, Progress In Electromagnetics Research C, V2, P117, DOI 10.2528/PIERC08031801
   Wang WX, 2003, INT J INFRARED MILLI, V24, P1469, DOI 10.1023/A:1025535808995
NR 27
TC 3
Z9 3
U1 4
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-9002
EI 1872-9576
J9 NUCL INSTRUM METH A
JI Nucl. Instrum. Methods Phys. Res. Sect. A-Accel. Spectrom. Dect. Assoc.
   Equip.
PD DEC 21
PY 2009
VL 612
IS 1
BP 176
EP 186
DI 10.1016/j.nima.2009.09.056
PG 11
WC Instruments & Instrumentation; Nuclear Science & Technology; Physics,
   Nuclear; Physics, Particles & Fields
SC Instruments & Instrumentation; Nuclear Science & Technology; Physics
GA 537GN
UT WOS:000273101300019
DA 2018-12-27
ER

PT J
AU Malhotra, D
   Thimmulappa, R
   Vij, N
   Navas-Acien, A
   Sussan, T
   Merali, S
   Zhang, L
   Kelsen, SG
   Myers, A
   Wise, R
   Tuder, R
   Biswal, S
AF Malhotra, Deepti
   Thimmulappa, Rajesh
   Vij, Neeraj
   Navas-Acien, Ana
   Sussan, Thomas
   Merali, Salim
   Zhang, Li
   Kelsen, Steven G.
   Myers, Allen
   Wise, Robert
   Tuder, Rubin
   Biswal, Shyam
TI RETRACTED: Heightened Endoplasmic Reticulum Stress in the Lungs of
   Patients with Chronic Obstructive Pulmonary Disease The Role of
   Nrf2-Regulated Proteasomal Activity (Retracted article. See vol. 193,
   pg. 344, 2016)
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article; Retracted Publication
DE Nrf2; proteasome system; endoplasmic reticulum stress; unfolded protein
   response; chronic obstructive pulmonary disease lungs
ID UNFOLDED PROTEIN RESPONSE; SMOKE-INDUCED EMPHYSEMA; NF-KAPPA-B;
   CIGARETTE-SMOKE; OXIDATIVE STRESS; CELL-SURVIVAL; SIGNALING PATHWAY;
   APOPTOSIS; EXPRESSION; MICE
AB Rationale Nuclear factor erythroid 2-related factor 2 (Nrf2), an important regulator of lung antioxidant defenses, declines in chronic obstructive pulmonary disease (COPD). However, Nrf2 also regulates the proteasome system that degrades damaged and misfolded proteins. Because accumulation of misfolded proteins in the endoplasmic reticulum (ER) causes ER stress and ER stress-induced apoptosis, Nrf2 may potentially prevent ER stress-mediated apoptosis in COPD.
   Objectives: To determine whether Nrf2-regulated proteasome function affects ER stress-mediated apoptosis in COPD.
   Methods: We assessed the expression of Nrf2, Nrf2-dependent proteasomal subunits, proteasomal activity, markers of ER stress, and apoptosis in emphysematous lungs of mice exposed to cigarette smoke (CS) as well as peripheral lung tissues from normal control subjects and patients with COPD.
   Measurements and Main Results: Compared with wild-type mice, emphysematous lungs of CS-exposed Nrf2-deficient mice exhibited markedly lower proteasomal activity and elevated markers of ER stress and apoptosis. Furthermore, compared with normal control subjects, lungs of patients with mild and advanced COPD showed a marked decrease in the expression of Nrf2-regulated proteasomal subunits and total proteasomal activity. However, they were associated with greater levels of ER stress and apoptosis markers. In vitro studies have demonstrated that enhancing proteasomal activity in Beas2B cells either by sulforaphane, an activator of Nrf2, or overexpression of Nrf2-regulated proteasomal subunit PSMB6, significantly inhibited cigarette smoke condensate (CSC)-induced ER stress and cell death.
   Conclusions: Impaired Nrf2 signaling causes significant decline in proteasomal activity and heightens ER stress response in lungs of patients with COPD and CS-exposed mice. Accordingly, pharmacological approaches that augment Nrf2 activity may protect against COPD progression by both up-regulating antioxidant defenses and relieving ER stress.
C1 [Malhotra, Deepti; Thimmulappa, Rajesh; Navas-Acien, Ana; Sussan, Thomas; Biswal, Shyam] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA.
   [Vij, Neeraj] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA.
   [Vij, Neeraj] Johns Hopkins Sch Med, Div Pulm Med, Baltimore, MD USA.
   [Biswal, Shyam] Johns Hopkins Sch Med, Div Pulm & Crit Care Med, Dept Med, Baltimore, MD USA.
   [Biswal, Shyam] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA.
   [Merali, Salim; Kelsen, Steven G.] Temple Univ, Sch Med, Div Pulm & Crit Care Med, Dept Biochem, Philadelphia, PA 19122 USA.
   [Merali, Salim; Kelsen, Steven G.] Temple Univ, Sch Med, Div Pulm & Crit Care Med, Dept Med, Philadelphia, PA 19122 USA.
   [Zhang, Li; Tuder, Rubin] Univ Colorado Denver, Sch Med, Div Pulm & Crit Care Med, Aurora, CO USA.
   [Myers, Allen] Johns Hopkins Univ, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA.
   [Wise, Robert] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA.
RP Biswal, S (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Room E7624,615 N Wolfe St, Baltimore, MD 21205 USA.
EM sbiswal@jhsph.edu
OI Wise, Robert/0000-0002-8353-2349; Sussan, Thomas/0000-0002-5240-4299
FU NIH [RO1HL081205, SCCOR P50HL084945, CTSA UL RR 025005, RHL096931];
   Center for Childhood Asthma in the Urban Environment [P50ES015903, P30
   ES003819]; Maryland Cigarette Restitution Fund; Flight Attendant Medical
   Research Institute; Cystic Fibrosis Foundation [R025-CR07, VIJ07IO]
FX Supported by NIH grants RO1HL081205 (S.B.), SCCOR P50HL084945 (S.B.),
   Center for Childhood Asthma in the Urban Environment P50ES015903, P30
   ES003819, Maryland Cigarette Restitution Fund (S.B.), Flight Attendant
   Medical Research Institute grant (S.B., A.N.), Cystic Fibrosis
   Foundation grants R025-CR07 and VIJ07IO (NV), and the NIH grant CTSA UL
   RR 025005 (NV), RHL096931 (NV).
CR Adair-Kirk TL, 2008, NAT MED, V14, P1024, DOI 10.1038/nm1008-1024
   Adair-Kirk TL, 2008, AM J RESP CELL MOL, V39, P400, DOI 10.1165/rcmb.2007-0295OC
   Aoshiba K, 2003, AM J RESP CELL MOL, V28, P555, DOI 10.1165/rcmb.2002.0090OC
   Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C
   Brown V, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-24
   Buist AS, 2007, LANCET, V370, P741, DOI 10.1016/S0140-6736(07)61377-4
   Chauhan D, 2008, BLOOD, V111, P1654, DOI 10.1182/blood-2006-10-050476
   Chondrogianni N, 2005, J BIOL CHEM, V280, P11840, DOI 10.1074/jbc.M413007200
   Chung KF, 2008, EUR RESPIR J, V31, P1334, DOI 10.1183/09031936.00018908
   Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003
   Cullinan SB, 2006, INT J BIOCHEM CELL B, V38, P317, DOI 10.1016/j.biocel.2005.09.018
   Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200
   Davenport EL, 2008, CELL CYCLE, V7, P865, DOI 10.4161/cc.7.7.5615
   Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0
   Dolcet X, 2006, J BIOL CHEM, V281, P22118, DOI 10.1074/jbc.M601350200
   FERRINGTON DA, 2005, FASEB J, V19, P644
   Giordano RJ, 2008, J BIOL CHEM, V283, P29447, DOI 10.1074/jbc.M804595200
   Goven D, 2008, THORAX, V63, P916, DOI 10.1136/thx.2007.091181
   He B, 2006, CELL DEATH DIFFER, V13, P393, DOI 10.1038/sj.cdd.4401833
   Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200
   Hubner RH, 2009, MOL MED, V15, P203, DOI 10.2119/molmed.2008.00130
   Iizuka T, 2005, GENES CELLS, V10, P1113, DOI 10.1111/j.1365-2443.2005.00905.x
   Ishii Y, 2005, J IMMUNOL, V175, P6968, DOI 10.4049/jimmunol.175.10.6968
   Jung T, 2008, IUBMB LIFE, V60, P743, DOI 10.1002/iub.114
   Kardosh A, 2008, CANCER RES, V68, P843, DOI 10.1158/0008-5472.CAN-07-5555
   Kasahara Y, 2001, AM J RESP CRIT CARE, V163, P737, DOI 10.1164/ajrccm.163.3.2002117
   Kelsen SG, 2008, AM J RESP CELL MOL, V38, P541, DOI 10.1165/rcmb.2007-0221OC
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Kincaid MM, 2007, ANTIOXID REDOX SIGN, V9, P2373, DOI 10.1089/ars.2007.1817
   Korfei M, 2008, AM J RESP CRIT CARE, V178, P838, DOI 10.1164/rccm.200802-313OC
   Kwak MK, 2007, FREE RADICAL BIO MED, V43, P809, DOI 10.1016/j.freeradbiomed.2007.05.029
   Kwak MK, 2006, BIOCHEM BIOPH RES CO, V345, P1350, DOI 10.1016/j.bbrc.2006.05.043
   Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003
   Lin JH, 2008, ANNU REV PATHOL-MECH, V3, P399, DOI 10.1146/annurev.patho1.3.121806.151434
   MacNee William, 2005, Proc Am Thorac Soc, V2, P50, DOI 10.1513/pats.200411-056SF
   MacNee William, 2005, Current Drug Targets - Inflammation and Allergy, V4, P627, DOI 10.2174/156801005774912815
   Malhotra D, 2008, AM J RESP CRIT CARE, V178, P592, DOI 10.1164/rccm.200803-380OC
   Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782
   Mandl Jozsef, 2007, Orvosi Hetilap, V148, P1779, DOI 10.1556/OH.2007.28166
   Marfella R, 2006, DIABETES, V55, P622, DOI 10.2337/diabetes.55.03.06.db05-0832
   Matus S, 2008, CURR MOL MED, V8, P157, DOI 10.2174/156652408784221324
   Menendez-Benito V, 2005, HUM MOL GENET, V14, P2787, DOI 10.1093/hmg/ddi312
   Nakatsukasa K, 2008, TRAFFIC, V9, P861, DOI 10.1111/j.1600-0854.2008.00729.x
   Oshitari T, 2008, VASC HEALTH RISK MAN, V4, P115, DOI 10.2147/vhrm.2008.04.01.115
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Petrache I, 2005, NAT MED, V11, P491, DOI 10.1038/nm1238
   Poppek D, 2006, ANTIOXID REDOX SIGN, V8, P173, DOI 10.1089/ars.2006.8.173
   Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO
   Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   Sussan TE, 2009, P NATL ACAD SCI USA, V106, P250, DOI 10.1073/pnas.0804333106
   Suzuki M, 2008, AM J RESP CELL MOL, V39, P673, DOI 10.1165/rcmb.2007-0424OC
   Tagawa Y, 2008, FREE RADICAL BIO MED, V45, P50, DOI 10.1016/j.freeradbiomed.2008.03.003
   Toth Ambrus, 2007, Cardiovascular & Hematological Disorders - Drug Targets, V7, P205, DOI 10.2174/187152907781745260
   Yang YL, 2009, CANCER SCI, V100, P24, DOI 10.1111/j.1349-7006.2008.01013.x
   Yokohori N, 2004, CHEST, V125, P626, DOI 10.1378/chest.125.2.626
   Yoshida T, 2007, PHYSIOL REV, V87, P1047, DOI 10.1152/physrev.00048.2006
NR 57
TC 112
Z9 119
U1 7
U2 17
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD DEC 15
PY 2009
VL 180
IS 12
BP 1196
EP 1207
DI 10.1164/rccm.200903-0324OC
PG 12
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 534IG
UT WOS:000272889200007
PM 19797762
OA Green Published
DA 2018-12-27
ER

PT J
AU Auten, RL
   Potts, EN
   Mason, SN
   Fischer, B
   Huang, Y
   Foster, WM
AF Auten, Richard L.
   Potts, Erin N.
   Mason, S. Nicholas
   Fischer, Bernard
   Huang, Yuhchin
   Foster, W. Michael
TI RETRACTED: Maternal Exposure to Particulate Matter Increases Postnatal
   Ozone-induced Airway Hyperreactivity in Juvenile Mice (Retracted
   article. See vol. 193, pg. 582, 2016)
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article; Retracted Publication
ID LOW-LEVEL OZONE; RESPIRATORY SYMPTOMS; ASTHMA SUSCEPTIBILITY; ALVEOLAR
   DEVELOPMENT; RHESUS-MONKEYS; DIESEL EXHAUST; BIRTH-WEIGHT; NEWBORN RATS;
   MOUSE MODEL; GUINEA-PIG
AB Rationale: Epidemiologic studies implicate air pollutant exposure during pregnancy as a risk factor for wheezing in offspring. Ozone exposure is linked to exacerbations of wheezing in children.
   Objectives: To determine if maternal pulmonary exposure to traffic-related particles during pregnancy augments ozone-induced airway hyperresponsiveness in offspring.
   Methods: C57BL6 time-mated mice were given NIST SRM#1648 (particulate matter [PM]) 0.48 mg, saline vehicle, or no treatment by tracheal insufflation twice weekly for 3 weeks. PM exposure augmented maternal lung inflammation and placental TNF-alpha, Keratinocyte-derived cytokine (KC), and IL-6 (measured at gestation Day 18). After parturition, dams and litters were exposed to air or ozone 1 ppm 3 h/d, every other day, thrice weekly for 4 weeks. Respiratory system resistance in pups was measured at baseline and after administration of nebulized methacholine.
   Measurements and Main Results: Ozone increased airway hyperresponsiveness, but the increase was greatest in pups born to PM-treated dams. Whole-lung TNF-alpha, IL-10, KC, IL-6, and MCPA were increased in ozone-treated pups, with the greatest increase in pups born to dams given PM. Airway epithelial mucous metaplasia estimated by periodic acid-Schiff Alcian blue staining was increased in ozone-exposed pups born to PM-treated dams. Alveolar development, determined by morphometry, and airway smooth muscle bulk, estimated using alpha-actin histochemistry, were unaffected by prenatal or postnatal treatment.
   Conclusions: Maternal pulmonary exposure to PM during pregnancy augments placental cytokine expression and postnatal ozone-induced pulmonary inflammatory cytokine responses and ozone-induced airway hyperresponsiveness without altering airway structure.
C1 [Auten, Richard L.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA.
   [Potts, Erin N.; Fischer, Bernard] Duke Univ, Dept Med, Durham, NC 27710 USA.
RP Auten, RL (reprint author), Duke Univ, Med Ctr, Dept Pediat, DUMC Box 3373, Durham, NC 27710 USA.
EM auten@duke.edu
FU US Environmental Protection Agency Children's Environmental Health
   Center [RD 83329301-0]; National Institutes of Health [ES-011961,
   ES-016347]
FX Supported by US Environmental Protection Agency Children's Environmental
   Health Center Award RD 83329301-0 and by National Institutes of Health
   grants ES-011961 and ES-016347.
CR Aaltonen R, 2005, OBSTET GYNECOL, V106, P802, DOI 10.1097/01.AOG.0000178750.84837.ed
   Archer AJ, 2004, AM J PHYSIOL-LUNG C, V286, pL337, DOI 10.1152/ajplung.00202.2003
   Auten RL, 2007, AM J RESP CRIT CARE, V176, P291, DOI 10.1164/rccm.200605-6620C
   Auten RL, 2001, AM J PHYSIOL-LUNG C, V281, pL336
   AUTEN RL, 2007, AM J RESP CRIT CARE, V175, pA542
   Becher R, 2007, INHAL TOXICOL, V19, P645, DOI 10.1080/08958370701353528
   Bozanich EM, 2007, J APPL PHYSIOL, V103, P542, DOI 10.1152/japplphysiol.01253.2006
   Brauer M, 2008, ENVIRON HEALTH PERSP, V116, P680, DOI 10.1289/ehp.10952
   Bry K, 2007, AM J RESP CELL MOL, V36, P32, DOI 10.1165/rcmb.2006-0116OC
   Cho HY, 2001, AM J PHYSIOL-LUNG C, V280, pL537
   Currie WD, 1998, EUR RESPIR J, V12, P288, DOI 10.1183/09031936.98.12020288
   DeLorme MP, 2002, J TOXICOL ENV HEAL A, V65, P1453, DOI 10.1080/00984100290071432
   Dezateux C, 2004, THORAX, V59, P60
   Enhorning G, 2008, CHEST, V133, P975, DOI 10.1378/chest.07-2404
   Fedulov AV, 2008, AM J RESP CELL MOL, V38, P57, DOI 10.1165/rcmb.2007-0124OC
   Fedulov AV, 2008, J IMMUNOTOXICOL, V5, P445, DOI 10.1080/15476910802481765
   FOLINSBEE LJ, 1994, AM J RESP CRIT CARE, V149, P98, DOI 10.1164/ajrccm.149.1.8111607
   Foster WM, 2001, J APPL PHYSIOL, V90, P1111
   Fujimoto A, 2005, ENVIRON TOXICOL, V20, P431, DOI 10.1002/tox.20129
   Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859
   Gilliland F, 2005, ENVIRON HEALTH PERSP, V113, P1447, DOI 10.1289/ehp.7673
   Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271
   GORDON T, 1984, J APPL PHYSIOL, V57, P1034
   Gouveia N, 2004, J EPIDEMIOL COMMUN H, V58, P11, DOI 10.1136/jech.58.1.11
   Gowdy K, 2008, TOXICOL APPL PHARM, V229, P310, DOI 10.1016/j.taap.2008.01.040
   Hamada K, 2007, J TOXICOL ENV HEAL A, V70, P688, DOI 10.1080/15287390600974692
   Hollingsworth John W, 2007, Proc Am Thorac Soc, V4, P240, DOI 10.1513/pats.200701-023AW
   Hollingsworth JW, 2004, AM J RESP CRIT CARE, V170, P126, DOI 10.1164/rccm.200311-1499OC
   Jang AS, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-24
   Jedrychowski W, 2005, EUR J EPIDEMIOL, V20, P775, DOI 10.1007/s10654-005-1048-1
   Johnston CJ, 2000, INHAL TOXICOL, V12, P205
   Kajekar R, 2007, RESP PHYSIOL NEUROBI, V155, P55, DOI 10.1016/j.resp.2006.03.002
   Kurukulaaratchy RJ, 2005, ACTA PAEDIATR, V94, P553, DOI 10.1080/08035250510027282
   Larson SD, 2004, TOXICOL APPL PHARM, V194, P211, DOI 10.1016/j.taap.2003.09.025
   Li ZW, 2006, AM J PHYSIOL-CELL PH, V291, pC357, DOI 10.1152/ajpcell.00365.2005
   Lim RH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004660
   Lim RH, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-56
   Lim RH, 2009, AM J REPROD IMMUNOL, V61, P1, DOI 10.1111/j.1600-0897.2008.00671.x
   Moore K, 2008, ENVIRON HEALTH PERSP, V116, P1063, DOI 10.1289/ehp.10497
   MORTOLA JP, 1983, J APPL PHYSIOL, V54, P1236
   Park JW, 2004, AM J RESP CELL MOL, V30, P830, DOI 10.1165/rcmb.2003.0373OC
   Perera FP, 2002, ENVIRON HEALTH PERSP, V110, P197, DOI 10.1289/ehp.02110197
   Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507
   Pinkerton Kent E, 2008, Res Rep Health Eff Inst, P3
   Polte T, 2008, J ALLERGY CLIN IMMUN, V122, P1022, DOI 10.1016/j.jaci.2008.09.014
   POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90, DOI 10.1080/00039896.1991.9937434
   Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228
   Salam MT, 2008, CURR OPIN PULM MED, V14, P3, DOI 10.1097/MCP.0b013e3282f1987a
   Savov JD, 2004, AM J RESP CELL MOL, V31, P69, DOI 10.1165/rcmb.2003-0001OC
   Schelegle ES, 2003, TOXICOL APPL PHARM, V191, P74, DOI 10.1016/S0041-008X(03)00218-7
   Shoenfelt J, 2009, J LEUKOCYTE BIOL, V86, P303, DOI 10.1189/jlb.1008587
   Shore SA, 2002, J APPL PHYSIOL, V92, P1019, DOI 10.1152/japplphysiol.00381.2001
   Smith KR, 1997, CHEM RES TOXICOL, V10, P828, DOI 10.1021/tx960164m
   Triche EW, 2006, ENVIRON HEALTH PERSP, V114, P911, DOI 10.1289/ehp.8559
   Vancza EM, 2009, TOXICOL SCI, V107, P535, DOI 10.1093/toxsci/kfn253
   Veres TZ, 2009, PHARMACOL THERAPEUT, V122, P203, DOI 10.1016/j.pharmthera.2009.02.007
   Verhein KC, 2008, AM J RESP CELL MOL, V39, P730, DOI 10.1165/rcmb.2008-0045OC
   VOYNOW JA, 2004, AM J PHYSIOL-LUNG C, V302, pL1293
   Wagers S, 2004, J APPL PHYSIOL, V96, P2019, DOI 10.1152/japplphysiol.00924.2003
   WIESTER MJ, 1988, TOXICOL APPL PHARM, V96, P140, DOI 10.1016/0041-008X(88)90256-6
   Wigle DT, 2007, J TOXICOL ENV HEAL B, V10, P3, DOI 10.1080/10937400601034563
   Woodin MA, 1999, J OCCUP ENVIRON MED, V41, P973, DOI 10.1097/00043764-199911000-00009
   Yost BL, 2005, AM J PHYSIOL-LUNG C, V289, pL627, DOI 10.1152/ajplung.00377.2004
   Yost BL, 1999, J APPL PHYSIOL, V87, P1272
   Zaretsky MV, 2004, OBSTET GYNECOL, V103, P546, DOI 10.1097/01.AOG.0000114980.40445.83
NR 65
TC 29
Z9 32
U1 3
U2 12
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD DEC 15
PY 2009
VL 180
IS 12
BP 1218
EP 1226
DI 10.1164/rccm.200901-0116OC
PG 9
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 534IG
UT WOS:000272889200009
PM 19762564
OA Green Published
DA 2018-12-27
ER

PT J
AU Bahi, A
   Mineur, YS
   Picciotto, MR
AF Bahi, Arnine
   Mineur, Yann S.
   Picciotto, Marina R.
TI RETRACTED: Blockade of Protein Phosphatase 2B Activity in the Amygdala
   Increases Anxiety- and Depression-Like Behaviors in Mice (Retracted
   article. See vol. 75, pg. 999, 2014)
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article; Retracted Publication
DE AAV; anxiety; calcineurin; cyclosporin-A; depression; elevated plus
   maze; forced swim; PP2B; shRNA; tail suspension
ID MALE C57BL/6J MICE; MAJOR DEPRESSION; RNA INTERFERENCE; BINDING PROTEIN;
   NERVOUS-SYSTEM; RAT-BRAIN; CALCINEURIN; CYCLOSPORINE; GENE; EXPRESSION
AB Background: Organ transplant patients receive chronic administration of the calcineurin inhibitor cyclosporin-A (CsA) and demonstrate increased incidence of mood disorders. Significant calcineurin expression can be observed with immunohistochemistry in the amygdala, a brain area important for behaviors related to mood disorders and anxiety. It is therefore important to determine whether chronic blockade of calcineurin might contribute to symptoms of anxiety and depression in these patients.
   Methods: Pharmacological CsA and viral-mediated gene transfer (adeno-associated viral expression of short hairpin RNA [AAV-shRNA]) approaches were used to inhibit calcineurin activity globally and selectively in the amygdala of the mouse brain to determine the role of calcineurin in behaviors related to depression and anxiety.
   Results: Systemic inhibition of calcineurin activity with CsA or local downregulation of calcineurin levels in the amygdala with AAV-delivered shRNAs targeting calcineurin A increased behavioral measures of anxiety in both the elevated plus maze and light/dark tests with no changes in locomotor activity. In the forced swim and tail suspension models of depression-like behavior, calcineurin blockade in the amygdala increased immobility similarly to manipulations that lead to a depression-like phenotype.
   Conclusions: Taken together, these data demonstrate that decreasing calcineurin activity in the amygdala increases anxiety- and depression-like behaviors. These studies suggest that chronic administration of CsA to organ transplant patients could have significant effects on anxiety and mood and that this should be recognized as a clinical consequence of treatment to prevent transplant rejection.
C1 [Bahi, Arnine; Mineur, Yann S.; Picciotto, Marina R.] Yale Univ, Sch Med, Abraham Ribicoff Res Facil, Div Mol Psychiat,Connecticut Mental Hlth Ctr, New Haven, CT USA.
RP Picciotto, MR (reprint author), 34 Pk St, New Haven, CT 06508 USA.
EM marina.picciotto@yale.edu
RI Picciotto, Marina/F-8747-2012; Mineur, Yann/E-2487-2018
OI Picciotto, Marina/0000-0002-4404-1280; Mineur, Yann/0000-0002-8030-6776
FU National Institutes of Health and the State of Connecticut, Department
   of Mental Health and Addiction Services [DA14241, MH77681, DA00436];
   Swiss National Science Foundation [PA00A-117453]
FX This work was supported by Grants DA14241, MH77681, and DA00436 from The
   National Institutes of Health and the State of Connecticut, Department
   of Mental Health and Addiction Services; AB was supported by a
   Fellowship for advanced researchers from the Swiss National Science
   Foundation (PA00A-117453). We express our gratitude to Dr. Ralph DiLeone
   (Yale University) for providing reagents and expertise in setting up the
   adeno-associated virus system. The authors declare no biomedical
   financial interests or potential conflicts of interest.
CR Bahi A, 2005, EUR J NEUROSCI, V21, P3415, DOI 10.1111/j.1460-9568.2005.04157.x
   BECK CHM, 1995, PHARMACOL BIOCHEM BE, V51, P331, DOI 10.1016/0091-3057(94)00391-U
   Benavides DR, 2007, J NEUROSCI, V27, P12967, DOI 10.1523/JNEUROSCI.4061-07.2007
   BUTTINI M, 1993, N-S ARCH PHARMACOL, V348, P679, DOI 10.1007/BF00167247
   Caldarone BJ, 2008, NEUROSCI LETT, V439, P187, DOI 10.1016/j.neulet.2008.05.023
   CALNE RY, 1978, LANCET, V2, P1323
   CALNE RY, 1979, LANCET, V2, P1033
   Clark CP, 2006, PSYCHIAT RES-NEUROIM, V146, P43, DOI 10.1016/j.pscychresns.2005.09.007
   CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431
   CRAWLEY J, 1980, PHARMACOL BIOCHEM BE, V13, P167, DOI 10.1016/0091-3057(80)90067-2
   CRAWLEY JN, 1985, NEUROSCI BIOBEHAV R, V9, P37, DOI 10.1016/0149-7634(85)90030-2
   Crozatier C, 2007, NEUROSCIENCE, V144, P1470, DOI 10.1016/j.neuroscience.2006.11.030
   Davis M, 2001, MOL PSYCHIATR, V6, P13, DOI 10.1038/sj.mp.4000812
   DEGROEN PC, 1987, NEW ENGL J MED, V317, P861, DOI 10.1056/NEJM198710013171404
   Drevets WC, 2001, CURR OPIN NEUROBIOL, V11, P240, DOI 10.1016/S0959-4388(00)00203-8
   DREVETS WC, 1992, J NEUROSCI, V12, P3628
   Franklin KBJ, 2001, MOUSE BRAIN STEREOTA
   HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924
   Hommel JD, 2003, NAT MED, V9, P1539, DOI 10.1038/nm964
   HUSI H, 1994, J BIOL CHEM, V269, P14199
   Jindel RM, 2003, TRANSPL P, V35, P2868, DOI 10.1016/j.transproceed.2003.10.052
   KAHAN BD, 1987, TRANSPLANTATION, V43, P197, DOI 10.1097/00007890-198702000-00007
   Katon WJ, 2003, BIOL PSYCHIAT, V54, P216, DOI 10.1016/S0006-3223(03)00273-7
   KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983
   KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0
   KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270
   Mansuy IM, 2003, BIOCHEM BIOPH RES CO, V311, P1195, DOI 10.1016/j.bbrc.2003.10.046
   Mathieu F, 2008, BEHAV BRAIN FUNCT, V4, DOI 10.1186/1744-9081-4-2
   Mineur YS, 2007, NEUROPHARMACOLOGY, V52, P1256, DOI 10.1016/j.neuropharm.2007.01.006
   Mineur YS, 2007, BIOL PSYCHIAT, V61, P250, DOI 10.1016/j.biopsych.2006.04.037
   Ormel J., 2002, J GERONTOL B-PSYCHOL, V57, P338, DOI [10.1093/geronb/57.4.P338, DOI 10.1093/GERONB/57.4.P338]
   Patten SB, 2001, J AFFECT DISORDERS, V63, P35, DOI 10.1016/S0165-0327(00)00186-5
   POLLI JW, 1991, DEV BRAIN RES, V63, P105, DOI 10.1016/0165-3806(91)90071-P
   Sato Y, 2007, ANESTH ANALG, V105, P1489, DOI 10.1213/01.ane.0000286173.60987.72
   Sheline YI, 1998, NEUROREPORT, V9, P2023, DOI 10.1097/00001756-199806220-00021
   Telarovic Sinisa, 2007, Lijec Vjesn, V129, P74
   van den Brink RHS, 2002, AM HEART J, V144, P219, DOI 10.1067/mhj.2002.123580
   VICTOR RG, 1995, P NATL ACAD SCI USA, V92, P6269, DOI 10.1073/pnas.92.14.6269
   Vyas A, 2002, J NEUROSCI, V22, P6810
   Wallace TL, 2004, BIOL PSYCHIAT, V56, P151, DOI 10.1016/j.biopsych.2004.04.010
   Wolfensberger SPA, 2008, NEUROIMAGE, V41, P544, DOI 10.1016/j.neuroimage.2008.01.053
   Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8
   Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499
   Zhu Y, 1997, J NEUROPHYSIOL, V78, P1161
   Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938
NR 45
TC 32
Z9 32
U1 4
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD DEC 15
PY 2009
VL 66
IS 12
BP 1139
EP 1146
DI 10.1016/j.biopsych.2009.07.004
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 530NL
UT WOS:000272599500010
PM 19716552
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Niture, SK
   Jain, AK
   Jaiswal, AK
AF Niture, Suryakant K.
   Jain, Abhinav K.
   Jaiswal, Anil K.
TI RETRACTED: Antioxidant-induced modification of INrf2 cysteine 151 and
   PKC-delta-mediated phosphorylation of Nrf2 serine 40 are both required
   for stabilization and nuclear translocation of Nrf2 and increased drug
   resistance(Retracted article. See vol.130, pg. 816, 2017)
SO JOURNAL OF CELL SCIENCE
LA English
DT Article; Retracted Publication
DE Protein kinase C; NQO1; ARE; Nrf2; INrf2 (Keap1); Serine
   phosphorylation; Detoxifying enzyme
ID PROTEIN-KINASE-C; OXIDOREDUCTASE-1 GENE-EXPRESSION; CUL3-BASED E3
   LIGASE; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; ENHANCES SUSCEPTIBILITY;
   PROTHYMOSIN-ALPHA; LUNG-CANCER; KEAP1; MICE
AB Antioxidants cause dissociation of nuclear factor erythroid 2-related factor 2 (Nrf2) from inhibitor of Nrf2 (INrf2) and so Nrf2: INrf2 can serve as a sensor of oxidative stress. Nrf2 translocates to the nucleus, binds to antioxidant response element (ARE) and activates defensive gene expression, which protects cells. Controversies exist regarding the role of antioxidant-induced modification of INrf2 cysteine 151 or protein kinase C (PKC)-mediated phosphorylation of Nrf2 serine 40 in the release of Nrf2 from INrf2. In addition, the PKC isoform that phosphorylates Nrf2S40 remains unknown. Here, we demonstrate that antioxidant-induced PKC-delta-mediated phosphorylation of Nrf2S40 leads to release of Nrf2 from INrf2. This was evident from specific chemical inhibitors of PKC isoenzymes in reporter assays, in vitro kinase assays with purified Nrf2 and PKC isoenzymes, in vivo analysis with dominant-negative mutants and siRNA against PKC isoforms, use of PKC-delta(+/+) and PKC-delta(-/-) cells, and use of Nrf2S40 phospho-specific antibody. The studies also showed that antioxidant-induced INrf2C151 modification was insufficient for the dissociation of Nrf2 from INrf2. PKC-delta-mediated Nrf2S40 phosphorylation was also required. Nrf2 and mutant Nrf2S40A both bind to INrf2. However, antioxidant treatment led to release of Nrf2 but not Nrf2S40A from INrf2. In addition, Nrf2 and mutant Nrf2S40A both failed to dissociate from mutant INrf2C151A. Furthermore, antioxidant-induced ubiquitylation of INrf2 in PKC-delta(+/+) and PKC-delta(-/-) cells occurred, but Nrf2 failed to be released in PKC-delta(-/-) cells. The antioxidant activation of Nrf2 reduced etoposide-mediated DNA fragmentation and promoted cell survival in PKC-delta(+/+) but not in PKC-delta(-/-) cells. These data together demonstrate that both modification of INrf2C151 and PKC-delta-mediated phosphorylation of Nrf2S40 play crucial roles in Nrf2 release from INrf2, antioxidant induction of defensive gene expression, promoting cell survival, and increasing drug resistance.
C1 [Niture, Suryakant K.; Jain, Abhinav K.; Jaiswal, Anil K.] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA.
RP Jaiswal, AK (reprint author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA.
EM ajaiswal@som.umaryland.edu
RI Jain, Abhinav/A-2540-2013
FU NIGMS [RO1 GM047466]
FX The contributions of David Bloom in some initial work are acknowledged.
   We also thank Janine Ondrus for English editing of the manuscript. We
   thank J. W. Soh and I. B. Weinstein for providing HA-PKC
   dominant-negative plasmids. This work was supported by NIGMS grant RO1
   GM047466. Deposited in PMC for release after 12 months.
CR Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200
   Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002
   Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943
   Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004
   Dhakshinamoorthy S, 2005, J BIOL CHEM, V280, P16891, DOI 10.1074/jbc.M500166200
   Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506
   Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198
   Eggler AL, 2007, CHEM RES TOXICOL, V20, P1878, DOI 10.1021/tx700217c
   Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102
   Ha H, 2001, AM J KIDNEY DIS, V38, pS204, DOI 10.1053/ajkd.2001.27446
   Hu XM, 2006, MOL CELL BIOL, V26, P940, DOI 10.1128/MCB.26.3.940-954.2006
   Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200
   Humphries MJ, 2008, ONCOGENE, V27, P3045, DOI 10.1038/sj.onc.1210967
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Jackson D, 2005, ONCOGENE, V24, P3067, DOI 10.1038/sj.onc.1208465
   Jain AK, 2007, J BIOL CHEM, V282, P16502, DOI 10.1074/jbc.M611336200
   Jain AK, 2006, J BIOL CHEM, V281, P12132, DOI 10.1074/jbc.M511198200
   Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200
   Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074
   Karapetian RN, 2005, MOL CELL BIOL, V25, P1089, DOI 10.1128/MCB.25.3.1089-1099.2005
   Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004
   Ma Q, 2006, AM J PATHOL, V168, P1960, DOI 10.2353/ajpath.2006.051113
   NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526
   Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626
   NISHIZUKA Y, 1995, FASEB J, V9, P484
   Niture SK, 2009, J BIOL CHEM, V284, P13856, DOI 10.1074/jbc.M808084200
   Niwa K, 2002, FREE RADICAL RES, V36, P1147, DOI 10.1080/1071576021000016409
   Otieno MA, 2000, CANCER RES, V60, P4391
   Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013
   Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798
   Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538
   Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146
   Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420
   Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200
   Velichkova M, 2005, MOL CELL BIOL, V25, P4501, DOI 10.1128/MCB.25.11.4501-4513.2005
   Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003
   Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004
   Zhang YJ, 2008, ASTIN BULL, V38, P1, DOI 10.2143/AST.38.1.2030400
NR 38
TC 130
Z9 136
U1 6
U2 17
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD DEC 15
PY 2009
VL 122
IS 24
BP 4452
EP 4464
DI 10.1242/jcs.058537
PG 13
WC Cell Biology
SC Cell Biology
GA 526XM
UT WOS:000272329300006
PM 19920073
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Guerra, DL
   Viana, RR
   Airoldi, C
AF Guerra, Denis L.
   Viana, Rubia R.
   Airoldi, Claudio
TI RETRACTED: Application of natural and modified hectorite clays as
   adsorbents to removal of Cr(VI) from aqueous solution-Thermodynamic and
   equilibrium study (Retracted article. See vol. 194, pg. 446, 2011)
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article; Retracted Publication
DE Hectorite; Chromium; Adsorption; Thermodynamic
ID HEXAVALENT CHROMIUM; SILICA-GEL; ADSORPTION PROCESS; FERROUS SAPONITE;
   REDUCTION; INTERCALATION; BIOSORBENT; CHEMISTRY; BRAZIL
AB A hectorite (H) clay sample has been modified with 2-mercaptobenzimidazole (MBI) using homogeneous and heterogeneous routes. Both modification methodologies resulted in similar products. named H-HOM and H-HET, respectively. These materials were characterized by CO2 gas adsorption, elemental analysis. nuclear magnetic nuclei of carbon-13 and silicon-29. The effect of two variables (contact time and metal concentration) has been studied using batch technique at room temperature and pH 2.0. After achieving the best conditions for Cr(VI) adsorption, isotherms of this adsorbate on using the chosen adsorbents were obtained, which were fitted to non-linear Sips isotherm model. The maximum number of moles adsorbed was determined to be 11.63, 12.85 and 14.01 mmol g(-1) for H, H-HOM and H-HET, respectively. reflecting the maximum adsorption order of H-HET > H-HOM > H. The energetic effects (Delta H-int degrees, Delta(int)G degrees, and Delta S-int degrees) caused by chromium ion adsorption were determined through calorimetric titrations. (C) 2009 Published by Elsevier B.V
C1 [Guerra, Denis L.; Airoldi, Claudio] Univ Estadual Campinas, Inst Chem, BR-13084971 Campinas, SP, Brazil.
   [Viana, Rubia R.] Univ Fed Mato Grosso, UFMT, Ctr Recursos Minerais, BR-76806090 Cuiaba, Mato Grosso, Brazil.
RP Guerra, DL (reprint author), Univ Estadual Campinas, Inst Chem, POB 6154, BR-13084971 Campinas, SP, Brazil.
EM dlguerra@iqm.unicamp.br
FU CNPq; FAPESP
FX The authors are indebted to CNPq for fellowships and FAPESP for
   financial support.
CR Ahmed MT, 2006, DESALINATION, V200, P419, DOI 10.1016/j.desal.2006.03.354
   Alcantara EFC, 2007, J COLLOID INTERF SCI, V311, P1, DOI 10.1016/j.jcis.2007.02.075
   Beurlen H, 2008, MINER DEPOSITA, V43, P207, DOI 10.1007/s00126-007-0152-4
   Blowes D, 2002, SCIENCE, V295, P2024, DOI 10.1126/science.1070031
   Brasil JL, 2006, J HAZARD MATER, V133, P143, DOI 10.1016/j.jhazmat.2005.10.002
   Cavaco SA, 2007, J HAZARD MATER, V144, P634, DOI 10.1016/j.jhazmat.2007.01.087
   Cestaria AR, 2009, J HAZARD MATER, V161, P307, DOI 10.1016/j.jhazmat.2008.03.091
   Dias NL, 1998, COLLOID SURFACE A, V144, P219, DOI 10.1016/S0927-7757(98)00569-X
   Guerra DL, 2008, J HAZARD MATER, V155, P230, DOI 10.1016/j.jhazmat.2007.11.054
   Guerra DL, 2008, INORG CHEM COMMUN, V11, P20, DOI 10.1016/j.inoche.2007.09.029
   Guerra DL, 2006, POLYHEDRON, V25, P2880, DOI 10.1016/j.poly.2006.04.015
   Ho YS, 1999, PROCESS BIOCHEM, V34, P451, DOI 10.1016/S0032-9592(98)00112-5
   Jacques RA, 2007, SEP PURIF TECHNOL, V57, P193, DOI 10.1016/j.seppur.2007.01.018
   Kim JG, 2002, ENVIRON GEOL, V42, P642, DOI 10.1007/s00254-002-0567-2
   Kumar PA, 2007, J HAZARD MATER, V143, P24, DOI 10.1016/j.jhazmat.2006.08.067
   Lazarin AM, 2007, THERMOCHIM ACTA, V454, P43, DOI 10.1016/j.tca.2006.12.016
   Macedo TR, 2007, CLAY CLAY MINER, V55, P151, DOI 10.1346/CCMN.2007.0550204
   Malkoc E, 2006, J HAZARD MATER, V138, P142, DOI 10.1016/j.jhazmat.2006.05.051
   Mohan D, 2005, IND ENG CHEM RES, V44, P1027, DOI 10.1021/ie0400898
   Parthasarathy G, 2007, NAT HAZARDS, V40, P647, DOI 10.1007/s11069-006-9015-z
   Parthasarathy G, 2003, AM MINERAL, V88, P1983, DOI 10.2138/am-2003-11-1242
   Patterson RR, 1997, ENVIRON SCI TECHNOL, V31, P2039, DOI 10.1021/es960836v
   Pavan FA, 2006, J HAZARD MATER, V137, P527, DOI 10.1016/j.jhazmat.2006.02.025
   Prado AGS, 2002, J MATER CHEM, V12, P3823, DOI 10.1039/b204060c
   QUINTANILLA DP, 2006, J HAZARD MATER, V134, P245
   Ruiz VSO, 2004, THERMOCHIM ACTA, V420, P73, DOI 10.1016/j.tca.2003.10.029
   SIPS R, 1948, J CHEM PHYS, V16, P490, DOI 10.1063/1.1746922
NR 27
TC 7
Z9 7
U1 4
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
EI 1873-3336
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD DEC 15
PY 2009
VL 172
IS 1
BP 507
EP 514
DI 10.1016/j.jhazmat.2009.07.016
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 513TP
UT WOS:000271346800069
PM 19643537
DA 2018-12-27
ER

PT J
AU Liu, MY
   Khachigian, LM
AF Liu, Mary Y.
   Khachigian, Levon M.
TI RETRACTED: Histone Deacetylase-1 Is Enriched at the Platelet-derived
   Growth Factor-D Promoter in Response to Interleukin-1 beta and Forms a
   Cytokine-inducible Gene-silencing Complex with NF-kappa B p65 and
   Interferon Regulatory Factor-1 (Retracted Article. See vol 285, pg
   21902, 2010)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID NECROSIS-FACTOR-ALPHA; CELL-ADHESION MOLECULE-1; SMOOTH-MUSCLE-CELLS;
   HUMAN ENDOTHELIAL-CELLS; FACTOR-A CHAIN; PDGF-D; DOWN-REGULATION;
   ANGIOTENSIN-II; CARDIOVASCULAR-DISEASE; TRANSCRIPTION FACTORS
AB Understanding the mechanisms governing cytokine control of growth factor expression in smooth muscle cells would provide invaluable insight into the molecular regulation of vascular phenotypes and create future opportunities for therapeutic intervention. Here, we report that the proinflammatory cytokine interleukin (IL)-1 beta suppresses platelet-derived growth factor (PDGF)-D promoter activity and mRNA and protein expression in smooth muscle cells. NF-kappa B p65, induced by IL-1 beta, interacts with a novel element in the PDGF-D promoter and inhibits PDGF-D transcription. Interferon regulatory factor-1 (IRF-1) is also induced by IL-1 beta and binds to a different element upstream in the promoter. Immunoprecipitation and chromatin immunoprecipitation experiments showed that IL-1 beta stimulates p65 interaction with IRF-1 and the accumulation of both factors at the PDGF-D promoter. Mutation of the IRF-1 and p65 DNA-binding elements relieved the promoter from IL-1 beta-mediated repression. PDGF-D repression by IL-1 beta involves histone deacetylation and interaction of HDAC-1 with IRF-1 and p65. HDAC-1 small interfering RNA ablates complex formation with IRF-1 and p65 and abrogates IRF-1 and p65 occupancy of the PDGF-D promoter. Thus, HDAC- 1 is enriched at the PDGF-D promoter in cells exposed to IL-1 beta and forms a cytokine-inducible gene-silencing complex with p65 and IRF-1.
C1 [Liu, Mary Y.; Khachigian, Levon M.] Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia.
RP Khachigian, LM (reprint author), Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia.
EM L.Khachigian@unsw.edu.au
OI Khachigian, Levon/0000-0003-3446-0323
FU National Health and Medical Research Council of Australia; Australian
   Research Council; National Heart Foundation of Australia
FX This work was supported by grants from the National Health and Medical
   Research Council of Australia, Australian Research Council, and National
   Heart Foundation of Australia.
CR Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200
   Anwar A, 2002, CIRCULATION, V105, P1220, DOI 10.1161/hc1002.105187
   Balasubramanian S, 2009, CANCER LETT, V280, P211, DOI 10.1016/j.canlet.2009.02.013
   Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588
   Bonello MR, 2004, J BIOL CHEM, V279, P2377, DOI 10.1074/jbc.M308254200
   Chamberlain J, 1999, CARDIOVASC RES, V44, P156, DOI 10.1016/S0008-6363(99)00175-3
   Changsirikulchai S, 2002, KIDNEY INT, V62, P2043, DOI 10.1046/j.1523-1755.2002.00662.x
   Chen JZ, 2005, BIOCHEM BIOPH RES CO, V329, P976, DOI 10.1016/j.bbrc.2005.02.062
   Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373
   Delbridge GJ, 1997, CIRC RES, V81, P282, DOI 10.1161/01.RES.81.2.282
   Englesbe MJ, 2004, J VASC SURG, V39, P1091, DOI 10.1016/j.jvs.2004.01.041
   Isoda K, 2003, CIRCULATION, V108, P516, DOI 10.1161/01.CIR.0000085567.18648.21
   Jiang BB, 2001, ARTERIOSCL THROM VAS, V21, P1915, DOI 10.1161/hq1201.099424
   Jung Young D., 2001, Angiogenesis, V4, P155, DOI 10.1023/A:1012291524723
   Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200
   Kenagy RD, 2000, J VASC RES, V37, P381, DOI 10.1159/000025754
   KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106
   KHACHIGIAN LM, 1995, BIOCHEM BIOPH RES CO, V206, P462, DOI 10.1006/bbrc.1995.1065
   KHACHIGIAN LM, 1993, PLATELETS, V4, P304, DOI 10.3109/09537109309013233
   LaRochelle WJ, 2002, CANCER RES, V62, P2468
   LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593
   Leung CH, 2005, MOL PHARMACOL, V68, P286, DOI 10.1124/mol.105.012765
   Li R, 2007, INVEST OPHTH VIS SCI, V48, P5722, DOI 10.1167/iovs.07-0327
   Liu MYX, 2006, BLOOD, V107, P2322, DOI 10.1182/blood-2005-06-2377
   Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0
   Mitchell A, 2004, NUCLEIC ACIDS RES, V32, P3065, DOI 10.1093/nar/gkh626
   Montgomery RL, 2007, GENE DEV, V21, P1790, DOI 10.1101/gad.1563807
   Morton AC, 2005, CARDIOVASC RES, V68, P493, DOI 10.1016/j.cardiores.2005.06.026
   Mountain DJH, 2008, J CELL PHYSIOL, V215, P337, DOI 10.1002/jcp.21315
   Nakano N, 1998, HYPERTENSION, V32, P444, DOI 10.1161/01.HYP.32.3.444
   NEISH AS, 1995, MOL CELL BIOL, V15, P2558
   NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583
   Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083
   Ponten A, 2005, CIRC RES, V97, P1036, DOI 10.1161/01.RES.0000190590.31545.d4
   Rafty LA, 1998, J BIOL CHEM, V273, P5758, DOI 10.1074/jbc.273.10.5758
   Raines EW, 2004, CYTOKINE GROWTH F R, V15, P237, DOI 10.1016/j.cytogfr.2004.03.004
   RAINES EW, 1990, HDB EXPT PHARM PEPTI, P173
   Resnick N, 1997, ADV EXP MED BIOL, V430, P155
   Saijonmaa O, 2001, J VASC RES, V38, P370, DOI 10.1159/000051068
   SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920
   Saura M, 1999, J MOL BIOL, V289, P459, DOI 10.1006/jmbi.1999.2752
   Sgarbanti M, 2008, J VIROL, V82, P3632, DOI 10.1128/JVI.00599-07
   Shi JR, 2004, J CARDIOVASC PHARM, V44, P26
   Shimokawa H, 1996, J CLIN INVEST, V97, P769, DOI 10.1172/JCI118476
   Sumpio BE, 1998, ARTERIOSCL THROM VAS, V18, P349, DOI 10.1161/01.ATV.18.3.349
   Tan NY, 2008, CIRC RES, V102, pE38, DOI 10.1161/CIRCRESAHA.107.167395
   Uutela M, 2004, BLOOD, V104, P3198, DOI 10.1182/blood-2004-04-1485
   Wang ZW, 2007, CANCER RES, V67, P11377, DOI 10.1158/0008-5472.CAN-07-2803
   Wang ZW, 2009, CURR DRUG TARGETS, V10, P38, DOI 10.2174/138945009787122914
   Wu YZ, 2007, GENES CELLS, V12, P905, DOI 10.1111/j.1365-2443.2007.01104.x
   Zhang N, 2009, J BIOL CHEM, V284, P27933, DOI 10.1074/jbc.M109.025742
NR 51
TC 9
Z9 9
U1 3
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 11
PY 2009
VL 284
IS 50
BP 35101
EP 35112
DI 10.1074/jbc.M109.061903
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 528JG
UT WOS:000272439600064
PM 19843519
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Boldt, J
   Suttner, S
   Brosch, C
   Lehmann, A
   Rohm, K
   Mengistu, A
AF Boldt, Joachim
   Suttner, Stephan
   Brosch, Christian
   Lehmann, Andreas
   Roehm, Kerstin
   Mengistu, Andinet
TI RETRACTED: Cardiopulmonary Bypass Priming Using a High Dose of a
   Balanced Hydroxyethyl Starch Versus an Albumin-Based Priming Strategy
   (Retracted Article. See vol 111, pg 1551, 2010)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID GELATINASE-ASSOCIATED LIPOCALIN; LACTATED RINGERS SOLUTION;
   PLATELET-FUNCTION; CARDIAC-SURGERY; HYPERCHLOREMIC ACIDOSIS; FLUID
   RESUSCITATION; EXPERIMENTAL SEPSIS; MOLECULAR-WEIGHT; MAJOR SURGERY;
   HETASTARCH
AB BACKGROUND: The optimal priming solution for cardiopulmonary bypass (CPB) is unclear. In this study, we evaluated the influence of high-volume priming with a modem balanced hydroxyethyl starch (HES) preparation on coagulation, inflammation, and organ function compared with an albumin-based CPB priming regimen.
   METHODS: In 50 patients undergoing coronary artery bypass grafting, the CPB circuit was prospectively and randomly primed with either 1500 mL of 6% HES 130/0.42 in a balanced electrolyte solution (Na+ 140 mmol/L, Cl- 118 mmol/L, K+ 4 mmol/L, Ca2+ 2.5 mmol/L, Mg++ 1 mmol/L, acetate 24 mmol/L, malate(-) 5 mmol/L) (n = 25) or with 500 mL of 5% human albumin plus 1000 mL 0.9% saline solution (n = 25). Inflammation (interleukins [IL]-6, -10), endothelial damage (soluble intercellular adhesion molecule-1), kidney function (kidney-specific proteins a-glutathione S-transferase, neutrophil gelatinase-associated lipocalin), coagulation (measured by thrombelastometry [ROTEMO (R), Pentapharm, Munich, Germany]), and platelet function (measured by whole blood aggregometry [Multiplate (R) analyzer, Dynabyte Medical, Munich, Germany]) were assessed after induction of anesthesia, immediately after surgery, 5 h after surgery, and on the morning of first and second postoperative days.
   RESULTS: Total Volume given during and after CPB was 3090 540 mL of balanced HES and 31.10 +/- 450 mL of albumin. Base excess after surgery was lower in the albumin-based priming group than in the balanced HES priming group (-5.9 +/- 1.2 mmol/L vs +0.2 +/- 0.2 mmol/L, P = 0.0003). Plasma levels of IL-6, IL-10, and intercellular adhesion molecule-1 were higher after CPB in the albumin-based priming group compared with the HES priming group at all time periods (P = 0.0002). Urinary concentrations of a-glutathione S-transferase and neutrophil gelatinase-associated lipocalin were higher after CPB through the end of the study in the albumin group compared with the balanced HES group (P = 0.00004). After surgery through the first postoperative day, thrombelastometry data (clotting time and clot formation time) revealed more impaired coagulation in the albumin-based priming group compared with the HES priming group (P = 0.004). Compared with baseline, platelet function was unchanged in the high-dose balanced HES priming group after CPB and 5 h after surgery, but it was significantly reduced in the albumin-based priming group.
   CONCLUSION: High-volume priming of the CPB circuit with a modern balanced HES solution resulted in reduced inflammation, less endothelial damage, and fewer alterations in renal tubular integrity compared with an albumin-based priming. Coagulation including platelet function was better preserved with high-dose balanced HES CPB priming compared with albumin-based CPB priming. (Anesth Analg 2009;109:1752-62)
C1 [Boldt, Joachim; Suttner, Stephan; Brosch, Christian; Lehmann, Andreas; Roehm, Kerstin; Mengistu, Andinet] Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Boldt, J (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM boldtj@gmx.net
CR Boldt J, 2007, BRIT J ANAESTH, V99, P312, DOI 10.1093/bja/aem219
   Boldt J, 2007, VOX SANG, V93, P139, DOI 10.1111/j.1423-0410,2007,00946.x
   Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716
   Deusch E, 2004, ANESTH ANALG, V99, P665, DOI 10.1213/01.ANE.0000130349.99727.58
   Franz A, 2001, ANESTH ANALG, V92, P1402, DOI 10.1097/00000539-200106000-00008
   Gan TJ, 1999, ANESTH ANALG, V88, P992, DOI 10.1097/00000539-199905000-00005
   Goodnough LT, 1999, NEW ENGL J MED, V340, P438, DOI 10.1056/NEJM199902113400606
   Han Won K, 2004, Curr Opin Crit Care, V10, P476, DOI 10.1097/01.ccx.0000145095.90327.f2
   Haynes GR, 2004, ANESTHESIOLOGY, V101, P560, DOI 10.1097/00000542-200408000-00055
   Hill GE, 1998, J CARDIOTHOR VASC AN, V12, P21
   Himpe D, 2003, Acta Anaesthesiol Belg, V54, P207
   Kellum JA, 2002, CRIT CARE MED, V30, P300, DOI 10.1097/00003246-200202000-00006
   Kellum JA, 2006, CHEST, V130, P962, DOI 10.1378/chest.130.4.962
   Kjeldsen L, 2000, BBA-PROTEIN STRUCT M, V1482, P272, DOI 10.1016/S0167-4838(00)00152-7
   Knutson JE, 2000, ANESTH ANALG, V90, P801, DOI 10.1213/00000539-200004000-00006
   Kozek-Langenecker SA, 2005, ANESTHESIOLOGY, V103, P654, DOI 10.1097/00000542-200509000-00031
   Lilley A, 2002, PERFUSION-UK, V17, P315, DOI 10.1191/0267659102pf538oa
   Liskaser FJ, 2000, ANESTHESIOLOGY, V93, P1170, DOI 10.1097/00000542-200011000-00006
   Martin G, 2002, J CARDIOTHOR VASC AN, V16, P441, DOI 10.1053/jcan.2002.125146
   Mengistu AM, 2008, J CARDIOTHOR VASC AN, V22, P40, DOI 10.1053/j.jvca.2007.02.015
   Mishra J, 2003, J AM SOC NEPHROL, V14, P2534, DOI 10.1097/01.ASN.0000088027.54400.C6
   MYERS GJ, 1998, 13 MECH PERF M
   Onorati F, 2003, INT J ARTIF ORGANS, V26, P211
   Palanzo DA, 1999, PERFUSION-UK, V14, P473, DOI 10.1177/026765919901400610
   Roche AM, 2002, ANAESTHESIA, V57, P950, DOI 10.1046/j.1365-2044.2002.02707.x
   Russell JA, 2004, J CARDIOTHOR VASC AN, V18, P429, DOI 10.1053/j.jvca.2004.05.019
   Stogermuller B, 2000, ANESTH ANALG, V91, P823
   Tamayo E, 2008, ACTA ANAESTH SCAND, V52, P1204, DOI 10.1111/j.1399-6576.2008.01758.x
   Tian J, 2004, ANESTH ANALG, V98, P768
   Varga R, 2008, CRIT CARE MED, V36, P2828, DOI 10.1097/CCM.0b013e318186ff48
   WILCOX CS, 1983, J CLIN INVEST, V71, P726, DOI 10.1172/JCI110820
NR 31
TC 58
Z9 57
U1 4
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD DEC
PY 2009
VL 109
IS 6
BP 1752
EP 1762
DI 10.1213/ANE.0b013e3181b5a24b
PG 11
WC Anesthesiology
SC Anesthesiology
GA 522LT
UT WOS:000272000100009
PM 19923501
DA 2018-12-27
ER

PT J
AU Elayappan, B
   Ravinarayannan, H
   Pasha, SPBS
   Lee, KJ
   Gurunathan, S
AF Elayappan, Banumathi
   Ravinarayannan, Haribalaganesh
   Pasha, Sheik Pran Babu Sardar
   Lee, Kyung-jin
   Gurunathan, Sangiliyandi
TI RETRACTED: PEDF inhibits VEGF- and EPO- induced angiogenesis in retinal
   endothelial cells through interruption of PI3K/Akt phosphorylation
   (Retracted article. See vol. 14, pg. 407, 2011)
SO ANGIOGENESIS
LA English
DT Article; Retracted Publication
DE Retinal angiogenesis; Diabetic retinopathy; PEDF; VEGF; Epo;
   PI3K/Akt-phosphorylation; Apoptosis; Caspase-3
ID EPITHELIUM-DERIVED FACTOR; RECEPTOR MESSENGER-RNA; GROWTH-FACTOR;
   MEDIATES ANGIOGENESIS; MACULAR DEGENERATION; SIGNAL-TRANSDUCTION;
   PROTEIN-KINASE; IN-VITRO; EXPRESSION; AKT
AB Retinal angiogenesis in diabetes may lead to visual impairment and even irreversible blindness in people of working age group worldwide. The main pathological feature of proliferative diabetic retinopathy (PDR) is hypoxia, and overproduction of growth factors like vascular endothelial growth factor (VEGF) and erythropoietin (Epo). This results in pathological proliferation of retinal endothelial cells (RECs), leading to new vessel formation (angiogenesis). Inhibition of angiogenesis is a promising strategy for treatment of PDR and other retinal neovascular disorders. Pigment epithelium-derived factor (PEDF), a 50-kDa protein secreted by retinal pigment epithelium, inhibits the growth of new blood vessel induced in the eye in a variety of ways with a yet elusive mechanism. Here, we investigated the possible mechanism by which PEDF inhibits VEGF- and Epo-induced angiogenic effects in RECs is mediated through PI3K/Akt pathway. PEDF treatment induced the apoptosis in RECs by activating caspase-3 and DNA fragmentation. We found a dose-dependent increase in cell survival with VEGF or Epo, which was attenuated in the presence of PEDF. In addition, PEDF significantly (P < 0.05) inhibited migration and in vitro tube formation in RECs in the presence of VEGF as like PI3K/Akt inhibitor. Of interest, PEDF effectively abrogated VEGF-mediated phosphorylation of PI3K/Akt. Further studies using RECs transfected with constitutively active and dominant-negative forms of Akt suggest that PEDF could inhibit VEGF- and also Epo-induced angiogenesis by disruption of PI3K/Akt signaling.
C1 [Elayappan, Banumathi; Ravinarayannan, Haribalaganesh; Pasha, Sheik Pran Babu Sardar; Gurunathan, Sangiliyandi] Kalasalingam Univ, Dept Biotechnol, Div Mol & Cellular Biol, Kalasalingam Acad Res & Educ, Madurai 626190, Tamil Nadu, India.
   [Lee, Kyung-jin] Gwangju Inst Sci & Technol, Dept Life Sci, Cell Dynam Res Ctr, Kwangju 500712, South Korea.
RP Gurunathan, S (reprint author), Kalasalingam Univ, Dept Biotechnol, Div Mol & Cellular Biol, Kalasalingam Acad Res & Educ, Madurai 626190, Tamil Nadu, India.
EM lvsangs@yahoo.com
FU ICMR [53/5/2006-BMS]; Department of Biotechnology
   [BT/PR/7704/MED/14/1065/2006]; Department of Science and Technology, New
   Delhi, India [SR/FT/L-118/2006]; Kalasalingam Anandammal Charities
FX This work was supported by a grant from ICMR ( ID No. 53/5/2006-BMS),
   Department of Biotechnology (Ref. No. BT/PR/7704/MED/14/1065/2006),
   Department of Science and Technology, New Delhi-110 029, India (Grant
   No. SR/FT/L-118/2006) and Kalasalingam Anandammal Charities. We thank
   Dr. H. Nellaiah for critical reading of the manuscript. The technical
   assistance of K. Kalishwaralal, V. Deepak and S. Ram Kumar Pandian is
   gratefully acknowledged.
CR Amin MA, 2003, CIRC RES, V93, P321, DOI 10.1161/01.RES.0000087641.56024.DA
   ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974
   Baldysiak-Figiel A, 2004, J ENDOCRINOL, V180, P417, DOI 10.1677/joe.0.1800417
   Banumathi E, 2009, MICROVASC RES, V77, P377, DOI 10.1016/j.mvr.2008.12.005
   Cai J, 2006, J BIOL CHEM, V281, P3604, DOI 10.1074/jbc.M5074401200
   CARLINI RG, 1995, KIDNEY INT, V47, P740, DOI 10.1038/ki.1995.113
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4
   Ek ETH, 2006, TRENDS MOL MED, V12, P497, DOI 10.1016/j.molmed.2006.08.009
   Filleur S, 2005, CANCER RES, V65, P5144, DOI 10.1158/0008-5472.CAN-04-3744
   FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0
   FRAKE TF, 1997, CELL, V88, P435
   Fuste B, 2002, THROMB HAEMOSTASIS, V88, P678
   Gao GQ, 2002, DRUG DISCOV TODAY, V7, P171, DOI 10.1016/S1359-6446(01)02160-2
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897
   Kirchmair R, 2007, MOL THER, V15, P69, DOI 10.1038/sj.mt.6300019
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lucas R, 1998, BLOOD, V92, P4730
   Ogata N, 2002, AM J OPHTHALMOL, V133, P851, DOI 10.1016/S0002-9394(02)01406-X
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Ren JG, 2005, MED HYPOTHESES, V64, P74, DOI 10.1016/j.mehy.2004.05.016
   Ribatti D, 1999, BLOOD, V93, P2627
   SPARGER J, 2001, DIABETES, V50, P2641
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Takenaka K, 2005, LIFE SCI, V77, P3231, DOI 10.1016/j.lfs.2005.05.048
   Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648
   Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349
   WATANABEA D, 2007, NEW ENGL J MED, V77, pS62
   Xi X, 2005, BIOCHEM BIOPH RES CO, V326, P548, DOI 10.1016/j.bbrc.2004.11.064
   XIAOJING S, 2003, MOL VIS, V9, P171
   Yamagishi SI, 2004, J MOL CELL CARDIOL, V37, P497, DOI 10.1016/j.yjmcc.2004.04.007
   Yamaji R, 1996, EUR J BIOCHEM, V239, P494, DOI 10.1111/j.1432-1033.1996.0494u.x
   Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345
NR 38
TC 30
Z9 33
U1 4
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-6970
EI 1573-7209
J9 ANGIOGENESIS
JI Angiogenesis
PD DEC
PY 2009
VL 12
IS 4
BP 313
EP 324
DI 10.1007/s10456-009-9153-5
PG 12
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 521RN
UT WOS:000271941800002
PM 19657716
DA 2018-12-27
ER

PT J
AU Blanco, G
   Lemus, JA
   Martinez, F
   Arroyo, B
   Garcia-Montijano, M
   Grande, J
AF Blanco, G.
   Lemus, J. A.
   Martinez, F.
   Arroyo, B.
   Garcia-Montijano, M.
   Grande, J.
TI RETRACTED: Ingestion of multiple veterinary drugs and associated impact
   on vulture health: implications of livestock carcass elimination
   practices (Retracted article. See vol. 16, pg. 248, 2013)
SO ANIMAL CONSERVATION
LA English
DT Article; Retracted Publication
DE BSE crisis; carcass; disease; quinolones; livestock; veterinary drugs;
   vultures
ID BEARDED VULTURES; CONSERVATION; MICROFLORA; RESIDUES; BEHAVIOR; HABITAT
AB Veterinary drugs present in livestock carcasses may be ingested by scavengers and may cause important declines in their populations, as reported for diclofenac in Asia. Drug content of carcasses may depend on the prevailing livestock operations and legal regulations for carcass elimination. In Spain, the main stronghold of vultures in Europe, legal measures to mitigate the spread of bovine spongiform encephalopathy (BSE) have caused the lack or scarcity of unstabled livestock carcasses available for avian scavengers, and the parallel increase in use of dumps of livestock carcasses supplied by farms, especially of intensively medicated pigs and poultry. We evaluated temporal trends in the presence and concentration of antibiotics and other veterinary drugs, and their associated health impacts on three vulture species, due to the ban of abandoning unstabled livestock carcasses in the countryside since the BSE crisis. An increasing presence and concentration of antibiotics since the BSE crisis, and residues of three non-steroidal anti-inflammatories (NSAIDs) and four anti-parasitics were found in the vultures. Quinolones were associated with infection by opportunistic pathogens in the three species and with generalized damage to internal organs in the cinereous vulture, but no clear health impacts of NSAIDs and anti-parasitics were found. Given that there is no evidence of BSE transmission risk due to the abandonment of unstabled livestock carcasses in the countryside, this traditional practice in the Mediterranean region should be legalized in order to increase the availability, dispersion and quality of food for threatened scavengers. Once legalized, this practice should be prioritized over the spatially concentrated disposal of large amounts of carcasses from medicated stabled livestock to reduce the risk and effects of drug ingestion and acquisition and transmission of pathogens by vultures.
C1 [Blanco, G.; Lemus, J. A.; Martinez, F.; Arroyo, B.; Garcia-Montijano, M.; Grande, J.] CSIC, Museo Nacl Ciencias Nat, Dept Ecol Evolut, E-28006 Madrid, Spain.
RP Blanco, G (reprint author), CSIC, Museo Nacl Ciencias Nat, Dept Ecol Evolut, J Gutierrez Abascal 2, E-28006 Madrid, Spain.
EM gblanco@mncn.csic.es
RI Blanco, Guillermo/L-3170-2014; Evolutionary Ecology, Ecologia
   Evolutiva/M-3553-2014
OI Blanco, Guillermo/0000-0001-5742-4929; 
FU Spanish Ministerio de Educacion y Ciencia [CGL2007-61395/BOS]
FX We thank F. Polo, J.C. Rincon, A. Tejedor, O. Frias, N. Baniandres for
   help with fieldwork, F. Esperon for helping with histopathology, and two
   reviewers for constructive comments and corrections on the paper. Funds
   were provided by the project CGL2007-61395/BOS of Spanish Ministerio de
   Educacion y Ciencia.
CR BLANCO G, 2007, ENV RES TRENDS, P153
   Blanco G., 2004, SPATIAL ANAL RAPTOR, P133
   Blanco G, 2007, ENVIRON MICROBIOL, V9, P1738, DOI 10.1111/j.1462-2920.2007.01291.x
   Blanco G, 2006, J APPL ECOL, V43, P990, DOI 10.1111/j.1365-2664.2006.01200.x
   Carrete M, 2007, BIOL CONSERV, V136, P143, DOI 10.1016/j.biocon.2006.11.025
   Carrete M, 2006, ECOL APPL, V16, P1674, DOI 10.1890/1051-0761(2006)016[1674:DPDIPB]2.0.CO;2
   Carrete M, 2006, BIOL LETTERS, V2, P624, DOI 10.1098/rsbl.2006.0498
   *CMIEET, 2001, INF AV CARR COM POS
   Crozet C, 2007, M S-MED SCI, V23, P1148, DOI 10.1051/medsci/200723121148
   Cuthbert R., 2007, Biology Letters, V3, P91
   DONAZAR JA, 1993, BUITRES IBERICOS
   Donazar Jose A., 1997, P117
   *EMEA, 2004, VET MED EV
   Food and Agriculture Organization, 2006, WHO TECHNICAL REPORT, V939, P1
   Green RE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000686
   Kahn CM, 2005, MERCK VET MANUAL
   Lemus JA, 2009, ENVIRON POLLUT, V157, P2421, DOI 10.1016/j.envpol.2009.03.013
   Lemus JA, 2009, P ROY SOC B-BIOL SCI, V276, P2307, DOI 10.1098/rspb.2009.0071
   Lemus JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001444
   Meteyer CU, 2005, J WILDLIFE DIS, V41, P707, DOI 10.7589/0090-3558-41.4.707
   Montagnac Richard, 2005, Nephrol Ther, V1, P44, DOI 10.1016/j.nephro.2005.02.005
   Sekercioglu CH, 2006, TRENDS ECOL EVOL, V21, P464, DOI 10.1016/j.tree.2006.05.007
   Steinfeld H, 2006, LIVESTOCKS LONG SHAD
   SWAN G., 2006, PLOS BIOL, V4, P396
   Tella JL, 2001, NATURE, V410, P408, DOI 10.1038/35068717
   Zimpfer A, 2004, VIRCHOWS ARCH, V444, P87, DOI 10.1007/s00428-003-0917-9
NR 26
TC 13
Z9 13
U1 3
U2 33
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1367-9430
J9 ANIM CONSERV
JI Anim. Conserv.
PD DEC
PY 2009
VL 12
IS 6
BP 571
EP 580
DI 10.1111/j.1469-1795.2009.00283.x
PG 10
WC Biodiversity Conservation; Ecology
SC Biodiversity & Conservation; Environmental Sciences & Ecology
GA 521VM
UT WOS:000271952900012
DA 2018-12-27
ER

PT J
AU Heidari, A
   Tayyari, SF
   Sammelson, RE
AF Heidari, Alireza
   Tayyari, Sayyed Faramarz
   Sammelson, Robert Erik
TI RETRACTED: An analytical approach to the solitonic solutions in the
   three-component plasma of the positive ion-electron-positron and
   investigating the effect of positron increase on the solitonic wave
   characteristics (Retracted article. See vol. 19, pg. 323, 2014)
SO COMMUNICATIONS IN NONLINEAR SCIENCE AND NUMERICAL SIMULATION
LA English
DT Article; Retracted Publication
DE Positive ion; Electron; Positron; Soliton
ID LARGE-AMPLITUDE; ACOUSTIC SOLITONS; SOLITARY WAVES; PROPAGATION;
   DYNAMICS; DENSITY
AB In this article, we first investigate the conditions of the presence of the solitonic solutions in three-component plasma of the positive ion-electron-positron. Then, we offer the results of the effect of the positron increase on the characteristics of solitonic wave. After investigating the stability of the low-domain solitonic solutions, we research the time evolution of these waves in passing through the border between these two plasma media, which are different in positron density or the ratio of positron and electron temperatures. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Heidari, Alireza; Tayyari, Sayyed Faramarz] Ferdowsi Univ Mashhad, Dept Chem, Mashhad 917751436, Iran.
   [Sammelson, Robert Erik] Ball State Univ, Dept Chem, Muncie, IN 47306 USA.
RP Tayyari, SF (reprint author), Ferdowsi Univ Mashhad, Dept Chem, Mashhad 917751436, Iran.
EM tayyari@ferdowsi.um.ac.ir
CR Antonova M, 2009, COMMUN NONLINEAR SCI, V14, P734, DOI 10.1016/j.cnsns.2007.12.004
   BEREZHIANI VI, 1995, PHYS REV E, V52, P1968, DOI 10.1103/PhysRevE.52.1968
   DAS GC, 1975, PLASMA PHYS CONTR F, V17, P1025, DOI 10.1088/0032-1028/17/12/002
   Emslie A. G., 1988, PHYS SOLAR FLARES
   FRANCIS FC, 1983, INTRO PLASMA PHYS CO
   Miller H R, 1987, ACTIVE GALACTIC NUCL
   Nejoh YN, 1997, AUST J PHYS, V50, P309, DOI 10.1071/P96064
   POPEL SI, 1995, PHYS PLASMAS, V2, P716, DOI 10.1063/1.871422
   Press H. P., 1992, NUMERICAL RECIPES FO
   Sagadeev R.Z., 1966, Reviews of Plasma Physics, P23
   Salahuddin M, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.036407
   Shatashvili NL, 1997, ASTROPHYS SPACE SCI, V250, P109, DOI 10.1023/A:1000406310526
   Sheridan TE, 1999, J APPL PHYS, V86, P3530, DOI 10.1063/1.371254
   Sheridan TE, 1998, J PLASMA PHYS, V60, P17, DOI 10.1017/S0022377898006758
   SURKO CM, 1990, PHYS FLUIDS B-PLASMA, V2, P1372, DOI 10.1063/1.859558
   SURKO CM, 1986, REV SCI INSTRUM, V57, P1862, DOI 10.1063/1.1139154
   TAJIRI M, 1985, J PHYS SOC JPN, V54, P19, DOI 10.1143/JPSJ.54.19
   Wazwaz AM, 2007, COMMUN NONLINEAR SCI, V12, P1395, DOI 10.1016/j.cnsns.2005.11.007
NR 18
TC 4
Z9 4
U1 4
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1007-5704
EI 1878-7274
J9 COMMUN NONLINEAR SCI
JI Commun. Nonlinear Sci. Numer. Simul.
PD DEC
PY 2009
VL 14
IS 12
BP 4090
EP 4099
DI 10.1016/j.cnsns.2009.02.027
PG 10
WC Mathematics, Applied; Mathematics, Interdisciplinary Applications;
   Mechanics; Physics, Fluids & Plasmas; Physics, Mathematical
SC Mathematics; Mechanics; Physics
GA 465MM
UT WOS:000267589600007
DA 2018-12-27
ER

PT J
AU Keri, RS
   Hosamani, KM
   Shingalapur, RV
   Reddy, HRS
AF Keri, Rangappa S.
   Hosamani, Kallappa M.
   Shingalapur, Ramya V.
   Reddy, Harisha R. Seetharama
TI RETRACTED: 2-Azetidinone derivatives: Design, synthesis, in vitro
   anti-microbial, cytotoxic activities and DNA cleavage study (Retracted
   article. See vol. 46, pg. 3177, 2011)
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article; Retracted Publication
DE 2-Azetidinone; Coumarin; Anti-microbial activity; Cytotoxicity; DNA
   cleavage
ID HUMAN CYTOMEGALOVIRUS PROTEASE; BETA-LACTAMS; INHIBITORS; EFFICIENT;
   MECHANISM; ELASTASE
AB A novel series of 3-chloro-4-[4-(2-oxo-2H-chromen-4-ylmethoxy)-phenyl]-1-phenyl-azetidin-2-one derivatives (5a-j) have been synthesized from 4-aryloxymethylcoumarins (la-e) and 4-aryliminomethylphenols (3a-b). The title compounds were screened for their in vitro anti-bacterial and anti-fungal activities. Results revealed that, compounds (5c), (5f), (5h) and (5j) showed excellent anti-microbial activity against a panel of microorganisms. Brine shrimp bioassay was also carried out to study their in vitro cytotoxic properties among which (5h) and (5j) displayed potent cytotoxic activity against Artemia salina. The DNA cleavage activity of some compounds was studied by agarose gel electrophoresis method. All synthesized compounds were characterized using IR, H-1 NMR, C-13 NMR, MS and elemental analysis. (C) 2009 Elsevier Masson SAS. All rights reserved.
C1 [Keri, Rangappa S.; Hosamani, Kallappa M.; Shingalapur, Ramya V.; Reddy, Harisha R. Seetharama] Karnatak Univ, PG Dept Studies Chem, Dharwad 580003, Karnataka, India.
RP Hosamani, KM (reprint author), Karnatak Univ, PG Dept Studies Chem, Pavate Nagar, Dharwad 580003, Karnataka, India.
EM dr_hosamani@yahoo.com
OI /0000-0001-6262-8379
CR Alcaide B, 2002, SYNLETT, P381
   Anaya J, 1999, BIOORGAN MED CHEM, V7, P837, DOI 10.1016/S0968-0896(98)00264-8
   Banik BK, 2004, BIOORGAN MED CHEM, V12, P2523, DOI 10.1016/j.bmc.2004.03.033
   Biradar JS, 2004, INDIAN J CHEM B, V43, P141
   BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001
   Brown K.S. Jr, 1990, Chemoecology, V1, P52, DOI 10.1007/BF01325228
   BURGER A, 1947, J ORG CHEM, V12, P342, DOI 10.1021/jo01166a021
   Castagnolo D, 2004, TETRAHEDRON-ASYMMETR, V15, P941, DOI 10.1016/j.tetasy.2004.01.035
   Chu DTW, 1996, J MED CHEM, V39, P3853, DOI 10.1021/jm960294s
   Delpiccolo CML, 2004, TETRAHEDRON LETT, V45, P4085, DOI 10.1016/j.tetlet.2004.03.145
   Desai JM, 2003, INDIAN J CHEM B, V42, P631
   EAGN D, 1990, DRUG METAB REV, V22, P503
   Finney D. J., 1971, PROBIT ANAL
   Francis JS, 2005, CLIN INFECT DIS, V40, P100, DOI 10.1086/427148
   GEORG GI, 1993, ORGANIC CHEM BETA LA
   Gerard S, 2002, TETRAHEDRON, V58, P2423, DOI 10.1016/S0040-4020(02)00112-6
   Gerona-Navarro G, 2005, J MED CHEM, V48, P2612, DOI 10.1021/jm0492812
   Hosamani KM, 2009, J ENZYM INHIB MED CH, V24, P1095, DOI 10.1080/14756360802632716
   Kruszewska D, 2004, J ANTIMICROB CHEMOTH, V54, P648, DOI 10.1093/jac/dkh387
   KULKARNI MV, 1983, ARCH PHARM, V316, P15, DOI 10.1002/ardp.19833160106
   Kumar A, 2007, BIOORGAN MED CHEM, V15, P3089, DOI 10.1016/j.bmc.2007.01.042
   MEYER BN, 1982, PLANTA MED, V45, P31, DOI 10.1055/s-2007-971236
   Powers JC, 2002, CHEM REV, V102, P4639, DOI 10.1021/cr010182v
   SAHM DF, 1991, ANTIBACTERIAL SUSCEP, P1105
   Singh Girija S., 2005, Farmaco (Lausanne), V60, P727, DOI 10.1016/j.farmac.2005.06.008
   Sperka T, 2005, BIOORG MED CHEM LETT, V15, P3086, DOI 10.1016/j.bmcl.2005.04.020
   Wang W, 2008, BIOORG MED CHEM LETT, V18, P1939, DOI 10.1016/j.bmcl.2008.01.126
   Yoakim C, 1998, J MED CHEM, V41, P2882, DOI 10.1021/jm980131z
NR 28
TC 42
Z9 42
U1 3
U2 17
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD DEC
PY 2009
VL 44
IS 12
BP 5123
EP 5130
DI 10.1016/j.ejmech.2009.09.011
PG 8
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 534WQ
UT WOS:000272928600041
PM 19815315
DA 2018-12-27
ER

PT J
AU Abou-Jaoude, MM
   Nawfal, N
   Najm, R
   Shaheen, J
   Almawi, WY
AF Abou-Jaoude, Maroun M.
   Nawfal, Naji
   Najm, Robert
   Shaheen, Joseph
   Almawi, Wassim Y.
TI RETRACTED: Effect of Pretransplant Hemoglobin Blood Level on Kidney
   Transplant Outcome (Retracted article. See vol. 11, pg. 83, 2013)
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article; Retracted Publication
DE Renal transplant; Dialysis; Transfusion
ID RENAL-TRANSPLANTATION; ANEMIA; HEMATOCRIT; EFFICACY; STAGE
AB Objectives: We investigated the effect of pretransplant hemoglobin level on the outcome of kidney transplant.
   Patients and Methods: Patients were divided in 2 groups: group A < 10 g/dL (80 patients; PTHb < 10 g/dL), and group B > 10 g/dL(69 patients; PTHb >= 10 g/dL), and were matched regarding donor age, recipient sex, blood group, donor-recipient HLA, and Cytomegalovirus status.
   Results: The frequency of acute rejection, together with the timing of rejection, the need for antithymocyte globulin Fresenius rescue therapy, infection rate, and posttransplant surgical complications were comparable between both groups. While the 1-year actuarial patient and graft survival rates, delayed graft function, and slow graft function rates were comparable between both groups, longer hospital stay was required for group B (> 10 g/dL) patients (P = .005). Mean serum creatinine levels upon discharge (P = .02), at 6 months (P = .05), and 1 year (P = .02) after discharge were higher in group B (> 10 g/dL) patients. While posttransplant hemoglobin levels were lower than pretransplant levels, they were higher in group B (> 10 g/dL) compared with group A (< 10 g/dL), (P = .019).
   Conclusions: Pretransplant hemoglobin level does not affect the outcome of kidney transplant, except for creatinine levels at 1 year.
C1 [Almawi, Wassim Y.] Arabian Gulf Univ, Coll Med & Med Sci, Dept Med Biochem, Manama, Bahrain.
   [Najm, Robert; Almawi, Wassim Y.] Lebanese Hosp, Dept Surg, Beirut, Lebanon.
   [Abou-Jaoude, Maroun M.; Nawfal, Naji; Shaheen, Joseph] Sacre Coeur Hosp, Dept Surg, Banbda Hazmieh, Lebanon.
RP Almawi, WY (reprint author), Arabian Gulf Univ, Coll Med & Med Sci, Dept Med Biochem, POB 22979, Manama, Bahrain.
EM wassim@agu.edu.bh
CR Campise M, 2005, NEPHROL DIAL TRANSPL, V20, P8, DOI 10.1093/ndt/gfh1110
   Einollahi B, 2005, TRANSPLANT P, V37, P3101, DOI 10.1016/j.transproceed.2005.08.023
   Fresnedo GF, 2005, TRANSPL P, V37, P3821, DOI 10.1016/j.transproceed.2005.10.054
   GLICKLICH D, 1990, AM J KIDNEY DIS, V15, P46, DOI 10.1016/S0272-6386(12)80591-9
   Joist H, 2006, ADV CHRONIC KIDNEY D, V13, P4, DOI 10.1053/j.ackd.2005.10.002
   Kawaguchi T, 2004, TRANSPLANT P, V36, P1293, DOI 10.1016/j.transproceed.2004.04.089
   Lorenz M, 2005, EUR J CLIN INVEST, V35, P89, DOI 10.1111/j.1365-2362.2005.01535.x
   McMahon LP, 2000, NEPHROL DIAL TRANSPL, V15, P1425, DOI 10.1093/ndt/15.9.1425
   Molnar MZ, 2005, CLIN TRANSPLANT, V19, P825, DOI 10.1111/j.1399-0012.2005.00428.x
   Muirhead N, 1999, KIDNEY INT, V55, pS86, DOI 10.1046/j.1523-1755.1999.055Suppl.69086.x
   Stigant CE, 2000, AM J KIDNEY DIS, V35, P58, DOI 10.1016/S0272-6386(00)70302-7
   Turkowski-Duhem A, 2005, TRANSPLANTATION, V80, P903, DOI 10.1097/01.tp.0000173791.42893.08
   Van Biesen W, 2005, TRANSPLANTATION, V79, P367, DOI 10.1097/01.TP.0000150370.51700.99
NR 13
TC 5
Z9 6
U1 2
U2 10
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD DEC
PY 2009
VL 7
IS 4
BP 214
EP 217
PG 4
WC Transplantation
SC Transplantation
GA 545VL
UT WOS:000273765000003
PM 20353369
DA 2018-12-27
ER

PT J
AU Chourak, M
   Tahiri, MH
   Majbar, A
   Allala, M
   Najih, M
   Iraki, H
   Yaka, M
   Ehrichou, A
   Alkandry, S
AF Chourak, M.
   Tahiri, M. H.
   Majbar, A.
   Allala, M.
   Najih, M.
   Iraki, H.
   Yaka, M.
   Ehrichou, A.
   Alkandry, S.
TI RETRACTED: Colorectal cancer discovered during pregnancy (Retracted
   article. See vol. 38, pg. 385, 2014)
SO GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
LA French
DT Article; Retracted Publication
ID COLON-CANCER; RECTAL-CANCER; CARCINOMA; FLUOROURACIL; LEUCOVORIN;
   MANAGEMENT
AB Colorectal carcinoma during pregnancy is very rare. Prognosis is severe because of the advanced stage due to delay in diagnosis and the aggressiveness of this widespread metastatic disease. We present two cases of colorectal. cancers, discovered during pregnancy, as well as the results of a literature review to apprehend this clinical situation, and we describe recommended medical and surgical management. (C) 2009 Elsevier Masson SAS. All rights reserved.
C1 [Chourak, M.; Tahiri, M. H.; Majbar, A.; Allala, M.; Najih, M.; Iraki, H.; Yaka, M.; Ehrichou, A.; Alkandry, S.] Hop Mil Instruct Mohamed V, Serv Chirurg Viscerale 2, Rabat, Morocco.
RP Chourak, M (reprint author), Appartement 5,Immeuble 6,Bloc 3,3 Ave Massira CYM, Rabat, Morocco.
EM ml.chourak@gmail.com
RI Majbar, Anass/P-6024-2014
OI Majbar, Anass/0000-0003-4329-2026
CR Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   AVILES A, 1991, AM J HEMATOL, V36, P243, DOI 10.1002/ajh.2830360404
   Balloni L, 2000, TUMORI, V86, P95
   BERNSTEIN MA, 1993, DIS COLON RECTUM, V36, P172, DOI 10.1007/BF02051174
   BIRNKRANT A, 1986, DIS COLON RECTUM, V29, P767, DOI 10.1007/BF02555331
   Chan YM, 1999, J REPROD MED, V44, P733
   Chen HP, 2006, RARE METAL MAT ENG, V35, P504
   Kitoh T, 1998, AM J PERINAT, V15, P165, DOI 10.1055/s-2007-993919
   KNOEPP LF, 1973, DIS COLON RECTUM, V16, P305, DOI 10.1007/BF02587706
   Lipton LR, 2004, J CLIN ONCOL, V22, P4934, DOI 10.1200/JCO.2004.11.084
   Mathonnet M, 2003, J CHIR-PARIS, V140, P221
   Minter Alex, 2005, Cancer Control, V12, P196
   Moran BJ, 2007, LANCET ONCOL, V8, P536, DOI 10.1016/S1470-2045(07)70171-7
   PARRY BR, 1994, AUST NZ J SURG, V64, P618, DOI 10.1111/j.1445-2197.1994.tb02304.x
   Pigeau H, 2005, B CANCER, V92, P953
   Saif AW, 2005, CLIN COLORECTAL CANC, V5, P247, DOI 10.3816/CCC.2005.n.035
   Shushan A, 1992, Obstet Gynecol Surv, V47, P222, DOI 10.1097/00006254-199204000-00002
   Walsh C, 1998, GASTROENTEROL CLIN N, V27, P257, DOI 10.1016/S0889-8553(05)70356-3
   Wibe A, 2002, BRIT J SURG, V89, P327, DOI 10.1046/j.0007-1323.2001.02024.x
   Wolmark N, 1999, J CLIN ONCOL, V17, P3553, DOI 10.1200/JCO.1999.17.11.3553
NR 20
TC 3
Z9 4
U1 6
U2 9
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0399-8320
J9 GASTROEN CLIN BIOL
JI Gastroenterol. Clin. Biol.
PD DEC
PY 2009
VL 33
IS 12
BP 1118
EP 1123
DI 10.1016/j.gcb.2009.02.045
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 548MX
UT WOS:000273968600013
PM 19556085
DA 2018-12-27
ER

PT J
AU Miabi, Z
   Nezami, N
   Midia, M
   Midia, R
AF Miabi, Zinat
   Nezami, Nariman
   Midia, Mehran
   Midia, Ramin
TI RETRACTED: Intracranial Displacement of the Eye After Blunt Trauma
   (Retracted article. See vol. 37, pg. 353, 2017)
SO JOURNAL OF NEURO-OPHTHALMOLOGY
LA English
DT Article; Retracted Publication
AB A 67-year-old man fell from an agricultural vehicle and struck his right eye on a protruding element. Eight hours later, he was brought to the emergency unit of an ophthalmology hospital where examiners could not find the right eye and believed it to have been completely destroyed. However, CT disclosed that the eye, apparently still intact, had been displaced into the anterior cranial fossa through a fracture in the orbital roof. This is the first documentation of such a phenomenon.
C1 [Nezami, Nariman] Tabriz Univ Med Sci, Drug Appl Res Ctr, Clin Pharm Lab, Pashmineh, Tabriz, Iran.
   [Miabi, Zinat; Nezami, Nariman] Tabriz Univ Med Sci, Dept Radiol, Pashmineh, Tabriz, Iran.
   [Nezami, Nariman] Tabriz Islamic Azad Univ, Young Researchers Club, Tabriz, Iran.
   [Midia, Mehran] McMaster Univ, Dept Radiol, Hamilton, ON, Canada.
   [Midia, Ramin] Univ Iowa Hlth Care, Dept Radiol, Iowa City, IA USA.
RP Nezami, N (reprint author), Tabriz Univ Med Sci, Drug Appl Res Ctr, Clin Pharm Lab, Daneshgah St, Pashmineh, Tabriz, Iran.
EM dr.nezami@gmail.com
NR 0
TC 2
Z9 2
U1 3
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1070-8022
EI 1536-5166
J9 J NEURO-OPHTHALMOL
JI J. Neuro-Ophthal.
PD DEC
PY 2009
VL 29
IS 4
BP 311
EP 311
DI 10.1097/WNO.0b013e3181bef65b
PG 1
WC Clinical Neurology; Ophthalmology
SC Neurosciences & Neurology; Ophthalmology
GA 530OV
UT WOS:000272603100010
PM 19952906
DA 2018-12-27
ER

PT J
AU Malik, AK
AF Malik, Aruna Kumar
TI RETRACTED: Conflict and Compliance: State Responses to International
   Human Rights Pressure (Retracted article. See vol. 38, pg. 865, 2010)
SO MILLENNIUM-JOURNAL OF INTERNATIONAL STUDIES
LA English
DT Book Review; Retracted Publication
C1 [Malik, Aruna Kumar] Univ Hyderabad, Dept Polit Sci, Sch Social Sci, Hyderabad 500134, Andhra Pradesh, India.
RP Malik, AK (reprint author), Univ Hyderabad, Dept Polit Sci, Sch Social Sci, Hyderabad 500134, Andhra Pradesh, India.
CR CARDENAS S, 2007, CONFLICT CONIPLIANCE
NR 1
TC 1
Z9 1
U1 2
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0305-8298
EI 1477-9021
J9 MILLENNIUM-J INT ST
JI Millennium-J. Int. Stud.
PD DEC
PY 2009
VL 38
IS 2
BP 477
EP 478
DI 10.1177/03058298090380020301
PG 2
WC International Relations
SC International Relations
GA 532GV
UT WOS:000272735300028
DA 2018-12-27
ER

PT J
AU Wenz, T
   Rossi, SG
   Rotundo, RL
   Spiegelman, BM
   Moraes, CT
AF Wenz, Tina
   Rossi, Susana G.
   Rotundo, Richard L.
   Spiegelman, Bruce M.
   Moraes, Carlos T.
TI RETRACTED: Increased muscle PGC-1 alpha expression protects from
   sarcopenia and metabolic disease during aging(Retracted article. See
   vol.113,pg.E8502,2016)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE mitochondria; PGC-1 alpha
ID TRANSCRIPTIONAL COACTIVATOR PGC-1-ALPHA; DUCHENNE MUSCULAR-DYSTROPHY;
   NEUROMUSCULAR-JUNCTION; MITOCHONDRIAL-FUNCTION; CALORIE RESTRICTION;
   SKELETAL-MUSCLE; INFLAMMATORY MARKERS; INSULIN SENSITIVITY; PPAR-GAMMA;
   MICE
AB Aging is a major risk factor for metabolic disease and loss of skeletal muscle mass and strength, a condition known as sarcopenia. Both conditions present a major health burden to the elderly population. Here, we analyzed the effect of mildly increased PGC-1 alpha expression in skeletal muscle during aging. We found that transgenic MCK-PGC-1 alpha animals had preserved mitochondrial function, neuromuscular junctions, and muscle integrity during aging. Increased PGC-1 alpha levels in skeletal muscle prevented muscle wasting by reducing apoptosis, autophagy, and proteasome degradation. The preservation of muscle integrity and function in MCK-PGC-1 alpha animals resulted in significantly improved whole-body health; both the loss of bone mineral density and the increase of systemic chronic inflammation, observed during normal aging, were prevented. Importantly, MCK-PGC-1 alpha animals also showed improved metabolic responses as evident by increased insulin sensitivity and insulin signaling in aged mice. Our results highlight the importance of intact muscle function and metabolism for whole-body homeostasis and indicate that modulation of PGC-1 alpha levels in skeletal muscle presents an avenue for the prevention and treatment of a group of age-related disorders.
C1 [Wenz, Tina; Moraes, Carlos T.] Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Rossi, Susana G.; Rotundo, Richard L.; Moraes, Carlos T.] Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
   [Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Cell Biol, Boston, MA 02115 USA.
RP Moraes, CT (reprint author), Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
FU Public Health Service [NS041777, CA85700, EY10804, AG0005917, DK61562,
   DK54477]; Muscular Dystrophy Association; Ellison Foundation; United
   Mitochondrial Disease Foundation
FX This work was supported by Public Health Service Grants NS041777,
   CA85700, and EY10804 (to C. T. M.); AG0005917 (to R. L. R.); and DK61562
   and DK54477 (to B. M. S.); the Muscular Dystrophy Association (C. T.
   M.); and the Ellison Foundation (B. M. S.). Dr. Wenz was supported by a
   fellowship from the United Mitochondrial Disease Foundation.
CR Adhihetty PJ, 2009, AM J PHYSIOL-CELL PH, V297, pC217, DOI 10.1152/ajpcell.00070.2009
   Anderson R, 2009, BBA-GEN SUBJECTS, V1790, P1059, DOI 10.1016/j.bbagen.2009.04.005
   Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613
   Armoni M, 2007, TRENDS ENDOCRIN MET, V18, P100, DOI 10.1016/j.tem.2007.02.001
   Bonkowski MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004567
   Calvo JA, 2008, J APPL PHYSIOL, V104, P1304, DOI 10.1152/japplphysiol.01231.2007
   Cesari M, 2003, AM J CARDIOL, V92, P522, DOI 10.1016/S0002-9149(03)00718-5
   Choi CS, 2008, P NATL ACAD SCI USA, V105, P19926, DOI 10.1073/pnas.0810339105
   Chung HY, 2009, AGEING RES REV, V8, P18, DOI 10.1016/j.arr.2008.07.002
   COURTNEY J, 1981, J PHYSIOL-LONDON, V320, P435, DOI 10.1113/jphysiol.1981.sp013960
   Dela F, 2006, ESSAYS BIOCHEM, V42, P75, DOI 10.1042/bse0420075
   Desai VG, 1996, ARCH BIOCHEM BIOPHYS, V333, P145, DOI 10.1006/abbi.1996.0375
   Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476
   Glaros T, 2009, FRONT BIOSCI-LANDMRK, V14, P3988, DOI 10.2735/3506
   GOLDSPINK G, 1994, NEUROMUSCULAR DISORD, V4, P183, DOI 10.1016/0960-8966(94)90019-1
   Guarente L, 2008, CELL, V132, P171, DOI 10.1016/j.cell.2008.01.007
   Handschin C, 2007, GENE DEV, V21, P770, DOI 10.1101/gad.1525107
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Lima RM, 2009, J CLIN DENSITOM, V12, P35, DOI 10.1016/j.jocd.2008.10.003
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Mammucari C, 2008, AUTOPHAGY, V4, P524, DOI 10.4161/auto.5905
   Marcell TJ, 2003, J GERONTOL A-BIOL, V58, P911, DOI 10.1093/gerona/58.10.M911
   Marzetti E, 2009, BIOFACTORS, V35, P28, DOI 10.1002/biof.5
   MCDOUALL RM, 1990, J NEUROL SCI, V99, P199, DOI 10.1016/0022-510X(90)90156-H
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200
   Ravaglia G, 2007, NEUROBIOL AGING, V28, P1810, DOI 10.1016/j.neurobiolaging.2006.08.012
   Rolland Y, 2008, J NUTR HEALTH AGING, V12, P433, DOI 10.1007/BF02982704
   Rotundo RL, 2003, J NEUROCYTOL, V32, P743, DOI 10.1023/B:NEUR.0000020621.58197.d4
   Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103
   Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007
   Sung HK, 2009, AM J PHYSIOL-ENDOC M, V297, pE402, DOI 10.1152/ajpendo.00122.2009
   Taaffe Dennis R, 2006, Aust Fam Physician, V35, P130
   TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006
   Wenz T, 2009, J APPL PHYSIOL, V106, P1712, DOI 10.1152/japplphysiol.91571.2008
NR 38
TC 408
Z9 429
U1 6
U2 53
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 1
PY 2009
VL 106
IS 48
BP 20405
EP 20410
DI 10.1073/pnas.0911570106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 525YQ
UT WOS:000272254400050
PM 19918075
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Trucco, A
   Gaspar, I
   Ephrussi, A
AF Trucco, Alvar
   Gaspar, Imre
   Ephrussi, Anne
TI RETRACTED: Assembly of Endogenous oskar mRNA Particles for
   Motor-Dependent Transport in the Drosophila Oocyte (Retracted article.
   See vol. 143, pg. 485, 2010)
SO CELL
LA English
DT Article; Retracted Publication
ID RESTRICTS POLE PLASM; POSTERIOR LOCALIZATION; MAGO NASHI; HNRNPA/B
   HOMOLOG; CELL-FORMATION; LIGHT-CHAIN; GERM PLASM; KINESIN I; DYNEIN;
   POLARITY
AB oskar mRNA localization at the oocyte posterior pole is essential for correct patterning of the Drosophila embryo. Here we show at the ultrastructural level that endogenous oskar ribonucleoprotein complexes (RNPs) assemble sequentially with initial recruitment of Hrp48 and the exon junction complex (EJC) to oskar transcripts in the nurse cell nuclei, and subsequent recruitment of Staufen and microtubule motors, following transport to the cytoplasm. oskar particles are non-membrane-bound structures that coalesce as they move from the oocyte anterior to the posterior pole. Our analysis uncovers a role for the EJC component Barentsz in recruiting Tropomyosin II (TmII) to oskar particles in the ooplasm and reveals that TmII is required for kinesin binding to the RNPs. Finally, we show that both kinesin and dynein associate with oskar particles and are the primary microtubule motors responsible for transport of the RNPs within the oocyte.
C1 [Trucco, Alvar; Gaspar, Imre; Ephrussi, Anne] European Mol Biol Lab, Dev Biol Unit, D-69117 Heidelberg, Germany.
RP Ephrussi, A (reprint author), European Mol Biol Lab, Dev Biol Unit, Meyerhofstr 1, D-69117 Heidelberg, Germany.
EM ephrussi@embl.de
OI Ephrussi, Anne/0000-0002-5061-4620
FU FEBS
FX We thank Bram Herpers and Catherine Rabouille for sharing their
   expertise in ISH-EM, Tom Hays for the PEP1 antibody, and Daniel St
   Johnston for the oskMS2-GFP flies. We also thank C. Antony, U.
   Haselmann, J. Richie, and the EMBL EM Core Facility for technical
   support, the EMBL ALMF for use of the LSM710, and F. Besse, S. Lopez de
   Quinto, S. De Renzis, S. Ghosh, and V. Marchand for comments on the
   manuscript and P. Riedinger for Figure S14. A. T. is supported by a FEBS
   long-term fellowship.
CR Brendza RP, 2000, SCIENCE, V289, P2120, DOI 10.1126/science.289.5487.2120
   Brendza RP, 2002, CURR BIOL, V12, P1541, DOI 10.1016/S0960-9822(02)01108-9
   Bullock SL, 2006, CURR BIOL, V16, P1447, DOI 10.1016/j.cub.2006.05.055
   Cha BJ, 2002, NAT CELL BIOL, V4, P592
   Clark A, 2007, DEVELOPMENT, V134, P1955, DOI 10.1242/dev.02832
   CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3
   Cohen RS, 2005, BIOL CELL, V97, P5
   Delanoue R, 2007, DEV CELL, V13, P523, DOI 10.1016/j.devcel.2007.08.022
   EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N
   EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0
   ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0
   Hachet O, 2004, NATURE, V428, P959, DOI 10.1038/nature02521
   Hachet O, 2001, CURR BIOL, V11, P1666, DOI 10.1016/S0960-9822(01)00508-5
   Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519
   Huynh JR, 2004, DEV CELL, V6, P625, DOI 10.1016/S1534-5807(04)00130-3
   Januschke J, 2006, DEVELOPMENT, V133, P129, DOI 10.1242/dev.02179
   KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M
   LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2
   LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475
   Martin KC, 2009, CELL, V136, P719, DOI 10.1016/j.cell.2009.01.044
   Micklem DR, 2000, EMBO J, V19, P1366, DOI 10.1093/emboj/19.6.1366
   Micklem DR, 1997, CURR BIOL, V7, P468, DOI 10.1016/S0960-9822(06)00218-1
   Mische S, 2007, MOL BIOL CELL, V18, P2254, DOI 10.1091/mbc.E06-10-0959
   Mohr SE, 2001, GENE DEV, V15, P2886
   Navarro C, 2004, NAT CELL BIOL, V6, P427, DOI 10.1038/ncb1122
   NEWMARK PA, 1994, DEVELOPMENT, V120, P1303
   Palacios IM, 2002, DEVELOPMENT, V129, P5473, DOI 10.1242/dev.00119
   Palacios IM, 2004, NATURE, V427, P753, DOI 10.1038/nature02351
   Serbus LR, 2005, DEVELOPMENT, V132, P3743, DOI 10.1242/dev.01956
   St Johnston D, 2005, NAT REV MOL CELL BIO, V6, P363, DOI 10.1038/nrm1643
   STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O
   THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169
   van Eeden FJM, 2001, J CELL BIOL, V154, P511, DOI 10.1083/jcb.200105056
   Vanzo N, 2007, DEV CELL, V12, P543, DOI 10.1016/j.devcel.2007.03.002
   Vanzo NF, 2002, DEVELOPMENT, V129, P3705
   Wilhelm JE, 2000, J CELL BIOL, V148, P427, DOI 10.1083/jcb.148.3.427
   Yano T, 2004, DEV CELL, V6, P637, DOI 10.1016/S1534-5807(04)00132-7
   Zimyanin VL, 2008, CELL, V134, P843, DOI 10.1016/j.cell.2008.06.053
NR 38
TC 9
Z9 9
U1 3
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD NOV 25
PY 2009
VL 139
IS 5
BP 983
EP 998
DI 10.1016/j.cell.2009.10.012
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 524UR
UT WOS:000272169400021
PM 19945381
OA Bronze
DA 2018-12-27
ER

PT J
AU Hosseini, E
   Kazeminezhad, M
AF Hosseini, E.
   Kazeminezhad, M.
TI RETRACTED: Nanostructure and mechanical properties of 0-7 strained
   aluminum by CGP: XRD, TEM and tensile test (Retracted article. See vol.
   640, pg. 480, 2015)
SO MATERIALS SCIENCE AND ENGINEERING A-STRUCTURAL MATERIALS PROPERTIES
   MICROSTRUCTURE AND PROCESSING
LA English
DT Article; Retracted Publication
DE CGP; XRD; Mechanical properties; Nanostructure; TEM
ID SEVERE PLASTIC-DEFORMATION; BONDING ARB PROCESS; CHANNEL ANGULAR
   EXTRUSION; X-RAY-DIFFRACTION; AL-MG ALLOY; GRAIN-REFINEMENT;
   MICROSTRUCTURE; BEHAVIOR; EVOLUTION; COPPER
AB Commercial purity aluminum sheets are subjected to a severe plastic deformation technique called constrained groove pressing. In this study for the first time by using some technical optimizations, a strain magnitude of 6.9 is imposed to the sheets. The grain size evolution during severe plastic deformation is studied using Williamson-Hall analysis on X-ray diffraction pattern of the deformed samples. These results and transmission electron microscopy observations show that constrained groove pressing process can effectively refine the coarse-grained structure to an ultrafine grain range. The results of mechanical tests show that imposing strain in range of 0-5.75 causes to strengthening of sheets, however imposing more strain reduces the strength and hardness of the sheets. Considering the hardness results and effect of specimen thinning before tensile test on yield stress and UTS, it is concluded that two mechanisms of micro-cracking and flow softening cause to observe a strength drop in the tensile test results of sheets with its original thickness. Also, the results show that the constrained groove pressing process causes to decrease of work hardening rate and increase of strain rate sensitivity of the sheets material. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Hosseini, E.; Kazeminezhad, M.] Sharif Univ Technol, Dept Mat Sci & Engn, Tehran, Iran.
RP Kazeminezhad, M (reprint author), Sharif Univ Technol, Dept Mat Sci & Engn, Azadi Ave, Tehran, Iran.
EM mkazemi@sharif.edu
RI Hosseini, Ehsan/D-1737-2009
OI Hosseini, Ehsan/0000-0002-8288-3139
FU Sharif University of Technology
FX The authors wish to thank the research board of Sharif University of
   Technology for the financial support and the provision of the research
   facilities used in this work.
CR Chakkingal U, 1998, SCRIPTA MATER, V39, P677, DOI 10.1016/S1359-6462(98)00234-6
   Cziraki A, 1995, NANOSTRUCT MATER, V6, P547
   Dieter G. E., 1986, MECH METALLURGY
   Estrin Y, 2008, J MECH PHYS SOLIDS, V56, P1186, DOI 10.1016/j.jmps.2007.10.004
   Gubicza J, 2006, CURR APPL PHYS, V6, P194, DOI 10.1016/j.cap.2005.07.039
   Hosseini E, 2009, COMP MATER SCI, V45, P855, DOI 10.1016/j.commatsci.2008.12.004
   Hosseini E, 2009, INT J REFRACT MET H, V27, P605, DOI 10.1016/j.ijrmhm.2008.09.006
   Hosseini E, 2009, COMP MATER SCI, V44, P1107, DOI 10.1016/j.commatsci.2008.07.024
   Hosseini E, 2009, J MATER SCI, V44, P1212, DOI 10.1007/s10853-009-3261-x
   Hosseini E, 2009, COMP MATER SCI, V44, P962, DOI 10.1016/j.commatsci.2008.07.002
   Huang JY, 2001, ACTA MATER, V49, P1497, DOI 10.1016/S1359-6454(01)00069-6
   Kapoor R, 2007, ACTA MATER, V55, P5408, DOI 10.1016/j.actamat.2007.05.049
   Kazeminezhad M, 2008, J MATER SCI, V43, P6081, DOI 10.1007/s10853-008-2953-y
   Korznikov A. V., 1994, Nanostructured Materials, V4, P159, DOI 10.1016/0965-9773(94)90075-2
   Krishnaiah A, 2005, MAT SCI ENG A-STRUCT, V410, P337, DOI 10.1016/j.msea.2005.08.101
   Krishnaiah A, 2005, SCRIPTA MATER, V52, P1229, DOI 10.1016/j.scriptamat.2005.03.001
   Kwan C, 2008, MAT SCI ENG A-STRUCT, V480, P148, DOI 10.1016/j.msea.2007.07.022
   Lee JW, 2002, J MATER PROCESS TECH, V130, P208, DOI 10.1016/S0924-0136(02)00722-7
   Lee SH, 2002, SCRIPTA MATER, V46, P281, DOI 10.1016/S1359-6462(01)01239-8
   Markushev MV, 1999, NANOSTRUCT MATER, V12, P839, DOI 10.1016/S0965-9773(99)00247-0
   Mckenzie PWJ, 2007, ACTA MATER, V55, P2985, DOI 10.1016/j.actamat.2006.12.038
   Mukherjee P, 2004, ACTA MATER, V52, P5687, DOI 10.1016/j.actamat.2004.08.030
   Pirgazi H, 2008, MAT SCI ENG A-STRUCT, V497, P132, DOI 10.1016/j.msea.2008.06.025
   Rao KV, 2008, J PHYS CHEM SOLIDS, V69, P87, DOI 10.1016/j.jpcs.2007.08.006
   Roters F, 2000, ACTA MATER, V48, P4181, DOI 10.1016/S1359-6454(00)00289-5
   Saito Y, 1999, ACTA MATER, V47, P579, DOI 10.1016/S1359-6454(98)00365-6
   Saito Y, 1998, SCRIPTA MATER, V39, P1221, DOI 10.1016/S1359-6462(98)00302-9
   Salishchev G, 1995, NANOSTRUCT MATER, V6, P913, DOI 10.1016/0965-9773(95)00208-1
   Shin DH, 2002, MAT SCI ENG A-STRUCT, V328, P98, DOI 10.1016/S0921-5093(01)01665-3
   Tham YW, 2007, J MATER PROCESS TECH, V192, P575, DOI 10.1016/j.jmatprotec.2007.04.076
   Tsuji N, 1999, SCRIPTA MATER, V40, P795, DOI 10.1016/S1359-6462(99)00015-9
   Valiev RZ, 1996, SCRIPTA MATER, V34, P1443, DOI 10.1016/1359-6462(95)00676-1
   Wang YM, 2004, ACTA MATER, V52, P1699, DOI 10.1016/j.actamat.2003.12.022
   Wei Q, 2003, MAT SCI ENG A-STRUCT, V358, P266, DOI 10.1016/S0921-5093(03)00305-8
   Zhang Z, 2003, METALL MATER TRANS A, V34A, P1349, DOI 10.1007/s11661-003-0246-2
   Zhao YH, 2008, SCRIPTA MATER, V59, P627, DOI 10.1016/j.scriptamat.2008.05.031
   Zhao YH, 2009, MAT SCI ENG A-STRUCT, V525, P68, DOI 10.1016/j.msea.2009.06.031
   Zrnik J, 2009, MAT SCI ENG A-STRUCT, V503, P126, DOI 10.1016/j.msea.2008.03.050
NR 38
TC 59
Z9 62
U1 3
U2 26
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0921-5093
EI 1873-4936
J9 MAT SCI ENG A-STRUCT
JI Mater. Sci. Eng. A-Struct. Mater. Prop. Microstruct. Process.
PD NOV 25
PY 2009
VL 526
IS 1-2
BP 219
EP 224
DI 10.1016/j.msea.2009.07.028
PG 6
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Metallurgy & Metallurgical Engineering
SC Science & Technology - Other Topics; Materials Science; Metallurgy &
   Metallurgical Engineering
GA 514AW
UT WOS:000271366700034
DA 2018-12-27
ER

PT J
AU Xiong, W
   Niu, PY
   Zhu, WT
   Chen, J
AF Xiong Wei
   Niu Peng-yan
   Zhu Wen-tao
   Chen Jing
TI RETRACTED: Tenascin-C as a prognostic biomarker in osteosarcoma?
   (Retracted article. See vol. 124, pg. 1120, 2011)
SO CHINESE MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
DE osteosarcoma; metastasis; Tenascin-C
ID EXTRACELLULAR-MATRIX COMPONENTS; BREAST-CANCER; EXPRESSION;
   CHEMOTHERAPY; PROGRESSION; SURVIVAL; GLYCOPROTEINS; ASSOCIATION;
   METASTASES; SIGNATURE
AB Background Treating metastatic osteosarcoma has been challenged in past decades. Extracelluar matrix (ECM) proteins play an important role in the progression of osteosarcoma as they are pivotal components of the tumor microenvironment. Here, we identified potential genes belonging to the ECM and characterized the roles of these genes in the progression of osteosarcoma and their association with outcomes.
   Methods Osteosarcoma parental cell line MG63 and its derivative MG63-A1 with a high metastatic potential underwent oligonucleotide microarray analysis. Gene ontology analysis was used to screen deregulated genes between the 2 cell lines which were either upregulated or downregulated by more than 4 fold, particularly focusing on mRNAs encoding extracellular matrix proteins. The expression of resulting candidate genes was then validated by reverse transcription-PCR for mRNA expression as well as Western blotting for protein expression. Immunohistochemistry was performed on 37 osteosarcoma specimens to examine the potential role of the candidate genes in a clinical context.
   Results Microarray data and gene ontology analysis showed that Tenascin-C, a critical component of the ECM, is significantly down-regulated in the highly metastatic cell line MG63-A1 compared with the parental osteosarcoma cell line MG63-wt. This finding was validated at mRNA and protein levels. Immunohistochemical analysis found that Tenascin-C is located in the intercellular space in osteosarcoma specimens. Furthermore, low-grade Tenascin-C expression (less than 20%) in osteosarcoma specimens was associated with poor survival.
   Conclusions Tenascin-C expression level correlates with the survival of osteosarcoma patients. Its biological functional role and underlying molecular mechanisms in the progression of osteosarcoma needs further investigation. Chin Med J 2009;122(22):2737-2743
C1 [Chen Jing] Huazhong Univ Sci & Technol, Dept Nucl Med, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.
   [Xiong Wei; Niu Peng-yan; Zhu Wen-tao] Huazhong Univ Sci & Technol, Dept Orthopaed, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.
RP Chen, J (reprint author), Huazhong Univ Sci & Technol, Dept Nucl Med, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.
EM wellcj@sina.com
FU Scientific Research Foundation
FX This research was supported by a grant from the Scientific Research
   Foundation for the Returned Overseas Chinese Scholars, State Education
   Ministry of China.
CR Assoian RK, 1996, J CLIN INVEST, V98, P2436, DOI 10.1172/JCI119059
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7
   Brunner A, 2004, J CLIN PATHOL, V57, P927, DOI 10.1136/jcp.2004.016576
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415
   Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5
   Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947
   Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490
   Hauben EI, 2002, EUR J CANCER, V38, P1218, DOI 10.1016/S0959-8049(02)00037-0
   HELFRICH MH, 1992, J BONE MINER RES, V7, P335
   Ioachim E, 2005, BJU INT, V95, P655, DOI 10.1111/j.1464-410X.2005.05357.x
   Ishiwata T, 2005, ANTICANCER RES, V25, P489
   Iskaros BF, 1997, J SURG ONCOL, V64, P98, DOI 10.1002/(SICI)1096-9098(199702)64:2<98::AID-JSO2>3.0.CO;2-J
   Jia SF, 1999, CLIN EXP METASTAS, V17, P501, DOI 10.1023/A:1006623001465
   JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577
   Kaarteenaho-Wiik R, 2003, HISTOPATHOLOGY, V42, P280, DOI 10.1046/j.1365-2559.2003.01568.x
   Korshunov A, 1999, Brain Tumor Pathol, V16, P37, DOI 10.1007/BF02478900
   Lev DC, 2003, CLIN EXP METASTAS, V20, P515
   Lewin A, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-426
   Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994
   Mackie EJ, 1998, MICROSC RES TECHNIQ, V43, P102
   Mackie EJ, 1996, J CELL SCI, V109, P1597
   Man TK, 2005, CANCER RES, V65, P8142, DOI 10.1158/0008-5472.CAN-05-0985
   Melillo G, 2006, CANCER RES, V66, P4558, DOI 10.1158/0008-5472.CAN'-06-0069
   Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008-5472.CAN-04-2463
   Nakano T, 2003, CLIN EXP METASTAS, V20, P665, DOI 10.1023/A:1027355610603
   Navazo MDP, 2001, J IMMUNOL, V167, P6431, DOI 10.4049/jimmunol.167.11.6431
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101
   Orend G, 2006, CANCER LETT, V244, P143, DOI 10.1016/j.canlet.2006.02.017
   Pilch H, 1999, GYNECOL ONCOL, V73, P415, DOI 10.1006/gyno.1999.5405
   Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142
   Shi XB, 2005, CHINESE MED J-PEKING, V118, P687
   Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071
   Suwiwat S, 2004, CLIN CANCER RES, V10, P2491, DOI 10.1158/1078-0432.CCR-03-0146
   Tanaka M, 2000, INT J MOL MED, V5, P505
   Tokes AE, 1999, ANTICANCER RES, V19, P175
   Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Zamecnik J, 2004, NEOPLASMA, V51, P214
   Zirbes TK, 1999, INT J MOL MED, V4, P39
NR 42
TC 5
Z9 5
U1 5
U2 18
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD NOV 20
PY 2009
VL 122
IS 22
BP 2737
EP 2743
DI 10.3760/cma.j.issn.0366-6999.2009.22.012
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 530HP
UT WOS:000272580300012
PM 19951606
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Sheikpranbabu, S
   Haribalaganesh, R
   Banumathi, E
   Sirishkumar, N
   Lee, KJ
   Gurunathan, S
AF Sheikpranbabu, Sardarpasha
   Haribalaganesh, Ravinarayanan
   Banumathi, Elayappan
   Sirishkumar, Namagiri
   Lee, Kyung-Jin
   Gurunathan, Sangiliyandi
TI RETRACTED: Pigment epithelium-derived factor inhibits advanced glycation
   end-product-induced angiogenesis and stimulates apoptosis in retinal
   endothelial cells (Retracted article. See vol. 89, pg. 504, 2011)
SO LIFE SCIENCES
LA English
DT Article; Retracted Publication
DE Pigment epithelium-derived factor (PEDF); Advanced glycation
   end-products (AGEs); Angiogenesis; Caspase-3; Apoptosis; Diabetic
   retinopathy
ID FORKHEAD TRANSCRIPTION FACTOR; PROTEIN-KINASE B; OXIDANT STRESS;
   GROWTH-FACTOR; FACTOR PEDF; FACTOR FKHR; EXPRESSION; RECEPTOR; CULTURE;
   PATHWAY
AB Aims: The purpose of this study was to investigate the effect of pigment epithelium-derived factor (PEDF) on the signaling cascade in porcine retinal endothelial cells (PRECs) related to angiogenesis induced by advanced glycation end-products (AGEs).
   Main methods: Endothelial cells were isolated from porcine retina by the enzymatic method. Immunocytochemistry was performed to confirm the identity of PRECs. The effect of AGEs and PEDF on cell viability was determined by the MTT assay. An in vitro wound-scratch assay was performed to study the migration of ECs, and in vitro tube formation was assessed by the on-gel assay system using an extracellular matrix. Inhibitor assays were carried out using LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, and Akt inhibitor VIII. PI3K/Akt activity was assessed by transient transfection and western blot analysis. Induction of apoptosis by PEDF was determined by caspase-3 colorimetric assay and DNA fragmentation analysis.
   Key findings: Treatment of PRECs with AGE-bovine serum albumin (AGE-BSA) significantly increased the cell proliferation, migration and tube formation compared to non-glycated BSA. AGE-BSA mediates cell survival via the PI3K/Akt/FKHR-dependent pathway as evidenced by transient transfection and western blot analyses. Furthermore, PEDF significantly inhibited the proliferation, migration and tube formation, both in the presence and absence of AGE-BSA in PRECs. PEDF inactivated the AGE-BSA-induced PI3K/Akt/FKHR activity and induced apoptosis via caspase-3.
   Significance: The results reveal that PEDF inhibits AGE-BSA-induced PI3K/Akt/FKHR signaling in PRECs. Thus, PEDF has potent anti-angiogenic effects against AGE-induced angiogenesis and is suggested to be a promising molecule for the treatment of diabetic retinopathy. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Sheikpranbabu, Sardarpasha; Haribalaganesh, Ravinarayanan; Banumathi, Elayappan; Gurunathan, Sangiliyandi] Kalasalingam Univ, Div Mol & Cellular Biol, Dept Biotechnol, Krishnankoil 626190, Tamil Nadu, India.
   [Sirishkumar, Namagiri] Meenakshi Mission Hosp & Res Ctr, Dept Ophthalmol, Madurai 625107, Tamil Nadu, India.
   [Lee, Kyung-Jin] Gwangju Inst Sci & Technol, Dept Life Sci, Cell Dynam Res Ctr, Kwangju 500712, South Korea.
RP Gurunathan, S (reprint author), Kalasalingam Univ, Div Mol & Cellular Biol, Dept Biotechnol, Krishnankoil 626190, Tamil Nadu, India.
EM lvsangs@yahoo.com
FU Department of Biotechnology (DBT), Ministry of Science and Technology,
   New Delhi [BT/PR/7704/MED/14/1065/2006]; University Grants Commission
   (UGC), New Delhi [F.10-4/2005/SA-I]
FX This study was supported by grants from the Department of Biotechnology
   (DBT), Ministry of Science and Technology, New Delhi (Sanction Letter
   No. BT/PR/7704/MED/14/1065/2006) and the University Grants Commission
   (UGC), New Delhi (Grant No. F.10-4/2005/SA-I). We thank Dr. H. Nellaiah
   and Mr. V. Deepak for critical reading of this manuscript.
CR Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1
   Banumathi E, 2009, MICROVASC RES, V77, P377, DOI 10.1016/j.mvr.2008.12.005
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Cha ST, 2005, MICROVASC RES, V70, P198, DOI 10.1016/j.mvr.2005.08.002
   Chen LL, 2006, BIOCHEM BIOPH RES CO, V348, P1288, DOI 10.1016/j.bbrc.2006.07.188
   Chibber R, 1997, DIABETOLOGIA, V40, P156, DOI 10.1007/s001250050657
   Cohen J, 2000, NEUROIMMUNOMODULAT, V7, P51, DOI 10.1159/000026420
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Frye CA, 2002, IN VITRO CELL DEV-AN, V38, P208
   Goldin A, 2006, CIRCULATION, V114, P597, DOI 10.1161/CIRCULATIONAHA.106.621854
   HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752
   Hutchings H, 2002, BIOCHEM BIOPH RES CO, V294, P764, DOI 10.1016/S0006-291X(02)00548-X
   Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897
   Kaji Y, 2003, INVEST OPHTH VIS SCI, V44, P521, DOI 10.1167/iovs.02-0268
   Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810
   Moore TCB, 2003, INVEST OPHTH VIS SCI, V44, P4457, DOI 10.1167/iovs.02-1063
   Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982
   Ren JG, 2005, MED HYPOTHESES, V64, P74, DOI 10.1016/j.mehy.2004.05.016
   Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179
   Sakata N, 2000, J Atheroscler Thromb, V7, P169
   Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005
   Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641
   Stitt Alan W., 2000, Molecular Cell Biology Research Communications, V3, P380, DOI 10.1006/mcbr.2000.0243
   Stitt AW, 2005, PHARMACOL REP, V57, P156
   Stitt AW, 2005, DIABETES, V54, P785, DOI 10.2337/diabetes.54.3.785
   SU T, 1992, INVEST OPHTH VIS SCI, V33, P2809
   Su XJ, 2003, MOL VIS, V9, P171
   Sugita Y, 1997, J NEUROSCI RES, V49, P710, DOI 10.1002/(SICI)1097-4547(19970915)49:6<710::AID-JNR5>3.3.CO;2-4
   Tanaka N, 2000, J BIOL CHEM, V275, P25781, DOI 10.1074/jbc.M001235200
   Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741
   Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998
   TEZUKA M, 1993, BIOCHEM BIOPH RES CO, V193, P674, DOI 10.1006/bbrc.1993.1677
   Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648
   Tombran-Tink J, 2003, TRENDS MOL MED, V9, P244, DOI 10.1016/S1471-4914(03)00074-1
   Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200
   Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349
   WANGER DD, 1982, J CELL BIOL, V95, P355
   Wautier JL, 2001, DIABETES METAB, V27, P535
   WONG HC, 1987, INVEST OPHTH VIS SCI, V28, P1767
   Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723
   Yamagishi S, 2003, INT J CLIN PHARM RES, V23, P129
   Yamagishi SI, 2007, OPHTHAL RES, V39, P92, DOI 10.1159/000099244
   Yamagishi S, 2006, J BIOL CHEM, V281, P20213, DOI 10.1074/jbc.M602110200
   Yan Q, 1996, INVEST OPHTH VIS SCI, V37, P2185
   YAN SD, 1994, J BIOL CHEM, V269, P9889
   Yoshida T, 2006, FEBS LETT, V580, P2788, DOI 10.1016/j.febslet.2006.04.050
   ZBIGNIEW RT, 1990, P NATL ACAD SCI USA, V88, P617
NR 49
TC 21
Z9 21
U1 3
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD NOV 18
PY 2009
VL 85
IS 21-22
BP 719
EP 731
DI 10.1016/j.lfs.2009.09.015
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 520DY
UT WOS:000271821500001
PM 19818798
DA 2018-12-27
ER

PT J
AU Wang, MY
   Sun, HS
   Zhang, W
   Zhang, YC
AF Wang, Meiying
   Sun, Hongsheng
   Zhang, Wei
   Zhang, Yuanchao
TI RETRACTED: Functional activation of proline-rich tyrosine kinase2 (PYK2)
   in peripheral blood mononuclear cells from patients with systemic lupus
   erythematosus (Retracted article. See vol. 16, pg. 152, 2015)
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article; Retracted Publication
ID FOCAL ADHESION KINASE; T-CELLS; RHEUMATOID-ARTHRITIS; INCREASED
   EXPRESSION; SIGNAL-TRANSDUCTION; AUTOIMMUNE-DISEASE; REVISED CRITERIA;
   MURINE LUPUS; CD40 LIGAND; PHOSPHORYLATION
AB Background: Systemic lupus erythematosus (SLE) is a representative systemic autoimmune disease characterized by activated T cells and polyclonally activated B cells that produce autoantibodies. Activation of autoreactive T and B cells plays a pivotal role in the pathogenesis of this disease. A role of focal adhesion kinase (FAK) in the pathogenesis has been suggested. Prolinerich tyrosine kinase2 (PYK2) is structurally related to FAK, however, the functional activation of PYK2 in SLE remains unclear. In the present study, we showed that PYK2 is significantly increased and activated in peripheral blood mononuclear cells (PBMCs) of patients with SLE. In addition, we showed the involvement of PYK2 proteins in the up-regulation of CD40L and CTLA4 expression and PBMC proliferation.
   Methods: Freshly isolated PBMCs from 48 SLE patients, 32 patients with rheumatoid arthritis(RA) and 24 healthy individuals were analyzed for the expression and activation of PYK2 by western-blotting and immunocytochemistry. The other isolated PBMCs from patients with this condition were cultured and stimulated with PMA or TyrA9, and then the expression of costimulatory molecules CD40L and CTLA4 was evaluated using flow cytometry, PBMCs proliferation was determined with [H-3]-thymidine incorporation (CPM).
   Results: Compared with RA patients and healthy donors, PBMCs from SLE patients expressed more of both the total PYK2 protein and its activated/phosphorylated form. The increase of activated PYK2 protein in SLE PBMCs was correlated with the complication of nephritis and inversly associated the level of serum complements. In active SLE patients, activation of PYK2 in PBMCs is accompanying the increased cell proliferation and the induced expression of costimulatory molecules CD40L and CTLA4.
   Conclusion: Our findings indicate that phosphorylated PYK2 in SLE PBMCs may induce the expression of CD40L and CTLA4, and subsequently the cell proliferation. PYK2 signaling enhances the autoreactive lymphocyte activation and plays an important role in the pathogenesis of SLE.
C1 [Wang, Meiying; Sun, Hongsheng; Zhang, Yuanchao] Shandong Univ, Prov Hosp Affiliated, Dept Rheumatol & Immunol, Jinan 250021, Peoples R China.
   [Zhang, Wei] Qingdao Univ, Coll Med, Hosp Affiliated, Dept Pain Management, Qingdao 266003, Peoples R China.
RP Zhang, YC (reprint author), Shandong Univ, Prov Hosp Affiliated, Dept Rheumatol & Immunol, Jinan 250021, Peoples R China.
EM wmy99wmy99@yahoo.cn; sunhongsheng_shs@126.com; zw99zw99@126.com;
   sdfs2004@sohu.com
CR ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302
   Berg NN, 1997, J IMMUNOL, V159, P1753
   BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606
   Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793
   Dayal AK, 1996, ARTHRITIS RHEUM-US, V39, P23, DOI 10.1002/art.1780390104
   Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301
   FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604
   Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055
   GANJU RK, 2000, J BIOL CHEM, V5, P275
   Gismondi A, 2000, J IMMUNOL, V164, P2272, DOI 10.4049/jimmunol.164.5.2272
   Grijelmo C, 2007, CELL SIGNAL, V19, P1722, DOI 10.1016/j.cellsig.2007.03.008
   Guinamard R, 2000, NAT IMMUNOL, V1, P31
   Horwitz DA, 1997, ARTHRITIS RHEUM-US, V40, P822, DOI 10.1002/art.1780400508
   Juang YT, 2005, J CLIN INVEST, V115, P996, DOI 10.1172/JCI200522854
   Kaneko H, 1996, CLIN EXP IMMUNOL, V106, P218, DOI 10.1046/j.1365-2249.1996.d01-849.x
   Koshy M, 1996, J CLIN INVEST, V98, P826, DOI 10.1172/JCI118855
   Kotzin BL, 1996, CELL, V85, P303, DOI 10.1016/S0092-8674(00)81108-3
   Kyttaris VC, 2005, CURR OPIN RHEUMATOL, V17, P518, DOI 10.1097/01.bor.0000170479.01451.ab
   Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233
   LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0
   Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147
   Mihara M, 2000, J CLIN INVEST, V106, P91, DOI 10.1172/JCI9244
   MILLS JA, 1994, NEW ENGL J MED, V330, P1871, DOI 10.1056/NEJM199406303302608
   MOHAN C, 1995, J IMMUNOL, V154, P1470
   Nakayamada S, 2003, ARTHRITIS RHEUM, V48, P1239, DOI 10.1002/art.10941
   Nakayamada S, 2007, ARTHRITIS RHEUM, V56, P1559, DOI 10.1002/art.22581
   Ostergaard HL, 2005, IMMUNOL RES, V31, P267, DOI 10.1385/IR:31:3:267
   Perl A, 2004, TRENDS IMMUNOL, V25, P360, DOI 10.1016/j.it.2004.05.001
   Pollard KM, 2004, J IMMUNOL, V173, P5880, DOI 10.4049/jimmunol.173.9.5880
   Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253
   Regoli M, 1999, BIOCHEM CELL BIOL, V77, P71, DOI 10.1139/bcb-77-1-71
   RODRIGUEZFERNAN.JL, 2001, J BIOL CHEM, V276, P40
   Sancho D, 2002, J IMMUNOL, V169, P292, DOI 10.4049/jimmunol.169.1.292
   SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206
   Shahrara S, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2318
   Takagi C, 2002, AM J KIDNEY DIS, V39, P174, DOI 10.1053/ajkd.2002.29912
   TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101
   Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621
   Weening JJ, 2004, J AM SOC NEPHROL, V15, P241, DOI 10.1097/01.ASN.0000108969.21691.5D
   Wong CK, 2005, RHEUMATOLOGY, V44, P989, DOI 10.1093/rheumatology/keh663
   Xiang Y, 2008, J CELL BIOCHEM, V103, P920, DOI 10.1002/jcb.21461
   Yi YJ, 2000, J IMMUNOL, V165, P6627, DOI 10.4049/jimmunol.165.11.6627
NR 42
TC 6
Z9 7
U1 4
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD NOV 17
PY 2009
VL 10
AR 141
DI 10.1186/1471-2474-10-141
PG 11
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 528BZ
UT WOS:000272416600001
PM 19919693
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Liu, H
   Ferrer, DA
   Ferdousi, F
   Banerjee, SK
AF Liu, Hai
   Ferrer, Domingo A.
   Ferdousi, Fahmida
   Banerjee, Sanjay K.
TI RETRACTED: Nonvolatile memory with Co-SiO2 core-shell nanocrystals as
   charge storage nodes in floating gate (Retracted article. See vol. 96
   art. no. 269902, 2010)
SO APPLIED PHYSICS LETTERS
LA English
DT Article; Retracted Publication
DE cobalt; flash memories; microemulsions; nanofabrication; nanostructured
   materials; silicon compounds; thermal stability
ID FLASH MEMORIES; FABRICATION; FILMS
AB In this letter, we reported nanocrystal floating gate memory with Co-SiO2 core-shell nanocrystal charge storage nodes. By using a water-in-oil microemulsion scheme, Co-SiO2 core-shell nanocrystals were synthesized and closely packed to achieve high density matrix in the floating gate without aggregation. The insulator shell also can help to increase the thermal stability of the nanocrystal metal core during the fabrication process to improve memory performance.
C1 [Liu, Hai; Ferrer, Domingo A.; Ferdousi, Fahmida; Banerjee, Sanjay K.] Univ Texas Austin, Microelect Res Ctr, Austin, TX 78758 USA.
RP Liu, H (reprint author), Univ Texas Austin, Microelect Res Ctr, R9950, Austin, TX 78758 USA.
EM liuhai@mailutexas.edu
FU DARPA; MARCO; Micro Foundation; NSF; NNIN program
FX This work was supported in part by DARPA, MARCO, and the Micro
   Foundation, as well as the NSF, NNIN program.
CR Braun PV, 2005, ADV FUNCT MATER, V15, P1745, DOI 10.1002/adfm.200500083
   Chen JH, 2004, IEEE T ELECTRON DEV, V51, P1840, DOI 10.1109/TED.2004.837011
   GUARINI KW, 2003, INT EL DEV M, P541
   Heitsch AT, 2008, J SOLID STATE CHEM, V181, P1590, DOI 10.1016/j.jssc.2008.05.002
   Kim DW, 2003, IEEE T ELECTRON DEV, V50, P1823, DOI 10.1109/TED.2003.815370
   KIM L, 1998, P INT EL DEV M UNPUB, P111
   Lee DC, 2006, J PHYS CHEM B, V110, P20906, DOI 10.1021/jp064050n
   Lee JJ, 2005, IEEE T ELECTRON DEV, V52, P507, DOI 10.1109/TED.2005.844793
   Li C, 1996, J VAC SCI TECHNOL A, V14, P170, DOI 10.1116/1.579915
   Liu ZT, 2002, IEEE T ELECTRON DEV, V49, P1614, DOI 10.1109/TED.2002.802618
   Liu ZT, 2002, IEEE T ELECTRON DEV, V49, P1606, DOI 10.1109/TED.2002.802617
   Ostraat ML, 2001, J ELECTROCHEM SOC, V148, pG265, DOI 10.1149/1.1360210
   Park M, 2001, APPL PHYS LETT, V79, P257, DOI 10.1063/1.1378046
   Ryu SW, 2009, IEEE T ELECTRON DEV, V56, P377, DOI 10.1109/TED.2008.2011677
   Shahrjerdi D, 2007, IEEE ELECTR DEVICE L, V28, P793, DOI 10.1109/LED.2007.902612
   Tang S, 2007, IEEE T ELECTRON DEV, V54, P433, DOI 10.1109/TED.2006.810234
   Tiwari S, 1996, APPL PHYS LETT, V68, P1377, DOI 10.1063/1.116085
NR 17
TC 4
Z9 4
U1 3
U2 16
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0003-6951
EI 1077-3118
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD NOV 16
PY 2009
VL 95
IS 20
AR 203112
DI 10.1063/1.3258471
PG 3
WC Physics, Applied
SC Physics
GA 523DN
UT WOS:000272052200059
DA 2018-12-27
ER

PT J
AU Handoyo, H
   Stafford, MJ
   McManus, E
   Baltzis, D
   Peggie, M
   Cohen, P
AF Handoyo, Hosea
   Stafford, Margaret J.
   McManus, Eamon
   Baltzis, Dionissios
   Peggie, Mark
   Cohen, Philip
TI RETRACTED: IRAK1-independent pathways required for the
   interleukin-1-stimulated activation of the Tpl2 catalytic subunit and
   its dissociation from ABIN2 (Retracted article. See vol. 457, pg. 227,
   2014)
SO BIOCHEMICAL JOURNAL
LA English
DT Article; Retracted Publication
DE innate immunity; interleukin-1 (IL-1); interleukin-1-receptor-associated
   kinase 1 (IRAK1); nuclear factor kappa B (NF-kappa B); tumour necrosis
   factor (TNF); tumour progression locus 2 (Tpl2)
ID KAPPA-B-KINASE; SIGNAL-REGULATED KINASE; PROTEIN-KINASE;
   LIPOPOLYSACCHARIDE ACTIVATION; NF-KAPPA-B1 P105; TERNARY COMPLEX; MAP
   KINASE; TNF-ALPHA; PHOSPHORYLATION; MACROPHAGES
AB The protein kinase Tpl2 (tumour progression locus 2) is activated by LPS (lipopolysaccharide), TNF alpha (tumour necrosis factor alpha) and IL (interleukin)-1. Activation of the native Tpl2 complex by these agonists requires the IKK beta {I kappa B [inhibitor of NF-kappa B (nuclear factor kappa B)] kinase beta}-catalysed phosphorylation of the p105/NF-kappa B1 subunit and is accompanied by the release of the catalytic subunit from both p105/NF-kappa B1 and another subunit ABIN2 (A20-binding inhibitor of NF-kappa B2). In the present study we report that IL-1 activates the transfected Tpl2 catalytic subunit in an HEK (human embryonic kidney)-293 cell line that stably expresses the IL-1R (IL-1 receptor), but does not express the protein kinase IRAK1 (IL-1R-associated kinase). In these cells IL-1 does not activate IKK beta or induce the phosphorylation of p105/NF-kappa B1, and nor does the IKK beta inhibitor PSI 145 prevent the IL-1-induced activation of transfected Tpl2. However, the IL-1-stimulated activation of transfected Tpl2 in IRAK1-null cells or activation of the endogenous Tpl2 complex in IRAK1-expressing cells is suppressed by the protein kinase inhibitor PP2 by a mechanism that does not involve inhibition of Src family protein tyrosine kinases. The IL-1-stimulated activation of transfected Tpl2 is accompanied by its phosphorylation at Thr(290) and Ser(400) and by enhanced phosphorylation of Ser(62), which we demonstrate are autophosphorylation events catalysed by Tpl2 itself. We further show that IL-1 triggers the dissociation of Tpl2 from co-transfected ABIN2 in IRAK1-null IL-1R cells, which is not Suppressed by PP2 or by the inhibition of Tpl2 or IKK beta. These studies identify two new signalling events involved in activation of the native Tpl2 complex by IL-1. First, the IRAK1-, IKK beta- and PP2-independent dissociation of Tpl2 from ABIN2; secondly, the IRAK1- and IKK beta-independent, but PP2-sensitive, activation of the Tpl2 catalytic subunit.
C1 [Handoyo, Hosea; Stafford, Margaret J.; McManus, Eamon; Baltzis, Dionissios; Peggie, Mark; Cohen, Philip] Univ Dundee, Coll Life Sci, Sir James Black Ctr, Prot Phosphorylat Unit,MRC, Dundee DD1 5EH, Scotland.
RP Cohen, P (reprint author), Univ Dundee, Coll Life Sci, Sir James Black Ctr, Prot Phosphorylat Unit,MRC, Dundee DD1 5EH, Scotland.
EM p.cohen@dundee.ac.uk
FU Boehringer Ingelheim Fonds; Royal Society; Medical Research Council;
   AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Merck-Serono; Pfizer
FX This work was supported by Boehringer Ingelheim Fonds (postgraduate
   fellowship to H. H.); The Royal Society (a Royal Society Research
   Professorship to P.C.); the Medical Research Council; AstraZeneca;
   Boehringer Ingelheim; GlaxoSmithKline; Merck-Serono; and Pfizer.
CR ALESSI DR, 1995, METHOD ENZYMOL, V255, P279
   AOKI M, 1993, J BIOL CHEM, V268, P22723
   Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797
   Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004
   Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018
   Cho J, 2005, J BIOL CHEM, V280, P20442, DOI 10.1074/jbc.M413554200
   Conze DB, 2008, MOL CELL BIOL, V28, P3538, DOI 10.1128/MCB.02098-07
   Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5
   Eliopoulos AG, 2003, EMBO J, V22, P3855, DOI 10.1093/emboj/cdg386
   Gottipati S, 2008, CELL SIGNAL, V20, P269, DOI 10.1016/j.cellsig.2007.08.009
   Hall JP, 2007, J BIOL CHEM, V282, P33295, DOI 10.1074/jbc.M703694200
   Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695
   Jia Y, 2006, ANAL BIOCHEM, V350, P268, DOI 10.1016/j.ab.2005.11.010
   Kontoyiannis D, 2002, J EXP MED, V196, P1563, DOI 10.1084/jem.20020281
   Lang V, 2004, MOL CELL BIOL, V24, P5235, DOI 10.1128/MCB.24.12.5235-5248.2004
   Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198
   Luciano BS, 2004, J BIOL CHEM, V279, P52117, DOI 10.1074/jbc.M403716200
   MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088
   Papoutsopoulou S, 2006, NAT IMMUNOL, V7, P606, DOI 10.1038/ni1334
   Robinson MJ, 2007, MOL CELL BIOL, V27, P7355, DOI 10.1128/MCB.00301-07
   Rodriguez C, 2006, CELL SIGNAL, V18, P1376, DOI 10.1016/j.cellsig.2005.10.016
   Rousseau S, 2008, J CELL SCI, V121, P149, DOI 10.1242/jcs.018671
   SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x
   Stafford MJ, 2006, FEBS LETT, V580, P4010, DOI 10.1016/j.febslet.2006.06.004
   Sun L, 1999, J MED CHEM, V42, P5120, DOI 10.1021/jm9904295
   Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040-6048.2004
   Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4
   Yang HT, 2008, CELL SIGNAL, V20, P375, DOI 10.1016/j.cellsig.2007.10.025
   Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870
NR 29
TC 16
Z9 19
U1 3
U2 9
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD NOV 15
PY 2009
VL 424
BP 109
EP 118
DI 10.1042/BJ20091271
PN 1
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 518EE
UT WOS:000271672400012
PM 19754427
OA Green Published
DA 2018-12-27
ER

PT J
AU Kim, J
   Song, I
   Jong, J
   Lee, S
   Kim, P
   Jeong, E
   Park, J
   Choung, Y
AF Kim, Joonkyu
   Song, Insang
   Jong, Jisun
   Lee, Sangjoon
   Kim, Pyoungsan
   Jeong, Euna
   Park, Joonhong
   Choung, Younkyoo
TI RETRACTED: Influence of aeration rate on nitrogen during blackwater
   composting (Retracted article. See vol. 256, pg. 203, 2010)
SO DESALINATION
LA English
DT Article; Proceedings Paper; Retracted Publication
CT International Workshop on Water and Sanitation in International
   Development and Disaster Relief
CY MAY 28-30, 2008
CL Edinburgh, SCOTLAND
DE Composting; Aeration rate; Biodegradation; Nitrogen; NH(4)(+)/NH(3);
   Ammonification
ID AMMONIA EMISSIONS; ORGANIC WASTES; MANURE; INTERMITTENT; TEMPERATURE
AB The paper aimed to study the influence of the aeration rate on nitrogen dynamics during the composting of Blackwater sludge with sawdust. The increased aeration was responsible for an increase in ammonia emissions and for the decrease in nitrogen losses through leaching. At high aeration rates, losses of nitrogen in leachates and as ammonia in exhaust gas accounted for 90.99% of the nitrogen removed from the material. At low aeration rates, those accounted for 47.85% of the nitrogen removed from the material. The nitrification rate was found to be proportional to the mean content of NH(4)(+)/NH(3) in the material, i.e., initial NH(4)(+)/NH(3) Plus NH(4)(+)/NH(3) released by ammonification minus the losses in leachates and in exhaust gas. The aeration rate was shown to be a main parameter affecting nitrogen dynamics during composting, since it controlled the ammonification, the ammonia emission and the nitrification processes.
C1 [Kim, Joonkyu; Song, Insang; Jong, Jisun; Lee, Sangjoon; Kim, Pyoungsan; Jeong, Euna; Park, Joonhong; Choung, Younkyoo] Yonsei Univ, Coll Engn, Dept Civil & Environm Engn, Seoul 120749, South Korea.
RP Choung, Y (reprint author), Yonsei Univ, Coll Engn, Dept Civil & Environm Engn, Seoul 120749, South Korea.
EM choung@yonsei.ac.kr
RI Choung, Younkyoo/G-8874-2012
CR Barrington S, 2003, BIORESOURCE TECHNOL, V86, P259, DOI 10.1016/S0960-8524(02)00155-4
   Berthe L, 2007, BIOSYST ENG, V97, P75, DOI 10.1016/j.biosystemseng.2007.01.013
   BHOYAR R, 1979, J ENV HLTH, V21, P23
   CRONJE AL, 2002, COMPOSTING COMPOST U, P845
   Eiland F, 2001, COMPOST SCI UTIL, V9, P186
   Ekinci K, 2000, COMPOST SCI UTIL, V8, P160
   Elwell DL, 2002, COMPOST SCI UTIL, V10, P142
   GUARDIA A, 2006, WASTE MANAGE, V10, P16
   HANSEN RC, 1989, T ASAE, V32, P2151
   Hao XY, 2001, J ENVIRON QUAL, V30, P376, DOI 10.2134/jeq2001.302376x
   Haug R. T, 1993, PRACTICAL HDB COMPOS
   He YW, 2000, SCI TOTAL ENVIRON, V254, P65, DOI 10.1016/S0048-9697(00)00439-3
   HESTER RE, 1995, WASTE TREATMENT DISP
   Hong JH, 1998, COMPOST SCI UTIL, V6, P74
   Hwang EY, 2006, J IND ENG CHEM, V12, P694
   JANZEN RA, 1997, SUSTAINABILITY MANUR
   KAYHANIAN M, 1992, BIOCYCLE, V33, P58
   Liang C, 2003, BIORESOURCE TECHNOL, V86, P131, DOI 10.1016/S0960-8524(02)00153-0
   Liang Y, 2006, BIORESOURCE TECHNOL, V97, P748, DOI 10.1016/j.biortech.2005.03.041
   Pagans E, 2006, CHEMOSPHERE, V62, P1534, DOI 10.1016/j.chemosphere.2005.06.044
   PAILLAT JM, 2005, ATMOS ENVIRON, V39, P833
NR 21
TC 5
Z9 5
U1 4
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0011-9164
J9 DESALINATION
JI Desalination
PD NOV 15
PY 2009
VL 248
IS 1-3
BP 298
EP 307
DI 10.1016/j.desal.2008.05.069
PG 10
WC Engineering, Chemical; Water Resources
SC Engineering; Water Resources
GA 511CJ
UT WOS:000271141200041
DA 2018-12-27
ER

PT J
AU Valastyan, S
   Benaich, N
   Chang, A
   Reinhardt, F
   Weinberg, RA
AF Valastyan, Scott
   Benaich, Nathan
   Chang, Amelia
   Reinhardt, Ferenc
   Weinberg, Robert A.
TI RETRACTED: Concomitant suppression of three target genes can explain the
   impact of a microRNA on metastasis (Retracted article. See vol. 29, pg.
   686, 2015)
SO GENES & DEVELOPMENT
LA English
DT Article; Retracted Publication
DE MicroRNA; metastasis; miR-31; breast cancer; colonization; pleiotropy
ID BREAST-CANCER CELLS; PROLIFERATION; FAMILY
AB It remains unclear whether a microRNA ( miRNA) affects a given phenotype via concomitant down-regulation of its entire repertoire of targets or instead by suppression of only a modest subset of effectors. We demonstrate that inhibition of breast cancer metastasis by miR-31-a miRNA predicted to modulate >200 mRNAs-can be entirely explained by miR-31's pleiotropic regulation of three targets. Thus, concurrent re-expression of integrin-alpha 5, radixin, and RhoA abrogates miR-31-imposed metastasis suppression. These effectors influence distinct steps of the metastatic process. Our findings have implications concerning the importance of pleiotropy for the biological actions of miRNAs and provide mechanistic insights into metastasis.
C1 [Valastyan, Scott; Benaich, Nathan; Chang, Amelia; Reinhardt, Ferenc; Weinberg, Robert A.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
   [Valastyan, Scott; Chang, Amelia; Weinberg, Robert A.] MIT, Dept Biol, Cambridge, MA 02139 USA.
   [Benaich, Nathan] Williams Coll, Dept Biol, Williamstown, MA 01267 USA.
   [Weinberg, Robert A.] MIT, Ludwig Ctr Mol Oncol, Cambridge, MA 02139 USA.
RP Weinberg, RA (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
EM weinberg@wi.mit.edu
FU NIH [RO1 CA078461]; MIT Ludwig Center for Molecular Oncology; U. S.
   Department of Defense; Breast Cancer Research Foundation; DoD BCRP Idea
   Award; American Cancer Society Research; Daniel K. Ludwig Foundation
FX We thank Julie Valastyan and Sandra McAllister for critical reading of
   this manuscript; M. Saelzler, L. Waldman, and other members of
   theWeinberg laboratory for discussions; G. Bokoch, S. Crouch, P. Klein,
   S. Kuwada, H. Surks, and S. Weiss for reagents; and M. Brown and the
   Koch Institute Histology Facility for tissue sectioning. This research
   was supported by the NIH (RO1 CA078461), MIT Ludwig Center for Molecular
   Oncology, U. S. Department of Defense, Breast Cancer Research
   Foundation, and DoD BCRP Idea Award. S. V. and R. A. W. are inventors on
   a patent application in part based on findings detailed in this
   manuscript. S. V. is a U. S. Department of Defense Breast Cancer
   Research Program Predoctoral Fellow. R. A. W. is an American Cancer
   Society Research Professor and a Daniel K. Ludwig Foundation Cancer
   Research Professor.
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Pille JY, 2005, MOL THER, V11, P267, DOI 10.1016/j.ymthe.2004.08.029
   Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253
   Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228
   Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229
   Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047
   van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089
   Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019
   Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005
   Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Zhao Y, 2007, CELL, V129, P303, DOI 10.1016/j.cell.2007.03.030
NR 22
TC 82
Z9 86
U1 3
U2 11
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD NOV 15
PY 2009
VL 23
IS 22
BP 2592
EP 2597
DI 10.1101/gad.1832709
PG 6
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 519XT
UT WOS:000271803900003
PM 19875476
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Wang, WT
   Yue, GX
   Ou, CX
AF Wang, Wentao
   Yue, Guangxue
   Ou, Chunxia
TI RETRACTED: Asymptotic constancy for a differential equation with
   multiple state-dependent delays (Retracted article. See vol. 235, pg.
   3367, 2011)
SO JOURNAL OF COMPUTATIONAL AND APPLIED MATHEMATICS
LA English
DT Article; Retracted Publication
DE Asymptotic constancy; Differential equation; Solution; State-dependent
   delay; omega-limit set
ID MONOTONE SEMIFLOWS; CONVERGENCE
AB In this paper, we investigate the asymptotic behavior of solutions to a differential equation with multiple state-dependent delays. It is shown that every bounded solution of such an equation tends to a constant as t -> infinity. Our results improve and extend some corresponding ones already known. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Ou, Chunxia] Guangdong Univ Technol, Inst Appl Math, Guangzhou 510290, Guangdong, Peoples R China.
   [Wang, Wentao; Yue, Guangxue] Jiaxing Univ, Coll Math & Informat Engn, Jiaxing 314001, Zhejiang, Peoples R China.
RP Ou, CX (reprint author), Guangdong Univ Technol, Inst Appl Math, Guangzhou 510290, Guangdong, Peoples R China.
EM chunxiaou1962@yahoo.com.cn
FU Scientific Research Fund of Zhejiang Provincial Education Department
   [20070605]
FX This work was supported by Scientific Research Fund of Zhejiang
   Provincial Education Department (20070605).
CR Bartha M, 2001, J MATH ANAL APPL, V254, P410, DOI 10.1006/jmaa.2000.7172
   BELAIR J, 1991, LECT NOTES PURE APPL, V131, P165
   Driver R. D., 1963, CONTRIB DIFFERENTIAL, V1, P317
   Hale J. K., 1993, INTRO FUNCTIONAL DIF, V1, P1
   LONGTIN A, 1989, B MATH BIOL, V51, P605
   LONGTIN A, 1988, MATH BIOSCI, V90, P183, DOI 10.1016/0025-5564(88)90064-8
   MACKEY MC, 1989, J ECON THEORY, V48, P497, DOI 10.1016/0022-0531(89)90039-2
   MALLETPARET J, 1989, SIAM J MATH ANAL, V20, P249, DOI 10.1137/0520019
   SMITH H, 1987, J DIFFER EQUATIONS, V66, P420, DOI 10.1016/0022-0396(87)90027-1
   TERJEKI J, 2006, DIFF EQUAT, V14, P195
   Yi TS, 2005, J DIFFER EQUATIONS, V214, P429, DOI 10.1016/j.jde.2005.02.005
NR 11
TC 4
Z9 4
U1 5
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0377-0427
EI 1879-1778
J9 J COMPUT APPL MATH
JI J. Comput. Appl. Math.
PD NOV 15
PY 2009
VL 233
IS 2
BP 356
EP 360
DI 10.1016/j.cam.2009.07.023
PG 5
WC Mathematics, Applied
SC Mathematics
GA 504MC
UT WOS:000270619900026
OA Bronze
DA 2018-12-27
ER

PT J
AU Guerra, DL
   Pinto, AA
   Viana, RR
   Airoldi, C
AF Guerra, Denis L.
   Pinto, Alane A.
   Viana, Rubia R.
   Airoldi, Claudio
TI RETRACTED: Layer silicates modified with
   1,4-bis(3-aminopropyl)piperazine for the removal of Th(IV), U(VI) and
   Eu(III) from aqueous media (Retracted article. See vol. 194, pg. 445,
   2011)
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article; Retracted Publication
DE Montmorillonite; Kanemite; Radionuclide; Adsorption; Thermodynamic
ID HEXAGONAL MESOPOROUS SILICAS; THERMOCHEMICAL DATA; ADSORPTION PROCESS;
   ACID ACTIVATION; IONIC-STRENGTH; METALS UPTAKE; INTERCALATION; SORPTION;
   WASTE; GEL
AB Natural montmorillonite (M) and synthetic kanemite (K) have been functionalized with 1,4-bis(3-aminopropyl)piperazine reacted with methylacrylate to yield new inorganic-organic chelating materials. The original and modified materials were characterized by X-ray diffractometry, textural analysis, SEM and nuclear magnetic nuclei of carbon-13 and silicon-29. The chemically modified clay samples (M-APPMA and K-APPMA) showed modification of its physical-chemical properties including: specific area 45.0 m(2) g(-1) (M) to 978.8 m(2) g(-1) (M-APPMA) and 23.5 m(2) g(-1) (K) to 898.9 m(2) g(-1) (K-APPMA). The ability of these materials to remove thorium(IV), uranyl(VI) and europium(III) from aqueous solution was followed by a series of adsorption isotherms, which were fitted to non-linear Sips adsorption isotherm model. To achieve the best adsorption conditions the influence of pH and variation of metal concentration were investigated. The energetic effects (Delta H-int degrees, Delta(int)G degrees and Delta S-int degrees) caused by metal ions adsorption were determined through calorimetric titrations. (C) 2009 Published by Elsevier B.V.
C1 [Guerra, Denis L.; Pinto, Alane A.; Airoldi, Claudio] Univ Estadual Campinas, Inst Chem, BR-13084971 Sao Paulo, Brazil.
   [Viana, Rubia R.] Univ Fed Mato Grosso, Ctr Recursos Minerais, BR-78060900 Cuiaba, Mato Grosso, Brazil.
RP Guerra, DL (reprint author), Univ Estadual Campinas, Inst Chem, POB 6154, BR-13084971 Sao Paulo, Brazil.
EM dlguerra@iqm.unicamp.br
FU CNPq; FAPESP
FX The authors are indebted to CNPq for fellowships and FAPESP for
   financial support.
CR ALBERT K, 1991, J CHROMATOGR, V544, P345, DOI 10.1016/S0021-9673(01)83995-9
   Babel S, 2003, J HAZARD MATER, V97, P219, DOI 10.1016/S0304-3894(02)00263-7
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   Bhattacharyya KG, 2006, COLLOID SURFACE A, V277, P191, DOI 10.1016/j.colsurfa.2005.11.060
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Cestaria AR, 2009, J HAZARD MATER, V161, P307, DOI 10.1016/j.jhazmat.2008.03.091
   Chen CL, 2007, APPL RADIAT ISOTOPES, V65, P155, DOI 10.1016/j.apradiso.2006.07.003
   DAY R, 2008, J HARZARD MAT, V156, P95
   Dias NL, 1998, COLLOID SURFACE A, V144, P219, DOI 10.1016/S0927-7757(98)00569-X
   Evangelista SM, 2007, SURF SCI, V601, P2194, DOI 10.1016/j.susc.2007.03.020
   Guerra DL, 2008, J HAZARD MATER, V155, P230, DOI 10.1016/j.jhazmat.2007.11.054
   Guerra DL, 2008, INORG CHEM COMMUN, V11, P20, DOI 10.1016/j.inoche.2007.09.029
   Guerra DL, 2006, POLYHEDRON, V25, P2880, DOI 10.1016/j.poly.2006.04.015
   Hughes M, 2006, MACROMOL SYMP, V235, P161, DOI 10.1002/masy.200650320
   Huheey J. E, 1993, INORGANIC CHEM PRINC
   Jacques RA, 2007, SEP SCI TECHNOL, V42, P591, DOI 10.1080/01496390601069952
   KANNO T, 1985, IAEATECDOC337, P237
   Karadag D, 2007, J HAZARD MATER, V144, P432, DOI 10.1016/j.jhazmat.2006.10.055
   Lazarin AM, 2007, THERMOCHIM ACTA, V454, P43, DOI 10.1016/j.tca.2006.12.016
   LEPPERT D, 1990, MINING ENG, V42, P604
   Macedo TR, 2007, CLAY CLAY MINER, V55, P151, DOI 10.1346/CCMN.2007.0550204
   Mohan D, 2005, IND ENG CHEM RES, V44, P1027, DOI 10.1021/ie0400898
   *OECD NUCL EN AG, 1999, GEOL DISP RAD WAST R
   Pavan FA, 2006, J HAZARD MATER, V137, P527, DOI 10.1016/j.jhazmat.2006.02.025
   Prado AGS, 2002, J MATER CHEM, V12, P3823, DOI 10.1039/b204060c
   Quintanilla D. P., 2007, J COLLOID INTERF SCI, V313, P551
   QUINTANILLA DP, 2006, J HAZARD MATER, V134, P245
   Ruiz VSO, 2004, THERMOCHIM ACTA, V420, P73, DOI 10.1016/j.tca.2003.10.029
   Sales JAA, 2005, SURF SCI, V590, P51, DOI 10.1016/j.susc.2005.06.007
   Sales JAA, 2005, THERMOCHIM ACTA, V427, P77, DOI 10.1016/j.tca.2004.08.015
   Salih B, 1998, TALANTA, V46, P1205, DOI 10.1016/S0039-9140(97)00362-7
   Shahwan T, 2005, RADIOCHIM ACTA, V93, P225, DOI 10.1524/ract.93.4.225.64066
   Sharma P, 2008, MICROPOR MESOPOR MAT, V116, P641, DOI 10.1016/j.micromeso.2008.05.036
   Sharma P, 2009, J COLLOID INTERF SCI, V332, P298, DOI 10.1016/j.jcis.2008.12.074
   Sheng GD, 2008, APPL RADIAT ISOTOPES, V66, P1313, DOI 10.1016/j.apradiso.2008.03.005
   SIPS R, 1948, J CHEM PHYS, V16, P490, DOI 10.1063/1.1746922
   Tang XW, 2009, J HAZARD MATER, V161, P824, DOI 10.1016/j.jhazmat.2008.04.059
   THOMAS JM, 2007, MICROPOR MESOPOR MAT, V114, P5
   Twyman LJ, 2004, TETRAHEDRON LETT, V45, P433, DOI 10.1016/j.tetlet.2003.10.087
   Villaescusa I, 2000, J CHEM TECHNOL BIOT, V75, P812, DOI 10.1002/1097-4660(200009)75:9<812::AID-JCTB284>3.3.CO;2-2
   XIUWEN W, 2007, J COLLOID INTERF SCI, V315, P555
   Yu MH, 2005, ENV TOXICOLOGY BIOL
NR 42
TC 6
Z9 6
U1 2
U2 28
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
EI 1873-3336
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD NOV 15
PY 2009
VL 171
IS 1-3
BP 514
EP 523
DI 10.1016/j.jhazmat.2009.06.032
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 511KZ
UT WOS:000271165100067
PM 19604631
DA 2018-12-27
ER

PT J
AU Raghunathan, AV
   Aluru, NR
AF Raghunathan, A. V.
   Aluru, N. R.
TI RETRACTED: An empirical potential based quasicontinuum theory for
   structural prediction of water (Retracted article. See vol. 132, art.
   no. 209901, 2010)
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article; Retracted Publication
ID SIMULATION; DYNAMICS
AB An empirical potential based quasicontinuum theory (EQT) is proposed to predict the structure, concentration, and various potential profiles of water in confined environments. EQT seamlessly unifies the continuum theory given by the Nernst-Planck equation and the atomistic theory governed by interatomic potentials. In particular, the interatomic potentials describing various interactions in water are directly incorporated into the Nernst-Planck theory. We introduce a new empirical potential to compute electrostatic interactions in water. The results from the EQT formalism are compared with molecular dynamics simulations and a good match is observed for channels with widths ranging from 2 sigma(ow) to 20 sigma(ow), where sigma(ow) is the water-oxygen Lennard-Jones distance parameter. While molecular dynamics can be limited to small length scales, EQT can be used at various length scales to effectively and accurately capture both the interfacial structure and bulk properties of water making it a robust and fast method that can predict properties in widths ranging from the macroscale down to the nanoscale. (C) 2009 American Institute of Physics. [doi: 10.1063/1.3258280]
C1 [Raghunathan, A. V.; Aluru, N. R.] Univ Illinois, Beckman Inst Adv Sci & Technol, Dept Engn Sci & Mech, Urbana, IL 61801 USA.
RP Aluru, NR (reprint author), Univ Illinois, Beckman Inst Adv Sci & Technol, Dept Engn Sci & Mech, Urbana, IL 61801 USA.
EM aluru@illinois.edu
CR Attinger S., 2004, MULTISCALE MODELLING
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Frenkel D., 2001, UNDERSTANDING MOL SI
   Karniadakis G., 2005, MICROFLOWS NANOFLOWS
   Karttunen M., 2004, NOVEL METHODS SOFT M
   Koneshan S, 1998, J PHYS CHEM B, V102, P4193, DOI 10.1021/jp980642x
   Lennard-Jones JE, 1931, P PHYS SOC, V43, P461, DOI 10.1088/0959-5309/43/5/301
   Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045
   NOSE S, 1984, J CHEM PHYS, V81, P511, DOI 10.1063/1.447334
   Praprotnik M, 2008, ANNU REV PHYS CHEM, V59, P545, DOI 10.1146/annurev.physchem.59.032607.093707
   Qiao R, 2003, J CHEM PHYS, V118, P4692, DOI 10.1063/1.1543140
   Raghunathan AV, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2793070
   Rodgers JM, 2008, P NATL ACAD SCI USA, V105, P19136, DOI 10.1073/pnas.0807623105
   SANGHI T, 2009, UNPUB
   Spalding D. B., 1972, International Journal for Numerical Methods in Engineering, V4, P551, DOI 10.1002/nme.1620040409
   STILLINGER FH, 1980, SCIENCE, V209, P451, DOI 10.1126/science.209.4455.451
   Tang YP, 1997, FLUID PHASE EQUILIBR, V134, P21, DOI 10.1016/S0378-3812(97)00049-6
   TEORELL T, 1953, PROG BIOPHYS BIOP CH, V3, P305, DOI 10.1016/S0096-4174(18)30049-0
NR 18
TC 4
Z9 6
U1 4
U2 19
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0021-9606
J9 J CHEM PHYS
JI J. Chem. Phys.
PD NOV 14
PY 2009
VL 131
IS 18
AR 184703
DI 10.1063/1.3258280
PG 7
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 528NY
UT WOS:000272454500034
PM 19916619
DA 2018-12-27
ER

PT J
AU Ide, T
   Brown-Endres, L
   Chu, K
   Ongusaha, PP
   Ohtsuka, T
   El-Deiry, WS
   Aaronson, SA
   Lee, SW
AF Ide, Takao
   Brown-Endres, Lauren
   Chu, Kiki
   Ongusaha, Pat P.
   Ohtsuka, Takao
   El-Deiry, Wafik S.
   Aaronson, Stuart A.
   Lee, Sam W.
TI RETRACTED: GAMT, a p53-Inducible Modulator of Apoptosis, Is Critical for
   the Adaptive Response to Nutrient Stress (Retracted article. See vol.
   51, pg. 552, 2013)
SO MOLECULAR CELL
LA English
DT Article; Retracted Publication
ID ACTIVATED PROTEIN-KINASE; GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;
   INBORN ERROR; CREATINE-DEFICIENCY; INSULIN-RESISTANCE; OXIDATIVE STRESS;
   MOUSE MODEL; CELL-DEATH; METABOLISM; P53
AB The p53 tumor suppressor protein has a well-established role in cell-fate decision-making processes. However, recent discoveries indicate that p53 has a non-tumor-suppressive role. Here we identify guanidinoacetate methyltransferase (GAMT), an enzyme involved in creatine synthesis, as a p53 target gene and a key downstream effector of adaptive response to nutrient stress. We show that GAMT is not only involved in p53-dependent apoptosis in response to genotoxic stress but is important for apoptosis induced by glucose deprivation. Additionally, p53 -> GAMT upregulates fatty acid oxidation (FAO) induced by glucose starvation, utilizing this pathway as an alternate ATP-generating energy source. These results highlight that p53-dependent regulation of GAMT allows cells to maintain energy levels sufficient to undergo apoptosis or survival under conditions of nutrient stress. The p53 -> GAMT pathway represents a new link between cellular stress responses and processes of creatine synthesis and FAO, demonstrating a further role of p53 in cellular metabolism.
C1 [Ide, Takao; Brown-Endres, Lauren; Chu, Kiki; Ongusaha, Pat P.; Lee, Sam W.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
   [Ide, Takao; Brown-Endres, Lauren; Chu, Kiki; Ongusaha, Pat P.; Lee, Sam W.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
   [Ohtsuka, Takao] Saga Univ, Fac Med, Dept Surg, Saga 8498501, Japan.
   [El-Deiry, Wafik S.] Univ Penn, Sch Med, Dept Med, Abramson Comprehens Canc Ctr, Philadelphia, PA 19104 USA.
   [Aaronson, Stuart A.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.
   [Lee, Sam W.] MIT, Broad Inst, Cambridge, MA 02142 USA.
   [Lee, Sam W.] Harvard Univ, Cambridge, MA 02142 USA.
RP Lee, SW (reprint author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
EM swlee@partners.org
FU National Institutes of Health [CA085681, CA127247, CA80058]
FX We thank the members of the Cutaneous Biology Research Center (CBRC) for
   helpful discussion, and the Yale University School of Medicine,
   Biochemical Disease Detection Laboratory for performing creatine and GAA
   assays. This work was supported by National Institutes of Health grants
   (CA085681, CA127247, and CA80058).
CR Amson R, 2000, P NATL ACAD SCI USA, V97, P5346, DOI 10.1073/pnas.97.10.5346
   Aylon Y, 2007, CELL, V130, P597, DOI 10.1016/j.cell.2007.08.005
   Bensaad K, 2007, TRENDS CELL BIOL, V17, P286, DOI 10.1016/j.tcb.2007.04.004
   Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036
   Bodamer OA, 2001, CLIN CHIM ACTA, V308, P173, DOI 10.1016/S0009-8981(01)00480-6
   Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366
   Ceddia RB, 2004, J PHYSIOL-LONDON, V555, P409, DOI 10.1113/jphysiol.2003.056291
   Choi H, 2001, MOL CELLS, V12, P412
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4
   Delarue J, 2007, CURR OPIN CLIN NUTR, V10, P142, DOI 10.1097/MCO.0b013e328042ba90
   Fabre C, 2007, ONCOGENE, V26, P4071, DOI 10.1038/sj.onc.1210187
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Hardie DG, 2002, BIOCHEM SOC T, V30, P1064, DOI 10.1042/BST0301064
   Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Item CB, 2001, AM J HUM GENET, V69, P1127, DOI 10.1086/323765
   Jelluma N, 2006, MOL CANCER RES, V4, P319, DOI 10.1158/1541-7786.MCR-05-0061
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509
   Kondoh H, 2005, CANCER RES, V65, P177
   LILLIE JW, 1993, CANCER RES, V53, P3172
   Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011
   Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863
   Mazzarelli P, 2007, CANCER BIOL THER, V6, P1606, DOI 10.4161/cbt.6.10.4742
   Meffert G, 2005, BMC GASTROENTEROL, V5, DOI 10.1186/1471-230X-5-9
   Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7
   Okoshi R, 2008, J BIOL CHEM, V283, P3979, DOI 10.1074/jbc.M705232200
   Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100
   Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525
   Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003
   Salomons GS, 2001, AM J HUM GENET, V68, P1497, DOI 10.1086/320595
   Schmidt A, 2004, HUM MOL GENET, V13, P905, DOI 10.1093/hmg/ddh112
   Schulze A, 2001, MOL GENET METAB, V74, P413, DOI 10.1006/mgme.2001.3257
   SHATTON JB, 1979, CANCER RES, V39, P492
   Stockler S, 1996, LANCET, V348, P789, DOI 10.1016/S0140-6736(96)04116-5
   STOCKLER S, 1994, PEDIATR RES, V36, P409
   Storlien L, 2004, P NUTR SOC, V63, P363, DOI 10.1079/PNS2004349
   Suzuki A, 2007, MOL CELL BIOL, V27, P4317, DOI 10.1128/MCB.02222-06
   Torremans A, 2005, J NEUROL SCI, V231, P49, DOI 10.1016/j.jns.2004.12.014
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   Wolfe RR, 1998, AM J CLIN NUTR, V67, p519S, DOI 10.1093/ajcn/67.3.519S
   Wyss M, 2000, PHYSIOL REV, V80, P1107
   Yeo JHM, 2006, BIOTECHNOL LETT, V28, P1445, DOI 10.1007/s10529-006-9110-y
   ZHAO JQ, 1994, MOL CELL BIOL, V14, P8483, DOI 10.1128/MCB.14.12.8483
NR 46
TC 61
Z9 62
U1 3
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD NOV 13
PY 2009
VL 36
IS 3
BP 379
EP 392
DI 10.1016/j.molcel.2009.09.031
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 529HH
UT WOS:000272506200006
PM 19917247
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Lee, SW
   Han, SW
   Sririyanum, M
   Park, CJ
   Seo, YS
   Ronald, PC
AF Lee, Sang-Won
   Han, Sang-Wook
   Sririyanum, Malinee
   Park, Chang-Jin
   Seo, Young-Su
   Ronald, Pamela C.
TI RETRACTED: A Type I-Secreted, Sulfated Peptide Triggers XA21-Mediated
   Innate Immunity (Retracted article. See vol. 342, pg. 191, 2013)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID DISEASE RESISTANCE; GENE; RICE; ARABIDOPSIS; FLAGELLIN; PLANTS;
   PERCEPTION; CAMPESTRIS; ACYLATION; ELICITOR
AB The rice Xa21 gene confers immunity to most strains of the bacterium Xanthomonas oryzae pv. oryzae (Xoo). Liquid chromatography-tandem mass spectrometry analysis of biologically active fractions from Xoo supernatants led to the identification of a 194-amino acid protein designated Ax21 (activator of XA21-mediated immunity). A sulfated, 17-amino acid synthetic peptide (axY(S)22) derived from the N-terminal region of Ax21 is sufficient for activity, whereas peptides lacking tyrosine sulfation are biologically inactive. Using coimmunoprecipitation, we found that XA21 is required for axY(S)22 binding and recognition. axY(S)22 is 100% conserved in all analyzed Xanthomonas species, confirming that Ax21 is a pathogen-associated molecular pattern and that XA21 is a pattern recognition receptor.
C1 [Lee, Sang-Won; Han, Sang-Wook; Sririyanum, Malinee; Park, Chang-Jin; Seo, Young-Su; Ronald, Pamela C.] Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA.
RP Ronald, PC (reprint author), Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA.
EM pcronald@ucdavis.edu
OI Sriariyanun, Malinee/0000-0002-3088-9256
FU KOSEF through PMRC of Kyung-Hee Univ., Korea; USDA Cooperative State
   Research, Education and Extension Service [006-01888, 2007-35319-18397];
   NIH [GM55962]
FX We thank B. Macek, M. Mann, C. Bertozzi, andD. Kliebenstein for
   technical assistance and discussions; R. Eigenheer and B. Phinney for
   LC-MS/MS service and HPLC equipment; and M. S. Chern, X. Chen, L.
   Bartley, A. Bent, J. Dangl, J. Dubcovsky, and B. Tyler for helpful
   comments and critical reading of the manuscript. S.-W. Lee was partially
   supported by KOSEF through PMRC of Kyung-Hee Univ., Korea. Supported by
   the USDA Cooperative State Research, Education and Extension Service (
   National Research Initiative grants 006-01888 and 2007-35319-18397) and
   by NIH grant GM55962.
CR Ausubel FM, 2005, NAT IMMUNOL, V6, P973, DOI 10.1038/ni1253
   Brunner F, 2002, EMBO J, V21, P6681, DOI 10.1093/emboj/cdf667
   Carneiro LAM, 2004, MICROBES INFECT, V6, P609, DOI 10.1016/j.micinf.2004.01.012
   da Silva FG, 2004, MOL PLANT MICROBE IN, V17, P593, DOI 10.1094/MPMI.2004.17.6.593
   Dardick Christopher, 2006, PLoS Pathogens, V2, P14
   Doz E, 2007, J BIOL CHEM, V282, P26014, DOI 10.1074/jbc.M702690200
   Flor HH, 1942, PHYTOPATHOLOGY, V32, P653
   Fu DL, 2009, SCIENCE, V323, P1357, DOI 10.1126/science.1166289
   Fukuoka S, 2009, SCIENCE, V325, P998, DOI 10.1126/science.1175550
   Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8
   JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631
   Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286
   Lee SW, 2006, P NATL ACAD SCI USA, V103, P18395, DOI 10.1073/pnas.0605508103
   Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5
   Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529
   Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5
   Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131
   Panstruga R, 2009, CELL, V136, P978, DOI 10.1016/j.cell.2009.02.020
   Park CJ, 2008, PLOS BIOL, V6, P1910, DOI 10.1371/journal.pbio.0060231
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Shan WX, 2004, MOL PLANT MICROBE IN, V17, P394, DOI 10.1094/MPMI.2004.17.4.394
   Shiu SH, 2004, PLANT CELL, V16, P1220, DOI 10.1105/tpc.020834
   Silipo A, 2008, CHEMBIOCHEM, V9, P896, DOI 10.1002/cbic.200700693
   SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804
   Sun WX, 2006, PLANT CELL, V18, P764, DOI 10.1105/tpc.105.037648
   Takeuchi K, 2003, J BACTERIOL, V185, P6658, DOI 10.1128/JB.22.6658-6665.2003
   Tyler BM, 2009, CELL MICROBIOL, V11, P13, DOI 10.1111/j.1462-5822.2008.01240.x
   Wang GL, 1996, MOL PLANT MICROBE IN, V9, P850, DOI 10.1094/MPMI-9-0850
   Wolfert MA, 2007, INFECT IMMUN, V75, P706, DOI 10.1128/IAI.01597-06
   Zipfel C, 2006, CELL, V125, P749, DOI 10.1016/j.cell.2006.03.037
   Zipfel C, 2009, CURR OPIN PLANT BIOL, V12, P414, DOI 10.1016/j.pbi.2009.06.003
NR 31
TC 173
Z9 196
U1 4
U2 62
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD NOV 6
PY 2009
VL 326
IS 5954
BP 850
EP 853
DI 10.1126/science.1173438
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 515KG
UT WOS:000271468000043
PM 19892983
DA 2018-12-27
ER

PT J
AU Tajima, K
   Fernandez, H
   Lopez-Ibor, JJ
   Carrasco, JL
   Diaz-Marsa, M
AF Tajima, K.
   Fernandez, H.
   Lopez-Ibor, J. J.
   Carrasco, J. L.
   Diaz-Marsa, M.
TI RETRACTED: Schizophrenia treatment. Critical review on the drugs and
   mechanisms of action of antipsychotics (Retracted article. See vol. 40,
   pg. 104, 2012)
SO ACTAS ESPANOLAS DE PSIQUIATRIA
LA English
DT Review; Retracted Publication
DE Schizophrenia; Antipsychotics; Dopamine partial agonist
ID IONOTROPIC GLUTAMATE RECEPTORS; RANDOMIZED CONTROLLED-TRIALS;
   DOUBLE-BLIND PET; ATYPICAL ANTIPSYCHOTICS; DOPAMINE-RECEPTORS;
   PREFRONTAL CORTEX; IN-VIVO; 2ND-GENERATION ANTIPSYCHOTICS;
   PHARMACOGENETIC PREDICTION; SCHIZOAFFECTIVE DISORDER
AB Schizophrenic treatment was developed during the second half of the last century, mainly within the context of the development of antipsychotic drugs. Even though there has been significant progress due to the availability and use of multiple drugs, these can still be classified into three basic groups of antipsychotic drugs (atypical antipsychotics, typical antipsychotics and dopamine partial agonist anti psychotics). Their primary antipsychotic mechanism is still the action on the dopamine systems. Many of the second-gene ration antipsychotics are believed to offer advantages over first-generation agents in the treatment for schizophrenia. However, the drug properties that provide the different therapeutic effects from those of the first generation are not clear and some adverse effects may still affect the patient's health and quality of life. Furthermore, the efficacy of the antipsychotics is limited. This has led to the use of adjuvant medications to strengthen the treatment effects. On the other hand, work is being done on the development of new research lines to develop new non-dopaminergic antipsychotic drugs, with not very successful results.
   The aim of this paper is to make a brief review on the current therapeutic armamentarium for schizophrenia, the strategies to develop drugs, and theories of mechanisms of action of antipsychotics. Emphasis is placed on the new therapeutic targets for the development of future treatments
C1 [Carrasco, J. L.] Hosp Clin San Carlos, Serv Psiquiatria, Madrid 28040, Spain.
RP Carrasco, JL (reprint author), Hosp Clin San Carlos, Serv Psiquiatria, C Martin Lagos S-N, Madrid 28040, Spain.
EM jcarrasco.hcsc@salud.madrid.org
CR Abi-Saab WM, 2001, CURRENT ISSUES IN THE PSYCHOPHARMACOLOGY OF SCHIZOPHRENIA, P304
   Adler LE, 1998, SCHIZOPHRENIA BULL, V24, P189, DOI 10.1093/oxfordjournals.schbul.a033320
   Allison DB, 1999, AM J PSYCHIAT, V156, P1686
   *AM PSYCH ASS, 2000, PRACT GUID TREATM PA, P299
   ANDREASSON S, 1987, LANCET, V2, P1483
   Arranz MJ, 2000, LANCET, V355, P1615, DOI 10.1016/S0140-6736(00)02221-2
   Arranz MJ, 2003, TOXICOLOGY, V192, P33, DOI 10.1016/S0300-483X(03)00248-8
   Bodick NC, 1997, ARCH NEUROL-CHICAGO, V54, P465, DOI 10.1001/archneur.1997.00550160091022
   Bontempi B, 2001, J PHARMACOL EXP THER, V299, P297
   Buchanan RW, 1996, INT CLIN PSYCHOPHARM, V11, P3, DOI 10.1097/00004850-199605002-00002
   Bymaster Frank P., 2002, Current Drug Targets - CNS and Neurological Disorders, V1, P163, DOI 10.2174/1568007024606249
   Carpenter WT, 2002, BIOL PSYCHIAT, V51, P969, DOI 10.1016/S0006-3223(02)01399-9
   CATALAN R, 2007, ACTAS ESP PSIQUIATR, V35
   *COLL WORK GROUP C, 1998, J CLIN PSYCHIAT S12, V59, P28
   CREESE I, 1976, SCIENCE, V192, P481, DOI 10.1126/science.3854
   Davis JM, 2003, ARCH GEN PSYCHIAT, V60, P553, DOI 10.1001/archpsyc.60.6.553
   DEUTSCH SI, 1989, CLIN NEUROPHARMACOL, V12, P1, DOI 10.1097/00002826-198902000-00001
   Deutsch SI, 1997, CLIN NEUROPHARMACOL, V20, P357, DOI 10.1097/00002826-199708000-00008
   Dev V, 2000, DRUG SAFETY, V23, P295, DOI 10.2165/00002018-200023040-00003
   Do KQ, 2000, EUR J NEUROSCI, V12, P3721, DOI 10.1046/j.1460-9568.2000.00229.x
   Duncan GE, 1999, MOL PSYCHIATR, V4, P418, DOI 10.1038/sj.mp.4000581
   Emrich HM, 1997, PHARMACOL BIOCHEM BE, V56, P803, DOI 10.1016/S0091-3057(96)00426-1
   FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538
   Friedman JI, 2001, NEUROPSYCHOPHARMACOL, V25, P402, DOI 10.1016/S0893-133X(01)00249-4
   Gaebel W, 1997, INT CLIN PSYCHOPHARM, V12, pS37, DOI 10.1097/00004850-199702001-00006
   Geddes J, 2000, BRIT MED J, V321, P1371, DOI 10.1136/bmj.321.7273.1371
   Giardino L, 1997, BRAIN RES, V762, P216, DOI 10.1016/S0006-8993(97)00478-2
   Goff DC, 1999, BIOL PSYCHIAT, V45, P512, DOI 10.1016/S0006-3223(98)00367-9
   Goff DC, 1999, SCHIZOPHR RES, V36, P280
   Goldman-Rakic PS, 2000, BRAIN RES REV, V31, P295, DOI 10.1016/S0165-0173(99)00045-4
   Gurevich EV, 1997, ARCH GEN PSYCHIAT, V54, P225
   Harvey PD, 2001, AM J PSYCHIAT, V158, P176, DOI 10.1176/appi.ajp.158.2.176
   Ichikawa J, 2001, J NEUROCHEM, V76, P1521, DOI 10.1046/j.1471-4159.2001.00154.x
   JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301
   Jungerman T, 1999, J CLIN PSYCHOPHARM, V19, P522, DOI 10.1097/00004714-199912000-00006
   KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789
   Kane JM, 2002, J CLIN PSYCHIAT, V63, P763, DOI 10.4088/JCP.v63n0903
   Kane JM, 1996, NEW ENGL J MED, V334, P34, DOI 10.1056/NEJM199601043340109
   Kapur S, 2000, ARCH GEN PSYCHIAT, V57, P553, DOI 10.1001/archpsyc.57.6.553
   Kapur S, 2001, AM J PSYCHIAT, V158, P360, DOI 10.1176/appi.ajp.158.3.360
   Kapur S, 1999, AM J PSYCHIAT, V156, P286
   Kapur S, 2000, AM J PSYCHIAT, V157, P514, DOI 10.1176/appi.ajp.157.4.514
   Kapur S, 1997, PSYCHOPHARMACOLOGY, V131, P148, DOI 10.1007/s002130050277
   Kapur S, 1996, AM J PSYCHIAT, V153, P948
   Kapur S, 1998, AM J PSYCHIAT, V155, P921, DOI 10.1176/ajp.155.7.921
   Keefe RSE, 1999, SCHIZOPHRENIA BULL, V25, P201, DOI 10.1093/oxfordjournals.schbul.a033374
   Keltner NL, 2002, PERSPECT PSYCHIATR C, V38, P157, DOI 10.1111/j.1744-6163.2002.tb01566.x
   KIKUCHI T, 1995, J PHARMACOL EXP THER, V274, P329
   Kinkead B, 2002, CURR OPIN PHARMACOL, V2, P99, DOI 10.1016/S1471-4892(01)00128-X
   Lahti RA, 1998, MOL PSYCHIATR, V3, P528, DOI 10.1038/sj.mp.4000423
   Lawler CP, 1999, NEUROPSYCHOPHARMACOL, V20, P612, DOI 10.1016/S0893-133X(98)00099-2
   Leucht S, 1999, SCHIZOPHR RES, V35, P51, DOI 10.1016/S0920-9964(98)00105-4
   Leucht S, 2002, AM J PSYCHIAT, V159, P180, DOI 10.1176/appi.ajp.159.2.180
   Lewis DA, 2000, NEURON, V28, P325, DOI 10.1016/S0896-6273(00)00111-2
   Li XM, 1998, PSYCHOPHARMACOLOGY, V136, P153, DOI 10.1007/s002130050551
   LIEBERMAN JA, 1993, BRIT J PSYCHIAT, V163, P7, DOI 10.1192/S0007125000292544
   Liljequist R, 1997, BEHAV BRAIN RES, V82, P195, DOI 10.1016/S0166-4328(97)80989-8
   Maelicke A, 2000, DEMENT GERIATR COGN, V11, P11, DOI 10.1159/000051227
   Marder SR, 1995, TXB PSYCHOPHARMACOLO, P247
   MAREK GJ, 2008, ACTAS ESP PSIQUIA S1, V36, P37
   Markowitz JS, 1999, ANN PHARMACOTHER, V33, P73, DOI 10.1345/aph.17215
   McCoy L, 1998, SYNAPSE, V28, P195, DOI 10.1002/(SICI)1098-2396(199803)28:3<195::AID-SYN2>3.0.CO;2-5
   McCullumsmith RE, 2002, NEUROPSYCHOPHARMACOL, V26, P368, DOI 10.1016/S0893-133X(01)00370-0
   McGlashan TH, 2001, SCHIZOPHRENIA BULL, V27, P563, DOI 10.1093/oxfordjournals.schbul.a006896
   Meltzer HY, 1999, SCHIZOPHRENIA BULL, V25, P233, DOI 10.1093/oxfordjournals.schbul.a033376
   MELTZER HY, 1985, ADV BIOCHEM PSYCHOPH, V40, P59
   MELTZER HY, 1989, J PHARMACOL EXP THER, V251, P238
   Meltzer HY, 1996, BRIT J PSYCHIAT, V168, P23, DOI 10.1192/S0007125000298280
   Millan MJ, 2000, J PHARMACOL EXP THER, V292, P54
   Miyamoto S, 2001, BRAIN RES, V894, P167, DOI 10.1016/S0006-8993(01)01991-6
   Miyamoto S, 2002, NEUROPSYCHOPHARMACOL, P775
   Miyamoto S, 2000, CURR OPIN CPNS INVES, V2, P25
   Miyamoto S, 2003, PSYCHIATRY, V2, P1928
   MIYAMOTO S, 2003, SCHIZOPHRENIA, P442
   Moghaddam B, 1997, J NEUROSCI, V17, P2921
   NORDSTROM AL, 1995, AM J PSYCHIAT, V152, P1444
   NORDSTROM AL, 1993, BIOL PSYCHIAT, V33, P227, DOI 10.1016/0006-3223(93)90288-O
   Nyberg S, 2000, PSYCHOPHARMACOLOGY, V148, P22, DOI 10.1007/s002130050020
   Ossowska K, 1999, N-S ARCH PHARMACOL, V359, P280, DOI 10.1007/PL00005353
   PATEL JK, 2003, PSYCHIATRY, P1131
   Perry KW, 1999, SCHIZOPHR RES, V36, P117
   Potkin SG, 2003, ARCH GEN PSYCHIAT, V60, P681, DOI 10.1001/archpsyc.60.7.681
   Rein W, 2003, EUR NEUROPSYCHOPHARM, V13, pS95, DOI 10.1016/S0924-977X(03)91598-7
   Remington G, 1999, J CLIN PSYCHIAT, V60, P15
   Remington G, 2003, J PSYCHIATR NEUROSCI, V28, P275
   Remington G, 2000, PSYCHOPHARMACOLOGY, V148, P3, DOI 10.1007/s002130050017
   Rezvani AH, 2001, BIOL PSYCHIAT, V49, P258, DOI 10.1016/S0006-3223(00)01094-5
   Ruiz JS, 2008, ACTAS ESP PSIQUIATRI, V36, P251
   SANDS DE, 1954, J MENT SCI, V100, P211
   Schmidt CJ, 2003, SCHIZOPHR RES, V60, P114, DOI 10.1016/S0920-9964(03)80867-8
   Schoemaker H, 1997, J PHARMACOL EXP THER, V280, P83
   Schreiber R, 2002, PSYCHOPHARMACOLOGY, V159, P248, DOI 10.1008/s00213-001-0927-8
   SCHULZ C, 2000, SCHIZOPHRENIA MOOD D
   SEEMAN P, 1987, SYNAPSE, V1, P133, DOI 10.1002/syn.890010203
   Seeman P, 1999, AM J PSYCHIAT, V156, P876, DOI 10.1176/ajp.156.6.876
   SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0
   SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0
   Shapiro DA, 2003, NEUROPSYCHOPHARMACOL, V28, P1400, DOI 10.1038/sj.npp.1300203
   Sharif ZA, 1998, J CLIN PSYCHIAT, V59, P5
   Shastry BS, 2002, INT J MOL MED, V9, P207
   Sicras-Mainar A, 2008, ACTAS ESP PSIQUIATRI, V36, P90
   Silvestri S, 2000, PSYCHOPHARMACOLOGY, V152, P174, DOI 10.1007/s002130000532
   SPOHN HE, 1989, J ABNORM PSYCHOL, V98, P367, DOI 10.1037//0021-843X.98.4.367
   Spurney CF, 1999, SYNAPSE, V34, P266, DOI 10.1002/(SICI)1098-2396(19991215)34:4<266::AID-SYN3>3.0.CO;2-2
   Stahl SM, 1998, J CLIN PSYCHIAT, V59, P277, DOI 10.4088/JCP.v59n0601
   STRAUSS EB, 1952, BRIT MED J, V2, P64, DOI 10.1136/bmj.2.4775.64
   STRAUSS EB, 1955, J NEUROL NEUROSUR PS, V18, P137, DOI 10.1136/jnnp.18.2.137
   Strous RD, 2003, ARCH GEN PSYCHIAT, V60, P133, DOI 10.1001/archpsyc.60.2.133
   Tarazi FI, 1996, PSYCHOPHARMACOLOGY, V128, P371, DOI 10.1007/s002130050147
   Tascedda F, 1999, NEUROPSYCHOPHARMACOL, V21, P211, DOI 10.1016/S0893-133X(99)00034-2
   Thome J, 1998, J NEURAL TRANSM, V105, P85, DOI 10.1007/s007020050040
   TOURNEY G, 1979, BIOL PSYCHIAT, V14, P395
   UHLEN S, 1995, PHARMACOL TOXICOL, V76, P353, DOI 10.1111/j.1600-0773.1995.tb00161.x
   WADDINGTON J, 2000, SCHIZOPHRENIA MOOD D, P3
   Watkins P, 2000, NEUROLOGY, V55, pS51
   WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660
   Weiss E, 2002, ARCH GEN PSYCHIAT, V59, P572, DOI 10.1001/archpsyc.59.6.572
NR 117
TC 17
Z9 18
U1 3
U2 18
PU JUAN JOSE LOPEZ-IBOR FOUNDATION
PI MADRID
PA NO 2, MADRID, 28035, SPAIN
SN 1139-9287
EI 1578-2735
J9 ACTAS ESP PSIQUIATRI
JI Actas Esp. Psiquiatri.
PD NOV-DEC
PY 2009
VL 37
IS 6
BP 330
EP 342
PG 13
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 562LN
UT WOS:000275052100005
PM 20066585
DA 2018-12-27
ER

PT J
AU Song, YL
   Yuan, SL
   Zhang, JM
AF Song, Yongli
   Yuan, Sanling
   Zhang, Jianming
TI RETRACTED: Bifurcation analysis in the delayed Leslie-Gower
   predator-prey system (Retracted article. See vol. 37, pg. 9451, 2013)
SO APPLIED MATHEMATICAL MODELLING
LA English
DT Article; Retracted Publication
DE Predator-prey system; Delay; Stability; Hopf bifurcation; Periodic
   solution
ID FUNCTIONAL-DIFFERENTIAL EQUATIONS; HOPF-BIFURCATION; NORMAL FORMS;
   STABILITY; MODEL
AB In this paper, the delayed Leslie-Gower predator-prey system is investigated. By choosing the delay as a bifurcation parameter, we show that Hopf bifurcations can Occur as the delay crosses some critical values. By deriving the equation describing the flow on the center manifold, we can determine the direction of the Hopf bifurcations and the stability of the bifurcating periodic solutions. In addition, special attention is paid to the global continuation of local Hopf bifurcations. Using a global Hopf bifurcation result of Wu [J. Wu, Symmetric functional differential equations neural networks with memory, Trans. Am. Math. Soc. 350 (1998) 4799-4838] for functional differential equations, we may show the global existence of periodic Solutions. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Song, Yongli] Tongji Univ, Dept Math, Shanghai 200092, Peoples R China.
   [Yuan, Sanling] Shanghai Univ Sci & Technol, Dept Basic Sci, Shanghai 200093, Peoples R China.
   [Zhang, Jianming] Zhejiang Sci Tech Univ, Dept Math, Hangzhou 310018, Zhejiang, Peoples R China.
RP Song, YL (reprint author), Tongji Univ, Dept Math, Shanghai 200092, Peoples R China.
EM syl.mail@163.com
FU Doctoral Fund of Ministry of Education of China [200802471024]; National
   Nature Science Foundation of China [10871129]; Innovation Program of
   Shanghai Municipal Education Commission [09ZZ33]
FX The authors Would like to acknowledge the Supports from Doctoral Fund of
   Ministry of Education of China (No.200802471024), from the National
   Nature Science Foundation of China (no.10871129) and from Innovation
   Program of Shanghai Municipal Education Commission (09ZZ33). We are
   grateful to thank the anonymous referees for their careful reading and
   constructive Suggestions which lead to truly significant improvement of
   the manuscript.
CR Beretta E, 1996, J MATH ANAL APPL, V204, P840, DOI 10.1006/jmaa.1996.0471
   Beretta E, 1998, NONLINEAR ANAL-THEOR, V32, P381, DOI 10.1016/S0362-546X(97)00491-4
   Braza PA, 2003, SIAM J APPL MATH, V63, P889, DOI 10.1137/S0036139901393494
   Chow SN, 1982, METHODS BIFURCATION
   COLLINGS JB, 1995, B MATH BIOL, V57, P63, DOI 10.1016/0092-8240(94)00024-7
   Cushing J. M., 1977, INTEGRODIFFERENTIAL
   FARIA T, 1995, J DIFFER EQUATIONS, V122, P201, DOI 10.1006/jdeq.1995.1145
   FARIA T, 1995, J DIFFER EQUATIONS, V122, P181, DOI 10.1006/jdeq.1995.1144
   Faria T, 2001, J MATH ANAL APPL, V254, P433, DOI 10.1006/jmaa.2000.7182
   GOPALSAMY K, 1984, J AUST MATH SOC B, V25, P473, DOI 10.1017/S0334270000004227
   GOPALSAMY K, 1983, B MATH BIOL, V45, P295, DOI 10.1016/S0092-8240(83)80058-5
   Gopalsamy K, 1992, STABILITY OSCILLATIO
   Hale J. K., 1993, INTRO FUNCTIONAL DIF, V1, P1
   HSU SB, 1995, SIAM J APPL MATH, V55, P763, DOI 10.1137/S0036139993253201
   Kuang Y., 1993, DELAY DIFFERENTIAL E
   LESLIE PH, 1960, BIOMETRIKA, V47, P219, DOI 10.1093/biomet/47.3-4.219
   Liu ZH, 2006, CHAOS SOLITON FRACT, V27, P1395, DOI 10.1016/j.chaos.2005.05.014
   Liu ZH, 2005, NONLINEAR ANAL-REAL, V6, P187, DOI 10.1016/j.nonwra.2004.08.005
   Liu ZH, 2004, J MATH ANAL APPL, V296, P521, DOI 10.1016/j.jmaa.2004.04.051
   May R. M, 1974, STABILITY COMPLEXITY
   MAY RM, 1973, ECOLOGY, V54, P315, DOI 10.2307/1934339
   Song YL, 2005, J MATH ANAL APPL, V301, P1, DOI 10.1016/j.jmaa.2004.06.056
   Song YL, 2008, J MATH ANAL APPL, V337, P466, DOI 10.1016/j.jmaa.2007.04.001
   TANNER JT, 1975, ECOLOGY, V56, P855, DOI 10.2307/1936296
   Wu JH, 1998, T AM MATH SOC, V350, P4799, DOI 10.1090/S0002-9947-98-02083-2
   XIAO D, 2003, P EDINBURGH MATH SOC, V46, P494
   Xiao DM, 2003, P EDINBURGH MATH SOC, V46, P205, DOI 10.1017/S0013091500001140
   Xiao DM, 2001, J DIFFER EQUATIONS, V176, P494, DOI 10.1006/jdeq.2000.3982
   Yan XP, 2008, NONLINEAR ANAL-REAL, V9, P114, DOI 10.1016/j.nonrwa.2006.09.007
NR 29
TC 38
Z9 41
U1 5
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0307-904X
EI 1872-8480
J9 APPL MATH MODEL
JI Appl. Math. Model.
PD NOV
PY 2009
VL 33
IS 11
BP 4049
EP 4061
DI 10.1016/j.apm.2009.02.008
PG 13
WC Engineering, Multidisciplinary; Mathematics, Interdisciplinary
   Applications; Mechanics
SC Engineering; Mathematics; Mechanics
GA 479HV
UT WOS:000268651200003
OA Bronze
DA 2018-12-27
ER

PT J
AU Vaidyanathan, R
   Kalishwaralal, K
   Gopalram, S
   Gurunathan, S
AF Vaidyanathan, Ramanathan
   Kalishwaralal, Kalimuthu
   Gopalram, Shubaash
   Gurunathan, Sangiliyandi
TI RETRACTED: Nanosilver-The burgeoning therapeutic molecule and its green
   synthesis (Retracted article. See vol. 28, pg. 940, 2010)
SO BIOTECHNOLOGY ADVANCES
LA English
DT Review; Retracted Publication
DE Green synthesis; Silver nanoparticles; Anti-bacterial; Antifungal;
   Anti-viral; Anti-inflammatory agent; Cancer therapy
ID SURFACE-ENHANCED RAMAN; SILVER NANOPARTICLES; EXTRACELLULAR
   BIOSYNTHESIS; NANOCRYSTALLINE SILVER; BACILLUS-LICHENIFORMIS; METAL
   NANOPARTICLES; CULTURE SUPERNATANT; MEDIATED SYNTHESIS;
   ENDOTHELIAL-CELLS; TEXTILE FABRICS
AB Nanotechnology is a field that is burgeoning day by day. making an impact in all spheres of human life. Biological methods of synthesis have paved way for the "greener synthesis" of nanoparticles and these have proven to be better methods due to slower kinetics, they offer better manipulation and control over crystal growth and their stabilization. This has motivated an upsurge in research on the synthesis routes that allow better control of shape and size for various nanotechnological applications Nanosilver has developed as a potent antibacterial. antifungal, anti-viral and anti-inflammatory agent The recent advancement in the Field includes the enzymatic method of synthesis suggesting enzymes to be responsible for the nanoparticle formation The biomedical applications of silver nanoparticle can be effective by the Use of biologically synthesized nanoparticles which minimize the factors such as toxicity and cost and are found to be exceptionally stable. The targeting of cancer cells using silver nanoparticles has proven to be effective, but neither the exact mechanism of action nor the modes of activation of the downstream signaling molecules have been revealed yet The review illustrates a probable signaling pathway and mechanism by which silver nanoparticles target the cancer cells. The current review also examines the historical background of nanoparticles. role of silver nanoparticles in various biomedical applications and also focusing oil better methods of the synthesis of nanoparticles (C) 2009 Elsevier Inc All rights reserved
C1 [Vaidyanathan, Ramanathan; Kalishwaralal, Kalimuthu; Gopalram, Shubaash; Gurunathan, Sangiliyandi] Kalasalingam Univ, Div Mol & Cellular Biol, Dept Biotechnol, Krishnankoil 626190, Tamil Nadu, India.
RP Gurunathan, S (reprint author), Kalasalingam Univ, Div Mol & Cellular Biol, Dept Biotechnol, Krishnankoil 626190, Tamil Nadu, India.
EM lvsangs@yahoo.com
CR Abraham Guy E., 1997, Journal of Nutritional and Environmental Medicine (Abingdon), V7, P295
   Ahmad A, 2003, COLLOID SURFACE B, V28, P313, DOI 10.1016/S0927-7765(02)00174-1
   Alt V, 2004, BIOMATERIALS, V25, P4383, DOI 10.1016/j.biomaterials.2003.10.078
   ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916
   Atiyeh BS, 2007, BURNS, V33, P139, DOI 10.1016/j.burns.2006.06.010
   Balaji DS, 2009, COLLOID SURFACE B, V68, P88, DOI 10.1016/j.colsurfb.2008.09.022
   Banumathi E, 2009, MICROVASC RES, V77, P377, DOI 10.1016/j.mvr.2008.12.005
   Basavaraja S, 2008, MATER RES BULL, V43, P1164, DOI 10.1016/j.materresbull.2007.06.020
   Bayler A, 1996, J AM CHEM SOC, V118, P7006, DOI 10.1021/ja961363v
   BEVERIDGE TJ, 1976, J BACTERIOL, V127, P1502
   BEVERIDGE TJ, 1985, CAN J EARTH SCI, V22, P1893, DOI 10.1139/e85-204
   Bfilainsa KC, 2006, COLLOID SURFACE B, V47, P160, DOI 10.1016/j.colsurfb.2005.11.026
   Bhat JSA, 2003, CURR SCI INDIA, V85, P147
   Bhattacharya R, 2008, ADV DRUG DELIVER REV, V60, P1289, DOI 10.1016/j.addr.2008.03.013
   Bhol KC, 2004, CLIN EXP DERMATOL, V29, P282, DOI 10.1111/j.1365-2230.2004.01515.x
   Bohr MT, 2002, IEEE T NANOTECHNOL, V1, P56, DOI 10.1109/TNANO.2002.1005426
   Bonet F, 1999, INT J INORG MATER, V1, P47, DOI 10.1016/S1463-0176(99)00007-1
   Breusch SJ, 2000, UNFALLCHIRURG, V103, P918, DOI 10.1007/s001130050647
   BUCHHOLZ HW, 1970, CHIRURG, V41, P511
   Carlson C, 2008, J PHYS CHEM B, V112, P13608, DOI 10.1021/jp712087m
   CHARLES RM, 2008, NAT IMMUNOL, V9, P988
   Chen X, 2008, TOXICOL LETT, V176, P1, DOI 10.1016/j.toxlet.2007.10.004
   CHU CS, 1988, J TRAUMA, V28, P1488, DOI 10.1097/00005373-198810000-00016
   DAVID MB, 2005, TOXICOL SCI, V88, P298
   DEITCH EA, 1987, J TRAUMA, V27, P301
   Demling R. H., 2002, LEADERSHIP MEDICA, V16, P1
   DENNIS A, 2004, NAT REV MICROBIOL, V2, P217
   DEVIKA CB, 2006, NANO LETT, V6, P662
   DOYLE RJ, 1980, J BACTERIOL, V143, P471
   Duran N, 2007, J BIOMED NANOTECHNOL, V3, P203, DOI 10.1166/jbn.2007.022
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Fan FRF, 2002, J PHYS CHEM B, V106, P279, DOI 10.1021/jp012548d
   Forster MJ, 2000, J MOL BIOL, V298, P841, DOI 10.1006/jmbi.2000.3715
   Fu JK, 1999, CHEM J CHINESE U, V20, P1452
   Gade AK, 2008, J BIOBASED MATER BIO, V2, P243, DOI 10.1166/.jbmb.2008.401
   GADE AK, 2008, J BIOBASED MATER BIO, V3, P123
   Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994
   Ghosh P, 2008, ADV DRUG DELIVER REV, V60, P1307, DOI 10.1016/j.addr.2008.03.016
   GOODSELL DS, 2004, BIONANOTECHNOLOGY LE, P224
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   Groll AH, 1996, J INFECTION, V33, P23, DOI 10.1016/S0163-4453(96)92700-0
   Gurunathan S, 2002, EMBO J, V21, P602, DOI 10.1093/emboj/21.4.602
   Gurunathan S, 2000, MOL BIOL CELL, V11, P3629, DOI 10.1091/mbc.11.10.3629
   HAEFELI C, 1984, J BACTERIOL, V158, P389
   Hartsel S, 1996, TRENDS PHARMACOL SCI, V17, P445, DOI 10.1016/S0165-6147(96)01012-7
   HOPE PG, 1989, J BONE JOINT SURG BR, V71, P851
   Hsin YH, 2008, TOXICOL LETT, V179, P130, DOI 10.1016/j.toxlet.2008.04.015
   Huang JL, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/10/105104
   James EM, 1999, ULTRAMICROSCOPY, V78, P125, DOI 10.1016/S0304-3991(99)00018-2
   James VR, 2008, NANO RES LET, V3, P129
   John C.P., 2008, DIABETES-METAB RES, V24, P604
   Kairemo K, 2008, CURR RADIOPHARM, V1, P30, DOI 10.2174/1874471010801010030
   Kalimuthu K, 2008, COLLOID SURFACE B, V65, P150, DOI 10.1016/j.colsurfb.2008.02.018
   Kalishwaralal K, 2008, MATER LETT, V62, P4411, DOI 10.1016/j.matlet.2008.06.051
   Kalishwaralal K, 2009, COLLOID SURFACE B, V73, P51, DOI 10.1016/j.colsurfb.2009.04.025
   KAPOOR S, 1994, LANGMUIR, V10, P3018, DOI 10.1021/la00021a026
   Kauffman CA, 1997, DRUGS, V53, P539, DOI 10.2165/00003495-199753040-00001
   Kim KJ, 2008, J MICROBIOL BIOTECHN, V18, P1482
   Kim SH, 2008, J ADHES SCI TECHNOL, V22, P235, DOI 10.1163/156856108X305156
   Klasen HJ, 2000, BURNS, V26, P131, DOI 10.1016/S0305-4179(99)00116-3
   Klasen HJ, 2000, BURNS, V26, P117, DOI 10.1016/S0305-4179(99)00108-4
   Klaus T, 1999, P NATL ACAD SCI USA, V96, P13611, DOI 10.1073/pnas.96.24.13611
   Kowanetz M, 2006, CLIN CANCER RES, V12, P5018, DOI 10.1158/1078-0432.CCR-06-1520
   Kreibig U., 1995, OPTICAL PROPERTIES M, P207
   Kumagai K, 2008, J CARDIOVASC ELECTR, V19, P495, DOI 10.1111/j.1540-8167.2007.01085.x
   Kumar SA, 2007, BIOTECHNOL LETT, V29, P439, DOI 10.1007/s10529-006-9256-7
   Lanone S, 2006, CURR MOL MED, V6, P651, DOI 10.2174/156652406778195026
   Law N, 2008, APPL ENVIRON MICROB, V74, P7090, DOI 10.1128/AEM.01069-08
   Lee HJ, 2003, J MATER SCI, V38, P2199, DOI 10.1023/A:1023736416361
   LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025
   Li YD, 1999, J COLLOID INTERF SCI, V209, P347, DOI 10.1006/jcis.1998.5879
   Lin ZY, 2005, SPECTROCHIM ACTA A, V61, P1195, DOI 10.1016/j.saa.2004.06.041
   LUT L, 2008, ANTIVIR THER, V13, P253
   MARGRAF HW, 1977, ARCH SURG-CHICAGO, V112, P699
   MARIA Y, 2002, SCIENCE, V296, P490
   MIZUSHIMA Y, 1965, JPN J PHARMACOL, V15, P131, DOI 10.1254/jjp.15.131
   Moyer C A, 1965, Trans Stud Coll Physicians Phila, V33, P53
   Moyer C A, 1965, J Natl Med Assoc, V57, P95
   MOYER CA, 1965, ARCH SURG-CHICAGO, V90, P812
   Mukherjee P, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/7/075103
   Mukherjee P, 2001, NANO LETT, V1, P515, DOI 10.1021/nl0155274
   MULLEN MD, 1989, APPL ENVIRON MICROB, V55, P3143
   Nadworny P.L., 2008, NANOMEDICINE, V3, P241
   Nair B, 2002, CRYST GROWTH DES, V2, P293, DOI 10.1021/cg0255164
   Nickel U, 2000, LANGMUIR, V16, P9087, DOI 10.1021/la000536y
   NIES DH, 1992, PLASMID, V27, P17, DOI 10.1016/0147-619X(92)90003-S
   Otrock ZK, 2007, BLOOD CELL MOL DIS, V38, P258, DOI 10.1016/j.bcmd.2006.12.003
   Pal S, 2007, APPL ENVIRON MICROB, V73, P1712, DOI 10.1128/AEM.02218-06
   Parikh RY, 2008, CHEMBIOCHEM, V9, P1415, DOI 10.1002/cbic.200700592
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Petersen S, 1996, J CONSTR PSYCHOL, V9, P75
   Portney NG, 2006, ANAL BIOANAL CHEM, V384, P620, DOI 10.1007/s00216-005-0247-7
   Raveendran P, 2003, J AM CHEM SOC, V125, P13940, DOI 10.1021/ja029267j
   Rigobello MP, 2002, BRIT J PHARMACOL, V136, P1162, DOI 10.1038/sj.bjp.0704823
   Rivas L, 2001, LANGMUIR, V17, P574, DOI 10.1021/la001038s
   Sahoo SK, 2003, DRUG DISCOV TODAY, V8, P1112, DOI 10.1016/S1359-6446(03)02903-9
   Saifuddin N, 2009, E-J CHEM, V6, P61, DOI 10.1155/2009/734264
   SCHNEIDER S, 1994, PHOTOCHEM PHOTOBIOL, V60, P605, DOI 10.1111/j.1751-1097.1994.tb05156.x
   Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276
   Shahverdi AR, 2007, PROCESS BIOCHEM, V42, P919, DOI 10.1016/j.procbio.2007.02.005
   Shankar SS, 2004, J COLLOID INTERF SCI, V275, P496, DOI 10.1016/j.jcis.2004.03.003
   Shirtcliffe N, 1999, J COLLOID INTERF SCI, V211, P122, DOI 10.1006/jcis.1998.5980
   Silver S, 2003, FEMS MICROBIOL REV, V27, P341, DOI 10.1016/S0168-6445(03)00047-0
   Silver S, 2006, J IND MICROBIOL BIOT, V33, P627, DOI 10.1007/s10295-006-0139-7
   Sondi I, 2004, J COLLOID INTERF SCI, V275, P177, DOI 10.1016/j.jcis.2004.02.012
   Taniguchi N., 1974, P INT C PROD ENG T 2, P18
   Tao A, 2006, ANGEW CHEM INT EDIT, V45, P4597, DOI 10.1002/anie.200601277
   TAS J, 1981, J HISTOCHEM CYTOCHEM, V29, P929, DOI 10.1177/29.8.6168679
   THIERSE L, 1978, Z ORTHOP GRENZGEB, V116, P847
   Tian J, 2007, CHEMMEDCHEM, V2, P129, DOI 10.1002/cmdc.200600171
   Vigneshwaran N, 2007, MATER LETT, V61, P1413, DOI 10.1016/j.matlet.2006.07.042
   Vigneshwaran N, 2006, COLLOID SURFACE B, V53, P55, DOI 10.1016/j.colsurfb.2006.07.014
   Viswanathan M, 2003, CLIN CANCER RES, V9, P1057
   Wadhera Akhil, 2005, Dermatol Online J, V11, P12
   Wannske M., 1979, AKTUELLE PROBLEME CH, V12, P201
   White C, 1997, FEMS MICROBIOL REV, V20, P503, DOI 10.1016/S0168-6445(97)00029-6
   White C, 1998, NAT BIOTECHNOL, V16, P572, DOI 10.1038/nbt0698-572
   Wiley B, 2005, CHEM-EUR J, V11, P454, DOI 10.1002/chem.200400927
   WOODLEAND MC, 2005, NANO TODAY, V8, P34
   Wright JB, 2002, WOUND REPAIR REGEN, V10, P141, DOI 10.1046/j.1524-475X.2002.10308.x
   Zhang HR, 2005, J CHEM TECHNOL BIOT, V80, P285, DOI 10.1002/jctb.1191
NR 121
TC 141
Z9 147
U1 4
U2 65
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0734-9750
EI 1873-1899
J9 BIOTECHNOL ADV
JI Biotechnol. Adv.
PD NOV-DEC
PY 2009
VL 27
IS 6
BP 924
EP 937
DI 10.1016/j.biotechadv.2009.08.001
PG 14
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 516PH
UT WOS:000271554200021
PM 19686832
DA 2018-12-27
ER

PT J
AU Lorenzo, VF
   Yang, YZ
   Simonson, TS
   Nussenzveig, R
   Jorde, LB
   Prchal, JT
   Ge, RL
AF Lorenzo, Felipe, V
   Yang, Yingzhong
   Simonson, Tatum S.
   Nussenzveig, Roberto
   Jorde, Lynn B.
   Prchal, Josef T.
   Ge, Ri-Li
TI RETRACTED: Genetic adaptation to extreme hypoxia: Study of high-altitude
   pulmonary edema in a three-generation Han Chinese family (Retracted
   Article. See vol 44, pg 198, 2010)
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Article; Retracted Publication
DE Hypoxia; Erythropoietin; High-altitude pulmonary edema (HAPE);
   Endothelial nitric oxide (eNOS); Hypoxia inducible factor (HIF)
ID OXIDE SYNTHASE GENE; CHRONIC MOUNTAIN-SICKNESS; ASSOCIATION; EXPRESSION;
   RESPONSES; POLYMORPHISMS; TIBETAN; HIF-1
AB Organismal response to hypoxia is essential for critical regulation of erythropoiesis, other physiological functions, and survival. There is evidence of individual variation in response to hypoxia as some but not all of the affected individuals develop polycythemia, and or pulmonary and cerebral edema. A significant population difference in response to hypoxia exist as many highland Tibetan, Ethiopian, and Andean natives developed adaptive mechanisms to extreme hypoxia. A proportion of non-adapted individuals exposed to high attitude develop pulmonary edema (HAPE), pulmonary hypertension, cerebral edema, and extreme polycythemia. The isolation of causative gene(s) responsible for HAPE and other extreme hypoxia complications would provide a rational basis for specific targeted therapy of HAPE, allow its targeted prevention for at-risk populations, and clarify the pathophysiology of other hypoxic maladaptations. The only suggested genetic linkage among unrelated individuals with HAPE has been with endothelial nitric oxide synthase (eNOS) gene. Here we describe a family with multiple members affected with HAPE in three generations. Families with multiple affected members with HAPE have not been described. We first ruled out linkage of HAPE with the eNOS gene. We then performed an analysis of the whole genome using high-density SNP arrays (Affymetrix v5.0) and, assuming a single gene causation of HAPE, ruled out linkage with 34 other candidate genes. Only the HIF2A haplotype was shared by individuals who exhibit the HAPE phenotype, and work on its possible causative role in HAPE is in progress. The small size of our family does not provide sufficient power for a conclusive analysis of linkage. We hope that collaboration with other investigators with access to more HAPE patients will lead to the identification of gene(s) responsible for HAPE and possibly other maladaptive hypoxic complications. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Lorenzo, Felipe, V; Yang, Yingzhong; Prchal, Josef T.] Univ Utah, Sch Med, Div Hematol, Salt Lake City, UT 84132 USA.
   [Yang, Yingzhong; Ge, Ri-Li] Qinghai Univ, Res Ctr High Attitude Med, Xining 810001, Qinghai, Peoples R China.
   [Simonson, Tatum S.; Jorde, Lynn B.] Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84132 USA.
   [Nussenzveig, Roberto; Prchal, Josef T.] ARUP Labs, Salt Lake City, UT 84108 USA.
RP Prchal, JT (reprint author), Univ Utah, Sch Med, Div Hematol, SOM 5C210,30 N 1900 E, Salt Lake City, UT 84132 USA.
EM josef.prchal@hsc.utah.edu; geriligao@hotmail.com
FU NIH [R01 HL50077-11, GM-59290]
FX The presented study was supported by R01 HL50077-11, VAH Merit review
   grant (JTP) NIH grant GM-59290 (LJ).
CR Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786
   *AFF, 2006, BRLMM IMPR GEN CALL
   Ahsan A, 2006, CHEST, V130, P1511, DOI 10.1378/chest.130.5.1511
   ANGELO G, 2003, J BIOL CHEM, V278, P38183
   Beall CM, 2006, INTEGR COMP BIOL, V46, P18, DOI 10.1093/icb/icj004
   Beall CM, 2007, P NATL ACAD SCI USA, V104, P8655, DOI 10.1073/pnas.0701985104
   Cattaruzza M, 2004, CIRC RES, V95, P841, DOI 10.1161/01.RES.0000145359.47708.2f
   Droma Y, 2002, CIRCULATION, V106, P826, DOI 10.1161/01.CIR.0000024409.30143.70
   Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047
   GE RL, 2001, APPL PHYSL, V92, P2361
   Gluecker T, 1999, RADIOGRAPHICS, V19, P1507, DOI 10.1148/radiographics.19.6.g99no211507
   Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.citrevonc.2005.12.003
   Jedlickova K, 2003, BLOOD CELL MOL DIS, V31, P175, DOI 10.1016/S1079-9796(03)00153-0
   Jefferson JA, 2002, LANCET, V359, P407, DOI 10.1016/S0140-6736(02)07594-3
   KAWASHIMA A, 1989, J APPL PHYSIOL, V67, P1982
   Kline DD, 2002, P NATL ACAD SCI USA, V99, P821, DOI 10.1073/pnas.022634199
   Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592
   Liu SP, 2007, J INFRARED MILLIM W, V26, P217
   Maggiorini M, 2006, CARDIOVASC RES, V72, P41, DOI 10.1016/j.cardiores.2006.07.004
   Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958
   MATSUZAWA Y, 1989, J APPL PHYSIOL, V66, P1152
   Mejia OM, 2005, HAEMATOLOGICA, V90, P13
   Miyamoto Y, 2000, HUM MOL GENET, V9, P2629, DOI 10.1093/hmg/9.18.2629
   Qutub AA, 2007, BBA-MOL CELL RES, V1773, P1511, DOI 10.1016/j.bbamcr.2007.07.004
   Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117
   Tesauro M, 2000, P NATL ACAD SCI USA, V97, P2832, DOI 10.1073/pnas.97.6.2832
   Tsukada T, 1998, BIOCHEM BIOPH RES CO, V245, P190, DOI 10.1006/bbrc.1998.8267
   Wang XL, 2000, FEBS LETT, V471, P45, DOI 10.1016/S0014-5793(00)01356-9
NR 28
TC 16
Z9 22
U1 5
U2 17
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
EI 1096-0961
J9 BLOOD CELL MOL DIS
JI Blood Cells Mol. Dis.
PD NOV-DEC
PY 2009
VL 43
IS 3
BP 221
EP 225
DI 10.1016/j.bcmd.2009.04.006
PG 5
WC Hematology
SC Hematology
GA 515PO
UT WOS:000271484600001
PM 19481479
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Hazra, A
   Barua, A
   Nguyen, N
   Wadade, T
   Bodmann, B
   Josic, K
   Ziburkus, J
AF Hazra, Anupam
   Barua, A.
   Nguyen, N.
   Wadade, T.
   Bodmann, B.
   Josic, K.
   Ziburkus, J.
TI RETRACTED: SPATIOTEMPORAL DYNAMICS OF EPILEPTIFORM ACTIVITY IN VITRO
   (Retracted article. See vol. 51, pg. 1647, 2010)
SO EPILEPSIA
LA English
DT Meeting Abstract; Retracted Publication
CT 63rd Annual Meeting of the American-Epilepsy-Society
CY DEC 04-08, 2009
CL Boston, MA
SP Amer Epilepsy Soc
C1 [Hazra, Anupam; Barua, A.; Nguyen, N.; Wadade, T.; Bodmann, B.; Josic, K.; Ziburkus, J.] Univ Houston, Houston, TX USA.
NR 0
TC 1
Z9 1
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD NOV
PY 2009
VL 50
SU 11
BP 348
EP 349
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 503PP
UT WOS:000270550500773
DA 2018-12-27
ER

PT J
AU Schreiber, TD
   Steinl, C
   Essl, M
   Abele, H
   Geiger, K
   Muller, CA
   Aicher, WK
   Klein, G
AF Schreiber, Thomas D.
   Steinl, Carolin
   Essl, Mike
   Abele, Harald
   Geiger, Konstanze
   Mueller, Claudia A.
   Aicher, Wilhelm K.
   Klein, Gerd
TI RETRACTED: The integrin alpha 9 beta 1 on hematopoietic stem and
   progenitor cells: involvement in cell adhesion, proliferation and
   differentiation (Retracted Article. See vol 95, pg 344, 2010)
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Article; Retracted Publication
DE cell adhesion; bone marrow microenvironment; hematopoietic stem and
   progenitor cells; osteoblasts
ID BONE-MARROW; NICHE; EXPRESSION; MOBILIZATION; OSTEOPONTIN; MUTATIONS;
   COMPONENT; MICE; OSTEOBLASTS; MIGRATION
AB Background
   Hematopoietic stem and progenitor cells can interact with their microenvironment via integrins which are adhesion receptors consisting of alpha and beta subunits. Current knowledge suggests that the integrin subunits alpha 4 and alpha 6 expressed on hematopoietic stem and progenitor cells have distinct roles in retaining stem cells in the bone marrow. The aim of our study was to gain insight into the expression and functions of the integrin subunits alpha 7-alpha 11 within the endosteal stem cell niche.
   Design and Methods
   Human osteoblasts isolated from trabecular bone and hematopoietic stem and progenitor cells purified from umbilical cord blood or bone marrow aspirates were analyzed for the expression of integrin alpha 7-alpha 11 chains by reverse transcriptase polymerase chain reaction. The involvement of the integrin alpha 9 beta 1 in hematopoietic stem and progenitor cell adhesion, proliferation and differentiation was analyzed in functional assays.
   Results
   Transcripts for all investigated integrin chains were found in primary osteoblasts. Highly purified hematopoietic stem and progenitor cells, however, expressed only transcripts encoding integrin subunits alpha 7 and alpha 9. Flow cytometric analysis verified extracellular expression of the integrin alpha 9 beta 1 on hematopoietic stem and progenitor cells. Cell-cell adhesion assays with osteoblasts and dye-labeled CD34(+) hematopoietic stem and progenitor cells in the presence of function-blocking antibodies revealed a role of integrin alpha 9 in hematopoietic stem and progenitor cell adhesion to osteoblasts. Furthermore, the addition of anti-integrin a9 antibodies significantly inhibited proliferation and in vitro differentiation of CD34(+) hematopoietic stem and progenitor cells.
   Conclusions
   The integrin alpha 9 beta 1 has been identified as a new member of the integrin beta 1-subfamily expressed on human hematopoietic stem and progenitor cells. The functional studies strongly suggest that integrin alpha 9 beta 1 contributes to adhesion and differentiation of hematopoietic stem and progenitor cells in the endosteal stem cell niche.
C1 [Schreiber, Thomas D.; Steinl, Carolin; Essl, Mike; Geiger, Konstanze; Mueller, Claudia A.; Klein, Gerd] Univ Tubingen, Univ Med Clin, Med Res Ctr, Sect Transplantat Immunol & Immunohematol, D-72072 Tubingen, Germany.
   [Abele, Harald] Univ Tubingen, Dept Gynecol & Obstet, D-72072 Tubingen, Germany.
   [Aicher, Wilhelm K.] Univ Tubingen, Ctr Regenerat Med, D-72072 Tubingen, Germany.
RP Klein, G (reprint author), Univ Tubingen, Univ Med Clin, Med Res Ctr, Sect Transplantat Immunol & Immunohematol, Waldhornlestr 22, D-72072 Tubingen, Germany.
EM gerd.klein@uni-tuebin-gen.de
RI Klein, Gerd/C-8499-2013
OI Aicher, Wilhelm K/0000-0003-2210-6773
FU Landesstiftung Baden-Wurttemberg gGmbH [P-LS-AS/HSPA8-13]
FX this work was supported by a grant from the Landesstiftung
   Baden-Wurttemberg gGmbH (grant N.P-LS-AS/HSPA8-13).
CR ARMEANU S, 1995, J CELL BIOL, V131, P243, DOI 10.1083/jcb.131.1.243
   BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9
   Bouvard D, 2001, CIRC RES, V89, P211, DOI 10.1161/hh1501.094874
   Bridges LC, 2005, CURR PHARM DESIGN, V11, P837, DOI 10.2174/1381612053381747
   CHAN TY, 2001, BRIT J HAEMATOL, V112, P541
   Chen C, 2006, IMMUNITY, V25, P895, DOI 10.1016/j.immuni.2006.10.013
   Gu YC, 2003, BLOOD, V101, P877, DOI 10.1182/blood-2002-03-0796
   Hergeth SP, 2008, EXP HEMATOL, V36, P1022, DOI 10.1016/j.exphem.2008.03.013
   Huang XZ, 2000, MOL CELL BIOL, V20, P5208, DOI 10.1128/MCB.20.14.5208-5215.2000
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Hynes RO, 1997, THROMB HAEMOSTASIS, V78, P83
   Jaatinen T, 2006, STEM CELLS, V24, P631, DOI 10.1634/stemcells.2005-0185
   Jones DL, 2008, NAT REV MOL CELL BIO, V9, P11, DOI 10.1038/nrm2319
   Kiel MJ, 2008, NAT REV IMMUNOL, V8, P290, DOI 10.1038/nri2279
   KLEIN G, 1995, BLOOD, V86, P1740
   Kopp HG, 2005, PHYSIOLOGY, V20, P349, DOI 10.1152/physiol.00025.2005
   LIESVELD JL, 1993, BLOOD, V81, P112
   Liu FL, 2000, BLOOD, V95, P3025
   MACKIE EJ, 1992, J CELL SCI, V103, P765
   MARK MP, 1987, J HISTOCHEM CYTOCHEM, V35, P707, DOI 10.1177/35.7.3295029
   Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood-2004-11-4422
   PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289
   Papayannopoulou T, 2000, SEMIN HEMATOL, V37, P11, DOI 10.1016/S0037-1963(00)90084-2
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qian H, 2006, BLOOD, V107, P3503, DOI 10.1182/blood-2005-10-3932
   Qian H, 2007, BLOOD, V110, P2399, DOI 10.1182/blood-2006-10-051276
   REUSSBORST MA, 1995, LEUKEMIA, V9, P869
   Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945-053X(00)00065-2
   Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485
   Staniszewska I, 2007, CIRC RES, V100, P1308, DOI 10.1161/01.RES.0000266662.98355.66
   Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992
   Taichman RS, 2005, BLOOD, V105, P2631, DOI 10.1182/blood-2004-06-2480
   Tanaka Y, 1998, CANCER RES, V58, P4138
   Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413
   van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417
   Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779
   Yin T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568
   YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691
NR 38
TC 40
Z9 41
U1 3
U2 16
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD NOV
PY 2009
VL 94
IS 11
BP 1493
EP 1501
DI 10.3324/haematol.2009.006072
PG 9
WC Hematology
SC Hematology
GA 524TJ
UT WOS:000272165800005
PM 19608669
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Kasper, CK
   Buzin, CH
AF Kasper, C. K.
   Buzin, C. H.
TI RETRACTED: Mosaics and haemophilia (Retracted article. See vol. 16, pg.
   972, 2010)
SO HAEMOPHILIA
LA English
DT Review; Retracted Publication
DE factor VIII; factor IX; haemophilia A; haemophilia B; mosaics; mutation
ID X-CHROMOSOME INACTIVATION; SOMATIC MOSAICISM; OSTEOGENESIS IMPERFECTA;
   GERMLINE MOSAICISM; MUTATION; FEMALE; GENE; DISEASE; CONSEQUENCES;
   TRANSMISSION
AB Some mosaic conditions may affect the haemophilia phenotype. Well-known instances include chromosomal mosaicism because of aneuploidy and pseudo-mosaicism because of varying patterns of X-chromosome inactivation. Chromosomal mosaicism in a chimera is a potential source of phenotypic variation. Gene mosaicism is commonplace. Its pattern and effect depend on the stage of development at which a mutation occurs. Proven or possible genetic mosaicism is an important consideration when predicting the likelihood of transmission of haemophilia to a future generation. A mosaic is an individual who has two or more cell lines, genetically different with regard to chromosomes or genes. As techniques improve and studies accumulate, mosaics are being found to be more common than hitherto believed. Some mosaic conditions may affect the phenotype of haemophilia in males and of the carrier state in females. Cells may be mosaic with regard to chromosomes, as in some instances of aneuploidy, and in chimeras, and in females owing to the pattern of X-chromosome inactivation. Cells may be mosaic with regard to new gene mutations. The pattern of mosaicism depends upon the stage in embryogenesis or in germ-cell formation in which the mutation arose.
C1 [Kasper, C. K.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Kasper, C. K.] Orthoped Hosp, Los Angeles, CA USA.
   [Buzin, C. H.] MEDomics LLC, Azusa, CA USA.
RP Kasper, CK (reprint author), 385 S Parkwood Ave, Pasadena, CA 91107 USA.
EM carolkasper@hotmail.com
CR ALLEN JW, 1995, MUTAT RES-FUND MOL M, V330, P219, DOI 10.1016/0027-5107(95)00042-H
   Becker J, 1996, AM J HUM GENET, V58, P657
   BERNARDS A, 1994, NEW ENGL J MED, V331, P1447, DOI 10.1056/NEJM199411243312110
   COLEMAN R, 1993, J MED GENET, V30, P497, DOI 10.1136/jmg.30.6.497
   Crow JF, 2000, NAT REV GENET, V1, P40, DOI 10.1038/35049558
   Cutler JA, 2004, AM J MED GENET A, V129A, P13, DOI 10.1002/ajmg.a.30162
   Edwards Matthew J., 1992, Human Mutation, V1, P47, DOI 10.1002/humu.1380010108
   Ellegren H, 2007, P ROY SOC B-BIOL SCI, V274, P1, DOI 10.1098/rspb.2006.3720
   Evans DGR, 1998, AM J HUM GENET, V63, P727, DOI 10.1086/512074
   Favier R, 2000, BLOOD, V96, P4373
   GILCHRIST GS, 1965, NEW ENGL J MED, V273, P1402, DOI 10.1056/NEJM196512232732602
   Green PM, 1999, AM J HUM GENET, V65, P1572, DOI 10.1086/302651
   Happle R, 2006, ACTA PAEDIATR, V95, P16, DOI 10.1080/08035320600618775
   Huttley GA, 2000, MOL BIOL EVOL, V17, P929, DOI 10.1093/oxfordjournals.molbev.a026373
   Kasper CK, 2007, HAEMOPHILIA, V13, P90, DOI 10.1111/j.1365-2516.2006.01397.x
   Ketterling RP, 1999, HUM GENET, V105, P629, DOI 10.1007/s004390051155
   Knobe KE, 2008, HAEMOPHILIA, V14, P846, DOI 10.1111/j.1365-2516.2008.01754.x
   Leuer M, 2001, AM J HUM GENET, V69, P75, DOI 10.1086/321285
   LI WH, 2002, CURR OPIN GENE DEV, V3, P748
   Ljung RCR, 1999, BRIT J HAEMATOL, V106, P870, DOI 10.1046/j.1365-2141.1999.01631.x
   Malan V, 2006, CLIN GENET, V70, P363, DOI 10.1111/j.1399-0004.2006.00689.x
   MONK M, 1995, DEV GENET, V17, P188, DOI 10.1002/dvg.1020170303
   MOTTES M, 1993, HUM MUTAT, V2, P196, DOI 10.1002/humu.1380020308
   NISEN PD, 1989, J CLIN INVEST, V83, P1400, DOI 10.1172/JCI114028
   Oldenburg J, 2000, BLOOD, V96, P2905
   Orstavik KH, 2006, ACTA PAEDIATR, V95, P24, DOI 10.1080/08035320600618783
   ROSSITER JP, 1994, HUM MOL GENET, V3, P1035, DOI 10.1093/hmg/3.7.1035
   Sommer SS, 2001, MUTAT RES-DNA REPAIR, V487, P1, DOI 10.1016/S0921-8777(01)00108-2
   Sommer SS, 1996, HUM MOL GENET, V5, P1505, DOI 10.1093/hmg/5.Supplement_1.1505
   SOMMER SS, 1995, HUM MOL GENET, V4, P2181, DOI 10.1093/hmg/4.11.2181
   SORIANO P, 1986, CELL, V46, P19, DOI 10.1016/0092-8674(86)90856-1
   Soucie JM, 1998, AM J HEMATOL, V59, P288, DOI 10.1002/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I
   Sparkes R, 1996, INT J LEGAL MED, V109, P186, DOI 10.1007/BF01225517
   STRACHAN T, 2004, HUM MOL GENET, P1
   TAYLOR SAM, 1991, P NATL ACAD SCI USA, V88, P39, DOI 10.1073/pnas.88.1.39
   Waisfisz Q, 1999, NAT GENET, V22, P379
   WHISSELL DY, 1965, AM J MED, V38, P119, DOI 10.1016/0002-9343(65)90165-8
   WITKOWSKI R, 1992, HUM GENET, V88, P359
   Youssoufian H, 2002, NAT REV GENET, V3, P748, DOI 10.1038/nrg906
   Zlotogora J, 1998, HUM GENET, V102, P381, DOI 10.1007/s004390050708
NR 40
TC 17
Z9 19
U1 3
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-8216
EI 1365-2516
J9 HAEMOPHILIA
JI Haemophilia
PD NOV
PY 2009
VL 15
IS 6
BP 1181
EP 1186
DI 10.1111/j.1365-2516.2009.02003.x
PG 6
WC Hematology
SC Hematology
GA 511SN
UT WOS:000271187500001
PM 19473426
DA 2018-12-27
ER

PT J
AU Guerra, DL
   Airoldi, C
   Viana, RR
AF Guerra, Denis Lima
   Airoldi, Claudio
   Viana, Rubia Ribeiro
TI RETRACTED: Amazon silicates modified by organofunctionalization for use
   in removing Hg(II) from aqueous medium: A thermodynamic approach
   (Retracted article. See vol. 14, pg. 1987, 2011)
SO INORGANIC CHEMISTRY COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE Smectite; Zeolite; Mercury; Adsorption; Thermodynamic
ID MESOPOROUS SILICA; MERCURY ADSORPTION; CATION; ACID; NMR; GEL
AB Smectite and zeolite samples have been used for chemical modification process with 1,4-bis(3-aminopropyl)piperazine reacted with methyl acrylate to yield the new inorganic-organic chelating materials. The resulting matrices have been characterized through carbon and silicon nuclear magnetic resonance in the solid-state. The natural (S and Z) and modified silicate (S-APPMA and Z-APPMA) samples have been tested as potential adsorbents for the removal of to Hg(II) from aqueous solution at pH 2.0 and 298 +/- 1 K. The adsorption process was fitted to Sips model for non-linear regression method. The adsorption experiments performed under batch process with pH and mercury concentration as variables. These interactions were calorimetrically followed and the thermodynamic data showed the following exothermic enthalpy (-8.0 to -7.5 kJ mol(-1)), negative Gibbs free energy (-22.0 to -23.6 kJ mol(-1)), and positive entropy (47.0-54.0 J K-1 mol(-1)). These thermodynamic data confirmed the energetically favorable condition of such interaction solid/liquid for all systems. (c) 2009 Published by Elsevier B.V.
C1 [Guerra, Denis Lima; Airoldi, Claudio] Univ Estadual Campinas, Inst Chem, BR-13084971 Campinas, SP, Brazil.
   [Viana, Rubia Ribeiro] Univ Fed Mato Grosso, Ctr Recursos Minerais, BR-78060900 Cuiaba, MG, Brazil.
RP Guerra, DL (reprint author), Univ Estadual Campinas, Inst Chem, POB 6154, BR-13084971 Campinas, SP, Brazil.
EM denis@cpd.ufmt.br
FU CNPq; FAPESP
FX The authors are indebted to CNPq for fellowships and FAPESP for
   financial support.
CR Balys M, 2002, STUD SURF SCI CATAL, V144, P225
   Busche B, 2009, INORG CHEM COMMUN, V12, P312, DOI 10.1016/j.inoche.2009.02.003
   Dey RK, 2008, J HAZARD MATER, V156, P95, DOI 10.1016/j.jhazmat.2007.12.005
   Evangelista SM, 2007, SURF SCI, V601, P2194, DOI 10.1016/j.susc.2007.03.020
   Grudzien RM, 2007, APPL SURF SCI, V253, P5660, DOI 10.1016/j.apsusc.2006.12.033
   Guerra DL, 2008, INORG CHEM COMMUN, V11, P20, DOI 10.1016/j.inoche.2007.09.029
   Hughes M, 2006, MACROMOL SYMP, V235, P161, DOI 10.1002/masy.200650320
   JARONIEC M, 1998, STUD SURF SCI CATAL, V177, P325
   Liang Z, 2008, MICROPOR MESOPOR MAT, V111, P536, DOI 10.1016/j.micromeso.2007.08.030
   LIPPMAA E, 1980, J AM CHEM SOC, V102, P4889, DOI 10.1021/ja00535a008
   LIU J, 2001, STUD SURF SCI CATAL, V129, P729
   Nakai K, 2007, MICROPOR MESOPOR MAT, V100, P328, DOI 10.1016/j.micromeso.2006.11.023
   Olkhovyk O, 2004, COLLOID SURFACE A, V236, P69, DOI 10.1016/j.colsurfa.2003.12.032
   PARKS GA, 1965, CHEM REV, V65, P177, DOI 10.1021/cr60234a002
   Prado AGS, 2001, ANAL CHIM ACTA, V432, P201, DOI 10.1016/S0003-2670(00)01372-6
   Prouzet E, 2009, MICROPOR MESOPOR MAT, V119, P9, DOI 10.1016/j.micromeso.2008.09.031
   SIPS R, 1948, J CHEM PHYS, V16, P490, DOI 10.1063/1.1746922
   Sutra P, 1999, COLLOID SURFACE A, V158, P21, DOI 10.1016/S0927-7757(99)00126-0
   Thomas JM, 2007, MICROPOR MESOPOR MAT, V104, P5, DOI 10.1016/j.micromeso.2007.01.002
   Walcarius A, 1999, ENVIRON SCI TECHNOL, V33, P4278, DOI 10.1021/es990525v
   Zub YL, 2001, MENDELEEV COMMUN, P208
NR 21
TC 2
Z9 2
U1 4
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1387-7003
EI 1879-0259
J9 INORG CHEM COMMUN
JI Inorg. Chem. Commun.
PD NOV
PY 2009
VL 12
IS 11
BP 1107
EP 1111
DI 10.1016/j.inoche.2009.08.033
PG 5
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA 521LI
UT WOS:000271922500007
DA 2018-12-27
ER

PT J
AU Guerra, DL
   Viana, RR
   Airoldi, C
AF Guerra, Denis L.
   Viana, Rubia R.
   Airoldi, Claudio
TI RETRACTED: Immobilization of 5-amino-1,3,4-thiadiazole-thiol onto
   analogue of heulandite for divalent toxic metals removal (Retracted
   article. See vol. 14, pg. 1986, 2011)
SO INORGANIC CHEMISTRY COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE Heulandite; Toxic metals; Adsorption; Calorimetry; Thermodynamic
ID AQUEOUS WASTE; SILICA-GEL; SORPTION; ADSORPTION; INTERCALATION;
   EUROPIUM(III); THORIUM(IV); MAGADIITE; ACID
AB The compound 5-amino-1,3,4-thiadiazole-thiol was anchored onto analogue of heulandite by heterogeneous route. The original (HEU) and modified heulandite (HEUATT) samples were characterized through elemental analysis and nuclear magnetic nuclei of carbon-13 and silicon-29. The ability of these materials to remove Mn(II), Zn(II) and Pb(II) from aqueous solution was followed by a series of adsorption isotherms adjusted to a Sips equation. To achieve the best adsorption conditions the influence of pH and contact time were investigated. Based on the capacity of adsorption of HEUATT to interact with metal ions, the following results were obtained 13.0, 10.1 and 7.4 mmol g(-1) for Pb(II), Zn(II) and Mn(II), respectively, reflecting a maximum adsorption order of Pb(II) > Zn(II) > Mn(II). The energetic effects caused by metal cation adsorption were determined through calorimetric titrations. (c) 2009 Published by Elsevier B.V.
C1 [Guerra, Denis L.; Airoldi, Claudio] Univ Estadual Campinas, Inst Chem, BR-13084971 Campinas, SP, Brazil.
   [Viana, Rubia R.] Univ Fed Mato Grosso, Ctr Recursos Minerais, BR-78060900 Cuiaba, MG, Brazil.
RP Guerra, DL (reprint author), Univ Estadual Campinas, Inst Chem, POB 6154, BR-13084971 Campinas, SP, Brazil.
EM denis@cpd.ufmt.br
FU CNPq; FAPESP
FX The authors are indebted to CNPq for fellowships and FAPESP for
   financial support.
CR FYFE CA, 1982, NATURE, V296, P530, DOI 10.1038/296530a0
   Guerra DL, 2008, J HAZARD MATER, V155, P230, DOI 10.1016/j.jhazmat.2007.11.054
   Guerra DL, 2008, J SOLID STATE CHEM, V181, P2507, DOI 10.1016/j.jssc.2008.06.028
   Guerra DL, 2008, J SOLID STATE CHEM, V181, P3374, DOI 10.1016/j.jssc.2008.09.006
   Ho YS, 1999, PROCESS BIOCHEM, V34, P451, DOI 10.1016/S0032-9592(98)00112-5
   Komiyama M, 2004, APPL SURF SCI, V237, P503, DOI 10.1016/j.apsusc.2004.06.114
   Lagergren S, 1898, KUNGLIGA SVENSKA VET, V24, P1, DOI DOI 10.1007/BF01501332
   LEPPERT D, 1990, MINING ENG, V42, P604
   Macedo TR, 2007, CLAY CLAY MINER, V55, P151, DOI 10.1346/CCMN.2007.0550204
   Ng JCY, 2003, CHEMOSPHERE, V52, P1021, DOI 10.1016/S0045-6535(03)00223-6
   Prado AGS, 2002, GREEN CHEM, V4, P288, DOI 10.1039/b202420a
   Prado AGS, 2001, ANAL CHIM ACTA, V432, P201, DOI 10.1016/S0003-2670(00)01372-6
   Quintanilla D. P., 2007, J COLLOID INTERF SCI, V313, P551
   Ruiz VSO, 2004, THERMOCHIM ACTA, V420, P73, DOI 10.1016/j.tca.2003.10.029
   Sharma P, 2008, MICROPOR MESOPOR MAT, V116, P641, DOI 10.1016/j.micromeso.2008.05.036
   Sharma P, 2009, J COLLOID INTERF SCI, V332, P298, DOI 10.1016/j.jcis.2008.12.074
   Sheng GD, 2008, APPL RADIAT ISOTOPES, V66, P1313, DOI 10.1016/j.apradiso.2008.03.005
   SIPS R, 1948, J CHEM PHYS, V16, P490, DOI 10.1063/1.1746922
   SMITH JV, 1983, NATURE, V303, P223, DOI 10.1038/303223a0
   Thomas JM, 2007, MICROPOR MESOPOR MAT, V104, P5, DOI 10.1016/j.micromeso.2007.01.002
NR 20
TC 4
Z9 4
U1 4
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1387-7003
EI 1879-0259
J9 INORG CHEM COMMUN
JI Inorg. Chem. Commun.
PD NOV
PY 2009
VL 12
IS 11
BP 1145
EP 1149
DI 10.1016/j.inoche.2009.08.029
PG 5
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA 521LI
UT WOS:000271922500016
DA 2018-12-27
ER

PT J
AU Ahmad, A
   Kong, DJ
   Wang, ZW
   Sarkar, SH
   Banerjee, S
   Sarkar, FH
AF Ahmad, Aamir
   Kong, Dejuan
   Wang, Zhiwei
   Sarkar, Sanila. H.
   Banerjee, Sanjeev
   Sarkar, Fazlul H.
TI RETRACTED: Down-Regulation of uPA and uPAR by 3,3 '-Diindolylmethane
   Contributes to the Inhibition of Cell Growth and Migration of Breast
   Cancer Cells (Retracted article. See vol. 117, pg. 1959, 2016)
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE 3, 3 '-DIINDOLYLMETHANE; BREAST CANCER; uPA; uPAR; MDA-MB-231; MCF-7;
   MIGRATION; VEGF; MMP-9
ID PLASMINOGEN-ACTIVATOR RECEPTOR; NF-KAPPA-B; PROSTATE-CANCER;
   3,3'-DIINDOLYLMETHANE DIM; GENE-EXPRESSION; APOPTOSIS; UROKINASE;
   INDUCTION; ANGIOGENESIS; INDOLE-3-CARBINOL
AB 3,3'-Diindolylmethane (DIM) is a known anti-tumor agent against breast and other cancers; however, its exact mechanism of action remains unclear. The urokinase plasminogen activator (uPA) and its receptor (uPAR) system are involved in the degradation of basement membrane and extracellular matrix, leading to tumor cell invasion and metastasis. Since uPA-uPAR system is highly activated in aggressive breast cancer, we hypothesized that the biological activity of B-DIM could be mediated via inactivation of uPA-uPAR system. We found that B-DIM treatment as well as silencing of uPA-uPAR led to the inhibition of cell growth and motility of MDA-MB-23 I cells, which was in part due to inhibition of VEGF and MMP-9. Moreover, silencing of uPA-uPAR led to decreased sensitivity ofthese cells to B-DIM indicating an important role of uPA-uPAR in B-DIM-mediated inhibition of cell growth and migration. We also found similar effects of B-DIM on MCF-7, cells expressing low levels of uPA-uPAR, which was due to direct down-regulation of MMP-9 and VEGF, independent of uPA-uPAR system. Interestingly, over-expression or uPA-uPAR in MCF-7 cells attenuated the inhibitory effects of B-DIM. Our results, therefore, suggest that B-DIM down-regulales uPA-uPAR in aggressive breast cancers but in the absence of uPA-uPAR, B-DIM can directly inhibit VEGF and MMP-9 leading to the inhibition of cell growth and migration of breast cancer cells. J. Cell. Biochem. 108: 916-925, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Ahmad, Aamir; Kong, Dejuan; Wang, Zhiwei; Sarkar, Sanila. H.; Banerjee, Sanjeev; Sarkar, Fazlul H.] Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Ctr, Detroit, MI 48201 USA.
RP Sarkar, FH (reprint author), Karmanos Canc Inst, Dept Pathol, 740 HWCRC Bldg,4100 John R St, Detroit, MI 48201 USA.
EM fsarkar@med.wayne.edu
RI Wang, Zhiwei/A-6809-2011; Ahmad, Aamir/E-8747-2010
FU NCI NIH HHS [R01 CA132794, 5R01CA108535-06, R01 CA108535]
CR Ahmad A, 2008, J CELL BIOCHEM, V105, P1461, DOI 10.1002/jcb.21966
   Ahmad A, 2009, J CELL BIOCHEM, V107, P516, DOI 10.1002/jcb.22152
   Ali S, 2008, MOL CANCER THER, V7, P1708, DOI 10.1158/1535-7163.MCT-08-0354
   Anderton MJ, 2004, DRUG METAB DISPOS, V32, P632, DOI 10.1124/dmd.32.6.632
   Ass K, 2008, CANCER TREAT REV, V34, P122, DOI 10.1016/j.ctrv.2007.10.005
   Bhuiyan MMR, 2006, CANCER RES, V66, P10064, DOI 10.1158/0008-5472.CAN-06-2011
   Bradlow HL, 2008, IN VIVO, V22, P441
   Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233
   Chang XF, 2005, CARCINOGENESIS, V26, P771, DOI 10.1093/carcin/bgi018
   Degner SC, 2009, J NUTR, V139, P26, DOI 10.3945/jn.108.099259
   Giannopoulou I, 2007, CANCER LETT, V246, P262, DOI 10.1016/j.canlet.2006.03.003
   Gong YX, 2006, CANCER RES, V66, P4880, DOI 10.1158/0008-5472.CAN-05-4162
   Gutova M, 2008, STEM CELLS, V26, P1406, DOI 10.1634/stemcells.2008-0141
   Heber D, 2001, J NUTR, V131, p3078S, DOI 10.1093/jn/131.11.3078S
   Higdon JV, 2007, PHARMACOL RES, V55, P224, DOI 10.1016/j.phrs.2007.01.009
   Hildenbrand R, 2009, HISTOL HISTOPATHOL, V24, P869, DOI 10.14670/HH-24.869
   Hong C, 2002, BIOCHEM PHARMACOL, V63, P1085, DOI 10.1016/S0006-2952(02)00856-0
   Hong CB, 2002, CARCINOGENESIS, V23, P1297, DOI 10.1093/carcin/23.8.1297
   Hsu EL, 2008, CANCER LETT, V265, P113, DOI 10.1016/j.canlet.2008.02.033
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kim EJ, 2007, J NUTR, V137, P31
   Kong DJ, 2007, CANCER RES, V67, P3310, DOI 10.1158/0008-5472.CAN-06-4277
   Koopman JL, 1998, J BIOL CHEM, V273, P33267, DOI 10.1074/jbc.273.50.33267
   Kunigal S, 2007, INT J CANCER, V121, P2307, DOI 10.1002/ijc.22962
   Li YW, 2007, J BIOL CHEM, V282, P21542, DOI 10.1074/jbc.M701978200
   Nachshon-Kedmi M, 2004, PROSTATE, V61, P153, DOI 10.1002/pros.20092
   Nachshon-Kedmi M, 2004, BRIT J CANCER, V91, P1358, DOI 10.1038/sj.bjc.6602145
   Nam RK, 1999, J UROLOGY, V161, P1521, DOI 10.1016/S0022-5347(05)68943-4
   Okino ST, 2009, CANCER PREV RES, V2, P251, DOI 10.1158/1940-6207.CAPR-08-0146
   Pacheco MM, 2001, INT J BIOL MARKER, V16, P62
   Pillay V, 2007, TRENDS BIOTECHNOL, V25, P33, DOI 10.1016/j.tibtech.2006.10.011
   Rahman KMW, 2006, MOL CANCER THER, V5, P2747, DOI 10.1158/1535-7163.MCT-06-0221
   Rahman KMW, 2006, CANCER RES, V66, P4952, DOI 10.1158/0008-5472.CAN-05-3918
   Rahman KMW, 2005, CANCER RES, V65, P364
   Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Sheng SJ, 2001, CANCER METAST REV, V20, P287, DOI 10.1023/A:1015539612576
   STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672
   Subramanian R, 2006, INT J ONCOL, V28, P831
   Wang Y, 2001, MED RES REV, V21, P146, DOI 10.1002/1098-1128(200103)21:2<146::AID-MED1004>3.0.CO;2-B
   Wang ZW, 2008, MOL CANCER THER, V7, P341, DOI 10.1158/1535-7163.MCT-07-0476
   Xue L, 2005, ONCOGENE, V24, P2343, DOI 10.1038/sj.onc.1208434
NR 42
TC 37
Z9 40
U1 4
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD NOV 1
PY 2009
VL 108
IS 4
BP 916
EP 925
DI 10.1002/jcb.22323
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 515TI
UT WOS:000271495400020
PM 19693769
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Ma, DY
   Liao, WY
   Wang, RQ
   Han, ZX
   Liu, SW
AF Ma Deying
   Liao, Wenyan
   Wang, Ruiqin
   Han, Zongxi
   Liu, Shengwang
TI RETRACTED: Two Novel Duck Antibacterial Peptides, Avian beta-Defensins 9
   and 10, with Antimicrobial Activity (Retracted article. See vol. 23, pg.
   1046, 2013)
SO JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article; Retracted Publication
DE Antimicrobial peptides; duck; avian beta-defensins; antimicrobial
   activity
ID MAMMALIAN DEFENSINS; CHICKEN; UPDATE; GALLINACIN-9; PERSPECTIVE;
   HETEROPHILS; PATHOGENS; EVOLUTION
AB Two novel avian beta-defensins (AvBDs) isolated from duck liver were characterized and their homologies with other AvBDs were analyzed. They were shown to be duck AvBD9 and AvBD10. The mRNA expression of the two genes was analyzed in 17 different tissues from 1-28-day-old ducks. AvBD9 was differentially expressed in the tissues, with especially high levels of expression in liver, kidney, crop, and trachea, whereas AvBD10 was only expressed in the liver and kidney of ducks at all the ages investigated. We produced and purified GST-tagged recombinant AvBD9 and AvBD10 by expressing the two genes in Escherichia coli. Both recombinant proteins exhibited antimicrobial activity against several bacterial strains. The results revealed that both recombinant proteins retained their antimicrobial activities against Staphylococcus aureus under a range of different temperatures (-70 degrees C - 100 degrees C) and pH values (pH 3-12).
C1 [Liao, Wenyan; Wang, Ruiqin; Han, Zongxi; Liu, Shengwang] Chinese Acad Agr Sci, Harbin Vet Res Inst, Natl Key Lab Vet Biotechnol, Div Avian Infect Dis, Harbin 150001, Peoples R China.
   [Ma Deying; Liao, Wenyan; Wang, Ruiqin] NE Agr Univ, Inst Anim Nutr, Harbin 150030, Peoples R China.
RP Liu, SW (reprint author), Chinese Acad Agr Sci, Harbin Vet Res Inst, Natl Key Lab Vet Biotechnol, Div Avian Infect Dis, Harbin 150001, Peoples R China.
EM swliu@hvri.ac.cn
FU National Natural Science Foundation of China [30600435, 30972110]; NOVUS
   international research fellowship; Key research program of the
   educational department of Heilongjiang province [11531z05]
FX The study was supported by the National Natural Science Foundation of
   China (30600435;30972110), NOVUS international research fellowship, Key
   research program of the educational department of Heilongjiang province
   (No. 11531z05).
CR BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BULET P, 1993, J BIOL CHEM, V268, P14893
   Evans EW, 1995, VET MICROBIOL, V47, P295, DOI 10.1016/0378-1135(95)00126-3
   EVANS EW, 1994, J LEUKOCYTE BIOL, V56, P661
   Froy O, 2003, TRENDS GENET, V19, P684, DOI 10.1016/j.tig.2003.10.010
   Ganz T, 2005, COMB CHEM HIGH T SCR, V8, P209, DOI 10.2174/1386207053764594
   Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180
   HARMON BG, 1988, POULTRY SCI, V77, P972
   HARWIG SSL, 1994, FEBS LETT, V342, P281, DOI 10.1016/0014-5793(94)80517-2
   HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7
   Higgs R, 2005, IMMUNOGENETICS, V57, P90, DOI 10.1007/s00251-005-0777-3
   Hughes AL, 1997, J MOL EVOL, V44, P675, DOI 10.1007/PL00006191
   Hughes AL, 1999, CELL MOL LIFE SCI, V56, P94, DOI 10.1007/s000180050010
   Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X
   Lynn DJ, 2007, IMMUNOL LETT, V110, P86, DOI 10.1016/j.imlet.2007.03.007
   Lynn DJ, 2004, IMMUNOGENETICS, V56, P170, DOI 10.1007/s00251-004-0675-0
   Ma DY, 2008, PROTEIN EXPRES PURIF, V58, P284, DOI 10.1016/j.pep.2007.11.017
   Milona P, 2007, BIOCHEM BIOPH RES CO, V356, P169, DOI 10.1016/j.bbrc.2007.02.098
   Satchell DP, 2003, J BIOL CHEM, V278, P13838, DOI 10.1074/jbc.M212115200
   SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2
   Schutte BC, 2002, ANNU REV PHYSIOL, V64, P709, DOI 10.1146/annurev.physiol.64.081501.134340
   Sugiarto H, 2006, INT J ANTIMICROB AG, V27, P229, DOI 10.1016/j.ijantimicag.2005.10.013
   Sugiarto H, 2004, BIOCHEM BIOPH RES CO, V323, P721, DOI 10.1016/j.bbrc.2004.08.162
   Thomma BPHJ, 2002, PLANTA, V216, P193, DOI 10.1007/s00425-002-0902-6
   Thouzeau C, 2003, J BIOL CHEM, V278, P51053, DOI 10.1074/jbc.M306839200
   van Dijk A, 2007, ANTIMICROB AGENTS CH, V51, P912, DOI 10.1128/AAC.00568-06
   Xiao YJ, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-56
   Yu PL, 2001, BIOTECHNOL LETT, V23, P207, DOI 10.1023/A:1005623806445
NR 28
TC 16
Z9 32
U1 0
U2 10
PU KOREAN SOC MICROBIOLOGY & BIOTECHNOLOGY
PI SEOUL
PA KOREA SCI TECHNOL CENTER #507,  635-4 YEOGSAM-DONG, KANGNAM-GU, SEOUL
   135-703, SOUTH KOREA
SN 1017-7825
EI 1738-8872
J9 J MICROBIOL BIOTECHN
JI J. Microbiol. Biotechnol.
PD NOV
PY 2009
VL 19
IS 11
BP 1447
EP 1455
DI 10.4014/jmb.0904.04028
PG 9
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA 526PC
UT WOS:000272302200024
PM 19996700
DA 2018-12-27
ER

PT J
AU Guerra, DL
   Viana, RR
   da Costa, LP
   Airoldi, C
AF Guerra, Denis L.
   Viana, Rubia R.
   da Costa, Luiz P.
   Airoldi, Claudio
TI RETRACTED: Sodium alginate films modified by raw and functionalized
   attapulgite for use of thorium(IV) adsorption: A thermodynamic approach
   (Retracted article. See vol. 73, pg. 142, 2012)
SO JOURNAL OF PHYSICS AND CHEMISTRY OF SOLIDS
LA English
DT Article; Retracted Publication
DE Interfaces; Chemical Synthesis; Surface properties; Thermodynamic
   properties
ID SILICA-GEL; CONTROLLED-RELEASE; AQUEOUS-SOLUTION; CATION REMOVAL;
   INTERCALATION; ACID; MONTMORILLONITE; SEPARATION; ZEOLITE; MERCURY
AB Hybrid composite films were prepared by incorporating 0.2, 0.4 and 0.6 g of natural and modified attapulgite clays particles into sodium alginate films. Attapulgite sample has been chemically modified with organofunctionalization of 3-mercaptopropyltrimethoxysilane and 3-aminopropyltriethoxysilane. These hybrid films were used for thorium adsorption from aqueous solutions under batch process with pH and Th4+ concentration as variables. The effect of attapulgite incorporation in sodium alginate films has been investigated by silicon and carbon nuclei solid-state MAS/NMR, elemental analysis, CHN, textural analysis, SEM, and mechanical properties (0-30 wt% of clay samples). The reactive centers attached to the pendant chains inside the sodium alginate films can coordinate thorium(IV), by presenting and isotherm saturated at 33.70 x 10(-5) mol g(-1) of this actinide. From calorimetric determinations the quantitative thermal effects for all thorium/film surfaces gave exothermic enthalpy (Delta H-int=-4.35 to -5.90 kJ mol(-1)), negative Gibbs free energy (Delta(int)G=-22.62 to -24.51 kJ mol(-1)), and positive entropy (Delta S-int=61.18 to 62.36 JK(-1) mol(-1)). These thermodynamic data confirmed the energetically favorable condition of such interaction solid/liquid for all systems. (C) 2009 Published by Elsevier Ltd.
C1 [Guerra, Denis L.; da Costa, Luiz P.; Airoldi, Claudio] Univ Estadual Campinas, Inst Chem, BR-13084971 Sao Paulo, Brazil.
   [Viana, Rubia R.] Univ Fed Mato Grosso, UFMT, Ctr Recursos Minerais, BR-68060900 Cuiaba, Mato Grosso, Brazil.
RP Guerra, DL (reprint author), Univ Estadual Campinas, Inst Chem, POB 6154, BR-13084971 Sao Paulo, Brazil.
EM denis@cpd.ufmt.br
FU CNPq [150060/2006-8]; FAPESP
FX The authors are indebted to CNPq (Proc. no. 150060/2006-8) for
   fellowships and FAPESP for financial support.
CR CARMEN RL, 1997, CONTROLLED RELEASE, V44, P215
   [董战峰 Dong Zhanfeng], 2004, [功能高分子学报, Journal of Functional Polymer], V17, P61
   Dong ZF, 2006, J MEMBRANE SCI, V280, P37, DOI 10.1016/j.memsci.2006.01.002
   Evangelista SM, 2007, SURF SCI, V601, P2194, DOI 10.1016/j.susc.2007.03.020
   Guerra DL, 2008, J HAZARD MATER, V155, P230, DOI 10.1016/j.jhazmat.2007.11.054
   Guerra DL, 2008, INORG CHEM COMMUN, V11, P20, DOI 10.1016/j.inoche.2007.09.029
   Guerra DL, 2008, QUIM NOVA, V31, P353, DOI 10.1590/S0100-40422008000200031
   Guerra DL, 2006, POLYHEDRON, V25, P2880, DOI 10.1016/j.poly.2006.04.015
   Haung A., 1966, ACTA CHEM SCAND, V20, P183
   Karadag D, 2007, J HAZARD MATER, V144, P432, DOI 10.1016/j.jhazmat.2006.10.055
   Katz A, 2001, WASTE MANAGE, V21, P543, DOI 10.1016/S0956-053X(00)00105-7
   Kazemimoghadam M, 2006, SEP PURIF TECHNOL, V47, P173, DOI 10.1016/j.seppur.2005.06.013
   Kulkarni AR, 1999, PHARM ACTA HELV, V74, P29, DOI DOI 10.1016/S0031-6865(99)00015-1
   Lazarin AM, 2007, THERMOCHIM ACTA, V454, P43, DOI 10.1016/j.tca.2006.12.016
   [冷延国 Leng Yanguo], 2002, [高分子材料科学与工程, Polymer Materials Science & Engineering], V18, P93
   LOW KS, 1995, BIORESOURCE TECHNOL, V51, P227, DOI 10.1016/0960-8524(94)00123-I
   Macedo TR, 2007, CLAY CLAY MINER, V55, P151, DOI 10.1346/CCMN.2007.0550204
   Machado RSA, 2004, TALANTA, V63, P317, DOI 10.1016/j.talanta.2003.10.048
   Monteiro OAC, 2005, J COLLOID INTERF SCI, V282, P32, DOI 10.1016/j.jcis.2004.08.165
   Musa SA, 1999, J CONTROL RELEASE, V57, P223
   Park KW, 2004, B KOR CHEM SOC, V25, P965
   PARKS GA, 1965, CHEM REV, V65, P177, DOI 10.1021/cr60234a002
   Prado AGS, 2001, ANAL CHIM ACTA, V432, P201, DOI 10.1016/S0003-2670(00)01372-6
   RUBIO MR, 1994, DRUG DEV IND PHARM, V20, P1239, DOI 10.3109/03639049409038364
   Ruiz VSO, 2006, J MATER CHEM, V16, P2338, DOI 10.1039/b515676a
   Ruiz VSO, 2004, THERMOCHIM ACTA, V420, P73, DOI 10.1016/j.tca.2003.10.029
   Sales JAA, 2004, POLYHEDRON, V23, P719, DOI 10.1016/j.poly.2003.11.051
   SANTOSHKUMAR D, 2006, SEP PURIF TECHNOL, V51, P85
   Soliman EM, 2001, TALANTA, V54, P243, DOI 10.1016/S0039-9140(00)00648-2
   Vaghetti JCP, 2008, BIOCHEM ENG J, V42, P67, DOI 10.1016/j.bej.2008.05.021
   Veerapur RS, 2008, SEP PURIF TECHNOL, V58, P377, DOI 10.1016/j.seppur.2007.05.015
   Villaescusa I, 2000, J CHEM TECHNOL BIOT, V75, P812, DOI 10.1002/1097-4660(200009)75:9<812::AID-JCTB284>3.3.CO;2-2
NR 32
TC 11
Z9 11
U1 2
U2 40
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3697
EI 1879-2553
J9 J PHYS CHEM SOLIDS
JI J. Phys. Chem. Solids
PD NOV
PY 2009
VL 70
IS 11
BP 1413
EP 1421
DI 10.1016/j.jpcs.2009.08.012
PG 9
WC Chemistry, Multidisciplinary; Physics, Condensed Matter
SC Chemistry; Physics
GA 521JK
UT WOS:000271917000005
DA 2018-12-27
ER

PT J
AU Forster, J
   Epstude, K
   Ozelsel, A
AF Forster, Jens
   Epstude, Kai
   Ozelsel, Amina
TI RETRACTED: Why Love Has Wings and Sex Has Not: How Reminders of Love and
   Sex Influence Creative and Analytic Thinking (Retracted article. See
   vol. 42, pg. 1445, 2016)
SO PERSONALITY AND SOCIAL PSYCHOLOGY BULLETIN
LA English
DT Article; Retracted Publication
DE love; sex; processing styles; priming; construal level
ID AVOIDANCE MOTOR ACTIONS; ROMANTIC LOVE; COUNTERFACTUAL THINKING; CLOSE
   RELATIONSHIPS; PROTOTYPE ANALYSIS; DESIRE; SELF; COGNITION; ACCURACY;
   INSIGHT
AB This article examines cognitive links between romantic love and creativity and between sexual desire and analytic thought based on construal level theory. It suggests that when in love, people typically focus on a long-term perspective, which should enhance holistic thinking and thereby creative thought, whereas when experiencing sexual encounters, they focus on the present and on concrete details enhancing analytic thinking. Because people automatically activate these processing styles when in love or when they experience sex, subtle or even unconscious reminders of love versus sex should suffice to change processing modes. Two studies explicitly or subtly reminded participants of situations of love or sex and found support for this hypothesis.
C1 [Forster, Jens] Univ Amsterdam, Dept Social Psychol, NL-1018 WB Amsterdam, Netherlands.
   [Forster, Jens; Ozelsel, Amina] Jacobs Univ Bremen, Bremen, Germany.
   [Epstude, Kai] Univ Groningen, NL-9700 AB Groningen, Netherlands.
RP Forster, J (reprint author), Univ Amsterdam, Dept Social Psychol, Roetersstr 15, NL-1018 WB Amsterdam, Netherlands.
EM j.a.forster@uva.nl
CR Amabile T., 1996, CREATIVITY CONTEXT
   ANDERSEN BL, 1994, J PERS SOC PSYCHOL, V67, P1079, DOI 10.1037//0022-3514.67.6.1079
   Andersen SM, 2002, PSYCHOL REV, V109, P619, DOI 10.1037//0033-295X.109.4.619
   Aries P., 2000, HIST VIE PRIVEE
   Aron A, 1996, J PERS SOC PSYCHOL, V70, P535, DOI 10.1037/0022-3514.70.3.535
   ARON A, 1992, J PERS SOC PSYCHOL, V63, P596, DOI 10.1037/0022-3514.63.4.596
   Bartels A, 2000, NEUROREPORT, V11, P3829, DOI 10.1097/00001756-200011270-00046
   BECK JG, 1991, J SEX RES, V28, P443, DOI 10.1080/00224499109551618
   Berscheid E, 1969, INTERPERSONAL ATTRAC
   Buss D., 1996, SOCIAL PSYCHOL HDB B, P3
   Buss D. M., 2004, EVOLUTIONARY PSYCHOL
   BUSS DM, 1986, J PERS SOC PSYCHOL, V50, P559, DOI 10.1037/0022-3514.50.3.559
   Chartrand TL, 1996, J PERS SOC PSYCHOL, V71, P464, DOI 10.1037/0022-3514.71.3.464
   Darwin Charles, 1871, DESCENT MAN SELECTIO, Vone
   Derryberry D, 1998, PERS INDIV DIFFER, V25, P745, DOI 10.1016/S0191-8869(98)00117-2
   Diamond LM, 2004, CURR DIR PSYCHOL SCI, V13, P116, DOI 10.1111/j.0963-7214.2004.00287.x
   Diamond LM, 2003, PSYCHOL REV, V110, P173, DOI 10.1037/0033-295X.110.1.173
   Dion K. L., 1988, PSYCHOL LOVE, P264
   Epstude K, 2008, PERS SOC PSYCHOL REV, V12, P168, DOI 10.1177/1088868308316091
   FEHR B, 1988, J PERS SOC PSYCHOL, V55, P557, DOI 10.1037//0022-3514.55.4.557
   FINKE RA, 1995, CREATIVE COGNITION A, P303
   Forster J, 2006, J EXP SOC PSYCHOL, V42, P133, DOI 10.1016/j.jesp.2005.02.004
   Forster J, 2005, J EXP SOC PSYCHOL, V41, P220, DOI 10.1016/j.jesp.2004.06.009
   Forster J, 2004, J PERS SOC PSYCHOL, V87, P177, DOI 10.1037/0022-3514.87.2.177
   FORSTER J, 2009, LOVE LUST CHAN UNPUB
   Forster J., 2007, SOCIAL PSYCHOL HDB B, P201
   FREUD S, 2000, 3 ABHANDLUNGEN SEXUA
   Friedman RS, 2008, HANDBOOK OF APPROACH AND AVOIDANCE MOTIVATION, P235
   Friedman RS, 2005, J PERS SOC PSYCHOL, V88, P263, DOI 10.1067/0022-3514.88.2.263
   Friedman RS, 2003, CREATIVITY RES J, V15, P277, DOI 10.1207/S15326934CRJ152&3_18
   Friedman RS, 2002, J EXP SOC PSYCHOL, V38, P41, DOI 10.1006/jesp.2001.1488
   Friedman RS, 2001, J PERS SOC PSYCHOL, V81, P1001, DOI 10.1037//0022-3514.81.6.1001
   Friedman RS, 2000, J PERS SOC PSYCHOL, V79, P477, DOI 10.1037//0022-3514.79.4.477
   Gagne FM, 2004, PERS SOC PSYCHOL REV, V8, P322, DOI 10.1207/s15327957pspr0804_1
   Gasper K, 2002, PSYCHOL SCI, V13, P34, DOI 10.1111/1467-9280.00406
   Gasper K, 2004, COGNITION EMOTION, V18, P405, DOI 10.1080/02699930341000068
   Gonzaga GC, 2006, EMOTION, V6, P163, DOI 10.1037/1528-3542.6.2.163
   Griskevicius V., 2006, J PERS SOC PSYCHOL, V91, P52
   HAMPSON SE, 1986, J PERS SOC PSYCHOL, V51, P37, DOI 10.1037/0022-3514.51.1.37
   HATFIELD E, ENCY HUMAN IN PRESS
   Hatfield E., 2005, LOVE SEX CROSS CULTU
   HAZAN C, 1987, J PERS SOC PSYCHOL, V52, P511, DOI 10.1037//0022-3514.52.3.511
   Higgins ET, 1997, AM PSYCHOL, V52, P1280, DOI 10.1037/0003-066X.52.12.1280
   JOHN OP, 1991, J PERS SOC PSYCHOL, V60, P348, DOI 10.1037//0022-3514.60.3.348
   Kenny D. A., 1998, HDB SOCIAL PSYCHOL, P233, DOI DOI 10.1177/0146167208331253
   Kuhnen U, 2002, J EXP SOC PSYCHOL, V38, P492, DOI 10.1016/S0022-1031(02)00011-2
   Li NP, 2002, J PERS SOC PSYCHOL, V82, P947, DOI 10.1037//0022-3514.82.6.947
   Liberman N, 1998, J PERS SOC PSYCHOL, V75, P5, DOI 10.1037/0022-3514.75.1.5
   Liberman N, 2008, SCIENCE, V322, P1201, DOI 10.1126/science.1161958
   Luu P, 1998, COGNITIVE THER RES, V22, P577, DOI 10.1023/A:1018742120255
   Markman KD, 2007, PERS SOC PSYCHOL B, V33, P312, DOI 10.1177/0146167206296106
   Marsh RL, 1999, MEM COGNITION, V27, P94, DOI 10.3758/BF03201216
   Mikulincer M, 1998, J PERS SOC PSYCHOL, V74, P1209, DOI 10.1037/0022-3514.74.5.1209
   Mikulincer M., 2007, ATTACHMENT ADULTHOOD
   Moller AP, 2002, BEHAV ECOL, V13, P248, DOI 10.1093/beheco/13.2.248
   Murray SL, 1999, PSYCHOL INQ, V10, P23, DOI 10.1207/s15327965pli1001_3
   Murray SL, 1997, PERS SOC PSYCHOL B, V23, P586, DOI 10.1177/0146167297236003
   Mussweiler T, 2000, J PERS SOC PSYCHOL, V79, P507, DOI 10.1037//0022-3514.79.4.507
   NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3
   Neff LA, 2005, J PERS SOC PSYCHOL, V88, P480, DOI 10.1037/0022-3514.88.3.480
   Neff LA, 2002, J PERS, V70, P1079, DOI 10.1111/1467-6494.05032
   Noller P, 1996, PERS RELATIONSHIP, V3, P97, DOI 10.1111/j.1475-6811.1996.tb00106.x
   Regan PC, 1998, J SOC PERS RELAT, V15, P411, DOI 10.1177/0265407598153006
   Regan PC, 1995, PERS RELATIONSHIP, V2, P345, DOI 10.1111/j.1475-6811.1995.tb00097.x
   Roese NJ, 1999, J PERS SOC PSYCHOL, V77, P1109, DOI 10.1037/0022-3514.77.6.1109
   Roese NJ, 2006, PERS SOC PSYCHOL B, V32, P770, DOI 10.1177/0146167206286709
   RUBIN Z, 1970, J PERS SOC PSYCHOL, V16, P265, DOI 10.1037/h0029841
   Schooler Jonathan W, 1995, CREATIVE COGNITION A, P97
   Schooler JonathanW, 1997, PSYCHOL LEARN MOTIV, V37, P291, DOI DOI 10.1016/S0079-7421(08)60505-8
   Schooler JW, 2002, APPL COGNITIVE PSYCH, V16, P989, DOI 10.1002/acp.930
   SCHOOLER JW, 1993, J EXP PSYCHOL GEN, V122, P166, DOI 10.1037/0096-3445.122.2.166
   Shah J, 2003, J PERS SOC PSYCHOL, V85, P424, DOI 10.1037/0022-3514.85.3.424
   SMITH ER, 1989, J EXP SOC PSYCHOL, V25, P500, DOI 10.1016/0022-1031(89)90003-6
   STERNBERG RJ, 1986, PSYCHOL REV, V93, P119, DOI 10.1037//0033-295X.93.2.119
   Trope J., 2007, SOCIAL PSYCHOL HDB B, V2, P353
   Trope Y, 2003, PSYCHOL REV, V110, P403, DOI 10.1037/0033-295X.110.3.403
   Tucker D. M., 1994, HEARTS EYE EMOTIONAL, P167, DOI [10.1016/B978-0-12-410560-7.50014-4, DOI 10.1016/B978-0-12-410560-7.50014-4]
   TUCKER DM, 1984, PSYCHOL REV, V91, P185, DOI 10.1037//0033-295X.91.2.185
   TULVING E, 1990, SCIENCE, V247, P301, DOI 10.1126/science.2296719
   Ward T. B., 1995, CREATIVE COGNITION A, P157
   Zahavi A., 1997, HANDICAP PRINCIPLE M
NR 81
TC 35
Z9 35
U1 2
U2 33
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0146-1672
EI 1552-7433
J9 PERS SOC PSYCHOL B
JI Pers. Soc. Psychol. Bull.
PD NOV
PY 2009
VL 35
IS 11
BP 1479
EP 1491
DI 10.1177/0146167209342755
PG 13
WC Psychology, Social
SC Psychology
GA 503DP
UT WOS:000270512900005
PM 19690153
DA 2018-12-27
ER

PT J
AU Sanna, LJ
   Chang, EC
   Parks, CD
   Kennedy, LA
AF Sanna, Lawrence J.
   Chang, Edward C.
   Parks, Craig D.
   Kennedy, Lindsay A.
TI RETRACTED: Construing Collective Concerns: Increasing Cooperation by
   Broadening Construals in Social Dilemmas (Retracted article. See vol.
   23, pg. 949, 2012)
SO PSYCHOLOGICAL SCIENCE
LA English
DT Article; Retracted Publication
ID PERFORMANCE; OTHERS
C1 [Sanna, Lawrence J.; Kennedy, Lindsay A.] Univ N Carolina, Dept Psychol, Chapel Hill, NC 27599 USA.
   [Sanna, Lawrence J.] Duke Univ, Fuqua Sch Business, Durham, NC 27706 USA.
   [Chang, Edward C.] Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA.
   [Parks, Craig D.] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA.
RP Sanna, LJ (reprint author), Univ N Carolina, Dept Psychol, CB 3270 Davie Hall, Chapel Hill, NC 27599 USA.
EM sanna@unc.edu
OI Parks, Craig/0000-0001-5299-093X
CR Eyal T, 2008, J EXP SOC PSYCHOL, V44, P1204, DOI 10.1016/j.jesp.2008.03.012
   Freitas AL, 2004, J EXP SOC PSYCHOL, V40, P739, DOI 10.1016/j.jesp.2004.04.003
   Fujita K, 2006, J PERS SOC PSYCHOL, V90, P351, DOI 10.1037/0022-3514.90.3.351
   Fujita K, 2008, SOC PERSONAL PSYCHOL, V2, P1475, DOI 10.1111/j.1751-9004.2008.00118.x
   HARDIN G, 1968, SCIENCE, V162, P1243
   Henderson MD, 2006, J PERS SOC PSYCHOL, V91, P712, DOI 10.1037/0022-3514.91.4.712
   Joireman J., 2006, JUDGMENTS TIME INTER, P82, DOI DOI 10.1093/ACPR0F:0S0/9780195177664.003.0006
   KELLEY HH, 2003, ATLAS INTERPERSONAL
   Kerr NL, 2004, ANNU REV PSYCHOL, V55, P623, DOI 10.1146/annurev.psych.55.090902.142009
   Komorita S.S, 1996, SOCIAL DILEMMAS
   Liberman N, 2002, J EXP SOC PSYCHOL, V38, P523, DOI 10.1016/S0022-1031(02)00535-8
   Messick D. M., 1983, REV PERSONALITY SOCI, V4, P11
   Parks CD, 2001, PERS SOC PSYCHOL B, V27, P345, DOI 10.1177/0146167201273008
   Sanna LJ, 2003, GROUP DYN-THEOR RES, V7, P26, DOI 10.1037/1089-2699.7.1.26
   Schroeder D. A, 1995, SOCIAL DILEMMAS
   SHEPPERD JA, 1993, PSYCHOL BULL, V113, P67, DOI 10.1037/0033-2909.113.1.67
   Trope Y, 2003, PSYCHOL REV, V110, P403, DOI 10.1037/0033-295X.110.3.403
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
NR 18
TC 15
Z9 16
U1 3
U2 18
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0956-7976
EI 1467-9280
J9 PSYCHOL SCI
JI Psychol. Sci.
PD NOV
PY 2009
VL 20
IS 11
BP 1319
EP 1321
DI 10.1111/j.1467-9280.2009.02458.x
PG 3
WC Psychology, Multidisciplinary
SC Psychology
GA 516FF
UT WOS:000271526700004
PM 19845890
DA 2018-12-27
ER

PT J
AU Shin, KR
   Kang, Y
   Park, HJ
   Heitkemper, M
AF Shin, Kyung Rim
   Kang, Younhee
   Park, Hyo Jung
   Heitkemper, Margaret
TI RETRACTED: Effects of Exercise Program on Physical Fitness, Depression,
   and Self-Efficacy of Low-Income Elderly Women in South Korea (Retracted
   article. See vol. 30, pg. 90, 2013)
SO PUBLIC HEALTH NURSING
LA English
DT Article; Retracted Publication
DE depression; elderly women; exercise; physical fitness; self-efficacy
ID OLDER-ADULTS
AB Objective
   This study aimed to examine the effects of exercise programs on physical fitness, depression, and self-efficacy in low-income elderly women (age >= 75).
   Design and Sample
   A pretest-posttest experimental research design with a control group was used. The sample consisted of 26 women in the exercise group and 22 women in the wait-list control group in Seoul, Korea.
   Measures
   The measures of physical fitness included body mass index, cardiopulmonary endurance (blood pressure and heart rate), muscle strength (hand grip strength), flexibility (degree of bending of the upper body), and balance (duration of time for which the subject could stand on one foot). Depression and self-efficacy were measured by the Center for Epidemiological Studies Depression scale and a modified form of Lee's scale, respectively. All measures were obtained twice: at baseline and at the completion of the exercise program.
   Intervention
   The exercise program consisted of 4 weeks of education along with 8 weeks of physical exercise.
   Results
   After the intervention, significant improvements were found in depression, self-efficacy, and all measures of physical fitness, except heart rate and flexibility, in the experimental group.
   Conclusion
   The exercise program may be recommended as a method to maintain and promote the health of low-income elderly women.
C1 [Shin, Kyung Rim; Kang, Younhee; Park, Hyo Jung] Ewha Womans Univ, Coll Hlth Sci, Seoul 120750, South Korea.
   [Heitkemper, Margaret] Univ Washington, Sch Nursing, Seattle, WA 98195 USA.
RP Shin, KR (reprint author), Ewha Womans Univ, Coll Hlth Sci, 11-1 Daehyun Dong, Seoul 120750, South Korea.
EM krshin@ewha.ac.kr
CR Bandura A., 1997, SELF EFFICACY EXERCI
   Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P25
   CHO WJ, 1998, KOREAN J NURSING QUE, V7, P169
   CHOI SK, 2001, THESIS E WOMANS U SE
   Christmas C, 2000, J AM GERIATR SOC, V48, P318, DOI 10.1111/j.1532-5415.2000.tb02654.x
   Conn VS, 2003, WOMEN HEALTH ISS, V13, P158, DOI 10.1016/S1049-3867(03)00037-9
   Fatouros IG, 2002, INT J SPORTS MED, V23, P112, DOI 10.1055/s-2002-20130
   Grant S, 2004, PUBLIC HEALTH, V118, P31, DOI 10.1016/S0033-3506(03)00131-8
   JEON MY, 1996, THESIS SEOUL NATL U
   JUNG Y, 2002, J KOREAN FUNDAMENTAL, V4, P93
   KIM HJ, 1994, THESIS SEOUL NATL U
   KIM JH, 2004, KOREAN SPORTS RES, V15, P1207
   Kim SY, 2001, J VET DIAGN INVEST, V13, P516, DOI 10.1177/104063870101300611
   *KNSO, 2001, 2000 NAT SURV POP HO
   *KOR MIN HLTH WELF, 2007, AG SOC KOR
   LEE KE, 1999, J KOREAN WOMENS HLTH, V5, P43
   LEE MR, 1996, J NURSES ACAD SOC, V26, P556
   LEE MR, 2001, J KOREAN ACAD ADULTS, V13, P610
   LEE SJ, 2000, J KOREAN ACAD NURS, V30, P776
   LEE WY, 2003, THESIS CHUNGANG U SE
   LIM SK, 2003, J SPORTS SCI RES, V13, P191
   MOON JH, 2004, SPORTS SCI, V13, P77
   Oka Roberta K, 2005, Eur J Cardiovasc Nurs, V4, P215, DOI 10.1016/j.ejcnurse.2005.04.004
   Ourania Matsouka, 2003, J Gerontol Nurs, V29, P50
   PARK IY, 2004, J SPORT LEISURE STUD, V22, P459
   Park JJ, 2000, J KOREAN SOC AEROBIC, V4, P13
   PARK JM, 2003, J KOREAN ACAD NURS, V33, P220
   RADROFF LS, 1977, APPL PSYCH MEAS, V1, P385
   Resnick B, 2008, PUBLIC HEALTH NURS, V25, P221, DOI 10.1111/j.1525-1446.2008.00699.x
   Resnick Barbara, 2006, Cultur Divers Ethnic Minor Psychol, V12, P17, DOI 10.1037/1099-9809.12.1.17
   Timonen L, 2002, INT J GERIATR PSYCH, V17, P1106, DOI 10.1002/gps.757
   WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455
   YANG K, 2005, CLIN NURS RES, V11, P47
   YESAVAGE JA, 1988, PSYCHOPHARMACOL BULL, V24, P709
   YOON SR, 2002, J KOREAN GERONTOLOGI, V16, P135
NR 35
TC 17
Z9 17
U1 4
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0737-1209
EI 1525-1446
J9 PUBLIC HEALTH NURS
JI Public Health Nurs.
PD NOV-DEC
PY 2009
VL 26
IS 6
BP 523
EP 531
DI 10.1111/j.1525-1446.2009.00812.x
PG 9
WC Public, Environmental & Occupational Health; Nursing
SC Public, Environmental & Occupational Health; Nursing
GA 509VA
UT WOS:000271045600005
PM 19903272
DA 2018-12-27
ER

PT J
AU Misra, A
   Urban, MW
AF Misra, Anuradha
   Urban, Marek W.
TI RETRACTED: Environmentally Compliant Fluoro-Containing MMA/nBA Colloidal
   Dispersions; Synthesis, Molecular Modeling, and Coalescence (Retracted
   article. See vol. 50, pg. 9857, 2017)
SO MACROMOLECULES
LA English
DT Article; Retracted Publication
ID SUPERCRITICAL CARBON-DIOXIDE; PHOSPHOLIPID-ASSISTED SYNTHESIS; FILM
   FORMATION; EMULSION POLYMERIZATION; AQUEOUS DISPERSIONS;
   SURFACE-TENSION; POLYMERS; LATEXES; FLUOROPOLYMERS; PARTICLES
AB While aqueous phase colloidal synthesis of F-containing dispersions is often restricted by low solubility and surface tension of monomers. the use of bioactive dispersing agents, such as phospholipids, may alleviate these problems. Using 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC). we copolymerized heptafluorobutyl methacrylate (FBMA), heptafluorobutyl acrylate (FBA), heptadecafluorodecyl methacrylate (FMA), heptadecafluorodecyl acrylate (FA) with methyl methacrylate (MMA) and n-butyl acrylate (nBA) monomers which resulted in the formation of stable nonspherical colloidal dispersions that contain Lip to 15% (w/w) of the fluoropolymer (FT) phase. These studies report for the First time an aqueous phase FP colloidal dispersion synthesis without the use of fluoro-dispersing agents. Experimentally determined by transmission electron microscopy (TEM) particle phase-separated morphologies consist of the FP phase that polymerize on the surface of p-MMA/nBA core particles. Thermodynamic molecular modeling simulations show that the coexistence of fluorinated and nonfluorinated segments is energetically favorable and the presence of the I-P phase decreases the cohesive energy density of macromolecular chains. These theoretical predictions are in agreement with the experimental results. Nonspherical FP containing colloidal particles coalesce to form stable films With ultra low static and kinetic coefficients of friction as well as the low surface energy which result from stratification of the FP phase near the film-air (F-A) interface. As a result, property gradients are achieved, which are manifested by the low static and kinetic coefficients of friction near the F-A interface due to the presence of the FP phase and lower glass transition temperature (T-g) of p-M MA/nBA phase near the film-substrate (F-S) interface. The latter facilitates the flow during coalescence.
C1 [Misra, Anuradha; Urban, Marek W.] Univ So Mississippi, Sch Polymers & High Performace Mat, Shelby F Thames Polymer Sci Res Ctr, Hattiesburg, MS 39406 USA.
RP Urban, MW (reprint author), Univ So Mississippi, Sch Polymers & High Performace Mat, Shelby F Thames Polymer Sci Res Ctr, Hattiesburg, MS 39406 USA.
EM marek.urban@usm.edu
FU National Science Foundation Materials Research Science Engineering
   Center (NSF MRSEC) [DMR 0213883, DMR 0215873]
FX Major support for these studies from the National Science Foundation
   Materials Research Science Engineering Center (NSF MRSEC) (DMR 0213883)
   is acknowledged. The authors also acknowledge use of instrumentation and
   facilities through the Materials Research Facilities Network (MRFN)
   supported by the NSF MRSEC program (DMR 0213883) as well as Major
   Research Instrumentation program DMR 0215873.
CR BRANDRUP J, 1966, POLYM HDB
   Cinar H, 2005, MACROMOLECULES, V38, P5078, DOI 10.1021/ma050065s
   DAVIS SD, 1985, ENCY EMULSION TECHNO, V2
   DESIMONE JM, 1994, SCIENCE, V265, P356, DOI 10.1126/science.265.5170.356
   DESIMONE JM, 1992, SCIENCE, V257, P945, DOI 10.1126/science.257.5072.945
   Dreher WR, 2005, MACROMOLECULES, V38, P4666, DOI 10.1021/ma0580070w
   Dreher WR, 2005, MACROMOLECULES, V38, P2205, DOI 10.1021/ma0479161
   Dreher WR, 2004, LANGMUIR, V20, P10455, DOI 10.1021/la049494u
   Dreher WR, 2003, LANGMUIR, V19, P10254, DOI 10.1021/la035078i
   EVANSON KW, 1991, J APPL POLYM SCI, V42, P2309, DOI 10.1002/app.1991.070420822
   Ha JW, 2002, MACROMOLECULES, V35, P6811, DOI 10.1021/ma011692u
   HYATT JA, 1984, J ORG CHEM, V49, P5097, DOI 10.1021/jo00200a016
   Koenderink GH, 2001, LANGMUIR, V17, P6086, DOI 10.1021/la010181y
   Landfester K, 2002, MACROMOLECULES, V35, P1658, DOI 10.1021/ma011608a
   Lau W, 2002, MACROMOL SYMP, V182, P283, DOI 10.1002/1521-3900(200206)182:1<283::AID-MASY283>3.0.CO;2-H
   Lestage DJ, 2005, BIOMACROMOLECULES, V6, P1561, DOI 10.1021/bm049195j
   Lestage DJ, 2005, LANGMUIR, V21, P2150, DOI 10.1021/la0475526
   Linemann RF, 1999, MACROMOLECULES, V32, P1715, DOI 10.1021/ma981580b
   McClain JB, 1996, SCIENCE, V274, P2049, DOI 10.1126/science.274.5295.2049
   Michel U, 2003, MACROMOLECULES, V36, P7107, DOI 10.1021/ma0344240
   Misra A, 2007, MACROMOLECULES, V40, P6190, DOI 10.1021/ma070852k
   Nii T, 2004, COLLOID SURFACE B, V39, P57, DOI 10.1016/j.colsurfb.2004.08.017
   Otts DB, 2002, LANGMUIR, V18, P6473, DOI 10.1021/la025684y
   Pinazo A, 2002, LANGMUIR, V18, P8888, DOI 10.1021/la020476r
   ROMACK TJ, 1995, MACROMOLECULES, V28, P8429, DOI 10.1021/ma00128a065
   Sacanna S, 2004, LANGMUIR, V20, P8398, DOI 10.1021/la049811x
   SCHAEFER J, 1977, MACROMOLECULES, V10, P384, DOI 10.1021/ma60056a031
   SILVERSTEIN RM, 1998, SPECTROMETERIC INDEN
   Singh A, 2006, LANGMUIR, V22, P524, DOI 10.1021/la052528t
   SOLOMON S, 1986, NATURE, V321, P755, DOI 10.1038/321755a0
   Thomas RR, 2000, MACROMOLECULES, V33, P8828, DOI 10.1021/ma000221p
   Voet D., 1995, BIOCHEMISTRY
   Wood CD, 2002, MACROMOLECULES, V35, P6743, DOI 10.1021/ma025506b
NR 33
TC 11
Z9 12
U1 2
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0024-9297
EI 1520-5835
J9 MACROMOLECULES
JI Macromolecules
PD OCT 27
PY 2009
VL 42
IS 20
BP 7828
EP 7835
DI 10.1021/ma9012303
PG 8
WC Polymer Science
SC Polymer Science
GA 506WJ
UT WOS:000270807300030
OA Bronze
DA 2018-12-27
ER

PT J
AU Yamagata, K
   Fujiyama, S
   Ito, S
   Ueda, T
   Murata, T
   Naitou, M
   Takeyama, K
   Minami, Y
   O'Malley, BW
   Kato, S
AF Yamagata, Kaoru
   Fujiyama, Sally
   Ito, Saya
   Ueda, Takashi
   Murata, Takuya
   Naitou, Masanori
   Takeyama, Ken-ichi
   Minami, Yasuhiro
   O'Malley, Bert W.
   Kato, Shigeaki
TI RETRACTED: Maturation of MicroRNA Is Hormonally Regulated by a Nuclear
   Receptor (Retracted article. See vol. 54, pg. 536, 2014)
SO MOLECULAR CELL
LA English
DT Article; Retracted Publication
ID ACTIVATION DOMAIN; STEROID-HORMONES; GENE-EXPRESSION; RNA; COMPLEX;
   ALPHA; LIGAND; LIN28; METHYLTRANSFERASE; TUMORIGENESIS
AB Steroid hormones and their cognate nuclear receptors exert a wide spectrum of biological actions through regulation of transcriptional and posttranscriptional processes. However, the underlying molecular mechanism by which steroid hormones control posttranscriptional processes is largely unknown. We now report that estrogen receptor alpha (ER alpha) inhibits the maturation of a particular microRNA (miRNA) and thereby stabilizes the mRNA of an ER alpha target gene through the 3'UTR. Estrogen-bound ER alpha downregulated expression of a set of miRNAs in both animals and cultured cells. Activated ER alpha attenuated the processing of primary miRNAs into pre-miRNAs through estrogen-dependent association with the Drosha complex, resulting in stabilization of the transcript of an ER alpha target gene through its 3'UTR. Thus, a steroid hormone achieves posttranscriptional control by regulating the maturation of miRNA.
C1 [Yamagata, Kaoru; Fujiyama, Sally; Ito, Saya; Ueda, Takashi; Murata, Takuya; Takeyama, Ken-ichi; Kato, Shigeaki] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   [Yamagata, Kaoru; Fujiyama, Sally; Ito, Saya; Kato, Shigeaki] Japan Sci & Technol Agcy, ERATO, Kawaguchi, Saitama 3320012, Japan.
   [Naitou, Masanori] Astellas Pharma Inc, Adv Genom, Mol Med Res Labs, Drug Discovery Res, Tsukuba, Ibaraki 3058585, Japan.
   [Minami, Yasuhiro] Kobe Univ, Dept Physiol & Cell Biol, Grad Sch Med, Chuo Ku, Kobe, Hyogo 6500017, Japan.
   [O'Malley, Bert W.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
FU Ministry of Education, Culture, Sports, Science, and Technology
FX We thank Y. Imai, S. Takemasa, S. Kondo, and N. Tsuji for expertise in
   ovariectornizing mice; F. Ohtake for technical support in preparing
   mouse enclometrial epithelial cells; V.N. Kim for sharing reagents: H.
   Suzuki, E. Suzuki, S. Sawatsubashi, M. Tanabe, S. Kimura, J. Lim, Y.
   Zhao, and A. Kouzmenko for helpful discussions; and M. Yamaki for
   manuscript preparation. This work was supported by priority areas from
   the Ministry of Education, Culture, Sports, Science, and Technology (to
   S.K.).
CR Abdelmohsen K, 2007, CELL CYCLE, V6, P1288, DOI 10.4161/cc.6.11.4299
   Acevedo ML, 2004, MOL CELL, V13, P725, DOI 10.1016/S1097-2765(04)00121-2
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30
   Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294
   Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086
   Endoh H, 1999, MOL CELL BIOL, V19, P5363
   Fujiki R, 2009, NATURE, V459, P455, DOI 10.1038/nature07954
   Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577
   Fuller-Pace FV, 2008, BIOCHEM SOC T, V36, P609, DOI 10.1042/BST0360609
   Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120
   Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250
   He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232
   Heo I, 2008, MOL CELL, V32, P276, DOI 10.1016/j.molcel.2008.09.014
   Hobert O, 2008, SCIENCE, V319, P1785, DOI 10.1126/science.1151651
   Hua Z, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000116
   Ing NH, 2005, BIOL REPROD, V72, P1290, DOI 10.1095/biolreprod.105.040014
   Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7
   Kracht M, 2002, CYTOKINE, V20, P91, DOI 10.1006/cyto.2002.0895
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Liu JG, 2008, HIGH PERFORM POLYM, V20, P221, DOI 10.1177/0954008307082508
   Lonard DM, 2007, MOL CELL, V27, P691, DOI 10.1016/j.molcel.2007.08.012
   Michlewski G, 2008, MOL CELL, V32, P383, DOI 10.1016/j.molcel.2008.10.013
   Miller VM, 2008, PHARMACOL REV, V60, P210, DOI 10.1124/pr.107.08002
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683
   Okada M, 2008, EMBO REP, V9, P563, DOI 10.1038/embor.2008.55
   Ruohola JK, 1999, MOL CELL ENDOCRINOL, V149, P29, DOI 10.1016/S0303-7207(99)00003-9
   Sakamoto S, 2009, MOL CELL BIOL, V29, P3754, DOI 10.1128/MCB.01836-08
   Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537
   Staton JM, 2000, J MOL ENDOCRINOL, V25, P17, DOI 10.1677/jme.0.0250017
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040
   Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341
   Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1
   Yekta S, 2008, NAT REV GENET, V9, P789, DOI 10.1038/nrg2400
NR 36
TC 186
Z9 190
U1 2
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD OCT 23
PY 2009
VL 36
IS 2
BP 340
EP 347
DI 10.1016/j.molcel.2009.08.017
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 519XC
UT WOS:000271801900020
PM 19854141
OA Bronze
DA 2018-12-27
ER

PT J
AU Lombardi, VC
   Ruscetti, FW
   Das Gupta, J
   Pfost, MA
   Hagen, KS
   Peterson, DL
   Ruscetti, SK
   Bagni, RK
   Petrow-Sadowski, C
   Gold, B
   Dean, M
   Silverman, RH
   Mikovits, JA
AF Lombardi, Vincent C.
   Ruscetti, Francis W.
   Das Gupta, Jaydip
   Pfost, Max A.
   Hagen, Kathryn S.
   Peterson, Daniel L.
   Ruscetti, Sandra K.
   Bagni, Rachel K.
   Petrow-Sadowski, Cari
   Gold, Bert
   Dean, Michael
   Silverman, Robert H.
   Mikovits, Judy A.
TI RETRACTED: Detection of an Infectious Retrovirus, XMRV, in Blood Cells
   of Patients with Chronic Fatigue Syndrome (Retracted article. See vol.
   334, pg. 1636, 2011)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID MURINE LEUKEMIA-VIRUS; FOCUS-FORMING VIRUS; CENTRIFUGAL ENHANCEMENT;
   GROWTH-FACTOR; RNASE-L; GENE; LYMPHOMA; REGION
AB Chronic fatigue syndrome (CFS) is a debilitating disease of unknown etiology that is estimated to affect 17 million people worldwide. Studying peripheral blood mononuclear cells (PBMCs) from CFS patients, we identified DNA from a human gammaretrovirus, xenotropic murine leukemia virus-related virus (XMRV), in 68 of 101 patients (67%) as compared to 8 of 218 (3.7%) healthy controls. Cell culture experiments revealed that patient-derived XMRV is infectious and that both cell-associated and cell-free transmission of the virus are possible. Secondary viral infections were established in uninfected primary lymphocytes and indicator cell lines after their exposure to activated PBMCs, B cells, T cells, or plasma derived from CFS patients. These findings raise the possibility that XMRV may be a contributing factor in the pathogenesis of CFS.
C1 [Lombardi, Vincent C.; Pfost, Max A.; Hagen, Kathryn S.; Peterson, Daniel L.; Mikovits, Judy A.] Whittemore Peterson Inst, Reno, NV 89557 USA.
   [Ruscetti, Francis W.; Gold, Bert; Dean, Michael] NCI, Expt Immunol Lab, Frederick, MD 21701 USA.
   [Das Gupta, Jaydip; Silverman, Robert H.] Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA.
   [Ruscetti, Sandra K.] NCI, Lab Canc Prevent, Frederick, MD 21701 USA.
   [Bagni, Rachel K.] NCI, Adv Technol Program, Frederick, MD 21701 USA.
   [Petrow-Sadowski, Cari] NCI, Basic Res Program, Sci Applicat Int Corp, Frederick, MD 21701 USA.
RP Mikovits, JA (reprint author), Whittemore Peterson Inst, Reno, NV 89557 USA.
EM judym@wpinstitute.org
FU Whittemore Peterson Institute; Whittemore Family foundation; National
   Cancer Institute (NCI); NIH [HHSN26120080001E]; NCI/ NIH [CA104943]; U.
   S. DoD Prostate Cancer Research Program [W81XWH-07-1338]; V Foundation
   for Cancer Research; Charlotte Geyer Foundation; Mal and Lea Bank
FX We thank D. Bertolette, Y. Huang, C. Hanson, and J. Troxler for
   technical assistance; K. Nagashima for EM; and C. Ware and K. Hunter for
   discussions. Funded by the Whittemore Peterson Institute and the
   Whittemore Family foundation; the National Cancer Institute (NCI); NIH
   (under contract HHSN26120080001E); and grants to R. H. S. from NCI/ NIH
   (CA104943), the U. S. DoD Prostate Cancer Research Program
   (W81XWH-07-1338), the V Foundation for Cancer Research, the Charlotte
   Geyer Foundation, and Mal and Lea Bank. The content of this publication
   does not reflect the views or policies of the U. S. DHHS, nor does
   mention of trade names, commercial products, or organizations imply
   endorsement by the U. S. government. R. H. S. may receive royalty
   payments in the future from Abbott Laboratories. GenBank accession
   numbers are as follows: WPI-1130, GQ483508; WPI-1138, GQ483509;
   WPI-1169,GQ483510; WPI-1178, GQ497343; WPI-1106, GQ497344; and WPI-1104,
   GQ497345.; Note added in proof: V. C. L. is operations manager of Viral
   Immune Pathologies Laboratory, which is in negotiations with the
   Whittemore Peterson Institute to offer a diagnostic test for XMRV.
CR Casey G, 2002, NAT GENET, V32, P582, DOI 10.1038/ng1021
   CHESEBRO B, 1983, VIROLOGY, V127, P134, DOI 10.1016/0042-6822(83)90378-1
   Devanur LD, 2006, J CLIN VIROL, V37, P139, DOI 10.1016/j.jcv.2006.08.013
   Dong B, 2007, P NATL ACAD SCI USA, V104, P1655, DOI 10.1073/pnas.0610291104
   Dunn GP, 2005, CANCER RES, V65, P3447, DOI 10.1158/0008-5472.CAN-04-4316
   LEVINE PH, 1992, CANCER RES, V52, pS5516
   Li XJ, 2009, J VIROL, V83, P4912, DOI 10.1128/JVI.02343-08
   Lisco Andrea, 2009, Curr HIV/AIDS Rep, V6, P5, DOI 10.1007/s11904-009-0002-3
   Peterson KE, 2006, CURR TOP MICROBIOL, V303, P67, DOI 10.1007/978-3-540-33397-5_4
   PIETROBONI GR, 1989, J VIROL METHODS, V24, P85, DOI 10.1016/0166-0934(89)90010-4
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Power C, 2001, TRENDS NEUROSCI, V24, P162, DOI 10.1016/S0166-2236(00)01737-9
   SMITH KA, 1981, ADV IMMUNOL, V31, P137, DOI 10.1016/S0065-2776(08)60920-7
   Suhadolnik RJ, 1997, J INTERF CYTOK RES, V17, P377, DOI 10.1089/jir.1997.17.377
   Urisman A, 2006, PLOS PATHOG, V2, P211, DOI 10.1371/journal.ppat.0020025
   Whiteside Theresa L., 1998, American Journal of Medicine, V105, p27S, DOI 10.1016/S0002-9343(98)00155-7
   WOLFF L, 1983, P NATL ACAD SCI-BIOL, V80, P4718, DOI 10.1073/pnas.80.15.4718
   WOLFF L, 1982, J VIROL, V43, P472
   Xiang Y, 2003, CANCER RES, V63, P6795
   Yoo SM, 2008, J VIROL METHODS, V154, P160, DOI 10.1016/j.jviromet.2008.07.026
NR 20
TC 379
Z9 387
U1 7
U2 59
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD OCT 23
PY 2009
VL 326
IS 5952
BP 585
EP 589
DI 10.1126/science.1179052
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 509LN
UT WOS:000271019400045
PM 19815723
OA Green Published
DA 2018-12-27
ER

PT J
AU Kim, MS
   Kondo, T
   Takada, I
   Youn, MY
   Yamamoto, Y
   Takahashi, S
   Matsumoto, T
   Fujiyama, S
   Shirode, Y
   Yamaoka, I
   Kitagawa, H
   Takeyama, KI
   Shibuya, H
   Ohtake, F
   Kato, S
AF Kim, Mi-Sun
   Kondo, Takeshi
   Takada, Ichiro
   Youn, Min-Young
   Yamamoto, Yoko
   Takahashi, Sayuri
   Matsumoto, Takahiro
   Fujiyama, Sally
   Shirode, Yuko
   Yamaoka, Ikuko
   Kitagawa, Hirochika
   Takeyama, Ken-Ichi
   Shibuya, Hiroshi
   Ohtake, Fumiaki
   Kato, Shigeaki
TI RETRACTED: DNA demethylation in hormone-induced transcriptional
   derepression (Retracted article. See vol. 486, pg. 280, 2012)
SO NATURE
LA English
DT Article; Retracted Publication
ID VITAMIN-D-RECEPTOR; NUCLEAR RECEPTOR; GLYCOSYLASE; EPIGENETICS;
   PROMOTER; ACTIVATION; METHYLATION; REPAIR; SITES; DNMT1
AB Epigenetic modifications at the histone level affect gene regulation in response to extracellular signals(1,2). However, regulated epigenetic modifications at the DNA level, especially active DNA demethylation, in gene activation are not well understood(3-5). Here we report that DNA methylation/demethylation is hormonally switched to control transcription of the cytochrome p450 27B1 (CYP27B1) gene. Reflecting vitamin-D-mediated transrepression of the CYP27B1 gene by the negative vitamin D response element (nVDRE)(6,7), methylation of CpG sites ((5m)CpG) is induced by vitamin D in this gene promoter. Conversely, treatment with parathyroid hormone, a hormone known to activate the CYP27B1 gene(8), induces active demethylation of the (5m)CpG sites in this promoter. Biochemical purification of a complex associated with the nVDRE-binding protein (VDIR, also known as TCF3)(6,7) identified two DNA methyl-transferases, DNMT1 and DNMT3B, for methylation of CpG sites(9), as well as a DNA glycosylase, MBD4 (ref. 10). Protein-kinase-C-phosphorylated MBD4 by parathyroid hormone stimulation promotes incision of methylated DNA through glycosylase activity(11), and a base-excision repair process seems to complete DNA demethylation in the MBD4-bound promoter. Such parathyroid-hormone- induced DNA demethylation and subsequent transcriptional derepression are impaired in Mbd4(-/-) mice(12). Thus, the present findings suggest that methylation switching at the DNA level contributes to the hormonal control of transcription.
C1 [Kim, Mi-Sun; Matsumoto, Takahiro; Fujiyama, Sally; Shirode, Yuko; Yamaoka, Ikuko; Ohtake, Fumiaki; Kato, Shigeaki] Japan Sci & Technol Agcy, ERATO, Kawaguchisi, Saitama 3320012, Japan.
   [Kim, Mi-Sun; Kondo, Takeshi; Takada, Ichiro; Youn, Min-Young; Yamamoto, Yoko; Takahashi, Sayuri; Matsumoto, Takahiro; Fujiyama, Sally; Shirode, Yuko; Yamaoka, Ikuko; Kitagawa, Hirochika; Takeyama, Ken-Ichi; Ohtake, Fumiaki; Kato, Shigeaki] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   [Kim, Mi-Sun; Shibuya, Hiroshi] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cell Biol, Bunkyo Ku, Tokyo 1138510, Japan.
   [Kim, Mi-Sun; Shibuya, Hiroshi] Tokyo Med & Dent Univ, Sch Biomed Sci, Bunkyo Ku, Tokyo 1138510, Japan.
RP Kato, S (reprint author), Japan Sci & Technol Agcy, ERATO, 4-1-8 Honcho, Kawaguchisi, Saitama 3320012, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology
FX We thank A. Murayama, K. Saito and A. Matsukage for discussions, Y. Imai
   and R. Fujiki for technical assistance, K. Sugasawa for plasmids, and M.
   Yamaki and H. Yamazaki for preparing the manuscript. This work was
   supported in part by priority areas from the Ministry of Education,
   Culture, Sports, Science and Technology (to F. O. and S. K.).
CR Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x
   Barreto G, 2007, NATURE, V445, P671, DOI 10.1038/nature05515
   Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913
   Brenza HL, 1998, P NATL ACAD SCI USA, V95, P1387, DOI 10.1073/pnas.95.4.1387
   Chambon P, 1996, FASEB J, V10, P940
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002
   Fuks F, 2000, NAT GENET, V24, P88
   Gehring M, 2006, CELL, V124, P495, DOI 10.1016/j.cell.2005.12.034
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325
   Hendrich B, 1999, NATURE, V401, P301
   Jiricny J, 2008, CELL, V135, P1167, DOI 10.1016/j.cell.2008.12.008
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355
   McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4
   Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354
   Murayama A, 2004, EMBO J, V23, P1598, DOI 10.1038/sj.emboj.7600157
   Murayama A, 1998, BIOCHEM BIOPH RES CO, V249, P11, DOI 10.1006/bbrc.1998.9098
   Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683
   Potts JT, 2007, ANN NY ACAD SCI, V1117, P196, DOI 10.1196/annals.1402.088
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Takezawa S, 2007, EMBO J, V26, P764, DOI 10.1038/sj.emboj.7601548
   Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7
   Trojer P, 2006, CELL, V125, P213, DOI 10.1016/j.cell.2006.04.003
   Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67
   Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391
   Zhu B, 2000, NUCLEIC ACIDS RES, V28, P4157, DOI 10.1093/nar/28.21.4157
NR 30
TC 165
Z9 170
U1 5
U2 61
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD OCT 15
PY 2009
VL 461
IS 7266
BP 1007
EP 1012
DI 10.1038/nature08456
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 506ZF
UT WOS:000270817700053
PM 19829383
DA 2018-12-27
ER

PT J
AU Zhang, N
   Khachigian, LM
AF Zhang, Ning
   Khachigian, Levon M.
TI RETRACTED: Injury-induced Platelet-derived Growth Factor Receptor-alpha
   Expression Mediated by Interleukin-1 beta (IL-1 beta) Release and
   Cooperative Transactivation by NF-kappa B and ATF-4 IL-1 beta
   FACILITATES HDAC-1/2 DISSOCIATION FROM PROMOTER (Retracted Article. See
   vol 285, pg 21902, 2010)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID SMOOTH-MUSCLE-CELLS; BINDING PROTEIN-DELTA; ENDOTHELIAL-CELLS;
   GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; EPITHELIAL-CELLS; CANCER
   CELLS; IN-VIVO; PDGF-AA; APOPTOSIS
AB Platelet-derived growth factors are a family of potent mitogens and chemoattractants for fibroblasts and other cells of mesenchymal origin. Platelet-derived growth factor (PDGF) dimeric ligands (composed of A-, B-, C-, and D-chains) exert their biological activity through high affinity interactions with cell surface receptor subunits (alpha and beta). PDGF-receptor-alpha is widely implicated in the pathogenesis of hyperplastic fibrotic disease, yet the molecular mechanisms controlling its expression in response to injury are poorly understood. Here we show that PDGF-R alpha expression is induced in fibroblasts by mechanical injury and interleukin (IL)-1 beta, which was abolished by neutralizing IL-1 beta antibodies in the culture supernatant or inhibitors of NF-kappa B Chromatin immunoprecipitation and electrophoretic mobility shift assays revealed the existence of a new NF-kappa B binding site at -531/-521 bp in the PDGF-R alpha promoter. We have recently shown that ATF-4 is also induced by injury (Malabanan, K. P., Kanellakis, P., Bobik, A., and Khachigian, L. M. (2008) Circ. Res. 103, 378-387), and we demonstrate here that ATF-4 binds a novel element -259/-254 and stimulates PDGF-R alpha transcription. ATF-4 and NF-kappa B interact, occupy the PDGF-R alpha promoter, and induce PDGF-R alpha transcription in a cooperative manner. IL-1 beta facilitates the dissociation of histone deacetylase (HDAC)-1/2 from the PDGF-R alpha promoter, whereas the HDAC inhibitors suberoylanilide hydroxamic acid and trichostatin A potentiate IL-1 beta induction of PDGF-R alpha transcription. These findings, taken together, demonstrate that injury stimulates IL-1 beta secretion by fibroblasts, which activates NF-kappa B and ATF-4 and stimulates interaction with the PDGF-R alpha promoter, triggering PDGF-R alpha transcription. Physical and functional interactions between NF-kappa B and ATF-4 have not been reported in any gene. This is also the first report of HDAC regulation of PDGF-R alpha transcription.
C1 [Zhang, Ning; Khachigian, Levon M.] Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia.
RP Khachigian, LM (reprint author), Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia.
EM L.Khachigian@unsw.edu.au
OI Khachigian, Levon/0000-0003-3446-0323
FU National Health and Medical Research Council (NHMRC); Australian
   Research Council; National Heart Foundation
FX This work was supported by grants from the National Health and Medical
   Research Council (NHMRC), Australian Research Council, and National
   Heart Foundation.
CR Alvarez RH, 2006, MAYO CLIN PROC, V81, P1241, DOI 10.4065/81.9.1241
   Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   Arend WR, 2002, CYTOKINE GROWTH F R, V13, P323, DOI 10.1016/S1359-6101(02)00020-5
   Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524-475X.2008.00410.x
   Beer HD, 1997, J INVEST DERMATOL, V109, P132, DOI 10.1111/1523-1747.ep12319188
   Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Bonello MR, 2004, J BIOL CHEM, V279, P2377, DOI 10.1074/jbc.M308254200
   Bonello MR, 2005, AM J PATHOL, V167, P1149, DOI 10.1016/S0002-9440(10)61203-5
   Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6
   Choudhury P, 1997, INVEST OPHTH VIS SCI, V38, P824
   Clark JD, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-28
   Dai Y, 2004, BLOOD, V103, P2761, DOI 10.1182/blood-2003-09-3037
   Delbridge GJ, 1997, CIRC RES, V81, P282, DOI 10.1161/01.RES.81.2.282
   Dieguez-Acuna FJ, 2004, TOXICOL SCI, V82, P114, DOI 10.1093/toxsci/kfh236
   Ding WX, 2007, MOL CANCER THER, V6, P1062, DOI 10.1158/1535-7163.MCT-06-0541
   Englesbe MJ, 2004, J VASC SURG, V39, P1091, DOI 10.1016/j.jvs.2004.01.041
   Fukuoka T, 1999, J BIOL CHEM, V274, P25576, DOI 10.1074/jbc.274.36.25576
   GOLDBLUM SE, 1988, INFECT IMMUN, V56, P2255
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9
   Heldin CH, 1999, PHYSIOL REV, V79, P1283
   Ikezoe T, 2005, MOL CANCER THER, V4, P578, DOI 10.1158/1535-7163.MCT-04-0277
   Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200
   KAWAGISHI J, 1995, GENOMICS, V30, P224, DOI 10.1006/geno.1995.9883
   Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427
   KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106
   Kitami Y, 1999, CIRC RES, V84, P64
   Letoha T, 2005, FREE RADICAL BIO MED, V39, P1142, DOI 10.1016/j.freeradbiomed.2005.06.003
   Li J, 2000, J BIOL CHEM, V275, P2951, DOI 10.1074/jbc.275.4.2951
   Li XR, 2000, NAT CELL BIOL, V2, P302
   Liu JW, 2007, INT IMMUNOPHARMACOL, V7, P945, DOI 10.1016/j.intimp.2007.03.001
   Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI126322
   Luo RX, 1999, J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288
   Malabanan KP, 2008, CIRC RES, V103, P378, DOI 10.1161/CIRCRESAHA.107.168682
   Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736
   Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619
   NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903
   PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0
   PERACCHIA F, 1991, EXP CELL RES, V193, P208, DOI 10.1016/0014-4827(91)90557-B
   Rafty LA, 1998, J BIOL CHEM, V273, P5758, DOI 10.1074/jbc.273.10.5758
   RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498
   Raines EW, 2004, CYTOKINE GROWTH F R, V15, P237, DOI 10.1016/j.cytogfr.2004.03.004
   Resch ZT, 2006, ENDOCRINOLOGY, V147, P885, DOI 10.1210/en.2005-0908
   Rutkowski DT, 2003, DEV CELL, V4, P442, DOI 10.1016/S1534-5807(03)00100-X
   Soriano P, 1997, DEVELOPMENT, V124, P2691
   Sumpio BE, 1998, ARTERIOSCL THROM VAS, V18, P349, DOI 10.1161/01.ATV.18.3.349
   Tallquist M, 2004, CYTOKINE GROWTH F R, V15, P205, DOI 10.1016/j.cytogfr.2004.03.003
   Wang XJ, 2005, ACTA PHARMACOL SIN, V26, P934, DOI 10.1111/j.1745-7254.2005.00152.x
   Warshamana GS, 1998, AM J PHYSIOL-LUNG C, V274, pL499, DOI 10.1152/ajplung.1998.274.4.L499
   Wente MN, 2005, ONCOL REP, V14, P1635
   Yu JH, 2001, BIOCHEM BIOPH RES CO, V282, P697, DOI 10.1006/bbrc.2001.4622
   Zheng X, 2008, INT J ONCOL, V32, P257
   Zhou GB, 2007, CELL RES, V17, P274, DOI 10.1038/cr.2007.21
NR 53
TC 8
Z9 9
U1 2
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 9
PY 2009
VL 284
IS 41
BP 27933
EP 27943
DI 10.1074/jbc.M109.025742
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 505FP
UT WOS:000270676300021
PM 19648113
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Beloqui, A
   Guazzaroni, ME
   Pazos, F
   Vieites, JM
   Godoy, M
   Golyshina, OV
   Chernikova, TN
   Waliczek, A
   Silva-Rocha, R
   Al-ramahi, Y
   La Cono, V
   Mendez, C
   Salas, JA
   Solano, R
   Yakimov, MM
   Timmis, KN
   Golyshin, PN
   Ferrer, M
AF Beloqui, Ana
   Guazzaroni, Maria-Eugenia
   Pazos, Florencio
   Vieites, Jose M.
   Godoy, Marta
   Golyshina, Olga V.
   Chernikova, Tatyana N.
   Waliczek, Agnes
   Silva-Rocha, Rafael
   Al-ramahi, Yamal
   La Cono, Violetta
   Mendez, Carmen
   Salas, Jose A.
   Solano, Roberto
   Yakimov, Michail M.
   Timmis, Kenneth N.
   Golyshin, Peter N.
   Ferrer, Manuel
TI RETRACTED: Reactome Array: Forging a Link Between Metabolome and Genome
   (Retracted article. See vol. 330, pg. 912, 2010)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID SYSTEMS MICROBIOLOGY; ENZYME-ACTIVITY; METAGENOMICS; COMMUNITIES;
   ENVIRONMENT; ECOSYSTEMS; PATHWAYS; ARCHAEA; STRESS
AB We describe a sensitive metabolite array for genome sequence-independent functional analysis of metabolic phenotypes and networks, the reactomes, of cell populations and communities. The array includes 1676 dye-linked substrate compounds collectively representing central metabolic pathways of all forms of life. Application of cell extracts to the array leads to specific binding of enzymes to cognate substrates, transformation to products, and concomitant activation of the dye signals. Proof of principle was shown by reconstruction of the metabolic maps of model bacteria. Utility of the array for unsequenced organisms was demonstrated by reconstruction of the global metabolisms of three microbial communities derived from acidic volcanic pool, deep-sea brine lake, and hydrocarbon-polluted seawater. Enzymes of interest are captured on nanoparticles coated with cognate metabolites, sequenced, and their functions unequivocally established.
C1 [Golyshina, Olga V.; Chernikova, Tatyana N.; Waliczek, Agnes; Timmis, Kenneth N.; Golyshin, Peter N.] HZI Helmholtz Ctr Infect Res, D-38124 Braunschweig, Germany.
   [Pazos, Florencio; Godoy, Marta; Silva-Rocha, Rafael; Solano, Roberto] CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain.
   [Beloqui, Ana; Guazzaroni, Maria-Eugenia; Vieites, Jose M.; Al-ramahi, Yamal; Ferrer, Manuel] CSIC, Inst Catalysis, E-28049 Madrid, Spain.
   [La Cono, Violetta; Yakimov, Michail M.] CNR, Inst Coastal Marine Environm, I-98122 Messina, Italy.
   [Mendez, Carmen; Salas, Jose A.] Univ Oviedo, E-33006 Oviedo, Spain.
   [Timmis, Kenneth N.] Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, D-38106 Braunschweig, Germany.
   [Golyshin, Peter N.] Bangor Univ, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales.
   [Golyshin, Peter N.] Aberystwyth Univ Bangor Univ Partnership CIRRE, Ctr Integrated Res Rural Environm, Aberystwyth, Dyfed, Wales.
RP Golyshin, PN (reprint author), HZI Helmholtz Ctr Infect Res, D-38124 Braunschweig, Germany.
EM p.golyshin@bangor.ac.uk; mferrer@icp.csic.es
OI Yakimov, Michail/0000-0003-1418-363X; Guazzaroni,
   Maria-Eugenia/0000-0002-4657-3731; Ferrer, Manuel/0000-0003-4962-4714;
   Mendez-Fernandez, Maria del Carmen/0000-0003-2729-841X; La Cono,
   Violetta/0000-0002-3306-4938
FU Spanish MEC [BIO2006-15318]; Federal Ministry for Science and Education
   (BMBF); Fonds der Chemischen Industrie;  [BIO2006-11738]; 
   [CSD2007-00005];  [GEN2006-27750-C-4-E];  [BFU2008-04398-E/BMC]; 
   [KBBE-226977]
FX This research was supported by the BIO2006-11738, CSD2007-00005,
   GEN2006-27750-C-4-E, BFU2008-04398-E/BMC, and KBBE-226977 projects. A. B
   and Y. A-R thank the Spanish MEC for the FPU and FPI fellowships. F. P.
   thanks the Spanish MEC for the BIO2006-15318 project. K. N. T, O. V. G.,
   and P. N. G acknowledge the Federal Ministry for Science and Education
   (BMBF) for a grant in the framework of the BiotechGenoMik program, and
   K. N. T. thanks the Fonds der Chemischen Industrie for generous support.
   Authors are deeply indebted to A. Yanenko for sampling Kolguev Island
   coastal water and to the captain and crew of Research Vessel Urania for
   their assistance in deep-sea sampling in the Mediterranean Sea and to J.
   Manuel Franco for statistical analyses.
CR Biddle JF, 2008, P NATL ACAD SCI USA, V105, P10583, DOI 10.1073/pnas.0709942105
   Daffonchio D, 2006, NATURE, V440, P203, DOI 10.1038/nature04418
   Dinsdale EA, 2008, NATURE, V452, P629, DOI 10.1038/nature06810
   Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010
   Gianoulis TA, 2009, P NATL ACAD SCI USA, V106, P1374, DOI 10.1073/pnas.0808022106
   Gilbert MTP, 2007, SCIENCE, V317, P1927, DOI 10.1126/science.1146971
   Golyshina OV, 2005, ENVIRON MICROBIOL, V7, P1277, DOI 10.1111/j.1462-2920.2005.00861.x
   Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3
   Huang EY, 1997, J BACTERIOL, V179, P5648, DOI 10.1128/jb.179.17.5648-5653.1997
   Jiao YYQ, 2005, APPL ENVIRON MICROB, V71, P4487, DOI 10.1128/AEM.71.8.4487-4496.2005
   Jimenez JI, 2002, ENVIRON MICROBIOL, V4, P824, DOI 10.1046/j.1462-2920.2002.00370.x
   Kalyuzhnaya MG, 2008, NAT BIOTECHNOL, V26, P1029, DOI 10.1038/nbt.1488
   Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063
   Lombardot T, 2006, NUCLEIC ACIDS RES, V34, pD390, DOI 10.1093/nar/gkj070
   Northen TR, 2008, P NATL ACAD SCI USA, V105, P3678, DOI 10.1073/pnas.0712332105
   Pearce DA, 1999, J BACTERIOL, V181, P4774
   PRONK AF, 1995, J BACTERIOL, V177, P75, DOI 10.1128/jb.177.1.75-81.1995
   Raes J, 2008, NAT REV MICROBIOL, V6, P693, DOI 10.1038/nrmicro1935
   Service RF, 2006, SCIENCE, V311, P1544, DOI 10.1126/science.311.5767.1544
   Turnbaugh PJ, 2008, CELL, V134, P708, DOI 10.1016/j.cell.2008.08.025
   Tyson GW, 2004, NATURE, V428, P37, DOI 10.1038/nature02340
   van der Wielen PWJJ, 2005, SCIENCE, V307, P121, DOI 10.1126/science.1103569
   Vieites JM, 2009, FEMS MICROBIOL REV, V33, P236, DOI 10.1111/j.1574-6976.2008.00152.x
   Whitham TG, 2008, SCIENCE, V320, P492, DOI 10.1126/science.1153918
   Woodson JD, 2003, J BACTERIOL, V185, P7193, DOI 10.1128/JB.185.24.7193-7201.2003
   Yakimov MM, 2007, CURR OPIN BIOTECH, V18, P257, DOI 10.1016/j.copbio.2007.04.006
NR 26
TC 29
Z9 31
U1 7
U2 39
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD OCT 9
PY 2009
VL 326
IS 5950
BP 252
EP 257
DI 10.1126/science.1174094
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 504EX
UT WOS:000270599500034
PM 19815770
DA 2018-12-27
ER

PT J
AU Khodakovskaya, M
   Dervishi, E
   Mahmood, M
   Xu, Y
   Li, ZR
   Watanabe, F
   Biris, AS
AF Khodakovskaya, Mariya
   Dervishi, Enkeleda
   Mahmood, Meena
   Xu, Yang
   Li, Zhongrui
   Watanabe, Fumiya
   Biris, Alexandru S.
TI RETRACTED: Carbon Nanotubes Are Able To Penetrate Plant Seed Coat and
   Dramatically Affect Seed Germination and Plant Growth (Retracted
   article. See vol. 6, pg. 7541, 2012)
SO ACS NANO
LA English
DT Article; Retracted Publication
DE carbon nanotubes; tomato plants; enhanced germination; seed coat; water
   uptake
ID RAMAN-SPECTROSCOPY; ULTRAFINE PARTICLES; NANOPARTICLES; CELLS;
   PHYTOTOXICITY; DELIVERY; TISSUES; FATE
AB Carbon nanotubes (CNTs) were found to penetrate tomato seeds and affect their germination and growth rates. The germination Was found to be dramatically higher for seeds that germinated on medium containing CNTs (10-40 mu g/mL) compared to control. Analytical methods indicated that the CNTs are able to penetrate the thick seed coat and support water uptake inside seeds, a process which can affect seed germination and growth of tomato seedlings.
C1 [Khodakovskaya, Mariya; Dervishi, Enkeleda; Mahmood, Meena; Xu, Yang; Li, Zhongrui; Biris, Alexandru S.] Univ Arkansas, Dept Appl Sci, Little Rock, AR 72211 USA.
   [Dervishi, Enkeleda; Mahmood, Meena; Xu, Yang; Li, Zhongrui; Watanabe, Fumiya; Biris, Alexandru S.] Univ Arkansas, Nanotechnol Ctr, Little Rock, AR 72211 USA.
RP Khodakovskaya, M (reprint author), Univ Arkansas, Dept Appl Sci, Little Rock, AR 72211 USA.
EM mvkhodakovsk@ualr.edu; asbiris@ualr.edu
RI Dervishi, Enkeleda/B-2239-2010; Khodakovskaya, Mariya/F-3681-2010; Li,
   Zhongrui/D-6343-2018; Biris, Alexandru/A-8507-2010
FU Arkansas Science and Technology Authority (ASTA) [08-CAT-03];
   EPSCoR-NSF-P3 Center [P3-202]
FX We are grateful to Mrs. V. Knowlton (Center for Electron Microscopy,
   North Carolina State University) for help with preparation samples for
   the electron microscopy. We thank Mrs. B. Laska for help with
   sterilization of tomato seeds. The financial support from Arkansas
   Science and Technology Authority (ASTA) Grant No. 08-CAT-03 and
   EPSCoR-NSF-P3 Center (Grant P3-202) is highly appreciated.
CR Borm P. J. A., 2006, PART FIBRE TOXICOL, V3, P1, DOI DOI 10.1186/1743-8977-3-11
   Bradford K. J, 1995, SEED DEV GERMINATION, P351
   Canas JE, 2008, ENVIRON TOXICOL CHEM, V27, P1922, DOI 10.1897/08-117.1
   Dresselhaus MS, 2002, CARBON, V40, P2043, DOI 10.1016/S0008-6223(02)00066-0
   Dresselhaus MS, 2005, PHYS REP, V409, P47, DOI 10.1016/j.physrep.2004.10.006
   Geiser M, 2005, ENVIRON HEALTH PERSP, V113, P1555, DOI 10.1289/ehp.8006
   Gonzalez-Melendi P, 2008, ANN BOT-LONDON, V101, P187, DOI 10.1093/aob/mcm283
   Harrison BS, 2007, BIOMATERIALS, V28, P344, DOI 10.1016/j.biomaterials.2006.07.044
   Jorio A, 2003, NEW J PHYS, V5, DOI 10.1088/1367-2630/5/1/139
   JOSEPH T, 2006, NANOTECHNOLOGY AGR O
   Klaine SJ, 2008, ENVIRON TOXICOL CHEM, V27, P1825, DOI 10.1897/08-090.1
   Lin DH, 2007, ENVIRON POLLUT, V150, P243, DOI 10.1016/j.envpol.2007.01.016
   Liu HY, 2007, CELL RES, V17, P638, DOI 10.1038/cr.2007.34
   Liu QL, 2009, NANO LETT, V9, P1007, DOI 10.1021/nl803083u
   Liu Z, 2008, P NATL ACAD SCI USA, V105, P1410, DOI 10.1073/pnas.0707654105
   Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Pitsillides CM, 2003, BIOPHYS J, V84, P4023, DOI 10.1016/S0006-3495(03)75128-5
   Serrato-Valenti G, 2000, ANN BOT-LONDON, V85, P625, DOI 10.1006/anbo.2000.1114
   Torney F, 2007, NAT NANOTECHNOL, V2, P295, DOI 10.1038/nnano.2007.108
   Tyerman SD, 1999, J EXP BOT, V50, P1055, DOI 10.1093/jexbot/50.suppl_1.1055
   WAGGONER PE, 1976, PLANT PHYSIOL, V57, P153, DOI 10.1104/pp.57.2.153
   Wierzbicka M, 1998, PLANT SCI, V137, P155, DOI 10.1016/S0168-9452(98)00138-1
   Wong N., 2005, P NATL ACAD SCI USA, V102, P11600
   Xia T, 2006, NANO LETT, V6, P1794, DOI 10.1021/nl061025k
   Yang L, 2005, TOXICOL LETT, V158, P122, DOI 10.1016/j.toxlet.2005.03.003
   Yoshida A, 2006, CARBON, V44, P2333, DOI 10.1016/j.carbon.2006.05.020
   Zanello LP, 2006, NANO LETT, V6, P562, DOI 10.1021/nl051861e
   Zharov VP, 2005, LASER SURG MED, V37, P219, DOI 10.1002/lsm.20223
   Zheng L, 2005, BIOL TRACE ELEM RES, V104, P83, DOI 10.1385/BTER:104:1:083
NR 30
TC 304
Z9 335
U1 11
U2 144
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD OCT
PY 2009
VL 3
IS 10
BP 3221
EP 3227
DI 10.1021/nn900887m
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 510QR
UT WOS:000271106100047
PM 19772305
DA 2018-12-27
ER

PT J
AU Huang, Q
   Sui, YH
   Zhang, GX
AF Huang, Qiang
   Sui, Yu-Hua
   Zhang, Guo-Xiang
TI RETRACTED: {6,6 '-Dimethoxy-2,2
   '-[ethane-1,2-diylbis(nitrilomethylidyne)]diphenolato-1 kappa O-4(1),O-1
   ',O-6,O-6 ':2 kappa O-4(1),N,N ',O-1 '}(ethanol-1 kappa
   O)-mu-nitrato-1:2 kappa O-2:O '-dinitrato-1 kappa O-4,O
   '-samarium(III)zinc(II) (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the title heteronuclear Zn-II-Sm-III complex, [SmZn(C18H18-N2O4)(NO3)(3)(CH3CH2OH)], with the hexadentate Schiff base compartmental ligand N,N'-bis(3-methoxysalicylidene)ethylenediamine (H2L), the Sm-III and Zn-II ions are triply bridged by two phenolate O atoms from the Schiff base ligand and one nitrate anion. The five-coordinate Zn-II ion is in a square-pyramidal geometry formed by the donor centers of two imine N atoms, two phenolate O atoms and one of the bridging nitrate O atoms. The Sm-III center is in a ten-fold coordination of O atoms, involving the phenolate O atoms, two methoxy O atoms, one ethanol O atom, and two O atoms from two nitrate anions and one from the bridging nitrate anion. In the crystal, intermolecular O-H center dot center dot center dot O and C-H center dot center dot center dot O interactions generate a layer structure extending parallel to (101).
C1 [Huang, Qiang] Jiujiang Univ, Coll Mech & Mat Engn, Jiujiang 332005, Jiangxi, Peoples R China.
   [Sui, Yu-Hua] Vacat Educ Ctr JiLin Oil Feild, Songyuan 131200, JiLin, Peoples R China.
   [Zhang, Guo-Xiang] Well Drilling Technol & Serv Corp Jilin Oil Field, Pipeline Tools Subsidiary, Songyuan 131200, JiLin, Peoples R China.
RP Huang, Q (reprint author), Jiujiang Univ, Coll Mech & Mat Engn, Jiujiang 332005, Jiangxi, Peoples R China.
EM qhuang111@163.com
FU Educational Commission of Jiangxi Province of of China [GJJ08448];
   Natural Science Foundation of Jiangxi Province of China [2008GQC0002]
FX We gratefully acknowledge financial support from the Educational
   Commission of Jiangxi Province of of China (GJJ08448) and the Natural
   Science Foundation of Jiangxi Province of China (2008GQC0002).
CR Baggio R, 2000, J CHEM SOC DALTON, P2061, DOI 10.1039/a909544f
   Bruker, 2004, APEX2 SAINT SADABS
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Edder C, 2000, INORG CHEM, V39, P5059, DOI 10.1021/ic000687o
   KNOER R, 2005, INORG CHEM, V44, P3524
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   WESTRIP SP, 2009, PUBLCIF UNPUB
NR 7
TC 1
Z9 1
U1 2
U2 15
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD OCT
PY 2009
VL 65
BP M1161
EP +
DI 10.1107/S1600536809033558
PN 10
PG 12
WC Crystallography
SC Crystallography
GA 502IE
UT WOS:000270450400009
PM 21577700
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Liu, X
   Miller, YD
   Burton, NW
   Brown, WJ
AF Liu, X.
   Miller, Y. D.
   Burton, N. W.
   Brown, W. J.
TI RETRACTED: Preliminary study of the effects of Tai Chi and Qigong
   medical exercise on indicators of metabolic syndrome and glycaemic
   control in adults with raised blood glucose levels (Retracted article.
   See vol. 44, pg. 608, 2010)
SO BRITISH JOURNAL OF SPORTS MEDICINE
LA English
DT Article; Retracted Publication
ID INSULIN RESISTANCE; AEROBIC EXERCISE; HYPERTENSION; PRESSURE; OBESITY;
   TRIAL; NIDDM
AB Objectives: To evaluate the feasibility, acceptability and effects of a Tai Chi and Qigong medical exercise programme that aimed to improve indicators of metabolic syndrome and glycaemic control in adults with raised blood glucose levels.
   Design, setting, and participants: A single-group pre-post trial of 11 participants (3 men and 8 women; age 42-65 years) with raised blood glucose levels conducted from August to November 2005 at a university in Australia.
   Invervention: Participants attended Tai Chi and Qigong exercise training for 1-1.5 h 3 times per week for 12 weeks and were encouraged to practise the exercises at home.
   Main outcome measures: Indicators of metabolic syndrome (body mass index, waist circumference, blood pressure, fasting blood glucose, triglycerides, HDL-cholesterol) and glucose control (HbA1c, fasting insulin and insulin resistance).
   Results: There was good adherence and high acceptability for the group-based programme. Significant improvements were seen in four of the seven indicators of metabolic syndrome including body mass index (mean difference 21.05 (95% CI -1.48 to -0.63), p < 0.001), waist circumference (-2.80 cm (95% CI -4.97 to -0.62), p < 0.05) and both systolic (-11.64 mm Hg (95% CI -19.46 to -3.51), p < 0.01) and diastolic blood pressure (-9.73 mm Hg (95% CI -13.58 to -5.88), p < 0.001). There were also small improvements in HbA1c (-0.32% (95% CI -0.49% to -0.15%), p < 0.01), fasting insulin (-9.93 pmol/l (95% CI -19.93 to 0.07), p = 0.051) and insulin resistance (-0.53 (95% CI -0.97 to -0.09), p < 0.05).
   Conclusions: The programme was shown to be feasible and acceptable and the findings suggest that it may be helpful for the control of indicators of metabolic syndrome and glycaemic control. Larger controlled studies are needed to confirm these promising results.
C1 [Liu, X.; Burton, N. W.; Brown, W. J.] Univ Queensland, Sch Human Movement Studies, Brisbane, Qld 4072, Australia.
   [Miller, Y. D.] Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia.
RP Liu, X (reprint author), Univ Queensland, Sch Human Movement Studies, Brisbane, Qld 4072, Australia.
EM liuxin@hms.uq.edu.au
RI Brown, Wendy/G-2201-2010; Burton, Nicola/G-3313-2010
OI Brown, Wendy/0000-0001-9093-4509; Burton, Nicola/0000-0002-3221-2265;
   Miller, Yvette D/0000-0002-5393-7142
FU Diabetes Australia Research Trust; University of Queensland; NHMRC
   [252977]; School of Human Movement Studies, University of Queensland; 
   [301200]
FX This research project was funded by a grant from the Diabetes Australia
   Research Trust. XL was supported by a University of Queensland
   scholarship. YDM and NWB were supported by NHMRC capacity building
   (Owen, Brown, Bauman and Trost #252977) and program (Owen, Bauman and
   Brown #301200) grants in physical activity and health at the School of
   Human Movement Studies, University of Queensland.
CR *AIHW, 2003, ACT AUSTR SURV GUID, P2
   AINSWORTH BE, 2000, MED SCI SPORTS EXERC, V32, P498, DOI DOI 10.1097/00005768-200009001-00009
   *AUSTR I HLTH WELF, 2005, PERS BLOOD PRESS SYS
   Brotman DJ, 2002, CLEV CLIN J MED, V69, P990, DOI 10.3949/ccjm.69.12.990
   Brown WJ, 2004, J SCI MED SPORT, V7, P205, DOI 10.1016/S1440-2440(04)80010-0
   Castaneda C, 2002, DIABETES CARE, V25, P2335, DOI 10.2337/diacare.25.12.2335
   Channer KS, 1996, POSTGRAD MED J, V72, P349, DOI 10.1136/pgmj.72.848.349
   DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173
   Dunstan DW, 2002, DIABETES CARE, V25, P1729, DOI 10.2337/diacare.25.10.1729
   FERRANNINI E, 1991, DIABETOLOGIA, V34, P416, DOI 10.1007/BF00403180
   Holland John H, 1999, EMERGENCE CHAOS ORDE, P3
   *INT DIAB FED W PA, 2005, TYP 2 DIAB PRACT TAR, P43
   JING YZ, 1994, QIGONG SCI, V1, P23
   LIU X, 2007, J ALTERN COMPLEM MED, V13, P427
   LIU X, 2006, KAIMAI TAI JI, P46
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Mayer M, 1999, J ALTERN COMPLEM MED, V5, P371, DOI 10.1089/acm.1999.5.371
   Mensink M, 2003, INT J OBESITY, V27, P377, DOI [10.1038/sj.ijo.0802249, 10.1038/sj.ijo.802249]
   Miller Y D, 2004, J Sci Med Sport, V7, P52, DOI 10.1016/S1440-2440(04)80278-0
   Mourier A, 1997, DIABETES CARE, V20, P385, DOI 10.2337/diacare.20.3.385
   *NAT HEART FDN, 2004, HYP MAN GUID DOCT, P14
   NORTON K, 2000, ANTHROPOMETRICA TXB, P58
   NORTON K, 2000, ANTHROPOMETRICA TXB, P35
   OBRIENCOUSINS S, 2000, J GERONTOL, V55, P283
   PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006
   POWERS SK, 2003, TOTAL FITNESS WELLNE, P204
   Tessier D, 2000, ARCH GERONTOL GERIAT, V31, P121, DOI 10.1016/S0167-4943(00)00076-5
   Thornton EW, 2004, HEALTH PROMOT INT, V19, P33, DOI 10.1093/heapro/dah105
   TU DY, 1987, CHIN J REHABIL MED, V2, P203
   VAGUE J, 1956, AM J CLIN NUTR, V4, P220
   Wang CC, 2004, ARCH INTERN MED, V164, P493, DOI 10.1001/archinte.164.5.493
   [王敬浩 Wang Jinghao], 2002, [中国运动医学杂志, Chinese Journal of Sports Medicine], V21, P357
   *WHO, PREV DIAB WORLDW PAG
   *WHO, 1999, DEF DIAGN CLASS DIAB, P32
   Young DR, 1999, J AM GERIATR SOC, V47, P277, DOI 10.1111/j.1532-5415.1999.tb02989.x
NR 35
TC 6
Z9 6
U1 3
U2 15
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-3674
J9 BRIT J SPORT MED
JI Br. J. Sports Med.
PD OCT
PY 2009
VL 43
IS 11
BP 840
EP 844
DI 10.1136/bjsm.2007.045476
PG 5
WC Sport Sciences
SC Sport Sciences
GA 512NZ
UT WOS:000271258200009
DA 2018-12-27
ER

PT J
AU Ibric, S
   Djuric, Z
   Parojcic, J
   Petrovic, J
AF Ibric, Svetlana
   Djuric, Zorica
   Parojcic, Jelena
   Petrovic, Jelena
TI RETRACTED: ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL PRODUCT
   FORMULATION: NEURAL COMPUTING (Retracted article. See vol. 17, pg. 543,
   2011)
SO CHEMICAL INDUSTRY & CHEMICAL ENGINEERING QUARTERLY
LA English
DT Article; Retracted Publication
DE artificial neural networks; pharmaceutical formulation; genetic
   algorithms; fuzzy logic; optimization
ID SOLID DOSAGE FORM; MODELING TECHNIQUE; NETWORK ANALYSIS; DATA SETS;
   OPTIMIZATION; TABLET; PREDICTION; REGRESSION; ANN; DISSOLUTION
AB The properties of a formulation are determined not only by the ratios in which the ingredients are combined but also by the processing conditions. Although the relationships between the ingredient levels, processing conditions, and product performance may be known anecdotally, they can rarely be quantified. In the past, formulators tended to use statistical techniques to model their formulations, relying on response surfaces to provide a mechanism for optimization However the optimization by such a method can be misleading, especially if the formulation is complex. More recently, advances in mathematics and computer science have led to the development of alternative modeling and date mining techniques which work with a wider range of data sources: neural networks (an attempt to mimic the processing of the human brain), genetic algorithms (an attempt to mimic the evolutionary process by which biological systems self-organize and adapt), and fuzzy logic (an attempt to mimic the ability of the human brain to draw conclusions and generate responses based on incomplete or imprecise information). In this review the current technology will be examined, as well as its application in pharmaceutical formulation and processing. The challenges, benefits and future possibilities of neural computing will be discussed.
C1 [Ibric, Svetlana; Djuric, Zorica; Parojcic, Jelena; Petrovic, Jelena] Inst Pharmaceut Technol, Fac Pharm, Belgrade 11221, Serbia.
RP Ibric, S (reprint author), Inst Pharmaceut Technol, Fac Pharm, Vojvode Stepe 450, Belgrade 11221, Serbia.
EM ibric@pharmacy.bg.ac.rs
CR Agatonovic-Kustrin S, 2003, PHARM RES, V20, P1760, DOI 10.1023/B:PHAM.0000003372.56993.39
   BOSSLEY KM, 1997, THESIS U SOUTHAMPTON
   Bourquin J, 1998, EUR J PHARM SCI, V6, P287, DOI 10.1016/S0928-0987(97)10025-2
   Bourquin J, 1997, Pharm Dev Technol, V2, P111, DOI 10.3109/10837459709022616
   Bourquin J, 1998, EUR J PHARM SCI, V7, P17, DOI 10.1016/S0928-0987(97)10027-6
   Bourquin J, 1998, EUR J PHARM SCI, V7, P5, DOI 10.1016/S0928-0987(97)10028-8
   Bozic DZ, 1997, EUR J PHARM SCI, V5, P163
   Chen YX, 1999, J CONTROL RELEASE, V59, P33, DOI 10.1016/S0168-3659(98)00171-0
   Chen YX, 2001, DRUG DEV IND PHARM, V27, P623, DOI 10.1081/DDC-100107318
   Colbourn E.A., 1996, PHARM TECHNOL EUR, V8, P46
   DO QM, 2000, TAP CHI DUOC HOC, V6, P16
   Ghaffari A, 2006, INT J PHARMACEUT, V327, P126, DOI 10.1016/j.ijpharm.2006.07.056
   Goh WY, 2002, NEURAL COMPUT APPL, V10, P311, DOI 10.1007/s005210200003
   Holland J. H., 1975, ADAPTATION NATURAL A
   Ibric S, 2002, J CONTROL RELEASE, V82, P213, DOI 10.1016/S0168-3659(02)00044-5
   IBRIC S, 2003, PHARM SCI TECHNOL TO, V4, P62
   Ibric S, 2007, J PHARM PHARMACOL, V59, P745, DOI 10.1211/jpp.59.5.0017
   Kesavan J G, 1996, Pharm Dev Technol, V1, P391
   Koza JR, 1992, GENETIC PROGRAMMING
   LEANE MM, 2003, PHARM SCI TECHNOL TO, V4, P218
   LINDBERG NO, 2004, PHARM TECH EUR, V16, P35
   Mendyk A, 2005, EXPERT SYST APPL, V28, P285, DOI 10.1016/j.eswa.2004.10.007
   Mendyk A, 2007, EXPERT SYST APPL, V32, P1124, DOI 10.1016/j.eswa.2006.02.019
   Parojcic J, 2007, EUR J PHARM SCI, V30, P264, DOI 10.1016/j.ejps.2006.11.010
   Peh KK, 2000, PHARMACEUT RES, V17, P1384, DOI 10.1023/A:1007578321803
   Pillay V, 2002, J PHARM SCI, V91, P2559, DOI 10.1002/jps.10251
   Plumb AP, 2005, EUR J PHARM SCI, V25, P395, DOI 10.1016/j.ejps.2005.04.010
   Plumb AP, 2003, EUR J PHARM SCI, V18, P259, DOI 10.1016/S0928-0987(03)00016-2
   Plumb AP, 2002, EUR J PHARM SCI, V16, P281, DOI 10.1016/S0928-0987(02)00112-4
   QWEK SS, 2001, INT J COMP INTEL APP, V1, P187
   REES C, 1996, NEURAL COMPUTING LEA
   Rocksloh K, 1999, DRUG DEV IND PHARM, V25, P1015, DOI 10.1081/DDC-100102264
   Rowe R.C., 1998, INTELLIGENT SOFTWARE
   ROWE RC, 2000, PHARM TECH EUR, V12, P24
   ROWE RC, 1996, PHARM TECH EUR, V9, P46
   ROWE RC, 1999, PHARM SCI TECHNOL TO, V2, P495
   Sathe PM, 2003, DRUG DEV IND PHARM, V29, P349, DOI 10.1081/DDC-120018209
   Shao Q, 2006, EUR J PHARM SCI, V28, P394, DOI 10.1016/j.ejps.2006.04.007
   Sunada H, 2002, POWDER TECHNOL, V122, P188, DOI 10.1016/S0032-5910(01)00415-6
   Takayama K, 2000, J CONTROL RELEASE, V68, P175, DOI 10.1016/S0168-3659(00)00248-0
   Turkoglu M, 2004, EUR J PHARM BIOPHARM, V57, P279, DOI 10.1016/j.ejpb.2003.10.008
   TURKOGLU M, 1995, EUR J PHARM BIOPHARM, V41, P315
   Vaithiyalingam S, 2002, INT J PHARM, V234, P179, DOI 10.1016/S0378-5173(01)00959-0
   VAITHIYALINGAM S, 2000, PHARM TECH, V24, P60
   VERDUIN WH, 1994, BETTER PRODUCTS FAST
   Wu TO, 2000, DRUG DEV IND PHARM, V26, P211, DOI 10.1081/DDC-100100347
   ZADEH LA, 1965, INFORM CONTROL, V8, P338, DOI 10.1016/S0019-9958(65)90241-X
   ZOLOTARIOU R, 1998, J PHARM PHARMACOL, V50, P190
NR 48
TC 4
Z9 4
U1 4
U2 25
PU ASSOC CHEMICAL ENG
PI BELGRADE
PA KNEZA MILOSO 9-I, BELGRADE, 11000, SERBIA
SN 1451-9372
EI 2217-7434
J9 CHEM IND CHEM ENG Q
JI Chem. Ind. Chem. Eng. Q.
PD OCT-DEC
PY 2009
VL 15
IS 4
BP 227
EP 236
DI 10.2298/CICEQ0904227I
PG 10
WC Chemistry, Applied; Engineering, Chemical
SC Chemistry; Engineering
GA 567WG
UT WOS:000275477600005
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Noordewier, MK
   Stapel, DA
AF Noordewier, Marret K.
   Stapel, Diederik A.
TI RETRACTED: Judging the unexpected: Disconfirmation of situation-specific
   expectancies (Retracted article. See vol. 42, pg. 665, 2012)
SO EUROPEAN JOURNAL OF SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
ID SOCIAL JUDGMENTS; ATTRIBUTION; CONTRAST; TRAITS; IMPACT;
   PSYCHOPATHOLOGY; CONSISTENCY; INTEGRATION; INFORMATION; PERCEPTION
AB People's interactions with others typically take place in specific situations. Therefore, it is likely that expectancies of others are often situation-specific. In two studies, we examined when and how this situation-specificity of expectancies affects judgment. We showed that situation-specific expectancies ("Michael is kind at work")lead to surprise and contrast effects when incongruent behavior refers to the same specific situation (work), but not in other situations (general or home), whereas general expectancies ("Michael is kind") lead to such surprise and contrast effects, regardless of the target situation. These results suggest that people sometimes are "situationalists" and do not always show dispositional biases. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Noordewier, Marret K.] Tilburg Univ, TIBER, Dept Social Psychol, NL-5000 LE Tilburg, Netherlands.
RP Noordewier, MK (reprint author), Tilburg Univ, TIBER, Dept Social Psychol, POB 90153, NL-5000 LE Tilburg, Netherlands.
EM m.k.noordewier@uvt.nl
CR BANAJI MR, 1993, J PERS SOC PSYCHOL, V65, P272, DOI 10.1037/0022-3514.65.2.272
   BEM DJ, 1974, PSYCHOL REV, V81, P506, DOI 10.1037/h0037130
   Bettencourt BA, 1997, J EXP SOC PSYCHOL, V33, P244, DOI 10.1006/jesp.1996.1323
   Biernat M., 2005, STANDARDS EXPECTANCI
   Burgoon J. K., 1993, J LANG SOC PSYCHOL, V12, P30, DOI [10.1177/0261927X93121003, DOI 10.1177/0261927X93121003]
   CARLSTON DE, 1980, J EXP SOC PSYCHOL, V16, P303, DOI 10.1016/0022-1031(80)90025-6
   GILBERT DT, 1995, PSYCHOL BULL, V117, P21, DOI 10.1037/0033-2909.117.1.21
   GILBERT DT, 1988, J PERS SOC PSYCHOL, V54, P733, DOI 10.1037/0022-3514.54.5.733
   GILBERT DT, 1998, ORDINARY PERSONOLOGY
   HILTON JL, 1990, PERS SOC PSYCHOL B, V16, P430, DOI 10.1177/0146167290163003
   JACKSON LA, 1993, J PERS SOC PSYCHOL, V65, P69, DOI 10.1037//0022-3514.65.1.69
   JONES EE, 1979, AM PSYCHOL, V34, P107, DOI 10.1037//0003-066X.34.2.107
   JONES EE, 1967, J EXP SOC PSYCHOL, V3, P1, DOI 10.1016/0022-1031(67)90034-0
   JUSSIM L, 1987, J PERS SOC PSYCHOL, V52, P536, DOI 10.1037/0022-3514.52.3.536
   Krull DS, 1995, SOC COGNITION, V13, P417, DOI 10.1521/soco.1995.13.4.417
   Malle BF, 2006, PSYCHOL BULL, V132, P895, DOI 10.1037/0033-2909.132.6.895
   MANIS M, 1984, J EXP SOC PSYCHOL, V20, P217, DOI 10.1016/0022-1031(84)90048-9
   MANIS M, 1984, J EXP SOC PSYCHOL, V20, P363, DOI 10.1016/0022-1031(84)90032-5
   MARINGER M, EUROPEAN J IN PRESS
   MISCHEL W, 1982, PSYCHOL REV, V89, P730, DOI 10.1037//0033-295X.89.6.730
   Moskowitz GB, 1999, J PERS SOC PSYCHOL, V76, P911, DOI 10.1037/0022-3514.76.6.911
   REEDER GD, 1979, PSYCHOL REV, V86, P61, DOI 10.1037//0033-295X.86.1.61
   Roese N. J., 2007, SOCIAL PSYCHOL HDB B, P91
   ROSS L, 1977, INTUITIVE PSYCHOL HI, V10
   Srull T.K, 1989, MEMORY COGNITION ITS
   Stapel DA, 1998, J PERS SOC PSYCHOL, V74, P878, DOI 10.1037//0022-3514.74.4.878
   Stapel DA, 2000, J PERS SOC PSYCHOL, V78, P19, DOI 10.1037//0022-3514.78.1.19
   Stapel DA, 2007, ASSIMILATION AND CONTRAST IN SOCIAL PSYCHOLOGY, P1
   Stapel DA, 1998, J EXP SOC PSYCHOL, V34, P136, DOI 10.1006/jesp.1997.1346
   Stapel DA, 1998, PERS SOC PSYCHOL B, V24, P797, DOI 10.1177/0146167298248002
   Stapel DA, 1998, J EXP SOC PSYCHOL, V34, P227, DOI 10.1006/jesp.1997.9997
   SWANN WB, 1984, PSYCHOL REV, V91, P457, DOI 10.1037/0033-295X.91.4.457
   Trafimow D, 1998, PERS SOC PSYCHOL B, V24, P314, DOI 10.1177/0146167298243008
   Trafimow D, 2001, PERS SOC PSYCHOL B, V27, P1463, DOI 10.1177/01461672012711007
   Trope Y, 2000, J PERS SOC PSYCHOL, V79, P344, DOI 10.1037//0022-3514.79.3.344
NR 35
TC 4
Z9 4
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0046-2772
EI 1099-0992
J9 EUR J SOC PSYCHOL
JI Eur. J. Soc. Psychol.
PD OCT
PY 2009
VL 39
IS 6
BP 944
EP 956
DI 10.1002/ejsp.591
PG 13
WC Psychology, Social
SC Psychology
GA 500BK
UT WOS:000270271800006
DA 2018-12-27
ER

PT J
AU Wang, XC
   Tian, LL
   Tian, J
   Wu, HL
   Meng, AM
AF Wang, Xiao-Chun
   Tian, Li-Li
   Tian, Jing
   Wu, Hai-Liang
   Meng, Ai-min
TI RETRACTED: Overexpression of Cks1 is associated with poor survival by
   inhibiting apoptosis in breast cancer (Retracted Article. See vol 136,
   pg 637, 2010)
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE Cks1; Amplification; Overexpression; Apoptosis; Breast cancer
ID BLADDER-CANCER; CHROMOSOME 1Q; EXPRESSION; GENE; IDENTIFICATION;
   CARCINOMA; P27
AB The present study was undertaken to examine the amplification and expression status of Cks1 in breast cancer and its significance.
   The amplification and expression status of Cks1 gene was examined by FISH, real-time PCR and immunohistochemistry, respectively. RNA interference was used to detect the effects of Cks1 on migration, invasion, cell cycle progress and apoptosis of breast cancer cells.
   Cks1 gene amplification was highly correlated with protein overexpression. Overexpression of Cks1 was strongly associated with lymph node metastasis and poor prognosis (P = 0.000, 95% CI (0.00-0.02); P = 0.008, 95% CI (0.001-0.05), respectively). Knockdown of Cks1 expression by RNA interference inhibited the cell cycle progress, migration and invasion ability of breast cancer cells. Moreover, overexpression of Cks1 inhibited apoptosis of breast cancer cells through MEK-Erk pathway.
   Cks1 may be considered as potential novel prognostic markers and targets for the future development of specific therapeutic interventions in breast cancer.
C1 [Wang, Xiao-Chun; Tian, Li-Li; Meng, Ai-min] Chinese Acad Med Sci, Inst Radiat Med, Tianjin 300192, Peoples R China.
   [Tian, Jing] Canc Prevent & Treatment Inst Shandong Prov, Dept Internal Med 4, Jinan 250117, Shandong, Peoples R China.
   [Wu, Hai-Liang] Shandong Prov Chest Hosp, Dept Tumor Med, Jinan 250013, Peoples R China.
RP Wang, XC (reprint author), Chinese Acad Med Sci, Inst Radiat Med, Tianjin 300192, Peoples R China.
EM wxc3188@126.com
CR Albertson DG, 2003, BREAST CANCER RES TR, V78, P289, DOI 10.1023/A:1023025506386
   BORG A, 1992, GENE CHROMOSOME CANC, V5, P311, DOI 10.1002/gcc.2870050406
   Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126
   Huang WC, 2002, DNA CELL BIOL, V21, P707, DOI 10.1089/104454902760599681
   Lan YS, 2008, INT J CANCER, V123, P543, DOI 10.1002/ijc.23548
   Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593
   Orsetti B, 2006, BRIT J CANCER, V95, P1439, DOI 10.1038/sj.bjc.6603433
   Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320
   Shapira M, 2005, CANCER-AM CANCER SOC, V103, P1336, DOI 10.1002/cncr.20917
   Sitry D, 2002, J BIOL CHEM, V277, P42233, DOI 10.1074/jbc.M205254200
   Slotky M, 2005, BREAST CANCER RES, V7, pR737, DOI 10.1186/bcr1278
   Valeri A, 1999, PROG UROL, V9, P680
   Wei F, 2002, CANCER GENET CYTOGEN, V138, P38, DOI 10.1016/S0165-4608(02)00586-1
NR 13
TC 5
Z9 5
U1 3
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD OCT
PY 2009
VL 135
IS 10
BP 1393
EP 1401
DI 10.1007/s00432-009-0582-8
PG 9
WC Oncology
SC Oncology
GA 484WJ
UT WOS:000269079300011
PM 19352700
DA 2018-12-27
ER

PT J
AU Guerra, DL
   Carvalho, MA
   Leidens, VL
   Pinto, AA
   Viana, RR
   Airoldi, C
AF Guerra, Denis L.
   Carvalho, Marcos A.
   Leidens, Victor L.
   Pinto, Alane A.
   Viana, Rubia R.
   Airoldi, Claudio
TI RETRACTED: Immobilization of 5-amino-1,3,4-thiadiazole-thiol onto
   kanemite for thorium(IV) removal: Thermodynamics and equilibrium study
   (Retracted article. See vol. 357, pg. 558, 2011)
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article; Retracted Publication
DE Kanemite; Thorium; Adsorption; Calorimetry; Thermodynamic
ID SILICA-GEL SURFACE; SOLID-STATE NMR; MESOPOROUS SILICA; THERMOCHEMICAL
   DATA; ADSORPTION PROCESS; AQUEOUS-SOLUTIONS; IONIC-STRENGTH; METALS
   UPTAKE; CONTACT TIME; SORPTION
AB The compound 5-amino-1,3,4-thiadiazole-thiol (ATT) was anchored onto an Amazon kanemite surface (K) by homogeneous and heterogeneous routes. Both kanemite modification methodologies resulted in similar products, named K(CTT) and K(ATT), respectively. The modified and natural kanemite samples were characterized by textural analysis. FT-Raman, and nuclear magnetic nuclei of (29)Si and (13)C. Elemental analysis proved that the matrix K(ATT) presented a higher ATT immobilization than K(CTT), with values 1.42 and 1.38 mmol g(-1), respectively. NMR and FT-Raman confirmed the immobilization of ATT on both surfaces. The ability of these materials to remove thorium(IV) from aqueous solution was followed by a series of adsorption isotherms adjusted to a Sips equation at room temperature and pH 4.0. The maximum number of moles adsorbed was determined to be 7.48 x 10(-3), 9.82 x 10(-3), and 12.94 x 10(-3) mmol g(-1) for K, K(CTT), and K(ATT), respectively. The energetic effects (Delta(int)H degrees, Delta(int)G degrees, and Delta(int)S degrees) caused by metal cation adsorption were determined through calorimetric titrations. (C) 2009 Published by Elsevier Inc.
C1 [Guerra, Denis L.; Pinto, Alane A.; Airoldi, Claudio] Univ Estadual Campinas, Inst Chem, BR-13084971 Sao Paulo, Brazil.
   [Carvalho, Marcos A.; Leidens, Victor L.; Viana, Rubia R.] Univ Fed Mato Grosso, UFMT, Ctr Recursos Minerais, BR-78060900 Cuiaba, Mato Grosso, Brazil.
RP Guerra, DL (reprint author), Univ Estadual Campinas, Inst Chem, POB 6154, BR-13084971 Sao Paulo, Brazil.
EM dlguerra@iqm.unicamp.br
FU CNPq; FAPESP
FX The authors are indebted to CNPq for fellowships and FAPESP for
   financial support.
CR Airoldi C, 2002, J COLLOID INTERF SCI, V249, P1, DOI 10.1006/jcis.2001.8192
   ALBERT K, 1991, J CHROMATOGR, V544, P345, DOI 10.1016/S0021-9673(01)83995-9
   Arakaki LNH, 2000, POLYHEDRON, V19, P367, DOI 10.1016/S0277-5387(99)00347-2
   Arogunjo AM, 2009, J ENVIRON RADIOACTIV, V100, P232, DOI 10.1016/j.jenvrad.2008.12.004
   Babel S, 2003, J HAZARD MATER, V97, P219, DOI 10.1016/S0304-3894(02)00263-7
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   Bhainsa KC, 2009, J HAZARD MATER, V165, P670, DOI 10.1016/j.jhazmat.2008.10.033
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Cestari AR, 2001, J COLLOID INTERF SCI, V241, P45, DOI 10.1006/jcis.2001.7711
   Cestaria AR, 2009, J HAZARD MATER, V161, P307, DOI 10.1016/j.jhazmat.2008.03.091
   Chufan EE, 1997, VIB SPECTROSC, V15, P191, DOI 10.1016/S0924-2031(97)00033-7
   Dey RK, 2008, COLLOID SURFACE A, V324, P41, DOI 10.1016/j.colsurfa.2008.03.030
   Dias NL, 1998, COLLOID SURFACE A, V144, P219, DOI 10.1016/S0927-7757(98)00569-X
   EDWARDS HGM, 1995, J MOL STRUCT, V351, P51, DOI 10.1016/0022-2860(94)08485-Z
   Freundlich H, 1906, Z PHYS CHEM-STOCH VE, V57, P385
   Guerra DL, 2008, J HAZARD MATER, V155, P230, DOI 10.1016/j.jhazmat.2007.11.054
   Guerra DL, 2008, INORG CHEM COMMUN, V11, P20, DOI 10.1016/j.inoche.2007.09.029
   Guerra DL, 2006, POLYHEDRON, V25, P2880, DOI 10.1016/j.poly.2006.04.015
   GUERRA DL, 2008, J BRAZIL CHEM SOC, V20, P19
   Ho YS, 1999, PROCESS BIOCHEM, V34, P451, DOI 10.1016/S0032-9592(98)00112-5
   Ho YS, 1996, ENVIRON TECHNOL, V17, P71, DOI 10.1080/09593331708616362
   Huheey J. E, 1993, INORGANIC CHEM PRINC
   Kosuge K, 2001, CHEM MATER, V13, P2476, DOI 10.1021/cm000623b
   Kumar KV, 2007, DYES PIGMENTS, V74, P595, DOI 10.1016/j.dyepig.2006.03.026
   Largegren S., 1898, KUNGLIGA SUENSK VETE, V241, P1
   Lazarin AM, 2007, THERMOCHIM ACTA, V454, P43, DOI 10.1016/j.tca.2006.12.016
   LEPPERT D, 1990, MINING ENG, V42, P604
   Macedo TR, 2007, CLAY CLAY MINER, V55, P151, DOI 10.1346/CCMN.2007.0550204
   Ng JCY, 2003, CHEMOSPHERE, V52, P1021, DOI 10.1016/S0045-6535(03)00223-6
   Pavan FA, 2006, J HAZARD MATER, V137, P527, DOI 10.1016/j.jhazmat.2006.02.025
   Prado AGS, 2004, J NON-CRYST SOLIDS, V333, P61, DOI 10.1016/j.jnoncrysol.2003.09.053
   Prado AGS, 2002, GREEN CHEM, V4, P288, DOI 10.1039/b202420a
   Prado AGS, 2001, J COLLOID INTERF SCI, V236, P161, DOI 10.1006/jcis.2000.7401
   Quintanilla D. P., 2007, J COLLOID INTERF SCI, V313, P551
   QUINTANILLA DP, 2006, J HAZARD MATER, V134, P245
   Reiller P, 2005, ENVIRON SCI TECHNOL, V39, P1641, DOI 10.1021/es047756h
   Ruiz VSO, 2004, THERMOCHIM ACTA, V420, P73, DOI 10.1016/j.tca.2003.10.029
   Ryabchikov DI, 1963, ANAL CHEM THORIUM
   Sales JAA, 2005, THERMOCHIM ACTA, V427, P77, DOI 10.1016/j.tca.2004.08.015
   Sar P, 2004, INT BIODETER BIODEGR, V54, P193, DOI 10.1016/j.ibiod.2004.05.004
   Sharma P, 2008, MICROPOR MESOPOR MAT, V116, P641, DOI 10.1016/j.micromeso.2008.05.036
   Sheng GD, 2008, APPL RADIAT ISOTOPES, V66, P1313, DOI 10.1016/j.apradiso.2008.03.005
   SIPS R, 1948, J CHEM PHYS, V16, P490, DOI 10.1063/1.1746922
   Tan XL, 2007, COLLOID SURFACE A, V296, P109, DOI 10.1016/j.colsurfa.2006.09.032
   Tan XL, 2007, APPL RADIAT ISOTOPES, V65, P375, DOI 10.1016/j.apradiso.2006.10.014
   Thomas JM, 2007, MICROPOR MESOPOR MAT, V104, P5, DOI 10.1016/j.micromeso.2007.01.002
   Vieira EFS, 2005, J COLLOID INTERF SCI, V289, P42, DOI 10.1016/j.jcis.2005.03.043
   Xia K, 1997, GEOCHIM COSMOCHIM AC, V61, P2223, DOI 10.1016/S0016-7037(97)00080-X
   Xu D, 2006, RADIOCHIM ACTA, V94, P429, DOI 10.1524/ract.2006.94.8.429
NR 49
TC 5
Z9 7
U1 4
U2 23
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0021-9797
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD OCT 1
PY 2009
VL 338
IS 1
BP 30
EP 39
DI 10.1016/j.jcis.2009.06.004
PG 10
WC Chemistry, Physical
SC Chemistry
GA 489DX
UT WOS:000269401200005
PM 19635619
DA 2018-12-27
ER

PT J
AU Ma, DY
   Wang, RQ
   Liao, WY
   Han, ZX
   Liu, SW
AF Ma, Deying
   Wang, Ruiqin
   Liao, Wenyan
   Han, Zongxi
   Liu, Shengwang
TI RETRACTED: Identification and characterization of a novel antibacterial
   peptide, avian beta-defensin 2 from ducks (Retracted article. See vol.
   51, pg. 273, 2013)
SO JOURNAL OF MICROBIOLOGY
LA English
DT Article; Retracted Publication
DE duck; AvBD; recombinant protein; antimicrobial activity
ID ANTIMICROBIAL PEPTIDES; MAMMALIAN DEFENSINS; ADAPTIVE IMMUNITY;
   ESCHERICHIA-COLI; MAST-CELLS; CHICKEN; UPDATE; INNATE; GALLINACIN-9;
   PURIFICATION
AB In this study, a novel avian beta-defensin (AvBD) was isolated from duck pancreas. The complete nucleotide sequence of the gene contained an 195 bp open reading frame encoding 64 amino acids. Homology, characterization and comparison of the gene with AvBD from other avian species confirmed that it was duck AvBD2. The mRNA expression of the gene was analyzed in 17 tissues from 21-day-old ducks. AvBD2 was highly expressed in the trachea, crop, heart, bone marrow, and pancreas; moderately expressed in the muscular stomach, small intestine, kidney, spleen, thymus, and bursa of Fabricius; and weakly expressed in skin. We produced and purified recombinant AvBD2 by expressing the gene in Escherichia coli. As expected, the recombinant peptide exhibited strong bactericidal properties against Bacillus cereus, Staphylococcus aureus, and Pasteurella multocida, and weak bactericidal properties against E. coli and Salmonella choleraesuis. In addition, the recombinant protein retained antimicrobial activity against S. aureus under different temperatures (range, -20A degrees C to 100A degrees C) and pH values (range, 3 to 12).
C1 [Wang, Ruiqin; Liao, Wenyan; Han, Zongxi; Liu, Shengwang] Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Div Avian Infect Dis, Harbin 150001, Peoples R China.
   [Ma, Deying; Wang, Ruiqin; Liao, Wenyan] NE Agr Univ, Inst Anim Nutr, Harbin 150030, Peoples R China.
RP Liu, SW (reprint author), Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Div Avian Infect Dis, Harbin 150001, Peoples R China.
EM swliu@hvri.ac.cn
FU National Natural Science Foundation of China [30600435]; NOVUS
   international research; educational department of Heilongjiang province
   [1153lz05]
FX The study was supported by National Natural Science Foundation of China
   (30600435), NOVUS international research fellowship, Key research
   program of the educational department of Heilongjiang province (No.
   1153lz05).
CR Befus AD, 1999, J IMMUNOL, V163, P947
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brockus CW, 1998, ANIM GENET, V29, P283, DOI 10.1046/j.1365-2052.1998.00338.x
   Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098
   BULET P, 1993, J BIOL CHEM, V268, P14893
   Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935
   Evans EW, 1995, VET MICROBIOL, V47, P295, DOI 10.1016/0378-1135(95)00126-3
   EVANS EW, 1994, J LEUKOCYTE BIOL, V56, P661
   FLEISCHMANN J, 1985, DIAGN MICR INFEC DIS, V3, P233, DOI 10.1016/0732-8893(85)90035-5
   Froy O, 2003, TRENDS GENET, V19, P684, DOI 10.1016/j.tig.2003.10.010
   Ganz T, 2005, COMB CHEM HIGH T SCR, V8, P209, DOI 10.2174/1386207053764594
   Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180
   Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7
   Harmon BG, 1998, POULTRY SCI, V77, P972, DOI 10.1093/ps/77.7.972
   HARWIG SSL, 1994, FEBS LETT, V342, P281, DOI 10.1016/0014-5793(94)80517-2
   HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7
   Higgs R, 2005, IMMUNOGENETICS, V57, P90, DOI 10.1007/s00251-005-0777-3
   Hughes AL, 1997, J MOL EVOL, V44, P675, DOI 10.1007/PL00006191
   Hughes AL, 1999, CELL MOL LIFE SCI, V56, P94, DOI 10.1007/s000180050010
   Ichinose M, 1996, IMMUNOPHARMACOLOGY, V35, P103, DOI 10.1016/S0162-3109(96)00118-X
   Jung WJ, 2008, J MICROBIOL BIOTECHN, V18, P1836, DOI 10.4014/jmb.0800.120
   Lee HJ, 1999, J BIOSCI BIOENG, V88, P153, DOI 10.1016/S1389-1723(99)80194-7
   Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X
   Lynn DJ, 2007, IMMUNOL LETT, V110, P86, DOI 10.1016/j.imlet.2007.03.007
   Lynn DJ, 2004, IMMUNOGENETICS, V56, P170, DOI 10.1007/s00251-004-0675-0
   Ma DY, 2008, PROTEIN EXPRES PURIF, V58, P284, DOI 10.1016/j.pep.2007.11.017
   MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128
   Milona P, 2007, BIOCHEM BIOPH RES CO, V356, P169, DOI 10.1016/j.bbrc.2007.02.098
   Niyonsaba F, 2002, INT IMMUNOL, V14, P421, DOI 10.1093/intimm/14.4.421
   Oppenheim JJ, 2003, ANN RHEUM DIS, V62, P17, DOI 10.1136/ard.62.suppl_2.ii17
   Powers JPS, 2003, PEPTIDES, V24, P1681, DOI 10.1016/j.peptides.2003.08.023
   Satchell DP, 2003, J BIOL CHEM, V278, P13838, DOI 10.1074/jbc.M212115200
   SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2
   Schutte BC, 2002, ANNU REV PHYSIOL, V64, P709, DOI 10.1146/annurev.physiol.64.081501.134340
   Sugiarto H, 2006, INT J ANTIMICROB AG, V27, P229, DOI 10.1016/j.ijantimicag.2005.10.013
   Sugiarto H, 2004, BIOCHEM BIOPH RES CO, V323, P721, DOI 10.1016/j.bbrc.2004.08.162
   Sugiarto H, 2007, FEMS MICROBIOL LETT, V270, P195, DOI 10.1111/j.1574-6968.2007.00642.x
   TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394
   Thomma BPHJ, 2002, PLANTA, V216, P193, DOI 10.1007/s00425-002-0902-6
   Thouzeau C, 2003, J BIOL CHEM, V278, P51053, DOI 10.1074/jbc.M306839200
   van Dijk A, 2007, ANTIMICROB AGENTS CH, V51, P912, DOI 10.1128/AAC.00568-06
   Xiao YJ, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-56
   Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525
   Yu PL, 2001, BIOTECHNOL LETT, V23, P207, DOI 10.1023/A:1005623806445
NR 44
TC 25
Z9 40
U1 6
U2 20
PU MICROBIOLOGICAL  SOCIETY KOREA
PI SEOUL
PA KOREA SCIENCE & TECHNOLOGY CENTER 803, 635-4 YEOGSAM-DONG, KANGNAM-KU,
   SEOUL 135-703, SOUTH KOREA
SN 1225-8873
J9 J MICROBIOL
JI J. Microbiol.
PD OCT
PY 2009
VL 47
IS 5
BP 610
EP 618
DI 10.1007/s12275-009-0068-z
PG 9
WC Microbiology
SC Microbiology
GA 510LB
UT WOS:000271088900013
PM 19851734
DA 2018-12-27
ER

PT J
AU Yavari, AA
   Hamedi, M
   Haghbin, S
AF Yavari, Alireza Ashkmehr
   Hamedi, M.
   Haghbin, S.
TI RETRACTED: Investigation of Frying Oil Quality Using VIS/NIR
   Hyperspectral Analysis (Retracted article. See vol. 90, pg. 163, 2013)
SO JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY
LA English
DT Article; Retracted Publication
DE Spectroscopy; Fatty acid; Viscosity; Total polar component; Partial
   least squares method; Multivariate statistical analysis
ID NEAR-INFRARED SPECTROSCOPY; CLASSIFICATION; SYSTEM
AB Traditional chemical methods of analyzing frying oil quality are time-consuming and not amenable to on-line measurement. The main objective of this study was to evaluate quality changes of heated oils based on visible/near infrared spectral analysis using a hyperspectroradiometer. The reflectance spectra of the heated oils were analyzed within the range 400-1,750 nm. Acid value, total polar component, and viscosity of oil samples were used as indicators of different quality levels of oil. Partial least squares calibration models were developed for quantitative evaluations of these parameters. The R (2) and root mean square error for each prediction were calculated to assess the prediction capability of calibration models. The study demonstrated that using the established calibration models, quality parameters could be predicted with R (2) values over 0.92.
C1 [Yavari, Alireza Ashkmehr; Hamedi, M.] Univ Tehran, Dept Food Technol, Agr Biosyst Engn Fac, Karaj, Iran.
   [Haghbin, S.] Agr Bioengn Res Inst, Rasht, Iran.
RP Yavari, AA (reprint author), Univ Tehran, Dept Food Technol, Agr Biosyst Engn Fac, Karaj, Iran.
EM alireza.yavari@gmail.com
CR *AM OIL CHEM SOC, 2000, OFF METH REC PRACT A
   Benedito J, 2002, J AGR FOOD CHEM, V50, P4531, DOI 10.1021/jf020230s
   Danowska-Oziewicz M, 2005, J FOOD LIPIDS, V12, P159, DOI 10.1111/j.1745-4522.2005.00014.x
   GOBURDHUN D, 1995, INT J FOOD SCI NUTR, V46, P363, DOI 10.3109/09637489509012568
   Hazuka Z, 2000, J FOOD LIPIDS, V7, P225
   Hourant P, 2000, APPL SPECTROSC, V54, P1168, DOI 10.1366/0003702001950733
   Innawong B, 2004, LEBENSM-WISS TECHNOL, V37, P35, DOI 10.1016/S0023-6438(03)00122-1
   Innawong B, 2004, LEBENSM-WISS TECHNOL, V37, P23, DOI 10.1016/S0023-6438(03)00120-8
   Lankmayr E, 2004, J BIOCHEM BIOPH METH, V61, P95, DOI 10.1016/j.jbbm.2004.04.007
   Li H, 2000, J AM OIL CHEM SOC, V77, P1061, DOI 10.1007/s11746-000-0167-5
   Li H, 2000, J AM OIL CHEM SOC, V77, P137, DOI 10.1007/s11746-000-0023-7
   Li H, 2000, J AM OIL CHEM SOC, V77, P29, DOI 10.1007/s11746-000-0005-9
   MOREIRA RG, 1999, DEEP FAT FRYING FUND, P33
   ORTHOEFER FT, 1988, J AM OIL CHEM SOC, V65, P1417, DOI 10.1007/BF02898301
   SINGH RP, 1995, FOOD TECHNOL-CHICAGO, V49, P134
   *THERM, 2007, PLS PLUS IQ US GUID
NR 16
TC 10
Z9 11
U1 3
U2 31
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0003-021X
EI 1558-9331
J9 J AM OIL CHEM SOC
JI J. Am. Oil Chem. Soc.
PD OCT
PY 2009
VL 86
IS 10
BP 941
EP 947
DI 10.1007/s11746-009-1393-4
PG 7
WC Chemistry, Applied; Food Science & Technology
SC Chemistry; Food Science & Technology
GA 495HD
UT WOS:000269880500002
DA 2018-12-27
ER

PT J
AU Lichtenthaler, U
AF Lichtenthaler, Ulrich
TI RETRACTED: Product business, foreign direct investment, and licensing:
   Examining their relationships in international technology exploitation
   (Retracted article. See vol. 47, pg. 706, 2012)
SO JOURNAL OF WORLD BUSINESS
LA English
DT Article; Retracted Publication
DE Technology exploitation; Technology licensing; Foreign direct
   investment; Technological turbulence
ID FIRM PERFORMANCE; DYNAMIC CAPABILITIES; DIVERSIFICATION STRATEGIES;
   MULTINATIONAL FIRMS; MARKET ENTRY; KNOWLEDGE; INNOVATION; DIVERSITY;
   MODE; COMPENSATION
AB In the past, most industrial firms focused on internally exploiting technological knowledge in their own products. By contrast, external technology exploitation through out-licensing was primarily an entry mode into foreign markets or into product markets for which a firm had limited complementary assets. Outward technology transfer was mainly regarded as a substitute for foreign direct investment and for a firm's internal product business. The recent trend towards active licensing questions this traditional role of international licensing. To overcome the focus on market entry in prior research, we analyze the motives for technology licensing. On this basis, we use data from 152 firms to test six hypotheses relating product diversification, technological diversification, and foreign direct investment to the extent of technology out-licensing, considering technological turbulence as a moderator. The results provide support for a capability-based understanding of technology licensing, and they may lead us to fundamentally rethink traditional assumptions on the relation between product marketing, foreign direct investment, and licensing. (C) 2009 Elsevier Inc. All rights reserved.
C1 WHU, Otto Beisheim Sch Management Technol & Innovat Ma, D-56179 Vallendar, Germany.
RP Lichtenthaler, U (reprint author), WHU, Otto Beisheim Sch Management Technol & Innovat Ma, Burgpl 2, D-56179 Vallendar, Germany.
EM lichtenthaler@whu.edu
CR ADAM Y, 1988, J PROD INNOVAT MANAG, V5, P32, DOI 10.1111/1540-5885.510032
   Atuahene-Gima K., 1993, J INT MARKETING, V1, P71
   Aulakh PS, 1997, J INT BUS STUD, V28, P145, DOI 10.1057/palgrave.jibs.8490096
   Aulakh PS, 1998, J INT BUS STUD, V29, P409, DOI 10.1057/palgrave.jibs.8490043
   BARKEMA HG, 1998, ACAD MANAGE J, V41, P20
   Bartlett C.A., 1998, MANAGING BORDERS TRA
   Bosworth D., 2000, INT BUSINESS REV, V9, P453
   Breschi S, 2003, RES POLICY, V32, P69, DOI 10.1016/S0048-7333(02)00004-5
   Brouthers KD, 2007, J MANAGE, V33, P395, DOI 10.1177/0149206307300817
   Burpitt WJ, 2004, J WORLD BUS, V39, P136, DOI 10.1016/j.jwb.2003.08.011
   Cameron A.C., 1998, REGRESSION ANAL COUN
   Cantwell J, 2005, STRATEGIC MANAGE J, V26, P1109, DOI 10.1002/smj.497
   Cassiman B, 2006, MANAGE SCI, V52, P68, DOI 10.1287/rrmsc.1050.0470
   Cesaroni F, 2004, RES POLICY, V33, P1547, DOI 10.1016/j.respol.2004.08.003
   Chang SC, 2007, J WORLD BUS, V42, P61, DOI 10.1016/j.jwb.2006.11.002
   Chesbrough H, 2007, CALIF MANAGE REV, V49, P45, DOI 10.2307/41166394
   CHO KR, 1988, MANAGE INT REV, V28, P70
   CLEGG J, 2000, INT BUSINESS REV, V9, P407
   Cohen J., 2003, APPL MULTIPLE REGRES
   Contractor F.J., 1981, INT TECHNOLOGY LICEN
   Contractor F. J., 2007, MANAGE INT REV, V47, P453, DOI DOI 10.1007/S11575-007-0024-2
   CONTRACTOR FJ, 2002, INT BUSINESS REV, V11, P485, DOI DOI 10.1016/S0969-5931(02)00021-5
   DAVIS JL, 2001, EDISON BOARDROOM LEA
   Delios A, 1999, STRATEGIC MANAGE J, V20, P711, DOI 10.1002/(SICI)1097-0266(199908)20:8<711::AID-SMJ41>3.0.CO;2-8
   Doukas JA, 2003, J INT BUS STUD, V34, P153, DOI 10.1057/palgrave.jibs.8400014
   Dunning J.H., 1993, MULTINATIONAL ENTERP
   Dunning JH, 2007, INT BUS REV, V16, P531, DOI 10.1016/j.ibusrev.2007.01.005
   Ellis PD, 2007, INT BUS REV, V16, P573, DOI 10.1016/j.ibusrev.2007.06.001
   Ernst H, 2001, RES POLICY, V30, P143, DOI 10.1016/S0048-7333(99)00098-0
   Fang YL, 2007, STRATEGIC MANAGE J, V28, P1053, DOI 10.1002/smj.619
   Fosfuri A, 2006, STRATEGIC MANAGE J, V27, P1141, DOI 10.1002/smj.562
   Gambardella A, 2001, MARKETS TECHNOLOGY E
   Gambardella A, 2007, RES POLICY, V36, P1163, DOI 10.1016/j.respol.2007.07.006
   Garcia-Vega M, 2006, RES POLICY, V35, P230, DOI 10.1016/j.respol.2005.09.006
   Gassmann O, 2007, J WORLD BUS, V42, P350, DOI 10.1016/j.jwb.2007.04.006
   Geringer JM, 2000, STRATEGIC MANAGE J, V21, P51, DOI 10.1002/(SICI)1097-0266(200001)21:1<51::AID-SMJ77>3.0.CO;2-K
   GLEASON KC, 2000, INT BUSINESS REV, V9, P431
   Granstrand O, 2000, EC MANAGEMENT INTELL
   Hair J., 2006, MULTIVARIATE DATA AN
   Helfat C. E., 2007, DYNAMIC CAPABILITIES
   Hennart J. -F., 2007, MANAGE INT REV, V47, P423, DOI DOI 10.1007/S11575-007-0023-3
   Hitt MA, 1997, ACAD MANAGE J, V40, P767, DOI 10.2307/256948
   HITT MA, 1994, J MANAGE, V20, P297, DOI 10.1177/014920639402000203
   Hoopes D. G., 1999, MANAGE INT REV, V39, P277
   JAWORSKI BJ, 1993, J MARKETING, V57, P53, DOI 10.2307/1251854
   Jiang MS, 2007, MANAGE INT REV, V47, P869, DOI 10.1007/s11575-007-0056-7
   Johanson J, 2003, J INT ENTREPRENEURSH, V1, P83, DOI DOI 10.1023/A:1023219207042
   Kaufmann L, 2005, J WORLD BUS, V40, P235, DOI 10.1016/j.jmb.2005.05.002
   KOGUT B, 1992, ORGAN SCI, V3, P383, DOI 10.1287/orsc.3.3.383
   KOGUT B, 1991, REV ECON STAT, V73, P401, DOI 10.2307/2109564
   Kotabe M, 1996, J MARKETING, V60, P73, DOI 10.2307/1251889
   Lichtenthaler U, 2008, J BUS VENTURING, V23, P445, DOI 10.1016/j.jbusvent.2007.06.002
   Lichtenthaler U, 2007, CALIF MANAGE REV, V49, P67, DOI 10.2307/41166406
   Lichtenthaler U, 2007, RES POLICY, V36, P37, DOI 10.1016/j.respol.2006.08.005
   Liesch PW, 1999, J INT BUS STUD, V30, P383, DOI 10.1057/palgrave.jibs.8490075
   Lin BW, 2006, IEEE T ENG MANAGE, V53, P17, DOI 10.1109/TEM.2005.861813
   Lindell MK, 2001, J APPL PSYCHOL, V86, P114, DOI 10.1037//0021-9010.86.1.114
   Lu JW, 2004, ACAD MANAGE J, V47, P598, DOI 10.2307/20159604
   Luo YD, 2007, J WORLD BUS, V42, P129, DOI 10.1016/j.jwb.2006.08.007
   Luo YD, 2000, J WORLD BUS, V35, P355, DOI 10.1016/S1090-9516(00)00043-2
   Madhok A, 1997, STRATEGIC MANAGE J, V18, P39, DOI 10.1002/(SICI)1097-0266(199701)18:1<39::AID-SMJ841>3.3.CO;2-A
   MADURA J, 1987, MANAGE INT REV, V27, P38
   Makino S, 1996, J INT BUS STUD, V27, P905, DOI 10.1057/palgrave.jibs.8490156
   March JG, 1991, ORGAN SCI, V2, P71, DOI 10.1287/orsc.2.1.71
   Miller DJ, 2004, STRATEGIC MANAGE J, V25, P1097, DOI 10.1002/smj.411
   Miller DJ, 2006, STRATEGIC MANAGE J, V27, P601, DOI 10.1002/smj.533
   MIRUS R, 1980, J INT BUS STUD, V11, P86, DOI 10.1057/palgrave.jibs.8490599
   Mottner S, 2000, J WORLD BUS, V35, P171, DOI 10.1016/S1090-9516(00)00031-6
   Muthel M., 2007, Z BETRIEBSWIRT, V4, P103
   Patel P, 1997, RES POLICY, V26, P141, DOI 10.1016/S0048-7333(97)00005-X
   Prashantham S, 2005, J INT ENTREP, V3, P37, DOI 10.1007/s10843-005-0304-5
   Rivette K, 2000, REMBRANDTS ATTIC UNL
   Robins JA, 2003, STRATEGIC MANAGE J, V24, P39, DOI 10.1002/smj.282
   Root F. R, 1994, ENTRY STRATEGIES INT
   Sambharya R. B., 1995, MANAGE INT REV, V35, P197
   Tallman S, 1996, ACAD MANAGE J, V39, P179, DOI 10.2307/256635
   Tallman S, 2007, ORGAN SCI, V18, P252, DOI 10.1287/orsc.1060.0227
   Teece DJ, 2007, STRATEG MANAGE J, V28, P1319, DOI 10.1002/smj.640
   Teece DJ, 2006, RES POLICY, V35, P1131, DOI 10.1016/j.respol.2006.09.009
   Teece DJ, 1997, STRATEGIC MANAGE J, V18, P509, DOI 10.1002/(SICI)1097-0266(199708)18:7<509::AID-SMJ882>3.0.CO;2-Z
   Tsang E.W.K., 1997, MANAGE INT REV, V37, P151
   VACHANI S, 1991, J INT BUS STUD, V22, P307, DOI 10.1057/palgrave.jibs.8490305
   Yang DL, 2005, J WORLD BUS, V40, P281, DOI 10.1016/j.jwb.2005.05.005
   Zahra SA, 2000, ACAD MANAGE J, V43, P925, DOI 10.2307/1556420
NR 84
TC 5
Z9 5
U1 4
U2 34
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1090-9516
EI 1878-5573
J9 J WORLD BUS
JI J. World Bus.
PD OCT
PY 2009
VL 44
IS 4
BP 407
EP 420
DI 10.1016/j.jwb.2009.01.003
PG 14
WC Business
SC Business & Economics
GA 504NT
UT WOS:000270624400006
DA 2018-12-27
ER

PT J
AU Anand, G
   Jenny, P
AF Anand, Gaurav
   Jenny, Patrick
TI RETRACTED: A unified probability density function formulation to model
   turbulence modification in two-phase flow (Retracted article. See vol.
   24, 069901, 2012)
SO PHYSICS OF FLUIDS
LA English
DT Article; Retracted Publication
ID ISOTROPIC TURBULENCE; REACTIVE FLOWS; PARTICLES; MODULATION; SIMULATION
AB In the present study, a unified probability density function formulation for capturing the phenomena of turbulence modification of the continuous phase due to the dispersed phase turbulence is presented. A stochastic model based on dispersed phase turbulence length scale has been proposed for the purpose. The model has been validated with experimental data [Poelma et al., "Particle fluid interactions in grid-generated turbulence," J. Fluid Mech. 589, 315 (2007)] on the decay of turbulence of the flow seeded with ceramic particles in a vertical recirculating water channel. The obtained simulation results are in good agreement with the experimental data. Numerical experiments have been performed to investigate the influence of gravity on the decay of the continuous phase Reynolds stresses. For comparison, the influence of dispersed phase turbulence on the continuous phase turbulence without taking gravity into consideration has also been studied. (C) 2009 American Institute of Physics. [doi:10.1063/1.3231831]
C1 [Anand, Gaurav; Jenny, Patrick] ETH, Inst Fluid Dynam, CH-8092 Zurich, Switzerland.
RP Anand, G (reprint author), ETH, Inst Fluid Dynam, Sonneggstr 3, CH-8092 Zurich, Switzerland.
EM anand@ifd.mavt.ethz.ch
CR Anand G, 2009, J COMPUT PHYS, V228, P2063, DOI 10.1016/j.jcp.2008.11.022
   Boivin M, 1998, J FLUID MECH, V375, P235, DOI 10.1017/S0022112098002821
   Boivin M, 2000, PHYS FLUIDS, V12, P2080, DOI 10.1063/1.870453
   ELGHOBASHI S, 1993, PHYS FLUIDS A-FLUID, V5, P1790, DOI 10.1063/1.858854
   GORE RA, 1989, INT J MULTIPHASE FLO, V86, P491
   HETSRONI G, 1971, J APPL MECH, V38, P315, DOI 10.1115/1.3408779
   Jenny P, 2001, J COMPUT PHYS, V166, P218, DOI 10.1006/jcph.2000.6646
   Miller RS, 1998, INT J MULTIPHAS FLOW, V24, P1025, DOI 10.1016/S0301-9322(98)00028-7
   Muradoglu M, 2001, J COMPUT PHYS, V172, P841, DOI 10.1006/jcph.2001.6861
   Naud B, 2003, THESIS DELFT U TECHN
   OOMS G, 2008, INT J MULTIPHASE FLO, V589, P315
   Poelma C, 2007, J FLUID MECH, V589, P315, DOI 10.1017/S0022112007007793
   Sundaram S, 1999, J FLUID MECH, V379, P105, DOI 10.1017/S0022112098003073
   YUAN Z, 1992, INT J MULTIPHAS FLOW, V18, P779, DOI 10.1016/0301-9322(92)90045-I
   ZAICHIK LI, 1990, INZH FIZ ZH, V58, P556
NR 15
TC 3
Z9 3
U1 4
U2 15
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 1070-6631
EI 1089-7666
J9 PHYS FLUIDS
JI Phys. Fluids
PD OCT
PY 2009
VL 21
IS 10
AR 105101
DI 10.1063/1.3231831
PG 17
WC Mechanics; Physics, Fluids & Plasmas
SC Mechanics; Physics
GA 513YA
UT WOS:000271358900028
DA 2018-12-27
ER

PT J
AU Sreenivas, M
   Srinivas, T
AF Sreenivas, M.
   Srinivas, T.
TI RETRACTED: A SHORT NOTE ON MARGINAL ANALYSIS OF A TRANSPORTATION PROBLEM
   (Retracted article. See vol. 44, pg. 1, 2010)
SO RAIRO-OPERATIONS RESEARCH
LA English
DT Article; Retracted Publication
DE Marginal analysis; parameter; optimal value; transportation; sink and
   source
AB Decision analysis is a structured approach to decision-making, which allows managers to gain enhanced insight and sharper intuition about the problems they face. Marginal analysis is a concept employed, in microeconomics where the marginal change in some parameter might be of interest to the decision-maker. A marginal change is a ration of very small addition or subtraction to the total quantity of some parameter. Marginal analysis is the analysis of the relationships between such changes in relation to the performance measure. Examples of marginal analysis are: marginal cost; marginal revenue; marginal product; marginal rate of substitution; marginal propensity to save, and so on. In optimization, the marginal analysis is employed primarily to explicate various changes in the parameters and their impact on optimal value. Sensitivity analysis, i.e., the analysis of the effect of small variations in system parameters on the output measures can be studied by computing the derivatives of the output measures with respect to the parameter.
C1 [Sreenivas, M.] Alluri Inst Management Sci, Dept Math, Hanamkonda 506001, Andhra Pradesh, India.
   [Srinivas, T.] Kakatiya Univ, Dept Math, Warangal 506009, Andhra Pradesh, India.
RP Sreenivas, M (reprint author), Alluri Inst Management Sci, Dept Math, Hunter Rd, Hanamkonda 506001, Andhra Pradesh, India.
EM allurimaster@gmail.com; tsrinivasku@gmail.com
CR ADLAKHA V, 2006, J MANAGE SCI ENG MAN, V1, P47
   Deineko VG, 2003, DISCRETE APPL MATH, V130, P495, DOI 10.1016/S0166-218X(03)00327-5
   OLMSTED SM, 1983, THESIS STANFORD U ST
   Raiffa H., 1961, APPL STAT DECISION T
   Samuelson PA, 1952, AM ECON REV, V42, P56
   Swann M., 2003, MICROECONOMICS CONT
   von Neumann J, 1947, THEORY GAMES EC BEHA
   Yildirim EA, 2004, J OPTIMIZ THEORY APP, V122, P405, DOI 10.1023/B:JOTA.0000042528.76868.22
NR 8
TC 1
Z9 1
U1 4
U2 9
PU EDP SCIENCES S A
PI LES ULIS CEDEX A
PA 17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A,
   FRANCE
SN 0399-0559
EI 1290-3868
J9 RAIRO-OPER RES
JI Rairo-Oper. Res.
PD OCT-DEC
PY 2009
VL 43
IS 4
BP 331
EP 337
DI 10.1051/ro/2009021
PG 7
WC Operations Research & Management Science
SC Operations Research & Management Science
GA 504TA
UT WOS:000270639400001
OA Bronze
DA 2018-12-27
ER

PT J
AU Saridi, M
   Pappa, V
   Kyriazis, I
   Toska, A
   Giolis, A
   Liachapoulou, A
   Skliros, E
   Birbas, K
AF Saridi, M.
   Pappa, V.
   Kyriazis, I.
   Toska, A.
   Giolis, A.
   Liachapoulou, A.
   Skliros, E.
   Birbas, K.
TI RETRACTED: Knowledge and attitudes to sun exposure among adolescents in
   Korinthos, Greece (Retracted article. See vol. 13, 2494, 2013)
SO RURAL AND REMOTE HEALTH
LA English
DT Article; Retracted Publication
DE attitudes of teenagers; Greece; melanoma; sun protection; sun protection
   factor
ID CUTANEOUS MALIGNANT-MELANOMA; ULTRAVIOLET-RADIATION; SCHOOL-STUDENTS;
   SKIN-CANCER; PROTECTION; BEHAVIORS; CHILDREN; SUNBURN; TRENDS; AGE
AB Introduction: Extended sun exposure may lead to serious health problems, and evidence of this is in the increase in skin cancer and malignant melanoma worldwide. Extended sun exposure during childhood or adolescence increases the probability of skin cancer in adulthood. The aim of the study was to identify and examine the knowledge, attitude, behaviour and beliefs of Greek adolescents (high school students) related to sun exposure and its adverse effects on health. The majority of participants (89.7%) were of Greek nationality.
   Methods: The study took place in 5 schools in the prefecture of Korinthos, and 816 of the total 925 students aged 15-18 years participated. The questionnaire was pilot tested and assessed for validity and reliability, both of which were adequate (Cronbach's alpha = 0.70 and r(s) = 0.78); SPSS 13.0 software was used for analysis.
   Results: Only 37.9% of participants knew that melanoma was a type of skin cancer; 50% said they did not know what melanoma was. Regarding behavior, 35.5% reported that during the last summer they went to the beach on 20 to 50 occasions, and only 50% reported that they wore a sunhat or stayed in the shade. The frequency of sunscreen use was alarmingly low, with the majority of the adolescents unfamiliar with its proper use, and 50% not using a sunscreen with sufficient sun protection factor. Television was an important source of information about protection from sun exposure, while the family was the most important provider of advice.
   Conclusions: Participants' knowledge of sun exposure was insufficient and they reported risky behaviours in the summer months. Despite health promotion and community education programs focusing on sun smart strategies, these young people still associated suntans with beauty. Health promotion and education programs need to challenge such beliefs. However, as a sole approach to health promotion, teaching protective measures and appropriate ways for youth to protect themselves against the harmful effects of sunbathing may be insufficient to reduce the epidemic of skin cancer.
C1 [Saridi, M.; Pappa, V.; Toska, A.; Liachapoulou, A.; Birbas, K.] Univ Athens, Athens 11528, Greece.
   [Kyriazis, I.; Giolis, A.] Korinthos Gen Hosp, Dept Internal Med, Korinthos, Greece.
   [Skliros, E.] Nemea Hlth Ctr, Nemea, Greece.
RP Saridi, M (reprint author), Univ Athens, Athens 11528, Greece.
OI SARIDI, MARIA/0000-0002-9008-824X
CR Alberg AJ, 2002, J ADOLESCENT HEALTH, V31, P372, DOI 10.1016/S1054-139X(02)00377-4
   Aquilina S, 2004, J EUR ACAD DERMATOL, V18, P670, DOI 10.1111/j.1468-3083.2004.01046.x
   ARMSTRONG BK, 1994, INT J EPIDEMIOL, V23, P873, DOI 10.1093/ije/23.5.873
   ARMSTRONG BK, 1993, MELANOMA RES, V3, P395, DOI 10.1097/00008390-199311000-00002
   ARTHEY S, 1995, SOC SCI MED, V40, P265, DOI 10.1016/0277-9536(94)E0063-X
   AUTIER P, 1994, INT J CANCER, V58, P809, DOI 10.1002/ijc.2910580610
   Balk SJ, 2004, PEDIATRICS, V114, P1056, DOI 10.1542/peds.2004-1305
   BALZI D, 1997, EUROPEAN J CANC PREV, V8, P128
   Benvenuto-Andrade C, 2005, PHOTOCHEM PHOTOBIOL, V81, P630, DOI 10.1562/2005-01-25-RA-428.1
   Boldeman C, 2001, EUR J CANCER, V37, P2441, DOI 10.1016/S0959-8049(01)00310-0
   BROADSTOCK M, 1992, J APPL SOC PSYCHOL, V22, P157, DOI 10.1111/j.1559-1816.1992.tb01527.x
   Buller DB, 2006, AM J PREV MED, V30, P13, DOI 10.1016/j.amepre.2005.08.046
   CDC, 2003, MMWR SURVEILL SUMM, V52, P13
   Chen YT, 1998, INT J EPIDEMIOL, V27, P758, DOI 10.1093/ije/27.5.758
   Cokkinides VE, 2002, PEDIATRICS, V109, P1124, DOI 10.1542/peds.109.6.1124
   Cokkinides V, 2006, PEDIATRICS, V118, P853, DOI 10.1542/peds.2005-3109
   Davis KJ, 2002, PEDIATRICS, V110, P27, DOI 10.1542/peds.110.1.27
   de Vries H, 2005, EUR J CANCER PREV, V14, P39, DOI 10.1097/00008469-200502000-00006
   Devos SA, 2003, INT J DERMATOL, V42, P352, DOI 10.1046/j.1365-4362.2003.01665.x
   Dixon H, 1999, PREV MED, V28, P119, DOI 10.1006/pmed.1998.0392
   El Sayed F, 2006, PHOTODERMATOL PHOTO, V22, P18, DOI 10.1111/j.1600-0781.2006.00198.x
   English DR, 1998, INT J CANCER, V77, P347, DOI 10.1002/(SICI)1097-0215(19980729)77:3<347::AID-IJC7>3.0.CO;2-O
   Esteve E, 2003, ANN DERMATOL VENER, V130, P171
   Filiz TM, 2006, J ADOLESCENT HEALTH, V38, P469, DOI 10.1016/j.jadohealth.2005.01.016
   Geller AC, 2005, PEDIATR DERMATOL, V22, P112, DOI 10.1111/j.1525-1470.2005.22204.x
   Gies PH, 1998, MUTAT RES-FUND MOL M, V422, P15, DOI 10.1016/S0027-5107(98)00181-X
   Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707
   Gonzalez H, 2006, BRIT J DERMATOL, V154, P337, DOI 10.1111/j.1365-2133.2005.07007.x
   GORDON B, 2002, WHO CHRONICLE
   HABIF TP, 2005, SKIN DIS DIAGNOSIS T, P298
   HENGGE UR, 2006, J GERMAN SOC DERMATO, V10, P898
   HOLMAN CDJ, 1983, JNCI-J NATL CANCER I, V71, P651
   Horsley L, 2002, HEALTH EDUC RES, V17, P715, DOI 10.1093/her/17.6.715
   KATSAMBAS AD, 1998, CLIN DERMATOL, V16, P517
   Kristjansson S, 2003, EUR J CANCER PREV, V12, P501, DOI 10.1097/01.cej.0000102805.33147.65
   LaBat K, 2005, FAM CONSUM SCI RES J, V33, P240, DOI 10.1177/1077727X04272367
   LEE GA, 1999, OPHTHAL EPIDEMIOL, V3, P171
   Livingston PM, 2001, HEALTH EDUC RES, V16, P269, DOI 10.1093/her/16.3.269
   Livingston PM, 2003, PREV MED, V37, P577, DOI 10.1016/j.ypmed.2003.09.004
   Lowe JB, 2000, HEALTH EDUC RES, V15, P271, DOI 10.1093/her/15.3.271
   MARKS R, 1990, MED J AUSTRALIA, V152, P62
   McDermott LJ, 2005, HEALTH EDUC BEHAV, V32, P504, DOI 10.1177/1090198105276214
   MCKINLAY AF, 2006, AUSTR NZ J PUBLIC HL, V200, P13
   Molgo M, 2005, REV MED CHILE, V133, P662
   Montague M, 2001, HEALTH EDUC BEHAV, V28, P290, DOI 10.1177/109019810102800304
   Robinson JK, 1997, J AM ACAD DERMATOL, V37, P179, DOI 10.1016/S0190-9622(97)80122-3
   Savona MR, 2005, EUR J CANCER PREV, V14, P57, DOI 10.1097/00008469-200502000-00008
   Stinco G, 2005, PEDIATR DERMATOL, V22, P520, DOI 10.1111/j.1525-1470.2005.00131.x
   Stratigos A, 2007, J EUR ACAD DERMATOL, V21, P56, DOI 10.1111/j.1468-3083.2006.01865.x
   VRIES DE, 2004, EUR J CANCER, V40, P2355
   WEINSTOCK MA, 1989, PEDIATRICS, V84, P199
   Westerdahl J, 2000, BRIT J CANCER, V82, P1593
   Wright C, 2008, J PAEDIATR CHILD H, V44, P692, DOI 10.1111/j.1440-1754.2008.01408.x
   ZABORSKIS A, 2004, MEDICINA, V40, P386
   ZIEMKE JR, 2005, INVESTIGATOR AURA OM
NR 55
TC 11
Z9 11
U1 1
U2 14
PU AUSTRALIAN RURAL HEALTH EDUC NETWORK
PI DEAKIN WEST
PA PO BOX 242, DEAKIN WEST, ACT 2600, AUSTRALIA
SN 1445-6354
J9 RURAL REMOTE HEALTH
JI Rural Remote Health
PD OCT-DEC
PY 2009
VL 9
IS 4
AR 1162
PG 19
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA V15LM
UT WOS:000207803500004
PM 20001166
DA 2018-12-27
ER

PT J
AU Salama, N
   Kishimoto, T
   Kanayama, H
   Kagawa, S
AF Salama, Nader
   Kishimoto, Tomoteru
   Kanayama, Hiro-omi
   Kagawa, Susumu
TI RETRACTED: The Mobile Phone Decreases Fructose But Not Citrate in Rabbit
   Semen: A Longitudinal Study (Retracted article. See vol. 58, pg. 175,
   2012)
SO SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE
LA English
DT Article; Retracted Publication
DE citrate; fructose; mobile phone; rabbit; semen
ID WHOLE-BODY EXPOSURE; HZ MAGNETIC-FIELD; OXIDATIVE STRESS;
   SEMINAL-VESICLE; CELL PHONE; RATS; RADIATION; TESTOSTERONE; PROTECTION;
   PARAMETERS
AB The negative impact of mobile phones on sperm motility has been previously described. Both fructose and citrate are important components in semen that facilitate sperm motility. To date, no studies have investigated the effect of exposure to electromagnetic radiation emitted from the mobile phone on their levels.. Therefore, a longitudinal study using the adult rabbit as a model was undertaken. A total of 30 adult male rabbits were randomly divided into three groups. The first (phone) group was placed in specially designed cages, and exposed to radio frequency emitted from a mobile phone (900 MHz) kept in standby mode and positioned adjacent to the genitalia for 8 h daily for 12 weeks. The other two groups served as controls; the stress group which was housed in the same kind of cages to evaluate any cage-induced anxiety, and die control group which was housed in the conventional roomy cages. Semen samples were retrieved weekly. Sperm motility and viability, semen fructose and citrate, and serum testosterone were measured. Histological sections from the prostatic complex, ampulla, and vesicular gland were evaluated. A significant drop in both fructose levels (257 +/- 11.6 vs. 489 +/- 8.4 mg %, the baseline level) and number of motile sperms (50 vs. 72%) was observed in the phone group at the 10th week. However, no correlation was found between the two values. The stress control animals showed a similar but significantly less decline in motility No significant changes in citrate levels or other study parameters were seen in die three animal groups throughout the study. In conclusion, the pulsed radio frequency emitted by the mobile phone kept in die standby position longitudinally affected sperm motility and fructose but not citrate levels in rabbit semen.
C1 [Salama, Nader; Kishimoto, Tomoteru; Kanayama, Hiro-omi; Kagawa, Susumu] Univ Tokushima, Sch Med, Dept Urol, Tokushima 770, Japan.
RP Salama, N (reprint author), Univ Alexandria, Dept Urol, Fac Med, Alexandria, Egypt.
EM nadersalama58@yahoo.com
CR Agarwal A, 2008, FERTIL STERIL, V89, P124, DOI 10.1016/j.fertnstert.2007.01.166
   Al-Akhras MA, 2006, BIOELECTROMAGNETICS, V27, P127, DOI 10.1002/bem.20186
   ANDERSON RA, 1979, CLIN CHEM, V25, P1780
   Bhardwaj SK, 1998, MOL CHEM NEUROPATHOL, V34, P157, DOI 10.1007/BF02815077
   BLACKWELL RP, 1979, NATURE, V282, P360, DOI 10.1038/282360a0
   BLOM E, 1950, FERTIL STERIL, V1, P176
   BREDDERMAN PJ, 1964, J REPROD FERTIL, V7, P401
   Dasdag S, 2003, BIOELECTROMAGNETICS, V24, P182, DOI 10.1002/bem.10083
   Ehren I, 1997, UROL RES, V25, P433, DOI 10.1007/BF01268862
   Elbetieha A, 2002, BIOELECTROMAGNETICS, V23, P168, DOI 10.1002/bem.109
   ELIASSON R, 1977, FERTIL STERIL, V28, P1257
   GAVELLA M, 1983, INT J ANDROL, V6, P585, DOI 10.1111/j.1365-2605.1983.tb00349.x
   Gonenc S, 2005, PHYSIOL RES, V54, P341
   Guney M, 2007, TOXICOL IND HEALTH, V23, P411, DOI 10.1177/0748233707080906
   HERS HG, 1960, BIOCHIM BIOPHYS ACTA, V37, P120, DOI 10.1016/0006-3002(60)90085-8
   HOLTZ W, 1978, BIOL REPROD, V18, P286, DOI 10.1095/biolreprod18.2.286
   Hyland GJ, 2000, LANCET, V356, P1833, DOI 10.1016/S0140-6736(00)03243-8
   Irmak MK, 2002, CELL BIOCHEM FUNCT, V20, P279, DOI 10.1002/cbf.976
   Justulin LA, 2006, CELL BIOL INT, V30, P354, DOI 10.1016/j.cellbi.2006.01.002
   Khaki Amir Afshin, 2008, Pak J Biol Sci, V11, P692
   KOENIG H, 1976, BIOCHEM J, V158, P543, DOI 10.1042/bj1580543
   Linares V, 2005, TOXICOL LETT, V158, P186, DOI 10.1016/j.toxlet.2005.03.015
   MANN T, 1948, J AGR SCI-CAMBRIDGE, V38, P323, DOI 10.1017/S0021859600006109
   Mann T, 1964, BIOCH SEMEN MALE REP
   Mann T., 1981, MALE REPROD FUNCTION
   MCGIVERN RF, 1990, TERATOLOGY, V41, P1, DOI 10.1002/tera.1420410102
   Morelli G, 2000, BIOL PSYCHOL, V53, P1, DOI 10.1016/S0301-0511(00)00041-7
   Oktem F, 2005, ARCH MED RES, V36, P350, DOI 10.1016/j.arcmed.2005.03.021
   QUINN PJ, 1968, J REPROD FERTIL, V17, P35
   SAFFRAN M, 1948, J BIOL CHEM, V175, P849
   SALAMA N, 2008, INT J ANDROL    1202
   Yan JG, 2007, FERTIL STERIL, V88, P957, DOI 10.1016/j.fertnstert.2006.12.022
   Yilmaz F, 2008, ELECTROMAGN BIOL MED, V27, P65, DOI 10.1080/15368370701878978
NR 33
TC 16
Z9 20
U1 2
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1939-6368
EI 1939-6376
J9 SYST BIOL REPROD MED
JI Syst. Biol. Reprod. Med.
PD OCT-DEC
PY 2009
VL 55
IS 5-6
BP 181
EP 187
DI 10.3109/19396360903013126
PG 7
WC Andrology; Reproductive Biology
SC Endocrinology & Metabolism; Reproductive Biology
GA 535NE
UT WOS:000272975100002
PM 19938952
DA 2018-12-27
ER

PT J
AU Liu, SP
   Zhang, L
   Li, QB
   Zhao, P
   Duan, J
   Cheng, DJ
   Xiang, ZH
   Xia, QY
AF Liu, Shiping
   Zhang, Liang
   Li, Qibin
   Zhao, Ping
   Duan, Jun
   Cheng, Daojun
   Xiang, Zhonghuai
   Xia, Qingyou
TI RETRACTED: MicroRNA expression profiling during the life cycle of the
   silkworm (Bombyx mori) (Retracted article. See vol. 12, artn no. 284,
   2011)
SO BMC GENOMICS
LA English
DT Article; Retracted Publication
ID GENE-EXPRESSION; DROSOPHILA METAMORPHOSIS; EMBRYONIC-DEVELOPMENT;
   DEVELOPMENTAL-STAGES; MICROARRAY ANALYSIS; ECDYSONE-RECEPTOR;
   STEROID-HORMONE; ZEBRAFISH; PATTERNS; CANCER
AB Background: MicroRNAs ( miRNAs) are expressed by a wide range of eukaryotic organisms, and function in diverse biological processes. Numerous miRNAs have been identified in Bombyx mori, but the temporal expression profiles of miRNAs corresponding to each stage transition over the entire life cycle of the silkworm remain to be established. To obtain a comprehensive overview of the correlation between miRNA expression and stage transitions, we performed a whole-life test and subsequent stage-by-stage examinations on nearly one hundred miRNAs in the silkworm.
   Results: Our results show that miRNAs display a wide variety of expression profiles over the whole life of the silkworm, including continuous expression from embryo to adult (miR-184), upregulation over the entire life cycle (let-7 and miR-100), down-regulation over the entire life cycle ( miR-124), expression associated with embryogenesis (miR-29 and miR-92), up-regulation from early 3rd instar to pupa (miR-275), and complementary pulses in expression between miR-34b and miR-275. Stage-by-stage examinations revealed further expression patterns, such as emergence at specific time-points during embryogenesis and up-regulation of miRNA groups in late embryos (miR-1 and bantam), expression associated with stage transition between instar and molt larval stages (miR-34b), expression associated with silk gland growth and spinning activity (miR-274), continuous high expression from the spinning larval to pupal and adult stages (miR-252 and miR-31a), a coordinate expression trough in day 3 pupae of both sexes (miR-10b and miR-281), upregulation in pupal metamorphosis of both sexes (miR-29b), and down-regulation in pupal metamorphosis of both sexes (miR-275).
   Conclusion: We present the full-scale expression profiles of miRNAs throughout the life cycle of Bombyx mori. The whole-life expression profile was further investigated via stage-by-stage analysis. Our data provide an important resource for more detailed functional analysis of miRNAs in this animal.
C1 [Liu, Shiping; Zhao, Ping; Cheng, Daojun; Xiang, Zhonghuai; Xia, Qingyou] Southwest Univ, Coll Biotechnol, Key Sericultural Lab Agr Minist, Chongqing 400715, Peoples R China.
   [Zhang, Liang] Natl Engn Ctr Beijing Biochip Technol, Beijing 102206, Peoples R China.
   [Li, Qibin] Beijing Genom Inst Shenzhen, Shenzhen 518083, Peoples R China.
   [Li, Qibin] Chinese Acad Sci, Beijing Inst Genom, Beijing 100000, Peoples R China.
   [Duan, Jun; Xia, Qingyou] Chongqing Univ, Inst Agr & Life Sci, Chongqing 400030, Peoples R China.
RP Xia, QY (reprint author), Southwest Univ, Coll Biotechnol, Key Sericultural Lab Agr Minist, Chongqing 400715, Peoples R China.
EM lsp98668@163.com; lzhang@capitalbio.com; liqb@genomics.org.cn;
   zhaop@swu.edu.cn; duanjunhyq@163.com; chengdj@swu.edu.cn;
   xzh@swu.edu.cn; xiaqy@swu.edu.cn
OI Xia, Qingyou/0000-0002-9263-2886
FU National Basic Research Program of China [2005CB121000]; Program for
   Changjiang Scholars and Innovative Research Team in University
   [IRT0750]; doctor foundation of Southwest University [SWUB2008063];
   doctorial innovation fund of Southwest University [b2007002]
FX We are very grateful to Dr. Keith Mitchelson, and Professor Goldsmith,
   M. R., for critical reading of the manuscript, and apologize to
   colleagues whose work we could not cite due to space limitations. This
   work was supported by grant 2005CB121000 from the National Basic
   Research Program of China, grant IRT0750 from Program for Changjiang
   Scholars and Innovative Research Team in University, and, in part, the
   doctor foundation (SWUB2008063) and the doctorial innovation fund
   (b2007002) of Southwest University.
CR Aboobaker AA, 2005, P NATL ACAD SCI USA, V102, P18017, DOI 10.1073/pnas.0508823102
   Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   BADE ML, 1962, BIOCHEM J, V83, P470, DOI 10.1042/bj0830470
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bashirullah A, 2003, DEV BIOL, V259, P1, DOI 10.1016/S0012-1606(03)00063-0
   Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590
   Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031
   Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253
   Biemar F, 2005, P NATL ACAD SCI USA, V102, P15907, DOI 10.1073/pnas.0507817102
   Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901
   Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406
   CALVEZ B, 1976, FEBS LETT, V71, P57, DOI 10.1016/0014-5793(76)80898-8
   Cao J, 2008, INSECT BIOCHEM MOLEC, V38, P1066, DOI 10.1016/j.ibmb.2008.09.008
   Carney GE, 2000, GENETICS, V154, P1203
   Chen PY, 2005, GENE DEV, V19, P1288, DOI 10.1101/gad.1310605
   Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585
   COULON M, 1977, DEV GROWTH DIFFER, V19, P181
   Cullen BR, 2006, NAT GENET, V38, pS25, DOI 10.1038/ng1793
   Darnell DK, 2006, DEV DYNAM, V235, P3156, DOI 10.1002/dvdy.20956
   DENMAN RB, 1993, BIOTECHNIQUES, V15, P1090
   Dsouza M, 1997, TRENDS GENET, V13, P497, DOI 10.1016/S0168-9525(97)01347-4
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024
   Funaguma S, 2007, INSECT BIOCHEM MOLEC, V37, P147, DOI 10.1016/j.ibmb.2006.11.001
   Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020
   Goldsmith MR, 2005, ANNU REV ENTOMOL, V50, P71, DOI 10.1146/annurev.ento.50.071803.130456
   Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Guo Y, 2008, CANCER RES, V68, P26, DOI 10.1158/0008-5472.CAN-06-4418
   Hatfield SD, 2005, NATURE, V435, P974, DOI 10.1038/nature03816
   He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   He PA, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-248
   Hodin J, 1998, DEV GENES EVOL, V208, P304, DOI 10.1007/s004270050186
   Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599
   Kapsimali M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r173
   Kato M, 2008, BIOL CELL, V100, P71, DOI 10.1042/BC20070078
   Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372
   Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403
   Liu SP, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-88
   Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599
   Miska EA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r68
   MIYA K, 2003, EARLY EMBRYONIC DEV, P42
   Mizoguchi A, 2001, INSECT BIOCHEM MOLEC, V31, P349, DOI 10.1016/S0965-1748(00)00127-2
   MIZUNO T, 1981, DEV GROWTH DIFFER, V23, P543
   Morita A, 2003, J INSECT PHYSIOL, V49, P1093, DOI 10.1016/j.jinsphys.2003.08.009
   Moss EG, 2007, CURR BIOL, V17, pR425, DOI 10.1016/j.cub.2007.03.43
   OHNISHI E, 1977, DEV GROWTH DIFFER, V19, P67
   Ote M, 2004, INSECT BIOCHEM MOLEC, V34, P775, DOI 10.1016/j.ibmb.2004.04.002
   Park SM, 2007, CELL CYCLE, V6, P2585, DOI 10.4161/cc.6.21.4845
   PASSONNEAU JV, 1953, J EXP BIOL, V30, P545
   Riddiford L M, 2000, Vitam Horm, V60, P1, DOI 10.1016/S0083-6729(00)60016-X
   Rougvie AE, 2005, DEVELOPMENT, V132, P3787, DOI 10.1242/dev.01972
   Sandmann T, 2007, GENE DEV, V21, P436, DOI 10.1101/gad.1509007
   Seitz H, 2009, CURR BIOL, V19, P870, DOI 10.1016/j.cub.2009.03.059
   Sernpere LF, 2003, DEV BIOL, V259, P9, DOI 10.1016/S0012-1606(03)00208-2
   Shell S, 2007, P NATL ACAD SCI USA, V104, P11400, DOI 10.1073/pnas.0704372104
   Sokol NS, 2008, GENE DEV, V22, P1591, DOI 10.1101/gad.1671708
   Stoleru D, 2007, CELL, V129, P207, DOI 10.1016/j.cell.2007.02.038
   Sunkar R, 2005, PLANT CELL, V17, P1397, DOI 10.1105/tpc.105.031682
   Swevers L, 1998, MECH DEVELOP, V72, P3, DOI 10.1016/S0925-4773(97)00180-9
   Takada S, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl653
   Terashima J, 2000, DEV GENES EVOL, V210, P545, DOI 10.1007/s004270000100
   Varghese J, 2007, GENE DEV, V21, P2277, DOI 10.1101/gad.439807
   Vaucheret H, 2004, GENE DEV, V18, P1187, DOI 10.1101/gad.1201404
   Wang QL, 2007, FRONT BIOSCI-LANDMRK, V12, P3975
   Watanabe T, 2005, FEBS LETT, V579, P318, DOI 10.1016/j.febslet.2004.11.067
   Wienholds E, 2003, NAT GENET, V35, P217, DOI 10.1038/ng1251
   Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519
   Xia QY, 2004, SCIENCE, V306, P1937, DOI 10.1126/science.1102210
   XU WH, 1995, J BIOL CHEM, V270, P3804, DOI 10.1074/jbc.270.8.3804
   YAMAUCHI H, 1984, J MORPHOL, V179, P21, DOI 10.1002/jmor.1051790104
   Yu XM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002997
   Zhang Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004677
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
   ZURHAUSEN H, 2008, INT J CANCER, V122, pR9
NR 81
TC 33
Z9 39
U1 3
U2 26
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD SEP 28
PY 2009
VL 10
AR 455
DI 10.1186/1471-2164-10-455
PG 16
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 511HG
UT WOS:000271154000003
PM 19785751
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Kim, HW
   Chang, YC
   Chen, M
   Rapoport, SI
   Rao, JS
AF Kim, Hyung-Wook
   Chang, Yunyoung C.
   Chen, Mei
   Rapoport, Stanley I.
   Rao, Jagadeesh S.
TI RETRACTED: Chronic NMDA administration to rats increases brain
   pro-apoptotic factors while decreasing anti-Apoptotic factors and causes
   cell death(Retracted article. See vol. 18, Artn no. 41, 2017)
SO BMC NEUROSCIENCE
LA English
DT Article; Retracted Publication
ID SPINAL-CORD NEURONS; CYTOSOLIC PHOSPHOLIPASE A(2); D-ASPARTATE RECEPTOR;
   ARACHIDONIC-ACID; ALZHEIMERS-DISEASE; FRONTAL-CORTEX; CELL-DEATH;
   UNANESTHETIZED RATS; MOOD STABILIZERS; BIPOLAR DISORDER
AB Background: Chronic N-Methyl-d-aspartate (NMDA) administration to rats is reported to increase arachidonic acid signaling and upregulate neuroinflammatory markers in rat brain. These changes may damage brain cells. In this study, we determined if chronic NMDA administration (25 mg/kg i.p., 21 days) to rats would alter expression of pro-and anti-apoptotic factors in frontal cortex, compared with vehicle control.
   Results: Using real time RT-PCR and Western blotting, chronic NMDA administration was shown to decrease mRNA and protein levels of anti-apoptotic markers Bcl-2 and BDNF, and of their transcription factor phospho-CREB in the cortex. Expression of pro-apoptotic Bax, Bad, and 14-3-3 zeta was increased, as well as Fluoro-Jade B (FJB) staining, a marker of neuronal loss.
   Conclusion: This alteration in the balance between pro-and anti-apoptotic factors by chronic NMDA receptor activation in this animal model may contribute to neuronal loss, and further suggests that the model can be used to examine multiple processes involved in excitotoxicity.
C1 [Kim, Hyung-Wook; Chang, Yunyoung C.; Chen, Mei; Rapoport, Stanley I.; Rao, Jagadeesh S.] NIA, Brain Physiol & Metab Sect, NIH, Bethesda, MD 20892 USA.
RP Rao, JS (reprint author), NIA, Brain Physiol & Metab Sect, NIH, Bethesda, MD 20892 USA.
EM kimhyung@mail.nih.gov; yunyoung.chang@gmail.com; chenmei@mail.nih.gov;
   sir@helix.nih.gov; jrao@mail.nih.gov
FU National Institute on Aging, National Institutes of Health
FX This work was entirely supported by the Intramural Research Program of
   the National Institute on Aging, National Institutes of Health. We thank
   Dr Sang-Ho Choi for assistance with florescence microscopy. We thank
   Kathy Benjamin for critically reading the manuscript.
CR ABRAMSON SB, 1991, J IMMUNOL, V147, P231
   Amada N, 2005, NEUROREPORT, V16, P1809, DOI 10.1097/01.wnr.0000185015.44563.5d
   ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8
   Arita K, 2001, BIOCHEM PHARMACOL, V62, P821, DOI 10.1016/S0006-2952(01)00723-7
   Basselin M, 2005, NEUROPSYCHOPHARMACOL, V30, P1064, DOI 10.1038/sj.npp.1300671
   Basselin M, 2008, NEUROCHEM RES, V33, P1373, DOI 10.1007/s11064-008-9595-y
   Basselin M, 2007, BIOL PSYCHIAT, V62, P934, DOI 10.1016/j.biopsych.2007.04.021
   Basselin M, 2006, NEUROPSYCHOPHARMACOL, V31, P1659, DOI 10.1038/sj.npp.1300920
   Brock TG, 2008, NEUROCHEM RES, V33, P801, DOI 10.1007/s11064-007-9498-3
   Chalovich EM, 2006, J BIOL CHEM, V281, P17870, DOI 10.1074/jbc.M602632200
   Chang YC, 2008, NEUROCHEM RES, V33, P2318, DOI 10.1007/s11064-008-9731-8
   Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003
   Chuang DM, 2005, ANN NY ACAD SCI, V1053, P195, DOI 10.1196/annals.1344.018
   Clinton SM, 2004, NEUROPSYCHOPHARMACOL, V29, P1353, DOI 10.1038/sj.npp.1300451
   Duman RS, 2000, BIOL PSYCHIAT, V48, P732, DOI 10.1016/S0006-3223(00)00935-5
   Fang MR, 2005, J NEUROSCI RES, V81, P269, DOI 10.1002/jnr.20558
   Garrido R, 2003, J NEUROTRAUM, V20, P1201, DOI 10.1089/089771503322584628
   Garrido R, 2001, J NEUROCHEM, V76, P1395, DOI 10.1046/j.1471-4159.2001.00135.x
   Hallett PJ, 2005, NEUROPHARMACOLOGY, V48, P503, DOI 10.1016/j.neuropharm.2004.11.008
   Hynd MR, 2004, J NEUROCHEM, V89, P240, DOI 10.1111/j.1471-4159.2003.02330.x
   KURE S, 1991, BIOCHEM BIOPH RES CO, V179, P39, DOI 10.1016/0006-291X(91)91330-F
   Kwon KJ, 2005, J NEUROSCI RES, V81, P73, DOI 10.1002/jnr.20520
   Lee HJ, 2008, J LIPID RES, V49, P162, DOI 10.1194/jlr.M700406-JLR200
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Manji HK, 2000, MOL PSYCHIATR, V5, P578, DOI 10.1038/sj.mp.4000811
   MONAGHAN DT, 1985, J NEUROSCI, V5, P2909
   MORII H, 1994, BIOCHEM BIOPH RES CO, V205, P6, DOI 10.1006/bbrc.1994.2621
   Mueller HT, 2004, SCHIZOPHR RES, V71, P361, DOI 10.1016/j.schres.2004.02.016
   NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206
   ORMANDY GC, 1991, EXP NEUROL, V111, P356, DOI 10.1016/0014-4886(91)90103-J
   Rao JS, 2008, MOL PSYCHIATR, V13, P585, DOI 10.1038/mp.2008.31
   Rao JS, 2007, MOL PSYCHIATR, V12, P151, DOI 10.1038/sj.mp.4001887
   Rao JS, 2007, MOL PSYCHIATR, V12, P36, DOI 10.1038/sj.mp.4001888
   Rao JS, 2007, J NEUROCHEM, V102, P1918, DOI 10.1111/j.1471-4159.2007.04648.x
   Saitoh M, 2003, BRAIN RES, V991, P187, DOI 10.1016/j.brainres.2003.08.039
   Schelman WR, 2004, MOL BRAIN RES, V128, P160, DOI 10.1016/j.molbrainres.2004.06.011
   Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111
   SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1
   Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503
   Stephenson DT, 1996, NEUROBIOL DIS, V3, P51, DOI 10.1006/nbdi.1996.0005
   Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200
   Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241
   Tilleux S, 2007, J NEUROSCI RES, V85, P2059, DOI 10.1002/jnr.21325
   Toborek M, 1999, J NEUROCHEM, V73, P684, DOI 10.1046/j.1471-4159.1999.0730684.x
   Umahara T, 2004, ACTA NEUROPATHOL, V108, P279, DOI 10.1007/s00401-004-0885-4
   Umahara T, 2004, NEUROSCI LETT, V371, P215, DOI 10.1016/j.neulet.2004.08.079
   Wajapeyee N, 2006, J BIOL CHEM, V281, P16207, DOI 10.1074/jbc.M600539200
   Weichel O, 1999, N-S ARCH PHARMACOL, V360, P609, DOI 10.1007/s002109900131
   Wiltfang J, 1999, J NEUROCHEM, V73, P2485, DOI 10.1046/j.1471-4159.1999.0732485.x
   Xifro X, 2008, J NEUROCHEM, V105, P1596, DOI 10.1111/j.1471-4159.2008.05252.x
   Yang HZ, 2001, BBA-PROTEIN STRUCT M, V1547, P313, DOI 10.1016/S0167-4838(01)00202-3
   YOUNG AB, 1988, SCIENCE, V241, P981, DOI 10.1126/science.2841762
   Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3
   Zhang YM, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-49
NR 54
TC 9
Z9 9
U1 4
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2202
J9 BMC NEUROSCI
JI BMC Neurosci.
PD SEP 28
PY 2009
VL 10
AR 123
DI 10.1186/1471-2202-10-123
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 513LK
UT WOS:000271323600001
PM 19785755
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Yao, Q
   Qu, X
   Yang, QF
   Good, DA
   Dai, SZ
   Kong, BH
   Wei, MQ
AF Yao, Qin
   Qu, Xun
   Yang, Qifeng
   Good, David A.
   Dai, Shuzhen
   Kong, Beihua
   Wei, Ming Q.
TI RETRACTED: Blockage of transdifferentiation from fibroblast to
   myofibroblast in experimental ovarian cancer models (Retracted Article.
   See vol 8, ARTN 84, 2009)
SO MOLECULAR CANCER
LA English
DT Article; Retracted Publication
ID CHANNEL PROTEIN CLIC4; STROMAL FIBROBLASTS; TUMOR-STROMA; GROWTH;
   PROGRESSION; CELLS; ANGIOGENESIS
AB Background: Tumour stromal myofibroblasts can promote tumour invasion. As these cells are genetically more stable than cancer cells, there has been enormous interest in developing targeted molecular therapies against them. Chloride intracellular channel 4 (CLIC4) and reactive oxygen species (ROS) have been linked with promoting stromal cell transdifferentiation in various cancers, but little is known of their roles in ovarian cancer. In this study, we examined the functional roles that both CLIC4 and ROS play in the process of ovarian cancer cell-stimulated or TGF-beta 1 induced fibroblast-to-myofibroblast transdifferentiation. We also examine whether it is possible to reverse such a process, with the aim of developing novel therapies against ovarian cancer by targeting activated transdifferentiated myofibroblasts.
   Results: We demonstrate that TGF-beta 1 induced or CMSKOV3 activate transdifferentiated myofibroblasts (fibroblasts). These fibroblasts mimic "reactive" stromal myofibroblasts and demonstrate significant up-regulation of CLIC4 expression and increased level of ROS production. Blocking the production of ROS with an antioxidant consequently reduces the expression of CLIC4, and is accompanied by disappearance of alpha-smooth-muscle actin (alpha-SMA), a myofibroblast marker, suggesting ROS acts as a signalling molecule that promotes and enhances CLIC4 activities in the myofibroblast transdifferentiaton process. Down-regulation of CLIC4 with a generic agent or specific siRNA both significantly reduces the expression of factors related to the phenotypes and functions of myofibroblasts, such as alpha-SMA, hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF), thus reversing the myofibroblast phenotype back to fibroblasts. These results convincingly show that ROS and CLIC4 are responsible for TGF-beta 1 induced fibroblast-to-myofibroblast transdifferentiaton and down-regulation of both is sufficient to block transdifferentiated myofibroblasts.
   Conclusion: Molecular targeting of ROS and CLIC4 has the potential to develop novel therapies for ovarian cancer.
C1 [Yao, Qin; Good, David A.; Wei, Ming Q.] Griffith Univ, Div Mol & Gene Therapies, Griffith Inst Hlth & Med Res, Sch Med Sci, Southport, Qld 4222, Australia.
   [Yao, Qin; Kong, Beihua] Shandong Univ, Dept Obstet & Gynaecol, Qilu Hosp, Jinan 250012, Shandong, Peoples R China.
   [Yao, Qin; Dai, Shuzhen] Qingdao Univ, Dept Obstet & Gynaecol, Affiliated Hosp, Qingdao 266003, Shandong, Peoples R China.
   [Qu, Xun; Yang, Qifeng] Shandong Univ, Inst Basic Med Sci, Qilu Hosp, Jinan 250012, Shandong, Peoples R China.
RP Wei, MQ (reprint author), Griffith Univ, Div Mol & Gene Therapies, Griffith Inst Hlth & Med Res, Sch Med Sci, Gold Coast Campus, Southport, Qld 4222, Australia.
EM Dr.yaoqin@yahoo.com.cn; quxun@yahoo.com.cn; yangqifeng@yahoo.com.cn;
   d.good@griffith.edu.au; shuzhendai@yahoo.com.cn; kongbeihua@hotmail.com;
   m.wei@griffith.edu.au
FU Queensland state government; National Health and Medical Research
   Council and Cancer Council, Queensland
FX This work was supported by the Dr. Jian Zhou Smart State Fellowship from
   the Queensland state government, and grants from the National Health and
   Medical Research Council and Cancer Council, Queensland to MQW.
CR Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Bohman S, 2005, J BIOL CHEM, V280, P42397, DOI 10.1074/jbc.M506724200
   Cat B, 2006, J CELL SCI, V119, P2727, DOI 10.1242/jcs.03011
   Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044
   Granot D, 2007, CANCER RES, V67, P9180, DOI 10.1158/0008-5472.CAN-07-0684
   Guo XY, 2008, J BIOL CHEM, V283, P19864, DOI 10.1074/jbc.M800798200
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Levi F, 2004, INT J CANCER, V110, P155, DOI 10.1002/ijc.20097
   Littler DR, 2005, FEBS J, V272, P4996, DOI 10.1111/j.1742-4658.2005.04909.x
   Mahadevan D, 2007, MOL CANCER THER, V6, P1186, DOI 10.1158/1535-7163.MCT-06-0686
   MUELLER MM, 2006, NAT REV CANCER, V4, pF839
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9
   Parrott JA, 2001, MOL CELL ENDOCRINOL, V175, P29, DOI 10.1016/S0303-7207(01)00436-1
   Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688
   Ronnov-Jessen L, 2002, AM J PATHOL, V161, P471, DOI 10.1016/S0002-9440(10)64203-4
   Samoszuk M, 2005, BREAST CANCER RES, V7, pR274, DOI 10.1186/bcr995
   Stuhlmann D, 2004, BIOCHEM BIOPH RES CO, V319, P321, DOI 10.1016/j.bbrc.2004.05.004
   Suginta W, 2001, BIOCHEM J, V359, P55, DOI 10.1042/0264-6021:3590055
   Suh KS, 2004, J BIOL CHEM, V279, P4632, DOI 10.1074/jbc.M311632200
   SUH KS, 2007, J CELL SCI, V120
   Suh KS, 2007, MOL CARCINOGEN, V46, P599, DOI 10.1002/mc.20324
   Suh KS, 2007, CLIN CANCER RES, V13, P121, DOI 10.1158/1078-0432.CCR-06-1562
   Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224
   Yang F, 2008, ONCOGENE, V27, P450, DOI 10.1038/sj.onc.1210663
   Yang KL, 2008, BIOCHEM BIOPH RES CO, V373, P219, DOI 10.1016/j.bbrc.2008.05.192
NR 26
TC 6
Z9 8
U1 4
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD SEP 27
PY 2009
VL 8
AR 78
DI 10.1186/1476-4598-8-78
PG 8
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA 517IG
UT WOS:000271606100001
PM 19781102
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Tan, H
   Yang, XM
   Cui, SH
   Yang, Z
AF Tan, Hu
   Yang, Xuemei
   Cui, Shehuai
   Yang, Zhao
TI RETRACTED: A novel pseudovirus encoding Diphtheriatoxin A fragment
   eliminates autoantibody-producing B cells and inhibits lupus in the BWF1
   mouse model (Retracted Article. See vol 136, pg 114, 2011)
SO IMMUNOLOGY LETTERS
LA English
DT Article; Retracted Publication
DE Pseudovirus; B cells; Lupus; BWF1
ID MRL/LPR MICE; A-CHAIN; GENETIC CONSTRUCTION; FUSION PROTEIN; T-CELL;
   ERYTHEMATOSUS; TOXIN; LYMPHOCYTES; EXPRESSION; ANTIBODIES
AB Lupus-associated anti-dsDNA Abs plays an important role in the triggering and development of human systemic lupus erythematosus (SCE). The method of targeting B cells that produce anti-dsDNA Abs has become a promising way to treat autoantibody-mediated SLE in the immunotherapy field. In this study, we reported a novel pseudovirus, which consisted of the peptide DWEYSVWLSN and a plasmid encoding the Diphtheriatoxin A fragment (DTA). Our data demonstrated that vaccination of lupus-prone (BWF1) mice with the pseudovirus could eliminate anti-dsDNA antibody-producing B cells, reduce serum anti-dsDNA antibody levels, impede the development of proteinuria and improve survival. These findings suggested that this novel pseudovirus ablated autoreactive B cells and might represent a promising therapeutic strategy for autoantibody-mediated diseases. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Yang, Xuemei; Cui, Shehuai] Third Mil Med Univ, Daping Hosp, Resp Dept, Chongqing 400042, Peoples R China.
   [Tan, Hu; Yang, Zhao] Third Mil Med Univ, Xinqiao Hosp, Dept Cardiovasc Dis, Chongqing 400037, Peoples R China.
RP Cui, SH (reprint author), Third Mil Med Univ, Daping Hosp, Resp Dept, Chongqing 400042, Peoples R China.
EM cuishehuai@hotmail.com; yangzhao5140@sohu.com
FU National Natural Science Foundation of China (NSFC) [30800479]
FX This work was supported by National Natural Science Foundation of China
   (NSFC No. 30800479).
CR CASELLAS P, 1982, INT J CANCER, V30, P437, DOI 10.1002/ijc.2910300410
   CAWLEY DB, 1980, CELL, V22, P563, DOI 10.1016/0092-8674(80)90366-9
   Clarke SH, 2008, IMMUNOL RES, V41, P203, DOI 10.1007/s12026-008-8023-3
   Cohen-Solal JFG, 2008, LUPUS, V17, P528, DOI 10.1177/0961203308089402
   Daugas E, 2008, REV MED INTERNE, V29, P710, DOI 10.1016/j.revmed.2008.04.019
   Deocharan B, 2002, LUPUS, V11, P865, DOI 10.1191/0961203302lu308rr
   Dorner T, 2007, EXPERT OPIN BIOL TH, V7, P1287, DOI 10.1517/14712598.7.9.1287
   Eisenberg Robert, 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P345
   Fairhurst AM, 2006, ADV IMMUNOL, V92, P1, DOI 10.1016/S0065-2776(06)92001-X
   GREENFIELD L, 1987, SCIENCE, V238, P536, DOI 10.1126/science.3498987
   Khalil M, 2001, J IMMUNOL, V166, P1667, DOI 10.4049/jimmunol.166.3.1667
   Khan Islam U, 2003, Curr Dir Autoimmun, V6, P89
   KLINMAN DM, 1994, ADV EXP MED BIOL, V347, P115
   KREITMAN RJ, 1994, LEUKEMIA LYMPHOMA, V13, P1
   Kreitman RJ, 2005, J CLIN ONCOL, V23, P6719, DOI 10.1200/JCO.2005.11.437
   Kreitman RJ, 2001, NEW ENGL J MED, V345, P241, DOI 10.1056/NEJM200107263450402
   KROLICK KA, 1980, P NATL ACAD SCI-BIOL, V77, P5419, DOI 10.1073/pnas.77.9.5419
   MAXWELL IH, 1991, CANCER RES, V51, P4299
   McMahon M, 2007, CURR OPIN IMMUNOL, V19, P633, DOI 10.1016/j.coi.2007.11.001
   Mormeaux F, 2007, ADV EXP MED BIOL, V601, P105
   MURPHY JR, 1986, P NATL ACAD SCI USA, V83, P8258, DOI 10.1073/pnas.83.21.8258
   Nag TC, 2006, CURR NEUROVASC RES, V3, P159, DOI 10.2174/156720206776875821
   Takiguchi M, 1999, LAB INVEST, V79, P317
   Takiguchi M, 2000, LIFE SCI, V66, P991, DOI 10.1016/S0024-3205(99)00664-5
   Tchorbanov AL, 2007, EUR J IMMUNOL, V37, P3587, DOI 10.1002/eji.2007371431
   Tieng AT, 2008, SEMIN ARTHRITIS RHEU, V38, P218, DOI 10.1016/j.semarthrit.2007.11.003
   Voynova E, 2008, IMMUNOL LETT, V116, P168, DOI 10.1016/j.imlet.2007.12.016
   Waite L, 2007, LUPUS, V16, P841, DOI 10.1177/0961203307081118
   WILLIAMS DP, 1987, PROTEIN ENG, V1, P493, DOI 10.1093/protein/1.6.493
   ZANDMANGODDARD G, 2000, EUR J INTERN MED, V11, P130
NR 30
TC 2
Z9 2
U1 5
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
EI 1879-0542
J9 IMMUNOL LETT
JI Immunol. Lett.
PD SEP 22
PY 2009
VL 126
IS 1-2
BP 43
EP 47
DI 10.1016/j.imlet.2009.07.011
PG 5
WC Immunology
SC Immunology
GA 509XG
UT WOS:000271052000007
PM 19660498
DA 2018-12-27
ER

PT J
AU Schlaberg, R
   Choe, DJ
   Brown, KR
   Thaker, HM
   Singh, IR
AF Schlaberg, Robert
   Choe, Daniel J.
   Brown, Kristy R.
   Thaker, Harshwardhan M.
   Singh, Ila R.
TI RETRACTED: XMRV is present in malignant prostatic epithelium and is
   associated with prostate cancer, especially high-grade tumors (Retracted
   article. See vol. 111, pg. 12270, 2014)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE Gleason; immunohistochemistry; retrovirus; RNaseL; xenotropic
ID CELLULAR-TRANSFORMATION; VIRUS; STATISTICS; MECHANISMS; MORTALITY;
   PROTEIN
AB Xenotropic murine leukemia virus-related virus (XMRV) was recently discovered in human prostate cancers and is the first gammaretrovirus known to infect humans. While gammaretroviruses have wellcharacterized oncogenic effects in animals, they have not been shown to cause human cancers. We provide experimental evidence that XMRV is indeed a gammaretrovirus with protein composition and particle ultrastructure highly similar to Moloney murine leukemia virus (MoMLV), another gammaretrovirus. We analyzed 334 consecutive prostate resection specimens, using a quantitative PCR assay and immunohistochemistry (IHC) with an anti-XMRV specific antiserum. We found XMRV DNA in 6% and XMRV protein expression in 23% of prostate cancers. XMRV proteins were expressed primarily in malignant epithelial cells, suggesting that retroviral infection may be directly linked to tumorigenesis. XMRV infection was associated with prostate cancer, especially higher-grade cancers. We found XMRV infection to be independent of a common polymorphism in the RNASEL gene, unlike results previously reported. This finding increases the population at risk for XMRV infection from only those homozygous for the RNASEL variant to all individuals. Our observations provide evidence for an association of XMRV with malignant cells and with more aggressive tumors.
C1 [Schlaberg, Robert; Brown, Kristy R.; Singh, Ila R.] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY 10032 USA.
   [Choe, Daniel J.; Thaker, Harshwardhan M.; Singh, Ila R.] Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA.
RP Singh, IR (reprint author), Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, 622 W 168th St, New York, NY 10032 USA.
EM ila.singh@path.utah.edu
FU Department of Defense [PC060433]
FX We thank Drs. J. L. DeRisi and D. Ganem (UCSF) for clones AM-2-9 and
   AO-H4 and Drs. R. H. Silverman and C. Magi-Galluzzi (Cleveland Clinic)
   for prostate tissues from patients VP62 and VP45, and Drs. S. P. Goff
   and J. Rodriguez of Columbia University Medical Center (CUMC) for the
   XMRV-SU antisera. We thank Drs. H. Hibshoosh and B. Tycko (CUMC) for
   advice human tissue samples, the staff of the Histology and
   Immunohistochemistry Laboratories (Pathology Department) and the Tissue
   Bank (Herbert Irving Comprehensive Cancer Center, both at CUMC),
   especially S. Alexander, L. Yang, T. Wu, J. Cusmai, and K. Sun. We thank
   P. M. Pringle for queries of clinical databases, J. Smith for equipment
   maintenance (both at CUMC), and Drs. M. M. Mansukhani (CUMC) and V.
   Planelles (University of Utah) for generously sharing space and
   equipment. We thank Drs. S. P. Goff, V. Planelles, and D. R. Hillyard
   (University of Utah) for reading of the manuscript. This work was
   supported by grant PC060433 from the Department of Defense (to I. R.
   S.).
CR Andriole GL, 2009, NEW ENGL J MED, V360, P1310, DOI 10.1056/NEJMoa0810696
   Auerbach MR, 2007, J VIROL, V81, P12337, DOI 10.1128/JVI.01286-07
   Casey Graham, 2002, Nature Genetics, V32, P581, DOI 10.1038/ng1021
   Cousens C, 2007, VIROLOGY, V367, P413, DOI 10.1016/j.virol.2007.06.004
   De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090
   Dong B, 2007, P NATL ACAD SCI USA, V104, P1655, DOI 10.1073/pnas.0610291104
   Fischera N, 2008, J CLIN VIROL, V43, P277, DOI 10.1016/j.jcv.2008.04.016
   Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978
   Hayat MJ, 2007, ONCOLOGIST, V12, P20, DOI 10.1634/theoncologist.12-1-20
   Hayes RB, 2000, BRIT J CANCER, V82, P718, DOI 10.1054/bjoc.1999.0986
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kim S, 2008, J VIROL, V82, P9964, DOI 10.1128/JVI.01299-08
   Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111
   Parkin DM, 2001, EUR J CANCER, V37, pS4
   PAYNE GS, 1981, CELL, V23, P311, DOI 10.1016/0092-8674(81)90127-6
   Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084
   Telesnitsky A, 1995, METHOD ENZYMOL, V262, P347
   Urisman A, 2006, PLOS PATHOG, V2, P211, DOI 10.1371/journal.ppat.0020025
   Yeager M, 1998, P NATL ACAD SCI USA, V95, P7299, DOI 10.1073/pnas.95.13.7299
   Yuan B, 1999, EMBO J, V18, P4700, DOI 10.1093/emboj/18.17.4700
NR 20
TC 219
Z9 224
U1 4
U2 21
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 22
PY 2009
VL 106
IS 38
BP 16351
EP 16356
DI 10.1073/pnas.0906922106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 497PF
UT WOS:000270071600064
PM 19805305
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Di Lorenzo, E
   Sauro, R
   Varricchio, A
   Carbone, G
   Cortese, G
   Capasso, M
   Lanzillo, T
   Manganelli, F
   Mariello, C
   Siano, F
   Pagliuca, MR
   Stanco, G
   Rosato, G
   De Luca, G
AF Di Lorenzo, Emilio
   Sauro, Rosario
   Varricchio, Attilio
   Carbone, Giannignazio
   Cortese, Giuliana
   Capasso, Michele
   Lanzillo, Tonino
   Manganelli, Fiore
   Mariello, Ciro
   Siano, Francesco
   Pagliuca, Maria Rosaria
   Stanco, Giovanni
   Rosato, Giuseppe
   De Luca, Giuseppe
TI RETRACTED: Long-Term Outcome of Drug-Eluting Stents Compared With Bare
   Metal Stents in ST-Segment Elevation Myocardial Infarction Results of
   the Paclitaxel- or Sirolimus-Eluting Stent Versus Bare Metal Stent in
   Primary Angioplasty (PASEO) Randomized Trial (Retracted article. See
   vol. 121, pg. E228, 2010)
SO CIRCULATION
LA English
DT Article; Retracted Publication
DE angioplasty; myocardial infarction; stents
ID CORONARY-ARTERY-DISEASE; UNCOATED STENTS; BALLOON ANGIOPLASTY;
   FOLLOW-UP; IMPLANTATION; METAANALYSIS; ABCIXIMAB; INTERVENTION;
   PREDICTORS; THERAPY
AB Background-Drug-eluting stents may offer benefits in terms of repeat revascularization that may be counterbalanced by a potential higher risk of stent thrombosis, especially among ST-segment elevation myocardial infarction (STEMI) patients. No data have been reported so far on the long-term benefits and safety of drug-eluting stents in STEMI. Thus, the aim of the present study was to evaluate the short-and long-term benefits of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) compared with bare metal stents (BMS) in patients undergoing primary angioplasty.
   Methods and Results-Consecutive STEMI patients admitted within 12 hours of symptom onset and undergoing primary angioplasty and stent implantation at a tertiary center with 24-hour primary percutaneous coronary intervention capability were randomly assigned to BMS, PES, or SES. All patients received upstream glycoprotein IIb/IIIa inhibitors. The primary end point was target lesion revascularization at the 1-year follow-up. Secondary end points were death and/or reinfarction, in-stent thrombosis, and major adverse cardiac events (combined death and/or reinfarction and/or target lesion revascularization) at long-term follow-up (up to 4 to 6 years). Cumulative incidence of end points was investigated. No patient was lost to follow-up. From October 1, 2003, to December 31, 2005, 270 patients with STEMI were randomized to BMS (n=90), PES (n=90), or SES (n=90). Procedural success was obtained in 93% to 95% of patients. Follow-up data were available for all patients. Compared with BMS (14.4%), both PES (4.4%; hazard ratio, 0.29; 95% confidence interval, 0.095 to 0.89; P=0.023) and SES (3.3%; hazard ratio, 0.21; 95% confidence interval, 0.06 to 0.75; P=0.016) were associated with a significant reduction in target lesion revascularization at the 1-year follow-up (primary study end point). At the long-term follow-up (4.3 years; 25th to 75th percentile, 3.7 to 5 years), no difference was observed in terms of death, reinfarction, and combined death and/or reinfarction, but compared with BMS (22.2%), both PES (6.7%; hazard ratio, 0.27; 95% confidence interval, 0.11 to 0.68; P=0.005) and SES (5.6%; hazard ratio, 0.22; 95% confidence interval, 0.083 to 0.59; P=0.003) were associated with a significant reduction in target lesion revascularization.
   Conclusions-This study shows that among STEMI patients undergoing primary angioplasty, both SES and PES are associated with significant benefits in terms of target lesion revascularization at the long-term follow-up compared with BMS with no excess risk of thrombotic complications. Thus, until the results of further large randomized trials with long-term follow-up become available, drug-eluting stents may be considered among STEMI patients undergoing primary angioplasty. (Circulation. 2009; 120: 964-972.)
C1 [Di Lorenzo, Emilio] SG Moscati Hosp, Lab Cardiac Catheterizat & Intervent Cardiol, Div Cardiol, I-83100 Avellino, Italy.
   [Cortese, Giuliana] Univ Padua, Dept Stat Sci, Padua, Italy.
   [De Luca, Giuseppe] Osped Maggiore La Carita, Div Cardiol, Novara, Italy.
   [De Luca, Giuseppe] Eastern Piedmont Univ, Ctr Biotecnol Ric Med Applicata, Novara, Italy.
RP Di Lorenzo, E (reprint author), SG Moscati Hosp, Lab Cardiac Catheterizat & Intervent Cardiol, Div Cardiol, Via Otranto, I-83100 Avellino, Italy.
EM emidilorenzo@tin.it
CR Andersen PK, 2002, STAT METHODS MED RES, V11, P203, DOI 10.1191/0962280202sm281ra
   Antoniucci D, 2004, CIRCULATION, V109, P1704, DOI 10.1161/01.CIR.0000126284.40075.98
   Ardissino D, 2004, JAMA-J AM MED ASSOC, V292, P2727, DOI 10.1001/jama.292.22.2727
   Chechi T, 2007, J INTERV CARDIOL, V20, P282, DOI 10.1111/j.1540-8183.2007.00270.x
   Colombo A, 2004, CIRCULATION, V109, P1244, DOI 10.1161/01.CIR.0000118474.71662.E3
   Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313
   De Luca G, 2006, AM HEART J, V151, P1256, DOI 10.1016/j.ahj.2005.06.047
   De Luca G, 2008, INT J CARDIOL, V126, P37, DOI 10.1016/j.ijcard.2007.03.112
   De Luca G, 2009, INT J CARDIOL, V133, P213, DOI 10.1016/j.ijcard.2007.12.040
   DELALLERA LSD, 2007, AM HEART J, V154
   Iakovou I, 2005, JAMA-J AM MED ASSOC, V293, P2126, DOI 10.1001/jama.293.17.2126
   KARJALAINEN, TITAX AMI TRIAL
   Kastrati A, 2007, EUR HEART J, V28, P2706, DOI 10.1093/eurheartj/ehm402
   Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7
   Kelbaek H, 2008, CIRCULATION, V118, P1155, DOI 10.1161/CIRCULATIONAHA.107.758698
   Kernis SJ, 2005, AM J CARDIOL, V96, p47H
   Laarman GJ, 2006, NEW ENGL J MED, V355, P1105, DOI 10.1056/NEJMoa062598
   Lagerqvist B, 2007, NEW ENGL J MED, V356, P1009, DOI 10.1056/NEJMoa067722
   Lawless J., 2003, STAT MODELS METHODS
   Lee JH, 2008, CATHETER CARDIO INTE, V72, P25, DOI 10.1002/ccd.21510
   McFadden EP, 2004, LANCET, V364, P1519, DOI 10.1016/S0140-6736(04)17275-9
   Menichelli M, 2007, J AM COLL CARDIOL, V49, P1924, DOI 10.1016/j.jacc.2007.01.081
   Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071
   Pasceri V, 2003, AM J CARDIOL, V92, p1L
   Pinto DS, 2006, J AM COLL CARDIOL, V48, P32, DOI 10.1016/j.jacc.2006.02.060
   Pittl U, 2006, EUR HEART J, V27, P650
   Roiron C, 2006, HEART, V92, P641, DOI 10.1136/hrt.2005.061622
   Sardella G, 2006, EUR HEART J, V27, P831
   Schomig A, 2007, J AM COLL CARDIOL, V50, P1373, DOI 10.1016/j.jacc.2007.06.047
   Spaulding C, 2006, NEW ENGL J MED, V355, P1093, DOI 10.1056/NEJMoa062006
   Spertus JA, 2006, CIRCULATION, V113, P2803, DOI 10.1161/CIRCULATIONAHA.106.618066
   Stone GW, 2009, NEW ENGL J MED, V360, P1946, DOI 10.1056/NEJMoa0810116
   Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404
   Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441
   Suryapranata H, 2005, HEART, V91, P641, DOI 10.1136/hrt.2004.056705
   Tierala I, HELSINKI AREA ACUTE
   Valgimigli M, 2005, JAMA-J AM MED ASSOC, V293, P2109, DOI 10.1001/jama.293.17.2109
   Valgimigli M, 2008, JAMA-J AM MED ASSOC, V299, P1788, DOI 10.1001/jama.299.15.joc80026
   van der Hoeven BL, 2008, J AM COLL CARDIOL, V51, P618, DOI 10.1016/j.jacc.2007.09.056
   STRATEGY STUDY
   ZEST AMI
   TYPHOON STUDY
NR 42
TC 35
Z9 37
U1 3
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD SEP 15
PY 2009
VL 120
IS 11
BP 964
EP 972
DI 10.1161/CIRCULATIONAHA.108.830372
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 493XO
UT WOS:000269772800008
PM 19720939
DA 2018-12-27
ER

PT J
AU Gong, ZZ
   Dai, F
   Cao, Y
   Zhang, WB
   Yang, JY
   Tong, JY
AF Gong Zizheng
   Dai Fu
   Cao Yan
   Zhang Wenbing
   Yang Jiyun
   Tong Jingyu
TI RETRACTED: The laser-driven flyer system for space debris hypervelocity
   impact simulations (Retracted article. See vol. 268, pg. 1532, 2010)
SO NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION B-BEAM
   INTERACTIONS WITH MATERIALS AND ATOMS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 9th International Conference on Computer Simulation of Radiation Effects
   in Solids
CY OCT 12-17, 2008
CL Beihang Univ, Beijing, PEOPLES R CHINA
HO Beihang Univ
DE Laser-driven flyer system; Hypervelocity impacts; Micro meteoroids and
   orbital debris; Cumulated damage characteristics; The outer surfaces
   functional material; Spacecraft
AB The laser-driven flyer system with a single pulses from a Q-switched Nd: glass laser, of 15 ns duration and up to 20 J energy, launched the aluminum films of 7 mu m thickness up to 8.3 km/s velocity in Beijing Institute of Spacecrafts Environment Engineering (BISEE) are briefly introduced. Some experimental aspects in our efforts on the space debris hypervelocity impacts on the outer surfaces functional of material, such as the thermal control material, window glass, OSR etc., are reviewed. Though still developing, the laser-driven flyer technique has been demonstrated promise in simulating micro M/OD hypervelocity impacting effects. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Gong Zizheng; Dai Fu; Cao Yan; Zhang Wenbing; Yang Jiyun; Tong Jingyu] Beijing Inst Spacecrafts Environm Engn, Beijing 100094, Peoples R China.
RP Gong, ZZ (reprint author), Beijing Inst Spacecrafts Environm Engn, Beijing 100094, Peoples R China.
EM gongzz@263.net
CR Greenaway MW, 2003, INT J IMPACT ENG, V29, P317, DOI [10.1016/j.ijimpeng.2003.09.027, 10.1016/jiimpeng.2003.09.027]
   HONGJIAN D, 2004, VAC SCI TECHNOL, V24, P109
   PAISLEY DL, 1992, P APS TOP C SHOCK CO, P825
   PAISLEY DL, 1990, P APS C SHOCK COMPR, P733
   Portree D. S., 1999, NASATP1999208856
   Roybal R, 1995, INT J IMPACT ENG, V17, P707, DOI 10.1016/0734-743X(95)99893-V
   Roybal R, 1999, INT J IMPACT ENG, V23, P811, DOI 10.1016/S0734-743X(99)00126-8
   Verker R, 2004, ACTA MATER, V52, P5539, DOI [10.1016/j.actamat.2004.08.013, 10.1016/j.acatamat.2004.08.013]
   WENBING Z, 2007, EQUIP ENV ENG, V4, P56
NR 9
TC 6
Z9 10
U1 4
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-583X
EI 1872-9584
J9 NUCL INSTRUM METH B
JI Nucl. Instrum. Methods Phys. Res. Sect. B-Beam Interact. Mater. Atoms
PD SEP 15
PY 2009
VL 267
IS 18
BP 3252
EP 3257
DI 10.1016/j.nimb.2009.06.095
PG 6
WC Instruments & Instrumentation; Nuclear Science & Technology; Physics,
   Atomic, Molecular & Chemical; Physics, Nuclear
SC Instruments & Instrumentation; Nuclear Science & Technology; Physics
GA 513UN
UT WOS:000271349500072
DA 2018-12-27
ER

PT J
AU Lipardi, C
   Paterson, BM
AF Lipardi, Concetta
   Paterson, Bruce M.
TI RETRACTED: Identification of an RNA-dependent RNA polymerase in
   Drosophila involved in RNAi and transposon suppression (Retracted
   article. See vol. 108, pg. 15010, 2011)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE elongator; genome defence; cellular stress
ID DOUBLE-STRANDED-RNA; ENDOGENOUS SIRNAS; MESSENGER-RNAS; FISSION YEAST;
   INTERFERENCE; PROTEIN; CELLS; MELANOGASTER; BIOGENESIS; INJECTION
AB Here, we show that recombinant Drosophila elp1 (D-elp1) produced in Sf9 cells or Escherichia coli, corresponding to the largest of the three subunits in the RNA polymerase II core elongator complex, has RNA-dependent RNA polymerase (RdRP) activity. D-elp1 is a noncanonical RdRP that can synthesize dsRNA from different ssRNA templates using either a primer-dependent or primer-independent initiation mechanism. Of the three core subunits, only D-elp1 depletion inhibits RNAi in S2 cells but does not affect micro RNA function. Furthermore, D-elp1 depletion results in increased steady state levels of representative transposon RNAs and a decrease in the corresponding transposon antisense transcripts and endo siRNAs. In contrast, although Dcr-2 depletion results in increased transposon RNA levels and a reduction in the corresponding endo siRNAs, there is no change in the transposon antisense RNA levels. In D-elp1 null third instar larvae transposon RNA levels are also increased and the corresponding transposon antisense RNAs are reduced. D-elp1 associates tightly with Dcr-2, similar to the Dicer-RdRP interaction observed in lower eukaryotes. These results identify an aspect of the RNAi pathway in Drosophila that suggest transposon derived endo siRNAs, critical for transposon suppression, are produced, in part, in a D-elp1 dependent step that converts transposon RNA into dsRNA that is subsequently processed by Dcr-2. The generality of this mechanism in genome defense and RNA silencing in higher eukaryotes is suggested.
C1 [Lipardi, Concetta; Paterson, Bruce M.] NCI, Biochem & Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
RP Paterson, BM (reprint author), NCI, Biochem & Mol Biol Lab, NIH, Bldg 37,Room 6118,9000 Rockville Pike, Bethesda, MD 20892 USA.
EM patersob@mail.nih.gov
CR Baulcombe DC, 2007, SCIENCE, V315, P199, DOI 10.1126/science.1138030
   Bergstrom CT, 2003, P NATL ACAD SCI USA, V100, P11511, DOI 10.1073/pnas.1931639100
   Brennecke J, 2007, CELL, V128, P1089, DOI 10.1016/j.cell.2007.01.043
   Chung WJ, 2008, CURR BIOL, V18, P795, DOI 10.1016/j.cub.2008.05.006
   Colmenares SU, 2007, MOL CELL, V27, P449, DOI 10.1016/j.molcel.2007.07.007
   Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954
   Dzitoyeva S, 2001, MOL PSYCHIATR, V6, P665, DOI 10.1038/sj.mp.4000955
   Friedman A, 2006, NATURE, V444, P230, DOI 10.1038/nature05280
   Ghildiyal M, 2008, SCIENCE, V320, P1077, DOI 10.1126/science.1157396
   Girard A, 2008, TRENDS CELL BIOL, V18, P136, DOI 10.1016/j.tcb.2008.01.004
   Goto A, 2003, NUCLEIC ACIDS RES, V31, P6619, DOI 10.1093/nar/gkg852
   Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950
   Holmberg C, 2002, J BIOL CHEM, V277, P31918, DOI 10.1074/jbc.M200719200
   ILYIN YV, 1980, NUCLEIC ACIDS RES, V8, P3439, DOI 10.1093/nar/8.15.3439
   Iyer LM, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-5
   Jaskiewicz L, 2008, CURR TOP MICROBIOL, V320, P77
   Johansen LD, 2008, J CELL SCI, V121, P854, DOI 10.1242/jcs.013722
   Kim JH, 2002, P NATL ACAD SCI USA, V99, P1241, DOI 10.1073/pnas.251672198
   Kim VN, 2005, MOL CELLS, V19, P1
   Lee DF, 2000, J VIROL, V74, P11873, DOI 10.1128/JVI.74.24.11873-11880.2000
   Lee SR, 2007, NAT STRUCT MOL BIOL, V14, P604, DOI 10.1038/nsmb1262
   Lipardi C, 2005, METHOD ENZYMOL, V392, P351, DOI 10.1016/S0076-6879(04)92021-6
   Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2
   Makeyev EV, 2002, MOL CELL, V10, P1417, DOI 10.1016/S1097-2765(02)00780-3
   Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007
   Obbard DJ, 2008, CURR BIOL, V18, pR561, DOI 10.1016/j.cub.2008.05.035
   Pal-Bhadra M, 2002, MOL CELL, V9, P315, DOI 10.1016/S1097-2765(02)00440-9
   Rehwinkel J, 2006, MOL CELL BIOL, V26, P2965, DOI 10.1128/MCB.26.8.2965-2975.2006
   Roguev A, 2008, SCIENCE, V322, P405, DOI 10.1126/science.1162609
   Roignant JY, 2003, RNA, V9, P299, DOI 10.1261/rna.2154103
   Saleh MC, 2009, NATURE, V458, P346, DOI 10.1038/nature07712
   Sigova A, 2004, GENE DEV, V18, P2359, DOI 10.1101/gad.1218004
   Slaugenhaupt SA, 2001, AM J HUM GENET, V68, P598, DOI 10.1086/318810
   Sugiyama T, 2005, P NATL ACAD SCI USA, V102, P152, DOI 10.1073/pnas.0407641102
   Svejstrup JQ, 2007, CURR OPIN CELL BIOL, V19, P331, DOI 10.1016/j.ceb.2007.04.005
   Tijsterman M, 2002, ANNU REV GENET, V36, P489, DOI 10.1146/annurev.genet.36.043002.091619
   Tolia NH, 2006, NAT METHODS, V3, P55, DOI 10.1038/nmeth0106-55
   Watanabe T, 2008, NATURE, V453, P539, DOI 10.1038/nature06908
   Winkler GS, 2001, J BIOL CHEM, V276, P32743, DOI 10.1074/jbc.M105303200
   Wynshaw-Boris A, 2009, CELL, V136, P393, DOI 10.1016/j.cell.2009.01.024
NR 40
TC 51
Z9 53
U1 5
U2 24
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 15
PY 2009
VL 106
IS 37
BP 15645
EP 15650
DI 10.1073/pnas.0904984106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 494IS
UT WOS:000269806600027
PM 19805217
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Xie, C
   Xu, FG
   Huang, XY
   Dong, CQ
   Ren, JC
AF Xie, Chao
   Xu, Fagong
   Huang, Xiangyi
   Dong, Chaoqing
   Ren, Jicun
TI RETRACTED: Single Gold Nanoparticles Counter: An Ultrasensitive
   Detection Platform for One-Step Homogeneous Immunoassays and DNA
   Hybridization Assays (Retracted Article. See vol 132, pg 15091, 2010)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article; Retracted Publication
ID RESONANCE ENERGY-TRANSFER; FLUORESCENCE CORRELATION SPECTROSCOPY;
   DYNAMIC LIGHT-SCATTERING; CAPILLARY-ELECTROPHORESIS; COLORIMETRIC
   DETECTION; PARTICLE TRACKING; PROBES; MOLECULES; SYSTEM;
   OLIGONUCLEOTIDES
AB In this paper, we present for the first time a single gold nanoparticle counter (SGNPC) in solution based on the photon bursting in a highly focused laser beam (less than 1 fL) due to the plasmon resonance scattering and Brownian motion of gold nanoparticles (GNPs). The photon burst intensity of single 36 nm GNPs is several tens to hundreds times stronger than that of quantum dots (QDs) and organic dyes. The relationship between the photon burst counts and GNPs concentration shows an excellent linearity. The linear range is over 4 orders of magnitude, and the detection limit of GNPs (36 nm) is 17 fM. On the basis of this single nanoparticle technique, we developed an ultrasensitive and highly selective detection platform for homogeneous immunoassay and DNA hybridization assays using GNPs as probes, which were 2-5 orders of magnitude more sensitive than current homogeneous methods. We used this technology to construct homogeneous sandwich immunoassays for cancer biomarkers, such as carcinoembryonic antigen (CEA) and alpha fetal protein (AFP), and aptamer recognition for thrombin. The detection limits are 130 fM for CEA, 714 fM for AFP and 2.72 pM for thrombin. Our method was successfully applied for direct determination of CEA, AFP and thrombin levels in sera from healthy subjects and cancer patients. In homogeneous DNA hybridization detection, we chose methylenetetrahydrofolate reductase (MTHFR) gene as a target. This assay successfully distinguished DNA sequences with single base mismatches, and the detection limits for the target were at 1 fM level.
C1 [Xie, Chao; Xu, Fagong; Huang, Xiangyi; Dong, Chaoqing; Ren, Jicun] Shanghai Jiao Tong Univ, Coll Chem & Chem Engn, State Key Lab Met Matrix Composites, Shanghai 200240, Peoples R China.
RP Ren, JC (reprint author), Shanghai Jiao Tong Univ, Coll Chem & Chem Engn, State Key Lab Met Matrix Composites, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.
EM jicunren@sjtu.edu.cn
CR Bailey RC, 2007, J AM CHEM SOC, V129, P1959, DOI 10.1021/ja065930i
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Cang H, 2008, CHEM PHYS LETT, V457, P285, DOI 10.1016/j.cplett.2008.03.098
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Chen G, 2009, J AM CHEM SOC, V131, P4218, DOI 10.1021/ja900809z
   Cruz-Aguado JA, 2008, ANAL CHEM, V80, P8853, DOI 10.1021/ac8017058
   Daniel DC, 2002, BIOPHYS J, V82, P1654, DOI 10.1016/S0006-3495(02)75516-1
   Dong CQ, 2006, J PHYS CHEM B, V110, P11069, DOI 10.1021/jp060279r
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Foldes-Papp Z, 2002, J IMMUNOL METHODS, V260, P117, DOI 10.1016/S0022-1759(01)00537-3
   Freeman RG, 1996, J PHYS CHEM-US, V100, P718, DOI 10.1021/jp951379s
   FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111
   Hayden EC, 2008, NATURE, V456, P850, DOI 10.1038/456850a
   He H, 2008, TALANTA, V77, P166, DOI 10.1016/j.talanta.2008.05.059
   He H, 2008, ANAL CHEM, V80, P5951, DOI 10.1021/ac8005796
   He W, 2008, ANAL CHEM, V80, P8424, DOI 10.1021/ac801005d
   Heyduk E, 2008, ANAL CHEM, V80, P5152, DOI 10.1021/ac8004154
   Hirsch LR, 2003, ANAL CHEM, V75, P2377, DOI 10.1021/ac0262210
   Huang CC, 2007, ANGEW CHEM INT EDIT, V46, P6824, DOI 10.1002/anie.200700803
   Jenison R, 2001, NAT BIOTECHNOL, V19, P62, DOI 10.1038/83530
   Jiang TT, 2009, CHEM COMMUN, P1972, DOI 10.1039/b818853j
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Jiang Y, 2008, ANGEW CHEM INT EDIT, V47, P8601, DOI 10.1002/anie.200804066
   Jiang ZL, 2008, ANAL CHEM, V80, P8681, DOI 10.1021/ac801647b
   Jin RC, 2008, ANGEW CHEM INT EDIT, V47, P6750, DOI 10.1002/anie.200801301
   Ke YG, 2008, SCIENCE, V319, P180, DOI 10.1126/science.1150082
   Kim SA, 2007, NAT METHODS, V4, P963, DOI 10.1038/NMETH1104
   Kotto T, 2008, ANAL CHEM, V80, P9763, DOI 10.1021/ac801875a
   Lee C, 2007, NAT GENET, V39, pS48, DOI 10.1038/ng2092
   Li JL, 2009, CANCER LETT, V274, P319, DOI 10.1016/j.canlet.2008.09.024
   Li YL, 2008, ELECTROPHORESIS, V29, P2570, DOI 10.1002/elps.200700798
   Liu GL, 2007, NAT METHODS, V4, P1015, DOI 10.1038/nmeth1133
   Liu JW, 2004, J AM CHEM SOC, V126, P12298, DOI 10.1021/ja046628h
   Liu LZ, 2008, ANAL CHEM, V80, P7735, DOI 10.1021/ac801106w
   Liu R, 2008, ANGEW CHEM INT EDIT, V47, P3081, DOI 10.1002/anie.200702773
   Liu X, 2008, J AM CHEM SOC, V130, P2780, DOI 10.1021/ja711298b
   Loos RJF, 2008, NAT GENET, V40, P768, DOI 10.1038/ng.140
   Lopez-Crapez E, 2008, ANAL BIOCHEM, V383, P301, DOI 10.1016/j.ab.2008.09.004
   Mishra A, 2009, J PHYS CHEM C, V113, P6976, DOI 10.1021/jp8096742
   Murphy CJ, 2008, ACCOUNTS CHEM RES, V41, P1721, DOI 10.1021/ar800035u
   Narayanan R, 2008, ANAL CHEM, V80, P2265, DOI 10.1021/ac7026436
   Otsuka H, 2001, J AM CHEM SOC, V123, P8226, DOI 10.1021/ja010437m
   Porter MD, 2008, CHEM SOC REV, V37, P1001, DOI 10.1039/b708461g
   Ramirez DC, 2007, NAT PROTOC, V2, P512, DOI 10.1038/nprot.2007.5
   Reynolds RA, 2000, J AM CHEM SOC, V122, P3795, DOI 10.1021/ja000133k
   Sharlow ER, 2008, NAT PROTOC, V3, P1350, DOI 10.1038/nprot.2008.111
   SHEN QP, 2009, CHEM COMMUN, V15, P929
   Shi WW, 2008, LAB CHIP, V8, P1432, DOI 10.1039/b808753a
   Shi XG, 2007, SMALL, V3, P1245, DOI 10.1002/smll.200700054
   Song H, 2006, ANGEW CHEM INT EDIT, V45, P7336, DOI 10.1002/anie.200601554
   Storhoff JJ, 2004, NAT BIOTECHNOL, V22, P883, DOI 10.1038/nbt977
   Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i
   Tachi T, 2009, LAB CHIP, V9, P966, DOI 10.1039/b813640h
   Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757
   Uyeda HT, 2005, J AM CHEM SOC, V127, P3870, DOI 10.1021/ja044031w
   Xiang MH, 2009, J PHYS CHEM B, V113, P2734, DOI 10.1021/jp8065822
   Xu CS, 2007, J PHYS CHEM C, V111, P32, DOI 10.1021/jp0671796
   Xu XY, 2007, ANAL CHEM, V79, P6650, DOI 10.1021/ac070867g
   Yang RH, 2008, J AM CHEM SOC, V130, P8351, DOI 10.1021/ja800604z
   Zhang HQ, 2008, J AM CHEM SOC, V130, P34, DOI 10.1021/ja0778747
   Zhang K, 2005, J PHYS CHEM B, V109, P21930, DOI 10.1021/jp0546047
NR 61
TC 48
Z9 48
U1 10
U2 184
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD SEP 9
PY 2009
VL 131
IS 35
BP 12763
EP 12770
DI 10.1021/ja903873n
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA 493KP
UT WOS:000269735800052
PM 19678640
DA 2018-12-27
ER

PT J
AU Yu, Y
   Lang, QB
   Chen, Z
   Li, B
   Yu, CQ
   Zhu, DZ
   Huang, XQ
   Zhai, XF
   Ling, CQ
AF Yu Yang
   Lang Qing-bo
   Chen Zhe
   Li Bai
   Yu Chao-qin
   Zhu De-zeng
   Huang Xue-qiang
   Zhai Xiao-feng
   Ling Chang-quan
TI RETRACTED: Prognostic analysis of transarterial chemoembolization
   combined with a traditional Chinese herbal medicine formula for
   treatment of unresectable hepatocellular carcinoma (Retracted article.
   See vol. 124, pg. 3048, 2011)
SO CHINESE MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
DE carcinoma; hepatocellular; chemoembolization; therapeutic; medicine;
   Chinese traditional; drug therapy; combination; prognostic factors
ID TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; RANDOMIZED CONTROLLED-TRIAL;
   PERCUTANEOUS ETHANOL INJECTION; COMBINATION THERAPY; LIPIODOL
   CHEMOEMBOLIZATION; NATIONWIDE SURVEY; LIVER-TISSUE; SURVIVAL; ABLATION;
   EMBOLIZATION
AB Background Transarterial chemoembolization (TACE) is the most widely used primary treatment for unresectable hepatocellular carcinoma (HCC) due to its survival benefit, though its clinical effect is still far from satisfactory. Jiedufang (JDF) granule preparation is a commonly used Chinese herbal medicine formula for HCC. The aim of this study was to evaluate the effect of combined therapy with TACE and JDF granule preparation in treatment of unresectable HCC on survival.
   Methods A retrospective study of TACE was performed in 165 patients with unresectable HCC who were admitted between January 2002 and December 2007 in Changhai Hospital, Shanghai, China. Of the 165 patients, 80 patients (study group) received combined therapy consisting of TACE and a long-term maintenance treatment with oral JDF granule preparation, and the remaining 85 patients (control group) received TALE alone. The survival rates of both groups were calculated by the Kaplan-Meier method. Factors possibly affecting survival were assessed by multivariate analysis in the Cox proportional hazard model, such as maximum tumor size, number of lesions, portal vein invasion, and etc.
   Results The median overall survival was 9.2 months (95% CI: 6.94-11.46) in the study group versus 5.87 months (95% CI: 4.21-7.52) in the control group. In the study group,survival rates of the 1-, 2- and 3-year follow-up were 41.2%, 18.4%, and 9.6%, respectively. Significant independent prognostic factors identified by the Cox regression analysis were as follows: serum hepatitis B surface antigen (HBsAg) (P=0.014), maximum tumor size (P=0.027), number of lesions (P <0.001), portal vein invasion (P <0.001), and the therapy model (P=0.006).
   Conclusion Combination therapy of TACE and JDF granule preparation may significantly prolong survival of patients with unresectable HCC. Chin Med J 2009;122(17):1990-1995
C1 [Yu Yang; Lang Qing-bo; Chen Zhe; Li Bai; Yu Chao-qin; Zhu De-zeng; Huang Xue-qiang; Zhai Xiao-feng; Ling Chang-quan] Second Mil Med Univ, Dept Tradit Chinese Med, Changhai Hosp, Shanghai 200433, Peoples R China.
RP Ling, CQ (reprint author), Second Mil Med Univ, Dept Tradit Chinese Med, Changhai Hosp, Shanghai 200433, Peoples R China.
EM higher98@msn.com
RI Ling, Changquan/J-2108-2016
OI Ling, Changquan/0000-0003-3476-6445
FU Science and Technology Department [2006BAI04A06]
FX This study was supported by a grant form Science and Technology
   Department 11th Five-year Plan State Science and Technology Support
   Projects of China (No. 2006BAI04A06).
CR Akamatsu M, 2004, LIVER INT, V24, P625, DOI 10.1111/j.1478-3231.2004.0963.x
   Arii S, 2000, HEPATOLOGY, V32, P1224, DOI 10.1053/jhep.2000.20456
   BARTOLOZZI C, 1995, RADIOLOGY, V197, P812, DOI 10.1148/radiology.197.3.7480761
   Bruix J, 2004, GASTROENTEROLOGY, V127, pS179, DOI 10.1053/j.gastro.23004.09.032
   Buscarini L, 1999, ULTRASCHALL MED, V20, P47, DOI 10.1055/s-1999-14233
   Caturelli E, 2000, RADIOLOGY, V215, P123, DOI 10.1148/radiology.215.1.r00ap21123
   *CHIN SOC LIV CANC, 2001, CHIN J HEPATOL, V9, P324
   Garcia M., 2007, GLOBAL CANC FACTS FI
   *GROUP ET TRAIT CA, 1995, NEW ENGL J MED, V332, P1256, DOI DOI 10.1056/NEJM199505113321903
   HATANAKA Y, 1995, RADIOLOGY, V195, P747, DOI 10.1148/radiology.195.3.7754005
   Ikai I, 2004, CANCER, V101, P796, DOI 10.1002/cncr.20426
   Koda M, 2001, CANCER, V92, P1516, DOI 10.1002/1097-0142(20010915)92:6<1516::AID-CNCR1477>3.0.CO;2-I
   Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1
   Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047
   Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X
   Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156
   Marelli L, 2006, CANCER TREAT REV, V32, P594, DOI 10.1016/j.ctrv.2006.08.002
   Poon RTP, 2002, ANN SURG, V235, P466, DOI 10.1097/00000658-200204000-00004
   Savastano S, 1999, J CLIN GASTROENTEROL, V28, P334, DOI 10.1097/00004836-199906000-00010
   Seki T, 2000, CANCER, V89, P1245, DOI 10.1002/1097-0142(20000915)89:6<1245::AID-CNCR8>3.0.CO;2-F
   Seong J, 2000, INT J RADIAT ONCOL, V47, P1331, DOI 10.1016/S0360-3016(00)00519-8
   Shim JS, 2004, PLANTA MED, V70, P171, DOI 10.1055/s-2004-815496
   Singletary SE, 2003, CANCER, V98, P2740, DOI 10.1002/cncr.11865
   Takayasu K, 2006, GASTROENTEROLOGY, V131, P461, DOI 10.1053/j.gastro.2006.05.021
   TANG ZY, 2001, TANG ZHAO YOUS HEPAT, P162
   Veltri A, 2006, EUR RADIOL, V16, P661, DOI 10.1007/s00330-005-0029-9
   Villa E, 2000, HEPATOLOGY, V32, P233, DOI 10.1053/jhep.2000.9603
   Wang P, 2008, CHINESE MED J-PEKING, V121, P557
   WONG CK, 1994, J INT MED RES, V22, P299, DOI 10.1177/030006059402200601
   WU MC, 2003, J CHIN INTEGR MED, V1, P163, DOI DOI 10.3736/JCIM20030302
   Xin HL, 2008, HELV CHIM ACTA, V91, P575, DOI 10.1002/hlca.200890060
   Yamakado K, 2004, ONCOL REP, V11, P105
NR 32
TC 5
Z9 6
U1 5
U2 17
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD SEP 5
PY 2009
VL 122
IS 17
BP 1990
EP 1995
DI 10.3760/cma.j.issn.0366-6999.2009.17.006
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 494BI
UT WOS:000269783700006
PM 19781383
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Wang, SW
   Yang, TY
   Li, ZF
   Yu, XJ
AF Wang, Suwen
   Yang, Tianyu
   Li, Zhongfang
   Yu, Xianjin
TI RETRACTED: Terephthalic acid-4,4 '-bipyridine (2/1) (Retracted article.
   See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the title compound, 2C(8)H(6)O(4)center dot C10H8N2, the 4,4'-bipyridine molecule is located on an inversion centre. In the crystal structure, strong intermolecular O-H center dot center dot center dot N hydrogen bonds between the terephthalic acid and 4,4'-bipyridine molecules lead to the formation of chains with graph-set motif C-2(2)(8) along the diagonal of the bc plane.
C1 [Wang, Suwen; Li, Zhongfang; Yu, Xianjin] Shandong Univ Technol, Coll Chem Engn, Zibo 255049, Peoples R China.
   [Yang, Tianyu] NW Univ Xian, Coll Life Sci, Xian 710069, Peoples R China.
RP Li, ZF (reprint author), Shandong Univ Technol, Coll Chem Engn, Zibo 255049, Peoples R China.
EM zhfli_sdut@yahoo.cn
FU NSFC [20776081]; Natural Science Foundation of Shandong Province
   [Y2006B37]
FX The authors thank the NSFC (grant No. 20776081) and the Natural Science
   Foundation of Shandong Province (grant No. Y2006B37).
CR BERNSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555, DOI 10.1002/anie.199515551
   *BRUK AXS INC, 2004, APEX2
   Bruker, 2001, SAINT PLUS SADABS
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Zhang XT, 2007, CRYST GROWTH DES, V7, P1699, DOI 10.1021/cg060723f
   Zhang XT, 2009, INORG CHIM ACTA, V362, P3325, DOI 10.1016/j.ica.2009.03.002
NR 6
TC 1
Z9 1
U1 3
U2 14
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD SEP
PY 2009
VL 65
BP O2198
EP U2403
DI 10.1107/S160053680903236X
PN 9
PG 9
WC Crystallography
SC Crystallography
GA 490SA
UT WOS:000269523400216
PM 21577601
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Li, J
   Zhang, K
   Ye, P
   Wang, S
   Xia, J
AF Li, J.
   Zhang, K.
   Ye, P.
   Wang, S.
   Xia, J.
TI RETRACTED: CCR5 blockade in combination with rapamycin prolongs cardiac
   allograft survival in mice (Retracted article. See vol. 177, pg. 555,
   2014)
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE allograft rejection; anti-CCR5 antibody; cardiac transplantation; immune
   system; rapamycin
ID REGULATORY T-CELLS; CHEMOKINE RECEPTORS; TRANSPLANTATION TOLERANCE;
   GRAFT-REJECTION; DENDRITIC CELLS; TARGETING CCR5; EXPRESSION;
   CD4(+)CD25(+); ARTERIOSCLEROSIS; INFLAMMATION
AB Both chemokine receptor 5 (CCR5) blockade and rapamycin ( rapa) are effective in modulating transplant immunity and led to prolonged allograft survival, yet a great many grafts were ultimately lost to acute rejection. In this study we examined the inhibition of CCR5 in combination with the treatment with rapa in cardiac transplantation. Fully major histocompatibility complex-mismatched murine cardiac allograft models were randomized to five groups. They were administered with anti-CCR5 antibody or control antibody and rapa or phosphate-buffered saline (PBS), respectively. An additional group was treated with anti-CCR5 antibody, rapa and anti-CD25 antibody. Allograft rejection was investigated by flow cytometric analyses and enzyme-linked immunospot assay. Allografts treated with anti-CCR5 antibody plus rapa showed significantly prolonged survival (83 +/- 3 days, P < 0.001) compared with control antibody plus PBS-treated allografts (6 +/- 1 days). Treatment with anti-CCR5 monoclonal antibody (mAb) plus rapa inhibited significantly the progression of chronic rejction. Further analysis of donor hearts in the anti-CCR5 antibody plus rapa-treated group demonstrated increased infiltration of CD4(+)CD25(+)forkhead box P3(+) regulatory T cells, and depletion of CD25(+) cells resulted in acute rejection of allografts in 18 +/- 1 day. CCR5 blockade in combination with rapa is effective in preventing acute and chronic rejection in a robust murine model. This effect is mediated by CD25+ T cell recruitment and control of T lymphocyte proliferation.
C1 [Li, J.; Zhang, K.; Ye, P.; Wang, S.; Xia, J.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiovasc Surg, Wuhan 430022, Peoples R China.
RP Xia, J (reprint author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiovasc Surg, Wuhan 430022, Peoples R China.
EM profxjh@163.com
FU National Natural Science Fund of China [30600574]
FX Sponsored by National Natural Science Fund of China, 30600574.
CR Akashi S, 2005, TRANSPLANTATION, V80, P378, DOI 10.1097/01.tp.0000166338.99933.e1
   Battaglia M, 2005, BLOOD, V105, P4743, DOI 10.1182/blood-2004-10-3932
   CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010
   DALLMAN MJ, 1991, J EXP MED, V174, P493, DOI 10.1084/jem.174.2.493
   ENG CP, 1991, TRANSPLANT P, V23, P868
   Flach R, 1998, CYTOKINE, V10, P445, DOI 10.1006/cyto.1997.0320
   Gabriel TS, 2008, J IMMUNOL, V180, P4714
   Gao W, 2001, TRANSPLANTATION, V72, P1199, DOI 10.1097/00007890-200110150-00003
   Geijtenbeek TBH, 2004, ANNU REV IMMUNOL, V22, P33, DOI 10.1146/annurev.immunol.22.012703.104558
   Graca L, 2002, J IMMUNOL, V168, P5558, DOI 10.4049/jimmunol.168.11.5558
   Groux H, 1997, NATURE, V389, P737
   Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097
   HALL BM, 1990, J EXP MED, V171, P141, DOI 10.1084/jem.171.1.141
   Heredia A, 2003, P NATL ACAD SCI USA, V100, P10411, DOI 10.1073/pnas.1834278100
   Hubeau C, 2007, J IMMUNOL, V178, P1477, DOI 10.4049/jimmunol.178.3.1477
   Karim M, 2004, J IMMUNOL, V172, P923, DOI 10.4049/jimmunol.172.2.923
   Kingsley CI, 2007, TRANSPL INT, V20, P828, DOI 10.1111/j.1432-2277.2007.00533.x
   Kingsley CI, 2002, J IMMUNOL, V168, P1080, DOI 10.4049/jimmunol.168.3.1080
   Koh KP, 2004, J CLIN INVEST, V114, P846, DOI 10.1172/JCI200421767
   KOPF H, 2007, INT IMMUNOPHARMACOL, V15, P1819
   Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706
   Murphy PM, 2000, PHARMACOL REV, V52, P145
   Nagano H, 1997, J CLIN INVEST, V100, P550, DOI 10.1172/JCI119564
   Qu YY, 2007, TRANSPL IMMUNOL, V17, P153, DOI 10.1016/j.trim.2007.01.002
   Raichlin E, 2008, TRANSPLANTATION, V86, P1395, DOI 10.1097/TP.0b013e318189049a
   Saiura A, 2001, TRANSPLANTATION, V72, P320, DOI 10.1097/00007890-200107270-00027
   SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151
   Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N
   Schenk S, 2005, J IMMUNOL, V174, P3741, DOI 10.4049/jimmunol.174.6.3741
   Schroder C, 2007, J IMMUNOL, V179, P2289, DOI 10.4049/jimmunol.179.4.2289
   Sho M, 2002, ANN SURG, V236, P667, DOI 10.1097/01.SLA.0000033322.80911.17
   Sho M, 2002, J IMMUNOL, V169, P3744, DOI 10.4049/jimmunol.169.7.3744
   SINHA SS, 2008, AM HEART J, V889, pE1
   Sozzani S, 1998, J IMMUNOL, V161, P1083
   SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143
   Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221
   Weis M, 1997, CIRCULATION, V96, P2069, DOI 10.1161/01.CIR.96.6.2069
   Wysocki CA, 2005, BLOOD, V106, P3300, DOI 10.1182/blood-2005-04-1632
   YAN L, 2008, TRANSPLANT INT, V21, P483
   Yates SF, 2007, J IMMUNOL, V179, P967, DOI 10.4049/jimmunol.179.2.967
   Yin R, 2007, J HEART LUNG TRANSPL, V26, P485, DOI 10.1016/j.healun.2007.02.006
   Yun JJ, 2004, CIRCULATION, V109, P932, DOI 10.1161/01.CIR.0000112595.65972.8A
NR 43
TC 12
Z9 14
U1 5
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD SEP
PY 2009
VL 157
IS 3
BP 437
EP 445
DI 10.1111/j.1365-2249.2009.03982.x
PG 9
WC Immunology
SC Immunology
GA 474OT
UT WOS:000268294500015
PM 19664153
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Heidari, A
   Tayyari, SF
   Sammelson, RE
AF Heidari, Alireza
   Tayyari, Sayyed Faramarz
   Sammelson, Robert Erik
TI RETRACTED: An analytical approach to the stability of solitary solutions
   of cubic-quintic coupled non-linear Schrodinger equations (Retracted
   article. See vol. 19, pg. 324, 2014)
SO COMMUNICATIONS IN NONLINEAR SCIENCE AND NUMERICAL SIMULATION
LA English
DT Article; Retracted Publication
DE Operators theory; Non-linear optical fibers; Non-linear Schrodinger
   equation; Non-linear effects
ID SOLITONS
AB In this article, the emphasis will be on the analytical investigation of the criterion of stability of solitary solutions of the cubic-quintic coupled non-linear Schrodinger equations (CQCNLSE) governing on the dispersion of electromagnetic pulses in non-linear dielectric medias (non-linear optical fiber) in which there are more than one-mode (because of the presence of binary breakdown of medias or two orthogonal polarized waves). These equations in a special occasion, in which the field amplitudes in two perpendicular directions are equal, possess the solitary solutions. By applying operator theory we will show that the solitary solutions remain stable under subsequent perturbations. Also. we will show that under subsequent perturbations, the first-order Hamiltonian variation of the two coupled fields remains zero and its second-order variation will be positive. Finally, regarding these two notions, it will be concluded that in spite of the coupling of the fields, the solitary solutions of these equations remain stable under subsequent perturbations. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Tayyari, Sayyed Faramarz] Ferdowsi Univ Mashhad, Dept Chem, Mashhad 917751436, Iran.
   [Heidari, Alireza] Islamic Azad Univ, Dept Chem, N Tehran Branch, Tehran, Iran.
   [Sammelson, Robert Erik] Ball State Univ, Dept Chem, Muncie, IN 47306 USA.
RP Tayyari, SF (reprint author), Ferdowsi Univ Mashhad, Dept Chem, Mashhad 917751436, Iran.
EM tayyari@ferdowsi.um.ac.ir
CR Adib B, 2009, COMMUN NONLINEAR SCI, V14, P2034, DOI 10.1016/j.cnsns.2008.07.008
   Agarwal GP, 1995, NONLINEAR FIBER OPTI
   AKHMEDIEV NN, 1997, SOLITONS NONLINEAR B
   Arnold JM, 1999, PHYS REV E, V60, P979, DOI 10.1103/PhysRevE.60.979
   Biswas A, 2003, OPT FIBER TECHNOL, V9, P224, DOI 10.1016/S1068-5200(03)00044-0
   Biswas A, 2006, INTRO NONKERR LAW OP
   Chen YJ, 1998, PHYS REV E, V57, P3542, DOI 10.1103/PhysRevE.57.3542
   Chen YJ, 1998, OPT COMMUN, V150, P381, DOI 10.1016/S0030-4018(98)00012-1
   HASAGAWA A, 1995, SOLITONS OPTICAL COM
   HASEGAWA A, 1989, OPTICAL SOLITONS FIB
   Kapany N. S., 1967, FIBER OPTICS PRINCIP
   KAPANY NS, 1959, J OPT SOC AM, V49, P770, DOI 10.1364/JOSA.49.000770
   Kivshar YS, 1998, OPT QUANT ELECTRON, V30, P571, DOI 10.1023/A:1006972912953
   KUZNETSOV EA, 1986, PHYS REP, V142, P103, DOI 10.1016/0370-1573(86)90016-5
   MITCHELL DJ, 1993, J OPT SOC AM B, V10, P1572, DOI 10.1364/JOSAB.10.001572
   PALAIS JC, 1988, FIBER OPTICS COMMUNI
NR 16
TC 2
Z9 2
U1 4
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1007-5704
EI 1878-7274
J9 COMMUN NONLINEAR SCI
JI Commun. Nonlinear Sci. Numer. Simul.
PD SEP-OCT
PY 2009
VL 14
IS 9-10
BP 3554
EP 3560
DI 10.1016/j.cnsns.2009.02.005
PG 7
WC Mathematics, Applied; Mathematics, Interdisciplinary Applications;
   Mechanics; Physics, Fluids & Plasmas; Physics, Mathematical
SC Mathematics; Mechanics; Physics
GA 440PM
UT WOS:000265712200009
DA 2018-12-27
ER

PT J
AU Zhao, Z
   Xu, N
   Nakamura, M
   Ikegami, Y
AF Zhao, Zhong
   Xu, Ning
   Nakamura, M.
   Ikegami, Y.
TI RETRACTED: Direct adaptive control based on gradient estimation and
   industrial application (Retracted article. See vol. 19, pg. 522, 2011)
SO CONTROL ENGINEERING PRACTICE
LA English
DT Article; Retracted Publication
DE Direct adaptive control; Embedding property; Gradient estimation; Robust
   convergence; Static control error; Polypropylene process
ID TIME NONLINEAR-SYSTEMS; NEURAL-NETWORKS; WAVELET TRANSFORM; PID CONTROL;
   NN CONTROL; IDENTIFICATION
AB A control method of direct adaptive control based on gradient estimation is proposed in this paper. The dynamic system is embedded in a linear model set. Based on the embedding property of the dynamic system, an adaptive optimal control algorithm is proposed. The robust convergence of the proposed control algorithm has been proved and the static control error with the proposed method is also analyzed. The application results of the proposed method to the industrial polypropylene process have verified its feasibility and effectiveness. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Zhao, Zhong] Beijing Inst Chem Technol, Dept Automat, Beijing 100029, Peoples R China.
   [Xu, Ning] SINOPEC Corp, Beijing Res Inst Chem Technol, Beijing 100023, Peoples R China.
   [Nakamura, M.] Saga Univ, Dept Adv Syst Control Engn, Grad Sch Sci & Engn, Saga 8408502, Japan.
   [Ikegami, Y.] Saga Univ, Inst Ocean Energy, Saga 8408502, Japan.
RP Zhao, Z (reprint author), Beijing Inst Chem Technol, Dept Automat, POB 81,Beisanhuan E Rd 15, Beijing 100029, Peoples R China.
EM zhaozhong@mail.buct.edu.cn
CR ASTROM KJ, 1992, AUTOMATICA, V28, P1
   CHUI CK, 1990, INTRO WAVELET
   DAUBECHIES I, 1990, IEEE T INFORM THEORY, V36, P961, DOI 10.1109/18.57199
   Fang C., 1988, PROCESS IDENTIFICATI
   Ge SS, 2003, AUTOMATICA, V39, P807, DOI 10.1016/S0005-1098(03)00032-3
   Ge SS, 2003, INT J CONTROL, V76, P334, DOI 10.1080/0020717031000073063
   Levin AU, 1996, IEEE T NEURAL NETWOR, V7, P30, DOI 10.1109/72.478390
   LEVIN AU, 1993, IEEE T NEURAL NETWOR, V4, P192, DOI 10.1109/72.207608
   Lewis FL, 1996, IEEE T NEURAL NETWOR, V7, P388, DOI 10.1109/72.485674
   MALLAT SG, 1989, IEEE T PATTERN ANAL, V11, P674, DOI 10.1109/34.192463
   MARSIK J, 1989, AUTOMATICA, V25, P273, DOI 10.1016/0005-1098(89)90081-2
   Narendra K S, 1990, IEEE Trans Neural Netw, V1, P4, DOI 10.1109/72.80202
   Polycarpou MM, 1996, IEEE T AUTOMAT CONTR, V41, P447, DOI 10.1109/9.486648
   Qin SJ, 2003, CONTROL ENG PRACT, V11, P733, DOI 10.1016/S0967-0661(02)00186-7
   RARDIN, 1998, OPTIMIZATION OPERATI
   Rugh WJ, 2000, AUTOMATICA, V36, P1401, DOI 10.1016/S0005-1098(00)00058-3
   Sjoberg J, 2009, CONTROL ENG PRACT, V17, P311, DOI 10.1016/j.conengprac.2008.08.001
   Smith O. J. M., 1957, CHEMICAL ENGINEERING, V53, P217
   Spall JC, 1997, IEEE T SYST MAN CY B, V27, P369, DOI 10.1109/3477.584945
   Spall JC, 1998, IEEE T AUTOMAT CONTR, V43, P1198, DOI 10.1109/9.718605
   YESILDIREK A, 1995, AUTOMATICA, V31, P1659, DOI 10.1016/0005-1098(95)00078-B
   Yu DL, 2007, CONTROL ENG PRACT, V15, P1577, DOI 10.1016/j.conengprac.2007.02.004
   Zhao Z, 2003, J PROCESS CONTR, V13, P41, DOI 10.1016/S0959-1524(02)00012-4
   Zhao Z, 2000, J CHEM ENG JPN, V33, P823, DOI 10.1252/jcej.33.823
NR 24
TC 1
Z9 1
U1 2
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0967-0661
EI 1873-6939
J9 CONTROL ENG PRACT
JI Control Eng. Practice
PD SEP
PY 2009
VL 17
IS 9
BP 1065
EP 1075
DI 10.1016/j.conengprac.2009.04.004
PG 11
WC Automation & Control Systems; Engineering, Electrical & Electronic
SC Automation & Control Systems; Engineering
GA 487RW
UT WOS:000269294000009
DA 2018-12-27
ER

PT J
AU Yassin, MF
   Kellnerova, R
   Janour, Z
AF Yassin, Mohamed F.
   Kellnerova, R.
   Janour, Z.
TI RETRACTED: Numerical simulation on pollutant dispersion from vehicle
   exhaust in street configurations(Retracted article. See vol. 189, 2017)
SO ENVIRONMENTAL MONITORING AND ASSESSMENT
LA English
DT Article; Retracted Publication
DE Atmospheric turbulent; CFD model; Pollutant dispersion; Street
   configurations
ID AIR-QUALITY; CANYON; FLOW; MODEL
AB The impact of the street configurations on pollutants dispersion from vehicles exhausts within urban canyons was numerically investigated using a computational fluid dynamics (CFD) model. Three-dimensional flow and dispersion of gaseous pollutants were modeled using standard kappa -aEuro parts per thousand epsilon turbulence model, which was numerically solved based on Reynolds-averaged Navier-Stokes equations by the commercial CFD code FLUENT. The concentration fields in the urban canyons were examined in three cases of street configurations: (1) a regular-shaped intersection, (2) a T-shaped intersection and (3) a Skew-shaped crossing intersection. Vehicle emissions were simulated as double line sources along the street. The numerical model was validated against wind tunnel results in order to optimize the turbulence model. Numerical predictions agreed reasonably well with wind tunnel results. The results obtained indicate that the mean horizontal velocity was very small in the center near the lower region of street canyon. The lowest turbulent kinetic energy was found at the separation and reattachment points associated with the corner of the down part of the upwind and downwind buildings in the street canyon. The pollutant concentration at the upwind side in the regular-shaped street intersection was higher than that in the T-shaped and Skew-shaped street intersections. Moreover, the results reveal that the street intersections are important factors to predict the flow patterns and pollutant dispersion in street canyon.
C1 [Yassin, Mohamed F.] Kuwait Univ, Dept Environm Technol Management, Coll Women, Safat 13060, Kuwait.
   [Yassin, Mohamed F.] Assiut Univ, Fac Engn, Assiut 71516, Egypt.
   [Kellnerova, R.; Janour, Z.] AS CR, Inst Thermomech, Prague, Czech Republic.
RP Yassin, MF (reprint author), Kuwait Univ, Dept Environm Technol Management, Coll Women, PO B5969, Safat 13060, Kuwait.
EM mohamed_f_yassin@hotmail.com
RI Janour, Zbynek/G-8079-2014; Kellnerova, Radka/G-7330-2014
CR Ahmadi G, 2000, J WIND ENG IND AEROD, V84, P23, DOI 10.1016/S0167-6105(99)00048-3
   Assimakopoulos VD, 2003, ATMOS ENVIRON, V37, P4037, DOI 10.1016/S1352-2310(03)00533-8
   Baik JJ, 1999, J APPL METEOROL, V38, P1576, DOI 10.1175/1520-0450(1999)038<1576:ANSOFA>2.0.CO;2
   Baik JJ, 2007, ATMOS ENVIRON, V41, P934, DOI 10.1016/j.atmosenv.2006.09.018
   Chan AT, 2003, ATMOS ENVIRON, V37, P2761, DOI 10.1016/1352-2310(03)00252-8
   Chan TL, 2002, ATMOS ENVIRON, V36, P861, DOI 10.1016/S1352-2310(01)00490-3
   *FLUENT INC, 2005, FLUENT 6 2 16 US MAN
   Hassan AA, 1998, ENVIRON MONIT ASSESS, V52, P281, DOI 10.1023/A:1005928630000
   Huang H, 2000, ATMOS ENVIRON, V34, P689, DOI 10.1016/S1352-2310(99)00333-7
   JANOUR Z, 2007, 6 INT C URB AIR QUAL
   Kim JJ, 2003, J WIND ENG IND AEROD, V91, P309, DOI 10.1016/S0167-6105(02)00395-1
   Koutsourakis N, 2005, INT J ENVIRON POLLUT, V25, P155, DOI 10.1504/IJEP.2005.007663
   Launder B. E., 1974, Computer Methods in Applied Mechanics and Engineering, V3, P269, DOI 10.1016/0045-7825(74)90029-2
   Leitl BM, 1997, J WIND ENG IND AEROD, V67-8, P293, DOI 10.1016/S0167-6105(97)00080-9
   Mensink C., 2002, WATER AIR SOIL POLL, V2, P339, DOI 10.1023/A:1021303922031
   Neofytou P, 2006, ENVIRON MODELL SOFTW, V21, P525, DOI 10.1016/j.envsoft.2004.08.012
   Patankar SV, 1980, NUMERICAL HEAT TRANS
   Sahm P., 2002, WATER AIR SOIL POLL, V2, P587
   Sini JF, 1996, ATMOS ENVIRON, V30, P2659, DOI 10.1016/1352-2310(95)00321-5
   Xie XM, 2005, ATMOS ENVIRON, V39, P4519, DOI 10.1016/j.atmosenv.2005.03.043
NR 20
TC 8
Z9 8
U1 3
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6369
EI 1573-2959
J9 ENVIRON MONIT ASSESS
JI Environ. Monit. Assess.
PD SEP
PY 2009
VL 156
IS 1-4
BP 257
EP 273
DI 10.1007/s10661-008-0482-4
PG 17
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 480ZQ
UT WOS:000268776400020
PM 18726702
DA 2018-12-27
ER

PT J
AU Portin, P
AF Portin, Petter
TI RETRACTED: The effect of the mus309 mutation, defective in DNA
   double-strand break repair, on crossing over in Drosophila melanogaster
   suggests a mechanism for interference (Retracted article. See vol. 148,
   pg. 50, 2011)
SO HEREDITAS
LA English
DT Article; Retracted Publication
ID SYNDROME GENE-PRODUCT; MEIOTIC RECOMBINATION; CHIASMA INTERFERENCE; SGS1
   HELICASE; X-CHROMOSOME; BLM HELICASE; MUTANTS; MEIOSIS; INITIATION;
   RESOLUTION
AB The mus309 gene in Drosophila melanogaster encodes a RecQ helicase which is involved in DNA double-strand break (DSB) repair. In a brood pattern analysis, it was observed that in mus309 mutant females, the frequency of single crossovers in the central cv - v interval of the X chromosome was decreased in young females but returned to the level of the wild type control as the females aged. In the proximal v - f interval, the frequency of single crossovers was increased during the whole experimental period. In particular, it was observed that the frequency of double crossovers, as well as the coefficient of coincidence first increased but then gradually decreased, finally reaching the level of the control flies, as the females aged. Map distances increased due to the mus309 mutation in both gene interval studies, but they did not change as the females aged, a result suggesting that the mus309 gene controls the distribution of DSBs to be repaired as crossovers instead of non-crossovers. The results are consistent with the hypothesis that in general the DSBs are initially independently distributed on the chromosome but non-randomly repaired so that the distribution of crossovers in the mutant flies becomes uniform, but uneven in wild-type flies. The results are consistent with the counting number model of crossover interference, based on genetic distance. On the other hand, the data are not consistent with the reaction-diffusion model based on physical distance. Consequently, the view that crossover interference in Drosophila is tightly tied to genetic distance is supported.
C1 Univ Turku, Dept Biol, Genet Lab, FIN-20014 Turku, Finland.
RP Portin, P (reprint author), Univ Turku, Dept Biol, Genet Lab, FIN-20014 Turku, Finland.
EM petter.portin@utu.fi
CR Adams MD, 2003, SCIENCE, V299, P265, DOI 10.1126/science.1077198
   Baker B. S., 1976, GENETICS BIOL DROS B, V1, P351
   BAKER BS, 1972, GENETICS, V71, P255
   Beadle GW, 1932, P NATL ACAD SCI USA, V18, P160, DOI 10.1073/pnas.18.2.160
   Beall EL, 1996, GENE DEV, V10, P921, DOI 10.1101/gad.10.8.921
   BOYD JB, 1981, GENETICS, V97, P607
   BOYD JB, 1987, J CELL SCI, P39
   BRABANT AJ, 2000, ANNU REV GENOM HUM G, V1, P409
   Bridges CB, 1915, J EXP ZOOL, V19, P1, DOI 10.1002/jez.1400190102
   Bridges CB, 1927, J GEN PHYSIOL, V8, P689, DOI 10.1085/jgp.8.6.689
   ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1
   FOSS E, 1993, GENETICS, V133, P681
   Fujitani Y, 2002, GENETICS, V161, P365
   Gravel S, 2008, GENE DEV, V22, P2767, DOI 10.1101/gad.503108
   GRELL RF, 1973, GENETICS, V73, P87
   Haldane JBS, 1919, J GENET, V8, P299
   Heyer WD, 2003, TRENDS BIOCHEM SCI, V28, P548, DOI 10.1016/j.tibs.2003.08.011
   Heyer WD, 2004, CURR BIOL, V14, pR56, DOI 10.1016/j.cub.2003.12.043
   Hillers KJ, 2004, CURR BIOL, V14, pR1036, DOI 10.1016/j.cub.2004.11.038
   Ip SCY, 2008, NATURE, V456, P357, DOI 10.1038/nature07470
   Johnson-Schlitz D, 2006, P NATL ACAD SCI USA, V103, P16840, DOI 10.1073/pnas.0607904103
   Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611
   Keeney S, 2006, BIOCHEM SOC T, V34, P523, DOI 10.1042/BST0340523
   Keeney S, 2001, CURR TOP DEV BIOL, V52, P1, DOI 10.1016/S0070-2153(01)52008-6
   Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0
   Kusano K, 2001, SCIENCE, V291, P2600, DOI 10.1126/science.291.5513.2600
   LAKE S, 1984, HEREDITAS, V100, P121, DOI 10.1111/j.1601-5223.1984.tb00113.x
   LANDE R, 1993, COLD SPRING HARB SYM, V58, P543, DOI 10.1101/SQB.1993.058.01.061
   Laurencon A, 2004, GENETICS, V167, P217, DOI 10.1534/genetics.167.1.217
   Lorenz A, 2006, BIOCHEM SOC T, V34, P537, DOI 10.1042/BST0340537
   LUNING KG, 1983, HEREDITAS, V99, P57, DOI 10.1111/j.1601-5223.1983.tb00732.x
   Martini E, 2006, CELL, V126, P285, DOI 10.1016/j.cell.2006.05.044
   Mather K, 1939, GENETICS, V24, P413
   McVey M, 2004, P NATL ACAD SCI USA, V101, P15694, DOI 10.1073/pnas.0406157101
   Mcvey M, 2007, GENETICS, V176, P1979, DOI 10.1534/genetics.106.070052
   Mimitou EP, 2008, NATURE, V455, P770, DOI 10.1038/nature07312
   Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843
   MORTIMER RK, 1974, MECHANISMS RECOMBINA, P263
   Muller HJ, 1916, AM NAT, V50, P193, DOI 10.1086/279534
   OLSENKROGH B, 2004, ANNU REV GENET, V38, P233
   Portin P, 2005, GENET RES, V86, P185, DOI 10.1017/S0016672305007883
   Portin P, 2008, GENET RES, V90, P297, DOI 10.1017/S0016672308009397
   Raynard S, 2008, GENE DEV, V22, P2903, DOI 10.1101/gad.1742408
   Rockmill B, 2003, CURR BIOL, V13, P1954, DOI 10.1016/j.cub.2003.10.059
   SANDLER L, 1968, GENETICS, V60, P525
   Stevens WL, 1936, J GENET, V32, P51, DOI 10.1007/BF02982501
   Sturtevant A. H., 1915, Zs indukt Abstamm Berlin, V13, DOI 10.1007/BF01792906
   Weinert BT, 2007, NUCLEIC ACIDS RES, V35, P1367, DOI 10.1093/nar/gkl831
   Weinstein A, 1936, GENETICS, V21, P155
   Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200
   Zhu Z, 2008, CELL, V134, P981, DOI 10.1016/j.cell.2008.08.037
NR 51
TC 1
Z9 1
U1 3
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1601-5223
J9 HEREDITAS
JI Hereditas
PD SEP
PY 2009
VL 146
IS 4
BP 162
EP 176
DI 10.1111/j.1601-5223.2009.02144.x
PG 15
WC Genetics & Heredity
SC Genetics & Heredity
GA 495OP
UT WOS:000269903400004
PM 19765096
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Jung, SW
   Kang, NY
AF Jung, Seok Won
   Kang, Nam Yeo
TI RETRACTED: A case of nodular fasciitis in the upper eyelid (Retracted
   article. See vol. 57, pg. 495, 2013)
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Letter; Retracted Publication
DE eyelid mass; eyelid tumor; nodular fasciitis
ID MASS
C1 [Jung, Seok Won] Sahmyook Med Ctr, Dept Ophthalmol, Seoul, South Korea.
   [Jung, Seok Won] Konyang Univ, Coll Med, Kims Eye Hosp, Seoul, South Korea.
   [Kang, Nam Yeo] Catholic Univ Korea, Coll Med, Dept Ophthalmol & Visual Sci, Seoul, South Korea.
RP Kang, NY (reprint author), Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Holy Family Hosp, Coll Med, 2 Sosa Dong, Puchon 420717, South Korea.
EM nyeokang@hanmail.net
CR de Paula SA, 2006, OPHTHAL PLAST RECONS, V22, P494, DOI 10.1097/01.iop.0000242164.13642.6a
   Enzinger FM, 1995, SOFT TISSUE TUMORS, P165
   Hymas DC, 1999, OPHTHALMIC PLAST REC, V15, P139, DOI 10.1097/00002341-199903000-00015
   Meffert JJ, 1996, INT J DERMATOL, V35, P548, DOI 10.1111/j.1365-4362.1996.tb03652.x
   VESTAL KP, 1990, OPHTHALMIC PLAST REC, V6, P130, DOI 10.1097/00002341-199006000-00010
NR 5
TC 2
Z9 2
U1 5
U2 14
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP
PY 2009
VL 53
IS 5
BP 546
EP 548
DI 10.1007/s10384-009-0707-2
PG 3
WC Ophthalmology
SC Ophthalmology
GA 509OF
UT WOS:000271026600020
PM 19847614
DA 2018-12-27
ER

PT J
AU Lin, XH
   Zhang, TW
AF Lin, Xianghong
   Zhang, Tianwen
TI RETRACTED: EFFECTS OF MUTATION OPERATORS ON DEVELOPMENTAL BIAS IN
   ARTIFICIAL CELL LINEAGES (Retracted article. See vol. 18, pg. 531, 2010)
SO JOURNAL OF BIOLOGICAL SYSTEMS
LA English
DT Article; Retracted Publication
DE Artificial Genome; Gene Regulatory Networks; Cell Lineages;
   Developmental Bias; Mutation Operators
ID PHENOTYPIC EVOLUTION; EVO-DEVO; DUPLICATION; MECHANISMS; COMPLEXITY;
   DIVERSITY; DIRECTION; DIVISION; QUESTION; BIOLOGY
AB There is a growing recognition that natural selection is not the sole determinant of the direction of evolutionary change. Recent work has attempted to show the importance of developmental bias in shaping organic form. Using the artificial genome model as a framework for describing gene regulatory networks, biologically grounded mutation operators can be mapped to network level mutations that reprogram developmental trajectories. We use a computational model of a developmental system to generate random organisms with different levels of phenotypic complexity and analyze mutation operators for their effects on developmental bias. We find that developmental bias exists in the model system and varies with the model parameter. We also show that developmental bias varies strongly with phenotypic complexity and mutation operator. Finally, we illustrate how developmental bias affects the direction of evolutionary modification from the manner in which accumulated mutations cause an increase in phenotypic complexity. These results suggest that mutation operators could have strong influences on developmental bias.
C1 [Lin, Xianghong; Zhang, Tianwen] Harbin Inst Technol, Sch Comp Sci & Technol, Harbin 150001, Peoples R China.
   [Lin, Xianghong] NW Normal Univ, Sch Math & Informat Sci, Lanzhou 730070, Peoples R China.
RP Lin, XH (reprint author), Harbin Inst Technol, Sch Comp Sci & Technol, POB 321, Harbin 150001, Peoples R China.
EM waihh@hit.edu.cn; twzhang@hit.edu.cn
CR ALBERCH P, 1985, EVOLUTION, V39, P8, DOI 10.1111/j.1558-5646.1985.tb04076.x
   ALBERTS B., 1994, MOL BIOL CELL
   Arthur W, 2004, EVOL DEV, V6, P282, DOI 10.1111/j.1525-142X.2004.04033.x
   Arthur W, 2002, HEREDITY, V89, P239, DOI 10.1038/sj.hdy.6800139
   Arthur W, 2002, NATURE, V415, P757
   Arthur W, 2001, EVOL DEV, V3, P271, DOI 10.1046/j.1525-142x.2001.003004271.x
   Arthur W, 2004, BIASED EMBRYOS EVOLU
   Azevedo RBR, 2005, NATURE, V433, P152, DOI 10.1038/nature03102
   Azevedo RBR, 2002, GENETICS, V162, P755
   BANZHAF W, 2003, P 7 EUR C ART LIF, P217
   Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447
   Bonner J, 1988, EVOLUTION COMPLEXITY
   Brakefield PM, 2003, ANNU REV ECOL EVOL S, V34, P633, DOI 10.1146/annurev.ecolsys.34.011802.132425
   Braun V, 2003, BIOINFORMATICS, V19, P851, DOI 10.1093/bioinformatics/btg087
   CARROLL SB, 2001, DNA DIVERSITY MOL GE
   Fusco G, 2001, EVOL DEV, V3, P279, DOI 10.1046/j.1525-142x.2001.003004279.x
   Gilbert SF, 1996, DEV BIOL, V173, P357, DOI 10.1006/dbio.1996.0032
   Gomez-Mestre I, 2006, P NATL ACAD SCI USA, V103, P19021, DOI 10.1073/pnas.0603562103
   GOULD SJ, 1979, PROC R SOC SER B-BIO, V205, P581, DOI 10.1098/rspb.1979.0086
   Hall BK, 1999, EVOLUTIONARY DEV BIO
   Hallinan J., 2004, P 2 AS PAC BIOINF C, P291
   He XL, 2005, GENETICS, V169, P1157, DOI 10.1534/genetics.104.037051
   HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R
   Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085
   Kopp A, 2000, NATURE, V408, P553, DOI 10.1038/35046017
   KOUFOPANOU V, 1991, EVOLUTION, V45, P1806, DOI 10.1111/j.1558-5646.1991.tb02689.x
   Kuo PD, 2006, BIOSYSTEMS, V85, P177, DOI 10.1016/j.biosystems.2006.01.004
   Lohaus R, 2007, P ROY SOC B-BIOL SCI, V274, P1741, DOI 10.1098/rspb.2007.0399
   McShea DW, 1996, EVOLUTION, V50, P477, DOI 10.1111/j.1558-5646.1996.tb03861.x
   McShea DW, 2001, J EVOLUTION BIOL, V14, P502, DOI 10.1046/j.1420-9101.2001.00283.x
   Psujek S, 2008, EVOL DEV, V10, P375, DOI 10.1111/j.1525-142X.2008.00245.x
   Quayle AP, 2006, J THEOR BIOL, V238, P737, DOI 10.1016/j.jtbi.2005.06.020
   Raff RA, 2000, NAT REV GENET, V1, P74, DOI 10.1038/35049594
   REIL T, 1999, P 5 EUR C ART LIF, P457
   Salazar-Ciudad I, 2004, EVOL DEV, V6, P6, DOI 10.1111/j.1525-142X.2004.04002.x
   Schuster P, 1999, PHYSICA D, V133, P427, DOI 10.1016/S0167-2789(99)00076-7
   Watson J, 2004, BIOSYSTEMS, V76, P239, DOI 10.1016/j.biosystems.2004.05.016
   Wray GA, 2003, INT J DEV BIOL, V47, P675
   Yampolsky LY, 2001, EVOL DEV, V3, P73, DOI 10.1046/j.1525-142x.2001.003002073.x
   Zhang JZ, 2003, TRENDS ECOL EVOL, V18, P292, DOI 10.1016/S0169-5347(03)00033-8
NR 40
TC 0
Z9 0
U1 4
U2 11
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0218-3390
EI 1793-6470
J9 J BIOL SYST
JI J. Biol. Syst.
PD SEP
PY 2009
VL 17
IS 3
BP 491
EP 509
DI 10.1142/S0218339009002892
PG 19
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA 485LV
UT WOS:000269124600008
DA 2018-12-27
ER

PT J
AU Wang, WR
   Chair, SY
   Thompson, DR
   Twinn, SF
AF Wang, Wenru
   Chair, Sek Ying
   Thompson, David R.
   Twinn, Sheila F.
TI RETRACTED: A psychometric evaluation of the Chinese version of the
   Hospital Anxiety and Depression Scale in patients with coronary heart
   disease (Retracted Article. See vol 18, pg 3068, 2009)
SO JOURNAL OF CLINICAL NURSING
LA English
DT Article; Retracted Publication
DE Chinese; coronary heart disease; cross-cultural validation; nurses;
   nursing; psychological distress
ID MYOCARDIAL-INFARCTION; VALIDITY; VALIDATION; CANCER; SAMPLE
AB Aim.
   To evaluate further the psychometric properties of the Chinese version of the Hospital Anxiety and Depression Scale (HADS) as a screening instrument for anxiety and depression in Chinese patients with coronary heart disease in Xian, China.
   Background.
   There is considerable evidence that anxiety and depression are common in patients with coronary heart disease (CHD) and are associated with increased morbidity and mortality. A valid, reliable and sensitive screening tool that can be used readily on this group of patients would be useful for assessment, intervention and outcome evaluation.
   Design.
   A single group, cross-sectional study.
   Method.
   Measurement performance was tested on 314 Chinese patients with coronary heart disease and repeated on 173 of them two weeks later.
   Results.
   The Chinese version of HADS (C-HADS) had acceptable internal consistency and test-retest reliability, with a Cronbach alpha of 0 center dot 85 and intraclass correlation coefficient of 0 center dot 90, respectively. There was acceptable concurrent validity with significant (p < 0 center dot 05) correlations between the anxiety and depression subscales of the C-HADS and CHD patients' perceived health status as measured by the Chinese Mandarin version of the Short Form-36 health survey (CM:SF-36). Principal components analysis revealed a three-factor solution accounting for 53% of the total variance. The three underlying sub-scale dimensions are depression, psychic anxiety and psychomotor anxiety. The responsiveness of the C-HADS was also satisfactory with significant correlation between the changes in the C-HADS score and the changes in the Mental Health domain of the CM:SF-36 (p < 0 center dot 01). Finally, over one-third of the patients demonstrated psychological distress.
   Conclusion.
   Empirical data support the C-HADS as a reliable and valid screening instrument for the assessment of anxiety and depression in Chinese-speaking patients with CHD. A tri-dimensional scoring approach should be considered as potentially clinically useful for this group of patients.
   Relevance to clinical practice.
   The C-HADS can guide and evaluate the delivery of psychological care for Chinese patients with CHD.
C1 [Wang, Wenru; Chair, Sek Ying; Twinn, Sheila F.] Chinese Univ Hong Kong, Nethersole Sch Nursing, Hong Kong, Hong Kong, Peoples R China.
   [Thompson, David R.] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England.
   [Thompson, David R.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England.
RP Wang, WR (reprint author), Chinese Univ Hong Kong, Nethersole Sch Nursing, Hong Kong, Hong Kong, Peoples R China.
EM wwenru@yahoo.com.cn
RI Chair, Sek Ying/G-9965-2016; Thompson, David/C-6320-2009; Thompson,
   David/E-2431-2018
OI Chair, Sek Ying/0000-0003-2387-7035; Thompson,
   David/0000-0001-8518-6307; Wang, Wenru/0000-0002-0265-8215
CR Beck AT., 1996, BECK DEPRESSION INVE
   Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
   Comrey A. L., 1992, 1 COURSE FACTOR ANAL
   Costantini M, 1999, SUPPORT CARE CANCER, V7, P121, DOI 10.1007/s005200050241
   Costello AB, 2005, PRACTICAL ASSESSMENT, V10, P1, DOI DOI 10.1316/S0782-051X03024046-9
   ENDLER NS, 1991, ENDLER MULTIDIMENSIO
   Freedland KE, 2002, PSYCHOSOM MED, V64, P897, DOI 10.1097/01.PSY.0000028826.64279.29
   Friedman S, 2001, PSYCHIAT RES, V104, P247, DOI 10.1016/S0165-1781(01)00309-2
   Glassman Alexander, 2003, J Psychiatr Pract, V9, P409, DOI 10.1097/00131746-200311000-00004
   GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5
   GUYATT GH, 1989, J GEN INTERN MED, V4, P101, DOI 10.1007/BF02602348
   Guyatt GH, 1996, QUALITY LIFE PHARMAC, P41
   Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4
   Kocovski NL, 2004, J PSYCHOPATHOL BEHAV, V26, P165, DOI 10.1023/B:JOBA.0000022108.20386.c9
   Lett HS, 2005, PSYCHOSOM MED, V67, pS58, DOI 10.1097/01.psy.0000163453.24417.97
   Leung C M, 1993, Int J Psychosom, V40, P29
   Leung CM, 1999, ACTA PSYCHIAT SCAND, V100, P456, DOI 10.1111/j.1600-0447.1999.tb10897.x
   LIU SJ, 2001, ACAD J W CHINA U MED, V32, P39
   MacCallum RC, 1999, PSYCHOL METHODS, V4, P84, DOI 10.1037/1082-989X.4.1.84
   Martin C R, 2000, Psychol Health Med, V5, P193, DOI 10.1080/713690189
   Martin CR, 2006, CURR PSYCHIATRY REV, V2, P245, DOI 10.2174/157340006776875923
   Martin CR, 2004, PSYCHIAT RES, V129, P279, DOI 10.1016/j.psychres.2004.06.012
   MOOREY S, 1991, BRIT J PSYCHIAT, V158, P255, DOI 10.1192/bjp.158.2.255
   Philp F., 2006, PRIMARY CARE MENTAL, V4, P159
   Polit D., 2004, NURSING RES PRINCIPL
   Portney LG, 2000, FDN CLIN RES APPL PR
   Samaan Z, 2008, J PSYCHOSOM RES, V65, P103, DOI 10.1016/j.jpsychores.2008.06.008
   *SCI ADV COMM, 1995, MED OUTCOMES TRUST B, V3, pR1
   Spielberger CD, 1983, MANUAL STATE TRAIT A
   Stevens L, 1996, APPL MULTIVARIATE ST, V3rd
   van Melle JP, 2004, PSYCHOSOM MED, V66, P814, DOI 10.1097/01.psy.0000146294.82810.9c
   Wang H, 2008, PERFORM EVALUATION, V65, P129, DOI 10.1016/j.peva.2007.05.005
   WANG W, 2006, HEALTH QUAL LIFE OUT, V4, P1
   Wang WR, 2006, QUAL LIFE RES, V15, P1525, DOI 10.1007/s11136-006-0012-1
   Wang YL, 2004, J UNIV SCI TECHNOL B, V11, P57
   XIE Y, 2005, CHINESE J NURSE TRAI, V2, P24
   ZHANG LM, 2001, CHINESE J ZHEJIANG C, V2, P83
   Zhang XH, 2008, HEART, V94, P1126, DOI 10.1136/hrt.2007.132423
   ZHENG L, 2003, SHANGHAI ARCH PSYCHI, V15, P264, DOI DOI 10.3969/J.ISSN.1002-0829.2003.05.003
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 40
TC 14
Z9 14
U1 5
U2 19
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0962-1067
J9 J CLIN NURS
JI J. Clin. Nurs.
PD SEP
PY 2009
VL 18
IS 17
BP 2436
EP 2443
DI 10.1111/j.1365-2702.2009.02807.x
PG 8
WC Nursing
SC Nursing
GA 480TM
UT WOS:000268759700006
PM 19694877
DA 2018-12-27
ER

PT J
AU Guerra, DL
   Viana, RR
   Airoldi, C
AF Guerra, Denis L.
   Viana, Rubia R.
   Airoldi, Claudio
TI RETRACTED: Designed pendant chain covalently bonded to analogue of
   heulandite for removal of divalent toxic metals from aqueous solution:
   Thermodynamic and equilibrium study (Retracted article. See vol. 357,
   pg. 559, 2011)
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article; Retracted Publication
DE Heulandite; Toxic metals; Adsorption; Calorimetry; Thermodynamic
ID SILICA-GEL; MESOPOROUS SILICA; CATION REMOVAL; ADSORPTION; SORPTION;
   INTERCALATION; EUROPIUM(III); TEMPERATURE; THORIUM(IV); MAGADIITE
AB An analogue of heulandite was synthesized by using inorganic salts as a source for silicon and aluminum in the hydrothermal synthesis of the material. The resulting solid was modified by organofunctionalization with 1,4-bis(3-aminopropyl)piperazine and subsequent reaction with methylacrylate in a heterogeneous route. The original (HEU) and modified silicate (HEUAPPMA) samples were characterized by textural analysis, SEM, and nuclear magnetic nuclei of Si-29 and C-13. The chemically modified silicate sample showed modification of its physical-chemical properties including specific area 459.0-978.8 m(2) g(-1). The ability of this material to remove nickel(II), cobalt(II), and copper(II) from aqueous solutions was followed by a series of adsorption isotherms adjusted to a Sips equation. The quick adsorption process reached the equilibrium before 10, 15, and 20 min for Cu(II), Ni(II), and Co(II), respectively, with maximum adsorptions at pH 4.0. Based on the capacity of adsorption of HEUAPPMA to interact with metal ions, the following results were obtained 12.9, 9.8, and 7.5 mmol g(-1) for Cu(II), Ni(II), and Co(II), respectively, reflecting a maximum adsorption order of Cu(II) > Ni(II) > Co(II). The energetic effects caused by metal cation adsorption were determined through calorimetric titrations. (C) 2009 Published by Elsevier Inc.
C1 [Guerra, Denis L.; Airoldi, Claudio] Univ Estadual Campinas, Inst Chem, BR-13084971 Campinas, SP, Brazil.
   [Viana, Rubia R.] Univ Fed Mato Grosso, UFMT, Ctr Recursos Minerais, BR-78060900 Cuiaba, Mato Grosso, Brazil.
RP Guerra, DL (reprint author), Univ Estadual Campinas, Inst Chem, POB 6154, BR-13084971 Campinas, SP, Brazil.
EM dlguerra@iqm.unicamp.br
FU CNPq; FAPESP
FX The authors are indebted to CNPq for fellowships and FAPESP for
   financial support.
CR Arenas LT, 2004, MATER LETT, V58, P895, DOI 10.1016/j.matlet.2003.07.031
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Cestaria AR, 2009, J HAZARD MATER, V161, P307, DOI 10.1016/j.jhazmat.2008.03.091
   Dey RK, 2008, J HAZARD MATER, V156, P95, DOI 10.1016/j.jhazmat.2007.12.005
   Dias NL, 1998, COLLOID SURFACE A, V144, P219, DOI 10.1016/S0927-7757(98)00569-X
   Evangelista SM, 2007, SURF SCI, V601, P2194, DOI 10.1016/j.susc.2007.03.020
   FYFE CA, 1982, NATURE, V296, P530, DOI 10.1038/296530a0
   Guerra DL, 2008, J HAZARD MATER, V155, P230, DOI 10.1016/j.jhazmat.2007.11.054
   Guerra DL, 2008, J SOLID STATE CHEM, V181, P2507, DOI 10.1016/j.jssc.2008.06.028
   Guerra DL, 2008, J SOLID STATE CHEM, V181, P3374, DOI 10.1016/j.jssc.2008.09.006
   Ho YS, 1999, PROCESS BIOCHEM, V34, P451, DOI 10.1016/S0032-9592(98)00112-5
   Komiyama M, 2004, APPL SURF SCI, V237, P503, DOI 10.1016/j.apsusc.2004.06.114
   Lagergren S, 1898, KUNGLIGA SVENSKA VET, V24, P1, DOI DOI 10.1007/BF01501332
   Lazarin AM, 2007, THERMOCHIM ACTA, V454, P43, DOI 10.1016/j.tca.2006.12.016
   Macedo TR, 2007, CLAY CLAY MINER, V55, P151, DOI 10.1346/CCMN.2007.0550204
   Ng JCY, 2003, CHEMOSPHERE, V52, P1021, DOI 10.1016/S0045-6535(03)00223-6
   Pavan FA, 2007, DYES PIGMENTS, V72, P256, DOI 10.1016/j.dyepig.2005.09.001
   Prado AGS, 2001, ANAL CHIM ACTA, V432, P201, DOI 10.1016/S0003-2670(00)01372-6
   Quintanilla D. P., 2007, J COLLOID INTERF SCI, V313, P551
   QUINTANILLA DP, 2006, J HAZARD MATER, V134, P254
   Ruiz VSO, 2004, THERMOCHIM ACTA, V420, P73, DOI 10.1016/j.tca.2003.10.029
   Sales JAA, 2005, THERMOCHIM ACTA, V427, P77, DOI 10.1016/j.tca.2004.08.015
   Salih B, 1998, TALANTA, V46, P1205, DOI 10.1016/S0039-9140(97)00362-7
   SELVAM T, 2002, STUD SURF SCI CATA A, V142, P4007
   Sharma P, 2008, MICROPOR MESOPOR MAT, V116, P641, DOI 10.1016/j.micromeso.2008.05.036
   Sharma P, 2009, J COLLOID INTERF SCI, V332, P298, DOI 10.1016/j.jcis.2008.12.074
   Sheng GD, 2008, APPL RADIAT ISOTOPES, V66, P1313, DOI 10.1016/j.apradiso.2008.03.005
   SIPS R, 1948, J CHEM PHYS, V16, P490, DOI 10.1063/1.1746922
   SMITH JV, 1983, NATURE, V303, P223, DOI 10.1038/303223a0
   Tang XW, 2009, J HAZARD MATER, V161, P824, DOI 10.1016/j.jhazmat.2008.04.059
   Thomas JM, 2007, MICROPOR MESOPOR MAT, V104, P5, DOI 10.1016/j.micromeso.2007.01.002
   XIUWEN W, 2007, J COLLOID INTERF SCI, V315, P555
NR 32
TC 10
Z9 10
U1 4
U2 21
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0021-9797
EI 1095-7103
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD SEP 1
PY 2009
VL 337
IS 1
BP 122
EP 130
DI 10.1016/j.jcis.2009.05.013
PG 9
WC Chemistry, Physical
SC Chemistry
GA 472EI
UT WOS:000268111800017
PM 19524249
DA 2018-12-27
ER

PT J
AU Alam, A
AF Alam, Anwar
TI RETRACTED: ISLAM AND POST-MODERNISM: LOCATING THE RISE OF ISLAMISM IN
   TURKEY (Retracted article. See vol. 24, pg. 127, 2013)
SO JOURNAL OF ISLAMIC STUDIES
LA English
DT Article; Retracted Publication
C1 Jamia Millia Islamia, Ctr W Asian Studies, New Delhi, India.
RP Alam, A (reprint author), Jamia Millia Islamia, Ctr W Asian Studies, New Delhi, India.
CR Asad T., 1993, GENEALOGIES RELIG DI, P200
   Casanova Jose, 1994, PUBLIC RELIG MODERN
   Cinar M, 2006, MUSLIM WORLD, V96, P469, DOI 10.1111/j.1478-1913.2006.00138.x
   DEMERATH NJ, 1991, DAEDALUS, V120, P21
   ERNST CE, 2005, FOLLOWING MUHAMMAD R, P37
   FICKLEMAN DF, 1998, WILSON Q, V22, P82
   Gulen Fethullah, 2001, SAIS REV, V21, P134
   GUPTA D, 2000, CULTURE SPACE NATION
   Kadioglu A, 1998, MUSLIM WORLD, V88, P1
   Kalaycioglu E, 2005, MIDDLE E FOCUS, P1, DOI 10.1057/9781403978660
   KALAYCIOGLU E, 2005, INTRO COMP POLITICS, P207
   KELES R, 1989, TURKEY YEAR 2000, P203
   MAHAJHAN G, 1998, IDENTITIES RIGHTS AS, P40
   MANDAVILLE P, 2007, GLOBAL POLITICAL ISL, P151
   MARDIN S, 1993, FUNDAMENTALISM STATE, P220
   MARDIN S, 1971, INT J MIDDLE E STUD, V2, P208
   Nasr V, 2005, J DEMOCR, V16, P13
   Nilufer NARLI, 1999, MIDDLE E REV INT AFF, V3, P38
   OZCAN YZ, 1994, INTELLECTUAL DISCOUR, V2, P19
   OZEK C, 1986, DEVLET DIN, P498
   PIETERSE JN, 1994, WOMEN FUNDAMENTALISM, V5, P5
   Rae H., 2002, STATE IDENTITIES HOM
   SALT J, 1995, MIDDLE EASTERN STUD, V31, P13, DOI 10.1080/00263209508701038
   SAYYID BS, 1997, FUNDAMENTAL FEAR EUR, P17
   *STAT I STAT, 1993, STAT YB TURK
   TOPRAK B, 1988, STATE DEMOCRACY MILI, P131
   UNAL A, 2000, ADVOCATE DIALOGUE F, P243
   WEBER E, 1976, PEASANT FRENCHMAN MO
   YAVUZ MH, 2003, ISLAMIC POLITICAL ID, P272
   YENIGUN HI, ISLAMISM NATL TURKEY, P50
   YILMAZ I, MUSLIM WORLD, V95, P392
NR 31
TC 3
Z9 3
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0955-2340
EI 1471-6917
J9 J ISLAM STUD
JI J. Islam. Stud.
PD SEP
PY 2009
VL 20
IS 3
BP 352
EP 375
DI 10.1093/jis/etp023
PG 24
WC Humanities, Multidisciplinary
SC Arts & Humanities - Other Topics
GA 486OK
UT WOS:000269206400002
DA 2018-12-27
ER

PT J
AU Ham, CM
   Pantalena, LC
   Kingsley, DM
   Yang, GP
AF Ham, Christine M.
   Pantalena, Luiz C.
   Kingsley, David M.
   Yang, George P.
TI RETRACTED: Mapping regulatory elements of bone morphogenetic protein
   (BMP) 5 expression in fracture repair (Retracted Article. See vol 209,
   pg 802, 2009)
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Meeting Abstract; Retracted Publication
CT 95th Annual Clinical Congress of the American-College-of-Surgeons/64th
   Annual Sessions of the Owen H Wangensteen Forum on Fundamental Surgical
   Problems
CY OCT 11-15, 2009
CL Chicago, IL
SP Amer Coll Surg
C1 [Ham, Christine M.; Pantalena, Luiz C.; Kingsley, David M.; Yang, George P.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
NR 0
TC 1
Z9 1
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
EI 1879-1190
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD SEP
PY 2009
VL 209
IS 3
SU S
BP S65
EP S65
DI 10.1016/j.jamcollsurg.2009.06.156
PG 1
WC Surgery
SC Surgery
GA 493RJ
UT WOS:000269755300138
DA 2018-12-27
ER

PT J
AU Xiao, W
   Zhou, RJ
   Dong, HG
   Meng, N
   Lin, CY
   Adi, VSK
AF Xiao, Wu
   Zhou, Rui-jie
   Dong, Hong-Guang
   Meng, Nan
   Lin, Chih-Yao
   Adi, Vincentius Surya Kurnia
TI RETRACTED: Simultaneous optimal integration of water utilization and
   heat exchange networks using holistic mathematical programming
   (Retracted article. See vol. 27, pg. 373, 2010)
SO KOREAN JOURNAL OF CHEMICAL ENGINEERING
LA English
DT Article; Retracted Publication
DE Simultaneous Optimization; Water Utilization Network; Heat Exchange
   Network; Evolutionary Strategy
ID SIMULTANEOUS-OPTIMIZATION MODELS; IN-PROCESS PLANTS; SYSTEMS; ENERGY;
   DESIGN; MINIMIZATION
AB A systematic holistic mathematical programming (HMP) is proposed to formulate a mixed integer nonlinear programming (MINLP) model for one-step optimization of water-allocation and heat exchange network (WAHEN) designs with single- or multi-contaminant water streams. The proposed model formulation and solution strategy are believed to be superior to the available ones in the following aspects. First, a comprehensive representation combining two separate superstructures is adopted to capture the structural characteristics of the integrated WAHEN. Then, a hybrid optimization strategy integrating stochastic and deterministic components is developed for the resulting MINLP model and, also, an interactive iteration method is adopted based on sensitivity analysis to guide the search toward a potential global optimum. Finally, evolutionary strategies and manipulations are executed to enhance WAHEN configurations. Two illustrative examples are presented to demonstrate the validity and advantages of the proposed approach.
C1 [Xiao, Wu; Dong, Hong-Guang; Meng, Nan] Dalian Univ Technol, Sch Chem Engn, Dalian 116012, Liao Ning, Peoples R China.
   [Lin, Chih-Yao; Adi, Vincentius Surya Kurnia] Natl Cheng Kung Univ, Dept Chem Engn, Tainan 70101, Taiwan.
   [Zhou, Rui-jie] Dalian Univ Technol, Dept Econ, Dalian 116024, Liao Ning, Peoples R China.
RP Dong, HG (reprint author), Dalian Univ Technol, Sch Chem Engn, Dalian 116012, Liao Ning, Peoples R China.
EM hgdong@dlut.edu.cn
OI Adi, Vincentius Surya Kurnia/0000-0002-6857-2772
FU National Natural Science Foundation of China [20876020]; National
   Science Council of ROC government [NSC 95-2221-E-006-421]; Talent
   Startup Funding of Dalian University of Technology [1000-893368]
FX This work was supported by the National Natural Science Foundation of
   China (20876020), the National Science Council of ROC government under
   grant NSC 95-2221-E-006-421 and the Talent Startup Funding of Dalian
   University of Technology (China, No. 1000-893368).
CR AHMAD S, 1990, COMPUT CHEM ENG, V14, P751, DOI 10.1016/0098-1354(90)87084-3
   Alva-Argaez A, 1998, COMPUT CHEM ENG, V22, pS741, DOI 10.1016/S0098-1354(98)00138-0
   Bagajewicz M, 2002, COMPUT CHEM ENG, V26, P59, DOI 10.1016/S0098-1354(01)00751-7
   Barbaro A, 2005, COMPUT CHEM ENG, V29, P1945, DOI [10.1016/j.compchemeng.2005.04.006, 10.1016/j.comchemeng.2005.04.006]
   Chang CT, 2005, IND ENG CHEM RES, V44, P3607, DOI 10.1021/ie049370c
   EL-HALWAGI MM, 1989, AICHE J, V35, P1233, DOI 10.1002/aic.690350802
   FERRIS MC, 2005, MATLAB GAMS INTERFAC
   Floudas CA, 2005, COMPUT CHEM ENG, V29, P1185, DOI 10.1016/j.compchemeng.2005.02.006
   FLOUDAS CA, 1986, AICHE J, V32, P276, DOI 10.1002/aic.690320215
   GROSSMANN IE, 1999, ADV MATH PROGRAMMING
   Hogg R. V., 1987, ENG STAT
   Huang CH, 1999, IND ENG CHEM RES, V38, P2666, DOI 10.1021/ie990043s
   Kaufman L., 1990, FINDING GROUPS DATA
   LINNHOFF B, 1990, COMPUT CHEM ENG, V14, P729, DOI 10.1016/0098-1354(90)87083-2
   LINNHOFF B, 1983, CHEM ENG SCI, V38, P745, DOI 10.1016/0009-2509(83)80185-7
   MANN JG, 1999, IND WATER REUSE WAST
   PAPALEXANDRI KP, 1994, COMPUT CHEM ENG, V18, P1125, DOI 10.1016/0098-1354(94)E0022-F
   SAVELSKI M, 1999, AICHE ANN M DALL
   Savelski MJ, 2000, CHEM ENG SCI, V55, P5035, DOI 10.1016/S0009-2509(00)00127-5
   Savulescu L, 2005, CHEM ENG SCI, V60, P3279, DOI 10.1016/j.ces.2004.12.037
   Savulescu L, 2005, CHEM ENG SCI, V60, P3291, DOI 10.1016/j.ces.2004.12.036
   Savulescu LE, 2002, APPL THERM ENG, V22, P981, DOI 10.1016/S1359-4311(02)00015-7
   SAVULESCU LE, 1998, AICHE ANN M MIAM
   SU JL, 1984, COMPUT CHEM ENG, V8, P67, DOI 10.1016/0098-1354(84)87014-3
   TAKAMA N, 1980, COMPUT CHEM ENG, V4, P251, DOI 10.1016/0098-1354(80)85005-8
   VISWANATHAN J, 1990, COMPUT CHEM ENG, V14, P769, DOI 10.1016/0098-1354(90)87085-4
   WANG YP, 1994, CHEM ENG SCI, V49, P981, DOI 10.1016/0009-2509(94)80006-5
   YEE TF, 1990, COMPUT CHEM ENG, V14, P1151, DOI 10.1016/0098-1354(90)85009-Y
   YEE TF, 1990, COMPUT CHEM ENG, V14, P1165, DOI 10.1016/0098-1354(90)85010-8
NR 29
TC 9
Z9 9
U1 3
U2 20
PU KOREAN INSTITUTE CHEMICAL  ENGINEERS
PI SEOUL
PA F.5, 119, ANAM-RO, SEONGBUK-GU, SEOUL 136-075, SOUTH KOREA
SN 0256-1115
EI 1975-7220
J9 KOREAN J CHEM ENG
JI Korean J. Chem. Eng.
PD SEP
PY 2009
VL 26
IS 5
BP 1161
EP 1174
DI 10.2478/s11814-009-0196-5
PG 14
WC Chemistry, Multidisciplinary; Engineering, Chemical
SC Chemistry; Engineering
GA 488AL
UT WOS:000269320800001
DA 2018-12-27
ER

PT J
AU Lane, KA
   Anninger, WV
   Katowitz, JA
AF Lane, Katherine A.
   Anninger, William V.
   Katowitz, James A.
TI RETRACTED: Expanding the Phenotype of a Neurofibromatosis Type 1-Like
   Syndrome: A Patient With a SPRED1 Mutation and Orbital Manifestations
   (Retracted Article. See vol. 26, pg 145, 2010)
SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article; Retracted Publication
ID NF1 GENE
AB A 4-year-old child with no medical history presented for evaluation of a small, palpable nodule near the left inferolateral rim. The lesion had a bluish hue and had been slowly enlarging over the course of several months. MRI of the orbits revealed a heterogenous and infiltrative preseptal and extraconal mass which enhanced with gadolinium, and sphenoid wing dysplasia on the left. A complete ophthalmic and physical examination failed to reveal any other stigmata of neurofibromatosis type 1 (NF1) or neurofibromatosis type 2 (NF2). An incisional biopsy of the palpable mass revealed a plexiform neurofibroma. Molecular sequencing of the NF1 and NF2 genes did not reveal causative mutations. Further investigation revealed a loss of function mutation in SPRED1 on chromosome 15. Although loss of function mutations in the SPRED1 gene are known to cause several dermatologic changes associated with the NF 1-like phenotype, to our knowledge, this is the first description of a SPRED1 gene mutation resulting in ophthalmic abnormalities.
C1 [Lane, Katherine A.] Univ Penn Hosp Syst, Dept Ophthalmol, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
RP Lane, KA (reprint author), Univ Penn Hosp Syst, Dept Ophthalmol, Childrens Hosp Philadelphia, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM katelane@verizon.net
OI Lane, Katherine/0000-0002-4110-5058
CR Abaza MM, 1996, LARYNGOSCOPE, V106, P694, DOI 10.1097/00005537-199606000-00007
   Brems H, 2007, NAT GENET, V39, P1120, DOI 10.1038/ng2113
   Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097
   Messiaen LM, 2000, HUM MUTAT, V15, P541, DOI 10.1002/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N
   Rasmussen SA, 2000, AM J EPIDEMIOL, V151, P33
NR 5
TC 1
Z9 1
U1 4
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0740-9303
EI 1537-2677
J9 OPHTHAL PLAST RECONS
JI Ophthalmic Plast. Reconstr. Surg.
PD SEP-OCT
PY 2009
VL 25
IS 5
BP 399
EP 401
DI 10.1097/IOP.0b013e3181b59eea
PG 3
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA 502WF
UT WOS:000270490300016
PM 19966658
DA 2018-12-27
ER

PT J
AU Patzer, T
   Hrabal, SA
   Timmesfeld, N
   Fuchs-Winkelmann, S
   Schofer, MD
AF Patzer, T.
   Hrabal, S. A.
   Timmesfeld, N.
   Fuchs-Winkelmann, S.
   Schofer, M. D.
TI RETRACTED: Incidence and Mechanism of Injuries in Cable-Wakeboarding, a
   Prospective Study (Retracted article. See vol. 22, pg. 583, 2012)
SO SPORTVERLETZUNG-SPORTSCHADEN
LA German
DT Review; Retracted Publication
DE wakeboard; water sports; injury mechanism; risk; prevention
ID KITESURFING INJURIES; PREVENTION; PATTERN; SOCCER; SPORT
AB Cable-wakeboarding has become more and more popular in the last years in Germany and worldwide as well. The mechanism, frequency and severity Of injuries is Still unclear and not described in the literature yet. Thus to compare the injuries of cable-wakeboarding with similar sports we decided to perform this prospective study during a six months summer season. The Study included 122 actives with a mean age of 25 years (15-42, +/- 5.876), 81,1% male, sending an online questionnaire to us every month. 98% of the participants Suffered 277 injuries during 8647 hours of activity, 108 (39%12/1000 h) had to be treated medically. We found Out most frequently mild injuries (61%19.5/1000 h), 15% very severe injuries (4.8/1000 h), 14% severe injuries (4.5/1000 h) and 10% medium-severe injuries (3.2/1000 h). Injuries of the knee and the shoulder dominated in more than 20% each with more than 70% distorsions and contusions. Conclusion: Cable-wakeboarding is not more dangerous in regard to injuries than similar trendy sports even though the rate of mild injuries not treated medically is quite higher.
C1 [Patzer, T.; Hrabal, S. A.; Fuchs-Winkelmann, S.; Schofer, M. D.] Orthopad Univ Klin Marburg, D-35043 Marburg, Germany.
   [Timmesfeld, N.] Univ Marburg, Inst Med Biometrie & Epidemiol, D-35032 Marburg, Germany.
RP Patzer, T (reprint author), Orthopad Univ Klin Marburg, Baldingerstr, D-35043 Marburg, Germany.
EM th.patzer@web.de
CR Baltzer A W, 1997, Knee Surg Sports Traumatol Arthrosc, V5, P46, DOI 10.1007/s001670050024
   BLADIN C, 1993, AM J SPORT MED, V21, P701, DOI 10.1177/036354659302100511
   Carson WG, 2004, AM J SPORT MED, V32, P164, DOI 10.1177/0363546503258910
   Chia JKK, 2000, PEDIATR NEUROSURG, V32, P291, DOI 10.1159/000028957
   Dann K, 2005, ORTHOPADE, V34, P433, DOI 10.1007/s00132-005-0797-6
   Emery CA, 2006, AM J SPORT MED, V34, P1636, DOI 10.1177/0363546506288018
   HENRY JH, 1982, AM J SPORT MED, V10, P16, DOI 10.1177/036354658201000104
   Horterer H, 2005, ORTHOPADE, V34, P426, DOI 10.1007/s00132-005-0793-x
   Hostetler SG, 2005, AM J SPORT MED, V33, P1065, DOI 10.1177/0363546504271748
   HUMMEL G, 1982, AM J SPORT MED, V10, P215, DOI 10.1177/036354658201000405
   Jerosch J, 2005, ORTHOPADE, V34, P441, DOI 10.1007/s00132-005-0794-9
   Knobloch Karsten, 2009, Cases J, V2, P100, DOI 10.1186/1757-1626-2-100
   Krosshaug T, 2005, BRIT J SPORT MED, V39, P330, DOI 10.1136/bjsm.2005.018358
   Narita Tetsuya, 2004, Journal of Nippon Medical School, V71, P57, DOI 10.1272/jnms.71.57
   Nickel C, 2004, AM J SPORT MED, V32, P921, DOI 10.1177/0363546503262162
   Olsen OE, 2006, SCAND J MED SCI SPOR, V16, P426, DOI 10.1111/j.1600-0838.2005.00484.x
   Petersen W, 2005, ORTHOPADE, V34, P419, DOI 10.1007/s00132-005-0792-y
   Petersen W, 2003, SPORTVERLETZ SPORTSC, V17, P118
   Rahnama N, 2002, BRIT J SPORT MED, V36, P354, DOI 10.1136/bjsm.36.5.354
   Su JW, 2007, J THORAC CARDIOV SUR, V134, P506, DOI 10.1016/j.jtcvs.2007.04.015
NR 20
TC 6
Z9 6
U1 4
U2 15
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0932-0555
EI 1439-1236
J9 SPORTVERLETZ SPORTSC
JI Sportverletz. Sportschaden
PD SEP
PY 2009
VL 23
IS 3
BP 141
EP 147
DI 10.1055/s-0028-1109712
PG 7
WC Orthopedics; Sport Sciences
SC Orthopedics; Sport Sciences
GA 503BP
UT WOS:000270506900010
PM 19750442
DA 2018-12-27
ER

PT J
AU Tan, NY
   Li, JM
   Stocker, R
   Khachigian, LM
AF Tan, Nicole Y.
   Li, Jian-Mei
   Stocker, Roland
   Khachigian, Levon M.
TI RETRACTED: Angiotensin II-Inducible Smooth Muscle Cell Apoptosis
   Involves the Angiotensin II Type 2 Receptor, GATA-6 Activation, and
   FasL-Fas Engagement (Retracted article. See vol. 118, pg. E31, 2016)
SO CIRCULATION RESEARCH
LA English
DT Article; Retracted Publication
DE Fas ligand; GATA-6; apoptosis; angiotensin II
ID HISTONE DEACETYLASE INHIBITORS; LIGAND GENE-EXPRESSION; TRANSCRIPTION
   FACTOR; KAPPA-B; ENDOTHELIAL-CELLS; NEOINTIMA FORMATION; T-LYMPHOCYTES;
   FACTOR FAMILY; CHAIN GENE; PROMOTER
AB Rationale: Fas ligand (FasL)-mediated smooth muscle cell (SMC) apoptosis within the vulnerable plaque may lead to plaque instability and rupture, events that underlie myocardial infarction and stroke.
   Objective: The molecular mechanisms underlying FasL transcription and FasL-dependent SMC apoptosis were investigated in this study in vitro and in vivo.
   Methods and Results: We demonstrate that GATA-6, the predominant GATA family member expressed in SMCs, stimulates SMC apoptosis in an extracellular FasL-dependent manner. Both GATA-6 and FasL were inducibly and transiently expressed following balloon injury to rat carotid arteries. We identified two potential GATA binding in the FasL promoter and demonstrated using DNA binding and chromatin immunoprecipitation assays that GATA-6 regulates FasL through one ((-298)TTATCA (-303)) but not both these elements. Angiotensin II (Ang II) stimulated expression of both GATA-6 and FasL. Ang II increased SMC apoptosis in an Ang II type 2 receptor-, caspase 8-, and FasL-dependent fashion. GATA-6 activation was MEK-ERK1/2- and JNK-dependent, and GATA-6 small interfering RNA blocked Ang II-inducible FasL expression and SMC apoptosis. Administration of Ang II to rats increased FasL expression and apoptosis in carotid artery SMCs in an Ang II type 2 receptor-and GATA-6-dependent manner.
   Conclusions: This study provides new insights into the transcriptional events underpinning FasL-dependent SMC apoptosis after exposure to Ang II. (Circ Res. 2009; 105: 422-430.)
C1 [Tan, Nicole Y.; Li, Jian-Mei; Khachigian, Levon M.] Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia.
   [Stocker, Roland] Univ Sydney, Ctr Vasc Res, Sydney, NSW 2006, Australia.
RP Khachigian, LM (reprint author), Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia.
EM L.Khachigian@unsw.edu.au
OI Khachigian, Levon/0000-0003-3446-0323
FU National Health and Medical Research Council (Australia); Australian
   Research Council, and National Heart Foundation (Australia); National
   Health and Medical Research Council
FX This work was supported by grants from the National Health and Medical
   Research Council (Australia), Australian Research Council, and National
   Heart Foundation (Australia). L. M. K. is an Australia Fellow and R. S.
   is a Senior Principal Research Fellow of the National Health and Medical
   Research Council.
CR Alcouffe J, 2004, FASEB J, V18, P122, DOI 10.1096/fj.02-0808fje
   Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Chou CW, 2008, FEBS LETT, V582, P4059, DOI 10.1016/j.febslet.2008.10.048
   Chow WA, 2000, J IMMUNOL, V164, P3512, DOI 10.4049/jimmunol.164.7.3512
   De Angelis N, 2002, J MOL CELL CARDIOL, V34, P1655, DOI 10.1006/jmcc.2002.2115
   Delbridge GJ, 1997, CIRC RES, V81, P282, DOI 10.1161/01.RES.81.2.282
   Geng YJ, 1998, CIRCULATION, V98, P48
   Geng YJ, 1997, ARTERIOSCL THROM VAS, V17, P2200, DOI 10.1161/01.ATV.17.10.2200
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661
   Kasibhatla S, 2000, CURR BIOL, V10, P1205, DOI 10.1016/S0960-9822(00)00727-2
   Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4
   Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987
   Kavurma MM, 2008, ARTERIOSCL THROM VAS, V28, P1694, DOI 10.1161/ATVBAHA.107.155143
   Kavurma MM, 2007, BIOCHEM J, V407, P79, DOI 10.1042/BJ20070380
   Kavurma MM, 2001, J BIOL CHEM, V276, P4964, DOI 10.1074/jbc.M009251200
   Kavurma MM, 2003, CELL DEATH DIFFER, V10, P36, DOI 10.1038/sj.cdd.4401179
   Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200
   Kavurma MM, 2003, J CELL BIOCHEM, V89, P289, DOI 10.1002/jcb.10497
   Khachigian LM, 2000, MOL CELL BIOCHEM, V212, P183, DOI 10.1023/A:1007153025897
   Khachigian LM, 2006, CIRC RES, V98, P186, DOI 10.1161/01.RES.0000200177.538882.c3
   Khachigian LM, 2002, J BIOL CHEM, V277, P22985, DOI 10.1074/jbc.M200977200
   Kiechle FL, 2002, CLIN CHIM ACTA, V326, P27, DOI 10.1016/S0009-8981(02)00297-8
   Kirchhoff S, 2002, J IMMUNOL, V168, P1226, DOI 10.4049/jimmunol.168.3.1226
   Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427
   Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751
   Lepore JJ, 2005, ARTERIOSCL THROM VAS, V25, P309, DOI 10.1161/01.ATV.0000152725.76020.3c
   Li YX, 2006, AM J PHYSIOL-HEART C, V290, pH2116, DOI 10.1152/ajpheart.00551.2005
   Li-Weber M, 1999, EUR J IMMUNOL, V29, P3017, DOI 10.1002/(SICI)1521-4141(199909)29:09<3017::AID-IMMU3017>3.0.CO;2-R
   Mano T, 1999, CIRC RES, V84, P647, DOI 10.1161/01.RES.84.6.647
   Martin-Ventura JL, 2004, STROKE, V35, P458, DOI 10.1161/01.STR.0000114876.51656.7A
   Matsui K, 1998, J IMMUNOL, V161, P3469
   Matter CM, 2006, CIRCULATION, V113, P1879, DOI 10.1161/CIRCULATIONAHA.106.611731
   Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744
   Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165
   Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7
   Narita N, 1996, GENOMICS, V36, P345, DOI 10.1006/geno.1996.0472
   Nelson JD, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj004
   Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2
   Rafty LA, 1998, J BIOL CHEM, V273, P5758, DOI 10.1074/jbc.273.10.5758
   Rivera I, 1998, J BIOL CHEM, V273, P22382, DOI 10.1074/jbc.273.35.22382
   Santiago FS, 2007, CIRC RES, V101, P146, DOI 10.1161/CIRCRESAHA.106.145235
   Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215
   Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9
   Sata M, 2000, J MOL CELL CARDIOL, V32, P1395, DOI 10.1006/jmcc.2000.1176
   Shimizu M, 2002, J AM COLL CARDIOL, V39, P585, DOI 10.1016/S0735-1097(01)01800-9
   Sokabe T, 2004, AM J PHYSIOL-HEART C, V287, pH2027, DOI 10.1152/ajpheart.00260.2004
   Song H, 2006, J CARDIOTHORAC REN R, V1, P135
   SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L
   Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002
   Sumpio BE, 1998, ARTERIOSCL THROM VAS, V18, P349, DOI 10.1161/01.ATV.18.3.349
   Suzuki YJ, 2003, J BIOL CHEM, V278, P17525, DOI 10.1074/jbc.M210465200
   Tsang SW, 2004, INT J BIOCHEM CELL B, V36, P330, DOI 10.1016/S1357-2725(03)00257-7
   Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057
   Wada H, 2000, J BIOL CHEM, V275, P25330, DOI 10.1074/jbc.M000828200
   Wang JG, 2007, J BIOL CHEM, V282, P28408, DOI 10.1074/jbc.M703586200
   Watanabe T, 2005, HYPERTENSION, V45, P163, DOI 10.1161/01.HYP.0000153321.13792.b9
   Xiao S, 1999, EUR J IMMUNOL, V29, P3456, DOI 10.1002/(SICI)1521-4141(199911)29:11<3456::AID-IMMU3456>3.0.CO;2-B
   Yin F, 2005, J BIOL CHEM, V280, P4745, DOI 10.1074/jbc.M411585200
   Yin Z, 2006, AM J PHYSIOL-LUNG C, V291, pL191, DOI 10.1152/ajplung.00385.2005
NR 62
TC 22
Z9 26
U1 3
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD AUG 28
PY 2009
VL 105
IS 5
BP 422
EP U41
DI 10.1161/CIRCRESAHA.109.203323
PG 15
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA 488XV
UT WOS:000269384600004
PM 19628789
OA Bronze
DA 2018-12-27
ER

PT J
AU Chemouri, H
   Mekelleche, SM
AF Chemouri, H.
   Mekelleche, S. M.
TI RETRACTED: Theoretical study of the mechanism, regio- and
   stereoselectivity of Diels-Alder reactions of 5-aryl-2-pyrones with
   substituted alkenes (Retracted article. See vol. 947, pg. 124, 2010)
SO JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM
LA English
DT Article; Retracted Publication
DE Diels-Alder reactions; Pyrones; Stereoselectivity; Regioselectivity;
   B3LYP calculations
ID 1,3-DIPOLAR CYCLOADDITION REACTIONS; DENSITY-FUNCTIONAL THEORY;
   LEWIS-ACID CATALYST; ELECTROPHILICITY INDEX; REACTIVITY INDEXES;
   CARBONYL-COMPOUNDS; METHYL PROPIOLATE; LOCAL SOFTNESS; VINYL-ACETATE;
   QUANTITATIVE CHARACTERIZATION
AB A theoretical study of the mechanism, regio- and stereoselectivity of Diels-Alder reactions of 5-aryl-2-pyrones with substituted alkenes is carried out at the B3LYP/6-31G(d) level of theory. The PES (potential energy surface) analysis and IRC (intrinsic reaction coordinate) calculations show that the studied reactions are undergoing through concerted asynchronous mechanisms yielding to the formation of the 5-endo compound as the major cycloadduct. The calculation of activation energies and reaction energies indicate that the 5-endo cycloadduct is favored both kinetically and thermodynamically. The experimental ratios of regioisomers (5/6) and stereoisomers (endo/exo) are correctly estimated at the MP2/6-31G(d)//B3LYP/6-31G(d) level of theory. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Chemouri, H.; Mekelleche, S. M.] Univ A Belkaid, Fac Sci, Dept Chim, Tilimsen 13000, Algeria.
RP Mekelleche, SM (reprint author), Univ A Belkaid, Fac Sci, Dept Chim, BP 119, Tilimsen 13000, Algeria.
EM sm_mekelleche@mail.univ-tlemcen.dz
RI Mekelleche, Sidi Mohamed/G-3396-2013
OI Mekelleche, Sidi Mohamed/0000-0002-5806-3333
FU "Ministere de l'Enseignement Superieur et de la Recherche Scientifique
   of the Algerian Government [CNEPRU E1301/55/05]
FX This work was supported by research funds provided by the "Ministere de
   l'Enseignement Superieur et de la Recherche Scientifique of the Algerian
   Government (project CNEPRU E1301/55/05).
CR Afarinkia K, 1997, TETRAHEDRON LETT, V38, P2369, DOI 10.1016/S0040-4039(97)00352-3
   AFARINKIA K, 1992, TETRAHEDRON, V48, P9111, DOI 10.1016/S0040-4020(01)85607-6
   Afarinkia K, 2000, TETRAHEDRON LETT, V41, P4955, DOI 10.1016/S0040-4039(00)00744-9
   Alves CN, 2006, TETRAHEDRON, V62, P5502, DOI 10.1016/j.tet.2006.03.037
   Arroyo P, 2005, TETRAHEDRON, V61, P7359, DOI 10.1016/j.tet.2005.05.080
   Barba C, 2006, J ORG CHEM, V71, P9831, DOI 10.1021/jo062200k
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   Benchouk W, 2008, J MOL STRUC-THEOCHEM, V852, P46, DOI 10.1016/j.theochem.2007.12.035
   Benmeddah A, 2007, J MOL STRUC-THEOCHEM, V821, P42, DOI 10.1016/j.theochem.2007.06.018
   BERKOWITZ M, 1985, J AM CHEM SOC, V107, P6811, DOI 10.1021/ja00310a011
   BOGER DL, 1987, HETERO DIELS ALDER M
   Chandra AK, 1997, J ORG CHEM, V62, P6417, DOI 10.1021/jo9703055
   Chattaraj P. K., 1993, CHEM HARDNESS STRUCT, V80, P11
   Chattaraj PK, 2003, J PHYS CHEM A, V107, P4973, DOI 10.1021/jp034707u
   Chattaraj PK, 2007, CHEM REV, V107, pPR46, DOI 10.1021/cr078014b
   Chattaraj PK, 2006, CHEM REV, V106, P2065, DOI 10.1021/cr040109f
   Chemouri H, 2007, J MOL STRUC-THEOCHEM, V813, P67, DOI 10.1016/j.theochem.2007.02.028
   Chermette H, 1999, J COMPUT CHEM, V20, P129, DOI 10.1002/(SICI)1096-987X(19990115)20:1<129::AID-JCC13>3.0.CO;2-A
   Chiacchio U, 2005, J ORG CHEM, V70, P8991, DOI 10.1021/jo051572a
   Contini A, 2006, J ORG CHEM, V71, P5507, DOI 10.1021/jo0604538
   Cossio FP, 1999, J AM CHEM SOC, V121, P6737, DOI 10.1021/ja9831397
   Damoun S, 1997, J PHYS CHEM A, V101, P886, DOI 10.1021/jp9611840
   Domingo LR, 2006, EUR J ORG CHEM, P2570, DOI 10.1002/ejoc.200500978
   Domingo LR, 2003, J ORG CHEM, V68, P8662, DOI 10.1021/jo030156s
   Domingo LR, 2002, TETRAHEDRON, V58, P4417, DOI 10.1016/S0040-4020(02)00410-6
   Domingo LR, 2007, J ORG CHEM, V72, P4220, DOI 10.1021/jo070373j
   Domingo LR, 2007, J MOL STRUC-THEOCHEM, V811, P125, DOI 10.1016/j.theochem.2006.12.051
   Domingo LR, 2006, J ORG CHEM, V71, P9319, DOI 10.1021/jo0613986
   Domingo LR, 2006, TETRAHEDRON, V62, P10408, DOI 10.1016/j.tet.2006.08.066
   Domingo LR, 2006, EUR J ORG CHEM, P3464, DOI 10.1002/ejoc.200600105
   Domingo LR, 2007, TETRAHEDRON, V63, P4464, DOI 10.1016/j.tet.2007.03.064
   Dominguez VR, 2007, AM ETHNOL, V34, P1, DOI 10.1525/ae.2007.34.1.1
   Elango M, 2006, INT J QUANTUM CHEM, V106, P852, DOI 10.1002/qua.20844
   Ess DH, 2006, ADV SYNTH CATAL, V348, P2337, DOI 10.1002/adsc.200600431
   Fleming I., 1976, FRONTIER ORBITALS OR
   Fringuelli F, 2001, EUR J ORG CHEM, P439, DOI 10.1002/1099-0690(200102)2001:3<439::AID-EJOC439>3.0.CO;2-B
   Frisch M. J., 1998, GAUSSIAN 98 REVISION
   FUKUI K, 1971, ACCOUNTS CHEM RES, V4, P57, DOI 10.1021/ar50038a003
   FUKUI K, 1981, ACCOUNTS CHEM RES, V14, P363, DOI 10.1021/ar00072a001
   Fukui K, 1964, MOL ORBITALS CHEM PH
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   Gomez-Bengoa E, 2007, J AM CHEM SOC, V129, P2691, DOI 10.1021/ja068527k
   Hehre W. J, 1986, AB INITIO MOL ORBITA
   HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRev.136.B864
   Jones GA, 2002, ORG LETT, V4, P3789, DOI 10.1021/o10264713
   Jones GO, 2008, J ORG CHEM, V73, P1333, DOI 10.1021/jo702295d
   KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133
   Koopmans T, 1934, PHYSICA, V1, P104, DOI 10.1016/S0031-8914(34)90011-2
   LANGENAEKER W, 1995, J PHYS CHEM-US, V99, P6424, DOI 10.1021/j100017a022
   LECEA B, 1994, J AM CHEM SOC, V116, P9613, DOI 10.1021/ja00100a028
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   MARKO IE, 1993, TETRAHEDRON LETT, V34, P7309, DOI 10.1016/S0040-4039(00)79316-6
   Mekelleche SM, 2004, J MOL STRUC-THEOCHEM, V709, P31, DOI 10.1016/j.theochem.2004.06.033
   Merino P, 2003, TETRAHEDRON, V59, P3581, DOI 10.1016/S0040-40200(03)00547-7
   Merino P, 2007, TETRAHEDRON, V63, P1448, DOI 10.1016/j.tet.2006.11.073
   Milet A, 2006, J COMPUT CHEM, V27, P157, DOI 10.1002/jcc.20322
   Min SJ, 2007, J AM CHEM SOC, V129, P10078, DOI 10.1021/ja073528d
   Molteni G, 2003, CHEM-EUR J, V9, P2770, DOI 10.1002/chem.200204681
   Morao I, 1997, J ORG CHEM, V62, P7033, DOI 10.1021/jo970347t
   MOYANO A, 1989, J ORG CHEM, V54, P573, DOI 10.1021/jo00264a014
   Nguyen LT, 1999, J AM CHEM SOC, V121, P5992, DOI 10.1021/ja983394r
   Nguyen LT, 2001, J ORG CHEM, V66, P6096, DOI 10.1021/jo015685f
   Nguyen T. A., 2007, FRONTIER ORBITALS PR
   Parr R. G., 1989, DENSITY FUNCTIONAL T
   Parr RG, 1999, J AM CHEM SOC, V121, P1922, DOI 10.1021/ja983494x
   PARR RG, 1983, J AM CHEM SOC, V105, P7512, DOI 10.1021/ja00364a005
   PARR RG, 1978, J CHEM PHYS, V68, P3801, DOI 10.1063/1.436185
   Pauling L., 1960, NATURE CHEM BOND
   Pearson R. G., 1997, CHEM HARDNESS APPL M
   PEARSON RG, 1988, INORG CHEM, V27, P734, DOI 10.1021/ic00277a030
   Perez P, 2003, TETRAHEDRON, V59, P3117, DOI 10.1016/S0040-4020(03)00374-0
   POIRIER RA, 1995, J ORG CHEM, V60, P2328, DOI 10.1021/jo00113a009
   Ponti A, 2000, J PHYS CHEM A, V104, P8843, DOI 10.1021/jp002279b
   Ponti A, 2006, CHEM-EUR J, V12, P1156, DOI 10.1002/chem.200500739
   Ponti A, 2001, J ORG CHEM, V66, P5252, DOI 10.1021/jo0156159
   POSNER GH, 1990, PURE APPL CHEM, V62, P1949, DOI 10.1351/pac199062101949
   POSNER GH, 1986, J AM CHEM SOC, V108, P7373, DOI 10.1021/ja00283a036
   Rauk A, 2001, ORBITAL INTERACTION
   Regas D, 2006, J ORG CHEM, V71, P9153, DOI 10.1021/jo061582r
   Roy RK, 1998, J PHYS CHEM A, V102, P3746, DOI 10.1021/jp973450v
   Roy RK, 2001, J PHYS CHEM A, V105, P2117, DOI 10.1021/jp0040087
   SCHLEGEL HB, 1982, J COMPUT CHEM, V3, P214, DOI 10.1002/jcc.540030212
   Schlegel HB, 1994, MODERN ELECT STRUCTU
   Sen K. D., 1987, STRUCTURE BONDING EL, V66
   Sen K. D., 1993, CHEM HARDNESS STRUCT
   Suzuki Y, 2002, J SYN ORG CHEM JPN, V60, P679, DOI 10.5059/yukigoseikyokaishi.60.679
   Ujaque G, 2002, CHEM-EUR J, V8, P3423, DOI 10.1002/1521-3765(20020802)8:15<3423::AID-CHEM3423>3.0.CO;2-X
   Wagner G, 2003, CHEM-EUR J, V9, P1503, DOI 10.1002/chem.200390172
   WIBERG KB, 1968, TETRAHEDRON, V24, P1083, DOI 10.1016/0040-4020(68)88057-3
   Xidos JD, 1998, J ORG CHEM, V63, P105, DOI 10.1021/jo9712815
   Xidos JD, 2001, J AM CHEM SOC, V123, P5482, DOI 10.1021/ja0030919
NR 91
TC 4
Z9 4
U1 2
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-1280
J9 J MOL STRUC-THEOCHEM
JI Theochem-J. Mol. Struct.
PD AUG 15
PY 2009
VL 907
IS 1-3
BP 9
EP 15
DI 10.1016/j.theochem.2009.04.010
PG 7
WC Chemistry, Physical
SC Chemistry
GA 471GB
UT WOS:000268042900002
DA 2018-12-27
ER

PT J
AU Wang, JP
   Jiang, C
   Li, X
   Liu, CL
   Cheng, NN
   Hao, YJ
AF Wang, Jianping
   Jiang, Chao
   Li, Xin
   Liu, Chunling
   Cheng, Ningning
   Hao, Yujin
TI RETRACTED: The protective mechanism of progesterone on blood-brain
   barrier in cerebral ischemia in rats (Retracted article. See vol. 81,
   pg. 524, 2010)
SO BRAIN RESEARCH BULLETIN
LA English
DT Article; Retracted Publication
DE Cerebral ischemia; Progesterone; Tumor necrosis factor alpha; Matrix
   metalloproteinase-9; Claudin5; Blood-brain barrier
ID TUMOR-NECROSIS-FACTOR; MATRIX METALLOPROTEINASES; INFLAMMATORY RESPONSE;
   ARTERY OCCLUSION; FACTOR-ALPHA; CELL-DEATH; INJURY; EXPRESSION;
   ALLOPREGNANOLONE; EDEMA
AB Recent studies demonstrate that progesterone (PROG) significantly reduces cerebral edema and enhances functional recovery from traumatic brain injury (TBI) and stroke in several animal models, but its concrete mechanism is still unknown. This study was designed to investigate the inhibitory effects of PROG on inflammatory response after stroke and its influence on the structure of blood-brain barrier (BBB). In the treatment group, PROG was dissolved in 22.5% 2-hydroxypropyl-bcyclodextrin and given in a dose of 8 mg/kg by intraperitoneal injection 1 h and 6 h after permanent occlusion of middle cerebral artery (pMCAO). Additional injections of 15 mg/kg were administered subcutaneously once a day after pMCAO. The expression of tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-9 (MMP-9) and claudin5 was measured by western blot technique. Evan's blue extravasation and brain water content in the ipsilateral hemisphere was also detected to evaluate the permeability of BBB. Western blot analysis revealed that the expression of TNF-alpha and MMP-9 were reduced while claudin5 was up-regulated in brain tissues of PROG-treated rats. In addition, examination of BBB permeability also showed that administration of PROG significantly reduced Evan's blue extravasation and brain water content in the ipsilateral hemisphere compared to vehicle-treated rats. Our findings reveal that PROG inhibited the inflammatory response after experimental stroke and mitigated the severity of brain damage, suggesting a role for PROG in the integrity of the BBB and subsequent edema formation following cerebral ischemia. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Wang, Jianping; Jiang, Chao; Li, Xin; Liu, Chunling; Cheng, Ningning; Hao, Yujin] Zhengzhou Univ, Affiliated Hosp 2, Dept Neurol, Zhengzhou 450014, Henan, Peoples R China.
RP Wang, JP (reprint author), Zhengzhou Univ, Affiliated Hosp 2, Dept Neurol, Zhengzhou 450014, Henan, Peoples R China.
EM jcmd666@126.com
CR Abdallah Y, 2007, CARDIOVASC RES, V73, P568, DOI 10.1016/j.cardiores.2006.11.027
   Begley DJ, 2003, PROG DRUG RES, V61, P39
   Botchkina GI, 1997, MOL MED, V3, P765, DOI 10.1007/BF03401714
   Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023
   Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169
   deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4
   Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023
   Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106
   Dziewulska D, 2003, CLIN NEUROPATHOL, V22, P35
   Fryclenlund DS, 2006, P NATL ACAD SCI USA, V103, P13532, DOI 10.1073/pnas.0605796103
   Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161
   GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0
   Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009
   Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00
   Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003
   GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513
   Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013
   He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008
   Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523
   Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848
   Mani SK, 2006, MOL ENDOCRINOL, V20, P1322, DOI 10.1210/me.2005-0466
   Manicone AM, 2008, SEMIN CELL DEV BIOL, V19, P34, DOI 10.1016/j.semcdb.2007.07.003
   Meistrell ME, 1997, SHOCK, V8, P341
   Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5
   Overall CM, 2002, BIOL CHEM, V383, P1059, DOI 10.1515/BC.2002.114
   Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156
   Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011
   Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151
   Schaeffer V, 2008, NEUROCHEM INT, V52, P948, DOI 10.1016/j.neuint.2008.01.010
   Schonbeck U, 1998, J IMMUNOL, V161, P3340
   Shen J, 2007, EUR J PHARMACOL, V558, P88, DOI 10.1016/j.ejphar.2006.11.059
   SMITH SS, 2004, CLIN J MED S, V2, pS4
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   Svedin P, 2007, J NEUROSCI, V27, P1511, DOI 10.1523/JNEUROSCI.4391-06.2007
   Tsukita S, 1998, GENES CELLS, V3, P569, DOI 10.1046/j.1365-2443.1998.00212.x
   Vagnerova K, 2008, ANESTH ANALG, V107, P201, DOI 10.1213/ane.0b013e31817326a5
   Vincent T, 2008, J IMMUNOL, V181, P5730, DOI 10.4049/jimmunol.181.8.5730
   Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246
   Williams AJ, 2006, NEUROCHEM INT, V49, P106, DOI 10.1016/j.neuint.2006.03.018
   Xi G, 2002, ACT NEUR S, V81, P253
NR 40
TC 16
Z9 21
U1 4
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0361-9230
EI 1873-2747
J9 BRAIN RES BULL
JI Brain Res. Bull.
PD AUG 14
PY 2009
VL 79
IS 6
BP 426
EP 430
DI 10.1016/j.brainresbull.2009.05.018
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 478UR
UT WOS:000268614400015
PM 19477244
DA 2018-12-27
ER

PT J
AU Mukherjee, S
   Lekli, I
   Goswami, S
   Das, DK
AF Mukherjee, Subhendu
   Lekli, Istvan
   Goswami, Shyamal
   Das, Dipak K.
TI RETRACTED: Freshly Crushed Garlic is a Superior Cardioprotective Agent
   than Processed Garlic (Retracted article. See vol. 60, pg. 2766, 2012)
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article; Retracted Publication
DE Garlic; ischemia/reperfusion; cardioprotection; hydrogen sulfide; redox
   signaling
ID HYDROGEN-SULFIDE; ANTIOXIDANT; HEART; RATS; CONSTITUENTS; CHOLESTEROL;
   MYOCYTES; ALLICIN; PATHWAY; DIET
AB In this study, we compared the cardioprotective effects of freshly crushed garlic vis-a-vis that of processed garlic. Two groups of rats were gavaged with respective garlic preparations while the control group received vehicle only. After 30 days, all of the rats were sacrificed and isolated the hearts were subjected to 30 min ischemia followed by 2 h of reperfusion. Both of the garlic preparations provided cardioprotection, but superior cardiac performance was noticed for those fed with freshly crushed garlic. Consistent with these results, the freshly crushed garlic group displayed significantly greater phosphorylation of antiapoptotic ERK1/2 proteins, reduced Bax/Bcl-2 ratio, and reduced phosphorylation of proapoptotic p-38MAPK and JNK. Moreover, the survival signaling network consisting of Akt-FoxOl was increased in the freshly crushed garlic treated hearts. Freshly crushed garlic, but not the processed garlic, showed enhanced redox signaling as evident by increased level of p65 subunit of NF kappa B, Nrf2, and enhanced GLUT 4, PPAR(X, and PPAR delta. The results thus show that although both freshly crushed garlic and processed garlic provide cardioprotection, the former has additional cardioprotective properties presumably due to the presence of H2S.
C1 [Mukherjee, Subhendu; Lekli, Istvan; Goswami, Shyamal; Das, Dipak K.] Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
RP Das, DK (reprint author), Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
EM DDAS@NEURON.UCHC.EDU
FU National Heart, Lung, Blood Institute [NIH HL-22559, HL-33889,
   HL-69910]; Indo-US Science and Technology Forum
FX This study was supported in part by National Heart, Lung, Blood
   Institute Grants NIH HL-22559, HL-33889, and HL-69910. S.K.G. was a
   recipient of travel grant from the Indo-US Science and Technology Forum.
CR Abe K, 1996, J NEUROSCI, V16, P1066
   Agarwal KC, 1996, MED RES REV, V16, P111, DOI 10.1002/(SICI)1098-1128(199601)16:1<111::AID-MED4>3.0.CO;2-5
   Banerjee SK, 2002, NUTR J, V1, DOI 10.1186/1475-2891-1-4
   Benavides GA, 2007, P NATL ACAD SCI USA, V104, P17977, DOI 10.1073/pnas.0705710104
   Bergkvist P., 1996, HEALING POWER GARLIC, P1
   Bian JS, 2006, J PHARMACOL EXP THER, V316, P670
   BUIATTI E, 1989, INT J CANCER, V44, P611, DOI 10.1002/ijc.2910440409
   Cavagnaro PF, 2007, J AGR FOOD CHEM, V55, P1280, DOI 10.1021/jf062587s
   CHUAH SC, 2001, AM J PHYSIOL, V293, pH2693
   Das DK, 2007, AM J PHYSIOL-HEART C, V293, pH2629, DOI 10.1152/ajpheart.00996.2007
   Dombkowski RA, 2005, AM J PHYSIOL-REG I, V288, pR243, DOI 10.1152/ajpregu.00324.2004
   Dudley JI, 2008, J AGR FOOD CHEM, V56, P9362, DOI 10.1021/jf801791d
   Elkayam A, 2003, AM J HYPERTENS, V16, P1053, DOI 10.1016/j.amjhyper.2003.07.011
   Gardner CD, 2007, ARCH INTERN MED, V167, P346, DOI 10.1001/archinte.167.4.346
   Gorinstein S, 2005, J AGR FOOD CHEM, V53, P2726, DOI 10.1021/jf0404593
   Gorinstein S, 2007, MOL NUTR FOOD RES, V51, P1365, DOI 10.1002/mnfr.200700064
   Ichikawa M, 2006, J AGR FOOD CHEM, V54, P9811, DOI 10.1021/jf062252a
   JENNER E, 1985, B ACAD NATL MED, V69, P771
   KAHN G, 1996, GARLIC SCI THERAPEUT, P25
   Kwon MJ, 2003, LIFE SCI, V72, P2953, DOI 10.1016/S0024-3205(03)00234-0
   Leelarungrayub N, 2006, NUTRITION, V22, P266, DOI 10.1016/j.nut.2005.05.010
   Liu YL, 2006, DEV GENES EVOL, V216, P531, DOI 10.1007/s00427-006-0063-x
   Lowicka E, 2007, PHARMACOL REP, V59, P4
   MCMAHON FG, 1993, PHARMACOTHERAPY, V13, P406
   Moller S, 2008, GUT, V57, P268, DOI 10.1136/gut.2006.112177
   Moyers S., 1996, GARLIC HLTH HIST WOR, P1
   Mukherjee S, 2008, BBA-MOL BASIS DIS, V1782, P498, DOI 10.1016/j.bbadis.2008.05.002
   Mukherjee S, 2008, J AGR FOOD CHEM, V56, P609, DOI 10.1021/jf0728146
   Ni YG, 2007, P NATL ACAD SCI USA, V104, P20517, DOI 10.1073/pnas.0610290104
   Oron-Herman M, 2005, ATHEROSCLEROSIS, V183, P238, DOI 10.1016/j.athersclerosis.2005.03.009
   Pan TT, 2006, J MOL CELL CARDIOL, V40, P119, DOI 10.1016/j.yjmcc.2005.10.003
   PASTEUR L, 1858, ANN CHIM PHYS, V52, P404
   Perez-Severiano F, 2004, NEUROCHEM INT, V45, P1175, DOI 10.1016/j.neuint.2004.06.008
   Pinto JT, 1997, AM J CLIN NUTR, V66, P398
   QU K, 2005, B JPN SOC NEUROCHEM, V44, P185
   Thomson M, 2006, J NUTR, V136, p800S, DOI 10.1093/jn/136.3.800S
   TYRRELL H, 1979, LANCET, V1, P1294
   Wang L, 2008, INVEST OPHTH VIS SCI, V49, P1671, DOI 10.1167/iovs.07-1099
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Yeh YY, 2001, J NUTR, V131, p989S, DOI 10.1093/jn/131.3.989S
NR 40
TC 20
Z9 22
U1 4
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD AUG 12
PY 2009
VL 57
IS 15
BP 7137
EP 7144
DI 10.1021/jf901301w
PG 8
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
SC Agriculture; Chemistry; Food Science & Technology
GA 477RW
UT WOS:000268537300089
PM 19722587
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Degenhardt, T
   Rybakova, KN
   Tomaszewska, A
   Mone, MJ
   Westerhoff, HV
   Bruggeman, FJ
   Carlberg, C
AF Degenhardt, Tatjana
   Rybakova, Katja N.
   Tomaszewska, Aleksandra
   Mone, Martijn J.
   Westerhoff, Hans V.
   Bruggeman, Frank J.
   Carlberg, Carsten
TI RETRACTED: Population-Level Transcription Cycles Derive from Stochastic
   Timing of Single-Cell Transcription (Retracted article. See vol. 143,
   pg. 651, 2010)
SO CELL
LA English
DT Article; Retracted Publication
ID GENE-EXPRESSION; IN-VIVO; ORDERED RECRUITMENT; NUCLEAR RECEPTORS;
   CHROMATIN; COACTIVATOR; DYNAMICS; COMPLEX; OSCILLATIONS; ACTIVATION
AB Eukaryotic transcription is a dynamic process relying on a large number of proteins. By measuring the cycling expression of the pyruvate dehydrogenase kinase 4 gene in human cells, we constructed a detailed stochastic model for single-gene transcription at the molecular level using realistic kinetics for diffusion and protein complex dynamics. We observed that gene induction caused an approximate 60 min periodicity of several transcription related processes: first, the covalent histone modifications and presence of many regulatory proteins at the transcription start site; second, RNA polymerase II activity; third, chromatin loop formation; and fourth, mRNA accumulation. Our model can predict the precise timing of single-gene activity leading to transcriptional cycling on the cell population level when we take into account the sequential and irreversible multistep nature of transcriptional initiation. We propose that the cyclic nature of population gene expression is primarily based on the intrinsic periodicity of the transcription process itself.
C1 [Degenhardt, Tatjana; Tomaszewska, Aleksandra; Carlberg, Carsten] Univ Kuopio, Dept Biosci, FIN-70211 Kuopio, Finland.
   [Rybakova, Katja N.; Mone, Martijn J.; Westerhoff, Hans V.; Bruggeman, Frank J.] Vrije Univ Amsterdam, Inst Mol Cell Biol, NL-1081 HV Amsterdam, Netherlands.
   [Tomaszewska, Aleksandra; Carlberg, Carsten] Univ Luxembourg, Life Sci Res Unit, L-1511 Luxembourg, Luxembourg.
   [Westerhoff, Hans V.] Univ Manchester, Manchester Ctr Integrat Syst Biol, Manchester Interdisciplinary Bioctr, Manchester M1 7ND, Lancs, England.
   [Bruggeman, Frank J.] Ctr Math & Comp Sci, Netherlands Inst Syst Biol Multiscale Modelling &, NL-1098 SJ Amsterdam, Netherlands.
RP Carlberg, C (reprint author), Univ Kuopio, Dept Biosci, FIN-70211 Kuopio, Finland.
EM carsten.carlberg@uni.lu
RI Kuopio, Dept Biosci/A-4529-2010
OI Westerhoff, Hans/0000-0002-0443-6114
FU European Union (Marie Curie RTN NucSys); University of Luxembourg;
   Academy of Finland; Juselius Foundation
FX We would like to thank M. Hiltunen, A. Hallama, and Dr. J. Bouwman for
   technical assistance and M. Dobrzynski for discussions. Grants from the
   European Union (Marie Curie RTN NucSys), the University of Luxembourg,
   the Academy of Finland, and the Juselius Foundation supported this
   research.
CR Antonson P, 2003, MOL CELL BIOL, V23, P1260, DOI 10.1128/MCB.23.4.1260-1268.2003
   Batchelor E, 2008, MOL CELL, V30, P277, DOI 10.1016/j.molcel.2008.03.016
   Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3
   BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0
   Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev
   CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x
   Casamassimi A, 2007, BIOCHIMIE, V89, P1439, DOI 10.1016/j.biochi.2007.08.002
   Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0
   Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866
   Chubb JR, 2006, CURR BIOL, V16, P1018, DOI 10.1016/j.cub.2006.03.092
   CLARKE KR, 1993, AUST J ECOL, V18, P117, DOI 10.1111/j.1442-9993.1993.tb00438.x
   Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4
   Degenhardt T, 2007, J MOL BIOL, V372, P341, DOI 10.1016/j.jmb.2007.06.091
   Dobrzynski M, 2009, P NATL ACAD SCI USA, V106, P2583, DOI 10.1073/pnas.0803507106
   GILLESPIE DT, 1976, J COMPUT PHYS, V22, P403, DOI 10.1016/0021-9991(76)90041-3
   Guenther MG, 2000, GENE DEV, V14, P1048
   Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200
   Karpova TS, 2008, SCIENCE, V319, P466, DOI 10.1126/science.1150559
   Kim S, 2005, J BONE MINER RES, V20, P305, DOI 10.1359/JBMR.041112
   Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293
   Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398
   Lemaire V, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.198102
   Leslie K. K., 2007, AM J OBSTET GYNECOL, V196, p[e1, e11]
   Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479
   Metivier R, 2006, EMBO REP, V7, P161, DOI 10.1038/sj.embor.7400626
   Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Mone MJ, 2004, P NATL ACAD SCI USA, V101, P15933, DOI 10.1073/pnas.0403664101
   Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2
   Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962
   Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3
   Pedraza JM, 2008, SCIENCE, V319, P339, DOI 10.1126/science.1144331
   Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393.6402.2004
   Raj A, 2008, CELL, V135, P216, DOI 10.1016/j.cell.2008.09.050
   Raj A, 2006, PLOS BIOL, V4, P1707, DOI 10.1371/journal.pbio.0040309
   Reid G, 2009, INT J BIOCHEM CELL B, V41, P155, DOI 10.1016/j.biocel.2008.08.028
   Richard P, 1996, YEAST, V12, P731
   Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007
   Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799
   Sun L, 2008, BIOCHEM BIOPH RES CO, V371, P912, DOI 10.1016/j.bbrc.2008.03.112
   Sun L, 2008, BIOCHEM BIOPH RES CO, V371, P900, DOI 10.1016/j.bbrc.2008.03.114
   Trotter KW, 2007, MOL CELL ENDOCRINOL, V265, P162, DOI 10.1016/j.mce.2006.12.015
   Vaisanen S, 2005, J MOL BIOL, V350, P65, DOI 10.1016/.jmb.2005.04.057
   WOLFFE AP, 1994, CURR OPIN GENET DEV, V4, P245, DOI 10.1016/S0959-437X(05)80051-6
   Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116
NR 44
TC 34
Z9 34
U1 2
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD AUG 7
PY 2009
VL 138
IS 3
BP 489
EP 501
DI 10.1016/j.cell.2009.05.029
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 480XZ
UT WOS:000268771900014
PM 19665971
OA Bronze
DA 2018-12-27
ER

PT J
AU Lichtenthaler, U
AF Lichtenthaler, Ulrich
TI RETRACTED: ABSORPTIVE CAPACITY, ENVIRONMENTAL TURBULENCE, AND THE
   COMPLEMENTARITY OF ORGANIZATIONAL LEARNING PROCESSES (Retracted article.
   See vol. 56, pg. 1830, 2013)
SO ACADEMY OF MANAGEMENT JOURNAL
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 22nd Annual Meeting of the
   Society-for-Industrial-and-Organizational-Psychology
CY APR 27-29, 2007
CL New York, NY
SP Soc Ind & Org Psychol
ID STRATEGIC ALLIANCES; COMPETITIVE ADVANTAGE; PRODUCT DEVELOPMENT;
   RESOURCE COMPLEMENTARITY; COMBINATIVE CAPABILITIES; INNOVATION
   PERFORMANCE; DYNAMIC CAPABILITIES; KNOWLEDGE TRANSFER; FIRM-LEVEL;
   EXPLORATION
AB Following the process-based definition of absorptive capacity, this article identifies technological and market knowledge as two critical components of prior knowledge in the organizational learning processes of absorptive capacity. Data from a multi-informant survey conducted in 175 industrial firms show that exploratory, transformative, and exploitative learning have complementary effects on innovation and performance. The results emphasize the multidimensional nature of absorptive capacity, and they help to explain interfirm discrepancies in profiting from external knowledge. Moreover, the findings underscore the importance of dynamic capabilities in contexts characterized by high degrees of technological and market turbulence.
EM lichtenthaler@whu.edu
CR Arbussa A, 2007, RES POLICY, V36, P1545, DOI 10.1016/j.respol.2007.04.013
   Argote L, 2003, MANAGE SCI, V49, P571, DOI 10.1287/mnsc.49.4.571.14424
   Arora A, 1996, ECON LETT, V50, P51, DOI 10.1016/0165-1765(95)00707-5
   Bagozzi R. P., 1988, J ACAD MARKET SCI, V16, P74, DOI DOI 10.1007/BF02723327
   Cassiman B, 2006, MANAGE SCI, V52, P68, DOI 10.1287/rrmsc.1050.0470
   Cesaroni F, 2004, RES POLICY, V33, P1547, DOI 10.1016/j.respol.2004.08.003
   Cohen J., 2003, APPL MULTIPLE REGRES
   COHEN WM, 1990, ADMIN SCI QUART, V35, P128, DOI 10.2307/2393553
   DAFT RL, 1984, ACAD MANAGE REV, V9, P284, DOI 10.2307/258441
   Droge C, 2008, J PROD INNOVAT MANAG, V25, P272, DOI 10.1111/j.1540-5885.2008.00300.x
   Dyer B, 1997, J INT BUS STUD, V28, P467, DOI 10.1057/palgrave.jibs.8490108
   Dyer JH, 1998, ACAD MANAGE REV, V23, P660, DOI 10.2307/259056
   Eisenhardt KM, 2000, STRATEGIC MANAGE J, V21, P1105, DOI 10.1002/1097-0266(200010/11)21:10/11<1105::AID-SMJ133>3.0.CO;2-E
   EISENHARDT KM, 1989, ACAD MANAGE REV, V14, P532, DOI 10.2307/258557
   Elenkov DS, 1997, STRATEGIC MANAGE J, V18, P287, DOI 10.1002/(SICI)1097-0266(199704)18:4<287::AID-SMJ865>3.3.CO;2-2
   Ernst H, 2001, RES POLICY, V30, P143, DOI 10.1016/S0048-7333(99)00098-0
   GARUD R, 1994, STRATEGIC MANAGE J, V15, P365, DOI 10.1002/smj.4250150504
   Greene William, 2007, ECONOMETRIC ANAL
   Gupta AK, 2006, ACAD MANAGE J, V49, P693, DOI 10.2307/20159793
   Hair J., 2006, MULTIVARIATE DATA AN
   HAMEL G, 1991, STRATEGIC MANAGE J, V12, P83, DOI 10.1002/smj.4250120908
   Harrison JS, 2001, J MANAGE, V27, P679, DOI 10.1016/S0149-2063(01)00118-0
   HASPESLAGH PC, 1987, SLOAN MANAGE REV, V28, P53
   Helfat C. E., 2007, DYNAMIC CAPABILITIES
   Hoegl M, 2001, ORGAN SCI, V12, P435, DOI 10.1287/orsc.12.4.435.10635
   Holmqvist M, 2004, ORGAN SCI, V15, P70, DOI 10.1287/orsc.1030.0056
   Huber GP, 1991, ORGAN SCI, V2, P88, DOI 10.1287/orsc.2.1.88
   Huston L, 2006, HARVARD BUS REV, V84, P58
   Ichniowski C, 1997, AM ECON REV, V87, P291
   Inkpen AC, 1998, ORGAN SCI, V9, P454, DOI 10.1287/orsc.9.4.454
   Ireland RD, 2002, J MANAGE, V28, P413, DOI 10.1016/S0149-2063(02)00134-4
   Jansen JJP, 2005, ACAD MANAGE J, V48, P999, DOI 10.5465/AMJ.2005.19573106
   Jansen JJP, 2006, MANAGE SCI, V52, P1661, DOI 10.1287/mnsc.1060.0576
   JAWORSKI BJ, 1993, J MARKETING, V57, P53, DOI 10.2307/1251854
   Kale P, 2007, STRATEG MANAGE J, V28, P981, DOI 10.1002/smj.616
   Katila R, 2002, ACAD MANAGE J, V45, P1183, DOI 10.2307/3069433
   Khanna T, 1998, STRATEGIC MANAGE J, V19, P193, DOI 10.1002/(SICI)1097-0266(199803)19:3<193::AID-SMJ949>3.3.CO;2-3
   KOGUT B, 1992, ORGAN SCI, V3, P383, DOI 10.1287/orsc.3.3.383
   Koza MP, 1998, ORGAN SCI, V9, P255, DOI 10.1287/orsc.9.3.255
   Lane PJ, 2006, ACAD MANAGE REV, V31, P833, DOI 10.5465/AMR.2006.22527456
   Lane PJ, 1998, STRATEGIC MANAGE J, V19, P461, DOI 10.1002/(SICI)1097-0266(199805)19:5<461::AID-SMJ953>3.0.CO;2-L
   Larsson R, 1998, ORGAN SCI, V9, P285, DOI 10.1287/orsc.9.3.285
   Laursen K, 2006, STRATEGIC MANAGE J, V27, P131, DOI 10.1002/smj.507
   Lenox M, 2004, STRATEGIC MANAGE J, V25, P331, DOI 10.1002/smj.379
   LEONARDBARTON D, 1992, STRATEGIC MANAGE J, V13, P111, DOI 10.1002/smj.4250131009
   LEVINTHAL DA, 1993, STRATEGIC MANAGE J, V14, P95, DOI 10.1002/smj.4250141009
   LICHTENTHALER U, 2005, ANN M AC MAN HON
   Lichtenthaler U, 2007, CALIF MANAGE REV, V49, P67, DOI 10.2307/41166406
   Lichtenthaler U, 2007, RES POLICY, V36, P37, DOI 10.1016/j.respol.2006.08.005
   Lord MD, 2000, J INT BUS STUD, V31, P573, DOI 10.1057/palgrave.jibs.8490923
   March JG, 1991, ORGAN SCI, V2, P71, DOI 10.1287/orsc.2.1.71
   Markides CC, 1996, ACAD MANAGE J, V39, P340, DOI 10.2307/256783
   MARSH HW, 1985, PSYCHOL BULL, V97, P562, DOI 10.1037/0033-2909.97.3.562
   Marsh SJ, 2006, J PROD INNOVAT MANAG, V23, P422, DOI 10.1111/j.1540-5885.2006.00214.x
   Matusik SF, 2005, J MANAGE, V31, P549, DOI 10.1177/0149206304272293
   McEvily B, 2005, STRATEGIC MANAGE J, V26, P1033, DOI 10.1002/smj.484
   McGrath RG, 2001, ACAD MANAGE J, V44, P118, DOI 10.2307/3069340
   Miles M B., 1994, QUALITATIVE DATA ANA
   MILGROM P, 1995, J ACCOUNT ECON, V19, P179, DOI 10.1016/0165-4101(94)00382-F
   Mowery DC, 1996, STRATEGIC MANAGE J, V17, P77, DOI 10.1002/smj.4250171108
   Narasimhan O, 2006, MARKET SCI, V25, P510, DOI 10.1287/mksc.1060.0219
   Nerkar A, 2003, MANAGE SCI, V49, P211, DOI 10.1287/mnsc.49.2.211.12747
   Nooteboom B, 2007, RES POLICY, V36, P1016, DOI 10.1016/j.respol.2007.04.003
   Powell WW, 1996, ADMIN SCI QUART, V41, P116, DOI 10.2307/2393988
   Reinartz W, 2004, J MARKETING RES, V41, P293, DOI 10.1509/jmkr.41.3.293.35991
   RINDSKOPF D, 1988, MULTIVAR BEHAV RES, V23, P51, DOI 10.1207/s15327906mbr2301_3
   Rothaermel FT, 2004, STRATEGIC MANAGE J, V25, P201, DOI 10.1002/smj.376
   Santos FA, 2005, ORGAN SCI, V16, P491, DOI 10.1287/orsc.1050.0152
   Sethi R, 2008, J MARKETING, V72, P118, DOI 10.1509/jmkg.72.1.118
   Shane S, 2000, ORGAN SCI, V11, P448, DOI 10.1287/orsc.11.4.448.14602
   SHARMA S, 1981, J MARKETING RES, V18, P291, DOI 10.2307/3150970
   Sidhu JS, 2007, ORGAN SCI, V18, P20, DOI 10.1287/orsc.1060.0212
   Siggelkow N, 2006, ACAD MANAGE J, V49, P779, DOI 10.5465/AMJ.2006.22083053
   Smith KG, 2005, ACAD MANAGE J, V48, P346
   Song M, 2005, STRATEGIC MANAGE J, V26, P259, DOI 10.1002/smj.450
   Song M, 2006, J ACAD MARKET SCI, V34, P341, DOI 10.1177/0092070306286705
   Szulanski G, 1996, STRATEGIC MANAGE J, V17, P27, DOI 10.1002/smj.4250171105
   Tanriverdi H, 2005, STRATEGIC MANAGE J, V26, P97, DOI 10.1002/smj.435
   Teece DJ, 2007, STRATEG MANAGE J, V28, P1319, DOI 10.1002/smj.640
   Todorova G, 2007, ACAD MANAGE REV, V32, P774
   Tsai WP, 2001, ACAD MANAGE J, V44, P996, DOI 10.2307/3069443
   Tsai WP, 1998, ACAD MANAGE J, V41, P464, DOI 10.2307/257085
   Tushman ML, 1996, CALIF MANAGE REV, V38, P8, DOI 10.2307/41165852
   Van den Bosch FAJ, 1999, ORGAN SCI, V10, P551, DOI 10.1287/orsc.10.5.551
   WALSH JP, 1991, ACAD MANAGE REV, V16, P57, DOI 10.2307/258607
   Whittington R, 1999, ORGAN SCI, V10, P583, DOI 10.1287/orsc.10.5.583
   Wiklund J, 2005, J BUS VENTURING, V20, P71, DOI 10.1016/j.jbusvent.2004.01.001
   Yin R. K., 2003, CASE STUDY RES DESIG
   Zahra SA, 2002, ACAD MANAGE REV, V27, P185, DOI 10.5465/AMR.2002.6587995
   ZHENG ZK, 2005, J MARKETING, V69, P42
   Zollo M, 2002, ORGAN SCI, V13, P701, DOI 10.1287/orsc.13.6.701.503
NR 91
TC 326
Z9 344
U1 16
U2 277
PU ACAD MANAGEMENT
PI BRIARCLIFF MANOR
PA PACE UNIV, PO BOX 3020, 235 ELM RD, BRIARCLIFF MANOR, NY 10510-8020 USA
SN 0001-4273
EI 1948-0989
J9 ACAD MANAGE J
JI Acad. Manage. J.
PD AUG
PY 2009
VL 52
IS 4
BP 822
EP 846
DI 10.5465/AMJ.2009.43670902
PG 25
WC Business; Management
SC Business & Economics
GA 489KS
UT WOS:000269419600010
DA 2018-12-27
ER

PT J
AU Bezier, D
   Darcel, C
AF Bezier, David
   Darcel, Christophe
TI RETRACTED: Iron-Catalyzed Suzuki-Miyaura Cross-Coupling Reaction
   (Retracted article. See vol. 352, pg. 1081, 2010)
SO ADVANCED SYNTHESIS & CATALYSIS
LA English
DT Article; Retracted Publication
DE bis-aryl compounds; boronic acid; cross-coupling; homogeneous catalysis;
   iron; Suzuki-Miyaura reaction
ID ARYL GRIGNARD-REAGENTS; ASYMMETRIC SULFIDE OXIDATION; AQUEOUS
   HYDROGEN-PEROXIDE; BEARING BETA-HYDROGENS; C-C BOND; ALKYL-HALIDES;
   ALKENYL HALIDES; ORGANOMANGANESE REAGENTS; ORGANOBORON COMPOUNDS;
   ORGANIC-SYNTHESIS
AB An efficient, mild, and simple protocol for iron-catalyzed Suzuki-Miyaura type cross-coupling reaction between iodo- or bromoaryl derivatives and arylboronic acids was developed. In the presence of iron(III) chloride (10 mol%) and a stoichiometric amount of potassium fluoride, aryl iodides and bromides reacted with arylboronic acids in ethanol at 100 degrees C under air to give the corresponding bis-aryl compounds with good to excellent yields.
C1 [Bezier, David; Darcel, Christophe] Univ Rennes 1, CNRS, UMR Sci Chim Rennes 6226, Equipe Catalyse & Organometall, F-35042 Rennes, France.
RP Darcel, C (reprint author), Univ Rennes 1, CNRS, UMR Sci Chim Rennes 6226, Equipe Catalyse & Organometall, Campus Beaulieu,Bat 10C,Ave Gen Leclerc, F-35042 Rennes, France.
EM christophe.darcel@univ-rennes1.fr
FU CNRS; Ministere de l'Enseignement Superieur et de la Recherche
FX We are grateful to CNRS and Ministere de l'Enseignement Superieur et de
   la Recherche for support, and the latter for a Ph. D grant to D.B.
CR Anilkumar G, 2007, CHEM COMMUN, P289, DOI 10.1039/b612048b
   Bart SC, 2004, J AM CHEM SOC, V126, P13794, DOI 10.1021/ja046753t
   Bedford RB, 2006, J ORG CHEM, V71, P1104, DOI 10.1021/jo052250+
   Bedford RB, 2004, CHEM COMMUN, P2822, DOI 10.1039/b413790f
   Bedford RB, 2005, CHEM COMMUN, P4161, DOI 10.1039/b507133j
   Bedford RB, 2009, CHEM COMMUN, P600, DOI 10.1039/b818961g
   Bellina F, 2004, SYNTHESIS-STUTTGART, P2419, DOI 10.1055/s-2004-831223
   Bitterlich B, 2008, EUR J ORG CHEM, P4867, DOI 10.1002/ejoc.200800712
   Bitterlich B, 2007, CHEM-ASIAN J, V2, P521, DOI 10.1002/asia.200600407
   Bolm C, 2004, CHEM REV, V104, P6217, DOI 10.1021/cr040664h
   Cahiez G, 2005, ORG LETT, V7, P1943, DOI 10.1021/ol050340v
   Cahiez G, 1998, SYNTHESIS-STUTTGART, P1199
   Cahiez G, 1996, TETRAHEDRON LETT, V37, P1773, DOI 10.1016/0040-4039(96)00116-5
   Cahiez G, 1996, PURE APPL CHEM, V68, P53, DOI 10.1351/pac199668010053
   Cahiez G., 2009, ANGEW CHEM, V121, P3013
   Cahiez G, 2007, ANGEW CHEM, V119, P4442
   Cahiez G, 2008, SYNTHESIS-STUTTGART, P2636, DOI 10.1055/s-2008-1067194
   Cahiez G, 2008, ORG LETT, V10, P2389, DOI 10.1021/ol800816f
   Cahiez G, 2007, ANGEW CHEM INT EDIT, V46, P4364, DOI 10.1002/anie.200700742
   Cahiez G, 2009, ANGEW CHEM INT EDIT, V48, P2969, DOI 10.1002/anie.200900175
   Chemler SR, 2001, ANGEW CHEM INT EDIT, V40, P4544, DOI 10.1002/1521-3773(20011217)40:24<4544::AID-ANIE4544>3.0.CO;2-N
   CHEMLER SR, 2001, ANGEW CHEM, V113, P4676
   Correa A, 2008, CHEM SOC REV, V37, P1108, DOI 10.1039/b801794h
   Dohle W, 2001, SYNLETT, P1901
   Doucet H, 2008, EUR J ORG CHEM, P2013, DOI 10.1002/ejoc.200700984
   Enthaler S., 2008, ANGEW CHEM, V120, P3363
   Enthaler S, 2008, ANGEW CHEM INT EDIT, V47, P3317, DOI 10.1002/anie.200800012
   Enthaler S, 2006, CHEM-ASIAN J, V1, P598, DOI 10.1002/asia.200600105
   Furstner A, 2002, ANGEW CHEM INT EDIT, V41, P609
   Furstner A, 2002, J AM CHEM SOC, V124, P13856, DOI 10.1021/ja027190t
   Furstner A, 2003, ANGEW CHEM INT EDIT, V42, P5358, DOI 10.1002/anie.200352413
   Furstner A, 2003, ANGEW CHEM INT EDIT, V42, P308, DOI 10.1002/anie.200390103
   Furstner A., 2002, ANGEW CHEM, V114, P632
   Furstner A., 2003, ANGEW CHEM, V115, P5513
   FURSTNER A, 2003, ANGEW CHEM, V115, P5516
   FURUTA A, 2007, TETRAHEDRON LETT, V48, P110
   Gaillard S, 2008, CHEMSUSCHEM, V1, P505, DOI 10.1002/cssc.200800071
   Gelalcha F. G., 2007, ANGEW CHEM, V119, P7431
   Gelalcha FG, 2008, CHEM-EUR J, V14, P7687, DOI 10.1002/chem.200800595
   Gelalcha FG, 2007, ANGEW CHEM INT EDIT, V46, P7293, DOI 10.1002/anie.200701235
   Guo Y, 2008, TETRAHEDRON LETT, V49, P5620, DOI 10.1016/j.tetlet.2008.07.060
   Hassan J, 2002, CHEM REV, V102, P1359, DOI 10.1021/cr000664r
   Hocek M, 2003, J ORG CHEM, V68, P5773, DOI 10.1021/jo034351i
   KNOCHEL P, 2006, Patent No. 102004049508
   KOCHI JK, 1974, ACCOUNTS CHEM RES, V7, P351, DOI 10.1021/ar50082a006
   Kofink CC, 2007, CHEM COMMUN, P1954, DOI 10.1039/b618617c
   Kotha S, 2002, TETRAHEDRON, V58, P9633, DOI 10.1016/S0040-4020(02)01188-2
   Kylmala T, 2008, TETRAHEDRON LETT, V49, P6679, DOI 10.1016/j.tetlet.2008.09.059
   Legros J, 2005, CHEM-EUR J, V11, P1086, DOI 10.1002/chem.200400857
   Legros J, 2004, ANGEW CHEM INT EDIT, V43, P4225, DOI 10.1002/anie.200460236
   Legros J, 2003, ANGEW CHEM INT EDIT, V42, P5487, DOI 10.1002/anie.200352635
   Legros J., 2004, ANGEW CHEM, V31, P4321
   Legros J., 2003, ANGEW CHEM, V115, P5645
   Li Z., 2007, ANGEW CHEM, V119, P6625
   Li Z., 2008, ANGEW CHEM, V120, P7607
   Li ZP, 2008, ANGEW CHEM INT EDIT, V47, P7497, DOI 10.1002/anie.200802215
   Li ZP, 2007, ANGEW CHEM INT EDIT, V46, P6505, DOI 10.1002/anie.200701782
   Liao L, 2007, J POLYM SCI POL CHEM, V45, P2048, DOI 10.1002/pola.21970
   Martin R, 2004, ANGEW CHEM INT EDIT, V43, P3955, DOI 10.1002/anie.200460504
   Martin R., 2004, ANGEW CHEM, V116, P4045
   Martin R, 2008, ACCOUNTS CHEM RES, V41, P1461, DOI 10.1021/ar800036s
   MIYAURA N, 1995, CHEM REV, V95, P2457, DOI 10.1021/cr00039a007
   Miyaura N, 2002, TOP CURR CHEM, V219, P11
   MOLANDER GA, 1983, TETRAHEDRON LETT, V24, P5449, DOI 10.1016/S0040-4039(00)94109-1
   Nagano T, 2004, ORG LETT, V6, P1297, DOI 10.1021/ol049779y
   Nakamura M, 2004, J AM CHEM SOC, V126, P3686, DOI 10.1021/ja049744t
   Nakanishi M, 2007, ADV SYNTH CATAL, V349, P861, DOI 10.1002/adsc.200600553
   NEUMANN SM, 1975, J ORG CHEM, V40, P599, DOI 10.1021/jo00893a013
   Nishiyama H, 2007, CHEM COMMUN, P760, DOI 10.1039/b617388h
   Pavan C, 2005, ADV SYNTH CATAL, V347, P703, DOI 10.1002/adsc.200404315
   Sapountzis I, 2005, ANGEW CHEM INT EDIT, V44, P1654, DOI 10.1002/anie.200462013
   Sapountzis I., 2005, ANGEW CHEM, V117, P1682
   Scheiper B, 2004, J ORG CHEM, V69, P3943, DOI 10.1021/jo0498866
   Schroeder K, 2007, TETRAHEDRON LETT, V48, P6339, DOI 10.1016/j.tetlet.2007.07.006
   Seidel G, 2004, J ORG CHEM, V69, P3950, DOI 10.1021/jo049885d
   Shaikh NS, 2008, ANGEW CHEM INT EDIT, V47, P2497, DOI 10.1002/anie.200705624
   Shaikh NS, 2007, ORG LETT, V9, P5429, DOI 10.1021/ol7021802
   SHAIKH NS, 2008, ANGEW CHEM, V120, P2531
   Sherry BD, 2008, ACCOUNTS CHEM RES, V41, P1500, DOI 10.1021/ar800039x
   Shi F, 2008, CHEM-EUR J, V14, P8793, DOI 10.1002/chem.200801432
   SHINOKUBO K, 2004, EUR J ORG CHEM, P2081
   SMITH RS, 1976, J ORG CHEM, V41, P502, DOI 10.1021/jo00865a019
   Suzuki A, 1999, J ORGANOMET CHEM, V576, P147, DOI 10.1016/S0022-328X(98)01055-9
   TAMURA M, 1971, SYNTH-INT J METHODS, P303
   TAMURA M, 1971, B CHEM SOC JPN, V44, P3063, DOI 10.1246/bcsj.44.3063
   TAMURA M, 1971, J ORGANOMET CHEM, V31, P289, DOI 10.1016/S0022-328X(00)86239-7
   TAMURA M, 1971, J AM CHEM SOC, V93, P1487, DOI 10.1021/ja00735a030
   Tondreau AM, 2008, ORG LETT, V10, P2789, DOI 10.1021/ol800906b
   WU XF, 2009, TETRAHEDRON, DOI DOI 10.1016/J.TET.2009-07.29>
   Wu XF, 2009, EUR J ORG CHEM, P1144, DOI 10.1002/ejoc.200801176
   Wu XF, 2009, ADV SYNTH CATAL, V351, P367, DOI 10.1002/adsc.200800666
   Yasuda N, 2002, J ORGANOMET CHEM, V653, P279, DOI 10.1016/S0022-328X(02)01263-9
   2009, ANGEW CHEM INT EDIT, DOI DOI 10.1002/ANIE.200902237
NR 93
TC 25
Z9 25
U1 5
U2 45
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1615-4150
J9 ADV SYNTH CATAL
JI Adv. Synth. Catal.
PD AUG
PY 2009
VL 351
IS 11-12
BP 1732
EP 1736
DI 10.1002/adsc.200900281
PG 5
WC Chemistry, Applied; Chemistry, Organic
SC Chemistry
GA 491MU
UT WOS:000269583900004
DA 2018-12-27
ER

PT J
AU Skarda, J
   Amariglio, N
   Rechavi, G
AF Skarda, Jozef
   Amariglio, Ninette
   Rechavi, Gideon
TI RETRACTED: RNA editing in human cancer: review (Retracted article. See
   vol. 118, pg. 337, 2010)
SO APMIS
LA English
DT Review; Retracted Publication
DE RNA editing; cancer; ADAR; tumor progression
ID DOUBLE-STRANDED-RNA; TO-INOSINE RNA; ADENOSINE DEAMINASES;
   MESSENGER-RNA; HUMAN TRANSCRIPTOME; HUMAN GLIOBLASTOMA; ADAR2; GENE;
   IDENTIFICATION; SUBUNITS
AB In eukaryotes mRNA transcripts are extensively processed by different post-transcriptional events such as alternative splicing and RNA editing in order to generate many different mRNAs from the same gene, increasing the transcriptome and then the proteome diversity. The most frequent RNA editing mechanism in mammals involves the conversion of specific adenosines into inosines by the ADAR family of enzymes. This editing event can alter the sequence and the secondary structure of RNA molecules, with consequences for final proteins and regulatory RNAs. Alteration in RNA editing has been connected to tumor progression and many other important human diseases. Analysis of many editing sites in various cancer types is expected to provide new diagnostic and prognostic markers and might contribute to early detection of cancer, the monitoring of response to therapy, and to the detection of minimal residual disease.
C1 [Skarda, Jozef] Palacky Univ, Fac Med, Dept Pathol, Olomouc 77900, Czech Republic.
   [Skarda, Jozef] Palacky Univ, Fac Med, Lab Mol Pathol, Olomouc 77900, Czech Republic.
   [Skarda, Jozef] Fac Hosp Olomouc, Olomouc 77900, Czech Republic.
   [Amariglio, Ninette; Rechavi, Gideon] Chaim Sheba Med Ctr, Canc Res Ctr, IL-52621 Tel Hashomer, Israel.
   [Amariglio, Ninette; Rechavi, Gideon] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel.
RP Skarda, J (reprint author), Palacky Univ, Fac Med, Dept Pathol, Olomouc 77900, Czech Republic.
EM jojos@email.cz
CR Athanasiadis A, 2004, PLOS BIOL, V2, P2144, DOI 10.1371/journal.pbio.0020391
   Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501
   BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X
   Beghini A, 2000, HUM MOL GENET, V9, P2297, DOI 10.1093/oxfordjournals.hmg.a018921
   Blow MJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r27
   Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0
   Cenci C, 2008, J BIOL CHEM, V283, P7251, DOI 10.1074/jbc.M708316200
   Cohen K J, 2001, Curr Treat Options Oncol, V2, P529
   Eisenberg E, 2005, TRENDS GENET, V21, P77, DOI 10.1016/j.tig.2004.12.005
   Gallo A, 2003, EMBO J, V22, P3421, DOI 10.1093/emboj/cdg327
   Gott JM, 2000, ANNU REV GENET, V34, P499, DOI 10.1146/annurev.genet.34.1.499
   Higuchi M, 2000, NATURE, V406, P78
   Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746
   Ishiuchi S, 2007, J NEUROSCI, V27, P7987, DOI 10.1523/JNEUROSCI.2180-07.2007
   Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100
   Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1011/gr.2094104
   Kawahara Y, 2007, EMBO REP, V8, P763, DOI 10.1038/sj.embor.7401011
   Kawahara Y, 2007, SCIENCE, V315, P1137, DOI 10.1126/science.1138050
   Keegan LP, 2001, NAT REV GENET, V2, P869, DOI 10.1038/35098584
   Kim DDY, 2004, GENOME RES, V14, P1719, DOI 10.1101/gr.285504
   Lai F, 1997, J NEUROCHEM, V69, P43
   Laurencikiene J, 2006, EMBO REP, V7, P303, DOI 10.1038/sj.embor.7400621
   Lehmann KA, 2000, BIOCHEMISTRY-US, V39, P12875, DOI 10.1021/bi001383g
   Levanon Erez Y., 2006, Briefings in Functional Genomics & Proteomics, V5, P43, DOI 10.1093/bfgp/ell014
   Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996
   Levanon K, 2005, EMBO REP, V6, P831, DOI 10.1038/sj.embor.7400507
   Luciano DJ, 2004, RNA, V10, P1174, DOI 10.1261/rna.7350304
   Maas S, 2001, P NATL ACAD SCI USA, V98, P14687, DOI 10.1073/pnas.251531398
   Maas Stefan, 2006, RNA Biol, V3, P1
   Macbeth MR, 2005, SCIENCE, V309, P1534, DOI 10.1126/science.1113150
   Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001
   Morse DP, 1999, P NATL ACAD SCI USA, V96, P6048, DOI 10.1073/pnas.96.11.6048
   Nie YZ, 2005, MOL CELL BIOL, V25, P6956, DOI 10.1128/MCB.25.16.6956-6963.2005
   Nishikura K, 2006, NAT REV MOL CELL BIO, V7, P919, DOI 10.1038/nrn2061
   Nishimoto Y, 2008, NEUROSCI RES, V61, P201, DOI 10.1016/j.neures.2008.02.009
   Paul MS, 1998, EMBO J, V17, P1120, DOI 10.1093/emboj/17.4.1120
   Paz N, 2007, GENOME RES, V17, P1586, DOI 10.1101/gr.6493107
   Pfeffer S, 2005, NAT METHODS, V2, P269, DOI 10.1038/NMETH746
   POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x
   Poulsen H, 2006, RNA, V12, P1350, DOI 10.1261/rna.2314406
   REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8
   Rickert CH, 2001, CHILD NERV SYST, V17, P503, DOI 10.1007/s003810100496
   Riedmann EM, 2008, RNA, V14, P1110, DOI 10.1261/rna.923308
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1
   Valente L, 2007, J BIOL CHEM, V282, P16054, DOI 10.1074/jbc.M611392200
   Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765
   Wong SK, 2001, RNA, V7, P846, DOI 10.1017/S135583820101007X
NR 48
TC 12
Z9 12
U1 3
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0903-4641
EI 1600-0463
J9 APMIS
JI APMIS
PD AUG
PY 2009
VL 117
IS 8
BP 551
EP 557
DI 10.1111/j.1600-0463.2009.02505.x
PG 7
WC Immunology; Microbiology; Pathology
SC Immunology; Microbiology; Pathology
GA 474CS
UT WOS:000268260600001
PM 19664125
DA 2018-12-27
ER

PT J
AU Jiang, LX
   Naganuma, H
   Oogane, M
   Ando, Y
AF Jiang, Lixian
   Naganuma, Hiroshi
   Oogane, Mikihiko
   Ando, Yasuo
TI RETRACTED: Large Tunnel Magnetoresistance of 1056% at Room Temperature
   in MgO Based Double Barrier Magnetic Tunnel Junction (Retracted article.
   See vol. 4, artn no. 019201, 2011)
SO APPLIED PHYSICS EXPRESS
LA English
DT Article; Retracted Publication
AB CoFeB/MgO/CoFeB/MgO/CoFeB double barrier magnetic tunnel junctions (DBMTJs) with thin middle layers were fabricated on SiO2/Si(001) substrates by r.f. magnetron sputtering. We successfully obtained a large tunnel magnetoresistance of 1056% at room temperature in a DBMTJ with a middle CoFeB layer thickness of 1.2 nm that was fabricated at a relatively low post-deposition annealing temperature of 350 degrees C. This DBMTJ also realized sharp magnetization switching in the free middle CoFeB layer, which is attributed to strong antiferromagnetic coupling between the exterior CoFeB and PtMn layers. These favorable magnetoresistive properties offer interesting possibilities for developing practical spintronics applications and noble magnetotransport physics. (C) 2009 The Japan Society of Applied Physics
C1 [Jiang, Lixian; Naganuma, Hiroshi; Oogane, Mikihiko; Ando, Yasuo] Tohoku Univ, Dept Appl Phys, Grad Sch Engn, Aoba Ku, Sendai, Miyagi 9808579, Japan.
RP Naganuma, H (reprint author), Tohoku Univ, Dept Appl Phys, Grad Sch Engn, Aoba Ku, Sendai, Miyagi 9808579, Japan.
EM naganuma@mlab.apph.tohoku.ac.jp
RI Naganuma, Hiroshi/Q-7195-2018
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT) of
   Japan
FX This study was supported by the "High-Performance Low-Power Consumption
   Spin Devices and Storage Systems" program under Research and Development
   for Next-Generation Information Technology, and also partially supported
   by the JSPS-NSFC joint program by the Ministry of Education, Culture,
   Sports, Science and Technology (MEXT) of Japan. The authors would like
   to thank ULVAC, Inc. for their assistance with the preparation of the
   stacked films for DBMTJs.
CR Butler WH, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.054416
   Djayaprawira DD, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1871344
   Hayakawaa J, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2402904
   Ikeda S, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2976435
   Lee YM, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2742576
   Mathon J, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.220403
   MIYAZAKI T, 1995, J MAGN MAGN MATER, V139, pL231, DOI 10.1016/0304-8853(95)90001-2
   MOODERA JS, 1995, PHYS REV LETT, V74, P3273, DOI 10.1103/PhysRevLett.74.3273
   Niizeki T, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.047207
   Nozaki T, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.027208
   Parkin SSP, 2004, NAT MATER, V3, P862, DOI 10.1038/nmat1256
   Yakushiji K, 2002, J APPL PHYS, V91, P7038, DOI 10.1063/1.1447189
   Yuasa S, 2004, JPN J APPL PHYS 2, V43, pL588, DOI 10.1143/JJAP.43.L588
   Yuasa S, 2002, SCIENCE, V297, P234, DOI 10.1126/science.1071300
   Yuasa S, 2004, NAT MATER, V3, P868, DOI 10.1038/nmat1257
   Zeng ZM, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.054419
NR 16
TC 54
Z9 55
U1 5
U2 34
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1882-0778
EI 1882-0786
J9 APPL PHYS EXPRESS
JI Appl. Phys. Express
PD AUG
PY 2009
VL 2
IS 8
AR 083002
DI 10.1143/APEX.2.083002
PG 3
WC Physics, Applied
SC Physics
GA 490PP
UT WOS:000269513500013
DA 2018-12-27
ER

PT J
AU Lee, MJ
   Ryoo, BY
   Sullivan, KT
   Hanna, AS
AF Lee, Min-Jae
   Ryoo, Boong Yeol
   Sullivan, Kenneth T.
   Hanna, Awad S.
TI RETRACTED: Development of automated change order impact detection and
   quantification system (Retracted article. See vol. 19, pg. 518, 2010)
SO AUTOMATION IN CONSTRUCTION
LA English
DT Review; Retracted Publication
DE Change orders; Productivity impact; Detection and quantification system
AB When change orders occur. adjustments in contract price and duration are usually agreed upon through negotiation or stipulated by contract terms and conditions. There are many pricing methods for change orders impact on productivity loss available, but negotiations using these methods do not always result in a contractor and client agreement. The most difficult issue to agree upon is how to quantify the cumulative impact of change orders on overall construction project. Cumulative impact claims imply that the disruption caused by a single change can have a ripple effect on the entire project, beyond the change itself. In order to recover cumulative impact damages, by law, the contractor is required to prove three basic components: liability, causation, and resultant injury (quantum). Of these elements, causation and resultant injury are the most difficult to prove. There has been some research performed to quantify the cumulative impact of change orders on labor productivity. CII and the University of Wisconsin have performed the most recent and extensive study related to this issue. This study used previous CII-Hanna research models to develop an automated system for the detection and quantification of change order impacts. In addition. a project demonstration is included to allow easy understanding for new system users. The developed system provides a simple guide for stakeholders to expedite the resolution of change order related disputes between contractors and owners by providing causation and resultant injury(quantum) analysis on troubled projects. (C) 2009 Published by Elsevier B.V.
C1 [Ryoo, Boong Yeol] Texas A&M Univ, Dept Construct Sci, Coll Architecture, College Stn, TX 77843 USA.
   [Lee, Min-Jae] Chungnam Natl Univ, Dept Civil Engn, Taejon 305764, South Korea.
   [Sullivan, Kenneth T.] Arizona State Univ, Del E Webb Sch Construct, Tempe, AZ 85287 USA.
   [Hanna, Awad S.] Univ Wisconsin, Dept Civil & Envir Engrg, Madison, WI 53706 USA.
RP Ryoo, BY (reprint author), Texas A&M Univ, Dept Construct Sci, Coll Architecture, 3137 TAMU, College Stn, TX 77843 USA.
EM Lmjcm@cnu.ac.kr; bryoo@tamu.edu; Kenneth.Sullivan@asu.edu;
   hanna@engr.wisc.edu
CR Cushman R. F., 1994, CONSTRUCTION CHANGE
   Hanna AS, 2002, J CONSTR ENG M ASCE, V128, P57, DOI 10.1061/(ASCE)0733-9364(2002)128:1(57)
   Hanna AS, 2004, J CONSTR ENG M ASCE, V130, P762, DOI 10.1061/(ASCE)0733-9364(2004)030:6(762)
   Hanna AS, 2002, J COMPUT CIVIL ENG, V16, P252, DOI 10.1061/(ASCE)0887-3801(2002)16:4(252)
   HANNA AS, 2001, 15811 CII U TEX
   HESTER, 1991, 66 CII
   Ibbs C. W., 1995, 108 U TEX CONSTR IND
   JONES RM, 2001, CONSTRUCTION LAW J, V1
   Lee Min-Jae, 2005, [Korean Journal of Construction Engineering and Management, 한국건설관리학회 논문집], V6, P69
   LEONARD C, 1991, CANADIAN J CIVIL ENG, V18, P484
   THOMAS HR, 1994, 99 CII
NR 11
TC 3
Z9 3
U1 5
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0926-5805
J9 AUTOMAT CONSTR
JI Autom. Constr.
PD AUG
PY 2009
VL 18
IS 5
BP 525
EP 535
DI 10.1016/j.autcon.2009.03.002
PG 11
WC Construction & Building Technology; Engineering, Civil
SC Construction & Building Technology; Engineering
GA 464CX
UT WOS:000267483700002
DA 2018-12-27
ER

PT J
AU Preabrazhenskaya, YV
   Kim, IY
   Stadtman, TC
AF Preabrazhenskaya, Y. V.
   Kim, I. Y.
   Stadtman, T. C.
TI RETRACTED: Binding of ATP and its derivatives to selenophosphate
   synthetase from Escherichia coli (Retracted Article. See vol 75, pg
   1302, 2010)
SO BIOCHEMISTRY-MOSCOW
LA English
DT Article; Retracted Publication
DE selenophosphate synthetase; truncated mutants; ATP-binding; fluorescence
   enhancement
ID SELENOPROTEIN SYNTHESIS; SELENIUM; ENZYME; SELENOCYSTEINE; PURIFICATION;
   MECHANISM; PROTEINS; AFFINITY; PEPTIDE; GENES
AB Mechanistically similar selenophosphate synthetases (SPS) have been isolated from different organisms. SPS from Escherichia coli is an ATP-dependent enzyme with a C-terminal glycine-rich Walker sequence that has been assumed to take part in the first step of ATP binding. Three C-terminally truncated mutants of SPS, containing the N-terminal 238 (SPS238), 262 (SPS262), and 332 (SPS332) amino acids of the 348-amino-acid protein, have been extracted from cell pellets, and two of these (SPS262 and SPS332) have been purified to homogeneity. SPS238 has been obtained in a highly purified form. Binding of the fluorescent ATP-derivative TNP-ATP and Mn-ATP to the proteins was examined for all truncated mutants of SPS and a catalytically inactive C17S mutant. It has been shown that TNP-ATP can be used as a structural probe for ATP-binding sites of SPS. We observed two TNP-ATP binding sites per molecule of enzyme for wild-type SPS and SPS332 mutant and one TNP-ATP binding site for SPS238 mutant. The stoichiometry of Mn-ATP-binding was 2 mol of ATP per mol of protein determined with [C-14]ATP by HPLC gel-filtration column chromatography under saturating conditions. The binding stoichiometries for SPS332, SPS262, and SPS238 were 2, 1.6, and 1, respectively. The C17S mutant exhibits about one third of wild type SPS TNP-ATP-binding ability and converts 12% of ATP in the ATPase reaction to ADP in the absence of selenide. The C-terminus contributes two thirds to the TNP-ATP binding; SPS238 likely has one ATP-binding site removed by truncation.
C1 [Preabrazhenskaya, Y. V.; Kim, I. Y.; Stadtman, T. C.] NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA.
   [Preabrazhenskaya, Y. V.] Grodno State Univ, Dept Biol & Ecol, Grodno 230015, BELARUS.
RP Preabrazhenskaya, YV (reprint author), NHLBI, Biochem Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM yuliya.preabrazh@gmail.com
CR CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895
   EHRENREICH A, 1992, EUR J BIOCHEM, V206, P767, DOI 10.1111/j.1432-1033.1992.tb16983.x
   HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8
   KIM IY, 1994, P NATL ACAD SCI USA, V91, P7326, DOI 10.1073/pnas.91.15.7326
   KIM IY, 1992, J BIOL CHEM, V267, P19650
   KIM IY, 1993, J BIOL CHEM, V268, P27020
   KO YH, 1994, J BIOL CHEM, V269, P14584
   Krepkiy DV, 2005, BIOCHEMISTRY-US, V44, P2671, DOI 10.1021/bi0484217
   Kubala M, 2003, EUR BIOPHYS J BIOPHY, V32, P363, DOI 10.1007/s00249-003-0278-y
   Lacourciere GM, 1999, P NATL ACAD SCI USA, V96, P44, DOI 10.1073/pnas.96.1.44
   Lacourciere GM, 2000, J BIOL CHEM, V275, P23769, DOI 10.1074/jbc.M000926200
   LEINFELDER W, 1988, J BACTERIOL, V170, P540, DOI 10.1128/jb.170.2.540-546.1988
   LEINFELDER W, 1990, P NATL ACAD SCI USA, V87, P543, DOI 10.1073/pnas.87.2.543
   LOW SC, 1995, J BIOL CHEM, V270, P21659, DOI 10.1074/jbc.270.37.21659
   Martin DW, 2000, J BIOL CHEM, V275, P24512, DOI 10.1074/jbc.M003179200
   Mullins LS, 1997, J AM CHEM SOC, V119, P6684, DOI 10.1021/ja971074m
   Ogasawara Y, 2005, P NATL ACAD SCI USA, V102, P1012, DOI 10.1073/pnas.0409042102
   Patteson KG, 2005, P NATL ACAD SCI USA, V102, P12029, DOI 10.1073/pnas.0505650102
   SIMONDS WF, 1980, P NATL ACAD SCI-BIOL, V77, P4623, DOI 10.1073/pnas.77.8.4623
   Soti C, 2003, EUR J BIOCHEM, V270, P2421, DOI 10.1046/j.1432-1033.2003.03610.x
   Tamura T, 2004, P NATL ACAD SCI USA, V101, P16162, DOI 10.1073/pnas.0406313101
   VERES Z, 1994, J BIOL CHEM, V269, P10597
   Walker H, 1998, P NATL ACAD SCI USA, V95, P2180, DOI 10.1073/pnas.95.5.2180
   Wolfe MD, 2003, IUBMB LIFE, V55, P689, DOI 10.1080/15216540310001643431
NR 24
TC 2
Z9 2
U1 3
U2 14
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0006-2979
EI 1608-3040
J9 BIOCHEMISTRY-MOSCOW+
JI Biochem.-Moscow
PD AUG
PY 2009
VL 74
IS 8
BP 910
EP 916
DI 10.1134/S0006297909080136
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 486QL
UT WOS:000269212600013
PM 19817692
DA 2018-12-27
ER

PT J
AU Langguth, B
   Sand, P
   Marek, R
   Landgrebe, M
   Frank, E
   Hajak, G
   Eichhammer, P
AF Langguth, Berthold
   Sand, Philipp
   Marek, Roger
   Landgrebe, Michael
   Frank, Elmar
   Hajak, Goeran
   Eichhammer, Peter
TI RETRACTED: Allelic Variation in the Serotonin Transporter Promoter
   Modulates Cortical Excitability (Retracted article. See vol. 67, pg.
   193, 2010)
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article; Retracted Publication
DE Excitability; human motor cortex; paired pulse transcranial magnetic
   stimulation; serotonin transporter polymorphism
ID HUMAN MOTOR CORTEX; TRANSCRANIAL MAGNETIC STIMULATION; AUDITORY-EVOKED
   POTENTIALS; INTENSITY DEPENDENCE; GENETIC-VARIATION; HUMAN BRAIN;
   POLYMORPHISM; ASSOCIATION; DEPRESSION; POPULATION
AB Background: Transcranial magnetic stimulation (TMS) is a noninvasive procedure that may be used to study individual differences in motor cortex excitability. Such differences are assumed to reflect serotonergic and other inputs to the motor cortex.
   Methods: Here we investigate the impact of a functional polymorphism in the promoter region of the 5-hydroxytryptamine transporter gene (5-HTLLPR) on measures of motor cortex excitability.
   Results: Sixty healthy subjects carrying one or two copies of the short 5-HTTLPR allele (s/s and s/I) showed a significant reduction in short intracortical inhibition (SICI, p = .012) and an increased cortical silent period (p = .042) compared with 60 age-and sex-matched individuals homozygous for the long allele (I/I). In contrast, motor threshold and intracortical facilitation did not differ significantly between groups.
   Conclusions: These results provide further evidence of a role for serotonergic transmission in the modulation of cortical excitability. Differential effects on the measures under study suggest a pattern of prioritization in bioamine regulation of cortical inhibition.
C1 [Langguth, Berthold; Sand, Philipp; Marek, Roger; Landgrebe, Michael; Frank, Elmar; Hajak, Goeran; Eichhammer, Peter] Univ Regensburg, Dept Psychiat, D-93053 Regensburg, Germany.
RP Langguth, B (reprint author), Univ Regensburg, Dept Psychiat, Univ Str 84, D-93053 Regensburg, Germany.
EM Berthold.Langguth@medbo.de
RI Marek, Roger/B-7327-2016
OI Marek, Roger/0000-0002-5773-2662
FU University of Regensburg.
FX The research was funded by the Department Psychiatry, of the University
   of Regensburg.
CR Ase AR, 2008, J CHEM NEUROANAT, V35, P356, DOI 10.1016/j.jchemneu.2008.02.007
   Bocchio-Chiavetto L, 2008, NEUROSCI LETT, V437, P130, DOI 10.1016/j.neulet.2008.04.005
   Brocke B, 2006, MOL PSYCHIATR, V11, P1106, DOI 10.1038/sj.mp.4001908
   Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968
   Cornelisse LN, 2007, J NEUROPHYSIOL, V98, P196, DOI 10.1152/jn.00109.2007
   David SP, 2005, J NEUROSCI, V25, P2586, DOI 10.1523/JNEUROSCI.3769-04.2005
   Deng PY, 2008, MOL CELL NEUROSCI, V39, P273, DOI 10.1016/j.mcn.2008.07.005
   Eichhammer P, 2003, PSYCHOPHARMACOLOGY, V166, P294, DOI 10.1007/s00213-002-1370-1
   Fallgatter AJ, 2004, NEUROPSYCHOPHARMACOL, V29, P1506, DOI 10.1038/sj.npp.1300409
   Fallgatter AJ, 1999, INT J NEUROPSYCHOP, V2, P115, DOI 10.1017/S1461145799001455
   Gallinat J, 2003, NEUROPSYCHOPHARMACOL, V28, P530, DOI 10.1038/sj.npp.1300042
   Greenberg BD, 2000, AM J MED GENET, V96, P202, DOI 10.1002/(SICI)1096-8628(20000403)96:2<202::AID-AJMG16>3.0.CO;2-J
   Hariri AR, 2002, SCIENCE, V297, P400, DOI 10.1126/science.1071829
   Heils A, 1996, J NEUROCHEM, V66, P2621
   Hensch T, 2006, NEUROPSYCHOPHARMACOL, V31, P2047, DOI 10.1038/sj.npp.1301020
   Ilic TV, 2002, NEUROSCI LETT, V319, P116, DOI 10.1016/S0304-3940(01)02563-0
   Jang KL, 2001, J PERS SOC PSYCHOL, V81, P295, DOI 10.1037//0022-3514.81.2.295
   Juckel G, 2007, PSYCHIAT RES, V153, P183, DOI 10.1016/j.psychres.2006.12.014
   Kleim JA, 2006, NAT NEUROSCI, V9, P735, DOI 10.1038/nn1699
   KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912
   Landgrebe M, 2008, PSYCHOL MED, V38, P1781, DOI 10.1017/S0033291708003097
   Landgrebe M, 2007, J PSYCHOSOM RES, V62, P283, DOI 10.1016/j.jpsychores.2006.11.007
   Lang N, 2006, EPILEPSIA, V47, P813, DOI 10.1111/j.1528-1167.2006.00544.x
   Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527
   Lesch KP, 1998, BIOL PSYCHIAT, V44, P179, DOI 10.1016/S0006-3223(98)00121-8
   Parsey RV, 2006, AM J PSYCHIAT, V163, P48, DOI 10.1176/appi.ajp.163.1.48
   Praschak-Rieder N, 2008, ARCH GEN PSYCHIAT, V65, P1072, DOI 10.1001/archpsyc.65.9.1072
   Robol E, 2004, J NEUROL SCI, V221, P41, DOI 10.1016/j.jns.2004.03.007
   ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9
   Siebner HR, 1998, MUSCLE NERVE, V21, P1209, DOI 10.1002/(SICI)1097-4598(199809)21:9<1209::AID-MUS15>3.0.CO;2-M
   Smith MJ, 1999, NEUROLOGY, V53, P2069, DOI 10.1212/WNL.53.9.2069
   Smith MJ, 2002, ANN NEUROL, V51, P599, DOI 10.1002/ana.10180
   Strobel A, 1999, MOL PSYCHIATR, V4, P378, DOI 10.1038/sj.mp.4000535
   Strobel A, 2003, AM J MED GENET B, V118B, P41, DOI 10.1002/ajmg.b.10019
   Torres-Escalante JL, 2004, J NEUROSCI RES, V78, P268, DOI 10.1002/jnr.20247
   Wassermann EM, 2002, CLIN NEUROPHYSIOL, V113, P1165, DOI 10.1016/S1388-2457(02)00144-X
   Wassermann EM, 2001, BIOL PSYCHIAT, V50, P377, DOI 10.1016/S0006-3223(01)01210-0
   Werhahn KJ, 1998, NEUROLOGY, V51, P896, DOI 10.1212/WNL.51.3.896
   Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x
   Zanardi R, 2007, EUR NEUROPSYCHOPHARM, V17, P651, DOI 10.1016/j.euroneuro.2007.03.008
   Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006
   Ziemann U, 1996, EXP BRAIN RES, V109, P127
   ZIEMANN U, 2000, TRANSCRANIAL MAGNETI, P45
NR 43
TC 3
Z9 3
U1 3
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD AUG 1
PY 2009
VL 66
IS 3
BP 283
EP 286
DI 10.1016/biopsych.2009.02.2005
PG 4
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 470FW
UT WOS:000267961600013
PM 19306990
DA 2018-12-27
ER

PT J
AU Vaish, R
   Varma, KBR
AF Vaish, Rahul
   Varma, K. B. R.
TI RETRACTED: Influence of seeding on crystallization behaviour of
   BaNaB9O15 glasses (Retracted article. See vol. 32, pg. 561, 2009)
SO BULLETIN OF MATERIALS SCIENCE
LA English
DT Article; Retracted Publication
DE Borates; glasses; nonlinear optic materials; crystallization; DSC
ID NONISOTHERMAL CRYSTALLIZATION; SURFACE CRYSTALLIZATION; PHASE-CHANGE;
   KINETICS; BORATE; APPLICABILITY; CRYSTALS; GROWTH; MODEL
AB Transparent BaNaB9O15 (BNBO) glasses were fabricated via the conventional melt-quenching technique. X-ray powder diffraction (XRD) followed by differential scanning calorimetric (DSC) studies confirmed the amorphous and glassy nature of the as-quenched samples, respectively. The effect of seeding on the crystallization of BNBO glasses was studied by non-isothermal DSC method and was modeled using the Johnson-Mehl-Avrami and Ozawa equations. The activation energy for seeded glasses decreased with the increase in fraction of crystallization. The values for the onset of crystallization and Avrami exponent were found to be lower for seeded samples which were associated with the heterogeneous nucleation and epitaxial processes.
C1 [Vaish, Rahul; Varma, K. B. R.] Indian Inst Sci, Mat Res Ctr, Bangalore 560012, Karnataka, India.
RP Varma, KBR (reprint author), Indian Inst Sci, Mat Res Ctr, Bangalore 560012, Karnataka, India.
EM kbrvarma@mrc.iisc.ernet.in
CR AFIFY N, 1991, J NON-CRYST SOLIDS, V128, P269, DOI 10.1016/0022-3093(91)90464-H
   Avrami M, 1941, J CHEM PHYS, V9, P177, DOI 10.1063/1.1750872
   Avrami M., 1940, Journal of Chemical Physics, V8, P212, DOI 10.1063/1.1750631
   Avrami M, 1939, J CHEM PHYS, V7, P1103, DOI 10.1063/1.1750380
   DING Y, 1994, J AM CERAM SOC, V77, P749, DOI 10.1111/j.1151-2916.1994.tb05360.x
   HOLAND W, 1995, J NON-CRYST SOLIDS, V180, P292, DOI 10.1016/0022-3093(94)00464-1
   Honma T, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2212272
   Jing FL, 2006, J CRYST GROWTH, V292, P454, DOI 10.1016/j.jcrysgro.2006.04.054
   Joraid AA, 2008, J NON-CRYST SOLIDS, V354, P3380, DOI 10.1016/j.jnoncrysol.2008.02.002
   Joraid AA, 2007, THERMOCHIM ACTA, V456, P1, DOI 10.1016/j.tca.2007.01.023
   LIU CL, 1992, J AM CERAM SOC, V75, P2665, DOI 10.1111/j.1151-2916.1992.tb05486.x
   LIU CL, 1994, J AM CERAM SOC, V77, P3105, DOI 10.1111/j.1151-2916.1994.tb04556.x
   Malek J, 1995, THERMOCHIM ACTA, V267, P61, DOI 10.1016/0040-6031(95)02466-2
   Murugan GS, 2002, J MATER CHEM, V12, P1426, DOI 10.1039/b107794p
   Murugan GS, 2001, APPL PHYS LETT, V78, P4019, DOI 10.1063/1.1380237
   Nishioka M, 2005, J CRYST GROWTH, V279, P76, DOI 10.1016/j.jcrysgro.2004.11.418
   OZAWA T, 1986, J THERM ANAL, V31, P547, DOI 10.1007/BF01914230
   Penin N, 2001, INT J INORG MATER, V3, P1015, DOI 10.1016/S1466-6049(01)00078-2
   Prasad NS, 2003, J SOLID STATE CHEM, V173, P209, DOI 10.1016/S0022-4596(03)00026-4
   SELVARAJ U, 1991, J MATER SCI, V26, P3689, DOI 10.1007/BF00557165
   SOUZA JED, 2007, APPL PHYS LETT, V91
   WANG Y, 1995, APPL PHYS LETT, V67, P2462, DOI 10.1063/1.114608
   YINNON H, 1983, J NON-CRYST SOLIDS, V54, P253, DOI 10.1016/0022-3093(83)90069-8
NR 23
TC 1
Z9 1
U1 4
U2 12
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0250-4707
EI 0973-7669
J9 B MATER SCI
JI Bull. Mat. Sci.
PD AUG
PY 2009
VL 32
IS 4
BP 387
EP 392
DI 10.1007/s12034-009-0056-2
PG 6
WC Materials Science, Multidisciplinary
SC Materials Science
GA 506ZB
UT WOS:000270817300004
DA 2018-12-27
ER

PT J
AU Shafer-Weaver, KA
   Watkins, SK
   Anderson, MJ
   Draper, LJ
   Malyguine, A
   Alvord, WG
   Greenberg, NM
   Hurwitz, AA
AF Shafer-Weaver, Kimberly A.
   Watkins, Stephanie K.
   Anderson, Michael J.
   Draper, Lauren J.
   Malyguine, Anatoli
   Alvord, W. Gregory
   Greenberg, Norman M.
   Hurwitz, Arthur A.
TI RETRACTED: Immunity to Murine Prostatic Tumors: Continuous Provision of
   T-Cell Help Prevents CD8 T-Cell Tolerance and Activates
   Tumor-Infiltrating Dendritic Cells (Retracted article. See vol. 76, pg.
   2490, 2016)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID ADOPTIVE IMMUNOTHERAPY; ANTITUMOR IMMUNITY; GROWTH-FACTOR; IN-VITRO;
   LYMPHOCYTES; CANCER; MEMORY; ANTIGEN; MELANOMA; LOCALIZATION
AB We reported previously that tumor-specific CD8(+) T cells (TcR-I) become tolerant in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. In this study, we show that CD4(+) TcR transgenic (TcR-II) T cells transferred into TRAMP mice became activated in lymph nodes, trafficked to the prostate, and initially functioned as T(H)1 cells. Although a single cotransfer of TcR-II cells delayed TcR-I cell tolerization, repeated transfer of TcR-II cells was required to prevent TcR-I cell tolerization and significantly slowed progression of TRAMP prostate tumors. After transfer of TcR-II cells, dendritic cells within the tumor expressed higher levels of costimulatory molecules and displayed an enhanced ability to stimulate proliferation of naive T cells. Blockade of CD40-CD40L interactions during TcR-II transfer resulted in a profound reduction in dendritic cell stimulatory capacity and a partial loss of TcR-I effector functions and tumor immunity. These data show that sustained provision of activated tumor-specific CD4(+) T cells alters the immunosuppressive tumor microenvironment, ultimately leading to the control of tumor growth. These findings will assist in the design of more effective immunotherapeutic approaches for cancer. [Cancer Res 2009;69(15):6256-64]
C1 [Hurwitz, Arthur A.] NCI, Canc & Inflammat Program, NIH, Tumor Immun & Tolerance Sect,Lab Mol Immunoregula, Frederick, MD 21701 USA.
   [Shafer-Weaver, Kimberly A.; Malyguine, Anatoli] SAIC Frederick Inc, Lab Cell Mediated Immun, Frederick, MD USA.
   [Alvord, W. Gregory] NCI, Div Biostat, Data Management Serv, Frederick, MD 21701 USA.
   [Greenberg, Norman M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
RP Hurwitz, AA (reprint author), NCI, Canc & Inflammat Program, NIH, Tumor Immun & Tolerance Sect,Lab Mol Immunoregula, 211 Bldg 567, Frederick, MD 21701 USA.
EM hurwitza@mail.nih.gov
FU National Cancer Institute/NIH [010954, N01-CO-12400]; Department of
   Defense prostate Cancer Research program; NCI [CA84296]
FX Grant support: Intramural Research Program of the National Cancer
   Institute/NIH Z01 grant 010954 (A.A. Hurwitz, S.K. Watkins, M.J.
   Anderson. and L.J. Draper), National Cancer Institute/NIH contract
   N01-CO-12400 (KA. Shafer-Weaver and A. Malyguine), Department of Defense
   prostate Cancer Research program (A.A. Hurwitz), and NCI grant. CA84296
   (N.M. Greenberg).
CR Anderson MJ, 2007, J IMMUNOL, V178, P1268, DOI 10.4049/jimmunol.178.3.1268
   Antony PA, 2005, J IMMUNOL, V174, P2591, DOI 10.4049/jimmunol.174.5.2591
   Bennett SRM, 1998, NATURE, V393, P478
   Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747
   CHANG AE, 1993, CANCER RES, V53, P1043
   CHEN QY, 1994, INT J CANCER, V56, P755, DOI 10.1002/ijc.2910560524
   de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388
   FORSTER I, 1995, IMMUNITY, V2, P573, DOI 10.1016/1074-7613(95)90002-0
   Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096
   Gattinoni L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480
   Gattinoni L, 2006, NAT REV IMMUNOL, V6, P383, DOI 10.1038/nri1842
   GEIGER T, 1992, P NATL ACAD SCI USA, V89, P2985, DOI 10.1073/pnas.89.7.2985
   GOEDEGEBUURE PS, 1995, IMMUNOL RES, V14, P119, DOI 10.1007/BF02918172
   GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439
   Huang H, 2007, IMMUNOLOGY, V120, P148, DOI 10.1111/j.1365-2567.2006.02452.x
   Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   Klebanoff CA, 2005, P NATL ACAD SCI USA, V102, P9571, DOI 10.1073/pnas.0503726102
   Marzo AL, 2000, J IMMUNOL, V165, P6047, DOI 10.4049/jimmunol.165.11.6047
   POCKAJ BA, 1994, CANCER, V73, P1731, DOI 10.1002/1097-0142(19940315)73:6<1731::AID-CNCR2820730630>3.0.CO;2-H
   Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321
   Ross Susan, 1993, Biotechnology Therapeutics, V4, P197
   Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002
   Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305
   Shinde S, 1996, J IMMUNOL, V157, P2764
   Staveley-O'Carroll K, 1998, P NATL ACAD SCI USA, V95, P1178, DOI 10.1073/pnas.95.3.1178
   Sun JC, 2004, NAT IMMUNOL, V5, P927, DOI 10.1038/ni1105
   SUN JC, 2003, SCIENCE, V300, P263
   Wechter WJ, 2000, CANCER RES, V60, P2203
   Whiteside TL, 1999, CANCER IMMUNOL IMMUN, V48, P346, DOI 10.1007/s002620050585
   Yee C, 2000, J EXP MED, V192, P1637, DOI 10.1084/jem.192.11.1637
NR 30
TC 46
Z9 46
U1 3
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD AUG 1
PY 2009
VL 69
IS 15
BP 6256
EP 6264
DI 10.1158/0008-5472.CAN-08-4516
PG 9
WC Oncology
SC Oncology
GA 480MC
UT WOS:000268737900033
PM 19622771
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Liu, ZC
   Wang, J
   Yin, P
   Qiu, JH
   Liu, RZ
   Li, WZ
   Fan, X
   Cheng, XF
   Chen, CX
   Zhang, JK
   Zhuang, GH
AF Liu, Zhongchen
   Wang, Juan
   Yin, Ping
   Qiu, Jinhua
   Liu, Ruizhen
   Li, Wenzhu
   Fan, Xin
   Cheng, Xiaofeng
   Chen, Caixia
   Zhang, Jiakai
   Zhuang, Guohong
TI RETRACTED: RGD-FasL Induces Apoptosis in Hepatocellular Carcinoma
   (Retracted article. See vol. 10, pg. 183, 2013)
SO CELLULAR & MOLECULAR IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE FasL; RGD-FasL; apoptosis; tumor targeting
ID TUMOR-NECROSIS-FACTOR; GLY-ASP SEQUENCE; FACTOR-ALPHA; INTERFERON-GAMMA;
   DRUG-DELIVERY; EXPRESSION; MELPHALAN; PERFUSION; INTEGRIN; BINDING
AB Despite impressive results obtained in animal models, the clinical use of Fas ligand (FasL) as an anticancer drug is limited by severe toxicity. Systemic toxicity of death ligands may be prevented by using genes encoding membrane-bound death ligands and by targeted transgene expression through either targeted transduction or targeted transcription. Selective induction of tumor cell death is a promising anticancer strategy. A fusion protein is created by fusing the extracellular domain of Fas ligand (FasL) to the peptide arginine-glycine-aspartic acid (RGD) that selectively targets av beta 3-integrins on tumor endothelial cells. The purpose of this study is to evaluate the effects of RGD-FasL on tumor growth and survival in a murine hepatocellular carcinoma (HCC) tumor model. Treatment with RGD-FasL displaying an obvious suppressive effect on the HCC tumor model as compared to that with FasL (p < 0.05) and resulted in a more additive effect on tumor growth delay in this model. RGD-FasL treatment significantly enhanced mouse survival and caused no toxic effect, such as weight loss, organ failure, or other treatment-related toxicities. Apoptosis was detected by flow cytometric analysis and TUNEL assays; those results also showed that RGD-FasL is a more potent inducer of cell apoptosis for H22 and H9101 cell lines than FasL (p < 0.05). In conclusion, RGD-FasL appears to be a low-toxicity selective inducer of tumor cell death, which merits further investigation in preclinical and clinical studies. Furthermore, this approach offers a versatile technology for complexing target ligands with therapeutic recombinant proteins. To distinguish the anti-tumor effects of FasL in vivo, tumor and liver tissues were harvested to examine for evidence of necrotic cells, tumor cells, or apoptotic cells by Hematoxylin and eosin (H&E) staining. Cellular & Molecular Immunology. 2009;6(4):285-293.
C1 [Liu, Zhongchen; Wang, Juan; Qiu, Jinhua; Liu, Ruizhen; Li, Wenzhu; Fan, Xin; Cheng, Xiaofeng; Chen, Caixia; Zhuang, Guohong] Xiamen Univ, Coll Med, Anticanc Res Ctr, Xiamen 361005, Peoples R China.
   [Wang, Juan; Li, Wenzhu; Chen, Caixia; Zhang, Jiakai] Xiamen Univ, Sch Life Sci, Xiamen 361005, Peoples R China.
   [Liu, Zhongchen; Yin, Ping] Xiamen Univ, Zhongshan Hosp, Xiamen 361004, Peoples R China.
RP Zhuang, GH (reprint author), Xiamen Univ, Coll Med, Anticanc Res Ctr, 422 Siming S Rd, Xiamen 361005, Peoples R China.
EM zhuangguohong@yahoo.com.cn
RI Zhuang, GH/G-3483-2010
FU Natural Science Foundation of Fujian Province [C0710046]
FX This work was supported by a grant from the Natural Science Foundation
   of Fujian Province (No.C0710046).
CR ADAMSON GM, 1994, J PHARMACOL EXP THER, V269, P367
   ALEXANDER HR, J CLIN ONCOL, V16, P1479
   Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377
   BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0
   DOCI R, 1988, CANCER, V61, P1983, DOI 10.1002/1097-0142(19880515)61:10<1983::AID-CNCR2820611009>3.0.CO;2-V
   EGGERMONT AM, 1996, J CLIN ONCOL, V14, P653
   Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934
   Fraker DL, 1996, J CLIN ONCOL, V14, P479, DOI 10.1200/JCO.1996.14.2.479
   KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205
   KURODA K, 1995, INT J CANCER, V63, P152, DOI 10.1002/ijc.2910630127
   LIENARD D, 1992, J CLIN ONCOL, V10, P52, DOI 10.1200/JCO.1992.10.1.52
   Lu X, 2006, CURR PHARM DESIGN, V12, P2749, DOI 10.2174/138161206777947713
   MIYATA K, 1995, J INTERF CYTOK RES, V15, P161, DOI 10.1089/jir.1995.15.161
   Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542
   Pinkoski MJ, 2000, CURR OPIN GENET DEV, V10, P114, DOI 10.1016/S0959-437X(99)00048-9
   Qin J, 2007, YAKUGAKU ZASSHI, V127, P1497, DOI 10.1248/yakushi.127.1497
   SHEN DW, 1991, J CELL SCI, V98, P317
   SHIKAMA H, 1995, J INTERF CYTOK RES, V15, P677, DOI 10.1089/jir.1995.15.677
   SHIKAMA H, 1994, MEDIAT INFLAMM, V3, P111, DOI 10.1155/S096293519400013X
   Shukla R, 2005, CHEM COMMUN, P5739, DOI 10.1039/b507350b
   SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L
   Villard V, 2006, J PEPT SCI, V12, P206, DOI 10.1002/psc.707
   Weissleder R, 2005, NAT BIOTECHNOL, V23, P1418, DOI 10.1038/nbt1159
   Wu PL, 2006, J BIOL CHEM, V281, P7937, DOI 10.1074/jbc.M513035200
NR 24
TC 8
Z9 9
U1 4
U2 16
PU CHIN SOCIETY IMMUNOLOGY
PI BEING
PA 5 DONGDAN SANTIAO, DONGCHEN DISTRICT, BEING, 100005, PEOPLES R CHINA
SN 1672-7681
J9 CELL MOL IMMUNOL
JI Cell. Mol. Immunol.
PD AUG
PY 2009
VL 6
IS 4
BP 285
EP 293
DI 10.1038/cmi.2009.38
PG 9
WC Immunology
SC Immunology
GA 552WH
UT WOS:000274324000007
PM 19728930
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Maringer, M
   Stapel, DA
AF Maringer, Marcus
   Stapel, Diederik A.
TI RETRACTED: Correction or comparison? The effects of prime awareness on
   social judgments (Retracted article. See vol. 46, pg. 132, 2016)
SO EUROPEAN JOURNAL OF SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
ID FLEXIBLE CORRECTION PROCESSES; IMPRESSION-FORMATION; CATEGORY
   ACCESSIBILITY; CONTRAST; IMPACT; ASSIMILATION; INFERENCE; MODEL; MOOD;
   INFORMATION
AB In previous research on the effects of accessible information on social judgments, divergent explanations have been offered for contrast effects that occur as a consequence of prime awareness. Some authors favor a comparison explanation, whereas others favor a correction explanation. In two studies, we successfully disentangled comparison and correction contrast by demonstrating that whereas correction for unwanted influences is a general process that leads to contrast on various dimensions on which a tat-get is judged, comparison effects are prime specific and occur mainly on comparison relevant dimensions. In addition, our findings indicate that for correction attempts to occur and succeed, respondents must have the feeling that these primes contaminate their target judgments and should be removed from their "true" reaction to the target. When people are not suspicious of the potential contaminating influences of priming stimuli, prime awareness is more likely to lead to prime-target comparisons than to correction efforts. Copyright (C) 2009 John Wiley & Sons, Ltd.
C1 [Maringer, Marcus] Univ Blaise Pascal, Dept Psychol, F-63037 Clermont Ferrand, France.
   [Stapel, Diederik A.] Tilburg Univ, Tilburg, Netherlands.
RP Maringer, M (reprint author), Univ Blaise Pascal, Dept Psychol, 34 Ave Carnot, F-63037 Clermont Ferrand, France.
EM m.maringer@rug.nl
CR BERKOWITZ L, 1990, COGNITION EMOTION, V4, P305, DOI 10.1080/02699939008408080
   BROWN DR, 1953, AM J PSYCHOL, V66, P199, DOI 10.2307/1418726
   CARLSTON DE, 1980, J EXP SOC PSYCHOL, V16, P303, DOI 10.1016/0022-1031(80)90025-6
   Chartrand TL, 1996, J PERS SOC PSYCHOL, V71, P464, DOI 10.1037/0022-3514.71.3.464
   DeCoster J, 2004, PERS SOC PSYCHOL REV, V8, P2, DOI 10.1207/S15327957PSPR0801_1
   Ford TE, 2000, PERS SOC PSYCHOL REV, V4, P317, DOI 10.1207/S15327957PSPR0404_3
   FORGAS JP, 1995, PSYCHOL BULL, V117, P39, DOI 10.1037//0033-2909.117.1.39
   HAMPSON SE, 1986, J PERS SOC PSYCHOL, V51, P37, DOI 10.1037/0022-3514.51.1.37
   HAMPSON SE, 1987, EUROPEAN J PERSONALI, V1, P241, DOI DOI 10.1002/PER.2410010405
   Helson H., 1964, ADAPTATION LEVEL THE
   HIGGINS E T, 1989, P75
   Higgins E. T., 1996, HDB BASIC PRINCIPLES, P133
   HIGGINS ET, 1977, J EXP SOC PSYCHOL, V13, P141
   KAHNEMAN D, 1986, PSYCHOL REV, V93, P136, DOI 10.1037//0033-295X.93.2.136
   LOMBARDI WJ, 1987, PERS SOC PSYCHOL B, V13, P411, DOI 10.1177/0146167287133009
   MANIS M, 1991, J PERS SOC PSYCHOL, V61, P203, DOI 10.1037//0022-3514.61.2.203
   MARINGER M, 2007, AFFECTIVE INFO UNPUB
   Maringer M, 2007, J EXP SOC PSYCHOL, V43, P712, DOI 10.1016/j.jesp.2006.07.007
   MARTIN LL, 1986, J PERS SOC PSYCHOL, V51, P493, DOI 10.1037/0022-3514.51.3.493
   MARTIN LL, 1983, J PERS SOC PSYCHOL, V44, P755, DOI 10.1037/0022-3514.44.4.755
   MURPHY ST, 1993, J PERS SOC PSYCHOL, V64, P723, DOI 10.1037/0022-3514.64.5.723
   Mussweiler T, 2003, PSYCHOL REV, V110, P472, DOI 10.1037/0033-295X.110.3.472
   NEWMAN LS, 1990, PERS SOC PSYCHOL B, V16, P224, DOI 10.1177/0146167290162004
   Ottati VC, 1996, J PERS SOC PSYCHOL, V71, P39, DOI 10.1037/0022-3514.71.1.39
   PETTY RE, 1993, J EXP SOC PSYCHOL, V29, P137, DOI 10.1006/jesp.1993.1007
   Postmes T, 1999, J PERS SOC PSYCHOL, V76, P320, DOI 10.1037//0022-3514.76.2.320
   Quinn KA, 1999, PERS SOC PSYCHOL B, V25, P1430, DOI 10.1177/0146167299259008
   Ric F, 2007, ASSIMILATION AND CONTRAST IN SOCIAL PSYCHOLOGY, P99
   SCHWARZ N, 1990, EUR J SOC PSYCHOL, V20, P357
   SCHWARZ N, 1983, J PERS SOC PSYCHOL, V45, P513, DOI 10.1037/0022-3514.45.3.513
   SCHWARZ N, 1992, CONSTRUCTION OF SOCIAL JUDGMENTS, P217
   SCHWARZ N, 1996, HDB BASIC PRINCIPLES, P433
   Schwarz N, 1988, AFFECT COGNITION SOC, P44, DOI DOI 10.2307/3172815
   Schwarz N., 1990, HDB MOTIVATION COGNI, V2, P527, DOI DOI 10.1016/J.NEUBIOREV.2008.01.001
   Schwetz I, 2007, WIEN KLIN WOCHENSCHR, V119, P1
   Sedikides C., 1991, PSYCHOL INQ, V2, P169, DOI DOI 10.1207/S15327965P1I0202_18
   Srull T.K, 1989, MEMORY COGNITION ITS
   SRULL TK, 1979, J PERS SOC PSYCHOL, V37, P1660, DOI 10.1037//0022-3514.37.10.1660
   Stapel DA, 1998, J PERS SOC PSYCHOL, V74, P878, DOI 10.1037//0022-3514.74.4.878
   Stapel DA, 1997, EUR J SOC PSYCHOL, V27, P357, DOI 10.1002/(SICI)1099-0992(199705)27:3<357::AID-EJSP818>3.0.CO;2-E
   Stapel DA, 1998, PERS SOC PSYCHOL B, V24, P634, DOI 10.1177/0146167298246007
   Stapel DA, 2000, J PERS SOC PSYCHOL, V78, P19, DOI 10.1037//0022-3514.78.1.19
   Stapel DA, 1996, J PERS SOC PSYCHOL, V70, P437, DOI 10.1037/0022-3514.70.3.437
   Stapel DA, 1996, PERS SOC PSYCHOL B, V22, P979, DOI 10.1177/01461672962210001
   Stapel DA, 2007, ASSIMILATION AND CONTRAST IN SOCIAL PSYCHOLOGY, P1
   Stapel DA, 1997, J EXP SOC PSYCHOL, V33, P47, DOI 10.1006/jesp.1996.1311
   Stapel DA, 1998, PERS SOC PSYCHOL B, V24, P797, DOI 10.1177/0146167298248002
   Stapel DA, 2002, J PERS SOC PSYCHOL, V83, P60, DOI 10.1037//0022-3514.83.1.60
   Stapel DA, 2001, J EXP SOC PSYCHOL, V37, P134, DOI 10.1006/jesp.2000.1440
   STRACK F, 1993, EUR J SOC PSYCHOL, V23, P53, DOI 10.1002/ejsp.2420230105
   Strack F., 1996, PSYCHOL ACTION LINKI, P579
   UPSHAW HS, 1984, HDB SOCIAL COGNITION, P237
   VELTEN E, 1968, BEHAV RES THER, V6, P473, DOI 10.1016/0005-7967(68)90028-4
   WEGENER DT, 1995, J PERS SOC PSYCHOL, V68, P36, DOI 10.1037/0022-3514.68.1.36
   Wegener DT, 1997, ADV EXP SOC PSYCHOL, V29, P141, DOI 10.1016/S0065-2601(08)60017-9
   WILSON TD, 1994, PSYCHOL BULL, V116, P117, DOI 10.1037/0033-2909.116.1.117
NR 56
TC 3
Z9 3
U1 4
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0046-2772
EI 1099-0992
J9 EUR J SOC PSYCHOL
JI Eur. J. Soc. Psychol.
PD AUG
PY 2009
VL 39
IS 5
BP 719
EP 733
DI 10.1002/ejsp.569
PG 15
WC Psychology, Social
SC Psychology
GA 476YF
UT WOS:000268482000006
DA 2018-12-27
ER

PT J
AU Noori, R
   Abdoli, MA
   Farokhnia, A
   Abbasi, M
AF Noori, Roohollah
   Abdoli, Mohammad Ali
   Farokhnia, Ashkan
   Abbasi, Maryam
TI RETRACTED: Results uncertainty of solid waste generation forecasting by
   hybrid of wavelet transform-ANFIS and wavelet transform-neural network
   (Retracted article. See vol. 63, pg. 461, 2016)
SO EXPERT SYSTEMS WITH APPLICATIONS
LA English
DT Article; Retracted Publication
DE Artificial neural network; Adaptive neuro-fuzzy inference system;
   Wavelet transform; Uncertainity
ID FUZZY MODELING TOOL; WATER-QUALITY; PREDICTION; RUNOFF; FLOW
AB Both planning and design of municipal solid waste management systems (MSWMS) require accurate prediction of waste generation (WG). In this study, the hybrid of wavelet transform-adaptive neuro-fuzzy inference system (WT-ANFIS) and wavelet transform-artificial neural network (WT-ANN) is used to predict the weekly WG in Tehran, concerning complexity and dynamic MSWMS. In order to input variables preprocessing is done by WT and then new variables entered to ANFIS and ANN models. Consequently, output uncertainty of WT-ANFIS and WT-ANN models is done. The results achieved in this research indicate the positive effect of input variables preprocessing by WT in the prediction of weekly WG in Tehran, and it has led to noticeable increase in the accuracy of two model calculations. However, WT-ANFIS model had better results than WT-ANN model, because of the smaller uncertainty than WT-ANN model. (C) 2009 Published by Elsevier Ltd.
C1 [Noori, Roohollah; Abdoli, Mohammad Ali; Abbasi, Maryam] Univ Tehran, Grad Fac Environm, Dept Environm Engn, Tehran, Iran.
   [Farokhnia, Ashkan] Tarbiat Modrates Univ, Dept Water Resources, Tehran, Iran.
RP Noori, R (reprint author), Univ Tehran, Grad Fac Environm, Dept Environm Engn, Tehran, Iran.
EM roohollahnoori@gmail.com
RI Abdoli, Mohammad Ali/W-8349-2018; zhao, dandan/B-5127-2012
OI Abdoli, Mohammad Ali/0000-0002-0158-4891; Noori,
   Roohollah/0000-0002-7463-8563
CR Abbaspour KC, 2007, J HYDROL, V333, P413, DOI 10.1016/j.jhydrol.2006.09.014
   Aqil M, 2007, J ENVIRON MANAGE, V85, P215, DOI 10.1016/j.jenvman.2006.09.009
   Aqil M, 2007, J HYDROL, V337, P22, DOI 10.1016/j.jhydrol.2007.01.013
   Bishop C. M., 1995, NEURAL NETWORK PATTE
   Brown M, 1994, NEUROFUZZY ADAPTIVE
   Chang NB, 1997, J ENVIRON SCI HEAL A, V32, P885, DOI 10.1080/10934529709376584
   Chen HW, 2000, RESOUR CONSERV RECY, V29, P1, DOI 10.1016/S0921-3449(99)00052-X
   Chi Y, 2005, J ENVIRON SCI-CHINA, V17, P699
   Chiu S., 1994, J INTELL FUZZY SYST, V2, P267, DOI DOI 10.3233/IFS-1994-2306
   Cybenko G., 1989, Mathematics of Control, Signals, and Systems, V2, P303, DOI 10.1007/BF02551274
   DEMUTH H, 1998, NEURAL NETWORK TOOLB
   Grossman D, 1974, J ENVIRON ENG-ASCE, V6, P1219
   Haykin S., 1994, NEURAL NETWORKS COMP
   HORNIK K, 1989, NEURAL NETWORKS, V2, P359, DOI 10.1016/0893-6080(89)90020-8
   Jain A, 2006, J HYDROL, V317, P291, DOI 10.1016/j.jhydrol.2005.05.022
   Jain A, 2003, J HYDROL ENG, V8, P93, DOI 10.1061/(ASCE)1084-0699(2003)8:2(93)
   Jalili M, 2008, INT J ENVIRON RES, V2, P22
   JANG JSR, 1995, P IEEE, V83, P378, DOI 10.1109/5.364486
   JANG JSR, 1991, P IFSA WORLD C, V4, P82
   Jang JSR, 1997, NEUROFUZZY SOFT COMP, P503
   Jang JSR, 1995, FUZZY LOGIC TOOLBOX
   Karaca F, 2006, ENVIRON MODELL SOFTW, V21, P1190, DOI 10.1016/j.envsoft.2005.06.006
   Liu ZF, 2002, J MATER PROCESS TECH, V129, P500, DOI 10.1016/S0924-0136(02)00625-8
   Lu RS, 2002, WATER RES, V36, P2265, DOI 10.1016/S0043-1354(01)00449-3
   Maguire LP, 1998, INFORM SCIENCES, V112, P125, DOI 10.1016/S0020-0255(98)10026-9
   Marce R, 2004, LIMNOL OCEANOGR-METH, V2, P342, DOI 10.4319/lom.2004.2.342
   MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030
   Nason GP, 1999, PHILOS T R SOC A, V357, P2511, DOI 10.1098/rsta.1999.0445
   Nie XH, 2007, J ENVIRON MANAGE, V84, P1, DOI 10.1016/j.jenvman.2006.04.006
   NIESSEN WR, 1972, P NAT WAST PROC C, P112
   NOORI R, 2008, J EARTH SPACE PHYS, P135
   NOORI R, 2008, ENVIRON PROG, DOI DOI 10.1002/EP.101317
   Openshaw S., 1997, ARTIFICIAL INTELLIGE
   Rajurkar MP, 2004, J HYDROL, V285, P96, DOI 10.1016/j.jhydrol.2003.08.011
   SARLE WS, 1995, P 27 S INT COMP SCI, V27, P352
   Shu HY, 2006, J AIR WASTE MANAGE, V56, P852, DOI 10.1080/10473289.2006.10464497
   Tchobanoglous G, 1977, SOLID WASTE ENG PRIN
   Zhang GQ, 1998, INT J FORECASTING, V14, P35, DOI 10.1016/S0169-2070(97)00044-7
NR 38
TC 43
Z9 43
U1 3
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0957-4174
EI 1873-6793
J9 EXPERT SYST APPL
JI Expert Syst. Appl.
PD AUG
PY 2009
VL 36
IS 6
BP 9991
EP 9999
DI 10.1016/j.eswa.2008.12.035
PG 9
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic; Operations Research & Management Science
SC Computer Science; Engineering; Operations Research & Management Science
GA 445YE
UT WOS:000266086600048
DA 2018-12-27
ER

PT J
AU Kodama, S
   Inoue, Y
   Mihara, H
   Sumi, S
   Kudo, K
   Okamura, K
   Ando, C
   Niimura, H
   Tsuchiya, Y
   Yamanouchi, Y
   Urata, H
AF Kodama, Sunao
   Inoue, Yukiko
   Mihara, Hiroyuki
   Sumi, Syunichiro
   Kudo, Keiko
   Okamura, Keisuke
   Ando, Chie
   Niimura, Hideya
   Tsuchiya, Yoshihiro
   Yamanouchi, Yoshio
   Urata, Hidenori
TI RETRACTED: Prognostic factors for the long-term survival in patients
   with vasospastic angina Analysis of effects of patients' characteristics
   and therapeutic drugs (Retracted Article. See vol 55, pg 285, 2010)
SO JOURNAL OF CARDIOLOGY
LA English
DT Article; Retracted Publication
DE Vasospastic angina; Long-term survival; Benidipine
ID OXIDE SYNTHASE GENE; RANDOMIZED CONTROLLED-TRIAL; CORONARY SPASTIC
   ANGINA; NITRIC-OXIDE; MYOCARDIAL-INFARCTION; PROVOCATION TEST; CHANNEL
   BLOCKER; VARIANT ANGINA; BLOOD-PRESSURE; ARTERY SPASM
AB Objectives: A retrospective study was conducted to elucidate contributing factors on the outcome of patients with vasospastic angina.
   Subjects and methods: Two hundred ninety-two patients with angina in whom coronary vasospasm was documented were followed up (mean 4.3 +/- 3.6 years) to determine the relationship between the occurrence of cardiovascular events with available clinical factors including therapeutic drugs. Cardiovascular events were defined as fatal and non-fatal cardiovascular disorder events.
   Results: Several clinical variables including age, elevated creatinine level, tow high-density lipoprotein (HDL) cholesterol level, presence of severe coronary artery stenosis, low left ventricutar ejection fraction, low cardiac index (CI) large left ventricutar mass, and use of beta-blockers proved to be significant risk factors for cardiovascular events. Further analysis by a stepwise regression analysis revealed that, older age (hazard ratio (HR)=1.42), tow HDL cholesterol level. (HR = 0.877), presence of severe coronary artery stenosis (HR = 49.32), and decreased CI (HR = 14.18) proved to be independent prognostic factors. Ca antagonists were prescribed to 261 patients (89.4%). Among four Ca antagonists, there were significant differences in the frequency of cardiovascular events (2.6% with benidipine, 4.2% with nifedipine, 6.0% with diltiazem, 23.1% with amlodipine; amlodipine vs. benidipine, P<0.05) although the background characteristics of the four different patient groups were non-equivalent.
   Conclusion: These results indicate that the morbidity of patients with vasospastic angina increased with older age, lower CI or HDL cholesterol, and presence of severe coronary artery stenosis, and that treatment with benidipine appeared to reduce cardiovascular events in patients with vasospastic angina. (C) 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Kodama, Sunao; Inoue, Yukiko; Mihara, Hiroyuki; Sumi, Syunichiro; Kudo, Keiko; Okamura, Keisuke; Ando, Chie; Niimura, Hideya; Tsuchiya, Yoshihiro; Yamanouchi, Yoshio; Urata, Hidenori] Fukuoka Univ, Chikushi Hosp, Dept Cardiovasc Dis, Chikushino, Fukui 8188502, Japan.
RP Kodama, S (reprint author), Fukuoka Univ, Chikushi Hosp, Dept Cardiovasc Dis, 1-1-1 Zokumyoin, Chikushino, Fukui 8188502, Japan.
EM sunaokunda@yahoo.co.jp
CR Ikeda JI, 2006, YAKUGAKU ZASSHI, V126, P1377, DOI 10.1248/yakushi.126.1377
   Ito A, 2004, J CARDIOVASC PHARM, V44, P480, DOI 10.1097/01.fjc.0000141473.29254.62
   KARASAWA A, 1988, JPN J PHARMACOL, V47, P35, DOI 10.1254/jjp.47.35
   Kawano Hiroaki, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P23, DOI 10.2174/1568006043481301
   Kido S, 1998, J Cardiol, V31, P135
   Kita T, 2005, HYPERTENS RES, V28, P959, DOI 10.1291/hypres.28.959
   Kitakaze M, 1999, J AM COLL CARDIOL, V33, P242, DOI 10.1016/S0735-1097(98)00556-7
   Kugiyama K, 1996, CIRCULATION, V94, P266, DOI 10.1161/01.CIR.94.3.266
   Miwa K, 2003, INT J CARDIOL, V87, P193, DOI 10.1016/S0167-5273(02)00250-4
   MORIYAMA T, 1994, BIOL PHARM BULL, V17, P1468
   NAKAMURA M, 1987, CIRCULATION, V75, P1110, DOI 10.1161/01.CIR.75.6.1110
   Nakayama M, 1999, CIRCULATION, V99, P2864, DOI 10.1161/01.CIR.99.22.2864
   Nakayama M, 2006, PHARMACOGENET GENOM, V16, P339, DOI 10.1097/01.fpc.0000199499.08725.d5
   Nissen SE, 2004, JAMA-J AM MED ASSOC, V292, P2217, DOI 10.1001/jama.292.18.2217
   NODA H, 1990, JPN PHARMACOL THER, V18, pS843
   Poole-Wilson PA, 2004, LANCET, V364, P849, DOI 10.1016/S0140-6736(04)16980-8
   Pristipino C, 2000, CIRCULATION, V101, P1102, DOI 10.1161/01.CIR.101.10.1102
   SAKATA K, 2003, THER RES, V24, P2093
   Sueda S, 2004, ANGIOLOGY, V55, P403, DOI 10.1177/000331970405500407
   Sueda S, 2003, CHEST, V123, P380, DOI 10.1378/chest.123.2.380
   Sueda S, 1999, AM J CARDIOL, V83, P1186, DOI 10.1016/S0002-9149(99)00057-0
   Suzuki H, 2007, ARZNEIMITTEL-FORSCH, V57, P20
   TAKENOUCHI N, 2004, THER RES, V25, P1591
   UCHIYAMA T, 1993, THER RES, V14, P2611
   VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1
   Wang NY, 2004, J CARDIOVASC PHARM, V43, P747, DOI 10.1097/00005344-200406000-00003
   Yamagishi M, 2003, CIRC J, V67, P1029, DOI 10.1253/circj.67.1029
   Yamashita T, 2001, J HYPERTENS, V19, P451, DOI 10.1097/00004872-200103000-00013
   YASUE H, 1988, CIRCULATION, V78, P1, DOI 10.1161/01.CIR.78.1.1
   YASUE H, 1979, CIRCULATION, V59, P938, DOI 10.1161/01.CIR.59.5.938
   Yasue H, 2008, J CARDIOL, V51, P2, DOI 10.1016/j.jjcc.2008.01.001
   Yoshimura M, 2000, J INVEST MED, V48, P367
   Yoshimura M, 1998, HUM GENET, V103, P65, DOI 10.1007/s004390050785
NR 33
TC 6
Z9 7
U1 4
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0914-5087
EI 1876-4738
J9 J CARDIOL
JI J. Cardiol.
PD AUG
PY 2009
VL 54
IS 1
BP 10
EP 20
DI 10.1016/j.jjcc.2009.02.013
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 484TJ
UT WOS:000269070100002
PM 19632515
OA Bronze
DA 2018-12-27
ER

PT J
AU Chan, MF
   Lou, FL
   Cao, FL
   Li, P
   Liu, L
   Wu, LH
AF Chan, Moon Fai
   Lou, Feng-lan
   Cao, Feng-lin
   Li, Ping
   Liu, Li
   Wu, Lai Har
TI RETRACTED: Investigating factors associated with nurses' attitudes
   towards perinatal bereavement care: a study in Shandong and Hong Kong
   (Retracted article. See vol. 24, pg. 2687, 2015)
SO JOURNAL OF CLINICAL NURSING
LA English
DT Article; Retracted Publication
DE bereavement care; China; nurses; nursing; women
ID EXPERIENCES; SUPPORT; STILLBIRTH
AB Aims.
   To explore nurses' attitudes towards perinatal bereavement care and to identify factors associated with these attitudes.
   Background.
   It is likely that the attitude of nursing staff can influence recovery from a pregnancy loss and that nurses with positive attitudes to bereavement care can help bereaved parents to cope during their grieving period.
   Design.
   Survey.
   Method.
   Data were collected through a structured questionnaire; 657 nurses were recruited from Obstetrics and Gynaecology units in Hong Kong and Shandong during 2006. Outcome measures included attitudes towards perinatal bereavement care, importance of hospital policy and training support for bereavement care.
   Results.
   The majority of nurses in this study had a positive attitude to bereavement care. Results show that only 21 center dot 6% (n = 141) of the nurses surveyed had bereavement-related training. In contrast, about 89 center dot 8% (n = 300) believed they needed to be equipped with relevant knowledge, skills and understanding in the care and support of bereaved parents and more than 88 center dot 5% (n = 592) would share their experiences with their colleagues and seek support when feeling under stress. A regression model showed that age, past experience in handling grieving parents, recent ranking and nurses' perceived attitudes to hospital policy and training provided for bereavement care were the factors associated with nurses' attitudes to perinatal bereavement care.
   Conclusions.
   Nurses in both cities emphasised their need for increased knowledge and experience, improved communication skills and greater support from team members and the hospital for perinatal bereavement care.
   Relevance to clinical practice.
   These findings may be used by nursing educators to educate their students on issues related to delivery of sensitive bereavement care in perinatal settings and to enhance nursing school curricula.
C1 [Chan, Moon Fai] Natl Univ Singapore, Alice Lee Ctr Nursing Studies, Singapore 117574, Singapore.
   [Lou, Feng-lan; Cao, Feng-lin; Li, Ping; Liu, Li] Shandong Univ, Sch Nursing, Jinan, Shandong, Peoples R China.
   [Wu, Lai Har] Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Hong Kong, Peoples R China.
RP Chan, MF (reprint author), Natl Univ Singapore, Alice Lee Ctr Nursing Studies, Block E3A,Level 3,7 Engn Dr 1, Singapore 117574, Singapore.
EM nurcmf@nus.edu.sg
FU Hong Kong Polytechnic University [A-PH28]
FX This study was funded by the Hong Kong Polytechnic University A-PH28.
   The authors would like to thank the nurses who volunteered to
   participate in this study, and offer special thanks to Kathryn Mennier
   for her technical writing support.
CR Arbuckle JL, 1999, AMOS 4 01
   Beem EE, 1998, PATIENT EDUC COUNS, V34, P53, DOI 10.1016/S0738-3991(98)00044-5
   BENTLER PM, 1990, PSYCHOL BULL, V12, P151
   Birtwistle J, 2002, J ADV NURS, V38, P467, DOI 10.1046/j.1365-2648.2002.02208.x
   BLACK D, 2006, CURRENT PAEDIAT, V16, P464
   Chambers H.M., 2000, SUPPORT WOMEN FAMILI
   CHAN C, 1998, HONG KONG J SOCIAL W, V32, P1
   Chan CLW, 2005, DEATH STUD, V29, P923, DOI 10.1080/07481180500299287
   Chan MF, 2004, NURS EDUC TODAY, V24, P202, DOI 10.1016/j.nedt.2003.11.009
   Chan MF, 2007, MIDWIFERY, V23, P309, DOI 10.1016/j.midw.2006.05.005
   CHOW AYM, 2000, PSYCHOSOCIAL ONCOLOG, P233
   Cox Erin, 2004, Crit Care Nurse, V24, P16
   Doka K. J., 2002, DISENFRANCHISED GRIE
   Doka K. J., 2005, MORTALITY, V10, P83, DOI DOI 10.1080/13576270500031105
   ENGLER AJ, 2000, ILLNESS CRISIS LOSS, V8, P227
   Gao G., 1996, HDB CHINESE PSYCHOL, P280
   Gardner J M, 1999, J Transcult Nurs, V10, P120, DOI 10.1177/104365969901000205
   GAZE H, 2000, COMMUNITY PRACTITION, V73, P504
   GENSCH BK, 2000, ILLNESS CRISIS LOSS, V8, P286
   Gibson M., 1998, ORDER CHAOS RESPONDI
   Hughes PM, 1999, BRIT MED J, V318, P1721, DOI 10.1136/bmj.318.7200.1721
   Joreskog K., 1993, LISREL 8 USERS REFER
   Keeney GB, 2004, J MIDWIFERY WOM HEAL, V49, P1, DOI 10.1016/j.jmwh.2004.05.008
   LI P, 1998, HONG KONG J EMERGENC, V5, P21
   Lundqvist A, 2002, BIRTH-ISS PERINAT C, V29, P192, DOI 10.1046/j.1523-536X.2002.00187.x
   MARSH HW, 1985, PSYCHOL BULL, V97, P562, DOI 10.1037/0033-2909.97.3.562
   Martinson I M, 1998, Oncol Nurs Forum, V25, P1756
   *NQUER ADV, 2001, STAT SOL
   Nunnally JC, 1978, PSYCHOMETRIC THEORY
   Paterson JG, 1988, HUMANISTIC NURSING
   PAULI RM, 1999, WISSPERS, V6
   Ping SL, 2002, J CLIN NURS, V11, P289, DOI 10.1046/j.1365-2702.2002.00589.x
   POLIT DF, 1995, NURSING RES PRINCIPL
   Robinson M, 1999, DEATH STUD, V23, P257, DOI 10.1080/074811899201073
   Saflund K, 2004, BIRTH-ISS PERINAT C, V31, P132, DOI 10.1111/j.0730-7659.2004.00291.x
   *SANDS, 1991, MISC STILLB NEON DEA
   SPECK P, 1978, LOSS GRIEF MED
   Wu D. Y. H., 1985, CHINESE CULTURE MENT, P3
   Yam BMC, 2001, J CLIN NURS, V10, P651, DOI 10.1046/j.1365-2702.2001.00532.x
   2001, SPSS BASE 12 1 APPL
NR 40
TC 7
Z9 8
U1 6
U2 18
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0962-1067
EI 1365-2702
J9 J CLIN NURS
JI J. Clin. Nurs.
PD AUG
PY 2009
VL 18
IS 16
BP 2344
EP 2354
DI 10.1111/j.1365-2702.2008.02689.x
PG 11
WC Nursing
SC Nursing
GA 467PS
UT WOS:000267753400012
PM 19583665
DA 2018-12-27
ER

PT J
AU Talukdar, D
AF Talukdar, Dibyendu
TI RETRACTED: Dwarf mutations in grass pea (Lathyrus sativus L.): origin,
   morphology, inheritance and linkage studies (Retracted article. See vol.
   97, pg. 353, 2018)
SO JOURNAL OF GENETICS
LA English
DT Article; Retracted Publication
DE dwarf mutations; inheritance; linkage; trisomic analysis; grass pea
   (Lathyrus sativus L.)
ID PRIMARY TRISOMICS; GRAIN LEGUMES; MUTANT; NEUROTOXIN; FLOWER; RICE
AB Induction of mutation has been used to create additional genetic variability in grass pea (Lathyrus sativus L.). During the ongoing investigations on different induced-morphological mutants, the author detected three types of dwarf mutants in grass pea. One mutant, designated as dwf1 type was earlier identified in colchicine-induced C-2 generation of grass pea variety BioR-231 while the other two, designated as dwf2 and dwf3 were isolated in 250 Gy and 300 Gy gamma ray irradiated M-2 progeny of variety 'BioR-231' and 'Hooghly Local', respectively. As compared to their parental varieties (controls), all the three mutants manifested stunted, erect and determinate stem, early maturity and tolerance to pod shattering habit. The mutants differed from each other, as well as with controls, in number of primary branches, nature of stipules and internodes, length of peduncle, leaflet and seed coat colour, seed yield and seed neurotoxin content. The three dwarf mutants were monogenically recessive and bred true in successive generations. F-2 segregation pattern obtained from the crosses involving the three mutants indicated that dwarf mutation in grass pea was controlled by two independent non-allelic genes, assigned as df1 (for dwf1 type), df2 (for dwf2 type) and df3 (for dwf3 type), with the df1 locus being multiple allelic. Primary trisomic analyses revealed the presence of df1/df2 locus on the extra chromosome of trisomic type I, whereas df3 was located on the extra chromosome of type III. Linkage studies involving five other phenotypic markers suggested linked association of df1/df2 locus with lfc (leaflet colour) and wgn (winged internode) and df3 locus with cbl (seed coat colour). Both the loci; however, assorted independently with flower colour and stipule character. The dwarf types can be utilized as valuable tools for further cytogenetic research and breeding of grass pea.
C1 Univ Kalyani, Dept Bot, Kalyani 741235, W Bengal, India.
RP Talukdar, D (reprint author), Univ Kalyani, Dept Bot, Kalyani 741235, W Bengal, India.
EM dib_tal@rediffmail.com
CR Biswas A. K., 2007, Breeding of neglected and under-utilized crops, spices and herbs, P29
   BISWAS SC, 1998, THESIS U KALYANI KAL
   Das P. K., 1999, Indian Journal of Genetics and Plant Breeding, V59, P117
   Dibyendu Talukdar, 2007, Indian Journal of Genetics and Plant Breeding, V67, P85
   DIRKS V. A., 1956, JOUR HEREDITY, V47, P229
   DOWNES RW, 1983, EUPHYTICA, V32, P757, DOI 10.1007/BF00042156
   *FAO, 2002, CROP PLANT, P1
   FOSTER A. E., 1961, CROP SCI, V1, P272
   Gaur PM, 2008, EUPHYTICA, V159, P35, DOI 10.1007/s10681-007-9454-y
   GUTIERREZ JF, 2001, LATHYRUS LATHYRISM N, V2, P74
   HONEYCUTT RJ, 1990, J HERED, V81, P123
   JAIN HK, 1975, INDIAN J GENET PL BR, V35, P169
   KHANNACHOPRA R, 1990, P INT C PLANT PHYS S, V1, P268
   KHUSH GS, 1984, GENETICS, V107, P141
   KOLB FL, 1984, CROP SCI, V24, P699, DOI 10.2135/cropsci1984.0011183X002400040018x
   Kosambi DD, 1943, ANN EUGENIC, V12, P172, DOI 10.1111/j.1469-1809.1943.tb02321.x
   LATHER VS, 2000, INT CHICKPEA PIGEONP, V7, P26
   Lesley JW, 1926, GENETICS, V11, P352
   MCCUTCHAN JS, 2003, LATHYRUS LATHYRISM N, V3, P21
   MEHRA RB, 1995, LATHYRUS GENETIC RES, P37
   Qin RZ, 2008, EUPHYTICA, V160, P379, DOI 10.1007/s10681-007-9548-6
   RAI KN, 1990, CROP SCI, V30, P23, DOI 10.2135/cropsci1990.0011183X003000010005x
   RAO SLN, 1978, ANAL BIOCHEM, V86, P386, DOI 10.1016/0003-2697(78)90762-5
   Rybinski W., 2003, LATHYRISM LATHYRISM, V3, P30
   SETHI GS, 1974, EUPHYTICA, V23, P237, DOI 10.1007/BF00035863
   Skiba B, 2004, THEOR APPL GENET, V109, P1726, DOI 10.1007/s00122-004-1812-8
   SMARTT J, 1984, EXP AGR, V20, P275, DOI 10.1017/S0014479700017968
   TALUKDAR D, 2006, PERSPECTIVES CYTOLOG, V12, P267
   TALUKDAR D, 2001, PERSPECTIVES CYTOLOG, V10, P481
   TALUKDAR D, 2005, P 4 INT FOOD LEG RES, P200
   Talukdar Dibyendu, 2007, Indian Journal of Genetics & Plant Breeding, V67, P396
   Talukdar Dibyendu, 2007, Cytologia (Tokyo), V72, P385, DOI 10.1508/cytologia.72.385
   Talukdar Dibyendu, 2002, Indian Journal of Genetics and Plant Breeding, V62, P162
   Talukdar Dibyendu, 2001, Indian Journal of Genetics and Plant Breeding, V61, P383
   Talukder Dibyendu, 2005, Indian Journal of Genetics & Plant Breeding, V65, P135
   Tiwari KR, 1996, EUPHYTICA, V91, P195
   Tsuchiya T., 1975, Barley Genetics Newsletter, V5, P67
   Waghmare V. N., 2000, Indian Journal of Genetics and Plant Breeding, V60, P81
   WEIGLE JL, 1983, J HERED, V74, P200, DOI 10.1093/oxfordjournals.jhered.a109764
NR 39
TC 22
Z9 24
U1 1
U2 16
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0022-1333
EI 0973-7731
J9 J GENET
JI J. Genet.
PD AUG
PY 2009
VL 88
IS 2
BP 165
EP 175
DI 10.1007/s12041-009-0024-z
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 489LD
UT WOS:000269420700004
PM 19700854
DA 2018-12-27
ER

PT J
AU Arvinda, HR
   Kesavadas, C
   Sarma, PS
   Thomas, B
   Radhakrishnan, VV
   Gupta, AK
   Kapilamoorthy, TR
   Nair, S
AF Arvinda, H. R.
   Kesavadas, C.
   Sarma, P. S.
   Thomas, B.
   Radhakrishnan, V. V.
   Gupta, A. K.
   Kapilamoorthy, T. R.
   Nair, S.
TI RETRACTED: Glioma grading: sensitivity, specificity, positive and
   negative predictive values of diffusion and perfusion imaging (Retracted
   article. See vol. 114, pg. 255, 2013)
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article; Retracted Publication
DE Diffusion; Glioma; Grading; MRI; Perfusion
ID CEREBRAL BLOOD-VOLUME; MAGNETIC-RESONANCE-SPECTROSCOPY; EXPERIMENTAL
   BRAIN-TUMORS; DIFFUSION/PERFUSION-WEIGHTED MRI; INTRACRANIAL MASS
   LESIONS; CONTRAST-ENHANCED MR; GLIOBLASTOMA-MULTIFORME;
   HISTOLOGIC-FINDINGS; COEFFICIENT; HISTOPATHOLOGY
AB Purpose The purpose of our study was to determine the statistical significance of thresholds of relative cerebral blood volume (rCBV), apparent diffusion coefficient (ADC) and ADC ratios in grading cerebral gliomas. Materials and methods In this retrospective study, 51 patients with histopathologically confirmed primary cerebral gliomas who had undergone conventional MR imaging, dynamic contrast-enhanced T2*-weighted perfusion MR imaging and diffusion MR imaging were included. A retrospective blinded analysis of the imaging findings including the perfusion and diffusion parameters was done. The rCBV measurements were obtained from regions of maximum perfusion. Minimum ADC values were obtained from the region of maximum hypointensity within the tumor and from the corresponding opposite white matter. Tumor grade determined with the two methods were then compared with the histopathologic grade. Mann-Whitney tests were performed to compare the DWI and PWI between tumor types. Receiver operating characteristic analyses were performed to determine optimum thresholds for tumor grading and also to calculate the sensitivity, specificity, PPV, and NPV for identifying high-grade gliomas. Results Statistical analysis demonstrated a threshold value of 2.91 for rCBV to provide sensitivity, specificity, PPV, and NPV of 94.7, 93.75, 90.0, and 96.8%, respectively, in determining high-grade gliomas. An ADC value of 98.50 mm(2)/s was defined as a threshold below which tumors were classified as high-grade gliomas and a sensitivity, specificity, PPV, and NPV of 90, 87.1, 81.81 and 93.10% respectively, were obtained. Significant differences were noted in the rCBV ratios, ADC and ADC ratios between low- and high-grade gliomas (P < 0.0001). Conclusion Combining PWI and DWI with conventional MR imaging increases the accuracy of pre-operative imaging grading of glial neoplasms. The rCBV measurements had the most superior diagnostic performance in predicting glioma grade. Absolute ADC values or ADC ratios were also helpful in preoperative grading of gliomas. Threshold values can be used in a clinical setting to evaluate tumors preoperatively for histologic grade and provide a means for guiding treatment and predicting postoperative patient outcome.
C1 [Arvinda, H. R.; Kesavadas, C.; Thomas, B.; Gupta, A. K.; Kapilamoorthy, T. R.] Sree Chitra Tirunal Inst Med Sci & Technol, Dept Imaging Sci & Intervent Radiol, Trivandrum 695011, Kerala, India.
   [Sarma, P. S.] Sree Chitra Tirunal Inst Med Sci & Technol, Dept Biostat, Trivandrum 695011, Kerala, India.
   [Radhakrishnan, V. V.] Sree Chitra Tirunal Inst Med Sci & Technol, Dept Pathol, Trivandrum 695011, Kerala, India.
   [Nair, S.] Sree Chitra Tirunal Inst Med Sci & Technol, Dept Neurosurg, Trivandrum 695011, Kerala, India.
RP Kesavadas, C (reprint author), Sree Chitra Tirunal Inst Med Sci & Technol, Dept Imaging Sci & Intervent Radiol, Trivandrum 695011, Kerala, India.
EM chandkesav@yahoo.com
OI Kesavadas, Chandrasekharan/0000-0003-4914-8666
CR ARONEN HJ, 1994, RADIOLOGY, V191, P41, DOI 10.1148/radiology.191.1.8134596
   Batra A, 2004, Australas Radiol, V48, P324, DOI 10.1111/j.0004-8461.2004.01315.x
   BRANTZAWADZKI M, 1986, AM J ROENTGENOL, V147, P1223, DOI 10.2214/ajr.147.6.1223
   BRANTZAWADZKI M, 1984, RADIOLOGY, V150, P435, DOI 10.1148/radiology.150.2.6691098
   Bruening R, 1996, AM J NEURORADIOL, V17, P831
   Bulakbasi N, 2003, AM J NEURORADIOL, V24, P225
   BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2
   BURGER PC, 1986, SEMIN ONCOL, V13, P16
   BYDDER GM, 1982, AM J ROENTGENOL, V139, P215, DOI 10.2214/ajr.139.2.215
   Castillo M, 2001, AM J NEURORADIOL, V22, P60
   Catalaa I, 2006, NMR BIOMED, V19, P463, DOI 10.1002/nbm.1059
   Cha S, 2002, RADIOLOGY, V223, P11, DOI 10.1148/radiol.2231010594
   Chenevert TL, 1997, CLIN CANCER RES, V3, P1457
   Christoforidis GA, 2002, AM J NEURORADIOL, V23, P1553
   DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T
   DEAN BL, 1990, RADIOLOGY, V174, P411, DOI 10.1148/radiology.174.2.2153310
   EIS M, 1995, MAGN RESON MED, V34, P835, DOI 10.1002/mrm.1910340608
   EIS M, 1994, ACTA NEUROCHIR, P344
   Els T, 1995, MAGMA, V3, P13, DOI 10.1007/BF02426396
   Fan GG, 2006, BRIT J RADIOL, V79, P652, DOI 10.1259/bjr/25349497
   Fan GG, 2005, ACAD RADIOL, V12, P640, DOI 10.1016/j.acra.2005.01.024
   FELIX R, 1985, RADIOLOGY, V156, P681, DOI 10.1148/radiology.156.3.4040643
   Filippi CG, 2001, AM J NEURORADIOL, V22, P65
   Gauvain KM, 2001, AM J ROENTGENOL, V177, P449, DOI 10.2214/ajr.177.2.1770449
   Guo AC, 2002, RADIOLOGY, V224, P177, DOI 10.1148/radiol.2241010637
   Gupta RK, 1999, MAGNET RESON MED, V41, P2, DOI 10.1002/(SICI)1522-2594(199901)41:1<2::AID-MRM2>3.3.CO;2-P
   Gupta RK, 2000, J NEURO-ONCOL, V50, P215, DOI 10.1023/A:1006431120031
   GUYTON AC, 1991, CEREBRAL BLOOD FLOW, P285
   JUST M, 1988, RADIOLOGY, V169, P779, DOI 10.1148/radiology.169.3.3187000
   Knopp EA, 1999, RADIOLOGY, V211, P791, DOI 10.1148/radiology.211.3.r99jn46791
   KONDZIOLKA D, 1993, J NEUROSURG, V79, P533, DOI 10.3171/jns.1993.79.4.0533
   Kono K, 2001, AM J NEURORADIOL, V22, P1081
   Krabbe K, 1997, NEURORADIOLOGY, V39, P483, DOI 10.1007/s002340050450
   KURKI T, 1995, MAGN RESON IMAGING, V13, P501, DOI 10.1016/0730-725X(95)00006-3
   Law M, 2004, AM J NEURORADIOL, V25, P746
   Law M, 2003, AM J NEURORADIOL, V24, P1989
   Lev MH, 2004, AM J NEURORADIOL, V25, P214
   Lev MH, 1999, NEUROIMAG CLIN N AM, V9, P309
   Maia ACM, 2005, AM J NEURORADIOL, V26, P777
   Mihara F, 1995, Radiat Med, V13, P11
   Moller-Hartmann W, 2002, NEURORADIOLOGY, V44, P371, DOI 10.1007/s00234-001-0760-0
   Nonomura Y, 2001, J MAGN RESON IMAGING, V13, P757, DOI 10.1002/jmri.1105
   Peters AM, 1998, BRIT J RADIOL, V71, P1116, DOI 10.1259/bjr.71.851.10434905
   Petrella JR, 2000, AM J ROENTGENOL, V175, P207, DOI 10.2214/ajr.175.1.1750207
   Rees J, 2003, CURR OPIN NEUROL, V16, P643, DOI 10.1097/01.wco.0000102626.38669.b9
   RINGERTZ N, 1950, ACTA PATHOL MIC SC, V27, P51
   Roberts HC, 2000, AM J NEURORADIOL, V21, P891
   Scott JN, 2002, NEUROLOGY, V59, P947, DOI 10.1212/WNL.59.6.947
   Shin JH, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.3.1790783
   Stadnik TW, 2001, AM J NEURORADIOL, V22, P969
   Sugahara T, 1998, AM J ROENTGENOL, V171, P1479, DOI 10.2214/ajr.171.6.9843274
   Sugahara T, 1999, JMRI-J MAGN RESON IM, V9, P53, DOI 10.1002/(SICI)1522-2586(199901)9:1<53::AID-JMRI7>3.0.CO;2-2
   Sugahara T, 1999, Top Magn Reson Imaging, V10, P114, DOI 10.1097/00002142-199904000-00004
   TIEN RD, 1994, AM J ROENTGENOL, V162, P671, DOI 10.2214/ajr.162.3.8109520
   WATANABE M, 1992, NEURORADIOLOGY, V34, P463, DOI 10.1007/BF00598951
   Wong ET, 1998, NEUROLOGY, V50, P777, DOI 10.1212/WNL.50.3.777
   Wong JC, 2000, AM J ROENTGENOL, V174, P1147, DOI 10.2214/ajr.174.4.1741147
NR 57
TC 110
Z9 124
U1 4
U2 28
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD AUG
PY 2009
VL 94
IS 1
BP 87
EP 96
DI 10.1007/s11060-009-9807-6
PG 10
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 466SS
UT WOS:000267683600010
PM 19229590
DA 2018-12-27
ER

PT J
AU Chauhan, SR
   Patnaik, A
   Kaith, BS
   Satapathy, A
   Dwivedy, M
AF Chauhan, S. R.
   Patnaik, Amar
   Kaith, B. S.
   Satapathy, Alok
   Dwivedy, Maheshwar
TI RETRACTED: Analysis of Mechanical Behavior of Phenol Formaldehyde Matrix
   Composites Using Flax-g-Poly (MMA) as Reinforcing Materials (Retracted
   article. See vol. 29, pg. 2076, 2010)
SO JOURNAL OF REINFORCED PLASTICS AND COMPOSITES
LA English
DT Article; Retracted Publication
DE wear; scanning electron microscope; mechanical properties;
   phenol-formaldehyde; flax graft co-polymer
ID GRAFT-COPOLYMERIZATION; WOOL
AB This article deals with synthesis of phenol-formaldehyde resin and preparation of phenol-formaldehyde matrix based composites using raw flax and flax graft co-polymer as reinforcing agent. Prior to using the graft co-polymer as a reinforcing material, its strength vis-a-vis that of raw flax are studied in this study. Composites thus prepared are subjected to different mechanical tests such as wear, tensile, and compression tests etc. The graft co-polymers are characterized by using FTIR and scanning electron microscope (SEM). It has been observed that the composites refined with raw flax are more wear resistant as compared to the graft copolymer refined composites. In the case of the tensile test, composites reinforced with grafted flax showed more extension as compared to that of raw flax reinforcement, but required less loading at break point. However, composites with raw flax reinforcement initially showed more compression as compared to reinforcement with grafted fiber but at higher applied load grafted fiber reinforcement is found to show more compressive strength. Moreover, water repellency property of the fiber could be improved on grafting with methyl methacrylate (MMA) whereas the raw flax is found to be more vulnerable to water.
C1 [Chauhan, S. R.; Patnaik, Amar] Natl Inst Technol, Dept Mech Engn, Hamirpur 177005, HP, India.
   [Satapathy, Alok] Natl Inst Technol, Dept Mech Engn, Rourkela 769008, Orissa, India.
   [Dwivedy, Maheshwar] BITS, Dept Mech Engn, Pilani, Rajasthan, India.
RP Patnaik, A (reprint author), Natl Inst Technol, Dept Mech Engn, Hamirpur 177005, HP, India.
EM patnaik.amar@gmail.com
RI Satapathy, Alok/N-4297-2017
CR Bhattacharya A, 2004, PROG POLYM SCI, V29, P767, DOI 10.1016/j.progpolymsci.2004.05.002
   Bledzki A. K., 1997, HDB ENG POLYM MAT, P787
   BLEDZKI AK, 1995, KUNSTSTOFFE UMWELT R, P27
   Haber F, 1932, NATURWISSENSCHAFTEN, V20, P948, DOI 10.1007/BF01504715
   Haber F, 1934, P ROY SOC LOND A MAT, V147, P332, DOI DOI 10.1098/rspa.1934.0221
   Kaith BS, 2003, J POLYM MATER, V20, P195
   Kaith BS, 2003, INT J PLAST TECH, V7, P119
   KOHLER R, 1995, INT TECHT S FRANKF, P17
   Mahapatra SS, 2008, WEAR, V265, P214, DOI 10.1016/j.wear.2007.10.001
   MIECK KP, 1995, KUNSTST-PLAST EUR, V85, P366
   Mieck KP, 1994, MELLIAND TEXTILBERIC, V11, P892
   MISRA BN, 1982, J APPL POLYM SCI, V27, P1321, DOI 10.1002/app.1982.070270421
   MISRA BN, 1978, J POLYM SCI POL CHEM, V16, P1801, DOI 10.1002/pol.1978.170160803
   MUKHERJEE PS, 1986, J MATER SCI, V21, P4162, DOI 10.1007/BF01106524
   Pal P. K., 1984, Plastics and Rubber Processing and Applications, V4, P215
   Patnaik Amar, 2007, International Journal of Manufacturing Research, V2, P462, DOI 10.1504/IJMR.2007.015089
   Patnaik A, 2008, J REINF PLAST COMP, V27, P1093, DOI 10.1177/0731684407087688
   Patnaik A, 2008, J REINF PLAST COMP, V27, P1039, DOI 10.1177/0731684407086867
   Patnaik A, 2008, J REINF PLAST COMP, V27, P871, DOI 10.1177/0731684407085728
   Patnaik A, 2009, J REINF PLAST COMP, V28, P1305, DOI 10.1177/0731684407086589
   Patnaik A, 2009, J REINF PLAST COMP, V28, P513, DOI 10.1177/0731684407085644
NR 21
TC 2
Z9 2
U1 4
U2 12
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0731-6844
EI 1530-7964
J9 J REINF PLAST COMP
JI J. Reinf. Plast. Compos.
PD AUG
PY 2009
VL 28
IS 16
BP 1933
EP 1944
DI 10.1177/0731684407089131
PG 12
WC Materials Science, Composites; Polymer Science
SC Materials Science; Polymer Science
GA 478XC
UT WOS:000268621000002
DA 2018-12-27
ER

PT J
AU Luo, YH
AF Luo, Yu-Hui
TI RETRACTED: Directional motion, current reversal and mass separation in
   an asymmetrical periodic potential (Retracted article)
SO JOURNAL OF STATISTICAL MECHANICS-THEORY AND EXPERIMENT
LA English
DT Article; Retracted Publication
DE stochastic particle dynamics (theory); fluctuations (theory); transport
   properties (theory); molecular motors (theory)
ID BROWNIAN MOTORS; STOCHASTIC RESONANCE; INERTIA RATCHETS; TRANSPORT;
   PARTICLES; NOISE; MOVEMENT; DRIVEN
AB Fluctuation-induced transport in an asymmetric periodic potential driven by a static bias and correlated noises is investigated for the overdamped and underdamped cases. Using both theoretical predictions and numerical simulations, we study the steady current of an overdamped Brownian particle moving in the potential. It is shown that an asymmetric periodic potential driven by a static bias and the correlated noises is simultaneously able to exhibit directional transport and current reversal. For the underdamped case, we examine the dynamics at various inertial strengths by means of direct simulations of the stochastic differential equations. We especially focus on the influence of inertial terms in the particle dynamics for the noise-induced, directed current. It is found that the inertial ratchet possesses current reversals as a function of the mass of the particle; thus an efficient scheme for separating different species of particles according to their different masses is suggested.
   "This paper has substantial overlap with the papers 'Directional motion, current reversals and mass separation in a symmetrical periodic potential' by Yu-Hui Luo and Chong-Wei Xie (2009 Phys. Lett. A 373 3217-22) and 'Current inversion in an asymmetric periodic potential driven by cross-correlated white noise sources' by Yu-Hui Luo and Chong-Wei Xie (2009 Phys. Scr. 80 015003). Therefore this article has been retracted by IOP Publishing and SISSA, and by the author, Yu-Hui Luo."
C1 Zhaotong Teachers Coll, Dept Phys, Zhaotong 657000, Peoples R China.
RP Luo, YH (reprint author), Zhaotong Teachers Coll, Dept Phys, Zhaotong 657000, Peoples R China.
EM yuhuiluo@yahoo.cn
FU Natural Science Foundation of The Educational Department of Yunnan
   province [08C0235]
FX This work was supported by the Natural Science Foundation of The
   Educational Department of Yunnan province (Grant No. 08C0235).
CR Ai BQ, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.031101
   ALBERTS B., 1994, MOL BIOL CELL
   Bartussek R, 1996, PHYS REV LETT, V76, P1166, DOI 10.1103/PhysRevLett.76.1166
   Borromeo M, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.031121
   Borromeo M, 2005, CHAOS, V15, DOI 10.1063/1.1858651
   Borromeo M, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.150605
   Cao L, 2000, PHYS REV E, V62, P7478, DOI 10.1103/PhysRevE.62.7478
   CHAUWIN JF, 1994, EUROPHYS LETT, V27, P421, DOI 10.1209/0295-5075/27/6/002
   Gomez-Marin A, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.031108
   Gommers R, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.240604
   Gommers R, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.143001
   Gommers R, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.073003
   Hanggi P, 2009, REV MOD PHYS, V81, P387, DOI 10.1103/RevModPhys.81.387
   Hanggi P, 2005, ANN PHYS-BERLIN, V14, P51, DOI 10.1002/andp.200410121
   Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022
   Jia Y, 1997, PHYS REV LETT, V78, P994, DOI 10.1103/PhysRevLett.78.994
   Jung P, 1996, PHYS REV LETT, V76, P3436, DOI 10.1103/PhysRevLett.76.3436
   KARGER K, 1992, DIFFUSION ZEOLITES O
   Kettner C, 2000, PHYS REV E, V61, P312, DOI 10.1103/PhysRevE.61.312
   Li JH, 1998, PHYS REV E, V57, P3917, DOI 10.1103/PhysRevE.57.3917
   Li JH, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.011113
   Lindner B, 1999, PHYS REV E, V59, P1417, DOI 10.1103/PhysRevE.59.1417
   Lutz C, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.026001
   MADDOX J, 1994, NATURE, V368, P287, DOI 10.1038/368287a0
   Madureira AJR, 1996, PHYS LETT A, V217, P248, DOI 10.1016/0375-9601(96)00345-3
   MAGNASCO MO, 1993, PHYS REV LETT, V71, P1477, DOI 10.1103/PhysRevLett.71.1477
   Marchesoni F, 1997, PHYS LETT A, V231, P61, DOI 10.1016/S0375-9601(97)00232-6
   Marchesoni F, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.021102
   Marchesoni F, 1998, PHYS LETT A, V237, P126, DOI 10.1016/S0375-9601(97)00841-4
   Matthias S, 2003, NATURE, V424, P53, DOI 10.1038/nature01736
   Mei DC, 2004, EUR PHYS J B, V41, P107, DOI 10.1140/epjb/e2004-00300-1
   Reimann P, 1998, CHAOS, V8, P629, DOI 10.1063/1.166345
   Reimann P, 1997, PHYS REV LETT, V79, P10, DOI 10.1103/PhysRevLett.79.10
   Reimann P, 2002, PHYS REP, V361, P57, DOI 10.1016/S0370-1573(01)00081-3
   ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0
   Savel'ev S, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.214303
   Silva CCD, 2006, NATURE, V440, P651, DOI 10.1038/nature04595
   Xie CW, 2003, EUR PHYS J B, V33, P83, DOI 10.1140/epjb/e2003-00144-1
NR 38
TC 0
Z9 0
U1 6
U2 18
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1742-5468
J9 J STAT MECH-THEORY E
JI J. Stat. Mech.-Theory Exp.
PD AUG
PY 2009
AR P08008
DI 10.1088/1742-5468/2009/08/P08008
PG 12
WC Mechanics; Physics, Mathematical
SC Mechanics; Physics
GA 488LT
UT WOS:000269351900008
DA 2018-12-27
ER

PT J
AU Yu, JH
   Dai, L
AF Yu, J. H.
   Dai, L.
TI RETRACTED: Strain rate and interfacial property effects of random fibre
   cementitious composites (Retracted article. See vol. 45, pg. 659, 2010)
SO JOURNAL OF STRAIN ANALYSIS FOR ENGINEERING DESIGN
LA English
DT Article; Retracted Publication
DE polyvinyl alcohol (PVA) engineered cementitious composite (ECC); strain
   rate; interfacial property; microstructure
ID BEHAVIOR; MATRIX
AB This study investigates the rate dependence of engineered cementitious composite (ECC) and explores the microstructure and micromechanical sources responsible for the rate effect. A composite uniaxial tensile test under different strain rates and a single fibre pullout test are conducted to examine the rate dependence of fibre/matrix interfacial properties. Drop weight impact tests are also performed to evaluate the impact resistance of circular plate. It is revealed that a change in the interface chemical debonding energy with rate is responsible for the alteration of composite tensile ductility. ECC is shown to be a promising material for seismic, impact-loading, and blast applications. Finally, it is demonstrated that ECC is suitable for high-rate loading and that the optimization methods proposed in this study enable protective structure applications to be achieved.
C1 [Yu, J. H.; Dai, L.] Shenyang Jianzhu Univ, Sch Civil Engn, Liaoning 110168, Peoples R China.
RP Yu, JH (reprint author), Shenyang Jianzhu Univ, Sch Civil Engn, Hunnan E Rd, Liaoning 110168, Peoples R China.
EM jiahuan@umich.edu
FU National Natural Science Foundation of China [5077811]; China
   Scholarship Council
FX Financial support from the National Natural Science Foundation of China
   under grant no. 5077811 and the China Scholarship Council are gratefully
   acknowledged. Helpful discussions with Professor V. C. Li of the
   University of Michigan on micromechanics and microstructure of PVA ECC
   were also much appreciated by the authors.
CR Fischer G, 2002, ACI STRUCT J, V99, P781
   Kanda T, 1998, J MATER CIVIL ENG, V10, P5, DOI 10.1061/(ASCE)0899-1561(1998)10:1(5)
   KESNER KE, 2002, P JCI WORKSH DFRCC, P289
   Kim DJ, 2009, MATER STRUCT, V42, P399, DOI 10.1617/s11527-008-9390-x
   Li VC, 2002, ACI MATER J, V99, P11
   Lin Z, 1997, J MECH PHYS SOLIDS, V45, P763, DOI 10.1016/S0022-5096(96)00095-6
   Maalej M, 2005, J MATER CIVIL ENG, V17, P143, DOI 10.1061/(ASCE)0899-1561(2005)17:2(143)
   Parra-Montesinos G, 2000, J STRUCT ENG-ASCE, V126, P1113, DOI 10.1061/(ASCE)0733-9445(2000)126:10(1113)
   Yang E.-H, 2008, THESIS U MICHIGAN
   Yu JH, 2009, MATER SCI TECH-LOND, V25, P651, DOI 10.1179/174328408X327731
NR 10
TC 8
Z9 9
U1 4
U2 14
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0309-3247
EI 2041-3130
J9 J STRAIN ANAL ENG
JI J. Strain Anal. Eng. Des.
PD AUG
PY 2009
VL 44
IS 6
BP 417
EP 425
DI 10.1243/03093247JSA513
PG 9
WC Engineering, Mechanical; Mechanics; Materials Science, Characterization
   & Testing
SC Engineering; Mechanics; Materials Science
GA 484DW
UT WOS:000269024800002
DA 2018-12-27
ER

PT J
AU Siddall, M
   Stocker, TF
   Clark, PU
AF Siddall, Mark
   Stocker, Thomas F.
   Clark, Peter U.
TI RETRACTED: Constraints on future sea-level rise from past sea-level
   change (Retracted article. See vol. 3, pg. 217, 2010)
SO NATURE GEOSCIENCE
LA English
DT Article; Retracted Publication
ID LAST INTERGLACIAL PERIOD; ICE-SHEET; GLACIAL MAXIMUM; CLIMATE-CHANGE;
   TEMPERATURE; DURATION; CYCLES; CORE
AB It is difficult to project sea-level rise in response to warming climates by the end of the century, especially because the response of the Greenland and Antarctic ice sheets to warming is not well understood(1). However, sea-level fluctuations in response to changing climate have been reconstructed for the past 22,000 years from fossil data, a period that covers the transition from the Last Glacial Maximum to the warm Holocene interglacial period. Here we present a simple model of the integrated sea-level response to temperature change that implicitly includes contributions from the thermal expansion and the reduction of continental ice. Our model explains much of the centennial-scale variability observed over the past 22,000 years, and estimates 4-24 cm of sea-level rise during the twentieth century, in agreement with the Fourth Assessment Report of the Intergovernmental Panel on Climate Change(1) (IPCC). In response to the minimum (1.1 degrees C) and maximum (6.4 degrees C) warming projected for AD 2100 by the IPCC models, our model predicts 7 and 82 cm of sea-level rise by the end of the twenty-first century, respectively. The range of sea-level rise is slightly larger than the estimates from the IPCC models of 18-76 cm, but is sufficiently similar to increase confidence in the projections.
C1 [Siddall, Mark] Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.
   [Stocker, Thomas F.] Univ Bern, Inst Phys, CH-3012 Bern, Switzerland.
   [Clark, Peter U.] Oregon State Univ, Dept Geosci, Corvallis, OR 97331 USA.
RP Siddall, M (reprint author), Univ Bristol, Dept Earth Sci, Wills Mem Bldg,Queens Rd, Bristol BS8 1RJ, Avon, England.
EM mark.siddall@bristol.ac.uk
RI Stocker, Thomas/B-1273-2013
FU Lamont Doherty Earth Observatory; University of Bristol; Swiss National
   Science Foundation; University of Bern; US National Science Foundation
FX M. S. acknowledges support from Lamont Doherty Earth Observatory and the
   University of Bristol (LDEO and RCUK fellowships). Conversations with J.
   Shepherd and D. Pollard have been very useful in bringing this work
   together and it could not have been completed without their suggestions.
   Support from the Swiss National Science Foundation and the University of
   Bern (T. F. S.) and the US National Science Foundation (P. U. C.) is
   acknowledged.
CR Alley RB, 2005, SCIENCE, V310, P456, DOI 10.1126/science.1114613
   [Anonymous], 2004, NATURE, V429, P623
   Church J. A, 2001, CLIMATE CHANGE 2001, P639
   Cutler KB, 2003, EARTH PLANET SC LETT, V206, P253, DOI 10.1016/S0012-821X(02)01107-X
   Dansgaard W., 1984, GEOPHYS MONOGR SER, P288, DOI DOI 10.1029/GM029P0288
   Domingues CM, 2008, NATURE, V453, P1090, DOI 10.1038/nature07080
   Fleming K, 1998, EARTH PLANET SC LETT, V163, P327, DOI 10.1016/S0012-821X(98)00198-8
   Gregory JM, 2006, PHILOS T R SOC A, V364, P1709, DOI 10.1098/rsta.2006.1796
   Gregory JM, 2006, J CLIMATE, V19, P4576, DOI 10.1175/JCLI3881.1
   Grinsted A, 2010, CLIM DYNAM, V34, P461, DOI 10.1007/s00382-008-0507-2
   Hansen J, 2007, PHILOS T R SOC A, V365, P1925, DOI 10.1098/rsta.2007.2052
   IPCC, 2007, CLIM CHANG 2007 PHYS
   LEAR CH, 2007, PERSPECTIVES CLIMATE, P313
   Masson-Delmotte V, 2006, CLIM DYNAM, V26, P513, DOI [10.1007/s00382-005-0081-9, 10.1007/S00382-005-0081-9]
   Muhs DR, 2002, QUATERNARY RES, V58, P36, DOI 10.1006/qres.2002.2339
   NORTH GR, 1984, J ATMOS SCI, V41, P3390, DOI 10.1175/1520-0469(1984)041<3390:TSICII>2.0.CO;2
   Otto-Bliesner BL, 2006, SCIENCE, V311, P1751, DOI 10.1126/science.1120808
   Peltier WR, 2006, QUATERNARY SCI REV, V25, P3322, DOI 10.1016/j.quascirev.2006.04.010
   Pollard D, 2005, GLOBAL PLANET CHANGE, V45, P9, DOI 10.1016/j.gloplacha.2004.09.011
   Rahmstorf S, 2007, SCIENCE, V315, P368, DOI 10.1126/science.1135456
   Rohling EJ, 2009, NAT GEOSCI, V2, P500, DOI 10.1038/ngeo557
   Schellmann G, 2004, EARTH-SCI REV, V64, P157, DOI 10.1016/S0012-8252(03)00043-6
   Siddall M, 2008, REV GEOPHYS, V46, DOI 10.1029/2007RG000226
   Siddall M, 2003, NATURE, V423, P853, DOI 10.1038/nature01690
   Stirling CH, 1998, EARTH PLANET SC LETT, V160, P745, DOI 10.1016/S0012-821X(98)00125-3
   Waelbroeck C, 2002, QUATERNARY SCI REV, V21, P295, DOI 10.1016/S0277-3791(01)00101-9
   WEERTMAN J, 1964, J GLACIOL, V6, P145
   Yokoyama Y, 2000, NATURE, V406, P713, DOI 10.1038/35021035
   2004, NATURE, V431, P147
NR 29
TC 26
Z9 30
U1 4
U2 29
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1752-0894
EI 1752-0908
J9 NAT GEOSCI
JI Nat. Geosci.
PD AUG
PY 2009
VL 2
IS 8
BP 571
EP 575
DI 10.1038/NGEO587
PG 5
WC Geosciences, Multidisciplinary
SC Geology
GA 497LU
UT WOS:000270061800017
DA 2018-12-27
ER

PT J
AU Durani, Y
   Brecher, D
   Walmsley, D
   Attia, MW
   Loiselle, JM
AF Durani, Yamini
   Brecher, Deena
   Walmsley, Daniel
   Attia, Magdy W.
   Loiselle, John M.
TI RETRACTED: The Emergency Severity Index Version 4 Reliability in
   Pediatric Patients (Retracted article. See vol. 25, pg. 808, 2009)
SO PEDIATRIC EMERGENCY CARE
LA English
DT Article; Retracted Publication
DE triage; Emergency Severity Index; reliability
ID TRIAGE ALGORITHM
AB Objectives: The Emergency Severity Index version 4 (ESI v.4) is a triage system, which demonstrates reliability in adult populations, however, it has not been extensively studied in pediatrics. The goal of this study was to measure interrater reliability and agreement rates within and between a group of pediatric emergency medicine physicians and pediatric triage (PT) nurses using ES1 v.4 in a pediatric population.
   Methods: Pediatric emergency medicine physicians and PT nurses completed ESI v.4 training and a survey of 20 pediatric case scenarios, requiring them to assign a triage category to each case. Cases and standardized responses were adapted from the ESI v.4 training materials. Unweighted and weighted kappa was measured, and agreement rates for each group were compared with the standard response.
   Results: Sixteen physicians and 17 nurses completed the study. The group had a mean of 10.2 (+/- 7.7) years experience in pediatrics. Nurses had a mean of 7.6 (+/- 8.7) years experience in triage. Unweighted K for physicians and nurses was 0.68 and 0.67, respectively Weighted K for physicians and nurses was 0.92 and 0.93, respectively. The agreement rate among physicians and nurses with the standardized responses to case scenarios was 83%.
   Conclusions: ESI v.4 is a reliable tool for triage assessments in pediatric patients when used by experienced pediatric emergency medicine physicians and PT nurses. It is a triage system with high agreement between physicians and nurses.
C1 [Durani, Yamini; Brecher, Deena; Walmsley, Daniel; Attia, Magdy W.; Loiselle, John M.] Thomas Jefferson Univ, Alfred I dupont Hosp Children, Div Pediat Emergency Med, Dept Pediat, Wilmington, DE 19899 USA.
RP Durani, Y (reprint author), Thomas Jefferson Univ, Alfred I dupont Hosp Children, Div Pediat Emergency Med, Dept Pediat, 1600 Rockland Rd, Wilmington, DE 19899 USA.
EM ydurani@nemours.org
CR *AM COLL EM PHYS, 2003, TRIAG SCAL STAND POL
   Baumann MR, 2005, ACAD EMERG MED, V12, P219, DOI 10.1197/j.aem.2004.09.023
   CONGER AJ, 1980, PSYCHOL BULL, V88, P322, DOI 10.1037//0033-2909.88.2.322
   Davison A.C., 1997, BOOTSTRAP METHODS TH, P5
   Eitel DR, 2003, ACAD EMERG MED, V10, P1070, DOI 10.1197/S1069-6563(03)00350-6
   *EM NURS ASS, 2003, ENA BOARD APPR STAT
   Fernandes CMB, 2005, J EMERG NURS, V31, P39, DOI 10.1016/j.jen.2004.11.002
   Gilboy N, 2005, J EMERG NURS, V31, P357, DOI 10.1016/j.jen.2005.05.011
   Gilboy N, 2005, AHRQ PUBLICATION
   GILBOY N, 2003, EMERGENCY SEVERITY I
   Gill JM, 1996, ANN EMERG MED, V28, P474, DOI 10.1016/S0196-0644(96)70108-7
   MACLEAN S, 2002, ENA NATL BENCHMARK G
   R Development Core Team, 2005, R LANG ENV STAT COMP
   Tanabe P, 2004, ACAD EMERG MED, V11, P59, DOI 10.1197/S1069-6563(03)00585-2
   Tanabe Paula, 2004, J Emerg Nurs, V30, P22, DOI 10.1016/j.jen.2003.11.004
   Travers Debbie A, 2002, J Emerg Nurs, V28, P395, DOI 10.1067/men.2002.127184
   Wuerz R, 1998, ANN EMERG MED, V32, P431, DOI 10.1016/S0196-0644(98)70171-4
   Wuerz RC, 2001, ACAD EMERG MED, V8, P170, DOI 10.1111/j.1553-2712.2001.tb01283.x
NR 18
TC 3
Z9 4
U1 2
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0749-5161
EI 1535-1815
J9 PEDIATR EMERG CARE
JI Pediatr. Emerg. Care
PD AUG
PY 2009
VL 25
IS 8
BP 504
EP 507
PG 4
WC Emergency Medicine; Pediatrics
SC Emergency Medicine; Pediatrics
GA 485CU
UT WOS:000269099200005
PM 19633587
DA 2018-12-27
ER

PT J
AU Leman, ES
   Magheli, A
   Cannon, GW
   Mangold, L
   Partin, AW
   Getzenberg, RH
AF Leman, Eddy S.
   Magheli, Ahmed
   Cannon, Grant W.
   Mangold, Leslie
   Partin, Alan W.
   Getzenberg, Robert H.
TI RETRACTED: Analysis of a Serum Test for Prostate Cancer That Detects a
   Second Epitope of EPCA-2 (Retracted article. See vol. 72, pg. 1157,
   2012)
SO PROSTATE
LA English
DT Article; Retracted Publication
DE prostate cancer; proteomics; biomarkers; nuclear matrix; immunoassay
ID NUCLEAR-MATRIX PROTEINS
AB BACKGROUND. We have previously shown that EPCA-2 can serve as a highly specific and sensitive serum marker for prostate cancer. As a component of our validation of this marker, we have performed an initial evaluation of an assay that detects a distinct epitope of the same protein: EPCA-2.19. The goals of this study are to characterize the sensitivity and specificity of the EPCA-2.19 assay, in a non-screening population, and to demonstrate that such test based has similar characteristics as the initial assay produced.
   METHODS. Three hundred twenty-eight serum samples from men with PSA values < and >2.5 ng/ml who had negative biopsies, men with BPH, men with organ-confined and non-organ-confined prostate cancer, as well as control populations were evaluated using the EPCA-2.19 assay.
   RESULTS. At a cut-off of 0.5 ng/ml and above, EPCA-2.19 has a specificity of 94% and a sensitivity of 91% in separating normal men with PSA < and >2.5 ng/ml, and men with BPH from those with prostate cancer. Receiver Operator Curve analyses of the EPCA-2.19 assay demonstrate an area under the curve of 0.982 (95% CI 0.952-0.996, P < 0.0001).
   CONCLUSIONS. This study confirms our earlier findings that the assay that detects against a second epitope of EPCA-2 yields almost identical results to those obtained for the first published assay (EPCA-2.22). While this provides some validation of our earlier studies, larger multi-institutional studies still need to be performed. Prostate 69: 1188.1, 194, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Leman, Eddy S.; Magheli, Ahmed; Cannon, Grant W.; Mangold, Leslie; Partin, Alan W.; Getzenberg, Robert H.] Johns Hopkins Univ Hosp, Brady Urol Inst, Sch Med, Baltimore, MD 21287 USA.
RP Getzenberg, RH (reprint author), Johns Hopkins Univ Hosp, Brady Urol Inst, Sch Med, Marburg 121,600 N Wolfe St, Baltimore, MD 21287 USA.
EM rgetzen1@jhmi.edu
FU NCI NIH HHS [U02CA86323, U01 CA086323, U01 CA086323-10]
CR GETZENBERG RH, 1991, CANCER RES, V51, P6514
   Konety BR, 1999, J CELL BIOCHEM, P183
   Lakshmanan Y, 1998, J UROLOGY, V159, P1354, DOI 10.1016/S0022-5347(01)63615-2
   Leman ES, 2007, UROLOGY, V69, P714, DOI 10.1016/j.urology.2007.01.097
   Leman ES, 2002, J CELL BIOCHEM, V86, P203, DOI 10.1002/jcb.10216
   PARTIN AW, 1993, CANCER RES, V53, P744
   PIENTA KJ, 1993, PROSTATE, V23, P61, DOI 10.1002/pros.2990230106
NR 7
TC 13
Z9 17
U1 4
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-4137
EI 1097-0045
J9 PROSTATE
JI Prostate
PD AUG 1
PY 2009
VL 69
IS 11
BP 1188
EP 1194
DI 10.1002/pros.20963
PG 7
WC Endocrinology & Metabolism; Urology & Nephrology
SC Endocrinology & Metabolism; Urology & Nephrology
GA 474LT
UT WOS:000268286100005
PM 19418497
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Sui, XH
   Zha, QF
   Wu, MB
   Guo, YS
AF Sui Xihua
   Zha QingFang
   Wu MingBo
   Guo YanSheng
TI RETRACTED: Microenvironment characterization for a novel biocompatible
   hybrid carbon-silicon material (Retracted article. See vol. 57, pg.
   1602, 2014)
SO SCIENCE IN CHINA SERIES B-CHEMISTRY
LA English
DT Article; Retracted Publication
DE biocompatibility; carbon-silicon complex; microenvironment;
   characterization
ID FLUORESCENCE ANISOTROPY DECAY; RHODAMINE 6G; COMPOSITES
AB The compatible carbon-silicon complex materials originated from precursor diglycerylsilane (DGS) and sugar-modified silane N-(3-triethoxysilylpropyl)gluconamide (GLS) have gained substantial popularity by demonstrating admirable properties to stabilize entrapped biomolecules. The microenvironment inside these materials, especially the distribution of sugar moieties inside the matrix, which is likely the most critical factor determining compatibility of these materials, still remains unclear. To deeply investigate the biocompatibility mechanism of these materials, we have adopted two different preparation routes for these materials by introducing GLS into the starting DGS sol stage, but things are different after the DGS gel is formed. A fluorescence probe rhodamine 6G is introduced herein in the DGS sol to monitor the distribution of GLS moieties, as well as the evolution of the microenvironment inside resulting materials. All in all, the findings demonstrated that the timing of GLS addition plays a critical role in controlling the evolution of the inner structure of materials, suggesting that this factor provides a promising route to tune the properties of the resulting materials.
C1 [Sui Xihua; Zha QingFang; Wu MingBo; Guo YanSheng] China Univ Petr, State Key Lab Heavy Oil, Dongying 257061, Peoples R China.
RP Zha, QF (reprint author), China Univ Petr, State Key Lab Heavy Oil, Dongying 257061, Peoples R China.
EM xihua_sui@yahoo.com; cqf@sdkj.hdpu.edu.cn
FU National Natural Science Foundation of China [20876176]; Scientific
   Research Foundation for the Returned Overseas Chinese Scholars by the
   State Education Ministry; Chinese Ministry of Education [109100];
   Doctoral Project of Shandong Province [2008BS09013]; Research Foundation
   of Key Laboratory of Carbon Materials; Institute of Coal Chemistry, [CAS
   KFJJ0506]; Natural Science Foundation of Shandong Province [Q2007B02]
FX Supported by the National Natural Science Foundation of China (Grant No.
   20876176), Scientific Research Foundation for the Returned Overseas
   Chinese Scholars by the State Education Ministry, Key Project of Chinese
   Ministry of Education (Grant No. 109100), Doctoral Project of Shandong
   Province (Grant No. 2008BS09013), Research Foundation of Key Laboratory
   of Carbon Materials, Institute of Coal Chemistry, CAS (Grant No.
   KFJJ0506), and Natural Science Foundation of Shandong Province (Grant
   No. Q2007B02)
CR Baker GA, 1999, J SOL-GEL SCI TECHN, V15, P37, DOI 10.1023/A:1008708913243
   Baker GA, 1998, J SOL-GEL SCI TECHN, V11, P43, DOI 10.1023/A:1008680714826
   Besanger TR, 2003, ANAL CHEM, V75, P2382, DOI 10.1021/ac026370i
   Birch DJS, 2000, PHYS REV E, V62, P2977, DOI 10.1103/PhysRevE.62.2977
   Castelvetro V, 2004, ADV COLLOID INTERFAC, V108, P167, DOI 10.1016/j.cis.2003.10.017
   Cruz-Aguado JA, 2004, J AM CHEM SOC, V126, P6878, DOI 10.1021/ja0490424
   DINA T, 2004, LANGMUIR, V20, P101
   DINA T, 2004, LANGMUIR, V20, P848
   DINA T, 2003, J PHYS CHEM B, V107, P10127
   Geddes CD, 2000, J NON-CRYST SOLIDS, V270, P191, DOI 10.1016/S0022-3093(99)00962-X
   Geddes CD, 2002, J FLUORESC, V12, P343, DOI 10.1023/A:1021353707955
   Geddes CD, 2002, J FLUORESC, V12, P113, DOI 10.1023/A:1015331807971
   Geddes CD, 2002, J FLUORESC, V12, P135, DOI 10.1023/A:1016879810487
   Sui J, 2005, LANGMUIR, V21, P4996, DOI 10.1021/la0473963
   Tleugabulova D, 2005, J PHYS CHEM B, V109, P7850, DOI 10.1021/jp045569r
   Tleugabulova D, 2004, LANGMUIR, V20, P5924, DOI 10.1021/la0495478
NR 16
TC 1
Z9 1
U1 4
U2 12
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1006-9291
J9 SCI CHINA SER B
JI Sci. China Ser. B-Chem.
PD AUG
PY 2009
VL 52
IS 8
BP 1120
EP 1127
DI 10.1007/s11426-009-0149-1
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA 477JH
UT WOS:000268514800008
DA 2018-12-27
ER

PT J
AU Jin, X
   Smith, K
   Sun, YL
   Ding, GW
   Yao, Y
   Xu, JJ
   Chang, DF
   Wang, GX
   Zhu, Y
   Wang, N
AF Jin, Xia
   Smith, Kumi
   Sun, Yongli
   Ding, Guowei
   Yao, Yan
   Xu, Junjie
   Chang, Dongfang
   Wang, Guixiang
   Zhu, Yun
   Wang, Ning
TI RETRACTED: Association Between Testing for Human Immunodeficiency Virus
   and Changes in Risk Behaviors Among Injecting Drug Users in Southern
   China (Retracted Article. See vol 36, pg 735, 2009)
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article; Retracted Publication
ID SEXUAL TRANSMISSION; HIV TRANSMISSION; PERSONS AWARE; INDIVIDUALS;
   UNAWARE
AB Background: There is growing need for research in China regarding posttest risk behavior differences among injecting drug users that explores the effect of various testing modes (nonvoluntary vs. voluntary) and other related factors on changes in posttest risk behaviors.
   Methods: One hundred seventy-two study subjects self-reported human immunodeficiency virus (HIV)-related personal risk behaviors including condom use rates and needle-sharing habits. Fisher exact test and multivariate regression analysis compared the impact of HIV testing mode on ongoing risk behaviors for HIV transmission.
   Results: The study found that those who received positive test results were 5.37 times more likely to increase condom use with regular sexual partners, that men were 8.8 times more likely than women to increase posttest condom use in commercial sexual activities. Needlesharing behavior was significantly lower for subjects who tested HIV-positive (odds ratio [OR]: 4.5). who notified sexual partners of test results (OR: 0.03), and who had tested voluntarily (OR: 0.04).
   Conclusion: Based on the study results this report concludes that voluntary HIV testing and encouragement of partner notification of test results should be incorporated into China's national testing strategy.
C1 [Jin, Xia; Smith, Kumi; Sun, Yongli; Ding, Guowei; Yao, Yan; Xu, Junjie; Wang, Ning] China CDC, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China.
   [Jin, Xia] Tsinghua Univ, Peking Union Med Coll, Sch Publ Hlth, Beijing 100084, Peoples R China.
   [Chang, Dongfang; Wang, Guixiang] Kaiyuan Municipal Ctr Dis Control & Prevent, Kunming, Peoples R China.
   [Zhu, Yun] Peoples Municipal Hosp Kaiyuan, Yunnan, Peoples R China.
RP Wang, N (reprint author), China Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, 27 Nanwei Rd, Beijing 100050, Peoples R China.
EM wangnbj@163.com
FU China Ministry of Science and Technology; Tenth Five-year National Key
   Technologies R and D Program grant [(2004BA719A02) 2]; United States
   National Institutions of Health grant [U19AI51915]; China Integrated
   Programs for Research on AIDS (CIPRA)
FX Supported by China Ministry of Science and Technology; Tenth Five-year
   National Key Technologies R and D Program grant (2004BA719A02) 2; United
   States National Institutions of Health grant (U19AI51915); and China
   Integrated Programs for Research on AIDS (CIPRA).
CR BECKWITH C, 2004, RESID STAFF PHYS, V50, P9
   Beckwith CG, 2005, CLIN INFECT DIS, V40, P1037, DOI 10.1086/428620
   Chen HT, 2007, AIDS BEHAV, V11, P778, DOI 10.1007/s10461-007-9215-x
   *CHIN MIN HLTH UN, 2005, 3 C HIV AIDS INT COO
   Colfax GN, 2002, AIDS, V16, P1529, DOI 10.1097/00002030-200207260-00010
   George N, 1998, INT J STD AIDS, V9, P291, DOI 10.1258/0956462981922223
   Janssen RS, 2001, AM J PUBLIC HEALTH, V91, P1019, DOI 10.2105/AJPH.91.7.1019
   Kalichman SC, 2001, AM J PREV MED, V21, P84, DOI 10.1016/S0749-3797(01)00324-5
   Kilmarx PH, 1998, SEX TRANSM DIS, V25, P28, DOI 10.1097/00007435-199801000-00007
   Marks G, 2005, JAIDS-J ACQ IMM DEF, V39, P446, DOI 10.1097/01.qai.0000151079.33935.79
   Marks G, 1999, AIDS, V13, P297, DOI 10.1097/00002030-199902250-00001
   Marks G, 2006, AIDS, V20, P1447, DOI 10.1097/01.aids.0000233579.79714.8d
   McGowan JP, 2004, CLIN INFECT DIS, V38, P122, DOI 10.1086/380128
   *MIN HLTH EXP CONS, 2005, REP HIV SCREEN KEY P
   *MIN HLTH PEOPL RE, 2005 UPD HIV AIDS EP
   Schroder KEE, 2003, ANN BEHAV MED, V26, P104, DOI 10.1207/S15324796ABM2602_03
   *STAT COUNC AIDS W, 2007, JOINT ASSESSMENT S8, V21, pS109
   WU Z, 2006, SCI MAG, V12, P1475
   Yang HM, 2005, SEX TRANSM DIS, V32, P572, DOI 10.1097/01.olq.0000175418.48665.95
NR 19
TC 6
Z9 7
U1 4
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD AUG
PY 2009
VL 36
IS 8
BP 473
EP 477
DI 10.1097/OLQ.0b013e3181a2a90c
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 476GD
UT WOS:000268425900002
PM 19455077
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Mowat, V
   Turton, J
   Stewart, J
   Lui, KC
   Pilling, AM
AF Mowat, Vasanthi
   Turton, John
   Stewart, Jacqui
   Lui, Kai Chiu
   Pilling, Andrew M.
TI RETRACTED: Histopathological Features of Capillaria hepatica Infection
   in Laboratory Rabbits (Retracted article. See vol. 43 pg. 749, 2015)
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Capillaria hepatica; nematode; infection; rabbit; hepatic granuloma
ID RATS RATTUS-NORVEGICUS; SEPTAL FIBROSIS; LIVER; EGGS
AB Capillaria hepatica is a nematode parasite of wild rodents and other mammals. Adult worms inhabit the liver. Recently, during the necropsy examination of a group of 160 rabbits from a commercial supplier, firm pale or cystic areas (1-5 mm) were noted on the liver in thirteen animals. On further investigation, these animals were found to be infected with C. hepatica. The histopathological features of the infection in the rabbit are described for the first time and diagnostic features recorded. Lesions were identified predominantly in portal tracts consisting of dilated bile ducts with luminal debris, peribiliary inflammatory cell infiltrates, and fibrosis. Large granulomas (macrogranulomas) were evident in portal areas and involved the bile ducts. Macrogranulomas contained collections of characteristic C. hepatica eggs, macrophages, eosinophils, and lymphocytes. Small granulomas (microgranulomas), characterized by epithelioid macrophages surrounded by lymphocytes and eosinophils, were also identified. C. hepatica eggs were also observed in the lumina of the bile ducts and gall bladder. No adult C. hepatica worms were identified. Oocysts of Eimeria stiedae were also evident in the biliary epithelium in some animals. The unique characteristics of the C. hepatica life cycle are described, and the differential diagnosis of hepatic capillariasis is discussed.
C1 [Mowat, Vasanthi; Stewart, Jacqui; Lui, Kai Chiu] Huntingdon Life Sci, Dept Pathol, Huntingdon PE28 4HS, Cambs, England.
   [Turton, John] UCL, Div Surg & Intervent Sci, Prostate Canc Res Ctr, London WC1E 6BT, England.
   [Pilling, Andrew M.] ToxPath Consultancy Ltd, Sandy, Beds, England.
RP Mowat, V (reprint author), Huntingdon Life Sci, Dept Pathol, Woolley Rd, Huntingdon PE28 4HS, Cambs, England.
EM Mowatv@ukorg.huntingdon.com
CR BALFOUR A., 1922, Parasitology, V14, P282
   Cameron TWM, 1956, PARASITES PARASITISM
   Ceruti R, 2001, J VET MED B, V48, P235, DOI 10.1046/j.1439-0450.2001.00436.x
   De Souza MM, 2006, PATHOL RES PRACT, V202, P883, DOI 10.1016/j.prp.2006.07.004
   de Souza MM, 2006, HEPATOL RES, V35, P31, DOI 10.1016/j.hepres.2006.01.010
   el-Nassery S F, 1991, J Egypt Soc Parasitol, V21, P467
   FARHANGAZAD A, 1977, J PARASITOL, V63, P701, DOI 10.2307/3279576
   FERREIRA LA, 1993, MEM I OSWALDO CRUZ, V88, P441, DOI 10.1590/S0074-02761993000300015
   Gomes AT, 2006, MEM I OSWALDO CRUZ, V101, P895, DOI 10.1590/S0074-02762006000800012
   Gotardo B M, 2000, Rev Soc Bras Med Trop, V33, P341, DOI 10.1590/S0037-86822000000400002
   KELLY WR, 1992, PATHOLOGY DOMESTIC A, P376
   Lapage G, 1956, VET PARASITOLOGY
   LAPAGE G, 1956, MONNINGS VET HELMINT
   LAYNE JN, 1968, ZOOLOGICA-N Y, V53, P107
   Levine ND, 1968, NEMATODE PARASITES D
   Lloyd S, 2002, VET REC, V151, P419, DOI 10.1136/vr.151.14.419
   Luttermoser GW, 1938, AM J HYG, V27, P275, DOI 10.1093/oxfordjournals.aje.a118389
   Luttermoser GW, 1938, AM J HYG, V27, P321, DOI 10.1093/oxfordjournals.aje.a118395
   Mowat V, 2008, TOXICOL PATHOL, V36, P164
   MUNROE GA, 1984, EQUINE VET J, V16, P221, DOI 10.1111/j.2042-3306.1984.tb01913.x
   Neva FA, 1994, BASIC CLIN PARASITOL
   Nicoll W, 1911, P ZOOL SOC LOND, V1911, P677
   OLDHAM J. N., 1967, Pathology of laboratory Rats and Mice., P641
   Oliveira Ludmila, 2004, Rev. Soc. Bras. Med. Trop., V37, P123, DOI 10.1590/S0037-86822004000200001
   Oliveira RF, 2001, MEM I OSWALDO CRUZ, V96, P1001, DOI 10.1590/S0074-02762001000700020
   OWEN D, 1972, COMMON PARASITES LAB
   PETERS W, 1989, COLOUR ATLAS TROPICA
   Santos A B, 2001, Rev Soc Bras Med Trop, V34, P503
   Shadduck J. A., 1978, Pathology of laboratory animals, Volume II., P1587
   SLAIS J, 1974, Folia Parasitologica (Ceske Budejovice), V21, P95
   SOLOMON GB, 1973, EXP PARASITOL, V33, P458, DOI 10.1016/0014-4894(73)90113-6
   Spratt David M., 2001, P365, DOI 10.1002/9780470377000.ch14
   SUN T, 1999, PARASITIC DISORDERS
   WEBSTER JP, 1995, PARASITOLOGY, V111, P247, DOI 10.1017/S0031182000081804
   WRIGHT KA, 1961, CAN J ZOOLOG, V39, P167, DOI 10.1139/z61-022
NR 35
TC 8
Z9 9
U1 3
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0192-6233
EI 1533-1601
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PD AUG
PY 2009
VL 37
IS 5
BP 661
EP 666
DI 10.1177/0192623309339501
PG 6
WC Pathology; Toxicology
SC Pathology; Toxicology
GA 476WF
UT WOS:000268476400009
PM 19581239
DA 2018-12-27
ER

PT J
AU Qin, W
   Li, X
   Qi, JY
AF Qin, Wu
   Li, Xin
   Qi, Jingyao
TI RETRACTED: Experimental and Theoretical Investigation of the Catalytic
   Ozonation on the Surface of NiO-CuO Nanoparticles (Retracted Article.
   See vol 26, pg 6864, 2010)
SO LANGMUIR
LA English
DT Article; Retracted Publication
ID TOTAL-ENERGY CALCULATIONS; WAVE BASIS-SET; OXALIC-ACID; OZONE
   DECOMPOSITION; AQUEOUS-SOLUTIONS; PHENOL OXIDATION; WATER TREATMENT;
   NICKEL-OXIDE; CUO/AL2O3; GAS
AB NiO-CuO nanoparticles prepared by the sol-gel method were used as catalyst for the degradation of dichloroacetic acid by ozone. Catalyst samples were characterized by measuring the specific area (SBET), X-ray diffraction (XRD), transmission electron microscopy (TEM), and high-resolution transmission electron microscopy (HRTEM). The catalytic activity of NiO-CuO nanoparticles wits investigated for the removal of dichloroacetic acid in aqueous solutions, using different experimental conditions like catalyst dose, initial reaction temperature, and pH have been examined. Ozonation processes were significantly influenced by tert-butyl alcohol, which confirmed that NiO-CuO catalytic ozonation follows a radical-type mechanism, which the hydroxyl radicals were truly identified by spintrapping/electron spin resonance (EPR) technique and density functional theory (DFT) calculation. In our DFT calculation, we illustrated the atomistic details with three surface models of NiO-CuO nanoparticle and presented a mechanism depicting how all ozone molecule interacted with the surface and how hydroxyl radicals were generated on the surface with a quantitative and qualitative discussion including electronic structure characteristics and relative energetic diagrams. We found partial electron transfer from these surfaces to the adsorbed ozone, which directly led to the decomposition of ozone and promoted the generation of superoxide radical ions and hydroxyl radicals. Results suggested that the introduction of NiO-CuO nanoparticles led to violent interaction between ozone and the catalyst surface, hence promoting the decomposition of ozone and the generation of center dot OH which, in turn, might lead to an increase in their catalytic ozonation efficiency.
C1 [Qin, Wu; Li, Xin] Harbin Inst Technol, Dept Chem, Harbin 150090, Peoples R China.
   [Qi, Jingyao] Harbin Inst Technol, Sch Municipal & Environm Engn, Harbin 150090, Peoples R China.
RP Li, X (reprint author), Harbin Inst Technol, Dept Chem, Harbin 150090, Peoples R China.
EM lixin@hit.edu.cn
FU National Natural Science Foundation of China [50878061]; Scientific
   Research Foundation of Harbin [2007RFXXS022]
FX The authors wish to acknowledge the financial support from financial
   support from the National Natural Science Foundation of China (50878061)
   and Scientific Research Foundation of Harbin (Grant No. 2007RFXXS022).
CR Acero JL, 2000, OZONE-SCI ENG, V22, P305, DOI 10.1080/01919510008547213
   ACERO JL, 1998, P OZ AOPS WAT TREATM
   Andreozzi R, 1999, CATAL TODAY, V53, P51, DOI 10.1016/S0920-5861(99)00102-9
   Andreozzi R, 1996, APPL CATAL A-GEN, V138, P75, DOI 10.1016/0926-860X(95)00247-2
   BADER H, 1981, WATER RES, V15, P449, DOI 10.1016/0043-1354(81)90054-3
   Bai P, 2008, J MATER CHEM, V18, P74, DOI 10.1039/b713283b
   Bansal R. C., 1988, ACTIVE CARBON
   BARBARA KH, 2003, APPL CATAL B-ENVIRON, V46, P639
   Beltran FJ, 2004, APPL CATAL B-ENVIRON, V47, P101, DOI 10.1016/j.apcatb.2003.07.007
   Beltran FJ, 2003, IND ENG CHEM RES, V42, P3218, DOI 10.1021/ie020999u
   Beltran FJ, 2002, APPL CATAL B-ENVIRON, V39, P221, DOI 10.1016/S0926-3373(02)00102-9
   Cavazzoni C, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.033103
   Claesson EM, 2005, LANGMUIR, V21, P9412, DOI 10.1021/la051127a
   Coca M, 2005, CHEMOSPHERE, V60, P1408, DOI 10.1016/j.chemosphere.2005.01.090
   Colle R, 2007, J PHYS CHEM B, V111, P2800, DOI 10.1021/jp067847n
   Cooper C, 1999, WATER RES, V33, P3695, DOI 10.1016/S0043-1354(99)00091-3
   Cooper WJ, 2009, CHEM REV, V109, P1302, DOI 10.1021/cr078024c
   Devulapelli VG, 2008, APPL CATAL A-GEN, V348, P86, DOI 10.1016/j.apcata.2008.06.038
   Dieguez O, 2006, SOLID STATE COMMUN, V137, P129, DOI 10.1016/j.ssc.2005.11.009
   Elliott SD, 2008, NANO LETT, V8, P2452, DOI 10.1021/nl801453g
   Elovitz MS, 2000, OZONE-SCI ENG, V22, P123, DOI 10.1080/01919510008547216
   Fenoglio RJ, 2007, J CHEM TECHNOL BIOT, V82, P481, DOI 10.1002/jctb.1694
   FUJIMORI A, 1984, PHYS REV B, V30, P957, DOI 10.1103/PhysRevB.30.957
   Govind N, 2003, COMP MATER SCI, V28, P250, DOI 10.1016/S0927-0256(03)00111-3
   Gracia R, 2000, WATER RES, V34, P1525, DOI 10.1016/S0043-1354(99)00297-3
   Hildebrand H, 2008, GLOBAL NEST J, V10, P47
   HILDEBRAND H, 2007, NANOTECHNOLOGY, V2, P639
   HOIGNE J, 1983, WATER RES, V17, P173, DOI 10.1016/0043-1354(83)90098-2
   Huang C. P., 1993, Waste Management, V13, P361, DOI 10.1016/0956-053X(93)90070-D
   Huang WJ, 2005, COLLOID SURFACE A, V260, P45, DOI 10.1016/j.colsurfa.2005.01.031
   HUFNER S, 1994, ADV PHYS, V43, P183, DOI 10.1080/00018739400101495
   Irwin MD, 2008, P NATL ACAD SCI USA, V105, P2783, DOI 10.1073/pnas.0711990105
   Jana NR, 2000, LANGMUIR, V16, P2457, DOI 10.1021/la990507r
   JANZEN EG, 1969, J AM CHEM SOC, V91, P4481, DOI 10.1021/ja01044a028
   Jia ZH, 2007, CHEM ENG TECHNOL, V30, P1221, DOI 10.1002/ceat.200700139
   Kim J, 2003, DESALINATION, V151, P1, DOI 10.1016/S0011-9164(02)00967-0
   Kim W, 2001, POWDER TECHNOL, V114, P12, DOI 10.1016/S0032-5910(00)00256-4
   Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169
   KRESSE G, 1993, PHYS REV B, V47, P558, DOI 10.1103/PhysRevB.47.558
   Kresse G, 1996, COMP MATER SCI, V6, P15, DOI 10.1016/0927-0256(96)00008-0
   LeLacheur RM, 1996, ENVIRON SCI TECHNOL, V30, P1072, DOI 10.1021/es940544z
   Meyre ME, 2008, LANGMUIR, V24, P4421, DOI 10.1021/la703650d
   Monti S, 2008, LANGMUIR, V24, P3205, DOI 10.1021/la702956t
   Nakagawa N, 2006, NAT MATER, V5, P204, DOI 10.1038/nmat1569
   Noguera C, 2000, J PHYS-CONDENS MAT, V12, pR367, DOI 10.1088/0953-8984/12/31/201
   Nolan M, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.235424
   Nolan M, 2008, SURF SCI, V602, P2734, DOI 10.1016/j.susc.2008.06.028
   Nolan M, 2008, CHEM MATER, V20, P5522, DOI 10.1021/cm703395k
   Nolan M, 2009, PHYS CHEM CHEM PHYS, V11, P2156, DOI 10.1039/b819724e
   Nolan M, 2009, J PHYS CHEM C, V113, P2425, DOI 10.1021/jp809292u
   Oh SK, 2005, LANGMUIR, V21, P10209, DOI 10.1021/la050524i
   Ohta H, 2003, THIN SOLID FILMS, V445, P317, DOI 10.1016/S0040-6090(03)01178-7
   Ouahab A, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.035421
   Pankove J. I, 1975, OPTICAL PROCESSES SE
   Patcas F, 2006, CATAL TODAY, V117, P253, DOI 10.1016/j.cattod.2006.05.052
   Patil PS, 2002, APPL SURF SCI, V199, P211, DOI 10.1016/S0169-4332(02)00839-5
   PERDEW JP, 1992, PHYS REV B, V45, P13244, DOI 10.1103/PhysRevB.45.13244
   PERDEW JP, 1981, PHYS REV B, V23, P5048, DOI 10.1103/PhysRevB.23.5048
   Persson P, 2002, CHEM PHYS LETT, V364, P469, DOI 10.1016/S0009-2614(02)01370-2
   Pines DS, 2003, OZONE-SCI ENG, V25, P25, DOI 10.1080/713610648
   Pirkanniemi K, 2002, CHEMOSPHERE, V48, P1047, DOI 10.1016/S0045-6535(02)00168-6
   Qu JH, 2004, CATAL TODAY, V90, P291, DOI 10.1016/j.cattod.2004.04.032
   Sacanna S, 2006, LANGMUIR, V22, P10209, DOI 10.1021/la0616505
   SEHESTED K, 1991, ENVIRON SCI TECHNOL, V25, P1589, DOI 10.1021/es00021a010
   Sen R, 2008, LANGMUIR, V24, P5970, DOI 10.1021/la7040086
   SIEGEL DJ, 2001, MAT RES SOC S P, V654
   SINCLAIR JE, 1974, J PHYS C SOLID STATE, V7, P864, DOI 10.1088/0022-3719/7/5/009
   SOMIYA I, 1997, P 13 OZ WORLD C KYOT, V1, P493
   STAEHELIN J, 1984, J PHYS CHEM-US, V88, P5999, DOI 10.1021/j150668a051
   STAEHELIN J, 1982, ENVIRON SCI TECHNOL, V16, P676, DOI 10.1021/es00104a009
   Stoyanova M, 2006, CHEM ENG J, V122, P41, DOI 10.1016/j.cej.2006.05.018
   SUDDHASATTWA N, 2003, COLLOID INTERFACE SC, V264, P89
   Tian ZRR, 2003, NAT MATER, V2, P821, DOI 10.1038/nmat1014
   Tong SP, 2003, CHEMOSPHERE, V50, P1359, DOI 10.1016/S0045-6535(02)00761-0
   Turky AM, 2003, APPL CATAL A-GEN, V247, P83, DOI 10.1016/S0926-860X(03)00089-9
   UTSUMI H, 1994, WATER SCI TECHNOL, V30, P91
   Yang YX, 2007, J MOL CATAL A-CHEM, V267, P41, DOI 10.1016/j.molcata.2006.09.010
   Yu JL, 2000, APPL CATAL B-ENVIRON, V28, P275, DOI 10.1016/S0926-3373(00)00184-3
   Yuan G, 2003, CATAL TODAY, V88, P27, DOI 10.1016/j.cattod.2003.08.004
NR 79
TC 14
Z9 15
U1 16
U2 78
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD JUL 21
PY 2009
VL 25
IS 14
BP 8001
EP 8011
DI 10.1021/la900476m
PG 11
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 472NI
UT WOS:000268138400031
PM 19466811
DA 2018-12-27
ER

PT J
AU Nangia, Y
   Wangoo, N
   Goyal, N
   Shekhawat, G
   Suri, CR
AF Nangia, Yogesh
   Wangoo, Nishima
   Goyal, Nisha
   Shekhawat, G.
   Suri, C. Raman
TI RETRACTED: A novel bacterial isolate Stenotrophomonas maltophilia as
   living factory for synthesis of gold nanoparticles (Retracted article.
   See vol. 8, art. no. 52, 2009)
SO MICROBIAL CELL FACTORIES
LA English
DT Article; Retracted Publication
ID SILVER NANOPARTICLES; BIOLOGICAL APPROACH; BIOSYNTHESIS; IONS
AB Background: The synthesis of gold nanoparticles (GNPs) has received considerable attention with their potential applications in various life sciences related applications. Recently, there has been tremendous excitement in the study of nanoparticles synthesis by using some natural biological system, which has led to the development of various biomimetic approaches for the growth of advanced nanomaterials. In the present study, we have demonstrated the synthesis of gold nanoparticles by a novel bacterial strain isolated from a site near the famous gold mines in India. A promising mechanism for the biosynthesis of GNPs by this strain and their stabilization via charge capping was investigated.
   Results: A bacterial isolate capable of gold nanoparticle synthesis was isolated and identified as a novel strain of Stenotrophomonas malophilia (AuRed02) based on its morphology and an analysis of its 16S rDNA gene sequence. After 8 hrs of incubation, monodisperse preparation of gold nanoparticles was obtained. Gold nanoparticles were characterized and found to be of similar to 40 nm size. Electrophoresis, Zeta potential and FTIR measurements confirmed that the particles are capped with negatively charged phosphate groups from NADP rendering them stable in aqueous medium.
   Conclusion: The process of synthesis of well-dispersed nanoparticles using a novel microorganism isolated from the gold enriched soil sample has been reported in this study, leading to the development of an easy bioprocess for synthesis of GNPs. This is the first study in which an extensive characterization of the indigenous bacterium isolated from the actual gold enriched soil was conducted. Promising mechanism for the biosynthesis of GNPs by the strain and their stabilization via charge capping is suggested, which involves an NADPH-dependent reductase enzyme that reduces Au3+ to Au-0 through electron shuttle enzymatic metal reduction process.
C1 [Nangia, Yogesh; Wangoo, Nishima; Goyal, Nisha; Suri, C. Raman] CSIR, Inst Microbial Technol, Chandigarh 160036, India.
   [Shekhawat, G.] Northwestern Univ, Inst Nanotechnol, Evanston, IL USA.
RP Suri, CR (reprint author), CSIR, Inst Microbial Technol, Sector 39-A, Chandigarh 160036, India.
EM yogesh.nangia@imtech.res.in; nishima@imtech.res.in;
   nishagoyal@imtech.res.in; g-shekhawat@northwestern.edu;
   raman@imtech.res.in
FU Indo-Russia Integrated Long Term Programme (ILTP)
FX This work was funded by a grant from the joint Indo-Russia Integrated
   Long Term Programme (ILTP), which we gratefully acknowledge. Authors
   gratefully acknowledge Mr Kumar Rajesh for necessary technical support.
CR Ahmad A, 2003, NANOTECHNOLOGY, V14, P824, DOI 10.1088/0957-4484/14/7/323
   Duran Nelson, 2005, J Nanobiotechnology, V3, P8, DOI 10.1186/1477-3155-3-8
   He SY, 2007, MATER LETT, V61, P3984, DOI 10.1016/j.matlet.2007.01.018
   Holt J. G., 1994, BERGEYS MANUAL DETER
   Husseiny MI, 2007, SPECTROCHIM ACTA A, V67, P1003, DOI 10.1016/j.saa.2006.09.028
   Jana NR, 2001, J PHYS CHEM B, V105, P4065, DOI 10.1021/jp0107964
   Kalimuthu K, 2008, COLLOID SURFACE B, V65, P150, DOI 10.1016/j.colsurfb.2008.02.018
   Klaus T, 1999, P NATL ACAD SCI USA, V96, P13611, DOI 10.1073/pnas.96.24.13611
   Mandal S, 2002, P INDIAN AS-CHEM SCI, V114, P513
   MIRKIN CA, 1996, NATURE, V382, P609
   Mukherjee P, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/7/075103
   Mukherjee P, 2002, CHEMBIOCHEM, V3, P461, DOI 10.1002/1439-7633(20020503)3:5<461::AID-CBIC461>3.0.CO;2-X
   Mukherjee P, 2001, NANO LETT, V1, P515, DOI 10.1021/nl0155274
   Pum D, 1999, TRENDS BIOTECHNOL, V17, P8, DOI 10.1016/S0167-7799(98)01221-9
   Salata O.V., 2004, J NANOBIOTECHNOL, V2, P3, DOI DOI 10.1186/1477-3155-2-3
   Senapati S, 2005, SMALL, V1, P517, DOI 10.1002/smll.200400053
   Shahverdi AR, 2007, PROCESS BIOCHEM, V42, P919, DOI 10.1016/j.procbio.2007.02.005
   Silver S, 1996, GENE, V179, P9, DOI 10.1016/S0378-1119(96)00323-X
   Thomas M, 2003, P NATL ACAD SCI USA, V100, P9138, DOI 10.1073/pnas.1233634100
   TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055
   WOESE CR, 1983, MICROBIOL REV, V47, P621
   Xiao Y, 2003, SCIENCE, V299, P1877, DOI 10.1126/science.1080664
   Zhou XL, 2007, J COLLOID INTERF SCI, V308, P381, DOI 10.1016/j.jcis.2007.01.040
NR 23
TC 39
Z9 40
U1 4
U2 20
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2859
J9 MICROB CELL FACT
JI Microb. Cell. Fact.
PD JUL 20
PY 2009
VL 8
AR 39
DI 10.1186/1475-2859-8-39
PG 7
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 486CY
UT WOS:000269174300002
PM 19619318
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Lee, HJ
   Lee, JH
   Lee, EO
   Lee, HJ
   Kim, KH
   Kim, SH
   Lee, KS
   Jung, HJ
   Kim, SH
AF Lee, Hyo-Jeong
   Lee, Jae-Ho
   Lee, Eun-Ok
   Lee, Hyo-Jung
   Kim, Kwan-Hyun
   Kim, Sun-Hyung
   Lee, Keun-Sung
   Jung, Hee-Jae
   Kim, Sung-Hoon
TI RETRACTED: Substance P and beta-endorphin mediate electro-acupuncture
   induced analgesia in mouse cancer pain model (Retracted article. See
   vol. 28, art. no. 137, 2009)
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID DIFFERENT FREQUENCIES; DORSAL-HORN; NERVE; RATS; STIMULATION; SYSTEMS;
   MICE
AB Background: Opioid analgesics are generally used to combat the pain associated with cancerous conditions. These agents not only inhibit respiratory function and cause constipation, but also induce other significant side effects such as addiction and tolerance, all of which further contribute to a reduced quality of life for cancer patients. Thus, in the present study, the effects of electro-acupuncture treatment (EA) on mechanical allodynia were examined in a cancer pain mouse model.
   Methods: In order to produce a neuropathic cancer pain model, S-180 sarcoma cells were inoculated around the sciatic nerve of left legs of Balb/c mice. Magnetic Resonance Imaging (MRI) scanning confirmed the mass of S-180 cancer cells embedded around the sciatic nerve. Mechanical allodynia was most consistently induced in the mouse sarcoma cell line S-180 (2 x 10(6) sarcoma cells)-treated group compared to all the other groups studied. EA stimulation (2 Hz) was administered daily to ST36 (Zusanli) of S-180 bearing mice for 30 min for 9 days after S-180 inoculation.
   Results: EA treatment significantly prolonged paw withdrawal latency from 5 days after inoculation. It also shortened the cumulative lifting duration from 7 days after inoculation, compared to the tumor control. Also, the overexpression of pain peptide substance P in the dorsal horn of the spinal cord was significantly decreased in the EA-treated group compared to the tumor control on Day 9 post inoculation. Furthermore, EA treatment effectively increased the concentration of beta-endorphin in blood and brain samples of the mice to a greater extent than that of the tumor control as well as the normal group. The concentration of beta-endorphin for EA treatment group increased by 51.457% in the blood and 12.6% in the brain respectively, compared to the tumor control group.
   Conclusion: The findings of this study suggest that a S-180 cancer pain model is useful as a consistent and short time animal model. It also indicated that EA treatment could be used as an alternative therapeutic method for cancer pain due to a consequent decrease in substance P and increase in beta-endorphin levels.
C1 [Lee, Hyo-Jeong; Lee, Jae-Ho; Lee, Eun-Ok; Lee, Hyo-Jung; Kim, Kwan-Hyun; Kim, Sun-Hyung; Lee, Keun-Sung; Kim, Sung-Hoon] Kyung Hee Univ, Coll Oriental Med, Seoul 130701, South Korea.
   [Jung, Hee-Jae] Kyung Hee Univ, Med Ctr, Seoul 130701, South Korea.
RP Kim, SH (reprint author), Kyung Hee Univ, Coll Oriental Med, Seoul 130701, South Korea.
EM strong79@khu.ac.kr; llijh5102@hotmail.com; leook88@hotmail.com;
   hyonice77@hanmail.net; kwanhyunkim@khu.ac.kr; peaceful-sea@hanmail.net;
   truesung80@naver.com; hanfish@khmc.or.kr; sungkim7@khu.ac.kr
FU Medical Research Center (MRC) [R13-2007-019-00000-0]
FX This work was supported by Medical Research Center (MRC) grant
   (R13-2007-019-00000-0).
CR Aurilio C, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-61
   Brown SM, 1997, ARCH OPHTHALMOL-CHIC, V115, P926, DOI 10.1001/archopht.1997.01100160096021
   Cain DM, 2001, PAIN MED, V2, P15, DOI 10.1046/j.1526-4637.2001.002001015.x
   Chang FC, 2004, J BIOMED SCI, V11, P179, DOI 10.1159/000076030
   CHEN XH, 1992, BEHAV BRAIN RES, V47, P143, DOI 10.1016/S0166-4328(05)80120-2
   CHENG RSS, 1979, LIFE SCI, V25, P1957, DOI 10.1016/0024-3205(79)90598-8
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Han Z, 1999, NEUROSCI LETT, V274, P75, DOI 10.1016/S0304-3940(99)00670-9
   Koeda T, 2007, J PHYSIOL SCI, V57, P361, DOI 10.2170/physiolsci.RP007607
   Kuai Le, 2008, Zhong Xi Yi Jie He Xue Bao, V6, P197
   Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G
   Omura Y, 1975, ACUPUNCTURE ELECTRO, V1, P157
   Park IB, 2006, AM J CHINESE MED, V34, P417, DOI 10.1142/S0192415X06003953
   Park MB, 2004, J NEUROIMMUNOL, V151, P40, DOI 10.1016/j.jneuroim.2004.02.003
   QUIGLEY C, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004847
   SAMUELSSON H, 1993, ACTA ANAESTH SCAND, V37, P502, DOI 10.1111/j.1399-6576.1993.tb03755.x
   Schrijvers D, 2007, ANN ONCOL, V18, P37, DOI 10.1093/annonc/mdm292
   SHAHI PK, 2007, AN MED INTERN, V24, P553
   Shimoyama M, 2005, PAIN, V114, P221, DOI 10.1016/j.pain.2004.12.018
   Silva GA, 2007, SURG NEUROL, V67, P113, DOI 10.1016/j.surneu.2006.08.033
   Siu FKW, 2004, LIFE SCI, V75, P1323, DOI 10.1016/j.lfs.2004.02.025
   SOMMER C, 1995, ACTA NEUROPATHOL, V90, P478
   Takaishi K, 1996, PAIN, V66, P297, DOI 10.1016/0304-3959(96)03023-0
   Yim YK, 2007, EVID-BASED COMPL ALT, V4, P51, DOI 10.1093/ecam/nel054
NR 24
TC 9
Z9 9
U1 4
U2 23
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD JUL 16
PY 2009
VL 28
AR 102
DI 10.1186/1756-9966-28-102
PG 9
WC Oncology
SC Oncology
GA 485TC
UT WOS:000269146200002
PM 19607689
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Pushparaj, PN
   Tay, HK
   Wang, CC
   Hong, WJ
   Melendez, AJ
AF Pushparaj, Peter N.
   Tay, Hwee Kee
   Wang, Cheng-Chun
   Hong, Wanjin
   Melendez, Alirio J.
TI RETRACTED: VAMP8 Is Essential in Anaphylatoxin-Induced Degranulation,
   TNF-alpha Secretion, Peritonitis, and Systemic Inflammation (Retracted
   article. See vol. 190, pg. 3007, 2013)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID CYTOKINE PRODUCTION; SPHINGOSINE KINASE; COMPLEMENT-SYSTEM;
   ENDOTHELIAL-CELLS; C5A RECEPTOR; KEY ROLE; IN-VIVO; V-SNARE; SEPSIS;
   EXPRESSION
AB VAMP8, a member of the soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor (SNARE) family of fusion proteins, initially characterized in endosomal and endosomal-lysosomal fusion, may also function in regulated exocytosis. VAMP8 physiological function in inflammation has not been elucidated. In this paper, we show that deficiency of VAMP8 protects mice from anaphylatoxin (C5a)-induced neutropenia, peritonitis, and systemic inflammation. We show that, in vivo, VAMP8 deletion inhibits neutropenia and phagocyte recruitment. We also show that in macrophages, VAMP8 localizes on secretory granules and degranulation is inhibited in VAMPS-deficient macrophages. Moreover, VAMP8(-/-) mice show reduced systemic inflammation with inhibition of serum TNF-alpha levels, whereas IL-1 beta, IL-6, and MIP1 alpha release are not affected. In wild-type macrophages, TNF-alpha colocalizes with VAMPS-positive vesicles, and in VAMP8-deficient macrophages, the TNF-alpha release is inhibited. Furthermore, VAMP8 regulates the release of TNF-alpha and beta-hexosaminidase triggered by fMLP, and VAMP8(-/-) mice are protected from fMLP-induced peritonitis. These data demonstrate that the VAMP8 vesicle-associated-SNARE is required for the proper trafficking of secretory lysosomal granules for exocytosis in macrophages and for the release of the potent proinflammatory cytokine, TNF-alpha. The Journal of Immunology, 2009, 183: 1413-1418.
C1 [Pushparaj, Peter N.; Tay, Hwee Kee; Melendez, Alirio J.] Univ Glasgow, Glasgow Biomed Res Ctr, Fac Med, Div Immunol Infect & Inflammat, Glasgow G12 8TA, Lanark, Scotland.
   [Pushparaj, Peter N.; Tay, Hwee Kee; Melendez, Alirio J.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore.
   [Wang, Cheng-Chun; Hong, Wanjin] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore.
RP Melendez, AJ (reprint author), Univ Glasgow, Glasgow Biomed Res Ctr, Fac Med, Div Immunol Infect & Inflammat, 120 Univ Pl, Glasgow G12 8TA, Lanark, Scotland.
EM a.melendez-romero@clinmed.gla.ac.uk
RI ASTAR, IMCB/E-2320-2012; HONG, Wanjin/E-9927-2010
FU National University of Singapore Academic Research [R-185-000-109-112];
   Medical Research Council [G0700794]
FX This work was supported by a National University of Singapore Academic
   Research Fund Grant No. R-185-000-109-112 and a University of Glasgow
   Start-up Fund. We thank A.-K. Fraser-Andrews for proofreading the
   manuscript.
CR Albrecht EA, 2004, CURR ALLERGY ASTHM R, V4, P359, DOI 10.1007/s11882-004-0084-3
   Albrecht EA, 2004, AM J PATHOL, V164, P849, DOI 10.1016/S0002-9440(10)63173-2
   Arumugam TV, 2004, SHOCK, V21, P401, DOI 10.1097/01.shk.0000121227.73012.86
   BULLARD DC, 1995, J CLIN INVEST, V95, P1782, DOI 10.1172/JCI117856
   Cosen-Binker LI, 2008, J CLIN INVEST, V118, P2535, DOI 10.1172/JCI34672
   Czermak BJ, 1998, P ASSOC AM PHYSICIAN, V110, P306
   FFRENCHCONSTANT C, 1994, LANCET, V343, P271, DOI 10.1016/S0140-6736(94)91118-5
   Guo RF, 2002, J IMMUNOL, V169, P307, DOI 10.4049/jimmunol.169.1.307
   Hawlisch H, 2004, MOL IMMUNOL, V41, P123, DOI 10.1016/j.molimm.2004.03.019
   Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193
   Ibrahim FBM, 2004, J BIOL CHEM, V279, P44802, DOI 10.1074/jbc.M403977200
   Laudes IJ, 2002, J IMMUNOL, V169, P5962, DOI 10.4049/jimmunol.169.10.5962
   Laudes IJ, 2002, AM J PATHOL, V160, P1867, DOI 10.1016/S0002-9440(10)61133-9
   Linton SM, 1999, MOL IMMUNOL, V36, P905, DOI 10.1016/S0161-5890(99)00113-3
   MARDER SR, 1985, J IMMUNOL, V134, P3325
   Melendez AJ, 2004, J IMMUNOL, V173, P1596, DOI 10.4049/jimmunol.173.3.1596
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321
   Pushparaj PN, 2008, INT J BIOCHEM CELL B, V40, P1817, DOI 10.1016/j.biocel.2008.01.015
   Ren QS, 2007, MOL BIOL CELL, V18, P24, DOI 10.1091/mbc.E06-09-0785
   Riedemann NC, 2002, J IMMUNOL, V168, P1919, DOI 10.4049/jimmunol.168.4.1919
   Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402
   Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753
   Sarma VJ, 2006, AUTOIMMUNITY, V39, P387, DOI 10.1080/08916930600739456
   Struyf S, 2005, EUR J IMMUNOL, V35, P1583, DOI 10.1002/eji.200425753
   Tiwari N, 2008, BLOOD, V111, P3665, DOI 10.1182/blood-2007-07-103309
   Vlasenko LP, 2005, J IMMUNOL, V174, P6456, DOI 10.4049/jimmunol.174.10.6456
   Wang CC, 2004, DEV CELL, V7, P359, DOI 10.1016/j.devcel.2004.08.002
   Ward PA, 2004, NAT REV IMMUNOL, V4, P133, DOI 10.1038/nri1269
   Welch TR, 2002, NAT GENET, V31, P333, DOI 10.1038/ng933
   Wong SH, 1998, MOL BIOL CELL, V9, P1549, DOI 10.1091/mbc.9.6.1549
   Zhang F, 2004, J BIOL CHEM, V279, P38668, DOI 10.1074/jbc.M404904200
NR 31
TC 15
Z9 16
U1 2
U2 11
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JUL 15
PY 2009
VL 183
IS 2
BP 1413
EP 1418
DI 10.4049/jimmunol.0804061
PG 6
WC Immunology
SC Immunology
GA 468JD
UT WOS:000267812600069
PM 19564343
OA Bronze
DA 2018-12-27
ER

PT J
AU Zhou, T
   Zhou, RJ
   An, Z
AF Zhou, Tian
   Zhou, Ru-Jin
   An, Zhe
TI RETRACTED: Bis(6-methoxy-2-{[tris(hydroxymethyl)methyl-kappa
   O]iminomethyl}phenolato-kappa N-2,O-1)nickel(II) dihydrate (Retracted
   article. See vol. 67, pg. E16, 2011)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the title compound, [Ni(C12H16NO5)2]center dot 2H(2)O, the Ni-II atom is coordinated by four O atoms and two N atoms from the two 6-methoxy-2-{[tris(hydroxymethyl)methyl]iminomethyl}-phenolate ligands in a distorted octahedral coordination geometry. O-H center dot center dot center dot O hydrogen bonds link the complexes and uncoordinated water molecules into two-dimensional networks parallel to (001).
C1 [Zhou, Tian; Zhou, Ru-Jin; An, Zhe] Maoming Univ, Sch Chem & Life Sci, Maoming 525000, Peoples R China.
RP Zhou, T (reprint author), Maoming Univ, Sch Chem & Life Sci, Maoming 525000, Peoples R China.
EM zhoutian016@163.com
FU Science Foundation of Maoming University [208033]
FX The authors acknowledge financial support from the Science Foundation of
   Maoming University (grant No. 208033).
CR *BRUK AXS INC, 2004, APEX2
   Bruker, 2001, SAINT PLUS
   KRITAGAWA S, 1998, B CHEM SOC JPN, V71, P1739
   Sheldrick G. M, 2003, SADABS
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Yaghi OM, 1996, J AM CHEM SOC, V118, P9096, DOI 10.1021/ja960746q
   Zhang YG, 1998, CHEM LETT, P1051, DOI 10.1246/cl.1998.1051
NR 7
TC 6
Z9 6
U1 5
U2 17
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD JUL
PY 2009
VL 65
BP M779
EP U846
DI 10.1107/S1600536809022028
PN 7
PG 12
WC Crystallography
SC Crystallography
GA 462VM
UT WOS:000267385300066
PM 21582708
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Waxman, BP
AF Waxman, B. P.
TI RETRACTED: Medicine in small doses (Retracted article. See vol. 85, pg.
   595, 2015)
SO ANZ JOURNAL OF SURGERY
LA English
DT Editorial Material; Retracted Publication
NR 0
TC 1
Z9 1
U1 3
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1445-1433
EI 1445-2197
J9 ANZ J SURG
JI ANZ J. Surg.
PD JUL-AUG
PY 2009
VL 79
IS 7-8
BP 564
EP 564
DI 10.1111/j.1445-2197.2009.05038.x
PG 1
WC Surgery
SC Surgery
GA 478KK
UT WOS:000268587000019
OA Bronze
DA 2018-12-27
ER

PT J
AU Banerjee, S
   Kaseb, AO
   Wang, ZW
   Kong, DJ
   Mohammad, M
   Padhye, S
   Sarkar, FH
   Mohammad, RM
AF Banerjee, Sanjeev
   Kaseb, Ahmed O.
   Wang, Zhiwei
   Kong, Deujan
   Mohammad, Mussop
   Padhye, Subhash
   Sarkar, Fazlul H.
   Mohammad, Ramzi M.
TI RETRACTED: Antitumor Activity of Gemcitabine and Oxaliplatin Is
   Augmented by Thymoquinone in Pancreatic Cancer (Retracted article. See
   vol. 78, pg. 5468, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; IN-VITRO; CELL-LINES; CYCLOOXYGENASE-2 EXPRESSION; SURVIVIN
   EXPRESSION; MOLECULAR EVIDENCE; ORTHOTOPIC MODEL; CARCINOMA-CELLS;
   APOPTOSIS; THERAPY
AB Previous studies have shown biological activity of thymoquinone, an active compound extracted from Nigella sativa, in pancreatic cancer cells; however, preclinical animal studies are lacking. Here, we report, for the first time, the chemosensitizing effect of thymoquinone to conventional chemotherapeutic agents both in vitro and in vivo using an orthotopic model of pancreatic cancer. In vitro studies revealed that preexposure of cells with thymoquinone (25 mu mol/L) for 48 h followed by gemcitabine or oxaliplatin resulted in 60% to 80% growth inhibition compared with 15% to 25% when gemcitabine or oxaliplatin was used alone. Moreover, we found that thymoquinone could potentiate the killing of pancreatic cancer cells induced by chemotherapeutic agents by down-regulation of nuclear factor-kappa B (NF-kappa B), Bcl-2 family, and NF-kappa B-dependent antiapoptotic genes (X-linked inhibitors of apoptosis, survivin, and cyclooxygenase-2). As shown previously by our laboratory, NF-kappa B gets activated on exposure of pancreatic cancer cells to conventional chemotherapeutic agents; interestingly, thymoquinone was able to down-regulate NF-kappa B in vitro, resulting in chemosensitization. In addition to in vitro results, here we show for the first time, that thymoquinone in combination with gemcitabine and/or oxatiplatin is much more effective as an antitumor agent compared with either agent alone. Most importantly, our data also showed that a specific target, such as NF-kappa B, was inactivated in animal tumors pretreated with thymoquinone followed by gemcitabine and/or oxatiplatin. These results provide strong in vivo molecular evidence in support of our hypothesis that thymoquinone could abrogate gemcitabine- or oxaliplatin-induced activation of NF-kappa B, resulting in the chemosensitization of pancreatic tumors to conventional therapeutics. [Cancer. Res 2009;69(13):5575-83]
C1 [Banerjee, Sanjeev; Wang, Zhiwei; Kong, Deujan; Padhye, Subhash; Sarkar, Fazlul H.] Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA.
   [Mohammad, Mussop; Mohammad, Ramzi M.] Wayne State Univ, Sch Med, Div Hematol & Oncol, Barbara Ann Karmanos Canc Inst, Detroit, MI USA.
   [Kaseb, Ahmed O.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.
RP Mohammad, RM (reprint author), Room 732,HWCRC Bldg,4100 John R St, Detroit, MI 48201 USA.
EM mohammar@karmanos.org
RI Wang, Zhiwei/A-6809-2011
CR Albazaz R, 2005, PANCREATOLOGY, V5, P361, DOI 10.1159/000086536
   Ali S, 2008, MOL CANCER THER, V7, P1708, DOI 10.1158/1535-7163.MCT-08-0354
   Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968
   Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390
   Bai JR, 2005, CANCER RES, V65, P2344, DOI 10.1158/0008-5472.CAN-04-3502
   Banerjee S, 2005, CANCER RES, V65, P9064, DOI 10.1158/0008-5472.CAN-05-1330
   Banerjee S, 2007, INT J CANCER, V120, P906, DOI 10.1002/ijc.22332
   Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949
   Chu JS, 2003, MOL CANCER THER, V2, P1
   Chuang SE, 2002, BIOCHEM PHARMACOL, V63, P1709, DOI 10.1016/S0006-2952(02)00931-0
   Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914
   Ducreux M, 2007, SEMIN ONCOL, V34, pS25, DOI 10.1053/j.seminoncol.2007.01.006
   El Mezayen R, 2006, IMMUNOL LETT, V106, P72, DOI 10.1016/j.imlet.2006.04.012
   El-Mahdy MA, 2005, INT J CANCER, V117, P409, DOI 10.1002/ijc.21205
   El-Rayes BF, 2003, CANCER INVEST, V21, P73, DOI 10.1081/CNV-120016406
   Ferrandina G, 2005, BRIT J CANCER, V92, P271, DOI 10.1038/sj.bjc.6602332
   Gali-Muhtasib H, 2008, CANCER RES, V68, P5609, DOI 10.1158/0008-5472.CAN-08-0884
   Kaseb AO, 2007, CANCER RES, V67, P7782, DOI 10.1158/0008-5472.CAN-07-1483
   Kato J, 2001, INT J CANCER, V95, P92
   Lage H, 2002, J CANCER RES CLIN, V128, P349, DOI 10.1007/s00432-002-0349-y
   Lee MA, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-127
   Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141
   Liu WS, 2009, DIGEST DIS SCI, V54, P89, DOI 10.1007/s10620-008-0329-4
   Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100
   Norwood AA, 2006, BIOMED SCI INSTRUM, V42, P350
   O'Reilly EM, 2007, SEMIN ONCOL, V34, P347, DOI 10.1053/j.seminoncol.2007.05.009
   Padhye Subhash, 2008, Cancer Ther, V6, P495
   Roepke M, 2007, CANCER BIOL THER, V6, P160, DOI 10.4161/cbt.6.2.3575
   Rooney S, 2005, ANTICANCER RES, V25, P2199
   Sarkar FH, 2008, INT REV IMMUNOL, V27, P293, DOI 10.1080/08830180802276179
   Sarkar FH, 2008, FRONT BIOSCI-LANDMRK, V13, P2950, DOI 10.2741/2900
   Sarkar FH, 2007, TOXICOL APPL PHARM, V224, P326, DOI 10.1016/j.taap.2006.11.007
   Sarkar FH, 2007, ACTA PHARMACOL SIN, V28, P1305, DOI 10.1111/j.1745-7254.2007.00689.x
   Sarkar FH, 2007, MINI-REV MED CHEM, V7, P599
   Sethi G, 2008, MOL CANCER RES, V6, P1059, DOI 10.1158/1541-7786.MCR-07-2088
   Shoieb AM, 2003, INT J ONCOL, V22, P107
   Tamm I, 2000, CLIN CANCER RES, V6, P1796
   Tanaka K, 2000, CLIN CANCER RES, V6, P127
   Wilson-Simpson F, 2007, BIOMED SCI INSTRUM, V43, P378
   Xiong HQ, 2006, DRUGS, V66, P1059, DOI 10.2165/00003495-200666080-00003
   Yi TF, 2008, MOL CANCER THER, V7, P1789, DOI 10.1158/1535-7163.MCT-08-0124
   Yip-Schneider MT, 2000, CARCINOGENESIS, V21, P139, DOI 10.1093/carcin/21.2.139
   Zalatnai A, 2007, IN VIVO, V21, P339
NR 43
TC 140
Z9 155
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 1
PY 2009
VL 69
IS 13
BP 5575
EP 5583
DI 10.1158/0008-5472.CAN-08-4235
PG 9
WC Oncology
SC Oncology
GA 466VP
UT WOS:000267691800040
PM 19549912
OA Bronze
DA 2018-12-27
ER

PT J
AU Banerjee, S
   Wang, ZW
   Kong, DJ
   Sarkar, FH
AF Banerjee, Sanjeev
   Wang, Zhiwei
   Kong, Dejuan
   Sarkar, Fazlul H.
TI RETRACTED: 3,3 '-Diindolylmethane Enhances Chemosensitivity of Multiple
   Chemotherapeutic Agents in Pancreatic Cancer (Retracted article. See
   vol. 78, pg. 5467, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; PROSTATE-CANCER; IN-VITRO; SURVIVIN EXPRESSION;
   CELL-PROLIFERATION; MOLECULAR EVIDENCE; ORTHOTOPIC MODEL;
   CARCINOMA-CELLS; BCL-X; APOPTOSIS
AB Clinical management of pancreatic cancer is a major problem, which is in part due to both de novo and acquired resistance to conventional therapeutics. Here, we present in vitro and in vivo preclinical evidence in support of chemosensitization of pancreatic cancer cells by 3,3-diindolylmethane (DIM), a natural compound that can be easily obtained by consuming cruciferous vegetables. DIM pretreatment of pancreatic cancer cells led to a significantly increased apoptosis (P < 0.01) with suboptimal concentrations of chemotherapeutic agents (cisplatin, gemcitabine, and oxaliplatin) compared with monotherapy. It is known that resistance to chemotherapy in pancreatic cancer is associated with constitutively activated nuclear factor-kappa B (NF-kappa B), which becomes further activated by chemotherapeutic drugs. Our data provide mechanistic evidence for the first time showing that DIM potentiates the killing of pancreatic cancer cells by down-regulation of constitutive as well as drug-induced activation of NF-kappa B and its downstream genes (Bcl-xL, XIAP, cIAP, and survivin). Most importantly, using an orthotopic animal model, we found reduction in tumor size (P < 0.001) when DIM was given in combination with oxaliplatin compared with monotherapy. This was accompanied by loss of phospho-p65 and down-regulation of NF-kappa B activity and its downstream genes (Bcl-xL, survivin, and XIAP), which correlated with reduced cell proliferation (as assessed by Ki-67 immunostaining of tumor specimens) and evidence of apoptosis [as assessed by poly(ADP-ribose) polymease cleavage and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining]. These results provide strong in vivo evidence in support of our hypothesis that DIM could abrogate chemotherapeutic drug (cisplatin, gemcitabine, and/or oxaliplatin)-induced activation of NF-kappa B, resulting in the chemosensitization of pancreatic tumors to conventional therapeutics. [Cancer Res 2009;69(13):5592-600]
C1 [Banerjee, Sanjeev; Wang, Zhiwei; Kong, Dejuan; Sarkar, Fazlul H.] Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA.
RP Sarkar, FH (reprint author), Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, 740 HWCRC,4100 John R St, Detroit, MI 48201 USA.
EM fsarkar@med.wayne.edu
RI Wang, Zhiwei/A-6809-2011
FU NIH [R01 CA101870]
FX NIH grant R01 CA101870 (F.H. Sarkar).
CR Abdelrahim M, 2006, CARCINOGENESIS, V27, P717, DOI 10.1093/carcin/bgi270
   Aggarwal BB, 2005, CELL CYCLE, V4, P1201, DOI 10.4161/cc.4.9.1993
   Ali S, 2008, MOL CANCER THER, V7, P1708, DOI 10.1158/1535-7163.MCT-08-0354
   Arlt A, 2002, INT J CLIN PHARM TH, V40, P336
   Azmi AS, 2008, PHARM RES-DORDR, V25, P2117, DOI 10.1007/s11095-008-9581-8
   Bai JR, 2005, CANCER RES, V65, P2344, DOI 10.1158/0008-5472.CAN-04-3502
   Banerjee S, 2005, CANCER RES, V65, P9064, DOI 10.1158/0008-5472.CAN-05-1330
   Banerjee S, 2007, INT J CANCER, V120, P906, DOI 10.1002/ijc.22332
   Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949
   Bhuiyan MMR, 2006, CANCER RES, V66, P10064, DOI 10.1158/0008-5472.CAN-06-2011
   Carter TH, 2002, J NUTR, V132, P3314
   Chang XF, 2006, CARCINOGENESIS, V27, P541, DOI 10.1093/carcin/bgi230
   Chinnakannu K, 2009, J CELL PHYSIOL, V219, P94, DOI 10.1002/jcp.21650
   Chuang SE, 2002, BIOCHEM PHARMACOL, V63, P1709, DOI 10.1016/S0006-2952(02)00931-0
   Crowell JA, 2006, TOXICOL APPL PHARM, V211, P115, DOI 10.1016/j.taap.2005.06.011
   Ducreux M, 2007, SEMIN ONCOL, V34, pS25, DOI 10.1053/j.seminoncol.2007.01.006
   Ferrandina G, 2005, BRIT J CANCER, V92, P271, DOI 10.1038/sj.bjc.6602332
   Fujioka S, 2003, ONCOGENE, V22, P1365, DOI 10.1038/sj.onc.1206323
   GROSE KR, 1992, CHEM RES TOXICOL, V5, P188, DOI 10.1021/tx00026a007
   Holcom B, 2008, PANCREAS, V36, P225, DOI 10.1097/MPA.0b013e31815b3207
   Hu X, 2008, CANCER LETT, V259, P127, DOI 10.1016/j.canlet.2007.11.007
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Keck Anna-Sigrid, 2004, Integr Cancer Ther, V3, P5, DOI 10.1177/1534735403261831
   Kong D, 2008, CANCER RES, V68, P1927, DOI 10.1158/0008-5472.CAN-07-3241
   Kong DJ, 2007, CANCER RES, V67, P3310, DOI 10.1158/0008-5472.CAN-06-4277
   Lage H, 2002, J CANCER RES CLIN, V128, P349, DOI 10.1007/s00432-002-0349-y
   Lee JU, 1999, EUR J CANCER, V35, P1374, DOI 10.1016/S0959-8049(99)00134-3
   Lee MA, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-127
   Li YW, 2007, J BIOL CHEM, V282, P21542, DOI 10.1074/jbc.M701978200
   Li YW, 2005, FRONT BIOSCI, V10, P236, DOI 10.2741/1523
   Liptay S, 2003, INT J CANCER, V105, P735, DOI 10.1002/ijc.11081
   Liu WS, 2009, DIGEST DIS SCI, V54, P89, DOI 10.1007/s10620-008-0329-4
   Martinez-Cardus A, 2009, MOL CANCER THER, V8, P194, DOI 10.1158/1535-7163.MCT-08-0659
   Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525
   Nachshon-Kedmi M, 2004, PROSTATE, V61, P153, DOI 10.1002/pros.20092
   O'Reilly EM, 2007, SEMIN ONCOL, V34, P347, DOI 10.1053/j.seminoncol.2007.05.009
   Pan X, 2008, CLIN CANCER RES, V14, P8143, DOI [10.1168/1078-0432.CCR-08-1539, 10.1158/1078-0432.CCR-08-1539]
   Rahman KMW, 2007, MOL CANCER THER, V6, P2757, DOI 10.1158/1535-7163.MCT-07-0336
   Rahman KMW, 2005, CANCER RES, V65, P364
   Reed GA, 2008, CANCER EPIDEM BIOMAR, V17, P2619, DOI 10.1158/1055-9965.EPI-08-0520
   Reed GA, 2006, CANCER EPIDEM BIOMAR, V15, P2477, DOI 10.1158/1055-9655.EPI-06-0396
   Saif MW, 2007, EXPERT OPIN PHARMACO, V8, P2719, DOI 10.1517/14656566.8.16.2719
   Sarkar FH, 2006, CANCER RES, V66, P3347, DOI 10.1158/0008-5472.CAN-05-4526
   Sharma J, 2005, PANCREAS, V30, P337, DOI 10.1097/01.mpa.0000160282.64451.f1
   Takai N, 2004, CURR CANCER DRUG TAR, V4, P511, DOI 10.2174/1568009043332871
   Tamm I, 2000, CLIN CANCER RES, V6, P1796
   Wheatley SP, 2005, INT REV CYTOL, V247, P35, DOI 10.1016/S0074-7696(05)47002-3
   Xiong HQ, 2006, DRUGS, V66, P1059, DOI 10.2165/00003495-200666080-00003
   Zhang YX, 2008, CANCER RES, V68, P9519, DOI 10.1158/0008-5472.CAN-08-1549
NR 49
TC 65
Z9 68
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 1
PY 2009
VL 69
IS 13
BP 5592
EP 5600
DI 10.1158/0008-5472.CAN-09-0838
PG 9
WC Oncology
SC Oncology
GA 466VP
UT WOS:000267691800042
PM 19531648
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Graham, AJ
   Potti, A
AF Graham, Aubrey Jolly
   Potti, Anil
TI RETRACTED: Translating Genomics Into Clinical Practice: Applications in
   Lung Cancer (Retracted Article. See vol 11, pg 413, 2009)
SO CURRENT ONCOLOGY REPORTS
LA English
DT Article; Retracted Publication
ID RETRACTED ARTICLE. SEE; GROWTH-FACTOR RECEPTOR; PHASE-III TRIAL;
   CHEMOTHERAPY; SIGNATURES; METASTASIS; EXPRESSION; MUTATIONS; ERLOTINIB;
   REPAIR
AB Non-small cell lung cancer (NSCLC) is the leading cause of death from cancer worldwide and has a poor overall survival across all stages of disease. The recent advancement of gene expression technology addresses the phenotypic complexity of many diseases, including NSCLC. These genomic approaches have shown great promise in NSCLC in helping to improve risk stratification, prognosis, and the clinician's ability to match the right therapy to an individual patient. Large prospective clinical trials are under way to evaluate the application and clinical impact of the use of genomics-based predictors of prognosis and therapy compared with current standard-of-care methods in patients with NSCLC. Several challenges of genomics-based therapy must be addressed before widespread application of these techniques becomes a reality. Genomic approaches in NSCLC have the potential to advance our understanding of underlying disease biology, to improve current prognostic and treatment paradigms, and to identify new targets for treatment, ultimately improving survival in patients with NSCLC and providing an opportunity for "personalized medicine."
C1 [Potti, Anil] Duke Univ, Dept Med, Med Ctr, Durham, NC 27708 USA.
RP Potti, A (reprint author), Duke Univ, Dept Med, Med Ctr, Box 3382,CIEMAS Bldg,101 Sci Dr, Durham, NC 27708 USA.
EM anil.potti@duke.edu
CR Balko JM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164/7/289
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Bild AH, 2006, NAT REV CANCER, V6, P735, DOI 10.1038/nrc1976
   Breathnach OS, 2001, J CLIN ONCOL, V19, P1734, DOI 10.1200/JCO.2001.19.6.1734
   Chen HY, 2007, NEW ENGL J MED, V356, P11, DOI 10.1056/NEJMoa060096
   Cobo M, 2007, J CLIN ONCOL, V25, P2747, DOI 10.1200/JCO.2006.09.7915
   Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857
   Ettinger DS, 2006, J NATL COMPR CANC NE, V4, P548
   Georgoulias V, 2001, LANCET, V357, P1478, DOI 10.1016/S0140-6736(00)04644-4
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760
   Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3
   Hsu DS, 2007, J CLIN ONCOL, V25, P4350, DOI 10.1200/JCO.2007.11.0593
   Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8
   Lu Y, 2006, PLOS MED, V3, P2229, DOI 10.1371/journal.pmed.0030467
   Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104
   MOUNTAIN CF, 1993, CLIN CHEST MED, V14, P43
   Nevins JR, 2007, NAT REV GENET, V8, P601, DOI 10.1038/nrg2137
   Noble J, 2006, J THORAC ONCOL, V1, P1042, DOI 10.1097/01243894-200611000-00021
   Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570
   Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Potti A, 2008, CURR OPIN GENET DEV, V18, P62, DOI 10.1016/i.gde.2008.01.018
   Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491
   Potti A, 2006, NEW ENGL J MED, V355, P570, DOI 10.1056/NEJMoa060467
   Pusztai L, 2006, CLIN CANCER RES, V12, P7209, DOI 10.1158/1078-0432.CCR-06-2649
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Riedel RF, 2008, MOL CANCER THER, V7, P3141, DOI 10.1158/1535-7163.MCT-08-0642
   Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954
   Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753
   Simon G, 2007, J CLIN ONCOL, V25, P2741, DOI 10.1200/JCO.2006.08.2099
   Smit EF, 2003, J CLIN ONCOL, V21, P3909, DOI 10.1200/JCO.2003.03.195
   Taron M, 2005, CLIN CANCER RES, V11, P5878, DOI 10.1158/1078-0432.CCR-04-2618
   Tokumo M, 2005, CLIN CANCER RES, V11, P1167
   Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736
   Zheng Z, 2007, NEW ENGL J MED, V356, P800, DOI 10.1056/NEJMoa065411
   Zinner RG, 2005, CANCER, V104, P2449, DOI 10.1002/cncr.21480
NR 38
TC 6
Z9 6
U1 2
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3790
EI 1534-6269
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD JUL
PY 2009
VL 11
IS 4
BP 263
EP 268
DI 10.1007/s11912-009-0037-z
PG 6
WC Oncology
SC Oncology
GA V16BH
UT WOS:000207844600003
DA 2018-12-27
ER

PT J
AU Tahara, T
   Shibata, T
   Hirata, I
   Nakano, H
   Arisawa, T
AF Tahara, Tomomitsu
   Shibata, Tomoyuki
   Hirata, Ichiro
   Nakano, Hiroshi
   Arisawa, Tomiyasu
TI RETRACTED: CD14 Promoter-159 Polymorphism Is Associated with Reduced
   Risk of Intestinal-Type Gastric Cancer in a Japanese Population
   (Retracted article. See vol. 57, pg. 2720, 2012)
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article; Retracted Publication
DE Gastric cancer; H. pylori; TLR4; CD14; Polymorphism
ID HELICOBACTER-PYLORI INFECTION; MONOCYTE RECEPTOR; CHINESE PATIENTS;
   ENDOTOXIN; TLR4; GENE; CLASSIFICATION; BACTERIAL; BINDING; PROTEIN
AB Host genetic factors may play a key role in determining the long-term outcome of the Helicobacter pylori infection. Toll-like receptor 4 (TLR4) and CD14-mediated recognition of lipo-polysaccharide (LPS) is required for efficient recognition of Gram-negative bacterial infections. We investigated the effects of common polymorphisms of TLR4 Asp299Gly, Thr399Ile, and CD14 promoter-C159T on the risk of gastric cancer including its subtypes and clinicopathologic features. We also investigated the effects of these polymorphisms on histologic degree of H. pylori-induced gastritis. The study was performed in 149 gastric cancer (GC) cases [mean age 64.0 +/- A 12.4, M:F = 109:40] and 94 patients without evidence of GC (mean age 64.1 +/- A 12.3, M:F = 65:25, Peptic ulcer diseases = 43.6%, gastritis = 56.4%) as the control group. TLR4 Asp299Gly, Thr399Ile, and CD14 promoter-C159T were determined by PCR-RFLP in all the patients. Gastritis scores of non-cancerous gastric mucosa were assessed according to the updated Sydney system in H. pylori-positive subjects (n = 179). The frequencies of CD14-260 TT and T carrier were significantly lower in patents with intestinal-type gastric cancer than in controls (OR = 0.31; 95%CI = 0.12-0.78, OR = 0.38; 95%CI = 0.18-0.81, respectively). Compared to patients older than 61 years, the atrophy score in antrum was significantly lower in TT and CT patients. TLR4 Asp299Gly and Thr399Ile were not detected in all the patients. Our data suggests that CD14 promoter-159TT and T carrier were associated with a lower risk of developing gastric mucosal atrophy in H. pylori-infected patients of more than 61 years of age, and these genotypes may reduce the risk of intestinal-type gastric cancer.
C1 [Tahara, Tomomitsu; Shibata, Tomoyuki; Hirata, Ichiro; Nakano, Hiroshi] Fujita Hlth Univ, Sch Med, Dept Gastroenterol, Aichi 4701192, Japan.
   [Arisawa, Tomiyasu] Kanazawa Med Univ, Dept Gastroenterol, Uchinada, Ishikawa 9200293, Japan.
RP Tahara, T (reprint author), Fujita Hlth Univ, Sch Med, Dept Gastroenterol, 1-98 Dengakugakubo,Kutsukake Cho, Aichi 4701192, Japan.
EM tomomiccyu@yahoo.co.jp
CR Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048
   Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494
   Bamford KB, 1998, GASTROENTEROLOGY, V114, P482, DOI 10.1016/S0016-5085(98)70531-1
   Bliss CM, 1998, INFECT IMMUN, V66, P5357
   Chao YC, 1997, HEPATOLOGY, V25, P112
   CORREA P, 1975, LANCET, V2, P58
   CORREA P, 1995, AM J SURG PATHOL, V19, pS37
   Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001
   Fernandez-Real JM, 2003, J CLIN ENDOCR METAB, V88, P1780, DOI 10.1210/jc.2002-020173
   Guo QS, 2006, J GASTROEN HEPATOL, V21, P92, DOI 10.1111/j.1440-1746.2005.04156.x
   Hubacek JA, 1999, CIRCULATION, V99, P3218, DOI 10.1161/01.CIR.99.25.3218
   *IARC WORK GROUP E, 1994, IARC MONOGR EVAL CAR, V61, P1
   Ito D, 2000, STROKE, V31, P2661, DOI 10.1161/01.STR.31.11.2661
   Janeway CA, 1998, SEMIN IMMUNOL, V10, P349, DOI 10.1006/smim.1998.0142
   Karhukorpi J, 2002, CLIN EXP IMMUNOL, V128, P326, DOI 10.1046/j.1365-2249.2002.01837.x
   LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31
   LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838
   Lorenz E, 2001, BIOTECHNIQUES, V31, P22, DOI 10.2144/01311bm01
   RIETSCHEL ET, 1994, FASEB J, V8, P217
   Risley P, 2003, STROKE, V34, P600, DOI 10.1161/01.STR.0000055941.61801.5A
   Schmausser B, 2004, CLIN EXP IMMUNOL, V136, P521, DOI 10.1111/j.1365-2249.2004.02464.x
   Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8
   Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999
   ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253
   WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311
NR 25
TC 10
Z9 14
U1 4
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD JUL
PY 2009
VL 54
IS 7
BP 1508
EP 1512
DI 10.1007/s10620-009-0793-5
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 454AV
UT WOS:000266654900018
PM 19326213
DA 2018-12-27
ER

PT J
AU Horner, O
   Oddou, JL
   Jeandey, C
   Michaud-Soret, I
   Mouesca, JM
AF Horner, Olivier
   Oddou, Jean-Louis
   Jeandey, Claudine
   Michaud-Soret, Isabelle
   Mouesca, Jean-Marie
TI RETRACTED: Detailed Mossbauer Characterization of Fe(2+)Fur, the Active
   Form of the Ferric Uptake Regulation Protein from E-coli and Density
   Functional Calculations on Some Related Models (Retracted article. See
   pg. 5449, 2009)
SO EUROPEAN JOURNAL OF INORGANIC CHEMISTRY
LA English
DT Article; Retracted Publication
DE Moessbauer spectroscopy; Density functional calculations; Iron;
   Bioinorganic chemistry; Protein models
ID CRYSTAL-STRUCTURE; IRON ENVIRONMENT; FUR PROTEIN; APPROXIMATION;
   COORDINATION; LIPOXYGENASE; SPECTROSCOPY; NITROGENASE; COFACTOR;
   SYMMETRY
AB The Fe2+ center of iron-substituted ferric uptake regulation protein (Fur) has been fully characterized by applied-field Mossbauer spectroscopy, and two structural models for this center in Fur from E. coli (EC-Fe(2+)Fur) have been developed by combining the crystallographic data available for Fur from Pseudomonas aeruginosa (PA-Fur) in complex with Zn2+ and the EXAFS data for a PA-Fur sample dialyzed against a Fe2+ solution or EC-Fur in complex with Fe2+. The Mossbauer (isomer shift excluded) and spin-Hamiltonian parameters have been estimated by density functional calculations for these models and compared to the experimental data. The geometry and the environment of the iron-binding center in EC-Fur and PA-Fur are found to be similar, and the comparison of the observed and calculated quadrupole splitting values indicates that the model with a (3O,2N,1O) coordination (Delta E-Q>0) is a better representation of the environment around the iron center in EC-Fe(2+)Fur. ((C) Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)
C1 [Horner, Olivier; Oddou, Jean-Louis; Jeandey, Claudine; Michaud-Soret, Isabelle] Univ Grenoble 1, CNRS, CEA,Dept Reponse & Dynam Cellulaires, Lab Physicochim Met Biol,CEA Grenoble,UMR 5155, F-38054 Grenoble 9, France.
   [Mouesca, Jean-Marie] Univ Grenoble 1, CEA Grenoble, CEA,Dept Rech Fondamentale Mat Condensee,UMR E3, Lab Resonances Magnet,Serv Chim Inorgan & Biol, F-38054 Grenoble 9, France.
RP Horner, O (reprint author), Univ Grenoble 1, CNRS, CEA,Dept Reponse & Dynam Cellulaires, Lab Physicochim Met Biol,CEA Grenoble,UMR 5155, F-38054 Grenoble 9, France.
EM olhorner@free.fr
OI Michaud-Soret, Isabelle/0000-0002-8936-4964
CR Adrait A, 1999, BIOCHEMISTRY-US, V38, P6248, DOI 10.1021/bi9823232
   Althaus EW, 1999, BIOCHEMISTRY-US, V38, P6559, DOI 10.1021/bi982788s
   Baerends EJ, 1973, CHEM PHYS, V2, P52, DOI 10.1016/0301-0104(73)80060-6
   BAERENDS EJ, 1978, INT J QUANTUM CHEM, V12, P169
   BAERENDS EJ, 1973, CHEM PHYS, V2, P51
   BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098
   BICKELHAUPT FM, 1990, INORG CHEM, V29, P350, DOI 10.1021/ic00327a039
   D'Autreaux B, 2002, P NATL ACAD SCI USA, V99, P16619, DOI 10.1073/pnas.252591299
   de Peredo AG, 1999, BIOCHEMISTRY-US, V38, P8582, DOI 10.1021/bi9902283
   DUNHAM WR, 1990, EUR J BIOCHEM, V190, P611, DOI 10.1111/j.1432-1033.1990.tb15616.x
   GUTLICH P, 1979, MOSSBAUER SPECTROSCO
   HAMALAINEN R, 1989, ACTA CHEM SCAND, V43, P15, DOI 10.3891/acta.chem.scand.43-0015
   Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x
   Horner O, 2004, BIOCHEMISTRY-US, V43, P8815, DOI 10.1021/bi0498151
   Jacquamet L, 1998, BIOCHEMISTRY-US, V37, P2564, DOI 10.1021/bi9721344
   Jacquamet L, 2000, J AM CHEM SOC, V122, P394, DOI 10.1021/ja991932+
   JACQUAMET L, 1999, THESIS U J FOURIER
   Lovell T, 2002, J AM CHEM SOC, V124, P5890, DOI 10.1021/ja0121282
   Lovell T, 2001, J AM CHEM SOC, V123, P12392, DOI 10.1021/ja011860y
   Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u
   MUNCK E, 2000, PHYS METHODS BIOINOR, pCH6
   Neese F, 2002, INORG CHIM ACTA, V337, P181, DOI 10.1016/S0020-1693(02)01031-9
   NOODLEMAN L, 1985, J AM CHEM SOC, V107, P3418, DOI 10.1021/ja00298a004
   PAINTER GS, 1981, PHYS REV B, V24, P4264, DOI 10.1103/PhysRevB.24.4264
   PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PhysRevB.33.8822
   PETERSSON L, 1985, BIOCHIM BIOPHYS ACTA, V828, P81, DOI 10.1016/0167-4838(85)90012-3
   Pohl E, 2003, MOL MICROBIOL, V47, P903, DOI 10.1046/j.1365-2958.2003.03337.x
   TEVELDE G, 1992, J COMPUT PHYS, V99, P84, DOI DOI 10.1016/0021-9991(92)90277-6
   VARRET F, 1976, J PHYS CHEM SOLIDS, V37, P265, DOI 10.1016/0022-3697(76)90086-X
   VOSKO SH, 1980, CAN J PHYS, V58, P1200, DOI 10.1139/p80-159
   Vrajmasu V, 2003, INORG CHEM, V42, P5974, DOI 10.1021/ic0301371
   ZIMMERMANN R, 1974, J PHYS, P439
NR 32
TC 1
Z9 1
U1 4
U2 18
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1434-1948
J9 EUR J INORG CHEM
JI Eur. J. Inorg. Chem.
PD JUL
PY 2009
IS 20
BP 2959
EP 2966
DI 10.1002/ejic.200900091
PG 8
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA 474NE
UT WOS:000268290000009
DA 2018-12-27
ER

PT J
AU Kaya, I
AF Kaya, Ihsan
TI RETRACTED: A genetic algorithm approach to determine the sample size for
   control charts with variables and attributes (Retracted article. See
   vol. 39, pg. 4633, 2012)
SO EXPERT SYSTEMS WITH APPLICATIONS
LA English
DT Article; Retracted Publication
DE Process control; Genetic algorithms; u-Control chart; x - R control
   charts; Process capability
ID (X)OVER-BAR CONTROL CHARTS; T-2 CONTROL CHARTS; ECONOMIC DESIGN;
   MANUFACTURING PROCESS; MULTISTAGE PROCESSES; STATISTICAL DESIGN;
   OPTIMIZATION; QUALITY
AB Generally today's production systems consist of multistage processes. Control of these processes is a very important to meet customer's and engineering's specifications. Generally control charts which are used to monitor the process and process capability analysis (PCA) which is a summary statistic to show the process performance are used to determine whether or not the process is in statistical control and meet specifications. Although control charts have been applied in very large area of process control, determining the sample size for control charts is generally a problem. In the literature many techniques to solve this problem have been executed. Kaya and Engin [Kaya, i. & Engin, O. 2007. A new approach to define sample size at attributes control chart in multistage processes: An application in engine piston manufacturing process. Journal of Materials Processing Technology, 183,38-48] also proposed a model based on minimum cost and maximum acceptance probability to determine the sample size in Attribute Control Charts (ACCs). In this paper, this model is solved by Genetic Algorithms (GAs) with linear real-valued representation and a new chromosome structure is suggested to increase the efficiency of GAs. The performance of GAs is affected by mutation and crossover operators and their ratios. To determine the most appropriate operators, five different mutation and crossover operators are used and they are compared with each other, For this purpose a computer program is coded by MS Visual Basic and it has been run to determine the suitable operators and ratios, respectively. One of the results of the model is sample size, n, and it is suggested to set up ACCs and Variable Control Charts (VCCs). Also the sample size, n, is used to PCA. To show the usage of the proposed model an application from a motor engine factory is illustrated. For quality characteristics cannot be easily represented in numerical form, "u-control charts" and for characteristics measurable on numerical scales, "(x) over bar - R control charts" are constructed for every stage by taking into account the sample size, n, determined by GAs from the proposed model. These control charts are used to determine whether or not the every stage is in statistical control. Then PCA has been executed for every stage and capability ratios are determined. (c) 2008 Elsevier Ltd. All rights reserved.
C1 Istanbul Tech Univ, Dept Ind Engn, TR-34367 Istanbul, Turkey.
RP Kaya, I (reprint author), Istanbul Tech Univ, Dept Ind Engn, TR-34367 Istanbul, Turkey.
EM kayai@itu.edu.tr
CR Aparisi F, 2004, COMPUT OPER RES, V31, P1437, DOI 10.1016/S0305-0548(03)00099-6
   Aparisi F, 2007, COMPUT OPER RES, V34, P2096, DOI 10.1016/j.cor.2005.08.003
   Bakir MA, 2004, J APPL STAT, V31, P753, DOI 10.1080/0266476042000214484
   Celano G, 1999, COMPUT IND ENG, V37, P129, DOI 10.1016/S0360-8352(99)00038-8
   Chen YK, 2007, EXPERT SYST APPL, V33, P683, DOI 10.1016/j.eswa.2006.06.007
   Chen YK, 2004, INT J ADV MANUF TECH, V24, P32, DOI 10.1007/s00170-003-1706-y
   Chen YK, 2003, INT J ADV MANUF TECH, V22, P602, DOI 10.1007/s00170-003-1612-3
   Chen YK, 2004, INT J PROD ECON, V92, P61, DOI 10.1016/j.ijpe.2003.09.011
   Cheng TM, 2007, AUTOMAT CONSTR, V16, P345, DOI 10.1016/j.autcon.2006.07.003
   Chou CY, 2008, EXPERT SYST APPL, V34, P419, DOI 10.1016/j.eswa.2006.09.009
   Chou CY, 2006, COMMUN STAT-SIMUL C, V35, P1027, DOI 10.1080/03610910600880575
   Chou CY, 2006, EXPERT SYST APPL, V30, P233, DOI 10.1016/j.eswa.2005.07.010
   Engin O, 2008, APPL SOFT COMPUT, V8, P1654, DOI 10.1016/j.asoc.2008.01.005
   Gen M, 2000, GENETIC ALGORITHMS E
   Goldberg D. E., 1989, GENETIC ALGORITHMS S
   Gulbay M, 2006, COMPUT STAT DATA AN, V51, P434, DOI 10.1016/j.csda.2006.04.031
   Guh RS, 2004, INT J PATTERN RECOGN, V18, P75, DOI 10.1142/S0218001404003095
   He D, 2006, EUR J OPER RES, V168, P122, DOI 10.1016/j.ejor.2004.04.033
   He D, 2002, INT J PROD RES, V40, P1387, DOI 10.1080/00207540110118415
   Holland J. H., 1975, ADAPTATION NATURAL A
   Hsu LF, 2004, INT J PROD RES, V42, P1043, DOI 10.1080/00207540310001632439
   Kahraman C, 2009, STOCH ENV RES RISK A, V23, P451, DOI 10.1007/s00477-008-0232-8
   Kaya I, 2008, J INTELL FUZZY SYST, V19, P259
   Kaya I, 2007, J MATER PROCESS TECH, V183, P38, DOI 10.1016/j.jmatprotec.2006.09.022
   Kaya I, 2009, INFORM SCIENCES, V179, P1552, DOI 10.1016/j.ins.2008.09.024
   Kaya I, 2009, STOCH ENV RES RISK A, V23, P529, DOI 10.1007/s00477-008-0238-2
   LANGNER HA, 2002, INT J PROD RES, V40, P1923
   Lin HH, 2009, EXPERT SYST APPL, V36, P3048, DOI 10.1016/j.eswa.2008.01.016
   Mitchell M., 1996, INTRO GENETIC ALGORI
   Mitra A., 1998, FUNDAMENTALS QUALITY
   Montgomery D. C., 2005, INTRO STAT QUALITY C
   Sanchez MS, 2000, CHEMOMETR INTELL LAB, V53, P69, DOI 10.1016/S0169-7439(00)00094-0
   Tsai CC, 2006, INT J ADV MANUF TECH, V30, P334, DOI 10.1007/s00170-005-0052-7
   Viharos J. Z., 1997, 8 DAAAM INT S U ZAGR
   Wehrens R, 1999, ANAL CHIM ACTA, V388, P265, DOI 10.1016/S0003-2670(99)00081-1
   Zarandi MHF, 2008, INFORM SCIENCES, V178, P1152, DOI 10.1016/j.ins.2007.09.028
NR 36
TC 21
Z9 21
U1 4
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0957-4174
EI 1873-6793
J9 EXPERT SYST APPL
JI Expert Syst. Appl.
PD JUL
PY 2009
VL 36
IS 5
BP 8719
EP 8734
DI 10.1016/j.eswa.2008.12.011
PG 16
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic; Operations Research & Management Science
SC Computer Science; Engineering; Operations Research & Management Science
GA 427MG
UT WOS:000264782800002
DA 2018-12-27
ER

PT J
AU Li, ZY
   Fallon, J
   Mandeli, J
   Wetmur, J
   Woo, SLC
AF Li, Zhiyu
   Fallon, John
   Mandeli, John
   Wetmur, James
   Woo, Savio L. C.
TI RETRACTED: The Oncopathic Potency of Clostridium perfringens Is
   Independent of Its alpha-Toxin Gene (Retracted Article. See vol 21, pg
   363, 2010)
SO HUMAN GENE THERAPY
LA English
DT Article; Retracted Publication
ID EXPERIMENTAL GAS-GANGRENE; PANCREATIC-CANCER; LISTERIA-MONOCYTOGENES;
   DELIVERY SYSTEM; THETA-TOXIN; TUMORS; THERAPY; INFECTION; BACTERIA;
   PURIFICATION
AB Hypoxia in solid tumors is a major obstacle in conventional treatment because of inefficient delivery of therapeutic agents to the lesions, but offers the potential for anaerobic bacterial colonization that can lead to tumor destruction. We have previously reported a recombinant Clostridium perfringens (Cp) strain constructed by deletion of the superoxide dismutase (sod) gene and insertion of the Panton-Valentine leukocidin (PVL) gene, Cp/sod(-)/PVL, which showed elevated oxygen sensitivity, tumor selectivity, and oncopathic potency in an orthotopic model of pancreatic cancer in immune-competent and syngeneic mice, and that led to substantial prolongation of animal survival. A major limitation to Cp/sod(-)/PVL in clinical applications is that it expresses phospholipase C (plc), the alpha-toxin and the major virulence determinant in Cp that is causative in the development of gas gangrene. In this study, the plc gene in Cp/sod(-)/PVL was knocked out to create Cp/plc(-)/sod(-)/PVL, which was shown to be incapable of inducing gas gangrene in mice. Intravenous injection of Cp/plc(-)/sod(-)/PVL spores led to a significant survival advantage in tumor-bearing mice with the same efficacy as Cp/sod(-)/PVL, indicating that the oncopathic potency of Cp is independent of a functional plc gene. The treatment also did not lead to an attenuated immune response to a subsequent pathogen challenge, indicating that a systemic immune-suppressive effect in the host is absent. Consequently, Cp/plc(-)/sod(-)/PVL is a novel oncopathic bacterial agent for the effective treatment of pancreatic cancer and other poorly vascularized tumors, with a substantially enhanced safety profile, which is essential for the development of translational studies in the future.
C1 [Li, Zhiyu; Woo, Savio L. C.] Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA.
   [Fallon, John] Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA.
   [Mandeli, John] Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA.
   [Wetmur, James] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.
RP Woo, SLC (reprint author), Mt Sinai Sch Med, Dept Gene & Cell Med, 1 Gustave L Levy Pl,Box 1496, New York, NY 10029 USA.
EM savio.woo@mssm.edu
OI Fallon, John/0000-0002-7677-4868
FU NIH [CA-120017]
FX The authors thank Drs. Tian-gui Huang, Lan Wu, and Marcia Meseck for
   helpful discussions, and Ms. Yafang Wang and Mr. Boxun Xie for technical
   assistance. This research was supported by NIH grant CA-120017.
CR AWAD MM, 1995, MOL MICROBIOL, V15, P191, DOI 10.1111/j.1365-2958.1995.tb02234.x
   Block A, 1997, PANCREAS, V15, P25, DOI 10.1097/00006676-199707000-00004
   Briolat V, 2002, J BACTERIOL, V184, P2333, DOI 10.1128/JB.184.9.2333-2343.2002
   BROWN EJ, 1981, J CLIN INVEST, V67, P975, DOI 10.1172/JCI110148
   CASPER ES, 1993, EUR J CANCER, V29A, P171, DOI 10.1016/0959-8049(93)90167-E
   Cheong I, 2006, SCIENCE, V314, P1308, DOI 10.1126/science.1130651
   Cote CK, 2004, MICROB PATHOGENESIS, V37, P169, DOI 10.1016/j.micpath.2004.06.013
   Critchley R, 2004, GENE THER, V11, P1224, DOI 10.1038/sj.gt.3302281
   Dang LH, 2001, P NATL ACAD SCI USA, V98, P15155, DOI 10.1073/pnas.251543698
   DARKE SG, 1977, BRIT J SURG, V64, P104, DOI 10.1002/bjs.1800640207
   Ellemor DM, 1999, INFECT IMMUN, V67, P4902
   ENGELBART K, 1964, CANCER RES, V24, P239
   Evans Douglas B., 1997, P1054
   EZAKI T, 2000, MOL ECOLOGICAL DETEC, P214
   Geissmann TA, 1999, J BACTERIOL, V181, P7136
   Genestier AL, 2005, J CLIN INVEST, V115, P3117, DOI 10.1172/JCI22684
   Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15
   Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8
   Kato I, 1981, Nihon Saikingaku Zasshi, V36, P445
   Kondoh S. K., 2003, CANCER SCI, V94, P1021
   Lebedeva IV, 2006, CANCER RES, V66, P2403, DOI 10.1158/0008-5472.CAN-05-3510
   Lehmann Y, 1996, J BACTERIOL, V178, P7152, DOI 10.1128/jb.178.24.7152-7158.1996
   Lemmon MJ, 1997, GENE THER, V4, P791, DOI 10.1038/sj.gt.3300468
   Li ZY, 2008, JNCI-J NATL CANCER I, V100, P1389, DOI 10.1093/jnci/djn308
   MACLENNAN JD, 1962, BACTERIOL REV, V26, P177
   MCNEE JW, 1917, BRIT MED J, V1, P727
   MOLLBY R, 1973, BIOCHIM BIOPHYS ACTA, V321, P569, DOI 10.1016/0005-2744(73)90200-3
   OKUMOTO M, 1985, INT OPHTHALMOL CLIN, V25, P133, DOI 10.1097/00004397-198502520-00015
   Pawelek JM, 2003, LANCET ONCOL, V4, P548, DOI 10.1016/S1470-2045(03)01194-X
   ROGERS DE, 1960, BACTERIOL REV, V24, P50
   Rood JI, 1998, ANNU REV MICROBIOL, V52, P333, DOI 10.1146/annurev.micro.52.1.333
   Seki E, 2002, J IMMUNOL, V169, P3863, DOI 10.4049/jimmunol.169.7.3863
   Sener SF, 1999, J AM COLL SURGEONS, V189, P1, DOI 10.1016/S1072-7515(99)00075-7
   SMITH LDS, 1975, PATHOGENIC ANAEROBIC, P115
   Stephens C D, 1998, Oncol Nurs Forum, V25, P87
   Stevens D. L., 1997, CLOSTRIDIA MOL BIOL, P141
   STEVENS DL, 1987, J INFECT DIS, V155, P220, DOI 10.1093/infdis/155.2.220
   Storniolo AM, 1999, CANCER, V85, P1261, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.3.CO;2-K
   Theys J, 2001, CANCER GENE THER, V8, P294, DOI 10.1038/sj.cgt.7700303
   Theys J., 2003, Current Gene Therapy, V3, P207, DOI 10.2174/1566523034578357
   TITBALL R, 2000, BACTERIAL PROTEIN TO, P529
   WAGNER RD, 1994, INFECT IMMUN, V62, P2345
   Yazawa K, 2001, BREAST CANCER RES TR, V66, P165, DOI 10.1023/A:1010644217648
NR 43
TC 3
Z9 3
U1 3
U2 11
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
J9 HUM GENE THER
JI Hum. Gene Ther.
PD JUL
PY 2009
VL 20
IS 7
BP 751
EP 758
DI 10.1089/hum.2008.145
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 476FO
UT WOS:000268424300009
PM 19298132
OA Green Published
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Itakura, M
AF Fujii, Yoshitaka
   Itakura, Michiyo
TI RETRACTED: Low-dose propofol to prevent nausea and vomiting after
   laparoscopic surgery (Retracted article. See vol. 120, pg. 108, 2013)
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article; Retracted Publication
DE Antiemetics; Complications; Gynecologic laparoscopic surgery; Propofol;
   Vomiting
ID POSTOPERATIVE NAUSEA; ANTIEMETIC EFFICACY; DOUBLE-BLIND; ONDANSETRON;
   TRIAL
AB Objective: To evaluate the efficacy of administering a low dose of propofol at the end of surgery in preventing postoperative nausea/vomiting in women undergoing gynecologic laparoscopic surgery. Method: In a randomized, double-blind, placebo-controlled study, 90 patients received intravenous injections of a placebo or propofol at 2 different low doses, 0.25 mg/kg or 0.5 mg/kg. All episodes of nausea, retching, or vomiting were then recorded for 24 hours. Results: The percentages of patients experiencing nausea, retching, or vomiting were 67% in the placebo group, 60% in the propofol 0.25 mg/kg group (P=0.39), and 33% in the propofol 0.5 mg/kg group (P = 0.009). A significant difference in the rates of nausea/vomiting was found between the 2 propofol groups (P = 0.03). No adverse events attributed to the study drug were observed. Conclusion: Prophylactic therapy with 0.5 mg/kg of propofol was found to be effective in preventing nausea/vomiting in patients undergoing gynecologic laparoscopic surgery. (C) 2009 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Fujii, Yoshitaka; Itakura, Michiyo] Ushiku Aiwa Gen Hosp, Dept Anesthesiol, Ibaraki, Japan.
RP Fujii, Y (reprint author), Toho Univ, Sch Med, Dept Anesthesiol 1, Ohta Ku, 6-11-1 Ohmori Nishi, Tokyo 1438541, Japan.
EM yfujii@med.toho-u.ac.jp
CR Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196
   BODNER M, 1991, ANESTH ANALG, V73, P250
   BORGEAT A, 1992, ANESTH ANALG, V74, P539
   BORGEAT A, 1993, ONCOLOGY, V50, P456
   Cechetto DF, 2001, ANESTH ANALG, V92, P934
   Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95
   Hammas B, 1998, ACTA ANAESTH SCAND, V42, P447, DOI 10.1111/j.1399-6576.1998.tb05140.x
   *JIHO INC, 2008, DRUGS JAP ETH DRUGS
   Koivuranta M, 1997, ACTA ANAESTH SCAND, V41, P1273, DOI 10.1111/j.1399-6576.1997.tb04644.x
   Kovac AL, 2000, DRUGS, V59, P213, DOI 10.2165/00003495-200059020-00005
   OSTMAN PL, 1990, ANESTH ANALG, V71, P536
   RAMSAY TM, 1994, CAN J ANAESTH, V41, P798, DOI 10.1007/BF03011586
   RAPHAEL JH, 1993, BRIT J ANAESTH, V71, P845, DOI 10.1093/bja/71.6.845
   SANCHEZ LA, 1995, J RES PHARM EC, V6, P35
   SMITH I, 1994, ANESTHESIOLOGY, V81, P1005
   Song DJ, 1998, ANESTHESIOLOGY, V89, P838, DOI 10.1097/00000542-199810000-00007
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
NR 17
TC 8
Z9 10
U1 2
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD JUL
PY 2009
VL 106
IS 1
BP 50
EP 52
DI 10.1016/j.ijgo.2009.03.008
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 465FQ
UT WOS:000267568200013
PM 19358990
DA 2018-12-27
ER

PT J
AU Ueda, T
   Hasezaki, K
AF Ueda, Takashi
   Hasezaki, Kazuhiro
TI RETRACTED: Preliminary Study of Single Phase Preparation and Doping
   Effect of beta-Zn4Sb3 (Retracted article. See vol. 53, pg. 457, 2012)
SO JOURNAL OF ELECTRONIC MATERIALS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 27th International Conference on Thermoelectrics
CY AUG 03-07, 2008
CL Univ Oregon, Corvallis, OR
SP Int Thermoelect Soc
HO Univ Oregon
DE beta-Zn4Sb3; two-stage heat treatment; thermoelectric material
ID THERMOELECTRIC PROPERTIES; ZN4SB3
AB Single phase beta-Zn4Sb3 was prepared by the application of a two-stage heat treatment, and impurity elements were doped. The undoped and doped samples were prepared by direct melting followed by two-stage heat treatment at 450A degrees C and 400A degrees C after solidification of the samples in sealed quartz ampoules. Impurity doping of the samples was performed by the addition of 1 at.% of Se, In, Pb, Te, or Bi. The resulting samples were characterized by x-ray diffraction (XRD), differential thermal analysis (DTA), optical microscopy, and electron probe microanalysis, and their Seebeck coefficients were determined at room temperature. The undoped samples were determined by XRD and DTA to comprise single phase beta-Zn4Sb3, while the doped samples were composed of multiple phases. From the measurements of the Seebeck coefficient, all samples were found to be p-type and all were found to have almost the same values. These results indicate that beta-Zn4Sb3 has limited solubility for these impurity elements.
C1 [Ueda, Takashi; Hasezaki, Kazuhiro] Shimane Univ, Dept Mat Sci, Matsue, Shimane 6908504, Japan.
RP Ueda, T (reprint author), Shimane Univ, Dept Mat Sci, Nishikawatsu Cho 1060, Matsue, Shimane 6908504, Japan.
EM s089107@matsu.shimane-u.ac.jp
CR Caillat T, 1997, J PHYS CHEM SOLIDS, V58, P1119, DOI 10.1016/S0022-3697(96)00228-4
   Ioffe A.F., 1957, SEMICONDUCTOR THERMO
   Pedersen BL, 2007, CHEM MATER, V19, P6304, DOI 10.1021/cm702247b
   Pedersen BL, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2404612
   Pedersen BL, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2916705
   TAPIERO M, 1985, SOL ENERG MATER, V12, P257, DOI 10.1016/0165-1633(85)90051-6
   Tsutsui M, 2004, INTERMETALLICS, V12, P809, DOI 10.1016/j.intermet.2004.04.030
   UGAI YA, 1969, INORG MATER, V5, P1180
   ZABDYR LA, 1993, CALPHAD, V17, P269, DOI 10.1016/0364-5916(93)90005-V
   Zhu TJ, 2000, MATER LETT, V46, P44, DOI 10.1016/S0167-577X(00)00140-3
NR 10
TC 3
Z9 3
U1 3
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0361-5235
EI 1543-186X
J9 J ELECTRON MATER
JI J. Electron. Mater.
PD JUL
PY 2009
VL 38
IS 7
BP 1025
EP 1029
DI 10.1007/s11664-009-0699-1
PG 5
WC Engineering, Electrical & Electronic; Materials Science,
   Multidisciplinary; Physics, Applied
SC Engineering; Materials Science; Physics
GA 466LA
UT WOS:000267662500023
DA 2018-12-27
ER

PT J
AU Hamachiyo, T
   Ashida, M
   Hasezaki, K
AF Hamachiyo, Takashi
   Ashida, Maki
   Hasezaki, Kazuhiro
TI RETRACTED: Thermal Conductivity of Bi0.5Sb1.5Te3 Affected by Grain Size
   and Pores (Retracted article. See vol. 53, pg. 457, 2012)
SO JOURNAL OF ELECTRONIC MATERIALS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 27th International Conference on Thermoelectrics
CY AUG 03-07, 2008
CL Univ Oregon, Corvallis, OR
SP Int Thermoelect Soc
HO Univ Oregon
DE Bismuth telluride; thermal conductivity
AB A fine measurement system for measuring thermal conductivity was constructed. An accuracy of 1% was determined for the reference quartz with a value of 1.411 W/m K. Bi0.5Sb1.5Te3 samples were prepared by mechanical alloying followed by hot-pressing. Grain sizes were varied in the range from 1 mu m to 10 mu m by controlling the sintering temperature in the temperature range from 623 K to 773 K. The thermal conductivity was 0.89 W/m K for the sample sintered at 623 K, while a grain size of 1.75 mu m was measured by optical microscopy and scanning electron microscopy. The thermal conductivity increased on the sample sintered at 673 K because of grain growth and decreased on those sintered at the temperatures from 673 K to 773 K because the increase of pore size caused to decrease thermal conductivity. The increase of thermal conductivity for the samples sintered at temperatures above 773 K was affected by the increase of carrier concentration.
C1 [Hamachiyo, Takashi; Ashida, Maki; Hasezaki, Kazuhiro] Shimane Univ, Dept Mat Sci, Matsue, Shimane 6908504, Japan.
RP Hamachiyo, T (reprint author), Shimane Univ, Dept Mat Sci, Nishikawatsu Cho 1060, Matsue, Shimane 6908504, Japan.
EM Warriors59chiyo@yahoo.co.jp
CR Caillat T, 1997, J PHYS CHEM SOLIDS, V58, P1119, DOI 10.1016/S0022-3697(96)00228-4
   HASEZAKI K, 2007, J JPN SOC POWDER POW, V54, P543, DOI DOI 10.2497/JJSPM.54.543
   HASEZAKI K, 1994, MAT T JIM, V35, P28
   Kohri H, 2001, TWENTIETH INTERNATIONAL CONFERENCE ON THERMOELECTRICS, PROCEEDINGS, P121, DOI 10.1109/ICT.2001.979837
   MIRKOVIC.VV, 1965, J AM CERAM SOC, V48, P387, DOI 10.1111/j.1151-2916.1965.tb14773.x
   SATTERTHWAITE CB, 1957, PHYS REV, V108, P1164, DOI 10.1103/PhysRev.108.1164
   SCHERRER H, 2006, THERMOELECTRICS HDB, P1
   SUGA Y, 1966, THERMOELECTRIC SEMIC, P317
   TERRY TM, 2006, THERMOELECTRICS HDB, P11
   TERRY TM, 2004, THERMAL CONDUCTIVITY, P187
NR 10
TC 12
Z9 14
U1 4
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0361-5235
EI 1543-186X
J9 J ELECTRON MATER
JI J. Electron. Mater.
PD JUL
PY 2009
VL 38
IS 7
BP 1048
EP 1051
DI 10.1007/s11664-009-0718-2
PG 4
WC Engineering, Electrical & Electronic; Materials Science,
   Multidisciplinary; Physics, Applied
SC Engineering; Materials Science; Physics
GA 466LA
UT WOS:000267662500027
DA 2018-12-27
ER

PT J
AU Sanna, LJ
   Kennedy, LA
   Chang, EC
   Miceli, PM
AF Sanna, Lawrence J.
   Kennedy, Lindsay A.
   Chang, Edward C.
   Miceli, Paul M.
TI RETRACTED: When thoughts don't feel like they used to: Changing feelings
   of subjective ease in judgments of the past (Retracted article. See vol.
   49, pg. 319, 2013)
SO JOURNAL OF EXPERIMENTAL SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
DE Hindsight bias; Subjective ease; Metacognition; Temporal judgment
ID HINDSIGHT BIAS; ACCESSIBILITY EXPERIENCES; METACOGNITIVE EXPERIENCES; I
   KNEW; RETRIEVAL; INFORMATION; GENERATION; MODEL; AVAILABILITY;
   METAANALYSIS
AB Thinking about the past is critical to everyday experiences, but people are not unbiased when doing so. Feelings of subjective ease that accompany generating reasons for known or alternative outcomes influence hindsight bias. But people do not always make decisions immediately after thinking about issues. Three experiments demonstrated that generating versus reading earlier generated reasons has markedly different effects on judgments, with theoretical and practical implications. Inevitability judgments were consistent with feelings of ease when generating reasons, but with numbers of reasons (content) when later reading those reasons. Experiments 2 and 3 also found that feelings of ease can be reconstructed if people reconsider their feelings when initially generating reasons. Discussion centers on the operation of subjective ease and its role in understanding judgment and decision making. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Sanna, Lawrence J.; Kennedy, Lindsay A.; Miceli, Paul M.] Univ N Carolina, Dept Psychol, Chapel Hill, NC 27599 USA.
   [Sanna, Lawrence J.] Duke Univ, Fuqua Sch Business, Mkt Area, Durham, NC 27708 USA.
   [Chang, Edward C.] Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA.
RP Sanna, LJ (reprint author), Univ N Carolina, Dept Psychol, CB 3270 Davie Hall, Chapel Hill, NC 27599 USA.
EM sanna@unc.edu
CR Aarts H, 1999, ACTA PSYCHOL, V103, P77, DOI 10.1016/S0001-6918(99)00035-9
   Birch SAJ, 2007, PSYCHOL SCI, V18, P382, DOI 10.1111/j.1467-9280.2007.01909.x
   Broemer P, 2004, EUR J SOC PSYCHOL, V34, P103, DOI 10.1002/ejsp.185
   Bryant FB, 2002, BASIC APPL SOC PSYCH, V24, P27, DOI 10.1207/S15324834BASP2401_3
   Caruso EM, 2008, J EXP SOC PSYCHOL, V44, P148, DOI 10.1016/j.jesp.2006.11.003
   CHRISTENSENSZALANSKI JJJ, 1991, ORGAN BEHAV HUM DEC, V48, P147, DOI 10.1016/0749-5978(91)90010-Q
   *CNN, 2008, CNN POLL POLLS NAT
   Eagly A, 1993, PSYCHOL ATTITUDES, P305
   FISCHHOFF B, 1975, J EXP PSYCHOL HUMAN, V1, P288, DOI 10.1037//0096-1523.1.3.288
   Guilbault RL, 2004, BASIC APPL SOC PSYCH, V26, P103, DOI 10.1207/s15324834basp2602&3_1
   HAWKINS SA, 1990, PSYCHOL BULL, V107, P311, DOI 10.1037/0033-2909.107.3.311
   Herzog SM, 2007, J EXP SOC PSYCHOL, V43, P483, DOI 10.1016/j.jesp.2006.05.008
   Jacoby L. L, 1989, VARIETIES MEMORY CON, P391, DOI DOI 10.1002/ACP.2350050509
   Keys DJ, 2007, PERSPECT PSYCHOL SCI, V2, P162, DOI 10.1111/j.1745-6916.2007.00035.x
   KOEHLER DJ, 1994, J EXP PSYCHOL LEARN, V20, P461, DOI 10.1037/0278-7393.20.2.461
   Markman KD, 2002, SOC COGNITION, V20, P58, DOI 10.1521/soco.20.1.58.20943
   Pezzo MV, 2007, SOC COGNITION, V25, P147, DOI 10.1521/soco.2007.25.1.147
   Pezzo MV, 2003, MEMORY, V11, P421, DOI 10.1080/09658210244000603
   Plous S., 1993, PSYCHOL JUDGMENT DEC
   Raghubir P, 2001, MARKET LETT, V12, P145, DOI 10.1023/A:1011165019311
   Robinson MD, 2002, PSYCHOL BULL, V128, P934, DOI 10.1037//0033-2909.128.6.934
   Rosenthal R., 2000, CONTRASTS EFFECT SIZ
   Rothman AJ, 1998, PERS SOC PSYCHOL B, V24, P1053
   Sanna LJ, 2007, SOC COGNITION, V25, P185, DOI 10.1521/soco.2007.25.1.185
   Sanna LJ, 2003, J EXP SOC PSYCHOL, V39, P287, DOI 10.1016/S0022-1031(02)00528-0
   Sanna LJ, 2002, MEM COGNITION, V30, P1288, DOI 10.3758/BF03213410
   Sanna LJ, 2002, J EXP PSYCHOL LEARN, V28, P497, DOI 10.1037//0278-7393.28.3.497
   SCHWARZ N, 1991, J PERS SOC PSYCHOL, V61, P195, DOI 10.1037/0022-3514.61.2.195
   Schwarz N, 1998, Pers Soc Psychol Rev, V2, P87, DOI 10.1207/s15327957pspr0202_2
   Schwarz N, 2007, ADV EXP SOC PSYCHOL, V39, P127, DOI 10.1016/S0065-2601(06)39003-X
   SLAMECKA NJ, 1978, J EXP PSYCHOL-HUM L, V4, P592, DOI 10.1037//0278-7393.4.6.592
   Tormala ZL, 2007, J PERS SOC PSYCHOL, V93, P143, DOI 10.1037/0022-3514.93.2.143
   Vaughn LA, 2002, J SOC CLIN PSYCHOL, V21, P686, DOI 10.1521/jscp.21.6.686.22794
   Wanke M, 1997, J CONSUM RES, V24, P170, DOI 10.1086/209502
   Wilson TD, 2008, PERSPECT PSYCHOL SCI, V3, P370, DOI 10.1111/j.1745-6924.2008.00085.x
   Winkielman P, 2001, PSYCHOL SCI, V12, P176, DOI 10.1111/1467-9280.00330
   Winkielman P, 1998, PSYCHOL SCI, V9, P124, DOI 10.1111/1467-9280.00022
NR 37
TC 5
Z9 5
U1 1
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-1031
EI 1096-0465
J9 J EXP SOC PSYCHOL
JI J. Exp. Soc. Psychol.
PD JUL
PY 2009
VL 45
IS 4
BP 940
EP 946
DI 10.1016/j.jesp.2009.05.012
PG 7
WC Psychology, Social
SC Psychology
GA 487MN
UT WOS:000269278800041
DA 2018-12-27
ER

PT J
AU Yuan, SL
   Song, YL
AF Yuan, Sanling
   Song, Yongli
TI RETRACTED: Stability and Hopf bifurcations in a delayed Leslie-Gower
   predator-prey system (Retracted article. See vol. 413, pg. 546, 2014)
SO JOURNAL OF MATHEMATICAL ANALYSIS AND APPLICATIONS
LA English
DT Article; Retracted Publication
DE Time delay; Stability switches; Local Hopf bifurcation; Global Hopf
   bifurcation; Periodic solutions
ID FUNCTIONAL-DIFFERENTIAL EQUATIONS; GLOBAL PERIODIC-SOLUTIONS; NORMAL
   FORMS; MODEL
AB In this paper, we consider the following delayed Leslie-Gower predator-prey system
   x'(t) = r(1)x(t)(1 - x(t -tau)/K) - mx(t)y(t)
   y'(t) = r(2)y(t)(1 - y(t)/yx(t).
   By choosing the delay tau as a bifurcation parameter, we show that Hopf bifurcations can occur as the delay crosses some critical values. By deriving the equation describing the flow on the center manifold, we can determine the direction of the Hopf bifurcations and the stability of the bifurcating periodic solutions. In addition, special attention is paid to the global continuation of local Hopf bifurcations. Using a global Hopf bifurcation result of Wu U. Wu, Symmetric functional differential equations and neural networks with memory, Trans. Amer. Math. Soc. 350 (1998) 4799-4838] for functional differential equations, we may show the global existence of periodic solutions. Computer simulations illustrate the results. (c) 2009 Elsevier Inc. All rights reserved.
C1 [Yuan, Sanling] Shanghai Univ Sci & Technol, Coll Sci, Shanghai 200093, Peoples R China.
   [Song, Yongli] Tongji Univ, Dept Math, Shanghai 200092, Peoples R China.
RP Yuan, SL (reprint author), Shanghai Univ Sci & Technol, Coll Sci, Shanghai 200093, Peoples R China.
EM yuansanling@263.net
FU National Natural Science Foundation of China [10871129]; Educational
   Committee Foundation of Shanghai [09YZ208]
FX Research is supported by the National Natural Science Foundation of
   China (10871129) and the Educational Committee Foundation of Shanghai
   (09YZ208).
CR Beretta E, 1996, J MATH ANAL APPL, V204, P840, DOI 10.1006/jmaa.1996.0471
   Beretta E, 1998, NONLINEAR ANAL-THEOR, V32, P381, DOI 10.1016/S0362-546X(97)00491-4
   BRAZA PA, 2003, SIAM J APPL MATH, V63, P898
   Chow SN, 1982, METHODS BIFURCATION
   COLLINGS JB, 1995, B MATH BIOL, V57, P63, DOI 10.1016/0092-8240(94)00024-7
   Cushing J. M., 1977, INTEGRODIFFERENTIAL
   FARIA T, 1995, J DIFFER EQUATIONS, V122, P201, DOI 10.1006/jdeq.1995.1145
   FARIA T, 1995, J DIFFER EQUATIONS, V122, P181, DOI 10.1006/jdeq.1995.1144
   GOPALSAMY K, 1984, J AUST MATH SOC B, V25, P473, DOI 10.1017/S0334270000004227
   GOPALSAMY K, 1983, B MATH BIOL, V45, P295, DOI 10.1016/S0092-8240(83)80058-5
   Gopalsamy K, 1992, STABILITY OSCILLATIO
   Hsu SB, 1999, TAIWAN J MATH, V3, P35, DOI 10.11650/twjm/1500407053
   HUTCHINSON GE, 1948, ANN NY ACAD SCI, V50, P221, DOI 10.1111/j.1749-6632.1948.tb39854.x
   Kuang Y., 1993, DELAY DIFFERENTIAL E
   LESLIE PH, 1960, BIOMETRIKA, V47, P219, DOI 10.1093/biomet/47.3-4.219
   Liu ZH, 2004, J MATH ANAL APPL, V296, P521, DOI 10.1016/j.jmaa.2004.04.051
   May R.M., 1973, ECOLOGY, V4, P315
   Song YL, 2005, J MATH ANAL APPL, V301, P1, DOI 10.1016/j.jmaa.2004.06.056
   TANNER JT, 1975, ECOLOGY, V56, P855, DOI 10.2307/1936296
   Wu JH, 1998, T AM MATH SOC, V350, P4799, DOI 10.1090/S0002-9947-98-02083-2
   Xiao DM, 2001, J DIFFER EQUATIONS, V176, P494, DOI 10.1006/jdeq.2000.3982
   Yan XP, 2008, NONLINEAR ANAL-REAL, V9, P114, DOI 10.1016/j.nonrwa.2006.09.007
   Yan XP, 2006, APPL MATH COMPUT, V177, P427, DOI 10.1016/j.amc.2005.11.020
NR 23
TC 42
Z9 46
U1 5
U2 39
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-247X
EI 1096-0813
J9 J MATH ANAL APPL
JI J. Math. Anal. Appl.
PD JUL 1
PY 2009
VL 355
IS 1
BP 82
EP 100
DI 10.1016/j.jmaa.2009.01.052
PG 19
WC Mathematics, Applied; Mathematics
SC Mathematics
GA 441WS
UT WOS:000265801800008
OA Bronze
DA 2018-12-27
ER

PT J
AU Seely, KA
   Levi, MS
   Prather, PL
AF Seely, Kathryn A.
   Levi, Mark S.
   Prather, Paul L.
TI RETRACTED: The Dietary Polyphenols trans-Resveratrol and Curcumin
   Selectively Bind Human CB1 Cannabinoid Receptors with Nanomolar
   Affinities and Function as Antagonists/Inverse Agonists (Retracted
   Article. See vol 331, pg 1147, 2009)
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article; Retracted Publication
ID IN-VIVO; ALZHEIMERS-DISEASE; PLANT POLYPHENOLS; BIOAVAILABILITY;
   INHIBITION; ANTIOXIDANTS; MECHANISMS; PROMISES; OBESITY; RATS
AB The dietary polyphenols trans-resveratrol [5-[(1E)-2-(4-hydroxyphenyl) ethenyl]-1,3-benzenediol; found in red wine] and curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1E, 6E-heptadiene-3,5-dione] (found in curry powders) exert anti-inflammatory and antioxidant effects via poorly defined mechanisms. It is interesting that cannabinoids, derived from the marijuana plant (Cannabis sativa), produce similar protective effects via CB1 and CB2 receptors. We examined whether trans-resveratrol, curcumin, and ASC-J9 [1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-1E, 4E, 6E-heptatriene-3-one] (a curcumin analog) act as ligands at cannabinoid receptors. All three bind to human (h) CB1 and mouse CB1 receptors with nanomolar affinities, displaying only micromolar affinities for hCB2 receptors. Characteristic of inverse agonists, the polyphenols inhibit basal G-protein activity in membranes prepared from Chinese hamster ovary (CHO)-hCB1 cells or mouse brain that is reversed by a neutral CB1 antagonist. Furthermore, they competitively antagonize G-protein activation produced by a CB1 agonist. In intact CHO-hCB1 cells, the polyphenols act as neutral antagonists, producing no effect when tested alone, whereas competitively antagonizing CB1 agonist mediated inhibition of adenylyl cyclase activity. Confirming their neutral antagonist profile in cells, the polyphenols similarly attenuate stimulation of adenylyl cyclase activity produced by a CB1 inverse agonist. In mice, the polyphenols dose-dependently reverse acute hypothermia produced by a CB1 agonist. Upon repeated administration, the polyphenols also reduce body weight in mice similar to that produced by a CB1 antagonist/inverse agonist. Finally, trans-resveratrol and curcumin share common structural motifs with other known cannabinoid receptor ligands. Collectively, we suggest that trans-resveratrol and curcumin act as antagonists/inverse agonists at CB1 receptors at dietary relevant concentrations. Therefore, these polyphenols and their derivatives might be developed as novel, nontoxic CB1 therapeutics for obesity and/or drug dependence.
C1 [Seely, Kathryn A.; Levi, Mark S.; Prather, Paul L.] Univ Arkansas Med Sci, Coll Med, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA.
RP Prather, PL (reprint author), Univ Arkansas Med Sci, Coll Med, Dept Pharmacol & Toxicol, Slot 611,4301 W Markham St, Little Rock, AR 72205 USA.
EM pratherpaull@uams.edu
FU Amyotrophic Lateral Sclerosis Association [1311]
FX This work was supported by the Amyotrophic Lateral Sclerosis Association
   [Grant 1311].
CR Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Asensi M, 2002, FREE RADICAL BIO MED, V33, P387, DOI 10.1016/S0891-5849(02)00911-5
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Begum AN, 2008, J PHARMACOL EXP THER, V326, P196, DOI 10.1124/jpet.108.137455
   Buryanovskyy L, 2004, BIOCHEMISTRY-US, V43, P11417, DOI 10.1021/bi049162o
   BUSTANJI Y, 2008, J ENZYME INHIB MED C, V1
   Espin JC, 2007, PHYTOCHEMISTRY, V68, P2986, DOI 10.1016/j.phytochem.2007.09.014
   Chainani-Wu N, 2003, J ALTERN COMPLEM MED, V9, P161, DOI 10.1089/107555303321223035
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   El-Mowafy AM, 2003, CARCINOGENESIS, V24, P869, DOI 10.1093/carcin/bgg015
   Fraga CG, 2007, IUBMB LIFE, V59, P308, DOI 10.1080/15216540701230529
   Gutierrez T, 2007, BRIT J PHARMACOL, V150, P153, DOI 10.1038/sj.bjp.0706984
   Hadi SM, 2007, SEMIN CANCER BIOL, V17, P370, DOI 10.1016/j.semcancer.2007.04.002
   Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268
   Han YS, 2006, J PHARMACOL EXP THER, V318, P238, DOI 10.1124/jpet.106.102319
   Hayeshi R, 2007, FOOD CHEM TOXICOL, V45, P286, DOI 10.1016/j.fct.2006.07.027
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Jones D, 2008, NAT REV DRUG DISCOV, V7, P961, DOI 10.1038/nrd2775
   Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602
   Kundu JK, 2006, BIOCHEM PHARMACOL, V72, P1506, DOI 10.1016/j.bcp.2006.08.005
   Lekli I, 2008, AM J PHYSIOL-HEART C, V294, pH859, DOI 10.1152/ajpheart.01048.2007
   MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0
   Muccioli GG, 2007, CHEM BIODIVERS, V4, P1805, DOI 10.1002/cbdv.200790153
   MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0
   Pan MH, 1999, DRUG METAB DISPOS, V27, P486
   Pavon FJ, 2008, J NEUROENDOCRINOL, V20, P116, DOI 10.1111/j.1365-2826.2008.01693.x
   Rahman I, 2006, BIOCHEM PHARMACOL, V72, P1439, DOI 10.1016/j.bcp.2006.07.004
   Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096
   Shoemaker JL, 2005, J PHARMACOL EXP THER, V314, P868, DOI 10.1124/jpet.105.085282
   Singh M, 2008, J AGR FOOD CHEM, V56, P4855, DOI 10.1021/jf0735073
   SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219
   Song ZH, 1999, MOL PHARMACOL, V56, P834
   Stevenson DE, 2007, CELL MOL LIFE SCI, V64, P2900, DOI 10.1007/s00018-007-7237-1
   Surh YJ, 2005, J NUTR, V135, p2993S, DOI 10.1093/jn/135.12.2993S
   Tilak JC, 2004, PHYTOTHER RES, V18, P798, DOI 10.1002/ptr.1553
   Vincent HK, 2007, DIABETES OBES METAB, V9, P813, DOI 10.1111/j.1463-1326.2007.00692.x
   Wang HW, 2008, J MED CHEM, V51, P2439, DOI 10.1021/jm701519h
   Wang Yong-jun, 2003, Zhonghua Yi Xue Za Zhi, V83, P534
   Wiley JL, 2002, J PHARMACOL EXP THER, V301, P679, DOI 10.1124/jpet.301.2.679
   Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200
   Yao BB, 2006, BRIT J PHARMACOL, V149, P145, DOI 10.1038/sj.bjp.0706838
NR 41
TC 15
Z9 16
U1 3
U2 15
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD JUL
PY 2009
VL 330
IS 1
BP 31
EP 39
DI 10.1124/jpet.109.151654
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 461PL
UT WOS:000267280300004
PM 19359525
OA Bronze
DA 2018-12-27
ER

PT J
AU Doreian, BW
   Fulop, TG
   Meklemburg, RL
   Smith, CB
AF Doreian, Bryan W.
   Fulop, Tiberiu G.
   Meklemburg, Robert L.
   Smith, Corey B.
TI RETRACTED: Cortical F-Actin, the Exocytic Mode, and Neuropeptide Release
   in Mouse Chromaffin Cells Is Regulated by Myristoylated Alanine-rich
   C-Kinase Substrate and Myosin II (Retracted article. See vol. 24, pg.
   1251, 2013)
SO MOLECULAR BIOLOGY OF THE CELL
LA English
DT Article; Retracted Publication
ID FUSION PORE; VESICLE TRANSPORT; COMPENSATORY ENDOCYTOSIS; CATECHOLAMINE
   RELEASE; TRANSMITTER RELEASE; ACTION POTENTIALS; ADRENAL-MEDULLA;
   CHROMOGRANIN-A; WHOLE-CELL; SECRETION
AB Adrenal medullary chromaffin cells are innervated by the sympathetic splanchnic nerve and translate graded sympathetic firing into a differential hormonal exocytosis. Basal sympathetic firing elicits a transient kiss-and-run mode of exocytosis and modest catecholamine release, whereas elevated firing under the sympathetic stress response results in full granule collapse to release catecholamine and peptide transmitters into the circulation. Previous studies have shown that rearrangement of the cell actin cortex regulates the mode of exocytosis. An intact cortex favors kiss-and-run exocytosis, whereas disrupting the cortex favors the full granule collapse mode. Here, we investigate the specific roles of two actin-associated proteins, myosin II and myristoylated alanine-rich C-kinase substrate (MARCKS) in this process. Our data demonstrate that MARCKS phosphorylation under elevated cell firing is required for cortical actin disruption but is not sufficient to elicit peptide transmitter exocytosis. Our data also demonstrate that myosin II is phospho-activated under high stimulation conditions. Inhibiting myosin II activity prevented disruption of the actin cortex, full granule collapse, and peptide transmitter release. These results suggest that phosphorylation of both MARCKS and myosin II lead to disruption of the actin cortex. However, myosin II, but not MARCKS, is required for the activity-dependent exocytosis of the peptide transmitters.
C1 [Doreian, Bryan W.; Fulop, Tiberiu G.; Meklemburg, Robert L.; Smith, Corey B.] Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.
RP Smith, CB (reprint author), Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.
EM corey.smith@case.edu
FU National Science Foundation [IBN-0344768]; National Institutes of Health
   [1R01 NS-052123, T32 HL-07887]
FX We thank Dr. Shyue-An Chan for expert help in design of the experiments
   as well as critical comments of the manuscript, and Katherine
   Trueblood-Doreian for critical comments of the manuscript. This work was
   supported by National Science Foundation grant IBN-0344768 and National
   Institutes of Health grants 1R01 NS-052123 (to C. S.) and T32 HL-07887
   (for support of B. D.).
CR Albillos A, 1997, NATURE, V389, P509
   Allingham JS, 2005, NAT STRUCT MOL BIOL, V12, P378, DOI 10.1038/nsmb908
   Angleson JK, 1999, NAT NEUROSCI, V2, P440
   Aunis D, 1998, INT REV CYTOL, V181, P213, DOI 10.1016/S0074-7696(08)60419-2
   Bader MF, 2002, ANN NY ACAD SCI, V971, P178, DOI 10.1111/j.1749-6632.2002.tb04461.x
   Berberian K, 2009, J NEUROSCI, V29, P863, DOI 10.1523/JNEUROSCI.2818-08.2009
   Bhat P, 2009, MOL BIOL CELL, V20, P1795, DOI 10.1091/mbc.E08-10-1048
   BRANDT BL, 1976, J PHYSIOL-LONDON, V263, P417, DOI 10.1113/jphysiol.1976.sp011638
   Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0
   Cai YF, 2006, BIOPHYS J, V91, P3907, DOI 10.1529/biophysj.106.084806
   Cavadas C, 2002, ANN NY ACAD SCI, V971, P335, DOI 10.1111/j.1749-6632.2002.tb04489.x
   Chan SA, 2003, J PHYSIOL-LONDON, V553, P707, DOI 10.1113/jphysiol.2003.053918
   Chan SA, 2003, PFLUG ARCH EUR J PHY, V445, P540, DOI 10.1007/s00424-002-0966-y
   Chan SA, 2001, J PHYSIOL-LONDON, V537, P871
   Chen P, 2000, BIOPHYS J, V79, P2162, DOI 10.1016/S0006-3495(00)76464-2
   CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0
   Cuchillo-Ibanez I, 2004, J PHYSIOL-LONDON, V560, P63, DOI 10.1113/jphysiol.2004.064063
   DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0
   Doreian BW, 2008, J NEUROSCI, V28, P4470, DOI 10.1523/JNEUROSCI.0008-08.2008
   Elhamdani A, 2001, NEURON, V31, P819, DOI 10.1016/S0896-6273(01)00418-4
   Elhamdani A, 2006, J NEUROSCI, V26, P3030, DOI 10.1523/JNEUROSCI.5275-05.2006
   Fulop T, 2005, J NEUROSCI, V25, P7324, DOI 10.1523/JNEUROSCI.2042-05.2005
   Fulop T, 2006, BIOCHEM J, V399, P111, DOI 10.1042/BJ20060654
   Fulop T, 2007, J NEUROSCI METH, V166, P195, DOI 10.1016/j.jneumeth.2007.07.004
   Gasman S, 2003, CELL SIGNAL, V15, P893, DOI 10.1016/S0898-6568(03)00052-4
   Gillis Kevin D., 1995, P155
   Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200
   Gomez JF, 2002, ANN NY ACAD SCI, V971, P647, DOI 10.1111/j.1749-6632.2002.tb04544.x
   Habib KE, 2001, ENDOCRIN METAB CLIN, V30, P695, DOI 10.1016/S0889-8529(05)70208-5
   HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0
   KIDOKORO Y, 1980, J PHYSIOL-LONDON, V307, P199, DOI 10.1113/jphysiol.1980.sp013431
   KORN SJ, 1989, J GEN PHYSIOL, V94, P789, DOI 10.1085/jgp.94.5.789
   Lindau M, 2003, BBA-MOL CELL RES, V1641, P167, DOI 10.1016/S0167-4889(03)00085-5
   Ludowyke RI, 1996, J IMMUNOL, V157, P5130
   Moser T, 1997, P NATL ACAD SCI USA, V94, P6735, DOI 10.1073/pnas.94.13.6735
   Mosharov EV, 2005, NAT METHODS, V2, P651, DOI 10.1038/nmeth782
   Neco P, 2004, J BIOL CHEM, V279, P27450, DOI 10.1074/jbc.M311462200
   Neco P, 2002, BIOCHEM J, V368, P405, DOI 10.1042/BJ20021090
   Neco P, 2008, J BIOL CHEM, V283, P10949, DOI 10.1074/jbc.M709058200
   NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712
   OCONNOR DT, 1984, J BIOL CHEM, V259, P3237
   Perrais D, 2004, J PHYSIOL-LONDON, V560, P413, DOI 10.1113/jphysiol.2004.064410
   Rahamimoff R, 1997, NEURON, V18, P17, DOI 10.1016/S0896-6273(01)80043-X
   Rose SD, 2001, J BIOL CHEM, V276, P36757, DOI 10.1074/jbc.M006518200
   Smith C, 1998, NEURON, V20, P1243, DOI 10.1016/S0896-6273(00)80504-8
   Sokac AM, 2003, NAT CELL BIOL, V5, P727, DOI 10.1038/ncb1025
   Takahashi N, 2002, SCIENCE, V297, P1349, DOI 10.1126/science.1073806
   TAKIYYUDDIN MA, 1994, J AUTON PHARMACOL, V14, P187, DOI 10.1111/j.1474-8673.1994.tb00601.x
   Trifaro JM, 2008, ACTA PHYSIOL, V192, P165, DOI 10.1111/j.1748-1716.2007.01808.x
   TRIFARO JM, 1977, ANNU REV PHARMACOL, V17, P27, DOI 10.1146/annurev.pa.17.040177.000331
   TRIFARO JM, 1985, CAN J BIOCHEM CELL B, V63, P661, DOI 10.1139/o85-084
   Trifaro JM, 2000, BIOCHIMIE, V82, P339, DOI 10.1016/S0300-9084(00)00193-0
   Trifaro JM, 2002, NEUROCHEM RES, V27, P1371, DOI 10.1023/A:1021627800918
   Urven LE, 2006, J CELL SCI, V119, P4342, DOI 10.1242/jcs.03197
   VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057
   VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0
   WATKINSON A, 1990, PEPTIDES, V11, P435, DOI 10.1016/0196-9781(90)90039-8
   WIELAND T, 1986, PEPTIDES POISONOUS A
   WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754
   Wilson JR, 1999, DIABETES, V48, P2383, DOI 10.2337/diabetes.48.12.2383
   WINKLER H, 1976, NEUROSCIENCE, V1, P65, DOI 10.1016/0306-4522(76)90001-4
   Yu HYE, 2007, MOL BIOL CELL, V18, P4096, DOI 10.1091/mbc.E06-11-0993
   Zanella B, 2002, BIOCHEM BIOPH RES CO, V290, P1010, DOI 10.1006/bbrc.2001.6284
NR 63
TC 24
Z9 25
U1 4
U2 14
PU AMER SOC CELL BIOLOGY
PI BETHESDA
PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA
SN 1059-1524
J9 MOL BIOL CELL
JI Mol. Biol. Cell
PD JUL 1
PY 2009
VL 20
IS 13
BP 3142
EP 3154
DI 10.1091/mbc.E09-03-0197
PG 13
WC Cell Biology
SC Cell Biology
GA 464VO
UT WOS:000267536400013
PM 19420137
OA Green Published
DA 2018-12-27
ER

PT J
AU Ren, HJ
   Wu, ZW
   Cao, JT
   Chu, PK
AF Ren, Haijun
   Wu, Zhengwei
   Cao, Jintao
   Chu, Paul K.
TI RETRACTED: Jeans instability in quantum magnetoplasma with resistive
   effects (Retracted article. See vol 16, 079907, 2009)
SO PHYSICS OF PLASMAS
LA English
DT Article; Retracted Publication
DE plasma instability; plasma magnetohydrodynamics; quantum theory
ID PLASMA; MODEL
AB The Jeans instability in dense quantum plasmas is investigated in the presence of two dimensional magnetic fields and resistive effects. The resistive effects are shown to introduce instability whether the perturbation is stable or not in the ideal magnetohydrodynamic model. The analytical expressions of the growth rate of Jeans instability are obtained for both the finite and remarkable resistive effects cases. The results are relevant to dense astrophysical objects, e.g., neutron stars and the interior of white dwarfs, as well as low-temperature laboratory plasmas.
C1 [Ren, Haijun; Wu, Zhengwei; Cao, Jintao] Univ Sci & Technol China, CAS Key Lab Basic Plasma Phys, Hefei 230026, Peoples R China.
   [Ren, Haijun; Wu, Zhengwei; Chu, Paul K.] City Univ Hong Kong, Dept Phys & Mat Sci, Kowloon, Hong Kong, Peoples R China.
   [Wu, Zhengwei] Univ Sydney, Sch Phys, Sydney, NSW 2006, Australia.
RP Wu, ZW (reprint author), Univ Sci & Technol China, CAS Key Lab Basic Plasma Phys, Hefei 230026, Peoples R China.
EM wzhengwei2@student.cityu.edu.hk
RI Chu, Paul/B-5923-2013
OI Chu, Paul/0000-0002-5581-4883
FU Hong Kong Research Grants Council (RGC) General Research Funds (GRF)
   [112306, 112307]
FX This work was supported by Hong Kong Research Grants Council (RGC)
   General Research Funds (GRF) CityU 112306 and 112307.
CR Bingham R, 2004, PLASMA PHYS CONTR F, V46, pR1, DOI 10.1088/0741-3335/46/1/R01
   Brodin G, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.175001
   Brodin G, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.245002
   Haas F, 2005, PHYS PLASMAS, V12, DOI 10.1063/1.1939947
   Haas F, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.046404
   Jeans J H, 1929, ASTRONOMY COSMOLOGY
   Khan SA, 2009, PHYS PLASMAS, V16, DOI 10.1063/1.3055599
   Kremp D, 1999, PHYS REV E, V60, P4725, DOI 10.1103/PhysRevE.60.4725
   Lundin J, 2008, PHYS PLASMAS, V15, DOI 10.1063/1.2956641
   Manfredi G, 2005, FIELDS I COMMUN, V46, P263
   Marklund M, 2005, PLASMA PHYS CONTR F, V47, pL25, DOI 10.1088/0741-3335/47/7/L02
   MARKLUND M, 2006, REV MOD PHYS, V78, P455
   Marklund M, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.025001
   Markowich P, 1990, SEMICONDUCTOR EQUATI
   Masood W, 2008, PHYS LETT A, V372, P6757, DOI 10.1016/j.physleta.2008.09.034
   Mushtaq A, 2009, PHYS PLASMAS, V16, DOI 10.1063/1.3073669
   PANDEY BP, 1994, PHYS REV E, V49, P5599, DOI 10.1103/PhysRevE.49.5599
   RAOA NN, 2001, PHYS PLASMAS, V8, P4740
   Ren HJ, 2007, PHYS PLASMAS, V14, DOI 10.1063/1.2738848
   Salimullah M, 2009, PHYS PLASMAS, V16, DOI 10.1063/1.3070664
   Shaikh D, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.125002
   Shukla PK, 2006, PHYS PLASMAS, V13, DOI 10.1063/1.2261851
   SKULA PK, 2008, PHYS LETT A, V355, P378
NR 23
TC 38
Z9 38
U1 4
U2 16
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 1070-664X
J9 PHYS PLASMAS
JI Phys. Plasmas
PD JUL
PY 2009
VL 16
IS 7
AR 072101
DI 10.1063/1.3168612
PG 5
WC Physics, Fluids & Plasmas
SC Physics
GA 478UZ
UT WOS:000268615200003
DA 2018-12-27
ER

PT J
AU Wang, C
   Kang, YF
   Weaver, L
   Chang, ZH
AF Wang, Chao
   Kang, Yifan
   Weaver, Larry
   Chang, Zenghu
TI RETRACTED: High-resolution reflecting time-of-flight momentum and energy
   mapping system (Retracted article. See vol. 80, pg NIL_0335, 2009)
SO REVIEW OF SCIENTIFIC INSTRUMENTS
LA English
DT Article; Retracted Publication
DE time of flight mass spectroscopy
ID MASS-SPECTROMETER; DISSOCIATIVE PHOTOIONIZATION; PHOTOELECTRON
   SPECTROMETER; VECTOR CORRELATIONS; ELECTRON-EMISSION; ION OPTICS;
   SPECTROSCOPY; DYNAMICS; ANALYZER; DETECTOR
AB A new system to map electron momentum and energy is proposed. A reflecting electrode is introduced into a time-of-flight (TOF) system whose decelerating electric field sends all the electrons back to a position-sensitive detector close to but behind the source of the electrons. The longer flying distance that results makes it possible to significantly improve the energy-resolved performance, especially in the higher energy region. The dependence of the new TOF system on its characteristic parameters is analyzed, along with its application to attosecond streak cameras. Experimental results verified a relative energy resolution better than 0.2 eV for 22 eV electrons and also revealed the availability of the improved relative energy resolution smaller than 1.0% for electron energy ranging from 30 to 40 eV.
C1 [Wang, Chao] Xi An Jiao Tong Univ, Sch Elect & Informat Engn, Xian 710049, Peoples R China.
   [Wang, Chao; Chang, Zenghu] Kansas State Univ, Dept Phys, JR Macdonald Lab, Manhattan, KS 66506 USA.
   [Kang, Yifan] AF Engn Univ, Sch Sci, Xian 710051, Peoples R China.
RP Wang, C (reprint author), Xi An Jiao Tong Univ, Sch Elect & Informat Engn, Xian 710049, Peoples R China.
RI Weaver, Larry/I-5201-2013
OI Weaver, Larry/0000-0003-3083-2724
FU U.S. Army Research Office [W911NF-07-1-0475]; NSF [0457269]; Chemical
   Sciences, Geosciences, and Biosciences Division, Office of Basic Energy
   Sciences, Office of Science, U. S. Department of Energy; China
   Scholarship Council (CSC)
FX This material was supported by the U.S. Army Research Office under Grant
   No. W911NF-07-1-0475, by the NSF under Grant No. 0457269, and by the
   Chemical Sciences, Geosciences, and Biosciences Division, Office of
   Basic Energy Sciences, Office of Science, U. S. Department of Energy.
   Chao Wang also presents his thanks for the support of China Scholarship
   Council (CSC). L. W. did not participate in the experimental work.
CR Agostini P, 2004, REP PROG PHYS, V67, P813, DOI 10.1088/0034-4885/67/6/R01
   BERGMANN T, 1990, REV SCI INSTRUM, V61, P2585, DOI 10.1063/1.1141842
   Bhowmick A, 2005, INT J MOD PHYS B, V19, P2621, DOI 10.1142/S0217979205031420
   BHOWMICK A, 2005, B INDIAN VACUUM SOC, V8, P19
   BHOWMICK A, 2005, BARC NEWSLETTER FOUN, V261, P61
   CAMERON AE, 1948, REV SCI INSTRUM, V19, P605, DOI 10.1063/1.1741336
   CHESHNOVSKY O, 1987, REV SCI INSTRUM, V58, P2131, DOI 10.1063/1.1139475
   Coutinho LH, 2007, NUCL INSTRUM METH A, V571, P748, DOI 10.1016/j.nima.2006.11.030
   Czerwieniec GA, 2005, J AM SOC MASS SPECTR, V16, P1866, DOI 10.1016/j.jasms.2005.06.013
   Damascelli A, 2004, PHYS SCRIPTA, VT109, P61, DOI 10.1238/Physica.Topical.109a00061
   DEBRUIJN DP, 1982, REV SCI INSTRUM, V53, P1020, DOI 10.1063/1.1137102
   Dorner R, 2000, PHYS REP, V330, P95, DOI 10.1016/S0370-1573(99)00109-X
   Drescher M, 2002, NATURE, V419, P803, DOI 10.1038/nature01143
   Flechard X, 2001, J PHYS B-AT MOL OPT, V34, P2759, DOI 10.1088/0953-4075/34/14/301
   Gisselbrecht M, 2005, REV SCI INSTRUM, V76, DOI 10.1063/1.1832411
   Hanold KA, 1999, REV SCI INSTRUM, V70, P2268, DOI 10.1063/1.1149751
   Hemmers O, 1998, REV SCI INSTRUM, V69, P3809, DOI 10.1063/1.1149183
   Hentschel M, 2001, NATURE, V414, P509, DOI 10.1038/35107000
   Itatani J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.173903
   Kollmus H, 1997, NUCL INSTRUM METH B, V124, P377, DOI 10.1016/S0168-583X(96)00819-1
   Kosev K, 2008, NUCL INSTRUM METH A, V594, P178, DOI 10.1016/j.nima.2008.06.014
   Lafosse A, 2000, PHYS REV LETT, V84, P5987, DOI 10.1103/PhysRevLett.84.5987
   Lange M, 2008, REV SCI INSTRUM, V79, DOI 10.1063/1.2912824
   Lavollee M, 1999, REV SCI INSTRUM, V70, P2968, DOI 10.1063/1.1149855
   Lebech M, 2002, REV SCI INSTRUM, V73, P1866, DOI 10.1063/1.1458063
   Lebedev G, 2007, NUCL INSTRUM METH A, V582, P168, DOI 10.1016/j.nima.2007.08.099
   Mamishin S, 2005, SURF INTERFACE ANAL, V37, P225, DOI 10.1002/sia.1970
   Michelato P, 2003, REV SCI INSTRUM, V74, P2977, DOI 10.1063/1.1574393
   MOMIN T, 2008, J PHYS C SER, V114
   Moon JH, 2005, B KOREAN CHEM SOC, V26, P763
   Moshammer R, 1996, NUCL INSTRUM METH B, V108, P425, DOI 10.1016/0168-583X(95)01259-1
   Oelsner A, 2001, REV SCI INSTRUM, V72, P3968, DOI 10.1063/1.1405781
   Paulus A, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2194475
   Pedersen HB, 1999, REV SCI INSTRUM, V70, P3289, DOI 10.1063/1.1149906
   POLLARD JE, 1989, REV SCI INSTRUM, V60, P3171, DOI 10.1063/1.1140548
   Prumper G, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2774823
   Quiniou ML, 2000, RAPID COMMUN MASS SP, V14, P361, DOI 10.1002/(SICI)1097-0231(20000315)14:5<361::AID-RCM891>3.0.CO;2-E
   Samarin SN, 2003, REV SCI INSTRUM, V74, P1274, DOI 10.1063/1.1537044
   Santacruz CP, 2007, J AM SOC MASS SPECTR, V18, P92, DOI 10.1016/j.jasms.2006.08.020
   SATOH T, 1969, J AM SOC MASS SPECTR, V16, P2005
   STEPHENS WE, 1946, PHYS REV, V69, P691
   Tremsin AS, 2007, NUCL INSTRUM METH A, V582, P172, DOI 10.1016/j.nima.2007.08.101
   TREVOR DJ, 1989, REV SCI INSTRUM, V60, P1051, DOI 10.1063/1.1140315
   Unruh T, 2007, NUCL INSTRUM METH A, V580, P1414, DOI 10.1016/j.nima.2007.07.015
   Vredenborg A, 2008, REV SCI INSTRUM, V79, DOI 10.1063/1.2949142
   WILEY WC, 1955, REV SCI INSTRUM, V26, P1150, DOI 10.1063/1.1715212
   WOLFF MM, 1953, REV SCI INSTRUM, V24, P616, DOI 10.1063/1.1770801
   WOOD RM, 1976, REV SCI INSTRUM, V47, P1471, DOI 10.1063/1.1134557
NR 48
TC 1
Z9 1
U1 2
U2 3
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0034-6748
EI 1089-7623
J9 REV SCI INSTRUM
JI Rev. Sci. Instrum.
PD JUL
PY 2009
VL 80
IS 7
AR 075101
DI 10.1063/1.3170140
PG 8
WC Instruments & Instrumentation; Physics, Applied
SC Instruments & Instrumentation; Physics
GA 478VD
UT WOS:000268615700040
PM 19655975
DA 2018-12-27
ER

PT J
AU Liu, CS
   Lai, MY
AF Liu, Chang-Shi
   Lai, Ming-Yong
TI RETRACTED: The vehicle routing problem with uncertain demand at nodes
   (Retracted article. See vol. 47, pg. 571, 2011)
SO TRANSPORTATION RESEARCH PART E-LOGISTICS AND TRANSPORTATION REVIEW
LA English
DT Article; Retracted Publication
DE Sweeping algorithm; Fuzzy arithmetic rule; Vehicle routing problem;
   Vehicle coordinated strategy
AB The vehicle routing problem with uncertain demand at nodes is considered. The approximate reasoning algorithm is developed to determine the preference strength to send the vehicle to next node, and the improved sweeping algorithm with vehicle coordinated strategy is originally proposed to determine a set of vehicle routes that minimizes costs. Finally the computational results are presented to show the high effectiveness and performance of the solution approaches. Crown Copyright (C) 2008 Published by Elsevier Ltd. All rights reserved.
C1 [Liu, Chang-Shi; Lai, Ming-Yong] Key Lab Logist Informat & Simulat Technol Hunan P, Changsha 410079, Hunan, Peoples R China.
   [Liu, Chang-Shi] Hunan Univ, Econ & Trade Coll, Changsha 410079, Hunan, Peoples R China.
RP Lai, MY (reprint author), Key Lab Logist Informat & Simulat Technol Hunan P, Changsha 410079, Hunan, Peoples R China.
EM liulongstone964@126.com
FU National High Technology [2006BAJ07B03]; Higher Education of China
   [20050532029]
FX The authors are grateful to the constructive comments of the
   Editor-in-Chief and two anonymous referees. This work was supported by
   Project supported by the National High Technology joint Research Program
   of China (Grant No. 2006BAJ07B03) and Project supported by the
   Specialized Research Fund for the Doctoral Program of Higher Education
   of China (Grant No. 20050532029).
CR ERERA AL, 2000, DESIGN LARGE SCALE S
   GILLETT BE, 1974, OPER RES, V22, P340, DOI 10.1287/opre.22.2.340
   Kaufmann A, 1985, INTRO FUZZY ARITHMET
   LIN CKY, 2008, COMPUT IND ENG, V4, P766
   [刘兴 Liu Xing], 2005, [系统工程, Systems Engineering], V23, P105
   MAMDANI E, 1999, INT J MAN MACH STUD, V7, P135
   Runkler T. A., 1993, P 2 IEEE INT C FUZZ, P1161
   RUNKLER TA, 1993, P EUFIT 93 1 EUR C F, P845
   Shang JS, 1996, COMPUT IND ENG, V30, P631, DOI 10.1016/0360-8352(95)00181-6
   Teodorovic D, 1996, FUZZY SET SYST, V82, P307, DOI 10.1016/0165-0114(95)00276-6
NR 10
TC 6
Z9 6
U1 2
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1366-5545
J9 TRANSPORT RES E-LOG
JI Transp. Res. Pt. e-Logist. Transp. Rev.
PD JUL
PY 2009
VL 45
IS 4
BP 517
EP 524
DI 10.1016/j.tre.2008.11.002
PG 8
WC Economics; Engineering, Civil; Operations Research & Management Science;
   Transportation; Transportation Science & Technology
SC Business & Economics; Engineering; Operations Research & Management
   Science; Transportation
GA 458MB
UT WOS:000267026700001
DA 2018-12-27
ER

PT J
AU Sim, CM
   Kim, YK
   Kim, TJ
   Hong, KP
   Em, VT
   Lee, YH
   Kim, YJ
   Kim, JU
AF Sim, Cheul Muu
   Kim, Yi Kyung
   Kim, Tae Joo
   Hong, Kwang Pyo
   Em, V. T.
   Lee, Ye Hong
   Kim, Young Jin
   Kim, Jeong Uk
TI RETRACTED: Fast neutron interrogation system development for the
   detection of explosive materials (Retracted article. See vol. 615, pg.
   340, 2010)
SO NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS
   SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 6th International Topical Meeting on Neutron Radiography
CY SEP 14-18, 2008
CL Kobe Univ, Kobe, JAPAN
HO Kobe Univ
DE Fast neutron interrogation system (FNIS); Associated particle imaging
   method (APIM); Time calibration; Energy calibration; Explosive materials
AB Fast neutron interrogation system (FNIS) based on an associated particle imaging method (APIM) using a neutron generator with an imbedded alpha-particle detector is one of the perspective methods for detecting hidden hazardous materials. Laboratory prototype of a one-side geometry and a two side geometry with a collapsible shielding was assembled. All the different parts (gamma detectors, shielding) and different geometries for developing the tagged neutron inspection system were tested. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Sim, Cheul Muu; Kim, Yi Kyung; Kim, Tae Joo; Hong, Kwang Pyo; Em, V. T.; Lee, Ye Hong; Kim, Young Jin] Korea Atom Energy Res Inst, Taejon 305353, South Korea.
   [Kim, Jeong Uk] Hoseo Univ, Seoul 137867, South Korea.
RP Sim, CM (reprint author), Korea Atom Energy Res Inst, 150 Deokjin Dong, Taejon 305353, South Korea.
EM cmsim@kaeri.re.kr; sohwang@kaeri.re.kr; tj@kaeri.re.kr
CR BOGOLUBOV YP, 2004, P CON PORT NEUTR GEN, P18
   HURLEY JP, 1992, 106173008 STL EGG
   KUZNETSOV AV, 2004, P CON PORT NEUTR GEN
   Viesti G, 1999, NUCL INSTRUM METH A, V422, P918, DOI 10.1016/S0168-9002(98)01046-8
NR 4
TC 1
Z9 1
U1 4
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-9002
EI 1872-9576
J9 NUCL INSTRUM METH A
JI Nucl. Instrum. Methods Phys. Res. Sect. A-Accel. Spectrom. Dect. Assoc.
   Equip.
PD JUN 21
PY 2009
VL 605
IS 1-2
BP 65
EP 68
DI 10.1016/j.nima.2009.01.220
PG 4
WC Instruments & Instrumentation; Nuclear Science & Technology; Physics,
   Nuclear; Physics, Particles & Fields
SC Instruments & Instrumentation; Nuclear Science & Technology; Physics
GA 472WK
UT WOS:000268163300019
DA 2018-12-27
ER

PT J
AU Ali, S
   Varghese, L
   Pereira, L
   Tulunay-Ugur, OE
   Kucuk, O
   Carey, TE
   Wolf, GT
   Sarkar, FH
AF Ali, Shadan
   Varghese, Lalee
   Pereira, Lucio
   Tulunay-Ugur, Ozlem E.
   Kucuk, Omer
   Carey, Thomas E.
   Wolf, Gregory T.
   Sarkar, Fazlul H.
TI RETRACTED: Sensitization of squamous cell carcinoma to cisplatin induced
   killing by natural agents (Retracted article. See vol. 423, pg. 154,
   2018)
SO CANCER LETTERS
LA English
DT Article; Retracted Publication
DE Uterine cervix cancer; 3,3 '-Dindolylmethane; G2535; Cisplatin
   resistance; NF-kappa B
ID FACTOR-KAPPA-B; SOY ISOFLAVONE GENISTEIN; ENDOPLASMIC-RETICULUM STRESS;
   BREAST-CANCER CELLS; PANCREATIC-CANCER; NECK-CANCER;
   3,3'-DIINDOLYLMETHANE DIM; CHEMOTHERAPEUTIC-AGENTS; CERVICAL-CANCER;
   ADVANCED HEAD
AB Cisplatin resistance is a major problem in the successful treatment of squamous cell carcinoma (SCC). In the present study we showed, for the first time, that the constitutive activation of NF-kappa B partly contributes to cisplatin resistance and that the inactivation of NF-kappa B by natural agents [G2535 (isoflavone mixture containing genistein and diadzein), 3,3'-diindolylmethane (Bioresponse BR-DIM referred to as B-DIM)] could overcome this resistance, resulting in the inhibition of cell growth and induction of apoptosis, which might be an useful strategy for achieving better treatment outcome in patients diagnosed with cisplatin-resistant tumors of SCC. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Varghese, Lalee; Sarkar, Fazlul H.] Wayne State Univ, Dept Pathol, Karmanos Canc Ctr, Detroit, MI 48202 USA.
   [Ali, Shadan; Kucuk, Omer] Wayne State Univ, Div Hematol Oncol, Karmanos Canc Ctr, Detroit, MI USA.
   [Pereira, Lucio; Tulunay-Ugur, Ozlem E.] Wayne State Univ, Dept Otolaryngol, Karmanos Canc Ctr, Detroit, MI 48201 USA.
   [Carey, Thomas E.; Wolf, Gregory T.] Univ Michigan, Dept Otolaryngol, Ann Arbor, MI 48109 USA.
RP Sarkar, FH (reprint author), Wayne State Univ, Dept Pathol, Karmanos Canc Ctr, Detroit, MI 48202 USA.
EM fsarkar@med.wayne.edu
OI Carey, Thomas/0000-0002-5202-7518
FU NCI NIH HHS [P50 CA097248-07, P50 CA097248]
CR Abdelrahim M, 2006, CARCINOGENESIS, V27, P717, DOI 10.1093/carcin/bgi270
   ALSARRAF M, 1984, CRC CR REV ONCOL-HEM, V1, P323, DOI 10.1016/S1040-8428(84)80007-4
   BANERJEE S, 2007, PANCREAS
   Bauer JA, 2007, INT J RADIAT ONCOL, V69, pS106, DOI 10.1016/j.ijrobp.2007.05.080
   Bernier J, 2008, EXPERT REV ANTICANC, V8, P1023, DOI 10.1586/14737140.8.7.1023
   Castellsague X, 2008, GYNECOL ONCOL, V110, pS4, DOI 10.1016/j.ygyno.2008.07.045
   Chen Jake Y, 2007, J Bioinform Comput Biol, V5, P383, DOI 10.1142/S0219720007002606
   El-Rayes BF, 2006, CANCER RES, V66, P10553, DOI 10.1158/0008-5472.CAN-06-2333
   El-Rayes BF, 2004, MOL CANCER THER, V3, P1421
   Fahy BN, 2005, CANCER CHEMOTH PHARM, V56, P46, DOI 10.1007/s00280-004-0944-5
   Fahy BN, 2003, BRIT J CANCER, V89, P391, DOI 10.1038/sj.bjc.6601037
   Glick J H, 1980, Am J Otolaryngol, V1, P306, DOI 10.1016/S0196-0709(80)80034-2
   Harper ME, 2002, FASEB J, V16, P1550, DOI 10.1096/fj.02-0541com
   Hong CB, 2002, CARCINOGENESIS, V23, P1297, DOI 10.1093/carcin/23.8.1297
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5
   Kim ES, 2002, CURR OPIN ONCOL, V14, P334, DOI 10.1097/00001622-200205000-00014
   Kumar B, 2008, ARCH OTOLARYNGOL, V134, P363, DOI 10.1001/archotol.134.4.363
   Lee KC, 2008, INT J RADIAT ONCOL, V71, P187, DOI 10.1016/i.ijrobp.2007.09.023
   Lee TK, 2007, CANCER RES, V67, P8800, DOI 10.1158/0008-5472.CAN-07-0801
   Li YW, 2005, CANCER RES, V65, P6934, DOI 10.1158/0008-5472.CAN-04-4604
   Li YW, 2005, FRONT BIOSCI, V10, P236, DOI 10.2741/1523
   Li YW, 2004, PANCREAS, V28, pE90, DOI 10.1097/00006676-200405000-00020
   LIANG XJ, 2008, MOL CANC RES
   Longuet M, 1996, J CLIN MICROBIOL, V34, P738
   Merrill RM, 2000, INT J EPIDEMIOL, V29, P197, DOI 10.1093/ije/29.2.197
   Pignon J-P, 2005, Cancer Radiother, V9, P31, DOI 10.1016/j.canrad.2004.11.002
   Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4
   Rahman KMW, 2000, ONCOGENE, V19, P5764
   Rahman KMW, 2003, NUTR CANCER, V45, P101, DOI 10.1207/S15327914NC4501_12
   Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957
   Sarkar FH, 2002, CANCER METAST REV, V21, P265, DOI 10.1023/A:1021210910821
   Savino JA, 2006, MOL CANCER THER, V5, P556, DOI 10.1158/1535-7163.MCT-05-0355
   Sun SS, 2004, CELL STRESS CHAPERON, V9, P76
   Tahara Makoto, 2008, Gan To Kagaku Ryoho, V35, P745
   TANNOCK IF, 1984, J OTOLARYNGOL, V13, P99
   Venkatraman M, 2005, MOL CARCINOGEN, V44, P51, DOI 10.1002/mc.20116
   Verhoeven DTH, 1997, CHEM-BIOL INTERACT, V103, P79, DOI 10.1016/S0009-2797(96)03745-3
   Vokes EE, 2000, SEMIN ONCOL, V27, P34
NR 40
TC 22
Z9 24
U1 1
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD JUN 18
PY 2009
VL 278
IS 2
BP 201
EP 209
DI 10.1016/j.canlet.2009.01.009
PG 9
WC Oncology
SC Oncology
GA 446UJ
UT WOS:000266146400010
PM 19231069
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Pschierer, J
   Plenio, H
AF Pschierer, Jan
   Plenio, Herbert
TI RETRACTED: Suzuki-Miyaura and Sonogashira Coupling of 6-Chloropurines
   and -Nucleosides in Water (Retracted article. see vol 12, pg 5358, 2010)
SO ORGANIC LETTERS
LA English
DT Article; Retracted Publication
ID BOND-FORMING REACTIONS; UNPROTECTED HALONUCLEOSIDES; CYTOSTATIC
   ACTIVITY; HALOPURINE BASES; ARYL CHLORIDES; PURINES; CATALYSTS;
   HETEROCYCLES; ARYLATION; HALIDES
AB A general protocol is reported for the efficient Suzuki-Miyaura and the copper-free Sonogashira coupling of unprotected 6-chloropurines and unprotected beta-D-ribofuranosyl-6-chloropurine in water or in water/n-butanol utilizing Na2PdCl4 and a disulfonated and highly water-soluble fluorenylphosphine (cataCXium F sulk).
C1 [Pschierer, Jan; Plenio, Herbert] Tech Univ Darmstadt, Anorgan Chem Zintl Inst, D-64287 Darmstadt, Germany.
RP Plenio, H (reprint author), Tech Univ Darmstadt, Anorgan Chem Zintl Inst, Petersenstr 18, D-64287 Darmstadt, Germany.
EM plenio@tu-darmstadt.de
FU DFG; Fonds der Chemischen Industrie
FX This work was supported by the DFG and the Fonds der Chemischen
   Industrie.
CR Alonso N, 2008, SYNTHESIS-STUTTGART, P1845, DOI 10.1055/s-2008-1067091
   an der Heiden M, 2004, CHEM-EUR J, V10, P1789, DOI 10.1002/chem.200305562
   Braendvang M, 2005, BIOORGAN MED CHEM, V13, P6360, DOI 10.1016/j.bmc.2005.06.054
   Capek P, 2006, SYNTHESIS-STUTTGART, P3515, DOI 10.1055/s-2006-950240
   Capek P, 2006, ORG BIOMOL CHEM, V4, P2278, DOI 10.1039/b604010a
   Cerna I, 2008, J ORG CHEM, V73, P9048, DOI 10.1021/jo8018126
   Firth AG, 2006, TETRAHEDRON LETT, V47, P3529, DOI 10.1016/j.tetlet.2006.03.100
   Fleckenstein CA, 2008, CHEM-EUR J, V14, P4267, DOI 10.1002/chem.200701877
   Fleckenstein CA, 2008, J ORG CHEM, V73, P3236, DOI 10.1021/jo8001886
   Fleckenstein CA, 2008, GREEN CHEM, V10, P563, DOI 10.1039/b800154e
   Fleckenstein CA, 2008, ORG PROCESS RES DEV, V12, P475, DOI 10.1021/op7001479
   Fleckenstein CA, 2007, GREEN CHEM, V9, P1287, DOI 10.1039/b711965h
   Fleckenstein CA, 2007, CHEM-EUR J, V13, P2701, DOI 10.1002/chem.200601142
   Garcia MD, 2006, SYNTHESIS-STUTTGART, P3967, DOI 10.1055/s-2006-950316
   Hartwig JF, 2006, SYNLETT, P1283, DOI 10.1055/s-2006-939728
   Hocek M, 2005, J MED CHEM, V48, P5869, DOI 10.1021/jm050335x
   Hocek M, 2004, CHEM-EUR J, V10, P2058, DOI 10.1002/chem.200305621
   Hocek M, 2003, EUR J ORG CHEM, P245
   Kang FA, 2008, J AM CHEM SOC, V130, P11300, DOI 10.1021/ja804804p
   Kollhofer A, 2003, ANGEW CHEM INT EDIT, V42, P1056, DOI 10.1002/anie.200390273
   Lakshman MK, 2005, J ORG CHEM, V70, P10329, DOI 10.1021/jo0513764
   Legraverend M, 2006, BIOORGAN MED CHEM, V14, P3987, DOI 10.1016/j.bmc.2005.12.060
   Liu JQ, 2005, ORG LETT, V7, P1149, DOI 10.1021/ol050063s
   Liu JQ, 2004, ORG LETT, V6, P2917, DOI 10.1021/ol48987n
   Plenio H, 2001, CHEM-EUR J, V7, P4438, DOI 10.1002/1521-3765(20011015)7:20<4438::AID-CHEM4438>3.0.CO;2-K
   TANJI K, 1988, CHEM PHARM BULL, V36, P1935
   Volpini R, 2002, J MED CHEM, V45, P3271, DOI 10.1021/jm0109762
   Western EC, 2005, J ORG CHEM, V70, P6378, DOI 10.1021/jo0508321
   Western EC, 2003, J ORG CHEM, V68, P6767, DOI 10.1021/jo034289p
   Zapf A, 2005, CHEM COMMUN, P431, DOI 10.1039/b410937f
NR 30
TC 23
Z9 23
U1 4
U2 31
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1523-7060
EI 1523-7052
J9 ORG LETT
JI Org. Lett.
PD JUN 18
PY 2009
VL 11
IS 12
BP 2551
EP 2554
DI 10.1021/ol9007475
PG 4
WC Chemistry, Organic
SC Chemistry
GA 457LT
UT WOS:000266930900019
PM 19514790
DA 2018-12-27
ER

PT J
AU Pushparaj, PN
   Tay, HK
   H'ng, SC
   Pitman, N
   Xu, D
   McKenzie, A
   Liew, FY
   Melendez, AJ
AF Pushparaj, Peter N.
   Tay, Hwee Kee
   H'ng, Shiau Chen
   Pitman, Nick
   Xu, Damo
   McKenzie, Andrew
   Liew, Foo Y.
   Melendez, Alirio J.
TI RETRACTED: The cytokine interleukin-33 mediates anaphylactic shock
   (Retracted article. See vol. 109, pg. 15527, 2012)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE anaphylaxis; cytokine biology; IL-33
ID HUMAN MAST-CELLS; FC-EPSILON-RI; NF-KAPPA-B; GAMMA-RI; IL-13 PRODUCTION;
   GENE-EXPRESSION; RECEPTOR; IL-33; IGE; ST2
AB Anaphylactic shock is characterized by elevated immunoglobulin-E (IgE) antibodies that signal via the high affinity Fc epsilon receptor (Fc epsilon RI) to release inflammatory mediators. Here we report that the novel cytokine interleukin-33 (IL-33) potently induces anaphylactic shock in mice and is associated with the symptom in humans. IL-33 is a new member of the IL-1 family and the ligand for the orphan receptor ST2. In humans, the levels of IL-33 are substantially elevated in the blood of atopic patients during anaphylactic shock, and in inflamed skin tissue of atopic dermatitis patients. In murine experimental atopic models, IL-33 induced antigen-independent passive cutaneous and systemic anaphylaxis, in a T cell-independent, mast cell-dependent manner. In vitro, IL-33 directly induced degranulation, strong eicosanoid and cytokine production in IgE-sensitized mast cells. The molecular mechanisms triggering these responses include the activation of phospholipase D1 and sphingosine kinase1 to mediate calcium mobilization, Nuclear factor-kappa B activation, cytokine and eicosanoid secretion, and degranulation. This report therefore reveals a hitherto unrecognized pathophysiological role of IL-33 and suggests that IL-33 may be a potential therapeutic target for anaphylaxis, a disease of considerable unmet medical need.
C1 [Pushparaj, Peter N.; Tay, Hwee Kee; Pitman, Nick; Xu, Damo; Liew, Foo Y.; Melendez, Alirio J.] Univ Glasgow, Glasgow Biomed Res Ctr, Div Immunol Infect & Inflammat, Glasgow G12 8QQ, Lanark, Scotland.
   [H'ng, Shiau Chen; Melendez, Alirio J.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore.
   [McKenzie, Andrew] MRC, Mol Biol Lab, Cambridge CB2 2QH, England.
RP Liew, FY (reprint author), Univ Glasgow, Glasgow Biomed Res Ctr, Div Immunol Infect & Inflammat, Glasgow G12 8QQ, Lanark, Scotland.
EM f.y.liew@clinmed.gla.ac.uk; a.melendez-romero@clinmed.gla.ac.uk
RI Xu, Damo/A-8212-2011
FU National University Hospital, Singapore; Wellcome Trust; Medical
   Research Council, U. K; Medical Research Council [G0700794, G9818261,
   MC_U105178805, G0801198]
FX We thank M. Rauff (National University Hospital, Singapore) for help in
   procuring human samples. We thank A.-K. Fraser-Andrews and H. Arthur for
   proofreading the manuscript. This work was supported by grants from The
   Wellcome Trust and The Medical Research Council, U. K.
CR Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051
   ANDO A, 1993, J CLIN INVEST, V92, P1639, DOI 10.1172/JCI116749
   Blank U, 2004, TRENDS IMMUNOL, V25, P266, DOI 10.1016/j.it.2004.03.005
   Brint EK, 2004, NAT IMMUNOL, V5, P373, DOI 10.1038/ni1050
   Coward WR, 2002, J IMMUNOL, V169, P5287, DOI 10.4049/jimmunol.169.9.5287
   Dolmetsch RE, 1998, NATURE, V392, P933
   Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025
   Ho LH, 2007, J LEUKOCYTE BIOL, V82, P1481, DOI 10.1189/jlb.0407200
   Iikura M, 2007, LAB INVEST, V87, P971, DOI 10.1038/labinvest.3700663
   Jayapal M, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-210
   Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931
   Malbec O, 2007, J IMMUNOL, V178, P6465, DOI 10.4049/jimmunol.178.10.6465
   Marquardt DL, 2000, J ALLERGY CLIN IMMUN, V105, P500, DOI 10.1067/mai.2000.104942
   MARTIN TR, 1989, J CLIN INVEST, V83, P1375, DOI 10.1172/JCI114025
   Masuda A, 2002, J IMMUNOL, V169, P3801, DOI 10.4049/jimmunol.169.7.3801
   Melendez A, 1998, CURR BIOL, V8, P210, DOI 10.1016/S0960-9822(98)70085-5
   Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200
   Melendez AJ, 1999, IMMUNOLOGY, V98, P1
   Melendez AJ, 2001, BLOOD, V98, P3421, DOI 10.1182/blood.V98.12.3421
   Melendez AJ, 2007, NAT MED, V13, P1375, DOI 10.1038/nm1654
   Miller AM, 2008, J EXP MED, V205, P339, DOI 10.1084/jem.20071868
   MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G
   Moritz DR, 1998, J IMMUNOL, V161, P4866
   Moulin D, 2007, CYTOKINE, V40, P216, DOI 10.1016/j.cyto.2007.09.013
   O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X
   Oshikawa K, 2001, AM J RESP CRIT CARE, V164, P277, DOI 10.1164/ajrccm.164.2.2008120
   Sanada S, 2007, J CLIN INVEST, V117, P1538, DOI 10.1172/JCI30634
   Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015
   Shimpo M, 2004, CIRCULATION, V109, P2186, DOI 10.1161/01.CIR.0000127958.21003.5A
   Stassen M, 2001, J IMMUNOL, V166, P4391, DOI 10.4049/jimmunol.166.7.4391
   Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069
   Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573
   Verri WA, 2008, P NATL ACAD SCI USA, V105, P2723, DOI 10.1073/pnas.0712116105
   Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0
   Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787
NR 35
TC 202
Z9 215
U1 3
U2 27
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 16
PY 2009
VL 106
IS 24
BP 9773
EP 9778
DI 10.1073/pnas.0901206106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 458TD
UT WOS:000267045500042
PM 19506243
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Paleari, L
   Negri, E
   Catassi, A
   Cilli, M
   Servent, D
   D'Angelillo, R
   Cesario, A
   Russo, P
   Fini, M
AF Paleari, Laura
   Negri, Eva
   Catassi, Alessia
   Cilli, Michele
   Servent, Denis
   D'Angelillo, Rolando
   Cesario, Alfredo
   Russo, Patrizia
   Fini, Massimo
TI RETRACTED: Inhibition of Nonneuronal alpha 7-Nicotinic Receptor for Lung
   Cancer Treatment (Retracted article. See vol. 182, pg. 1456, 2010)
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article; Retracted Publication
DE alpha 7-nicotinic receptor; non-small cell lung cancer; apoptosis;
   caspase-9; antitumor activity
ID NICOTINIC ACETYLCHOLINE-RECEPTOR; AFFECT GROWTH-REGULATION; CHOLINERGIC
   SYSTEM; EPITHELIAL-CELLS; CURAREMIMETIC TOXINS; SUSCEPTIBILITY LOCUS;
   TARGETED THERAPIES; MICHAELIS-MENTEN; KINETIC SYSTEMS; MULTIPLE ROLES
AB Rationale: Studies strongly suggest that the nicotinic acetylcholine receptors for nicotine (nAChRs) play a significant role in lung cancer predisposition and natural history. The nAChR alpha 7 subunit has been found to be pivotal in the control of nicotine-induced lung cancer development and in growth signal transduction induced by nicotine binding to nAChRs.
   Objectives: To investigate the anticancer effects of alpha 7-nAChR antagonists.
   Methods: (1) To check the correlation between alpha 7-nAChR presence and alpha-cobratoxin (alpha-CbT) sensitivity, binding experiments were performed in various normal human cells, lung cancer cell lines, and primary tumoral cells; (2) to demonstrate that alpha-CbT might be an efficient adjuvant therapy for non-small cell lung cancer (NSCLC) we expanded our previous observations to a panel of NSCLCs of various subtypes orthotopically grafted on nonobese diabetic/severe combined immunodeficient mice; (3) to gain insight into the mechanism of alpha-CbT-induced tumor reduction, the cells obtained after enzymatic digestion of tumors were analyzed for procaspase-9, Bax, Bad, and BCl-X-L protein; and (4) Snail/E-cadherin expression was evaluated to acquire information about the chemoresistance of cancer cells to alpha-CbT.
   Measurements and Main Results: We report herein the results of an experimental strategy aimed at investigating the antitumor effects of a powerful alpha 7-nAChR antagonist, alpha-CbT, in an in vivo setting set to mimic the clinical setting of lung cancer; in addition, a possible explanation for alpha-CbT selectivity toward cancer cells is presented.
   Conclusions: We report the prolonged survival of alpha-CbT-treated animals in our mouse model of NSCLC, which is most likely the result of multiple mechanisms, including various antiproliferative and antiangiogenic effects.
C1 [Paleari, Laura; Catassi, Alessia; Russo, Patrizia] Natl Inst Canc Res, Lung Canc Unit, Genoa, Italy.
   [Negri, Eva] Ist Ric Farmacol Mario Negri, Milan, Italy.
   [Catassi, Alessia] Univ Insubria, Thorac Surg Unit, Varese, Italy.
   [Cilli, Michele] Natl Inst Canc Res, Anim Facil Unit, Genoa, Italy.
   [Servent, Denis] Serv Ingn Mol Prot, Inst Biol & Technol Saclay, Commissariat Energie Atom, Gif Sur Yvette, France.
   [D'Angelillo, Rolando] Campus Biomed Univ, Radiotherapy & Oncol Unit, Rome, Italy.
   [Cesario, Alfredo] Catholic Univ, Thorac Surg Unit, Rome, Italy.
   [Cesario, Alfredo; Fini, Massimo] Ist Ricovero & Cura Carattere Sci San Raffaele, Rome, Italy.
RP Russo, P (reprint author), Diagnost Natl Canc Res Inst, Dept Adv Technol, Lung Canc Unit, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.
EM patrizia.russo@istge.it
RI CESARIO, Alfredo/O-4215-2015
OI CESARIO, Alfredo/0000-0003-4687-0709
CR Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109
   Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851
   ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1
   Arredondo J, 2006, J CANCER RES CLIN, V132, P653, DOI 10.1007/s00432-006-0113-9
   Besse B, 2007, ANN ONCOL, V18, P135, DOI 10.1093/annonc/mdm308
   Catassi A, 2008, MUTAT RES-REV MUTAT, V659, P221, DOI 10.1016/j.mrrev.2008.04.002
   Catassi A, 2008, EUR J CANCER, V44, P2296, DOI 10.1016/j.ejca.2008.06.045
   CATTANEO MG, 1993, CANCER RES, V53, P5566
   CHOU TC, 1977, J BIOL CHEM, V252, P6438
   CHOU TC, 2001, EUR J BIOCHEM, V115, P207
   Dasgupta P, 2006, J CLIN INVEST, V116, P3083, DOI 10.1172/JCI28164C1
   Egleton RD, 2008, TRENDS PHARMACOL SCI, V29, P151, DOI 10.1016/j.tips,2007.12.006
   Fruchart-Gaillard C, 2002, P NATL ACAD SCI USA, V99, P3216, DOI 10.1073/pnas.042699899
   Grozio Alessia, 2007, Anti-Cancer Agents in Medicinal Chemistry, V7, P461
   Grozio A, 2008, INT J CANCER, V122, P1911, DOI 10.1002/ijc.23298
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885
   Kummer W, 2008, HISTOCHEM CELL BIOL, V130, P219, DOI 10.1007/s00418-008-0455-2
   Lam DCL, 2007, CANCER RES, V67, P4638, DOI 10.1158/0008-5472.CAN-06-4628
   MANECKJEE R, 1990, P NATL ACAD SCI USA, V87, P3294, DOI 10.1073/pnas.87.9.3294
   MANECKJEE R, 1994, CELL GROWTH DIFFER, V5, P1033
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Paleari L, 2009, CELL PROLIFERAT, V42, P122, DOI 10.1111/j.1365-2184.2008.00596.x
   Paleari L, 2008, CELL PROLIFERAT, V41, P936, DOI 10.1111/j.1365-2184.2008.00566.x
   Paleari L, 2008, SEMIN CANCER BIOL, V18, P211, DOI 10.1016/j.semcancer.2007.12.009
   Paleari L, 2009, INT J CANCER, V125, P199, DOI 10.1002/ijc.24299
   Pascal LE, 2004, TOXICOL LETT, V147, P143, DOI 10.1016/j.toxlet.2003.11.004
   Plummer HK, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-29
   RENAN MJ, 1993, MOL CARCINOGEN, V7, P139
   Russo P, 2006, CURR MED CHEM, V13, P3493, DOI 10.2174/092986706779026192
   Russo P, 2005, AM J RESP CELL MOL, V33, P589, DOI 10.1165/rcmb.2005-0213OC
   Saccone SF, 2007, HUM MOL GENET, V16, P36, DOI 10.1093/hmg/ddl438
   Sathornsumetee S, 2008, J CLIN ONCOL, V26, P271, DOI 10.1200/JCO.2007.13.3652
   Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c
   Schuller HM, 2008, ANTI-CANCER DRUG, V19, P655, DOI 10.1097/CAD.0b013e3283025b58
   SCHULLER HM, 1989, BIOCHEM PHARMACOL, V38, P3439, DOI 10.1016/0006-2952(89)90112-3
   Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279
   Song PF, 2003, CANCER RES, V63, P214
   Stevens KE, 1996, NEUROPSYCHOPHARMACOL, V15, P152, DOI 10.1016/0893-133X(95)00178-G
   Sun S, 2007, J CLIN INVEST, V117, P2740, DOI 10.1172/JCI31809
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846
   Trombino S, 2004, CANCER RES, V64, P1559
   Trombino S, 2004, CANCER RES, V64, P135, DOI 10.1158/0008-5472.CAN-03-1672
   Wessler I, 1998, PHARMACOL THERAPEUT, V77, P59, DOI 10.1016/S0163-7258(97)00085-5
   West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147
   Zheng Y, 2007, AM J RESP CELL MOL, V37, P681, DOI 10.1165/rcmb.2007-00510C
   Zia S, 1997, RES COMMUN MOL PATH, V97, P243
NR 48
TC 38
Z9 40
U1 3
U2 10
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD JUN 15
PY 2009
VL 179
IS 12
BP 1141
EP 1150
DI 10.1164/rccm.200806-908OC
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 455TB
UT WOS:000266787500013
PM 19151195
DA 2018-12-27
ER

PT J
AU Valastyan, S
   Reinhardt, F
   Benaich, N
   Calogrias, D
   Szasz, AM
   Wang, ZGC
   Brock, JE
   Richardson, AL
   Weinberg, RA
AF Valastyan, Scott
   Reinhardt, Ferenc
   Benaich, Nathan
   Calogrias, Diana
   Szasz, Attila M.
   Wang, Zhigang C.
   Brock, Jane E.
   Richardson, Andrea L.
   Weinberg, Robert A.
TI RETRACTED: A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast
   Cancer Metastasis (Retracted article. See vol. 161, pg. 417, 2015)
SO CELL
LA English
DT Article; Retracted Publication
ID EXPRESSION SIGNATURE; TUMOR INVASION; MAMMARY-TUMOR; CELLS; RNAS;
   SURVIVAL; TARGETS; GENES
AB MicroRNAs are well suited to regulate tumor metastasis because of their capacity to coordinately repress numerous target genes, thereby potentially enabling their intervention at multiple steps of the invasion-metastasis cascade. We identify a microRNA exemplifying these attributes, miR-31, whose expression correlates inversely with metastasis in human breast cancer patients. Overexpression of miR-31 in otherwise-aggressive breast tumor cells suppresses metastasis. We deploy a stable microRNA sponge strategy to inhibit miR-31 in vivo; this allows otherwise-nonaggressive breast cancer cells to metastasize. These phenotypes do not involve confounding influences on primary tumor development and are specifically attributable to miR-31-mediated inhibition of several steps of metastasis, including local invasion, extravasation or initial survival at a distant site, and metastatic colonization. Such pleiotropy is achieved via coordinate repression of a cohort of metastasis-promoting genes, including RhoA. Indeed, RhoA re-expression partially reverses miR-31-imposed metastasis suppression. These findings indicate that miR-31 uses multiple mechanisms to oppose metastasis.
C1 [Valastyan, Scott; Reinhardt, Ferenc; Benaich, Nathan; Weinberg, Robert A.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
   [Valastyan, Scott; Weinberg, Robert A.] MIT, Dept Biol, Cambridge, MA 02139 USA.
   [Benaich, Nathan] Williams Coll, Dept Biol, Williamstown, MA 01267 USA.
   [Calogrias, Diana; Szasz, Attila M.; Brock, Jane E.; Richardson, Andrea L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   [Wang, Zhigang C.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
   [Wang, Zhigang C.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
   [Weinberg, Robert A.] MIT Ludwig Ctr Mol Oncol, Cambridge, MA 02139 USA.
RP Weinberg, RA (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
EM weinberg@wi.mit.edu
OI Szasz, Attila Marcell/0000-0003-2739-4196
FU NIH [RO1 CA078461, PO1 CA080111]; MIT Ludwig Center for Molecular
   Oncology; U. S. Department of Defense; Breast Cancer Research
   Foundation; Harvard Breast Cancer SPORE; DoD BCRP Idea Award
FX We thank Matthew Saelzler, Julie Valastyan, Lynne Waldman, and Sandra
   McAllister for critical reading of this manuscript and insightful
   discussions; W. Guo, T. Shibue, A. Spiegel, and other members of the
   Weinberg lab for dialogue and materials; D. Bartel, G. Bokoch, S.
   Crouch, P. Klein, S. Kuwada, P. Sharp, H. Surks, and S. Weiss for
   reagents; and M. Brown, the MIT Koch Institute Histology Facility, and
   the MIT Histology Lab for tissue sectioning. This research was supported
   by the NIH (R. A. W.: RO1 CA078461, PO1 CA080111), MIT Ludwig Center for
   Molecular Oncology (R. A. W.), U. S. Department of Defense (S. V.),
   Breast Cancer Research Foundation (Z. C. W., A. L. R., R. A. W.),
   Harvard Breast Cancer SPORE (A. L. R., R. A. W.), and a DoD BCRP Idea
   Award (R. A. W.). S. V. and R. A. W. are inventors on a patent
   application in part based on findings detailed in this manuscript. S. V.
   is a U. S. Department of Defense Breast Cancer Research Program
   Predoctoral Fellow. R. A. W. is an American Cancer Society Research
   Professor and a Daniel K. Ludwig Foundation Cancer Research Professor.
CR Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756
   Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681
   Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Krutzfeldt J, 2006, NAT GENET, V38, pS14, DOI 10.1038/ng1799
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   MATTIE MD, 2006, MOL CANCER, V19, P5
   McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JC1200522320
   MORRIS VL, 1993, CLIN EXP METASTAS, V11, P103, DOI 10.1007/BF00880071
   Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725
   Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375
   Sathyan P, 2007, J NEUROSCI, V27, P8546, DOI 10.1523/JNEUROSCI.1269-07.2007
   Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083
   Silahtaroglu AN, 2007, NAT PROTOC, V2, P2520, DOI 10.1038/nprot.2007.313
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037
   Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
   Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24
NR 40
TC 632
Z9 671
U1 5
U2 81
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD JUN 12
PY 2009
VL 137
IS 6
BP 1032
EP 1046
DI 10.1016/j.cell.2009.03.047
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 457GL
UT WOS:000266916400016
PM 19524507
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Yoshimura, K
   Kitagawa, H
   Fujiki, R
   Tanabe, M
   Takezawa, S
   Takada, I
   Yamaoka, I
   Yonezawa, M
   Kondo, T
   Furutani, Y
   Yagi, H
   Yoshinaga, S
   Masuda, T
   Fukuda, T
   Yamamoto, Y
   Ebihara, K
   Li, DY
   Matsuoka, R
   Takeuchi, JK
   Matsumoto, T
   Kato, S
AF Yoshimura, Kimihiro
   Kitagawa, Hirochika
   Fujiki, Ryoji
   Tanabe, Masahiko
   Takezawa, Shinichiro
   Takada, Ichiro
   Yamaoka, Ikuko
   Yonezawa, Masayoshi
   Kondo, Takeshi
   Furutani, Yoshiyuki
   Yagi, Hisato
   Yoshinaga, Shin
   Masuda, Takeyoshi
   Fukuda, Toru
   Yamamoto, Yoko
   Ebihara, Kanae
   Li, Dean Y.
   Matsuoka, Rumiko
   Takeuchi, Jun K.
   Matsumoto, Takahiro
   Kato, Shigeaki
TI RETRACTED: Distinct function of 2 chromatin remodeling complexes that
   share a common subunit, Williams syndrome transcription factor (WSTF)
   (Retracted article. See vol. 111, pg. 2398, 2014)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE WICH; WINAC; heart development; SWI/SNF; ISWI
ID STRAND BREAK REPAIR; HISTONE METHYLATION; NUCLEAR RECEPTOR; REPLICATION
   FOCI; GENE; HEART; LIGAND; PCNA; ISWI; IDENTIFICATION
AB A number of nuclear complexes modify chromatin structure and operate as functional units. However, the in vivo role of each component within the complexes is not known. ATP-dependent chromatin remodeling complexes form several types of protein complexes, which reorganize chromatin structure cooperatively with histone modifiers. Williams syndrome transcription factor (WSTF) was biochemically identified as a major subunit, along with 2 distinct complexes: WINAC, a SWI/SNF-type complex, and WICH, an ISWI-type complex. Here, WSTF-/- mice were generated to investigate its function in chromatin remodeling in vivo. Loss of WSTF expression resulted in neonatal lethality, and all WSTF-/- neonates and approximate to 10% of WSTF+/- neonates suffered cardiovascular abnormalities resembling those found in autosomal-dominant Williams syndrome patients. Developmental analysis of WSTF-/- embryos revealed that Gja5 gene regulation is aberrant from E9.5, conceivably because of inappropriate chromatin reorganization around the promoter regions where essential cardiac transcription factors are recruited. In vitro analysis in WSTF-/- mouse embryonic fibroblast (MEF) cells also showed impaired transactivation functions of cardiac transcription activators on the Gja5 promoter, but the effects were reversed by overexpression of WINAC components. Likewise in WSTF-/- MEF cells, recruitment of Snf2h, an ISWI ATPase, to PCNA and cell survival after DNA damage were both defective, but were ameliorated by overexpression of WICH components. Thus, the present study provides evidence that WSTF is shared and is a functionally indispensable subunit of the WICH complex for DNA repair and the WINAC complex for transcriptional control.
C1 [Yoshimura, Kimihiro; Kitagawa, Hirochika; Fujiki, Ryoji; Tanabe, Masahiko; Takezawa, Shinichiro; Takada, Ichiro; Yamaoka, Ikuko; Yonezawa, Masayoshi; Kondo, Takeshi; Fukuda, Toru; Yamamoto, Yoko; Matsumoto, Takahiro; Kato, Shigeaki] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   [Yagi, Hisato; Matsuoka, Rumiko] Tokyo Womens Med Univ, Grad Sch Med, Div Genom Med, Inst Adv Biomed Engn & Sci,Shinjuku Ku, Tokyo 1628666, Japan.
   [Furutani, Yoshiyuki; Yoshinaga, Shin; Masuda, Takeyoshi; Matsuoka, Rumiko] Tokyo Womens Med Univ, Heart Inst Japan, Shinjuku Ku, Tokyo 1628666, Japan.
   [Yoshinaga, Shin; Masuda, Takeyoshi] Shibaura Inst Technol, Grad Sch Engn, Div Elect Engn & Comp Sci, Minato Ku, Tokyo 1080023, Japan.
   [Li, Dean Y.] Univ Utah, Dept Med, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA.
   [Takeuchi, Jun K.] Frontier Res Ctr, Tokyo Inst Technol, Global Edge Inst, Midori Ku, Kanagawa 2268503, Japan.
   [Fujiki, Ryoji; Takezawa, Shinichiro; Yamaoka, Ikuko; Ebihara, Kanae; Matsumoto, Takahiro; Kato, Shigeaki] Exploratory Res Adv Technol, Kawaguchi, Saitama 3320012, Japan.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
FU Human Frontier Science Program; Mitsubishi Foundation; Encouraging
   Development of Strategic Research Centers; Special Coordination Funds
   for Promoting Science and Technology; Ministry of Education, Culture,
   Sports, Science and Technology, Japan
FX We thank A. Moorman ( Academic Medical Center, Amsterdam) for kindly
   providing the Gja5( Cx40) plasmid, T. Ogura (Tohoku University, Sendai,
   Japan) for Gata4 and Irx3 plasmids, W. Wang ( National Institute on
   Aging, Baltimore) and L. Chen ( National Institute on Aging, Baltimore)
   for the BAF 180 antibody, and B. Bruneau ( Gladstone Institute of
   Cardiovascular Disease, San Francisco) for Irx3, Cx40, Bmp10, Nppa,
   Tbx20, and Bmp4 probes. We also thank Z. Wang for helpful discussions,
   Barbara Levene and Alexander Kouzmenko for editing the manuscript,
   Haruko Higuchi, Hiroko Yamazaki, and Mai Yamaki for manuscript
   preparation, and Yuko Shirode and Keiko Komatsu for technical support.
   This work was supported by a grant from Human Frontier Science Program,
   Mitsubishi Foundation ( to J. K. T), and the Encouraging Development of
   Strategic Research Centers, Special Coordination Funds for Promoting
   Science and Technology, Ministry of Education, Culture, Sports, Science
   and Technology, Japan ( H. K. and S. K.).
CR Balajee AS, 2001, NUCLEIC ACIDS RES, V29, P1341, DOI 10.1093/nar/29.6.1341
   Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Bozhenok L, 2002, EMBO J, V21, P2231, DOI 10.1093/emboj/21.9.2231
   Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7
   Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1
   Christoffels VM, 2000, DEV BIOL, V224, P263, DOI 10.1006/dbio.2000.9801
   de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882
   Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611
   Fujiki R, 2005, EMBO J, V24, P3881, DOI 10.1038/sj.emboj.7600853
   GARABEDIAN M, 1985, NEW ENGL J MED, V312, P948, DOI 10.1056/NEJM198504113121503
   Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7
   Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143
   Korenberg JR, 2000, J COGNITIVE NEUROSCI, V12, P89, DOI 10.1162/089892900562002
   Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145
   Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a
   Lickert H, 2004, NATURE, V432, P107, DOI 10.1038/nature03071
   Linhares VLF, 2004, CARDIOVASC RES, V64, P402, DOI 10.1016/j.cardiores.2004.09.021
   Lu XJ, 1998, GENOMICS, V54, P241, DOI 10.1006/geno.1998.5578
   LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654
   MacCallum DE, 2002, MOL BIOL CELL, V13, P25, DOI 10.1091/mbc.01-09-0441
   Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003
   Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Oishi H, 2006, J BIOL CHEM, V281, P20, DOI 10.1074/jbc.M510157200
   Osley MA, 2006, TRENDS GENET, V22, P671, DOI 10.1016/j.tig.2006.09.007
   Poot RA, 2004, NAT CELL BIOL, V6, P1236, DOI 10.1038/ncb1196
   Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273
   Small EM, 2004, TRENDS CARDIOVAS MED, V14, P13, DOI 10.1016/j.tcm.2003.09.005
   Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827
   Takezawa S, 2007, EMBO J, V26, P764, DOI 10.1038/sj.emboj.7601548
   van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033
   Wang Z, 2004, GENE DEV, V18, P3106, DOI 10.1101/gad.1238104
   Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391
NR 34
TC 40
Z9 41
U1 144
U2 155
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 9
PY 2009
VL 106
IS 23
BP 9280
EP 9285
DI 10.1073/pnas.0901184106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 456CN
UT WOS:000266817500033
PM 19470456
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Wang, XY
   Ren, XF
   Kahen, K
   Hahn, MA
   Rajeswaran, M
   Maccagnano-Zacher, S
   Silcox, J
   Cragg, GE
   Efros, AL
   Krauss, TD
AF Wang, Xiaoyong
   Ren, Xiaofan
   Kahen, Keith
   Hahn, Megan A.
   Rajeswaran, Manju
   Maccagnano-Zacher, Sara
   Silcox, John
   Cragg, George E.
   Efros, Alexander L.
   Krauss, Todd D.
TI RETRACTED: Non-blinking semiconductor nanocrystals (Retracted article.
   See vol. 527, 2015)
SO NATURE
LA English
DT Article; Retracted Publication
ID SINGLE-QUANTUM-DOT; CADMIUM SELENIDE NANOCRYSTALS; FLUORESCENCE
   INTERMITTENCY; SPECTROSCOPY; SUPPRESSION; EMISSION; DYNAMICS
AB The photoluminescence from a variety of individual molecules(1) and nanometre-sized crystallites(2) is defined by large intensity fluctuations, known as 'blinking', whereby their photoluminescence turns 'on' and 'off' intermittently, even under continuous photoexcitation(2). For semiconductor nanocrystals, it was originally proposed(3) that these 'off' periods corresponded to a nanocrystal with an extra charge. A charged nanocrystal could have its photoluminescence temporarily quenched owing to the high efficiency of non-radiative ( for example, Auger) recombination processes between the extra charge and a subsequently excited electron-hole pair; photoluminescence would resume only after the nanocrystal becomes neutralized again. Despite over a decade of research, completely non-blinking nanocrystals(4,5) have not been synthesized and an understanding of the blinking phenomenon(6) remains elusive. Here we report ternary core/shell CdZnSe/ZnSe semiconductor nanocrystals that individually exhibit continuous, non-blinking photoluminescence. Unexpectedly, these nanocrystals strongly photoluminesce despite being charged, as indicated by a multi-peaked photoluminescence spectral shape and short lifetime. To model the unusual photoluminescence properties of the CdZnSe/ZnSe nanocrystals, we softened the abrupt confinement potential of a typical core/shell nanocrystal, suggesting that the structure is a radially graded alloy of CdZnSe into ZnSe. As photoluminescence blinking severely limits the usefulness of nanocrystals in applications requiring a continuous output of single photons, these non-blinking nanocrystals may enable substantial advances in fields ranging from single-molecule biological labelling(7) to low-threshold lasers(8).
C1 [Wang, Xiaoyong; Hahn, Megan A.; Krauss, Todd D.] Univ Rochester, Dept Chem, Rochester, NY 14627 USA.
   [Krauss, Todd D.] Univ Rochester, Inst Opt, Rochester, NY 14627 USA.
   [Ren, Xiaofan; Kahen, Keith; Rajeswaran, Manju] Eastman Kodak Co, Rochester, NY 14650 USA.
   [Maccagnano-Zacher, Sara; Silcox, John] Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14583 USA.
   [Cragg, George E.; Efros, Alexander L.] USN, Res Lab, Washington, DC 20375 USA.
RP Krauss, TD (reprint author), Univ Rochester, Dept Chem, Rochester, NY 14627 USA.
EM keith.kahen@kodak.com; efros@dave.nrl.navy.mil;
   krauss@chem.rochester.edu
RI Wang, Xiaoyong/F-9542-2012; Wang, Xiaoyong/D-5956-2012
OI Krauss, Todd/0000-0002-4860-874X
FU DOE [DE-FC26-06NT42864]; NSF [CHE 0616378, CHE 0619418, EEC-0117770,
   DMR-9632275]; NYSTAR; University of Rochester Center for Electronic
   Imaging Systems; Cornell Center for Nanoscale Systems; Office of Naval
   Research; Alexander von Humboldt Foundation
FX We acknowledge financial support by the DOE (DE-FC26-06NT42864), NSF
   (CHE 0616378, CHE 0619418, EEC-0117770, DMR-9632275), NYSTAR, University
   of Rochester Center for Electronic Imaging Systems, the Cornell Center
   for Nanoscale Systems, the Office of Naval Research and the Alexander
   von Humboldt Foundation ( A. L. E.).
CR Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Chen Y, 2008, J AM CHEM SOC, V130, P5026, DOI 10.1021/ja711379k
   COLVIN VL, 1994, NATURE, V370, P354, DOI 10.1038/370354a0
   Crooker SA, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.186802
   Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525
   Dekel E, 1998, PHYS REV LETT, V80, P4991, DOI 10.1103/PhysRevLett.80.4991
   Efros AL, 1997, PHYS REV LETT, V78, P1110, DOI 10.1103/PhysRevLett.78.1110
   Efros AL, 1996, PHYS REV B, V54, P4843, DOI 10.1103/PhysRevB.54.4843
   Empedocles SA, 1996, PHYS REV LETT, V77, P3873, DOI 10.1103/PhysRevLett.77.3873
   Fomenko V, 2008, NANO LETT, V8, P287, DOI 10.1021/nl0726609
   Frantsuzov P, 2008, NAT PHYS, V4, P519, DOI 10.1038/nphys1001
   Hartschuh A, 2003, SCIENCE, V301, P1354, DOI 10.1126/science.1087118
   HELLWEGE KH, 1983, SEMICONDUCTORS PHY B, V17
   Hohng S, 2004, J AM CHEM SOC, V126, P1324, DOI 10.1021/ja039686w
   Klimov VI, 2000, SCIENCE, V290, P314, DOI 10.1126/science.290.5490.314
   Krauss TD, 1999, PHYS REV LETT, V83, P4840, DOI 10.1103/PhysRevLett.83.4840
   Kuno M, 2001, J CHEM PHYS, V115, P1028, DOI 10.1063/1.1377883
   Landsberg P. T., 1991, RECOMBINATION SEMICO
   Mahler B, 2008, NAT MATER, V7, P659, DOI 10.1038/nmat2222
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Michler P, 2000, NATURE, V406, P968
   Moerner WE, 1999, SCIENCE, V283, P1670, DOI 10.1126/science.283.5408.1670
   Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0
   Nozik AJ, 2001, ANNU REV PHYS CHEM, V52, P193, DOI 10.1146/annurev.physchem.52.1.193
   Paskov PP, 2000, PHYSICA E, V6, P440, DOI 10.1016/S1386-9477(99)00212-X
   Shimizu KT, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.205316
   Talapin DV, 2004, J PHYS CHEM B, V108, P18826, DOI 10.1021/jp046481g
   Yu ZH, 2005, NANO LETT, V5, P565, DOI 10.1021/nl048245n
   Zhong XH, 2003, J AM CHEM SOC, V125, P8589, DOI 10.1021/ja035096m
NR 30
TC 493
Z9 499
U1 8
U2 318
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUN 4
PY 2009
VL 459
IS 7247
BP 686
EP 689
DI 10.1038/nature08072
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 453KF
UT WOS:000266608600040
PM 19430463
DA 2018-12-27
ER

PT J
AU Wenz, T
   Luca, C
   Torraco, A
   Moraes, CT
AF Wenz, Tina
   Luca, Corneliu
   Torraco, Alessandra
   Moraes, Carlos T.
TI RETRACTED: mTERF2 Regulates Oxidative Phosphorylation by Modulating
   mtDNA Transcription (Retracted article. See vol. 22, pg. 751, 2015)
SO CELL METABOLISM
LA English
DT Article; Retracted Publication
ID MITOCHONDRIAL RNA-POLYMERASE; TERMINATION FACTOR MTERF; INITIATION
   SITES; DNA; PROTEIN; CELLS; SPECIFICITY; PHENOTYPE; MONOMER; MELAS
AB Regulation of mitochondrial protein expression is crucial for the function of the oxidative phosphorylation (OXPHOS) system. Although the basal machinery for mitochondrial transcription is known, the regulatory mechanisms are not completely understood. Here, we characterized mTERF2, a mitochondria-localized homolog of the mitochondrial transcription termination factor mTERF1. We show that inactivation of mTERF2 in the mouse results in a myopathy and memory deficits associated with decreased levels of mitochondrial transcripts and imbalanced tRNA pool. These, aberrations were associated with decreased steady-state levels of OXPHOS proteins causing a decrease in respiratory function. mTERF2 binds to the mtDNA promoter region, suggesting that it affects transcription initiation. In vitro interaction studies suggest that mtDNA mediates interactions between mTERF2 and mTERF3. Our results indicate that mTERF1, mTERF2, and mTERF3 regulate transcription by acting in the same site in the mtDNA promoter region and thereby mediate fine-tuning of mitochondrial transcription and hence OXPHOS function.
C1 [Wenz, Tina; Torraco, Alessandra; Moraes, Carlos T.] Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Luca, Corneliu; Moraes, Carlos T.] Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
RP Moraes, CT (reprint author), Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
RI Torraco, Alessandra/J-9127-2016
OI Torraco, Alessandra/0000-0002-2489-8535
FU Public Health Service grants [NS041777, CA85700, EY10804]; Muscular
   Dystrophy Association; American Heart Association; United Mitochondrial
   Disease Foundation
FX Our work is supported by Public Health Service grants NS041777, CA85700,
   and EY10804 and by the Muscular Dystrophy Association. Dr. Luca was
   supported by a fellowship from the American Heart Association, and Dr.
   Wenz was supported by a fellowship from the United Mitochondrial Disease
   Foundation. We are grateful to Dr. Francisca Diaz for fruitful
   discussions and Dr. Nils Larson for the mtDNA ChIP protocol.
CR Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Asin-Cayuela J, 2004, J BIOL CHEM, V279, P15670, DOI 10.1074/jbc.M312537200
   Bonawitz ND, 2006, MOL CELL, V24, P813, DOI 10.1016/j.molcel.2006.11.024
   Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   DAGA A, 1993, J BIOL CHEM, V268, P8123
   Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307
   Fernandez-Silva P, 1996, Methods Enzymol, V264, P129, DOI 10.1016/S0076-6879(96)64014-2
   FernandezSilva P, 1997, EMBO J, V16, P1066, DOI 10.1093/emboj/16.5.1066
   HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0
   KING MP, 1993, J BIOL CHEM, V268, P10228
   KOGA Y, 1993, NUCLEIC ACIDS RES, V21, P657, DOI 10.1093/nar/21.3.657
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   Laffel L, 1999, DIABETES-METAB RES, V15, P412, DOI 10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-8
   Linder T, 2005, CURR GENET, V48, P265, DOI 10.1007/s00294-005-0022-5
   Polosa PL, 2007, NUCLEIC ACIDS RES, V35, P2413, DOI 10.1093/nar/gkm159
   Martin M, 2005, CELL, V123, P1227, DOI 10.1016/j.cell.2005.09.040
   MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195
   Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5
   Park CB, 2007, CELL, V130, P273, DOI 10.1016/j.cell.2007.05.046
   Pellegrini M, 2009, BBA-BIOENERGETICS, V1787, P294, DOI 10.1016/j.bbabio.2009.01.018
   Roberti M, 2003, NUCLEIC ACIDS RES, V31, P1597, DOI 10.1093/nar/gkg272
   Rossignol R, 2000, BIOCHEM J, V347, P45, DOI 10.1042/0264-6021:3470045
   Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Vives-Bauza C, 2007, METHOD CELL BIOL, V80, P155, DOI 10.1016/S0091-679X(06)80007-5
   Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116
   Wang ZB, 2007, J BIOL CHEM, V282, P12610, DOI 10.1074/jbc.M700461200
   Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006
NR 29
TC 67
Z9 71
U1 4
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD JUN 3
PY 2009
VL 9
IS 6
BP 499
EP 511
DI 10.1016/j.cmet.2009.04.010
PG 13
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 453ZU
UT WOS:000266652200005
PM 19490905
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Gromann, TW
   Birkelbach, O
   Hetzer, R
AF Gromann, Tom W.
   Birkelbach, Oliver
   Hetzer, Roland
TI RETRACTED: Balloon Dilatational Tracheostomy: Initial Experience with
   the Ciaglia Blue Dolphin Method (Retracted article. See vol. 111, pg.
   1524, 2010)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID PERCUTANEOUS DILATIONAL TRACHEOSTOMY; CARDIAC-SURGERY; COMPLICATIONS;
   METAANALYSIS; TRACHEOTOMY; GUIDELINES; RHINO
AB BACKGROUND: Percutaneous dilational tracheostomy has become an established technique for ensuring safe and uncomplicated access to the respiratory systems of patients undergoing prolonged intubation. We studied a new balloon dilation percutaneous dilational tracheostomy technique which primarily uses radial force to widen the tracheostoma, the Ciaglia Blue Dolphin system.
   METHODS: We report our initial clinical experience with this method in 20 patients from a cardiosurgical intensive care unit. We analyzed the results with regard to the practical feasibility of balloon dilation as well as possible complications.
   RESULTS: Tracheostomy surgery time averaged 3.3 +/- 1.9 min. The new technique caused neither bleeding requiring treatment nor injuries of the posterior tracheal wall. Routine bronchoscopic checks revealed one fracture of a single tracheal cartilage ring (5%). One patient developed subcutaneous emphysema during the balloon dilation, but this regressed spontaneously without treatment. No wound infections or prolonged wound healing of the tracheostoma were observed in any patient. There were no differences in terms of practical feasibility or bleeding complications when skin incisions of different lengths were analyzed.
   CONCLUSIONS: The balloon dilational tracheostomy proved to be a feasible, easy, and successful technique. Its use of mainly radial force may reduce typical complications such as fractures of tracheal cartilage rings or injuries of the posterior tracheal wall. The new balloon-facilitated Ciaglia Blue Dolphin dilational tracheostomy technique uses mainly radial force to widen the tracheostoma. Radial outward dilation minimizes bleeding and injury to tracheal rings, and achieves good cosmetic results after decannulation. This technique proved to be a promising and efficient option for intensive care unit tracheostomies during our pilot trial. (Anesth Analg 2009:108:1862-1866)
C1 [Gromann, Tom W.; Birkelbach, Oliver; Hetzer, Roland] Deutsch Herzzentrum Berlin, Dept Cardiothorac & Vasc Surg, D-13353 Berlin, Germany.
RP Gromann, TW (reprint author), Deutsch Herzzentrum Berlin, Dept Cardiothorac & Vasc Surg, Augustenburger Pl 1, D-13353 Berlin, Germany.
EM gromann@dhzb.de
CR Ambesh SP, 2005, ANAESTHESIA, V60, P708, DOI 10.1111/j.1365-2044.2005.04236.x
   Bacchetta MD, 2005, ANN THORAC SURG, V79, P1879, DOI 10.1016/j.athoracsur.2004.10.042
   Beiderlinden M, 2002, INTENS CARE MED, V28, P59, DOI 10.1007/s00134-001-1151-z
   Byhahn C, 2000, ANAESTHESIST, V49, P202, DOI 10.1007/s001010050815
   CIAGLIA P, 1985, CHEST, V87, P715, DOI 10.1378/chest.87.6.715
   Cosgrove JF, 2006, ANAESTH INTENS CARE, V34, P782
   De Leyn P, 2007, EUR J CARDIO-THORAC, V32, P412, DOI 10.1016/j.ejcts.2007.05.018
   Fantoni A, 1997, INTENS CARE MED, V23, P386, DOI 10.1007/s001340050345
   Frova G, 2002, INTENS CARE MED, V28, P299, DOI 10.1007/s00134-002-1218-5
   Griffiths J, 2005, BRIT MED J, V330, P1243, DOI 10.1136/bmj.38467.485671.E0
   GRIGGS WM, 1990, SURG GYNECOL OBSTET, V170, P543
   Higgins KM, 2007, LARYNGOSCOPE, V117, P447, DOI 10.1097/01.mlg.0000251585.31778.c9
   Kearney PA, 2000, ANN SURG, V231, P701, DOI 10.1097/00000658-200005000-00010
   Kost Karen M, 2005, Laryngoscope, V115, P1, DOI 10.1097/01.MLG.0000163744.89688.E8
   Pandit Rahul A, 2006, Crit Care Resusc, V8, P146
   Rahmanian PB, 2007, ANN THORAC SURG, V84, P1984, DOI 10.1016/j.athoracsur.2007.07.024
   RODRIGUEZ JL, 1990, SURGERY, V108, P655
   Rumbak MJ, 2004, CRIT CARE MED, V32, P1689, DOI 10.1097/01.CCM.0000135835.05161.B6
   Silvester W, 2006, CRIT CARE MED, V34, P2145, DOI 10.1097/01.CCM.0000229882.09677.FD
   Wagner F, 1998, THORAC CARDIOV SURG, V46, P352, DOI 10.1055/s-2007-1010252
   Zgoda MA, 2005, CHEST, V128, P3688, DOI 10.1378/chest.128.5.3688
NR 21
TC 17
Z9 17
U1 3
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD JUN
PY 2009
VL 108
IS 6
BP 1862
EP 1866
DI 10.1213/ane.0b013e3181a1a494
PG 5
WC Anesthesiology
SC Anesthesiology
GA 448TS
UT WOS:000266285500023
PM 19448213
DA 2018-12-27
ER

PT J
AU Wansink, B
   van Ittersum, K
   Werle, C
AF Wansink, Brian
   van Ittersum, Koert
   Werle, Carolina
TI RETRACTED: How negative experiences shape long-term food preferences.
   Fifty years from the World War II combat front (Retracted article. See
   vol. 131, pg. 171, 2018)
SO APPETITE
LA English
DT Article; Retracted Publication
DE Mood; Food preference; Stress; Memory; Unfamiliar food; Neophobia; World
   War II; Animosity; Long-term preferences; Chinese food; Japanese food;
   Combat veterans; Pacific veterans; European veterans; MREs; Ration;
   Combat
ID LESSONS
AB How does a person's first experience with a foreign or unfamiliar food shape their long-term preference and behavior toward that food? To investigate this, 493 American veterans of World War 11 were surveyed about their preference for Japanese and Chinese food. Pacific veterans who experienced high levels of combat had a stronger dislike for these Asian foods than those Pacific veterans experiencing lower levels of combat. Consistent with expectations, combat experience for European veterans had no impact on their preference for Asian food. The situation in which one is initially exposed to an unfamiliar food may long continue to shape preferences. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Wansink, Brian] Cornell Univ, Ithaca, NY 14853 USA.
   [van Ittersum, Koert] Georgia Inst Technol, Atlanta, GA 30308 USA.
   [Werle, Carolina] Grenoble Ecole Management CERAG, Grenoble, France.
RP Wansink, B (reprint author), Cornell Univ, 110 Warren Hall, Ithaca, NY 14853 USA.
EM bcw28@Cornell.edu
RI Wansink, Brian/G-4284-2010
CR Bradburn N. M., 2004, ASKING QUESTIONS DEF
   Brunstrom JM, 2005, PHYSIOL BEHAV, V85, P57, DOI 10.1016/j.physmeh.2005.04.004
   Chin A, 2005, IEEE CIRCUITS DEVICE, V21, P27, DOI 10.1109/MCD.2005.1388766
   Klein JG, 1998, J MARKETING, V62, P89, DOI 10.2307/1251805
   KLEIN JG, 1996, ADV CONSUM RES, V22, P134
   Klein JG, 1998, J INT CONSUMER MARKE, V4, P134
   NIJSSEN EJ, 1999, AMA GLOB MARK SIG JO
   Nordgren LF, 2006, PSYCHOL SCI, V17, P635, DOI 10.1111/j.1467-9280.2006.01756.x
   Scott CL, 2007, J PSYCHOL, V141, P127, DOI 10.3200/JRLP.141.2.127-134
   Stallberg-White C, 1999, APPETITE, V33, P209, DOI 10.1006/appe.1999.0263
   Stouffer Samuel A., 1949, AM SOLDIER COMBAT IT
   Wansink B, 2002, J PUBLIC POLICY MARK, V21, P90, DOI 10.1509/jppm.21.1.90.17614
   Wansink B, 2006, MINDLESS EATING WHY
   Wansink B, 2008, LEADERSHIP QUART, V19, P547, DOI 10.1016/j.leaqua.2008.07.010
NR 14
TC 7
Z9 7
U1 1
U2 8
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0195-6663
EI 1095-8304
J9 APPETITE
JI Appetite
PD JUN
PY 2009
VL 52
IS 3
BP 750
EP 752
DI 10.1016/j.appet.2009.01.001
PG 3
WC Behavioral Sciences; Nutrition & Dietetics
SC Behavioral Sciences; Nutrition & Dietetics
GA 465EU
UT WOS:000267565500028
PM 19522080
DA 2018-12-27
ER

PT J
AU Wang, QL
   Dai, YM
   Zhao, BZ
   Song, SS
   Chen, SZ
   Yan, LG
AF Wang, Qiuliang
   Dai, Yinming
   Zhao, Baozhi
   Song, Souseng
   Chen, Shunzhong
   Yan, Luguang
TI RETRACTED: Development of a cryogenic test bed for high amperage
   critical current measurement on high temperature superconductor wire
   (Retracted article. See vol. 87, pg. 110, 2017)
SO CRYOGENICS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 4th Asian Conference on Applied Superconductivity and Cryogenics
CY DEC 02-04, 2007
CL Xian, PEOPLES R CHINA
SP China Natl Ctr Res & Dev Superconduct, NW Inst Nonferrous Metal Res, W Superconduct Technol Co, Inst Elect Engn Chinese Acad Sci, Korea Inst Appl Superconduct & Cryogen, Cryogen Assoc Japan, Inter Univ Accelerator Cr
DE Conduction-cooled superconducting magnet; HTS test devices; FEM
   electro-plastic model
ID MAGNET
AB Many areas of research have benefited from the application of conduction-cooled Superconducting magnet technology. The middle and small-scale magnets immersed in the liquid helium will be replaced by the easy-operating conduction-cooled superconducting magnet due to convenient operation, lower operating cost and easy for user. For the goal of superconducting magnet applications in the advanced testing for high temperature superconducting (HTS) wire and sample coils, a wide bore conduction-cooled superconducting magnet with available warm bore of phi 186 mm and center field of 5-6 T for background magnetic field applications was designed, fabricated and tested. The system allows measurements to be performed in a repeatable and reliable fashion. In order to support the high stress in magnet, the detailed finite element (FE) analysis with electro-plastic model is proposed. The sample cryostat is designed with cryofree. It includes two GM cryocoolers. The detailed design, fabrication and thermal analysis are presented in the paper. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Wang, Qiuliang; Dai, Yinming; Zhao, Baozhi; Song, Souseng; Chen, Shunzhong; Yan, Luguang] Chinese Acad Sci, Inst Elect Engn, Key Lab Appl Superconduct, Beijing 100080, Peoples R China.
RP Wang, QL (reprint author), Chinese Acad Sci, Inst Elect Engn, Key Lab Appl Superconduct, POB 2703, Beijing 100080, Peoples R China.
EM qiuliang@mail.iee.ac.cn
CR Wang Q, 2007, MATER SCI FORUM, V546-549, P1935, DOI 10.4028/www.scientific.net/MSF.546-549.1935
   Wang QL, 2004, IEEE T APPL SUPERCON, V14, P372, DOI 10.1109/TASC.2004.829673
   Watanabe K, 2003, PHYSICA C, V386, P485, DOI 10.1016/S0921-4534(02)02232-3
NR 3
TC 5
Z9 5
U1 7
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0011-2275
EI 1879-2235
J9 CRYOGENICS
JI Cryogenics
PD JUN
PY 2009
VL 49
IS 6
SI SI
BP 305
EP 312
DI 10.1016/j.cryogenics.2008.10.010
PG 8
WC Thermodynamics; Physics, Applied
SC Thermodynamics; Physics
GA 462NR
UT WOS:000267361400018
DA 2018-12-27
ER

PT J
AU Ivan, L
   Torkos, A
   Paczona, R
   Szentpali, K
   Jori, J
AF Ivan, Laszlo
   Torkos, Attila
   Paczona, Robert
   Szentpali, Karoly
   Jori, Jozsef
TI RETRACTED: Minimally Invasive Peroral Endoscopic Removal of a
   Regurgitated Giant Polysegmented Fibrovascular Polyp of the Esophagus
   (Retracted Article. See vol 25, pg 168, 2010)
SO DYSPHAGIA
LA English
DT Editorial Material; Retracted Publication
DE Minimally invasive surgery; Endoscopy; Esophageal neoplasm;
   Fibrovascular polyp; Deglutition; Deglutition disorders
AB Giant fibrovascular polyps (FVP) are relatively rare benign neoplasms of the upper part of the esophagus. Without a previous history, their diagnosis might be difficult because the endoscopic findings are sometimes misinterpreted. The present report describes a case in which the patient regurgitated a giant polypoid mass into his mouth and captured it between his teeth and buccal surface until emergency endoscopic removal. Although the adequate therapy for these lesions is open surgical resection, most often via cervical esophagotomy, in our case the polyp was removed successfully by peroral endoscopy with minimally invasive surgery. After 5 years of follow-up the patient is doing well, without recurrence.
C1 [Ivan, Laszlo; Torkos, Attila; Paczona, Robert; Jori, Jozsef] Univ Szeged, Dept Otorhinolaryngol & Head & Neck Surg, H-6725 Szeged, Hungary.
   [Szentpali, Karoly] Univ Szeged, Dept Surg, H-6725 Szeged, Hungary.
RP Ivan, L (reprint author), Univ Szeged, Dept Otorhinolaryngol & Head & Neck Surg, H-6725 Szeged, Hungary.
EM Ivan@ORL.SZOTE.U-Szeged.hu
CR Alobid I, 2007, LARYNGOSCOPE, V117, P944, DOI 10.1097/MLG.0b013e318033310f
   AVEZZANO EA, 1990, AM J GASTROENTEROL, V85, P299
   Burdick JS, 1999, ENDOSCOPY, V31, P401
   Eliashar R, 1998, OTOLARYNG HEAD NECK, V118, P734, DOI 10.1016/S0194-5998(98)70255-4
   Levine MS, 1996, AM J ROENTGENOL, V166, P781, DOI 10.2214/ajr.166.4.8610549
   McLean JN, 2007, AM J OTOLARYNG, V28, P115, DOI 10.1016/j.amjoto.2006.03.005
   OWENS JJ, 1994, ANN OTO RHINOL LARYN, V103, P838
   Ozcelik Cemal, 2004, Interact Cardiovasc Thorac Surg, V3, P260, DOI 10.1016/j.icvts.2003.11.013
   Palanivelu C, 2007, JCPSP-J COLL PHYSICI, V17, P51
   PATEL J, 1984, GASTROENTEROLOGY, V87, P953
   Ridge C, 2006, EUR RADIOL, V16, P764, DOI 10.1007/s00330-005-0112-2
   Sargent RL, 2006, ARCH PATHOL LAB MED, V130, P725
   Solerio D, 2005, DIS ESOPHAGUS, V18, P410, DOI 10.1111/j.1442-2050.2005.00525.x
   Somani BK, 2005, EUR J CARDIO-THORAC, V28, P643, DOI 10.1016/j.ejcts.2005.06.019
   Zevallos JP, 2005, LARYNGOSCOPE, V115, P876, DOI 10.1097/01.MLG.0000158351.00602.86
   2006, J KOREAN MED, V21, P749
NR 16
TC 4
Z9 4
U1 4
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0179-051X
EI 1432-0460
J9 DYSPHAGIA
JI Dysphagia
PD JUN
PY 2009
VL 24
IS 2
BP 230
EP 233
DI 10.1007/s00455-008-9165-0
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 451CM
UT WOS:000266448300013
PM 18688676
DA 2018-12-27
ER

PT J
AU Cassar, L
   Nicholls, C
   Pinto, AR
   Li, H
   Liu, JP
AF Cassar, Lucy
   Nicholls, Craig
   Pinto, Alex R.
   Li, He
   Liu, Jun-Ping
TI RETRACTED: Bone morphogenetic protein-7 induces telomerase inhibition,
   telomere shortening, breast cancer cell senescence, and death via Smad3
   (Retracted article. See vol 23, pg 2790, 2009)
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE TGFb receptor; signal transduction; cross-talk; immortalization;
   luciferase gene reporter
ID GROWTH-FACTOR-BETA; TGF-BETA; IN-VIVO; C-MYC; HTERT GENE; MESENCHYMAL
   TRANSITION; TUMOR-GROWTH; MOUSE CELLS; BMP7; TRANSCRIPTION
AB Human telomerase reverse transcriptase (hTERT) is central to maintain telomeres for continuous cell proliferation, but it remains unknown how extracellular cues regulate telomerase maintenance of telomeres. Here we report that the cytokine bone morphogenetic protein-7 (BMP7) induces Smad3 phosphorylation, nuclear translocation, and hTERT gene repression. BMP7 induces Smad3-dependent telomerase inhibition in a time- and concentration-dependent manner in breast cancer cells. Chronic exposure of breast cancer cells to BMP7 results in short telomeres, cell senescence, and apoptosis. Mutation of BMPRII receptor, but not TGF beta RII, ACTRIIA, or ACTRIIB, blocked BMP7-induced repression of the hTERT gene promoter activity, leading to increased telomerase activity, lengthened telomeres, and continued cell proliferation. Expression of hTERT inhibits BMP7-induced breast cancer cell senescence and apoptosis. Thus, our data suggest that BMP7 induces breast cancer cell aging and death by a mechanism involving inhibition of telomerase activity and telomere maintenance via BMPRII receptor- and Smad3-mediated repression of the hTERT gene.-Cassar, L., Nicholls, C., Pinto, A. R., Li, H., Liu, J.-P. Bone morphogenetic protein-7 induces telomerase inhibition, telomere shortening, breast cancer cell senescence, and death via Smad3. FASEB J. 23, 1880-1892 (2009)
C1 [Cassar, Lucy; Nicholls, Craig; Pinto, Alex R.; Li, He; Liu, Jun-Ping] Monash Univ, Cent Eastern Clin Sch, Dept Immunol, Mol Signaling Lab, Melbourne, Vic 3004, Australia.
RP Li, H (reprint author), Monash Univ, Cent Eastern Clin Sch, Dept Immunol, Commercial Rd, Prahran, Vic 3181, Australia.
EM he.li@med.monash.edu.au; jun-ping.liu@med.monash.edu.au
FU National Health and Medical Research Council of Australia; Australia
   Research Council; Cancer Council of Victoria, Australia.
FX We thank Claude Labrie (Universite Laval, Quebec, QC, Canada) for the
   plasmid construct encoding BMPRII truncation and Peter Lansdorp (British
   Columbia Cancer Agency, Vancouver, BC, Canada) for the TFL-Telo 2.2
   software program for telomere analysis. This work was supported by
   grants from the National Health and Medical Research Council of
   Australia, Australia Research Council, and Cancer Council of Victoria,
   Australia.
CR Alarmo EL, 2006, GENE CHROMOSOME CANC, V45, P411, DOI 10.1002/gcc.20307
   Alarmo EL, 2007, BREAST CANCER RES TR, V103, P239, DOI 10.1007/s10549-006-9362-1
   Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592
   Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809
   Bestilny LJ, 1996, CANCER RES, V56, P3796
   Biswas S, 2007, J CLIN INVEST, V117, P1305, DOI 10.1172/JCI30740
   Blackburn EH, 2006, NAT MED, V12, P1133, DOI 10.1038/nm1006-1133
   Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656
   Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490
   Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168
   de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080
   Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065
   Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091
   Galliher AJ, 2007, CANCER RES, V67, P3752, DOI 10.1158/0008-5472.CAN-06-3851
   Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743
   Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5
   Holt SE, 1996, MOL CELL BIOL, V16, P2932
   Hu B, 2006, ONCOGENE, V25, P1030, DOI 10.1038/sj.onc.1209140
   Jacobs JJL, 2005, CELL CYCLE, V4, P1364, DOI 10.4161/cc.4.10.2104
   James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706
   Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159
   Jena N, 1997, EXP CELL RES, V230, P28, DOI 10.1006/excr.1996.3411
   Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084
   Kyo S, 2002, ONCOGENE, V21, P688, DOI 10.1038/sj.onc.1205163
   Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669
   Li H, 2005, J NEUROCHEM, V95, P891, DOI 10.1111/j.1471-4159.2005.03439.x
   Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729
   Li H, 2007, ANN NY ACAD SCI, V1114, P56, DOI 10.1196/annals.1396.016
   Li H, 2006, J BIOL CHEM, V281, P25588, DOI 10.1074/jbc.M602381200
   Liu XJ, 1998, CANCER RES, V58, P4752
   Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098
   Ma T, 2007, BONE, V41, P386, DOI 10.1016/j.bone.2007.05.015
   Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   Miyazaki H, 2004, ONCOGENE, V23, P9326, DOI 10.1038/sj.onc.1208127
   Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091
   Notting I, 2007, INVEST OPHTH VIS SCI, V48, P4882, DOI 10.1167/iovs.07-0505
   Parsch D, 2004, J MOL MED-JMM, V82, P49, DOI 10.1007/s00109-003-0506-z
   Patel SR, 2005, TRENDS MOL MED, V11, P512, DOI 10.1016/j.molmed.2005.09.007
   Piek E, 1999, J CELL SCI, V112, P4557
   Rees JRE, 2006, CANCER RES, V66, P9583, DOI 10.1158/0008-5472.CAN-06-1842
   Ro TB, 2004, ONCOGENE, V23, P3024, DOI 10.1038/sj.onc.1207386
   Rothhammer Tania, 2007, Cancer Biomarkers, V3, P111
   Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743
   Shay JW, 2006, NAT REV DRUG DISCOV, V5, P577, DOI 10.1038/nrd2081
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   Simic P, 2006, J BIOL CHEM, V281, P25509, DOI 10.1074/jbc.M513276200
   Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433
   Sugimoto H, 2007, DIABETES, V56, P1825, DOI 10.2337/db06-1226
   Takakura M, 2005, MOL CELL BIOL, V25, P8037, DOI 10.1128/MCB.25.18.8037-8043.2005
   Varga AC, 2005, ONCOGENE, V24, P5713, DOI 10.1038/sj.onc.1208919
   Wang SN, 2004, J BIOL CHEM, V279, P23200, DOI 10.1074/jbc.M311998200
   Wu KJ, 1999, NAT GENET, V21, P220
   Xu DK, 2008, J BIOL CHEM, V283, P23567, DOI 10.1074/jbc.M800790200
   Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529
   Yang SX, 2005, CANCER RES, V65, P5769, DOI 10.1158/0008-5472.CAN-05-0289
   Yang ZY, 2001, J BIOL CHEM, V276, P4251, DOI 10.1074/jbc.M006371200
   Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613
NR 57
TC 21
Z9 21
U1 4
U2 13
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2009
VL 23
IS 6
BP 1880
EP 1892
DI 10.1096/fj.08-119529
PG 13
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 453ZW
UT WOS:000266652400028
PM 19193721
DA 2018-12-27
ER

PT J
AU Tomita, M
   Toyota, M
   Ishikawa, C
   Nakazato, T
   Okudaira, T
   Matsuda, T
   Uchihara, JN
   Taira, N
   Ohshiro, K
   Senba, M
   Tanaka, Y
   Ohshima, K
   Saya, H
   Tokino, T
   Mori, N
AF Tomita, Mariko
   Toyota, Minoru
   Ishikawa, Chie
   Nakazato, Tetsuro
   Okudaira, Taeko
   Matsuda, Takehiro
   Uchihara, Jun-Nosuke
   Taira, Naoya
   Ohshiro, Kazuiku
   Senba, Masachika
   Tanaka, Yuetsu
   Ohshima, Koichi
   Saya, Hideyuki
   Tokino, Takashi
   Mori, Naoki
TI RETRACTED: Overexpression of Aurora A by loss of CHFR gene expression
   increases the growth and survival of HTLV-1-infected T cells through
   enhanced NF-kappa B activity (Retracted article. See vol. 129, pg. 2763,
   2011)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE Aurora A; Aurora kinase inhibitor; HTLV-1; ATL; CHFR
ID VIRUS TYPE-I; HTLV-I; LEUKEMIA-LYMPHOMA; CENTROSOME AMPLIFICATION;
   KINASE; TAX; TRANSFORMATION; ACTIVATION; PROTEIN; LINES
AB Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent for adult T-cell leukemia (ATL). Aurora A, a mitotic checkpoint protein, is overexpressed in human cancer cells. The cell cycle-dependent turnover of Aurora A is regulated by E3 ubiquitin ligases such as checkpoint with fork head-associated and ring finger (CHFR). Here, we found overexpression of Aurora A protein in HTLV-1-infected T-cell lines and primary ATL cells. The expression of CHFR mRNA was reduced in these cells by abnormal methylation of CHFR promoter region. Knockdown of Aurora A using small interfering RNA suppressed the growth of HTLV-1-infected T-cell line. Transfection of Aurora A expression plasmid enhanced Tax-induced nuclear factor-kappa B (NF-kappa B) reporter activity. Transfection of CHFR expression plasmid into an HTLV-1-infected T-cell line reduced cell growth, Aurora A protein level and constitutive NF-kappa B reporter activity. Aurora kinase inhibitor suppressed the growth and survival of HTLV-1-infected T-cell lines and primary ATL cells. It also reduced constitutive NF-kappa B activity in an HTLV-1-infected T-cell line by reducing I kappa B kinase beta phosphorylation and the expression or antiapoptotic protein survivin. Our results suggested that loss of CHFR expression resulted to accumulation of Aurora A, which increased NF-kappa B activity. These findings highlight the critical role of Aurora A in HTLV-1-infected T cells, making this molecule a potentially suitable target for future therapies for ATL. (C) 2009 Wiley-Liss, Inc.
C1 [Tomita, Mariko; Ishikawa, Chie; Nakazato, Tetsuro; Okudaira, Taeko; Matsuda, Takehiro; Mori, Naoki] Univ Ryukyus, Div Mol Virol & Oncol, Grad Sch Med, Okinawa 9030215, Japan.
   [Toyota, Minoru; Tokino, Takashi] Sapporo Med Univ, Inst Canc Res, Dept Mol Biol, Sapporo, Hokkaido 0608543, Japan.
   [Ishikawa, Chie; Matsuda, Takehiro] Univ Ryukyus, Fac Med, Div Child Hlth & Welf, Okinawa 9030215, Japan.
   [Nakazato, Tetsuro; Okudaira, Taeko] Univ Ryukyus, Fac Med, Div Endocrinol & Metab, Okinawa 9030215, Japan.
   [Uchihara, Jun-Nosuke] Naha City Hosp, Dept Internal Med, Okinawa 9028511, Japan.
   [Taira, Naoya] Heart Life Hosp, Dept Internal Med, Okinawa 9012492, Japan.
   [Ohshiro, Kazuiku] Okinawa Prefectural Nanbu Med Ctr, Dept Internal Med, Nakagusu Ku, Okinawa 9011193, Japan.
   [Ohshiro, Kazuiku] Childrens Med Ctr, Okinawa 9011193, Japan.
   [Senba, Masachika] Nagasaki Univ, Inst Trop Med, Dept Pathol, Nagasaki 8528523, Japan.
   [Tanaka, Yuetsu] Univ Ryukyus, Fac Med, Div Immunol, Okinawa 9030215, Japan.
   [Ohshima, Koichi] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka 8300011, Japan.
   [Saya, Hideyuki] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat, Tokyo 1608582, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Div Mol Virol & Oncol, Grad Sch Med, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [19591122]; Foundation for Promotion of Cancer Research in Japan, Uehara
   Memorial Foundation, Public Trust Haraguchi Memorial Cancer Research
   Fund, Takeda Science Foundation, Japan Leukemia Research Fund; Princes
   Takamatsu Cancer Research Fund [07-23905]
FX Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Grant number: 19591122; Grant sponsors: Foundation for Promotion of
   Cancer Research in Japan, Uehara Memorial Foundation, Public Trust
   Haraguchi Memorial Cancer Research Fund, Takeda Science Foundation,
   Japan Leukemia Research Fund; Grant sponsor: Princes Takamatsu Cancer
   Research Fund; Grant number: 07-23905.
CR Afonso PV, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-27
   Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0
   Andrews PD, 2005, ONCOGENE, V24, P5005, DOI 10.1038/sj.onc.1208752
   Briassouli P, 2007, CANCER RES, V67, P1689, DOI 10.1158/0008-5472.CAN-06-2272
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990
   Garber K, 2005, J NATL CANCER I, V97, P874, DOI 10.1093/jnci/97.12.874
   Giet R, 1999, J CELL SCI, V112, P3591
   GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603
   Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1
   Ikezoe T, 2007, MOL CANCER THER, V6, P1851, DOI 10.1158/1535-7163.MCT-07-0067
   Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518
   Kamihira S, 2001, BRIT J HAEMATOL, V114, P63, DOI 10.1046/j.1365-2141.2001.02902.x
   Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Kawakami H, 2005, INT J CANCER, V115, P967, DOI 10.1002/ijc.20954
   Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766
   KOEFFLER HP, 1984, BLOOD, V64, P482
   Marriott SJ, 2005, ONCOGENE, V24, P5986, DOI 10.1038/sj.onc.1208976
   Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526
   Matsumoto K, 1997, J VIROL, V71, P4445
   MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0
   Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151
   Mori N, 2001, BIOCHEM BIOPH RES CO, V282, P1110, DOI 10.1006/bbrc.2001.4708
   Mori N, 1999, BLOOD, V93, P2360
   Mortlock A, 2005, CURR TOP MED CHEM, V5, P805, DOI 10.2174/1568026054637719
   Mountzios G, 2008, CANCER TREAT REV, V34, P175, DOI 10.1016/j.ctrv.2007.09.005
   Nitta T, 2006, CANCER SCI, V97, P836, DOI 10.1111/j.1349-7006.2006.00254.x
   Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108
   Sun CB, 2007, BIOCHEM BIOPH RES CO, V352, P220, DOI 10.1016/j.bbrc.2006.11.004
   Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969
   TAJIMA K, 1990, INT J CANCER, V45, P237, DOI 10.1002/ijc.2910450206
   TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x
   Tomita M, 2004, ONCOGENE, V23, P8272, DOI 10.1038/sj.onc.1208059
   Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100
   Warner SL, 2003, MOL CANCER THER, V2, P589
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046/j.1365-2141.2001.02737.x
   YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
   Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538
   Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496
NR 45
TC 11
Z9 12
U1 2
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JUN 1
PY 2009
VL 124
IS 11
BP 2607
EP 2615
DI 10.1002/ijc.24257
PG 9
WC Oncology
SC Oncology
GA 442NT
UT WOS:000265848600012
PM 19230025
OA Bronze
DA 2018-12-27
ER

PT J
AU Danielides, V
   Bassioukas, K
   Katotomichelakis, M
   Kontogiannis, N
   Vlasis, K
   Filippou, D
   Simopoulos, C
AF Danielides, Vassilios
   Bassioukas, Konstantinos
   Katotomichelakis, Michael
   Kontogiannis, Nikolaos
   Vlasis, Konstantinos
   Filippou, Dimitrios
   Simopoulos, Constantinos
TI RETRACTED: Report of a case of recurrent prurigo nodularis clinically
   related to internal foci of infected tonsils (Retracted Article. See vol
   48, pg 1033, 2009)
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Letter; Retracted Publication
C1 [Danielides, Vassilios] Democritus Univ Thrace, Dept Otorhinolaryngol, Sch Med, GR-68100 Dragana, Alexandroupolis, Greece.
   Univ Ioannina, Sch Med, Dept Dermatol, GR-45110 Ioannina, Greece.
   Univ Athens, Sch Med, GR-10679 Athens, Greece.
   Univ Athens, Sch Nursing, Dept Anat, GR-10679 Athens, Greece.
   Democritus Univ Thrace, Dept Surg 2, Sch Med, GR-68100 Dragana, Alexandroupolis, Greece.
RP Danielides, V (reprint author), Democritus Univ Thrace, Dept Otorhinolaryngol, Sch Med, GR-68100 Dragana, Alexandroupolis, Greece.
EM vasdan@med.duth.gr
RI Filippou, Dimitrios/E-3703-2018
OI Filippou, Dimitrios/0000-0001-5410-3046
CR Accioly JW, 2000, J EUR ACAD DERMATOL, V14, P75, DOI 10.1046/j.1468-3083.2000.00021.x
   GOMES PA, 1994, AN BRAS DERMATOL, V69, P301
   HYDE JN, 1909, PRACTICAL TREATISE D, P67
   JORIZZO JL, 1981, J AM ACAD DERMATOL, V4, P723, DOI 10.1016/S0190-9622(81)80205-8
   PAYNE C M E R, 1985, British Journal of Dermatology, V113, P431
   SHELNITZ LS, 1990, PEDIATR DERMATOL, V7, P136, DOI 10.1111/j.1525-1470.1990.tb00670.x
   WAHLBERG AJ, 2001, TXB CONTACT DERMATIT, P439
   WONG E, 1982, CLIN EXP DERMATOL, V7, P499, DOI 10.1111/j.1365-2230.1982.tb02466.x
NR 8
TC 1
Z9 1
U1 2
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0011-9059
EI 1365-4632
J9 INT J DERMATOL
JI Int. J. Dermatol.
PD JUN
PY 2009
VL 48
IS 6
BP 660
EP 662
DI 10.1111/j.1365-4632.2009.03578.x
PG 4
WC Dermatology
SC Dermatology
GA 451HM
UT WOS:000266461300023
PM 19538383
DA 2018-12-27
ER

PT J
AU Maniar, HM
   Bhatt, R
   Maniyar, DM
AF Maniar, Hiren M.
   Bhatt, Rajesh
   Maniyar, Dharmesh M.
TI RETRACTED: "Expiration hour effect of futures and options markets on
   stock market" - A case study on NSE (National Stock Exchange of India)
   (Retracted article. See vol. 30, pg. 149, 2014)
SO INTERNATIONAL REVIEW OF ECONOMICS & FINANCE
LA English
DT Article; Retracted Publication
DE Futures markets; GARCH; CNX nifty; Expiration etc
ID VOLATILITY
AB This paper studies the effect of expiration day of the Index futures and Options on the trading volume, variance and price of the underlying shares. The impact of derivatives trading on the underlying stock market has been widely documented in the Finance literature. In particular, significant differences in the statistical properties of asset returns (for instance, mean and variance) during expiration and non-expiration days have been advanced as an evidence for the destabilization effect (or lack there of) of derivative instruments. The earlier studies have, however, drawn their conclusions without rigorously modelling the underlying stochastic data generation process. Given that the statistical properties mentioned before are merely traits of the asset returns, this approach can lead to spurious results if analyzed in isolation of the underlying process. We propose to address this crucial shortcoming by examining the expiration day effect from a GARCH (Generalized Auto Regressive Conditional Heteroskedastic) framework. We use both daily and high frequency (5 min and 10 min) data on S&P CNX Nifty Index. Our central finding using intra-day data is that while there is no pressure - downward or upward - on index returns, the volatility is indeed significantly affected by the expiration of contracts. This effect, however, doesn't show up in daily data. (C) 2008 Published by Elsevier Inc.
C1 [Maniyar, Dharmesh M.] Aston Univ, Neural Comp Res Grp, Birmingham B4 7ET, W Midlands, England.
   [Maniar, Hiren M.; Bhatt, Rajesh] Bhavnagar Univ, Dept Business Management, Bhavnagar, Gujarat, India.
RP Maniyar, DM (reprint author), Aston Univ, Neural Comp Res Grp, Birmingham B4 7ET, W Midlands, England.
EM hm_maniar@rediffmail.com; rajjayesh@yahoo.co.in; maniyard@aston.ac.uk
CR ANTONIOU A, 1995, J BANK FINANC, V19, P117, DOI 10.1016/0378-4266(94)00059-C
   BOLLEN NPB, 1998, DO EXPIRATIONS HANG
   BOLLERSLEV T, 1986, J ECONOMETRICS, V31, P307, DOI 10.1016/0304-4076(86)90063-1
   BOLLERSLEV T, 1992, J ECONOMETRICS, P5
   CHEN C, 1994, J FUTURES MARKETS, V14, P275, DOI 10.1002/fut.3990140304
   ENGLE RF, 1993, J FINANC, V48, P1749, DOI 10.2307/2329066
   GUPTA OP, 2002, 6 CAP MARK C 2002 IU
   HANCOCK GD, 1991, J FUTURES MARKETS, V11, P319, DOI 10.1002/fut.3990110306
   Karolyi A. G., 1996, J DERIV, V4, P23
   Pope P. F., 1992, J BUSINESS FINANCE A, V19, P329
   Schlag C., 1996, EUROPEAN FINANCIAL M, V2, P69
   Stoll Hans R., 1991, FINANCIAL ANAL J, P58, DOI DOI 10.2469/FAJ.V47.N1.58
   STOLL HR, 1997, AUSTR J MANAGEMENT, V22, P139, DOI DOI 10.1177/031289629702200202
   STOLL HR, 1986, MONOGRAPH SERIES FIN
NR 14
TC 4
Z9 4
U1 3
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1059-0560
EI 1873-8036
J9 INT REV ECON FINANC
JI Int. Rev. Econ. Financ.
PD JUN
PY 2009
VL 18
IS 3
SI SI
BP 381
EP 391
DI 10.1016/j.iref.2008.09.008
PG 11
WC Business, Finance; Economics
SC Business & Economics
GA 467IE
UT WOS:000267731200003
DA 2018-12-27
ER

PT J
AU Goessler, UR
   Bugert, P
   Bieback, K
   Stern-Straeter, J
   Bran, G
   Sadick, H
   Hormann, K
   Riedel, F
AF Goessler, Ulrich Reinhart
   Bugert, Peter
   Bieback, Karen
   Stern-Straeter, Jens
   Bran, Gregor
   Sadick, Haneen
   Hoermann, Karl
   Riedel, Frank
TI RETRACTED: In vitro analysis of integrin expression in stem cells from
   bone marrow and cord blood during chondrogenic differentiation
   (Retracted article. See vol. 13, pg. 4085, 2009)
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article; Retracted Publication
DE integrin; cartilage; tissue engineering; differentiation; extracellular
   matrix; mesenchymal stem cells; chondrogenic differentiation
ID MESENCHYMAL PROGENITOR CELLS; UMBILICAL-CORD; ARTICULAR CHONDROCYTES;
   REGENERATIVE MEDICINE; PROTEIN-KINASE; ADHESION; MODULATION; EXPANSION;
   COLLAGEN; CULTURE
AB The use of adult mesenchymal stem cells (MSC) in cartilage tissue engineering has been implemented in the field of regenerative medicine and offers new perspectives in the generation of transplants for reconstructive surgery. The extracellular matrix (ECM) plays a key role in modulating function and phenotype of the embedded cells and contains the integrins as adhesion receptors mediating cell-cell and cell-matrix interactions. In our study, characteristic changes in integrin expression during the course of chondrogenic differentiation of MSC from bone marrow and foetal cord blood were compared. MSC were isolated from bone marrow biopsies and cord blood. During cell culture, chondrogenic differentiation was performed. The expression of integrins and their signalling components were analysed with microarray and immunohistochemistry in freshly isolated MSC and after chondrogenic differentiation. The fibronectin-receptor (integrin a5b1) was expressed by undifferentiated MSC, expression rose during chondrogenic differentiation in both types of MSC. The components of the vitronectin/osteopontin-receptors (avb5) were not expressed by freshly isolated MSC, expression rose with ongoing differentiation. Receptors for collagens (a1b1, a2b1, a3b1) were weakly expressed by undifferentiated MSC and were activated during differentiation. As intracellular signalling components integrin linked kinase (ILK) and CD47 showed increasing expression with ongoing differentiation. For all integrins, no significant differences could be found in the two types of MSC. Integrin-mediated signalling seems to play an important role in the generation and maintenance of the chondrocytic phenotype during chondrogenic differentiation. Especially the receptors for fibronectin, vitronectin, osteopontin and collagens might be involved in the generation of the ECM. Intracellularly, their signals might be transduced by ILK and CD47. To fully harness the potential of these cells, future studies should be directed to ascertain their cellular and molecular characteristics for optimal identification, isolation and expansion.
C1 [Goessler, Ulrich Reinhart; Stern-Straeter, Jens; Bran, Gregor; Sadick, Haneen; Hoermann, Karl; Riedel, Frank] Heidelberg Univ, Univ Hosp Mannheim, Dept Otolaryngol Head & Neck Surg, D-68135 Mannheim, Germany.
   [Bugert, Peter; Bieback, Karen] Heidelberg Univ, Fac Clin Med Mannheim, Red Cross Blood Serv Baden Wurttemberg Hessen gGm, Inst Transfus Med & Immunol, D-6900 Heidelberg, Germany.
RP Goessler, UR (reprint author), Heidelberg Univ, Univ Hosp Mannheim, Dept Otolaryngol Head & Neck Surg, D-68135 Mannheim, Germany.
EM ulrich.goessler@hno.ma.uni-heidelberg.de
CR ALBELDA SM, 1990, FASEB J, V4, P2868
   Atala A, 2004, REJUV RES, V7, P15, DOI 10.1089/154916804323105053
   Atala A, 2006, CURR OPIN PEDIATR, V18, P167, DOI 10.1097/01.mop.0000193294.94646.be
   Beyer Nardi N, 2006, HANDB EXP PHARM, V174, P249
   Bieback K, 2004, STEM CELLS, V22, P625, DOI 10.1634/stemcells.22-4-625
   Bouvard D, 1998, BIOCHEM BIOPH RES CO, V252, P46, DOI 10.1006/bbrc.1998.9592
   BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828
   Bugert P, 2003, THROMB HAEMOSTASIS, V90, P738
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Chen SF, 2004, CHINESE MED J-PEKING, V117, P1443
   Eichler H, 2001, Z GEBURTSH NEONATOL, V205, P218, DOI 10.1055/s-2001-19053
   Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365-2141.2000.01986.x
   Gao J, 2003, Chir Organi Mov, V88, P305
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Gladson CL, 1997, AM J PATHOL, V150, P1631
   Goessler UR, 2006, INT J MOL MED, V17, P301
   Goessler UR, 2005, INT J MOL MED, V15, P899
   Goessler UR, 2005, IN VIVO, V19, P501
   Goessler UR, 2004, INT J MOL MED, V13, P505
   Goodwin HS, 2001, BIOL BLOOD MARROW TR, V7, P581, DOI 10.1053/bbmt.2001.v7.pm11760145
   Gutierrez-Rodriguez M, 2000, STEM CELLS, V18, P46, DOI 10.1634/stemcells.18-1-46
   Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0
   Hering Thomas M., 1999, Frontiers in Bioscience, V4, pd743, DOI 10.2741/Hering
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7
   Lee JW, 2002, J ORTHOP RES, V20, P66, DOI 10.1016/S0736-0266(01)00073-0
   LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214
   LOESER RF, 1995, EXP CELL RES, V217, P248, DOI 10.1006/excr.1995.1084
   Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415
   Mareschi K, 2001, HAEMATOLOGICA, V86, P1099
   MAWBY WJ, 1994, BIOCHEM J, V304, P525, DOI 10.1042/bj3040525
   MCLEAN JW, 1990, J BIOL CHEM, V265, P17126
   Minguell JJ, 2001, EXP BIOL MED, V226, P507
   Mueller SM, 2001, J CELL BIOCHEM, V82, P583, DOI 10.1002/jcb.1174
   Nishida S, 1999, J BONE MINER METAB, V17, P171, DOI 10.1007/s007740050081
   Oakes BW, 2004, MED J AUSTRALIA, V180, pS35
   Pei XT, 2002, INT J HEMATOL, V76, P155, DOI 10.1007/BF03165233
   Ringe J, 2002, NATURWISSENSCHAFTEN, V89, P338, DOI 10.1007/s00114-002-0344-9
   RUBINSTEIN P, 1993, BLOOD, V81, P1679
   SALTER DM, 1992, BRIT J RHEUMATOL, V31, P231
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Szolomicka-Kurzawa P, 2001, Ann Acad Med Stetin, V47, P107
   Wang WG, 2003, TISSUE CELL, V35, P69, DOI 10.1016/S0040-8166(02)00106-4
   Wexler SA, 2003, BRIT J HAEMATOL, V121, P368, DOI 10.1046/j.1365-2141.2003.04284.x
NR 46
TC 11
Z9 11
U1 3
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUN
PY 2009
VL 13
IS 6
BP 1175
EP 1184
DI 10.1111/j.1582-4934.2008.00451.x
PG 10
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 466ZG
UT WOS:000267703900012
PM 18681910
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Wang, L
AF Wang, Lijuan
TI RETRACTED: Asymptotic behavior of solutions to a system of differential
   equations with state-dependent delays (Retracted article. See vol. 235,
   pg. 3366, 2011)
SO JOURNAL OF COMPUTATIONAL AND APPLIED MATHEMATICS
LA English
DT Article; Retracted Publication
DE Asymptotic behavior; Differential system; Solution; State-dependent
   delay; omega-limit set
ID MONOTONE SEMIFLOWS; CONVERGENCE
AB In this paper, we investigate the asymptotic behavior of solutions to a system of differential equations with state-dependent delays. It is shown that every bounded solution of such a system tends to a constant vector as t -> infinity. Our results improve and extend some corresponding ones already known. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Wang, Lijuan] Jiaxing Univ, Coll Math & Informat Engn, Jiaxing 314001, Zhejiang, Peoples R China.
   [Wang, Lijuan] Capital Normal Univ, Dept Math, Beijing 100037, Peoples R China.
RP Wang, L (reprint author), Jiaxing Univ, Coll Math & Informat Engn, Jiaxing 314001, Zhejiang, Peoples R China.
EM wanglijuan1976@yahoo.com.cn
FU Scientific Research Fund of Zhejiang Provincial Education Department
   [20070605]
FX This work was supported by Scientific Research Fund of Zhejiang
   Provincial Education Department (20070605).
CR Bartha M, 2001, J MATH ANAL APPL, V254, P410, DOI 10.1006/jmaa.2000.7172
   BELAIR J, 1991, LECT NOTES PURE APPL, V131, P165
   Driver R. D., 1963, CONTRIB DIFFERENTIAL, V1, P317
   Hale J. K., 1993, INTRO FUNCTIONAL DIF, V1, P1
   LONGTIN A, 1989, B MATH BIOL, V51, P605
   LONGTIN A, 1988, MATH BIOSCI, V90, P183, DOI 10.1016/0025-5564(88)90064-8
   MACKEY MC, 1989, J ECON THEORY, V48, P497, DOI 10.1016/0022-0531(89)90039-2
   MALLETPARET J, 1989, SIAM J MATH ANAL, V20, P249, DOI 10.1137/0520019
   SMITH H, 1987, J DIFFER EQUATIONS, V66, P420, DOI 10.1016/0022-0396(87)90027-1
   TERJEKI J, 2006, DIFF EQUAT, V14, P195
   Yi TS, 2005, J DIFFER EQUATIONS, V214, P429, DOI 10.1016/j.jde.2005.02.005
NR 11
TC 5
Z9 5
U1 4
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0377-0427
EI 1879-1778
J9 J COMPUT APPL MATH
JI J. Comput. Appl. Math.
PD JUN 1
PY 2009
VL 228
IS 1
BP 226
EP 230
DI 10.1016/j.cam.2008.09.015
PG 5
WC Mathematics, Applied
SC Mathematics
GA 443EJ
UT WOS:000265892700025
OA Bronze
DA 2018-12-27
ER

PT J
AU Atamanalp, SS
   Yildirgan, MI
   Basoglu, M
   Oren, D
   Aydinli, B
   Kargi, A
   Onbas, O
AF Atamanalp, S. S.
   Yildirgan, M. I.
   Basoglu, M.
   Oren, D.
   Aydinli, B.
   Kargi, A.
   Onbas, O.
TI RETRACTED: Clinical presentation and diagnosis of sigmoid volvulus:
   Outcomes of 40-year and 859-patient experience (Retracted article)
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Correction; Retracted Publication
ID COLONIC VOLVULUS; CHILDREN; SIGN
CR Ares DM, 2003, REV ESP ENFERM DIG, V95, P544
   ARNOLD GJ, 1973, ANN SURG, V177, P527, DOI 10.1097/00000658-197305000-00004
   Atamanalp SS, 2004, PEDIATR SURG INT, V20, P492, DOI 10.1007/s00383-004-1222-7
   AVOTSAVOTINS KV, 1982, SURG CLIN N AM, V62, P249
   BAK MP, 1986, AM J SURG, V151, P71, DOI 10.1016/0002-9610(86)90014-0
   BALLANTYNE GH, 1985, ANN SURG, V202, P83, DOI 10.1097/00000658-198507000-00014
   Bhatnagar BNS, 2004, CLIN ANAT, V17, P236, DOI 10.1002/ca.10204
   Bhatnagar BNS, 2004, INT J COLORECTAL DIS, V19, P134, DOI 10.1007/s00384-003-0534-8
   BROTHERS TE, 1987, ANN SURG, V206, P1, DOI 10.1097/00000658-198707000-00001
   Catalano O, 1996, ABDOM IMAGING, V21, P314, DOI 10.1007/s002619900071
   Feldman D, 2000, RADIOLOGY, V216, P178, DOI 10.1148/radiology.216.1.r00jl17178
   Javors BR, 1999, AM J ROENTGENOL, V173, P571, DOI 10.2214/ajr.173.3.10470881
   Lord SA, 1996, AM SURGEON, V62, P380
   MELLOR MFA, 1994, AM J ROENTGENOL, V162, P1157, DOI 10.2214/ajr.162.5.8166002
   ONCU M, 1991, S AFR J SURG, V29, P48
   PAHLMAN L, 1989, ACTA CHIR SCAND, V155, P53
   Raveenthiran V, 2004, J Postgrad Med, V50, P27
   Slidell M, 2004, J CLIN GASTROENTEROL, V38, P910, DOI 10.1097/00004836-200411000-00017
   STARLING JR, 1979, ANN SURG, V190, P36, DOI 10.1097/00000658-197907000-00008
   Tsang TK, 2005, J GASTROEN HEPATOL, V20, P790, DOI 10.1111/j.1400-1746.2005.03934.x
   Wai C T, 2005, Singapore Med J, V46, P483
NR 21
TC 3
Z9 3
U1 3
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
EI 1440-1746
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD JUN
PY 2009
VL 24
IS 6
BP 1154
EP U8
DI 10.1111/j.1440-1746.2007.04946.x
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 451IX
UT WOS:000266465000043
OA Bronze
DA 2018-12-27
ER

PT J
AU Dudley, J
   Das, S
   Mukherjee, S
   Das, DK
AF Dudley, Jocelyn
   Das, Samarjit
   Mukherjee, Subhendu
   Das, Dipak K.
TI RETRACTED: Resveratrol, a unique phytoalexin present in red wine,
   delivers either survival signal or death signal to the ischemic
   myocardium depending on dose (Retracted article. See vol. 23, pg. 852,
   2012)
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE Resveratrol; Death signal; Survival signal; Heart; Redox; Thioredoxin;
   Glutaredoxin
ID TRANS-RESVERATROL; CIS-RESVERATROL; ADENOSINE-A(3) RECEPTOR; REPERFUSION
   INJURY; MASS-SPECTROMETRY; PICEID; GRAPE; THIOREDOXIN; PEANUTS; RATS
AB Recent studies have demonstrated the cardioprotective abilities of resveratrol, a polyphenolic antioxidant present in red wine. Resveratrol can also kill cancer cells at relatively higher doses by exerting a death signal. We reasoned that resveratrol might possess the ability to protect the cells at lower doses as observed during pharmacological preconditioning of the heart, while at higher doses cause cell death as found for cancer cells. To test this hypothesis, rats were randomly fed for 14 days by gavaging any of the four doses of resveratrol - 2.5, 5.0, 25 or 50 mg/kg - while vehicle-fed animals served as placebo control. After 14 days, isolated working hearts were prepared from both experimental and control animals, and the hearts were subjected to 30-min global ischemia followed by 2 It of reperfusion. The rats fed either 2.5 or 5 mg/kg dose of resveratrol for 14 days provided cardioprotection as evidenced by improved post-ischemic ventricular recovery and reduction of myocardial infarct size and cardiomyocyte apoptosis compared to control. In contrast, the hearts fed either 25 or 50 mg/kg dose of resveratrol depressed cardiac function and increased myocardial infarct size and number of apoptotic cells. The results for Western blots and RT-PCR demonstrated an increase of protein and RNA transcripts of redox proteins including thioredoxin (Trx)-1, Trx-2, glutaredoxin (Grx)-1, Grx-2, redox factor Ref-1 as well as redox-sensitive transcription factor NF kappa B, and survival factors such as phosphorylated-Akt (p-Akt), and Bcl-2 in the animals fed lower doses (2.5 and 5 mg/kg) of resveratrol, while the reverse was true for the animals fed higher doses (25 and 50 mg/kg) of resveratrol. The results thus indicate that at lower doses (2.5 or 5 mg/kg), resveratrol exerts survival signal by up-regulating anti-apoptotic and redox proteins Akt and Bcl-2, while at higher doses (>25 mg/kg), it potentiates a death signal by down-regulating redox proteins and upregulating pro-apoptotic proteins. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Dudley, Jocelyn; Das, Samarjit; Mukherjee, Subhendu; Das, Dipak K.] Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
RP Das, DK (reprint author), Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
EM ddas@neuron.uchc.edu
FU NIH [HL 22559, HL 33889, HL 56803, HL 56322]
FX This study was supported in part by NIH HL 22559, HL 33889, HL 56803 and
   HL 56322. JD was supported by a NIH Minority grant.
CR Aggarwal BB, 2004, ANTICANCER RES, V24, P2783
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Bertelli AAE, 1996, DRUG EXP CLIN RES, V22, P61
   Bhat KPL, 2001, CANCER RES, V61, P6137
   BOYER RF, 1988, J INORG BIOCHEM, V32, P171, DOI 10.1016/0162-0134(88)80025-4
   Bradamante S, 2000, INT J TISSUE REACT, V22, P1
   Brakenhielm E, 2001, FASEB J, V15, P1798, DOI 10.1096/fj.01-0028fje
   Burns J, 2002, J AGR FOOD CHEM, V50, P3337, DOI 10.1021/jf0112973
   Careri M, 2004, J AGR FOOD CHEM, V52, P6868, DOI 10.1021/jf049219d
   Chen CK, 1996, GEN PHARMACOL, V27, P363
   CREASY LL, 1988, J AM SOC HORTIC SCI, V113, P230
   Crowell JA, 2004, TOXICOL SCI, V82, P614, DOI 10.1093/toxsci/kfh263
   Das DK, 2004, ANTIOXID REDOX SIGN, V6, P405, DOI 10.1089/152308604322899477
   Das S, 2005, VASC PHARMACOL, V42, P281, DOI 10.1016/j.vph.2005.02.013
   Das S, 2005, AM J PHYSIOL-HEART C, V288, pH328, DOI 10.1152/ajpheart.00453.2004
   Das S, 2005, J PHARMACOL EXP THER, V314, P762, DOI 10.1124/jpet.105.084285
   Das S, 2006, ARZNEIMITTEL-FORSCH, V56, P700
   Das S, 2006, FREE RADICAL RES, V40, P1066, DOI 10.1080/10715760600833085
   de Lima MTR, 1999, J AGR FOOD CHEM, V47, P2666, DOI 10.1021/jf9900884
   DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.bi.63.070194.004411
   Dong Hao Han, 2004, Bratisl Lek Listy, V105, P225
   DUBASH BD, 1999, PHYTOCHEMICALS PHYTO
   Edwards M, 1998, J NEUROSCI RES, V54, P635, DOI 10.1002/(SICI)1097-4547(19981201)54:5<635::AID-JNR8>3.3.CO;2-8
   El-Mohsen MA, 2006, BRIT J NUTR, V96, P62, DOI 10.1079/BJN20061810
   Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5
   Fukuhara K, 1998, BIOORG MED CHEM LETT, V8, P3187, DOI 10.1016/S0960-894X(98)00585-X
   GOLDBERG DM, 1995, AM J ENOL VITICULT, V46, P159
   Hattori R, 2002, AM J PHYSIOL-HEART C, V282, pH1988, DOI 10.1152/ajpheart.01012.2001
   Hsieh TC, 1999, CANCER RES, V59, P2596
   Hung LM, 2004, FREE RADICAL BIO MED, V36, P774, DOI 10.1016/j.freeradbiomed.2003.12.016
   Ibern-Gomez M, 2000, J AGR FOOD CHEM, V48, P6352, DOI 10.1021/jf000786k
   Imamura G, 2002, AM J PHYSIOL-HEART C, V282, pH1996, DOI 10.1152/ajpheart.01013.2001
   Kiraly-Veghely Z, 1998, ACTA BIOL HUNG, V49, P281
   Kopp P, 1998, EUR J ENDOCRINOL, V138, P619, DOI 10.1530/eje.0.1380619
   Lee KW, 2006, BIOFACTORS, V26, P105, DOI 10.1002/biof.5520260202
   Lyons MM, 2003, J AGR FOOD CHEM, V51, P5867, DOI 10.1021/jf034150f
   MA XL, 1993, CIRC RES, V72, P403, DOI 10.1161/01.RES.72.2.403
   Malik G, 2006, ANTIOXID REDOX SIGN, V8, P2101, DOI 10.1089/ars.2006.8.2101
   Mark L, 2005, J CHROMATOGR SCI, V43, P445, DOI 10.1093/chromsci/43.9.445
   Matsuoka A, 2001, MUTAT RES-GEN TOX EN, V494, P107, DOI 10.1016/S1383-5718(01)00184-X
   MINOTTI G, 1989, CHEM-BIOL INTERACT, V71, P1, DOI 10.1016/0009-2797(89)90087-2
   Miura T, 2000, PHARMACOL TOXICOL, V86, P203, DOI 10.1034/j.1600-0773.2000.d01-36.x
   Rattan SIS, 2004, MECH AGEING DEV, V125, P285, DOI 10.1016/j.amd.2004.01.006
   Ray PS, 1999, FREE RADICAL BIO MED, V27, P160, DOI 10.1016/S0891-5849(99)00063-5
   Reimer KA, 1996, ANN NY ACAD SCI, V793, P13, DOI 10.1111/j.1749-6632.1996.tb33501.x
   RICEEVANS C, 1993, PROG LIPID RES, V32, P71, DOI 10.1016/0163-7827(93)90006-I
   Rimando AM, 2004, J AGR FOOD CHEM, V52, P4713, DOI 10.1021/jf040095e
   Romero-Perez AI, 2001, J AGR FOOD CHEM, V49, P210, DOI 10.1021/jf000745o
   Romero-Perez AI, 1999, J AGR FOOD CHEM, V47, P1533, DOI 10.1021/jf981024g
   Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596
   Sanders TH, 2000, J AGR FOOD CHEM, V48, P1243, DOI 10.1021/jf990737b
   Sato M, 2000, FREE RADICAL RES, V32, P135, DOI 10.1080/10715760000300141
   Shioji K, 2002, CIRCULATION, V106, P1403, DOI 10.1161/01.CIR.0000027817.55925.B4
   Sobolev VS, 1999, J AGR FOOD CHEM, V47, P1435, DOI 10.1021/jf9809885
   Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5
   SOLEAS GJ, 1995, AM J ENOL VITICULT, V46, P346
   SOTOMATSU A, 1990, ARCH BIOCHEM BIOPHYS, V283, P334, DOI 10.1016/0003-9861(90)90651-E
   Tokusoglu O, 2005, J AGR FOOD CHEM, V53, P5003, DOI 10.1021/jf050496+
   Turner RT, 1999, ENDOCRINOLOGY, V140, P50, DOI 10.1210/en.140.1.50
   Turoczi T, 2003, J MOL CELL CARDIOL, V35, P695, DOI 10.1016/S0022-2828(03)00117-2
   de Almeida LMV, 2007, CELL MOL NEUROBIOL, V27, P661, DOI 10.1007/s10571-007-9152-2
   Vitrac X, 2005, J AGR FOOD CHEM, V53, P5664, DOI 10.1021/jf050122g
   Wang Y, 2002, J AGR FOOD CHEM, V50, P431, DOI 10.1021/jf010812u
   Whitsett Timothy, 2006, J Carcinog, V5, P15, DOI 10.1186/1477-3163-5-15
   Wilson T, 1996, LIFE SCI, V59, pPL15, DOI 10.1016/0024-3205(96)00260-3
   YAMAZAKI I, 1990, J BIOL CHEM, V265, P13589
   Zamora-Ros R, 2006, CLIN CHEM, V52, P1373, DOI 10.1373/clinchem.2005.065870
NR 67
TC 87
Z9 90
U1 5
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0955-2863
EI 1873-4847
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD JUN
PY 2009
VL 20
IS 6
BP 443
EP 452
DI 10.1016/j.jnutbio.2008.05.003
PG 10
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA 448XD
UT WOS:000266294400005
PM 18789672
DA 2018-12-27
ER

PT J
AU Avolio, BJ
   Rotundo, M
   Walumbwa, FO
AF Avolio, Bruce J.
   Rotundo, Maria
   Walumbwa, Fred O.
TI RETRACTED: Early life experiences as determinants of leadership role
   occupancy: The importance of parental influence and rule breaking
   behavior (Retracted article. See vol. 25, pg. 1069, 2014)
SO LEADERSHIP QUARTERLY
LA English
DT Article; Retracted Publication
DE Leader heritability; Rule breaking; Parental influence
ID INDIVIDUAL-DIFFERENCES; ANTISOCIAL-BEHAVIOR; TWIN FAMILY; ADOLESCENCE;
   PERSONALITY; ADJUSTMENT; COOCCURRENCE; MOTIVATION
AB The limited behavioral genetics research reported in the leadership literature has not investigated the degree to which early life experiences predict future emergence into leadership roles. This is the first study to focus on parenting style and early life experiences of rule breaking, and their relationships to leadership roles assumed in adulthood, while controlling for genetic and personality contributions. Using a sample of male twins reared together. we found that authoritative parenting practices was negatively related to modest and serious rule breaking, while being positively related to emergence in leadership roles into adulthood. We also found that modest rule breaking behavior positively predicted the number of leadership roles taken on by individuals, while serious rule breaking negatively predicted the number of leadership roles. Implications for future leadership research and practice are discussed. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Avolio, Bruce J.] Michael G Foster Sch Business, Dept Management & Org, Seattle, WA 98195 USA.
   [Rotundo, Maria] Univ Toronto, Joseph L Rotman Sch Management, Toronto, ON M5S 3E6, Canada.
   [Walumbwa, Fred O.] Arizona State Univ, Dept Management, WP Carey Sch Business, Tempe, AZ 85287 USA.
RP Avolio, BJ (reprint author), Michael G Foster Sch Business, Dept Management & Org, POB 353200, Seattle, WA 98195 USA.
EM bavolio@u.washington.edu; Rotundo@Rotman.Utoronto.Ca;
   Fred.Walumbwa@asu.edu
CR ANDERSON JC, 1988, PSYCHOL BULL, V103, P411, DOI 10.1037//0033-2909.103.3.411
   Arbuckle J., 1999, AMOS 4 0 USERS GUIDE
   Arvey RD, 2006, LEADERSHIP QUART, V17, P1, DOI 10.1016/j.leaqua.2005.10.009
   Arvey RD, 2007, J APPL PSYCHOL, V92, P693, DOI 10.1037/0021-9010.92.3.693
   Ashforth BE, 1996, ACAD MANAGE J, V39, P149, DOI 10.2307/256634
   Avolio B., 2005, LEADERSHIP DEV BALAN
   Avolio B. J., 1988, CHARISMATIC LEADERSH, P276
   Avolio BJ, 2004, LEADERSHIP QUART, V15, P801, DOI 10.1016/j.leaqua.2004.09.003
   Bandura A, 1986, SOCIAL FDN THOUGHT A
   Bandura A., 2008, POSITIVE PSYCHOL, V1, P167
   Bass B., 1985, LEADERSHIP PERFORMAN
   Bass B. M., 1998, TRANSFORMATIONAL LEA
   Bass B. M, 1990, BASS STOGDILLS HDB L
   Baumrind D., 1991, J EARLY ADOLESC, V11, P56, DOI DOI 10.1177/0272431691111004
   Bennis W. G., 2002, GEEKS GEEZERS ERA VA
   Buckingham M., 1999, 1 BREAK ALL RULES
   Byrne B. M., 2001, STRUCTURAL EQUATION
   Cairns R. B., 1994, LIFELINES RISKS
   Campbell D. P., 1992, MANUAL CAMPBELL INTE
   Capaldi DM, 1999, DEV PSYCHOPATHOL, V11, P59, DOI 10.1017/S0954579499001959
   Caprara GV, 2000, PSYCHOL SCI, V11, P302, DOI 10.1111/1467-9280.00260
   Chan KY, 2001, J APPL PSYCHOL, V86, P481, DOI 10.1037//0021-9010.86.3.481
   Clark DB, 2004, ADDICTION, V99, P5, DOI 10.1111/j.1360-0443.2004.00851.x
   DARLING N, 1993, PSYCHOL BULL, V113, P487, DOI 10.1037/0033-2909.113.3.487
   Day DV, 2004, PERS PSYCHOL, V57, P573, DOI 10.1111/j.1744-6570.2004.00001.x
   EISENBERG N, 1995, CHILD DEV, V66, P1179, DOI 10.1111/j.1467-8624.1995.tb00930.x
   Elkins IJ, 1997, DEV PSYCHOL, V33, P351, DOI 10.1037/0012-1649.33.2.351
   Furstenberg F.F., 1999, ADOLESCENT DEV URBAN
   Gerard JM, 2004, J MARRIAGE FAM, V66, P702, DOI 10.1111/j.0022-2445.2004.00048.x
   Hindelang M. J., 1981, MEASURING DELINQUENC
   Ibarra H, 2003, WORKING IDENTITY UNC
   Ilies R, 2004, INT J SELECT ASSESS, V12, P207, DOI 10.1111/j.0965-075X.2004.00275.x
   Jessor R, 1977, PROBLEM BEHAV PSYCHO
   Judge TA, 2002, J APPL PSYCHOL, V87, P765, DOI 10.1037/0021-9010.87.4.765
   Kasser T, 2002, PERS SOC PSYCHOL B, V28, P826, DOI 10.1177/0146167202289011
   KEGAN J, 1994, OUR HEADS MENTAL DEM
   KEGAN J, 1982, EVOLVING SELF PROBLE
   Kirkpatrick S., 1991, ACAD MANAGEMENT EXEC, V5, P48, DOI DOI 10.5465/AME.1991.4274679
   Koopman P. L., 2001, HDB IND WORK ORG PSY, V2, P166
   Krueger RF, 2001, PSYCHOL SCI, V12, P397, DOI 10.1111/1467-9280.00373
   Lawford H, 2005, J RES ADOLESCENCE, V15, P261, DOI 10.1111/j.1532-7795.2005.00096.x
   LYKKEN DT, 1990, ACTA GENET MED GEMEL, V39, P35, DOI 10.1017/S0001566000005572
   MARTIN JA, 1981, MONOGR SOC RES CHILD, V46, P1
   Maurer T. J., 2002, HUMAN RESOURCE DEV R, V1, P9, DOI DOI 10.1177/1534484302011002
   McCauley C. D., 2001, NATURE ORG LEADERSHI, P347
   McClelland D. C., 1975, POWER INNER EXPERIEN
   McCord J, 1986, DEV ANTISOCIAL PROSO, P343
   McLeod JD, 2004, AM SOCIOL REV, V69, P636, DOI 10.1177/000312240406900502
   MOFFITT TE, 1993, PSYCHOL REV, V100, P674, DOI 10.1037//0033-295X.100.4.674
   MOXLEY RS, 1998, CTR CREATIVE LEADERS, P194
   Mumford M. D., 1990, PATTERNS LIFE HIST E
   Mumford M. D., 1992, LEADERSHIP QUART, V2, P289
   MUMFORD MD, 1992, HDB IND ORG PSYCHOL, V3, P61
   OSBORN SG, 1978, J ADOLESCENCE, V1, P101, DOI 10.1016/S0140-1971(78)80024-4
   PARKER G, 1996, HDB SOCIAL SUPPORT F, P193
   PATTERSON GR, 1986, AM PSYCHOL, V41, P432, DOI 10.1037/0003-066X.41.4.432
   PLOMIN R, 1987, BEHAV BRAIN SCI, V10, P1, DOI 10.1017/S0140525X00055941
   PLOMIN R, 2001, BEHAV GENETICS
   Podsakoff PM, 2003, J APPL PSYCHOL, V88, P879, DOI 10.1037/0021-9101.88.5.879
   Pratt MW, 2004, INT J BEHAV DEV, V28, P139, DOI 10.1080/01650250344000343
   RAMSEY E, 1989, GENERATION ANTISOCIA
   Rest J. R., 1979, DEV JUDGING MORAL IS
   Sameroff AJ, 1998, FAMILIES, RISK, AND COMPETENCE, P161
   Schmitt-Rodermund E, 2004, J VOCAT BEHAV, V65, P498, DOI 10.1016/j.jvb.2003.10.007
   Schneider B, 1999, LEADERSHIP QUART, V10, P609, DOI 10.1016/S1048-9843(99)00038-7
   Socolar RRS, 1997, AGGRESS VIOLENT BEH, V2, P355, DOI 10.1016/S1359-1789(97)00021-9
   STAHL MJ, 1983, PERS PSYCHOL, V36, P775, DOI 10.1111/j.1744-6570.1983.tb00512.x
   STEINBERG L, 1994, CHILD DEV, V65, P754, DOI 10.2307/1131416
   Stogdill RM, 1948, J PSYCHOL, V25, P35, DOI 10.1080/00223980.1948.9917362
   Strage A, 1999, J EDUC PSYCHOL, V91, P146
   Taylor J, 2000, J CHILD PSYCHOL PSYC, V41, P433, DOI 10.1111/1469-7610.00628
   Tellegen A., 1982, BRIEF MANUAL DIFFERE
   WERNER EE, 1989, SCI AM, V260, P106, DOI 10.1038/scientificamerican0489-106
   West S. G, 1991, MULTIPLE REGRESSION
   WHITE HR, 1994, J DRUG ISSUES, V24, P55, DOI 10.1177/002204269402400104
   WHITE J, 1982, REJECTION
   Willoughby T, 2004, J CONSULT CLIN PSYCH, V72, P1022, DOI 10.1037/0022-006X.72.6.1022
   Yukl G., 2006, LEADERSHIP ORG
   Zhang LN, 2002, CRIM JUSTICE BEHAV, V29, P161, DOI 10.1177/0093854802029002003
NR 79
TC 34
Z9 35
U1 7
U2 53
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1048-9843
EI 1873-3409
J9 LEADERSHIP QUART
JI Leadersh. Q.
PD JUN
PY 2009
VL 20
IS 3
BP 329
EP 342
DI 10.1016/j.leaqua.2009.03.015
PG 14
WC Psychology, Applied; Management
SC Psychology; Business & Economics
GA 449DS
UT WOS:000266311600007
DA 2018-12-27
ER

PT J
AU Xu, Y
   Li, ZR
   Saini, V
   Kunets, VP
   Dervishi, E
   Salamo, GJ
   Biris, AR
   Biris, AS
AF Xu, Yang
   Li, Zhongrui
   Saini, Viney
   Kunets, Vasyl P.
   Dervishi, Enkeleda
   Salamo, Gregory J.
   Biris, Alexandru R.
   Biris, Alexandru S.
TI RETRACTED: One Step Synthesis of Ceramic Carbon Nanotube Composites with
   Nanojunctions (Retracted Article)
SO NANOSCIENCE AND NANOTECHNOLOGY LETTERS
LA English
DT Article; Retracted Publication
DE MgO; Pellet; Carbon Nanotubes; Ceramic Nanocomposite; n-Type
ID ELECTRONIC-PROPERTIES; FABRICATION
AB Pelletized ceramic carbon nanotube composites were synthesized through a one step process using Radio Frequency-Chemical Vapor Deposition (RF-CVD) method. Surface resistance of the insulating MgO was found to drop dramatically as the result of the graphitic nanostructures forming within the ceramic matrix through the catalytic assistance of Fe/Co. The Hall effect measurement for such nanocomposite indicated n-type electrical behavior, with carrier densities of around 2.5 x 10(20) cm(-3) and high electrical mobility in the range of 0.6-1.5 cm(2)/V s.
C1 [Xu, Yang; Li, Zhongrui; Saini, Viney; Dervishi, Enkeleda; Biris, Alexandru S.] Univ Arkansas, Nanotechnol Ctr, Little Rock, AR 72204 USA.
   [Xu, Yang; Li, Zhongrui; Saini, Viney; Dervishi, Enkeleda; Biris, Alexandru S.] Univ Arkansas, Dept Appl Sci, Little Rock, AR 72204 USA.
   [Kunets, Vasyl P.; Salamo, Gregory J.] Univ Arkansas, Dept Phys, Fayetteville, AR 72701 USA.
   [Biris, Alexandru R.] Natl Inst Res & Dev Isotop & Mol Technol, RO-3400 Cluj Napoca, Romania.
RP Xu, Y (reprint author), Univ Arkansas, Nanotechnol Ctr, Little Rock, AR 72204 USA.
FU DOE [DE-FG 36-06 GO 86072]; Arkansas Science and Technology Authority
   (ASTA) [08-CAT-03]
FX This research was partially supported by the DOE (Grant No. DE-FG 36-06
   GO 86072). Also the financial support from Arkansas Science and
   Technology Authority (ASTA) grant # 08-CAT-03 is highly appreciated.
CR AREAN CO, 1994, J CATAL, V148, P403, DOI 10.1006/jcat.1994.1223
   Biris AR, 2008, CHEM MATER, V20, P3466, DOI 10.1021/cm703680n
   Collins PG, 2000, SCIENCE, V287, P1801, DOI 10.1126/science.287.5459.1801
   Cordier A, 2005, J MATER CHEM, V15, P4041, DOI 10.1039/b505654c
   Fischer JE, 1997, PHYS REV B, V55, pR4921, DOI 10.1103/PhysRevB.55.R4921
   Flahaut E, 2000, J MATER CHEM, V10, P249, DOI 10.1039/a908593i
   Fuhrer MS, 2000, SCIENCE, V288, P494, DOI 10.1126/science.288.5465.494
   Hecht D, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2356999
   Kanai Y, 2008, NANO LETT, V8, P908, DOI 10.1021/nl0732777
   KIMURA T, 1994, J ADHESION, V47, P179, DOI 10.1080/00218469408027098
   Kwon SJ, 2006, JPN J APPL PHYS 1, V45, P8709, DOI 10.1143/JJAP.45.8709
   Lee DH, 2008, ADV MATER, V20, P2480, DOI 10.1002/adma.200702712
   Lee YH, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2838736
   Li SD, 2004, NANO LETT, V4, P2003, DOI 10.1021/nl048687z
   LIU B, 2007, PHYS REV B, V75
   Mieszawska AJ, 2007, SMALL, V3, P722, DOI [10.1002/smll.200600727, 10.1002/smll.2006007]
   NOVAKOVA AA, 2006, HYDROGEN MAT SCI CHE, V3, P509
   Odom TW, 1998, NATURE, V391, P62
   Tans SJ, 1998, NATURE, V393, P49
   Uozumi G, 2007, MATER SCI FORUM, V534-536, P1361, DOI 10.4028/www.scientific.net/MSF.534-536.1361
   Wildoer JWG, 1998, NATURE, V391, P59, DOI 10.1038/34139
NR 21
TC 2
Z9 2
U1 3
U2 11
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1941-4900
EI 1941-4919
J9 NANOSCI NANOTECH LET
JI Nanosci. Nanotechnol. Lett.
PD JUN
PY 2009
VL 1
IS 2
BP 107
EP 110
DI 10.1166/nnl.2009.1023
PG 4
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA V18OI
UT WOS:000208013700007
DA 2018-12-27
ER

PT J
AU Barnett, RLE
AF Barnett, R. -L. Etienne
TI RETRACTED: The semiotics of "Transit" in Joyce's Ulysses (Retracted
   article. See vol. 42, pg. 359, 2015)
SO NEOHELICON
LA English
DT Article; Retracted Publication
AB An analogous combination of accumulating change and persisting habit is superbly formulated in Alfred North Whitehead's account of process or becoming: "There is the aspect of permanence in which a given type of attainment is endlessly repeated for its own sake; and there is the aspect of transition to other things..." Alternatively formulated, to interpolate additional phrases from Whitehead, "transference" and "passage" (ergo, metempsychosis) for Stephen and Bloom concern an unfolding process, one which entails both conservation and novelty - both "inheritance of aspects from their own past" and "continuous transition" to the future. And it is such that, though, in the Joycean schema, "vital growth" is indeed continuous "from infancy through maturity to decay" (817), it nevertheless entails convulsive transitional phases ("convulsions of metamorphosis"), involving psychologically turbulent oppositions between that which was and that which is coming to be. Bloomsday - June 16, 1904 - concerns precisely such transitional phases. All is subjected to the aura of endless modification and reification, all entrapped within a world of oft haunting refrain, a universe wherein re-inscription overtakes otherness, wherein renewal subsumes defeat: whence, ultimately, Ulysses is, as a literary construct, a scrupulously coordinated writ on the ludic contortions of difference and sameness.
C1 Clark Atlanta Univ, Off Univ Provost & Execut Vice President Operat, Atlanta, GA 30360 USA.
RP Barnett, RLE (reprint author), Clark Atlanta Univ, Off Univ Provost & Execut Vice President Operat, Atlanta, GA 30360 USA.
EM RLEBarnett@UofA.edu
CR AQUINAS T, 1952, FATHERS ENGLISH DOMI, P76
   BARNETT RLE, ADVERSARIAL IN PRESS
   Brivic Sheldon, 1980, JOYCE FREUD JUNG
   FEDERMAN R, 1981, SURFICTION FICTION N, P7
   FRANKL P, 1962, GOTHIC ARCHITECTURE, P187
   GILSON E, 1956, CHRISTIAN PHILOS STT, P187
   GOLDBERG SL, 1969, CLASSICAL TEMPER STU, P74
   GOSE EB, 1980, TRANSFORMATION PROCE
   HAYMAN D, 1970, ULYSSES MECH MEANING, P35
   HENKE SA, 1978, JOYCES MORACULOUS SI, P83
   JOYCE J, 1992, PORTRAIT ARTIST YOUN, P239
   Joyce James, 1992, ULYSSES
   KAIN RM, 1966, J JOYCE TODAY ESSAYS, P87
   MCBRIDE M, 2001, ULYSSES METAMORPHOSI, P29
   MCCARTHY PA, 1990, ULYSSES PORTALS DISC, P104
   SHECHNER M, 1974, JOYCE NIGHTTOWN
   WHITEHEAD, 1925, SCI MODERN WORLD, P100
   WHITEHEAD AN, 1933, ADVENTURES IDEAS, P105
   WHITEHEAD AN, 1948, SCI MODERN WORLD, P84
   WHITEHEAD AN, 1978, PROCESS REALITY ESSA, P104
NR 20
TC 1
Z9 1
U1 2
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0324-4652
EI 1588-2810
J9 NEOHELICON
JI Neohelicon
PD JUN
PY 2009
VL 36
IS 1
BP 153
EP 166
DI 10.1007/s11059-009-1015-z
PG 14
WC Literature
SC Literature
GA 447BV
UT WOS:000266167500015
DA 2018-12-27
ER

PT J
AU Kuehnle, K
   Ledesma, MD
   Kalvodova, L
   Smith, AE
   Crameri, A
   Skaanes-Brunner, F
   Thelen, KM
   Kulic, L
   Lutjohann, D
   Heppner, FL
   Nitsch, RM
   Mohajeri, MH
AF Kuehnle, Katrin
   Ledesma, Maria D.
   Kalvodova, Lucie
   Smith, Alicia E.
   Crameri, Arames
   Skaanes-Brunner, Fabienne
   Thelen, Karin M.
   Kulic, Luka
   Luetjohann, Dieter
   Heppner, Frank L.
   Nitsch, Roger M.
   Mohajeri, M. Hasan
TI RETRACTED: Age-dependent Increase in Desmosterol Restores DRM Formation
   and Membrane-related Functions in Cholesterol-free DHCR24(-/-) Mice
   (Retracted Article. See vol 34, pg 1522, 2009)
SO NEUROCHEMICAL RESEARCH
LA English
DT Article; Retracted Publication
DE BACE; Cholesterol; Seladin-1; Plasmin; Proteoliposomes; Sterols; GM1
ID AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE BRAINS; LIPID RAFTS;
   OXIDATIVE STRESS; BETA-SECRETASE; IN-VIVO; REPLACE CHOLESTEROL;
   ALPHA-SECRETASE; GAMMA-SECRETASE; GENERATION
AB Cholesterol is a prominent modulator of the integrity and functional activity of physiological membranes and the most abundant sterol in the mammalian brain. DHCR24-knock-out mice lack cholesterol and accumulate desmosterol with age. Here we demonstrate that brain cholesterol deficiency in 3-week-old DHCR24(-/-) mice was associated with altered membrane composition including disrupted detergent-resistant membrane domain (DRM) structure. Furthermore, membrane-related functions differed extensively in the brains of these mice, resulting in lower plasmin activity, decreased beta-secretase activity and diminished A beta generation. Age-dependent accumulation and integration of desmosterol in brain membranes of 16-week-old DHCR24(-/-) mice led to the formation of desmosterol-containing DRMs and rescued the observed membrane-related functional deficits. Our data provide evidence that an alternate sterol, desmosterol, can facilitate processes that are normally cholesterol-dependent including formation of DRMs from mouse brain extracts, membrane receptor ligand binding and activation, and regulation of membrane protein proteolytic activity. These data indicate that desmosterol can replace cholesterol in membrane-related functions in the DHCR24(-/-) mouse.
C1 [Kuehnle, Katrin] Swiss Acad Med Sci, CH-4051 Basel, Switzerland.
   [Kuehnle, Katrin; Crameri, Arames; Skaanes-Brunner, Fabienne; Kulic, Luka; Nitsch, Roger M.; Mohajeri, M. Hasan] Univ Zurich, Div Psychiat Res, CH-8008 Zurich, Switzerland.
   [Ledesma, Maria D.] Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain.
   [Kalvodova, Lucie] Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany.
   [Smith, Alicia E.] ETH Honggerberg, Inst Biochem, CH-8093 Zurich, Switzerland.
   [Thelen, Karin M.; Luetjohann, Dieter] Univ Bonn, Dept Clin Pharmacol, D-53105 Bonn, Germany.
   [Heppner, Frank L.] Charite, Inst Neuropathol, D-13353 Berlin, Germany.
RP Kuehnle, K (reprint author), Swiss Acad Med Sci, Peterspl 13, CH-4051 Basel, Switzerland.
EM k.kuehnle@samw.ch
RI Ledesma, Maria Dolores/I-5619-2015
OI Ledesma, Maria Dolores/0000-0002-5679-6891; , Lucie/0000-0003-3270-9463
FU Swiss National Science Foundation [3200BO-112616, 451NF40-111381];
   University of Zurich; Swiss Academy of Medical Sciences; Hermann Klaus;
   Hartmann Muller; Novartis Foundations; Regione Piemonte to MDL; US
   National Institutes of Health to FLH [NINDS R01 NS046006]; EU
   [LSHM-CT-2003-503330, DFGSFB6027]
FX We thank Dr. E. Feinstein (Quark Biotech Inc.) for providing the DHCR24
   deficient mice and Takeda Pharmaceutical Company Limited for providing
   the anti-Ab antibodies for the murine Ab ELISA. We thank E. Biondi for
   technical assistance. This work was supported by grants from the Swiss
   National Science Foundation # 3200BO-112616 and 451NF40-111381 (NCCR
   Neuro), the University of Zurich, the Swiss Academy of Medical Sciences,
   Hermann Klaus, Hartmann Muller and the Novartis Foundations to MHM,
   Regione Piemonte to MDL, by grants of the US National Institutes of
   Health to FLH (NINDS R01 NS046006), and by EU grant LSHM-CT-2003-503330
   (APOPIS) and DFGSFB6027 to RMN.
CR Abad-Rodriguez J, 2004, J CELL BIOL, V167, P953, DOI 10.1083/jcb.200404149
   Andersson HC, 2002, AM J MED GENET, V113, P315, DOI 10.1002/ajmg.10873
   AUFENANGER J, 1986, BIOCHEM PHARMACOL, V35, P911, DOI 10.1016/0006-2952(86)90076-6
   BANKER G, 1991, CELLULAR MOL NEUROSC
   Barenholz Y, 2002, PROG LIPID RES, V41, P1, DOI 10.1016/S0163-7827(01)00016-9
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790
   BOOGAARD A, 1987, BIOCHEM J, V241, P345, DOI 10.1042/bj2410345
   Burns M, 2003, J NEUROSCI, V23, P5645
   Collen D, 1999, THROMB HAEMOSTASIS, V82, P259
   Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100
   Crameri A, 2006, EMBO J, V25, P432, DOI 10.1038/sj.emboj.7600938
   Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113
   Fliesler SJ, 2000, LIPIDS, V35, P289, DOI 10.1007/s11745-000-0525-y
   Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381
   Gondre-Lewis MC, 2006, J CELL SCI, V119, P1876, DOI 10.1242/jcs.02906
   Greeve I, 2000, J NEUROSCI, V20, P7345
   Heverin M, 2007, ARTERIOSCL THROM VAS, V27, P2191, DOI 10.1161/ATVBAHA.107.149823
   Huster D, 2005, BIOPHYS J, V88, P1838, DOI 10.1529/biophysj.104.048926
   Jansen M, 2008, J BIOL CHEM, V283, P14610, DOI 10.1074/jbc.M710355200
   Kaether C, 2004, J CELL BIOL, V167, P809, DOI 10.1083/jcb.200410090
   Kalvodova L, 2005, J BIOL CHEM, V280, P36815, DOI 10.1074/jbc.M504484200
   Keller RK, 2004, J LIPID RES, V45, P347, DOI 10.1194/jlr.M300232-JLR200
   Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998
   Kuehnle K, 2008, MOL CELL BIOL, V28, P539, DOI 10.1128/MCB.00584-07
   Ledesma MD, 2003, EMBO REP, V4, P1190, DOI 10.1038/sj.embor.7400021
   Ledesma MD, 2003, BRAIN RES, V987, P107, DOI 10.1016/S0006-8993(03)03296-7
   Ledesma MD, 2000, EMBO REP, V1, P530
   Lusa S, 2003, J BIOL CHEM, V278, P19844, DOI 10.1074/jbc.M212503200
   Lutjohann D, 2002, J LIPID RES, V43, P1078, DOI 10.1194/jlr.M200071-JLR200
   Massey JB, 2005, BIOCHEMISTRY-US, V44, P10423, DOI 10.1021/bi0506425
   Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216
   Megha M, 2006, J BIOL CHEM, V281, P21903, DOI 10.1074/jbc.M600395200
   MERRITT EA, 1994, PROTEIN SCI, V3, P166
   Ohyama Y, 2006, J BIOL CHEM, V281, P3810, DOI 10.1074/jbc.M505179200
   Ollila OHS, 2007, J STRUCT BIOL, V159, P311, DOI 10.1016/j.jsb.2007.01.012
   Parvathy S, 2004, J NEUROCHEM, V90, P1005, DOI 10.1111/j.1471-4159.2004.02521.x
   Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200
   PLOW EF, 1995, FASEB J, V9, P939
   Porter FD, 2002, J CLIN INVEST, V110, P715, DOI 10.1172/JCI200216386
   Refolo LM, 2001, NEUROBIOL DIS, V8, P890, DOI 10.1006/nbdi.2001.0422
   Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3
   Runz H, 2002, J NEUROSCI, V22, P1679, DOI 10.1523/JNEUROSCI.22-05-01679.2002
   SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130
   Selkoe DJ, 2001, PHYSIOL REV, V81, P741
   Shrivastava S, 2008, BIOCHEMISTRY-US, V47, P5668, DOI 10.1021/bi8001677
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390
   Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460
   Song BL, 2005, CELL METAB, V1, P179, DOI 10.1016/j.cmet.2005.01.001
   Stottrup BL, 2006, BIOPHYS J, V90, P3176, DOI 10.1529/biophysj.105.072959
   Vainio S, 2006, J BIOL CHEM, V281, P348, DOI 10.1074/jbc.M509530200
   Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200
   Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470
   Wang JW, 2004, BIOCHEMISTRY-US, V43, P1010, DOI 10.1021/bi035696y
   Waterham HR, 2001, AM J HUM GENET, V69, P685, DOI 10.1086/323473
   Wechsler A, 2003, SCIENCE, V302, P2087, DOI 10.1126/science.1090776
   Wood WG, 2002, NEUROBIOL AGING, V23, P685, DOI 10.1016/S0197-4580(02)00018-0
   Wu CW, 2004, NATURE, V432, P640, DOI 10.1038/nature03173
   Xu F, 2005, P NATL ACAD SCI USA, V102, P14551, DOI 10.1073/pnas.0503590102
   Yang CD, 2006, J BIOL CHEM, V281, P27816, DOI 10.1074/jbc.M603781200
NR 62
TC 5
Z9 5
U1 4
U2 11
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-3190
EI 1573-6903
J9 NEUROCHEM RES
JI Neurochem. Res.
PD JUN
PY 2009
VL 34
IS 6
BP 1167
EP 1182
DI 10.1007/s11064-008-9893-4
PG 16
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 430BX
UT WOS:000264964900017
PM 19115107
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Nikitakis, NG
   Scheper, MA
   Papanikolaou, VS
   Sauk, JJ
AF Nikitakis, Nikolaos G.
   Scheper, Mark A.
   Papanikolaou, Vasileios S.
   Sauk, John J.
TI RETRACTED: The oncogenic effects of constitutive Stat3 signaling in
   salivary gland cancer cells are mediated by survivin and modulated by
   the NSAID sulindac (Retracted article. See vol. 118, pg. 748, 2014)
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND
   ENDODONTOLOGY
LA English
DT Article; Retracted Publication
ID EPIDERMAL-GROWTH-FACTOR; ADENOID CYSTIC CARCINOMA; NONSTEROIDAL
   ANTIINFLAMMATORY DRUGS; FACTOR-RECEPTOR; NECK-CANCER; IN-VIVO;
   CYCLOOXYGENASE-2 EXPRESSION; MUCOEPIDERMOID CARCINOMA; PLEOMORPHIC
   ADENOMA; COX-2 INHIBITORS
AB Objective. Constitutive activation of the signal transducer and activator of transcription 3 (Stat3) has been detected in various human cancers and has been linked to tumor development and progression. Oncogenic Stat3 signaling results in induction of specific target genes, among which survivin is implicated in the proliferation and survival of cancer cells. Targeting of Stat3 constitutive expression by the nonsteroidal antiinflammatory drug (NSAID) sulindac has been demonstrated to exert antineoplastic effects in oral squamous cell carcinoma cells in vitro and in vivo.
   Study design. The expression and functional role of Stat3 and survivin was evaluated in 2 salivary gland adenocarcinoma cell lines (HSY and HSG). In addition, the effects of the NSAID sulindac and other cyclooxygenase (COX) inhibitors on Stat3 and survivin expression and on cell proliferation and apoptosis of HSY and HSG cells were analyzed.
   Results. Messenger RNA and protein expression of Stat3 and survivin was detected in HSY and HSG cell lines. Treatment of these cells with siRNA against Stat3 or survivin inhibited cell proliferation and induced apoptosis. Moreover, Stat3 siRNA treatment down-regulated the protein and mRNA expression of survivin, and survivin forced expression partially reversed the antineoplastic effects of Stat3 siRNA treatment. Treatment of HSY and HSG cells with the NSAID sulindac, but not other COX inhibitors, induced significant decreases in cell proliferation and increases in apoptosis, accompanied by down-regulation of Stat3 and survivin expression. In contrast, survivin forced expression or transfection with constitutively active Stat3 attenuated the effects of sulindac on cell growth and apoptosis.
   Conclusions. Taken together, these data support the importance of the constitutive Stat3 signaling for growth and survival of salivary gland cancer cells through the induction of survivin. Inhibition of the oncogenic Stat3-survivin pathway in these cells can be achieved by selective targeting techniques or treatment with the NSAID sulindac and holds promise for the treatment of salivary gland cancer. (Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 107: 826-836)
C1 [Nikitakis, Nikolaos G.] Univ Athens, Dept Oral Pathol & Med, Sch Dent, Athens 11528, Greece.
   [Scheper, Mark A.] Univ Maryland, Dept Diagnost Sci & Pathol, College Pk, MD 20742 USA.
   [Scheper, Mark A.] Univ Maryland, Greenebaum Canc Ctr, College Pk, MD 20742 USA.
   [Sauk, John J.] Univ Louisville, Sch Dent, Louisville, KY 40292 USA.
RP Nikitakis, NG (reprint author), Univ Athens, Dept Oral Pathol & Med, Sch Dent, 2 Thivon St, Athens 11527, Greece.
EM nnikitakis1@yahoo.com
FU National Institutes of Health [DE13118, DE12606]; University of Maryland
   Greenebaum Cancer Center Pilot Grant Program
FX Supported by grants from the National Institutes of Health (DE13118 and
   DE12606 to J.S.) and the University of Maryland Greenebaum Cancer Center
   Pilot Grant Program (to N.N.).
CR Agulnik M., 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P543, DOI 10.2174/1568011043352641
   ALADIB W, 1990, CANCER RES, V50, P7650
   Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
   Aoki T, 2006, ORAL ONCOL, V42, P51, DOI 10.1016/j.oraloncology.2005.06.012
   Aoki T, 2004, ORAL ONCOL, V40, P954, DOI 10.1016/j.oraloncology.2004.04.014
   Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130
   Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527
   Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5
   Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0
   Bu RF, 1996, P SOC EXP BIOL MED, V211, P257
   Buettner R, 2002, CLIN CANCER RES, V8, P945
   CHIOU SK, 2003, MED SCI MONITOR, V9, P43
   de Araujo VC, 2008, ORAL ONCOL, V44, P439, DOI 10.1016/j.oraloncology.2007.05.011
   Elder DJE, 1997, CLIN CANCER RES, V3, P1679
   Fan CY, 2001, ARCH OTOLARYNGOL, V127, P1075, DOI 10.1001/archotol.127.9.1075
   Gibbons MD, 2001, LARYNGOSCOPE, V111, P1373, DOI 10.1097/00005537-200108000-00011
   Grandis JR, 2000, LARYNGOSCOPE, V110, P868, DOI 10.1097/00005537-200005000-00016
   Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227
   Grosch S, 2006, J NATL CANCER I, V98, P736, DOI 10.1093/jnci/djj206
   Han EKH, 1998, BREAST CANCER RES TR, V48, P195, DOI 10.1023/A:1005924730450
   Jaskoll T, 2001, BMC Dev Biol, V1, P5, DOI 10.1186/1471-213X-1-5
   Kanda N, 2004, ONCOGENE, V23, P4921, DOI 10.1038/sj.onc.1207606
   Kaye FJ, 2006, CLIN CANCER RES, V12, P3878, DOI 10.1158/1078-0432.CCR-06-0791
   Kijima T, 2002, CELL GROWTH DIFFER, V13, P355
   Kobayashi M, 2005, EUR J HAEMATOL, V75, P212, DOI 10.1111/j.1600-0609.2005.00498.x
   Krysan K, 2004, FASEB J, V18, P205, DOI 10.1096/fj.03-0369fje
   Krysan Kostyantyn, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P209, DOI 10.2174/187152006776930882
   KYAKUMOTO S, 1994, ARCH ORAL BIOL, V39, P569, DOI 10.1016/0003-9969(94)90132-5
   Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327
   Li J, 2005, CANCER, V104, P771, DOI 10.1002/cncr.21215
   Licitra L, 2004, CURR OPIN ONCOL, V16, P236, DOI 10.1097/00001622-200405000-00008
   Lim JTE, 1999, BIOCHEM PHARMACOL, V58, P1097, DOI 10.1016/S0006-2952(99)00200-2
   Lo Muzio L, 2003, BRIT J CANCER, V89, P2244, DOI 10.1038/sj.bjc.6601402
   Loy AHC, 2005, J LARYNGOL OTOL, V119, P515
   Mohan S, 2003, ORAL ONCOL, V39, P537, DOI 10.1016/S1368-8375(03)00035-6
   Molina MA, 1999, CANCER RES, V59, P4356
   Neville BW, 2002, ORAL MAXILLOFACIAL P, P406
   Nikitakis NG, 2002, INT J CANCER, V98, P817, DOI 10.1002/ijc.10278
   Nikitakis NG, 2002, CANCER RES, V62, P1004
   Nikitakis NG, 2004, CURR CANCER DRUG TAR, V4, P637, DOI 10.2174/1568009043332736
   PIAZZA GA, 1995, CANCER RES, V55, P3110
   Piechocki MP, 2006, INT J CANCER, V119, P441, DOI 10.1002/ijc.21837
   Pramoonjago P, 2006, ONCOGENE, V25, P5626, DOI 10.1038/sj.onc.1209566
   Rahman MA, 2000, CANCER RES, V60, P2085
   Sakamoto T, 2005, ACTA OTO-LARYNGOL, V125, P191, DOI 10.1080/00016480410017693
   Sakurai K, 2001, PATHOL INT, V51, P762, DOI 10.1046/j.1440-1827.2001.01280.x
   Sato N, 1996, BIOCHEM MOL BIOL INT, V38, P597
   Scheper MA, 2007, INT J ORAL MAX SURG, V36, P632, DOI 10.1016/j.ijom.2007.04.003
   Scheper MA, 2007, NEOPLASIA, V9, P192, DOI 10.1593/neo.06781
   Scheper MA, 2006, ANTICANCER RES, V26, P4103
   SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060
   Siavash H, 2004, BRIT J CANCER, V91, P1074, DOI 10.1038/sj.bjc.6602055
   Sriuranpong V, 2003, CANCER RES, V63, P2948
   Stenman G, 2005, SEMIN CANCER BIOL, V15, P224, DOI 10.1016/j.semcancer.2005.01.0002
   Sturmer T, 2006, AM J MED, V119, P494, DOI 10.1016/j.amjmed.2005.11.011
   Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3
   Szlavik V, 2008, J CELL BIOCHEM, V103, P284, DOI 10.1002/jcb.21404
   Teh SH, 2004, J CELL BIOCHEM, V91, P796, DOI 10.1016/jcb.10767
   Thompson HJ, 1997, CANCER RES, V57, P267
   Vered M, 2002, HEAD NECK-J SCI SPEC, V24, P632, DOI 10.1002/hed.10104
   Weinman EC, 2003, CANCER, V97, P2203, DOI 10.1002/cncr.11311
   Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204
   Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200
   Dai Y, 2006, WORLD J GASTROENTERO, V12, P2884, DOI 10.3748/wjg.v12.i18.2884
   Zhang T, 2004, J PHARMACOL EXP THER, V308, P434, DOI 10.1124/jpet.103.059378
NR 65
TC 8
Z9 9
U1 3
U2 12
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1079-2104
EI 1528-395X
J9 ORAL SURG ORAL MED O
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.
PD JUN
PY 2009
VL 107
IS 6
BP 826
EP 836
DI 10.1016/j.tripleo.2008.12.054
PG 11
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 448QY
UT WOS:000266278300022
PM 19272804
DA 2018-12-27
ER

PT J
AU Nakai, Y
   Kitagawa, S
   Ishida, K
   Kamihara, Y
   Hirano, M
   Hosono, H
AF Nakai, Yusuke
   Kitagawa, Shunsaku
   Ishida, Kenji
   Kamihara, Yoichi
   Hirano, Masahiro
   Hosono, Hideo
TI RETRACTED: Systematic As-75 NMR study of the dependence of low-lying
   excitations on F doping in the iron oxypnictide LaFeAsO1-xFx (Retracted
   article, see vol. 81, art. no. 019902, 2010)
SO PHYSICAL REVIEW B
LA English
DT Article; Retracted Publication
DE antiferromagnetic materials; doping; electrical resistivity; fluorine;
   iron compounds; lanthanum compounds; nuclear magnetic resonance;
   spin-lattice relaxation; superconducting energy gap; superconducting
   materials
ID SUPERCONDUCTOR; CU
AB We report As-75 NMR studies on LaFeAs(O1-xFx) (0 < x < 0.14). At x=0.04 near the phase boundary, from resistivity, spin-lattice relaxation rate 1/T-1, and NMR spectrum measurements, we found weak magnetic order at T-N similar or equal to 30 K. Antiferromagnetic (AFM) fluctuations proved through 1/T-1 are suppressed significantly with F doping, and pseudogap behavior without pronounced AFM fluctuations is observed at x=0.11 where T-C is maximum. This significant suppression of 1/T1T upon F doping while T-C remains nearly unchanged suggests that low-energy AFM fluctuations probed with As-75 NMR do not play a crucial role in the superconductivity.
C1 [Nakai, Yusuke; Kitagawa, Shunsaku; Ishida, Kenji] Kyoto Univ, Dept Phys, Grad Sch Sci, Kyoto 6068502, Japan.
   [Nakai, Yusuke; Kitagawa, Shunsaku; Ishida, Kenji; Kamihara, Yoichi] JST, TRIP, Chiyoda Ku, Tokyo 1020075, Japan.
   [Hirano, Masahiro; Hosono, Hideo] Tokyo Inst Technol, JST, ERATO, SORST, Yokohama, Kanagawa 2268503, Japan.
   [Hirano, Masahiro; Hosono, Hideo] Tokyo Inst Technol, Frontier Res Ctr, Yokohama, Kanagawa 2268503, Japan.
   [Hosono, Hideo] Tokyo Inst Technol, Mat & Struct Lab, Yokohama, Kanagawa 2268503, Japan.
RP Nakai, Y (reprint author), Kyoto Univ, Dept Phys, Grad Sch Sci, Kyoto 6068502, Japan.
EM nakai@scphys.kyoto-u.ac.jp
RI Ishida, Kenji/U-8940-2017; Hosono, Hideo/J-3489-2013; Kamihara,
   Yoichi/C-4471-2008; Nakai, Yusuke/Q-6590-2017; Kitagawa,
   Shunsaku/M-2667-2014
OI Hosono, Hideo/0000-0001-9260-6728; Nakai, Yusuke/0000-0002-0106-6752;
   Kitagawa, Shunsaku/0000-0002-1855-4760
CR Baek SH, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.212509
   Bang Y, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.134523
   Boeri L, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.026403
   Chubukov AV, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.134512
   COX A, 1985, J PHYS C SOLID STATE, V18, P1123
   de la Cruz C, 2008, NATURE, V453, P899, DOI 10.1038/nature07057
   Ding H, 2008, EPL-EUROPHYS LETT, V83, DOI 10.1209/0295-5075/83/47001
   Fukazawa H, 2008, J PHYS SOC JPN, V77, DOI 10.1143/JPSJ.77.093706
   Hashimoto K, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.017002
   Ikeda H, 2008, J PHYS SOC JPN, V77, DOI 10.1143/JPSJ.77.123707
   Imai T, 2008, J PHYS SOC JPN, V77, P47, DOI 10.1143/JPSJS.77SC.47
   Kamihara Y, 2008, J AM CHEM SOC, V130, P3296, DOI 10.1021/ja800073m
   Kim SW, 2008, J PHYS SOC JPN, V77, P23
   Kitagawa K, 2008, J PHYS SOC JPN, V77, DOI 10.1143/JPSJ.77.114709
   KLINGELER R, ARXIV08080708
   Kohama Y, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.020512
   Kuroki K, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.087004
   Mazin II, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.057003
   Mukuda H, 2008, J PHYS SOC JPN, V77, DOI 10.1143/JPSJ.77.093704
   Nagai Y, 2008, NEW J PHYS, V10, DOI 10.1088/1367-2630/10/10/103026
   Nakai Y, 2008, J PHYS SOC JPN, V77, DOI 10.1143/JPSJ.77.073701
   Nomura T, 2008, SUPERCOND SCI TECH, V21, DOI 10.1088/0953-2048/21/12/125028
   OHSUGI SK, 1994, J PHYS SOC JPN, V63, P700, DOI 10.1143/JPSJ.63.700
   Parish MM, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.144514
   Parker D, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.134524
   Singh DJ, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.237003
   Takeshita S, 2008, J PHYS SOC JPN, V77, DOI 10.1143/JPSJ.77.103703
   TAKIGAWA M, 1991, PHYS REV B, V43, P247, DOI 10.1103/PhysRevB.43.247
   Terasaki N, 2009, J PHYS SOC JPN, V78, DOI 10.1143/JPSJ.78.013701
NR 29
TC 25
Z9 25
U1 2
U2 12
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 2469-9950
EI 2469-9969
J9 PHYS REV B
JI Phys. Rev. B
PD JUN
PY 2009
VL 79
IS 21
AR 212506
DI 10.1103/PhysRevB.79.212506
PG 4
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 466XR
UT WOS:000267699200025
DA 2018-12-27
ER

PT J
AU Naghash, HJ
   Massah, AR
   Arman, M
AF Naghash, Hamid Javaherian
   Massah, Ahmad Reza
   Arman, Masoud
TI RETRACTED: Silicone secondary cross-linked IPN based on
   poly(vinylacetate-co-hydroxyethyl methacrylate) and SiO2 (Retracted
   article. See vol. 121, pg. 263. 2018)
SO PROGRESS IN ORGANIC COATINGS
LA English
DT Review; Retracted Publication
DE IPNs; PVAc-HEMA; Tetraethyl orthosilicate
ID INTERPENETRATING POLYMER NETWORKS; THIN-FILMS; POLYURETHANE;
   POLYSILOXANE; MORPHOLOGY; SURFACE; COPOLYMERS; KINETICS; SYSTEM
AB Silicone secondary cross-linked interpenetrating polymer networks (IPNs) of poly(vinylacetate-cohydroxyethyl methacrylate) (PVAc-HEMA) and SiO2 were prepared by free radical polymerization and condensation methods. The resulting copolymers were characterized by using Fourier transform infrared spectroscopy (FTIR). Thermal properties of the copolymers were Studied by using thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). The morphology of copolymers was also investigated by optical microscopy (OM) and then the effects of silicone concentrations, the reflux time, and composition on the phase morphology of the IPNs of PVAc-HEMA/SiO2 Were discussed. The broadening of the transition region was observed with the increase of the prolongation of the reflux time and the tendency of the aggregation of silicon in the surface was also observed with Teflon as a substrate plate. However, an optically transparent film was easily achieved at higher temperature due to the chemical cross-link and physical entanglement between the two phases of PVAc-HEMA and SiO2. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Naghash, Hamid Javaherian; Massah, Ahmad Reza; Arman, Masoud] Islamic Azad Univ, Dept Chem, Shahreza Branch, Shahreza, Isfahan, Iran.
RP Naghash, HJ (reprint author), Islamic Azad Univ, Dept Chem, Shahreza Branch, POB 311-86145, Shahreza, Isfahan, Iran.
EM javaherian@iaush.ac.ir
CR Bajpai AK, 2001, REACT FUNCT POLYM, V50, P9
   BARROS BG, 1992, J APPL POLYM SCI, V44, P255
   Bastani S, 2006, PROG ORG COAT, V56, P248, DOI 10.1016/j.porgcoat.2005.06.014
   BRINKER CJ, 1984, J NON-CRYST SOLIDS, V63, P45, DOI 10.1016/0022-3093(84)90385-5
   Chang TC, 1999, POLYM DEGRAD STABIL, V66, P127, DOI 10.1016/S0141-3910(99)00061-0
   Dean KM, 2006, EUR POLYM J, V42, P2872, DOI 10.1016/j.eurpolymj.2006.04.013
   ELLSWORTH MW, 1991, J AM CHEM SOC, V113, P2756, DOI 10.1021/ja00007a062
   Erdodi G, 2006, PROG POLYM SCI, V31, P1, DOI 10.1016/j.progpolymsci.2005.11.001
   Fichet O, 2005, POLYMER, V46, P37, DOI 10.1016/j.polymer.2004.10.053
   GAINES GL, 1981, MACROMOLECULES, V14, P208, DOI 10.1021/ma50002a043
   GUPTA N, 1995, MACROMOLECULES, V28, P827, DOI 10.1021/ma00108a004
   HE XW, 1989, POLYMER, V30, P364, DOI 10.1016/0032-3861(89)90131-6
   HE XW, 1992, POLYMER, V33, P866, DOI 10.1016/0032-3861(92)90351-V
   HOLOHAN AT, 1994, POLYMER, V35, P977, DOI 10.1016/0032-3861(94)90941-5
   Ivanova Y, 2006, THIN SOLID FILMS, V515, P271, DOI 10.1016/j.tsf.2005.12.080
   KLEIN PG, 1988, POLYMER, V29, P1079, DOI 10.1016/0032-3861(88)90018-3
   LEDUC L, 1980, J MACROMOL SCI CHEM, V14, P389
   Liu L, 2005, BIOMATERIALS, V26, P233, DOI 10.1016/j.biomaterials.2004.02.025
   MCNEIL KJ, 1980, J AM CHEM SOC, V102, P1859, DOI 10.1021/ja00526a015
   Miura S, 2003, THIN SOLID FILMS, V438, P253, DOI 10.1016/S0040-6090(03)00793-4
   Murthy PSK, 2006, REACT FUNCT POLYM, V66, P1482, DOI 10.1016/j.reactfunctpolym.2006.04.010
   NOVAK BM, 1990, POLYM PREPR AM CHEM, V31, P698
   OKKEMA AZ, 1989, BIOMATERIALS, V10, P23, DOI 10.1016/0142-9612(89)90005-7
   Olabisi O., 1979, POLYM POLYM MISCIBIL
   Plesse C, 2007, POLYMER, V48, P696, DOI 10.1016/j.polymer.2006.11.053
   POUXVIEL JC, 1987, J NON-CRYST SOLIDS, V89, P345, DOI 10.1016/S0022-3093(87)80277-6
   Qiu L, 2005, THIN SOLID FILMS, V471, P96, DOI 10.1016/j.tsf.2004.04.034
   Roberts RJ, 2005, COMPOS PART A-APPL S, V36, P95, DOI 10.1016/j.compositesa.2003.05.001
   SCHMIDT H, 1982, J NON-CRYST SOLIDS, V48, P65, DOI 10.1016/0022-3093(82)90246-0
   SMITH AL, 1974, ANAL SILICONES, P271
   Vidal F, 2006, POLYMER, V47, P3747, DOI 10.1016/j.polymer.2006.03.030
   Vlad S, 2002, EUR POLYM J, V38, P829, DOI 10.1016/S0014-3057(01)00233-6
   Wu TB, 2007, THIN SOLID FILMS, V515, P5220, DOI 10.1016/j.tsf.2006.12.029
   XIAO H, 1990, J POLYM SCI POL CHEM, V28, P585, DOI 10.1002/pola.1990.080280310
NR 34
TC 10
Z9 10
U1 4
U2 26
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0300-9440
J9 PROG ORG COAT
JI Prog. Org. Coat.
PD JUN
PY 2009
VL 65
IS 2
BP 275
EP 280
DI 10.1016/j.porgcoat.2008.12.005
PG 6
WC Chemistry, Applied; Materials Science, Coatings & Films
SC Chemistry; Materials Science
GA 448OY
UT WOS:000266273100016
DA 2018-12-27
ER

PT J
AU Zakoshanskii, VM
AF Zakoshanskii, V. M.
TI RETRACTED: Alternative technologies for the producing phenol (Retracted
   article. See vol. 79, pg. 1588, 2009)
SO RUSSIAN JOURNAL OF GENERAL CHEMISTRY
LA English
DT Article; Retracted Publication
AB This paper presents an analysis of available alternative phenol production technologies that bypass acetone. It is demonstrated that development of these technologies, from both the scientific and engineering points of view, has not achieved a level that would anticipate their commercial implementation in near future. On the other hand, the modern cumene- process based technologies for combined production of phenol and acetone have achieved a maximum possible magnitude of selectivity, as well as potentially highest levels of process and environmental safety, and thus remain prevailing methods for producing phenol.
RP Zakoshanskii, VM (reprint author), 4756 Doncaster Court, Long Grove, IL 60047 USA.
EM vlazak@illallc.com
CR KRUZHALOV BD, 1963, SOVMESTNOE POLUCHENI
   SCHMIDT RJ, 2004, AICHE 3 INT AROM PRO, P491
   SCHMIDT RJ, 2006, 3 AS PHEN AC DER MAR
   Uriarte AK, 1997, STUD SURF SCI CATAL, V110, P857
   ZAKOSHANSKII VM, 1988, SOVREMENNOE SOSTOYAN
   ZAKOSHANSKII VM, 2005, PROTSESSY NEFTEPERER, P89
   ZAKOSHANSKII VM, 2006, MEZHDUNARIDNAYA K PE
   ZAKOSHANSKY V, 2000, NEFTEPERERABOTKA NEF, P34
   ZAKOSHANSKY VM, 1999, Patent No. 2125038
   ZAKOSHANSKY VM, 2001, Patent No. 6252124
   ZAKOSHANSKY VM, 2005, 2 AS PHEN AC DER MAR
   ZAKOSHANSKY VM, 2003, AICHE 2 INT AR PROC, P794
   ZAKOSHANSKY VM, 2003, AICHE 2 INT AR PROC, P756
   ZAKOSHANSKY VM, 1998, Patent No. 5908962
   ZAKOSHANSKY VM, 1993, Patent No. 5254751
   ZAKOSHANSKY VM, 2001, AICHE 1 INT AR PROC, P166
   ZAKOSHANSKY VM, Patent No. 2111203
   ZAKOSHANSKY VM, 2001, Patent No. 6225513
   ZAKOSHANSKY VM, 1999, Patent No. 6066767
   ZAKOSHANSKY VM, 1994, Patent No. 5502259
   ZAKOSHANSKY VM, 1998, Patent No. 6057483
   2004, Patent No. 20040236152
   1953, Patent No. 2663740
   1991, Patent No. 5059736
   CHEM MARKET, V250
   2000, Patent No. 2146670
   1982, Patent No. 936991
   1993, Patent No. 5191136
   2004, CHEM ENG         SEP, P17
   2005, TECNON ORBICHEM
   1997, CHEM WEEK       0101
   1996, Patent No. 2266275
NR 32
TC 1
Z9 1
U1 4
U2 20
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 1070-3632
EI 1608-3350
J9 RUSS J GEN CHEM+
JI Russ. J. Gen. Chem.
PD JUN
PY 2009
VL 79
IS 6
BP 1288
EP 1310
DI 10.1134/S1070363209060450
PG 23
WC Chemistry, Multidisciplinary
SC Chemistry
GA 474WL
UT WOS:000268314900045
OA Bronze
DA 2018-12-27
ER

PT J
AU Zakoshanskii, VM
   Budarev, AV
AF Zakoshanskii, V. M.
   Budarev, A. V.
TI RETRACTED: Mechanism of cumene oxidation (Retracted article. See vol.
   79, pg. 1588, 2009)
SO RUSSIAN JOURNAL OF GENERAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID AUTOXIDATION
AB Analysis based on in-depth experimental research on the cumene oxidation process is presented. It is demonstrated, in particular, that the process occurs by two independent paths: by oxygen in a gas phase which is present at the liquid-gas interface; and by oxygen dissolved in the reaction medium. It is established that the last plays a key role in formation of by-products of cumene oxidation and, therefore, in reduction of process selectivity.
C1 [Budarev, A. V.] Illa Int, St Petersburg 192148, Russia.
RP Zakoshanskii, VM (reprint author), 4756 Doncaster Court, Long Grove, IL 60047 USA.
EM vlazak@illallc.com; a.budarev@illallc.com
CR ANTONOVSKI VL, 1964, ZH PRIKL KHIM, V37, P2453
   ANTONOVSKII V, 1961, DOKL AKAD NAUK SSSR+, V140, P1070
   BEREZIN IV, 1955, VOPROSY KHIMICHESKOI, P273
   Emanuel' N.M., 1965, TSEPNYE REAKTSII OKI
   EMANUEL NM, 1984, OKISLENIE ETILHENZOL
   Farmer EH, 1942, T FARADAY SOC, V38, P0348, DOI 10.1039/tf9423800348
   FARMER EH, 1943, J CHEM SOC, V119
   KNORRE DG, 1957, USP KHIM+, V26, P416
   LEVSHTEIN VA, 1971, NEFTEPERERABOTKA NEF, P47
   MENSHCHIKOV VA, 1969, KHIM PROM ST, P43
   MENSHCHIKOV VA, 1970, KHIM TEKH TOPL MASEL, P43
   MUKHIN N, ZH PRIKL KHIM
   ROBERTSON A, 1946, T FARADAY SOC, V42, P201, DOI 10.1039/tf9464200201
NR 13
TC 1
Z9 1
U1 2
U2 13
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 1070-3632
EI 1608-3350
J9 RUSS J GEN CHEM+
JI Russ. J. Gen. Chem.
PD JUN
PY 2009
VL 79
IS 6
BP 1311
EP 1328
DI 10.1134/S1070363209060462
PG 18
WC Chemistry, Multidisciplinary
SC Chemistry
GA 474WL
UT WOS:000268314900046
OA Bronze
DA 2018-12-27
ER

PT J
AU Zakoshanskii, VM
AF Zakoshanskii, V. M.
TI RETRACTED: Reaction medium in the industrial synthesis of phenol
   (Retracted article. See vol. 79, pg. 1588, 2009)
SO RUSSIAN JOURNAL OF GENERAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID SHCHELOCHNOGO OKISLENIYA IZOPROPILBENZOLA; PROTSESSA OKISLENIYA;
   LIQUID-PHASE; OXIDATION; ACID
AB A review of the properties of reaction medium at each stage of the process of cumene based phenol/acetone industrial synthesis is presented. Analysis of the discovered properties, in conjunction with the consideration of proceeding chemical reactions allowed creation of the technologies that provide maximum possible selectivity at the each stage of the process.
RP Zakoshanskii, VM (reprint author), 4756 Doncaster Court, Long Grove, IL 60047 USA.
EM vlazak@illallc.com
CR ARMSTRONG GP, 1950, J CHEM SOC, P666, DOI 10.1039/jr9500000666
   ARMSTRONG JP, 1944, Patent No. 630286
   BERNIES KH, 1956, Patent No. 760367
   BHINDE MV, 2003, AICHE 2 INT AR PROC, P756
   BOOZER CE, 1956, J AM CHEM SOC, V78, P1506, DOI 10.1021/ja01588a062
   CONNER IS, 1953, Patent No. 2632774
   DOBROTVORSKII AM, 1983, 6 MEND DISC KHARK KH, P276
   DOLGOPLOSK BA, 1951, MEKHANIZM INGIHIROVA
   Emanuel' N.M., 1965, TSEPNYE REAKTSII OKI
   EMERSON WS, 1948, Patent No. 2447400
   EPIFANOVA AG, 1977, NEFTEPERERABOTKA NEF, P38
   FLID RM, 1954, ZH PRIKL KHIM, V27, P1145
   FORTUIN JP, 1953, CHEM ENG SCI, V2, P182, DOI 10.1016/0009-2509(53)80040-0
   FULMER JW, 2006, Patent No. 7109385
   GEORGE P, 1946, T FARADAY SOC, V42, P210, DOI 10.1039/tf9464200210
   Grieve WSM, 1934, J CHEM SOC, P1797, DOI 10.1039/jr9340001797
   GRYAZNOV AK, 1991, Patent No. 1699135
   HALL RH, 1948, Patent No. 610293
   HAROLD HR, 1951, Patent No. 2547938
   HAWKINS BLE, 1950, Patent No. 641250
   JORIS GG, 1951, Patent No. 2577768
   JORIS GG, 1954, Patent No. 508505
   JORIS GG, 1953, Patent No. 498028
   JORIS GG, 1952, Patent No. 2621213
   JORIS GG, 1953, Patent No. 498027
   JORIS GG, 1952, Patent No. 2613227
   JORIS GG, 1957, Patent No. 2776999
   JORIS GG, 1952, Patent No. 2619509
   KHARASCH MS, 1950, J ORG CHEM, V15, P753
   KISLINA IS, 1992, IAN SSSR KH, P72
   KISLINA IS, 1986, 4 ALL UN C MECH CA 1, P16
   KISLINA IS, 1989, KINET KATAL, V30, P227
   KISLINA IS, 1988, KINET KATAL, V29, P1471
   Librovich N. B., 1977, IAN SSSR KH, P684
   MOSKOVICH YL, 1987, Patent No. 1391030
   MOSNIER MM, 1954, Patent No. 2681937
   OSIPOVA GF, 1982, IAN SSSR KH, P1001
   SIFNIADES S, 1981, Patent No. 4358618
   SIMANOV VA, 1962, ZH OBSHCH KHIM+, V32, P3179
   SIMANOV VA, 1962, ZH OBSHCH KHIM+, V32, P2925
   SIMANOV VA, 1962, ZH OBSHCH KHIM+, V32, P2919
   SIMANOV VA, 1962, ZH OBSHCH KHIM+, V32, P2914
   SIMANOV VA, 1960, ZH OBSHCH KHIM+, V30, P1420
   SIMANOV VA, 1960, ZH OBSHCH KHIM+, V30, P2153
   VASILEVA II, 2000, NEFTEPERERABOTKA NEF, P34
   VASILEVA II, 2000, 13 INT SCI TECHN C R, P215
   VINNIK MI, 1973, B ACAD SCI USSR CH+, P998
   Weiss J, 1937, J PHYS CHEM-US, V41, P1107, DOI 10.1021/j150386a008
   YUREV YN, 1982, COORD M PROBL PHEN A, P59
   YUREV YN, 1982, COORD M PROBL PHEN A, P73
   ZAKOSHANSKII VM, 1984, ZH FIZ KHIM+, V58, P1265
   ZAKOSHANSKII VM, 1982, COORD M PROBL PHEN A, P75
   ZAKOSHANSKII VM, 1982, COORD M PROBL PHEN A, P59
   ZAKOSHANSKII VM, 2005, PROCESSES OIL TREATM, P108
   ZAKOSHANSKII VM, 1999, Patent No. 2142932
   ZAKOSHANSKII VM, 1999, Patent No. 2141938
   ZAKOSHANSKII VM, 1987, Patent No. 1361937
   ZAKOSHANSKII VM, 1987, SCI C ACID BAS EQ SO, P32
   ZAKOSHANSKII VM, 1985, NEFTEKHIMIYA COLLECT, P121
   ZAKOSHANSKII VM, 1990, Patent No. 1563181
   ZAKOSHANSKII VM, 2002, KATALIZ PROMYSHLENNO, P9
   ZAKOSHANSKII VM, 1982, COORD M PROBL PHEN A, P86
   ZAKOSHANSKII VM, 1998, Patent No. 2108318
   ZAKOSHANSKII VM, 1998, Patent No. 2111203
   ZAKOSHANSKII VM, 2005, Patent No. 2266275
   ZAKOSHANSKY VM, 1996, Patent No. 5530166
   ZAKOSHANSKY VM, 2002, Patent No. 0589588
   ZAKOSHANSKY VM, 2002, Patent No. 0873983
   ZAKOSHANSKY VM, 2000, Patent No. 6066767
   ZAKOSHANSKY VM, 2005, 2 AS PHEN AC DER MAR
   ZAKOSHANSKY VM, 2005, Patent No. 1142855
   ZAKOSHANSKY VM, 2000, Patent No. 0738698
   ZAKOSHANSKY VM, 2003, AICHE 2 INT AR PROC, P794
   ZAKOSHANSKY VM, 1993, Patent No. 5254751
   ZAKOSHANSKY VM, 2002, KATAL KHIM NEFTEKHIM, P29
   ZAKOSHANSKY VM, 2000, Patent No. 6057483
   ZAKOSHANSKY VM, 2001, AICHE 1 INT AR PROC, P166
   ZAKOSHANSKY VM, 1996, Patent No. 5502259
   1956, Patent No. 1111244
   1953, Patent No. 701298
   2002, Patent No. 20030088129
NR 81
TC 1
Z9 1
U1 2
U2 13
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 1070-3632
EI 1608-3350
J9 RUSS J GEN CHEM+
JI Russ. J. Gen. Chem.
PD JUN
PY 2009
VL 79
IS 6
BP 1329
EP 1344
DI 10.1134/S1070363209060474
PG 16
WC Chemistry, Multidisciplinary
SC Chemistry
GA 474WL
UT WOS:000268314900047
OA Bronze
DA 2018-12-27
ER

PT J
AU Zakoshanskii, VM
AF Zakoshanskii, V. M.
TI RETRACTED: Problems of product separation and purification in industrial
   production of phenol (Retracted article. See vol. 79, pg. 1588, 2009)
SO RUSSIAN JOURNAL OF GENERAL CHEMISTRY
LA English
DT Article; Retracted Publication
AB This paper discusses basic distinctions and challenges of available commercial process technologies for fractionation of phenol and acetone products, and for removal of contaminants therefrom. Theoretical improbability of complete removal of impurities from the desired products under fractionation process conditions is conclusively demonstrated. The challenge of achieving an adequate quality of desired products (i.e., of phenol, acetone, and alpha-methylstyrene) has been effectively met within the framework of state-of-the-art phenol/acetone production process.
RP Zakoshanskii, VM (reprint author), 4756 Doncaster Court, Long Grove, IL 60047 USA.
EM vlazak@illallc.com
CR BBINDE MV, 2003, AICHE M NEW ORL 31 M, P757
   KOSHELEV YN, 2005, Patent No. 2266275
   Ogorodnikov S.K., 1971, AZEOTROPNYE SMESI SP
   SIFNIADES S, 1982, Patent No. 4358618
   VASILEVA II, 2000, NEFTEPERERABOTKA NEF, P34
   VASILEVA II, 2001, THESIS PETERSBURG
   VASILEVA II, 2000, 13 INT SCI TECHN C R, P215
   Walas S. M, 1985, PHASE EQUILIBRIA CHE
   WICHTERLE I, 1973, VAPOR LIQUID EQUILIB
   ZAKOSHANSKII VM, 2002, KATALIZ PROMYSHLENNO, P9
   ZAKOSHANSKY VM, 2000, Patent No. 6066767
   ZAKOSHANSKY VM, 2001, Patent No. 6331654
   ZAKOSHANSKY VM, 2005, Patent No. 0944567
   ZAKOSHANSKY VM, 2004, AICHE M NEW ORL 25 2, P483
   ZAKOSHANSKY VM, 2001, Patent No. 0873983
   ZAKOSHANSKY VM, 1998, Patent No. 6057483
   2003, Patent No. 6573408
   2002, Patent No. 6340777
   2002, Patent No. 20030088129
NR 19
TC 1
Z9 1
U1 2
U2 9
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 1070-3632
EI 1608-3350
J9 RUSS J GEN CHEM+
JI Russ. J. Gen. Chem.
PD JUN
PY 2009
VL 79
IS 6
BP 1345
EP 1354
DI 10.1134/S1070363209060486
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA 474WL
UT WOS:000268314900048
OA Bronze
DA 2018-12-27
ER

PT J
AU Zakoshanskii, VM
   Koshelev, YN
AF Zakoshanskii, V. M.
   Koshelev, Yu. N.
TI RETRACTED: Alternative methods of processing of alpha-methylstyrene:
   Hydrogenation into cumene and isolation as commercial product (Retracted
   article. See vol. 79, pg. 1588, 2009)
SO RUSSIAN JOURNAL OF GENERAL CHEMISTRY
LA English
DT Article; Retracted Publication
AB This paper discusses alternative process technologies for hydrogenation of alpha-methylstyrene (AMS) and/or recovery of AMS as a desired product. High selectivity and reliability of existing commercial AMS hydrogenation technologies is demonstrated. A lack of knowledge of or failure to consider certain important details in implementation of technologies for fractionation and recovery of AMS product predictably prevent the plant operators from achieving its required purity, while any attempts to recover an AMS product having a purity of more than 99.5% by weight leads to unreasonable losses of the initial feed. It is further demonstrated that, in the absence of processing of AMS by any method, losses of cumene would exceed chemical losses over all of the stages of a phenol production process.
C1 [Koshelev, Yu. N.] Illa Int, St Petersburg 192148, Russia.
RP Zakoshanskii, VM (reprint author), 4756 Doncaster Court, Long Grove, IL 60047 USA.
EM vlazak@illallc.com; koshelev@illallc.com
CR KOGAN VB, 1966, RAVNOVESIE MEZHDU ZH
   Ogorodnikov S.K., 1971, AZEOTROPNYE SMESI SP
   WICHTERLE I, 1973, VAPOR LIQUID EQUILIB, P1053
   1973, Patent No. 33769358
   1966, Patent No. 3268608
NR 5
TC 1
Z9 1
U1 4
U2 16
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 1070-3632
EI 1608-3350
J9 RUSS J GEN CHEM+
JI Russ. J. Gen. Chem.
PD JUN
PY 2009
VL 79
IS 6
BP 1355
EP 1360
DI 10.1134/S1070363209060498
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA 474WL
UT WOS:000268314900049
OA Bronze
DA 2018-12-27
ER

PT J
AU Bose, JS
   Gangan, V
   Prakash, R
   Jain, SK
   Manna, SK
AF Bose, Julie S.
   Gangan, Vijay
   Prakash, Ravi
   Jain, Swatantra Kumar
   Manna, Sunil Kumar
TI RETRACTED: A Dihydrobenzofuran Lignan Induces Cell Death by Modulating
   Mitochondrial Pathway and G2/M Cell Cycle Arrest (Retracted article. See
   vol. 56, pg. 1787, 2013)
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID PROTEIN-TYROSINE PHOSPHORYLATION; TUMOR-NECROSIS-FACTOR; CYTOCHROME-C
   RELEASE; PERMEABILITY TRANSITION; INDUCED APOPTOSIS; KAPPA-B;
   ACTIVATION; INDUCTION; LEUKEMIA; THERAPY
AB A dihydrobenzofuran lignan, the dimerization product of caffeic acid methyl ester, has shown pronounced antileishmanial and antiplasmodial activities. The present study showed the effect of this compound on cell cycle and apoptosis. Flow cytometric analysis revealed that the cells were arrested in the G2/M phase. Activation of caspase 3, but not caspase 8, generation of ROS, upstream of caspase-3, release of cytochrome c,increase in Bax level, and decrease in Bcl-2 level suggested the involvement of mitochondrial damage. Loss of mitochondrial transmembrane potential independent of caspase activation further suggested the mode of apoptosis. Dihydrobenzofuran-mediated cell death was absent in Bcl-xL-overexpressed cells. Overall, our results justify the role of dihydrobenzofuran lignan as potential antitumor agent, causing G2/M arrest and apoptosis involving the mitochondrial controlled pathway. These findings open promising insights as to how this specific dihydrobenzofuran lignan mediates cytotoxicity and may prove a molecular rationale for future therapeutic interventions in carcinogenesis.
C1 [Prakash, Ravi; Manna, Sunil Kumar] Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India.
   [Bose, Julie S.; Gangan, Vijay] Reliance Life Sci Pvt Ltd, Bombay, Maharashtra, India.
   [Jain, Swatantra Kumar] All India Inst Med Sci, Dept Biotechnol, New Delhi 110029, India.
RP Manna, SK (reprint author), Ctr DNA Fingerprinting & Diagnost, Immunol Lab, ECIL Rd, Hyderabad 500076, Andhra Pradesh, India.
EM manna@cdfd.org.in
FU Reliance Life Sciences; Centre for DNA Fingerprinting and Diagnostics
   (CDFD)
FX This work was supported by the Reliance Life Sciences and core grant of
   Centre for DNA Fingerprinting and Diagnostics (CDFD). We duly thank Dr.
   J. V. Raman, Research Director and Head, Chemical Research Technology
   Group, Reliance Life Sciences, and Prof. T. Ramasarma, Distinguished
   Chair, CDFD, Hyderabad, for valuable comments on the work.
CR Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881
   Apers S, 2002, J NAT PROD, V65, P718, DOI 10.1021/np0103968
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941
   CANTLEY LC, 1991, CELL, V64, P707
   Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1
   FAR DF, 1994, CYTOMETRY, V15, P327, DOI 10.1002/cyto.990150408
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Groninger E, 2002, INT J ONCOL, V21, P1339
   HERSON PM, 2001, CURR BIOL, V11, pR795
   Hirsch T, 1998, CELL BIOL TOXICOL, V14, P141, DOI 10.1023/A:1007486022411
   Hu W, 2003, LANCET ONCOL, V4, P721, DOI 10.1016/S1470-2045(03)01277-4
   Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619
   Lee E, 1998, CANCER LETT, V134, P163, DOI 10.1016/S0304-3835(98)00253-5
   LEMIERE G, 1995, J CHEM SOC PERK T 1, P1775, DOI 10.1039/p19950001775
   LUI VW, 2002, ANTICANCER RES, V22, P681
   Manna SK, 2007, CELL DEATH DIFFER, V14, P158, DOI 10.1038/sj.cdd.4401929
   Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155
   MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x
   Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069
   O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306
   PAN G, 1998, J BIOL CHEM, V273, P5941
   Park JB, 2003, CANCER LETT, V202, P161, DOI 10.1016/j.canlet.2003.08.010
   PAUL MK, 2004, INT J MED SCI, V1, P101, DOI DOI 10.7150/IJMS.1.101
   Pepper C, 1997, BRIT J CANCER, V76, P935, DOI 10.1038/bjc.1997.487
   PIETERS L, 1993, J NAT PROD, V56, P899, DOI 10.1021/np50096a013
   Pieters L, 1999, J MED CHEM, V42, P5475, DOI 10.1021/jm990251m
   Raghavendra PB, 2007, APOPTOSIS, V12, P307, DOI 10.1007/s10495-006-0626-3
   SAINSBURY JRC, 1987, LANCET, V1, P1398
   Sarkar A, 2004, J BIOL CHEM, V279, P33768, DOI 10.1074/jbc.M403424200
   Sreenivasan Y, 2003, ONCOGENE, V22, P4356, DOI 10.1038/sj.onc.1206486
   Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9
   Taraphdar AK, 2001, CURR SCI INDIA, V80, P1387
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907
   Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696
   Van Miert S, 2005, BIOORGAN MED CHEM, V13, P661, DOI 10.1016/j.bmc.2004.10.058
   WARD RS, 1982, CHEM SOC REV, V11, P75, DOI 10.1039/cs9821100075
   Yoshimura FK, 2004, CANC THER, V2, P429
NR 39
TC 36
Z9 36
U1 4
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD MAY 28
PY 2009
VL 52
IS 10
BP 3184
EP 3190
DI 10.1021/jm8015766
PG 7
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 448XV
UT WOS:000266296200008
PM 19402632
DA 2018-12-27
ER

PT J
AU Karp, DD
   Paz-Ares, LG
   Novello, S
   Haluska, P
   Garland, L
   Cardenal, F
   Blakely, LJ
   Eisenberg, PD
   Langer, CJ
   Blumenschein, G
   Johnson, FM
   Green, S
   Gualberto, A
AF Karp, Daniel D.
   Paz-Ares, Luis G.
   Novello, Silvia
   Haluska, Paul
   Garland, Linda
   Cardenal, Felipe
   Blakely, L. Johnetta
   Eisenberg, Peter D.
   Langer, Corey J.
   Blumenschein, George, Jr.
   Johnson, Faye M.
   Green, Stephanie
   Gualberto, Antonio
TI RETRACTED: Phase II Study of the Anti-Insulin-Like Growth Factor Type 1
   Receptor Antibody CP-751,871 in Combination With Paclitaxel and
   Carboplatin in Previously Untreated, Locally Advanced, or Metastatic
   Non-Small-Cell Lung Cancer (Retracted article. See vol. 30, pg. 4179,
   2012)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 33rd Congress of the European-Society-for-Medical-Oncology (ESMO)
CY SEP 12-16, 2008
CL Stockholm, SWEDEN
SP European Soc Med Oncol (ESMO)
ID CHEMOTHERAPY-NAIVE PATIENTS; COMPARING CISPLATIN; PLASMA-LEVELS; IGF;
   BEVACIZUMAB; INHIBITION; EXPRESSION; RESISTANCE; CARCINOMA; THERAPY
AB Purpose
   We conducted a phase II study of combination of the anti-insulin-like growth factor 1 receptor antibody CP-751,871 with paclitaxel and carboplatin (PCI) in advanced treatment-naive non-small-cell lung cancer (NSCLC).
   Patients and Methods
   Patients were randomly assigned (2:1) to paclitaxel 200 mg/m(2), carboplatin (area under the plasma concentration-time curve of 6), and CP-751,871 10 to 20 mg/kg (PCI10, PCI20) or paclitaxel and carboplatin alone ( PC) every 3 weeks for up to six cycles. PCI10-20 patients could continue CP-751,871 ( figitumumab) treatment after chemotherapy discontinuation. Patients treated with PC experiencing disease progression were eligible to receive CP-751,871 at investigator's discretion. An additional nonrandomized single-arm cohort of 30 patients with nonadenocarcinoma tumor histology receiving PCI20 was enrolled on completion of the randomized study.
   Results
   A total of 156 patients were enrolled onto the randomized portion of the study. Safety and efficacy information are available for 151 patients (98 patients treated with PCI and 53 patients treated with PC). Forty-eight patients treated with PCI received PCI10 and 50 patients received PCI20 in two sequential stages. Twenty of 53 patients treated with PC received CP-751,871 after disease progression. PCI was well tolerated. Fifty-four percent of patients treated with PCI and 42% of patients treated with PC had objective responses. Sixteen of 23 patients assessable for efficacy in the nonrandomized single-arm extension cohort also responded to treatment. Of note, 14 of 18 randomly assigned and 11 of 14 nonrandomly assigned patients treated with PCI with squamous cell carcinoma histology had response to treatment, including nine objective responses in bulky disease. Responses were also observed in two patients with squamous histology receiving CP-751,871 on PC discontinuation. PCI20/PC hazard ratio for progression-free survival was 0.8 to 0.56, according to censorship.
   Conclusion
   These data suggest that PCI20 is safe and effective in patients with NSCLC.
C1 [Gualberto, Antonio] Pfizer Global Res & Dev, New London, CT 06320 USA.
   Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Univ Hosp Doce de Octubre, Madrid, Spain.
   Inst Catala Oncol, Barcelona, Spain.
   Univ Turin, Turin, Italy.
   Mayo Clin Fdn, Rochester, MN USA.
   Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA.
   West Clin, Memphis, TN USA.
   Calif Canc Care, Greenbrae, CA USA.
   Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
RP Gualberto, A (reprint author), Pfizer Global Res & Dev, 50 Pequot Ave,MS6025-A3266, New London, CT 06320 USA.
EM antonio.gualberto@pfizer.com
RI IBIS, NUEVAS TERAPIA/P-3415-2015
CR Ardizzoni A, 2006, J CLIN ONCOL, V24, p366S
   Beasley MB, 2005, SEMIN ROENTGENOL, V40, P90, DOI 10.1053/j.ro.2005.01.001
   Blumenschein GR, 2005, J CLIN ONCOL, V23, p621S
   Bunn PA, 2002, J CLIN ONCOL, V20, P3565, DOI 10.1200/JCO.2002.20.17.3565
   Buyse ME, 2008, J CLIN ONCOL S, V26, p428s
   CARLES J, 1993, LUNG CANCER, V10, P209, DOI 10.1016/0169-5002(93)90181-V
   Chang NS, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-8
   Chiappori AA, 2008, CLIN CANCER RES, V14, P1464, DOI 10.1158/1078-0432.CCR-07-1508
   Cohen BD, 2005, CLIN CANCER RES, V11, P2063, DOI 10.1158/1078-0432.CCR-04-1070
   Haluska P, 2007, CLIN CANCER RES, V13, P5834, DOI 10.1158/1078-0432.CCR-07-1118
   Han CH, 2006, ONCOL REP, V16, P1205
   Han JY, 2006, LUNG CANCER, V54, P227, DOI 10.1016/j.lungcan.2006.07.014
   Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022
   Jones HE, 2006, ENDOCR-RELAT CANCER, V13, pS45, DOI 10.1677/erc.1.01275
   KAISER U, 1993, J CANCER RES CLIN, V119, P665, DOI 10.1007/BF01215985
   Kato T, 2007, CLIN CANCER RES, V13, P434, DOI 10.1158/1078-0432.CCR-06-1297
   Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437
   Lacy MQ, 2008, J CLIN ONCOL, V26, P3196, DOI 10.1200/JCO.2007.15.9319
   MANEGOLD C, 2007, J CLIN ONCOL S, V25, pS388
   MERRICK DT, 2007, J CLIN ONCOL S, V25, pS397
   Morgillo F, 2007, CLIN CANCER RES, V13, P2795, DOI 10.1158/1078-0432.CCR-06-2077
   Pavelic J, 2005, AM J RESP CELL MOL, V32, P65, DOI 10.1165/rcmb.2004-0232OC
   PIRKER R, 2008, J CLIN ONCOL S, V26, pS6
   POLLAK M, 2007, AM ASS CANC RES ANN
   Riedemann J, 2006, ENDOCR-RELAT CANCER, V13, pS33, DOI 10.1677/erc.1.01280
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375
   Shevah O, 2007, GROWTH HORM IGF RES, V17, P54, DOI 10.1016/j.ghir.2006.10.007
   SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9
   Spitz MR, 2002, CANCER EPIDEM BIOMAR, V11, P1413
   Suh Y, 2008, P NATL ACAD SCI USA, V105, P3438, DOI 10.1073/pnas.0705467105
   Yamazaki S, 2005, LUNG CANCER-J IASLC, V49, P217, DOI 10.1016/j.lungcan.2005.01.008
   Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151
NR 33
TC 216
Z9 221
U1 4
U2 23
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2009
VL 27
IS 15
BP 2516
EP 2522
DI 10.1200/JCO.2008.19.9331
PG 7
WC Oncology
SC Oncology
GA 447MO
UT WOS:000266195400018
PM 19380445
DA 2018-12-27
ER

PT J
AU Takai, N
   Ueda, T
   Nasu, K
   Yamashita, S
   Toyofuku, M
   Narahara, H
AF Takai, Noriyuki
   Ueda, Tami
   Nasu, Kaei
   Yamashita, Satoko
   Toyofuku, Mayo
   Narahara, Hisashi
TI RETRACTED: Targeting calcium/calmodulin-dependence kinase I and II as a
   potential anti-proliferation remedy for endometrial carcinomas
   (Retracted article. See vol. 338, pg. 329, 2013)
SO CANCER LETTERS
LA English
DT Article; Retracted Publication
DE Calcium; Calmodulin; Cell cycle; Apoptosis; Endometrial cancer
ID CELL-CYCLE PROGRESSION; BREAST-CANCER CELLS; CAMK-II; APOPTOSIS;
   CALMODULIN; EXPRESSION; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION;
   INHIBITORS
AB Calcium/calmodulin-dependent kinase (CaMK) I and II expression in endometrial cancer cells correlates with the malignant potential of this tumor, and CaMKI and II are potential therapeutic targets in endometrial cancer. CaMKI and II expression was significantly associated with PCNA-labeling index, clinical stage, histological grade, the presence of invasion to greater than one-half the myometrium, and clinical outcome. All endometrial cancer cell lines examined were sensitive to the growth-inhibitory effect of KN-93, a membrane-permeant CaMKs-selective inhibitor that is competitive with calmodulin. KN-93 induced the G0/G1 arrest and apoptosis, rising hopes that KN-93 may become a useful treatment for endometrial cancers. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Takai, Noriyuki; Ueda, Tami; Nasu, Kaei; Yamashita, Satoko; Toyofuku, Mayo; Narahara, Hisashi] Oita Univ, Fac Med, Dept Obstet & Gynecol, Yufu, Oita 8795593, Japan.
RP Takai, N (reprint author), Oita Univ, Fac Med, Dept Obstet & Gynecol, 1-1 Idaigaioka,Hasama Machi, Yufu, Oita 8795593, Japan.
EM takai@med.oita-u.ac.jp
FU Japan Society of Gynecologic Oncology [FK344]; Ministry of Education,
   Culture, Sports, Science, and Technology, Japan [16790961]
FX The study was supported by a Grant (project code FK344 to NT) from Japan
   Society of Gynecologic Oncology and a Grant-in-Aid (No. 16790961 to NT)
   for Scientific Research from the Ministry of Education, Culture, Sports,
   Science, and Technology, Japan.
CR Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108
   Chen Y, 2001, CANCER RES, V61, P6437
   Colbran RJ, 2004, BIOCHEM J, V378, P1, DOI 10.1042/BJ20031547
   Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179
   Fladmark KE, 2002, J BIOL CHEM, V277, P2804, DOI 10.1074/jbc.M109049200
   Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2
   Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959
   HICKIE RA, 1983, CAN J BIOCHEM CELL B, V61, P934, DOI 10.1139/o83-119
   Howe CJ, 2002, J BIOL CHEM, V277, P30469, DOI 10.1074/jbc.M205036200
   Howe CJ, 2004, J BIOL CHEM, V279, P44573, DOI 10.1074/jbc.M404175200
   Hsu LS, 2001, J BIOL CHEM, V276, P31113, DOI 10.1074/jbc.M011720200
   Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295
   Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003-0008
   Kahl CR, 2004, J BIOL CHEM, V279, P15411, DOI 10.1074/jbc.M312543200
   Kawamura KI, 1996, BIOCHEM PHARMACOL, V52, P1903, DOI 10.1016/S0006-2952(96)00692-2
   Kyushima N, 2002, J CANCER RES CLIN, V128, P307, DOI 10.1007/s00432-002-0328-3
   Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473
   Racioppi L, 2008, TRENDS IMMUNOL, V29, P600, DOI 10.1016/j.it.2008.08.005
   Rimon G, 1997, J NEUROSCI RES, V48, P563, DOI 10.1002/(SICI)1097-4547(19970615)48:6<563::AID-JNR9>3.0.CO;2-8
   Rodriguez-Mora OG, 2005, CANCER RES, V65, P5408, DOI 10.1158/0008-5472.CAN-05-0271
   Satsu H, 2004, FEBS LETT, V569, P123, DOI 10.1016/j.febslet.2004.05.062
   Shang SJ, 2003, INT J MOL MED, V11, P181
   Sherr CJ, 2000, CANCER RES, V60, P3689
   SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1
   SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E
   Sutherland RL, 2002, BREAST CANCER RES, V4, P14, DOI 10.1186/bcr411
   Takai N, 2000, CANCER, V89, P2059, DOI 10.1002/1097-0142(20001115)89:10<2059::AID-CNCR5>3.0.CO;2-3
   Takai N, 2004, CANCER-AM CANCER SOC, V101, P2760, DOI 10.1002/cncr.20709
   TAKAI N, 2001, CLIN CANCER RES, V10, P1141
   TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640
   TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063
   Tombes RM, 1997, BBA-MOL CELL RES, V1355, P281, DOI 10.1016/S0167-4889(96)00141-3
   Wang CM, 2008, J BIOL CHEM, V283, P11565, DOI 10.1074/jbc.M800436200
   WEI JW, 1983, CANCER CHEMOTH PHARM, V11, P86
   Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200
NR 35
TC 16
Z9 23
U1 67
U2 82
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAY 18
PY 2009
VL 277
IS 2
BP 235
EP 243
DI 10.1016/j.canlet.2008.12.018
PG 9
WC Oncology
SC Oncology
GA 437GT
UT WOS:000265475600016
PM 19168280
DA 2018-12-27
ER

PT J
AU Gadgeel, SM
   Ali, S
   Philip, PA
   Wozniak, A
   Sarkar, FH
AF Gadgeel, Shirish M.
   Ali, Shadan
   Philip, Philip A.
   Wozniak, Antoinette
   Sarkar, Fazlul H.
TI RETRACTED: Genistein Enhances the Effect of Epidermal Growth Factor
   Receptor Tyrosine Kinase Inhibitors and Inhibits Nuclear Factor Kappa B
   in Nonsmall Cell Lung Cancer Cell Lines (Retracted article. See vol.
   122, pg. 3248, 2016)
SO CANCER
LA English
DT Article; Retracted Publication
DE genistein; erlotinib; gefitinib; epidermal growth factor receptor
   mutations; nonsmall cell lung cancer
ID E-CADHERIN EXPRESSION; MESENCHYMAL TRANSITION; EGFR GENE; GEFITINIB;
   SENSITIVITY; ERLOTINIB; AKT; ACTIVATION; MUTATIONS; PROTEIN
AB BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have shown modest clinical benefit in patients with relapsed nonsmall cell lung cancer (NSCLC). Down-regulation of Akt appears to correlate with the antitumor activity of EGFR-TKIs. Akt activates nuclear factor kappa B (NF-kappa B), which transcribes genes important for cell survival, invasion, and metastasis. The authors hypothesized that genistein, through the inhibition of NF-kappa B, could enhance the activity of EGFR-TKIs in NSCLCs. METHODS: Three NSCLC cell lines with various EGFR mutation status and sensitivities to EGFR-TKIs were selected: H3255 (L858R), H16SO (del E746-A750), and H1781 (wild-type EGFR). Cells were treated with erlotinib, gefitinib, genistein, or the combination of each of the EGFR-TKIs with genistein. Cell survival and apoptosis were assessed, and expression levels of EGFR, pAkt, cyclooxygenase-2 (COX-2), E-cadherin, prostaglandin E-2 (PGE(2)), and NF-kappa B were measured, RESULTS: Both EGFR-TKIs demonstrated growth inhibition and apoptosis in each of the cell lines, but H1650 and H1781 were much less sensitive. Genistein demonstrated some antitumor activity in all cell lines, but enhanced growth inhibition and apoptosis when combined with the EGFR-TKIs in each of the cell lines. Both combinations down-regulated NF-KB significantly more than either agent alone in H3255. In addition, the combinations reduced the expression of EGFR, pAkt, COX-2, and PGE2, consistent with inactivation of NF-KB. CONCLUSIONS: The authors concluded that genistein enhances the antitumor effects of EGFR-TKIs in 3 separate NSCLC cell lines. This enhanced activity is in part because of greater reduction in the DNA-binding activity of NF-kappa B when EGFR-TKIs were combined with genistein. Cancer 2009;115:2165-76. (C) 2009 American Cancer Society.
C1 [Gadgeel, Shirish M.; Ali, Shadan; Philip, Philip A.; Wozniak, Antoinette] Wayne State Univ, Karmanos Canc Ctr, Div Hematol Oncol, Detroit, MI 48201 USA.
   [Sarkar, Fazlul H.] Wayne State Univ, Karmanos Canc Ctr, Dept Pathol, Detroit, MI 48201 USA.
RP Gadgeel, SM (reprint author), Wayne State Univ, Karmanos Canc Ctr, Div Hematol Oncol, 4100 John R St,4 HWCRC, Detroit, MI 48201 USA.
EM gadgeels@karmanos.org
CR Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0
   Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1
   Cappuzzo F, 2005, J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112
   Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808
   El-Rayes BF, 2006, CANCER RES, V66, P10553, DOI 10.1158/0008-5472.CAN-06-2333
   Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102
   Gadgeel SM, 2007, CANCER-AM CANCER SOC, V110, P2775, DOI 10.1002/cncr.23100
   Gazdar AF, 2008, CANCER PREV RES, V1, P156, DOI 10.1158/1940-6207.CAPR-08-0080
   Hirsch FR, 2007, ANN ONCOL, V18, P752, DOI 10.1093/annonc/mdm003
   Janmaat ML, 2006, INT J CANCER, V118, P209, DOI 10.1002/ijc.21290
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546
   Li TH, 2008, J THORAC ONCOL, V3, P643, DOI 10.1097/JTO.0b013e3181753b24
   Li YW, 2005, CANCER RES, V65, P6934, DOI 10.1158/0008-5472.CAN-04-4604
   Lind J S W, 2008, Ned Tijdschr Geneeskd, V152, P928
   Ling YH, 2008, MOL PHARMACOL, V74, P793, DOI 10.1124/mol.107.044396
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Rho JK, 2009, LUNG CANCER, V63, P219, DOI 10.1016/j.lungcan.2008.05.017
   Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957
   Sethi G, 2007, ONCOGENE, V26, P7324, DOI 10.1038/sj.onc.1210544
   Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753
   Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189
   Tang XM, 2006, CANCER, V107, P2637, DOI 10.1002/cncr.22315
   Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8
   Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492
   Zhang Xiaozhu, 2008, Int J Med Sci, V5, P209
NR 30
TC 66
Z9 72
U1 5
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAY 15
PY 2009
VL 115
IS 10
BP 2165
EP 2176
DI 10.1002/cncr.24250
PG 12
WC Oncology
SC Oncology
GA 439HB
UT WOS:000265617100020
PM 19288574
OA Bronze
DA 2018-12-27
ER

PT J
AU Coats, AJS
AF Coats, Andrew J. S.
TI RETRACTED: Resynchronization of the infarcted myocardium (Retracted
   Article. See vol 131, 2009)
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Correction; Retracted Publication
C1 Univ Sydney, Sydney, NSW 2006, Australia.
RP Coats, AJS (reprint author), Univ Sydney, Sydney, NSW 2006, Australia.
EM ajscoats@aol.com
CR Coats AJS, 2009, INT J CARDIOL, V131, P149, DOI 10.1016/j.ijcard.2008.11.048
   COATS JSA, 2009, RESYNCHRONIZATION IN
   Pijnappels DA, 2007, CIRCULATION, V116, P2018, DOI 10.1161/CIRCULATIONAHA.107.712935
   SONG ZZ, 2009, INT J CARDIOL   0109
NR 4
TC 1
Z9 1
U1 2
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD MAY 15
PY 2009
VL 134
IS 2
BP 149
EP 149
DI 10.1016/j.ijcard.2009.03.068
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 448LQ
UT WOS:000266264500001
PM 19344963
DA 2018-12-27
ER

PT J
AU Gangadharan, C
   Thoh, M
   Manna, SK
AF Gangadharan, Charitha
   Thoh, Maikho
   Manna, Sunil K.
TI RETRACTED: Inhibition of Constitutive Activity of Nuclear Transcription
   Factor kappaB Sensitizes Doxorubicin-Resistant Cells to Apoptosis
   (Retracted article. See vol. 114, pg. 1456, 2013)
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE NF-kappa B; DOXORUBICIN; APOPTOSIS; DRUG-RESISTANCE; P-3-25
ID TUMOR-NECROSIS-FACTOR; ACTIVATOR PROTEIN-1; POTENTIATES APOPTOSIS;
   ANTICANCER DRUG; B ACTIVATION; CANCER-CELLS; EXPRESSION; PATHWAY;
   2-ACETYLAMINOFLUORENE; CHEMORESISTANCE
AB Doxorubicin is one of the most effective agents used in the treatment of various tumors. Its use is restricted by the development of resistance to apoptosis, the mechanism of which is not fully understood. Nuclear transcription factor kappaB (NF-kappa B) has been shown both to block apoptosis and to promote cell proliferation, and hence has been considered as an important target for anticancer drug development. We found that in wild type and Dox-revertant MCF-7 cells, Doxorubicin induced NF-kappa B was transient and Dox-resistant cells showed high basal activity of NF-kappa B and expression of genes dependent on it. Moreover, in resistant cells Doxorubicin was unable to induce apoptosis as detected by assays for reactive oxygen intermediates generation, lipid peroxidation, cytotoxicity, PARP degradation and Bcl-2 expression. High basal expressions of multi-drug resistant protein and transglutaminase were found in Dox-resistant cells and inhibition of NF-kappa B decreased those amounts and also sensitized these cells by Doxorubicin. These observations collectively suggest that high NF-kappa B activity confers resistance to Doxorubicin and its inhibition potentiates apoptosis. This study indicates that NF-kappa B plays an important role in chemoresistance and establishes the fact that inhibition of NF-kappa B will be a novel approach in chemotherapy. J. Cell. Biochem. 107: 203-213, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Gangadharan, Charitha; Thoh, Maikho; Manna, Sunil K.] Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India.
RP Manna, SK (reprint author), Ctr DNA Fingerprinting & Diagnost, Immunol Lab, ECIL Rd, Hyderabad 500076, Andhra Pradesh, India.
EM manna@cdfd.org.in
FU Institutional Core Grant (Department of Biotechnology); Department of
   Science and Technology Fast Track [SR/FT/L-50/2003]
FX Grant sponsor: Institutional Core Grant (Department of Biotechnology);
   Grant sponsor: Department of Science and Technology Fast Track; Grant
   number: SR/FT/L-50/2003.
CR Andrassy M, 2002, CLIN NEPHROL, V58, P179
   Barre B, 2007, EMBO J, V26, P4841, DOI 10.1038/sj.emboj.7601899
   BLUM RH, 1974, ANN INTERN MED, V80, P249, DOI 10.7326/0003-4819-80-2-249
   Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008
   Chen JSK, 2002, BREAST CANCER RES TR, V71, P237, DOI 10.1023/A:1014461832403
   Christman JW, 1998, INTENS CARE MED, V24, P1131, DOI 10.1007/s001340050735
   Chuang SE, 2002, BIOCHEM PHARMACOL, V63, P1709, DOI 10.1016/S0006-2952(02)00931-0
   Cusack JC, 1999, DRUG RESIST UPDATE, V2, P271, DOI 10.1054/drup.1999.0094
   Deng L, 2001, J BIOL CHEM, V276, P413, DOI 10.1074/jbc.M004551200
   Devarajan E, 2002, INT J ONCOL, V20, P913
   Fischer Uwe M, 2006, Interact Cardiovasc Thorac Surg, V5, P531, DOI 10.1510/icvts.2006.130765
   Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008
   HARRIS GR, 1993, CANC BREAST, P1264
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Jobin C, 2000, AM J PHYSIOL-CELL PH, V278, pC451
   Jurisicova A, 2006, CELL DEATH DIFFER, V13, P1466, DOI 10.1038/sj.cdd.4401819
   Kalivendi SV, 2005, BIOCHEM J, V389, P527, DOI 10.1042/BJ20050285
   Kuo MT, 2002, ONCOGENE, V21, P1945, DOI 10.1038/sj/onc/1205117
   Manna SK, 2007, CELL DEATH DIFFER, V14, P158, DOI 10.1038/sj.cdd.4401929
   Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245
   Manna SK, 1999, J IMMUNOL, V162, P1510
   Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811
   Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509
   Mikami T, 2006, ANTICANCER RES, V26, P1153
   Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151
   Reynolds CP, 2004, CANCER LETT, V206, P169, DOI 10.1016/j.canlet.2003.08.034
   Rojo AI, 2004, J NEUROSCI, V24, P7324, DOI 10.1523/JNEUROSCI.2111-04.2004
   Sarkar A, 2004, J BIOL CHEM, V279, P33768, DOI 10.1074/jbc.M403424200
   SHIMOKAWA I, 2004, GERIATR GERONTOL INT, V4, P5149
   Sreenivasan Y, 2003, BIOCHEM PHARMACOL, V66, P2223, DOI 10.1016/j.bcp.2003.07.010
   Verma A, 2007, DRUG RESIST UPDATE, V10, P144, DOI 10.1016/j.drup.2007.06.002
   Wang CY, 1999, MOL CELL BIOL, V19, P5923
   Wang CY, 1999, NAT MED, V5, P412
NR 33
TC 26
Z9 28
U1 3
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAY 15
PY 2009
VL 107
IS 2
BP 203
EP 213
DI 10.1002/jcb.22115
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 442SG
UT WOS:000265860300003
PM 19242952
DA 2018-12-27
ER

PT J
AU Hah, SS
AF Hah, Sang Soo
TI RETRACTED: Determination of Protein-Ligand Interactions Using
   Accelerator Mass Spectrometry: Modified Crosslinking Assay (Retracted
   article. See vol. 28, pg. 827, 2012)
SO ANALYTICAL SCIENCES
LA English
DT Article; Retracted Publication
ID IDENTIFICATION
AB A highly sensitive detection method for the determination of protein-ligand interactions has been developed. Radiocarbon-labeled 17 beta-estradiol was incubated with estrogen receptor-alpha as it selective binding partner, and covalently attached using crosslinking agents, to form covalently linked protein-ligand complexes. After separation using a denaturing gel, the C-14 content in the sliced gels was identified by accelerator mass spectrometry. The obtained data demonstrated specific binding of the small molecule to its binding partner. In theory, this method can be applied to most protein-ligand interaction studies.
C1 [Hah, Sang Soo] Kyung Hee Univ, Dept Chem, Seoul 130701, South Korea.
   [Hah, Sang Soo] Kyung Hee Univ, Res Inst Basic Sci, Seoul 130701, South Korea.
RP Hah, SS (reprint author), Kyung Hee Univ, Dept Chem, Seoul 130701, South Korea.
EM sshah@khu.ac.kr
RI Hah, Sang Soo/D-2621-2011
FU U. S. Department of Energy by Lawrence Livermore National Laboratory
   [DE-AC52-07NA27344]; National Institutes of Health [RR13461]; Kyung Hee
   University Research Fund in 2008 [KHU-20081559]
FX Kurt Hack is acknowledged for preparing AMS samples, as well as Paul T.
   Henderson and Kenneth W. Turteltaub for helpful advice and the
   interpretation of data. This work was performed at the Research Resource
   for Biomedical Accelerator Mass Spectrometry under the auspices of the
   U. S. Department of Energy by Lawrence Livermore National Laboratory
   under contract DE-AC52-07NA27344, and was supported in part by National
   Institutes of Health Grants RR13461 and by the Kyung Hee University
   Research Fund in 2008 (KHU-20081559).
CR Biggin MD, 2001, NAT GENET, V28, P303, DOI 10.1038/91045
   Carlson KE, 1997, BIOCHEMISTRY-US, V36, P14897, DOI 10.1021/bi971746l
   Jenke ACW, 2004, P NATL ACAD SCI USA, V101, P11322, DOI 10.1073/pnas.0401355101
   Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197
   Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925
   Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863
   Lappin G, 2003, NAT REV DRUG DISCOV, V2, P233, DOI 10.1038/nrd1037
   Toth J, 2000, Nucleic Acids Res, V28, pe4, DOI 10.1093/nar/28.2.e4
   Vogel JS, 2001, ELECTROPHORESIS, V22, P2037, DOI 10.1002/1522-2683(200106)22:10<2037::AID-ELPS2037>3.0.CO;2-8
   VOGEL JS, 2005, BIOTECHNIQUES S, P25
   Wang L, 2005, ANGEW CHEM INT EDIT, V44, P34, DOI 10.1002/anie.200460627
   Zhang CX, 2004, J AM CHEM SOC, V126, P6536, DOI 10.1021/ja049533o
NR 12
TC 7
Z9 7
U1 4
U2 18
PU JAPAN SOC ANALYTICAL CHEMISTRY
PI TOKYO
PA 26-2 NISHIGOTANDA 1 CHOME SHINAGAWA-KU, TOKYO, 141, JAPAN
SN 0910-6340
EI 1348-2246
J9 ANAL SCI
JI Anal. Sci.
PD MAY
PY 2009
VL 25
IS 5
BP 731
EP 733
DI 10.2116/analsci.25.731
PG 3
WC Chemistry, Analytical
SC Chemistry
GA 447IZ
UT WOS:000266186100025
PM 19430162
OA Bronze
DA 2018-12-27
ER

PT J
AU Hocker, J
   Stapelfeldt, C
   Leiendecker, J
   Meybohm, P
   Hanss, R
   Scholz, J
   Bein, B
AF Hoecker, Jan
   Stapelfeldt, Claudia
   Leiendecker, Joern
   Meybohm, Patrick
   Hanss, Robert
   Scholz, Jens
   Bein, Berthold
TI RETRACTED: Postoperative Neurocognitive Dysfunction in Elderly Patients
   after Xenon versus Propofol Anesthesia for Major Noncardiac Surgery A
   Double-blinded Randomized Controlled Pilot Study (Retracted article. See
   vol. 121, pg. 772, 2014)
SO ANESTHESIOLOGY
LA English
DT Article; Retracted Publication
ID COGNITIVE DYSFUNCTION; CARDIOPULMONARY BYPASS; GENERAL-ANESTHESIA;
   CEREBRAL-ISCHEMIA; ELECTROENCEPHALOGRAM; DAMAGE; RATS
AB Background: Postoperative cognitive dysfunction (POCD) in elderly patients after noncardiac surgery is a common problem. The noble gas xenon has been demonstrated to exert substantial neuroprotective proper-ties in animal studies. Therefore, this study was designed to assess POCD after xenon anesthesia in comparison to propofol in elderly patients undergoing major noncardiac surgery.
   Methods: After approval of the local ethical committee was obtained, 101 patients (American Society of Anesthesiologists physical status I-III; age, 65-83 yr) undergoing elective abdominal or urologic surgery (duration, > 2 h) were enrolled into this randomized, double-blinded controlled pilot study. Patients received anesthesia with sufentanil and either propofol or xenon and were assessed before treatment and 1, 6, and 30 days after treatment using a neuropsychological test battery based on previous studies investigating POCD.
   Results: There were no significant differences in terms of age, American Society of Anesthesiologists status, education, duration of surgery, administered analgetics, and preoperative neurocognitive status between study groups. POCD as classified was present in 22 patients (44%) of the xenon group versus 25 patients (50%) of the propofol group 1 day after treatment, in 6 xenon patients (12%) versus 9 propofol patients (18%) 6 days after treatment, and in 3 xenon patients (6%) versus 6 propofol patients (12%) 30 days after treatment. These differences were not statistically significant.
   Conclusion: Postoperative impairment of neurocognitive function was observed in a substantial proportion of elderly patients even 30 days after treatment. Xenon-based anesthesia was not associated with decreased incidence of POCD in comparison to propofol.
C1 [Hoecker, Jan; Stapelfeldt, Claudia; Leiendecker, Joern; Meybohm, Patrick; Hanss, Robert; Scholz, Jens; Bein, Berthold] Univ Hosp Schleswig Holstein, Dept Anaesthesiol & Intens Care Med, D-24105 Kiel, Germany.
RP Hocker, J (reprint author), Univ Hosp Schleswig Holstein, Dept Anaesthesiol & Intens Care Med, Campus Kiel,Schwanenweg 21, D-24105 Kiel, Germany.
EM hoecker@anaesthesie.uni-kiel.de
RI Meybohm, Patrick/K-4066-2017
OI Meybohm, Patrick/0000-0002-2666-8696
CR Ancelin ML, 2001, BRIT J PSYCHIAT, V178, P360, DOI 10.1192/bjp.178.4.360
   Bayona NA, 2004, ANESTHESIOLOGY, V100, P1151, DOI 10.1097/00000542-200405000-00017
   BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561
   Bland JM, 1996, BMJ-BRIT MED J, V312, P1153
   Canet J, 2003, ACTA ANAESTH SCAND, V47, P1204, DOI 10.1046/j.1399-6576.2003.00238.x
   CHOI DW, 1988, J NEUROSCI, V8, P185
   Coburn M, 2007, BRIT J ANAESTH, V98, P756, DOI 10.1093/bja/aem103
   Coburn M, 2005, EUR J ANAESTH, V22, P870, DOI 10.1017/S026502150500147X
   Crawley F, 2000, STROKE, V31, P1329, DOI 10.1161/01.STR.31.6.1329
   Engelhard K, 2004, ANESTHESIOLOGY, V101, P912, DOI 10.1097/00000542-200410000-00016
   Enlund M, 1998, UPSALA J MED SCI, V103, P43, DOI 10.3109/03009739809178944
   Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525
   Gelb AW, 2002, ANESTHESIOLOGY, V96, P1183, DOI 10.1097/00000542-200205000-00023
   Goto T, 2000, BRIT J ANAESTH, V85, P359, DOI 10.1093/bja/85.3.359
   Homi HM, 2003, ANESTHESIOLOGY, V99, P876, DOI 10.1097/00000542-200310000-00020
   Iohom G, 2004, ANESTH ANALG, V99, P1245, DOI 10.1213/01.ANE.0000132971.00206.4A
   Johnson T, 2002, ANESTHESIOLOGY, V96, P1351, DOI 10.1097/00000542-200206000-00014
   Laitio RM, 2008, ANESTHESIOLOGY, V108, P63, DOI 10.1097/01.anes.0000296106.52472.a6
   Lezak M, 1995, NEUROPSYCHOLOGICAL A
   Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258
   Ma DQ, 2003, ANESTHESIOLOGY, V98, P690, DOI 10.1097/00000542-200303000-00017
   MARSH B, 1991, BRIT J ANAESTH, V67, P41, DOI 10.1093/bja/67.1.41
   Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0
   Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e
   Papaioannou A, 2005, EUR J ANAESTH, V22, P492, DOI 10.1017/S0265021505000840
   Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023
   Rasmussen LS, 2006, BRIT J ANAESTH, V97, P154, DOI 10.1093/bja/ae1141
   Rasmussen L S, 2000, Anesthesiol Clin North America, V18, P59, DOI 10.1016/S0889-8537(05)70149-8
   Rasmussen LS, 2003, ACTA ANAESTH SCAND, V47, P260, DOI 10.1034/j.1399-6576.2003.00057.x
   Rasmussen LS, 2001, ACTA ANAESTH SCAND, V45, P275, DOI 10.1034/j.1399-6576.2001.045003275.x
   Schmidt M, 2005, ANESTHESIOLOGY, V102, P929, DOI 10.1097/00000542-200505000-00011
   SMITH PLC, 1986, LANCET, V1, P823
   Wilhelm S, 2002, ANESTHESIOLOGY, V96, P1485, DOI 10.1097/00000542-200206000-00031
NR 33
TC 37
Z9 45
U1 3
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD MAY
PY 2009
VL 110
IS 5
BP 1068
EP 1076
PG 9
WC Anesthesiology
SC Anesthesiology
GA 437QW
UT WOS:000265503000019
PM 19352169
OA Bronze
DA 2018-12-27
ER

PT J
AU Hu, P
   Luo, GA
   Wang, Q
   Zhao, ZZ
   Wang, W
   Jiang, ZH
AF Hu, Ping
   Luo, Guo-An
   Wang, Qing
   Zhao, Zhong-Zhen
   Wang, Wan
   Jiang, Zhi-Hong
TI RETRACTED: The retention behavior of ginsenosides in HPLC and its
   application to quality assessment of Radix Ginseng (Retracted Article.
   See vol 32, pg 963, 2009)
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Article; Retracted Publication
DE Ginsenoside; HPLC; Retention behavior; Radix Ginseng; Quantitation;
   Panax
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; PANAX-QUINQUEFOLIUM; SALVIAE
   MILTIORRHIZAE; QUANTIFICATION; EXTRACTS
AB This study systematically investigated the retention behavior of seven neutral ginsenosides Rg(1), Re, Rf, Rb(1), Rb(2), Rc, Rd, and an acidic ginsenoside R(0), the major pharmacologically active components of Radix Ginseng with RP-HPLC. The effects of solvent, pH value, ionic strength of the mobile phase, and column temperature were investigated using an octadecylsiloxanebonded silica gel column. Based on the ginsenosides' retention characteristics, the concentration of acetonitrile and the gradient of the mobile phase needed to maintain the baseline separation of the major neutral ginsenosides in Radix Ginseng were theoretically predicted. Furthermore, the ionic strength of mobile-phase necessary to achieve good resolution of the neutral ginsenosides and acidic ginsenosides was carefully investigated. According to the results of the quantitative analysis of ginsenosides in eight batches of ginseng samples from different sources, the developed HPLC technique may be a valuable tool for the quality assessment of Radix Ginseng.
C1 [Zhao, Zhong-Zhen; Jiang, Zhi-Hong] Hong Kong Baptist Univ, Sch Chinese Med, Kowloon Tong, Peoples R China.
   [Luo, Guo-An] Tsinghua Univ, Anal Ctr, Beijing 100084, Peoples R China.
   [Hu, Ping; Luo, Guo-An; Wang, Qing; Wang, Wan] E China Univ Sci & Technol, Sch Chem & Mol Engn, Shanghai 200237, Peoples R China.
RP Jiang, ZH (reprint author), Hong Kong Baptist Univ, Sch Chinese Med, Kowloon Tong, Peoples R China.
EM huping@ecust.edu.cn; zhjiang@hkbu.edu.hk
CR [Anonymous], 1996, AN DET LIM GUID LAB
   Bahrke MS, 2000, SPORTS MED, V29, P113, DOI 10.2165/00007256-200029020-00004
   CHEN W, 2000, CHINESE J CHROMATOGR, V18, P439
   *CHIN PHARM U, 1993, DICT TRAD CHIN MED, V1
   CHUANG WC, 1995, PLANTA MED, V61, P459, DOI 10.1055/s-2006-958137
   CHUANG WC, 1994, J CHROMATOGR A, V685, P243, DOI 10.1016/0021-9673(94)00724-1
   *COUNC EUR, 2002, EUR PHARM
   Court WA, 1996, J CHROMATOGR A, V755, P11, DOI 10.1016/S0021-9673(96)00580-8
   Du XW, 2004, FOOD CHEM, V86, P155, DOI 10.1016/j.foodchem.2003.11.003
   FUZZATI N, 2004, J CHROMATOGR B, V812, P124
   Harkey MR, 2001, AM J CLIN NUTR, V73, P1101
   HASEGAWA H, 2003, CANC PREVENTION GINS
   Hu P, 2005, CHEM PHARM BULL, V53, P705, DOI 10.1248/cpb.53.705
   Hu P, 2005, CHEM PHARM BULL, V53, P481, DOI 10.1248/cpb.53.481
   Kim SN, 2007, J PHARMACEUT BIOMED, V45, P164, DOI 10.1016/j.jpba.2007.05.001
   KITAGAWA I, 1983, CHEM PHARM BULL, V31, P3353
   Lang W., 1993, J CHIN PHARM SCI, V2, P133
   Li WK, 2002, J LIQ CHROMATOGR R T, V25, P2485, DOI 10.1081/JLC-120014269
   Liu JH, 2007, J AGR FOOD CHEM, V55, P8830, DOI 10.1021/jf070735o
   LU PZ, 1989, THEORETICAL BASIS CH
   Ren GX, 1999, J AGR FOOD CHEM, V47, P1501, DOI 10.1021/jf980678m
   SAMUKAWA K, 1995, CHEM PHARM BULL, V43, P137
   Snyder LR, 1998, ADV CHROMATOGR, V38, P115
   Snyder LR, 1997, PRACTICAL HPLC METHO
   *USP, 2004, USP27NF22 US PHARM C
   Xie JT, 2005, AM J CHINESE MED, V33, P397, DOI 10.1142/S0192415X05003004
   YAMAGUCHI H, 1988, CHEM PHARM BULL, V363, P468
   2005, PHARMACOPOEIA PRC 20
NR 28
TC 9
Z9 9
U1 4
U2 26
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489-3 SUHCHO-DONG, SUHCHO-KU, SEOUL 137-071, SOUTH KOREA
SN 0253-6269
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD MAY
PY 2009
VL 32
IS 5
BP 667
EP 676
DI 10.1007/s12272-009-1504-7
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 450XK
UT WOS:000266434500005
PM 19471880
DA 2018-12-27
ER

PT J
AU Iwamoto, J
   Takeda, T
   Matsumoto, H
AF Iwamoto, J.
   Takeda, T.
   Matsumoto, H.
TI RETRACTED: Efficacy of risedronate against hip fracture in patients with
   neurological diseases: A meta-analysis of randomized controlled trials
   (Retracted article. See vol. 33, pg. 1179, 2017)
SO BONE
LA English
DT Meeting Abstract; Retracted Publication
CT 2nd Joint Meeting of the
   International-Bone-and-Mineral-Society/Australian-New-Zealand-Bone-and-M
   ineral-Society
CY MAR 21-25, 2009
CL Sydney, AUSTRALIA
SP Int Bone & Mineral Soc, Australian & New Zealand Bone & Mineral Soc
C1 [Iwamoto, J.; Takeda, T.; Matsumoto, H.] Keio Univ, Dept Sports Med, Shinjuku Ku, Tokyo, Japan.
RI Matsumoto, Hideo/A-2304-2014
NR 0
TC 0
Z9 0
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
EI 1873-2763
J9 BONE
JI Bone
PD MAY
PY 2009
VL 44
SU 1
MA 057
BP S37
EP S37
DI 10.1016/j.bone.2009.01.095
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 436SP
UT WOS:000265436200053
DA 2018-12-27
ER

PT J
AU Ding, JY
   Kreipke, CW
   Schafer, P
   Schafer, S
   Speirs, SL
   Rafols, JA
AF Ding, Jamie Y.
   Kreipke, Christian W.
   Schafer, Patrick
   Schafer, Steven
   Speirs, Susan L.
   Rafols, Jose A.
TI RETRACTED: Synapse loss regulated by matrix metalloproteinases in
   traumatic brain injury is associated with hypoxia inducible factor-1
   alpha expression (Retracted article. See vol. 1694, pg. 150, 2018)
SO BRAIN RESEARCH
LA English
DT Article; Retracted Publication
DE Closed-head injury; Hypoxia; MnSOD; Synaptophysin; MMP; Treatment
ID CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA;
   CENTRAL-NERVOUS-SYSTEM; SEVERE HEAD-INJURY; OXIDATIVE STRESS; MMP
   EXPRESSION; CELL-DEATH; KNOCK-OUT; RAT; PLASTICITY
AB The present study assessed the role of matrix metalloproteinase-2 (MMP-2) and -9 in synapse loss after traumatic brain injury (TBI) and the role of hypoxia inducible factor-1 alpha (HIF-1 alpha), a transcription factor up-regulated during hypoxia, in the regulation of MMP-2 and -9 expression post-TBI. Adult male Sprague-Dawley rats (n=6 per group, 400 g-425 g) were injury using Marmarou's closed-head acceleration impact model and allowed to survive for 1,4,24 and 48 h. In another set of experiments, 30 min after TBI, animals were treated with Minocrycline (inhibitor of MMPs), or 2-Methoxyestradiol (2ME2, inhibitor of HIF-1 alpha) and sacrificed at 4 h after injury. Relative amounts of synaptophysin, a presynaptic vesicular protein, HIF-1 alpha, as well as MMP-2 and -9 were assessed by real-time PCR and Western blotting. Activity levels of MMP-2 and -9 were determined by zymography. Synaptophysin expression was significantly (p<0.05) decreased at 1 h through 48 h after TBI. A significant increase in gene and protein expressions of HIF-1 alpha, MMP-2 and -9, as well as enzyme activity of MMP-2 and -9 at the same time points was also detected. Inhibition of either MMPs or HIF-1 alpha significantly reversed the TBI-induced decrease in synaptophysin. Inhibition of HIF-1 alpha reduced expression of MMP-2 and -9. This study showed an early detection of a correlation between synaptic loss and MMP expression after TBI. The data also supports a role HIF-1 alpha in the MMP regulatory cascade in synapse loss after TBI, suggesting potential targets for reducing loss of synaptic terminals. Published by Elsevier B.V.
C1 [Ding, Jamie Y.; Kreipke, Christian W.; Schafer, Patrick; Schafer, Steven; Speirs, Susan L.; Rafols, Jose A.] Wayne State Univ, Sch Med, Detroit, MI USA.
RP Rafols, JA (reprint author), 9312 Scott Hall,540 Canfield St, Detroit, MI 48201 USA.
EM jrafols@med.wayne.edu
FU NINDS NIH HHS [NS 39860, R01 NS039860, R01 NS039860-08]
CR Agrawal SM, 2008, SEMIN CELL DEV BIOL, V19, P42, DOI 10.1016/j.semcdb.2007.06.003
   Bozdagi O, 2007, J NEUROPHYSIOL, V98, P334, DOI 10.1152/jn.00202.2007
   BROCK TO, 1987, J NEUROSCI, V7, P931
   Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013
   Carney N, 1999, Evid Rep Technol Assess (Summ), P1
   Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31
   Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169
   DASH PK, 1995, J NEUROSCI, V15, P2030
   Ding YC, 2003, NEUROSCI LETT, V353, P173, DOI 10.1016/j.neulet.2003.09.055
   Duffau H, 2006, J CLIN NEUROSCI, V13, P885, DOI 10.1016/j.jocn.2005.11.045
   Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109
   French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514
   Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634
   Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005
   Haddad JJ, 2005, INT IMMUNOPHARMACOL, V5, P461, DOI 10.1016/j.intimp.2004.11.009
   Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2
   HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11
   Helton R, 2005, J NEUROSCI, V25, P4099, DOI 10.1523/JNEUROSCI.4555-04.2005
   HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417
   Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Kreipke CW, 2007, NEUROL RES, V29, P369, DOI 10.1179/016164107X204684
   Le NTV, 2007, FRONT BIOSCI, V12, P1475, DOI 10.2741/2161
   Leonardo CC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-34
   LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009
   Li LH, 2008, ACTA NEUROPATHOL, V115, P297, DOI 10.1007/s00401-008-0339-5
   Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106
   LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A
   Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1
   Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56
   MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291
   Meighan SE, 2006, J NEUROCHEM, V96, P1227, DOI 10.1111/j.1471-4159.2005.03565.x
   Meng HD, 2006, BRAIN RES, V1124, P197, DOI 10.1016/j.brainres.2006.09.086
   Mu DZ, 2003, NEUROBIOL DIS, V14, P524, DOI 10.1016/j.nbd.2003.08.020
   Nagel S, 2008, BRAIN RES, V1188, P198, DOI 10.1016/j.brainres.2007.10.052
   Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594
   NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511
   Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657
   Ratan RR, 2007, J MOL MED, V85, P1331, DOI 10.1007/s00109-007-0283-1
   Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719
   Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615
   SCOTTJUPP R, 1992, ARCH DIS CHILD, V67, P222, DOI 10.1136/adc.67.2.222
   Semchenko V V, 2006, Neurosci Behav Physiol, V36, P613, DOI 10.1007/s11055-006-0065-1
   Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0
   Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551
   Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142
   Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003
   Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259
   SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0
   Swann K, 2007, BRAIN RES, V1129, P26, DOI 10.1016/j.brainres.2006.10.061
   Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037//0894-4105.13.1.76
   Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150
   Vaynman S, 2006, NEUROSCIENCE, V139, P1221, DOI 10.1016/j.neuroscience.2006.01.062
   VON GC, 2003, J NEUROSCI RES, V73, P803
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang XY, 2000, J NEUROSCI, V20, P7037
   WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049
   Wells JEA, 2003, J NEUROSCI, V23, P10107
   WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9
   Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457
   Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004
   Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460.9568.2004.03246.x
NR 62
TC 42
Z9 48
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD MAY 1
PY 2009
VL 1268
BP 125
EP 134
DI 10.1016/j.brainres.2009.02.060
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 444BV
UT WOS:000265956000013
PM 19285046
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Tomita, M
   Dewan, MZ
   Yamamoto, N
   Kikuchi, A
   Mori, N
AF Tomita, Mariko
   Dewan, Md Zahidunnabi
   Yamamoto, Naoki
   Kikuchi, Akira
   Mori, Naoki
TI RETRACTED: Epstein-Barr virus-encoded latent membrane protein 1
   activates beta-catenin signaling in B lymphocytes (Retracted article.
   See vol. 102, pg. 500, 2011)
SO CANCER SCIENCE
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; GROWTH TRANSFORMATION; EPITHELIAL-CELLS; FAMILY PROTEINS;
   C-TERMINUS; PATHWAY; LMP1; CANCER; DOMAIN; IMMUNODEFICIENCY
AB The Epstein-Barr virus-encoded latent membrane protein 1 is considered the Epstein-Barr virus oncogene based on its importance in Epstein-Barr virus-induced B-lymphocyte transformation. beta-Catenin is a potential oncogene, and its accumulation has been implicated in a variety of human cancers. Here, we found that beta-catenin protein was highly expressed in Epstein-Barr virus-immortalized B-cell lines compared with peripheral blood mononuclear cells from healthy donors. beta-Catenin expression in Epstein-Barr virus-immortalized B-cell line decreased following treatment with LY294002, an inhibitor of phosphatidylinositol 3-kinase. Treatment with LY294002 or knockdown of beta-catenin by small interfering RNA reduced the growth of Epstein-Barr virus-immortalized B-cell line. Transient transfection of latent membrane protein 1 expression plasmid increased beta-catenin protein expression and beta-catenin-dependent transcription. Latent membrane protein 1 deletions mutants lacking the carboxyl-terminal activating region 1 domain failed to enhance beta-catenin protein expression and beta-catenin-dependent transcriptional activity. They also failed to increase phosphorylated AKT expression. Dominant-negative AKT suppressed latent membrane protein 1-induced beta-catenin-dependent transcriptional activity. These results suggest that latent membrane protein 1 activates beta-catenin through the phosphatidylinositol 3-kinase/AKT signaling pathway. Activation of the beta-catenin pathway by Epstein-Barr virus may contribute to the lymphoproliferation characteristic of Epstein-Barr virus-infected B-cells. (Cancer Sci 2009; 100: 807-812).
C1 [Tomita, Mariko; Mori, Naoki] Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Okinawa, Japan.
   [Dewan, Md Zahidunnabi; Yamamoto, Naoki] Tokyo Med & Dent Univ, Grad Sch, Dept Mol Virol, Tokyo, Japan.
   [Dewan, Md Zahidunnabi; Yamamoto, Naoki] Natl Inst Infect Dis, AIDS Res Ctr, Tokyo, Japan.
   [Kikuchi, Akira] Hiroshima Univ, Dept Biochem, Grad Sch Biomed Sci, Hiroshima, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Okinawa, Japan.
EM n-mori@med.u-ryukyu.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [19591122]; Takeda Science Foundation; Japan Leukemia Research Fund;
   Princes Takamatsu Cancer Research Fund [07-23905]; Kanehara Ichiro
   Memorial Foundation for Promotion of Medicine
FX We thank Dr B. Vogelstein for providing reporter plasmids pGL3-OT and
   pGL3-OF, Dr M. Rowe for providing LMP1 and LMP1 mutant plasmids, and Dr
   D. Alessi for the dominant-negative AKT. We also thank all members of
   our laboratories for the helpful comments and collaborations. This work
   was supported in part by grants-in-aid from the Ministry of Education,
   Culture, Sports, Science and Technology of Japan (No. 19591122); Takeda
   Science Foundation; and Japan Leukemia Research Fund; and a grant from
   the Princes Takamatsu Cancer Research Fund (No. 07-23905) and Kanehara
   Ichiro Memorial Foundation for Promotion of Medicine.
CR Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200
   Dawson CW, 2008, J VIROL, V82, P3654, DOI 10.1128/JVI.01888-07
   Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200
   Eliopoulos AG, 1999, J VIROL, V73, P1023
   Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085
   Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359
   Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829
   Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064
   HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496
   HUEN DS, 1995, ONCOGENE, V10, P549
   Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518
   Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592
   KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150
   Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478
   Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200
   Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   LIEBOWITZ D, 1986, J VIROL, V58, P233
   Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4
   Mainou BA, 2005, ONCOGENE, V24, P6917, DOI 10.1038/sj.onc.1208846
   MILLER G, 1973, J EXP MED, V138, P1398, DOI 10.1084/jem.138.6.1398
   Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P
   Morrison JA, 2003, J VIROL, V77, P12276, DOI 10.1128/JVI.77.22.12276-12284.2003
   PAINE E, 1995, J VIROL, V69, P4572
   Polakis P, 2000, GENE DEV, V14, P1837
   Rickinson AB, 2006, FIELDS VIROLOGY, P2655
   Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901
   Shackelford J, 2003, P NATL ACAD SCI USA, V100, P15572, DOI 10.1073/pnas.2636947100
   Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200
   Shih IM, 2000, CANCER RES, V60, P1671
   Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390
   Tomita M, 2004, ONCOGENE, V23, P8272, DOI 10.1038/sj.onc.1208059
   Tomita M, 2006, J VIROL, V80, P10497, DOI 10.1128/JVI.00739-06
NR 33
TC 8
Z9 8
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD MAY
PY 2009
VL 100
IS 5
BP 807
EP 812
DI 10.1111/j.1349-7006.2009.01121.x
PG 6
WC Oncology
SC Oncology
GA 434CA
UT WOS:000265251600004
PM 19309363
OA Bronze
DA 2018-12-27
ER

PT J
AU Saccomanni, B
AF Saccomanni, Bernardino
TI RETRACTED: Inflammation and shoulder pain-a perspective on rotator cuff
   disease, adhesive capsulitis, and osteoarthritis: conservative treatment
   (Retracted article. See vol. 31, pg. 583, 2012)
SO CLINICAL RHEUMATOLOGY
LA English
DT Review; Retracted Publication
DE Conservative treatment; Inflammation; Shoulder pain
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SUBACROMIAL IMPINGEMENT SYNDROME;
   SODIUM HYALURONATE; ANTERIOR ACROMIOPLASTY; CLINICAL-EVALUATION; FROZEN
   SHOULDER; DOUBLE-BLIND; FOLLOW-UP; INJECTION; PHYSIOTHERAPY
AB Shoulder pain may occur as a secondary symptom to a wide range of conditions, including rotator cuff disorders, glenohumeral osteoarthritis, or adhesive capsulitis. One common factor linking these diseases is inflammation. Understanding the role of inflammation in shoulder disorders can help physicians to manage and treat these common problems. Here, I document a perspective on these pathologies of shoulder.
C1 [Saccomanni, Bernardino] Univ G dAnnunzio, I-66013 Chieti, Italy.
   [Saccomanni, Bernardino] Sondalo Hosp, Sondalo, Italy.
RP Saccomanni, B (reprint author), Univ G dAnnunzio, Via Vestini, I-66013 Chieti, Italy.
EM bernasacco@yahoo.it
CR Agrawal NM, 2000, ARCH INTERN MED, V160, P1455, DOI 10.1001/archinte.160.10.1455
   Akarca US, 2005, CURR PHARM DESIGN, V11, P1779, DOI 10.2174/1381612053764904
   Akgun K, 2004, CLIN RHEUMATOL, V23, P496, DOI 10.1007/s10067-004-0930-7
   ALTMAN R, 2005, AM COLL RHEUM SAN DI
   Altman Roy D, 2003, Curr Rheumatol Rep, V5, P7, DOI 10.1007/s11926-003-0077-6
   Alvarez CM, 2005, AM J SPORT MED, V33, P255, DOI 10.1177/0363546504267345
   American Academy of Orthopedic Surgeons, 2001, AAOS CLIN GUID SHOUL
   Andrews JR, 2005, ARTHROSCOPY, V21, P333, DOI 10.1016/j.arthro.2004.11.003
   BIGLIANI LU, 1991, CLIN SPORT MED, V10, P823
   Bigliani LU, 1997, J BONE JOINT SURG AM, V79A, P1854, DOI 10.2106/00004623-199712000-00012
   Blaine TA, 2005, J SHOULDER ELB SURG, V14, p84S, DOI 10.1016/j.jse.2004.09.022
   BLAINE TA, 2002, ARTHROSCOPY ARTHRITI, P525
   Blair B, 1996, J BONE JOINT SURG AM, V78A, P1685, DOI 10.2106/00004623-199611000-00007
   Bolten WW, 2006, ANN RHEUM DIS, V65, P7, DOI 10.1136/ard.2005.036269
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Buchbinder R, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004016
   BUNKER TD, 1995, J BONE JOINT SURG BR, V77, P677
   Carette S, 2003, ARTHRITIS RHEUM, V48, P829, DOI 10.1002/art.10954
   FERRO T, 2003, ADV STUD MED, V3, P518
   Forman JP, 2005, HYPERTENSION, V46, P500, DOI 10.1161/01.HYP.0000177437.07240.70
   Gotoh M, 1999, J ORTHOP RES, V17, P392, DOI 10.1002/jor.1100170314
   Gotoh M, 2001, RHEUMATOLOGY, V40, P995, DOI 10.1093/rheumatology/40.9.995
   Graham DJ, 2005, LANCET, V365, P475, DOI 10.1016/S0140-6736(05)17864-7
   Guler-Uysal F, 2004, SWISS MED WKLY, V134, P353
   Haahr JP, 2005, ANN RHEUM DIS, V64, P760, DOI 10.1136/ard.2004.021188
   Hannafin JA, 1994, J SHOULDER ELB SU S, V3, P5
   Hawkey CJ, 1998, NEW ENGL J MED, V338, P727, DOI 10.1056/NEJM199803123381105
   Heller B, 2004, CURR MED RES OPIN, V20, P1279, DOI 10.1185/030079904125004411
   ITOKAZU M, 1995, CLIN THER, V17, P946, DOI 10.1016/0149-2918(95)80072-7
   KAMKAR A, 1993, J ORTHOP SPORT PHYS, V17, P212, DOI 10.2519/jospt.1993.17.5.212
   Kibler W B, 2001, Orthop Clin North Am, V32, P527, DOI 10.1016/S0030-5898(05)70222-4
   Lastayo PC, 1998, J BONE JOINT SURG AM, V80A, P1002, DOI 10.2106/00004623-199807000-00009
   LEARDINI G, 1988, CLIN THER, V10, P521
   Lo GH, 2003, JAMA-J AM MED ASSOC, V290, P3115, DOI 10.1001/jama.290.23.3115
   Mao CY, 1997, ARCH PHYS MED REHAB, V78, P857, DOI 10.1016/S0003-9993(97)90200-8
   Maybach A, 1995, Semin Arthroplasty, V6, P297
   NEER C, 1990, CUFF TEARS BICEPS LE, P141
   NEER CS, 1983, CLIN ORTHOP RELAT R, P70
   Neer CS, 2005, J BONE JOINT SURG AM, V87A, P1399, DOI 10.2106/JBJS.8706.cl
   NEER CS, 1972, J BONE JOINT SURG AM, VA 54, P41, DOI 10.2106/00004623-197254010-00003
   NEER CS, 1992, CLIN ORTHOP RELAT R, P182
   NEVIASER JS, 1945, J BONE JOINT SURG, V27, P211
   Peterson Gregory M, 2005, Am J Ther, V12, P67, DOI 10.1097/00045391-200501000-00010
   Petri M, 2004, J RHEUMATOL, V31, P1614
   Raab M G, 1996, Am J Orthop (Belle Mead NJ), V25, P214
   Raffa RB, 2001, J CLIN PHARM THER, V26, P257, DOI 10.1046/j.1365-2710.2001.00355.x
   RAMONDA R, 1998, RIV IT BIOL MED S2, V18, P51
   RATCLIFFE A, 1996, CLIN ORTHOP RELAT R, V330, P45
   Ray WA, 2003, PHARMACOEPIDEM DR S, V12, P67, DOI 10.1002/pds.798
   Rodeo SA, 1997, J ORTHOPAED RES, V15, P427, DOI 10.1002/jor.1100150316
   Rovetta G, 1998, INT J TISSUE REACT, V20, P125
   Ryans I, 2005, RHEUMATOLOGY, V44, P529, DOI 10.1093/rheumatology/keh535
   Sakai Hiroshige, 2001, Kobe Journal of Medical Sciences, V47, P25
   Savage R, 2005, DRUG AGING, V22, P185, DOI 10.2165/00002512-200522030-00001
   Shibita Y, 2001, J SHOULDER ELB SURG, V10, P209, DOI 10.1067/mse.2001.113501
   Siegel LB, 1999, AM FAM PHYSICIAN, V59, P1843
   Stollberger C, 2003, Z KARDIOL, V92, P721, DOI 10.1007/s00392-003-0964-x
   Stone D, 1999, J ORTHOP RES, V17, P168, DOI 10.1002/jor.1100170204
   Voloshin I, 2005, ARTHROSCOPY, V21, P1076, DOI 10.1016/j.arthro.2005.05.017
   Walther M, 2004, J SHOULDER ELB SURG, V13, P417, DOI 10.1016/j.jse.2004.02.002
   Wang CT, 2004, J BONE JOINT SURG AM, V86A, P538, DOI 10.2106/00004623-200403000-00012
   WHITE RH, 1986, J RHEUMATOL, V13, P608
   Yoshida M, 2003, CLIN ORTHOP RELAT R, P57, DOI 10.1097/01.blo.0000071757.07450.3f
NR 63
TC 19
Z9 19
U1 5
U2 17
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD MAY
PY 2009
VL 28
IS 5
BP 495
EP 500
DI 10.1007/s10067-009-1109-z
PG 6
WC Rheumatology
SC Rheumatology
GA 428VJ
UT WOS:000264879200002
PM 19224130
DA 2018-12-27
ER

PT J
AU Adib, B
   Heidari, A
   Tayyari, SF
AF Adib, Behrooz
   Heidari, Alireza
   Tayyari, Sayyed Faramarz
TI RETRACTED: An analytical approach to soliton of the saturable non-linear
   Schrodinger equation determination and consideration of stability of
   solitary solutions of cubic-quintic non-linear Schrodinger equation
   (CQNLSE) (Retracted article. See vol. 19, pg. 325, 2014)
SO COMMUNICATIONS IN NONLINEAR SCIENCE AND NUMERICAL SIMULATION
LA English
DT Article; Retracted Publication
DE Non-linear Schrodinger equation; Saturable soliton; Non-linear effects;
   Solitary solutions
ID OPTICAL-FIBERS; ANOMALOUS-DISPERSION; WAVE-PROPAGATION; INDEX CHANGE;
   TRANSMISSION; BISTABILITY; COLLISION; REGION; GUIDES
AB Non-linear Schrodinger equation for optical medias with saturable non-linear refractive index is obtained and numerical calculation method is applied and soliton solution in anomalous dispersion region is also obtained. A comparison between its several main characters such as normalization, self-energy, and width with Kerr soliton is drawn. It is shown that despite Kerr medias, there are two soliton solutions with similar width and different amplitude in saturable medias. in addition, the stability of solitary solutions of cubic-quintic non-linear Schrodinger equation (CQNLSE). which controls electromagnetic pulse propagation in non-linear optical fibers, is analytically studied. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Tayyari, Sayyed Faramarz] Ferdowsi Univ Mashhad, Dept Chem, Mashhad 917751436, Iran.
   [Adib, Behrooz; Heidari, Alireza] Islamic Azad Univ, Dept Chem, N Tehran Branch, Tehran, Iran.
RP Tayyari, SF (reprint author), Ferdowsi Univ Mashhad, Dept Chem, Mashhad 917751436, Iran.
EM tayyari@ferdowsi.um.ac.ir
CR Agrawal GP, 1995, NONLINEAR FIBER OPTI
   Aicklen GH, 1996, J OPT SOC AM B, V13, P1999, DOI 10.1364/JOSAB.13.001999
   Akhmediev N., 1997, SOLITONS NONLINEAR P
   [Anonymous], 1960, ELECTRODYNAMICS CONT
   Arnold JM, 1999, PHYS REV E, V60, P979, DOI 10.1103/PhysRevE.60.979
   Biswas A, 2003, OPT FIBER TECHNOL, V9, P224, DOI 10.1016/S1068-5200(03)00044-0
   Biswas A, 2006, INTRO NONKERR LAW OP
   Boyd RW., 1992, NONLINEAR OPTICS
   Chen YJ, 1998, PHYS REV E, V57, P3542, DOI 10.1103/PhysRevE.57.3542
   Chen YJ, 1998, OPT COMMUN, V150, P381, DOI 10.1016/S0030-4018(98)00012-1
   CORLESS R. M., CS9303 U WAT DEP COM
   COWAN S, 1986, CAN J PHYS, V64, P311, DOI 10.1139/p86-054
   Drazin P. G., 1989, SOLITONS INTRO
   GATZ S, 1991, J OPT SOC AM B, V8, P2296, DOI 10.1364/JOSAB.8.002296
   GATZ S, 1992, IEEE J QUANTUM ELECT, V28, P1732, DOI 10.1109/3.142561
   GATZ S, 1992, OPT LETT, V17, P484, DOI 10.1364/OL.17.000484
   GEORGES T, 1993, J OPT SOC AM B, V10, P1880, DOI 10.1364/JOSAB.10.001880
   GOUTAZ JL, 1991, J OPT SOC AM B, V8, P95
   HASEGAWA A, 1973, APPL PHYS LETT, V23, P142, DOI 10.1063/1.1654836
   Hasegawa A., 1995, SOLITONS OPTICAL COM
   KROLIKOWSKI W, 1992, OPT LETT, V17, P1414, DOI 10.1364/OL.17.001414
   KROLIKOWSKI W, 1993, OPT LETT, V18, P188, DOI 10.1364/OL.18.000188
   KUZNETSOV EA, 1986, PHYS REP, V142, P103, DOI 10.1016/0370-1573(86)90016-5
   MITCHELL DJ, 1993, J OPT SOC AM B, V10, P1572, DOI 10.1364/JOSAB.10.001572
   MOLLENAUER LF, 1980, PHYS REV LETT, V45, P1095, DOI 10.1103/PhysRevLett.45.1095
   Pushkarov D, 1996, OPT COMMUN, V124, P354, DOI 10.1016/0030-4018(95)00552-8
   Remoissenet M., 1996, WAVES CALLED SOLITON
   RUSSELL H, 1992, AM SCI, V80, P350
   Tanev S, 1997, OPT COMMUN, V141, P322, DOI 10.1016/S0030-4018(97)00230-7
   ZAKHAROV VE, 1972, SOV PHYS JETP-USSR, V34, P62
   ZAKHAROV VE, 1973, ZH EKSP TEOR FIZ+, V64, P1627
NR 31
TC 13
Z9 14
U1 4
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1007-5704
EI 1878-7274
J9 COMMUN NONLINEAR SCI
JI Commun. Nonlinear Sci. Numer. Simul.
PD MAY
PY 2009
VL 14
IS 5
BP 2034
EP 2045
DI 10.1016/j.cnsns.2008.07.008
PG 12
WC Mathematics, Applied; Mathematics, Interdisciplinary Applications;
   Mechanics; Physics, Fluids & Plasmas; Physics, Mathematical
SC Mathematics; Mechanics; Physics
GA 420NH
UT WOS:000264296000029
DA 2018-12-27
ER

PT J
AU Peng, LQ
AF Peng, Lequn
TI RETRACTED: Asymptotic behavior of solutions to a differential equation
   with state-dependent delay (Retracted article. See vol. 61, pg. 513,
   2011)
SO COMPUTERS & MATHEMATICS WITH APPLICATIONS
LA English
DT Article; Retracted Publication
DE Asymptotic behavior; Differential equation; Solution; State-dependent
   delay; omega-limit set
ID MONOTONE SEMIFLOWS; CONVERGENCE
AB In this paper, we investigate the asymptotic behavior of solutions to a differential equation with state-dependent delay. It is shown that every bounded solution of such an equation tends to a constant as t -> infinity. Our results improve and extend some corresponding ones already known. (C) 2009 Elsevier Ltd. All rights reserved.
C1 Hunan Univ Arts & Sci, Dept Math, Changde 415000, Hunan, Peoples R China.
RP Peng, LQ (reprint author), Hunan Univ Arts & Sci, Dept Math, Changde 415000, Hunan, Peoples R China.
EM penglql956@yahoo.com.cn
FU Hunan Provincial Natural Science Foundation of China [06J12063,
   07JJ46001]; Hunan Provincial Education Department of China [08C616]
FX This work was supported by grants (06J12063, 07JJ46001) from the
   Scientific Research Fund of Hunan Provincial Natural Science Foundation
   of China, and the Scientific Research Fund (08C616) of Hunan Provincial
   Education Department of China.
CR Bartha M, 2001, J MATH ANAL APPL, V254, P410, DOI 10.1006/jmaa.2000.7172
   BELAIR J, 1991, LECT NOTES PURE APPL, V131, P165
   Driver R. D., 1963, CONTRIB DIFFERENTIAL, V1, P317
   Hale J. K., 1993, INTRO FUNCTIONAL DIF, V1, P1
   LONGTIN A, 1989, B MATH BIOL, V51, P605
   LONGTIN A, 1988, MATH BIOSCI, V90, P183, DOI 10.1016/0025-5564(88)90064-8
   MACKEY MC, 1989, J ECON THEORY, V48, P497, DOI 10.1016/0022-0531(89)90039-2
   MALLETPARET J, 1989, SIAM J MATH ANAL, V20, P249, DOI 10.1137/0520019
   SMITH H, 1987, J DIFFER EQUATIONS, V66, P420, DOI 10.1016/0022-0396(87)90027-1
   TERJEKI J, 2006, DIFF EQUAT, V14, P195
   Yi TS, 2005, J DIFFER EQUATIONS, V214, P429, DOI 10.1016/j.jde.2005.02.005
NR 11
TC 3
Z9 3
U1 5
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0898-1221
EI 1873-7668
J9 COMPUT MATH APPL
JI Comput. Math. Appl.
PD MAY
PY 2009
VL 57
IS 9
BP 1511
EP 1514
DI 10.1016/j.camwa.2009.01.016
PG 4
WC Mathematics, Applied
SC Mathematics
GA 441HQ
UT WOS:000265760300010
OA Bronze
DA 2018-12-27
ER

PT J
AU Li, XB
AF Li Xuebin
TI RETRACTED: Study of multi-objective optimization and multi-attribute
   decision-making for economic and environmental power dispatch (Retracted
   article. See vol. 82, pg. 98, 2012)
SO ELECTRIC POWER SYSTEMS RESEARCH
LA English
DT Article; Retracted Publication
DE Economic/environmental load dispatch; Multi-objective optimization;
   Multi-attribute decision-making (MADM); Entropy weight; TOPSIS
ID GENERATION DISPATCH; EMISSION; ALGORITHMS; SYSTEMS
AB Environmental awareness and the recent environmental policies have forced many electric utilities to restructure their practices to account for their emission impacts. One way to accomplish this is by reformulating the traditional economic dispatch problem such that emission effects are included in the mathematical model. The economic/environmental dispatch problem is a multi-objective non-linear optimization problem with constraints. This study presents a hybrid approach to solve the combined economic-emission dispatch problem (CEED). In the first stage,a non-dominated sorting genetic algorithm II (NSGA II) is employed to approximate the set of Pareto solution through an evolutionary optimization process. in the subsequent stage, a multi-attribute decision-making (MADM) approach is adopted to rank these solutions from best to worst and to determinate the best solution in a deterministic environment with a single decision maker. This hybrid approach is tested on a six-unit system to illustrate the analysis process in present analysis. Pareto, frontiers are obtained and the ranking of Pareto solutions is based on entropy weight and TOPSIS method. Results obtained show that the hybrid approach has a great potential in handling multi-objective optimization problem. (C) 2008 Elsevier B.V. All rights reserved.
C1 Ctr Res & Dev, Wuhan Ship Design & Res Inst 2, Wuhan 430064, Hubei, Peoples R China.
RP Li, XB (reprint author), Ctr Res & Dev, Wuhan Ship Design & Res Inst 2, Wuhan 430064, Hubei, Peoples R China.
EM li-xuebin@163.com
CR Abido MA, 2003, IEEE T POWER SYST, V18, P1529, DOI 10.1109/TPWRS.2003.818693
   ABIDO MA, 2001, P IEEE POW ENG SOC S, V2, P1263
   BASU M, 2008, ELECT POWER ENERGY S, V30, P140, DOI DOI 10.1016/J.IJEPES.2007.06.009
   Chang CS, 1996, IEEE T POWER SYST, V11, P1009, DOI 10.1109/59.496188
   Deb K, 2002, IEEE T EVOLUT COMPUT, V6, P182, DOI 10.1109/4235.996017
   Gjengedal T, 1996, IEEE T ENERGY CONVER, V11, P132, DOI 10.1109/60.486587
   GRANELLI GP, 1992, ELECTR POW SYST RES, V24, P55, DOI 10.1016/0378-7796(92)90045-3
   Huang CM, 2003, IEEE T POWER SYST, V18, P288, DOI 10.1109/TPWRS.2002.807071
   Hwang C. L., 1981, MULTIPLE ATTRIBUTE D
   *IEEE CURR OP PROB, 1995, IEEE T POWER SYSTEMS, V10, P647
   JAYNES ET, 1957, PHYS REV, V106, P620, DOI 10.1103/PhysRev.106.620
   Jessop A, 1999, J MULTICRITERIA DECI, V70, P61
   KING TD, 1995, IEEE T POWER SYST, V10, P1559, DOI 10.1109/59.466488
   Mendes V. M. S., 2004, 39th International Universities Power Engineering Conference (UPEC), P1068
   Muslu M, 2004, ELECTR POW SYST RES, V71, P153, DOI 10.1016/j.epsr.2004.01.009
   NANDA J, 1988, IEEE T ENERGY CONVER, V3, P26, DOI 10.1109/60.4195
   OLSON DL, 1996, DECISION AIDS SELECT
   ROASEPULVEDA CA, 1996, UPEC 96 U POW ENG C, P1001
   Sen P, 1998, MULTIPLE CRITERIA DE
   Shannon C. E., 1947, MATH THEORY COMMUNIC
   Song YH, 1997, IEE P-GENER TRANSM D, V144, P377, DOI 10.1049/ip-gtd:19971100
   Srinivasan D, 1997, IEEE T POWER SYST, V12, P336, DOI 10.1109/59.574956
   TALAQ JH, 1994, IEEE T POWER SYST, V9, P1508, DOI 10.1109/59.336110
   Vincke P., 1992, MULTICRITERIA DECISI
   WOOD AJ, 1984, OPERATION CONTROL
   YALCINOZ T, 2007, ELECT POWER ENERGY S, V29, P42
   YOKOYAMA R, 1988, IEEE T POWER SYST, V3, P317, DOI 10.1109/59.43217
   Zeleny M, 1982, MULTIPLE CRITERIA DE
NR 28
TC 14
Z9 17
U1 4
U2 12
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0378-7796
EI 1873-2046
J9 ELECTR POW SYST RES
JI Electr. Power Syst. Res.
PD MAY
PY 2009
VL 79
IS 5
BP 789
EP 795
DI 10.1016/j.epsr.2008.10.016
PG 7
WC Engineering, Electrical & Electronic
SC Engineering
GA 426JR
UT WOS:000264704600010
DA 2018-12-27
ER

PT J
AU Blanco, G
   Lemus, JA
   Grande, J
AF Blanco, Guillermo
   Lemus, Jesus A.
   Grande, Javier
TI RETRACTED: Microbial pollution in wildlife: Linking agricultural
   manuring and bacterial antibiotic resistance in red-billed choughs
   (Retracted article. See vol. 126, pg. 222, 2013)
SO ENVIRONMENTAL RESEARCH
LA English
DT Article; Retracted Publication
DE Antibiotics; Agriculture; Bacterial resistance; Birds; Manuring;
   Wildlife
ID ANTIMICROBIAL RESISTANCE; LAND APPLICATION; PATHOGENIC MICROORGANISMS;
   ESCHERICHIA-COLI; HIGH PREVALENCE; ANIMAL ORIGIN; SALMONELLA; GENES;
   SOIL; CONSEQUENCES
AB The spread of pathogens in the environment due to human activities (pathogen pollution) may be involved in the emergence of many diseases in humans, livestock and wildlife. When manure from medicated livestock and urban effluents is spread onto agricultural land, both residues of antibiotics and bacteria carrying antibiotic resistance may be introduced into the environment. The transmission of bacterial resistance from livestock and humans to wildlife remains poorly understood even while wild animals may act as reservoirs of resistance that. may be amplified and spread in the environment. We determined bacterial resistance to antibiotics in wildlife using the red-billed chough Pyrrhocorax pyrrhocorax as a potential bioindicator of soil health, and evaluated the role of agricultural manuring with waste of different origins in the acquisition and characteristics of such resistance. Agricultural manure was found to harbor high levels of bacterial resistance to multiple antibiotics. Choughs from areas where manure landspreading is a common agricultural practice harbor a high bacterial resistance to multiple antibiotics, resembling the resistance profile found in the waste (pig slurry and sewage sludge) used in each area. The transfer of bacterial resistance to wildlife should be considered as an important risk for environmental health when agricultural manuring involves fecal material containing multiresistant enteric bacteria including pathogens from livestock operations and urban areas. The assessment of bacterial resistance in wild animals may be valuable for the monitoring of environmental health and for the management of emergent infectious diseases influenced by the impact of different human activities in the environment. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Blanco, Guillermo; Lemus, Jesus A.; Grande, Javier] CSIC, Museo Ciencias Nat, Dept Ecol & Evolut, Madrid 28006, Spain.
RP Blanco, G (reprint author), CSIC, Museo Ciencias Nat, Dept Ecol & Evolut, J Gutierrez Abascal 2, Madrid 28006, Spain.
EM gublanco2@yahoo.es
RI Blanco, Guillermo/L-3170-2014
OI Blanco, Guillermo/0000-0001-5742-4929
FU Ministerio de Ciencia y Tecnologia [BOS2003-05066, PAI-05-051]; Junta de
   Castilla-La Mancha
FX We thank F. Martinez for help with fieldwork, and two anonymous
   reviewers for constructive comments and corrections on the manuscript.
   Funds were provided by the projects BOS2003-05066 and PAI-05-051 of
   Ministerio de Ciencia y Tecnologia and Junta de Castilla-La Mancha.
CR Aarestrup FM, 2005, BASIC CLIN PHARMACOL, V96, P271, DOI 10.1111/j.1742-7843.2005.pto960401.x
   Angulo FJ, 2000, MICROB DRUG RESIST, V6, P77, DOI 10.1089/mdr.2000.6.77
   Baquero F, 1997, TRENDS ECOL EVOL, V12, P482, DOI 10.1016/S0169-5347(97)01223-8
   BIGNAL EM, 1989, CHOUGHS LAND USE EUR
   Blanco G, 1998, J APPL ECOL, V35, P232, DOI 10.1046/j.1365-2664.1998.00296.x
   Blanco G, 1999, ANIM BEHAV, V57, P1219, DOI 10.1006/anbe.1999.1103
   Blanco G., 1991, Ardeola, V38, P91
   BLANCO G, 2007, ENV RES TRENDS, P153
   BLANCO G, 2003, CHOVA PIQUIRROJA EDI
   BLANCO G, 1996, BIOL CONSERV, V79, P117
   Blanco G, 2007, ENVIRON MICROBIOL, V9, P1738, DOI 10.1111/j.1462-2920.2007.01291.x
   Blanco G, 2006, J APPL ECOL, V43, P990, DOI 10.1111/j.1365-2664.2006.01200.x
   Cole D, 2005, EMERG INFECT DIS, V11, P935
   *COM MADR, 2001, PLAN REG LOD DEP 200
   Daszak P, 2000, SCIENCE, V287, P443, DOI 10.1126/science.287.5452.443
   Diputacion de Segovia, 2006, PROP PLAN PROV GEST
   Dobson A, 2001, PHILOS T R SOC B, V356, P1001, DOI 10.1098/rstb.2001.0900
   Dolejska M, 2007, J APPL MICROBIOL, V103, P11, DOI 10.1111/j.1365-2672.2006.03241.x
   FRIEND M, 1999, FIELD MANUAL WILDLIF
   Gerba CP, 2005, J ENVIRON QUAL, V34, P42
   Guan TY, 2003, J ENVIRON QUAL, V32, P383, DOI 10.2134/jeq2003.0383
   Harrison EZ, 1999, INT J ENVIRON POLLUT, V11, P1, DOI 10.1504/IJEP.1999.002247
   Heuer H, 2007, ENVIRON MICROBIOL, V9, P657, DOI 10.1111/j.1462-2920.2006.01185.x
   Hubalek Z, 2004, J WILDLIFE DIS, V40, P639, DOI 10.7589/0090-3558-40.4.639
   Jensen LB, 2001, ENVIRON INT, V26, P581, DOI 10.1016/S0160-4120(01)00045-9
   Kapperud G, 1998, AM J EPIDEMIOL, V147, P774
   Lemus JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001444
   Levy S, 2002, ANTIBIOTIC PARADOX M
   Literak I, 2007, LETT APPL MICROBIOL, V45, P616, DOI 10.1111/j.1472-765X.2007.02236.x
   MCCRACKEN DI, 1994, P 4 EUR FOR NAT CONS
   Molbak K, 2004, J VET MED B, V51, P364, DOI 10.1111/j.1439-0450.2004.00788.x
   O'Brien TF, 2002, CLIN INFECT DIS, V34, pS78, DOI 10.1086/340244
   O'Connor GA, 2005, J ENVIRON QUAL, V34, P7, DOI 10.2134/jeq2005.0007
   Riesenfeld CS, 2004, ENVIRON MICROBIOL, V6, P981, DOI 10.1111/j.1462-2920.2004.00664.x
   ROLLAND RM, 1985, APPL ENVIRON MICROB, V49, P791
   Sarmah AK, 2006, CHEMOSPHERE, V65, P725, DOI 10.1016/j.chemosphere.2006.03.026
   Shaw PJA, 2003, MULTIVARIATE STAT EN
   Sherley M, 2000, ENVIRON MICROBIOL, V2, P620, DOI 10.1046/j.1462-2920.2000.00145.x
   Smalla K, 2000, APPL ENVIRON MICROB, V66, P4854, DOI 10.1128/AEM.66.11.4854-4862.2000
   Sukul P, 2007, REV ENVIRON CONTAM T, V191, P131, DOI 10.1007/978-0-387-69163-3_5
   Swartz MN, 2002, CLIN INFECT DIS, V34, pS111, DOI 10.1086/340248
   *WHO, 1998, US QUIN FOOD AN POT
   WHO, 2005, CRIT IMP ANT AG HUM
   WOODWARD KN, 1999, GEN APPL TOXICOLOGY, P1633
   WRAY C, 2000, SALMONELLA DOMESTIC
NR 45
TC 50
Z9 51
U1 4
U2 57
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0013-9351
EI 1096-0953
J9 ENVIRON RES
JI Environ. Res.
PD MAY
PY 2009
VL 109
IS 4
BP 405
EP 412
DI 10.1016/j.envres.2009.01.007
PG 8
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 443GH
UT WOS:000265897700006
PM 19264302
DA 2018-12-27
ER

PT J
AU Mehrara, M
   Moeini, A
   Ahrari, M
   Erfanifard, A
AF Mehrara, Mohsen
   Moeini, Ali
   Ahrari, Mehdi
   Erfanifard, Ali
TI RETRACTED: Investigating the efficiency in oil futures market based on
   GMDH approach (Retracted article. See vol. 42, pg. 5401, 2015)
SO EXPERT SYSTEMS WITH APPLICATIONS
LA English
DT Article; Retracted Publication
DE GMDH neural network; Futures market; Oil prices
ID TECHNICAL TRADING RULES; MOVING AVERAGE RULES; GENETIC ALGORITHMS;
   SECURITY RETURNS; NEURAL-NETWORKS; STOCK-MARKET; PREDICTION;
   PROFITABILITY
AB If the crude oil futures market is not efficient in the Fama sense, profitable trading opportunities may exist. This paper uses a GMDH neural network model with moving average crossover inputs to predict price in the crude oil futures market. The predictions of price are used to construct buy and sell signals for traders. Compared to those of benchmark models. cumulative returns, year-to-year returns, returns over a market cycle, and Sharpe ratios all favor the GMDH model by a large factor. The significant profitability of the GMDH model casts doubt on the efficiency of the oil futures market. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Mehrara, Mohsen; Ahrari, Mehdi; Erfanifard, Ali] Univ Tehran, Fac Econ, Tehran, Iran.
   [Moeini, Ali] Univ Tehran, Fac Engn, Dept Algorithms & Computat, Tehran, Iran.
RP Mehrara, M (reprint author), Univ Tehran, Fac Econ, Tehran, Iran.
EM mmehrara@ut.ac.ir
CR Allen F, 1999, J FINANC ECON, V51, P245, DOI 10.1016/S0304-405X(98)00052-X
   Bauer R. J., 1994, GENETIC ALGORITHMS I
   BAUER RJ, 1992, EXPERT SYSTEMS FINAN
   BROCK W, 1992, J FINANC, V47, P1731, DOI 10.2307/2328994
   Campbell J. Y., 1997, ECONOMETRICS FINANCI
   DEBONDT WFM, 1985, J FINANC, V40, P793, DOI 10.1111/j.1540-6261.1985.tb05004.x
   FAMA EF, 1970, J FINANC, V25, P383, DOI 10.2307/2325486
   Farlow S. J, 1984, SELF ORGANIZING METH
   Fernandez-Rodriguez F, 2000, ECON LETT, V69, P89, DOI 10.1016/S0165-1765(00)00270-6
   FERNANDEZRODRIG.F, 2001, WORKING PAPERS FEDEA
   Fleming J, 1999, ENERG ECON, V21, P135, DOI 10.1016/S0140-9883(99)00003-1
   FRANSES PH, 1997, STUDIES NONLINEAR DY, V2, P108
   Gencay R, 1998, ECON LETT, V59, P249, DOI 10.1016/S0165-1765(98)00051-2
   Gencay R, 1998, J FORECASTING, V17, P401, DOI 10.1002/(SICI)1099-131X(1998090)17:5/6<401::AID-FOR704>3.3.CO;2-3
   Gencay R, 1996, J FORECASTING, V15, P165, DOI 10.1002/(SICI)1099-131X(199604)15:3<165::AID-FOR617>3.0.CO;2-V
   Gencay R, 1999, J INT ECON, V47, P91, DOI 10.1016/S0022-1996(98)00017-8
   Gencay R., 1998, J EMPIR FINANC, V5, P347, DOI DOI 10.1016/S0927-5398(97)00022-4
   Gulen S. G., 1998, J ENERGY FINANCE DEV, V3, P13
   HOYLE, 1898, GAME WALL STREET PLA
   IBA H, 1996, EVOLUTIONARY COMPUTA, V3, P417, DOI DOI 10.1162/EVCO.1995.3.4.417
   IVAKHNENKO AG, 1971, IEEE T SYST MAN CYB, VSMC1, P364, DOI 10.1109/TSMC.1971.4308320
   Mahfoud S, 1996, APPL ARTIF INTELL, V10, P543, DOI 10.1080/088395196118425
   Nariman-Zadeh N, 2003, P I MECH ENG B-J ENG, V217, P779, DOI 10.1243/09544050360673161
   NEELY C, 1997, P FORECASTING FINANC
   NEFTCI SN, 1991, J BUS, V64, P549, DOI 10.1086/296551
   Sanchez E., 1997, GENETIC ALGORITHMS F
   Sanders DR, 2004, ENERG ECON, V26, P425, DOI 10.1016/j.eneco.2004.04.010
   Shleifer A, 1997, J FINANC, V52, P35, DOI 10.2307/2329555
   Shleifer A, 2000, INEFFICIENT MARKETS
   *TIM NEWSP INC, 2004, SPEC REP SPEC HIJ OI
   Trippi R., 1996, NEURAL NETWORKS FINA
NR 31
TC 23
Z9 24
U1 2
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0957-4174
EI 1873-6793
J9 EXPERT SYST APPL
JI Expert Syst. Appl.
PD MAY
PY 2009
VL 36
IS 4
BP 7479
EP 7483
DI 10.1016/j.eswa.2008.09.055
PG 5
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic; Operations Research & Management Science
SC Computer Science; Engineering; Operations Research & Management Science
GA 423WX
UT WOS:000264528600018
DA 2018-12-27
ER

PT J
AU Li, TS
   Huang, HH
AF Li, Te-Sheng
   Huang, Hsing-Hsin
TI RETRACTED: Applying TRIZ and Fuzzy AHP to develop innovative design for
   automated manufacturing systems (Retracted article. See vol. 42, pg.
   5402, 2015)
SO EXPERT SYSTEMS WITH APPLICATIONS
LA English
DT Article; Retracted Publication
DE TRIZ; Fuzzy analytical hierarchy process; Contradiction matrix table;
   Automated manufacturing system
ID ANALYTIC HIERARCHY PROCESS; SUPPORT-SYSTEM; JUSTIFICATION; SELECTION
AB Innovative design in the development of new product and process has become the core value in most business establishments. These innovative designs are often associated with the long-established trade-off compromises or conflicting performance parameters where speed and reliability, or quality and cost are readily acknowledged. The rate of change in technology and the commercial environment suggests that the opportunity for innovative design is accelerating, and systematic support for innovation process is needed. This study combines the Russian Theory of Inventive Problem Solving (TRIZ) and the fuzzy analytical hierarchy process (AHP) for designing the automated manufacturing systems. This study applied the contradiction matrix table, 40 innovative principles, and 39 engineering parameters to compromise the trade-off between design contradictions and engineering parameters. The design engineers can acquire more feasible solutions and inspiration through the proposed approach. However, due to vagueness and uncertainty in the decision-maker's judgment, a fuzzy AHP is employed as a decision support tool that can adequately represent qualitative and subjective assessments under the multiple criteria decision making environment. Moreover, the proposed approach can help decision makers facilitate the selection and evaluation of innovative designs in the presence of intangible attributes and uncertainty. In short, the objectives of this research are to use TRIZ to propose the automated design alternatives under the innovative design consideration, and to use a fuzzy AHP to evaluate and select the best feasible alternative under multiple criteria. A case study of designing automated connector assembly line has been used to demonstrate the applicability of the proposed approach. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Li, Te-Sheng] Minghsin Univ Sci & Technol, Dept Ind Engn & Management, Hsinchu 30401, Taiwan.
   [Huang, Hsing-Hsin] Minghsin Univ Sci & Technol, Dept Mech Engn, Hsinchu 30401, Taiwan.
RP Li, TS (reprint author), Minghsin Univ Sci & Technol, Dept Ind Engn & Management, 1 Hsin Hsin Rd, Hsinchu 30401, Taiwan.
EM jeff@must.edu.tw
CR Altshuller G., 1999, INNOVATION ALGORITHM
   ARIEL S, 2003, P INT C ENG DES STOC
   Ayag Z, 2006, J INTELL MANUF, V17, P179, DOI 10.1007/s10845-005-6635-1
   Ayag Z, 2005, IIE TRANS, V37, P827, DOI 10.1080/07408170590969852
   BYUN BS, 2004, INT J ADV MANUF TECH, V26, P1338, DOI DOI 10.1007/S00170-004-2099-2
   Chan FTS, 2000, INT J PROD ECON, V65, P73, DOI 10.1016/S0925-5273(99)00091-2
   Chang HT, 2004, ADV ENG SOFTW, V35, P553, DOI 10.1016/j.advengsoft.2004.06.003
   CHENG CH, 1994, FUZZY SET SYST, V63, P1, DOI 10.1016/0165-0114(94)90140-6
   Cheng CH, 1999, FUZZY SET SYST, V107, P25, DOI 10.1016/S0165-0114(97)00348-5
   CHI SC, 2001, IFSA WORLD C 20 NAFI, V3, P1312
   DATTA V, 1992, INT J PROD ECON, V28, P227, DOI 10.1016/0925-5273(92)90035-6
   DOMB E, 1997, TRIZ J 1997      JUL
   DOMB E, 1997, TRIZ J 1997      FEB
   DOMB E, 1998, TRIZ J 1998      NOV
   FALK DA, 1990, FOREST ECOL MANAG, V35, P91, DOI 10.1016/0378-1127(90)90234-3
   FRENKLACH G, 1998, TRIZ J 1998      MAR
   Frey DD, 2000, RES ENG DES, V12, P90, DOI 10.1007/s001630050025
   GUPTA MM, 1977, FUZZY AUTOMATA DECIS
   Jaganathan S, 2007, INT J ADV MANUF TECH, V32, P1253, DOI 10.1007/s00170-006-0446-1
   JUNG H, 2006, TRIZ J 2006      AUG
   KWONG CK, 2003, IIE T, V13, P367
   LIU CC, 2001, TRIZ J 2001      SEP
   MAO YJ, 2000, TRIZ J 2000      MAR
   Negoita C.V, 1985, EXPERT SYSTEMS FUZZY
   PETROV V, 2002, TRIZ J 2002      MAR
   SAAARI DG, 2004, RES ENG DES, V3, P87
   Saaty T. L., 1980, ANAL HIERARCHY PROCE
   Saaty T. L., 1989, ANAL HIERARCHY PROCE, P59, DOI 10.1007/978-3-642-50244-6_4
   SAATY TL, 1986, MANAGE SCI, V32, P841, DOI 10.1287/mnsc.32.7.841
   SAMABASIVARAO V, 1997, PROD PLAN CONTROL, V8, P270
   Scott MJ, 2007, RES ENG DES, V17, P175, DOI 10.1007/s00163-006-0025-3
   Singh RK, 2007, INT J PROD RES, V45, P3165, DOI 10.1080/00207540600844043
   TERNINKO J, 2000, TRIZ J 2000
   TERNINKO J, 2000, TRIZ J 2000      FEB
   TOMPKINS M, 2006, TRIZ J 2006      MAR
   Ullman DG, 2002, RES ENG DES, V13, P55, DOI 10.1007/S00163-001-0007-4
   WABALICKIS RN, 1988, MANF SYS, V17, P175, DOI DOI 10.1016/0278-6125(8890002-7
   WOOD WH, 2005, ASME, V127, P2
   Xiao AR, 2005, RES ENG DES, V16, P57, DOI 10.1007/s00163-005-0007-x
   ZADEH LA, 1994, COMMUN ACM, V37, P77, DOI 10.1145/175247.175255
   ZIMMERMANN HJ, 1996, FUZZY SET THEORY ITS
   ZLOTIN B, 1999, TRIZ J 1998      MAR
   ZOYZEN Z, 1997, TRIZ J 1997      FEB
NR 43
TC 57
Z9 61
U1 9
U2 94
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0957-4174
EI 1873-6793
J9 EXPERT SYST APPL
JI Expert Syst. Appl.
PD MAY
PY 2009
VL 36
IS 4
BP 8302
EP 8312
DI 10.1016/j.eswa.2008.10.025
PG 11
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic; Operations Research & Management Science
SC Computer Science; Engineering; Operations Research & Management Science
GA 423WX
UT WOS:000264528600112
DA 2018-12-27
ER

PT J
AU Veldman, C
   Pahl, A
   Hertl, M
AF Veldman, Christian
   Pahl, Andreas
   Hertl, Michael
TI RETRACTED: Desmoglein 3-specific T regulatory 1 cells consist of two
   subpopulations with differential expression of the transcription factor
   Foxp3 (Retracted article. See vol. 134, pg. 107, 2011)
SO IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE autoimmunity; human; regulatory T cells; skin; transcription factor
ID IMMATURE DENDRITIC CELLS; PEMPHIGUS-VULGARIS; RETINOIC-ACID; TARGETED
   DISRUPTION; HEALTHY-INDIVIDUALS; MEMORY CELLS; IN-VIVO; PHENOTYPE;
   ANTIGEN; ACTIVATION
AB Pemphigus vulgaris (PV) is an autoimmune bullous skin disorder associated with autoantibodies against desmoglein (Dsg) 3. An imbalance of type 1 regulatory T (Tr1) cells and T helper type 2 (Th2) cells specific for Dsg3 may be critical for the loss of tolerance against Dsg3 in PV. Within the population of Dsg3-responsive, interleukin (IL)-10-secreting Tr1 cell clones, two major subpopulations were identified and sorted by fluorescence-activated cell sorting (FACS) based on their size and granularity. Upon in vitro culture, the larger subpopulation differentiated back into the two former subpopulations of the Tr1 cell clones, while the smaller subpopulation died within 2 weeks. The smaller subpopulation of the Tr1 cell clones was characterized by the expression of Foxp3, the secretion of IL-10, transforming growth factor (TGF)-beta and IL-5 upon stimulation with Dsg3, a proliferative response to IL-2 but not to Dsg3 or mitogenic stimuli, and an inhibitory effect on the proliferative response of Dsg3-responsive Th clones in a Dsg3-specific manner. In contrast, the larger subpopulation showed a Th-like phenotype, lacking Foxp3, cytotoxic T-lymphocyte antigen 4 (CTLA4) and glucocorticoid-induced tumour necrosis factor receptor (GITR) expression and IL-2 secretion, and did not mount a proliferative response to Dsg3 and mitogenic stimuli. The two Tr1 subpopulations showed expression of identical T-cell receptor (TCR) V beta chains which varied among the PV patients studied. Upon inhibition of Foxp3, the smaller Tr1 subpopulation developed a proliferate response to Dsg3 and mitogenic stimuli, no longer suppressed Dsg3-specific Th cells, lost expression of GITR and CTLA4 and secreted IL-2. Thus, our observations suggest a distinct relationship between Dsg3-specific Tr1 and Th-like cells which may be critical for the continuous generation and survival of Dsg3-specific Tr1 cells.
C1 [Veldman, Christian; Hertl, Michael] Univ Marburg, Dept Dermatol, D-35033 Marburg, Germany.
   [Pahl, Andreas] Univ Erlangen Nurnberg, Inst Expt & Clin Pharmacol & Toxicol, Erlangen, Germany.
RP Veldman, C (reprint author), Univ Marburg, Dept Dermatol, Deutschhausstr 9, D-35033 Marburg, Germany.
EM veldman@med.uni-marburg.de; hertl@med.uni-marburg.de
FU Deutsche Forschungsgemeinschaft [He 1602/7-1, He 1602/7-2]
FX We wish to thank Dr Masayuki Amagai, Dermatology, Keio University,
   Japan, for providing recombinant PVhis (Dsg3) baculovirus; and Eva
   Podstawa for her excellent help with the preparation of recombinant
   Dsg3. This study was supported by grants He 1602/7-1 and He 1602/7-2 (to
   CV and MH) from the German Research Society (Deutsche
   Forschungsgemeinschaft).
CR Allan SE, 2005, J CLIN INVEST, V115, P3276, DOI 10.1172/JCI24685
   AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B
   Amagai M, 2000, J CLIN INVEST, V105, P625, DOI 10.1172/JCI8748
   AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968
   Arif S, 2004, J CLIN INVEST, V113, P451, DOI 10.1172/JCI200419585
   Bacchetta R, 2002, EUR J IMMUNOL, V32, P2237, DOI 10.1002/1521-4141(200208)32:8<2237::AID-IMMU2237>3.0.CO;2-2
   Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629
   Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784
   Bystryn JC, 2005, LANCET, V366, P61, DOI 10.1016/S0140-6736(05)66829-8
   Charbonnier LM, 2006, J IMMUNOL, V177, P3806, DOI 10.4049/jimmunol.177.6.3806
   Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152
   Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590
   Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103
   Geginat J, 2001, J EXP MED, V194, P1711, DOI 10.1084/jem.194.12.1711
   Groux H, 1997, NATURE, V389, P737
   GROUX H, 2003, TRANSPLATATION, V75, P8
   Hertl M, 2001, SKIN PHARMACOL APPL, V14, P408, DOI 10.1159/000056375
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Kemper C, 2003, NATURE, V421, P388, DOI 10.1038/nature01315
   Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909
   Khattri R, 2001, J IMMUNOL, V167, P6312, DOI 10.4049/jimmunol.167.11.6312
   Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091
   Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075
   Levings MK, 2001, J IMMUNOL, V166, P5530, DOI 10.4049/jimmunol.166.9.5530
   Levings MK, 2005, BLOOD, V105, P1162, DOI 10.1182/blood-2004-03-1211
   Li JC, 2003, J EXP MED, V198, P1807, DOI 10.1084/jem.20030725
   Li XC, 2001, NAT MED, V7, P114, DOI 10.1038/83253
   Lin MS, 1997, J CLIN INVEST, V99, P31, DOI 10.1172/JCI119130
   Liu KB, 2002, P NATL ACAD SCI USA, V99, P6192, DOI 10.1073/pnas.092675799
   Loser K, 2005, GENE THER, V12, P1294, DOI 10.1038/sj.gt.3302567
   Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252
   Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276
   Maynard CL, 2007, NAT IMMUNOL, V8, P931, DOI 10.1038/ni1504
   McKinlay A, 2007, IMMUNOLOGY, V120, P392, DOI 10.1111/j.1365-2567.2006.02515.x
   Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697
   Nishifuji K, 2000, J INVEST DERMATOL, V114, P88, DOI 10.1046/j.1523-1747.2000.00840.x
   Pahl A, 2002, BRIT J PHARMACOL, V135, P1915, DOI 10.1038/sj.bjp.0704656
   SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0
   Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602
   Veldman C, 2006, J IMMUNOL, V176, P3215, DOI 10.4049/jimmunol.176.5.3215
   Veldman C, 2004, J IMMUNOL, V172, P6468, DOI 10.4049/jimmunol.172.10.6468
   Veldman C, 2003, J IMMUNOL, V170, P635, DOI 10.4049/jimmunol.170.1.635
   Veldman CM, 2004, J IMMUNOL, V172, P3883, DOI 10.4049/jimmunol.172.6.3883
   von Boehmer H, 2007, J EXP MED, V204, P1737, DOI 10.1084/jem.20071251
NR 46
TC 14
Z9 16
U1 4
U2 11
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD MAY
PY 2009
VL 127
IS 1
BP 40
EP 49
DI 10.1111/j.1365-2567.2008.02932.x
PG 10
WC Immunology
SC Immunology
GA 427MY
UT WOS:000264784600005
PM 18800988
OA Green Published
DA 2018-12-27
ER

PT J
AU Yoon, HS
   Aslam, Z
   Song, GC
   Kim, SW
   Jeon, CO
   Chon, TS
   Chung, YR
AF Yoon, Hwan Sik
   Aslam, Zubair
   Song, Geun Cheol
   Kim, Seon Won
   Jeon, Che Ok
   Chon, Tae Soo
   Chung, Young Ryun
TI RETRACTED: Flavobacterium sasangense sp nov., isolated from a wastewater
   stream polluted with heavy metals (Retracted article. See vol. 60, pg.
   267, 2010)
SO INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY
LA English
DT Article; Retracted Publication
ID EMENDED DESCRIPTION; ANTARCTIC LAKES; TREATMENT-PLANT; MICROBIAL MATS;
   COMB. NOV; GEN. NOV.; BACTERIUM; CHINA; SOIL; RECLASSIFICATION
AB A Gram-negative, rod-shaped bacterium, designated strain YC6274(T), was isolated from a stream (Sasang) carrying wastewater polluted with heavy metals in Busan, Korea. Growth was observed at 10-35 degrees C (optimum, 30 degrees C) and pH 6.0-9.5 (optimum, pH 7.5-8.0). Comparative 16S rRNA gene sequence analyses showed that the strain was most closely related to Flavobacterium cucumis R2A45-3(T) (96.6% similarity), F. aquatile ATCC 11947(T) (93.7%), F. croceum EMB47(T) (93.3%), F. indicum GPTSA100-9(T) (93.3%) and F. terrigena DS-20(T) (93.2%). Sequence similarities with strains of other Flavobacterium species with validly published names were lower than 93.0%. Phylogenetic analysis based on the 16S rRNA gene sequence showed that strain YC6274(T) formed a distinct phyletic lineage within the genus Flavobacterium. The predominant fatty acids of strain YC6274(T) were iso-C-15:0, iso-C-16:0, iso-C-15:1 G, iso-(17:0) 3-OH, iso-C-16:0 3-OH and iso-C-15:0 3-OH. The G + C content of the genomic DNA was 32.5 mol% and the major quinone was MK-6. On the basis of phenotypic, chemotaxonomic and molecular data, it is clear that strain YC6274(T) represents a novel species within the genus Flavobacterium, for which the name Flavobacterium sasangense sp. nov. is proposed. The type strain is YC6274(T) (=KCTC 22246(T) DSM 21067(T)).
C1 [Yoon, Hwan Sik; Aslam, Zubair; Song, Geun Cheol; Kim, Seon Won; Chung, Young Ryun] Gyeongsang Natl Univ, Div Appl Life Sci BK21, PMBBRC, Jinju 660701, South Korea.
   [Yoon, Hwan Sik; Aslam, Zubair; Song, Geun Cheol; Kim, Seon Won; Chung, Young Ryun] Gyeongsang Natl Univ, EB NCRC, Jinju 660701, South Korea.
   [Jeon, Che Ok] Chung Ang Univ, Div Life Sci, Seoul 156756, South Korea.
   [Chon, Tae Soo] Pusan Natl Univ, Div Biol Sci, Pusan 609735, South Korea.
RP Chung, YR (reprint author), Gyeongsang Natl Univ, Div Appl Life Sci BK21, PMBBRC, Jinju 660701, South Korea.
EM yrchung@gnu.ac.kr
FU Basic Research Program of the Korea Science & Engineering Foundation
   [RO1-2004-000-11036-0]; Ministry of Education and Human Resources
   Development, Korea
FX This work was supported by a grant no. RO1-2004-000-11036-0 from the
   Basic Research Program of the Korea Science & Engineering Foundation.
   H.S.Y. and Z.A. were Supported by scholarships from the BK21 Program
   (2007-2008), Ministry of Education and Human Resources Development,
   Korea.
CR Aslam Z, 2005, INT J SYST EVOL MICR, V55, P747, DOI 10.1099/ijs.0.63459-0
   Bernardet J.-F., 2006, PROKARYOTES HDB BIOL, V7, P481, DOI DOI 10.1007/0-8_
   Bernardet JF, 1996, INT J SYST BACTERIOL, V46, P128, DOI 10.1099/00207713-46-1-128
   Bernardet JF, 2002, INT J SYST EVOL MICR, V52, P1049, DOI 10.1099/ijs.0.02136-0
   CHON TS, 2007, BASIC RES PROGRAM KO, P79
   Chung YR, 1999, INT J SYST BACTERIOL, V49, P753, DOI 10.1099/00207713-49-2-753
   Cousin S, 2007, INT J SYST EVOL MICR, V57, P243, DOI 10.1099/ijs.0.64556-0
   Felsenstein J, 2002, PHYLIP PHYLOGENY INF
   GOMORI G, 1955, METHOD ENZYMOL, V1, P138, DOI 10.1016/0076-6879(55)01020-3
   Humphry DR, 2001, INT J SYST EVOL MICR, V51, P1235, DOI 10.1099/00207713-51-4-1235
   Jeon CO, 2005, INT J SYST EVOL MICR, V55, P1891, DOI 10.1099/ijs.0.63456-0
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   KOMAGATA K, 1987, METHOD MICROBIOL, V19, P161
   Lane DJ, 1991, NUCL ACID TECHNIQUES, P115, DOI DOI 10.1007/S00227-012-2133-0
   LANYI B, 1987, METHOD MICROBIOL, V19, P1
   Liu H, 2008, INT J SYST EVOL MICR, V58, P756, DOI 10.1099/ijs.0.65536-0
   McCammon SA, 2000, INT J SYST EVOL MICR, V50, P1055, DOI 10.1099/00207713-50-3-1055
   Park M, 2006, INT J SYST EVOL MICR, V56, P2443, DOI 10.1099/ijs.0.64436-0
   Ryu SH, 2007, INT J SYST EVOL MICR, V57, P2026, DOI 10.1099/ijs.0.65138-0
   Saha P, 2006, INT J SYST EVOL MICR, V56, P2617, DOI 10.1099/ijs.0.64309-0
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406
   Smibert Robert M., 1994, P607
   Tamaki H, 2003, INT J SYST EVOL MICR, V53, P519, DOI 10.1099/ijs.0.02369-0
   TAMAOKA J, 1984, FEMS MICROBIOL LETT, V25, P125, DOI 10.1016/0378-1097(84)90059-4
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Van Trappen S, 2005, INT J SYST EVOL MICR, V55, P769, DOI 10.1099/ijs.0.03056-0
   Van Trappen S, 2004, INT J SYST EVOL MICR, V54, P85, DOI 10.1099/ijs.0.02857-0
   Vela AI, 2007, INT J SYST EVOL MICR, V57, P2604, DOI 10.1099/ijs.0.65154-0
   WAKABAYASHI H, 1989, INT J SYST BACTERIOL, V39, P213, DOI 10.1099/00207713-39-3-213
   Weon HY, 2007, INT J SYST EVOL MICR, V57, P1594, DOI 10.1099/ijs.0.64935-0
   Yoon JH, 2007, INT J SYST EVOL MICR, V57, P947, DOI 10.1099/ijs.0.64776-0
   Zhang DC, 2006, INT J SYST EVOL MICR, V56, P2921, DOI 10.1099/ijs.0.64564-0
   Zhu F, 2003, INT J SYST EVOL MICR, V53, P853, DOI 10.1099/ijs.0.02310-0
NR 34
TC 13
Z9 13
U1 4
U2 17
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 1466-5026
EI 1466-5034
J9 INT J SYST EVOL MICR
JI Int. J. Syst. Evol. Microbiol.
PD MAY
PY 2009
VL 59
BP 1162
EP 1166
DI 10.1099/ijs.0.004978-0
PN 5
PG 5
WC Microbiology
SC Microbiology
GA 450UL
UT WOS:000266426400043
PM 19406812
OA Bronze
DA 2018-12-27
ER

PT J
AU Malik, AA
   Bari, SU
AF Malik, Ajaz A.
   Bari, Shams-ul
TI RETRACTED: Conservative Management of Acute Appendicitis (Retracted
   article. See vol. 15, pg. 2302, 2011)
SO JOURNAL OF GASTROINTESTINAL SURGERY
LA English
DT Article; Retracted Publication
DE Acute appendicitis; Peritonitis; Antibiotics; Ultrasonography
ID MODIFIED ALVARADO SCORE; APPENDECTOMY; MASS; TRIAL
AB The acute appendicitis is the most common abdominal emergency, and the primary treatment has been appendicectomy. Antibiotics are started preoperatively and continued postoperatively as needed.
   This prospective study was carried out at Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir, India to determine the role of antibiotics as the only treatment in acute appendicitis and the analgesic consumption needed. Total of 80 patients were included in the study with a duration of abdominal pain less than 72 h. Out of 80 patients, 40 patients received antibiotics intravenously for 2 days followed by oral treatment for 7 days, while another 40 patients considered as controls were randomized to surgery.
   Patients managed conservatively were discharged within 3 days except for two-patients who required surgery after 12 and 24 h, respectively, because of peritonitis due to perforated appendicitis. Four patients were readmitted within 1 year as a result of recurrent appendicitis and had to undergo surgery when appendicitis was confirmed. The diagnostic accuracy within the operated group was 90%. Two patients had perforated appendicitis at operation.
   Our conclusion is that antibiotic treatment in the patients with acute appendicitis is quite effective, and these patients may not need surgery. The patients managed conservatively with antibiotics alone experience less pain and require less analgesia but have high recurrent rate.
C1 [Malik, Ajaz A.; Bari, Shams-ul] Sherikashmir Inst Med Sci, Srinagar 19006, Jammu & Kashmir, India.
RP Bari, SU (reprint author), Sherikashmir Inst Med Sci, Srinagar 19006, Jammu & Kashmir, India.
EM ajazamalik@yahoo.com; shamsulbari@rediffmail.com
CR ADAMS ML, 1990, MIL MED, V155, P345
   AMBJOMMSON E, 1984, CURR SURG, V41, P4
   Arnbjornsson E, 1984, Curr Surg, V41, P354
   ATHEY PA, 1984, J CLIN ULTRASOUND, V12, P333, DOI 10.1002/jcu.1870120604
   BAGI P, 1987, SURGERY, V101, P602
   Coldrey E., 1959, J INT COLL SURG, V32, P255
   *EACS, 2006, AC APP OP VERS CONS, P387
   ENGKVIST O, 1971, ACTA CHIR SCAND, V137, P797
   ERIKSSON S, 1995, BRIT J SURG, V82, P166, DOI 10.1002/bjs.1800820207
   ERIKSSON S, 1989, ACTA CHIR SCAND, V155, P11
   ERIKSSON S, 1993, BR J SURG S, V80, P4, DOI DOI 10.1002/BJS.1800800104
   Granstromm L., 1992, SURG RES COMM, V11, P309
   GROSFELD JL, 1971, J PEDIATR SURG, V6, P630, DOI 10.1016/0022-3468(71)90389-7
   Gurin N N, 1992, Vestn Khir Im I I Grek, V148, P144
   Horton MD, 2001, AM J SURG, V182, P305, DOI 10.1016/S0002-9610(01)00645-6
   HUSKISSON EC, 1974, LANCET, V2, P1127
   KALAN M, 1994, ANN ROY COLL SURG, V76, P418
   Malik AA, 1998, AUST NZ J SURG, V68, P504, DOI 10.1111/j.1445-2197.1998.tb04811.x
   McBurney C, 1889, NY MED J, V50, P1676
   MCPHERSON AG, 1945, BRIT J SURG, V32, P365, DOI 10.1002/bjs.18003212705
   MOSEGAARD A, 1979, ACTA CHIR SCAND, V145, P109
   OEUTSCH AA, 1983, J R COLL SURG EDINB, V28, P35
   PIEPER R, 1982, ACTA CHIR SCAND, V148, P51
   PUYLAERT JBCM, 1986, RADIOLOGY, V158, P355, DOI 10.1148/radiology.158.2.2934762
   RAF LE, 1969, ACTA CHIR SCAND, V135, P73
   ROGGO A, 1993, ANN SURG, V217, P385, DOI 10.1097/00000658-199304000-00010
   SIMPSON J, 2006, FDN YEARS, V2, P72
   Singh A, 2007, RADIOGRAPHICS, V27, DOI 10.1148/rg.275065021
   SURANA R, 1993, BRIT MED J, V306, P1168, DOI 10.1136/bmj.306.6886.1168
   THOMAS DR, 1973, SURGERY, V73, P677
   WEINBERG RW, 1976, BRIT J UROL, V48, P234, DOI 10.1111/j.1464-410X.1976.tb03007.x
   1977, CHIN MED J, V3, P266
NR 32
TC 68
Z9 72
U1 4
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1091-255X
J9 J GASTROINTEST SURG
JI J. Gastrointest. Surg.
PD MAY
PY 2009
VL 13
IS 5
BP 966
EP 970
DI 10.1007/s11605-009-0835-5
PG 5
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 431VO
UT WOS:000265092500022
PM 19277796
DA 2018-12-27
ER

PT J
AU Gressner, OA
   Siluschek, M
   Lahme, B
   Gressner, AM
AF Gressner, Olav A.
   Siluschek, Monika
   Lahme, Birgit
   Gressner, Axel M.
TI RETRACTED: Intraperitoneal application of caffeine prevents
   D-galactosamine-induced hepatic expression of connective tissue growth
   factor (CTGF/CCN2) in the rat (Retracted article. See vol. 53, pg. 590,
   2010)
SO JOURNAL OF HEPATOLOGY
LA English
DT Letter; Retracted Publication
ID TGF-BETA; HEPATOCYTES; FIBROSIS
C1 [Gressner, Olav A.; Siluschek, Monika; Lahme, Birgit; Gressner, Axel M.] RWTH Univ Hosp, Inst Clin Chem & Pathobiochem, Cent Lab, Pauwelsstr 30, D-52074 Aachen, Germany.
RP Gressner, OA (reprint author), RWTH Univ Hosp, Inst Clin Chem & Pathobiochem, Cent Lab, Pauwelsstr 30, D-52074 Aachen, Germany.
EM ogressner@ukaachen.de
CR George J, 2007, GENE THER, V14, P790, DOI 10.1038/sj.gt.3302929
   Gressner AM, 2006, CLIN CHEM, V52, P1815, DOI 10.1373/clinchem.2006.070466
   Gressner OA, 2008, J HEPATOL, V49, P758, DOI 10.1016/j.jhep.2008.03.029
   Gressner OA, 2008, J CELL MOL MED, V12, P2717, DOI 10.1111/j.1582-4934.2008.00260.x
   Ruhl CE, 2005, GASTROENTEROLOGY, V129, P1928, DOI 10.1053/j.gast.2005.08.056
NR 5
TC 4
Z9 4
U1 4
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD MAY
PY 2009
VL 50
IS 5
BP 1053
EP 1055
DI 10.1016/j.jhep.2009.02.001
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 450EU
UT WOS:000266384600029
PM 19321219
DA 2018-12-27
ER

PT J
AU Degenhardt, T
   Vaisanen, S
   Rakhshandehroo, M
   Kersten, S
   Carlberg, C
AF Degenhardt, Tatjana
   Vaisanen, Sami
   Rakhshandehroo, Maryam
   Kersten, Sander
   Carlberg, Carsten
TI RETRACTED: Peroxisome Proliferator-Activated Receptor alpha controls
   Hepatic Heme Biosynthesis Through ALAS1 (Retracted article. See vol.
   404, pg. 172, 2010)
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article; Retracted Publication
DE nuclear receptor; transcriptional regulation; chromatin; metabolism;
   PPAR alpha
ID ACID SYNTHASE GENE; NUCLEAR RECEPTORS; TRANSCRIPTIONAL CONTROL; PRIMARY
   TARGET; RETINOIC ACID; EXPRESSION; PORPHYRIAS; CELLS; METABOLISM;
   DIAGNOSIS
AB Heme is an essential prosthetic group of proteins involved in oxygen transport, energy metabolism and nitric oxide production. ALAS' (5-aminolevulinate synthase) is the rate-limiting enzyme in heme synthesis in the liver and is highly regulated to adapt to the metabolic demand of the hepatocyte. In the present study, we describe human hepatic ALAS1 as a new direct target for the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR alpha). In primary human hepatocytes and in HepG2 cells, PPAR alpha agonists induced an increase in ALAS1 mRNA levels, which was abolished by PPAR alpha silencing. These effects are mediated by two functional PPAR binding sites at positions -9 and -2.3 kb relative to the ALAS1 transcription start site. PPAR alpha ligand treatment also up-regulated the mRNA levels of the genes ALAD (5-aminolevulinate dehydratase), UROS (uroporphyrinogen III synthase), UROD (uroporphyrinogen decarboxylase), CPOX (coproporphyrinogen oxidase) and PPOX (protoporphyrinogen oxidise) encoding for enzymes controlling further steps in heme biosynthesis. In HepG2 cells treated with PPAR alpha agonists and in mouse liver upon fasting, the association of PPAR alpha, its partner retinoid X receptor, PPAR gamma coactivator 1 alpha and activated RNA polymerase II with the transcription start site region of all six genes was increased, leading to higher levels of the metabolite heme. In conclusion, these data strongly support a role of PPAR alpha in the regulation of human ALAS1 and of five additional genes of the pathway, consequently leading to increased heme synthesis. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Degenhardt, Tatjana; Vaisanen, Sami; Carlberg, Carsten] Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland.
   [Rakhshandehroo, Maryam; Kersten, Sander] Wageningen Univ, Top Inst Food & Nutr, Nutrigenom Consortiton, NL-6701 HD Wageningen, Netherlands.
   [Rakhshandehroo, Maryam; Kersten, Sander] Wageningen Univ, Div Human Nutr, Metab & Genom Grp, NL-6701 HD Wageningen, Netherlands.
   [Carlberg, Carsten] Univ Luxembourg, Life Sci Res Unit, L-1511 Luxembourg, Luxembourg.
RP Carlberg, C (reprint author), Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland.
EM carsten.carlberg@uni.lu
RI Kersten, Sander/A-1116-2011
OI Kersten, Sander/0000-0003-4488-7734
FU Academy of Finland; Juselius Foundation; European Union (Marie Curie RTN
   NucSys)
FX This work was supported by grants from the Academy of Finland, the
   Juselius Foundation and the European Union (Marie Curie RTN NucSys).
CR Akiyama TE, 2004, J BIOL CHEM, V279, P20874, DOI 10.1074/jbc.M312802200
   Anderson KE, 2005, ANN INTERN MED, V142, P439, DOI 10.7326/0003-4819-142-6-200503150-00010
   Atamna H, 2004, AGEING RES REV, V3, P303, DOI 10.1016/j.arr.2004.02.002
   Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866
   Degenhardt T, 2006, J BIOL CHEM, V281, P39607, DOI 10.1074/jbc.M605623200
   Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9
   Fraser DJ, 2003, J BIOL CHEM, V278, P39392, DOI 10.1074/jbc.M306148200
   Fraser DJ, 2002, J BIOL CHEM, V277, P34717, DOI 10.1074/jbc.M204699200
   Frederiksen KS, 2004, J LIPID RES, V45, P592, DOI 10.1194/jlr.D300239-JLR200
   GRANICK S, 1975, J BIOL CHEM, V250, P9215
   Handschin C, 2005, CELL, V122, P505, DOI 10.1016/j.cell.2005.06.040
   Heinaniemi M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r147
   Heuvel JPV, 2003, TOXICOL APPL PHARM, V188, P185, DOI 10.1016/S0041-008X(03)00015-2
   Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108
   Kauppinen R, 2005, LANCET, V365, P241
   Kersten S, 2000, NATURE, V405, P421
   KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0
   Kohany O, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-474
   Kolluri S, 2005, BIOCHEM J, V392, P173, DOI 10.1042/BJ20050354
   Li B, 1999, J BIOL CHEM, V274, P17534, DOI 10.1074/jbc.274.25.17534
   Lindberg RLP, 1996, NAT GENET, V12, P195, DOI 10.1038/ng0296-195
   Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3
   MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0
   Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560
   MAY BK, 1995, PROG NUCLEIC ACID RE, V51, P1, DOI 10.1016/S0079-6603(08)60875-2
   Peyer AK, 2007, HEPATOLOGY, V46, P1960, DOI 10.1002/hep.21879
   Podvinec M, 2004, P NATL ACAD SCI USA, V101, P9127, DOI 10.1073/pnas.0401845101
   Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004
   Rakhshandehroo M, 2007, PPAR RES, DOI 10.1155/2007/26839
   Sassa S, 2002, PHOTODERMATOL PHOTO, V18, P56, DOI 10.1034/j.1600-0781.2002.180202.x
   SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015
   Thunell S, 2000, SCAND J CLIN LAB INV, V60, P581
   Tsiftsoglou AS, 2006, PHARMACOL THERAPEUT, V111, P327, DOI 10.1016/j.pharmthera.2005.10.017
   Tudor C, 2007, J BIOL CHEM, V282, P4417, DOI 10.1074/jbc.M608172200
   Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000
   Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154
   Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g
   Yamazaki K, 2002, BIOCHEM BIOPH RES CO, V290, P1114, DOI 10.1006/bbrc.2001.6319
   Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939
NR 39
TC 11
Z9 11
U1 4
U2 16
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD MAY 1
PY 2009
VL 388
IS 2
BP 225
EP 238
DI 10.1016/j.jmb.2009.03.024
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 444FR
UT WOS:000265966600003
PM 19289130
DA 2018-12-27
ER

PT J
AU Leone, JE
AF Leone, James E.
TI RETRACTED: MUSCLE DYSMORPHIA SYMPTOMATOLOGY AND EXTREME DRIVE FOR
   MUSCULARITY IN A 23-YEAR-OLD WOMAN: A CASE STUDY (Retracted article. See
   vol. 23, pg. 1632, 2009)
SO JOURNAL OF STRENGTH AND CONDITIONING RESEARCH
LA English
DT Article; Retracted Publication
DE reverse anorexia; bodybuilders; spectrum disorder; culture
ID BODY-IMAGE; MALE BODYBUILDERS; ANOREXIA-NERVOSA; WOMEN; MEN;
   WEIGHTLIFTERS; DISORDERS
AB Leone, JE. Muscle dysmorphia symptomatology and extreme drive for muscularity in a 23-year-old woman: a case study. J Strength Cond Res 23(3): 988-995, 2009-We describe a 23-year-old woman with muscle dysmorphia symptomatology and extreme drive for muscularity. In addition to structured case study interviews, 3 questionnaires and a series of semi-structured interview questions were administered for elaboration on key issues. The case studies allowed for triangulation of data garnered from the questionnaires. Responses revealed high scores for drive for muscularity, moderate scores for the Adonis complex, and high scores for symptoms of muscle dysmorphia. Muscle dysmorphia and drive for muscularity are more prevalent in men; however, unique cases such as this need to be further explored both empirically and theoretically. Cross-cultural references are needed to assess the overall impact of global social influences. Instruments measuring muscle dysmorphia need to be devised and validated for women as well as men. The strength and conditioning professional needs to be both aware and vigilant in helping people affected with psychosomatic disorders such as muscle dysmorphia or exercise addiction.
C1 Bridgewater State Coll, Dept Movement Arts Hlth Promot & Leisure Studies, Sch Educ & Allied Studies, Bridgewater, MA 02325 USA.
RP Leone, JE (reprint author), Bridgewater State Coll, Dept Movement Arts Hlth Promot & Leisure Studies, Sch Educ & Allied Studies, Bridgewater, MA 02325 USA.
EM jleoneatc@yahoo.com
CR Anderson RH, 2004, CARDIOL YOUNG, V14, P13
   BAXTER AE, 2004, INT C EAT DIS ORL AP
   Cafri G, 2004, ASSESSMENT, V11, P224, DOI 10.1177/1073191104267652
   Choi PYL, 2002, BRIT J SPORT MED, V36, P375, DOI 10.1136/bjsm.36.5.375
   Chung B, 2001, PERSPECT BIOL MED, V44, P565, DOI 10.1353/pbm.2001.0062
   Duggan SJ, 2004, J HOMOSEXUAL, V47, P45, DOI 10.1300/J082v47n03_03
   Esco MR, 2005, STRENGTH COND J, V27, P76, DOI 10.1519/1533-4295(2005)27[76:MDAEBI]2.0.CO;2
   GARNER DM, 1984, PSYCHOSOM MED, V46, P255, DOI 10.1097/00006842-198405000-00007
   Gruber AJ, 1999, COMPR PSYCHIAT, V40, P273, DOI 10.1016/S0010-440X(99)90127-X
   Gruber AJ, 2000, PSYCHOTHER PSYCHOSOM, V69, P19, DOI 10.1159/000012362
   Hitzeroth V, 2001, PSYCHIAT CLIN NEUROS, V55, P521, DOI 10.1046/j.1440-1819.2001.00899.x
   HOLDEN R, 2002, ANN M AM PSYCH ASS C
   Lantz CD, 2002, J STRENGTH COND RES, V16, P649
   Leit RA, 2002, INT J EAT DISORDER, V31, P334, DOI 10.1002/eat.10019
   Leone JE, 2005, J ATHL TRAINING, V40, P352
   Maida D. M., 2005, INT J MENS HLTH, V4, P73, DOI DOI 10.3149/JMH.0401.73
   Mangweth B, 2001, PSYCHOTHER PSYCHOSOM, V70, P38, DOI 10.1159/000056223
   McCreary D. R., 2004, PSYCHOL MEN MASCULIN, V5, P49, DOI DOI 10.1037/1524-9220.5.1.49
   McCreary DR, 2000, J AM COLL HEALTH, V48, P297, DOI 10.1080/07448480009596271
   Olivardia R, 2000, AM J PSYCHIAT, V157, P1291, DOI 10.1176/appi.ajp.157.8.1291
   Olivardia R, 2001, HARVARD REV PSYCHIAT, V9, P254, DOI 10.1080/713854919
   Phillips KA, 2000, ADONIS COMPLEX SECRE
   POPE HG, 1993, COMPR PSYCHIAT, V34, P406, DOI 10.1016/0010-440X(93)90066-D
   Pope HG, 2000, AM J PSYCHIAT, V157, P1297, DOI 10.1176/appi.ajp.157.8.1297
   Pope HG, 1997, PSYCHOSOMATICS, V38, P548, DOI 10.1016/S0033-3182(97)71400-2
   Ung E. K., 2000, Annals Academy of Medicine Singapore, V29, P135
NR 26
TC 7
Z9 8
U1 2
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-8011
J9 J STRENGTH COND RES
JI J. Strength Cond. Res.
PD MAY
PY 2009
VL 23
IS 3
BP 988
EP 995
DI 10.1519/JSC.0b013e3181a0547a
PG 8
WC Sport Sciences
SC Sport Sciences
GA 514NF
UT WOS:000271400900038
PM 19387376
DA 2018-12-27
ER

PT J
AU Johannigman, JA
   Branson, RD
   Edwards, MG
AF Johannigman, Jay A.
   Branson, Richard D.
   Edwards, Michael G.
TI RETRACTED: Closed Loop Control of Inspired Oxygen Concentration in
   Trauma Patients (Retracted article. See vol. 213, pg. 456, 2011)
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 120th Annual Meeting of the Southern-Surgical-Association
CY DEC, 2008
CL Palm Beach, FL
SP SE Surg Assoc
ID EN-ROUTE CARE; MECHANICAL VENTILATION; SUPPLEMENTAL OXYGEN; AUTONOMOUS
   CONTROL; NEWBORN-INFANTS
AB BACKGROUND: Transport of mechanically ventilated patients in a combat zone presents challenges, including conservation Of resources. In the battlefield setting, provision of oxygen supplies remains an important issue. Autonomous control of oxygen concentration can allow a reduction In Oxygen usage and reduced mission weight.
   METHODS: Trauma patients requiring ventilation and inspired oxygen concentration (FIO2) > 0.40 were evaluated for study. patients were randomized to consecutive 4-hour periods of closed loop control or standard care. The system for autonomous control consisted of a ventilator, oximeter, and a portable Computer. The computer housed the control algorithm and collected data every 5 seconds. The controller goal was to maintain Pulse oximetry (SpO(2)) at 94 +/- 2% through discrete changes of 1% to 5% every 30 seconds. Ventilator settings and SpO(2) were recorded every 5 seconds for analysis.
   RESULTS: Fore-five patients were enrolled in this study. Oxygen saturation was maintained in the 92% to 96% saturation range 33 +/- 36% of the time during clinician control versus 83 +/- 21% during closed loop control. Time spent at the target SpO(2) 92% to 96% was 193.3 +/- 59.18 minutes during closed loop control and 87.08 +/- 87.95 Minutes during clinician control (p < 0.001). Hyperoxemia was more frequent during clinician control (144.29 +/- 90.09 Minutes) than during closed loop control (38.91 +/- 55.86 minutes; p < 0.001). There were no differences in the number of episodes of SpO(2) < 88%. Oxygen usage was reduced by 32% during closed loop control.
   CONCLUSION: Closed loop control of FIO2 offers the opportunity for maximizing oxygen resources, reducing mission weight, and providing targeted normoxemia without increasing risk of hypoxemia in ventilated trauma patients. (J Am Coll Surg 2009;208:763-769. (C) 2009 by the American College of Surgeons)
C1 [Johannigman, Jay A.; Branson, Richard D.; Edwards, Michael G.] Univ Cincinnati, Dept Surg, Cincinnati, OH 45267 USA.
RP Johannigman, JA (reprint author), Univ Cincinnati, Dept Surg, 231 Albert Sabin Way,ML 0558, Cincinnati, OH 45267 USA.
EM jay.johannigman@uc.edu
CR Barnes SL, 2008, J TRAUMA, V64, pS129, DOI 10.1097/TA.0b013e318160a5b4
   Branson Richard D, 2002, Respir Care, V47, P427
   Johannigman JA, 2008, CRIT CARE MED, V36, pS377, DOI 10.1097/CCM.0b013e31817e31e1
   Johannigman JA, 2008, J TRAUMA, V64, pS302, DOI 10.1097/TA.0b013e31816bf4e2
   Johannigman JA, 2008, J TRAUMA, V64, pS295, DOI 10.1097/TA.0b013e31816bce54
   Lellouche F, 2006, AM J RESP CRIT CARE, V174, P894, DOI 10.1164/rccm.200511-1780OC
   Raemer DB, 1997, J CLIN MONITOR, V13, P91, DOI 10.1023/A:1007384122804
   Stockinger ZT, 2004, MIL MED, V169, P609, DOI 10.7205/MILMED.169.8.609
   Sun Y, 1997, J PEDIATR-US, V131, P754, DOI 10.1016/S0022-3476(97)70107-0
   Tehrani FT, 2001, P ANN INT IEEE EMBS, V23, P2059, DOI 10.1109/IEMBS.2001.1020638
   TEHRANI FT, 1994, MED ENG PHYS, V16, P329, DOI 10.1016/1350-4533(94)90060-4
NR 11
TC 9
Z9 9
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
EI 1879-1190
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD MAY
PY 2009
VL 208
IS 5
BP 763
EP 768
DI 10.1016/j.jamcollsurg.2009.01.033
PG 6
WC Surgery
SC Surgery
GA 441WP
UT WOS:000265801500024
PM 19476833
DA 2018-12-27
ER

PT J
AU Jamal, SA
   Goltzman, D
   Hanley, DA
   Papaioannou, A
   Prior, JC
   Josse, RG
AF Jamal, S. A.
   Goltzman, D.
   Hanley, D. A.
   Papaioannou, A.
   Prior, J. C.
   Josse, R. G.
TI RETRACTED: Nitrate use and changes in bone mineral density: the Canadian
   Multicentre Osteoporosis Study (Retracted article. See vol. 28, pg. 421,
   2017)
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE Bone mineral density; Men; Organic nitrates; Prospective study; Women
ID NITRIC-OXIDE SYNTHASE; POSTMENOPAUSAL WOMEN; RESORPTION; INHIBITION;
   FRACTURES; CAMOS; RISK
AB Nitrates may have beneficial effects on bone. To determine if nitrates were associated with increased bone mineral density (BMD), we conducted a secondary analysis using data from subjects in a prospective study. Subjects reporting nitrate use had increased BMD compared with non-users, confirming that nitrates have positive BMD effects in women and men.
   Prior studies suggest positive associations between nitrates and bone.
   We used linear regression models, stratified by gender and adjusted for age, weight, and baseline differences, to determine the association between daily nitrate use and BMD among subjects participating in the Canadian Multicentre Osteoporosis Study. All results are reported as annualised percent change in BMD at the hip and spine among nitrate users compared to non-users.
   We included 1,419 men (71 reported daily nitrate use) and 2,587 women (97 reported daily nitrate use). Male non-users had decreased hip BMD (-1.3%; 95% confidence interval [95%CI] = -1.6 to -1.1) and increased spine BMD (2.8%; 95%CI = 2.5 to 3.1). Male nitrate users had increased hip BMD (1.4%; 95%CI = 0.1 to 2.8) and spine BMD (4.5%; 95%CI = 3.2 to 5.7). Among women, non-users had decreased hip BMD (-1.9; 95%CI = -2.1 to -1.7) and increased spine BMD (2.1%; 95%CI = 1.9 to 2.4) whilst users had an increase in hip BMD (2.0%; 95%CI = 1.2 to 2.8) and spine BMD (4.1%; 95%CI = 3.4 to 4.9).
   Nitrate use is associated with increased BMD at the hip and spine in men and women.
C1 [Jamal, S. A.; Josse, R. G.] Univ Toronto, Toronto, ON, Canada.
   [Goltzman, D.] McGill Univ, Montreal, PQ, Canada.
   [Hanley, D. A.] Univ Calgary, Calgary, AB, Canada.
   [Papaioannou, A.] McMaster Univ, Hamilton, ON, Canada.
   [Prior, J. C.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
RP Jamal, SA (reprint author), 76 Grenville St,Suite 805, Toronto, ON M5S 1B2, Canada.
EM sophie.jamal@utoronto.ca; david.goltzman@muhc.mcgill.ca;
   dahanley@ucalgary.ca; papaioannou@hhsc.ca; jerilynn.prior@vch.ca;
   josser@smh.toronto.on.ca
FU Canadian Institutes of Health Research; Merck Frosst Canada; Eli Lilly
   Canada; Novartis Pharmaceuticals; Alliance for Better Bone Health
   (Sanofi-Aventis and Procter and Gamble Pharmaceuticals Canada); Dairy
   Farmers of Canada; Arthritis Society
FX This study was supported by the Canadian Institutes of Health Research,
   Merck Frosst Canada, Eli Lilly Canada, Novartis Pharmaceuticals, The
   Alliance for Better Bone Health (Sanofi-Aventis and Procter and Gamble
   Pharmaceuticals Canada), The Dairy Farmers of Canada and The Arthritis
   Society.
CR BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001
   BRANDI ML, 1995, P NATL ACAD SCI USA, V92, P2954, DOI 10.1073/pnas.92.7.2954
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   COLLINOSDOBY P, 1995, J CELL BIOCHEM, V57, P399, DOI 10.1002/jcb.240570305
   CUMMINGS SR, 1995, J BONE MINER RES, V10, P518
   GENANT HK, 1994, J BONE MINER RES, V9, P1503
   Jackson SA, 2000, OSTEOPOROSIS INT, V11, P680, DOI 10.1007/s001980070066
   Jamal SA, 2004, J BONE MINER RES, V19, P1512, DOI 10.1359/JBMR.040716
   Jamal SA, 1998, J BONE MINER RES, V13, P1755, DOI 10.1359/jbmr.1998.13.11.1755
   KASTEN TP, 1994, P NATL ACAD SCI USA, V91, P3569, DOI 10.1073/pnas.91.9.3569
   Kreiger N, 1999, CAN J AGING, V18, P376, DOI 10.1017/S0714980800009934
   LOWIK CWGM, 1994, J CLIN INVEST, V93, P1465, DOI 10.1172/JCI117124
   MACINTYRE I, 1991, P NATL ACAD SCI USA, V88, P2936, DOI 10.1073/pnas.88.7.2936
   Papaioannou A, 2005, OSTEOPOROSIS INT, V16, P568, DOI 10.1007/s00198-004-1735-x
   Rejnmark L, 2006, J BONE MINER RES, V21, P1811, DOI 10.1359/JBMR.060804
   Thadani U, 1997, CARDIOVASC DRUG THER, V10, P735, DOI 10.1007/BF00053031
   Ware JE, 1993, SF 36 HLTH SURVEY MA
   Wimalawansa SJ, 1997, BONE, V21, P275, DOI 10.1016/S8756-3282(97)00125-7
   Wimalawansa SJ, 1996, BONE, V18, P301, DOI 10.1016/8756-3282(96)00005-1
   WIMALAWANSA SJ, 1997, P 79 ANN M END SOC M
NR 20
TC 16
Z9 16
U1 3
U2 6
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
EI 1433-2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAY
PY 2009
VL 20
IS 5
BP 737
EP 744
DI 10.1007/s00198-008-0727-7
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 428LC
UT WOS:000264848400008
PM 18800179
DA 2018-12-27
ER

PT J
AU Chawla, S
   Ghosh, AK
   Avasthi, DK
   Kulriya, PK
   Ahnnad, S
AF Chawla, S.
   Ghosh, A. K.
   Avasthi, D. K.
   Kulriya, P. K.
   Ahnnad, S.
TI RETRACTED: Grafting of Glycidyl Methacrylate onto Swift-Nickel-Ions
   Irradiated Polypropylene Films Using Chemical Initiator (Retracted
   article. See vol. 50, pg. 428, 2010)
SO POLYMER ENGINEERING AND SCIENCE
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 16th Annual Polychar World Forum on Advanced Materials
CY FEB 17-21, 2008
CL Lucknow, INDIA
ID HEAVY-ION; TRACK MEMBRANES; MALEIC-ANHYDRIDE; GAMMA-RADIATION;
   ACRYLIC-ACID; POLYMERS; COPOLYMERIZATION; POLYMERIZATION; SPECTROSCOPY;
   BEHAVIOR
AB Polypropylene (PP) films were irradiated with swift nickel ions, (90 MeV Ni8+ ions) at different fluencies varying from 10(10) to 3 x 10(11) ions/cm(2) and then grafted with glycidyl methacrylate (GMA) using benzoyl peroxide (BPO) as chemical initiator. It is shown that GMA could be grafted onto PP film. A comparison for the GMA grafting using BPO initiator in virgin as well as in the swift nickel ions irradiated PP films was given. The exposure of PP film to SHI results in a reduction in the effect of the BPO for graft copolymerization. Furthermore, as the fluency of swift nickel ions increased beyond an optimum value, the overlapping of the latent tracks reduced the grafting yield. Contact angle measurements and surface energy calculations showed an increasing hydrophilic nature in the direction from pure PP to grafted PP-g-GMA. These results are intended to benefit the synthesis and properties of a functional polymer. POLYM. ENG. SCI., 49:881-888, 2009. (C) 2009 Society of Plastics Engineers
C1 [Chawla, S.] Amity Sch Engn & Technol, Dept Appl Chem, New Delhi, India.
   [Ghosh, A. K.] Indian Inst Technol, Ctr Polymer Sci & Engn, New Delhi, India.
   [Avasthi, D. K.; Kulriya, P. K.] Inter Univ Accelerator Ctr, New Delhi, India.
   [Chawla, S.; Ahnnad, S.] Indian Inst Technol, Dept Chem, Mat Res Lab, New Delhi 110016, India.
RP Ahnnad, S (reprint author), Amity Sch Engn & Technol, Dept Appl Chem, New Delhi, India.
EM sharifahmad_jmi@yahoo.co.in
RI Kulriya, Pawan/H-3391-2011; Avasthi, Devesh/D-4712-2013
OI Kulriya, Pawan/0000-0001-5563-7584; 
CR Apel P, 2003, NUCL INSTRUM METH B, V208, P11, DOI 10.1016/S0168-583X(03)00634-7
   Betz N, 1997, NUCL INSTRUM METH B, V131, P252, DOI 10.1016/S0168-583X(97)00384-4
   BETZ N, 1992, MACROMOLECULES, V25, P213, DOI 10.1021/ma00027a036
   Betz N, 1995, NUCL INSTRUM METH B, V105, P55, DOI 10.1016/0168-583X(95)00911-6
   CHAPIRO A, 1988, NUCL INSTRUM METH B, V32, P111, DOI 10.1016/0168-583X(88)90191-7
   Chawla S, 2007, J APPL POLYM SCI, V105, P3578, DOI 10.1002/app.26425
   Chawla S, 2006, NUCL INSTRUM METH B, V244, P248, DOI 10.1016/j.nimb.2005.11.159
   Chu LY, 2001, J MEMBRANE SCI, V192, P27, DOI 10.1016/S0376-7388(01)00464-1
   Fleischer RL, 1975, NUCL TRACKS SOLIDS P
   Fleisher R. L., 1975, NUCL TRACKS SOLIDS
   Hatada K, 1997, MACROMOLECULES, V30, P6754, DOI 10.1021/ma970672i
   Kaetsu I, 1995, NUCL INSTRUM METH B, V105, P294, DOI 10.1016/0168-583X(95)00996-5
   Lee EH, 1999, NUCL INSTRUM METH B, V151, P29, DOI 10.1016/S0168-583X(99)00129-9
   Li J, 2003, POLYM TEST, V22, P217, DOI 10.1016/S0142-9418(02)00085-5
   Mazzei R, 2008, NUCL INSTRUM METH B, V266, P3170, DOI 10.1016/j.nimb.2008.03.177
   Mazzei R, 2006, NUCL INSTRUM METH B, V251, P99, DOI 10.1016/j.nimb.2006.05.014
   Mazzei R, 2004, NUCL INSTRUM METH B, V226, P575, DOI 10.1016/j.nimb.2004.08.001
   Mazzei R, 2000, NUCL INSTRUM METH B, V170, P419, DOI 10.1016/S0168-583X(00)00243-3
   Mazzei RO, 1996, RADIAT MEAS, V26, P577, DOI 10.1016/1350-4487(96)00029-7
   Mazzei RO, 2002, RADIAT PHYS CHEM, V64, P149, DOI 10.1016/S0969-806X(01)00457-1
   Nasef MM, 2004, PROG POLYM SCI, V29, P499, DOI 10.1016/j.progpolymsci.2004.01.003
   NOVAK I, 1995, J MATER SCI LETT, V14, P1298, DOI 10.1007/BF01262273
   Novak I, 2007, POLYM ENG SCI, V47, P1207, DOI 10.1002/pen.20796
   ODIAN G, 2004, PRINCIPLES POLYMERIZ, P718
   Omichi H, 1995, NUCL INSTRUM METH B, V105, P302, DOI 10.1016/0168-583X(95)00546-3
   Pan YK, 1997, J APPL POLYM SCI, V65, P1905
   Parthasarthy G, 2002, J POLYM SCI POL PHYS, V40, P2539, DOI 10.1002/polb.10304
   Porte-Durrieu MC, 2000, J BIOMED MATER RES, V52, P119, DOI 10.1002/1097-4636(200010)52:1<119::AID-JBM15>3.0.CO;2-Q
   RENGARAJAN R, 1989, POLYMER, V30, P933, DOI 10.1016/0032-3861(89)90195-X
   Shtanko NI, 2000, J MEMBRANE SCI, V179, P155, DOI 10.1016/S0376-7388(00)00494-4
   Shtanko NI, 1999, NUCL INSTRUM METH B, V151, P416, DOI 10.1016/S0168-583X(99)00108-1
   SPOHR R, 1990, FRIED
   Stojanovic Z, 2005, POLYM DEGRAD STABIL, V87, P279, DOI 10.1016/j.polymdegradstab.2004.07.021
   TURNERJONES A, 1964, MAKROMOL CHEM, V75, P134, DOI DOI 10.1002/MACP.1964.020750113
   XU GX, 1994, SCI REV MACROMOL C C, V34, P555
   ZHU X, 2001, J PHYS CHEM B, V27, P124
NR 36
TC 1
Z9 1
U1 4
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0032-3888
EI 1548-2634
J9 POLYM ENG SCI
JI Polym. Eng. Sci.
PD MAY
PY 2009
VL 49
IS 5
SI SI
BP 881
EP 888
DI 10.1002/pen.21390
PG 8
WC Engineering, Chemical; Polymer Science
SC Engineering; Polymer Science
GA 436XI
UT WOS:000265449000008
DA 2018-12-27
ER

PT J
AU Singh, VR
   Garg, A
   Agrawal, DC
AF Singh, V. R.
   Garg, A.
   Agrawal, D. C.
TI RETRACTED: Structure and properties of lanthanum-doped bismuth ferrite
   thin films (Retracted article. See vol. 151, pg. 916, 2011)
SO SOLID STATE COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE Thin films; Ferroelectrics; Multiferroics; Chemical solution deposition
ID BIFEO3; CRYSTAL
AB Here we report on the subtle changes in structure of BiFeO3 thin films induced by lanthanum (La) doping and subsequent impact on the film's properties. Bi1-xLaxFeO3 (BLFO) thin films (x = 0.0 to 0.30) were deposited by the chemical solution deposition method on indium tin oxide coated glass substrates. X-ray diffraction analyses of the films indicate the gradual structural changes in the films from a rhombohedral type towards a cubic like structure as the La content increases, also evident from changes in the lattice parameters and disappearance of peak splitting upon increasing doping. This was also accompanied by an increase in the remanent polarization, dielectric constant, magnetization and a marginal decrease in the leakage current density up to x = 0.20 followed by a reverse trend at higher doping levels. Crown Copyright (C) 2009 Published by Elsevier Ltd. All rights reserved.
C1 [Singh, V. R.] Univ Tokyo, Dept Phys, Bunkyo Ku, Tokyo 1130033, Japan.
   [Garg, A.] Indian Inst Technol, Dept Mat & Met Engn, Kanpur 208016, Uttar Pradesh, India.
   [Agrawal, D. C.] Indian Inst Technol, Mat Sci Program, Kanpur 208016, Uttar Pradesh, India.
RP Singh, VR (reprint author), Univ Tokyo, Dept Phys, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.
EM vijay.iitb@gmail.com
FU Defense Research and Development Organization, Government of India
   [ERIP/ER/0500302/M/01/919]
FX The authors thank the Defense Research and Development Organization,
   Government of India, for financial support (Grant No.
   ERIP/ER/0500302/M/01/919).
CR Das SR, 2006, J APPL PHYS, V99, DOI 10.1063/1.2180451
   Ederer C, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.060401
   Fiebig M, 2002, NATURE, V419, P818, DOI 10.1038/nature01077
   Hill NA, 2000, J PHYS CHEM B, V104, P6694, DOI [10.1021/jp000114x, 10.1021/jpc00114x]
   Huang FZ, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2404942
   Iakovlev S, 2005, J APPL PHYS, V97, DOI 10.1063/1.1881776
   Kim JK, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2189453
   Kiselev S. V., 1963, SOV PHYS DOKL, V7, P742
   KUBEL F, 1990, ACTA CRYSTALLOGR B, V46, P698, DOI 10.1107/S0108768190006887
   Lee D, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1941474
   MICHEL C, 1969, SOLID STATE COMMUN, V7, P701, DOI 10.1016/0038-1098(69)90597-3
   Nalwa KS, 2008, J APPL PHYS, V103, DOI 10.1063/1.2838483
   SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551
   Simoes AZ, 2007, J APPL PHYS, V101, DOI 10.1063/1.2715513
   Singh SK, 2006, JPN J APPL PHYS 1, V45, P3194, DOI 10.1143/JJAP.45.3194
   Singh SK, 2005, JPN J APPL PHYS 2, V44, pL734, DOI 10.1143/JJAP.44.L734
   Singh VR, 2008, APPL PHYS A-MATER, V90, P197, DOI 10.1007/s00339-007-4257-5
   TEAGUE JR, 1970, SOLID STATE COMMUN, V8, P1073, DOI 10.1016/0038-1098(70)90262-0
   Uchida H, 2006, J APPL PHYS, V100, DOI 10.1063/1.2210167
   Wang J, 2003, SCIENCE, V299, P1719, DOI 10.1126/science.1080615
   Yun KY, 2004, J APPL PHYS, V96, P3399, DOI 10.1063/1.1775045
NR 21
TC 10
Z9 10
U1 4
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0038-1098
EI 1879-2766
J9 SOLID STATE COMMUN
JI Solid State Commun.
PD MAY
PY 2009
VL 149
IS 17-18
BP 734
EP 737
DI 10.1016/j.ssc.2009.02.014
PG 4
WC Physics, Condensed Matter
SC Physics
GA 440WJ
UT WOS:000265730100019
DA 2018-12-27
ER

PT J
AU Oettle, GJ
AF Oettle, G. J.
TI RETRACTED: HIV vasculopathy reviewed (Retracted Article)
SO SOUTH AFRICAN JOURNAL OF SURGERY
LA English
DT Editorial Material; Retracted Publication
NR 0
TC 0
Z9 0
U1 1
U2 10
PU SA MEDICAL ASSOC
PI PRETORIA
PA BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA
SN 0038-2361
EI 2078-5151
J9 S AFR J SURG
JI South Afr. J. Surg.
PD MAY
PY 2009
VL 47
IS 2
BP 35
EP 35
PG 1
WC Surgery
SC Surgery
GA 480PH
UT WOS:000268747800001
PM 19626777
DA 2018-12-27
ER

PT J
AU Lichtenthaler, U
   Ernst, H
AF Lichtenthaler, Ulrich
   Ernst, Holger
TI RETRACTED: Technology licensing strategies: the interaction of process
   and content characteristics (Retracted article. See vol. 10, pg. 466,
   2012)
SO STRATEGIC ORGANIZATION
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 67th Annual Meeting of the Academy-of-Management
CY AUG 03-08, 2007
CL Philadelphia, PA
SP Acad Management
DE corporate strategy; mixed methods research; strategic planning; strategy
   content; strategy process; technology licensing
ID INTELLECTUAL PROPERTY; CORPORATE-STRATEGY; FINANCIAL PERFORMANCE;
   COMPETITIVE ADVANTAGE; COMPLEMENTARY ASSETS; ABSORPTIVE-CAPACITY; PATENT
   LITIGATION; INNOVATION; INDUSTRY; FIRMS
AB Industrial firms increasingly license their technological knowledge exclusively or in addition to its application inside the organization. Given the relative lack of prior research, this study uses qualitative data from interviews in 25 industrial firms to examine the role of strategy process and content characteristics in technology out-licensing. Following a mixed methods design, the study further uses quantitative data from a survey of 136 firms to test multiple hypotheses relating a firm's licensing performance to two process characteristics of corporate licensing strategies, i.e. formalization and integration, and to two strategy content issues, i.e. openness and activeness. The findings provide support for the combined explanatory power of strategy process and content variables, which strongly interact in their effect on licensing performance. The results help to understand the discrepancies between the success of some pioneering firms in technology licensing and the managerial difficulties of many others.
C1 [Lichtenthaler, Ulrich; Ernst, Holger] WHU Otto Beisheim Sch Management Technol & Innova, D-56179 Vallendar, Germany.
RP Lichtenthaler, U (reprint author), WHU Otto Beisheim Sch Management Technol & Innova, Burgpl 2, D-56179 Vallendar, Germany.
EM lichtenthaler@whu.edu; hernst@whu.edu
CR Agrawal A, 2006, STRATEGIC MANAGE J, V27, P63, DOI 10.1002/smj.508
   Anand BN, 2000, J IND ECON, V48, P103
   ANDERSEN PH, 1972, STRATEG ORGAN, V6, P13
   Andersen TJ, 2004, J MANAGE STUD, V41, P1271, DOI 10.1111/j.1467-6486.2004.00475.x
   ANSOFF H. I, 1965, CORPORATE STRATEGY
   Arbussa A, 2007, RES POLICY, V36, P1545, DOI 10.1016/j.respol.2007.04.013
   Argote L, 2003, MANAGE SCI, V49, P571, DOI 10.1287/mnsc.49.4.571.14424
   Arora A, 2006, MANAGE SCI, V52, P293, DOI 10.1287/mnsc.1050.0437
   BADENFULLER C, 1994, RIJUVENATING MATURE
   Bagozzi RP, 1998, ORGAN RES METHODS, V1, P45, DOI 10.1177/109442819800100104
   BARNEY J, 1991, J MANAGE, V17, P99, DOI 10.1177/014920639101700108
   Bartunek JM, 2002, J ORGAN BEHAV, V23, P237, DOI 10.1002/job.132
   Bowman EH, 2001, STRATEGIC MANAGE J, V22, P1
   BOYD BK, 1991, J MANAGE STUD, V28, P353, DOI 10.1111/j.1467-6486.1991.tb00286.x
   Boyd BK, 1998, STRATEGIC MANAGE J, V19, P181, DOI 10.1002/(SICI)1097-0266(199802)19:2<181::AID-SMJ945>3.3.CO;2-Q
   Brown S. L., 1998, COMPETING EDGE STRAT
   BROWN SL, 1995, ACAD MANAGE REV, V20, P343, DOI 10.2307/258850
   Brush TH, 1999, STRATEGIC MANAGE J, V20, P519
   BURGELMAN RA, 1983, ACAD MANAGE REV, V8, P61
   Burgelman RA, 2007, STRATEG MANAGE J, V28, P965, DOI 10.1002/smj.625
   Cassiman B, 2006, MANAGE SCI, V52, P68, DOI 10.1287/rrmsc.1050.0470
   Chesbrough H, 2007, CALIF MANAGE REV, V49, P45, DOI 10.2307/41166394
   CHOW GC, 1960, ECONOMETRICA, V28, P591, DOI 10.2307/1910133
   Cliff JE, 2006, J BUS VENTURING, V21, P633, DOI 10.1016/j.jbusvent.2005.02.010
   Cohen J., 2003, APPL MULTIPLE REGRES
   Cohen W. M., 2000, 7552 NAT BUR EC RES
   COHEN WM, 1990, ADMIN SCI QUART, V35, P128, DOI 10.2307/2393553
   CONNER KR, 1995, MANAGE SCI, V41, P209, DOI 10.1287/mnsc.41.2.209
   DAVIS JL, 2001, EDISON BOARDROOM LEA
   Donaldson L., 2001, CONTINGENCY THEORY O
   EDMONDSON A, 1999, ADM SCI Q, V46, P685
   Edmondson AC, 2007, ACAD MANAGE REV, V32, P1155
   EISENHARDT KM, 1989, ACAD MANAGE REV, V14, P532, DOI 10.2307/258557
   Ernst H, 2001, RES POLICY, V30, P143, DOI 10.1016/S0048-7333(99)00098-0
   FAHEY L, 1986, J MANAGE, V12, P167, DOI 10.1177/014920638601200203
   Farjoun M, 2002, STRATEGIC MANAGE J, V23, P561, DOI 10.1002/smj.239
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   Fosfuri A, 2006, STRATEGIC MANAGE J, V27, P1141, DOI 10.1002/smj.562
   Foss N. J., 2003, Strategic Organization, V1, P139, DOI 10.1177/1476127003001002304
   Gambardella A, 2001, MARKETS TECHNOLOGY E
   Gambardella A, 2007, RES POLICY, V36, P1163, DOI 10.1016/j.respol.2007.07.006
   Gans JS, 2008, MANAGE SCI, V54, P982, DOI 10.1287/mnsc.1070.0814
   Gans JS, 2003, RES POLICY, V32, P333, DOI 10.1016/S0048-7333(02)00103-8
   Gavetti G, 2007, ORGAN SCI, V18, P420, DOI 10.1287/orsc.1070.0282
   Granstrand O, 2000, EC MANAGEMENT INTELL
   Grant RM, 2003, STRATEGIC MANAGE J, V24, P491, DOI 10.1002/smj.314
   Greene William, 2007, ECONOMETRIC ANAL
   Grindley PC, 1997, CALIF MANAGE REV, V39, P8, DOI 10.2307/41165885
   Hair J., 2006, MULTIVARIATE DATA AN
   Hamel G, 2000, LEADING REVOLUTION
   Heimeriks KH, 2007, STRATEG ORGAN, V5, P373, DOI 10.1177/1476127007083347
   Helfat C. E., 2007, DYNAMIC CAPABILITIES
   HILL CWL, 1992, ORGAN SCI, V3, P428, DOI 10.1287/orsc.3.3.428
   HINKIN TR, 1995, J MANAGE, V21, P967, DOI 10.1016/0149-2063(95)90050-0
   Hodgkinson GP, 2006, LONG RANGE PLANN, V39, P479, DOI 10.1016/j.lrp.2006.07.003
   HUFF AS, 1987, J MANAGE, V13, P211, DOI 10.1177/014920638701300203
   Hutzschenreuter T, 2006, J MANAGE, V32, P673, DOI 10.1177/0149206306291485
   Judge WQ, 1998, J MANAGE STUD, V35, P241, DOI 10.1111/1467-6486.00092
   Kearns GS, 2007, IEEE T ENG MANAGE, V54, P628, DOI 10.1109/TEM.2007.906848
   Ketchen DJ, 1996, J MANAGE, V22, P231, DOI 10.1016/S0149-2063(96)90048-3
   Khanna T, 2000, STRATEGIC MANAGE J, V21, P781, DOI 10.1002/1097-0266(200007)21:7<781::AID-SMJ119>3.0.CO;2-2
   Kim AH, 2006, REM SPEC EDUC, V27, P235, DOI 10.1177/07419325060270040401
   King N., 1994, QUALITATIVE METHODS, P14
   Kotabe M, 1996, J MARKETING, V60, P73, DOI 10.2307/1251889
   Langley A, 2007, STRATEG ORGAN, V5, P271, DOI 10.1177/1476127007079965
   Lawrence P. R., 1967, ORG ENV
   Lee T. W., 1999, USING QUALITATIVE ME
   LEVIN R. C., 1987, BROOKINGS PAPERS EC, V3, P783, DOI DOI 10.2307/2534454
   Lichtenthaler U, 2007, CALIF MANAGE REV, V49, P67, DOI 10.2307/41166406
   Lichtenthaler U, 2007, RES POLICY, V36, P37, DOI 10.1016/j.respol.2006.08.005
   Lindell MK, 2001, J APPL PSYCHOL, V86, P114, DOI 10.1037//0021-9010.86.1.114
   March JG, 1991, ORGAN SCI, V2, P71, DOI 10.1287/orsc.2.1.71
   Markides C, 1998, SLOAN MANAGE REV, V39, P31
   Martens ML, 2007, ACAD MANAGE J, V50, P1107
   Miles M B., 1994, QUALITATIVE DATA ANA
   Miles R. E., 1978, ORG STRATEGY STRUCTU
   MILLER CC, 1994, ACAD MANAGE J, V37, P1649, DOI 10.2307/256804
   MINTZBERG H, 1994, HARVARD BUS REV, V72, P107
   Motohashi K, 2008, RES POLICY, V37, P1548, DOI 10.1016/j.respol.2007.12.014
   Neuenschwander CR, 2004, LICENSING J, V24, P10
   Nickerson JA, 2007, STRATEG ORGAN, V5, P211, DOI 10.1177/1476127007079969
   Noda T, 1996, STRATEGIC MANAGE J, V17, P159
   PEARCE JA, 1987, STRATEGIC MANAGE J, V8, P125, DOI 10.1002/smj.4250080204
   Pisano GP, 2007, CALIF MANAGE REV, V50, P278, DOI 10.2307/41166428
   Pitkethly RH, 2001, RES POLICY, V30, P425, DOI 10.1016/S0048-7333(00)00084-6
   Podsakoff PM, 2003, J APPL PSYCHOL, V88, P879, DOI 10.1037/0021-9101.88.5.879
   PORTER ME, 1987, HARVARD BUS REV, V65, P43
   RAMANUJAM V, 1986, ACAD MANAGE J, V29, P347, DOI 10.2307/256192
   Rivette K, 2000, REMBRANDTS ATTIC UNL
   ROBINSON RB, 1988, STRATEGIC MANAGE J, V9, P43, DOI 10.1002/smj.4250090105
   Rogers PR, 1999, STRATEGIC MANAGE J, V20, P567, DOI 10.1002/(SICI)1097-0266(199906)20:6<567::AID-SMJ36>3.0.CO;2-K
   Ruderman MN, 2002, ACAD MANAGE J, V45, P369, DOI 10.2307/3069352
   RUMELT RP, 1991, STRATEGIC MANAGE J, V12, P5, DOI 10.1002/smj.4250121003
   Santos FA, 2005, ORGAN SCI, V16, P491, DOI 10.1287/orsc.1050.0152
   SCHENDEL D, 1992, STRATEGIC MANAGE J, V13, P1
   SCHOONHOVEN CB, 1981, ADM SCI Q, V26, P177
   SENDJAYA S, 2008, J MANAGE STUD, V45, P403
   Shah SK, 2006, J MANAGE STUD, V43, P1821, DOI 10.1111/j.1467-6486.2006.00662.x
   SHAN WJ, 1994, STRATEGIC MANAGE J, V15, P387, DOI 10.1002/smj.4250150505
   Shane S, 2007, J ECON BEHAV ORGAN, V63, P739, DOI 10.1016/j.jebo.2006.05.012
   Silverman BS, 1999, MANAGE SCI, V45, P1109, DOI 10.1287/mnsc.45.8.1109
   Somaya D, 2003, STRATEGIC MANAGE J, V24, P17, DOI 10.1002/smj.281
   Teece DJ, 2007, STRATEG MANAGE J, V28, P1319, DOI 10.1002/smj.640
   Tripsas M, 1997, STRATEGIC MANAGE J, V18, P119, DOI 10.1002/(SICI)1097-0266(199707)18:1+<119::AID-SMJ921>3.3.CO;2-S
   TSABBAR D, 2008, STRATEG ORGAN, V6, P375
   Walker G, 2007, STRATEG ORGAN, V5, P227, DOI 10.1177/1476127007079970
   WHITE RE, 1986, STRATEGIC MANAGE J, V7, P217, DOI 10.1002/smj.4250070304
   Williamson OE, 1991, NATURE FIRM ORIGINS
   Yauch CA, 2003, ORGAN RES METHODS, V6, P465, DOI 10.1177/1094428103257362
   Yin R. K., 2003, CASE STUDY RES DESIG
   Zhao ZJ, 2004, STRATEG ORGAN, V2, P133
   Ziedonis AA, 2007, MANAGE SCI, V53, P1618, DOI 10.1287/mnsc.1070.0705
   Ziedonis RH, 2004, MANAGE SCI, V50, P804, DOI 10.1287/mnsc.1040.0208
NR 113
TC 24
Z9 24
U1 3
U2 42
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1476-1270
EI 1741-315X
J9 STRATEG ORGAN
JI Strateg. Organ.
PD MAY
PY 2009
VL 7
IS 2
BP 183
EP 221
DI 10.1177/1476127009102672
PG 39
WC Business; Management
SC Business & Economics
GA 445RA
UT WOS:000266068000003
DA 2018-12-27
ER

PT J
AU Brouillat, E
AF Brouillat, Eric
TI RETRACTED: An evolutionary model of recycling and product lifetime
   extension (Retracted article. See vol. 79, pg. 1568, 2012)
SO TECHNOLOGICAL FORECASTING AND SOCIAL CHANGE
LA English
DT Article; Retracted Publication
DE Recycling; Product lifetime extension; Environmental innovation;
   Evolutionary modeling
ID CONSUMERS; WASTE
AB This paper presents a model-based analysis of the development and diffusion of so-called 'green' products, i.e. those which are easily recyclable and which have a long lifetime. We address this problem by developing an evolutionary simulation model to identify the impact of the environmental R&D strategies of business firms on the economy and the environment. The simulation results show that R&D investment both in product recyclability and in product lifetime extension can be positive for the firm. Adopting Such a strategy means that the firm can then market green products, which provides it with a competitive advantage on firms investing mainly in product recyclability whatever consumers' preferences. From an environmental point of view, the diffusion of green products will reduce both waste flows in the economy and pressure on virgin resources. However, diversifying R&D investment to develop both product recyclability and lifetime can mean slowing down the flow of recycled materials and may lead to even greater quantities of unrecycled waste. Our results suggest introducing regulation policies aiming at encouraging firms to invest both in product recyclability and lifetime in order to benefit from their complementarities. Furthermore, simulations show that it should be better to direct environmental policies on firms' environmental innovation strategies than on demand attributes because significant changes in these strategies would provide much more radical environmental changes. (C) 2008 Elsevier Inc. All rights reserved.
C1 Univ Montesquieu Bordeaux IV, CNRS, GREThA, UMR 5113, F-33608 Pessac, France.
RP Brouillat, E (reprint author), Univ Montesquieu Bordeaux IV, CNRS, GREThA, UMR 5113, Ave Leon Duguit, F-33608 Pessac, France.
EM eric.brouillat@u-bordeaux4.fr
CR Bellmann K, 2000, TECHNOVATION, V20, P677, DOI 10.1016/S0166-4972(00)00012-2
   Boons F, 2002, J CLEAN PROD, V10, P495, DOI 10.1016/S0959-6526(02)00017-3
   *COMM EUR COMM, 2006, COM200131 COMM EUR C
   *COMM EUR COMM, 2006, COM2006406 COMM EUR
   Di Vita G, 2001, ENERG ECON, V23, P549, DOI 10.1016/S0140-9883(01)00075-5
   FULLERTON D, 1996, NBER WORKING PAPER, V5594
   Giarini Orio, 1989, LIMITS CERTAINTY FAC
   Janssen MA, 2002, J EVOL ECON, V12, P283, DOI 10.1007/s00191-002-0120-1
   LACOSTE E, 2006, RARE INFINI PANORAMA
   Lindhqvist T., 2000, EXTENDED PRODUCER RE
   Malerba F., 1999, IND CORP CHANGE, V8, P3, DOI DOI 10.1093/ICC/8.1.3
   Malerba F, 2007, J EVOL ECON, V17, P371, DOI 10.1007/s00191-007-0060-x
   Nakamura S, 1999, ECOL ECON, V28, P133, DOI 10.1016/S0921-8009(98)00031-7
   Saint-Jean M., 2005, European Journal of Economic and Social Systems, V18, P255
   Silverberg G., 1995, EVOLUTIONARY PRINCIP
   SMALLWOOD DE, 1979, Q J ECON, V93, P1, DOI 10.2307/1882595
   Stahel W., 1976, JOBS TOMORROW POTENT
   Stahel W., 1983, PRODUCT LIFE FACTOR
   Stahel WR, 1994, GREENING IND ECOSYST
   van den Bergh JCJM, 2007, J EVOL ECON, V17, P521, DOI 10.1007/s00191-006-0054-0
   van Schaik A, 2004, RESOUR CONSERV RECY, V40, P301, DOI 10.1016/S0921-3449(03)00074-0
   VENABLES WN, 1999, MODERN APPL STAT S P
NR 22
TC 6
Z9 6
U1 1
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0040-1625
J9 TECHNOL FORECAST SOC
JI Technol. Forecast. Soc. Chang.
PD MAY
PY 2009
VL 76
IS 4
SI SI
BP 471
EP 486
DI 10.1016/j.techfore.2008.03.023
PG 16
WC Business; Planning & Development
SC Business & Economics; Public Administration
GA 437WL
UT WOS:000265517500004
DA 2018-12-27
ER

PT J
AU Tai, YT
   Soydan, E
   Song, WH
   Fulciniti, M
   Kim, K
   Hong, FX
   Li, XF
   Burger, P
   Rumizen, MJ
   Nahar, S
   Podar, K
   Hideshima, T
   Munshi, NC
   Tonon, G
   Carrasco, RD
   Afar, DEH
   Anderson, KC
AF Tai, Yu-Tzu
   Soydan, Ender
   Song, Weihua
   Fulciniti, Mariateresa
   Kim, Kihyun
   Hong, Fangxin
   Li, Xian-Feng
   Burger, Peter
   Rumizen, Matthew J.
   Nahar, Sabikun
   Podar, Klaus
   Hideshima, Teru
   Munshi, Nikhil C.
   Tonon, Giovanni
   Carrasco, Ruben D.
   Afar, Daniel E. H.
   Anderson, Kenneth C.
TI RETRACTED: CS1 promotes multiple myeloma cell adhesion, clonogenic
   growth, and tumorigenicity via c-maf-mediated interactions with bone
   marrow stromal cells (Retracted article. See vol. 115, pg. 2983, 2010)
SO BLOOD
LA English
DT Article; Retracted Publication
ID IMMUNOGLOBULIN SUPERFAMILY; CYTOTOXICITY; EXPRESSION; ANTIBODY; BIOLOGY;
   CD2; OVEREXPRESSION; PROLIFERATION; BIOCONDUCTOR; LYMPHOCYTES
AB CS1 is highly expressed on tumor cells from the majority of multiple myeloma (MM) patients regardless of cytogenetic abnormalities or response to current treatments. Furthermore, CS1 is detected in MM patient sera and correlates with active disease. However, its contribution to MM pathophysiology is undefined. We here show that CS1 knockdown using lentiviral short-interfering RNA decreased phosphorylation of ERK1/2, AKT, and STAT3, suggesting that CS1 induces central growth and survival signaling pathways in MM cells. Serum deprivation markedly blocked survival at earlier time points in CS1 knockdown compared with control MM cells, associated with earlier activation of caspases, poly(ADP-ribose) polymerase, and proapoptotic proteins BNIP3 and BIK. CS1 knockdown further delayed development of MM tumor and prolonged survival in mice. Conversely, CS1 overexpression promoted myeloma cell growth and survival by significantly increasing myeloma adhesion to bone marrow stromal cells (BMSCs) and enhancing myeloma colony formation in semisolid culture. Moreover, CS1 increased c-maf-targeted cyclin D2-dependent proliferation, -integrin beta 7/alpha E-mediated myeloma adhesion to BMSCs, and -vascular endothelial growth factor-induced bone marrow angiogenesis in vivo. These studies provide direct evidence of the role of CS1 in myeloma pathogenesis, define molecular mechanisms regulating its effects, and further support novel therapies targeting CS1 in MM. (Blood. 2009; 113: 4309-4318)
C1 [Tai, Yu-Tzu; Soydan, Ender; Song, Weihua; Fulciniti, Mariateresa; Kim, Kihyun; Li, Xian-Feng; Burger, Peter; Rumizen, Matthew J.; Nahar, Sabikun; Podar, Klaus; Hideshima, Teru; Munshi, Nikhil C.; Tonon, Giovanni; Carrasco, Ruben D.; Anderson, Kenneth C.] Dana Farber Canc Inst, Dept Med Oncol, LeBow Inst Myeloma Therapeut, Medford, MA 02155 USA.
   [Tai, Yu-Tzu; Soydan, Ender; Song, Weihua; Fulciniti, Mariateresa; Kim, Kihyun; Li, Xian-Feng; Burger, Peter; Rumizen, Matthew J.; Nahar, Sabikun; Podar, Klaus; Hideshima, Teru; Munshi, Nikhil C.; Tonon, Giovanni; Carrasco, Ruben D.; Anderson, Kenneth C.] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Medford, MA 02155 USA.
   [Kim, Kihyun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea.
   [Hong, Fangxin] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   [Tonon, Giovanni] Ist Sci San Raffaele, Funct Genom Canc Unit, Div Oncol, Milan, Italy.
   [Carrasco, Ruben D.] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Afar, Daniel E. H.] Facet Biotech, Oncol Programs, Redwood City, CA USA.
RP Tai, YT (reprint author), Dana Farber Canc Inst, Dept Med Oncol, LeBow Inst Myeloma Therapeut, M551,44 Binney St, Medford, MA 02155 USA.
EM yu-tzu_tai@dfci.harvard.edu; kenneth_anderson@dfci.harvard.edu
RI Kim, Kihyun/D-5175-2013
OI Kim, Kihyun/0000-0002-5878-8895
FU Multiple Myeloma Research Foundation Research Award; National Institutes
   of Health [RO-150947, PO1-78378, P50CA100707]; Lebow Fund
FX The authors thank Dr Sophia Adamia and Dr Alexei Protopopov (Dana-Farber
   Cancer Institute) for microscopy and helpful discussions and Dr William
   Hahn (Dana-Farber Cancer Institute) for providing lentiviral CS1 shRNA
   constructs. This work was supported by a Multiple Myeloma Research
   Foundation Research Award (Y.- T. T.), National Institutes of Health
   grants (RO-150947, PO1-78378, and SPORE P50CA100707), and the Lebow Fund
   to Cure Myeloma (K. C. A.).
CR Bhat R, 2006, J LEUKOCYTE BIOL, V79, P417, DOI 10.1189/jlb.0905537
   Boles KS, 2001, IMMUNOGENETICS, V52, P302, DOI 10.1007/s002510000274
   Cagnoni F, 2004, J IMMUNOL, V172, P3205, DOI 10.4049/jimmunol.172.5.3205
   EYCHENE A, 2008, NAT REV CANCER, P683
   Fischer A, 2007, CURR OPIN IMMUNOL, V19, P348, DOI 10.1016/j.coi.2007.04.006
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Hong FX, 2006, BIOINFORMATICS, V22, P2825, DOI 10.1093/bioinformatics/btl476
   Hsi ED, 2008, CLIN CANCER RES, V14, P2775, DOI 10.1158/1078-0432.CCR-07-4246
   Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Kienast J, 2004, CANCER CELL, V5, P109, DOI 10.1016/S1535-6108(04)00030-3
   Korff T, 2007, CIRCULATION, V116, P2288, DOI 10.1161/CIRCULATIONAHA.107.730309
   Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746
   Kumaresan PR, 2002, MOL IMMUNOL, V39, P1, DOI 10.1016/S0161-5890(02)00094-9
   Lee JK, 2007, J IMMUNOL, V179, P4672, DOI 10.4049/jimmunol.179.7.4672
   Lombardi L, 2007, GENE CHROMOSOME CANC, V46, P226, DOI 10.1002/gcc.20404
   Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040
   Morito N, 2006, CANCER RES, V66, P812, DOI 10.1158/0008-5472.CAN-05-2154
   Murakami YI, 2007, AM J SURG PATHOL, V31, P1695, DOI 10.1097/PAS.0b013e318054dbcf
   Murphy JJ, 2002, BIOCHEM J, V361, P431, DOI 10.1042/0264-6021:3610431
   O'Connell FP, 2004, AM J CLIN PATHOL, V121, P254, DOI 10.1309/617DWB5GNFWXHW4L
   Pelech Steven, 2003, Methods Mol Biol, V218, P99
   Tai YT, 2005, CANCER RES, V65, P5898, DOI 10.1158/0008-5472.CAN-04-4125
   Tai YT, 2004, CANCER RES, V64, P2846, DOI 10.1158/0008-5472.CAN-03-3630
   Tai YT, 2003, CANCER RES, V63, P5850
   Tai YT, 2008, BLOOD, V112, P1329, DOI 10.1182/blood-2007-08-107292
   Tai YT, 2007, BLOOD, V110, P1656, DOI 10.1182/blood-2007-03-081240
   Tai YT, 2006, CANCER RES, V66, P6675, DOI 10.1158/0008-5472.CAN-06-0190
   Tassi I, 2005, J IMMUNOL, V175, P7996, DOI 10.4049/jimmunol.175.12.7996
   Veillette A, 2006, IMMUNOL REV, V214, P22, DOI 10.1111/j.1600-065X.2006.00453.x
   Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood-2005-11-013458
NR 33
TC 45
Z9 49
U1 3
U2 14
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 30
PY 2009
VL 113
IS 18
BP 4309
EP 4318
DI 10.1182/blood-2008-10-183772
PG 10
WC Hematology
SC Hematology
GA 442MW
UT WOS:000265846300027
PM 19196658
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Iwamoto, J
   Matsumoto, H
   Tadeda, T
   Sato, Y
   Yeh, JK
AF Iwamoto, Jun
   Matsumoto, Hideo
   Tadeda, Tsuyoshi
   Sato, Yoshihiro
   Yeh, James K.
TI RETRACTED: Comparison of the Effect of Vitamin K-2 and Risedronate on
   Trabecular Bone in Glucocorticoid-Treated Rats: A Bone Histomorphometry
   Study (Retracted article. See vol. 59, pg. 168, 2018)
SO YONSEI MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
DE Glucocorticoid; trabecular bone; bone histomorphometry; risedronate;
   vitamin K-2
ID INDUCED OSTEOPOROSIS; INDUCED OSTEOPENIA; SALMON-CALCITONIN; CORTICAL
   BONE; THERAPY; PREDNISOLONE; COMBINATION; MATRIX; OSTEOCALCIN;
   CALCITRIOL
AB Purpose: To compare the effect of vitamin K-2 and risedronate on trabecular bone in glucocorticoid (GC)-treated rats. Materials and Methods: Forty-eight Sprague-Dawley female rats, 3 months of age, were randomized by the stratified weight method into 5 groups according to the following treatment schedule: age-matched control, GC administration, and GC administration with concomitant administration of vitamin K-2, risedronate, or vitamin K-2 + risedronate. GC (methylprednisolone sodium succinate, 5.0 mg/kg) and risedronate (10 mu g/kg) were administered subcutaneously three and five times a week, respectively. Vitamin K-2 (menatetrenone, 30 mg/kg) was administered orally three times a week. At the end of the 8-week experiment, bone histomorphometric analysis was performed on trabecular bone of the tibial proximal metaphysis. Results: GC administration decreased trabecular bone mass compared with age-matched controls because of decreased bone formation (mineralizing surface, mineral apposition rate, and bone formation rate) and increased bone erosion. Vitamin K-2 attenuated GC-induced trabecular bone loss by preventing GC-induced decrease in bone formation (mineralizing surface) and subsequently reducing GC-induced increase in bone erosion. Risedronate prevented GC-induced trabecular bone loss by preventing GC-induced increase in bone erosion although it also suppressed bone formation (mineralizing surface, mineral apposition rate, and bone formation rate). Vitamin K-2 mildly attenuated suppression of bone formation (mineralizing surface) and bone erosion caused by risedronate without affecting trabecular bone mass when administered in combination. Conclusion: The present study showed differential effect of vitamin K-2 and risedronate on trabecular bone in GC-treated rats.
C1 [Iwamoto, Jun] Keio Univ, Sch Med, Inst Integrated Sports Med, Shinjuku Ku, Tokyo 1608582, Japan.
   [Sato, Yoshihiro] Mitate Hosp, Dept Neurol, Fukuoka, Japan.
   [Yeh, James K.] Winthrop Univ Hosp, Dept Med, Metab Lab, New York, NY USA.
RP Iwamoto, J (reprint author), Keio Univ, Sch Med, Inst Integrated Sports Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM jiwamoto@sc.itc.keio.ac.ip
RI Matsumoto, Hideo/A-2304-2014
CR Balooch G, 2007, ARTHRITIS RHEUM, V56, P3726, DOI 10.1002/art.22976
   Erben RG, 1997, J HISTOCHEM CYTOCHEM, V45, P307, DOI 10.1177/002215549704500215
   Furuichi H, 2000, BIOL PHARM BULL, V23, P946
   Hara K, 2002, BONE, V31, P575, DOI 10.1016/S8756-3282(02)00874-8
   HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990
   ITO M, 2002, J JPN SOC BONE MORPH, V12, P51
   Iwamoto J, 2006, YONSEI MED J, V47, P157, DOI 10.3349/ymj.2006.47.2.157
   Iwamoto J, 2006, J NUTR SCI VITAMINOL, V52, P21, DOI 10.3177/jnsv.52.21
   Iwamoto J, 2003, J BONE MINER RES, V18, P776, DOI 10.1359/jbmr.2003.18.4.776
   Iwamoto J, 2006, EXP ANIM TOKYO, V55, P349, DOI 10.1538/expanim.55.349
   Iwasaki Y, 2003, J BONE MINER METAB, V21, P154, DOI 10.1007/s007740300024
   Koshihara Y, 1997, J BONE MINER RES, V12, P431, DOI 10.1359/jbmr.1997.12.3.431
   Longui CA, 2007, J PEDIAT, V83, pS163, DOI 10.2223/JPED.1713
   Manolagas SC, 1999, J BONE MINER RES, V14, P1061, DOI 10.1359/jbmr.1999.14.7.1061
   Nawata H, 2005, J BONE MINER METAB, V23, P105, DOI 10.1007/s00774-004-0596-x
   *NIH CONS DEV PAN, 2001, JAMA-J AM MED ASSOC, V285, P785, DOI DOI 10.1001/JAMA.285.6.785
   Nitta T, 1999, JPN J PHARMACOL, V79, P379, DOI 10.1254/jjp.79.379
   Noa Miriam, 2004, Drugs R D, V5, P281, DOI 10.2165/00126839-200405050-00004
   Otomo H, 2004, J BONE MINER METAB, V22, P404, DOI 10.1007/s00774-004-0502-6
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Prakasam G, 1999, BONE, V24, P491, DOI 10.1016/S8756-3282(99)00018-6
   REID DM, 2000, BONE MINER RES, V15, P1006
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756-3282(99)00070-8
   SHEARER MJ, 1995, LANCET, V345, P229, DOI 10.1016/S0140-6736(95)90227-9
   Shen V, 1997, BONE, V21, P345, DOI 10.1016/S8756-3282(97)00153-1
   Tabb MM, 2003, J BIOL CHEM, V278, P43919, DOI 10.1074/jbc.M303136200
   Tanaka Ikuko, 2007, Clin Calcium, V17, P1738
   Tanaka Y, 1996, J BONE MINER RES, V11, P325
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   VERMEER C, 1995, ANNU REV NUTR, V15, P1, DOI 10.1146/annurev.nutr.15.1.1
   Wallach S, 2000, CALCIFIED TISSUE INT, V67, P277, DOI 10.1007/s002230001146
NR 32
TC 5
Z9 6
U1 4
U2 6
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD APR 30
PY 2009
VL 50
IS 2
BP 189
EP 194
DI 10.3349/ymj.2009.50.2.189
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 438RU
UT WOS:000265573900003
PM 19430549
OA Other Gold, Green Published
DA 2018-12-27
ER

PT J
AU Rodriguez, BA
   Delferro, M
   Marks, TJ
AF Rodriguez, Brandon A.
   Delferro, Massimiliano
   Marks, Tobin J.
TI RETRACTED: Bimetallic Effects for Enhanced Polar Comonomer Enchainment
   Selectivity in Catalytic Ethylene Polymerization (Retracted article. See
   vol. 135, pg. 17651, 2013)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Review; Retracted Publication
ID NEUTRAL NICKEL(II) COMPLEXES; SIMULTANEOUS POLYOLEFIN BRANCH;
   FUNCTIONAL-GROUP INTRODUCTION; DINUCLEAR RHODIUM COMPLEXES;
   LATE-METAL-CATALYSTS; OLEFIN POLYMERIZATION; METHYL-METHACRYLATE; C-13
   NMR; METALLOCENE CATALYSTS; BINUCLEAR CATALYSTS
AB The synthesis and characterization of the bimetallic 2,7-di-[(2,6-diisopropylphenyl)imino]-1,8-naphthalenediolato group 10 metal polymerization catalysts {[Ni(CH3)](2)[1,8-(O)(2)C10H4-2,7-[CH=N(2,6-(Pr2C6H3)-Pr-i)](PMe3)(2)} and {[Ni(1-naphthyl)](2)[1,8-(O)(2)C10H4-2,7-[CH=N(2,6-(Pr2C6H3)-Pr-i)](PPh3)(2)} [FI2-Ni-2(PR3)(2)] are presented, along with the synthesis and characterization of the mononuclear analogues [Ni(CH3)[3-Bu-t-2-(O)C6H3CH=N(2,6-(Pr2C6H3)-Pr-i)](PMe)(3)} and (Ni(1-naphthyl)[3-Bu-t-2-(O)C6H3CH=N(2,6-(Pr2C6H3)-Pr-i)](PPh)(3)} [FI-Ni (PR3)]. Monometallic Ni catalysts were also prepared by functionalizing one ligation center of the bimetallic ligand with a trimethylsilyl group (TMS), yielding {Ni(CH3)[1,8-(O)(TMSO)C10H4-2,7-[CH=N(2,6-(Pr2C6H3)-Pr-i)](PMe3)} [TMS-FI2-Ni(PMe3)]. The FI2-Ni-2 catalysts exhibit significant increases in ethylene homopolymerization activity versus the monometallic analogues, as well as increased branching and methyl branch selectivity, even in the absence of a Ni(cod)(2) cocatalyst. Increasing ethylene concentrations significantly suppress branching and alter branch morphology. FI2-Ni-2-mediated copolymerizations with ethylene + polar-functionalized norbornenes exhibit a 4-fold increase in comonomer incorporation versus FI-Ni, yielding copolymers with up to 10% norbornene copolymer incorporation. FI2-Ni-2-catalyzed copolymerizations with ethylene + methylacrylate or methyl methacrylate incorporate up to 11% acrylate comonomer, while the corresponding mononuclear FI-Ni catalysts incorporate negligible amounts. Furthermore, the FI2-Ni-2-mediated polymerizations exhibit appreciable polar solvent tolerance, turning over in the presence of ethyl ether, acetone, and even water. The mechanism by which the present cooperative effects take place is investigated, as is the nature of the copolymer microstructures; produced.
C1 [Rodriguez, Brandon A.; Delferro, Massimiliano; Marks, Tobin J.] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA.
RP Marks, TJ (reprint author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.
EM t-marks@northwestern.edu
FU DOE [86ER13511]
FX Financial support by DOE under Grant 86ER13511 is acknowledged. M.D.
   thanks U. of Parma (Italy) for a study leave. We thank Mr. M. Weberski,
   Jr. for helpful discussions, and Dr. E. Szuromi and Prof. R. F. Jordan
   (U. of Chicago) for hospitality in GPC measurements.
CR Akitsu T, 2005, POLYHEDRON, V24, P1869, DOI 10.1016/poly.2005.06.019
   Alt HG, 2005, DALTON T, P3271, DOI 10.1039/b506074p
   Amin SB, 2006, J AM CHEM SOC, V128, P4506, DOI 10.1021/ja057947r
   Amin SB, 2008, ANGEW CHEM INT EDIT, V47, P2006, DOI 10.1002/anie.200703310
   Amin SB, 2007, J AM CHEM SOC, V129, P2938, DOI 10.1021/ja0675292
   Bauers FM, 2001, MACROMOLECULES, V34, P1165, DOI 10.1021/ma001704w
   Boffa LS, 2000, CHEM REV, V100, P1479, DOI 10.1021/cr990251u
   Borkar S, 2007, ORGANOMETALLICS, V26, P4711, DOI 10.1021/om7006024
   Brandrup J., 1975, POLYM HDB
   Brookhart M, 2007, P NATL ACAD SCI USA, V104, P6908, DOI 10.1073/pnas.0610747104
   BRUCE MI, 1994, J ORGANOMET CHEM, V469, P89, DOI 10.1016/0022-328X(94)80082-0
   *BRUK AN XRAY SYST, 1999, SAINT SOFTW US GUID
   Buback M, 2001, MACROMOL CHEM PHYS, V202, P1173, DOI 10.1002/1521-3935(20010401)202:7<1173::AID-MACP1173>3.0.CO;2-N
   CARMONA E, 1987, ORGANOMETALLICS, V6, P1757, DOI 10.1021/om00151a023
   Chen QH, 2007, ORGANOMETALLICS, V26, P617, DOI 10.1021/om060778e
   Collman JP, 2004, CHEM REV, V104, P561, DOI 10.1021/cr0206059
   Connor EF, 2003, CHEM COMMUN, P2272, DOI 10.1039/b306701g
   Connor EF, 2002, J POLYM SCI POL CHEM, V40, P2842, DOI 10.1002/pola.10370
   Cotts PM, 2000, MACROMOLECULES, V33, P6945, DOI 10.1021/ma000926r
   Delacroix O, 2003, CHEM COMMUN, P665, DOI 10.1039/b207963c
   Desjardins SY, 1997, J ORGANOMET CHEM, V544, P163, DOI 10.1016/S0022-328X(96)06953-7
   Diaz-Requejo MM, 2005, MACROMOLECULES, V38, P4966, DOI 10.1021/ma050626f
   Domski GJ, 2007, PROG POLYM SCI, V32, P30, DOI 10.1016/j.progpolymsci.2006.11.001
   Drent E, 2002, CHEM COMMUN, P744, DOI 10.1039/b111252j
   Elia C, 2002, ORGANOMETALLICS, V21, P4249, DOI 10.1021/om020435q
   Esswein AJ, 2008, ORGANOMETALLICS, V27, P1073, DOI 10.1021/om7007748
   Gates DP, 2000, MACROMOLECULES, V33, P2320, DOI 10.1021/ma991234+
   Gibson VC, 2003, CHEM REV, V103, P283, DOI 10.1021/cr980461r
   GLADYSZ JA, 2000, CHEM REV, V100
   Guo N, 2004, J AM CHEM SOC, V126, P6542, DOI 10.1021/ja048761f
   Guo N, 2008, J AM CHEM SOC, V130, P2246, DOI 10.1021/ja076407m
   Hicks FA, 2001, ORGANOMETALLICS, V20, P3217, DOI 10.1021/om010211s
   Hu T, 2006, J MOL CATAL A-CHEM, V253, P155, DOI 10.1016/j.molcata.2006.03.008
   Hu T, 2005, ORGANOMETALLICS, V24, P2628, DOI 10.1021/om049223e
   Hughes RP, 2005, ORGANOMETALLICS, V24, P4845, DOI 10.1021/om0504654
   Ittel SD, 2000, CHEM REV, V100, P1169, DOI 10.1021/cr9804644
   Jacobsen EN, 2000, ACCOUNTS CHEM RES, V33, P421, DOI 10.1021/ar960061v
   JENKINS JC, 2004, J AM CHEM SOC, V126, P5824
   JOHNSON L, 2002, 223 NAT M AM CHEM SO, P319
   JOHNSON L, 2002, 223 NAT M AM CHEM SO
   Johnson LK, 1996, J AM CHEM SOC, V118, P267, DOI 10.1021/ja953247i
   Jurkiewicz A, 1999, MACROMOLECULES, V32, P5471, DOI 10.1021/ma990339+
   Kabir SE, 2006, J ORGANOMET CHEM, V691, P97, DOI 10.1016/j.jorganchem.2005.08.034
   Kaminsky W, 2004, J POLYM SCI POL CHEM, V42, P3911, DOI 10.1002/pola.20292
   Kaminsky W, 2001, ADV CATAL, V46, P89, DOI 10.1016/S0360-0564(02)46022-1
   Kaminsky W, 2000, CATAL TODAY, V62, P23, DOI 10.1016/S0920-5861(00)00406-5
   Kaminsky W., 2002, APPL HOMOGENEOUS CAT
   Kang M, 2005, ORGANOMETALLICS, V24, P3508, DOI 10.1021/om050126a
   KARSCH HH, 1987, J CHEM SOC CHEM COMM, P1033, DOI 10.1039/c39870001033
   KARSCH HH, 1988, J ORGANOMET CHEM, V352, P47, DOI 10.1016/0022-328X(88)83018-3
   KERR JA, 1966, CHEM REV, V66, P465, DOI 10.1021/cr60243a001
   KLABUNDE U, 1987, J MOL CATAL, V41, P123, DOI 10.1016/0304-5102(87)80023-8
   KLABUNDE U, 1987, J POLYM SCI POL CHEM, V25, P1989, DOI 10.1002/pola.1987.080250719
   KLEIN HF, 1973, CHEM BER-RECL, V106, P1433, DOI 10.1002/cber.19731060509
   Konsler RG, 1998, J AM CHEM SOC, V120, P10780, DOI 10.1021/ja982683c
   Krishnan R, 2003, J AM CHEM SOC, V125, P4422, DOI 10.1021/ja0346577
   KUPTSOV AH, 1998, HDB FT RAMAN INFRARE
   KURTEV K, 1994, J MOL CATAL, V88, P141, DOI 10.1016/0304-5102(93)E0274-K
   Li C, 2007, J AM CHEM SOC, V129, P13327, DOI 10.1021/ja073339v
   Li HB, 2005, J AM CHEM SOC, V127, P14756, DOI 10.1021/ja052995x
   Li HB, 2004, ANGEW CHEM INT EDIT, V43, P4937, DOI 10.1002/anie.200460288
   Li HB, 2005, MACROMOLECULES, V38, P9015, DOI 10.1021/ma050959c
   Li HB, 2003, J AM CHEM SOC, V125, P10788, DOI 10.1021/ja036289c
   Li HB, 2006, P NATL ACAD SCI USA, V103, P15295, DOI 10.1073/pnas.0603396103
   Li XF, 2005, ORGANOMETALLICS, V24, P2502, DOI 10.1021/om049080w
   Lin S, 2002, ACCOUNTS CHEM RES, V35, P765, DOI 10.1021/ar010081j
   Liu WX, 1999, MACROMOLECULES, V32, P3817, DOI 10.1021/ma990009p
   Marks TJ, 2006, P NATL ACAD SCI USA, V103, P15288, DOI 10.1073/pnas.0606076103
   MATHEWS RC, 1996, ANGEW CHEM INT EDIT, V35, P2253
   Mayo FR, 1944, J AM CHEM SOC, V66, P1594, DOI 10.1021/ja01237a052
   McCord EF, 2001, MACROMOLECULES, V34, P362, DOI 10.1021/ma0012898
   McCord EF, 2007, MACROMOLECULES, V40, P410, DOI 10.1021/ma061547m
   Mecking S, 1998, J AM CHEM SOC, V120, P888, DOI 10.1021/ja964144i
   Molenveld P, 2000, CHEM SOC REV, V29, P75, DOI 10.1039/a804295k
   Molenveld P, 1997, J AM CHEM SOC, V119, P2948, DOI 10.1021/ja9638770
   Moore DR, 2003, J AM CHEM SOC, V125, P11911, DOI 10.1021/jp030085e
   MOTTA A, 2000, P 13 ISHHC 3 ISHHC B
   Motta A, 2009, J AM CHEM SOC, V131, P3974, DOI 10.1021/ja8077208
   Pangborn AB, 1996, ORGANOMETALLICS, V15, P1518, DOI 10.1021/om9503712
   Pechmann T, 2004, CHEM-EUR J, V10, P728, DOI 10.1002/chem.200305419
   Pechmann T, 2002, ANGEW CHEM INT EDIT, V41, P2301, DOI 10.1002/1521-3773(20020703)41:13<2301::AID-ANIE2301>3.0.CO;2-X
   Pechmann T, 2000, ANGEW CHEM INT EDIT, V39, P3909, DOI 10.1002/1521-3773(20001103)39:21<3909::AID-ANIE3909>3.0.CO;2-2
   Popelier PLA, 1998, J ORGANOMET CHEM, V555, P101, DOI 10.1016/S0022-328X(97)00710-9
   Rodriguez BA, 2008, ORGANOMETALLICS, V27, P2166, DOI 10.1021/om800208f
   Salata MR, 2008, J AM CHEM SOC, V130, P12, DOI 10.1021/ja076857e
   Salata MR, 2009, MACROMOLECULES, V42, P1920, DOI 10.1021/ma8020745
   Sammis GM, 2004, J AM CHEM SOC, V126, P9928, DOI 10.1021/ja046653n
   Sawamura M, 1996, J AM CHEM SOC, V118, P3309, DOI 10.1021/ja954223e
   Schweier G, 2001, MACROMOL SYMP, V173, P89, DOI 10.1002/1521-3900(200108)173:1<89::AID-MASY89>3.0.CO;2-O
   Sen A, 2007, J ORGANOMET CHEM, V692, P3291, DOI 10.1016/j.jorganchem.2007.03.026
   Sheldrick G. M., 1999, SADABS
   Sheldrick G. M., 1997, SHELXL 97 PROGRAM CR
   Skupov KM, 2007, MACROMOL RAPID COMM, V28, P2033, DOI 10.1002/marc.200700370
   Soldatov DV, 2001, INORG CHEM, V40, P1626, DOI 10.1021/ic000981g
   Stibrany RT, 2003, MACROMOLECULES, V36, P8584, DOI 10.1021/ma034548c
   Sujith S, 2005, MACROMOLECULES, V38, P10027, DOI 10.1021/ma051344i
   Suzuki N, 2005, TOP ORGANOMETAL CHEM, V8, P177
   Tian GL, 2001, MACROMOLECULES, V34, P7656, DOI 10.1021/ma010857w
   TOSCANO PJ, 1990, INORG CHEM, V29, P2101, DOI 10.1021/ic00336a014
   Trost BM, 2003, J AM CHEM SOC, V125, P2410, DOI 10.1021/ja029708z
   VANSOOLINGEN J, 1990, SYNTHETIC COMMUN, V20, P3153, DOI 10.1080/00397919008051539
   Waltman AW, 2004, ORGANOMETALLICS, V23, P5121, DOI 10.1021/om049360b
   Wang CM, 1998, ORGANOMETALLICS, V17, P3149, DOI 10.1021/om980176y
   WANG L, 2002, 223 NAT M AM CHEM SO, P319
   Wang WQ, 2003, J POLYM MATER, V20, P1
   *WAV INC, 2006, SPART 06
   Wehrmann P, 2008, ORGANOMETALLICS, V27, P1399, DOI 10.1021/om700942z
   Weng ZQ, 2007, ORGANOMETALLICS, V26, P2950, DOI 10.1021/om0701322
   Yanjarappa MJ, 2002, PROG POLYM SCI, V27, P1347, DOI 10.1016/S0079-6700(02)00011-4
   Ydens I, 2005, EUR POLYM J, V41, P2255, DOI 10.1016/j.eurpolymj.2005.04.012
   YOUNG RJ, 1981, INTRO POLYM
   Younkin TR, 2000, SCIENCE, V287, P460, DOI 10.1126/science.287.5452.460
   Zhang D, 2003, ORGANOMETALLICS, V22, P2851, DOI 10.1021/om030068y
   Zhang L, 2006, ORGANOMETALLICS, V25, P1868, DOI 10.1021/om050931p
NR 114
TC 93
Z9 97
U1 7
U2 93
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD APR 29
PY 2009
VL 131
IS 16
BP 5902
EP 5919
DI 10.1021/ja900257k
PG 18
WC Chemistry, Multidisciplinary
SC Chemistry
GA 437BH
UT WOS:000265460200040
PM 19351155
DA 2018-12-27
ER

PT J
AU Hoskins, W
   Pollard, H
   Daff, C
   Odell, A
   Garbutt, P
   McHardy, A
   Hardy, K
   Dragasevic, G
AF Hoskins, Wayne
   Pollard, Henry
   Daff, Chris
   Odell, Andrew
   Garbutt, Peter
   McHardy, Andrew
   Hardy, Kate
   Dragasevic, George
TI RETRACTED: Low back pain status in elite and semi-elite Australian
   football codes: a cross-sectional survey of football (soccer),
   Australian rules, rugby league, rugby union and non-athletic controls
   (Retracted article. See vol. 12, art. no. 158, 2011)
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article; Retracted Publication
ID TERM-FOLLOW-UP; LUMBAR SPINE; PROFESSIONAL FOOTBALL; COUNTRY SKIERS;
   RADIOGRAPHIC ABNORMALITIES; INTERCOLLEGIATE ROWERS; THORACOLUMBAR SPINE;
   RHYTHMIC GYMNASTS; MUSCLE-ACTIVITY; RISK-FACTORS
AB Background: Our understanding of the effects of football code participation on low back pain (LBP) is limited. It is unclear whether LBP is more prevalent in athletic populations or differs between levels of competition. Thus it was the aim of this study to document and compare the prevalence, intensity, quality and frequency of LBP between elite and semi-elite male Australian football code participants and a non-athletic group.
   Methods: A cross-sectional survey of elite and semi-elite male Australian football code participants and a non-athletic group was performed. Participants completed a self-reported questionnaire incorporating the Quadruple Visual Analogue Scale (QVAS) and McGill Pain Questionnaire (short form) (MPQ-SF), along with additional questions adapted from an Australian epidemiological study. Respondents were 271 elite players (mean age 23.3, range 17-39), 360 semi-elite players (mean age 23.8, range 16-46) and 148 non-athletic controls (mean age 23.9, range 18-39).
   Results: Groups were matched for age (p = 0.42) and experienced the same age of first onset LBP (p = 0.40). A significant linear increase in LBP from the non-athletic group, to the semi-elite and elite groups for the QVAS and the MPQ-SF was evident (p < 0.001). Elite subjects were more likely to experience more frequent (daily or weekly OR 1.77, 95% CI 1.29-2.42) and severe LBP (discomforting and greater OR 1.75, 95% CI 1.29-2.38).
   Conclusion: Foolers in Australia have significantly more severe and frequent LBP than a non-athletic group and this escalates with level of competition.
C1 [Hoskins, Wayne; Pollard, Henry; Daff, Chris; McHardy, Andrew; Hardy, Kate; Dragasevic, George] Macquarie Univ, Dept Hlth & Chiropract, Div Environm & Life Sci, N Ryde, NSW 2109, Australia.
   [Odell, Andrew] Norwest Orthopaed & Sports Physiotherapy, Norwest, NSW 2153, Australia.
   [Garbutt, Peter] Enhance Chiropract & Massage Sports Injury Ctr, Ngunnawal, ACT 2913, Australia.
RP Hoskins, W (reprint author), Macquarie Univ, Dept Hlth & Chiropract, Div Environm & Life Sci, N Ryde, NSW 2109, Australia.
EM waynehoskins@iinet.com.au; hpollard@optushome.com.au;
   chirodaff_013@hotmail.com; boubblytang@hotmail.com;
   enhancehealthcare@iinet.net.au; golfinjury@optusnet.com.au;
   katie.hardy@optusnet.com.au; dragasev@tpg.com.au
OI de Luca, Katie/0000-0002-2763-771X
CR Arnau JM, 2006, EUR SPINE J, V15, P543, DOI 10.1007/s00586-005-1027-y
   Bahr R, 2004, SPINE, V29, P449, DOI 10.1097/01.BRS.0000096176.92881.37
   Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265
   Bono CM, 2004, J BONE JOINT SURG AM, V86A, P382, DOI 10.2106/00004623-200402000-00027
   Callaghan JP, 1998, PHYS THER, V78, P8, DOI 10.1093/ptj/78.1.8
   CARLSON H, 1988, ACTA PHYSIOL SCAND, V133, P343, DOI 10.1111/j.1748-1716.1988.tb08416.x
   Carragee E, 2006, SPINE, V31, P2942, DOI 10.1097/01.brs.0000248429.10963.13
   Cholewicki J, 2005, SPINE, V30, P2614, DOI 10.1097/01.brs.0000188273.27463.bc
   Cholewicki J, 2002, J ORTHOP SPORT PHYS, V32, P568, DOI 10.2519/jospt.2002.32.11.568
   Cupisti A, 2004, J SPORT MED PHYS FIT, V44, P49
   Eriksson K, 1996, SCAND J MED SCI SPOR, V6, P31
   Gatchel RJ, 1995, SPINE, V20, P2702, DOI 10.1097/00007632-199512150-00011
   GIBBS N, 1993, AM J SPORT MED, V21, P696, DOI 10.1177/036354659302100510
   Grafton KV, 2005, CLIN J PAIN, V21, P73, DOI 10.1097/00002508-200501000-00009
   Greene HS, 2001, AM J SPORT MED, V29, P795, DOI 10.1177/03635465010290062001
   Hanrahan S, 2005, J ATHL TRAINING, V40, P88
   Hestbaek L, 2003, J MANIP PHYSIOL THER, V26, P213, DOI 10.1016/S0161-4754(03)00006-X
   Hutchinson MR, 1999, MED SCI SPORT EXER, V31, P1686, DOI 10.1097/00005768-199911000-00027
   Iwai K, 2004, MED SCI SPORT EXER, V36, P1296, DOI 10.1249/01.MSS.0000135791.27929.C1
   Iwamoto J, 2005, SCAND J MED SCI SPOR, V15, P163, DOI 10.1111/j.1600-0838.2004.00414.x
   Iwamoto J, 2004, AM J SPORT MED, V32, P781, DOI 10.1177/0363546503261721
   Jacob T, 2004, MED SCI SPORT EXER, V36, P9, DOI 10.1249/01.MSS.0000106166.94343.02
   JENSEN MP, 1993, HDB PAIN ASSESSMENT, P15
   Kavcic N, 2004, SPINE, V29, P2319, DOI 10.1097/01.brs.0000142222.62203.67
   Koes BW, 2001, SPINE, V26, P2504, DOI 10.1097/00007632-200111150-00022
   Kujala UM, 1996, JAMA-J AM MED ASSOC, V276, P216, DOI 10.1001/jama.276.3.216
   Lamoth CJC, 2006, EUR SPINE J, V15, P23, DOI 10.1007/s00586-004-0825-y
   LEBOEUFYDE C, 1995, SPINE, V20, P2112, DOI 10.1097/00007632-199510000-00009
   Lundin O, 2001, SCAND J MED SCI SPOR, V11, P103, DOI 10.1034/j.1600-0838.2001.011002103.x
   MAHLAMAKI S, 1988, INT J SPORTS MED, V9, P196, DOI 10.1055/s-2007-1025004
   McHardy A, 2005, J CHIROPR MED, V4, P135, DOI 10.1016/S0899-3467(07)60122-0
   McManus A, 2004, J SCI MED SPORT, V7, P384, DOI 10.1016/S1440-2440(04)80033-1
   Meir RA, 1997, BRIT J SPORT MED, V31, P132, DOI 10.1136/bjsm.31.2.132
   MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8
   Nadler SF, 2002, ARCH PHYS MED REHAB, V83, P1753, DOI 10.1053/apmr.2002.35659
   Nadler SF, 2002, MED SCI SPORT EXER, V34, P9, DOI 10.1097/00005768-200201000-00003
   O'Kane JW, 2003, AM J SPORT MED, V31, P80, DOI 10.1177/03635465030310012501
   Ogon M, 2001, CLIN ORTHOP RELAT R, P151
   Orchard J, 2002, BRIT J SPORT MED, V36, P39, DOI 10.1136/bjsm.36.1.39
   Orchard J, 2001, BRIT J SPORT MED, V35, P212, DOI 10.1136/bjsm.35.4.212
   Orchard J., 2004, SPORT HLTH, V22, P11
   Orchard JW, 2004, SPORTS MED, V34, P209, DOI 10.2165/00007256-200434040-00001
   SWARD L, 1990, SPINE, V15, P124
   Teitz CC, 2003, AM J SPORT MED, V31, P590, DOI 10.1177/03635465030310041901
   van Tulder M, 2002, BEST PRACT RES CL RH, V16, P761, DOI 10.1053/berh.2002.0267
   VIDEMAN T, 1995, SPINE, V20, P699, DOI 10.1097/00007632-199503150-00011
   Walden M, 2005, BRIT J SPORT MED, V39, P542, DOI 10.1136/bjsm.2004.014571
   Walker BF, 2004, J MANIP PHYSIOL THER, V27, P238, DOI 10.1016/j.jmpt.2004.02.002
   Walker BF, 2000, J SPINAL DISORD, V13, P205, DOI 10.1097/00002517-200006000-00003
NR 49
TC 18
Z9 19
U1 3
U2 18
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD APR 17
PY 2009
VL 10
AR 38
DI 10.1186/1471-2474-10-38
PG 9
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 442OS
UT WOS:000265851100001
PM 19371446
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ramachandran, N
   Munteanu, I
   Wang, PX
   Aubourg, P
   Rilstone, JJ
   Israelian, N
   Naranian, T
   Paroutis, P
   Guo, R
   Ren, ZP
   Nishino, I
   Chabrol, B
   Pellissier, JF
   Minetti, C
   Udd, B
   Fardeau, M
   Tailor, CS
   Mahuran, DJ
   Kissel, JT
   Kalimo, H
   Levy, N
   Manolson, MF
   Ackerley, CA
   Minassian, BA
AF Ramachandran, Nivetha
   Munteanu, Iulia
   Wang, Peixiang
   Aubourg, Pauline
   Rilstone, Jennifer J.
   Israelian, Nyrie
   Naranian, Taline
   Paroutis, Paul
   Guo, Ray
   Ren, Zhi-Ping
   Nishino, Ichizo
   Chabrol, Brigitte
   Pellissier, Jean-Francois
   Minetti, Carlo
   Udd, Bjame
   Fardeau, Michel
   Tailor, Chetankumar S.
   Mahuran, Don J.
   Kissel, John T.
   Kalimo, Hannu
   Levy, Nicolas
   Manolson, Morris F.
   Ackerley, Cameron A.
   Minassian, Berge A.
TI RETRACTED: VMA21 Deficiency Causes an Autophagic Myopathy by
   Compromising V-ATPase Activity and Lysosomal Acidification (Retracted
   article. See vol. 142, pg. 984, 2010)
SO CELL
LA English
DT Article; Retracted Publication
ID X-LINKED MYOPATHY; RENAL TUBULAR-ACIDOSIS; EXCESSIVE AUTOPHAGY;
   SKELETAL-MUSCLES; SUBUNIT; MUTATIONS; PROTEIN; MICE; CARDIOMYOPATHY;
   OSTEOPETROSIS
AB X-linked myopathy with excessive autophagy (XMEA) is a childhood-onset disease characterized by progressive vacuolation and atrophy of skeletal muscle. We show that XMEA is caused by hypomorphic alleles of the VMA21 gene, that VMA21 is the diverged human ortholog of the yeast Vma21p protein, and that like Vma21p it is an essential assembly chaperone of the V-ATPase, the principal mammalian proton pump complex. Decreased VMA21 raises lysosomal pH, which reduces lysosomal degradative ability and blocks autophagy. This reduces cellular free amino acids, which upregulates the mTOR pathway and mTOR-dependent macroautophagy, resulting in proliferation of large and ineffective autolysosomes that engulf sections of cytoplasm, merge together, and vacuolate the cell. Our results uncover macroautophagic overcompensation leading to cell vacuolation and tissue atrophy as a mechanism of disease.
C1 [Ramachandran, Nivetha; Munteanu, Iulia; Wang, Peixiang; Rilstone, Jennifer J.; Israelian, Nyrie; Naranian, Taline; Guo, Ray; Ren, Zhi-Ping; Mahuran, Don J.; Minassian, Berge A.] Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON M5G 1X8, Canada.
   [Paroutis, Paul; Tailor, Chetankumar S.] Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada.
   [Ackerley, Cameron A.] Hosp Sick Children, Dept Pathol & Lab Med, Toronto, ON M5G 1X8, Canada.
   [Minassian, Berge A.] Hosp Sick Children, Dept Paediat, Div Neurol, Toronto, ON M5G 1X8, Canada.
   [Munteanu, Iulia; Rilstone, Jennifer J.; Minassian, Berge A.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada.
   [Aubourg, Pauline; Levy, Nicolas] Univ Aix Marseille 2, Fac Med Marseille, INSERM, UMR S910, F-13385 Marseille, France.
   [Nishino, Ichizo] Natl Ctr Neurol & Psychiat, Dept Neuromuscular Res, Kodaira, Tokyo 1878502, Japan.
   [Chabrol, Brigitte] CHU Timone, Hop Enfants, Unite Med Infantile, F-13385 Marseille, France.
   [Pellissier, Jean-Francois] Hop La Timone, Lab Anat Pathol & Neuropathol, F-13385 Marseille, France.
   [Minetti, Carlo] G Gaslini Inst Children, Muscular & Neurodegenerat Dis Unit, I-16147 Genoa, Italy.
   [Minetti, Carlo] Univ Genoa, I-16147 Genoa, Italy.
   [Udd, Bjame] Vaasa Cent Hosp, Dept Neurol, FIN-65130 Vaasa, Finland.
   [Udd, Bjame] Tampere Univ, FIN-65130 Vaasa, Finland.
   [Fardeau, Michel] Salpetriere Hosp, Myol Inst, F-75013 Paris, France.
   [Kissel, John T.] Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA.
   [Kalimo, Hannu] Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland.
   [Kalimo, Hannu] Univ Turku, Dept Pathol & Forens Med, FI-20520 Turku, Finland.
   [Manolson, Morris F.] Univ Toronto, Fac Dent, Toronto, ON M5G 1G6, Canada.
RP Minassian, BA (reprint author), Hosp Sick Children, Program Genet & Genome Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM berge.minassian@sickkids.ca
RI LEVY, Nicolas/J-1632-2014
OI LEVY, Nicolas/0000-0001-5171-6365; Nishino, Ichizo/0000-0001-9452-112X
FU Canadian Institutes of Health Research
FX I.M. identified the disease gene and characterized the effects of the
   mutations on the gene product (Figure 1). N.R. designed and performed
   the functional experiments that resolved the pathogenetic mechanisms of
   disease (Figures 2-7). Principal funding was from the Canadian
   Institutes of Health Research. B.A.M. holds the Canada Research Chair in
   Paediatric Neurogenetics. Additional acknowledgments are available in
   the Supplemental Data.
CR Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Chabrol B, 2001, NEUROMUSCULAR DISORD, V11, P376, DOI 10.1016/S0960-8966(00)00209-1
   Drose S, 1997, J EXP BIOL, V200, P1
   Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272
   Frattini A, 2000, NAT GENET, V25, P343
   KALIMO H, 1988, ANN NEUROL, V23, P258, DOI 10.1002/ana.410230308
   Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022
   Kornak U, 2008, NAT GENET, V40, P32, DOI 10.1038/ng.2007.45
   LI JB, 1976, AM J PHYSIOL, V231, P441
   Malicdan MC, 2008, NEUROMUSCULAR DISORD, V18, P521, DOI 10.1016/j.nmd.2008.04.010
   Malkus P, 2004, MOL BIOL CELL, V15, P5075, DOI 10.1091/mbc.E04-06-0514
   Mammucari C, 2008, AUTOPHAGY, V4, P524, DOI 10.4161/auto.5905
   Martinez-Vicente M, 2008, J CLIN INVEST, V118, P777, DOI 10.1172/JCI32806
   Minassian B, 2002, STRUCTURAL MOL BASIS, P145
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Munteanu I, 2008, NEUROLOGY, V71, P951, DOI 10.1212/01.wnl.0000325991.01899.35
   Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604
   Ochotny N, 2006, J BIOL CHEM, V281, P26102, DOI 10.1074/jbc.M601118200
   Ostenfeld MS, 2008, AUTOPHAGY, V4, P487, DOI 10.4161/auto.5774
   Paroutis P, 2004, PHYSIOLOGY, V19, P207, DOI 10.1152/physiol.00005.2004
   Scornik OA, 1997, AM J PHYSIOL-ENDOC M, V273, pE1158
   Shacka JJ, 2006, MOL PHARMACOL, V69, P1125, DOI 10.1124/mol.105.018408
   Sharma R, 2001, BIOCHEMISTRY-US, V40, P5440, DOI 10.1021/bi0029200
   STAUBER WT, 1981, EXP NEUROL, V71, P295, DOI 10.1016/0014-4886(81)90090-X
   Tanaka Y, 2000, NATURE, V406, P902
   VILLANOVA M, 1995, ANN NEUROL, V37, P637, DOI 10.1002/ana.410370514
NR 27
TC 48
Z9 52
U1 1
U2 15
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD APR 17
PY 2009
VL 137
IS 2
BP 235
EP 246
DI 10.1016/j.cell.2009.01.054
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 437AB
UT WOS:000265456800017
PM 19379691
OA Bronze
DA 2018-12-27
ER

PT J
AU Zhang, CL
   Song, QH
   Li, J
   Tian, Y
AF Zhang, Cuili
   Song, Q. H.
   Li, Jian
   Tian, Ye
TI RETRACTED: Hypoxia-induced expression of RTEF-1 (related transcriptional
   enhancer factor-1) in endothelial cells is independent of HIF-1
   (hypoxia-inducible factor-1) (Retracted article. See vol. 388, pg. 463,
   2009)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE Hypoxia; Related transcriptional enhancer factor-1 (RTEF-1);
   Hypoxia-inducible factor-1 (HIF-1)
ID CARDIAC MYOCYTES; GROWTH-FACTOR; ANGIOGENESIS; IDENTIFICATION;
   METABOLISM; GENE
AB Related transcriptional enhancer fictor-1 (RTEF-1) plays an important role in transcriptional regulation of angiogenic genes in hypoxic endothelial cells. The mechanisms involved in the induction of RTEF-1 expression in hypoxia are poorly understood. In bovine aortic endothelial cells (BAEC) subjected to hypoxia, Western blot and quantitative PCR analysis revealed that RTEF-1 protein and mRNA levels were significantly increased by hypoxia. To address the potential role of the hypoxia-inducible factor-1 (HIF-1) in RTFF-1 induction, a hepatoma cell line deficient in HIF-1 (c4) and a control HIF-1 positive cell line (vT{2}) were exposed to hypoxia. We report that RTEF-1 protein expression assessed by either Western blotting or immunofluorescence was increased in both cell lines. This demonstrates that HIF-1 is not required for RTEF-1 upregulation by hypoxia. Conversely, RTEF-1 appeared to regulate the expression of HIF-1: HIF-1 alpha promoter activity was increased (3.6-fold) by RTEF-1 overexpression in BAEC. Further-more, RTEF-1 enhanced BAEC proliferation and tubule formation; these were inhibited by RTEF-1 knockdown with siRNA. We propose that RTEF-1, acting via HIF-1, is a key regulator of angiogenesis ill response to hypoxia. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Zhang, Cuili; Song, Q. H.; Li, Jian] Harvard Univ, Harvard Med Sch, Div Cardiol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   [Zhang, Cuili; Tian, Ye] Harbin Med Univ, Dept Pathophysiol, Harbin 150081, Peoples R China.
   [Zhang, Cuili] Harbin Med Univ, Dept Cardiol, Affiliated Hosp 1, Harbin 150001, Peoples R China.
   [Tian, Ye] Harbin Med Univ, Dept Cardiol, Affiliated Hosp 2, Harbin 150086, Peoples R China.
RP Li, J (reprint author), Harvard Univ, Harvard Med Sch, Div Cardiol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
EM jli@bidm.harvard.edu; tianye@ems.hrbmu.edu.cn
FU foundation in Heilongjiang Province in China [LC06C31]; Research on
   National High-tech R&D Program (the 863 Program) in China
   [2007AA02Z450]; foundation in Harbin in China [RC2008LX004004]
FX This work was supported by homecoming overseas foundation in
   Heilongjiang Province in China (Grand LC06C31), the Research on National
   High-tech R&D Program (the 863 Program) in China (Grant No.
   2007AA02Z450) and homecoming overseas foundation in Harbin in China
   (RC2008LX004004).
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Airley RE, 2007, CHEMOTHERAPY, V53, P233, DOI 10.1159/000104457
   Appukuttan B, 2007, INVEST OPHTH VIS SCI, V48, P3775, DOI 10.1167/iovs.06-1172
   Bache M, 2008, CURR MED CHEM, V15, P322, DOI 10.2174/092986708783497391
   Chaudary Naz, 2006, Breast Dis, V26, P55
   CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293
   de Castro-Bernas G, 2003, CLIN HEMORHEOL MICRO, V29, P199
   Fischer I, 2005, BRAIN PATHOL, V15, P297
   Gan Q, 2007, CIRC RES, V101, P883, DOI 10.1161/CIRCRESAHA.107.154831
   Heinzman JM, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-11
   Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029
   Larkin SB, 1996, MOL CELL BIOL, V16, P3742
   Shie JL, 2004, J BIOL CHEM, V279, P25010, DOI 10.1074/jbc.M403103200
   Shohet RV, 2007, J MOL MED, V85, P1309, DOI 10.1007/s00109-007-0279-x
   Tsoporis JN, 2003, AM J PHYSIOL-HEART C, V284, pH193, DOI 10.1152/ajpheart.00161.2002
   Ueyama T, 2000, J BIOL CHEM, V275, P17476, DOI 10.1074/jbc.M001970200
   Wu JP, 2004, CIRCULATION, V109, P1660, DOI 10.1161/01.CIR.0000124067.35915.E0
NR 17
TC 3
Z9 3
U1 4
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 10
PY 2009
VL 381
IS 3
BP 333
EP 338
DI 10.1016/j.bbrc.2009.02.083
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 424KQ
UT WOS:000264566000007
PM 19236848
DA 2018-12-27
ER

PT J
AU Qian, YP
   Cai, YJ
   Fan, GJ
   Wei, QY
   Yang, J
   Zheng, LF
   Li, XZ
   Fang, JG
   Zhou, B
AF Qian, Yi-Ping
   Cai, Yu-Jun
   Fan, Gui-Juan
   Wei, Qing-Yi
   Yang, Jie
   Zheng, Li-Fang
   Li, Xiu-Zhuang
   Fang, Jian-Guo
   Zhou, Bo
TI RETRACTED: Antioxidant-Based Lead Discovery for Cancer Chemoprevention:
   The Case of Resveratrol (Retracted Article. See vol 52, pg 6504, 2009)
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID RADICAL-INDUCED PEROXIDATION; OXIDATIVE DNA-DAMAGE; ANTICANCER
   PROPERTIES; HYDROGEN-PEROXIDE; IN-VITRO; EPIGALLOCATECHIN GALLATE;
   DIETARY PHYTOCHEMICALS; PHENOLIC ANTIOXIDANTS; GEL-ELECTROPHORESIS;
   DEPENDENT APOPTOSIS
AB Resveratrol is a well-known natural antioxidant and cancer chemopreventive agent that has attracted much interest in the past decade. Resveratrol-directed compounds were synthesized, and their antioxidant effects against reactive oxygen species (ROS)-induced DNA damage, their prooxidant effects on DNA damage in the presence cupric ions, and their cytotoxic and apoptosis-inducing effects on human promyelocytic leukemia (HL-60) cells were investigated in vitro. It was found that the compounds bearing o-diphenoxyl groups exhibited remarkably higher activities in inhibiting ROS-induced DNA damage, accelerating DNA damage in the presence cupric ions, and inducing apoptosis of HL-60 cells compared with the ones bearing no such groups. The detail mechanism of the structure-activity relationship was also studied by the oxidative product analysis of resveratrol and its analogues with galvinoxyl radical or cupric ions and UV-visible spectra change in the presence cupric ions. This study reveals a good and interesting correlation between antioxidant and prooxidant activity, as well as cytotoxicity and apoptosis-inducing activity against HL-60 cells, and provides an idea for designing antioxidant-based cancer chemoprevention agents.
C1 [Qian, Yi-Ping; Cai, Yu-Jun; Fan, Gui-Juan; Wei, Qing-Yi; Yang, Jie; Zheng, Li-Fang; Li, Xiu-Zhuang; Fang, Jian-Guo; Zhou, Bo] Lanzhou Univ, State Key Lab Appl Organ Chem, Lanzhou 730000, Gansu, Peoples R China.
RP Cai, YJ (reprint author), Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, Rochester, NY 14627 USA.
EM yujun_cai@urmc.rochester.edu; bozhou@lzu.edu.cn
FU National Natural Science Foundation of China [20502010, 20621091]; New
   Century Excellent Talents in University [NCET-06-0906]
FX This work was funded by the National Natural Science Foundation of China
   (Grant Nos. 20502010 and 20621091) and the 111 Project and Program for
   New Century Excellent Talents in University (Grant NCET-06-0906).
CR AGARWAL K, 1989, CHEM-BIOL INTERACT, V69, P1, DOI 10.1016/0009-2797(89)90094-X
   Aggarwal BB, 2004, ANTICANCER RES, V24, P2783
   Ahmad A, 2000, CANCER LETT, V154, P29, DOI 10.1016/S0304-3835(00)00351-7
   de la Lastral CA, 2007, BIOCHEM SOC T, V35, P1156, DOI 10.1042/BST0351156
   Alberts DS, 1999, CANCER RES, V59, P4743
   Amorati R, 2004, J ORG CHEM, V69, P7101, DOI 10.1021/jo0497860
   Azmi AS, 2005, FEBS LETT, V579, P3131, DOI 10.1016/j.febslet.2005.04.077
   Azzi A, 2004, FEBS LETT, V558, P3, DOI 10.1016/S0014-5793(03)01526-6
   BACHELOR FW, 1970, CAN J CHEMISTRY, V48, P1554, DOI 10.1139/v70-253
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   BROWN DG, 1993, J BIOL CHEM, V268, P3037
   Cai L, 1998, CHEM-BIOL INTERACT, V115, P141, DOI 10.1016/S0009-2797(98)00069-6
   Cai YJ, 2004, ANTICANCER RES, V24, P999
   Cai YJ, 2003, BBA-MOL BASIS DIS, V1637, P31, DOI 10.1016/S0925-4439(02)00174-6
   CARPENTIERI U, 1986, CANCER RES, V46, P981
   Chen Q, 2008, P NATL ACAD SCI USA, V105, P11105, DOI 10.1073/pnas.0804226105
   Chen Q, 2007, P NATL ACAD SCI USA, V104, P8749, DOI 10.1073/pnas.0702854104
   Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6
   Cheng JC, 2006, BIOORG CHEM, V34, P142, DOI 10.1016/j.bioorg.2006.04.001
   CITTADINI A, 1975, MOL CELL BIOCHEM, V8, P49, DOI 10.1007/BF01731649
   Clement MV, 1998, BLOOD, V92, P996
   Collins AR, 2005, EUR J CANCER, V41, P1923, DOI 10.1016/j.ejca.2005.06.004
   Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev
   DAVIES R, 1976, TETRAHEDRON LETT, P313
   Delmas D, 2006, CURR DRUG TARGETS, V7, P423, DOI 10.2174/138945006776359331
   Doulias PT, 2001, FREE RADICAL BIO MED, V30, P679, DOI 10.1016/S0891-5849(00)00511-6
   Fabris S, 2008, BIOPHYS CHEM, V135, P76, DOI 10.1016/j.bpc.2008.03.005
   Fang JG, 2002, CHEM-EUR J, V8, P4191, DOI 10.1002/1521-3765(20020916)8:18<4191::AID-CHEM4191>3.0.CO;2-S
   FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5
   Foti M, 2001, J AGR FOOD CHEM, V49, P342, DOI 10.1021/jf0006527
   Fukuhara K, 1998, BIOORG MED CHEM LETT, V8, P3187, DOI 10.1016/S0960-894X(98)00585-X
   Fukuhara K, 2006, BIOORGAN MED CHEM, V14, P1437, DOI 10.1016/j.bmc.2005.09.070
   Galati G, 2004, FREE RADICAL BIO MED, V37, P287, DOI 10.1016/j.freeradbiomed.2004.04.034
   GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184
   Gupte A, 2007, FREE RADICAL BIO MED, V43, P1271, DOI 10.1016/j.freeradbiomed.2007.07.003
   Hadi SM, 2007, SEMIN CANCER BIOL, V17, P370, DOI 10.1016/j.semcancer.2007.04.002
   Haque ME, 2003, BBA-GEN SUBJECTS, V1619, P39, DOI 10.1016/S0304-4165(02)00440-3
   Hider RC, 2001, METHOD ENZYMOL, V335, P190
   Howes RM, 2006, ANN NY ACAD SCI, V1067, P22, DOI 10.1196/annals.1354.004
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   HUSSAIN RF, 1993, J IMMUNOL METHODS, V160, P89, DOI 10.1016/0022-1759(93)90012-V
   Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/ncr1046
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Javvadi P, 2008, MOL PHARMACOL, V73, P1491, DOI 10.1124/mol.107.043554
   Lozano C, 2006, FEBS J, V273, P2475, DOI 10.1111/j.1742-4658.2006.05255.x
   Lopez-Nicolas JM, 2008, J AGR FOOD CHEM, V56, P7600, DOI 10.1021/jf800843e
   McCarthy PJ, 1997, MUTAGENESIS, V12, P209, DOI 10.1093/mutage/12.4.209
   Muqbil I, 2006, FEBS LETT, V580, P3995, DOI 10.1016/j.febslet.2005.12.059
   Murata M, 2002, BIOSCI BIOTECH BIOCH, V66, P2525, DOI 10.1271/bbb.66.2525
   Murias M, 2005, BIOCHEM PHARMACOL, V69, P903, DOI 10.1016/j.bcp.2004.12.001
   Nakazato T, 2005, CLIN CANCER RES, V11, P6040, DOI 10.1158/1078-0432.CCR-04-2273
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O
   Ohyama M, 1999, BIOORG MED CHEM LETT, V9, P3057, DOI 10.1016/S0960-894X(99)00520-X
   Pan MH, 2008, MOL NUTR FOOD RES, V52, P43, DOI 10.1002/mnfr.200700380
   Pan MH, 2008, MOL NUTR FOOD RES, V52, P527, DOI 10.1002/mnfr.200700157
   PATEL KB, 1973, J CHEM SOC FARAD T 1, V69, P814, DOI 10.1039/f19736900814
   RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F
   Rosenau T, 2002, ORG LETT, V4, P4285, DOI 10.1021/ol026917f
   Russo GL, 2007, BIOCHEM PHARMACOL, V74, P533, DOI 10.1016/j.bcp.2007.02.014
   Saiko P, 2008, MUTAT RES-REV MUTAT, V658, P68, DOI 10.1016/j.mrrev.2007.08.004
   Samuni AM, 2003, P NATL ACAD SCI USA, V100, P5390, DOI 10.1073/pnas.0930078100
   Satoh K, 1997, ANTICANCER RES, V17, P2487
   Schweigert N, 2001, ENVIRON TOXICOL CHEM, V20, P239, DOI 10.1897/1551-5028(2001)020<0239:ATOCCA>2.0.CO;2
   Seifried HE, 2003, CANCER RES, V63, P4295
   Signorelli P, 2005, J NUTR BIOCHEM, V16, P449, DOI 10.1016/j.jnutbio.2005.01.017
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   Sporn MB, 2002, NAT REV CANCER, V2, P537, DOI 10.1038/nrc844
   STOEWE R, 1987, FREE RADICAL BIO MED, V3, P97, DOI 10.1016/S0891-5849(87)80003-5
   Sugumaran M, 2000, ARCH BIOCHEM BIOPHYS, V378, P404, DOI 10.1006/abbi.2000.1839
   Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189
   THAKKAR K, 1993, J MED CHEM, V36, P2950, DOI 10.1021/jm00072a015
   Ulrich S, 2005, MOL NUTR FOOD RES, V49, P452, DOI 10.1002/mnfr.200400081
   Wang YB, 2005, BIOCHEM PHARMACOL, V69, P249, DOI 10.1016/j.bcp.2004.09.013
   Win W, 2002, MUTAT RES-GEN TOX EN, V513, P113, DOI 10.1016/S1383-5718(01)00303-5
   Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789
   Wright JS, 2001, J AM CHEM SOC, V123, P1173, DOI 10.1021/ja002455u
   YOSHIDA Y, 1993, BIOCHIM BIOPHYS ACTA, V1210, P81, DOI 10.1016/0005-2760(93)90052-B
   Yu HN, 2004, J AGR FOOD CHEM, V52, P462, DOI 10.1021/jf035057u
   Zhang P, 2001, FOOD CHEM TOXICOL, V39, P239, DOI 10.1016/S0278-6915(00)00131-9
   Zheng LF, 2006, FREE RADICAL BIO MED, V41, P1807, DOI 10.1016/j.freeradbiomed.2006.09.007
NR 81
TC 36
Z9 37
U1 8
U2 28
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD APR 9
PY 2009
VL 52
IS 7
BP 1963
EP 1974
DI 10.1021/jm8015415
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 428GK
UT WOS:000264835800018
PM 19271734
DA 2018-12-27
ER

PT J
AU Patra, S
   Sarkar, S
   Bera, SK
   Ghosh, R
   Paul, GK
AF Patra, S.
   Sarkar, S.
   Bera, S. K.
   Ghosh, R.
   Paul, G. K.
TI RETRACTED: Hydrophobic self-cleaning surfaces of ZnO thin films
   synthesized by sol-gel technique (Retracted article. See vol. 44, artn
   no. 299801, 2011)
SO JOURNAL OF PHYSICS D-APPLIED PHYSICS
LA English
DT Article; Retracted Publication
ID OPTICAL-PROPERTIES; TRANSPARENT; WETTABILITY; ORIENTATION; BEHAVIOR;
   GROWTH; WATER
AB The authors report on hydrophobic self-cleaning surfaces of transparent zinc oxide (ZnO) thin films tuned by controlling uniformity of the film surfaces. ZnO films were synthesized by a simple, low-cost sol-gel technique. The degree of hydrophobicity of the films was strongly dependent on the number of coatings with ZnO. The surface of the polycrystalline ZnO thin film with 8-coatings was maximum hydrophobic with a static contact angle of 114 degrees +/- 3 degrees. The films were highly transparent with average transmission exceeding 80% in the visible region. Thus, new hydrophobic ZnO thin films can be of great importance in commercial application as transparent self-cleaning surfaces.
C1 [Ghosh, R.; Paul, G. K.] Haldia Inst Technol, Sch Appl Sci, Purba Medinipur 721657, W Bengal, India.
   [Bera, S. K.] Tamralipta Mahavidyalaya, Dept Phys, Purba Medinipur 721636, W Bengal, India.
   [Patra, S.; Sarkar, S.] Haldia Inst Technol, Dept Elect & Comp Engn, Purba Medinipur 721657, W Bengal, India.
RP Paul, GK (reprint author), Haldia Inst Technol, Sch Appl Sci, HIT Campus, Purba Medinipur 721657, W Bengal, India.
EM gautam76@yahoo.com
FU DST, West Bengal; Haldia Institute of Technology (HIT), Haldia
FX The authors acknowledge DST, West Bengal, for providing the financial
   support to carry out this research work (Sanction Letter no
   184/1(100)(Sanc.)/ST/P/S&T/Misc-1/2008, dated 02.07.2008). The authors
   also gratefully acknowledge the supports from the Haldia Institute of
   Technology (HIT), Haldia, in carrying out this work.
CR Alivov YI, 2003, APPL PHYS LETT, V83, P2943, DOI 10.1063/1.1615308
   Cassie ABD, 1944, T FARADAY SOC, V40, P0546, DOI 10.1039/tf9444000546
   Coulson SR, 2000, J PHYS CHEM B, V104, P8836, DOI 10.1021/jp0000174
   DAVIS EA, 1970, PHILOS MAG, V22, P903, DOI 10.1080/14786437008221061
   Du GT, 2003, VACUUM, V69, P473, DOI 10.1016/S0042-207X(02)00538-9
   Fujihara S, 2001, APPL SURF SCI, V180, P341, DOI 10.1016/S0169-4332(01)00367-1
   Genzer J, 2000, SCIENCE, V290, P2130, DOI 10.1126/science.290.5499.2130
   Ghosh R, 2005, MATER RES BULL, V40, P1905, DOI 10.1016/j.materresbull.2005.06.010
   GINGLEY DS, 2000, MRS BULL, V25, P15
   Guo M, 2007, THIN SOLID FILMS, V515, P7162, DOI 10.1016/j.tsf.2007.03.038
   Huang MH, 2001, ADV MATER, V13, P113, DOI 10.1002/1521-4095(200101)13:2<113::AID-ADMA113>3.0.CO;2-H
   *JCPDS, 1978, SEL POWD DIFFR DAT M, V1, P108
   Kong XY, 2003, NANO LETT, V3, P1625, DOI 10.1021/nl034463p
   Li HJ, 2001, ANGEW CHEM INT EDIT, V40, P1743, DOI 10.1002/1521-3773(20010504)40:9<1743::AID-ANIE17430>3.0.CO;2-#
   Marmur A, 2004, LANGMUIR, V20, P3517, DOI 10.1021/la036369u
   Mridha S, 2007, MATER RES BULL, V42, P875, DOI 10.1016/j.materresbull.2006.08.019
   Nakajima A, 1999, ADV MATER, V11, P1365, DOI 10.1002/(SICI)1521-4095(199911)11:16<1365::AID-ADMA1365>3.3.CO;2-6
   Ohyama M, 1998, J AM CERAM SOC, V81, P1622
   Onda T, 1996, LANGMUIR, V12, P2125, DOI 10.1021/la950418o
   Paul GK, 2008, CHEM PHYS LETT, V463, P117, DOI 10.1016/j.cplett.2008.08.065
   Pesika NS, 2002, J PHYS CHEM B, V106, P6985, DOI 10.1021/jp0144606
   PIZZINI S, 1989, J ELECTROCHEM SOC, V136, P1945, DOI 10.1149/1.2097092
   RASBOND WS, 1997, IMAGEJ NATL I HLTH
   Sun RD, 2001, J PHYS CHEM B, V105, P1984, DOI 10.1021/jp002525j
   Tadanaga K, 2000, CHEM MATER, V12, P590, DOI 10.1021/cm990643h
   Wenzel RN, 1936, IND ENG CHEM, V28, P988, DOI 10.1021/ie50320a024
   Young T., 1805, PHILOS T R SOC LONDO, V95, P65, DOI DOI 10.1098/RSTL.1805.0005
NR 27
TC 25
Z9 25
U1 3
U2 23
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0022-3727
EI 1361-6463
J9 J PHYS D APPL PHYS
JI J. Phys. D-Appl. Phys.
PD APR 7
PY 2009
VL 42
IS 7
AR 075301
DI 10.1088/0022-3727/42/7/075301
PG 4
WC Physics, Applied
SC Physics
GA 421VH
UT WOS:000264385900026
DA 2018-12-27
ER

PT J
AU Park, D
   Choi, SS
AF Park, Donghyun
   Choi, Sun Shim
TI RETRACTED: Why proteins evolve at different rates: The functional
   hypothesis versus the mistranslation-induced protein misfolding
   hypothesis (Retracted article. See vol. 583, pg. 3108, 2009)
SO FEBS LETTERS
LA English
DT Review; Retracted Publication
DE Protein evolutionary rate; Functional hypothesis; Mistranslation-induced
   protein misfolding hypothesis Translational robustness; Expression
   abundance
ID SYNONYMOUS CODON USAGE; EVOLUTIONARY RATE; GENE-EXPRESSION;
   CAENORHABDITIS-ELEGANS; SEQUENCE EVOLUTION; INTERACTION NETWORKS;
   SUBSTITUTION RATES; NATURAL-SELECTION; SIMPLE DEPENDENCE; MUTATION-RATE
AB Protein evolutionary rates have been presumed to be mostly determined by the density of functionally important amino acids in a given protein. They have been shown to correlate with variables intuitively related to functional importance of proteins, such as protein dispensability and protein-protein interactions. Surprisingly, the best correlate of the evolutionary rates has turned out to be not the functional importance of a protein, but the expression level of the protein. Drummond and Wilke suggest that the dominant role of expression levels in slowing the rate of protein evolution stems from a selection pressure against mistranslation-induced protein misfolding. We will review current evidence for and against different hypotheses on determining evolutionary rates. (C) 2009 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
C1 [Choi, Sun Shim] Kangwon Natl Univ, Inst Biosci & Biotechnol, Dept Mol & Med Biotechnol, Chunchon 200701, South Korea.
   [Park, Donghyun] Univ Chicago, Dept Human Genet, Howard Hughes Med Inst, Chicago, IL 60637 USA.
RP Choi, SS (reprint author), Kangwon Natl Univ, Inst Biosci & Biotechnol, Dept Mol & Med Biotechnol, Chunchon 200701, South Korea.
EM schoi@kangwon.ac.kr
FU Korea Science and Engineering Foundation (KOSEF) [2008-00903]
FX We thank Bruce T. Lahn, Croydon Fernandes, and Seung Gu Park for
   critically reading the manuscript and helpful comments. This work was
   supported by the program of Nuclear R&D Program (2008-00903) of the
   Korea Science and Engineering Foundation (KOSEF).
CR Agrafioti I, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-23
   AKASHI H, 1994, GENETICS, V136, P927
   Akashi H, 2003, GENETICS, V164, P1291
   Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389
   Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448
   Bamshad M, 2003, NAT REV GENET, V4, P99, DOI 10.1038/nrg999
   Batada NN, 2007, PLOS BIOL, V5, P1202, DOI 10.1371/journal.pbio.0050154
   Batada NN, 2006, PLOS COMPUT BIOL, V2, P748, DOI 10.1371/journal.pcbi.0020088
   Bertin N, 2007, PLOS BIOL, V5, P1206, DOI 10.1371/journal.pbio.0050153
   Bloom JD, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-14
   Bloom JD, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-21
   Bloom JD, 2006, MOL BIOL EVOL, V23, P1751, DOI 10.1093/molbev/msl040
   Cohen E, 2006, SCIENCE, V313, P1604, DOI 10.1126/science.1124646
   Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511
   Cutter AD, 2003, GENOME RES, V13, P2651, DOI 10.1101/gr.1659203
   Drummond DA, 2008, CELL, V134, P341, DOI 10.1016/j.cell.2008.05.042
   Drummond DA, 2006, MOL BIOL EVOL, V23, P327, DOI 10.1093/molbev/msj038
   Drummond DA, 2005, P NATL ACAD SCI USA, V102, P14338, DOI 10.1073/pnas.0504070102
   Duret L, 2000, MOL BIOL EVOL, V17, P68, DOI 10.1093/oxfordjournals.molbev.a026239
   Fraser HB, 2002, SCIENCE, V296, P750, DOI 10.1126/science.1068696
   Fraser HB, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-11
   Gidalevitz T, 2006, SCIENCE, V311, P1471, DOI 10.1126/science.1124514
   GOUY M, 1982, NUCLEIC ACIDS RES, V10, P7055, DOI 10.1093/nar/10.22.7055
   Guo HH, 2004, P NATL ACAD SCI USA, V101, P9205, DOI 10.1073/pnas.0403255101
   Hahn MW, 2005, MOL BIOL EVOL, V22, P803, DOI 10.1093/molbev/msi072
   Hirsh AE, 2001, NATURE, V411, P1046, DOI 10.1038/35082561
   Hurst LD, 1999, CURR BIOL, V9, P747, DOI 10.1016/S0960-9822(99)80334-0
   Ingvarsson PK, 2007, MOL BIOL EVOL, V24, P836, DOI 10.1093/molbev/msl212
   Jordan IK, 2003, BMC EVOL BIOL, V3, DOI 10.1186/1471-2148-3-1
   Jordan IK, 2004, MOL BIOL EVOL, V21, P2058, DOI 10.1093/molbev/msh222
   Jordan IK, 2002, GENOME RES, V12, P962, DOI 10.1101/gr.87702
   Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308
   Koonin EV, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100029
   Koonin EV, 2006, CURR OPIN BIOTECH, V17, P481, DOI 10.1016/j.copbio.2006.08.003
   Krylov DM, 2003, GENOME RES, V13, P2229, DOI 10.1101/gr.1589103
   Lee JW, 2006, NATURE, V443, P50, DOI 10.1038/nature05096
   Lemos B, 2005, MOL BIOL EVOL, V22, P1345, DOI 10.1093/molbev/msi112
   LIPMAN DJ, 1985, J MOL EVOL, V21, P161, DOI 10.1007/BF02100090
   Marais G, 2001, J MOL EVOL, V52, P275, DOI 10.1007/s002390010155
   MARGOLIASH E, 1963, P NATL ACAD SCI USA, V50, P672, DOI 10.1073/pnas.50.4.672
   MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458
   McInerney JO, 2006, TRENDS ECOL EVOL, V21, P230, DOI 10.1016/j.tree.2006.03.008
   Mintseris J, 2005, P NATL ACAD SCI USA, V102, P10930, DOI 10.1073/pnas.0502667102
   Pal C, 2006, NAT REV GENET, V7, P337, DOI 10.1038/nrg1838
   Pal C, 2003, NATURE, V421, P496, DOI 10.1038/421496b
   Pal C, 2001, GENETICS, V158, P927
   Plotkin JB, 2007, MOL BIOL EVOL, V24, P1113, DOI 10.1093/molbev/msm044
   Popescu CE, 2006, GENETICS, V172, P1567, DOI 10.1534/genetics.105.047399
   Rocha EPC, 2006, TRENDS GENET, V22, P412, DOI 10.1016/j.tig.2006.06.004
   Rocha EPC, 2004, MOL BIOL EVOL, V21, P108, DOI 10.1093/molbev/msh004
   Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007
   Subramanian S, 2004, GENETICS, V168, P373, DOI 10.1534/genetics.104.028944
   Wall DP, 2005, P NATL ACAD SCI USA, V102, P5483, DOI 10.1073/pnas.0501761102
   Wolf MY, 2008, BIOL DIRECT, V3, DOI 10.1186/1745-6150-3-40
   Wolf YI, 2006, P ROY SOC B-BIOL SCI, V273, P1507, DOI 10.1098/rspb.2006.3472
   Wright SI, 2004, MOL BIOL EVOL, V21, P1719, DOI 10.1093/molbev/msh191
   Wyckoff GJ, 2005, TRENDS GENET, V21, P381, DOI 10.1016/j.tig.2005.05.005
   Yang J, 2003, MOL BIOL EVOL, V20, P772, DOI 10.1093/molbev/msg078
   Zhang JZ, 2005, MOL BIOL EVOL, V22, P1147, DOI 10.1093/molbev/msi101
   Zhao LH, 2005, NAT GENET, V37, P974, DOI 10.1038/ng1620
   Zhou T, 2008, J MOL EVOL, V66, P395, DOI 10.1007/s00239-008-9094-4
   ZUCKERKANDL E, 1976, J MOL EVOL, V7, P167, DOI 10.1007/BF01731487
NR 62
TC 2
Z9 2
U1 2
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD APR 2
PY 2009
VL 583
IS 7
BP 1053
EP 1059
DI 10.1016/j.febslet.2009.02.033
PG 7
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 427EE
UT WOS:000264761800001
PM 19254718
DA 2018-12-27
ER

PT J
AU Deng, X
AF Deng, Xu
TI RETRACTED: Stimulated emission properties of an organic salt-doped
   polymer film in microcavity (Retracted Article)
SO ACTA PHYSICA SINICA
LA Chinese
DT Article; Retracted Publication
DE organic salt; energy transfer; microcavity; stimulated emission
ID THIN-FILMS
AB An organic vertical cavity surface emitting laser has been fabricated, using a Forster energy transfer system of organic pyridium salt dye ASPI and Alq(3) doped in PMMA film as the gain medium, which was sandwiched between a high-reflectance distributed Bragg reflector and a silver reflector. The stimulated emission properties were investigated by nanosecond-pulsed laser pumping. The lasing phenomenon was observed with a full width at half maximum of 2.43 nm at the lasing wavelength of 600 run, and the threshold energy for lasing was estimated to be about 8 mu J per pulse.
C1 Changzhou Inst Mechatron Technol, Changzhou 213164, Peoples R China.
RP Deng, X (reprint author), Changzhou Inst Mechatron Technol, Changzhou 213164, Peoples R China.
EM 1844@czmec.cn
CR Baldo MA, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.035321
   Berggren M, 1997, APPL PHYS LETT, V71, P2230, DOI 10.1063/1.120065
   Bulovic V, 1998, SCIENCE, V279, P553, DOI 10.1126/science.279.5350.553
   FORSTER T, 1959, DISCUSS FARADAY SOC, V27
   Koschorreck M, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2125128
   Kozlov VG, 1997, NATURE, V389, P362, DOI 10.1038/38693
   Otomo A, 2000, APPL PHYS LETT, V77, P3881, DOI 10.1063/1.1331092
   Persano L, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2179611
   Tessler N, 1996, NATURE, V382, P695, DOI 10.1038/382695a0
   Tessler N, 1999, ADV MATER, V11, P363, DOI 10.1002/(SICI)1521-4095(199903)11:5<363::AID-ADMA363>3.0.CO;2-Y
   WU DJ, 2000, THESIS CHINESE ACAD, P104
   Xia R, 2005, J APPL PHYS, V98, DOI 10.1063/1.2085311
   Xu D, 2008, ACTA PHYS SIN-CH ED, V57, P3267
NR 13
TC 0
Z9 0
U1 4
U2 8
PU CHINESE PHYSICAL SOC
PI BEIJING
PA P O BOX 603, BEIJING 100080, PEOPLES R CHINA
SN 1000-3290
J9 ACTA PHYS SIN-CH ED
JI Acta Phys. Sin.
PD APR
PY 2009
VL 58
IS 4
BP 2781
EP 2784
PG 4
WC Physics, Multidisciplinary
SC Physics
GA 435DU
UT WOS:000265324700105
DA 2018-12-27
ER

PT J
AU Shimada, T
   Hiramatsu, N
   Hayakawa, K
   Takahashi, S
   Kasai, A
   Tagawa, Y
   Mukai, M
   Yao, J
   Fujii-Kuriyama, Y
   Kitamura, M
AF Shimada, Tsuyoshi
   Hiramatsu, Nobuhiko
   Hayakawa, Kunihiro
   Takahashi, Shuhei
   Kasai, Ayumi
   Tagawa, Yasuhiro
   Mukai, Mai
   Yao, Jian
   Fujii-Kuriyama, Yoshiaki
   Kitamura, Masanori
TI RETRACTED: Dual suppression of adipogenesis by cigarette smoke through
   activation of the aryl hydrocarbon receptor and induction of endoplasmic
   reticulum stress (Retracted article. See vol. 301, pg. E1050, 2011)
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article; Retracted Publication
DE adipocyte; adiponectin; peroxisome proliferator-activated
   receptor-gamma; CCAAT/enhancer-binding protein-alpha; monocyte
   chemoattractant protein-1
ID POLYCYCLIC AROMATIC-HYDROCARBONS; UNFOLDED PROTEIN RESPONSE; MONOCYTE
   CHEMOATTRACTANT PROTEIN-1; NF-KAPPA-B; ADIPOCYTE DIFFERENTIATION;
   GROWTH-FACTOR; 3T3-L1 CELLS; IN-VIVO;
   2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; ADIPOSE DIFFERENTIATION
AB Shimada T, Hiramatsu N, Hayakawa K, Takahashi S, Kasai A, Tagawa Y, Mukai M, Yao J, Fujii-Kuriyama Y, Kitamura M. Dual suppression of adipogenesis by cigarette smoke through activation of the aryl hydrocarbon receptor and induction of endoplasmic reticulum stress. Am J Physiol Endocrinol Metab 296: E721-E730, 2009. First published January 13, 2009; doi:10.1152/ajpendo.90829.2008.-Cigarette smoking decreases body weight, whereas molecular mechanisms underlying this phenomenon have not been elucidated. In this report, we investigated regulation of adipogenesis by cigarette smoke and involvement of aryl hydrocarbon receptor (AhR) and endoplasmic reticulum (ER) stress. We found that cigarette smoke extract (CSE) inhibited differentiation of preadipocytes into adipocytes dose dependently. It was associated with a decrease in lipid accumulation, blunted expression of adipocyte markers (adiponectin, PPAR-gamma, and C/EBP alpha), and sustained expression of a preadipocyte marker MCP-1. CSE markedly induced activation of AhR, and AhR agonists (2,3,7,8-tetrachlorodibenzo-p-dioxin, benzo[a]pyrene and 3-methylcholanthrene) reproduced the inhibitory effect of CSE on adipocyte differentiation. Furthermore, knockout of the AhR gene or blockade of AhR by a dominant-negative mutant attenuated the suppressive effects of CSE on adipocyte differentiation. We also found that CSE induced ER stress in preadipocytes, and ER stress inducers (thapsigargin, tunicamycin, and A23187) reproduced the suppressive effect of CSE on the differentiation of preadipocytes. Interestingly, AhR agonists did not cause ER stress, and ER stress inducers did not activate AhR. These results suggested that cigarette smoke has the potential to inhibit adipocyte differentiation via dual, independent mechanisms, i.e., through activation of the AhR pathway and induction of the unfolded protein response.
C1 [Shimada, Tsuyoshi; Hiramatsu, Nobuhiko; Hayakawa, Kunihiro; Takahashi, Shuhei; Kasai, Ayumi; Tagawa, Yasuhiro; Mukai, Mai; Yao, Jian; Kitamura, Masanori] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Mol Signaling, Chuo Ku, Yamanashi 4093898, Japan.
   [Fujii-Kuriyama, Yoshiaki] Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki, Japan.
RP Kitamura, M (reprint author), Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Mol Signaling, Chuo Ku, Shimokato 1110, Yamanashi 4093898, Japan.
EM masanori@yamanashi.ac.jp
FU Smoking Research Foundation; Ministry of Education, Culture, Sports,
   Science and Technology, Japan [16390243, 17651026, 19651024]
FX This work was supported, in part, by grants from the Smoking Research
   Foundation and from Grants-in-Aid for Scientific Research from the
   Ministry of Education, Culture, Sports, Science and Technology, Japan
   (No. 16390243, No. 17651026, and No. 19651024) to M. Kitamura.
CR Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128
   ALBANES D, 1987, AM J PUBLIC HEALTH, V77, P439, DOI 10.2105/AJPH.77.4.439
   Alexander DL, 1998, J CELL SCI, V111, P3311
   Aoyama T., 2003, ORGANOHALOGEN COMPD, V65, P321
   BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x
   Bezy O, 2005, J BIOL CHEM, V280, P11432, DOI 10.1074/jbc.M411741200
   BONEY CM, 1994, ENDOCRINOLOGY, V135, P1863, DOI 10.1210/en.135.5.1863
   Brodie AE, 1997, TOXICOL LETT, V90, P91, DOI 10.1016/S0378-4274(96)03833-7
   CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538
   Cernkovich ER, 2007, ENDOCRINOLOGY, V148, P1598, DOI 10.1210/en.2006-1106
   CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798
   Chen H, 2005, NEUROPSYCHOPHARMACOL, V30, P713, DOI 10.1038/sj.npp.1300597
   Chibon F, 2004, GENE CHROMOSOME CANC, V40, P32, DOI 10.1002/gcc.20012
   Crowley-Weber CL, 2003, CHEM-BIOL INTERACT, V145, P53, DOI 10.1016/S0009-2797(02)00162-X
   Ding YS, 2005, ENVIRON SCI TECHNOL, V39, P471, DOI 10.1021/es048690k
   Fasshauer M, 2004, BIOCHEM BIOPH RES CO, V317, P598, DOI 10.1016/j.bbrc.2004.03.090
   Feve B, 2005, BEST PRACT RES CL EN, V19, P483, DOI 10.1016/j.beem.2005.07.007
   Fu YC, 2005, J LIPID RES, V46, P1369, DOI 10.1194/jlr.M400373-JLR200
   Hanlon PR, 2003, TOXICOL APPL PHARM, V189, P11, DOI 10.1016/S0041-008X(03)00083-8
   Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200
   Hiramatsu N, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl515
   Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697
   Kasai A, 2006, TOXICOL APPL PHARM, V211, P11, DOI 10.1016/j.taap.2005.05.005
   Kasai A, 2005, ANAL BIOCHEM, V337, P84, DOI 10.1016/j.ab.2004.10.004
   Kasai A, 2004, ANAL BIOCHEM, V335, P73, DOI 10.1016/j.ab.2004.08.017
   Kasai A, 2008, ENVIRON HEALTH PERSP, V116, P349, DOI 10.1289/ehp.10722
   Kasai A, 2006, CANCER RES, V66, P7143, DOI 10.1158/0008-5472.CAN-05-4541
   Katayama T, 2001, J BIOL CHEM, V276, P43446, DOI 10.1074/jbc.M104096200
   Kim R, 2006, APOPTOSIS, V11, P5, DOI 10.1007/s10495-005-3088-0
   Kitamura M, 1997, J IMMUNOL, V159, P1404
   Kitamura M, 2008, AM J PHYSIOL-RENAL, V295, pF323, DOI 10.1152/ajprenal.00050.2008
   Lodovici M, 2004, J APPL TOXICOL, V24, P277, DOI 10.1002/jat.992
   LOFROTH G, 1992, B ENVIRON CONTAM TOX, V48, P789
   Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x
   MUTO H, 1989, ARCH ENVIRON HEALTH, V44, P171, DOI 10.1080/00039896.1989.9935882
   Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160
   Patel NG, 2005, J CLIN ENDOCR METAB, V90, P1226, DOI 10.1210/jc.2004-1309
   Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256
   PERKINS KA, 1992, BRIT J ADDICT, V87, P193
   PHILLIPS M, 1995, J CELL SCI, V108, P395
   ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738
   Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001
   Sentinelli F, 2006, J ENDOCRINOL, V188, P271, DOI 10.1677/joe.1.06290
   Shimada T, 1998, ARCH BIOCHEM BIOPHYS, V357, P111, DOI 10.1006/abbi.1998.0808
   Shimada T, 2007, BIOCHEM BIOPH RES CO, V363, P355, DOI 10.1016/j.bbrc.2007.08.167
   Shimba S, 2001, J CELL SCI, V114, P2809
   Sogawa K, 2004, BIOCHEM BIOPH RES CO, V318, P746, DOI 10.1016/j.bbrc.2004.04.090
   Tagawa Y, 2008, FREE RADICAL BIO MED, V45, P50, DOI 10.1016/j.freeradbiomed.2008.03.003
   Tsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200
   Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708
   Yokouchi M, 2007, CELL DEATH DIFFER, V14, P1467, DOI 10.1038/sj.cdd.4402154
   Yokouchi M, 2008, J BIOL CHEM, V283, P4252, DOI 10.1074/jbc.M705951200
NR 52
TC 13
Z9 13
U1 4
U2 15
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
EI 1522-1555
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD APR
PY 2009
VL 296
IS 4
BP E721
EP E730
DI 10.1152/ajpendo.90829.2008
PG 10
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 423SB
UT WOS:000264514900018
PM 19141685
DA 2018-12-27
ER

PT J
AU Jagannathan, J
AF Jagannathan, Jay
TI RETRACTED: Role of calcium influx and modulation of local
   neurotransmitters as hallmarks of pediatric traumatic brain injury
   (Retracted article. See vol. 5, pg. 276, 2011)
SO BIOMARKERS IN MEDICINE
LA English
DT Editorial Material; Retracted Publication
ID SEVERE HEAD-INJURY; D-ASPARTATE ANTAGONISTS; DEVELOPING RAT-BRAIN; COMA
   DATA-BANK; APOPTOTIC NEURODEGENERATION; INTRACRANIAL HYPERTENSION;
   CELL-DEATH; CHILDREN; BCL-2; INCREASES
C1 Univ Virginia, Dept Neurol Surg, Hlth Sci Ctr, Charlottesville, VA 22902 USA.
RP Jagannathan, J (reprint author), Univ Virginia, Dept Neurol Surg, Hlth Sci Ctr, Box 800212, Charlottesville, VA 22902 USA.
EM jj5a@hscmaili.mcc.virginia.edu
CR Adelson P D, 2000, Clin Neurosurg, V47, P319
   ADELSON PD, 1998, ACTA NEUROCHIR S7, V1, P104
   ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450
   Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P
   CAMPAGNE MV, 1994, J CEREBR BLOOD F MET, V14, P1011, DOI 10.1038/jcbfm.1994.133
   CAMPAGNE MV, 1996, BRAIN RES DEV BRAIN, V93, P109
   Clark RSB, 1997, J NEUROSCI, V17, P9172
   Clark RSB, 1999, FASEB J, V13, P813
   Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903
   Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CMM.0000080493.04978.73
   Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161
   EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688
   Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950
   Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163
   GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135
   HEISKANEN O, 1974, DEV MED CHILD NEUROL, V16, P11
   Ikonomidou C, 1995, CURR OPIN NEUROL, V8, P487, DOI 10.1097/00019052-199512000-00017
   Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70
   Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056
   Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197
   Ishimaru MJ, 1999, J COMP NEUROL, V408, P461
   Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268
   Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101
   Jones PA, 2005, ACT NEUR S, V95, P29
   JOURDAN C, 1993, NEUROCHIRURGIE, V39, P304
   Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001
   MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3
   Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183
   Marmarou A, 2000, ACT NEUR S, V76, P349
   Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508
   Robertson CL, 2004, DEV BRAIN RES, V151, P141, DOI 10.1016/j.devbrainres.2004.04.007
   TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862
   Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777
   2000, J NEUROTRAUMA, V17, P471
NR 34
TC 2
Z9 2
U1 4
U2 10
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1752-0363
EI 1752-0371
J9 BIOMARK MED
JI Biomark. Med.
PD APR
PY 2009
VL 3
IS 2
BP 95
EP 97
DI 10.2217/BMM.09.1
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 434YD
UT WOS:000265309300001
PM 20477499
DA 2018-12-27
ER

PT J
AU Pavelko, KD
   Hansen, MJ
   Pease, LR
AF Pavelko, Kevin D.
   Hansen, Michael J.
   Pease, Larry R.
TI RETRACTED: CTL Activation Using the Natural Low-Affinity Epitope 222-229
   from Tyrosinase-Related Protein 1 Leads to Tumor Rejection (Retracted
   article. See vol. 70, pg. 9529, 2010)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID CROSS-LINKING ANTIBODY; T-CELLS; DENDRITIC CELLS; DIFFERENTIATION
   ANTIGEN; SELF ANTIGEN; ANTITUMOR IMMUNITY; ALTERED ANTIGEN; B16
   MELANOMA; IN-VITRO; B7-DC
AB Vaccine strategies for cancer immunotherapy have focused on peptide ligands with high affinity for MHC class I. Largely, these vaccines have not been therapeutic. We have examined the peptide specificity of a strongly protective T-cell response that eradicates established B16 melanoma and find that the recognized epitope is generated by a low-affinity MHC class I ligand from tyrosinase-related protein 1 (TRP1). Cytotoxic T-cell responses are induced against TRP1(222-229) by several vaccination schemes using a Toll-like receptor agonist T regulatory cell depletion, or the immune modulator B7-DCXAb to drive immunity. TRP1(222) CTL are generated from multiple antigen sources, including antigens expressed by tumors growing in situ, tumor cell lysates, and peptide vaccines. The key finding in this study is that protection from freshly implanted or established B16 tumors is primarily mediated by TRP1(222)-specific CTL and not by CTL specific for more traditional melanoma antigens such as TRP2 or gp100. This finding challenges the assumption that the optimal peptide antigens for cancer vaccines are high-affinity MHC ligands. We propose that when administered appropriately, native low-affinity MHC ligands are optimal inducers of immunotherapeutic CTL. [Cancer Res 2009;69(7):3114-20]
C1 [Pavelko, Kevin D.; Hansen, Michael J.; Pease, Larry R.] Mayo Clin, Dept Immunol, Coll Med, Rochester, MN 55905 USA.
RP Pease, LR (reprint author), Mayo Clin, Dept Immunol, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.
EM pease.larry@mayo.edu
OI Pavelko, Kevin/0000-0001-7555-1315
FU NIH [R01 CA104996, T32 AI07425]
FX NIH grants R01 CA104996 and T32 AI07425 (L.R. Pease).
CR Bloom MB, 1997, J EXP MED, V185, P453, DOI 10.1084/jem.185.3.453
   Curiel TJ, 2003, NAT MED, V9, P562, DOI 10.1038/nm863
   Dahl AM, 1996, J IMMUNOL, V157, P239
   Dyall R, 1998, J EXP MED, V188, P1553, DOI 10.1084/jem.188.9.1553
   Ercolini AM, 2005, J EXP MED, V201, P1591, DOI 10.1084/jem.20042167
   FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877
   Guevara-Patino JA, 2006, J CLIN INVEST, V116, P1382, DOI 10.1172/JCI25591
   Heckman KL, 2007, EUR J IMMUNOL, V37, P1827, DOI 10.1002/eji.200637002
   Hou YF, 2008, J IMMUNOL, V180, P1526, DOI 10.4049/jimmunol.180.3.1526
   Johnson AJ, 2001, FASEB J, V15, P2760, DOI 10.1096/fj.01-0373fje
   LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0
   MATTES MJ, 1983, INT J CANCER, V32, P717, DOI 10.1002/ijc.2910320610
   Naftzger C, 1996, P NATL ACAD SCI USA, V93, P14809, DOI 10.1073/pnas.93.25.14809
   Nava-Parada P, 2007, CANCER RES, V67, P1326, DOI 10.1158/0008-5472.CAN-06-3290
   Overwijk WW, 1998, J EXP MED, V188, P277, DOI 10.1084/jem.188.2.277
   PARKER KC, 1994, J IMMUNOL, V152, P163
   Pavelko KD, 2008, CANCER RES, V68, P2471, DOI 10.1158/0008-5472.CAN-07-5937
   Radhakrishnan S, 2005, J ALLERGY CLIN IMMUN, V116, P668, DOI 10.1016/j.jaci.2005.04.038
   Radhakrishnan S, 2004, CANCER RES, V64, P4965, DOI 10.1158/0008-5472.CAN-03-3025
   Radhakrishnan S, 2003, J IMMUNOL, V170, P1830, DOI 10.4049/jimmunol.170.4.1830
   Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494
   Sarangarajan R, 2000, PIGM CELL RES, V13, P337, DOI 10.1034/j.1600-0749.2000.130506.x
   Savage PA, 2008, SCIENCE, V319, P215, DOI 10.1126/science.1148886
   Schreurs MWJ, 2000, CANCER RES, V60, P6995
   Speiser DE, 2008, P NATL ACAD SCI USA, V105, P3849, DOI 10.1073/pnas.0800080105
   Tsai V, 1997, J IMMUNOL, V158, P1796
   van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355
   Van Keulen VP, 2006, CLIN EXP IMMUNOL, V143, P314, DOI 10.1111/j.1365-2249.2005.02992.x
   Xu YQ, 1997, J INVEST DERMATOL, V109, P788, DOI 10.1111/1523-1747.ep12340971
   Yang JC, 2000, J IMMUNOTHER, V23, P177, DOI 10.1097/00002371-200003000-00001
   Yewdell JTW, 1999, ANNU REV IMMUNOL, V17, P51, DOI 10.1146/annurev.immunol.17.1.51
   Zeh HJ, 1999, J IMMUNOL, V162, P989
NR 32
TC 5
Z9 6
U1 3
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 1
PY 2009
VL 69
IS 7
BP 3114
EP 3120
DI 10.1158/0008-5472.CAN-08-2448
PG 7
WC Oncology
SC Oncology
GA 429GE
UT WOS:000264908100055
PM 19276379
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Shyu, KG
   Wang, BW
   Chang, H
AF Shyu, Kou-Gi
   Wang, Bao-Wei
   Chang, Hang
TI RETRACTED: Hyperbaric oxygen activates discoidin domain receptor 2 via
   tumour necrosis factor-alpha and the p38 MAPK pathway to increase
   vascular smooth muscle cell migration through matrix metalloproteinase
   2(Retracted article.See vol.130,pg.1841,2016)
SO CLINICAL SCIENCE
LA English
DT Article; Retracted Publication
DE angiogenesis; discoidin domain receptor 2 (DDR2); hyperbaric oxygen;
   matrix metalloproteinase (MMP); p38 mitogen-activated protein kinase
   (p38 MAPK); smooth muscle cell
ID CYCLICAL MECHANICAL STRETCH; VEIN ENDOTHELIAL-CELLS;
   EXTRACELLULAR-MATRIX; TYROSINE KINASES; EXPRESSION; COLLAGEN;
   ANGIOGENESIS; THERAPY; DISCOIDIN-DOMAIN-RECEPTOR-2; PROLIFERATION
AB DDR2 (discoidin domain receptor 2) regulates collagen turnover mediated by SMCs (smooth muscle cells) in atherosclerosis. HBO (hyperbaric oxygen) has been used in medical practice; however, the molecular mechanism of the beneficial effects of HBO is poorly understood. Furthermore, the effect of HBO on DDR2 has not been reported previously. In the present study, we investigated the cellular and molecular mechanisms of DDR2 regulation by HBO in VSMCs (vascular SMCs). Cells were exposed to 2.5 ATA (atmosphere absolute) of oxygen in a hyperbaric chamber. DDR2 protein (3.63-fold) and mRNA (2.34-fold) expression were significantly increased after exposure to 2.5 ATA HBO for 1 h. Addition of SB203580 and p38 MAPK (mitogen-activated protein kinase) siRNA (small interfering RNA) 30 min before HBO inhibited the induction of DDR2 protein. HBO also significantly increased DNA-protein binding activity of Myc/Max. Addition of SB203580 and an anti-TNF-alpha (tumour necrosis factor-a) monoclonal antibody 30 min before HBO abolished the DNA-protein binding activity induced by HBO. HBO significantly increased the secretion of TNF-alpha from cultured VSMCs. Exogenous addition of TNF-alpha significantly increased DDR2 protein expression, whereas anti-TNF-alpha and anti-(TNF-alpha receptor) antibodies blocked the induction of DDR2 protein expression. HBO significantly increased VSMC migration and proliferation, whereas DDR2 siRNA inhibited the migration induced by HBO. HBO increased activated MMP2 (matrix metalloproteinase 2) protein expression, and DDR2 siRNA abolished the induction of activated MMP2 expression induced by HBO. In conclusion, HBO activates DDR2 expression in cultured rat VSMCs. HBO-induced DDR2 is mediated by TNF-alpha and at least in part through the p38 MAPK and Myc pathways.
C1 [Chang, Hang] Shin Kong Wu Ho Su Mem Hosp, Dept Emergency Med, Taipei 111, Taiwan.
   [Shyu, Kou-Gi; Wang, Bao-Wei] Shin Kong Wu Ho Su Mem Hosp, Div Cardiol, Taipei 111, Taiwan.
   [Shyu, Kou-Gi] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei 110, Taiwan.
   [Wang, Bao-Wei] Fu Jen Catholic Univ, Sch Med, Taipei 24205, Taiwan.
RP Chang, H (reprint author), Shin Kong Wu Ho Su Mem Hosp, Dept Emergency Med, Taipei 111, Taiwan.
EM m002018@ms.skh.org.tw
FU National Science Council, Taipei, Taiwan
FX This study was supported, in part, by the National Science Council,
   Taipei, Taiwan.
CR Abidia A, 2003, EUR J VASC ENDOVASC, V25, P513, DOI 10.1053/ejvs.2002.1911
   ALVES F, 1995, ONCOGENE, V10, P609
   Bouachour G, 1996, J TRAUMA, V41, P333, DOI 10.1097/00005373-199608000-00023
   Chang H, 2003, CLIN SCI, V105, P447, DOI 10.1042/CS20030088
   Chang H, 2003, BIOCHEM BIOPH RES CO, V302, P95, DOI 10.1016/S0006-291X(03)00111-6
   COCONI MT, 2003, J INVEST MED, V51, P227
   Ferri N, 2004, AM J PATHOL, V164, P1575, DOI 10.1016/S0002-9440(10)63716-9
   Gill AL, 2004, QJM-INT J MED, V97, P385, DOI 10.1093/qjmed/hch074
   Haas TL, 2000, AM J PHYSIOL-HEART C, V279, pH1540
   Ishii Y, 1999, TISSUE ENG, V5, P279, DOI 10.1089/ten.1999.5.279
   LAVAN FB, 1990, CLIN PLAST SURG, V17, P463
   Ledgerwood EC, 1999, LAB INVEST, V79, P1041
   Lee CC, 2006, J BIOMED SCI, V13, P143, DOI 10.1007/s11373-005-9037-7
   Liu G, 2007, HISTOL HISTOPATHOL, V22, P211, DOI 10.14670/HH-22.211
   MARX RE, 1990, AM J SURG, V160, P519, DOI 10.1016/S0002-9610(05)81019-0
   Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200
   Olaso E, 2001, J CLIN INVEST, V108, P1369, DOI 10.1172/JCI12373
   PAULY RR, 1994, CIRC RES, V75, P41, DOI 10.1161/01.RES.75.1.41
   Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0
   Shyu KG, 2005, HYPERTENSION, V46, P614, DOI 10.1161/01.HYP.0000175811.79863.e2
   Shyu KG, 2004, CARDIOVASC RES, V63, P98, DOI 10.1016/j.cardiores.2004.02.018
   Shyu KG, 2003, CLIN SCI, V105, P287, DOI 10.1042/CS20030025
   Shyu KG, 2008, ARTERIOSCL THROM VAS, V28, P1447, DOI 10.1161/ATVBAHA.108.165993
   Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com
   STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11
   Thom SR, 2003, AM J PHYSIOL-HEART C, V284, pH1230, DOI 10.1152/ajpheart.01043.2002
   Thom SR, 2002, NEW ENGL J MED, V347, P1105, DOI 10.1056/NEJMe020103
   Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9
   Vogel WF, 2006, CELL SIGNAL, V18, P1108, DOI 10.1016/j.cellsig.2006.02.012
   Wang BW, 2003, CARDIOVASC RES, V59, P460, DOI 10.1016/S0008-6363(03)00428-0
   Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5
   WOESSNER JF, 1991, FASEB J, V5, P2145
NR 32
TC 18
Z9 19
U1 4
U2 9
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0143-5221
EI 1470-8736
J9 CLIN SCI
JI Clin. Sci.
PD APR
PY 2009
VL 116
IS 7-8
BP 575
EP 583
DI 10.1042/CS20080215
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 429HM
UT WOS:000264911500003
PM 18821853
DA 2018-12-27
ER

PT J
AU Lindsay, C
   Downs, C
   Brown, M
AF Lindsay, Claire
   Downs, Colleen
   Brown, Mark
TI RETRACTED: Physiological variation in Amethyst Sunbirds (Chalcomitra
   amethystina) over an altitudinal gradient: A seasonal comparison
   (Retracted article. See vol. 155, pg. 271, 2010)
SO COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR & INTEGRATIVE
   PHYSIOLOGY
LA English
DT Article; Retracted Publication
DE Altitudinal variation; Amethyst Sunbird; Metabolic rates; Phenotypic
   flexibility; Seasonal acclimatization
ID BASAL METABOLIC-RATE; MOUNTAIN CHICKADEES; CARDUELINE FINCHES; JUNIPER
   TITMICE; ACCLIMATIZATION; TEMPERATURE; SPARROWS; THERMOREGULATION;
   FLEXIBILITY; ADJUSTMENTS
AB Southern Africa is characterised by an unpredictable environment with daily and seasonal temperature fluctuations, thus posing challenging thermal conditions and increased energetic stress for endothermic vertebrates. Amethyst Sunbirds (Chalcomitra amethystina) are relatively large African sunbirds (15 g). They are considered non-migratory and thus have to cope with the temperature changes and physiological stresses a new season brings. This study compared altitudinal subpopulations and the seasonal shifts in metabolic parameters between and within the subpopulations in metabolic parameters. Amethyst Sunbirds were caught in summer and winter at three different altitudinal subpopulations; Underberg (1555 m asl), Howick (1075 m asl) and Oribi Gorge (541 m asl). Upon capture, metabolic rates of the sunbirds were measured indirectly by quantifying oxygen consumption ((V)over dot(O2)) using flow through respirometry at 5 and 25 degrees C. Birds then underwent a 6-week acclimation period at 25 degrees C on a 12 L: 12D cycle. (V)over dot(O2) was measured post-acclimation at 8 different temperatures (15, 5, 10, 20, 30, 28, 25 and 33 degrees C), which were ordered randomly in the experimental protocol to avoid acclimation bias. Experiments were repeated for a winter and summer season. In general, Amethyst Sunbird subpopulations from Underberg and Howick showed higher post-acclimation resting metabolic rates per temperature in winter than in summer trials. Underberg and Howick subpopulations respectively showed a significant difference between summer and winter (V)over dot(O2) at 5 and 10 degrees C. Thermal neutral zones of all of the subpopulations of sunbirds shifted between winter and summer. Post-acclimation basal metabolic rate of sunbirds decreased significantly by 38.8% from winter to summer for the Underberg subpopulation, increased by 44.8% for the Howick subpopulation and did not change significantly for the Oribi Gorge subpopulation (5.8% decrease). (C) 2009 Elsevier Inc. All rights reserved.
C1 [Lindsay, Claire; Downs, Colleen; Brown, Mark] Univ KwaZulu Natal, Sch Biol & Conservat Sci, ZA-3209 Pietermaritzburg, South Africa.
RP Downs, C (reprint author), Univ KwaZulu Natal, Sch Biol & Conservat Sci, Private Bag X01, ZA-3209 Pietermaritzburg, South Africa.
EM downs@ukzn.ac.za
FU NRF
FX CL would like to thank the NRF and the Gay Langmuir bursary fund for
   financial assistance. Temperature data was obtained from the South
   African Weather Service. We would also like to thank Mike and Heidi
   Neethling (Oribi Gorge), Bill and Pam Nicol (Howick) and Prof. and Mrs.
   Piper (Underberg) for allowing us to "borrow" their Amethyst Sunbirds
   for the study period. Tracy Odendaal, Jaclyn Tennent, John Lindsay,
   Kelly Brown, Nicolette Taylor, Ashton Musgrave, Akeem Akilimali are
   thanked for their invaluable field trip assistance. Thanks also to
   students at UKZN for assisting with feeding and bird maintenance.
CR AMBROSE SJ, 1988, COMP BIOCHEM PHYS A, V89, P79, DOI 10.1016/0300-9629(88)91142-5
   Arens JR, 2005, CONDOR, V107, P433, DOI 10.1650/7651
   Bernardo J, 2007, BIOLOGY LETT, V3, P695, DOI 10.1098/rsbl.2007.0259
   Blem C.R., 1990, Current Ornithology, V7, P59
   CAREY C, 1978, J COMP PHYSIOL, V125, P101, DOI 10.1007/BF00686746
   Cavieres G, 2008, FUNCT ECOL, V22, P509, DOI 10.1111/j.1365-2435.2008.01382.x
   CLEMENS DT, 1988, J COMP PHYSIOL B, V158, P57, DOI 10.1007/BF00692729
   Cooper SJ, 2000, CONDOR, V102, P635, DOI 10.1650/0010-5422(2000)102[0635:SEOMCA]2.0.CO;2
   COOPER SJ, 1994, CONDOR, V96, P638, DOI 10.2307/1369467
   Cooper SJ, 2002, PHYSIOL BIOCHEM ZOOL, V75, P386, DOI 10.1086/342256
   Cossins A, 2006, J EXP BIOL, V209, P2328, DOI 10.1242/jeb.02256
   Crick HQP, 2004, IBIS, V146, P48, DOI 10.1111/j.1474-919X.2004.00327.x
   DAWSON WR, 1976, J COMP PHYSIOL, V112, P317, DOI 10.1007/BF00692302
   Dawson WR, 2003, ISR J ZOOL, V49, P95, DOI 10.1560/97CA-41H8-F9P2-1CTE
   Downs CT, 2002, AUK, V119, P251, DOI 10.1642/0004-8038(2002)119[0251:NHATIT]2.0.CO;2
   Furness RW, 2003, NATURE, V425, P779, DOI 10.1038/425779a
   HART J. S., 1962, PHYSIOL ZOOL, V35, P224
   Klaassen M, 2004, COMP BIOCHEM PHYS A, V137, P639, DOI 10.1016/j.cbpb.2003.12.004
   Liknes ET, 2002, CONDOR, V104, P548, DOI 10.1650/0010-5422(2002)104[0548:SAITAG]2.0.CO;2
   Lindsay CV, 2009, J EXP BIOL, V212, P483, DOI 10.1242/jeb.025262
   LINDSAY CV, J THERM BIOL
   Lovegrove BG, 2003, IBIS, V145, P547, DOI 10.1046/j.1474-919X.2003.00166.x
   Maddocks TA, 2000, J ZOOL, V252, P327
   McKechnie AE, 2008, J COMP PHYSIOL B, V178, P235, DOI 10.1007/s00360-007-0218-8
   PIERSMA T, 1995, J COMP PHYSIOL B, V165, P37, DOI 10.1007/BF00264684
   Rezende EL, 2004, J EXP BIOL, V207, P295, DOI 10.1242/jeb.00760
   Sharbaugh SM, 2001, PHYSIOL BIOCHEM ZOOL, V74, P568, DOI 10.1086/322170
   SHULTZ RE, 1997, S AFRICAN ATLAS AGRO
   Smit B, 2008, J THERM BIOL, V33, P76, DOI 10.1016/j.jtherbio.2007.11.001
   SOUTHWICK EE, 1980, AUK, V97, P76
   Swanson DL, 1997, CONDOR, V99, P478, DOI 10.2307/1369954
   TREE AJ, 2005, ROBERTS BIRDS SO AFR, P981
   WEATHERS WW, 1982, AUK, V99, P667
   WEATHERS WW, 1978, OECOLOGIA, V35, P173, DOI 10.1007/BF00344730
   Withers P. C, 1992, COMP ANIMAL PHYSL
NR 35
TC 5
Z9 5
U1 4
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1095-6433
EI 1531-4332
J9 COMP BIOCHEM PHYS A
JI Comp. Biochem. Physiol. A-Mol. Integr. Physiol.
PD APR
PY 2009
VL 152
IS 4
BP 593
EP 598
DI 10.1016/j.cbpa.2009.01.009
PG 6
WC Biochemistry & Molecular Biology; Physiology; Zoology
SC Biochemistry & Molecular Biology; Physiology; Zoology
GA 423QS
UT WOS:000264511400019
PM 19256084
DA 2018-12-27
ER

PT J
AU Trapasso, F
   Aqeilan, RI
   Iuliano, R
   Visone, R
   Gaudio, E
   Ciuffini, L
   Alder, H
   Paduano, F
   Pierantoni, GM
   Soddu, S
   Croce, CM
   Fusco, A
AF Trapasso, Francesco
   Aqeilan, Rami I.
   Iuliano, Rodolfo
   Visone, Rosa
   Gaudio, Eugenio
   Ciuffini, Laura
   Alder, Hansjuerg
   Paduano, Francesco
   Pierantoni, Giovanna Maria
   Soddu, Silvia
   Croce, Carlo M.
   Fusco, Alfredo
TI RETRACTED: Targeted Disruption of the Murine Homeodomain-Interacting
   Protein Kinase-2 Causes Growth Deficiency In Vivo and Cell Cycle Arrest
   In Vitro (Retracted article. See vol. 33, pg. 189, 2014)
SO DNA AND CELL BIOLOGY
LA English
DT Article; Retracted Publication
ID HIPK2; P53; TRANSCRIPTION; COMPLEX; FAMILY; PHOSPHORYLATION;
   DEGRADATION; ACTIVATION; APOPTOSIS; SURVIVAL
AB The homeodomain-interacting protein kinase 2 (HIPK2) protein is a member of a recently identified family of nuclear protein kinases that are well conserved in various organisms. HIPK2 can bind to several homeotic factors and to a series of proteins involved in the regulation of cell survival and proliferation in response to morphogenetic and genotoxic signals. Here we report Hipk2-targeted disruption in mouse; Hipk2(-/-) mice are viable and fertile but significantly smaller than their wild-type littermates. This feature is present at birth and retained throughout the mouse adulthood. Mouse embryo fibroblasts from Hipk2(-/-) mice show a reduced proliferation rate, compared to the wild-type counterparts, with accumulation in the G0/G1 phase of the cell cycle and altered levels of the cell cycle regulators cyclin D and CDK6. Restoration of wild-type HIPK2 expression in Hipk2(-/-) cells rescues the normal phenotype supporting a role for HIPK2 in the regulation of cell proliferation.
C1 [Fusco, Alfredo] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med & Chirurg Napoli, I-80131 Naples, Italy.
   [Trapasso, Francesco; Aqeilan, Rami I.; Gaudio, Eugenio; Alder, Hansjuerg; Croce, Carlo M.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
   [Trapasso, Francesco; Aqeilan, Rami I.; Gaudio, Eugenio; Alder, Hansjuerg; Croce, Carlo M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Trapasso, Francesco; Iuliano, Rodolfo; Gaudio, Eugenio; Paduano, Francesco] Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Catanzaro, Italy.
   [Ciuffini, Laura; Soddu, Silvia] Regina Elena Inst Canc Res, Dept Expt Oncol, Mol Oncogenesis Lab, Rome, Italy.
   [Fusco, Alfredo] NOGEC Naples Oncogenom Ctr CEINGE, I-80131 Naples, Italy.
RP Fusco, A (reprint author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med & Chirurg Napoli, Via Pansini 5, I-80131 Naples, Italy.
EM afusco@napoli.com
RI PADUANO, FRANCESCO/E-2106-2011; Soddu, Silvia/K-2467-2018; Aqeilan,
   Rami/R-4443-2016
OI Soddu, Silvia/0000-0001-8526-0044; Aqeilan, Rami/0000-0002-6034-023X;
   Fusco, Alfredo/0000-0003-3332-5197
FU Associazione Italiana per la Ricerca sul Cancro (AIRC)
FX This work was supported by the Associazione Italiana per la Ricerca sul
   Cancro (AIRC). We are grateful to Jan Guz for performing the blastocysts
   injections at the Kimmel Cancer Center Animal Facility. We are
   particularly grateful to Cinzia Rinaldo, Chiara Lazzari, and Giorgia
   Bracaglia for shearing their data on HIPK2-interfered cells.
CR Bossi G, 2004, ONCOGENE, V23, P418, DOI 10.1038/sj.onc.1207042
   Calzado MA, 2007, CELL CYCLE, V6, P139, DOI 10.4161/cc.6.2.3788
   Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194
   D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714
   Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077
   Harada J, 2003, J BIOL CHEM, V278, P38998, DOI 10.1074/jbc.M307112200
   Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715
   Hofmann TG, 2000, BIOCHIMIE, V82, P1123, DOI 10.1016/S0300-9084(00)01196-2
   IACOVELLI S, 2009, CELL PROLIF IN PRESS
   Isono K, 2006, MOL CELL BIOL, V26, P2758, DOI 10.1128/MCB.26.7.2758-2771.2006
   Kanei-Ishii C, 2004, J BIOL CHEM, V279, P44582, DOI 10.1074/jbc.M407831200
   Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200
   Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875
   Li QX, 2007, CANCER RES, V67, P66, DOI 10.1158/0008-5472.CAN-06-1671
   Pierantoni GM, 2006, CELL DEATH DIFFER, V13, P1554, DOI 10.1038/sj.cdd.4401839
   Pierantoni GM, 2007, J CLIN INVEST, V117, P693, DOI 10.1172/JC129852
   Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635
   Rinaldo C, 2008, BBA-MOL CELL RES, V1783, P2124, DOI 10.1016/j.bbamcr.2008.06.006
   Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008
   Roscic A, 2006, MOL CELL, V24, P77, DOI 10.1016/j.molcel.2006.08.004
   Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475
   Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104
   Wiggins AK, 2004, J CELL BIOL, V167, P257, DOI 10.1083/jcb.200406131
   Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255
   Zhang JS, 2007, NAT NEUROSCI, V10, P77, DOI 10.1038/nn1816
   Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X
NR 26
TC 14
Z9 15
U1 4
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD APR
PY 2009
VL 28
IS 4
BP 161
EP 167
DI 10.1089/dna.2008.0778
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA 432LY
UT WOS:000265136800001
PM 19364276
DA 2018-12-27
ER

PT J
AU Bhonagiri, P
   Pattar, GR
   Horvath, EM
   Habegger, KM
   McCarthy, AM
   Elmendorf, JS
AF Bhonagiri, Padma
   Pattar, Guruprasad R.
   Horvath, Emily M.
   Habegger, Kirk M.
   McCarthy, Alicia M.
   Elmendorf, Jeffrey S.
TI RETRACTED: Hexosamine Biosynthesis Pathway Flux Contributes to Insulin
   Resistance via Altering Membrane Phosphatidylinositol 4,5-Bisphosphate
   and Cortical Filamentous Actin (Retracted Article. See vol 151, pg 2967,
   2010)
SO ENDOCRINOLOGY
LA English
DT Article; Retracted Publication
ID ELEMENT-BINDING PROTEIN-1C; STIMULATED GLUCOSE-TRANSPORT; PORE COMPLEX
   GLYCOPROTEINS; OBESE NONDIABETIC WOMEN; O-GLCNAC TRANSFERASE; 3T3-L1
   ADIPOCYTES; GLUT4 TRANSLOCATION; GENE-EXPRESSION; TETRATRICOPEPTIDE
   REPEATS; PHOSPHOLIPID-COMPOSITION
AB We recently found that plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP2)-regulated filamentous actin (F-actin) polymerization was diminished in hyperinsulinemic cell culture models of insulin resistance. Here we delineated whether increased glucose flux through the hexosamine biosynthesis pathway (HBP) causes the PIP2/F-actin dysregulation and insulin resistance induced by hyperinsulinemia. Increased HBP activity was detected in 3T3-L1 adipocytes cultured under conditions closely resembling physiological hyperinsulinemia (5 nM insulin for 12 h) and in cells where HBP activity was amplified by 2 mM glucosamine (GlcN). Both the physiological hyperinsulinemia and experimental GlcN challenge induced comparable losses of PIP2 and F-actin. In addition to protecting against the insulin-induced membrane/cytoskeletal abnormality and insulin-resistant state, exogenous PIP2 corrected the GlcN-induced insult on these parameters. Moreover, in accordance with HBP flux directly weakening PIP2/F-actin structure, inhibition of the rate-limiting HBP enzyme (glutamine: fructose-6-phosphate amidotransferase) restored PIP2-regulated F-actin structure and insulin responsiveness. Conversely, overexpression of glutamine: fructose-6-phosphate amidotransferase was associated with a loss of detectable plasma membrane PIP2 and insulin sensitivity. A slight decrease in intracellular ATP resulted from amplifying HBP by hyperinsulinemia and GlcN. However, experimental maintenance of the intracellular ATP pool under both conditions with inosine did not reverse the PIP2/F-actin-based insulin-resistant state. Furthermore, less invasive challenges with glucose, in the absence of insulin, also led to PIP2/F-actin dysregulation. Accordingly, we suggest that the functionality of cell systems dependent on PIP2 and/or F-actin status, such as the glucose transport system, can be critically compromised by inappropriate HBP activity. (Endocrinology 150: 1636-1645, 2009)
C1 [Bhonagiri, Padma; Pattar, Guruprasad R.; Horvath, Emily M.; McCarthy, Alicia M.; Elmendorf, Jeffrey S.] Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Ctr Diabet Res, Indianapolis, IN 46202 USA.
   [Habegger, Kirk M.; Elmendorf, Jeffrey S.] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Ctr Diabet Res, Indianapolis, IN 46202 USA.
RP Elmendorf, JS (reprint author), Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Ctr Diabet Res, VanNuys Med Sci Bldg Room 308A, Indianapolis, IN 46202 USA.
EM jelmendo@iupui.edu
FU National Institutes of Health (NIH) Research [R01 AT001846]; National
   Center for Complementary and Alternative Medicine; American Diabetes
   Association Research [7-05-RA-37]; National Center for Complementary and
   Alternative Medicine [F31-AT003977-01]; American Heart Association
   Midwest Affiliation [0615574Z]
FX This work was supported by National Institutes of Health (NIH) Research
   Grant R01 AT001846 (J.S.E.) funded by the National Center for
   Complementary and Alternative Medicine and the NIH Office of Dietary
   Supplements, American Diabetes Association Research Award 7-05-RA-37 (J.
   S. E.), Predoctoral Fellowship F31-AT003977-01 (E. M. H.) funded by the
   National Center for Complementary and Alternative Medicine and the NIH
   Office of Dietary Supplements, and Predoctoral Fellowship 0615574Z (A.
   M. M.) funded by the American Heart Association Midwest Affiliation.
CR Advani A, 2004, EUR J CLIN INVEST, V34, P358, DOI 10.1111/j.1365-2362.2004.01346.x
   Advani A, 2002, DIABETOLOGIA, V45, P719, DOI 10.1007/s00125-002-0802-0
   Birnbaum MJ, 2001, J CLIN INVEST, V108, P655, DOI 10.1172/JCI200113714
   Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164
   Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5
   Buse MG, 2006, AM J PHYSIOL-ENDOC M, V290, pE1, DOI 10.1152/ajpendo.00329.2005
   Cagen LM, 2005, BIOCHEM J, V385, P207, DOI 10.1042/BJ20040162
   Candiloros H, 1996, J CLIN ENDOCR METAB, V81, P2912, DOI 10.1210/jc.81.8.2912
   Chakraborty C, 2006, CURR PROTEIN PEPT SC, V7, P113, DOI 10.2174/138920306776359759
   Chang L, 2004, MOL MED, V10, P65, DOI 10.2119/2005-00029
   Chen GL, 2006, MOL ENDOCRINOL, V20, P857, DOI 10.1210/me.2005-0255
   Chen GL, 2004, J BIOL CHEM, V279, P39705, DOI 10.1074/jbc.C400171200
   Chen GL, 2003, FEBS LETT, V534, P54, DOI 10.1016/S0014-5793(02)03774-2
   Comer FI, 1999, BBA-GEN SUBJECTS, V1473, P161, DOI 10.1016/S0304-4165(99)00176-2
   Cortes P, 2000, KIDNEY INT, V58, P2452, DOI 10.1046/j.1523-1755.2000.00428.x
   Deng X, 2007, J BIOL CHEM, V282, P17517, DOI 10.1074/jbc.M702228200
   Dentin R, 2008, SCIENCE, V319, P1402, DOI 10.1126/science.1151363
   Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222
   Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737
   GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068
   Guillet-Deniau I, 2002, DIABETES, V51, P1722, DOI 10.2337/diabetes.51.6.1722
   HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391
   He AB, 2007, CELL SIGNAL, V19, P1, DOI 10.1016/j.cellsig.2006.05.018
   Heart E, 2000, AM J PHYSIOL-ENDOC M, V278, pE103
   HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157
   Horvath EM, 2008, BIOCHEM BIOPH RES CO, V372, P639, DOI 10.1016/j.bbrc.2008.05.095
   Horvath EM, 2008, MOL ENDOCRINOL, V22, P937, DOI 10.1210/me.2007-0410
   Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658
   Kakuma T, 2000, P NATL ACAD SCI USA, V97, P8536, DOI 10.1073/pnas.97.15.8536
   Kanzaki M, 2006, ENDOCR J, V53, P267, DOI 10.1507/endocrj.KR-65
   Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411
   Kralik SF, 2002, ENDOCRINOLOGY, V143, P37, DOI 10.1210/en.143.1.37
   Kreppel LK, 1997, J BIOL CHEM, V272, P9308
   Lin Y, 2005, J BIOL CHEM, V280, P4617, DOI 10.1074/jbc.M411863200
   Lubas WA, 1997, J BIOL CHEM, V272, P9316
   MARSHALL S, 1991, J BIOL CHEM, V266, P4706
   McCarthy AM, 2006, AM J PHYSIOL-CELL PH, V291, pC860, DOI 10.1182/ajpcell.00107.2006
   Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1
   Nelson BA, 2000, DIABETES, V49, P981, DOI 10.2337/diabetes.49.6.981
   Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453
   Razidlo GL, 2004, J BIOL CHEM, V279, P47808, DOI 10.1074/jbc.M406395200
   Ross SA, 2000, BIOCHEM BIOPH RES CO, V273, P1033, DOI 10.1006/bbrc.2000.3082
   ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981
   Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2
   Santarius M, 2006, BIOCHEM J, V398, P1, DOI 10.1042/BJ20060565
   Sewter C, 2002, DIABETES, V51, P1035, DOI 10.2337/diabetes.51.4.1035
   Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028
   SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143
   STERNEMARR R, 1992, J CELL BIOL, V116, P271, DOI 10.1083/jcb.116.2.271
   Strawbridge AB, 2006, J CELL BIOCHEM, V97, P849, DOI 10.1002/jcb.20687
   Strawbridge AB, 2005, DIABETES, V54, P1698, DOI 10.2337/diabetes.54.6.1698
   Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837
   Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876
   VANPUTTEN JPM, 1985, J BIOL CHEM, V260, P7996
   Virkamaki A, 1999, DIABETES, V48, P1101, DOI 10.2337/diabetes.48.5.1101
   Yang XY, 2008, NATURE, V451, P964, DOI 10.1038/nature06668
   YKIJARVINEN H, 1987, DIABETES, V36, P892, DOI 10.2337/diabetes.36.8.892
   Younsi M, 2002, METABOLISM, V51, P1261, DOI 10.1053/meta.2002.35184
   Yu PK, 2005, CURR EYE RES, V30, P279, DOI 10.1080/02713680590923230
   ZHOU XP, 1995, LAB INVEST, V73, P372
NR 60
TC 7
Z9 8
U1 4
U2 13
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD APR
PY 2009
VL 150
IS 4
BP 1636
EP 1645
DI 10.1210/en.2008-1102
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 422QN
UT WOS:000264442900011
PM 19036880
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Shin, HS
   Park, JK
AF Shin, Ho Sang
   Park, Joong Keun
TI RETRACTED: Degradation of alloy 600 material component in a nuclear
   power plant in Korea (Retracted article. See vol. 17, pg. 1017, 2010)
SO ENGINEERING FAILURE ANALYSIS
LA English
DT Article; Retracted Publication
DE Alloy 600; Degradation
AB Recently some boron deposits were detected on components in the reactor coolant pressure boundary such as drain nozzle immediately below the steam generator (SG #1) and tube plugs of the tube-sheet inside steam generator at an operating Korean nuclear power plant. In this paper, the failure analysis of steam generator tube plugs pulled out from a pressurized water reactor is introduced. To investigate the cause of cracks, micro-structural and fracto-graphic examination were per-formed by optical microscope (OM) and scanning electron microscope (SEM). An elasto-plastic analysis using finite element techniques was also conducted to measure the residual stress applied to failed plugs. Based on these results, it was concluded that the failure mechanism was primary water stress corrosion cracking (PWSCC) and residual stresses remained after plug welding resulted in inter-granular cracking of tube plugs. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Shin, Ho Sang] Korea Inst Nucl Safety, Dept Mat Engn, Taejon 305338, South Korea.
   [Park, Joong Keun] Korea Adv Inst Sci & Technol, Dept Mat Sci & Engn, Taejon 305701, South Korea.
RP Shin, HS (reprint author), Korea Inst Nucl Safety, Dept Mat Engn, 19 Kuseong Dong, Taejon 305338, South Korea.
EM hsshin@kins.re.kr
RI Park, Joong-Keun/C-1799-2011
FU KHNP (Korea Hydro and Nuclear Power Co.)
FX The authors are grateful to the technical support of KAERI (Korea Atomic
   Energy Research Institute) and financial support of KHNP (Korea Hydro
   and Nuclear Power Co.).
CR *KHIC, 1990, T2919 KHIC
   *USNRC, 2005, NRC INF NOT 2005 09
   *USNRC, 2005, NRC INF NOT 2005 02
   *USNRC, 2004, NRC B 2004 01 INSP A
   *USNRC, 2003, NRC B 2003 02 LEAK R
   *USNRC, 2002, NRC B 2002 01 REACT
   *USNRC, 2001, NRC B 2001 01 CIRC C
NR 7
TC 1
Z9 1
U1 4
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-6307
EI 1873-1961
J9 ENG FAIL ANAL
JI Eng. Fail. Anal.
PD APR
PY 2009
VL 16
IS 3
BP 691
EP 698
DI 10.1016/j.engfailanal.2008.05.022
PG 8
WC Engineering, Mechanical; Materials Science, Characterization & Testing
SC Engineering; Materials Science
GA 412FN
UT WOS:000263709700001
DA 2018-12-27
ER

PT J
AU Yidana, SM
AF Yidana, Sandow Mark
TI RETRACTED: The hydrochemical framework of surface water basins in
   southern Ghana (Retracted article. See vol. 69, pg. 1783, 2013)
SO ENVIRONMENTAL GEOLOGY
LA English
DT Article; Retracted Publication
DE Ghana; Weathering; Hierarchical cluster analysis; Factor analysis;
   Sodium adsorption ratio
ID PRINCIPAL-COMPONENTS-ANALYSIS; MULTIVARIATE STATISTICAL-METHODS;
   CLUSTER-ANALYSIS; AQUIFER SYSTEM; GROUNDWATER; SPAIN; EXAMPLE;
   ARGENTINA; QUALITY; FACIES
AB Surface water resources play a crucial role in the domestic water delivery system in Ghana. In addition, sustainable food production is based on the quality and quantity of water resources available for irrigation purposes to supplement rain-fed agricultural activities in the country. The objective of this research was to determine the main controls on the hydrochemistry of surface water resources in the southern part of Ghana and assess the quality of water from these basins for irrigation activities in the area. R-mode factor and cluster analyses were applied to 625 data points from 6 river basins in southern Ghana after the data had been log transformed and standardized for homogeneity. This study finds that surface water chemistry in the south is controlled by the chemistry of silicate mineral weathering, chemistry of rainfall, fertilizers from agricultural activities in the area, as well as the weathering of carbonate minerals. A Gibb's diagram plotted with total dissolved solids (TDS) on the vertical axis against (Na+ + K+)/(Ca2+ + K+ + Na+) on the horizontal axis indicates that rock weathering plays a significant role in the hydrochemistry. Activity diagrams for the CaO-Na2O-Al2O-SiO2-H2O and CaO-MgO-Al2O3-SiO2-H2O systems suggest that kaolinite is the most stable clay mineral phase in the system. In addition, an assessment of the irrigation quality of water from these basins suggests that the basins are largely low sodium-low to medium salinity basins, delivering water of acceptable quality for irrigation purposes.
C1 Montclair State Univ, Dept Earth & Environm Studies, Montclair, NJ 07043 USA.
RP Yidana, SM (reprint author), Montclair State Univ, Dept Earth & Environm Studies, 1 Normal Ave, Montclair, NJ 07043 USA.
EM yidanas1@mail.montclair.edu
CR Adams S, 2001, J HYDROL, V241, P91, DOI 10.1016/S0022-1694(00)00370-X
   Alberto WD, 2001, WATER RES, V35, P2881, DOI 10.1016/S0043-1354(00)00592-3
   Appelo CAJ, 1993, GEOCHEMISTRY GROUNDW
   ASHLEY RP, 1978, J HYDROL, V39, P355, DOI 10.1016/0022-1694(78)90011-2
   BIRKE M, 1993, J GEOCHEM EXPLOR, V49, P35, DOI 10.1016/0375-6742(93)90038-N
   BRIZKISHORE BH, 1992, ENVIRON GEOL WATER S, V19, P3, DOI 10.1007/BF01740571
   Ceron JC, 1999, HYDROLOG SCI J, V44, P929, DOI 10.1080/02626669909492290
   DALTON MG, 1978, GROUND WATER, V16, P228, DOI 10.1111/j.1745-6584.1978.tb03229.x
   Dapaah-Siakwan S, 2000, HYDROGEOL J, V8, P405, DOI 10.1007/PL00010976
   Drever J. I., 1988, GEOCHEMISTRY NATURAL
   GIBBS RJ, 1970, SCIENCE, V170, P1088, DOI 10.1126/science.170.3962.1088
   Grande JA, 1996, GROUND WATER, V34, P155, DOI 10.1111/j.1745-6584.1996.tb01875.x
   Guler C, 2002, HYDROGEOL J, V10, P455, DOI 10.1007/s10040-002-0196-6
   Gyau-Boakye P, 2003, WATER INT, V28, P11, DOI 10.1080/02508060308691660
   Helena B, 2000, WATER RES, V34, P807, DOI 10.1016/S0043-1354(99)00225-0
   HERNANDEZ MA, 1991, WATER SCI TECHNOL, V24, P139
   Huizar R, 1998, HYDROLOG SCI J, V43, P669
   Join JL, 1997, J HYDROL, V190, P1, DOI 10.1016/S0022-1694(96)03070-3
   KAISER HF, 1960, EDUC PSYCHOL MEAS, V20, P141, DOI 10.1177/001316446002000116
   Kelly W. P, 1951, ALKALI SOILS THEIR F
   Liedholz T., 1998, P 4 ANN C INT ASS MA, P298
   Locsey KL, 2003, ENVIRON GEOL, V43, P698, DOI 10.1007/s00254-002-0667-z
   *NDPC, 1998, GHAN VIS 2020 PROGR
   NORTON D, 1974, GEOCHIM COSMOCHIM AC, V38, P267, DOI 10.1016/0016-7037(74)90110-0
   Ochsenkuhn KM, 1997, J HYDROL, V194, P64, DOI 10.1016/S0022-1694(96)03218-0
   Pereira HG, 2003, APPL GEOCHEM, V18, P37
   RAZACK M, 1990, J HYDROL, V114, P371, DOI 10.1016/0022-1694(90)90066-7
   Sanchez-Martos F, 2001, HYDROLOG SCI J, V46, P227, DOI 10.1080/02626660109492818
   SEYHAN E, 1985, WATER RESOUR RES, V21, P1010, DOI 10.1029/WR021i007p01010
   *SPSS INC, 2001, SPSS WIND REL 11 0 1
   STEINHORST RK, 1985, WATER RESOUR RES, V21, P1149, DOI 10.1029/WR021i008p01149
   Suk H, 1999, GROUND WATER, V37, P358, DOI 10.1111/j.1745-6584.1999.tb01112.x
   USSL, 1954, USDA AGR HDB, V60
   USUNOFF EJ, 1989, GROUND WATER, V27, P27, DOI 10.1111/j.1745-6584.1989.tb00004.x
   VANTONDER GJ, 1986, WATER SA, V12, P1
   Wang Y, 2001, J HYDROL, V246, P223, DOI 10.1016/S0022-1694(01)00376-6
NR 36
TC 7
Z9 7
U1 5
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0943-0105
J9 ENVIRON GEOL
JI Environ. Geol.
PD APR
PY 2009
VL 57
IS 4
BP 789
EP 796
DI 10.1007/s00254-008-1357-2
PG 8
WC Environmental Sciences; Geosciences, Multidisciplinary; Water Resources
SC Environmental Sciences & Ecology; Geology; Water Resources
GA 418UE
UT WOS:000264174100006
DA 2018-12-27
ER

PT J
AU Martinez, JC
   Muller, MM
   Turley, H
   Steers, G
   Choteau, L
   Li, JL
   Sainson, R
   Harris, AL
   Pezzella, F
   Gatter, KC
AF Martinez, Juan Carlos
   Mueller, Marcus M.
   Turley, Helen
   Steers, Graham
   Choteau, Ludovine
   Li, Ji-Liang
   Sainson, Richard
   Harris, Adrian L.
   Pezzella, Francesco
   Gatter, Kevin C.
TI RETRACTED: Nuclear and membrane expression of the angiogenesis regulator
   delta-like ligand 4 (DLL4) in normal and malignant human tissues
   (Retracted Article. See vol 55, pg 463, 2009)
SO HISTOPATHOLOGY
LA English
DT Article; Retracted Publication
DE delta-like ligand 4; human tissues; nuclear relocation
ID INHIBITS TUMOR-GROWTH; ELECTROPHORETIC TRANSFER; EMBRYONIC LETHALITY;
   POLYACRYLAMIDE GELS; NOTCH; CANCER; VEGF; ENDOCYTOSIS; RECEPTOR; THERAPY
AB Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues
   Delta-like ligand 4 (DLL4) is one of five known Notch ligands in mammals and interacts predominantly with Notch 1. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. This action was believed to occur only in vascular development, raising hopes that DLL4 could be a specific drug target for controlling vessel growth in tumours and other pathological conditions. Our aim was to pursue this by raising a monoclonal antibody to the internal domain of DLL4 and assess its distribution in normal and malignant tissues in comparison with antibodies against the external domain of DLL4.
   The anti-DLL4 monoclonal antibody was raised using conventional mouse hybridoma techniques. The antibody has been fully characterized by Western blotting and transfectant immunostaining. It has also been comprehensively compared with other antibodies against both the internal and external domains of DLL4. The antigen is widely expressed on human tissues not only on endothelium but also on epithelium and stromal cells. Indeed, in our comprehensive survey only pulmonary alveoli failed to express DLL4. Of a wide range of malignancies, most also expressed DLL4 on tumour cells with a predominantly cytoplasmic pattern, although a number also displayed nuclear positivity.
   Contrary to previous beliefs, DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. These findings raise many interesting possibilities for further study of DLL4 and its potential as a therapeutic target.
C1 [Martinez, Juan Carlos; Mueller, Marcus M.; Turley, Helen; Steers, Graham; Choteau, Ludovine; Pezzella, Francesco; Gatter, Kevin C.] Univ Oxford, CRUK Tumour Pathol Grp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England.
   [Li, Ji-Liang; Sainson, Richard; Harris, Adrian L.] John Radcliffe Hosp, Weatherall Inst Mol Med, CRUK Mol Oncol Labs, Oxford OX3 9DU, England.
RP Gatter, KC (reprint author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Headley Way, Oxford OX3 9DU, England.
EM kevin.gatter@ndcls.ox.ac.uk
OI Harris, Adrian/0000-0003-1376-8409
FU Cancer Research UK; EU; Fundacion de Investigacion Mutua Madrilena,
   Spain
FX Review of and comments on the in situ hybridization studies by
   Professors J. Bernal and Richard Poulsom were greatly appreciated. We
   thank Ms Irene Martinez-Iglesias for her contribution to the graphic
   work. Cancer Research UK, EU 6th Framework Grant Angiotargeting, and
   Fundacion de Investigacion Mutua Madrilena, Spain, supported this study.
CR Benedito R, 2005, GENE EXPR PATTERNS, V5, P750, DOI 10.1016/j.modgep.2005.04.004
   BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910
   Fung E, 2007, CIRCULATION, V115, P2948, DOI 10.1161/CIRCULATIONAHA.107.675462
   Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   Harrington LS, 2008, MICROVASC RES, V75, P144, DOI 10.1016/j.mvr.2007.06.006
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Ilagan Maria Xenia G, 2007, Cell, V128, P1246
   Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4
   Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403
   Kerbel RS, 2001, CANCER METAST REV, V20, P79, DOI 10.1023/A:1013172910858
   Laskin JJ, 2005, ONCOLOGY-NY, V19, P1671
   LASKIN JJ, 2005, ONCOLOGY, V19, P8
   Le Borgne R, 2005, DEVELOPMENT, V132, P1751, DOI 10.1242/dev.01789
   Leslie JD, 2007, DEVELOPMENT, V134, P839, DOI 10.1242/dev.003244
   Li JL, 2007, CANCER RES, V67, P11244, DOI 10.1158/0008-5472.CAN-07-0969
   Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104
   Mazella J, 2008, ENDOCRINOLOGY, V149, P15, DOI 10.1210/en.2007-0477
   Nichols JT, 2007, TRAFFIC, V8, P959, DOI 10.1111/j.1600-0854.2007.00592.x
   Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355
   Parks AL, 2000, DEVELOPMENT, V127, P1373
   Pelkmans L, 2005, NATURE, V436, P78, DOI 10.1038/nature03571
   Polo S, 2006, CELL, V124, P897, DOI 10.1016/j.cell.2006.02.025
   PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783
   Poulsom R, 1998, EUR J HISTOCHEM, V42, P121
   Radtke F, 2005, EMBO REP, V6, P1120, DOI 10.1038/sj.embor.7400585
   Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313
   Sainson RCA, 2007, TRENDS MOL MED, V13, P389, DOI 10.1016/j.molmed.2007.07.002
   Schaller MA, 2007, J EXP MED, V204, P2925, DOI 10.1084/jem.20070661
   Siekmann AF, 2007, NATURE, V445, P781, DOI 10.1038/nature05577
   Suchting S, 2007, P NATL ACAD SCI USA, V104, P3225, DOI 10.1073/pnas.0611177104
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Williams CK, 2006, BLOOD, V107, P931, DOI 10.1182/blood-2005-03-1000
   Yan MH, 2007, CLIN CANCER RES, V13, P7243, DOI 10.1158/1078-0432.CCR-07-1393
NR 39
TC 14
Z9 16
U1 3
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-0167
EI 1365-2559
J9 HISTOPATHOLOGY
JI Histopathology
PD APR
PY 2009
VL 54
IS 5
BP 598
EP 606
DI 10.1111/j.1365-2559.2009.03279.x
PG 9
WC Cell Biology; Pathology
SC Cell Biology; Pathology
GA 431AQ
UT WOS:000265034100009
PM 19413639
DA 2018-12-27
ER

PT J
AU Takeshima, E
   Tomimori, K
   Teruya, H
   Ishikawa, C
   Senba, M
   D'Ambrosio, D
   Kinjo, F
   Mimuro, H
   Sasakawa, C
   Hirayama, T
   Fujita, J
   Mori, N
AF Takeshima, Eriko
   Tomimori, Koh
   Teruya, Hiromitsu
   Ishikawa, Chie
   Senba, Masachika
   D'Ambrosio, Daniele
   Kinjo, Fukunori
   Mimuro, Hitomi
   Sasakawa, Chihiro
   Hirayama, Toshiya
   Fujita, Jiro
   Mori, Naoki
TI RETRACTED: Helicobacter pylori-Induced Interleukin-12 p40 Expression
   (Retracted article. See vol. 79, pg. 546, 2011)
SO INFECTION AND IMMUNITY
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; ACTIVATING TRANSCRIPTION FACTOR-2; GASTRIC EPITHELIAL-CELLS;
   ELEMENT-BINDING PROTEIN; LEUKEMIA-VIRUS TYPE-1; TUMOR-NECROSIS-FACTOR;
   VACUOLATING CYTOTOXIN; PROINFLAMMATORY CYTOKINES; PATHOGENICITY ISLAND;
   SIGNALING PATHWAY
AB Interleukin-12 (IL-12) is a heterodimeric cytokine produced by antigen-presenting cells that promotes the development of T-helper lymphocyte 1 (Th1). Chronic gastritis induced by Helicobacter pylori is considered a Th1-mediated process. IL-12 levels in gastric biopsy samples of H. pylori-infected patients are higher than in those of uninfected individuals, but the cellular source of IL-12 remains elusive. IL-12 staining was detected in mucosal epithelial cells, lymphocytes, and macrophages in specimens of patients with H. pylori-positive gastritis. Therefore, we investigated IL-12 p40 mRNA induction by H. pylori in gastric epithelial cells and T cells. Although cag pathogenicity island (PAI)-positive H. pylori induced IL-12 p40 mRNA expression, an isogenic mutant of the cag PAI failed to induce it in both cell types. Supernatants from H. pylori cultures and H. pylori VacA induced IL-12 p40 mRNA expression in T cells but not in epithelial cells. The activation of the IL-12 p40 promoter by H. pylori was mediated through NF-kappa B. The transfection of I kappa B kinase and NF-kappa B-inducing kinase dominant-negative mutants inhibited H. pylori-induced IL-12 p40 activation. Inhibitors of NF-kappa B, phosphatidylinositol 3-kinase, p38 mitogen-activated protein kinase, and Hsp90 suppressed H. pylori- and VacA-induced IL-12 p40 mRNA expression. The results indicate that H. pylori induces IL-12 p40 expression by the activation of NF-kappa B, phosphatidylinositol 3-kinase, and p38 mitogen-activated protein kinase. Hsp90 is also a crucial regulator of H. pylori- induced IL-12 p40 expression. In addition to the cag PAI, VacA might be relevant in the induction of IL-12 expression and a Th1-polarized response only in T cells.
C1 [Takeshima, Eriko; Tomimori, Koh; Teruya, Hiromitsu; Ishikawa, Chie; Mori, Naoki] Univ Ryukyus, Univ Hosp, Grad Sch Med, Div Mol Virol & Oncol, Okinawa 9030215, Japan.
   [Takeshima, Eriko; Tomimori, Koh; Teruya, Hiromitsu; Fujita, Jiro] Univ Ryukyus, Univ Hosp, Grad Sch Med, Div Control & Prevent Infect Dis, Okinawa 9030215, Japan.
   [Ishikawa, Chie] Univ Ryukyus, Univ Hosp, Fac Med, Div Child Hlth & Welf, Okinawa 9030215, Japan.
   [Kinjo, Fukunori] Univ Ryukyus, Univ Hosp, Dept Endoscopy, Okinawa 9030215, Japan.
   [Senba, Masachika] Nagasaki Univ, Inst Trop Med, Dept Pathol, Nagasaki 8528523, Japan.
   [Hirayama, Toshiya] Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan.
   [Mimuro, Hitomi; Sasakawa, Chihiro] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Tokyo 1088639, Japan.
   [D'Ambrosio, Daniele] BioXell SpA, Milan, Italy.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
FU Japan Society for the Promotion of Science [19591123]; Ministry of
   Education, Culture, Sports, Science and Technology [20012044]; Takeda
   Science Foundation
FX We thank D. W. Ballard for providing the I kappa B alpha and I kappa B
   beta dominant-negative mutants and R. Geleziunas for providing the NIK,
   IKK alpha, and IKK beta dominant-negative mutants.; This study was
   supported in part by grants-in-aid for scientific research (C) 19591123
   to N. M. from the Japan Society for the Promotion of Science; scientific
   research on priority areas 20012044 to N. M. from the Ministry of
   Education, Culture, Sports, Science and Technology; and the Takeda
   Science Foundation.
CR Akopyants NS, 1998, MOL MICROBIOL, V28, P37, DOI 10.1046/j.1365-2958.1998.00770.x
   Baldari CT, 2005, TRENDS IMMUNOL, V26, P199, DOI 10.1016/j.it.2005.01.007
   Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200
   BLASER MJ, 1995, CANCER RES, V55, P2111
   Boncristiano M, 2003, J EXP MED, V198, P1887, DOI 10.1084/jem.20030621
   BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809
   Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705
   BRUNDA MJ, 1994, J LEUKOCYTE BIOL, V55, P280
   Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648
   Chambers KA, 2004, CLIN EXP IMMUNOL, V137, P329, DOI 10.1111/j.1365-2249.2004.02513.x
   Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328
   Cover TL, 2005, NAT REV MICROBIOL, V3, P320, DOI 10.1038/nrmicro1095
   CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7
   D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050
   DElios MM, 1997, J IMMUNOL, V158, P962
   Dobreva ZG, 2008, CYTOKINE, V43, P76, DOI 10.1016/j.cyto.2008.04.003
   Foryst-Ludwig A, 2000, J BIOL CHEM, V275, P39779, DOI 10.1074/jbc.M007617200
   Gebert B, 2003, SCIENCE, V301, P1099, DOI 10.1126/science.1086871
   Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157
   Hisatsune J, 2008, J IMMUNOL, V180, P5017, DOI 10.4049/jimmunol.180.7.5017
   Hisatsune J, 2007, INFECT IMMUN, V75, P4472, DOI 10.1128/IAI.00500-07
   Hocker M, 2003, LANCET, V362, P1231, DOI 10.1016/S0140-6736(03)14547-3
   Houghton J, 2005, GASTROENTEROLOGY, V128, P1567, DOI 10.1053/j.gastro.2005.03.037
   Ito T, 2008, LAB INVEST, V88, P664, DOI 10.1038/labinvest.2008.33
   Jeremias I, 1998, BLOOD, V91, P4624
   Kalia N, 2002, GUT, V51, P641, DOI 10.1136/gut.51.5.641
   Kammanadiminti SJ, 2007, INFECT IMMUN, V75, P1765, DOI 10.1128/IAI.01442-06
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   KARTTUNEN R, 1995, GUT, V36, P341, DOI 10.1136/gut.36.3.341
   Kodama K, 1998, J GASTROENTEROL, V33, P14
   Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177
   Lankford CSR, 2003, J LEUKOCYTE BIOL, V73, P49, DOI 10.1189/jlb.0602326
   Lehmann FS, 2002, AM J PHYSIOL-GASTR L, V283, pG481, DOI 10.1152/ajpgi.00422.2001
   Ma XJ, 1997, J BIOL CHEM, V272, P10389
   Maeda S, 2000, GASTROENTEROLOGY, V119, P97, DOI 10.1053/gast.2000.8540
   Marshall B, 2002, CLIN MED, V2, P147, DOI 10.7861/clinmedicine.2-2-147
   McKinsey TA, 1996, MOL CELL BIOL, V16, P2083
   MCKNIGHT AJ, 1994, J IMMUNOL, V152, P2172
   MENARD R, 1993, J BACTERIOL, V175, P5899
   Montecucco C, 2003, J EXP MED, V198, P1767, DOI 10.1084/jem.20031839
   Mori N, 1999, BLOOD, V93, P2360
   Moss SF, 2003, CURR OPIN INFECT DIS, V16, P445, DOI 10.1097/01.qco.0000092816.64370.e2
   Nakayama M, 2004, J BIOL CHEM, V279, P7024, DOI 10.1074/jbc.M308898200
   NOACH LA, 1994, SCAND J GASTROENTERO, V29, P425, DOI 10.3109/00365529409096833
   PAPADIMITRIOU CS, 1988, VIRCHOWS ARCH A, V413, P197, DOI 10.1007/BF00718611
   Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703
   Pellicano A, 2007, INFECT IMMUN, V75, P1738, DOI 10.1128/IAI.01446-06
   Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096
   Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572
   Robinson K, 2007, BEST PRACT RES CL GA, V21, P237, DOI 10.1016/j.bpg.2007.01.001
   Rudi J, 1998, J CLIN MICROBIOL, V36, P944
   Seto K, 1998, FEBS LETT, V431, P347, DOI 10.1016/S0014-5793(98)00788-1
   Sewald X, 2008, CELL HOST MICROBE, V3, P20, DOI 10.1016/j.chom.2007.11.003
   Sharma SA, 1998, J IMMUNOL, V160, P2401
   Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542
   Supajatura V, 2002, J IMMUNOL, V168, P2603, DOI 10.4049/jimmunol.168.6.2603
   Tomimori K, 2007, INFECT IMMUN, V75, P5223, DOI 10.1128/IAT.00731-07
   Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001
   Tummuru MKR, 1995, MOL MICROBIOL, V18, P867, DOI 10.1111/j.1365-2958.1995.18050867.x
   Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285
   Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866
   Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693
   Yahiro K, 2003, J BIOL CHEM, V278, P19183, DOI 10.1074/jbc.M300117200
   Zandi E, 1999, MOL CELL BIOL, V19, P4547
NR 64
TC 15
Z9 18
U1 3
U2 15
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD APR
PY 2009
VL 77
IS 4
BP 1337
EP 1348
DI 10.1128/IAI.01456-08
PG 12
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 419AM
UT WOS:000264191500008
PM 19179414
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Bulanova, E
   Budagian, V
   Orinska, Z
   Koch-Nolte, F
   Haag, F
   Bulfone-Paus, S
AF Bulanova, Elena
   Budagian, Vadim
   Orinska, Zane
   Koch-Nolte, Friedrich
   Haag, Friedrich
   Bulfone-Paus, Silvia
TI RETRACTED: ATP induces P2X(7) receptor-independent cytokine and
   chemokine expression through P2X(1) and P2X(3) receptors in murine mast
   cells (Retracted Article. See vol 89, pg 489, 2011)
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article; Retracted Publication
DE apoptosis; cell permeabilization; degranulation
ID PHAGOSOME-LYSOSOME FUSION; EXTRACELLULAR ATP; NUCLEOTIDE RECEPTOR;
   DENDRITIC CELLS; MACROPHAGES; ACTIVATION; INDUCTION; RESPONSES; DEATH;
   INFLAMMATION
AB Extracellular ATP mediates a diverse array of biological responses in many cell types and tissues, including immune cells. We have demonstrated that ATP induces purinergic receptor P2X(7) mediated membrane permeabilization, apoptosis, and cytokine expression in murine mast cells (MCs). Here, we report that MCs deficient in the expression of the P2X(7) receptor are resistant to the ATP-induced membrane permeabilization and apoptosis. However, ATP affects the tyrosine phosphorylation pattern of P2X(7) knockout cells, leading to the activation of ERK1/2. Furthermore, ATP induces expression of several cytokines and chemokines in these cells, including IL-4, IL-6, IFN-gamma, TNF-alpha, RANTES, and MIP-2, at the mRNA level. In addition, the release of IL-6 and IL-13 to cell-conditioned medium was confirmed by ELISA. The ligand selectivity and pharmacological profile indicate the involvement of two P2X family receptors, P2X(1) and P2X(3). Thus, depending on genetic background, particular tissue microenvironment, and ATP concentration, MCs can presumably engage different P2X receptor subtypes, which may result in functionally distinct biological responses to extracellular nucleotides. This finding highlights a novel level of complexity in the sophisticated biology of MCs and may facilitate the development of new therapeutic approaches to modulate MC activities. J. Leukoc. Biol. 85: 692-702; 2009.
C1 [Bulanova, Elena; Budagian, Vadim; Orinska, Zane; Bulfone-Paus, Silvia] Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany.
   [Koch-Nolte, Friedrich; Haag, Friedrich] Univ Hamburg, Inst Immunol, Med Ctr Eppendorf, Hamburg, Germany.
RP Bulanova, E (reprint author), Res Ctr Borstel, Dept Immunol & Cell Biol, Parkallee 22, D-23845 Borstel, Germany.
EM ebulanova@fz-borstel.de
OI Koch-Nolte, Friedrich/0000-0003-1730-6674
CR Bankl HC, 2002, THROMB RES, V105, P359, DOI 10.1016/S0049-3848(02)00016-6
   BERGER SA, 1997, IMMUNOLOGY METHODS M, P1436
   Bours MJL, 2006, PHARMACOL THERAPEUT, V112, P358, DOI 10.1016/j.pharmthera.2005.04.013
   Budagian V, 2003, J BIOL CHEM, V278, P1549, DOI 10.1074/jbc.M206383200
   Bulanova E, 2005, J IMMUNOL, V174, P3880, DOI 10.4049/jimmunol.174.7.3880
   Burnstock G, 2007, CELL MOL LIFE SCI, V64, P1471, DOI 10.1007/s00018-007-6497-0
   Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587
   Fairbairn IP, 2001, J IMMUNOL, V167, P3300, DOI 10.4049/jimmunol.167.6.3300
   Falzoni S, 2000, MOL BIOL CELL, V11, P3169, DOI 10.1091/mbc.11.9.3169
   Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8
   Galli SJ, 2008, J DERMATOL SCI, V49, P7, DOI 10.1016/j.jdermsci.2007.09.009
   Gever JR, 2006, PFLUG ARCH EUR J PHY, V452, P513, DOI 10.1007/s00424-006-0070-9
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Harada H, 2000, KIDNEY INT, V57, P949, DOI 10.1046/j.1523-1755.2000.00911.x
   Huff Thomas F., 1997, P1393
   Humphreys BD, 2000, J BIOL CHEM, V275, P26792
   Koles L, 2007, CURR PHARM DESIGN, V13, P2368
   Kusner DJ, 2001, J IMMUNOL, V167, P3308, DOI 10.4049/jimmunol.167.6.3308
   Moller S, 2007, PURINERG SIGNAL, V3, P359, DOI 10.1007/s11302-007-9084-9
   Mutini C, 1999, J IMMUNOL, V163, P1958
   Nakamura H, 1989, Arerugi, V38, P1359
   Nihei OK, 2000, MEM I OSWALDO CRUZ, V95, P415, DOI 10.1590/S0074-02762000000300019
   Nihei OK, 2000, BLOOD, V96, P996
   North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002
   Orinska Z, 2005, BLOOD, V106, P978, DOI 10.1182/blood-2004-07-2656
   OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0
   Pfeiffer ZA, 2004, J LEUKOCYTE BIOL, V75, P1173, DOI 10.1189/jlb.1203648
   SAITO H, 1991, INT ARCH ALLER A IMM, V94, P68, DOI 10.1159/000235327
   Sayed BA, 2008, ANNU REV IMMUNOL, V26, P705, DOI 10.1146/annurev.immunol.26.021607.090320
   Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015
   Schulman ES, 1999, AM J RESP CELL MOL, V20, P530, DOI 10.1165/ajrcmb.20.3.3387
   Stelekati E, 2007, IMMUNOBIOLOGY, V212, P505, DOI 10.1016/j.imbio.2007.03.012
   Sudo N, 1996, J IMMUNOL, V156, P3970
   TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459
   Tsukimoto M, 2006, J IMMUNOL, V177, P2842, DOI 10.4049/jimmunol.177.5.2842
   Valent P, 2002, THROMB HAEMOSTASIS, V87, P786
   Virginio C, 1998, MOL PHARMACOL, V53, P969
   Yamasaki S, 2008, J PHARMACOL SCI, V106, P336, DOI 10.1254/jphs.FM0070251
   ZANOVELLO P, 1990, J IMMUNOL, V145, P1545
NR 39
TC 22
Z9 24
U1 5
U2 14
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD APR 1
PY 2009
VL 85
IS 4
BP 692
EP 702
DI 10.1189/jlb.0808470
PG 11
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 426KX
UT WOS:000264708300011
PM 19164130
DA 2018-12-27
ER

PT J
AU Briones, TL
   Rogozinska, M
   Woods, J
AF Briones, Teresita L.
   Rogozinska, Magdalena
   Woods, Julie
TI RETRACTED: Environmental Experience Modulates Ischemia-Induced
   Amyloidogenesis and Enhances Functional Recovery (Retracted article. See
   vol. 32, pg. 863, 2015)
SO JOURNAL OF NEUROTRAUMA
LA English
DT Article; Retracted Publication
DE A beta oligomers; beta-secretase amyloid cleaving enzyme (BACE);
   enriched environment; learning and memory; water maze
ID AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY
   OCCLUSION; ENRICHMENT IMPROVES COGNITION; DELAYED NEURONAL DEATH;
   TRANSGENIC MICE; BETA PEPTIDE; RAT-BRAIN; IN-VIVO; SYNAPTIC PLASTICITY
AB In this study, we examined whether ischemia-induced amyloidogenesis could be modulated by environmental "experience,'' and whether this modulation is associated with improved cognitive functioning. Rats were subjected to either global ischemia or sham surgery and then were randomly assigned to either enriched environment housing (EE) or socially paired housing (controls). After 14 days of differential environmental housing, the rats were tested in the water maze. Our results show decreased C-terminal fragments of the beta-amyloid precursor protein (beta APP) and decreased amyloid beta (A beta) load in the ischemic EE rats compared to the ischemic control animals. In addition, A beta oligomerization was significantly decreased in the ischemic EE animals compared to the ischemic control rats. Further, significantly increased levels of neprilysin, but not insulin-degrading enzyme, amyloid-degrading enzymes, were seen in the ischemic EE rats compared to the ischemic control animals. Behavioral analyses showed that ischemic EE rats performed significantly better on the memory task compared to the ischemic control group. These results suggest that use of multi-sensory environmental enrichment following cerebral ischemia may reduce the accumulation of A beta peptide in the more pathologic oligomeric form, and consequently may enhance functional recovery.
C1 [Briones, Teresita L.; Rogozinska, Magdalena; Woods, Julie] Univ Illinois, Chicago, IL 60612 USA.
RP Briones, TL (reprint author), Univ Illinois, 845 S Damen Ave,Room 750,M-C 802, Chicago, IL 60612 USA.
EM tbriones@uic.edu
FU National Institutes of Health; NINR [RO1 NR007666]
FX This work was supported by the National Institutes of Health, NINR grant
   no. RO1 NR007666. We are grateful for the assistance of Maggie Wadowska
   in animal handling and tissue imaging. We would also like to thank Mai
   Nguyen for assistance in the analysis of behavioral data.
CR Abramov AY, 2003, J NEUROSCI, V23, P5088
   Apelt J, 1997, INT J DEV NEUROSCI, V15, P95, DOI 10.1016/S0736-5748(96)00073-1
   Arendash GW, 2004, NEUROREPORT, V15, P1751, DOI 10.1097/01.wnr.0000137183.68847.4e
   Badan I, 2004, EUR J NEUROSCI, V19, P2270, DOI 10.1111/j.1460-9568.2004.03323.x
   BANATI RB, 1995, J CEREBR BLOOD F MET, V15, P647, DOI 10.1038/jcbfm.1995.80
   BHATIA P, 1994, ANAL BIOCHEM, V216, P223, DOI 10.1006/abio.1994.1028
   Bouet V, 2007, EXP NEUROL, V203, P555, DOI 10.1016/j.expneurol.2006.09.006
   BOWES MP, 1994, EXP NEUROL, V129, P112, DOI 10.1006/exnr.1994.1152
   Briones T L, 2000, Biol Res Nurs, V1, P299, DOI 10.1177/109980040000100406
   Briones Teresita L, 2005, Biol Res Nurs, V6, P167, DOI 10.1177/1099800404271328
   Briones TL, 2006, BEHAV BRAIN RES, V171, P17, DOI 10.1016/j.bbr.2006.03.011
   Briones TL, 2006, EXP NEUROL, V198, P530, DOI 10.1016/j.expneurol.2005.12.032
   Briones TL, 2006, BEHAV BRAIN RES, V168, P261, DOI 10.1016/j.bbr.2005.11.015
   Briones TL, 2004, BRAIN RES, V1018, P130, DOI 10.1016/j.brainres.2004.06.001
   Briones TL, 2004, BRAIN RES, V997, P137, DOI 10.1016/j.brainres.2003.10.030
   Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041
   Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372
   Costa DA, 2007, NEUROBIOL AGING, V28, P831, DOI 10.1016/j.neurobiolaging.2006.04.009
   Davidson CM, 2000, BRAIN RES, V859, P96, DOI 10.1016/S0006-8993(00)01937-5
   ESCORIHUELA RM, 1995, NEUROBIOL LEARN MEM, V64, P49, DOI 10.1006/nlme.1995.1043
   Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100
   Fu WM, 2002, J NEUROSCI, V22, P10710
   Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011
   GREENOUGH WT, 1973, EXP NEUROL, V40, P491, DOI 10.1016/0014-4886(73)90090-3
   Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5
   Huber G, 1997, NEUROSCIENCE, V80, P313, DOI 10.1016/S0306-4522(97)00120-6
   Ishimaru H, 1996, NEUROREPORT, V7, P3063, DOI 10.1097/00001756-199611250-00054
   Iwata N, 2004, J NEUROSCI, V24, P991, DOI 10.1523/JNEUROSCI.4792-03.2004
   Jankowsky JL, 2005, J NEUROSCI, V25, P5217, DOI 10.1523/JNEUROSCI.5080-04.2005
   Jankowsky JL, 2003, J NEUROPATH EXP NEUR, V62, P1220, DOI 10.1093/jnen/62.12.1220
   JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E
   KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025
   KALARIA RN, 1993, ANN NY ACAD SCI, V695, P190, DOI 10.1111/j.1749-6632.1993.tb23050.x
   Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7
   Kanemitsu H, 2003, NEUROSCI LETT, V350, P113, DOI 10.1016/S0304-3940(03)00898-X
   Kim HS, 1998, NEUROREPORT, V9, P533
   Kirino T, 2000, NEUROPATHOLOGY, V20, pS95
   Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234
   Kobayashi S, 2002, J NEUROSCI RES, V70, P340, DOI 10.1002/jnr.10442
   Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015
   Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009
   Marr RA, 2003, J NEUROSCI, V23, P1992
   Mattson MP, 1997, PHYSIOL REV, V77, P1081
   Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683
   Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100
   Mouri A, 2006, BEHAV BRAIN RES, V168, P83, DOI 10.1016/j.bbr.2005.10.014
   Nihashi T, 2001, ACTA NEUROCHIR, V143, P287, DOI 10.1007/s007010170109
   Paganelli RA, 2004, J NEUROSCI METH, V132, P9, DOI 10.1016/j.jneumeth.2003.08.012
   Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623
   Perry G, 2002, FREE RADICAL BIO MED, V33, P1475, DOI 10.1016/S0891-5849(02)01113-9
   Pham TM, 1999, NEUROSCIENCE, V94, P279, DOI 10.1016/S0306-4522(99)00316-4
   Pluta R, 2002, ANN NY ACAD SCI, V977, P102, DOI 10.1111/j.1749-6632.2002.tb04803.x
   Popa-Wagner A, 1998, STROKE, V29, P2196, DOI 10.1161/01.STR.29.10.2196
   Puurunen K, 2001, EXP NEUROL, V167, P348, DOI 10.1006/exnr.2000.7563
   Puurunen K, 1997, STROKE, V28, P623, DOI 10.1161/01.STR.28.3.623
   Qiao XX, 2001, EUR J NEUROSCI, V14, P474, DOI 10.1046/j.0953-816x.2001.01666.x
   Schrijver NCA, 2004, BEHAV BRAIN RES, V152, P307, DOI 10.1016/j.bbr.2003.10.006
   Selkoe DJ, 1996, ANN NY ACAD SCI, V777, P57, DOI 10.1111/j.1749-6632.1996.tb34401.x
   Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072
   SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781
   Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7
   VAN PH, 2000, NAT REV NEUROSCI, V1, P191
   Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009
   Wahl AS, 2009, NEUROSCIENCE, V158, P344, DOI 10.1016/j.neuroscience.2008.06.018
   Wang J, 2003, NEUROBIOL DIS, V14, P318, DOI 10.1016/j.nbd.2003.08.009
   Wen Y, 2004, BRAIN RES, V1009, P1, DOI 10.1016/j.brainres.2003.09.086
   WEST RW, 1972, BEHAV BIOL, V7, P279, DOI 10.1016/S0091-6773(72)80207-4
   Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4
   Yi JS, 2007, NEUROBIOL DIS, V26, P94, DOI 10.1016/j.nbd.2006.12.007
NR 69
TC 23
Z9 24
U1 4
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
EI 1557-9042
J9 J NEUROTRAUM
JI J. Neurotrauma
PD APR
PY 2009
VL 26
IS 4
BP 613
EP 625
DI 10.1089/neu.2008.0707
PG 13
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 430OV
UT WOS:000264999300012
PM 19271963
OA Green Published
DA 2018-12-27
ER

PT J
AU Ueda, K
   Tsuji, F
   Hirata, T
   Ueda, K
   Murai, M
   Aono, H
   Takaoka, M
   Matsumura, Y
AF Ueda, Kyoko
   Tsuji, Fumio
   Hirata, Tomoko
   Ueda, Kenji
   Murai, Masaaki
   Aono, Hiroyuki
   Takaoka, Masanori
   Matsumura, Yasuo
TI RETRACTED: Preventive Effect of SA13353
   [1-[2-(1-Adamantyl)ethyl]-1-entyl-3-[3-(4-pyridyl)propyl]urea], a Novel
   Transient Receptor Potential Vanilloid 1 Agonist, on
   Ischemia/Reperfusion-Induced Renal Injury in Rats (Retracted article.
   See vol. 349, pg. 346, 2014)
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article; Retracted Publication
ID GENE-RELATED PEPTIDE; TNF-ALPHA PRODUCTION; CAPSAICIN RECEPTOR; CELL
   INJURY; IN-VIVO; TRPV1; FAILURE; RESINIFERATOXIN; INFLAMMATION; CHANNELS
AB Tumor necrosis factor (TNF)-alpha plays a crucial role in the pathogenesis of ischemia/reperfusion-induced renal injury. We demonstrated recently that the preischemic treatment with resiniferatoxin, a transient receptor potential vanilloid 1 (TRPV1) agonist, attenuates renal TNF-alpha mRNA expression and improves ischemia/reperfusion-induced renal injury in rats. In addition, we found that SA13353 [ 1-[2-(1-adamantyl)ethyl]-1-pentyl--[3-(4-pyridyl)propyl]urea], a novel orally active TRPV1 agonist, inhibits TNF-alpha production through the activation of capsaicin-sensitive afferent neurons and reduces the severity of symptoms in established rat collagen-induced arthritis. In the present study, we investigated effects of treatment with SA13353 on ischemia/reperfusion-induced renal injury in rats. Ischemic acute kidney injury (AKI) was induced by occlusion of the left renal artery and vein for 45 min followed by reperfusion, 2 weeks after contralateral nephrectomy. Renal function in vehicle-treated AKI rats markedly decreased at 24 h after reperfusion. Treatment with SA13353 (3, 10, and 30 mg/kg p. o.) 30 min before ischemia dose-dependently attenuated the ischemia/reperfusion- induced renal dysfunction. Histopathological examination of the kidney of AKI rats revealed severe renal damage, which were significantly suppressed by the SA13353 treatment. In renal tissues exposed to ischemia/reperfusion, neutrophil infiltration, superoxide production, TNF-alpha mRNA expression, and cytokine-induced neutrophil chemoattractant-1 mRNA expression were augmented, but these alterations were attenuated by the treatment with SA13353. On the other hand, ischemia/reperfusion-enhanced renal interleukin-10 mRNA expression and its plasma concentration were further augmented by SA13353 treatment. These results demonstrate that the orally active TRPV1 agonist SA13353 prevents the ischemia/ reperfusion-induced AKI. This renoprotective effects seem to be closely related to the inhibition of inflammatory response via TRPV1 activation.
C1 [Ueda, Kyoko; Hirata, Tomoko; Takaoka, Masanori; Matsumura, Yasuo] Osaka Univ Pharmaceut Sci, Lab Pathol & Mol Pharmacol, Osaka 5691094, Japan.
   [Tsuji, Fumio; Ueda, Kenji; Murai, Masaaki; Aono, Hiroyuki] Santen Pharmaceut Co Ltd, Ctr Res & Dev, Nara, Japan.
RP Matsumura, Y (reprint author), Osaka Univ Pharmaceut Sci, Lab Pathol & Mol Pharmacol, 4-20-1 Nasahara, Osaka 5691094, Japan.
EM matumrh@gly.oups.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology
FX This work was supported in part by the Ministry of Education, Culture,
   Sports, Science and Technology ("High-Tech Research Center" Project for
   Private Universities, matching fund subsidy from 2007 to 2009).
CR Brady H, 2000, BRENNER RECTORS KIDN, P1201
   BUCK SH, 1986, PHARMACOL REV, V38, P179
   Caterina MJ, 1997, NATURE, V389, P816
   Clark N, 2007, FASEB J, V21, P3747, DOI 10.1096/fj.06-7460com
   Demirbilek S, 2004, ANESTH ANALG, V99, P1501, DOI 10.1213/01.ANE.0000132975.02854.65
   Deng JP, 2001, KIDNEY INT, V60, P2118, DOI 10.1046/j.1523-1755.2001.00043.x
   DEVRIES JE, 1995, ANN MED, V27, P537, DOI 10.3109/07853899509002465
   Docherty RJ, 1997, BRIT J PHARMACOL, V121, P1461, DOI 10.1038/sj.bjp.0701272
   Donnahoo KK, 1999, AM J PHYSIOL-REG I, V277, pR922
   Dux M, 2003, J PHYSIOL-LONDON, V552, P859, DOI 10.1113/physiol.2003.050633
   Edelstein CL, 1997, KIDNEY INT, V51, P1341, DOI 10.1038/ki.1997.183
   Feng NH, 2008, AM J PHYSIOL-RENAL, V294, pF316, DOI 10.1152/ajprenal.00308.2007
   Feng Y, 1997, LIFE SCI, V61, pPL281, DOI 10.1016/S0024-3205(97)00866-7
   Gomes RN, 2005, SHOCK, V24, P590, DOI 10.1097/01.shk.0000183395.29014.7c
   Harzenetter MD, 2007, J IMMUNOL, V179, P607, DOI 10.4049/jimmunol.179.1.607
   Helyes Z, 2007, AM J PHYSIOL-LUNG C, V292, pL1173, DOI 10.1152/ajplung.00406.2006
   HIROTA M, 1990, ARCH BIOCHEM BIOPHYS, V280, P269, DOI 10.1016/0003-9861(90)90329-W
   Keeble J, 2005, ARTHRITIS RHEUM, V52, P3248, DOI 10.1002/art.21297
   Kelly KJ, 2000, SEMIN NEPHROL, V20, P4
   Kissin EY, 2005, ANESTH ANALG, V101, P1433, DOI 10.1213/01.ANE.0000180998.29890.B0
   LANDA JI, 1995, RES EXP MED, V195, P317, DOI 10.1007/BF02576802
   Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477
   LINAS SL, 1992, KIDNEY INT, V42, P610, DOI 10.1038/ki.1992.325
   Liu L, 1997, NEUROSCI LETT, V228, P29, DOI 10.1016/S0304-3940(97)00358-3
   Marquez-Rodas I, 2006, J PHYSIOL BIOCHEM, V62, P45, DOI 10.1007/BF03165805
   Murai M, 2008, EUR J PHARMACOL, V588, P309, DOI 10.1016/j.ejphar.2008.04.037
   Nagy I, 2004, EUR J PHARMACOL, V500, P351, DOI 10.1016/j.ejphar.2004.07.037
   Nakajima A, 2006, J PHARMACOL EXP THER, V316, P1038, DOI 10.1124/jpet.105.092049
   Ramesh G, 2004, KIDNEY INT, V66, pS56, DOI 10.1111/j.1523-1755.2004.09109.x
   Saito Akemi, 1996, Journal of Toxicological Sciences, V21, P195
   Seabrook GR, 2002, J PHARMACOL EXP THER, V303, P1052, DOI 10.1124/jpet.102.040394
   SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0
   Szabo A, 2005, J PHARMACOL EXP THER, V314, P111, DOI 10.1124/jpet.104.082487
   Ueda K, 2008, J CARDIOVASC PHARM, V51, P513, DOI 10.1097/FJC.0b013e31816f6884
   van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x
   Venkataraman R, 2003, EXPERT OPIN INV DRUG, V12, P1353, DOI 10.1517/eoid.12.8.1353.21778
   Wang DH, 2005, ACTA PHARMACOL SIN, V26, P286, DOI 10.1111/j.1745-7254.2005.00057.x
   Wang LH, 2005, CIRCULATION, V112, P3617, DOI 10.1161/CIRCULATIONAHA.105.556274
   WATANABE K, 1992, EXP MOL PATHOL, V56, P60, DOI 10.1016/0014-4800(92)90023-5
   WEISS SJ, 1989, NEW ENGL J MED, V320, P365
NR 40
TC 22
Z9 22
U1 3
U2 8
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD APR
PY 2009
VL 329
IS 1
BP 202
EP 209
DI 10.1124/jpet.108.146241
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 426KW
UT WOS:000264708200022
PM 19147859
OA Bronze
DA 2018-12-27
ER

PT J
AU Ahmadian, MT
   Borhan, H
   Esmailzadeh, E
AF Ahmadian, M. T.
   Borhan, H.
   Esmailzadeh, E.
TI RETRACTED: Corotational Nonlinear Finite Element Formulation and
   Modeling of Electrostatically Actuated Microbeams (Retracted article.
   See vol. 17, pg. 159, 2011)
SO JOURNAL OF VIBRATION AND CONTROL
LA English
DT Article; Retracted Publication
DE Microbeam; electrostatic actuation; geometric nonlinearity; large
   deformation; dynamic modeling
ID PULL-IN VOLTAGE; MEMS; SIMULATION; DESIGN; BEAM; MICROSTRUCTURES;
   PERFORMANCE; RESONATORS; CAPACITOR; GRADIENT
AB A complete nonlinear finite element model for coupled-domain microelectromechanical system devices with electrostatic actuation and squeeze film effect was developed. for this purpose, a corotational finite element formulation for the dynamic analysis of planer Euler-Bernoulli microbeams considering geometrical nonlinearities due to both large structural deformation and electrostatic actuation is developed. In this method, the internal forces due to deformation and residual stresses, the elemental inertias, and the damping effect of the squeeze-film are systematically derived by consistent linearization of the fully geometrically nonlinear beam theory using d'Alembert and the virtual work principles. An incremental-iterative method based on the Newmark direct integration procedure and the Newton-Raphson algorithm is used to solve the nonlinear dynamic equilibrium equations. Several numerical examples are presented and their results are compared with those found experimentally, which indicate a very close agreement.
C1 [Ahmadian, M. T.; Borhan, H.] Sharif Univ Technol, Sch Mech Engn, Ctr Excellence Design Robot & Automat, Tehran, Iran.
   [Esmailzadeh, E.] Univ Ontario, Inst Technol, Fac Engn & Appl Sci, Oshawa, ON L1H 7K4, Canada.
RP Ahmadian, MT (reprint author), Sharif Univ Technol, Sch Mech Engn, Ctr Excellence Design Robot & Automat, POB 113659567, Tehran, Iran.
EM ezadeh@uoit.ca
CR Abdel-Rahman EM, 2002, J MICROMECH MICROENG, V12, P759, DOI 10.1088/0960-1317/12/6/306
   Ahn Y, 2001, J MICROMECH MICROENG, V11, P70, DOI 10.1088/0960-1317/11/1/311
   Bao MH, 2003, SENSOR ACTUAT A-PHYS, V108, P212, DOI 10.1016/S0924-4247(03)00263-2
   Bathe K. J, 1995, FINITE ELEMENT PROCE
   Belytschko T., 1973, International Journal for Numerical Methods in Engineering, V7, P255, DOI 10.1002/nme.1620070304
   BORHAN H, 2006, P 3 AUS INT S MECH A
   BORHAN H, 2006, P INT MEMS C SING MA
   Chowdhury S, 2005, J MICROMECH MICROENG, V15, P756, DOI 10.1088/0960-1317/15/4/012
   Crisfield M. A., 1997, ADV TOPICS, V2
   Fang W, 1996, J MICROMECH MICROENG, V6, P301, DOI 10.1088/0960-1317/6/3/002
   Felippa CA, 2005, COMPUT METHOD APPL M, V194, P2285, DOI 10.1016/j.cma.2004.07.035
   FLORES G, 2003, P IDETC CIE 19 ASME
   GUPTA RK, 1996, SPIE C MICR MICR AUS
   HORRIGMOE G, 1978, COMPUT METHOD APPL M, V16, P11, DOI 10.1016/0045-7825(78)90030-0
   HSIAO KM, 1994, INT J NUMER METH ENG, V37, P75, DOI 10.1002/nme.1620370106
   HSIAO KM, 1990, COMPUT STRUCT, V33, P1057
   Hu YC, 2004, SENSOR ACTUAT A-PHYS, V112, P155, DOI 10.1016/j.sna.2003.12.012
   Huang JM, 2001, SENSOR ACTUAT A-PHYS, V93, P273, DOI 10.1016/S0924-4247(01)00662-8
   Hung ES, 1999, J MICROELECTROMECH S, V8, P280, DOI 10.1109/84.788632
   IJNTEMA DJ, 1992, SENSOR ACTUAT A-PHYS, V35, P121, DOI 10.1016/0924-4247(92)80150-2
   JENSEN BD, 1999, P MSM 99 SAN JUAN PU
   Ko WH, 1999, SENSOR ACTUAT A-PHYS, V75, P242, DOI 10.1016/S0924-4247(99)00069-2
   Krylov S, 2004, J VIB ACOUST, V126, P332, DOI 10.1115/1.1760559
   Liang YC, 2001, J MICROMECH MICROENG, V11, P226, DOI 10.1088/0960-1317/11/3/311
   Lishchynska M, 2005, J MICROMECH MICROENG, V15, pS10, DOI 10.1088/0960-1317/15/7/002
   MAHONY CO, 2003, J MICROMECH MICROENG, V13, pS75
   McCarthy B, 2002, J MICROELECTROMECH S, V11, P276, DOI 10.1109/JMEMS.2002.1007406
   Nayfeh AH, 2005, NONLINEAR DYNAM, V41, P211, DOI 10.1007/s11071-005-2809-9
   Nayfeh AH, 2004, J MICROMECH MICROENG, V14, P170, DOI 10.1088/0960-1317/14/2/002
   Nayfeh AH, 2007, NONLINEAR DYNAM, V48, P153, DOI 10.1007/s11071-006-9079-z
   NOUROMID B, 1991, COMPUT METHOD APPL M, V93, P353, DOI 10.1016/0045-7825(91)90248-5
   NYGARD MK, 1984, STATET OF ART SURVEY, P305
   Olszewski Z, 2005, J MICROMECH MICROENG, V15, pS122, DOI 10.1088/0960-1317/15/7/018
   Osterberg P. M., 1995, THESIS MIT
   OZDOGANLAR OB, 2003, J EXPT MECH, V45, P498
   Pamidighantam S, 2002, J MICROMECH MICROENG, V12, P458, DOI 10.1088/0960-1317/12/4/319
   Pruessner MW, 2003, SENSOR ACTUAT A-PHYS, V105, P190, DOI 10.1016/S0924-4247(03)00102-X
   Senturia S.D., 2001, MICROSYSTEMS DESIGN
   Seshia AA, 2002, J MICROELECTROMECH S, V11, P784, DOI 10.1109/JMEMS.2002.805207
   TILMANS HAC, 1994, SENSOR ACTUAT A-PHYS, V45, P67, DOI 10.1016/0924-4247(94)00813-2
   VANDERMEIJS NP, 1984, INTEGRATION, V2, P85, DOI 10.1016/0167-9260(84)90016-6
   Wempner G., 1969, International Journal of Solids and Structures, V5, P117, DOI 10.1016/0020-7683(69)90025-0
   Younis MI, 2003, J MICROELECTROMECH S, V12, P672, DOI 10.1109/JMEMS.2003.818069
   ZOOK JD, 1992, SENSOR ACTUAT A-PHYS, V35, P51, DOI 10.1016/0924-4247(92)87007-4
NR 44
TC 7
Z9 7
U1 6
U2 14
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1077-5463
EI 1741-2986
J9 J VIB CONTROL
JI J. Vib. Control
PD APR
PY 2009
VL 15
IS 4
BP 617
EP 640
DI 10.1177/1077546308091210
PG 24
WC Acoustics; Engineering, Mechanical; Mechanics
SC Acoustics; Engineering; Mechanics
GA 419YC
UT WOS:000264254600008
DA 2018-12-27
ER

PT J
AU Han, CS
   Chun, CH
   Han, SO
AF Han, Chang-Suk
   Chun, Chang-Hwan
   Han, Seung-Oh
TI RETRACTED: The Behavior of alpha-Cr Precipitation on the High
   Temperature Deformation of B2-Ordered NiAl (Retracted article. See vol.
   21, pg. 611, 2015)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE nickel aluminides; age-hardening; cube-cube orientation relationship;
   spherical precipitate
ID MICROSTRUCTURE; CRYSTALS; CHROMIUM; ATOMS; CREEP; NI3AL; FE
AB Transmission electron microscope investigation has been performed concerning the effect of Cr-precipitation on the mechanical properties of B2-ordered NiAl containing 4 mol.% to 8 mol.% of Cr. By aging at temperatures around 973 K after solution annealing, fine spherical precipitates appeared homogeneously in the NiAl matrix and the alloys hardened appreciably. The selected area electron diffraction patterns have not revealed any additional extra-spots during aging, because the Cr-particles have a cube-cube orientation relationship and keep perfect coherency with the ordered matrix lattice. Dislocations bypass the particles during deformation. Although the dispersion of Cr-particles increases the yield strength of NiAl at intermediate temperature, the strength decreases appreciably at higher temperatures. Atom location by channeling enhanced microanalysis technique has been used to determine the Site Occupancy of Cr in NiAl.
C1 [Han, Chang-Suk; Chun, Chang-Hwan] Hoseo Univ, Dept Def Sci & Technol, Asan 336795, Chungnam, South Korea.
   [Han, Seung-Oh] Hoseo Univ, Res Ctr Convergence Technol, Asan 336795, Chungnam, South Korea.
RP Han, CS (reprint author), Hoseo Univ, Dept Def Sci & Technol, 165 Sechul Ri, Asan 336795, Chungnam, South Korea.
EM hancs@hoseo.edu
CR ARDELL AJ, 1985, METALL TRANS A, V16, P2131, DOI 10.1007/BF02670416
   Arzt E, 1998, ACTA MATER, V46, P2717, DOI 10.1016/S1359-6454(97)00474-6
   CLINE HE, 1971, ACTA METALL MATER, V19, P405, DOI 10.1016/0001-6160(71)90163-5
   FIELD RD, 1991, ACTA METALL MATER, V39, P2961, DOI 10.1016/0956-7151(91)90028-Y
   Frommeyer G, 2004, ULTRAMICROSCOPY, V101, P139, DOI 10.1016/j.ultramic.2004.05.006
   Ghosh B, 1997, MAT SCI ENG A-STRUCT, V240, P142, DOI 10.1016/S0921-5093(97)00573-X
   Guo JT, 2003, COMPOS STRUCT, V62, P323, DOI 10.1016/j.compstruct.2003.09.031
   Guo JT, 2002, J ALLOY COMPD, V343, P142, DOI 10.1016/S0925-8388(02)00205-0
   Han CS, 2007, MET MATER INT, V13, P31, DOI 10.1007/BF03027820
   HIPPSLEY CA, 1990, ACTA METALL MATER, V38, P2393, DOI 10.1016/0956-7151(90)90252-C
   HONG T, 1989, MATER RES SOC S P, V133, P573
   MIRACLE DB, 1989, MATER RES SOC SYMP P, V133, P225
   NAKATA Y, 1993, B JAPAN I MET, V32, P858
   PASCOE RT, 1968, METAL SCI J, V2, P138
   Raj SV, 2003, MAT SCI ENG A-STRUCT, V356, P283, DOI 10.1016/S0921-5093(03)00137-0
   ROGL P, 1991, TERNARY ALLOYS, V4, P400
   SHINDO D, 1988, T JPN I MET, V29, P956, DOI 10.2320/matertrans1960.29.956
   SPENCE JCH, 1983, J MICROSC-OXFORD, V130, P147, DOI 10.1111/j.1365-2818.1983.tb04213.x
   WALTER JL, 1969, T METALL SOC AIME, V245, P2073
   YAMAGUCHI M, 1990, PROG MATER SCI, V34, P1, DOI 10.1016/0079-6425(90)90002-Q
   YANG R, 1992, PHILOS MAG A, V65, P961, DOI 10.1080/01418619208205600
NR 21
TC 1
Z9 1
U1 4
U2 14
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD APR
PY 2009
VL 15
IS 2
BP 231
EP 238
DI 10.1007/s12540-009-0231-4
PG 8
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 443JI
UT WOS:000265905600011
DA 2018-12-27
ER

PT J
AU Hwang, CH
AF Hwang, Chang Ho
TI RETRACTED: The sequential magnetic resonance images of tri-methyl tin
   leukoencephalopathy (Retracted article. See vol. 33, pg. 717, 2012)
SO NEUROLOGICAL SCIENCES
LA English
DT Article; Retracted Publication
DE Intoxication; Tin; Magnetic resonance imaging; Leukoencephalopathy
ID TRIMETHYLTIN COMPOUNDS; TOXICOLOGY; TOXICITY
AB Organotin compounds are commonly used in industrial and agriculture. It causes toxic effects on skin, eyes, respiratory system, gastrointestinal system, and nervous system. After cleaning a di-methyl tin tank, 43-year-old man showed a dizziness, disorientation, visual hallucination, and agitation. Through a measurement by liquid chromatography and inductively coupled plasma-mass spectrometry, di-methyl tin and tri-methyl tin was detected. Although magnetic resonance (MR) image 3 days after exposure showed no abnormal signal intensity, follow-up MR images 15 days after exposure revealed abnormal extensive signal intensities in the white matter that was not ever coincident with previous reports. It was hardly explainable that previous abnormal signal intensities of MR image nearly disappeared 4 months later. We present a case of a patient who developed acute toxic leukoencephalopathy from an acute inhalational exposure to methyl tin with sequential MR images showing an involvement of white matter that was not ever reported.
C1 Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Phys Med & Rehabil, Ulsan 682714, South Korea.
RP Hwang, CH (reprint author), Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Phys Med & Rehabil, 290-3 Jeonha Dong, Ulsan 682714, South Korea.
EM chhwang1220ciba@yahoo.co.kr
CR ALDRIDGE WN, 1981, LANCET, V2, P692
   BARNES JM, 1959, PHARMACOL REV, V11, P211
   BESSER R, 1987, NEUROLOGY, V37, P945, DOI 10.1212/WNL.37.6.945
   BOULDIN TW, 1981, AM J PATHOL, V104, P237
   BROWN AW, 1979, AM J PATHOL, V97, P59
   BROWN AW, 1984, J APPL TOXICOL, V4, P12, DOI 10.1002/jat.2550040104
   Chang L W, 1990, J Toxicol Sci, V15 Suppl 4, P125
   EBISU T, 1993, JMRI-J MAGN RESON IM, V3, P863, DOI 10.1002/jmri.1880030612
   FELDMAN RG, 1993, ARCH NEUROL-CHICAGO, V50, P1320, DOI 10.1001/archneur.1993.00540120035010
   FORTEMPS E, 1978, INT ARCH OCC ENV HEA, V41, P1, DOI 10.1007/BF00377794
   GRUNNER J, 1958, REV NEUROL PARIS, V98, P106
   Jiang GB, 2000, B ENVIRON CONTAM TOX, V65, P277, DOI 10.1007/s001280000125
   KREYBERG S, 1992, CLIN NEUROPATHOL, V11, P256
   KRIGMAN MR, 1984, NEUROTOXICOLOGY, V5, P129
   Perretta G, 1993, Ann Ist Super Sanita, V29, P167
   PIVER W T, 1973, Environmental Health Perspectives, V4, P61, DOI 10.2307/3428183
   REITER LW, 1984, NEUROTOXICOLOGY, V5, P177
   YANOFSKY N N, 1991, Journal of Emergency Medicine, V9, P137, DOI 10.1016/0736-4679(91)90319-B
NR 18
TC 4
Z9 4
U1 2
U2 10
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1590-1874
EI 1590-3478
J9 NEUROL SCI
JI Neurol. Sci.
PD APR
PY 2009
VL 30
IS 2
BP 153
EP 158
DI 10.1007/s10072-009-0028-8
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 425FU
UT WOS:000264623200012
PM 19189042
DA 2018-12-27
ER

PT J
AU Balan, S
   Vrat, P
   Kumar, P
AF Balan, S.
   Vrat, Prem
   Kumar, Pradeep
TI RETRACTED: Information distortion in a supply chain and its mitigation
   using soft computing approach (Retracted article. See vol. 40, pg. 502,
   2012)
SO OMEGA-INTERNATIONAL JOURNAL OF MANAGEMENT SCIENCE
LA English
DT Article; Retracted Publication
DE supply chain management; bullwhip effect; neuro-fuzzy; SISO model; soft
   computing
ID FUZZY-SETS; BULLWHIP; IMPACT; INVENTORIES; CONTROLLER; SELECTION; SYSTEM
AB The information transferred in the form of orders between the nodes of a supply chain tends to be distorted when it moves from downstream to upstream. This phenomenon is called as bullwhip effect and this research is aimed to analyzed this effect deeply in a single input single output (SISO) model. A discrete time series SISO model is developed for the analysis and it Proves to very useful in revealing the dynamics characteristics of the system. The bullwhip effect is measured from the transfer function model and the effect call be reduced by applying soft computing approach. A detailed sensitivity analysis is carried out to investigate the behavior of the model under various conditions. The applied fuzzy logic theory controls the errors and change in errors associated with forecasted demand between the nodes of a supply chain and it allows a smooth information flow in the chain. Tuning of fuzzy logic controller has been performed using adaptive neuro-fuzzy inference system (ANFIS). The method is illustrated with a numerical example. The application of soft computing approach addresses the real situation of human judgment with fuzziness helps the managers to forecast the demand with less distortion and to improve the supply chain effectiveness. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Balan, S.] Natl Inst Technol, Dept Prod Engn, Tiruchchirappalli 620015, Tamil Nadu, India.
   [Vrat, Prem] Indian Inst Technol, Dept Mech Engn, New Delhi 110016, India.
   [Kumar, Pradeep] Indian Inst Technol, Dept Mech & Ind Engn, Roorkee 247667, Uttar Pradesh, India.
RP Balan, S (reprint author), Natl Inst Technol, Dept Prod Engn, Tiruchchirappalli 620015, Tamil Nadu, India.
EM balan@nitt.edu; pvrat@mech.iitd.ac.in; kumarfme@iitr.ernet.in
CR BLINDER AS, 1982, AM ECON REV, V72, P334
   CAPLIN AS, 1985, ECONOMETRICA, V53, P1395, DOI 10.2307/1913214
   CARLSON TD, 2002, J FAMILY PSYCHOTHERA, V13, P1, DOI DOI 10.1300/J085V13N01_01
   Chan FTS, 2007, OMEGA-INT J MANAGE S, V35, P417, DOI 10.1016/j.omega.2005.08.004
   Chen F, 2000, MANAGE SCI, V46, P436, DOI 10.1287/mnsc.46.3.436.12069
   Chen F, 2000, NAV RES LOG, V47, P269
   CULLEN P, 2002, SUPPLY CHAIN MANAG, V7, P164
   Dejonckheere J, 2003, EUR J OPER RES, V147, P567, DOI 10.1016/S0377-2217(02)00369-7
   Disney SM, 2003, OMEGA-INT J MANAGE S, V31, P157, DOI 10.1016/S0305-0483(03)00028-8
   Fiala P, 2005, OMEGA-INT J MANAGE S, V33, P419, DOI 10.1016/j.omega.2004.07.006
   Forrester J. W., 1961, IND DYNAMICS
   Graves S. C., 1999, Manufacturing & Service Operations Management, V1, P50, DOI 10.1287/msom.1.1.50
   Hosoda T, 2006, OMEGA-INT J MANAGE S, V34, P344, DOI 10.1016/j.omega.2004.11.005
   JOSE AD, 2004, TRANSPORT RES E-LOG, V40, P209
   KAHN JA, 1987, AM ECON REV, V77, P667
   Kongar E, 2006, OMEGA-INT J MANAGE S, V34, P550, DOI 10.1016/j.omega.2005.01.006
   Kumar M, 2004, COMPUT IND ENG, V46, P69, DOI 10.1016/j.cie.2003.09.010
   LEE CC, 1990, IEEE T SYST MAN CYB, V20, P419, DOI 10.1109/21.52552
   Lee HL, 1997, MANAGE SCI, V43, P546, DOI 10.1287/mnsc.43.4.546
   LEE J, 1997, INT J ENTREPRENEURIA, V3, P93, DOI DOI 10.1108/13552559710175392
   Lin PH, 2004, J PROCESS CONTR, V14, P487, DOI 10.1016/j.jprocont.2003.09.005
   LLARIA G, 2003, EUR J OPER RES, V149, P185
   MAMDANI EH, 1997, FUZZY SETS SYSTEMS, V26, P1182
   MERKURYEV P, 2002, P 14 EUR SIM S C SCS
   MIAO K, 2003, BULLWHIP EFFECT SUPP
   Sevastjanov P, 2007, OMEGA-INT J MANAGE S, V35, P505, DOI 10.1016/j.omega.2005.09.005
   SHEU JB, 2003, EUR J OPER RES, V148, P797
   Shore B., 2003, International Journal of Physical Distribution & Logistics Management, V33, P804, DOI 10.1108/09600030310503343
   STERMAN JD, 1989, MANAGE SCI, V35, P321, DOI 10.1287/mnsc.35.3.321
   Svensson G., 2003, International Journal of Physical Distribution & Logistics Management, V33, P103, DOI 10.1108/09600030310469135
   Wang TC, 2007, OMEGA-INT J MANAGE S, V35, P384, DOI 10.1016/j.omega.2005.07.007
   YANG T, 1991, FUZZY SETS SYSTEMS, V11, P39
   YAO K, 2001, THESIS U WISCONSIN M
   ZADEH LA, 1965, INFORM CONTROL, V8, P338, DOI 10.1016/S0019-9958(65)90241-X
   Zhang XL, 2004, INT J PROD ECON, V88, P15, DOI 10.1016/S0925-5273(03)00128-2
   Zimmermann H.-J., 1978, Fuzzy Sets and Systems, V1, P45, DOI 10.1016/0165-0114(78)90031-3
NR 36
TC 22
Z9 25
U1 4
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0305-0483
J9 OMEGA-INT J MANAGE S
JI Omega-Int. J. Manage. Sci.
PD APR
PY 2009
VL 37
IS 2
BP 282
EP 299
DI 10.1016/j.omega.2007.01.004
PG 18
WC Management; Operations Research & Management Science
SC Business & Economics; Operations Research & Management Science
GA 355TJ
UT WOS:000259731200004
DA 2018-12-27
ER

PT J
AU Lichtenthaler, U
AF Lichtenthaler, Ulrich
TI RETRACTED: The role of corporate technology strategy and patent
   portfolios in low-, medium- and high-technology firms (Retracted
   article. See vol. 41, pg. 1499, 2012)
SO RESEARCH POLICY
LA English
DT Article; Retracted Publication
DE Low- and medium-technology firms; High-technology firms; Technology
   strategy; Technological diversification; Intellectual property
   management
ID RESEARCH-AND-DEVELOPMENT; PRODUCT DEVELOPMENT; EMPIRICAL-ANALYSIS;
   MULTITECHNOLOGY CORPORATIONS; ORGANIZATION STRUCTURE; INTELLECTUAL
   PROPERTY; ABSORPTIVE-CAPACITY; MANAGING KNOWLEDGE; CORE COMPETENCES;
   INNOVATION
AB Previous research into technology strategies and patent portfolios has focused on high-technology firms, whereas low- and medium-technology companies have been relatively neglected. Therefore, we analyze how corporate technology strategy and the size and composition of patent portfolios affect the performance of low-, medium- and high-technology firms. Data from 136 European companies are used to examine four hypotheses relating financial performance to technological diversification, technological aggressiveness, patent portfolio size, and patent portfolio quality. The cross-industry sample allows analyzing the different consequences of these strategic parameters in low-, medium- and high-technology firms by considering technological intensity as a moderator. Our first finding is that the positive impact of technological aggressiveness is limited in low- and medium-technology companies. Secondly, technological diversification has a positive effect in high-technology firms and a negative effect in low-technology firms. Thirdly, patent portfolio size has a positive effect only in high-technology firms. Finally, patent portfolio quality has an equally positive influence on all firms' performance. In part, these results conflict with the findings of previous research into high-technology companies, and they call for rethinking the role of technology strategies and intellectual property portfolios in firms across industries. (C) 2008 Elsevier B.V. All rights reserved.
C1 WHU Otto Beisheim Sch Management, Chair Technol & Innovat Management, D-56179 Vallendar, Germany.
RP Lichtenthaler, U (reprint author), WHU Otto Beisheim Sch Management, Chair Technol & Innovat Management, Burgpl 2, D-56179 Vallendar, Germany.
EM lichtenthaler@whu.edu
CR ABERNATHY WJ, 1985, RES POLICY, V14, P3, DOI 10.1016/0048-7333(85)90021-6
   Argote L, 2003, MANAGE SCI, V49, P571, DOI 10.1287/mnsc.49.4.571.14424
   Argyres N, 1996, STRATEGIC MANAGE J, V17, P395, DOI 10.1002/(SICI)1097-0266(199605)17:5<395::AID-SMJ826>3.0.CO;2-E
   Argyres NS, 2004, STRATEGIC MANAGE J, V25, P929, DOI 10.1002/smj.387
   BAGOZZI RP, 1991, ADMIN SCI QUART, V36, P421, DOI 10.2307/2393203
   Bhatia V, 2007, MIT SLOAN MANAGE REV, V48, P15
   Breschi S, 2003, RES POLICY, V32, P69, DOI 10.1016/S0048-7333(02)00004-5
   BROCKHOFF K, 1992, IEEE T ENG MANAGE, V39, P318, DOI 10.1109/17.165413
   Casper S, 2007, RES POLICY, V36, P438, DOI 10.1016/j.respol.2007.02.018
   Chen JH, 1999, APPL ECON, V31, P1551, DOI 10.1080/000368499323076
   Chesbrough H., 2006, OPEN BUSINESS MODELS
   Chiesa V, 2004, R&D MANAGE, V34, P65, DOI 10.1111/j.1467-9310.2004.00323.x
   Cohen J., 2003, APPL MULTIPLE REGRES
   COHEN WM, 1990, ADMIN SCI QUART, V35, P128, DOI 10.2307/2393553
   da Silveira GJC, 2005, J OPER MANAG, V23, P662, DOI 10.1016/j.jom.2005.01.005
   Debackere K, 2005, RES POLICY, V34, P321, DOI 10.1016/j.respol.2004.12.003
   Deeds DL, 2001, J ENG TECHNOL MANAGE, V18, P29, DOI 10.1016/S0923-4748(00)00032-1
   Djeflat A, 1998, IND MARKET MANAG, V27, P483, DOI 10.1016/S0019-8501(98)00004-2
   Dosi G, 2006, RES POLICY, V35, P1110, DOI 10.1016/j.respol.2006.09.003
   Dugal S.S., 1994, J STRATEGIC MARKETIN, V2, P293
   Economides N, 2006, MANAGE SCI, V52, P1057, DOI 10.1287/mnsc.1060.0549
   EISENHARDT KM, 1989, ACAD MANAGE REV, V14, P532, DOI 10.2307/258557
   Ernst H, 2001, RES POLICY, V30, P143, DOI 10.1016/S0048-7333(99)00098-0
   EVANGELISTA R, 1998, INT J EC BUSINESS, V5, P311, DOI DOI 10.1080/13571519884413
   Fontana R, 2006, RES POLICY, V35, P309, DOI 10.1016/j.respol.2005.12.001
   Foreman-Peck J, 2006, REG STUD, V40, P307, DOI 10.1080/00343400600725160
   Fosfuri A, 2006, STRATEGIC MANAGE J, V27, P1141, DOI 10.1002/smj.562
   Freeman C., 1974, EC IND INNOVATION
   Gambardella A, 1998, RES POLICY, V27, P445, DOI 10.1016/S0048-7333(98)00062-6
   Gambardella A, 2001, MARKETS TECHNOLOGY E
   Garcia-Vega M, 2006, RES POLICY, V35, P230, DOI 10.1016/j.respol.2005.09.006
   Gatignon H, 1997, J MARKETING RES, V34, P77, DOI 10.2307/3152066
   GERBING DW, 1988, J MARKETING RES, V25, P186, DOI 10.2307/3172650
   Granstrand O, 1997, CALIF MANAGE REV, V39, P8, DOI 10.2307/41165908
   GRANSTRAND O, 1990, RES POLICY, V19, P35, DOI 10.1016/0048-7333(90)90033-3
   Granstrand O, 1998, RES POLICY, V27, P465, DOI 10.1016/S0048-7333(98)00067-5
   Hair J., 2006, MULTIVARIATE DATA AN
   Hall BH, 2005, RAND J ECON, V36, P16
   Hall BH, 2001, RAND J ECON, V32, P101, DOI 10.2307/2696400
   Harhoff D, 1999, REV ECON STAT, V81, P511, DOI 10.1162/003465399558265
   Hendricks KB, 2005, MANAGE SCI, V51, P695, DOI 10.1287/mnsc.1040.0353
   Hirsch-Kreinsen H., 2006, PROMETHEUS, V24, P3
   HOWELL R, 1992, MANAGEMENT ACCOUNTIN, V74, P28
   Hutzschenreuter T, 2006, J MANAGE, V32, P673, DOI 10.1177/0149206306291485
   Kortum S, 1999, RES POLICY, V28, P1, DOI 10.1016/S0048-7333(98)00082-1
   LAESTADIUS S, 2005, PILOT C BRUSS
   Leiponen A, 2006, J PROD INNOVAT MANAG, V23, P238, DOI 10.1111/j.1540-5885.2006.00196.x
   LERNER J, 1994, RAND J ECON, V25, P319, DOI 10.2307/2555833
   LEVIN R. C., 1987, BROOKINGS PAPERS EC, V3, P783, DOI DOI 10.2307/2534454
   Li MF, 1999, INFORM MANAGE-AMSTER, V35, P43, DOI 10.1016/S0378-7206(98)00075-5
   Lichtenthaler U, 2008, IEEE T ENG MANAGE, V55, P148, DOI 10.1109/TEM.2007.912932
   Lichtenthaler U, 2007, CALIF MANAGE REV, V49, P67, DOI 10.2307/41166406
   Lichtenthaler U, 2007, RES POLICY, V36, P37, DOI 10.1016/j.respol.2006.08.005
   Lin BW, 2006, IEEE T ENG MANAGE, V53, P17, DOI 10.1109/TEM.2005.861813
   Macher JT, 2006, MANAGE SCI, V52, P826, DOI 10.1287/mnsc.1060.0511
   MANSFIELD E, 1986, MANAGE SCI, V32, P173, DOI 10.1287/mnsc.32.2.173
   Mazzoleni R, 1998, RES POLICY, V27, P273, DOI 10.1016/S0048-7333(98)00048-1
   Mc Namara P, 2007, RES POLICY, V36, P548, DOI 10.1016/j.respol.2007.02.012
   McEvily B, 2005, STRATEGIC MANAGE J, V26, P1033, DOI 10.1002/smj.484
   McGahan AM, 2006, RES POLICY, V35, P1222, DOI 10.1016/j.respol.2006.09.006
   MERGES RP, 1990, COLUMBIA LAW REV, V90, P839, DOI 10.2307/1122920
   Miles I, 2007, R&D MANAGE, V37, P249, DOI 10.1111/j.1467-9310.2007.00473.x
   Miles M B., 1994, QUALITATIVE DATA ANA
   Miles R. E., 1978, ORG STRATEGY STRUCTU
   Miller DJ, 2006, STRATEGIC MANAGE J, V27, P601, DOI 10.1002/smj.533
   Molas-Gallart J, 2006, RES POLICY, V35, P200, DOI 10.1016/j.respol.2005.03.017
   Mytelka LK, 2002, RES POLICY, V31, P1467, DOI 10.1016/S0048-7333(02)00076-8
   Nickerson JA, 2007, STRATEG ORGAN, V5, P211, DOI 10.1177/1476127007079969
   NORDHAUS WD, 2001, 8096 NBER
   O'Shea RP, 2005, RES POLICY, V34, P994, DOI 10.1016/j.respol.2005.05.011
   Patel P, 1997, RES POLICY, V26, P141, DOI 10.1016/S0048-7333(97)00005-X
   Pisano G, 2006, RES POLICY, V35, P1122, DOI 10.1016/j.respol.2006.09.008
   Porter ME, 2000, ECON DEV Q, V14, P15, DOI 10.1177/089124240001400105
   PRICE M, 1986, HDB ORG MEASUREMENT
   Quintana-Garcia C, 2008, RES POLICY, V37, P492, DOI 10.1016/j.respol.2007.12.002
   Ramirez J, 2005, INT J TECHNOL MANAGE, V31, P288, DOI 10.1504/IJTM.2005.006636
   Ray G, 2004, STRATEGIC MANAGE J, V25, P23, DOI 10.1002/smj.366
   Reitzig M, 2007, RES POLICY, V36, P134, DOI 10.1016/j.respol.2006.10.003
   Robertson P. L., 2003, IND INNOV, V10, P457
   Robertson PL, 2007, RES POLICY, V36, P708, DOI 10.1016/j.respol.2007.01.008
   Rothaermel FT, 2004, STRATEGIC MANAGE J, V25, P201, DOI 10.1002/smj.376
   Shane S, 2001, MANAGE SCI, V47, P1173, DOI 10.1287/mnsc.47.9.1173.9785
   SHARMA S, 1981, J MARKETING RES, V18, P291, DOI 10.2307/3150970
   SMITH K, 2000, ENTERPRISE INNOVATIO, V1, P73, DOI DOI 10.1080/146324400363536
   Somaya D, 2003, STRATEGIC MANAGE J, V24, P17, DOI 10.1002/smj.281
   Souder WE, 1998, J PROD INNOVAT MANAG, V15, P520
   Suzuki J, 2004, RES POLICY, V33, P531, DOI 10.1016/j.respol.2003.10.005
   Teece DJ, 2006, RES POLICY, V35, P1131, DOI 10.1016/j.respol.2006.09.009
   TEECE DJ, 1986, RES POLICY, V15, P285, DOI 10.1016/0048-7333(86)90027-2
   Thornhill S, 2006, J BUS VENTURING, V21, P687, DOI 10.1016/j.jbusvent.2005.06.001
   TRAJTENBERG M, 1990, RAND J ECON, V21, P172, DOI 10.2307/2555502
   Wang YG, 2004, J ENG TECHNOL MANAGE, V21, P249, DOI 10.1016/j.jengtecman.2004.09.001
   WEISENFELDSCHENK U, 1994, R&D MANAGE, V24, P57, DOI 10.1111/j.1467-9310.1994.tb00847.x
   West J., 2006, OPEN INNOVATION RES, P285
   West S. G, 1991, MULTIPLE REGRESSION
   Yin R. K., 2003, CASE STUDY RES DESIG
   Zhang J, 2007, RES POLICY, V36, P515, DOI 10.1016/j.respol.2007.02.015
   Zhang MJ, 2005, J ENG TECHNOL MANAGE, V22, P163, DOI 10.1016/j.jengtecman.2005.06.003
   ZHENG ZK, 2005, J MARKETING, V69, P42
NR 99
TC 25
Z9 25
U1 3
U2 67
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0048-7333
J9 RES POLICY
JI Res. Policy
PD APR
PY 2009
VL 38
IS 3
SI SI
BP 559
EP 569
DI 10.1016/j.respol.2008.10.009
PG 11
WC Management; Planning & Development
SC Business & Economics; Public Administration
GA 432WD
UT WOS:000265164100012
DA 2018-12-27
ER

PT J
AU Cho, A
   Yamamoto, H
   Nagata, M
   Takiguchi, N
   Shimada, H
   Kainuma, O
   Souda, H
   Gunji, H
   Miyazaki, A
   Ikeda, A
   Tohma, T
AF Cho, Akihiro
   Yamamoto, Hiroshi
   Nagata, Matsuo
   Takiguchi, Nobuhiro
   Shimada, Hideaki
   Kainuma, Osamu
   Souda, Hiroaki
   Gunji, Hisashi
   Miyazaki, Akinari
   Ikeda, Atsushi
   Tohma, Tomoko
TI RETRACTED: A totally laparoscopic pylorus-preserving
   pancreaticoduodenectomy and reconstruction (Retracted article. See vol.
   46, pg. 631, 2016)
SO SURGERY TODAY
LA English
DT Article; Retracted Publication
DE Laparoscopy; Pancreaticoduodenectomy; Pylorus-preserving
   pancreaticoduodenectomy; Laparoscopic pancreaticoduodenectomy;
   Intraductal papillary-mucinous neoplasm
ID PANCREATIC RESECTION; SINGLE-INSTITUTION; DUCT; HEAD
AB Although many reports have described laparoscopic pancreatic surgery, laparoscopic pancreaticoduodenectomy (PD) has not been widely employed because of technical difficulties. This paper describes a totally laparoscopic pylorus-preserving PD performed for an intraductal papillary-mucinous neoplasm. After the laparoscopic resection, an end-to-side pancreaticojejunostomy including duct-to-mucosa anastomosis without a stenting tube, an approximation of the pancreas stump and jejunal wall, an end-to-side hepaticojejunostomy, and an end-to-side duodenojejunostomy were performed intracorporeally. The patient recovered without any complications and was discharged on the 14th postoperative day. The surgical margin was free of neoplastic changes. Although the experience is limited and the appropriate indications must await future studies, this case indicates that a laparoscopic pylorus-preserving PD can be feasible, safe, and effective in highly selected patients.
C1 [Cho, Akihiro; Yamamoto, Hiroshi; Nagata, Matsuo; Takiguchi, Nobuhiro; Shimada, Hideaki; Kainuma, Osamu; Souda, Hiroaki; Gunji, Hisashi; Miyazaki, Akinari; Ikeda, Atsushi; Tohma, Tomoko] Chiba Canc Ctr Hosp, Div Gastroenterol Surg, Chuo Ku, Chiba 2608717, Japan.
RP Cho, A (reprint author), Chiba Canc Ctr Hosp, Div Gastroenterol Surg, Chuo Ku, 666-2 Nitona Cho, Chiba 2608717, Japan.
CR Cho A, 2007, SURG ENDOSC, V21, P1466, DOI 10.1007/s00464-007-9253-5
   CHO A, 2008, SHUJUTSU, V62, P1427
   CULLEN JJ, 1994, AM J SURG, V168, P295, DOI 10.1016/S0002-9610(05)80151-5
   Cunha AS, 2008, ARCH SURG-CHICAGO, V143, P289, DOI 10.1001/archsurg.143.3.289
   Dulucq JL, 2006, SURG ENDOSC, V20, P1045, DOI 10.1007/s00464-005-0474-1
   Fernandez-Cruz L, 2007, J GASTROINTEST SURG, V11, P1607, DOI 10.1007/s11605-007-0266-0
   GAGNER M, 1994, SURG ENDOSC-ULTRAS, V8, P408, DOI 10.1007/BF00642443
   Imaizumi T, 2006, J HEPATO-BILIARY-PAN, V13, P194, DOI 10.1007/s00534-005-1037-5
   Kakita A, 2001, J Hepatobiliary Pancreat Surg, V8, P230, DOI 10.1007/s005340170022
   Kimura Y, 2005, AM J SURG, V189, P734, DOI 10.1016/j.amjsurg.2005.03.017
   Kleeff J, 2007, J HEPATO-BILIARY-PAN, V14, P480, DOI 10.1007/s00534-006-1178-1
   Melotti G, 2007, ANN SURG, V246, P77, DOI 10.1097/01.sla.0000258607.17194.2b
   Menon KV, 2007, J LAPAROENDOSC ADV S, V17, P775, DOI 10.1089/lap.2006.0236
   Palanivelu C, 2007, J AM COLL SURGEONS, V205, P222, DOI 10.1016/j.jamcollsurg.2007.04.004
   Rumstadt B, 1998, ANN SURG, V227, P236, DOI 10.1097/00000658-199802000-00013
   Takaori K, 2007, SURG TODAY, V37, P535, DOI 10.1007/s00595-007-3472-1
   Uyama I, 1996, SURG LAPAROSC ENDOSC, V6, P405, DOI 10.1097/00019509-199610000-00016
NR 17
TC 21
Z9 22
U1 4
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-1291
EI 1436-2813
J9 SURG TODAY
JI Surg. Today
PD APR
PY 2009
VL 39
IS 4
BP 359
EP 362
DI 10.1007/s00595-008-3853-0
PG 4
WC Surgery
SC Surgery
GA 424FN
UT WOS:000264551000018
PM 19319649
DA 2018-12-27
ER

PT J
AU Deng, J
   Zhang, XL
   Wang, JW
   Teng, LL
   Ge, J
   Takeiviori, H
   Xiong, ZQ
   Zhou, Y
AF Deng, J.
   Zhang, X. -L.
   Wang, J. -W.
   Teng, L. -L.
   Ge, J.
   Takeiviori, H.
   Xiong, Z. -Q.
   Zhou, Y.
TI RETRACTED: EXPRESSION AND REGULATED NUCLEAR TRANSPORT OF TRANSDUCERS OF
   REGULATED CREB 1 IN RETINAL GANGLION CELLS (Retracted article. See vol.
   169, pg. 950, 2010)
SO NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE TORC1; retinal ganglion cells; Ca2+; retinal ischemic injury
ID ELEMENT-BINDING PROTEIN; SENSITIVE COINCIDENCE DETECTOR;
   ISCHEMIA-REPERFUSION INJURY; MEDIATED GENE-EXPRESSION; REGENERATIVE
   CAPACITY; COACTIVATOR TORC2; IN-VIVO; PHOSPHORYLATION; ACTIVATION;
   TRANSCRIPTION
AB Calcium- and cAMP-dependent activation of CREB and transcription of cAMP-responsive element (CRE)-target genes play critical roles in various physiological and pathological conditions. TORCs (transducers of regulated CREB) represent a new family of conserved CREB coactivators that function as intracellular calcium- and cAMP-sensitive coincidence detectors, controlling the kinetics of CRE-mediated responses and long-term potentiation of synaptic transmission. Here we examined the expression and activity-dependent translocaition of TORCs in adult retinal ganglion cells (RGCs), the primary target of acute retinal ischemic injury as well as chronic: retinal degenerative diseases. We found that both mRNAs of TORC1 and TORC2, but not TORC3, were enriched in adult rat retina. Comparing with TORC2, TORC1 protein was highly and selectively expressed in RGCs. At resting condition, TORC1 protein was localized in the cytoplasm but not nucleus of RGCs. Activation of N-methyl-D-aspartate (NMDA) receptors by intravitreous injection of NMDA or increase of cAMP signaling by administration of forskolin triggered nuclear accumulation of TORC1. Furthermore, transient retinal ischemic injury resulted in peri-nuclear and nuclear accumulation of TORC1 as well as transcription of BDNF in RGCs. Our results demonstrate that TORC1 is enriched in RGCs and its subcellular location could be regulated by Ca2+ and cAMP, suggesting that manipulation of TORC1 activity may promote survival of IRGCs in some optic disease conditions. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Zhang, X. -L.; Teng, L. -L.; Ge, J.] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Deng, J.; Wang, J. -W.] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Ophthalmol, Guangzhou 510630, Guangdong, Peoples R China.
   [Takeiviori, H.] Natl Inst Biomed Innovat, Lab Cell Signal & Metab, Osaka 5670085, Japan.
   [Xiong, Z. -Q.; Zhou, Y.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China.
   [Xiong, Z. -Q.; Zhou, Y.] Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Neurosci, Shanghai 200031, Peoples R China.
RP Zhang, XL (reprint author), Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
EM zhangxl2@mail.sysu.edu.cn; yzhou@ion.ac.cn
FU Project of Science and Technology of Guangdong Province
   [2008B060600061]; Guangdong Natural Science Foundation Key Project
   [7117359]; National Natural Science Foundation of China [30872831];
   State Key Laboratory of Neuroscience, Chinese Academy of Sciences
   [SKLN-2008A03]; National Basic Research Project [2007CB512200]; National
   Nature Science Foundation of China [30800318]
FX This work was supported by grants from Project of Science and Technology
   of Guangdong Province (2008B060600061) to J.D.; Guangdong Natural
   Science Foundation Key Project (7117359), National Natural Science
   Foundation of China (30872831) and the opening project of State Key
   Laboratory of Neuroscience, Chinese Academy of Sciences (SKLN-2008A03)
   to XZ.; National Basic Research Project (973 Project, 2007CB512200) to
   J.G.; National Nature Science Foundation of China (30800318) to Y.Z.
CR Altarejos JY, 2008, NAT MED, V14, P1112, DOI 10.1038/nm.1866
   BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060
   BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095
   Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002
   Bleckmann SC, 2002, MOL CELL BIOL, V22, P1919, DOI 10.1128/MCB.22.6.1919-1925.2002
   Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000
   Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272
   Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013
   DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061
   Dong K, 1996, DEV BRAIN RES, V95, P55
   Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835
   Harvey AR, 2006, PROG RETIN EYE RES, V25, P449, DOI 10.1016/j.preteyeres.2006.07.002
   Hietakangas V, 2008, CELL METAB, V7, P357, DOI 10.1016/j.cmet.2008.04.006
   Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100
   Jiao JW, 2005, EMBO J, V24, P1068, DOI 10.1038/sj.emboj.7600589
   Kitagawa K, 2007, FEBS J, V274, P3210, DOI 10.1111/j.1742-4658.2007.05890.x
   Kolb H, 1991, PRINCIPLES PRACTICE, P25
   Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967
   Kovacs KA, 2007, P NATL ACAD SCI USA, V104, P4700, DOI 10.1073/pnas.0607524104
   Kuehn Markus H, 2005, Ophthalmol Clin North Am, V18, P383, DOI 10.1016/j.ohc.2005.04.002
   Kumar JP, 2004, GENETICS, V168, P877, DOI 10.1534/genetics.104.029850
   Lee B, 2005, J NEUROSCI, V25, P1137, DOI 10.1523/JNEUROSCI.4288-04.2005
   Li RS, 2006, INVEST OPHTH VIS SCI, V47, P2951, DOI 10.1167/iovs.05-1295
   LI S, 2009, J NEUROSCI IN PRESS
   Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0
   Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100
   Matsuda T, 2007, P NATL ACAD SCI USA, V104, P1027, DOI 10.1073/pnas.0610155104
   Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068
   Mo XF, 2002, INVEST OPHTH VIS SCI, V43, P2401
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Nonaka A, 2000, INVEST OPHTH VIS SCI, V41, P2689
   Pham TA, 2001, NEURON, V31, P409, DOI 10.1016/S0896-6273(01)00381-6
   POLO AD, 1998, P NATL ACAD SCI USA, V95, P3978
   Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Siu YT, 2008, MOL BIOL CELL, V19, P4750, DOI 10.1091/mbc.E08-04-0369
   Siu YT, 2006, J VIROL, V80, P7052, DOI 10.1128/JVI.00103-06
   So KF, 1998, VISION RES, V38, P1525, DOI 10.1016/S0042-6989(97)00226-5
   Stellwagen D, 1999, NEURON, V24, P673, DOI 10.1016/S0896-6273(00)81121-6
   Takemori H, 2007, FEBS J, V274, P3202, DOI 10.1111/j.1742-4658.2007.05889.x
   UNOKI K, 1994, INVEST OPHTH VIS SCI, V35, P907
   Wang B, 2008, CELL METAB, V7, P434, DOI 10.1016/j.cmet.2008.02.010
   Wu H, 2007, FEBS J, V274, P3218, DOI 10.1111/j.1742-4658.2007.05891.x
   Wu ZD, 2006, P NATL ACAD SCI USA, V103, P14379, DOI 10.1073/pnas.0606714103
   Yokoyama A, 2001, INVEST OPHTH VIS SCI, V42, P3283
   YOSHIDA K, 1995, J NEUROCHEM, V65, P1499
   YU F, 2006, J NEUROCHEM, V96, P1501
   Zhou Y, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000016
NR 48
TC 3
Z9 4
U1 4
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD MAR 31
PY 2009
VL 159
IS 3
BP 1023
EP 1031
DI 10.1016/j.neuroscience.2009.01.073
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 426NO
UT WOS:000264715200011
PM 19356686
DA 2018-12-27
ER

PT J
AU Arnold, C
AF Arnold, Carrie
TI RETRACTED: Profile of Phillip Cohen (Retracted article. See vol. 106,
   pg. 678, 2009)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Biographical-Item; Retracted Publication
CR COHEN P, PUBLICATION LIST
NR 1
TC 1
Z9 1
U1 1
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 24
PY 2009
VL 106
IS 12
BP 4581
EP 4583
DI 10.1073/pnas.0902168106
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 423VA
UT WOS:000264522600004
PM 19293376
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Niessen, F
   Furlan-Freguia, C
   Fernandez, JA
   Mosnier, LO
   Castellino, FJ
   Weiler, H
   Rosen, H
   Griffin, JH
   Ruf, W
AF Niessen, Frank
   Furlan-Freguia, Christian
   Fernandez, Jose A.
   Mosnier, Laurent O.
   Castellino, Francis J.
   Weiler, Hartmut
   Rosen, Hugh
   Griffin, John H.
   Ruf, Wolfram
TI RETRACTED: Endogenous EPCR/aPC-PAR1 signaling prevents
   inflammation-induced vascular leakage and lethality (Retracted article.
   See vol. 117, pg. 7188, 2011)
SO BLOOD
LA English
DT Article; Retracted Publication
ID ACTIVATED PROTEIN-C; DISSEMINATED INTRAVASCULAR COAGULATION; RANDOMIZED
   CONTROLLED-TRIAL; ENDOTHELIAL-CELLS; TISSUE FACTOR; SPHINGOSINE
   KINASE-1; ESCHERICHIA-COLI; MOUSE MODEL; HEMOSTATIC BALANCE; COUPLED
   RECEPTOR
AB Protease activated receptor 1 (PAR1) signaling can play opposing roles in sepsis, either promoting dendritic cell (DC)-dependent coagulation and inflammation or reducing sepsis lethality due to activated protein C (aPC) therapy. To further define this PAR1 paradox, we focused on the vascular effects of PAR1 signaling. Pharmacological perturbations of the intravascular coagulant balance were combined with genetic mouse models to dissect the roles of endogenously generated thrombin and aPC during escalating systemic inflammation. Acute blockade of the aPC pathway with a potent inhibitory antibody revealed that thrombin-PAR1 signaling increases inflammation- induced vascular hyperpermeability. Conversely, aPC-PAR1 signaling and the endothelial cell PC receptor (EPCR) prevented vascular leakage, and pharmacologic or genetic blockade of this pathway sensitized mice to LPS-induced lethality. Signaling-selective aPC variants rescued mice with defective PC activation from vascular leakage and lethality. Defects in the aPC pathway were fully compensated by sphingosine 1 phosphate receptor 3 (S1P3) deficiency or by selective agonists of the S1P receptor 1 (S1P1), indicating that PAR1 signaling contributes to setting the tone for the vascular S1P1/S1P3 balance. Thus, the activating proteases and selectivity in coupling to S1P receptor sub-types determine vascular PAR1 signaling specificity in systemic inflammatory response syndromes in vivo. (Blood. 2009;113:2859-2866)
C1 [Niessen, Frank; Furlan-Freguia, Christian; Rosen, Hugh; Ruf, Wolfram] Scripps Res Inst, Dept Immunol & Microbiol Sci, La Jolla, CA 92037 USA.
   [Fernandez, Jose A.; Mosnier, Laurent O.; Griffin, John H.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.
   [Castellino, Francis J.] Univ Notre Dame, Notre Dame, IN 46556 USA.
   [Weiler, Hartmut] Blood Ctr Wisconsin, Milwaukee, WI USA.
   [Rosen, Hugh] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA.
RP Ruf, W (reprint author), Scripps Res Inst, Dept Immunol & Microbiol Sci, SP258, La Jolla, CA 92037 USA.
EM ruf@scripps.edu
RI Fernandez, Jose/A-3211-2008
FU National Institutes of Health (NIH, Bethesda) [HL-78614, HL-16411,
   HL-31950, HL-52246, HL-73750, HL-60655, HL-87618, AI-55509]; American
   Heart Association Postdoctoral Fellowship
FX We thank Cindi Biazak, Jennifer Royce, Nora Leaf, Xiao Xu, and Ngan
   Pham-Mitchell for expert technical assistance.; This study was supported
   by National Institutes of Health (NIH, Bethesda, MD) grants HL-78614,
   HL-16411 (W.R.), HL-31950, HL-52246 (J.H.G.), HL-73750 (F.J.C.),
   HL-60655 (H.W.), HL-87618 (L.O.M.), and AI-55509 (H.R.) and an American
   Heart Association Postdoctoral Fellowship (C.F.F.). S1P3<SUP>-/-</SUP>,
   Sphk1<SUP>-/-</SUP>, and PAR1<SUP>-/-</SUP> mice were kindly provided by
   Drs Jerold Chun, Richard Prioa, and Patricia Andrade-Gordon.
CR Abraham E, 2003, JAMA-J AM MED ASSOC, V290, P238, DOI 10.1001/jama.290.2.238
   Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200
   Bae JS, 2008, J THROMB HAEMOST, V6, P954, DOI 10.1111/j.1538-7836.2008.02924.x
   Bae JS, 2007, BLOOD, V110, P3909, DOI 10.1182/blood-2007-06-096651
   Bae JS, 2007, P NATL ACAD SCI USA, V104, P2867, DOI 10.1073/pnas.0611493104
   Belperio JA, 2002, J CLIN INVEST, V110, P1703, DOI 10.1172/JCI200215849
   Bernard G.R., 2001, NEW ENGL J MED, V344, P759
   Camerer E, 2006, BLOOD, V107, P3912, DOI 10.1182/blood-2005-08-3130
   Castellino FJ, 2002, THROMB HAEMOSTASIS, V88, P462
   Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826
   Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229
   Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671
   Esmon CT, 2004, TRENDS IMMUNOL, V25, P536, DOI 10.1016/j.it.2004.08.003
   Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985
   Feistritzer C, 2006, J BIOL CHEM, V281, P20077, DOI 10.1074/jbc.M600506200
   Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200
   Ganopolsky JG, 2004, AM J PATHOL, V165, P1433, DOI 10.1016/S0002-9440(10)63401-3
   Han MH, 2008, NATURE, V451, P1076, DOI 10.1038/nature06559
   Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200
   Iwaki T, 2005, BLOOD, V105, P2364, DOI 10.1182/blood-2004-06-2456
   Kaneider NC, 2007, NAT IMMUNOL, V8, P1303, DOI 10.1038/ni1525
   Kerschen EJ, 2007, J EXP MED, V204, P2439, DOI 10.1084/jem.20070404
   Levi M, 2003, BLOOD, V101, P4823, DOI 10.1182/blood-2002-10-3254
   Li W, 2005, J THROMB HAEMOST, V3, P1351, DOI 10.1111/j.1538-7836.2005.01385.x
   Li X, 2008, BLOOD, V111, P3489, DOI 10.1182/blood-2007-05-092148
   Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905
   Mizugishi K, 2005, MOL CELL BIOL, V25, P11113, DOI 10.1128/MCB.25.24.11113-11121.2005
   Mosnier LO, 2007, J BIOL CHEM, V282, P33022, DOI 10.1074/jbc.M705824200
   Mosnier LO, 2007, BLOOD, V109, P3161, DOI 10.1182/blood-2006-09-003004
   MOSNIER LO, 2009, BLOOD           0224
   Niessen F, 2008, NATURE, V452, P654, DOI 10.1038/nature06663
   Opal SM, 2004, J ENDOTOXIN RES, V10, P125, DOI 10.1179/0968051042255004022
   Pawlinski R, 2004, BLOOD, V103, P1342, DOI 10.1182/blood-2003-09-3051
   Riewald M, 2005, J BIOL CHEM, V280, P19808, DOI 10.1074/jbc.M500747200
   Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699
   Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698
   Ruf W, 2004, TRENDS IMMUNOL, V25, P461, DOI 10.1016/j.it.2004.07.002
   Singleton PA, 2007, AM J RESP CELL MOL, V37, P222, DOI 10.1165/rcmb.2006-0327OC
   Tauseef M, 2008, CIRC RES, V103, P1164, DOI 10.1161/01.RES.0000338501.84810.51
   Taylor FB, 2001, BLOOD, V97, P1685, DOI 10.1182/blood.V97.6.1685
   TAYLOR FB, 1991, CIRC SHOCK, V33, P127
   TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902
   TAYLOR FB, 1991, BLOOD, V78, P364
   Warren BL, 2001, JAMA-J AM MED ASSOC, V286, P1869, DOI 10.1001/jama.286.15.1869
   Weiler H, 2001, ARTERIOSCL THROM VAS, V21, P1531, DOI 10.1161/hq0901.094496
   Xu H, 2006, J PATHOL, V210, P488, DOI 10.1002/path.2073
   Yano K, 2006, J EXP MED, V203, P1447, DOI 10.1084/jem.20060375
   Zheng X, 2007, J THROMB HAEMOST, V5, P1394, DOI 10.1111/j.1538-7836.2007.02592.x
   Zheng XZ, 2007, BLOOD, V109, P1003, DOI 10.1182/blood-2006-06-032086
NR 49
TC 62
Z9 67
U1 5
U2 15
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAR 19
PY 2009
VL 113
IS 12
BP 2859
EP 2866
DI 10.1182/blood-2008-12-192385
PG 8
WC Hematology
SC Hematology
GA 421MA
UT WOS:000264361800030
PM 19141861
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Zhong, J
   Gavrilescuc, LC
   Molnar, A
   Murray, L
   Garafalo, S
   Kehrl, JH
   Simon, AR
   Van Etten, RA
   Kyriakis, JM
AF Zhong, Jian
   Gavrilescuc, L. Cristina
   Molnar, Arpad
   Murray, Lauren
   Garafalo, Stephen
   Kehrl, John H.
   Simon, Amy R.
   Van Etten, Richard A.
   Kyriakis, John M.
TI RETRACTED: GCK is essential to systemic inflammation and pattern
   recognition receptor signaling to JNK and p38 (Retracted article. See
   vol. 109, pg. 5134, 2012)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE MAPK; sepsis; innate immunity; toll-like receptor; germinal center
   kinase
ID GERMINAL CENTER KINASE; NF-KAPPA-B; INNATE IMMUNITY; ADAPTER MOLECULE;
   ACTIVATION; PATHWAY; MICE; ATHEROSCLEROSIS; STRESS; TAK1
AB Systemic inflammation arising from the organismal distribution of pathogen-associated molecular patterns is a major cause of clinical morbidity and mortality. Herein we report a critical and previously unrecognized in vivo role for germinal center kinase (GCK, genome nomenclature: map4k2), a mammalian Sterile 20 (STE20) orthologue, in PAMP signaling, and systemic inflammation. We find that disruption of gck in mice strongly impairs PAMP-stimulated macrophage cytokine and chemokine release and renders mice resistant to endotoxin-mediated lethality. Bone marrow transplantation studies show that hematopoietic cell GCK signaling is essential to systemic inflammation. Disruption of gck substantially reduces PAMP activation of macrophage Jun-N-terminal kinase (JNK) and p38 mitogen-activated protein kinases (MAPKs) via reduced activation of the MAPK-kinase-kinases (MAP3Ks) mixed lineage kinases (MLKs)-2 and -3. Extracellular signal-regulated kinase (ERK) and nuclear factor-kappa B (NF-kappa B) activation are largely unaffected. Thus, GCK is an essential PAMP effector coupling JNK and p38, but not ERK or NF-kappa B to systemic inflammation.
C1 [Zhong, Jian; Molnar, Arpad; Kyriakis, John M.] Tufts Univ, Sch Med, Mol Cardiol Res Inst, Boston, MA 02111 USA.
   [Gavrilescuc, L. Cristina; Van Etten, Richard A.] Tufts Univ, Sch Med, Mol Oncol Res Inst, Boston, MA 02111 USA.
   [Murray, Lauren; Garafalo, Stephen; Simon, Amy R.] Tufts Univ, Sch Med, Div Pulmonol Crit Care & Sleep Med, Tufts Med Ctr, Boston, MA 02111 USA.
   [Zhong, Jian; Molnar, Arpad; Kyriakis, John M.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA.
   [Gavrilescuc, L. Cristina; Van Etten, Richard A.] Tufts Univ, Sch Med, Dept Hematol Oncol, Boston, MA 02111 USA.
   [Murray, Lauren; Garafalo, Stephen; Simon, Amy R.] Tufts Univ, Sch Med, Dept Cellular & Mol Physiol, Boston, MA 02111 USA.
   [Kehrl, John H.] NIAID, Bethesda, MD 20892 USA.
RP Kyriakis, JM (reprint author), Tufts Univ, Sch Med, Mol Cardiol Res Inst, Boston, MA 02111 USA.
EM jkyriakis@tuftsmedicalcenter.org
OI Kehrl, John/0000-0002-6526-159X
FU Cephalon, Inc. [CEP-11004]; National Institutes of Health [CA105043]
FX We thank Michael Mendelsohn for continued support; En Li for assistance
   in design of the targeting construct; Cheleste Thorpe for FliC and
   discussions; Cephalon, Inc. for CEP-11004; Roy Soberman for discussions;
   Sandro Goruppi for assistance with lentivirus preparation; and members
   of the Kyriakis laboratory for discussions. R. A. V. and L. C. G.
   acknowledge support from National Institutes of Health Grant CA105043.
CR Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003
   Bjorkbacka H, 2004, NAT MED, V10, P416, DOI 10.1038/nm1008
   Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002
   Ciallella JR, 2005, EUR J PHARMACOL, V515, P179, DOI 10.1016/j.ejphar.2005.04.016
   Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003
   Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8
   Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006
   Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5
   Dunne A., 2003, SCI STKE, pre, DOI DOI 10.1126/STKE.2003.171.RE3
   Hack CE, 1997, ADV IMMUNOL, V66, P101, DOI 10.1016/S0065-2776(08)60597-0
   Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180
   Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008
   Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2
   Kim K, 2007, IMMUNOLOGY, V120, P242, DOI 10.1111/j.1365-2567.2006.02495.x
   Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259
   Kyriakis JM, 2001, PHYSIOL REV, V81, P807
   Mansell A, 2004, J BIOL CHEM, V279, P37227, DOI 10.1074/jbc.C400289200
   Matsuzawa A, 2008, SCIENCE, V321, P663, DOI 10.1126/science.1157340
   Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246
   Meylan E, 2006, NATURE, V442, P39, DOI 10.1038/nature04946
   Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101
   Michelsen KS, 2004, J IMMUNOL, V173, P5901, DOI 10.4049/jimmunol.173.10.5901
   Mullick AE, 2005, J CLIN INVEST, V115, P3149, DOI 10.1172/JCI25482
   Murakata C, 2002, BIOORG MED CHEM LETT, V12, P147, DOI 10.1016/S0960-894X(01)00690-4
   Oberholzer A, 2002, CRIT CARE MED, V30, pS58, DOI 10.1097/00003246-200201001-00008
   Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886
   POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0
   Qin JZ, 2006, J BIOL CHEM, V281, P21013, DOI 10.1074/jbc.M512908200
   Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1
   Salojin KV, 2006, J IMMUNOL, V176, P1899, DOI 10.4049/jimmunol.176.3.1899
   Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255
   Schnare M, 2000, CURR BIOL, V10, P1139, DOI 10.1016/S0960-9822(00)00700-4
   Song MC, 2005, CRIT CARE MED, V33, pS463, DOI 10.1097/01.CCM.0000186784.62662.AI
   Tang MH, 2008, J EXP MED, V205, P1611, DOI 10.1084/jem.20080297
   Wan YSY, 2006, NAT IMMUNOL, V7, P851, DOI 10.1038/ni1355
   Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182
   Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262
   Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769
   Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681
   Zhong J, 2004, MOL CELL BIOL, V24, P9165, DOI 10.1128/MCB.24.20.9165-9175.2004
   Zhong J, 2007, J BIOL CHEM, V282, P24246, DOI 10.1074/jbc.M703422200
   Zisman DA, 1997, J CLIN INVEST, V99, P2832, DOI 10.1172/JCI119475
NR 47
TC 17
Z9 18
U1 3
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 17
PY 2009
VL 106
IS 11
BP 4372
EP 4377
DI 10.1073/pnas.0812642106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 420HD
UT WOS:000264278800058
PM 19246396
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Zhang, C
   Song, QH
   Khachigian, LM
   Lubenec, I
   Shie, JL
   Yang, B
   Li, J
   Tian, Y
AF Zhang, Cuili
   Song, Q. H.
   Khachigian, Levon M.
   Lubenec, I.
   Shie, Jue-Lon
   Yang, Baofeng
   Li, Jian
   Tian, Ye
TI RETRACTED: Related transcriptional enhancer factor-1 induces fibroblast
   growth factor receptor-1 expression in endothelial cells (Retracted
   article. See vol 388, pg 464, 2009)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE Related transcriptional enhancer factor-1 (RTEF-1); Fibroblast growth
   factor receptor-1 (FGFR-1); Endothelial cells
ID SMOOTH-MUSCLE-CELLS; CARDIAC MYOCYTES; ISCHEMIC-HEART; RTEF-1; GENE;
   ACTIVATION; INTERACTS; FAMILY
AB Fibroblast growth factor receptor-1 (FGFR-1) has been implicated in the process of cardiogenesis, although the underlying molecular mechanisms are poorly understood. In this study, we report the regulation of FGFR-1 expression by related transcriptional enhancer factor-1 (RTEF-1) in vitro (endothelial cells) and in vivo (RTEF-1 transgenic mice). FGFR-1 promoter activity, FGFR-1 mRNA and protein level Were Measured in bovine aortic endothelial cells (BAEC) in response to RTEF-1 and in endothelial cells isolated from livers in RTEF-1 transgenic mice. RTEF-1 stimulated FGFR-l promoter activity in a dose-dependent manner, RTEF-1 enhanced FGFR-1 mRNA (4-fold) and protein expression (3.5-fold) whereas RTEF-1 siRNA decreased FGFR-1 protein expression (4-fold). FGFR-1 mRNA and protein expression were also increased in endothelial cells isolated from livers of RTEF-1 transgenic mice. Furthermore, RTEF-1 enhanced tubule formation whereas this was decreased by RTEF-1 knockdown. Moreover, increased relaxation of microvessels was found in RTEF-1 transgenic mice compared to wild-type mice. Our results indicate that RTEF-1 acts as a transcriptional stimulator of FGFR-1 in endothelial cells through its activation of the FGFR-1 promoter, RTEF-1 thus plays ail important role in the regulation of FGFR-1 expression. These findings help further understand FGFR activity in angiogenesis and may lead to new therapeutic targets in ischemic vascular disorders. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Zhang, Cuili; Song, Q. H.; Lubenec, I.; Shie, Jue-Lon; Li, Jian] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA.
   [Zhang, Cuili; Yang, Baofeng; Tian, Ye] Harbin Med Univ, Harbin 150081, Heilongjiang, Peoples R China.
   [Khachigian, Levon M.] Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia.
   [Khachigian, Levon M.] Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia.
RP Li, J (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA.
EM jli@bidm.harvard.edu; tianye@ems.hrbmu.edu.cn
OI Khachigian, Levon/0000-0003-3446-0323
FU homecoming overseas foundation in Heilongjiang Province in China
   [LC06C31]; Research on National High-tech R&D Program (the 863 Program)
   in China [2007AA02Z450]; homecoming overseas foundation in Harbin in
   China [RC2008LX004004]
FX This work was supported by homecoming overseas foundation in
   Heilongjiang Province in China (Grand LC06C31), the Research on National
   High-tech R&D Program (the 863 Program) in China (Grant No.
   2007AA02Z450) and homecoming overseas foundation in Harbin in China
   (RC2008LX004004).
CR Appukuttan B, 2007, INVEST OPHTH VIS SCI, V48, P3775, DOI 10.1167/iovs.06-1172
   Chen HH, 2004, CIRCULATION, V110, P2980, DOI 10.1161/01.CIR.0000146902.84099.26
   Couper LL, 1997, CIRC RES, V81, P932
   Cuddapah S, 2008, FEBS LETT, V582, P391, DOI 10.1016/j.febslet.2007.12.033
   Dessy C, 2005, CIRCULATION, V112, P1198, DOI 10.1161/CIRCULATIONAHA.104.532960
   Do H, 1999, J BIOL CHEM, V274, P19587, DOI 10.1074/jbc.274.28.19587
   Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266
   Feng J, 2006, SURGERY, V140, P192, DOI 10.1016/j.surg.2006.05.002
   Gan Q, 2007, CIRC RES, V101, P883, DOI 10.1161/CIRCRESAHA.107.154831
   Jiang ZS, 2002, AM J PHYSIOL-HEART C, V282, pH1071, DOI 10.1152/ajpheart.00290.2001
   Maeda T, 2002, J BIOL CHEM, V277, P24346, DOI 10.1074/jbc.M201171200
   Maeda T, 2002, BIOCHEM BIOPH RES CO, V296, P1279, DOI 10.1016/S0006-291X(02)02085-5
   Mahoney WM, 2005, BIOCHEM J, V388, P217, DOI 10.1042/BJ20041434
   Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868
   Shie JL, 2004, J BIOL CHEM, V279, P25010, DOI 10.1074/jbc.M403103200
   Simons M, 2000, BIODRUGS, V14, P13, DOI 10.2165/00063030-200014010-00002
   Stewart AFR, 1996, GENOMICS, V37, P68, DOI 10.1006/geno.1996.0522
   Stewart AFR, 1998, CIRC RES, V83, P43, DOI 10.1161/01.RES.83.1.43
   Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601
   Vaudin P, 1999, DEVELOPMENT, V126, P4807
   Zhang CL, 2009, BIOCHEM BIOPH RES CO, V388, P464, DOI 10.1016/j.bbrc.2009.08.011
NR 21
TC 1
Z9 1
U1 3
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 13
PY 2009
VL 380
IS 3
BP 689
EP 694
DI 10.1016/j.bbrc.2009.01.151
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 419LZ
UT WOS:000264222400047
PM 19285023
DA 2018-12-27
ER

PT J
AU Day, D
   Gu, M
AF Day, Daniel
   Gu, Min
TI RETRACTED: A microfluidic microreactor for the synthesis of gold
   nanorods (Retracted article)
SO NANOTECHNOLOGY
LA English
DT Article; Retracted Publication
ID FEMTOSECOND LASER-PULSES; FABRICATION; GLASS; POLY(DIMETHYLSILOXANE);
   SURFACE; CHANNEL; DEVICES
AB A microfluidic microreactor for the synthesis of gold nanorods is fabricated using femtosecond pulse laser microfabrication techniques. Femtosecond pulse lasers are able to etch a wide range of materials that are required for a microreactor, from the photomasks to the microheaters. The heating of the fluid in the microreactor is achieved through the design and fabrication of a microscale heating element incorporated onto the bottom surface of the microreactor which is capable of reaching temperatures greater than 130 degrees C. Computational fluid dynamic simulations of the heating profile of an optimized microreactor show increased heating performance with respect to a serpentine microreactor. The synthesis of gold nanorods is demonstrated in the optimized microreactor, based on a flow rate of 0.5 mu g min(-1).
C1 [Day, Daniel; Gu, Min] Swinburne Univ Technol, Fac Engn & Ind Sci, Ctr Microphoton, Hawthorn, Vic 3122, Australia.
RP Day, D (reprint author), Swinburne Univ Technol, Fac Engn & Ind Sci, Ctr Microphoton, Hawthorn, Vic 3122, Australia.
EM dday@swin.edu.au
RI Gu, Min/B-6627-2008
FU Australian Research Council
FX The authors would like to thank Craig Bullen for his technical advice
   during the nanorod synthesis experiments and acknowledge the support
   from the Australian Research Council.
CR Chowdhury IH, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1901806
   Chung GS, 2004, SENSOR ACTUAT A-PHYS, V112, P55, DOI 10.1016/j.sna.2003.10.076
   Day D, 2002, APPL PHYS LETT, V80, P2404, DOI 10.1063/1.1467615
   Day D, 2006, OPT EXPRESS, V14, P10753, DOI 10.1364/OE.14.010753
   Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z
   Giridhar MS, 2004, APPL OPTICS, V43, P4584, DOI 10.1364/AO.43.004584
   Glezer EN, 1996, OPT LETT, V21, P2023, DOI 10.1364/OL.21.002023
   Heng Q, 2006, MICROFLUID NANOFLUID, V2, P357, DOI 10.1007/s10404-006-0078-7
   Krishnadasan S, 2007, LAB CHIP, V7, P1434, DOI 10.1039/b711412e
   Li Y, 2001, OPT LETT, V26, P1912, DOI 10.1364/OL.26.001912
   Lim D, 2003, LAB CHIP, V3, P318, DOI 10.1039/b308452c
   Liu JR, 2004, IEEE J SEL TOP QUANT, V10, P169, DOI 10.1109/JSTQE.2003.822945
   Masuda M, 2003, APPL PHYS A-MATER, V76, P857, DOI 10.1007/s00339-002-1937-z
   Sowa S, 2006, OPT EXPRESS, V14, P291, DOI 10.1364/OPEX.14.000291
   Tong T, 2004, SENSOR ACTUAT A-PHYS, V114, P102, DOI 10.1016/j.sna.2004.02.012
   Vanagas E, 2004, J MICROLITH MICROFAB, V3, P358, DOI 10.1117/1.1668274
   Ventura MJ, 2003, APPL PHYS LETT, V82, P1649, DOI 10.1063/1.1560870
   Wolfe DB, 2003, ADV MATER, V15, P62, DOI 10.1002/adma.200390012
   Wu J, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2840700
   Zijlstra P, 2006, J PHYS CHEM B, V110, P19315, DOI 10.1021/jp0635866
NR 20
TC 5
Z9 5
U1 5
U2 22
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0957-4484
EI 1361-6528
J9 NANOTECHNOLOGY
JI Nanotechnology
PD MAR 11
PY 2009
VL 20
IS 10
AR 105601
DI 10.1088/0957-4484/20/10/105601
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA 409GI
UT WOS:000263493800014
PM 19417521
DA 2018-12-27
ER

PT J
AU Ford, CE
   Ekstrom, EJ
   Andersson, T
AF Ford, Caroline E.
   Ekstrom, Elin J.
   Andersson, Tommy
TI RETRACTED: Wnt-5a signaling restores tamoxifen sensitivity in estrogen
   receptor-negative breast cancer cells (Retracted Article. See vol 107,
   pg 22360, 2010)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE breast cancer; ER
ID HISTONE DEACETYLASE INHIBITOR; EPITHELIAL-CELLS; ALPHA EXPRESSION;
   GENE-EXPRESSION; PROTEIN; METASTASIS; MOTILITY; METHYLATION; MODULATION;
   CARCINOMA
AB One third of all breast cancers are estrogen receptor alpha (ER alpha) negative, carry a poor overall prognosis, and do not respond well to currently available endocrine therapies. New treatment strategies are therefore required. Loss of Wnt-5a has previously been correlated with loss of ER alpha in clinical breast cancer samples, and we sought to investigate this association further. Three breast cancer cell lines (MDA-MB-231, MDA-MB-468, and 4T1) lacking expression of ER alpha and Wnt-5a, and one breast cancer cell line (T47D) expressing both proteins were used in this study. Wnt-5a signaling was generated in ER alpha-negative cell lines via stimulation with either recombinant Wnt-5a protein or a Wnt-5a-derived hexapeptide (Foxy-5) possessing Wnt-5a signaling properties. ER alpha expression was restored at both mRNA and protein level, after treatment with recombinant Wnt-5a or Foxy-5. This restoration of expression occurred in parallel with a reduction in methylation of the ER alpha promoter. Up-regulated ER alpha could be activated, initiate transcription of progesterone receptor and pS2, and activate an estrogen response element reporter construct. Significantly, breast cancer cells re-expressing ER alpha responded to treatment with the selective estrogen receptor modulator tamoxifen, as measured by induction of apoptosis and cell growth inhibition. Finally, Foxy-5 also increased ER alpha expression in an in vivo model of ER alpha-negative breast cancer. This represents the first evidence that Wnt-5a signaling acts to re-establish ER alpha expression in ER alpha-negative breast cancer cells. Our data suggest that combinatorial therapy with Foxy-5 and tamoxifen should be considered as a future treatment possibility for ER alpha-negative breast cancer patients.
C1 [Ford, Caroline E.; Ekstrom, Elin J.; Andersson, Tommy] Lund Univ, Malmo Univ Hosp, Dept Lab Med, S-20502 Malmo, Sweden.
   [Ford, Caroline E.] Univ New S Wales, Fac Med, Prince Wales Clin Sch, Integrated Canc Res Grp, Sydney, NSW 2052, Australia.
RP Ford, CE (reprint author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, S-20502 Malmo, Sweden.
EM caroline.ford@med.lu.se
RI Ford, Caroline/A-7850-2010
OI Ford, Caroline/0000-0002-4438-2309
CR Bandyopadhyay A, 2007, NEOPLASIA, V9, P113, DOI 10.1593/neo.06784
   Bruserud O, 2007, CURR PHARM BIOTECHNO, V8, P388, DOI 10.2174/138920107783018417
   CHEN D, 2002, ONCOGENE, V21, P4291
   Curtis CD, 2007, CANCER RES, V67, P10600, DOI 10.1158/0008-5472.CAN-07-0055
   DAUVOIS S, 1993, J CELL SCI, V106, P1377
   DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037
   Dejmek J, 2005, CANCER RES, V65, P9142, DOI 10.1158/0008-5472.CAN-05-1710
   Dejmek J, 2005, CLIN CANCER RES, V11, P520
   Dejmek J, 2006, MOL CELL BIOL, V26, P6024, DOI 10.1128/MCB.02354-05
   Dissanayake SK, 2007, J BIOL CHEM, V282, P17259, DOI 10.1074/jbc.M700075200
   FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883
   FOEKENS JA, 1990, CANCER RES, V50, P3832
   Gelmann EP, 1996, J NATL CANCER I, V88, P224, DOI 10.1093/jnci/88.5.224
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0
   Howell A, 2006, ENDOCR-RELAT CANCER, V13, P689, DOI 10.1677/erc.1.00846
   Janicke RU, 2009, BREAST CANCER RES TR, V117, P219, DOI 10.1007/s10549-008-0217-9
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Jansson M, 2001, J CELL SCI, V114, P2043
   Johnston SRD, 2003, NAT REV CANCER, V3, P821, DOI 10.1038/nrc1211
   Jonsson M, 2002, CANCER RES, V62, P409
   Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Leader JE, 2006, BIOCHEM PHARMACOL, V72, P1589, DOI 10.1016/j.bcp.2006.05.024
   Leandersson K, 2006, NUCLEIC ACIDS RES, V34, P3988, DOI 10.1093/nar/gkl571
   Li CG, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-11
   Liu XH, 2008, DIGEST LIVER DIS, V40, P560, DOI 10.1016/j.dld.2007.12.011
   Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Murphy LC, 2004, CLIN CANCER RES, V10, P5902, DOI 10.1158/1078-0432.CCR-04-0191
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Safholm A, 2006, J BIOL CHEM, V281, P2740, DOI 10.1074/jbc.M508386200
   Safholm A, 2008, CLIN CANCER RES, V14, P6556, DOI 10.1158/1078-0432.CCR-08-0711
   Schambony A, 2004, DIFFERENTIATION, V72, P307, DOI 10.1111/j.1432-0436.2004.07207002.x
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Suzuki T, 2001, BRIT J CANCER, V85, P1731, DOI 10.1054/bjoc.2001.2176
   Tsuchiya F, 2001, BIOCHEM BIOPH RES CO, V284, P2, DOI 10.1006/bbrc.2001.4892
   Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Zheng AP, 2007, ENDOCRINOLOGY, V148, P2764, DOI 10.1210/en.2006-1269
   Zoubir M, 2008, ANN ONCOL, V19, P1402, DOI 10.1093/annonc/mdn151
NR 42
TC 17
Z9 19
U1 1
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 10
PY 2009
VL 106
IS 10
BP 3919
EP 3924
DI 10.1073/pnas.0809516106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 416WT
UT WOS:000264036900050
PM 19237581
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Deraz, NM
AF Deraz, N. M.
TI RETRACTED: Influence of ceria on physicochemical, surface and catalytic
   properties of alumina supported manganese catalysts (Retracted article.
   See vol. 352, pg. 141, 2009)
SO COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS
LA English
DT Article; Retracted Publication
DE Catalytic activity; Manganese oxides; Activation energy; Alumina
ID OXIDE CATALYSTS; CO OXIDATION; COMBUSTION; OXYGEN; NONSTOICHIOMETRY;
   DECOMPOSITION
AB A series of catalysts containing manganese oxides supported on alumina and ceria-promoted alumina was prepared by wet impregnation method using finely powdered support material and manganese and/or cerium nitrate. The physicochemical, surface and catalytic properties of the thermally treated solids (500, 800 and 900 degrees C) were investigated using XRD, ESR, nitrogen adsorption at -196 degrees C and hydrogen peroxide decomposition in a aqueous solution at 30-50 degrees C.
   Experimental results show that Mn oxidation state changes from Mn(4+) to Mn(2+) by increasing the calcination temperature of solids studied. However, there are two unique features associated with CeO(2) as a material of interest. The first favors the dispersion of manganese oxides deposited on gamma-Al(2)O(3) catalyst calcined at 500 degrees C. The second enhances the formation of Mn(3)O(4) species from Mn(2)O(3) deposited initially on the alumina support calcined at 800 and 900 degrees C. These conclusions can be discussed in terms of modifications of both the oxygen storage capacity of ceria and structural properties of manganese oxides which are found in the investigated solids. The specific surface area of Mn/Al mixed oxides system calcined at 500 degrees C was found to increase by increasing the amount of dopant added. Opposite effect was observed by increasing the clacination temperature from 500 to 900 degrees C. The doping process followed by calcination at different temperatures brought about an increase in the catalytic activity of mixed oxides system.
   These treatments did not modify the mechanism of the catalyzed reaction but changed the number of catalytically active sites taking place in it without changing the energetic nature of these sites. (C) 2008 Elsevier B.V. All rights reserved.
C1 Natl Res Ctr, Dept Phys Chem, Lab Surface Chem & Catalysis, Cairo 12622, Egypt.
RP Deraz, NM (reprint author), Natl Res Ctr, Dept Phys Chem, Lab Surface Chem & Catalysis, Cairo 12622, Egypt.
EM nmderaz@yahoo.com
CR BALANDIN AA, 1953, DOKL AKAD NAUK SSSR+, V93, P55
   Baldi M, 1998, APPL CATAL B-ENVIRON, V16, P43, DOI 10.1016/S0926-3373(97)00061-1
   Baldi M., 1998, APPL CATAL B-ENVIRON, V17, P175
   BALTANAS MA, 1986, APPL CATAL, V28, P13, DOI 10.1016/S0166-9834(00)82490-2
   Bunluesin T, 1997, APPL CATAL B-ENVIRON, V14, P105, DOI 10.1016/S0926-3373(97)00016-7
   BUNLUESIN T, 1995, J CATAL, V157, P222, DOI 10.1006/jcat.1995.1282
   Carno J, 1997, APPL CATAL A-GEN, V155, P265, DOI 10.1016/S0926-860X(97)80129-9
   Chen H, 2001, APPL CATAL B-ENVIRON, V32, P195, DOI 10.1016/S0926-3373(01)00136-9
   Craciun R, 1998, CATAL LETT, V55, P25, DOI 10.1023/A:1019049921489
   Craciun R, 1997, CATAL LETT, V46, P229, DOI 10.1023/A:1019043224022
   Cullity BD, 1967, ELEMENTS XRAY DIFFRA
   Deraz N.M., 2001, MATER LETT, V53, P102
   Deraz NAM, 2005, COLLOID SURFACE A, V260, P95, DOI 10.1016/j.colsurfa.2004.08.043
   Deraz NAM, 2003, ADSORPT SCI TECHNOL, V21, P229, DOI 10.1260/026361703322404386
   Deraz NAM, 2001, ADSORPT SCI TECHNOL, V19, P541, DOI 10.1260/0263617011494385
   Deraz NAM, 2001, COLLOID SURFACE A, V190, P251, DOI 10.1016/S0927-7757(01)00708-7
   DERAZ NM, 2003, THERMOCHIM ACTA, V40, P175
   DEREN J, 1963, J CATAL, V2, P161, DOI 10.1016/0021-9517(63)90040-X
   FIEVET F, 1979, J APPL CRYSTALLOGR, V12, P387, DOI 10.1107/S0021889879012747
   Filotti L, 1997, APPL SURF SCI, V109, P249, DOI 10.1016/S0169-4332(96)00665-4
   Gallardo-Amores JM, 1999, APPL CATAL B-ENVIRON, V22, P249, DOI 10.1016/S0926-3373(99)00055-7
   Gandhi HS, 2003, J CATAL, V216, P433, DOI 10.1016/S0021-9517(02)00067-2
   GARCIA MF, 2004, CHEM REV, V104, P4063, DOI DOI 10.1021/CR030032F
   GREENWOOD NN, 1964, INORGANIC CRYSTAL LA, P37
   GROPPI G, 1993, APPL CATAL A-GEN, V104, P101, DOI 10.1016/0926-860X(93)85092-4
   Hasan MA, 1999, APPL CATAL A-GEN, V181, P171, DOI 10.1016/S0926-860X(98)00430-X
   Imamura S, 1996, APPL CATAL A-GEN, V142, P279, DOI 10.1016/0926-860X(96)00095-6
   KAPTEIJN F, 1994, J CATAL, V150, P94, DOI 10.1006/jcat.1994.1325
   Karlsson H.T., 1984, IND ENG CHEM P DES D, V23, P808
   Kim S, 2004, SURF SCI, V549, P196, DOI 10.1016/j.susc.2003.12.002
   Kroger F. A., 1964, CHEM IMPERFECT CRYST
   LAHOUSSE C, 1997, P 3 WORLD C OX CAT, pP777
   LANGFORD JI, 1978, J APPL CRYSTALLOGR, V11, P102, DOI 10.1107/S0021889878012844
   Lintz HG, 1996, CATAL TODAY, V29, P457, DOI 10.1016/0920-5861(95)00320-7
   LOJACONO M, 1976, PREPARATION CATALYST, P474
   Longya X., 1995, CATAL LETT, V31, P253
   MARTI PE, 1994, APPL CATAL B-ENVIRON, V4, P225, DOI 10.1016/0926-3373(94)00020-4
   Martin L, 2003, APPL CATAL B-ENVIRON, V44, P41, DOI 10.1016/S0926-3373(03)00008-0
   MILELLA F, 1998, J MATER CHEM, V8, P796
   Nishino A, 1991, CATAL TODAY, V10, P107, DOI 10.1016/0920-5861(91)80078-N
   NOHMAN AKH, 1994, ADSORPT SCI TECHNOL, V1, P1
   Normand F. L., 1988, J PHYS CHEM-US, V92, P2561
   OZAWA M, 1990, J MATER SCI LETT, V9, P291, DOI 10.1007/BF00725828
   OZKAN US, 1990, IND ENG CHEM RES, V29, pB113
   SERRE C, 1991, J CATAL, V141, P1
   Shaheen WM, 2002, MATER LETT, V52, P130, DOI 10.1016/S0167-577X(01)00380-9
   SINGOREDJO L, 1992, APPL CATAL B-ENVIRON, V1, P297, DOI 10.1016/0926-3373(92)80055-5
   SINGOREDJO L, 1992, THESIS U AMSTERDAM N
   STROHMEIER BR, 1984, J PHYS CHEM-US, V88, P4922, DOI 10.1021/j150665a026
   SU EC, 1986, J CATAL, V99, P506, DOI 10.1016/0021-9517(86)90376-3
   Trovarelli A, 1996, CATAL REV, V38, P439, DOI 10.1080/01614949608006464
   VANDERKLEUT D, 1994, THESIS U UTRECHT NET
   Velu S, 1999, MICROPOR MESOPOR MAT, V33, P61, DOI 10.1016/S1387-1811(99)00123-7
   WOLLNER A, 1993, J AGR FOOD CHEM, V26, P181
   ZHURAVLEV VA, 1994, ZH FIZ KHIM, V3, P271
NR 55
TC 3
Z9 3
U1 5
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7757
J9 COLLOID SURFACE A
JI Colloid Surf. A-Physicochem. Eng. Asp.
PD MAR 5
PY 2009
VL 335
IS 1-3
BP 8
EP 15
DI 10.1016/j.colsurfa.2008.10.045
PG 8
WC Chemistry, Physical
SC Chemistry
GA 408JO
UT WOS:000263431500002
DA 2018-12-27
ER

PT J
AU Nakamura, I
   Araki, T
   Terada, M
AF Nakamura, Itaru
   Araki, Toshiharu
   Terada, Masahiro
TI RETRACTED: Five-Bond Cleavage in Copper-Catalyzed Skeletal Rearrangement
   of O-Propargyl Arylaldoximes to beta-Lactams (Retracted Article. See vol
   133, pg 6861, 2011)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article; Retracted Publication
ID GOLD CATALYSIS; BUILDING-BLOCKS; BOND ACTIVATION; METAL;
   CYCLOISOMERIZATION; ESTERS; CYCLOADDITION; HETEROCYCLES;
   2-CYCLOPENTENONES; REORGANIZATION
AB Copper-catalyzed skeletal rearrangement of O-propargyl arylaldoximes 1 produced the corresponding 4-arylidene-2-azetidinones 2 and their regioisomers 2' in good to excellent yields. For example, the reaction of benzaldehyde O-1,3-diphenylprop-2-ynyl oxime (1b) in the presence of 10 mol% CuBr in toluene at 100 degrees C for 24 h gave (E)-4-benzylidene-1,3-diphenylazelidin-2-one (2b) in 96% yield. (13)C labeling experiments suggest that the present reaction proceeds through bond cleavage of five different covalent bonds: C=N, N O, C O, C C, and C C.
C1 [Nakamura, Itaru; Araki, Toshiharu; Terada, Masahiro] Tohoku Univ, Dept Chem, Grad Sch Sci, Sendai, Miyagi 9808578, Japan.
RP Nakamura, I (reprint author), Tohoku Univ, Dept Chem, Grad Sch Sci, Sendai, Miyagi 9808578, Japan.
EM itaru-n@mail.tains.tohoku.ac.jp
FU Japan Society for Promotion in Science (JSPS)
FX This work was financially supported by a Grant-in-Aid for Scientific
   Research from the Japan Society for Promotion in Science (JSPS). We also
   thank Dr. Eunsang Kwon (Research and Analytical Center for Giant
   Molecules, Graduate School of Science, Tohoku University) for X-ray
   crystallographic expertise.
CR Alcaide B, 2007, CHEM REV, V107, P4437, DOI 10.1021/cr0307300
   Asao N, 2003, J AM CHEM SOC, V125, P10921, DOI 10.1021/ja036927r
   Aubert C, 2002, CHEM REV, V102, P813, DOI 10.1021/cr980054f
   Brandi A, 2008, CHEM REV, V108, P3988, DOI 10.1021/cr800325e
   Buynak JD, 2004, CURR MED CHEM, V11, P1951, DOI 10.2174/0929867043364847
   CHATANI N, 1994, J AM CHEM SOC, V116, P6049, DOI 10.1021/ja00092a098
   Dudnik AS, 2008, J AM CHEM SOC, V130, P1440, DOI 10.1021/ja0773507
   Fehr C, 2006, ORG LETT, V8, P1839, DOI 10.1021/ol0603864
   Furstner A, 2008, J AM CHEM SOC, V130, P1992, DOI 10.1021/ja0777180
   Furstner A, 2007, ANGEW CHEM INT EDIT, V46, P3410, DOI 10.1002/anie.200604335
   Gorin DJ, 2007, NATURE, V446, P395, DOI 10.1038/nature05592
   Hashmi ASK, 2005, ANGEW CHEM INT EDIT, V44, P2798, DOI 10.1002/anie.200462672
   Ji KG, 2008, ORG LETT, V10, P3919, DOI 10.1021/ol8015463
   Jimenez-Nunez E, 2008, CHEM REV, V108, P3326, DOI 10.1021/cr0684319
   Jun CH, 2004, CHEM SOC REV, V33, P610, DOI 10.1039/b308864m
   KRONENTHAL DR, 1982, J ORG CHEM, V47, P2765, DOI 10.1021/jo00135a016
   Lee DY, 2003, J AM CHEM SOC, V125, P6372, DOI 10.1021/ja034337n
   Maddirala SJ, 2006, SYNLETT, P1173, DOI 10.1055/s-2006-926255
   Marion N, 2007, ANGEW CHEM INT EDIT, V46, P2750, DOI 10.1002/anie.200604773
   Michelet V, 2008, ANGEW CHEM INT EDIT, V47, P4268, DOI 10.1002/anie.200701589
   Miyanohana Y, 2006, ORG LETT, V8, P2155, DOI 10.1021/ol060606d
   Murai S., 1999, ACTIVATION UNREACTIV, V3
   Musaev DG, 2005, TOP ORGANOMETAL CHEM, V12, P1
   Ojima I, 1997, CHEM SOC REV, V26, P377, DOI 10.1039/cs9972600377
   Pal R, 2007, SYNLETT, P2321, DOI 10.1055/s-2007-986637
   Patil NT, 2008, CHEM REV, V108, P3395, DOI 10.1021/cr050041j
   Pujanauski BG, 2006, J AM CHEM SOC, V128, P6786, DOI 10.1021/ja061549m
   RAUTENSTRAUCH V, 1984, J ORG CHEM, V49, P950, DOI 10.1021/jo00179a044
   Schwier T, 2007, J AM CHEM SOC, V129, P9868, DOI 10.1021/ja072446m
   Shi XD, 2005, J AM CHEM SOC, V127, P5802, DOI 10.1021/ja051689g
   Shimada T, 2003, J AM CHEM SOC, V125, P6646, DOI 10.1021/ja034105o
   Sun JW, 2006, J AM CHEM SOC, V128, P9705, DOI 10.1021/ja063384n
   Tobisu M, 2008, CHEM SOC REV, V37, P300, DOI 10.1039/b702940n
   Trost BM, 2002, J AM CHEM SOC, V124, P2528, DOI 10.1021/ja011840w
   TROST BM, 1988, J AM CHEM SOC, V110, P1636, DOI 10.1021/ja00213a054
   TROST BM, 1991, J AM CHEM SOC, V113, P1850, DOI 10.1021/ja00005a070
   Wang SZ, 2006, J AM CHEM SOC, V128, P8414, DOI 10.1021/ja062777j
   Yeom HS, 2008, ANGEW CHEM INT EDIT, V47, P7040, DOI 10.1002/anie.200802802
   Yeom HS, 2007, SYNLETT, P2292, DOI 10.1055/s-2007-985571
   Zhang LM, 2006, ADV SYNTH CATAL, V348, P2271, DOI 10.1002/adsc.200600368
NR 40
TC 30
Z9 30
U1 4
U2 89
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD MAR 4
PY 2009
VL 131
IS 8
BP 2804
EP +
DI 10.1021/ja900133m
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 427PX
UT WOS:000264792300025
PM 19199800
DA 2018-12-27
ER

PT J
AU Gold, A
   Hunton, JE
   Gomaa, MI
AF Gold, Anna
   Hunton, James E.
   Gomaa, Mohamed I.
TI RETRACTED: The Impact of Client and Auditor Gender on Auditors'
   Judgments (Retracted article. See vol. 29, pg. 743, 2015)
SO ACCOUNTING HORIZONS
LA English
DT Article; Retracted Publication
DE audit judgment; auditor gender; client gender; gender stereotypes; risk
   taking; selectivity hypothesis
ID DECISION-MAKING; MANAGERS SCALE; RISK-TAKING; WOMEN; INFORMATION;
   ATTITUDES; DIMENSIONALITY; METAANALYSIS; STEREOTYPES; COMPETENCE
AB This study assesses the influence of client gender and auditor gender on auditors' judgments. In an experimental task, a client offers unverified explanations as to why the auditor's initial proposed adjusting journal entry (AJE) to lower the inventory value should not be recorded. The design includes one randomly manipulated variable (client gender: male or female) and one measured variable (auditor gender: male or female). The dependent variable assesses the influence of the client's explanations on the auditor's final proposed AJE recommendation. The results indicate that both male and female auditors exhibited a male favorability; that is, they were persuaded more by a male than female client to change their initial AJE recommendation. Furthermore, female auditors were more influenced by a male client and less influenced by a female client than male auditors. Using an expert panel's consensus opinion as a benchmark for the "best" solution, the male auditors were more accurate than female auditors, irrespective of client gender. Additional research will aid in substantiating, determining the limits, and generalizing the findings.
C1 [Gold, Anna] Erasmus Univ, NL-3000 DR Rotterdam, Netherlands.
   [Hunton, James E.] Bentley Univ, Waltham, MA USA.
   [Gomaa, Mohamed I.] Suffolk Univ, Boston, MA 02108 USA.
RP Gold, A (reprint author), Erasmus Univ, NL-3000 DR Rotterdam, Netherlands.
EM agold@rsm.nl
CR *AICPA, 2008, 2008 TRENDS SUPPL AC
   *AICPA, 2006, AICPA WORK LIF WOM I
   Almer E.D., 1998, ACCOUNT HORIZ, V12, P1
   ANDERSON JC, 1994, ACCOUNT ORG SOC, V19, P483, DOI 10.1016/0361-3682(94)90019-1
   ANDERSON U, 1994, AUDITING-J PRACT TH, V13, P137
   Berger J., 1977, STATUS CHARACTERISTI
   Biernat M, 2001, J SOC ISSUES, V57, P707, DOI 10.1111/0022-4537.00237
   BLUEDORN A, 1983, ACADEMY MANAGEMENT B, P397
   BRENNER OC, 2001, J SOC PSYCHOL, V129, P57
   BRODER IE, 1993, AM ECON REV, V83, P964
   Byrnes JP, 1999, PSYCHOL BULL, V125, P367, DOI 10.1037/0033-2909.125.3.367
   Carli LL, 2001, J SOC ISSUES, V57, P725, DOI 10.1111/0022-4537.00238
   CARLI LL, 1990, J PERS SOC PSYCHOL, V59, P941, DOI 10.1037/0022-3514.59.5.941
   Chung J., 1998, ACCOUNT FINANC, V38, P265, DOI DOI 10.1111/ACFI.1998.38.ISSUE-2
   Chung J, 2001, BEHAV RES ACCOUNT, V13, P111, DOI DOI 10.2308/BRIA.2001.13.1.111
   Collins K. M., 1993, ACCOUNT HORIZ, V7, P29
   Cordano M, 2003, J SOC PSYCHOL, V143, P141, DOI 10.1080/00224540309598436
   CRINO MD, 1981, ACAD MANAGE J, V24, P866, DOI 10.2307/256183
   Dennison JR, 1996, SPECTROSCOPY, V11, P38
   Dunning D, 1997, J PERS SOC PSYCHOL, V73, P459, DOI 10.1037/0022-3514.73.3.459
   Dwyer PD, 2002, ECON LETT, V76, P151, DOI 10.1016/S0165-1765(02)00045-9
   EAGLY AH, 1992, PSYCHOL BULL, V111, P3, DOI 10.1037/0033-2909.111.1.3
   GOLDBERG P, 1968, TRANS-ACT-SOC SCI MO, V5, P28
   GREENWALD AG, 1995, PSYCHOL REV, V102, P4, DOI 10.1037//0033-295X.102.1.4
   HACKENBRACK K, 1992, J ACCOUNTING RES, V30, P126, DOI 10.2307/2491095
   HARDIN JR, 2002, J MANAGERIAL ISSUES, V14, P251
   Heilman ME, 2004, J APPL PSYCHOL, V89, P416, DOI 10.1037/0021-9010.89.3.416
   Heilman ME, 2005, J APPL PSYCHOL, V90, P431, DOI 10.1037/0021-9010.90.3.431
   HEILMAN ME, 1989, J APPL PSYCHOL, V74, P935, DOI 10.1037//0021-9010.74.6.935
   Hinz R. P., 1997, POSITIONING PENSIONS, P91
   Hull RP, 1997, ACCOUNT ORG SOC, V22, P507, DOI 10.1016/S0361-3682(96)00028-1
   Jianakoplos NA, 1998, ECON INQ, V36, P620, DOI 10.1111/j.1465-7295.1998.tb01740.x
   Johnson E. N., 1998, BEHAV RES ACCOUNTING, V10, P47
   Lockheed M. E, 1985, STATUS REWARDS INFLU, P406
   MATHISON DL, 1986, J SOC PSYCHOL, V126, P599, DOI 10.1080/00224545.1986.9713632
   MEYERSLEVY J, 1991, J MARKETING RES, V28, P84, DOI 10.2307/3172728
   MEYERSLEVY J, 1991, J CONSUM RES, V18, P63, DOI 10.1086/209241
   MeyersLevy J., 1989, COGN AFFECT BEHAV NE, P219
   MEYERSLEVY J, 1998, CAPITAL IDEAS, V1
   Norton MI, 2004, J PERS SOC PSYCHOL, V87, P817, DOI 10.1037/0022-3514.87.6.817
   Noteberg A, 2005, ADV ACCT BEH RES, V8, P87, DOI 10.1016/S1475-1488(04)08004-4
   NYBERGSTUART A, 2006, CFO-MAG SR FINANC EX, V22, P46
   O'Donnell E., 2001, INT J AUDITING, V5, P91, DOI DOI 10.1111/IJAU.2001.5.ISSUE-2
   OLSEN RA, 2001, J PSYCHOL FINANCIAL, V2, P29, DOI DOI 10.1207/S15327760JPFM0201_3
   Owen Crystal L., 1993, BUS HORIZONS, P12
   Peters L.H., 1974, JSAS CATALOG SELECTE, V4, P27
   Pillsbury C. M., 1989, ACCOUNT HORIZ, V3, P63
   POWELL GN, 1989, GROUP ORGAN STUD, V14, P216, DOI 10.1177/105960118901400209
   PROPP KM, 1995, SMALL GR RES, V26, P451, DOI 10.1177/1046496495264001
   RAGINS BR, 1993, J MANAGE, V19, P97, DOI 10.1177/014920639301900107
   Rudman LA, 1999, J PERS SOC PSYCHOL, V77, P1004, DOI 10.1037/0022-3514.77.5.1004
   Rudman LA, 2000, PERS SOC PSYCHOL B, V26, P1315, DOI 10.1177/0146167200263001
   Rudman LA, 1998, J PERS SOC PSYCHOL, V74, P629, DOI 10.1037/0022-3514.74.3.629
   Schein VE, 2001, J SOC ISSUES, V57, P675, DOI 10.1111/0022-4537.00235
   SCHEIN VE, 1992, J ORGAN BEHAV, V13, P439, DOI 10.1002/job.4030130502
   Schein VE, 1996, J ORGAN BEHAV, V17, P33, DOI 10.1002/(SICI)1099-1379(199601)17:1<33::AID-JOB778>3.3.CO;2-6
   SCHNEIDER J, 1995, SMALL GR RES, V26, P372, DOI 10.1177/1046496495263004
   Sunden AE, 1998, AM ECON REV, V88, P207
   TERBORG JR, 1977, ACAD MANAGE J, V20, P89, DOI 10.2307/255464
   Trapp M., 1989, ACCOUNT HORIZ, V3, P71
   Wagner DG, 1997, SOCIOL PERSPECT, V40, P1, DOI 10.2307/1389491
   Williams JE, 1990, MEASURING SEX STEREO
   YOUNG SM, 1985, J ACCOUNTING RES, V23, P829, DOI 10.2307/2490840
NR 63
TC 32
Z9 32
U1 2
U2 24
PU AMER ACCOUNTING ASSOC
PI SARASOTA
PA 5717 BESSIE DR, SARASOTA, FL 34233 USA
SN 0888-7993
EI 1558-7975
J9 ACCOUNT HORIZ
JI Account. Horiz.
PD MAR
PY 2009
VL 23
IS 1
BP 1
EP 18
DI 10.2308/acch.2009.23.1.1
PG 18
WC Business, Finance
SC Business & Economics
GA 425CF
UT WOS:000264613900001
DA 2018-12-27
ER

PT J
AU Lin, JZ
   Feng, L
   Hamajima, Y
   Komori, M
   Burns, TC
   Fukudome, S
   Anderson, J
   Wang, D
   Verfaillie, CM
   Low, WC
AF Lin, Jizhen
   Feng, Ling
   Hamajima, Yuki
   Komori, Masahiro
   Burns, Terry C.
   Fukudome, Shinji
   Anderson, John
   Wang, Dong
   Verfaillie, Catherine M.
   Low, Walter C.
TI RETRACTED: Directed differentiation of mouse cochlear neural progenitors
   in vitro (Retracted article. See vol. 297, pg. C1596, 2009)
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article; Retracted Publication
DE growth factor; proliferation
ID AUDITORY HAIR-CELLS; PROGRESSIVE HEARING-LOSS; PLURIPOTENT STEM-CELLS;
   INNER-EAR; ACOUSTIC TRAUMA; SONIC HEDGEHOG; GENE-TRANSFER; MICE LACKING;
   PROLIFERATION; REGENERATION
AB Lin J, Feng L, Hamajima Y, Komori M, Burns TC, Fukudome S, Anderson J, Wang D, Verfaillie CM, Low WC. Directed differentiation of mouse cochlear neural progenitors in vitro. Am J Physiol Cell Physiol 296: C441-C452, 2009. First published December 17, 2008; doi:10.1152/ajpcell.00324.2008.-Multipotent cochlear neural progenitors (CNPs) in the organ of Corti hold the promise for cell replacement in degenerative hearing disorders. However, not much is known about the CNPs and the specific conditions for their differentiation. Here we isolate the CNPs from the postnatal day 1 organ of Corti in mice and demonstrate their capability to self-renew and to differentiate into hair cell-like and neuronal cell-like phenotypes under the guidance of sonic hedgehog (SHH), epidermal growth factor (EGF), retinoic acid (RA), and brain-derived neurotrophic factor (BDNF), herein termed SERB (abbreviation of SHH, EGF, RA, and BDNF) in an asymmetric or symmetric manner from clonal isolates. Differentiation of CNPs into hair cells by SERB was dependent on the ERK signaling pathway, whereas the differentiation of CNPs into neurons by SERB was not. This work develops a new in vitro methodology for the maintenance and self-regeneration of CNPs for future design of regenerative strategies for hearing disorders.
C1 [Lin, Jizhen; Feng, Ling; Hamajima, Yuki; Komori, Masahiro; Fukudome, Shinji; Anderson, John] Univ Minnesota, Dept Otolaryngol, Minneapolis, MN 55455 USA.
   [Burns, Terry C.; Anderson, John; Low, Walter C.] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
   [Burns, Terry C.; Low, Walter C.] Univ Minnesota, Grad Program Neurosci, Minneapolis, MN 55455 USA.
   [Lin, Jizhen; Burns, Terry C.; Verfaillie, Catherine M.; Low, Walter C.] Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA.
RP Lin, JZ (reprint author), Univ Minnesota, Dept Otolaryngol, 216 Lions Res Bldg,2001 6th St SE, Minneapolis, MN 55455 USA.
EM linxx004@tc.umn.edu
OI Verfaillie, Catherine/0000-0001-7564-4079; Terry,
   Burns/0000-0001-7633-3045
FU National Institute on Deafness and Other Communication Disorders [R01
   DC-008165, P30 CD-04660]; National Cancer Institute [R03 CA-107989];
   Academic Health Center; 5M Lions International Hearing Foundation
FX This study is in part supported by the National Institute on Deafness
   and Other Communication Disorders Grants R01 DC-008165 and P30 CD-04660,
   National Cancer Institute Grant R03 CA-107989, the Academic Health
   Center seed grant, and the 5M Lions International Hearing Foundation.
CR Adams JP, 2000, ACTA NEUROBIOL EXP, V60, P377
   ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D
   Bermingham NA, 1999, SCIENCE, V284, P1837, DOI 10.1126/science.284.5421.1837
   Bok JW, 2005, DEVELOPMENT, V132, P2115, DOI 10.1242/dev.01796
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Chen P, 2003, NAT CELL BIOL, V5, P422, DOI 10.1038/ncb976
   CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100
   CORWIN JT, 1991, CIBA F SYMP, V160, P103
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Doetzlhofer A, 2004, DEV BIOL, V272, P432, DOI 10.1016/j.ydbio.2004.05.013
   Gubbels SP, 2008, NATURE, V455, P537, DOI 10.1038/nature07265
   Inoue Y, 2006, BIOSCI BIOTECH BIOCH, V70, P2248, DOI 10.1271/bbb.60178
   Izumikawa M, 2005, NAT MED, V11, P271, DOI 10.1038/nm1193
   Kalinec F, 1999, CELL BIOL INT, V23, P175, DOI 10.1006/cbir.1998.0339
   Kawamoto K, 2003, J NEUROSCI, V23, P4395
   Kondo T, 2005, P NATL ACAD SCI USA, V102, P4789, DOI 10.1073/pnas.0408239102
   LEFEBVRE PP, 1993, SCIENCE, V260, P692, DOI 10.1126/science.8480180
   Li HW, 2004, TRENDS MOL MED, V10, P309, DOI 10.1016/j.molmed.2004.05.008
   Li HW, 2003, NAT MED, V9, P1293, DOI 10.1038/nm925
   Lin JZ, 2007, CURR MED CHEM, V14, P2937, DOI 10.2174/092986707782360051
   Liu W, 2002, DEV BIOL, V248, P240, DOI 10.1006/dbio.2002.0733
   Lu J, 2005, DEVELOPMENT, V132, P3231, DOI 10.1242/dev.01893
   Malgrange B, 2002, MECH DEVELOP, V112, P79, DOI 10.1016/S0925-4773(01)00642-6
   Oshima K, 2007, JARO-J ASSOC RES OTO, V8, P18, DOI 10.1007/s10162-006-0058-3
   Ozeki M, 2003, HEARING RES, V179, P43, DOI 10.1016/S0378-5955(03)00077-7
   Ozeki M, 2007, J NEUROSCI RES, V85, P515, DOI 10.1002/jnr.21133
   RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101
   Sage C, 2005, SCIENCE, V307, P1114, DOI 10.1126/science.1106642
   Sahly I, 1997, ANAT EMBRYOL, V196, P159, DOI 10.1007/s004290050088
   Sam TN, 2006, CELL TRANSPLANT, V15, P147, DOI 10.3727/000000006783982098
   Staecker H, 1996, NEUROREPORT, V7, P889, DOI 10.1097/00001756-199603220-00011
   Tio M, 2001, NATURE, V409, P1063, DOI 10.1038/35059124
   Vahava O, 1998, SCIENCE, V279, P1950, DOI 10.1126/science.279.5358.1950
   Xiang MQ, 1998, DEVELOPMENT, V125, P3935
   Zheng JL, 2000, NAT NEUROSCI, V3, P580
   Zheng JL, 2000, DEVELOPMENT, V127, P4551
   Zheng LL, 2000, CELL, V102, P377, DOI 10.1016/S0092-8674(00)00042-8
   Zindy F, 1999, P NATL ACAD SCI USA, V96, P13462, DOI 10.1073/pnas.96.23.13462
   Zine A, 1998, NEUROREPORT, V9, P263, DOI 10.1097/00001756-199801260-00016
NR 39
TC 7
Z9 7
U1 4
U2 11
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD MAR
PY 2009
VL 296
IS 3
BP C441
EP C452
DI 10.1152/ajpcell.00324.2008
PG 12
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 414YX
UT WOS:000263902500008
PM 19261910
OA Green Published
DA 2018-12-27
ER

PT J
AU Kumar, R
   Srinivasan, S
   Koduru, S
   Pahari, P
   Rohr, J
   Kyprianou, N
   Damodaran, C
AF Kumar, Raj
   Srinivasan, Sowmyalakshmi
   Koduru, Srinivas
   Pahari, Pallab
   Rohr, Juergen
   Kyprianou, Natasha
   Damodaran, Chendil
TI RETRACTED: Psoralidin, an Herbal Molecule, Inhibits Phosphatidylinositol
   3-Kinase-Mediated Akt Signaling in Androgen-Independent Prostate Cancer
   Cells (Retracted article. See vol. 4, pg. 1945, 2011)
SO CANCER PREVENTION RESEARCH
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; EMERGING ROLE; KINASE-B; PATHWAY; CORYLIFOLIA; APOPTOSIS;
   PROGRESSION; ACTIVATION; EXPRESSION; PHOSPHORYLATION
AB The protein kinase Akt plays an important role in cell proliferation and survival in many cancers, including prostate cancer. Due to its kinase activity, it serves as a molecular conduit for inhibiting apoptosis and promoting angiogenesis in most cell types. In most of the prostate tumors, Akt signaling is constitutively activated due to the deletion or mutation of the tumor suppressor PTEN, which negatively regulates phosphatidylinositol 3-kinase through lipid phosphatase activity. Recently, we identified a natural compound, psoralidin, which inhibits Akt phosphorylation, and its consequent activation in androgen-independent prostate cancer (AIPC) cells. Furthermore, ectopic expression of Akt renders AIPC cells resistant to chemotherapy; however, psoralidin overcomes Akt-mediated resistance and induces apoptosis in AIPC cells. While dissecting the molecular events, both upstream and downstream of Akt, we found that psoralidin inhibits phosphatidylinositol 3-kinase activation and transcriptionally represses the activation of nuclear factor-kappa B and its target genes (Bcl-2, Survivin, and Bcl-xL, etc.), which results in the inhibition of cell viability and induction of apoptosis in PC-3 and DU-145 cells. Interestingly, psoralidin selectively targets cancer cells without causing any toxicity to normal prostate epithelial cells. In vivo xenograft assays substantiate these in vitro findings and show that psoralidin inhibits prostate tumor growth in nude mice. Our findings are of therapeutic significance in the management of prostate cancer patients with advanced or metastatic disease, as they provide new directions for the development of a phytochemical-based platform for prevention and treatment strategies for AIPC.
C1 [Kumar, Raj; Srinivasan, Sowmyalakshmi; Koduru, Srinivas; Damodaran, Chendil] Univ Kentucky, Dept Clin Lab Sci, Coll Hlth Sci, Lexington, KY 40536 USA.
   [Pahari, Pallab; Rohr, Juergen] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA.
   [Kyprianou, Natasha] Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA.
   [Kyprianou, Natasha] Univ Kentucky, Dept Urol Surg, Lexington, KY 40536 USA.
   [Kyprianou, Natasha] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
RP Damodaran, C (reprint author), Univ Kentucky, Dept Clin Sci, Coll Hlth Sci, Room 124E,900 S Limestone St, Lexington, KY 40536 USA.
EM dchen2@uky.edu
RI Rohr, Jurgen/G-5375-2014
OI Rohr, Jurgen/0000-0001-6447-5951; Pahari, Pallab/0000-0003-3662-2015
FU NIH [R01 AT002890]; University of Kentucky Research Foundation
FX NIH R01 (R01 AT002890) and University of Kentucky Research Foundation
   grants (C. Damodaran).
CR Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900
   Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
   Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782
   Carson JP, 1999, CANCER RES, V59, P1449
   Chen TY, 2000, SERV IND J, V20, P95, DOI 10.1080/02642060000000006
   Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736
   Chendil D, 2004, ONCOGENE, V23, P1599, DOI 10.1038/sj.onc.1207284
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684
   Dancey JE, 2004, ANN ONCOL, V15, P233, DOI 10.1093/annonc/mdh932
   Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115
   Granville CA, 2006, CLIN CANCER RES, V12, P679, DOI 10.1158/1078-0432.CCR-05-1654
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690
   Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219
   Khatune NA, 2004, FITOTERAPIA, V75, P228, DOI 10.1016/j.fitote.2003.12.018
   Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272
   LaCasse EC, 1998, ONCOGENE, V17, P3247
   Le Page C, 2006, BRIT J CANCER, V94, P1906, DOI 10.1038/sj.bjc.6603184
   Le Page C, 2005, PROSTATE, V65, P306, DOI 10.1002/pros.20291
   Le Page C, 2005, PROSTATE, V65, P130, DOI 10.1002/pros.20234
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Li L, 2005, PROSTATE CANCER P D, V8, P108, DOI 10.1038/sj.pcan.4500776
   Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433
   Liao YD, 2003, INT J CANCER, V107, P676, DOI 10.1002/ijc.11471
   Lin JQ, 1999, CANCER RES, V59, P2891
   Majumder P, 2003, P NATL ACAD SCI USA, V100, P5223, DOI 10.1073/pnas.0830190100
   Malik SN, 2002, CLIN CANCER RES, V8, P1168
   Manin M, 2002, BIOCHEM J, V366, P729, DOI 10.1042/BJ20020585
   Mar W, 2001, ARCH PHARM RES, V24, P211, DOI 10.1007/BF02978259
   Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528
   Namiki M, 2007, INT J CLIN ONCOL, V12, P427, DOI 10.1007/s10147-007-0704-8
   *PHARM ED COMM, 2000, ED COMM PHARM PEOPL
   Priulla M, 2007, PROSTATE, V67, P782, DOI 10.1002/pros.20566
   Ranga RS, 2004, CANCER CHEMOTH PHARM, V54, P7, DOI 10.1007/s00280-004-0770-9
   Ryan CJ, 2005, J CLIN ONCOL, V23, P8242, DOI 10.1200/JCO.2005.03.3092
   Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797
   Shukla S, 2005, PROSTATE, V64, P224, DOI 10.1002/pros.20217
   Shulkla S, 2007, INT J CANCER, V121, P1424, DOI 10.1002/ijc.22862
   Srinivasan S, 2007, CANCER RES, V67, P246, DOI 10.1158/0008-5472.CAN-06-2430
   Tanaka T, 2007, NAT IMMUNOL, V8, P584, DOI 10.1038/ni1464
   Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007
   Varnai P, 2005, J CELL SCI, V118, P4879, DOI 10.1242/jcs.02606
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/mrc839
   Wang CY, 1999, NAT MED, V5, P412
   Wang DW, 2001, PLANTA MED, V67, P748, DOI 10.1055/s-2001-18343
   Xiong Z, 2003, PHARMAZIE, V58, P925
   Yang YM, 1996, PLANTA MED, V62, P353, DOI 10.1055/s-2006-957901
   ZHU YP, 1998, CHINESE MAT MED CHEM, P609
NR 50
TC 24
Z9 25
U1 3
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
EI 1940-6215
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD MAR
PY 2009
VL 2
IS 3
BP 234
EP 243
DI 10.1158/1940-6207.CAPR-08-0129
PG 10
WC Oncology
SC Oncology
GA 420MT
UT WOS:000264294600008
PM 19223576
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Aghaie, H
   Gholmi, MR
   Ganji, MD
   Taghavi, MM
AF Aghaie, H.
   Gholmi, M. R.
   Ganji, M. D.
   Taghavi, M. M.
TI RETRACTED: First principles study of the I-V characteristics of the
   alkane-thiols nano-molecular wires (Retracted article. See vol. 9, pg.
   1180, 2009)
SO CURRENT APPLIED PHYSICS
LA English
DT Article; Retracted Publication
DE Molecular electronics; DFT; Electron transport; Non-equilibrium Green's
   function; Alkane-thiols
ID CURRENT-VOLTAGE CHARACTERISTICS; NEGATIVE DIFFERENTIAL RESISTANCE;
   SCANNING-TUNNELING-MICROSCOPY; SELF-ASSEMBLED MONOLAYERS; 1ST-PRINCIPLES
   CALCULATION; CONDUCTANCE QUANTIZATION; ELECTRICAL-CONDUCTION; TRANSPORT;
   SYSTEMS; C-60
AB We report a density functional non-equilibrium Green's function study of electrical transport in a single molecular conductor consisting of an ethane-dithiolate (C2H4S2) Molecular wire with two sulfur end groups bonded to the Au(1 1 1) electrodes. We show that the Current was increased by increasing the external voltage biases. The projected density of states (PDOS) and transmission coefficients T(E) under various external voltage biases are analyzed, and it suggests that the variation of the coupling between the molecule and the electrodes with external bias leads to the increase of the current. Furthermore, the investigation of the transport properties of the pentane-dithiolate (C5H10S2) molecular wire shows that the pentane-dithiolate molecular wire has a lower conductivity than the ethanedithiolate wire. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Aghaie, H.; Ganji, M. D.] Islamic Azad Univ, Dept Chem, Tehran, Iran.
   [Gholmi, M. R.] Sharif Univ Technol, Dept Chem, Tehran, Iran.
   [Ganji, M. D.; Taghavi, M. M.] Islamic Azad Univ, Dept Chem, Ghaemshahr Branch, Mazandaran, Iran.
RP Aghaie, H (reprint author), Islamic Azad Univ, Dept Chem, Tehran, Iran.
EM hn_aghaie@yahoo.com
OI Taghavi, Mehdi/0000-0002-6381-2845
CR Agapito LA, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.115316
   AGRAIT N, 1993, PHYS REV B, V47, P12345, DOI 10.1103/PhysRevB.47.12345
   ANDERS RP, 1997, SCIENCE, V273, P1690
   Artacho E, 1999, PHYS STATUS SOLIDI B, V215, P809, DOI 10.1002/(SICI)1521-3951(199909)215:1<809::AID-PSSB809>3.0.CO;2-0
   AVIRAM A, 1974, CHEM PHYS LETT, V29, P277, DOI 10.1016/0009-2614(74)85031-1
   Brandbyge M, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.165401
   BRANDYGE M, 1997, PHYS REV B, V56
   BUTTIKER M, 1985, PHYS REV B, V31, P6207, DOI 10.1103/PhysRevB.31.6207
   Chen J, 1999, SCIENCE, V286, P1550, DOI 10.1126/science.286.5444.1550
   Collier CP, 2000, SCIENCE, V289, P1172, DOI 10.1126/science.289.5482.1172
   COLLIER CP, 1999, SCIENCE, V578, P152
   Cui XD, 2001, SCIENCE, V294, P571, DOI 10.1126/science.1064354
   Damle PS, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.201403
   Datta S, 1997, PHYS REV LETT, V79, P2530, DOI 10.1103/PhysRevLett.79.2530
   Derosa PA, 2001, J PHYS CHEM B, V105, P471, DOI 10.1021/jp003033+
   Di Ventra M, 2000, PHYS REV LETT, V84, P979, DOI 10.1103/PhysRevLett.84.979
   Emberly EG, 1998, PHYS REV B, V58, P10911, DOI 10.1103/PhysRevB.58.10911
   Ganji MD, 2008, PHYSICA E, V40, P2606, DOI 10.1016/j.physe.2007.09.123
   GOLBERG D, 2006, APPL PHYS LETT, V88
   Hall LE, 2000, J CHEM PHYS, V112, P1510, DOI 10.1063/1.480696
   Haug H., 1996, QUANTUM KINETICS TRA
   Hou JG, 1999, PHYS REV LETT, V83, P3001, DOI 10.1103/PhysRevLett.83.3001
   Hou SM, 2005, NANOTECHNOLOGY, V16, P239, DOI 10.1088/0957-4484/16/2/010
   JAUHO AP, 1994, PHYS REV B, V50, P5528, DOI 10.1103/PhysRevB.50.5528
   JOACHIM C, 1995, PHYS REV LETT, V74, P2102, DOI 10.1103/PhysRevLett.74.2102
   KRANS JM, 1995, NATURE, V375, P767, DOI 10.1038/375767a0
   Lee T, 2005, JPN J APPL PHYS 1, V44, P523, DOI 10.1143/JJAP.44.523
   MULLER CJ, 1992, PHYS REV LETT, V69, P140, DOI 10.1103/PhysRevLett.69.140
   Ortiz DO, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2781386
   Palacios JJ, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.035322
   Park H, 2000, NATURE, V407, P57, DOI 10.1038/35024031
   PASCUAL JI, 1993, PHYS REV LETT, V71, P1852, DOI 10.1103/PhysRevLett.71.1852
   Paulsson M, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.035416
   PERDEW JP, 1981, PHYS REV B, V23, P5048, DOI 10.1103/PhysRevB.23.5048
   Porath D, 1997, PHYS REV B, V56, P9829, DOI 10.1103/PhysRevB.56.9829
   Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252
   Reichert J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.176804
   Rocha AR, 2005, NAT MATER, V4, P335, DOI 10.1038/nmat1349
   ROCHA AR, SMEAGOL SPIN MOL ELE
   Roland C, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.035332
   SAMANTA M, 1999, THESIS PURDUE U
   Scheer E, 1998, NATURE, V394, P154, DOI 10.1038/28112
   SELLERS H, 1993, J AM CHEM SOC, V115, P9389, DOI 10.1021/ja00074a004
   Seminario JM, 2004, J PHYS CHEM B, V108, P17879, DOI 10.1021/jp046554w
   Seminario JM, 2003, P IEEE, V91, P1958, DOI 10.1109/JPROC.2003.818328
   Seminario JM, 2005, NAT MATER, V4, P111, DOI 10.1038/nmat1313
   Seminario JM, 2007, J PHYS B-AT MOL OPT, V40, pF275, DOI 10.1088/0953-4075/40/17/F03
   Seminario JM, 2006, IEEE SENS J, V6, P1614, DOI 10.1109/JSEN.2006.884163
   Shi XQ, 2005, J PHYS CHEM B, V109, P3334, DOI 10.1021/jp046349g
   Soler JM, 2002, J PHYS-CONDENS MAT, V14, P2745, DOI 10.1088/0953-8984/14/11/302
   Tans SJ, 1998, NATURE, V393, P49
   Tian WD, 1998, J CHEM PHYS, V109, P2874, DOI 10.1063/1.476841
   TROULLIER N, 1991, PHYS REV B, V43, P1993, DOI 10.1103/PhysRevB.43.1993
   Wang CS, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/4/044005
   Wang WY, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.035416
   Yan LM, 2006, INT J QUANTUM CHEM, V106, P1964, DOI 10.1002/qua.20949
   Yanson AI, 1997, PHYS REV LETT, V79, P2157, DOI 10.1103/PhysRevLett.79.2157
NR 57
TC 6
Z9 6
U1 4
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1739
EI 1878-1675
J9 CURR APPL PHYS
JI Curr. Appl. Phys.
PD MAR
PY 2009
VL 9
IS 2
BP 367
EP 373
DI 10.1016/j.cap.2008.03.014
PG 7
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA 378YE
UT WOS:000261360300014
DA 2018-12-27
ER

PT J
AU Faghri, J
   Razavi, MR
AF Faghri, Jamshid
   Razavi, Mohamad Reza
TI RETRACTED: Coagulase-Negative Staphylococci Isolated From Ocular Wound
   Infections After Laser Refractive Surgery: Attachment to and
   Accumulation on Soft Contact Lenses (Retracted article. See vol. 35, pg.
   113, 2009)
SO EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE
LA English
DT Article; Retracted Publication
DE Coagulase-negative staphylococci; Bacterial adhesion; ocular wound
   infections; laser refractive surgery; Soft contact lenses;
   Staphylococcal infections
ID BIOFILM FORMATION; INTERCELLULAR-ADHESION; EPIDERMIDIS STRAINS;
   GENE-CLUSTER; ICA OPERON; AUREUS; ADHERENCE; SURFACE; UNIT
AB Objectives: Disposable soft contact lenses that are commonly used after laser refractive surgery are known to be colonized by bacteria and play a key role in Bacterial Keraitis (BK) pathogenesis. Coagulase-negative staphylococci (CoNS) have been found to be the most common pathogen involved in this postoperative infection. In this study a rapid and a simple assay was developed for studying attachment and accumulation of CoNS on soft contact lenses in vitro using [H-3] thymidine.
   Methods: Thirty-five isolates of CoNS were obtained from 27 laser refractive surgery patients. Twenty-five of these thirty-five CoNS were isolated in Multiple cultures. Ten CoNS were isolated in cultures from patients who underwent reoperation. The assay was optimized using a biofilm-producing strain, S. epidermidis RP62A, which was subcultured overnight at 37 degrees C on blood agar medium. Quantitative determination of biofilm production was tested. Presence of the genes icaADB and icaD was determined in all isolates. All isolates were biochemically analyzed using the Phene Plate (PhP) system modified for typing of CoNS. The CoNS isolates were further characterized to species level using ID32Staph. Mann-Whitney rank sum test and chi-square test were used to identify statistical differences in adherence, index, antibiotic Susceptibility patterns, and biofilm production or presence of the ica operon between clinically significant isolates and non-postoperative BK isolates.
   Results: No differences in attachment and accumulation were found between isolates causing BK after laser refractive Surgery and contaminant isolates. In addition, there were no differences in the distribution of the ica operon between the two groups, as determined by polymerase chain reaction. Nevertheless, the ability to produce biofilm was found to be present significantly more frequently among BK isolates than among non-postoperative BK isolates.
   Conclusions: This study shows that the method using radioactive thymidine to analyze adherence of CoNS to soft contact lenses enables detection of differences in the adherence patterns of individual isolates.
C1 [Faghri, Jamshid] Isfahan Univ Med Sci, Sch Med, Dept Microbiol, Esfahan, Iran.
   [Razavi, Mohamad Reza] Inst Pasteur, Dept Mycobacteriol, Tehran, Iran.
RP Faghri, J (reprint author), Isfahan Univ Med Sci, Sch Med, Dept Microbiol, Esfahan, Iran.
EM Faghri@med.mui.ac.ir
RI faghri, jamshid/V-8503-2017
OI faghri, jamshid/0000-0001-7500-168X
CR Arciola CR, 2006, J BIOMED MATER RES A, V76A, P425, DOI 10.1002/jbm.a.30552
   Arciola CR, 2003, ACTA ORTHOP SCAND, V74, P617, DOI 10.1080/00016470310018054
   ASWAD MI, 1990, OPHTHALMOLOGY, V97, P296
   Cafiso V, 2004, CLIN MICROBIOL INFEC, V10, P1081, DOI 10.1111/j.1469-0691.2004.01024.x
   Chaieb K, 2005, J HOSP INFECT, V61, P225, DOI 10.1016/j.jhin.2005.05.014
   Cho SH, 2002, INT J ANTIMICROB AG, V19, P570, DOI 10.1016/S0924-8579(02)00101-2
   CHRISTENSEN GD, 1985, J CLIN MICROBIOL, V22, P996
   Cramton SE, 1999, INFECT IMMUN, V67, P5427
   de Silva GDI, 2002, J CLIN MICROBIOL, V40, P382, DOI [10.1128/JCM.40.02.382-388.2002, 10.1128/JCM.40.2.382-388.2002]
   Fitzpatrick F, 2005, CLIN MICROBIOL INFEC, V11, P967, DOI 10.1111/j.1469-0691.2005.01274.x
   Fitzpatrick F, 2005, J CLIN MICROBIOL, V43, P1973, DOI 10.1128/JCM.43.4.1973-1976.2005
   Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0
   Frebourg NB, 2000, J CLIN MICROBIOL, V38, P877
   Galdbart JO, 2000, J INFECT DIS, V182, P351, DOI 10.1086/315660
   Gotz F, 2002, MOL MICROBIOL, V43, P1367, DOI 10.1046/j.1365-2958.2002.02827.x
   Heilmann C, 1996, MOL MICROBIOL, V20, P1083, DOI 10.1111/j.1365-2958.1996.tb02548.x
   Heilmann C, 2000, GRAM-POSITIVE PATHOGENS, P442
   Heilmann C, 1997, MOL MICROBIOL, V24, P1013, DOI 10.1046/j.1365-2958.1997.4101774.x
   Klingenberg C, 2005, PEDIATR INFECT DIS J, V24, P817, DOI 10.1097/01.inf.0000176735.20008.cd
   MOLLBY R, 1993, REV MED MICROBIOL, V4, P231
   MULLER E, 1993, J INFECT DIS, V168, P1211, DOI 10.1093/infdis/168.5.1211
   VANPETT K, 1990, J ORTHOPAED RES, V8, P321, DOI 10.1002/jor.1100080303
   Veenstra GJC, 1996, J BACTERIOL, V178, P537, DOI 10.1128/jb.178.2.537-541.1996
   VON EC, 2000, LANCET INFECT DIS, V2, P677
   Yamanaka A, 2004, ORAL MICROBIOL IMMUN, V19, P150, DOI 10.1111/j.0902-0055.2004.00130.x
   Ziebuhr W, 1997, INFECT IMMUN, V65, P890
NR 26
TC 6
Z9 6
U1 4
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1542-2321
EI 1542-233X
J9 EYE CONTACT LENS
JI Eye Contact Lens-Sci. Clin. Pra.
PD MAR
PY 2009
VL 35
IS 2
BP 81
EP 87
DI 10.1097/ICL.0b013e318199b044
PG 7
WC Ophthalmology
SC Ophthalmology
GA 420SA
UT WOS:000264308300008
PM 19265329
DA 2018-12-27
ER

PT J
AU Mukherjee, S
   Lekli, I
   Gurusamy, N
   Bertelli, AAA
   Das, DK
AF Mukherjee, Subhendu
   Lekli, Istvan
   Gurusamy, Narasimman
   Bertelli, Alberto A. A.
   Das, Dipak K.
TI RETRACTED: Expression of the longevity proteins by both red and white
   wines and their cardioprotective components, resveratrol, tyrosol, and
   hydroxytyrosol (Retracted article. See vol. 53, pg. 641, 2012)
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article; Retracted Publication
DE White wine; Red wine; Resveratrol; Tyrosol; Hydroxytyrosol; PBEF; SirT1;
   FoxO1; Longevity; Cardioprotection
ID FOXO TRANSCRIPTION FACTORS; SIRT1; PHOSPHORYLATION; DEACETYLASE;
   SIRTUINS; DISEASE; MUSCLE; CELLS; NAD; ACETYLATION
AB Resveratrol increases longevity through SirT1, which is activated with NAD(+) supplied by an anti-aging enzyme PEER SirT1 interacts with an anti-aging transcription factor, FoxO1, which is negatively regulated by Akt. Since white wine could have similar health benefits as red wine, we determined if white wine and its cardioprotective components possess anti-aging properties by feeding rats with these compounds. The hearts expressed SirT, FoxO, and PBEF in the order of white wine>resveratrol>tyrosol>hydroxytyrosol>red wine, while cardioprotection shown by reduction of infarct size and cardiomyocyte apoptosis followed a different pattern: resveratrol>red wine>hydroxytyrosol>white wine>tyrosol, suggesting the existence of different signaling mechanisms for the induction of longevity and survival. Published by Elsevier Inc.
C1 [Mukherjee, Subhendu; Lekli, Istvan; Gurusamy, Narasimman; Das, Dipak K.] Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
   [Bertelli, Alberto A. A.] Univ Milan, Dept Human Anat, Milan, Italy.
RP Das, DK (reprint author), Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
EM DDAS@NEURON.UCHC.EDU
FU NIH [HL 22559, HL33889, HL34360]
FX This study was supported in part by NIH HL 22559, HL33889, and HL34360.
CR Baxter Richard A, 2008, J Cosmet Dermatol, V7, P2, DOI 10.1111/j.1473-2165.2008.00354.x
   Bertelli AAE, 2002, ANN NY ACAD SCI, V957, P295, DOI 10.1111/j.1749-6632.2002.tb02929.x
   Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200
   Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Carter ME, 2007, CURR BIOL, V17, pR113, DOI 10.1016/j.cub.2007.01.008
   Cui J, 2002, DRUG EXP CLIN RES, V28, P1
   Das S, 2006, FREE RADICAL RES, V40, P1066, DOI 10.1080/10715760600833085
   Dudley JI, 2008, J AGR FOOD CHEM, V56, P9362, DOI 10.1021/jf801791d
   ENGELMAN DT, 1995, CARDIOVASC RES, V29, P133, DOI 10.1016/0008-6363(96)88558-0
   FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V
   Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022
   Griswoldt AJ, 2008, P NATL ACAD SCI USA, V105, P8673, DOI 10.1073/pnas.0803837105
   Gruber J, 2007, ANN NY ACAD SCI, V1100, P530, DOI 10.1196/annals.1395.059
   Guarente L, 2007, COLD SPRING HARB SYM, V72, P483, DOI 10.1101/sqb.2007.72.024
   Jiang WJ, 2008, BIOCHEM BIOPH RES CO, V373, P341, DOI 10.1016/j.bbrc.2008.06.048
   JOHN M, 2003, TRENDS BIOCHEM SCI, V28, P41
   Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200
   KAREN C, 2002, ARCH BIOCHEM BIOPHYS, V403, P292
   Lam EWF, 2006, BIOCHEM SOC T, V34, P722, DOI 10.1042/BST0340722
   Mahmud DL, 2002, ONCOGENE, V21, P1556, DOI 10.1038/sj/onc/1205230
   Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100
   Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033
   Miyazaki R, 2008, ARTERIOSCL THROM VAS, V28, P1263, DOI 10.1161/ATVBAHA.108.166991
   Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6
   MUKHERJEE S, 2008, BIOCHIM BIOPHYS ACTA, V9, P498
   Mukherjee S, 2008, J AGR FOOD CHEM, V56, P609, DOI 10.1021/jf0728146
   Nakae J, 2006, J CLIN INVEST, V116, P2473, DOI 10.1172/JCI25518
   Onyango P, 2002, P NATL ACAD SCI USA, V99, P13653, DOI 10.1073/pnas.222538099
   Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200
   Terzibasi E, 2007, EXP GERONTOL, V42, P81, DOI 10.1016/j.exger.2006.06.039
   van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167
   van der Veer E, 2005, CIRC RES, V97, P25, DOI 10.1161/01.RES.0000173298.38808.27
   Vazquez-Agell M, 2007, J NUTR, V137, P2279
   Williams MJA, 2004, METABOLISM, V53, P318, DOI 10.1016/j.metabol.2003.10.012
   Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x
NR 36
TC 89
Z9 92
U1 5
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD MAR 1
PY 2009
VL 46
IS 5
BP 573
EP 578
DI 10.1016/j.freeradbiomed.2008.11.005
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 410LE
UT WOS:000263577700005
PM 19071213
DA 2018-12-27
ER

PT J
AU Boldt, J
   Suttner, S
   Brosch, C
   Lehmann, A
   Rohm, K
   Mengistu, A
AF Boldt, Joachim
   Suttner, Stephan
   Brosch, Christian
   Lehmann, Andreas
   Roehm, Kerstin
   Mengistu, Andinet
TI RETRACTED: The influence of a balanced volume replacement concept on
   inflammation, endothelial activation, and kidney integrity in elderly
   cardiac surgery patients (Retracted article. See vol. 37, pg. 1233,
   2011)
SO INTENSIVE CARE MEDICINE
LA English
DT Article; Retracted Publication
DE Volume replacement; Balanced volume replacement; Hydroxethylstarch;
   Inflammation; Kidney function; Cardiac surgery
ID HYDROXYETHYL STARCH; HEALTHY-VOLUNTEERS; SALINE; CHLORIDE;
   PHARMACOKINETICS; RESUSCITATION; HETASTARCH; COLLOIDS; ACIDOSIS; SEPSIS
AB A balanced fluid replacement strategy appears to be promising for correcting hypovolemia. The benefits of a balanced fluid replacement regimen were studied in elderly cardiac surgery patients.
   In a randomized clinical trial, 50 patients aged > 75 years undergoing cardiac surgery received a balanced 6% HES 130/0.42 plus a balanced crystalloid solution (n = 25) or a non-balanced HES in saline plus saline solution (n = 25) to keep pulmonary capillary wedge pressure/central venous pressure between 12-14 mmHg. Acid-base status, inflammation, endothelial activation (soluble intercellular adhesion molecule-1, kidney integrity (kidney-specific proteins glutathione transferase-alpha; neutrophil gelatinase-associated lipocalin) were studied after induction of anesthesia, 5 h after surgery, 1 and 2 days thereafter. Serum creatinine (sCr) was measured approximately 60 days after discharge.
   A total of 2,750 +/- A 640 mL of balanced and 2,820 +/- A 550 mL of unbalanced HES were given until the second POD. Base excess (BE) was significantly reduced in the unbalanced (from +1.21 +/- A 0.3 to -4.39 +/- A 1.0 mmol L-1 5 h after surgery; P < 0.001) and remained unchanged in the balanced group (from 1.04 +/- A 0.3 to -0.81 +/- A 0.3 mmol L-1 5 h after surgery). Evolution of the BE was significantly different. Inflammatory response and endothelial activation were significantly less pronounced in the balanced than the unbalanced group. Concentrations of kidney-specific proteins after surgery indicated less alterations of kidney integrity in the balanced than in the unbalanced group.
   A total balanced volume replacement strategy including a balanced HES and a balanced crystalloid solution resulted in moderate beneficial effects on acid-base status, inflammation, endothelial activation, and kidney integrity compared to a conventional unbalanced volume replacement regimen.
C1 [Boldt, Joachim; Suttner, Stephan; Brosch, Christian; Lehmann, Andreas; Roehm, Kerstin; Mengistu, Andinet] Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Boldt, J (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM BoldtJ@gmx.net
CR BASE E, 2006, CRIT CARE S1, V10, pP176
   BOLDT J, 2006, EJA, P231
   Boldt J, 2007, J CARDIOTHOR VASC AN, V21, P453, DOI 10.1053/j.jvca.2007.02.020
   Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716
   Conlon PJ, 1999, NEPHROL DIAL TRANSPL, V14, P1158, DOI 10.1093/ndt/14.5.1158
   CUSSAK RJ, 2002, INTENSIVMED, V39, P571
   Finfer S, 2004, NEW ENGL J MED, V350, P2247
   Franz A, 2001, ANESTH ANALG, V92, P1402, DOI 10.1097/00000539-200106000-00008
   Gan TJ, 1999, ANESTH ANALG, V88, P992, DOI 10.1097/00000539-199905000-00005
   Han Won K, 2004, Curr Opin Crit Care, V10, P476, DOI 10.1097/01.ccx.0000145095.90327.f2
   Haynes GR, 2004, ANESTHESIOLOGY, V101, P560, DOI 10.1097/00000542-200408000-00055
   Hill GE, 1998, J CARDIOTHOR VASC AN, V12, P21
   Jungheinrich C, 2005, CLIN PHARMACOKINET, V44, P681, DOI 10.2165/00003088-200544070-00002
   Kellum JA, 2002, CRIT CARE MED, V30, P259, DOI 10.1097/00003246-200201000-00046
   Kellum JA, 2006, CHEST, V130, P962, DOI 10.1378/chest.130.4.962
   KOTCHEN TA, 1983, ANN INTERN MED, V98, P817, DOI 10.7326/0003-4819-98-5-817
   Kozek-Langenecker SA, 2005, ANESTHESIOLOGY, V103, P654, DOI 10.1097/00000542-200509000-00031
   LACY JH, 1992, DRUGS, V44, P720, DOI 10.2165/00003495-199244050-00004
   LEGENDRE C, 1993, LANCET, V342, P248, DOI 10.1016/0140-6736(93)92345-T
   Leverve XM, 2008, INTENS CARE MED, V34, P1796, DOI 10.1007/s00134-008-1165-x
   Mills GH, 2007, BRIT J ANAESTH, V98, P157, DOI 10.1093/bja/ael359
   Mishra J, 2003, J AM SOC NEPHROL, V14, P2534, DOI 10.1097/01.ASN.0000088027.54400.C6
   MYTHEN MG, 1993, BLOOD REV, V7, P223, DOI 10.1016/0268-960X(93)90009-S
   Nuttall GA, 2007, J CARDIOTHOR VASC AN, V21, P457, DOI 10.1053/j.jvca.2007.02.017
   QUILLEY CP, 1993, BRIT J PHARMACOL, V108, P106, DOI 10.1111/j.1476-5381.1993.tb13447.x
   Rink L, 1998, MECH AGEING DEV, V102, P199, DOI 10.1016/S0047-6374(97)00153-X
   Roche AM, 2006, ANESTH ANALG, V102, P1274, DOI 10.1213/01.ane.0000197694.48429.94
   Waitzinger J, 1998, CLIN DRUG INVEST, V16, P151, DOI 10.2165/00044011-199816020-00008
   Wiedermann CJ, 2004, WIEN KLIN WOCHENSCHR, V116, P583, DOI 10.1007/s00508-004-0237-3
   WILCOX CS, 1983, J CLIN INVEST, V71, P726, DOI 10.1172/JCI110820
   Wilkes NJ, 2002, ANESTH ANALG, V94, P538, DOI 10.1097/00000539-200203000-00011
   Wilkes NJ, 2001, ANESTH ANALG, V93, P811, DOI 10.1097/00000539-200110000-00003
   Winkelmayer WC, 2003, KIDNEY INT, V64, P1046, DOI 10.1046/j.1523-1755.2003.00186.x
   Zaidi AM, 1999, HEART, V82, P134, DOI 10.1136/hrt.82.2.134
   ZANDER R, 2006, EJHP PRACT, V12, P1
NR 35
TC 34
Z9 35
U1 2
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD MAR
PY 2009
VL 35
IS 3
BP 462
EP 470
DI 10.1007/s00134-008-1287-1
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA 408FR
UT WOS:000263421400010
PM 18807007
DA 2018-12-27
ER

PT J
AU Young, SRL
   Gerard-O'Riley, R
   Kim, JB
   Pavalko, FM
AF Young, Suzanne R. L.
   Gerard-O'Riley, Rita
   Kim, Jae-Beom
   Pavalko, Fredrick M.
TI RETRACTED: Focal Adhesion Kinase Is Important for Fluid Shear
   Stress-Induced Mechanotransduction in Osteoblasts(Retracted article. See
   vol.31,pg.1483,2016)
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article; Retracted Publication
DE integrins; osteopontin; osteoblasts; mechanical loading; stress/strain
ID HUMAN OSTEOBLAST PROLIFERATION; ACTIVATED PROTEIN-KINASE; BONE-CELLS;
   MC3T3-E1 OSTEOBLASTS; SIGNALING PATHWAY; GENE-EXPRESSION; TYROSINE
   PHOSPHORYLATION; PROSTAGLANDIN RELEASE; INTEGRIN INTERACTIONS;
   EXTRACELLULAR-MATRIX
AB Mechanical loading of bone is important for maintenance of bone mass and structural stability of the skeleton. When bone is mechanically loaded, movement of fluid within the spaces surrounding bone cells generates fluid shear stress (FSS) that stimulates osteoblasts, resulting in enhanced anabolic activity. The mechanisms by which osteoblasts convert the external stimulation of FSS into biochemical changes, a process known as mechanotransduction, remain poorly understood. Focal adhesions are prime candidates for transducing external stimuli. Focal adhesion kinase (FAK), a nonreceptor tyrosine kinase found in focal adhesions, may play a key role in mechanotransduction, although its function has not been directly examined in osteoblasts. We examined the role of FAK in osteoblast mechanotransduction using short interfering RNA (siRNA), overexpression of a dominant negative FAK, and FAK(-/-) osteoblasts to disrupt FAK function in calvarial osteoblasts. Osteoblasts were subjected to varying periods oscillatory fluid flow (OFF) from 5 min to 4 h, and several physiologically important readouts of mechanotransduction were analyzed including: extracellular signal-related kinase 1/2 phosphorylation, upregulation of c-fos, cyclooxygenase-2, and osteopontin, and release of prostaglandin E-2. Osteoblasts with disrupted FAK signaling exhibited severely impaired mechanical responses in all endpoints examined. These data indicate the importance of FAK for both short and long periods of FSS-induced mechanotransduction in osteoblasts.
C1 [Young, Suzanne R. L.; Gerard-O'Riley, Rita; Pavalko, Fredrick M.] Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA.
   [Kim, Jae-Beom] Caliper Life Sci, Alameda, CA USA.
RP Pavalko, FM (reprint author), Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, 635 Barnhill Dr,MS 346A, Indianapolis, IN 46202 USA.
EM fpavalko@iupui.edu
FU NIH [AR049728, AR052682]
FX The authors thank Suzanne Ponik and Eric Rodenberg for helpful
   discussions and suggestions. This study was funded by NIH Grants
   AR049728 and AR052682.
CR Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5
   Bakker AD, 2001, J BIOMECH, V34, P671, DOI 10.1016/S0021-9290(00)00231-1
   Batra NN, 2005, J BIOMECH, V38, P1909, DOI 10.1016/j.jbiomech.2004.08.009
   Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481
   Buckbinder L, 2007, P NATL ACAD SCI USA, V104, P10619, DOI 10.1073/pnas.0701421104
   CALALB MB, 1995, MOL CELL BIOL, V15, P954
   CHAROONPATRAPON.K, 2007, J CELL BIOCHEM, V4, P13
   Chen NX, 2000, AM J PHYSIOL-CELL PH, V278, pC989
   Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8
   Damsky CH, 2002, CURR OPIN CELL BIOL, V14, P594, DOI 10.1016/S0955-0674(02)00368-X
   Ferraro JT, 2004, AM J PHYSIOL-CELL PH, V286, pC831, DOI 10.1152/ajpcell.00224.2003
   Gil-Henn H, 2007, J CELL BIOL, V178, P1053, DOI 10.1083/jcb.200701148
   Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1
   Guignandon A, 2006, BIOCHEM BIOPH RES CO, V343, P407, DOI 10.1016/j.bbrc.2006.02.162
   Guignandon A, 2003, CELL COMMUN ADHES, V10, P69, DOI 10.1080/15419060390260987
   Harder AT, 2003, J CLIN PHARMACOL, V43, P807, DOI 10.1177/0091270003256061
   Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631
   Hung CT, 1996, J BIOMECH, V29, P1411, DOI 10.1016/0021-9290(96)84536-2
   ILIC D, 1995, BIOCHEM BIOPH RES CO, V209, P300, DOI 10.1006/bbrc.1995.1503
   Inoue D, 2004, J BIOL CHEM, V279, P49795, DOI 10.1074/jbc.M404096200
   JACKSON ME, 1994, J CELL BIOCHEM, V55, P366, DOI 10.1002/jcb.240550314
   Jackson RA, 2006, J CELL PHYSIOL, V209, P894, DOI 10.1002/jcp.20779
   Jacobs CR, 1998, J BIOMECH, V31, P969, DOI 10.1016/S0021-9290(98)00114-6
   Jiang GL, 2002, AM J PHYSIOL-ENDOC M, V283, pE383, DOI 10.1152/ajpendo.00547.2001
   Juliano Rudy, 1996, Bioessays, V18, P911, DOI 10.1002/bies.950181110
   Kapur S, 2004, BONE, V35, P525, DOI 10.1016/j.bone.2004.04.007
   Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756-3282(02)00979-1
   Kim JB, 2007, BONE, V41, P39, DOI 10.1016/j.bone.2007.01.024
   KleinNulend J, 1997, J BONE MINER RES, V12, P45, DOI 10.1359/jbmr.1997.12.1.45
   Lee DY, 2008, J BONE MINER RES, V23, P1140, DOI 10.1359/JBMR.080302
   Leucht P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000390
   Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455
   Lu KK, 2005, AM J PHYSIOL-CELL PH, V289, pC1343, DOI 10.1152/ajpcell.00064.2005
   Mehrotra M, 2006, BIOCHEM BIOPH RES CO, V341, P1225, DOI 10.1016/j.bbrc.2006.01.084
   Mehrotra M, 2006, J CELL BIOCHEM, V98, P1271, DOI 10.1002/jcb.20864
   MILLER SB, 2006, ARTHRITIS RHEUM, V36, P37
   Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83
   Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011
   Neff L, 2003, J BIOL CHEM, V278, P27721, DOI 10.1074/jbc.M212065200
   Nomura S, 2000, MATRIX BIOL, V19, P91, DOI 10.1016/S0945-053X(00)00050-0
   Norvell SM, 2004, J APPL PHYSIOL, V96, P957, DOI 10.1152/japplphysiol.00869.2003
   Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200
   Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373
   Pavalko FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591
   Peake MA, 2003, FEBS LETT, V537, P117, DOI 10.1016/S0014-5793(03)00108-X
   Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080
   Ponik SM, 2004, J APPL PHYSIOL, V97, P135, DOI 10.1152/japplphysiol.01260.2003
   Ponik SM, 2007, J CELL BIOCHEM, V100, P794, DOI 10.1002/jcb.21089
   Radi ZA, 2005, INFLAMM RES, V54, P358, DOI 10.1007/s00011-005-1367-4
   RAISZ LG, 2001, AM J MED, V110, P43
   Reich KM, 1997, ENDOCRINOLOGY, V138, P1014, DOI 10.1210/en.138.3.1014
   REICH KM, 1991, AM J PHYSIOL, V261, pC428
   Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0
   Sawhney RS, 2006, J BIOL CHEM, V281, P8497, DOI 10.1074/jbc.M600787200
   SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785
   SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680
   Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0
   SHEFFIELD JB, 1987, ANAL BIOCHEM, V166, P49, DOI 10.1016/0003-2697(87)90544-6
   Smalt R, 1997, ADV EXP MED BIOL, V433, P311
   Tanaka SM, 2005, CALCIFIED TISSUE INT, V76, P261, DOI 10.1007/s00223-004-0238-2
   Triplett JW, 2006, AM J PHYSIOL-CELL PH, V291, pC909, DOI 10.1152/ajpcell.00113.2006
   Triplett Jason W., 2007, Molecular & Cellular Biomechanics, V4, P13
   Wadhwa S, 2002, BIOCHEM BIOPH RES CO, V297, P46, DOI 10.1016/S0006-291X(02)02124-1
   Wadhwa S, 2002, J BONE MINER RES, V17, P266, DOI 10.1359/jbmr.2002.17.2.266
   Wozniak M, 2000, J BONE MINER RES, V15, P1731, DOI 10.1359/jbmr.2000.15.9.1731
   XING Z, 1994, MOL BIOL CELL, V5, P413
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
NR 67
TC 89
Z9 95
U1 2
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
EI 1523-4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2009
VL 24
IS 3
BP 411
EP 424
DI 10.1359/JBMR.081102
PG 14
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 410JA
UT WOS:000263572100005
PM 19016591
OA Green Published
DA 2018-12-27
ER

PT J
AU Melo, SA
   Ropero, S
   Moutinho, C
   Aaltonen, LA
   Yamamoto, H
   Calin, GA
   Rossi, S
   Fernandez, AF
   Carneiro, F
   Oliveira, C
   Ferreira, B
   Liu, CG
   Villanueva, A
   Capella, G
   Schwartz, S
   Shiekhattar, R
   Esteller, M
AF Melo, Sonia A.
   Ropero, Santiago
   Moutinho, Catia
   Aaltonen, Lauri A.
   Yamamoto, Hiroyuki
   Calin, George A.
   Rossi, Simona
   Fernandez, Agustin F.
   Carneiro, Fatima
   Oliveira, Carla
   Ferreira, Bibiana
   Liu, Chang-Gong
   Villanueva, Alberto
   Capella, Gabriel
   Schwartz, Simo, Jr.
   Shiekhattar, Ramin
   Esteller, Manel
TI RETRACTED: A TARBP2 mutation in human cancer impairs microRNA processing
   and DICER1 function (Retracted article. See vol. 48, pg. 221, 2016)
SO NATURE GENETICS
LA English
DT Article; Retracted Publication
ID MICROSATELLITE INSTABILITY; EXPRESSION; GENE; CELLS; HYPERMETHYLATION;
   TUMORIGENESIS; REPRESSION; REGULATOR; PROMOTER; TRBP
AB microRNAs (miRNAs) are small noncoding RNAs that regulate gene expression by targeting messenger RNA (mRNA) transcripts. Recently, a miRNA expression profile of human tumors has been characterized by an overall miRNA downregulation(1-3). Explanations for this observation include a failure of miRNA post-transcriptional regulation(4), transcriptional silencing associated with hypermethylation of CpG island promoters(5-7) and miRNA transcriptional repression by oncogenic factors(8). Another possibility is that the enzymes and cofactors involved in miRNA processing pathways may themselves be targets of genetic disruption, further enhancing cellular transformation(9). However, no loss-of-function genetic alterations in the genes encoding these proteins have been reported. Here we have identified truncating mutations in TARBP2 (TAR RNA-binding protein 2), encoding an integral component of a DICER1-containing complex(10,11), in sporadic and hereditary carcinomas with microsatellite instability(12-14). The presence of TARBP2 frameshift mutations causes diminished TRBP protein expression and a defect in the processing of miRNAs. The reintroduction of TRBP in the deficient cells restores the efficient production of miRNAs and inhibits tumor growth. Most important, the TRBP impairment is associated with a destabilization of the DICER1 protein. These results provide, for a subset of human tumors, an explanation for the observed defects in the expression of mature miRNAs.
C1 [Melo, Sonia A.; Ropero, Santiago; Moutinho, Catia; Fernandez, Agustin F.; Ferreira, Bibiana; Esteller, Manel] Spanish Natl Canc Res Ctr CNIO, Canc Epigenet Lab, Madrid 28029, Spain.
   [Aaltonen, Lauri A.] Acad Finland, Tumor Genom Grp, F-00014 Helsinki, Finland.
   [Aaltonen, Lauri A.] Univ Helsinki, Genome Scale Biol Res Program, Biomedicum, Dept Med Genet, F-00014 Helsinki, Finland.
   [Yamamoto, Hiroyuki] Sapporo Med Univ, Chuo Ku, Sapporo, Hokkaido 0608556, Japan.
   [Calin, George A.; Rossi, Simona; Liu, Chang-Gong] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Carneiro, Fatima; Oliveira, Carla] Univ Porto, Fac Med, P-4200465 Oporto, Portugal.
   [Carneiro, Fatima; Oliveira, Carla] Hosp Sao Joao, P-4200465 Oporto, Portugal.
   [Carneiro, Fatima; Oliveira, Carla] Inst Mol Pathol & Immunol IPATIMUP, P-4200465 Oporto, Portugal.
   [Villanueva, Alberto; Capella, Gabriel] IDIBELL Inst Catala Oncol, Translat Res Lab, Barcelona 08907, Spain.
   [Schwartz, Simo, Jr.] Vall Hebron Univ Hosp, CIBBIM Nanomed, Mol Biol & Biochem Res Ctr Nanomed, Barcelona 08035, Catalonia, Spain.
   [Shiekhattar, Ramin] Ctr Genom Regulat, Barcelona 08003, Catalonia, Spain.
   [Shiekhattar, Ramin; Esteller, Manel] ICREA, Barcelona 08010, Catalonia, Spain.
   [Esteller, Manel] IDIBELL, ICO, PEBC, Barcelona 08907, Catalonia, Spain.
RP Esteller, M (reprint author), Spanish Natl Canc Res Ctr CNIO, Canc Epigenet Lab, Madrid 28029, Spain.
EM mesteller@iconcologia.net
RI Fernandez, Agustin/N-7302-2014; Esteller, Manel/L-5956-2014; MELO,
   SONIA/H-8972-2013; Schwartz, Simo/H-7776-2012; Carneiro,
   Fatima/J-6432-2013; Aaltonen, Lauri/A-5375-2010
OI Fernandez, Agustin/0000-0002-3792-4085; Esteller,
   Manel/0000-0003-4490-6093; MELO, SONIA/0000-0002-2291-4263; Carneiro,
   Fatima/0000-0002-1964-1006; Aaltonen, Lauri/0000-0001-6839-4286
FU FCT-Foundation Science and Technology Portugal [SFRH/BD/15900/2005,
   GABBA 2005]; ICREA;  [SAF2007-00027-65134];  [FIS PI08-0517]; 
   [Consolider CSD2006-49];  [CANCERDIP FP7-200620]; ICREA
FX This work was supported by Grants SAF2007-00027-65134, FIS PI08-0517,
   Consolider CSD2006-49 and CANCERDIP FP7-200620. S. A. M. is a research
   fellow of the FCT-Foundation Science and Technology Portugal
   SFRH/BD/15900/2005 GABBA 2005 PhD program. M. E. is an ICREA Research
   Professor.
CR Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30
   Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868
   Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103
   Fleisher AS, 1999, CANCER RES, V59, P1090
   Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Haase AD, 2005, EMBO REP, V6, P961, DOI 10.1038/sj.embor.7400509
   Hammond SM, 2007, NAT GENET, V39, P582
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242
   MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852
   Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967
   Raymond CK, 2005, RNA, V11, P1737, DOI 10.1261/rna.2148705
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645
   Schmittgen TD, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh040
   Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200
   Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.144406
NR 26
TC 266
Z9 278
U1 5
U2 45
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD MAR
PY 2009
VL 41
IS 3
BP 365
EP 370
DI 10.1038/ng.317
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 411HL
UT WOS:000263640200020
PM 19219043
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Chan, MF
   Wong, FKY
   Chang, K
   Chow, S
   Chung, L
   Lee, WM
   Lee, R
AF Chan, Moon-fai
   Wong, Frances K. Y.
   Chang, Katherine
   Chow, Susan
   Chung, Loretta
   Lee, Wai-man
   Lee, Rance
TI RETRACTED: Identifying patient readmission subtypes from unplanned
   readmissions to hospitals in Hong Kong: A cluster analysis (Retracted
   article. See vol. 16, pg. 411, 2014)
SO NURSING & HEALTH SCIENCES
LA English
DT Article; Retracted Publication
DE cluster analysis; unplanned readmission
ID CONGESTIVE-HEART-FAILURE; RANDOMIZED CONTROLLED-TRIAL; TRANSITIONAL
   CARE; BEHAVIORAL-MODEL; MEDICAL PATIENTS; ELDERLY-PATIENTS; OLDER
   PATIENTS; RISK-FACTORS; FOLLOW-UP; HEALTH
AB It has been conjectured with regard to patient readmission patterns that there might be significant differences in patient characteristics, need factors, enabling resources, and health behavior. The aim of this study was to identify the profiles of readmitted patients in Hong Kong (n = 120) based on their predisposing characteristics, needs, health behavior, and enabling resources. All the readmitted patients were recruited to the study in three hospitals from 2003 to 2005. A cluster analysis yielded three clusters: Clusters 1, 2, and 3 constituted 27.5% (n = 33), 27.5% (n = 33), and 45.0% (n = 54) of the total sample, respectively. The study results show that community nurse services do affect the rate at which patients are admitted to hospital for a second time. The findings might help by providing important information that will enable health-care policy-makers to identify strategies to target a specific group of patients in the hope of reducing its readmission rate.
C1 [Wong, Frances K. Y.; Chang, Katherine; Chow, Susan; Chung, Loretta; Lee, Wai-man] Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Hong Kong, Peoples R China.
   [Chan, Moon-fai] Natl Univ Singapore, Alice Lee Ctr Nursing Studies, Singapore 117548, Singapore.
   [Lee, Rance] Chinese Univ Hong Kong, Dept Sociol, Hong Kong, Hong Kong, Peoples R China.
RP Wong, FKY (reprint author), Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Hong Kong, Peoples R China.
EM hsfwong@inet.polyu.edu.hk
OI Chow, Susan KY/0000-0001-9471-4722
FU Hong Kong Special Administrative Region, China [5235/02H]
FX The authors would like to thank Amy S.W. Chan and Fion Ying for their
   assistance in the research project. We also express our appreciation to
   our clinical collaborators, Shirley Wong, registered nurse, Eva Kan,
   Nurse Specialist, Jack Kwan, Departmental Operations Manager (DOM),
   Kit-hoi Chan, DOM, Cecilia Chan, DOM, Sau-lan Cheung and Kam-chu Yeung,
   the managers of Community Nursing Services from the three study
   hospitals. The source of funding of this project is the Research Grants
   Council of the Hong Kong Special Administrative Region, China (Project
   no. PolyU 5235/02H).
CR ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284
   Anderson MA, 2006, J NURS CARE QUAL, V21, P160, DOI 10.1097/00001786-200604000-00012
   Anderson MA, 2005, J NURS CARE QUAL, V20, P26, DOI 10.1097/00001786-200501000-00006
   Belcher JVR, 1999, J NURS ADMIN, V29, P30, DOI 10.1097/00005110-199910000-00007
   Billings J, 2006, BRIT MED J, V333, P327, DOI 10.1136/bmj.38870.657917.AE
   BLASHFIELD RK, 1980, J CONSULT CLIN PSYCH, V48, P456
   BREWER M, 2000, HDB RES METHODS SOCI, P456
   Brooten D, 1988, Image J Nurs Sch, V20, P64
   Brooten D, 2002, J NURS SCHOLARSHIP, V34, P369, DOI 10.1111/j.1547-5069.2002.00369.x
   BURNS R, 1991, J GEN INTERN MED, V6, P389, DOI 10.1007/BF02598158
   Camberg LC, 1997, MED CARE, V35, P756, DOI 10.1097/00005650-199708000-00002
   Caplan GA, 1998, AGE AGEING, V27, P697, DOI 10.1093/ageing/27.6.697
   CATTELL RB, 1966, MULTIVAR BEHAV RES, V1, P245, DOI 10.1207/s15327906mbr0102_10
   Cattell V, 2001, SOC SCI MED, V52, P1501, DOI 10.1016/S0277-9536(00)00259-8
   Chan MF, 2004, NURS EDUC TODAY, V24, P202, DOI 10.1016/j.nedt.2003.11.009
   Chang Su-Hsien, 2003, Int J Nurs Pract, V9, P389, DOI 10.1046/j.1440-172X.2003.00443.x
   Chu LW, 1999, GERONTOLOGY, V45, P220, DOI 10.1159/000022091
   Cougnard A, 2006, ACTA PSYCHIAT SCAND, V113, P340, DOI 10.1111/j.1600-0447.2005.00694.x
   Dobrzanska L, 2006, J CLIN NURS, V15, P599, DOI 10.1111/j.1365-2702.2006.01333.x
   Fernandez-Mayoralas G, 2000, SOC SCI MED, V50, P17, DOI 10.1016/S0277-9536(99)00247-6
   GRAVELLE H, 2006, BMJ-BRIT MED J, V334, P451
   HAIR JF, 1992, MULTIVARIATE ANAL RE
   Hermiz O, 2002, BRIT MED J, V325, P938, DOI 10.1136/bmj.325.7370.938
   Hoskins L M, 1999, Home Healthc Nurse, V17, P373, DOI 10.1097/00004045-199906000-00007
   Kennedy BS, 2001, AM J EPIDEMIOL, V153, P232, DOI 10.1093/aje/153.3.232
   Kossovsky MP, 2000, AM J MED, V109, P386, DOI 10.1016/S0002-9343(00)00489-7
   Krumholz HM, 1997, ARCH INTERN MED, V157, P99, DOI 10.1001/archinte.157.1.99
   Kwok T, 2004, J AM GERIATR SOC, V52, P1240, DOI 10.1111/j.1532-5415.2004.52351.x
   Kwok T, 1999, J ROY COLL PHYS LOND, V33, P153
   Lee DTF, 1999, J CLIN NURS, V8, P478, DOI 10.1046/j.1365-2702.1999.0196b.x
   Lessler DS, 2000, HEALTH SERV RES, V34, P1315
   Marchand S, 1999, CLIN TRANSPLANT, V13, P17, DOI 10.1034/j.1399-0012.1999.t01-1-130103.x
   Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x
   *NQUERY ADV, 2000, STAT SOL R4 0 BELF
   Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358
   Phillips KA, 1998, HEALTH SERV RES, V33, P571
   Polit D.F., 2001, ESSENTIALS NURSING R
   Reznik M, 2006, J ASTHMA, V43, P37, DOI 10.1080/02770900500446997
   Rose R, 2000, SOC SCI MED, V51, P1421, DOI 10.1016/S0277-9536(00)00106-4
   Sethares KA, 2004, HEART LUNG, V33, P249, DOI 10.1016/j.hrtlng.2004.03.005
   Shy CM, 1997, AM J EPIDEMIOL, V145, P479
   Smith DM, 2000, J CLIN EPIDEMIOL, V53, P1113, DOI 10.1016/S0895-4356(00)00236-5
   *SPSS, 2004, ADV MOD 12 0
   Wong FKY, 2004, SOC SCI MED, V59, P2207, DOI 10.1016/j.socscimed.2004.03.028
   Wong FKY, 2002, NURS RES, V51, P40, DOI 10.1097/00006199-200201000-00007
NR 45
TC 4
Z9 5
U1 5
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1441-0745
EI 1442-2018
J9 NURS HEALTH SCI
JI Nurs. Health Sci.
PD MAR
PY 2009
VL 11
IS 1
BP 37
EP 44
DI 10.1111/j.1442-2018.2009.00427.x
PG 8
WC Nursing
SC Nursing
GA 417NU
UT WOS:000264083800006
PM 19298307
DA 2018-12-27
ER

PT J
AU Verma, SK
   Kumar, V
   Gill, KD
AF Verma, Suresh Kumar
   Kumar, Vijay
   Gill, Kiran Dip
TI RETRACTED: An acetylcholinesterase-independent mechanism for
   neurobehavioral impairments after chronic low level exposure to
   dichlorvos in rats (Retracted article. See vol. 96, pg. 114, 2010)
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Article; Retracted Publication
DE Organophosphate; Dichlorvos; Neurotoxicity; Muscarinic receptors;
   Neurobehavior; Morris Water Maze
ID MUSCARINIC RECEPTOR-BINDING; EARLY POSTNATAL EXPOSURE; ORGANOPHOSPHATE
   PESTICIDE; CHLORPYRIFOS-OXON; WATER-MAZE; IN-VITRO; MEMORY; BRAIN;
   NEUROTOXICITY; CHOLINESTERASE
AB The present study was designed to explore an alternate mechanism of action other than acetylcholinesterase inhibition for the chronic, low-level exposure to dichlorvos, an organophosphate, in vivo. Dichlorvos, at dose of 1.0 as well as 6.0 mg/kg b. wt. for 12 weeks to rats showed impairment in neurobehavioral indices viz. rota rod, passive avoidance and water maze tests. Though higher dose of dichlorvos had a detrimental effect on acetylcholinesterase activity. no significant inhibition was seen with lower dose of dichlorvos for the same period of exposure i.e. 12 weeks. Muscarinic acetylcholine receptor binding studies revealed a decrease in the number of binding sites (B(max)) in low as well as high dose groups but the dissociation constant (K(d)) value was unaffected with both doses of dichlorvos. Use of selective ligands against M(1), M(2) and M(3) receptor subtypes indicated that M(2)dd is the major receptor subtype being affected by chronic low-level exposure to dichlorvos. Western blot analysis and immunofluorescence studies also confirmed these biochemical findings. Thus, the present study suggests that M2 receptors may play a major role in the development of neurobehavioral impairments after chronic exposure to dichlorvos. (C) 2008 Elsevier Inc. All rights reserved
C1 [Verma, Suresh Kumar; Kumar, Vijay; Gill, Kiran Dip] Postgrad Inst Med Educ & Res, Dept Biochem, Chandigarh 160012, India.
RP Gill, KD (reprint author), Postgrad Inst Med Educ & Res, Dept Biochem, Chandigarh 160012, India.
EM kdgill2002@yahoo.co.in
OI kumar, Vijay/0000-0001-5559-0624
CR AGGARWAL AK, 1988, INDIAN J MED RES, V88, P91
   Betancourt AM, 2004, TOXICOL SCI, V77, P63, DOI 10.1093/toxsci/kfh003
   Bhatnagar V. K., 1994, Indian Journal of Toxicology, V1, P49
   Bomser JA, 2001, TOXICOL LETT, V119, P21, DOI 10.1016/S0378-4274(00)00294-0
   BURGOYNE RD, 1981, FEBS LETT, V127, P144, DOI 10.1016/0014-5793(81)80361-4
   Canadas F, 2005, TOXICOL SCI, V85, P944, DOI 10.1093/toxsci/kfi143
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   DAMODARAN TV, 2006, BIOCHEM PHARMACOL, V71, P479
   DEER HM, 1993, VET HUM TOXICOL, V35, P226
   Desi I, 1999, TOXICOL LETT, V107, P55, DOI 10.1016/S0378-4274(99)00031-4
   DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322
   Eddleston M, 2002, LANCET, V360, P1163, DOI 10.1016/S0140-6736(02)11204-9
   ELDEFRAWI AT, 1992, ORGANOPHOSPHATES CHE, P257
   ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9
   Eskenazi B, 1999, ENVIRON HEALTH PERSP, V107, P409, DOI 10.1289/ehp.99107s3409
   Farahat TM, 2003, OCCUP ENVIRON MED, V60, P279, DOI 10.1136/oem.60.4.279
   FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D
   FIEDLER N, 1997, AM J IND MED, V32, P482
   Jett DA, 2001, TOXICOL APPL PHARM, V174, P89, DOI 10.1006/taap.2001.9198
   JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5
   KARCZMAR AG, 1984, FUND APPL TOXICOL, V4, P513
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lazarini CA, 2004, NEUROTOXICOL TERATOL, V26, P607, DOI 10.1016/j.ntt.2004.03.006
   Litovitz TL, 2002, AM J EMERG MED, V20, P391, DOI 10.1053/ajem.2002.34955
   Liu J, 2002, TOXICOL APPL PHARM, V178, P102, DOI 10.1006/taap.2001.9326
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MCDONALD BE, 1988, TOXICOL LETT, V40, P47, DOI 10.1016/0378-4274(88)90182-8
   MILBY TH, 1971, J AMER MED ASSOC, V216, P2131, DOI 10.1001/jama.216.13.2131
   MORETTO A, 1987, J NEUROCHEM, V49, P1515, DOI 10.1111/j.1471-4159.1987.tb01022.x
   MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4
   Peter JV, 2000, ANAESTH INTENS CARE, V28, P11
   PIALA JJ, 1959, J PHARMACOL EXP THER, V127, P55
   PLUMLEE KH, 1994, J VET DIAGN INVEST, V6, P247, DOI 10.1177/104063879400600217
   Prendergast MA, 1997, PSYCHOPHARMACOLOGY, V129, P183, DOI 10.1007/s002130050179
   Raheja G, 2002, MOL CELL BIOCHEM, V232, P13, DOI 10.1023/A:1014873031013
   ROSENSTOCK L, 1991, LANCET, V338, P223, DOI 10.1016/0140-6736(91)90356-T
   Sarin S, 1998, PHARMACOL BIOCHEM BE, V59, P1081, DOI 10.1016/S0091-3057(97)00517-0
   Sarin S, 1999, MOL CELL BIOCHEM, V199, P87, DOI 10.1023/A:1006930511459
   Seeger T, 2004, J NEUROSCI, V24, P10117, DOI 10.1523/JNEUROSCI.3581-04.2004
   Sun TT, 2006, J BIOMED SCI, V13, P515, DOI 10.1007/s11373-006-9075-9
   Timofeeva OA, 2008, NEUROTOXICOL TERATOL, V30, P38, DOI 10.1016/j.ntt.2007.10.002
   VIANA GB, 1988, TOXICOL APPL PHARM, V93, P257, DOI 10.1016/0041-008X(88)90125-1
   Wang HZ, 2001, MOL PHARMACOL, V59, P1029
   YAKOYAMA K, 1998, J PHYSIOL-PARIS, V92, P317
   YAMAMURA HI, 1974, P NATL ACAD SCI USA, V71, P1725, DOI 10.1073/pnas.71.5.1725
   Zheng Q, 2000, TOXICOL SCI, V55, P124, DOI 10.1093/toxsci/55.1.124
NR 46
TC 13
Z9 13
U1 4
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0091-3057
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD MAR
PY 2009
VL 92
IS 1
BP 173
EP 181
DI 10.1016/j.pbb.2008.11.010
PG 9
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA 412FJ
UT WOS:000263709200027
PM 19101586
DA 2018-12-27
ER

PT J
AU Li, YC
   Li, SS
AF Li, Yan-Chao
   Li, Shu-Shen
TI RETRACTED: Quantum critical phenomena in the XY spin chain with the
   Dzyaloshinski-Moriya interaction (Retracted article. See vol 80, artn
   019903, 2009)
SO PHYSICAL REVIEW A
LA English
DT Article; Retracted Publication
DE entropy; ground states; Heisenberg model; magnetic susceptibility;
   quantum entanglement; spin-orbit interactions; X-Y model
ID MODEL; DOTS
AB We study the effects of the Dzyaloshinski-Moriya (DM) anisotropic interaction on the ground-state properties of the Heisenberg XY spin chain by means of the fidelity susceptibility, order parameter, and entanglement entropy. Our results show that the DM interaction could influence the distribution of the regions of quantum phase transitions and cause different critical regions in the XY spin model. Meanwhile, the DM interaction has effective influence on the degree of entanglement of the system and could be used to increase the entanglement of the spin system.
C1 [Li, Yan-Chao; Li, Shu-Shen] Chinese Acad Sci, Inst Semicond, State Key Lab Superlattices & Microstruct, Beijing 100083, Peoples R China.
RP Li, YC (reprint author), Chinese Acad Sci, Inst Semicond, State Key Lab Superlattices & Microstruct, POB 912, Beijing 100083, Peoples R China.
FU National Basic Research Program of China [G2009CB929300]; National
   Natural Science Foundation of China [60521001, 60776061]
FX This work was supported by the National Basic Research Program of China
   (973 Program) under Grant No. G2009CB929300 and the National Natural
   Science Foundation of China under Grants Nos. 60521001 and 60776061.
CR Buonsante P, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.110601
   Burkard G, 1999, PHYS REV B, V59, P2070, DOI 10.1103/PhysRevB.59.2070
   Chen S, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.061108
   Chen S, 2008, PHYS REV A, V77, DOI 10.1103/PhysRevA.77.032111
   Cozzini M, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.104420
   Cozzini M, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.014439
   Gegenwart P, 2008, NAT PHYS, V4, P186, DOI 10.1038/nphys892
   Giamarchi T, 2008, NAT PHYS, V4, P198, DOI 10.1038/nphys893
   Gu SJ, 2008, J PHYS A-MATH THEOR, V41, DOI 10.1088/1751-8113/41/2/025002
   Gu SJ, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.245109
   Gu SJ, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.086402
   KATSURA S, 1962, PHYS REV, V127, P1508, DOI 10.1103/PhysRev.127.1508
   Kuchler R, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.066405
   Li YC, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.184412
   LIEB E, 1961, ANN PHYS-NEW YORK, V16, P407, DOI 10.1016/0003-4916(61)90115-4
   Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120
   Mathur ND, 1998, NATURE, V394, P39
   Osterloh A, 2002, NATURE, V416, P608, DOI 10.1038/416608a
   PFEUTY P, 1970, ANN PHYS-NEW YORK, V57, P79, DOI 10.1016/0003-4916(70)90270-8
   Quan HT, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.140604
   QUAN HT, ARXIV08062476
   Sachdev S, 1999, QUANTUM PHASE TRANSI
   Sachdev S, 2008, NAT PHYS, V4, P173, DOI 10.1038/nphys894
   Su SQ, 2006, PHYS REV A, V74, DOI 10.1103/PhysRevA.74.032308
   Tzeng YC, 2008, PHYS REV A, V77, DOI 10.1103/PhysRevA.77.012311
   You WL, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.022101
   Zanardi P, 2007, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2007/02/L02002
   Zanardi P, 2007, PHYS REV A, V75, DOI 10.1103/PhysRevA.75.032109
   Zanardi P, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.031123
   Zhu LJ, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.066404
   Zhu SL, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.077206
NR 31
TC 20
Z9 21
U1 3
U2 12
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 2469-9926
EI 2469-9934
J9 PHYS REV A
JI Phys. Rev. A
PD MAR
PY 2009
VL 79
IS 3
AR 032338
DI 10.1103/PhysRevA.79.032338
PG 5
WC Optics; Physics, Atomic, Molecular & Chemical
SC Optics; Physics
GA 427HK
UT WOS:000264770200067
DA 2018-12-27
ER

PT J
AU Cao, NW
   Zhou, XB
   Li, SS
   Chen, ZR
AF Cao, Nianwen
   Zhou, Xiaobing
   Li, Shusun
   Chen, Zhongrong
TI RETRACTED: A new eye-safe lidar design for studying atmospheric aerosol
   distributions (Retracted article. See vol. 81, art. no. 029903, 2010)
SO REVIEW OF SCIENTIFIC INSTRUMENTS
LA English
DT Article; Retracted Publication
DE aerosols; air pollution; atmospheric humidity; atmospheric measuring
   apparatus; optical radar
AB This paper presents the design, eye-safe characteristics, and performance of a new eye-safe infrared lidar system for studying city fog. It includes a compact infrared (1574 nm) transmitter, a telescope receiver, and a computer to acquire, store, and process and analyze the measurement data. The development of such a system makes it possible for routine aerosol monitoring in a populated area using lidar technology. A simulation study and a field test show that the system was capable of aerosol monitoring in cities. This lidar system will be used to study the distribution of aerosol over an urban area of 100-200 km(2) and will be useful for routine multidimensional aerosol measurements with high resolution in an urban environment.
C1 [Cao, Nianwen; Chen, Zhongrong] Nanjing Univ Informat Sci & Technol, Sch Atmospher Phys, Nanjing 210044, Peoples R China.
   [Zhou, Xiaobing] Montana Tech Univ Montana, Dept Geophys Engn, Butte, MT 59701 USA.
   [Li, Shusun] Univ Alaska Fairbanks, Inst Geophys, Fairbanks, AK 99775 USA.
RP Cao, NW (reprint author), Nanjing Univ Informat Sci & Technol, Sch Atmospher Phys, Ningliu Rd 219, Nanjing 210044, Peoples R China.
CR *AM NAT STAND I, 1993, AM NAT STAND SAF US, P41
   BENSON CS, 1965, ICE FOG LOW TEMPERAT
   CAO N, 2002, P 5O ARCT SCI C FAIR, P75
   CAO N, 2002, P 21 INT LAS RAD C Q, P253
   Cao NW, 2002, OPT ENG, V41, P218, DOI 10.1117/1.1419191
   Cao NW, 2001, P SOC PHOTO-OPT INS, V4153, P607, DOI 10.1117/12.417099
   FOCHESATTO J, 2005, P SPIE, V5887
   HARRELL SR, 1995, THESIS U S FLORIDA
   HECHT J, 2000, LASER GUIDEBOOK
   Kuze H, 1998, APPL OPTICS, V37, P3128, DOI 10.1364/AO.37.003128
   MAYOR SD, 2007, APPL OPTICS, V43, P3915
   Schroeder D. J., 2000, ASTRONOMICAL OPTICS
   Spuler SM, 2007, APPL OPTICS, V46, P2990, DOI 10.1364/AO.46.002990
   Spuler SM, 2005, J ATMOS OCEAN TECH, V22, P696, DOI 10.1175/JTECH1755.1
   VANDEHULST HC, 1957, LIGHT SCATTERING SMA, P176
   VIEZEE W, 1975, LIDAR STUDIES URBAN
   WEBER MJ, 2000, HDB LASERS
NR 17
TC 1
Z9 1
U1 6
U2 7
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0034-6748
EI 1089-7623
J9 REV SCI INSTRUM
JI Rev. Sci. Instrum.
PD MAR
PY 2009
VL 80
IS 3
AR 035109
DI 10.1063/1.3103647
PG 9
WC Instruments & Instrumentation; Physics, Applied
SC Instruments & Instrumentation; Physics
GA 427JW
UT WOS:000264776600054
PM 19334954
DA 2018-12-27
ER

PT J
AU Lichtenthaler, U
   Lichtenthaler, E
   Frishammar, J
AF Lichtenthaler, Ulrich
   Lichtenthaler, Eckhard
   Frishammar, Johan
TI RETRACTED: Technology commercialization intelligence: Organizational
   antecedents and performance consequences (Retracted article. See vol.
   80, pg. 1445, 2013)
SO TECHNOLOGICAL FORECASTING AND SOCIAL CHANGE
LA English
DT Article; Retracted Publication
DE Technology intelligence; External technology commercialization;
   Licensing; Open innovation; Markets for technology
ID PRODUCT DEVELOPMENT PERFORMANCE; KNOWLEDGE MANAGEMENT; MARKET
   INTELLIGENCE; MANUFACTURING FIRMS; OPEN INNOVATION; DYNAMIC
   CAPABILITIES; INFORMATION; STRATEGY; PERSPECTIVE; ORIENTATION
AB External technology commercialization, e.g., by means of technology licensing. has recently gained in importance. Despite imperfections in technology markets, out-licensing constitutes a major technology commercialization channel. Although the identification of licensing opportunities represents a significant managerial challenge, prior research has relatively neglected these activities. Therefore, we develop the concept of technology commercialization intelligence'(TCI), which refers to the observation of a firm's environment with particular focus on identifying technology licensing opportunities. Grounded in a dynamic capabilities perspective, we test five hypotheses regarding organizational antecedents and performance consequences of TCI, drawing on data from a survey of 152 companies. The empirical findings provide strong support for the importance of the TO concept. The findings deepen our understanding of the discrepancies between successful pioneering firms active in technology licensing and many others being less successful. The results have major implications for technology exploitation in open innovation processes. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Lichtenthaler, Ulrich] Otto Beisheim Sch Management Technol & Innovat Ma, WHU, D-56179 Vallendar, Germany.
   [Lichtenthaler, Eckhard] Swiss Fed Inst Technol Zurich ETH, CH-8032 Zurich, Switzerland.
   [Frishammar, Johan] Lulea Univ Technol, Dept Business Adm & Management, S-97187 Lulea, Sweden.
RP Lichtenthaler, U (reprint author), Otto Beisheim Sch Management Technol & Innovat Ma, WHU, Burgpl 2, D-56179 Vallendar, Germany.
EM lichtenthaler@whu.edu; lic@bwi.bepr.ethz.ch; johan.frishammar@ltu.se
CR Agrawal A, 2006, STRATEGIC MANAGE J, V27, P63, DOI 10.1002/smj.508
   Alencar MSM, 2007, TECHNOL FORECAST SOC, V74, P1661, DOI 10.1016/j.techfore.2007.04.002
   Allen TJ, 1977, MANAGING FLOW TECHNO
   Anand BN, 2000, J IND ECON, V48, P103
   Argote L, 2003, MANAGE SCI, V49, P571, DOI 10.1287/mnsc.49.4.571.14424
   ARORA K, 2006, MANAGE SCI, V52, P293
   BALACHANDRA R, 1980, TECHNOL FORECAST SOC, V16, P75, DOI 10.1016/0040-1625(80)90075-X
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   Bartlett C.A., 1998, MANAGING BORDERS TRA
   Bierly PE, 2007, LONG RANGE PLANN, V40, P134, DOI 10.1016/j.lrp.2007.03.001
   BROCKHOFF K, 1991, IND MARKET MANAG, V20, P91, DOI 10.1016/0019-8501(91)90027-D
   BROWN SL, 1995, ACAD MANAGE REV, V20, P343, DOI 10.2307/258850
   Chesbrough H, 2003, CALIF MANAGE REV, V45, P33, DOI 10.2307/41166175
   Chesbrough H, 2007, CALIF MANAGE REV, V49, P45, DOI 10.2307/41166394
   Cohen J., 2003, APPL MULTIPLE REGRES
   COHEN WM, 1990, ADMIN SCI QUART, V35, P128, DOI 10.2307/2393553
   COOPER RG, 1995, J PROD INNOVAT MANAG, V12, P374, DOI 10.1016/0737-6782(95)00059-3
   Cummings JL, 2003, J ENG TECHNOL MANAGE, V20, P39, DOI 10.1016/S0923-4748(03)00004-3
   Daim TU, 2006, TECHNOL FORECAST SOC, V73, P981, DOI 10.1016/j.techfore.2006.04.004
   DAVIS JL, 2001, EDISON BOARDROOM LEA
   Eisenhardt KM, 2000, STRATEGIC MANAGE J, V21, P1105, DOI 10.1002/1097-0266(200010/11)21:10/11<1105::AID-SMJ133>3.0.CO;2-E
   Engwall M, 2003, RES POLICY, V32, P789, DOI 10.1016/S0048-7333(02)00088-4
   Ernst H, 1998, J ENG TECHNOL MANAGE, V15, P279, DOI 10.1016/S0923-4748(98)00018-6
   FAHEY L, 1986, MACROENVIRONMENTAL A
   Fosfuri A, 2006, STRATEGIC MANAGE J, V27, P1141, DOI 10.1002/smj.562
   Frishammar J, 2005, J PROD INNOVAT MANAG, V22, P251, DOI 10.1111/j.0737-6782.2005.00121.x
   Frishammar J, 2007, TECHNOL ANAL STRATEG, V19, P765, DOI 10.1080/09537320701711231
   Galbraith J.R, 1993, COMPETING FLEXIBLE L
   Gambardella A, 2001, MARKETS TECHNOLOGY E
   Gambardella A, 2007, RES POLICY, V36, P1163, DOI 10.1016/j.respol.2007.07.006
   Gans JS, 2003, RES POLICY, V32, P333, DOI 10.1016/S0048-7333(02)00103-8
   GERYBADZE A, 1994, R&D MANAGE, V24, P131, DOI 10.1111/j.1467-9310.1994.tb00865.x
   Granstrand O, 2000, EC MANAGEMENT INTELL
   Grant RM, 2004, J MANAGE STUD, V41, P61, DOI 10.1111/j.1467-6486.2004.00421.x
   Griffin A, 1996, J PROD INNOVAT MANAG, V13, P191, DOI 10.1016/0737-6782(96)00025-2
   Grindley PC, 1997, CALIF MANAGE REV, V39, P8, DOI 10.2307/41165885
   Hair J., 2006, MULTIVARIATE DATA AN
   HAMBRICK DC, 1982, STRATEGIC MANAGE J, V3, P159, DOI 10.1002/smj.4250030207
   HEDLUND C, 1990, MANAGING GLOBAL FIRM
   Huston L, 2006, HARVARD BUS REV, V84, P58
   JAWORSKI BJ, 1993, J MARKETING, V57, P53, DOI 10.2307/1251854
   Kahn KB, 2001, J PROD INNOVAT MANAG, V18, P314, DOI 10.1016/S0737-6782(01)00101-1
   Kale P, 2007, STRATEG MANAGE J, V28, P981, DOI 10.1002/smj.616
   Karaoz M, 2005, TECHNOL FORECAST SOC, V72, P866, DOI 10.1016/j.techfore.2004.09.005
   Klavans RA, 1997, KEEPING ABREAST SCI, P23
   Kline D, 2003, MIT SLOAN MANAGE REV, V44, P89
   KOGUT B, 1992, ORGAN SCI, V3, P383, DOI 10.1287/orsc.3.3.383
   Laursen K, 2006, STRATEGIC MANAGE J, V27, P131, DOI 10.1002/smj.507
   Lichtenthaler E, 2004, R&D MANAGE, V34, P121, DOI 10.1111/j.1467-9310.2004.00328.x
   Lichtenthaler E, 2007, TECHNOL FORECAST SOC, V74, P1109, DOI 10.1016/j.techfore.2006.10.001
   Lichtenthaler U, 2005, INT J MANAG REV, V7, P231, DOI 10.1111/j.1468-2370.2005.00115.x
   Lichtenthaler U, 2008, J BUS VENTURING, V23, P445, DOI 10.1016/j.jbusvent.2007.06.002
   Lichtenthaler U, 2008, RES TECHNOL MANAGE, V51, P45
   Lichtenthaler U, 2008, IEEE T ENG MANAGE, V55, P148, DOI 10.1109/TEM.2007.912932
   Lichtenthaler U, 2007, CALIF MANAGE REV, V49, P67, DOI 10.2307/41166406
   Lichtenthaler U, 2007, RES POLICY, V36, P37, DOI 10.1016/j.respol.2006.08.005
   Lichtenthaler U, 2006, R&D MANAGE, V36, P367, DOI 10.1111/j.1467-9310.2006.00443.x
   Lindell MK, 2001, J APPL PSYCHOL, V86, P114, DOI 10.1037//0021-9010.86.1.114
   Linstone HA, 1997, TECHNOL FORECAST SOC, V54, P1, DOI 10.1016/S0040-1625(97)87499-9
   LONG JS, 2002, REGRESSION MODELS CA
   MACDONALD S, 1993, J PROD INNOVAT MANAG, V10, P417
   MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037//1082-989X.7.1.83
   Madhavan R, 1998, J MARKETING, V62, P1, DOI 10.2307/1252283
   Makadok R, 2001, MANAGE SCI, V47, P1621, DOI 10.1287/mnsc.47.12.1621.10245
   Malanowski N, 2007, TECHNOL FORECAST SOC, V74, P1805, DOI 10.1016/j.techfore.2007.05.010
   Maltz E, 1996, J MARKETING RES, V33, P47, DOI 10.2307/3152012
   March JG, 1991, ORGAN SCI, V2, P71, DOI 10.1287/orsc.2.1.71
   Markman GD, 2005, J BUS VENTURING, V20, P241, DOI 10.1016/j.jbusvent.2003.12.003
   Markovitch DG, 2005, MANAGE SCI, V51, P1467, DOI 10.1287/mnsc.1050.0401
   MARTINEZ JI, 1991, J INT BUS STUD, V22, P429, DOI 10.1057/palgrave.jibs.8490309
   Mihm J, 2003, MANAGE SCI, V49, P733, DOI 10.1287/mnsc.49.6.733.16021
   Moorman C, 1997, J MARKETING RES, V34, P91, DOI 10.2307/3152067
   Nagaoka S, 2006, RES POLICY, V35, P1347, DOI 10.1016/j.respol.2006.05.007
   Ortt JR, 2007, TECHNOL FORECAST SOC, V74, P1788, DOI 10.1016/j.techfore.2007.05.009
   Patton KM, 2005, TECHNOL FORECAST SOC, V72, P1082, DOI 10.1016/j.techfore.2004.10.001
   Porter AL, 2005, TECHNOL FORECAST SOC, V72, P1070, DOI 10.1016/j.techfore.2004.10.007
   Rivette K, 2000, REMBRANDTS ATTIC UNL
   Rothaermel FT, 2006, J BUS VENTURING, V21, P429, DOI 10.1016/j.jbusvent.2005.02.006
   Rothaermel FT, 2004, STRATEGIC MANAGE J, V25, P201, DOI 10.1002/smj.376
   Santos FA, 2005, ORGAN SCI, V16, P491, DOI 10.1287/orsc.1050.0152
   Shepherd DA, 2002, IEEE T ENG MANAGE, V49, P140, DOI 10.1109/TEM.2002.1010882
   Sherman JD, 2005, J PROD INNOVAT MANAG, V22, P399
   Slater SF, 2000, J ACAD MARKET SCI, V28, P120, DOI 10.1177/0092070300281011
   Song XM, 1997, J MARKETING, V61, P1, DOI 10.2307/1251827
   Steensma HK, 1996, J ENG TECHNOL MANAGE, V12, P267, DOI 10.1016/0923-4748(95)00013-5
   Sternberg RJ, 2004, J BUS VENTURING, V19, P189, DOI 10.1016/S0883-9026(03)0006-5
   Teece DJ, 1998, CALIF MANAGE REV, V40, P55, DOI 10.2307/41165943
   Teece DJ, 1997, STRATEGIC MANAGE J, V18, P509, DOI 10.1002/(SICI)1097-0266(199708)18:7<509::AID-SMJ882>3.0.CO;2-Z
   TSCHIRKY HP, 1994, R&D MANAGE, V24, P121, DOI 10.1111/j.1467-9310.1994.tb00864.x
   TUSHMAN ML, 1981, ACAD MANAGE J, V24, P289, DOI 10.2307/255842
   Ucbasaran D., 2001, ENTREP THEORY PRACT, V25, P57, DOI DOI 10.1016/S0883-9026(99)00063-4
   UTTERBACK JM, 1975, TECHNOL FORECAST SOC, V8, P7, DOI 10.1016/0040-1625(75)90032-3
   Yoon B, 2005, TECHNOL FORECAST SOC, V72, P145, DOI 10.1016/j.techfore.2004.08.011
NR 93
TC 24
Z9 25
U1 3
U2 63
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0040-1625
J9 TECHNOL FORECAST SOC
JI Technol. Forecast. Soc. Chang.
PD MAR
PY 2009
VL 76
IS 3
BP 301
EP 315
DI 10.1016/j.techfore.2008.07.002
PG 15
WC Business; Planning & Development
SC Business & Economics; Public Administration
GA 421PW
UT WOS:000264371800002
DA 2018-12-27
ER

PT J
AU Sung, B
   Murakami, A
   Oyajobi, BO
   Aggarwal, BB
AF Sung, Bokyung
   Murakami, Akira
   Oyajobi, Babatunde O.
   Aggarwal, Bharat B.
TI RETRACTED: Zerumbone Abolishes RANKL-Induced NF-kappa B Activation,
   Inhibits Osteoclastogenesis, and Suppresses Human Breast Cancer-induced
   Bone Loss in Athymic Nude Mice (Retracted article. See vol. 78, pg.
   5186, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID ALPHA KINASE ACTIVATION; RECEPTOR ACTIVATOR; INFLAMMATORY ARTHRITIS;
   CELL-PROLIFERATION; SUBTROPICAL GINGER; ZINGIBER-ZERUMBET;
   MULTIPLE-MYELOMA; IN-VITRO; DIFFERENTIATION; EXPRESSION
AB Receptor activator of nuclear factor-kappa B (NF-kappa B) ligand (RANKL) has emerged as a major mediator of hone resorption, commonly associated with cancer and other chronic inflammatory diseases. Inhibitors of RANKL, signaling thus have potential in preventing bone loss. In the present report, the potential of zerumbone, a sesquiterpene derived from subtropical ginger, to modulate osteoclastogenesis induced by RANKL and breast cancer was examined. We found that zerumbone inhibited RANKL-induced NF-kappa B activation in mouse monocyte, an osteoclast precursor cell, through inhibition of activation of I kappa B alpha kinase, I kappa B alpha phosphorylation, and I kappa B alpha degradation. Zerumbone also suppressed RANKL-induced differentiation of these cells to osteoclasts. This sesquiterpene also inhibited the osteoclast formation induced by human breast tumor cells and by multiple myeloma cells. Finally, we examined whether zerumbone could prevent human breast cancer-induced bone loss in animals. We found that zerumbone decreased osteolysis in a dose-dependent manner in MDA-MB-231 breast cancer tumor-bearing athymic nude mice. These results indicate that zerumbone is an effective blocker of RANKL-induced NF-kappa B activation and of osteoclastogenesis induced by RANKL and tumor cells, suggesting its potential as a therapeutic agent for osteoporosis and cancer-associated bone loss. [Cancer Res 2009;69(4):1477-84]
C1 [Sung, Bokyung; Aggarwal, Bharat B.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA.
   [Murakami, Akira] Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto, Japan.
   [Oyajobi, Babatunde O.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
RP Aggarwal, BB (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd,Box 143, Houston, TX 77030 USA.
EM aggarwal@mdanderson.org
RI Aggarwal, Bharat/G-3388-2013
FU Clayton Foundation for Research; NIH/National Cancer Institute
   [IPOI-CA1248701-A2, KOICA104180]
FX Clayton Foundation for Research (B.B. Aggarwal) and NIH/National Cancer
   Institute grants IPOI-CA1248701-A2 (B.B. Aggarwal) and KOICA104180 (B.O.
   Oyajobi). B.B. Aggarwal is the Ransom Horne. Jr., Professor of Cancer
   Research.
CR Abu-Amer Y, 2001, J BIOL CHEM, V276, P30499, DOI 10.1074/jbc.M104725200
   Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184
   Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003
   Annamaria S, 2007, PANCREAS, V35, P249
   Assuma R, 1998, J IMMUNOL, V160, P403
   Berenson JR, 2002, SEMIN ONCOL, V29, P11, DOI 10.1053/sonc.2002.34071
   Bharti AC, 2004, BLOOD, V103, P3175, DOI 10.1182/blood-2003-06-2151
   Bhatia P, 2005, CLIN CANCER RES, V11, P162
   Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078-0432.CCR-05-1933
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Carlin Bruce I., 2000, Cancer, V88, P2989, DOI 10.1002/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.3.CO;2-H
   Cartsos VM, 2008, J AM DENT ASSOC, V139, P23, DOI 10.14219/jada.archive.2008.0016
   Chikatsu N, 2000, BIOCHEM BIOPH RES CO, V267, P632, DOI 10.1006/bbrc.1999.2008
   Clohisy JC, 2003, J IMMUNOL, V171, P5547, DOI 10.4049/jimmunol.171.10.5547
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2001.0210
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gevorgyan A, 2008, CURR OPIN OTOLARYNGO, V16, P325, DOI 10.1097/MOO.0b013e328304b445
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/jbmr.080205, 10.1359/JBMR.080205]
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Huang GC, 2005, PLANTA MED, V71, P219, DOI 10.1055/s-2005-837820
   Hunt NCA, 2001, BRIT J CANCER, V85, P78, DOI 10.1054/bjoc.2001.1856
   Kobayashi Y, 2005, J BIOL CHEM, V280, P11395, DOI 10.1074/jbc.M411189200
   Kong YY, 1999, NATURE, V397, P315
   Lai FPL, 2004, BRIT J HAEMATOL, V126, P192, DOI 10.1111/j.1365-2141.2004.05018.x
   Lipton A, 2006, CANCER TREAT REV, V32, P20, DOI 10.1016/S0305-7372(06)80005-8
   Mariotti A, 2008, J DENT EDUC, V72, P919
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Murakami A, 2004, INT J CANCER, V110, P481, DOI 10.1002/ijc.20175
   Murakami A, 2003, BIOCHEM PHARMACOL, V66, P1253, DOI 10.1016/S0006-2952(03)00446-5
   Murakami A, 1999, BIOSCI BIOTECH BIOCH, V63, P1811, DOI 10.1271/bbb.63.1811
   Nakashima T, 2003, CURR OPIN RHEUMATOL, V15, P280, DOI 10.1097/00002281-200305000-00016
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Oyajobi BO, 2001, CANCER RES, V61, P2572
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002-9440(10)64417-3
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3
   Sung B, 2007, MOL PHARMACOL, V71, P1703, DOI 10.1124/mol.107.034512
   Tada T, 2005, INT J CANCER, V116, P253, DOI 10.1002/ijc.21008
   Takada Y, 2005, ONCOGENE, V24, P6957, DOI 10.1038/sj.onc.1208845
   Tanaka T, 2001, LIFE SCI, V69, P1935, DOI 10.1016/S0024-3205(01)01277-2
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132
   Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
NR 49
TC 58
Z9 61
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD FEB 15
PY 2009
VL 69
IS 4
BP 1477
EP 1484
DI 10.1158/0008-5472.CAN-08-3249
PG 8
WC Oncology
SC Oncology
GA 407YB
UT WOS:000263399100031
PM 19190327
OA Bronze
DA 2018-12-27
ER

PT J
AU Lee, WS
   Chen, TH
AF Lee, Woei-Shyan
   Chen, Tao-Hsing
TI RETRACTED: Mechanical and microstructural response of aluminum-scandium
   (Al-Sc) alloy as a function of strain rate and temperature (Retracted
   article. See vol. 134, pg. 555, 2012)
SO MATERIALS CHEMISTRY AND PHYSICS
LA English
DT Article; Retracted Publication
DE Al-Sc alloy; Strain rate sensitivity; Activation energy; Shearing;
   Dislocation; Precipitates
ID GRAIN-REFINEMENT; FCC METALS; MG ALLOYS; BEHAVIOR; RECRYSTALLIZATION;
   DEFORMATION; PRECIPITATION
AB This study applies a compressive split Hopkinson bar to investigate the mechanical response, microstructural evolution and fracture characteristics of aluminum-scandium (Al-Sc) alloy at temperatures ranging from -100 degrees C to 300 degrees C and strain rates of 1.2 x 10(3) s(-1), 3.2 x 10(3) s(-1) and 5.8 x 10(3) s(-1). The relationship between the dynamic mechanical behaviour of the Al-Sc alloy and its microstructural characteristics is explored. The fracture features and microstructural evolution are observed using scanning and transmission electron microscopy techniques. The stress-strain relationships indicate that the flow stress, work hardening rate and strain rate sensitivity increase with strain rate, but decrease with increasing temperature. Conversely, the activation volume and activation energy increase as the temperature increases or the strain rate decreases. Additionally, the fracture strain reduces with increasing strain rate and decreasing temperature. However, at room temperature under a low strain rate of 1.2 x 10(3) s(-1), and at a high experimental temperature of 300 degrees C under all three tested strain rates, the specimens do not fracture, even under large strain deformations. The Zerilli-Armstrong fcc constitutive model is used to describe the plastic deformation behaviour of the Al-Sc alloy. Comparing the predicted flow stress values with the experimental values over all the considered strain rate and temperature conditions, the maximum error between the two sets of results is found to be less than 4%. SEM observations show that the specimens fracture predominantly as a result of a shearing mechanism. Moreover, the surfaces of the fractured specimens are characterised by transgranular dimpled features, which are indicative of a ductile fracture mode. Fine Al3Sc precipitates are found to be distributed in the matrix and at the grain boundaries. Finally, the TEM analysis results reveal that the dislocation density increases, but the dislocation cell size decreases, with increasing strain rate. However, a higher temperature causes the dislocation density to decrease, thereby increasing the dislocation cell size. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Lee, Woei-Shyan; Chen, Tao-Hsing] Natl Cheng Kung Univ, Dept Mech Engn, Tainan 701, Taiwan.
RP Lee, WS (reprint author), Natl Cheng Kung Univ, Dept Mech Engn, Tainan 701, Taiwan.
EM wslee@mail.ncku.edu.tw
RI Chen, Tao-Hsing/D-8084-2012; Liu, Vincent/B-2973-2011
OI Chen, Tao-Hsing/0000-0002-5433-1812; 
FU National Science Council (NSC) [NSC 95-2221-E-006-270]
FX The authors gratefully acknowledge the financial support provided to
   this study by the National Science Council (NSC) of Taiwan under
   contract no. NSC 95-2221-E-006-270. Furthermore, the authors wish to
   express their appreciation to Taiwan Hodaka Technology Co. Ltd. for
   their supply of Al-Sc alloy bars.
CR Akamatsu H, 2001, SCRIPTA MATER, V44, P759, DOI 10.1016/S1359-6462(00)00666-7
   Chiddister JL, 1963, EXPT MECHANICS, V3, P81, DOI DOI 10.1007/BF02325890
   CONRAD H, 1964, JOM-J MET, V16, P582, DOI 10.1007/BF03378292
   CUDDY J, 1989, MAT SCI ENG A-STRUCT, V113, P421, DOI 10.1016/0921-5093(89)90329-8
   Cuniberti A, 2001, PHYS STATUS SOLIDI A, V183, P373, DOI 10.1002/1521-396X(200102)183:2<373::AID-PSSA373>3.0.CO;2-N
   Furukawa M, 2001, ACTA MATER, V49, P3829, DOI 10.1016/S1359-6454(01)00262-2
   HAM RK, 1961, PHILOS MAG, V6, P1183, DOI 10.1080/14786436108239679
   Han BQ, 2005, METALL MATER TRANS A, V36A, P345, DOI 10.1007/s11661-005-0307-9
   Irving B, 1997, WELD J, V76, P53
   Johnson G.R., 1983, 7TH P INT S BALL HAG, P541
   Jones MJ, 2003, ACTA MATER, V51, P2149, DOI 10.1016/S1359-6454(03)00002-8
   KHARAKTEROVA ML, 1994, ACTA METALL MATER, V42, P2285, DOI 10.1016/0956-7151(94)90307-7
   KLEPACZKO JR, 1986, J MECH PHYS SOLIDS, V34, P29, DOI 10.1016/0022-5096(86)90004-9
   KOBAYASHI H, 1989, INT J IMPACT ENG, V8, P1, DOI 10.1016/0734-743X(89)90027-4
   Kramer LS, 1997, ADV MATER PROCESS, V152, P23
   Lee S, 2002, ACTA MATER, V50, P553, DOI 10.1016/S1359-6454(01)00368-8
   Lee W.S., 2000, SCRIPTA MATER, V42, P51
   Lee WS, 1998, MAT SCI ENG A-STRUCT, V241, P48, DOI 10.1016/S0921-5093(97)00471-1
   Lee WS, 2000, J MATER PROCESS TECH, V100, P116, DOI 10.1016/S0924-0136(99)00465-3
   Lukin V. I., 1996, WELD INT, V10, P987
   Murr L. E., 1981, SHOCK WAVES HIGH STR, P607
   Norman AF, 2003, MAT SCI ENG A-STRUCT, V354, P188, DOI 10.1016/S0921-5093(02)00942-5
   Ocenasek V, 2001, MATER CHARACT, V47, P157, DOI 10.1016/S1044-5803(01)00165-6
   Paglia CS, 2006, MAT SCI ENG A-STRUCT, V424, P196, DOI 10.1016/j.msea.2006.03.065
   Riddle YW, 2004, METALL MATER TRANS A, V35A, P341, DOI 10.1007/s11661-004-0135-3
   RIVAS JM, 1995, SCRIPTA METALL MATER, V33, P101, DOI 10.1016/0956-716X(95)00105-5
   Sakai G, 2005, MAT SCI ENG A-STRUCT, V393, P344, DOI 10.1016/j.msea.2004.11.007
   Seidman DN, 2002, ACTA MATER, V50, P4021, DOI 10.1016/S1359-6454(02)00201-X
   SHI L, 1995, ACTA METALL MATER, V43, P453, DOI 10.1016/0956-7151(94)00279-Q
   SHYU JC, 1999, THESIS NATL CHENG KU, P64
   TORMA T, 1989, J MATER SCI, V24, P3924, DOI 10.1007/BF01168955
   Xu YB, 2001, MAT SCI ENG A-STRUCT, V299, P287, DOI 10.1016/S0921-5093(00)01412-X
   ZERILLI FJ, 1987, J APPL PHYS, V61, P1816, DOI 10.1063/1.338024
   ZERILLI FJ, 1992, ACTA METALL MATER, V40, P1803, DOI 10.1016/0956-7151(92)90166-C
NR 34
TC 22
Z9 22
U1 3
U2 22
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0254-0584
J9 MATER CHEM PHYS
JI Mater. Chem. Phys.
PD FEB 15
PY 2009
VL 113
IS 2-3
BP 734
EP 745
DI 10.1016/j.matchemphys.2008.08.016
PG 12
WC Materials Science, Multidisciplinary
SC Materials Science
GA 405UK
UT WOS:000263249500045
DA 2018-12-27
ER

PT J
AU Xu, C
   Zhang, YB
   Jiang, H
AF Xu, Chong
   Zhang, Yanbing
   Jiang, Hua
TI RETRACTED: Ex vivo expansion of hematopoietic stem cell by fusion
   protein TAT-Zfx (Retracted article. See vol. 388, pg. 465, 2009)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE Hematopoietic stem cell; Self-renewal; Zfx; TAT
ID POLYCOMB-GROUP GENES; BONE-MARROW-CELLS; IN-VIVO; TRANSDUCTION;
   REPOPULATION; ACTIVATION
AB The relative inability of hemopoietic stem cells (HSCs) to reproduce themselves (self-renew) ex vivo imposes substantial limitations on the current use of HSC transplantation. Recently, the transcription factor Zfx has been demonstrated that played an important in controlling the self-renewal of hematopoietic stem cells. Here, we reported that Zfx could enable high-level expansion of HSCs in vitro, by combination of protein transduction domain, TAT. Furthermore, we also demonstrated that expanded HSCs population retains their normal in vivo potential of pluripotency. It is thus that TAT-Zfx has the potential to expand HSCs significantly in vitro, and will have enormous clinical potentials. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Jiang, Hua] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Dept Heamatol Oncol, Shanghai 200030, Peoples R China.
   [Xu, Chong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Lab Diagnost Ctr, Shanghai 200030, Peoples R China.
   [Zhang, Yanbing] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Dept Surg, Shanghai 200030, Peoples R China.
RP Jiang, H (reprint author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Dept Heamatol Oncol, Shanghai 200030, Peoples R China.
EM huajiang1@163.com
CR Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9
   Cellot S, 2007, CELL, V129, P239, DOI 10.1016/j.cell.2007.04.002
   Dolgilevich S, 2002, BIOCHEM BIOPH RES CO, V299, P505, DOI 10.1016/S0006-291X(02)02664-5
   FUKUCHI Y, 2008, STEM CELLS
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Katterle Y, 2004, BRIT J CANCER, V90, P230, DOI 10.1038/sj.bjc.6601506
   Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381
   Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691
   Lessard J, 1998, BLOOD, V91, P1216
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Pittet MJ, 2006, NAT PROTOC, V1, P73, DOI 10.1038/nprot.2006.11
   SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5
   Schuringa JJ, 2004, STEM CELLS, V22, P1191, DOI 10.1634/stemcells.2004-0033
   Sengoku T, 2004, EXP NEUROL, V188, P161, DOI 10.1016/j.expneurol.2004.03.018
   SZILVASSY SJ, 1990, P NATL ACAD SCI USA, V87, P8736, DOI 10.1073/pnas.87.22.8736
   Thorsteinsdottir U, 1999, MOL CELL BIOL, V19, P6355
NR 16
TC 4
Z9 8
U1 4
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 13
PY 2009
VL 379
IS 3
BP 771
EP 774
DI 10.1016/j.bbrc.2008.12.125
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 405XS
UT WOS:000263258100024
PM 19121620
DA 2018-12-27
ER

PT J
AU Takeshima, E
   Tomimori, K
   Kawakami, H
   Ishikawa, C
   Sawada, S
   Tomita, M
   Senba, M
   Kinjo, F
   Mimuro, H
   Sasakawa, C
   Fujita, J
   Mori, N
AF Takeshima, Eriko
   Tomimori, Koh
   Kawakami, Hirochika
   Ishikawa, Chie
   Sawada, Shigeki
   Tomita, Mariko
   Senba, Masachika
   Kinjo, Fukunori
   Mimuro, Hitomi
   Sasakawa, Chihiro
   Fujita, Jiro
   Mori, Naoki
TI RETRACTED: NF-kappa B activation by Helicobacter pylori requires
   Akt-mediated phosphorylation of p65 (Retracted article. See vol. 11,
   artn no. 128, 2011)
SO BMC MICROBIOLOGY
LA English
DT Article; Retracted Publication
ID CAG PATHOGENICITY ISLAND; GASTRIC EPITHELIAL-CELLS; VIRULENCE FACTORS;
   IV SECRETION; KINASE; PROTEIN; INTERLEUKIN-8; CANCER; INFLAMMATION;
   PATHWAY
AB Background: The inflammatory response in Helicobacter pylori-infected gastric tissue is mediated by cag pathogenicity island (PAI)-dependent activation of nuclear factor-kappa B (NF-kappa B). Phosphatidylinositol 3-kinase (PI3K)/Akt signaling is known to play a role in NF-kappa B activation, but little information is available on the relationship between H. pylori and PI3K/Akt signaling in gastric epithelial cells. We examined whether H. pylori activates Akt in gastric epithelial cells, the role of cag PAI in this process and the role of Akt in regulating H. pylori-induced NF-kappa B activation.
   Results: Phosphorylated Akt was detected in epithelial cells of H. pylori-positive gastric tissues. Although Akt was activated in MKN45 and AGS cells by coculture with cag PAI-positive H. pylori strains, a cag PAI-negative mutant showed no activation of Akt. H. pylori also induced p65 phosphorylation. PI3K inhibitor suppressed H. pylori-induced p65 phosphorylation and NF-kappa B transactivation, as well as interleukin-8 expression. Furthermore, transfection with a dominant-negative Akt inhibited H. pylori-induced NF-kappa B transactivation. Transfection with small interference RNAs for p65 and Akt also inhibited H. pylori-induced interleukin-8 expression.
   Conclusion: The results suggest that cag PAI-positive H. pylori activates Akt in gastric epithelial cells and this may contribute to H. pylori-mediated NF-kappa B activation associated with mucosal inflammation and carcinogenesis.
C1 [Takeshima, Eriko; Tomimori, Koh; Kawakami, Hirochika; Ishikawa, Chie; Sawada, Shigeki; Tomita, Mariko; Mori, Naoki] Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Okinawa 9030215, Japan.
   [Takeshima, Eriko; Tomimori, Koh; Fujita, Jiro] Univ Ryukyus, Grad Sch Med, Div Control & Prevent Infect Dis, Okinawa 9030215, Japan.
   [Ishikawa, Chie] Univ Ryukyus, Fac Med, Div Child Hlth & Welf, Okinawa 9030215, Japan.
   [Sawada, Shigeki] Univ Ryukyus, Fac Med, Div Oral & Maxillofacial Funct Rehabil, Okinawa 9030215, Japan.
   [Ishikawa, Chie] JSPS, Tokyo, Japan.
   [Senba, Masachika] Nagasaki Univ, Inst Trop Med, Dept Pathol, Nagasaki 8528523, Japan.
   [Kinjo, Fukunori] Univ Ryukyus, Univ Hosp, Dept Endoscopy, Okinawa 9030215, Japan.
   [Mimuro, Hitomi; Sasakawa, Chihiro] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Minato Ku, Tokyo 1088639, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Okinawa 9030215, Japan.
EM erichinai@yahoo.co.jp; koh-tomi@future.ocn.ne.jp;
   kawakami1975@yahoo.co.jp; chiezo@lab.u-ryukyu.ac.jp;
   k048707@eve.uryukyu.ac.jp; mtomita@med.u-ryukyu.ac.jp;
   mikiyo@net.nagasaki-u.ac.jp; kinjofuk@med.u-ryukyu.ac.jp;
   mim@ims.u-tokyo.ac.jp; sasakawa@ims.u-tokyo.ac.jp;
   fujita@med.u-ryukyu.ac.jp; n-mori@med.u-ryukyu.ac.jp
FU Takeda Science Foundation; Ministry of Education, Culture, Sports,
   Science and Technology [20012044]; Japan Society for the Promotion of
   Science [19591123]
FX The authors thank T. Hirayama for providing H. pylori strain (ATCC
   49503); J. Fujisawa for providing reporter plasmid kappa B-LUC; and D.
   R. Alessi for providing the dominant negative mutant of Akt. This work
   was supported in part by the Takeda Science Foundation and Grants-in-Aid
   for Scientific Research on Priority Areas from Ministry of Education,
   Culture, Sports, Science and Technology (20012044) and Scientific
   Research (C) from Japan Society for the Promotion of Science (19591123).
CR Aihara M, 1997, INFECT IMMUN, V65, P3218
   Akopyants NS, 1998, MOL MICROBIOL, V28, P37, DOI 10.1046/j.1365-2958.1998.00770.x
   Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797
   Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x
   BLASER MJ, 1995, CANCER RES, V55, P2111
   Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200
   Brandt S, 2005, P NATL ACAD SCI USA, V102, P9300, DOI 10.1073/pnas.0409873102
   Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200
   Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648
   Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368
   Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   CRABTREE JE, 1995, J CLIN PATHOL, V48, P967, DOI 10.1136/jcp.48.10.967
   CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7
   Fischer W, 2001, MOL MICROBIOL, V42, P1337, DOI 10.1046/j.1365-2958.2001.02714.x
   Foryst-Ludwig A, 2000, J BIOL CHEM, V275, P39779, DOI 10.1074/jbc.M007617200
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1
   Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200
   Hocker M, 2003, LANCET, V362, P1231, DOI 10.1016/S0140-6736(03)14547-3
   Houghton J, 2005, GASTROENTEROLOGY, V128, P1567, DOI 10.1053/j.gastro.2005.03.037
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   KUNSCH C, 1994, J IMMUNOL, V153, P153
   Kwok T, 2007, NATURE, V449, P862, DOI 10.1038/nature06187
   Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200
   Mori N, 1999, BLOOD, V93, P2360
   Moss SF, 2003, CURR OPIN INFECT DIS, V16, P445, DOI 10.1097/01.qco.0000092816.64370.e2
   Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251
   Naumann M, 2005, INT J MED MICROBIOL, V295, P335, DOI 10.1016/j.ijmm.2005.06.007
   Selbach M, 2002, INFECT IMMUN, V70, P665, DOI 10.1128/IAI.70.2.665-671.2002
   Tammer I, 2007, GASTROENTEROLOGY, V132, P1309, DOI 10.1053/j.gastro.2007.01.050
   Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483
   Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tiba.2004.11.009
NR 32
TC 20
Z9 23
U1 3
U2 23
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2180
J9 BMC MICROBIOL
JI BMC Microbiol.
PD FEB 12
PY 2009
VL 9
AR 36
DI 10.1186/1471-2180-9-36
PG 9
WC Microbiology
SC Microbiology
GA 418PN
UT WOS:000264160600001
PM 19216748
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Nemecek, J
   Nakayashiki, T
   Wickner, RB
AF Nemecek, Julie
   Nakayashiki, Toru
   Wickner, Reed B.
TI RETRACTED: A prion of yeast metacaspase homolog (Mca1p) detected by a
   genetic screen (Retracted article. See vol. 108, pg. 10022, 2011)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE cytoduction; metacaspase; prion
ID DE-NOVO APPEARANCE; SACCHAROMYCES-CEREVISIAE; PODOSPORA-ANSERINA;
   PROTEIN; PROPAGATION; APOPTOSIS; PIN+; URE3; INDEPENDENCE; STRAINS
AB Saccharomyces cerevisiae can be infected with four amyloid-based prions: [URE3], [PSI+], [PIN+], and [SWI+], due to self-propagating aggregation of Ure2p, Sup35p, Rnq1p and Swi1p, respectively. We searched for new prions of yeast by fusing random segments of yeast DNA to SUP35MC, encoding the Sup35 protein lacking its own prion domain, selecting clones in which Sup35MC function was impaired. Three different clones contained parts of the Q/N-rich amino-terminal domain of Mca1p/Yca1p with the Sup35 part of the fusion protein partially inactive. This inactivity was dominant, segregated 4: 0 in meiosis, and was efficiently transferred by cytoplasmic mixing. The inactivity was cured by overexpression of Hsp104, but the prion could arise again in the cured strain (reversible curing). Overproduction of the Mca1 N-terminal domain induced the de novo appearance of the prion form of the fusion. The prion state, which we name [MCA], was transmitted to the chromosomally encoded Mca1p based on genetic, cytological and biochemical tests.
C1 [Nemecek, Julie; Nakayashiki, Toru; Wickner, Reed B.] NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA.
RP Wickner, RB (reprint author), NIDDK, Lab Biochem & Genet, NIH, Bldg 8,Room 225,MSC 0830, Bethesda, MD 20892 USA.
EM wickner@helix.nih.gov
FU National Institute of Diabetes Digestive and Kidney Diseases
FX This work was supported by the Intramural Program of the National
   Institute of Diabetes Digestive and Kidney Diseases. We thank our
   colleagues for critical reading of the manuscript.
CR Balguerie A, 2003, EMBO J, V22, P2071, DOI 10.1093/emboj/cdg213
   Bradley ME, 2002, P NATL ACAD SCI USA, V99, P16392, DOI 10.1073/pnas.152330699
   CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373
   CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802
   CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651
   Coustou V, 1997, P NATL ACAD SCI USA, V94, P9773, DOI 10.1073/pnas.94.18.9773
   COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65
   Derkatch IL, 1997, GENETICS, V147, P507
   Derkatch IL, 2001, CELL, V106, P171, DOI 10.1016/S0092-8674(01)00427-5
   Derkatch IL, 2000, EMBO J, V19, P1942, DOI 10.1093/emboj/19.9.1942
   Du ZQ, 2008, NAT GENET, V40, P460, DOI 10.1038/ng.112
   ESTEBAN R, 1987, GENETICS, V117, P399
   Kryndushkin D, 2007, MOL BIOL CELL, V18, P2149, DOI 10.1091/mbc.E07-02-0128
   LACROUTE F, 1971, J BACTERIOL, V106, P519
   Lee REC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002956
   MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93
   Mazzoni C, 2008, BBA-MOL CELL RES, V1783, P1320, DOI 10.1016/j.bbamcr.2008.02.015
   Mitsui K, 2005, FEBS LETT, V579, P723, DOI 10.1016/j.febslet.2004.12.051
   Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000
   RIZET GEORGES, 1952, REV CYTOL ET BIOL VEG, V13, P51
   Ross ED, 2005, P NATL ACAD SCI USA, V102, P12825, DOI 10.1073/pnas.0506136102
   Ross ED, 2004, MOL CELL BIOL, V24, P7206, DOI 10.1128/MCB.24.16.7206-7213.2004
   Salnikova AB, 2005, J BIOL CHEM, V280, P8808, DOI 10.1074/jbc.M410150200
   Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2
   Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8
   TERAVANESYAN MD, 1994, GENETICS, V137, P671
   TUITE MF, 1981, GENETICS, V98, P691
   Vachova L, 2007, FEMS YEAST RES, V7, P12, DOI 10.1111/j.1567-1364.2006.00137.x
   Vitrenko YA, 2007, CURR GENET, V51, P309, DOI 10.1007/s00294-007-0127-0
   WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170
   WICKNER RB, 2006, FIELDS VIROLOGY
NR 31
TC 52
Z9 55
U1 4
U2 14
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 10
PY 2009
VL 106
IS 6
BP 1892
EP 1896
DI 10.1073/pnas.0812470106
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 405VO
UT WOS:000263252500041
PM 19174511
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Liu, J
   Zou, L
   Wang, J
   Schuler, C
   Zhao, ZH
   Li, XY
   Zhang, JY
   Liu, YR
AF Liu, Jun
   Zou, Ling
   Wang, Jun
   Schuler, Charles
   Zhao, Zhihe
   Li, Xiaoyu
   Zhang, Jingyi
   Liu, Yurong
TI RETRACTED: Hydrostatic pressure promotes Wnt10b and Wnt4 expression
   dependent and independent on ERK signaling in early-osteoinduced MSCs
   (Retracted article. See vol. 404, pg. 887, 2011)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE Extracellular signal-regulated kinase (ERK); Wnt signaling; Mesenchymal
   stem cells (MSCs); Mechanobiology; Osteogenic differentiation
ID MESENCHYMAL STEM-CELLS; MECHANICAL STRAIN; OSTEOGENIC DIFFERENTIATION;
   OSTEOBLAST PROGENITORS; MATRIX MINERALIZATION; BONE REGENERATION;
   IN-VITRO; ACTIVATION; PATHWAY; PROLIFERATION
AB Recent publications have shown that mechanical stress can regulate the direction of stein cell differentiation. The exact mechanobiological effects of pressure on initial osteodifferentiation have not been determined. Here, we show that ERK signaling participates in early osteodifferentiation and plays a positive but non-critical role in mechanotransduction, whereas p38 MAR is not involved in this process. Moreover, our findings provide evidence that in response to both types of pressure with high sensitivity, Wnt10b mRNA is ERK-dependent whereas Wnt4 mRNA is upregulated by treatment of the inhibitor of ERK signaling. The findings suggest novel mechanisms of the initial biological responses of bone remodeling and regeneration upon mechanical stimuli. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Liu, Jun; Zou, Ling; Wang, Jun; Zhao, Zhihe; Li, Xiaoyu; Zhang, Jingyi; Liu, Yurong] Sichuan Univ, W China Hosp Stomatol, W China Coll Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
   [Schuler, Charles] Univ British Columbia, Fac Dent, Vancouver, BC V5Z 1M9, Canada.
RP Zhao, ZH (reprint author), Sichuan Univ, W China Hosp Stomatol, W China Coll Stomatol, State Key Lab Oral Dis, 14,3rd Sect,Renmin S Rd, Chengdu 610041, Peoples R China.
EM wangjunv@yahoo.cn; zhaozhihe1963@yahoo.cn
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502165200
   Altman GH, 2001, FASEB J, V15, P270, DOI 10.1096/fj.01-0656fje
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Caverzasio J, 2007, ENDOCRINOLOGY, V148, P5323, DOI 10.1210/en.2007-0520
   Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200
   Cheng SL, 2008, J BIOL CHEM, V283, P20505, DOI 10.1074/jbc.M800851200
   Estes BT, 2004, CURR TOP DEV BIOL, V60, P91
   Fan M, 2006, J CELL PHYSIOL, V207, P454, DOI 10.1002/jcp.20581
   FRIEDENSTEIN AJ, 1992, BONE MINER, V18, P199, DOI 10.1016/0169-6009(92)90807-P
   Friedl G, 2007, OSTEOARTHR CARTILAGE, V15, P1293, DOI 10.1016/j.joca.2007.04.002
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210
   Huang CYC, 2004, STEM CELLS, V22, P313, DOI 10.1634/stemcells.22-3-313
   Jansen JHW, 2004, J CELL BIOCHEM, V93, P542, DOI 10.1002/jcb.20162
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Kanno T, 2007, J CELL BIOCHEM, V101, P1266, DOI 10.1002/jcb.21249
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Koike M, 2005, J BONE MINER METAB, V23, P219, DOI 10.1007/s00774-004-0587-y
   Lennon DP, 2006, EXP HEMATOL, V34, P1606, DOI 10.1016/j.exphem.2006.07.015
   Liu J, 2006, BIOCHEM BIOPH RES CO, V348, P1167, DOI 10.1016/j.bbrc.2006.07.175
   MCGUINNESS NJP, 1991, EUR J ORTHODONT, V13, P231, DOI 10.1093/ejo/13.3.231
   Nagatomi J, 2001, TISSUE ENG, V7, P717, DOI 10.1089/107632701753337672
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Simmons CA, 2003, J BIOMECH, V36, P1087, DOI 10.1016/S0021-9290(03)00110-6
   Sumanasinghe RD, 2006, TISSUE ENG, V12, P3459, DOI 10.1089/ten.2006.12.3459
   Ward DF, 2007, STEM CELLS DEV, V16, P467, DOI 10.1089/scd.2007.0034
   Yun MS, 2005, J CELL SCI, V118, P313, DOI 10.1242/jcs.01601
   Zhou H, 2008, J BIOL CHEM, V283, P1936, DOI 10.1074/jbc.M702687200
NR 29
TC 16
Z9 23
U1 5
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 6
PY 2009
VL 379
IS 2
BP 505
EP 509
DI 10.1016/j.bbrc.2008.12.087
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 401FF
UT WOS:000262924300065
PM 19118527
DA 2018-12-27
ER

PT J
AU Shi, MG
   Vivian, CJ
   Lee, KJ
   Ge, CM
   Morotomi-Yano, K
   Manzl, C
   Bock, F
   Sato, S
   Tomomori-Sato, C
   Zhu, RH
   Haug, JS
   Swanson, SK
   Washburn, MP
   Chen, DJ
   Chen, BPC
   Villunger, A
   Florens, L
   Du, CY
AF Shi, Mingan
   Vivian, Carolyn J.
   Lee, Kyung-Jong
   Ge, Chunmin
   Morotomi-Yano, Keiko
   Manzl, Claudia
   Bock, Florian
   Sato, Shigeo
   Tomomori-Sato, Chieri
   Zhu, Ruihong
   Haug, Jeffrey S.
   Swanson, Selene K.
   Washburn, Michael P.
   Chen, David J.
   Chen, Benjamin P. C.
   Villunger, Andreas
   Florens, Laurence
   Du, Chunying
TI RETRACTED: DNA-PKcs-PIDDosome: A Nuclear Caspase-2-Activating Complex
   with Role in G2/M Checkpoint Maintenance (Retracted article. See vol.
   145, pg. 161, 2011)
SO CELL
LA English
DT Article; Retracted Publication
ID DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; CELL-DEATH; IONIZING
   IRRADIATION; CASPASE-2; APOPTOSIS; ACTIVATION; DAMAGE; PHOSPHORYLATION;
   LOCALIZATION
AB Caspase-2 is unique among all the mammalian caspases in that it is the only caspase that is present constitutively in the cell nucleus, in addition to other cellular compartments. However, the functional significance of this nuclear localization is unknown. Here we show that DNA damage induced by gamma-radiation triggers the phosphorylation of nuclear caspase-2 at the S122 site within its prodomain, leading to its cleavage and activation. This phosphorylation is carried out by the nuclear serine/threonine protein kinase DNA-PKcs and promoted by the p53-inducible death-domain-containing protein PIDD within a large nuclear protein complex consisting of DNA-PKcs, PIDD, and caspase-2, which we have named the DNA-PKcs-PIDDosome. This phosphorylation and the catalytic activity of caspase-2 are involved in the maintenance of a G2/M DNA damage checkpoint and DNA repair mediated by the nonhomologous end-joining (NHEJ) pathway. The DNA-PKcs-PIDDosome thus represents a protein complex that impacts mammalian G2/M DNA damage checkpoint and NHEJ.
C1 [Shi, Mingan; Vivian, Carolyn J.; Ge, Chunmin; Sato, Shigeo; Tomomori-Sato, Chieri; Zhu, Ruihong; Haug, Jeffrey S.; Swanson, Selene K.; Washburn, Michael P.; Florens, Laurence; Du, Chunying] Stowers Inst Med Res, Kansas City, MO 64110 USA.
   [Lee, Kyung-Jong; Morotomi-Yano, Keiko; Chen, David J.; Chen, Benjamin P. C.] Univ Texas SW Med Ctr Dallas, Div Mol Radiat Biol, Dallas, TX 75390 USA.
   [Manzl, Claudia; Bock, Florian; Villunger, Andreas] Innsbruck Med Univ, Bioctr, Div Dev Immunol, A-6020 Innsbruck, Austria.
RP Du, CY (reprint author), Stowers Inst Med Res, Kansas City, MO 64110 USA.
EM cdu@stowers.org
OI Florens, Laurence/0000-0002-9310-6650; Washburn,
   Michael/0000-0001-7568-2585; Vivian, Carolyn J./0000-0001-9598-0109
FU Austrian Science Fund FWF [Y 212]; NCI NIH HHS [P01 CA092584, R01
   CA162804, P01-CA92584, R01 CA050519, CA50519, R37 CA050519]
CR Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2
   Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031
   Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283
   Baliga BC, 2003, J BIOL CHEM, V278, P4899, DOI 10.1074/jbc.M211512200
   Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304
   Brewerton SC, 2004, J STRUCT BIOL, V145, P295, DOI 10.1016/j.jsb.2003.11.024
   Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030
   Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021
   Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b
   Chen BPC, 2007, J BIOL CHEM, V282, P6582, DOI 10.1074/jbc.M611605200
   Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200
   Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332
   Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535
   Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003
   Gao ZH, 2005, J BIOL CHEM, V280, P38271, DOI 10.1074/jbc.M506488200
   GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W
   Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9
   Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036
   Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097
   KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613
   LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603
   Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038
   Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032
   O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033
   Park HH, 2007, CELL, V128, P533, DOI 10.1016/j.cell.2007.01.019
   Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186
   Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004
   Rotter B, 2004, BIOCHEM J, V378, P161, DOI 10.1042/BJ20030955
   Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723
   Shin S, 2005, EMBO J, V24, P3532, DOI 10.1038/sj.emboj.7600827
   Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916
   Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432
   Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175
   Tu S, 2006, NAT CELL BIOL, V8, P72, DOI 10.1038/ncb1340
   Veuger SJ, 2003, CANCER RES, V63, P6008
   Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182
   Wang HC, 2006, CANCER RES, V66, P1391, DOI 10.1158/0008-5472.CAN-05-3270
   WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7
   Wang XD, 2001, GENE DEV, V15, P2922
   Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002
   Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001
   Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073
   Zhivotovsky B, 2005, BIOCHEM BIOPH RES CO, V331, P859, DOI 10.1016/j.bbrc.2005.03.191
   Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536
NR 48
TC 70
Z9 73
U1 5
U2 20
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD FEB 6
PY 2009
VL 136
IS 3
BP 508
EP 520
DI 10.1016/j.cell.2008.12.021
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 403ZN
UT WOS:000263120600020
PM 19203584
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Zhang, B
   Chambers, KJ
   Leprince, D
   Faller, DV
   Wang, S
AF Zhang, B.
   Chambers, K. J.
   Leprince, D.
   Faller, D. V.
   Wang, S.
TI RETRACTED: Requirement for chromatin-remodeling complex in novel tumor
   suppressor HIC1-mediated transcriptional repression and growth control
   (Retracted article. See vol. 30, pg. 4374, 2011)
SO ONCOGENE
LA English
DT Article; Retracted Publication
DE HIC1; E2F1; Brg1; SWI/SNF; transcription; cell cycle
ID GENE HIC1; ANDROGEN RECEPTOR; SWI/SNF COMPLEX; PROHIBITIN; RB; E2F;
   EXPRESSION; CANCER; IDENTIFICATION; ACTIVATION
AB HIC1 is a newly discovered tumor suppressor and transcriptional repressor that is frequently silenced in human tumors. HIC1 protein expression has been linked to better outcomes in breast cancers. The molecular mechanism underlying HIC1-mediated transcriptional and growth suppression, and the relevant targets of HIC1-mediated transcriptional modulation, is currently unclear. We have identified an HIC1 DNA-binding site in E2F-responsive gene promoters and demonstrate that HIC1 targets E2F-responsive genes for transcriptional regulation and growth suppression. We and others have recently discovered that Brg1, a central component of the SWI/SNF chromatin-remodeling family, is required for the transcriptional regulation of multiple cell cycle control-related genes, including E2F-responsive promoters. We studied HIC1 interactions with, and dependence upon, Brg1 activity, and found that HIC1 can recruit Brg1 to E2F-responsive promoters and that its transcriptional repression of these genes is dependent upon Brg1. These data indicate that HIC1 is a central molecule in a novel mechanism controlling cell growth and that the disruption of this HIC1-mediated pathway may lead to abnormal cell proliferation and, ultimately, cancer.
C1 [Zhang, B.; Chambers, K. J.; Faller, D. V.; Wang, S.] Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA.
   [Leprince, D.] Inst Pasteur, Inst Biol Lille, CNRS, UMR 8161, F-59019 Lille, France.
RP Wang, S (reprint author), Boston Univ, Sch Med, Canc Res Ctr, R-906,715 Albany St, Boston, MA 02118 USA.
EM sw184@bu.edu
OI Leprince, Dominique/0000-0002-1999-0775
FU Susan G Komen Breast Cancer Foundation Research [BCTR0403163]; National
   Cancer Institute [CA102940, CA101992]; Karin Grunebaum Cancer Research
   Foundation; DOD/CDMRP 2008 Breast Cancer Concept Award; Carter Family
   Foundation for Melanoma Research; BUSM Department of Medicine Pilot
   Project Grant Award; Aid for Cancer Research
FX We thank Dr Srikumar P Chellappan for his continuous support. This study
   was partially supported by grants from Susan G Komen Breast Cancer
   Foundation Research Award (BCTR0403163)(SW) and the National Cancer
   Institute ((CA102940)(SW) and (CA101992)(DVF)) and by the Karin
   Grunebaum Cancer Research Foundation (DVF). SW is the recipient of
   DOD/CDMRP 2008 Breast Cancer Concept Award, Carter Family Foundation for
   Melanoma Research grant award, a BUSM Department of Medicine Pilot
   Project Grant Award and an Aid for Cancer Research grant award.
CR Aggerholm A, 2006, EUR J HAEMATOL, V76, P23, DOI 10.1111/j.1600-0609.2005.00559.x
   Banine F, 2005, CANCER RES, V65, P3542, DOI 10.1158/0008-5472.CAN-04-3554
   Bertrand S, 2004, BBA-GENE STRUCT EXPR, V1678, P57, DOI 10.1016/j.bbaexp.2004.01.009
   Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706
   Britschgi C, 2006, ONCOGENE, V25, P2030, DOI 10.1038/sj.onc.1209240
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2008.08.011
   Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077
   Chen WY, 2005, CELL CYCLE, V4, P10, DOI 10.4161/cc.4.1.1361
   Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030
   Chopin V, 2006, M S-MED SCI, V22, P54, DOI 10.1051/medsci/200622154
   Dai Y, 2008, CARCINOGENESIS, V29, P1725, DOI 10.1093/carcin/bgn117
   Dai Y, 2007, MOL ENDOCRINOL, V21, P1807, DOI 10.1210/me.2006-0467
   Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004
   Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002
   DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7
   Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551
   Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615
   Guerardel C, 1999, FEBS LETT, V451, P253, DOI 10.1016/S0014-5793(99)00583-9
   Inayoshi Y, 2006, J BIOCHEM, V139, P177, DOI 10.1093/jb/mvj015
   Lefebvre T, 2004, EUR J BIOCHEM, V271, P3843, DOI 10.1111/j.1432-1033.2004.04316.x
   Melki JR, 1999, LEUKEMIA, V13, P877, DOI 10.1038/sj.leu.2401401
   Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699
   Nicoll G, 2001, BRIT J CANCER, V85, P1878, DOI 10.1054/bjoc.2001.2163
   Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200
   Pinte S, 2004, ONCOGENE, V23, P4023, DOI 10.1038/sj.onc.1207504
   Stankovic-Valentin N, 2006, FEBS J, V273, P2879, DOI 10.1111/j.1742-4658.2006.05301.x
   Stevaux O, 2002, EMBO J, V21, P4927, DOI 10.1093/emboj/cdf501
   Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200
   Takahashi Y, 2000, GENE DEV, V14, P804
   Waha A, 2004, INT J CANCER, V110, P542, DOI 10.1002/ijc.20165
   Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302
   Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684
   Wang S, 2004, EMBO J, V23, P2293, DOI 10.1038/sj.emboj.7600231
   Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944
   Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559
   Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487
   Wong S, 2007, BIOCHEM J, V407, P451, DOI 10.1042/BJ20070151
   Zhang B, 2007, ONCOGENE, V26, P7153, DOI 10.1038/sj.onc.1210509
NR 38
TC 18
Z9 19
U1 4
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD FEB 5
PY 2009
VL 28
IS 5
BP 651
EP 661
DI 10.1038/onc.2008.419
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 403IN
UT WOS:000263076400003
PM 19015639
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Chang, CH
   Yu, P
   Yang, CS
AF Chang, C. H.
   Yu, Peichen
   Yang, C. S.
TI RETRACTED: Broadband and omnidirectional antireflection from conductive
   indium-tin-oxide nanocolumns prepared by glancing-angle deposition with
   nitrogen (Retracted article. See vol. 104, 269901, 2014)
SO APPLIED PHYSICS LETTERS
LA English
DT Article; Retracted Publication
DE antireflection coatings; electron beam deposition; indium compounds;
   nanostructured materials; semiconductor growth; semiconductor materials
ID THIN-FILMS; OPTICAL-PROPERTIES; REFRACTIVE-INDEX; LIGHT; REFLECTION;
   MECHANISM; SURFACES
AB Characteristic formation of highly oriented indium-tin-oxide (ITO) nanocolumns is demonstrated using electron-beam evaporation with an obliquely incident nitrogen flux. The nanocolumn material exhibits broadband and omnidirectional antireflective characteristics up to an incidence angle of 70 degrees for the 350-900 nm wavelength range for both s- and p-polarizations. Calculations based on a rigorous coupled-wave analysis indicate that the superior antireflection arises from the tapered column profiles which collectively function as a gradient-index layer. Since the nanocolumns have a preferential growth direction which follows the incident vapor flux, the azimuthal and polarization dependence of reflectivities are also investigated. The single ITO nanocolumn layer can function as antireflection contacts for light emitting diodes and solar cells.
C1 [Chang, C. H.] Natl Chiao Tung Univ, Dept Photon, Hsinchu 30010, Taiwan.
   Natl Chiao Tung Univ, Inst Electroopt Engn, Hsinchu 30010, Taiwan.
RP Chang, CH (reprint author), Natl Chiao Tung Univ, Dept Photon, Hsinchu 30010, Taiwan.
EM yup@faculty.nctu.edu.tw
FU National Science Council in Taiwan [NSC 96-2221-E-009-092-MY3, NSC
   97-2120-M-006-009]
FX The authors thank Dr. S. H. Hsu and Dr. Y. C. Chang at the Research
   Center for Applied Sciences, Academia Sinica in Taipei, Taiwan for the
   ellipsometry measurement. This work is supported by the National Science
   Council in Taiwan under Grant Nos. NSC 96-2221-E-009-092-MY3 and NSC
   97-2120-M-006-009.
CR ASPNES DE, 1982, THIN SOLID FILMS, V89, P249, DOI 10.1016/0040-6090(82)90590-9
   BALASUBRAMANIAN N, 1989, J PHYS D APPL PHYS, V22, P206, DOI 10.1088/0022-3727/22/1/030
   CHANG CH, 2008, P 33 IEEE PHOT SPEC
   CHEN CC, 2007, P 2007 IEEE LEOS INT, P107
   Chiu CH, 2008, OPT EXPRESS, V16, P8748, DOI 10.1364/OE.16.008748
   CLAPHAM PB, 1973, NATURE, V244, P281, DOI 10.1038/244281a0
   Gonzalez GB, 2004, J APPL PHYS, V96, P3912, DOI 10.1063/1.1783610
   Hawkeye MM, 2007, J VAC SCI TECHNOL A, V25, P1317, DOI 10.1116/1.2764082
   Hobbs D. S., 2007, P SPIE, V6545
   Horng RH, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1940723
   Huang YF, 2007, NAT NANOTECHNOL, V2, P770, DOI 10.1038/nnano.2007.389
   Kanamori Y, 1999, OPT LETT, V24, P1422, DOI 10.1364/OL.24.001422
   Kennedy SR, 2003, APPL OPTICS, V42, P4573, DOI 10.1364/AO.42.004573
   Kim H, 1999, J APPL PHYS, V86, P6451, DOI 10.1063/1.371708
   Kim JK, 2008, ADV MATER, V20, P801, DOI 10.1002/adma.200701015
   KOBAYASHI H, 1991, J APPL PHYS, V69, P1736, DOI 10.1063/1.347220
   Lalanne P, 1997, NANOTECHNOLOGY, V8, P53, DOI 10.1088/0957-4484/8/2/002
   Lee BH, 1997, THIN SOLID FILMS, V302, P25, DOI 10.1016/S0040-6090(96)09581-8
   MOTAMEDI ME, 1992, APPL OPTICS, V31, P4371, DOI 10.1364/AO.31.004371
   Neviere M., 2003, LIGHT PROPAGATION PE
   RAGUIN DH, 1993, APPL OPTICS, V32, P2582, DOI 10.1364/AO.32.002582
   Takaki S, 2007, JPN J APPL PHYS 1, V46, P3537, DOI 10.1143/JJAP.46.3537
   Xi JQ, 2007, NAT PHOTONICS, V1, P176, DOI 10.1038/nphoton.2007.26
   YU P, UNPUB
NR 24
TC 66
Z9 66
U1 5
U2 26
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0003-6951
EI 1077-3118
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD FEB 2
PY 2009
VL 94
IS 5
AR 051114
DI 10.1063/1.3079329
PG 3
WC Physics, Applied
SC Physics
GA 404QB
UT WOS:000263167000014
DA 2018-12-27
ER

PT J
AU Zhang, XT
   Wei, PH
   Dou, JM
   Li, B
   Hu, B
AF Zhang, Xiutang
   Wei, Peihai
   Dou, Jianmin
   Li, Bin
   Hu, Bo
TI RETRACTED:
   Bis(6-methoxy-2-{[tris(hydroxymethyl)methyl]iminomethyl}phenolato)copper
   (II) dihydrate (Retracted article. See vol. 67, pg. E16, 2011)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the title compound, [Cu(C(12)H(16)NO(5))(2)]center dot 2H(2)O, the Cu(II) ion adopts a trans-CuN(2)O(4) octahedral geometry arising from two N,O,O'-tridentate 6-methoxy-2-{[tris(hydroxymethyl)methyl]-iminomethyl} phenolate ligands. The Jahn-Teller distortion of the copper centre is unusally small. In the crystal structure, O-H center dot center dot center dot O hydrogen bonds, some of which are bifurcated, link the component species.
C1 [Zhang, Xiutang] Shandong Inst Educ, Dept Chem & Chem Engn, Adv Mat Inst Res, Jinan 250013, Peoples R China.
   [Zhang, Xiutang; Dou, Jianmin] Liaocheng Univ, Coll Chem & Chem Engn, Liaocheng 252059, Peoples R China.
RP Zhang, XT (reprint author), Shandong Inst Educ, Dept Chem & Chem Engn, Adv Mat Inst Res, Jinan 250013, Peoples R China.
EM xiutangzhang@yahoo.com.cn
FU National Ministry of Science and Technology of China [2001CB6105-07]
FX The authors thank the National Ministry of Science and Technology of
   China (grant No. 2001CB6105-07) for support.
CR *BRUK AXS INC, 2004, APEX2
   Bruker, 2001, SAINT PLUS SADABS
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Wang QW, 2007, ACTA CRYSTALLOGR E, V63, pM2537, DOI 10.1107/S160053680704384X
   Ward MD, 2007, COORDIN CHEM REV, V251, P1663, DOI 10.1016/j.ccr.2006.10.005
NR 5
TC 4
Z9 4
U1 5
U2 12
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD FEB
PY 2009
VL 65
BP M151
EP U372
DI 10.1107/S1600536808043948
PN 2
PG 12
WC Crystallography
SC Crystallography
GA 402VH
UT WOS:000263040700028
PM 21581764
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Huang, Q
   Wu, YT
   Tan, HL
   Ong, CN
   Shen, HM
AF Huang, Q.
   Wu, Y-T
   Tan, H-L
   Ong, C-N
   Shen, H-M
TI RETRACTED: A novel function of poly(ADP-ribose) polymerase-1 in
   modulation of autophagy and necrosis under oxidative stress (Retracted
   article. See vol. 17, pg. 1944, 2010)
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article; Retracted Publication
DE autophagy; AMPK; mTOR; ROS; PARP-1; necrosis
ID ACTIVATED PROTEIN-KINASE; NECROTIC CELL-DEATH; APOPTOSIS-INDUCING
   FACTOR; HYDROGEN-PEROXIDE; MAMMALIAN TARGET; DNA-DAMAGE; ROLES;
   TUMORIGENESIS; PATHWAY; MTOR
AB Under oxidative stress, poly(ADP-ribose) polymerase-1 (PARP-1) is activated and contributes to necrotic cell death through ATP depletion. On the other hand, oxidative stress is known to stimulate autophagy, and autophagy may act as either a cell death or cell survival mechanism. This study aims to explore the regulatory role of PARP-1 in oxidative stress-mediated autophagy and necrotic cell death. Here, we first show that hydrogen peroxide (H(2)O(2)) induces necrotic cell death in Bax-/- Bak-/- mouse embryonic fibroblasts through a mechanism involving PARP-1 activation and ATP depletion. Next, we provide evidence that autophagy is activated in cells exposed to H(2)O(2). More importantly, we identify a novel autophagy signaling mechanism linking PARP-1 to the serine/threonine protein kinase LKB1-AMP-activated protein kinase (AMPK)-mammalian target of rapamycin (mTOR) pathway, leading to stimulation of autophagy. Finally, we demonstrate that autophagy plays a cytoprotective role in H(2)O(2)-induced necrotic cell death, as suppression of autophagy by knockdown of autophagy-related gene ATG5 or ATG7 greatly sensitizes H(2)O(2)-induced cell death. Taken together, these findings demonstrate a novel function of PARP-1: promotion of autophagy through the LKB1-AMPK-mTOR pathway to enhance cell survival in cells under oxidative stress.
C1 [Huang, Q.; Wu, Y-T; Tan, H-L; Ong, C-N; Shen, H-M] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Community Occupat & Family Med, Singapore 117597, Singapore.
RP Shen, HM (reprint author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Community Occupat & Family Med, Singapore 117597, Singapore.
EM cofshm@nus.edu.sg
OI Ong, Choon Nam/0000-0002-4002-1725
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Castedo M, 2002, CELL DEATH DIFFER, V9, P99, DOI 10.1038/sj/cdd/4400978
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Ditsworth D, 2007, J BIOL CHEM, V282, P17845, DOI 10.1074/jbc.M701465200
   Fiers W, 1999, ONCOGENE, V18, P7719
   Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978
   Hadad SM, 2008, CRIT REV ONCOL HEMAT, V67, P1, DOI 10.1016/j.critrevonc.2008.01.007
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557
   Jagtap P, 2005, NAT REV DRUG DISCOV, V4, P421, DOI 10.1038/nrd1718
   Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36
   Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044
   Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291
   Sanders MJ, 2007, BIOCHEM J, V403, P139, DOI 10.1042/BJ20061520
   Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009
   Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Shen HM, 2004, MOL CELL BIOL, V24, P5914, DOI 10.1128/MCB.24.13.5914-5922.2004
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581
   Slupphaug G, 2003, MUTAT RES-FUND MOL M, V531, P231, DOI 10.1016/j.mrfmmm.2003.06.002
   Walker JW, 2006, BIOCHEM BIOPH RES CO, V342, P336, DOI 10.1016/j.bbrc.2006.01.145
   Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031
   Wu YT, 2008, AUTOPHAGY, V4, P457, DOI 10.4161/auto.5662
   Xu Y, 2006, J BIOL CHEM, V281, P19179, DOI 10.1074/jbc.M513377200
   Xu ZX, 2007, CELL DEATH DIFFER, V14, P1948, DOI 10.1038/sj.cdd.4402207
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103
   Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221
   Zhang S, 2007, CELL DEATH DIFFER, V14, P1001, DOI 10.1038/sj.cdd.4402088
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
   Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904
NR 45
TC 84
Z9 88
U1 4
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD FEB
PY 2009
VL 16
IS 2
BP 264
EP 277
DI 10.1038/cdd.2008.151
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 393GN
UT WOS:000262359400008
PM 18974775
OA Bronze
DA 2018-12-27
ER

PT J
AU Xu, YQ
   Peng, J
   Shao, XM
AF Xu Yue-qing
   Peng Jian
   Shao Xiao-mei
TI RETRACTED: Assessment of soil erosion using RUSLE and GIS: a case study
   of the Maotiao River watershed, Guizhou Province, China (Retracted
   article. See vol. 72, pg. 2217, 2014)
SO ENVIRONMENTAL GEOLOGY
LA English
DT Article; Retracted Publication
DE Soil erosion; RUSLE; GIS; Guizhou Province; China
AB Due to the existence of fragile karst geo-ecological environments, such as environments with extremely poor soil cover, low soil-forming velocity, and fragmentized terrain and physiognomy, as well as inappropriate and intensive land use, soil erosion is a serious problem in Guizhou Province, which is located in the centre of the karst areas of southwestern China; evaluation of soil loss and spatial distribution for conservation planning is urgently needed. This study integrated the revised universal soil loss equation (RUSLE) with a GIS to assess soil loss and identify risk erosion areas in the Maotiao River watershed of Guizhou. Current land use/cover and management practices were evaluated to determine their effects on average annual soil loss and future soil conservation practices were discussed. Data used to generate the RUSLE factors included a Landsat Thematic Mapper image (land cover), digitized topographic and soil maps, and precipitation data. The results of the study compare well with the other studies and local data, and provide useful information for decision makers and planners to take appropriate land management measures in the area. It thus indicates the RUSLE-GIS model is a useful tool for evaluating and mapping soil erosion quantitatively and spatially at a larger watershed scale in Guizhou.
C1 [Xu Yue-qing] China Agr Univ, Coll Resources & Environm, Dept Land Resources & Management, Beijing 100094, Peoples R China.
   [Peng Jian] Cent Univ Nationalities, Sch Management, Beijing 100081, Peoples R China.
   [Shao Xiao-mei] China Land Surveying & Planning Inst, Minist Land & Resources, Key Lab Land Use, Beijing 100035, Peoples R China.
RP Xu, YQ (reprint author), China Agr Univ, Coll Resources & Environm, Dept Land Resources & Management, Beijing 100094, Peoples R China.
EM xmoonq@sina.com
FU National Natural Science Foundation of China [40701091]; National
   Science and Technology Support Program of China [2006BAD20B07]
FX This research was supported by the Project of National Natural Science
   Foundation of China (40701091) and National Science and Technology
   Support Program of China (2006BAD20B07). The authors are grateful to the
   anonymous reviewers and the editors of the journal for their valuable
   comments and suggestions.
CR *AGR BUR GUIZH PRO, 1980, GUIZH SOIL
   *AGR SYNTH REG STA, 1988, AGR SYNTH REG GUIZH
   Angima SD, 2003, AGR ECOSYST ENVIRON, V97, P295, DOI 10.1016/S0167-8809(03)00011-2
   CAI C, 2000, B SOIL WATER CONSERV, V2, P19
   *CHIN AC SCI DEP S, 2003, ADV EARTH SCI, V4, P489
   DENG P, 2003, RURAL ECO-ENVIRON, V2, P1
   Fu BJ, 2005, LAND DEGRAD DEV, V16, P73, DOI 10.1002/ldr.646
   GAO H, 2006, B SOIL WATER CONSERV, V3, P118
   HE TB, 2000, J SOIL WATER CONSERV, V5, P28
   HICKEY R, 2000, CARTOGRAPHY, V29, P1, DOI DOI 10.1080/00690805.2000.9714334
   HUANG CY, 2006, ENVIRON GEOL, V8, P1173
   Lee YS, 2006, CELL METAB, V3, P135, DOI 10.1016/j.cmet.2006.01.006
   LIN C, 1999, RES SOIL WATER CONSE, V2, P109
   Liu B., 2001, SOIL LOSS PREDICTION
   LIU Z, 2004, 9 INT S RIV SED YICH
   Lu D, 2004, LAND DEGRAD DEV, V15, P499, DOI 10.1002/ldr.634
   Oldeman L. R, 1994, SOIL RESILIENCE SUST
   Parysow P, 2003, CATENA, V53, P65, DOI 10.1016/S0341-8162(02)00198-4
   RENARD KG, 1997, HDB USDA, V703
   Van Remortel R.D., 2001, CARTOGRAPHY, V30, P27, DOI DOI 10.1080/00690805.2001.9714133
   WANG J, 2003, ADV EARTH SCI, V3, P447
   WANG Q, 2001, P SOC PHOTO-OPT INS, V2, P99
   Wang SJ, 2004, LAND DEGRAD DEV, V15, P115, DOI 10.1002/ldr.592
   WISCHMEIER WH, 1971, J SOIL WATER CONSERV, V26, P189
   WISCHMEIER WH, 1978, USDA HDB, V537
   WU S, 2005, CARSOLOGICA SINICA, V3, P202
   XU Y, 2005, B SOIL WATER CONSERV, V4, P11
   YANG Z, 2002, J MOUNT SCI S, V20, P1
   YANG Z, 1999, BULLET SOIL WATER CO, V1, P1
   Yu B, 1998, AUST J SOIL RES, V36, P143, DOI 10.1071/S97025
   Zhang BP, 2006, AMBIO, V35, P94
   Zhang T, 2001, INFORM RETRIEVAL, V4, P5, DOI 10.1023/A:1011441423217
   ZHU A, 1994, J SOIL WATER CONSERV, V4, P17
NR 33
TC 27
Z9 35
U1 7
U2 27
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0943-0105
J9 ENVIRON GEOL
JI Environ. Geol.
PD FEB
PY 2009
VL 56
IS 8
BP 1643
EP 1652
DI 10.1007/s00254-008-1261-9
PG 10
WC Environmental Sciences; Geosciences, Multidisciplinary; Water Resources
SC Environmental Sciences & Ecology; Geology; Water Resources
GA 403HR
UT WOS:000263074200014
DA 2018-12-27
ER

PT J
AU Joly, JF
   Stapel, DA
AF Joly, Janneke F.
   Stapel, Diederik A.
TI RETRACTED: Staff, miter, book, share: How attributes of Saint Nicholas
   induce normative behavior (Retracted article. See vol. 42, pg. 800,
   2012)
SO EUROPEAN JOURNAL OF SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
ID SOCIAL-BEHAVIOR; PURSUIT; REPRESENTATIONS; STEREOTYPES; SCHEMAS; OTHERS;
   SELF
AB In three studies the hypothesis was tested that for young Dutch children, who associate Saint Nicholas with the norm to share one's wealth with othei-s, atti-iblites of Saint Nicholas (miter; book, and staff) would spontoneouslY activate the "sharing norm" and subsequent sharing behavior The results confirmed our expectations. In two studies, Young Dutch children share more candy with others after being primed with attributes of Saint Nicholas compared to being primed with a dwarf in the control condition. In a third study, children evaluate sharing more positively alter being printed with attributes of Saint Nicholas, and more negatively after being primed with the Toys R Us logo, compared to being primed with a dwarf. This is the first empirical evidence that attributes of normative symbols can induce normative behavior and change norm judgments. Copyright (C) 2008 John Wiley & Sons, Ltd.
C1 [Joly, Janneke F.] Univ Groningen, Dept Behav & Social Sci, Interuniv Ctr Social Sci Theory & Methodol ICS, NL-9700 AB Groningen, Netherlands.
   [Stapel, Diederik A.] Univ Groningen, Dept Cognit Social Psychol, NL-9700 AB Groningen, Netherlands.
RP Stapel, DA (reprint author), Tilburg Univ, TIBER, POB 90153, NL-5000 LE Tilburg, Netherlands.
EM d.a.stapel@uvt.nl
CR Aarts H, 2003, J PERS SOC PSYCHOL, V84, P18, DOI 10.1037/0022-3514.84.1.18
   BALDWIN MW, 1990, J EXP SOC PSYCHOL, V26, P435, DOI 10.1016/0022-1031(90)90068-W
   BALDWIN MW, 1987, J PERS SOC PSYCHOL, V52, P1087, DOI 10.1037//0022-3514.52.6.1087
   BALDWIN MW, 1992, PSYCHOL BULL, V112, P461, DOI 10.1037//0033-2909.112.3.461
   Bargh JA, 1996, J PERS SOC PSYCHOL, V71, P230, DOI 10.1037/0022-3514.71.2.230
   CIALDINI RB, 1990, J PERS SOC PSYCHOL, V58, P1015, DOI 10.1037//0022-3514.58.6.1015
   Cooley CH., 1902, HUMAN NATURE SOCIAL
   DEVINE PG, 1989, J PERS SOC PSYCHOL, V56, P5, DOI 10.1037/0022-3514.56.5.680
   Dijksterhuis A, 1998, J PERS SOC PSYCHOL, V74, P865, DOI 10.1037/0022-3514.74.4.865
   Epley N, 1999, J EXP SOC PSYCHOL, V35, P578, DOI 10.1006/jesp.1999.1390
   Fitzsimons GM, 2003, J PERS SOC PSYCHOL, V84, P148, DOI 10.1037//0022-3514.84.1.148
   Hertel G, 2001, J EXP SOC PSYCHOL, V37, P316, DOI 10.1006/jesp.2000.1447
   Herweijer L, 2004, OUDERS OPVOEDING OND
   Jonas KJ, 2006, J PERS SOC PSYCHOL, V90, P709, DOI 10.1037/0022-3514.90.5.709
   Kay AC, 2004, ORGAN BEHAV HUM DEC, V95, P83, DOI 10.1016/j.obhdp.2004.06.003
   Moretti MM, 1999, SOC COGNITION, V17, P186, DOI 10.1521/soco.1999.17.2.186
   PEPITONE EA, 1980, CHILDREN COOPERATION, P175
   Schubert TW, 2003, J EXP SOC PSYCHOL, V39, P577, DOI 10.1016/S0022-1031(03)00034-9
   Shah J, 2003, J PERS SOC PSYCHOL, V84, P661, DOI 10.1037/0022-3514.84.4.661
   SROUFE LA, 1996, CHILD DEV ITS NATURE
   Steenbekkers A., 2006, THUIS PLATTELAND LEE
NR 21
TC 1
Z9 1
U1 3
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0046-2772
EI 1099-0992
J9 EUR J SOC PSYCHOL
JI Eur. J. Soc. Psychol.
PD FEB
PY 2009
VL 39
IS 1
BP 145
EP 153
DI 10.1002/ejsp.491
PG 9
WC Psychology, Social
SC Psychology
GA 415UI
UT WOS:000263960700012
DA 2018-12-27
ER

PT J
AU Tovey, ER
   Ng, DSY
   Stelzer-Braid, S
   Rawlinson, WD
   Oliver, BG
AF Tovey, E. R.
   Ng, D. S. Y.
   Stelzer-Braid, S.
   Rawlinson, W. D.
   Oliver, B. G.
TI RETRACTED: Children With Asthma And No URTI, More Commonly Have
   Rhinovirus In Their Exhaled Breath, Than In Mucous (Retracted article.
   See vol. 127, pg. 551, 2011)
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract; Retracted Publication
CT 65th Annual Meeting of the
   American-Academy-of-Allergy-Asthma-and-Immunology
CY MAR 13-17, 2009
CL Washington, DC
SP Amer Acad Allergy, Asthma & Immunol
C1 [Tovey, E. R.] Woolcock Inst Med Res, Sydney, NSW, Australia.
   [Ng, D. S. Y.; Oliver, B. G.] Univ Sydney, Sydney, NSW 2006, Australia.
   [Stelzer-Braid, S.; Rawlinson, W. D.] Prince Wales Hosp, SEALS, Sydney, NSW, Australia.
RI Tovey, Euan/G-8604-2017
OI Tovey, Euan/0000-0002-1802-7266
NR 0
TC 1
Z9 1
U1 4
U2 12
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2009
VL 123
IS 2
SU S
MA 652
BP S171
EP S171
DI 10.1016/j.jaci.2008.12.643
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 410RR
UT WOS:000263596301125
DA 2018-12-27
ER

PT J
AU Yang, FJ
   Cheng, LL
   Zhang, L
   Dai, WJ
   Liu, Z
   Yao, N
   Xie, ZP
   Staehelin, C
AF Yang, Feng-Juan
   Cheng, Li-Li
   Zhang, Ling
   Dai, Wei-Jun
   Liu, Zhe
   Yao, Nan
   Xie, Zhi-Ping
   Staehelin, Christian
TI RETRACTED: Y4lO of Rhizobium sp Strain NGR234 Is a Symbiotic Determinant
   Required for Symbiosome Differentiation (Retracted article. See vol.
   197, pg. 3026, 2015)
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article; Retracted Publication
ID CAMPESTRIS PV. VESICATORIA; III EFFECTOR PROTEINS; PLANT-PATHOGENIC
   BACTERIA; AVIRULENCE GENE AVRRXV; NF-KAPPA-B; SECRETION SYSTEM;
   MOLECULAR-BASIS; SPECIES NGR234; YOPJ; EXPRESSION
AB Type 3 (T3) effector proteins, secreted by nitrogen-fixing rhizobia with a bacterial T3 secretion system, affect the nodulation of certain host legumes. The open reading frame Y4lO of Rhizobium sp. strain NGR234 encodes a protein with sequence similarities to T3 effectors from pathogenic bacteria (the YopJ effector family). Transcription studies showed that the promoter activity of Y4lO depended on the transcriptional activator TtsI. Recombinant Y4lO protein expressed in Escherichia coli did not acetylate two representative mitogen-activated protein kinase kinases (human MKK6 and MKK1 from Medicago truncatula), indicating that YopJ-like proteins differ with respect to their substrate specificities. The Y4lO gene was mutated in NGR234 (strain NGR Omega Y4lO) and in NGR Omega nopL, a mutant that does not produce the T3 effector NopL (strain NGR Omega nopL Omega Y4lO). When used as inoculants, the symbiotic properties of the mutants differed. Tephrosia vogelii, Phaseolus vulgaris cv. Yudou No. 1, and Vigna unguiculata cv. Sui Qing Dou Jiao formed pink effective nodules with NGR234 and NGR Omega nopL Omega Y4lO. Nodules induced by NGR Omega Y4lO were first pink but rapidly turned greenish (ineffective nodules), indicating premature senescence. An ultrastructural analysis of the nodules induced by NGR Omega Y4lO revealed abnormal formation of enlarged infection droplets in ineffective nodules, whereas symbiosomes harboring a single bacteroid were frequently observed in effective nodules induced by NGR234 or NGR Omega nopL Omega Y4lO. It is concluded that Y4lO is a symbiotic determinant involved in the differentiation of symbiosomes. Y4lO mitigated senescence-inducing effects caused by the T3 effector NopL, suggesting synergistic effects for Y4lO and NopL in nitrogen-fixing nodules.
C1 [Yang, Feng-Juan; Cheng, Li-Li; Zhang, Ling; Dai, Wei-Jun; Liu, Zhe; Yao, Nan; Xie, Zhi-Ping; Staehelin, Christian] Sun Yat Sen Zhongshan Univ, Sch Life Sci, State Key Lab Biocontrol, Guangzhou 510006, Guangdong, Peoples R China.
RP Staehelin, C (reprint author), Sun Yat Sen Zhongshan Univ, Sch Life Sci, State Key Lab Biocontrol, East Campus,Bei San Rd, Guangzhou 510006, Guangdong, Peoples R China.
EM cst@mail.sysu.edu.cn
FU National Natural Science Foundation of China [30671117, 30771150];
   Department of Science and Technology of Guangdong Province, China
   [2006B50104004]
FX This work was supported by the National Natural Science Foundation of
   China ( grants 30671117 and 30771150) and by the Department of Science
   and Technology of Guangdong Province, China ( grant 2006B50104004).
CR Alfano JR, 2000, P NATL ACAD SCI USA, V97, P4856, DOI 10.1073/pnas.97.9.4856
   Arnold DL, 2001, MICROBIOL-SGM, V147, P1171, DOI 10.1099/00221287-147-5-1171
   Astua-Monge G, 2000, MOL PLANT MICROBE IN, V13, P1346, DOI 10.1094/MPMI.2000.13.12.1346
   Ausmees N, 2004, J BACTERIOL, V186, P4774, DOI 10.1128/JB.186.14.4774-4780.2004
   Bartsev AV, 2004, PLANT PHYSIOL, V134, P871, DOI 10.1104/pp.103.031740
   Bartsev AV, 2003, FEBS LETT, V554, P271, DOI 10.1016/S0014-5793(03)01145-1
   BERINGER JE, 1974, J GEN MICROBIOL, V84, P188
   Bonshtien A, 2005, MOL PLANT MICROBE IN, V18, P300, DOI 10.1094/MPMI-18-0300
   Brewin N, 2008, CURR PLANT SCI BIOT, V42, P185
   Buttner D, 2006, CURR OPIN MICROBIOL, V9, P193, DOI 10.1016/j.mib.2006.02.006
   Cermola M, 2000, MOL PLANT MICROBE IN, V13, P733, DOI 10.1094/MPMI.2000.13.7.733
   CHEN WP, 1993, NUCLEIC ACIDS RES, V21, P2260, DOI 10.1093/nar/21.9.2260
   Ciesiolka LD, 1999, MOL PLANT MICROBE IN, V12, P35, DOI 10.1094/MPMI.1999.12.1.35
   Cooper JE, 2007, J APPL MICROBIOL, V103, P1355, DOI 10.1111/j.1365-2672.2007.03366.x
   Cunnac S, 2007, PLANT CELL, V19, P688, DOI 10.1105/tpc.106.048710
   Dai WJ, 2008, J BACTERIOL, V190, P5101, DOI 10.1128/JB.00306-08
   Deslandes L, 2003, P NATL ACAD SCI USA, V100, P8024, DOI 10.1073/pnas.1230660100
   FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648
   Freiberg C, 1997, NATURE, V387, P394, DOI 10.1038/387394a0
   GALYOV EE, 1994, J BACTERIOL, V176, P4543
   Ghosh P, 2004, MICROBIOL MOL BIOL R, V68, P771, DOI 10.1128/MMBR.68.4.771-795.2004
   Grant SR, 2006, ANNU REV MICROBIOL, V60, P425, DOI 10.1146/annurev.micro.60.080805.142251
   Hao YH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001375
   Hardt WD, 1997, P NATL ACAD SCI USA, V94, P9887, DOI 10.1073/pnas.94.18.9887
   Kiegerl S, 2000, PLANT CELL, V12, P2247, DOI 10.1105/tpc.12.11.2247
   Kobayashi H, 2004, MOL MICROBIOL, V51, P335, DOI 10.1046/j.1365-2958.2003.03841.x
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Lavie M, 2002, MOL PLANT MICROBE IN, V15, P1058, DOI 10.1094/MPMI.2002.15.10.1058
   Marie C, 2004, MOL PLANT MICROBE IN, V17, P958, DOI 10.1094/MPMI.2004.17.9.958
   Marie C, 2003, MOL PLANT MICROBE IN, V16, P743, DOI 10.1094/MPMI.2003.16.9.743
   Marie C, 2001, CURR OPIN PLANT BIOL, V4, P336, DOI 10.1016/S1369-5266(00)00182-5
   Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638
   Mittal R, 2006, P NATL ACAD SCI USA, V103, P18574, DOI 10.1073/pnas.0608995103
   Mudgett MB, 2005, ANNU REV PLANT BIOL, V56, P509, DOI 10.1146/annurev.arplant.56.032604.144218
   Mukherjee S, 2006, SCIENCE, V312, P1211, DOI 10.1126/science.1126867
   Mukherjee S, 2007, TRENDS BIOCHEM SCI, V32, P210, DOI 10.1016/j.tibs.2007.03.007
   Noel L, 2003, J BACTERIOL, V185, P7092, DOI 10.1128/JB.185.24.7092-7102.2003
   Oh CS, 2005, MOL PLANT PATHOL, V6, P125, DOI 10.1111/J.1364.3703.2005.00269.X
   Oke V, 1999, CURR OPIN MICROBIOL, V2, P641, DOI 10.1016/S1369-5274(99)00035-1
   Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594
   Perret X, 2000, MICROBIOL MOL BIOL R, V64, P180, DOI 10.1128/MMBR.64.1.180-201.2000
   PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3
   Puppo A, 2005, NEW PHYTOL, V165, P683, DOI 10.1111/j.1469-8137.2004.01285.x
   QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6
   Roden J, 2004, MOL PLANT MICROBE IN, V17, P633, DOI 10.1094/MPMI.2004.17.6.633
   Skorpil P, 2005, MOL MICROBIOL, V57, P1304, DOI 10.1111/j.1365-2958.2005.04768.x
   Staehelin C, 2006, J BACTERIOL, V188, P6168, DOI 10.1128/JB.00365-06
   Sweet CR, 2007, CELL MICROBIOL, V9, P2700, DOI 10.1111/j.1462-5822.2007.00990.x
   Thieme F, 2007, MOL PLANT MICROBE IN, V20, P1250, DOI 10.1094/MPMI-20-10-1250
   TRINICK MJ, 1980, J APPL BACTERIOL, V49, P39, DOI 10.1111/j.1365-2672.1980.tb01042.x
   Trosky JE, 2007, J BIOL CHEM, V282, P34299, DOI 10.1074/jbc.M706970200
   VANDENEEDE G, 1992, MOL PLANT MICROBE IN, V5, P228
   Viprey V, 1998, MOL MICROBIOL, V28, P1381, DOI 10.1046/j.1365-2958.1998.00920.x
   Voroshilova VA, 2001, MOL PLANT MICROBE IN, V14, P471, DOI 10.1094/MPMI.2001.14.4.471
   Wassem R, 2008, MOL MICROBIOL, V68, P736, DOI 10.1111/j.1365-2958.2008.06187.x
   WHALEN MC, 1988, P NATL ACAD SCI USA, V85, P6743, DOI 10.1073/pnas.85.18.6743
   WHALEN MC, 1993, MOL PLANT MICROBE IN, V6, P616, DOI 10.1094/MPMI-6-616
   Xi CW, 1999, J MICROBIOL METH, V35, P85, DOI 10.1016/S0167-7012(98)00103-1
   Ye ZD, 2007, AM J PATHOL, V171, P882, DOI 10.2353/ajpath.2007.070220
   Zhou HL, 2005, J EXP MED, V202, P1327, DOI 10.1084/jem.20051194
NR 60
TC 14
Z9 15
U1 4
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0021-9193
EI 1098-5530
J9 J BACTERIOL
JI J. Bacteriol.
PD FEB 1
PY 2009
VL 191
IS 3
BP 735
EP 746
DI 10.1128/JB.01404-08
PG 12
WC Microbiology
SC Microbiology
GA 396RQ
UT WOS:000262609200009
PM 19060155
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Gethin, G
   Cowman, S
AF Gethin, Georgina
   Cowman, Seamus
TI RETRACTED: Manuka honey vs. hydrogel - a prospective, open label,
   multicentre, randomised controlled trial to compare desloughing efficacy
   and healing outcomes in venous ulcers (Retracted article. See vol. 24,
   pg. 2686, 2015)
SO JOURNAL OF CLINICAL NURSING
LA English
DT Article; Retracted Publication
DE nursing; randomised control trials; research; tissue viability; venous
   leg ulcer; wound care
ID LEG ULCERS; CLINICAL-TRIAL; CHRONIC WOUNDS; PREVALENCE; DRESSINGS;
   DEBRIDEMENT; POPULATION; ULCERATION; ETIOLOGY; BANDAGES
AB Comparison of desloughing efficacy after four weeks and healing outcomes after 12 weeks in sloughy venous leg ulcers treated with Manuka honey (Woundcare 18+) vs. standard hydrogel therapy (IntraSite Gel).
   Expert opinion suggests that Manuka honey is effective as a desloughing agent but clinical evidence in the form of a randomised controlled trial is not available. There is a paucity of research which uses Manuka honey in venous ulcers.
   Prospective, multicentre, open label randomised controlled trial.
   Randomisation was via remote telephone. One hundred and eight patients with venous leg ulcers having >= 50% wound area covered in slough, not taking antibiotics or immunosuppressant therapy were recruited from vascular centres, acute and community care hospitals and leg ulcer clinics. The efficacy of WoundCare 18+ to deslough the wounds after four weeks and its impact on healing after 12 weeks when compared with IntraSite Gel control was determined. Treatment was applied weekly for four weeks and follow-up was made at week 12.
   At week 4, mean % reduction in slough was 67% WoundCare 18+ vs. 52.9% IntraSite Gel (p = 0.054). Mean wound area covered in slough reduced to 29% and 43%, respectively (p = 0.065). Median reduction in wound size was 34% vs. 13% (p = 0.001). At 12 weeks, 44% vs. 33% healed (p = 0.037). Wounds having > 50% reduction in slough had greater probability of healing at week 12 (95% confidence interval 1.12, 9.7; risk ratio 3.3; p = 0.029). Infection developed in 6 of the WoundCare 18+ group vs. 12 in the IntraSite Gel group.
   The WoundCare 18+ group had increased incidence of healing, effective desloughing and a lower incidence of infection than the control. Manuka honey has therapeutic value and further research is required to examine its use in other wound aetiologies.
   This study confirms that Manuka honey may be considered by clinicians for use in sloughy venous ulcers. Additionally, effective desloughing significantly improves healing outcomes.
C1 [Gethin, Georgina] Royal Coll Surgeons Ireland, Res Ctr, Fac Nursing & Midwifery, Dublin 2, Ireland.
RP Gethin, G (reprint author), Royal Coll Surgeons Ireland, Res Ctr, Fac Nursing & Midwifery, 123 St Stephens Green, Dublin 2, Ireland.
EM ggethin@rcsi.ie
OI Gethin, Georgina/0000-0001-5859-8357
FU Research and Education Foundation in Sligo General Hospital; European
   Wound Management Association; Health Research Board of Ireland
FX This study was funded by research grant-aid from the Research and
   Education Foundation in Sligo General Hospital, European Wound
   Management Association and the Health Research Board of Ireland. These
   funders had no role in design and conduct of the study, collection,
   analysis and interpretation of data or in the preparation of the
   manuscript, review or approval of manuscript, in protocol development,
   patient recruitment, data collection, data analysis or manuscript
   preparation. Grant-aid was obtained through an application, interview
   and international peer-review process.
CR Ayello Elizabeth A, 2004, Adv Skin Wound Care, V17, P66, DOI 10.1097/00129334-200403000-00012
   Baharestani M, 1999, CLIN RELEVANCE DEBRI
   BALE S, 2003, BRIT J NURSING S, V12, pS7
   Blair S., 1988, PHLEBOLOGY, V3, P129
   Bowler PG, 1999, INT J DERMATOL, V38, P573, DOI 10.1046/j.1365-4362.1999.00738.x
   BRADLEY M, 1999, HLTH TECHNOLOGY ASSE, V3, P3
   CHIRIFE J, 1982, LANCET, V1, P560
   CONDON RE, 1993, SURGERY, V113, P234
   Cooper RA, 2001, HONEY HEALING
   Daly L.E., 2000, INTERPRETATION USES
   DUBY T, 1993, WOUNDS, V5, P276
   FALANGA V, 2002, CLIN RELEVANCE WOUND
   FEAR M, 1996, INTRASITE GEL CLIN R
   Flanagan M, 2003, J Wound Care, V12, P189
   Flanagan M, 1995, J Wound Care, V4, P264
   FORREST RD, 1982, J ROY SOC MED, V75, P198
   Franks PJ, 2007, WOUND REPAIR REGEN, V15, P197, DOI 10.1111/j.1524-475X.2007.00205.x
   Gethin Georgina, 2005, Int Wound J, V2, P10, DOI 10.1111/j.1742-4801.2005.00078.x
   Gethin GT, 2008, INT WOUND J, V5, P185, DOI 10.1111/j.1742-481X.2007.00424.x
   Hansson C, 1998, INT J DERMATOL, V37, P390
   Ingle R, 2006, SAMJ S AFR MED J, V96, P831
   Jull A, 2008, BRIT J SURG, V95, P175, DOI 10.1002/bjs.6059
   Kantor J, 2000, BRIT J DERMATOL, V142, P960, DOI 10.1046/j.1365-2133.2000.03478.x
   Konig M, 2005, J Wound Care, V14, P320
   Margolis DJ, 2000, AM J MED, V109, P15, DOI 10.1016/S0002-9343(00)00379-X
   Meyer FJ, 2002, BRIT J SURG, V89, P40, DOI 10.1046/j.0007-1323.2001.01936.x
   Moffatt CJ, 2004, QJM-INT J MED, V97, P431, DOI 10.1093/qjmed/hch075
   Molan P C, 2001, Am J Clin Dermatol, V2, P13, DOI 10.2165/00128071-200102010-00003
   MOLAN PC, 2006, LOWER EXTREMITY WOUN, V5, P40
   MONK BE, 1982, CLIN EXP DERMATOL, V7, P397, DOI 10.1111/j.1365-2230.1982.tb02447.x
   Nelzen O, 1996, PHLEBOLOGY, V11, P50, DOI 10.1177/026835559601100204
   NICE, 2001, GUID US DEBR AG SPEC
   O'Brien JF, 2000, IRISH J MED SCI, V169, P110, DOI 10.1007/BF03166911
   O'Meara SM, 2001, BRIT J SURG, V88, P4, DOI 10.1046/j.1365-2168.2001.01631.x
   Oluwatosin O M, 2000, Afr J Med Med Sci, V29, P31
   Palfreyman S, 2006, COCHRANE DATABASE SY, V3
   Sieggreen M Y, 1997, Adv Wound Care, V10, P32
   Steed David L, 2006, Int Wound J, V3, P40, DOI 10.1111/j.1742-4801.2006.00178.x
   Steed DL, 1996, J AM COLL SURGEONS, V183, P61
   Tallman P, 1997, ARCH DERMATOL, V133, P1231, DOI 10.1001/archderm.133.10.1231
   Thomas S, 1997, J Wound Care, V6, P383
   Thomson B, 1996, J Wound Care, V5, P213
   Trengove N J, 1996, J Wound Care, V5, P277
   Wayman J, 2000, J Tissue Viability, V10, P91
   Wilkinson E, 1997, J Wound Care, V6, P339
   Williams D, 2005, WOUND REPAIR REGEN, V13, P131, DOI 10.1111/j.1067-1927.2005.130203.x
NR 46
TC 56
Z9 62
U1 3
U2 29
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0962-1067
EI 1365-2702
J9 J CLIN NURS
JI J. Clin. Nurs.
PD FEB
PY 2009
VL 18
IS 3
BP 466
EP 474
DI 10.1111/j.1365-2702.2008.02558.x
PG 9
WC Nursing
SC Nursing
GA 394UO
UT WOS:000262476100018
PM 18752540
DA 2018-12-27
ER

PT J
AU de Jong, D
   Xie, W
   Rosenwald, A
   Chhanabhai, M
   Gaulard, P
   Klapper, W
   Lee, A
   Sander, B
   Thorns, C
   Campo, E
   Molina, T
   Hagenbeek, A
   Horning, S
   Lister, A
   Raemaekers, J
   Salles, G
   Gascoyne, RD
   Weller, E
AF de Jong, D.
   Xie, W.
   Rosenwald, A.
   Chhanabhai, M.
   Gaulard, P.
   Klapper, W.
   Lee, A.
   Sander, B.
   Thorns, C.
   Campo, E.
   Molina, T.
   Hagenbeek, A.
   Horning, S.
   Lister, A.
   Raemaekers, J.
   Salles, G.
   Gascoyne, R. D.
   Weller, E.
TI RETRACTED: Immunohistochemical prognostic markers in diffuse large
   B-cell lymphoma: validation of tissue microarray as a prerequisite for
   broad clinical applications (a study from the Lunenburg Lymphoma
   Biomarker Consortium) (Retracted article. See vol. 65, pg. 861, 2012)
SO JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article; Retracted Publication
ID NON-HODGKINS-LYMPHOMA; BCL-2 PROTEIN EXPRESSION; GERMINAL-CENTER;
   R-CHOP; DLBCL; GENE; SURVIVAL; IMPACT; REARRANGEMENT; CHEMOTHERAPY
AB Background and Aims: The results of class prediction and the determination of prognostic markers in diffuse large B-cell lymphoma (DLBCL) have been variably reported. Apart from biological variations, this may be caused by differences in laboratory techniques, scoring definitions and inter-and intra-observer variation. In this study, an international collaboration of clinical lymphoma research groups has concentrated on validation and standardisation of immunohistochemistry of the currently potentially interesting prognostic markers in DLBCL.
   Methods: Sections of a tissue microarray with 36 cases of DLBCL were stained in eight laboratories with antibodies to CD20, CD5, bcl-2, bcl-6, CD10, HLA-DR, MUM-1 and Ki-67 according to local methods. The study was performed in two rounds, firstly focused on the evaluation of laboratory staining variation, and secondly on the scoring variation.
   Results: Different techniques resulted in highly variable results and poor reproducibility for almost all markers. Reproducibility of the nuclear markers was highly sensitive to technical variations, including immunological enhancement techniques (agreements 34%). With elimination of variation due to staining and uniformly agreed on scoring criteria, significant improvement was seen; however less so for bcl-6 and Ki-67 (agreement 53-58%). Absence of internal controls that preclude scoring, significantly influenced the results for CD10 and bcl-6.
   Conclusion: Semi-quantitative immunohistochemistry for subclassification of DLBCL is feasible, but with varying rates of concordance for different markers and only using optimised techniques and strict scoring criteria. These findings may explain the wide variation in prognostic impact reported in the literature. Harmonisation of techniques and centralised consensus review appears mandatory when using immunohistochemical biomarkers for treatment stratification.
C1 [de Jong, D.] Netherlands Canc Inst, Dept Pathol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.
   [Xie, W.; Weller, E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Rosenwald, A.] Univ Wurzburg, Inst Pathol, D-8700 Wurzburg, Germany.
   [Chhanabhai, M.; Gascoyne, R. D.] Univ British Columbia, British Columbia Canc Agcy, Vancouver, BC V5Z 1M9, Canada.
   [Gaulard, P.] Hop Henri Mondor, INSERM, Dept Pathol, U617, F-94010 Creteil, France.
   [Klapper, W.] Univ Hosp Schleswig Holstein, Hematopathol Sect, Dept Pathol, Lubeck, Germany.
   [Lee, A.] St Bartholomews Hosp, CRUK Med Oncol Unit, London, England.
   [Sander, B.] Karolinska Inst, Stockholm, Sweden.
   [Thorns, C.] Univ Clin Schleswig Holstein, Lubeck, Germany.
   [Campo, E.] Univ Barcelona, Hosp Clin, Barcelona, Spain.
   [Molina, T.] Univ Paris 05, Hotel Dieu, AP HP, Paris, France.
   [Hagenbeek, A.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
   [Horning, S.] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA.
   [Lister, A.] St Bartholomews Hosp, Dept Med Oncol, London, England.
   [Raemaekers, J.] Univ Med Ctr, Nijmegen, Netherlands.
   [Salles, G.] Univ Lyon 1, F-69365 Lyon, France.
   [Salles, G.] Hosp Civils Lyon, Lyon, France.
RP de Jong, D (reprint author), Netherlands Canc Inst, Dept Pathol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.
EM d.d.jong@nki.nl
RI Thorns, Christoph/E-2945-2010; Klapper, Wolfram/S-6314-2016; Klapper,
   Wolfram/D-2516-2010
OI Campo, elias/0000-0001-9850-9793
FU van Vlissingen Lymphoma Foundation; Genentech, Millennium
   Pharmaceuticals Inc.; Roche International and Schering AG; National
   Institute for Health Research [350]
FX The project is initiated and financially supported by the van Vlissingen
   Lymphoma Foundation. In addition, unrestricted grants were received from
   Genentech, Millennium Pharmaceuticals Inc., Roche International and
   Schering AG by the van Vlissingen Lymphoma Foundation.
CR Adida C, 2000, BLOOD, V96, P1921
   Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   Banham AH, 2005, CLIN CANCER RES, V11, P1065
   Barrans SL, 2004, BLOOD, V104, P2933, DOI 10.1182/blood-2004-03-1209
   Barrans SL, 2002, BLOOD, V99, P1136, DOI 10.1182/blood.V99.4.1136
   Berglund M, 2005, MODERN PATHOL, V18, P1113, DOI 10.1038/modpathol.3800396
   Chang CC, 2004, AM J SURG PATHOL, V28, P464, DOI 10.1097/00000478-200404000-00005
   Colomo L, 2003, BLOOD, V101, P78, DOI 10.1182/bllod-2002-04-1286
   De Paepe P, 2005, J CLIN ONCOL, V23, P7060, DOI 10.1200/JCO.2005.15.503
   Efron B., 1993, INTRO BOOTSTRAP
   Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901
   Gascoyne RD, 1997, BLOOD, V90, P244
   Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545
   Hermine O, 1996, BLOOD, V87, P265
   Hill ME, 1996, BLOOD, V88, P1046
   Iqbal J, 2006, J CLIN ONCOL, V24, P961, DOI 10.1200/JCO.2005.03.4264
   Iqbal J, 2004, AM J PATHOL, V165, P159, DOI 10.1016/S0002-9440(10)63284-1
   Kersten Marie Jose, 2004, Hematol J, V5, P202, DOI 10.1038/sj.thj.6200376
   Kramer MHH, 1996, J CLIN ONCOL, V14, P2131, DOI 10.1200/JCO.1996.14.7.2131
   Lossos IS, 2001, BLOOD, V98, P945, DOI 10.1182/blood.V98.4.945
   Monti S, 2005, BLOOD, V105, P1851, DOI 10.1182/blood-2004.07.2947
   Moskowitz CH, 2005, BLOOD, V106, P3383, DOI 10.1182/blood-2005-04-1603
   Mounier N, 2003, BLOOD, V101, P4279, DOI 10.1182/blood-2002-11-3442
   Oschlies I, 2006, BLOOD, V107, P4047, DOI 10.1182/blood-2005-10-4213
   Perez EA, 2006, J CLIN ONCOL, V24, P3032, DOI 10.1200/JCO.2005.03.4744
   Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914
   Sagaert X, 2006, J CLIN ONCOL, V24, P2490, DOI 10.1200/JCO.2006.05.6150
   van Imhoff GW, 2006, J CLIN ONCOL, V24, P4135, DOI 10.1200/JCO.2006-05.5897
   Winter JN, 2006, BLOOD, V107, P4207, DOI 10.1182/blood-2005-10-4222
   WOOLSON RF, 2002, STAT METHODS ANAL BI
   Zinzani PL, 2005, HAEMATOLOGICA, V90, P341
   Zu YL, 2005, LEUKEMIA LYMPHOMA, V46, P693, DOI 10.1080/10428190500051844
NR 32
TC 71
Z9 74
U1 4
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0021-9746
EI 1472-4146
J9 J CLIN PATHOL
JI J. Clin. Pathol.
PD FEB
PY 2009
VL 62
IS 2
BP 128
EP 138
DI 10.1136/jcp.2008.057257
PG 11
WC Pathology
SC Pathology
GA 401DI
UT WOS:000262918400006
PM 18794197
DA 2018-12-27
ER

PT J
AU Li, YM
   Ye, J
   Cao, SB
   Xiao, SB
   Zhao, Q
   Liu, XQ
   Jin, ML
   Chen, HC
AF Li, Yaoming
   Ye, Jing
   Cao, Shengbo
   Xiao, Shaobo
   Zhao, Qian
   Liu, Xueqin
   Jin, Meilin
   Chen, Huanchun
TI RETRACTED: Immunization with pseudotype baculovirus expressing envelope
   protein of Japanese encephalitis virus elicits protective immunity in
   mice (Retracted Article. See vol 11, pg 454, 2009)
SO JOURNAL OF GENE MEDICINE
LA English
DT Article; Retracted Publication
DE envelope protein; immunization; Japanese encephalitis virus; pseudotype
   baculovirus
ID RECOMBINANT PSEUDORABIES VIRUS; RESPIRATORY SYNDROME VIRUS; EFFICIENT
   GENE-TRANSFER; MAMMALIAN-CELLS; VACCINE SA14-14-2; VECTORS; RESPONSES;
   INDUCTION; IMMUNOGENICITY; GLYCOPROTEIN
AB Background Japanese encephalitis (JE) is a serious infection disease throughout southern and eastern Asia. The design and development of safer and more efficacious vaccines against Japanese encephalitis virus (JEV) is a matter of high priority. Recently, baculovirus pseudotyped with vesicular stornatitis virus glycoprotein was described as an attractive gene-delivery vehicle in mammalian cells and a potential vector for vaccine development. In the present study, we constructed recombinant pseudotype baculovirus encoding the Japanese encephalitis virus (JEV) envelope (E) protein and demonstrated that it could elicit high protective immunity in mice.
   Methods Recombinant pseudotype baculovirus (BV-G-E) was generated by inserting JEV E gene fragment into pFastBac-VSV/G vector. BALB/c mice were immunized with BV-G-E and challenged with JEV wild-type strain. The neutralization antibody, interferon (IFN)-gamma expression and release, and survival rate were analysed and compared with the group of immunized with inactivated vaccine and DNA vaccine (pc-E) encoding the same gene of JEV.
   Results We demonstrated that intramuscular injections of BV-G-E at various doses into mice produced higher levels of JEV-specific neutralizing antibodies, IFN-gamma and better protective efficacy against a lethal challenge with JEV than that of pc-E. Furthermore, BV-G-E could elicit a higher level cellular immunity response and provide equal protective efficacy against JEV challenge compared to inactivated vaccine.
   Conclusions Our data demonstrate that BV-G-E elicited higher levels of protective immunity than DNA vaccine and that pseudotype baculovirus-mediated gene delivery can be utilized as an alternative strategy to develop new generations of vaccines against JEV infection. Copyright (C) 2008 John Wiley & Sons, Ltd.
C1 [Li, Yaoming; Ye, Jing; Cao, Shengbo; Xiao, Shaobo; Zhao, Qian; Liu, Xueqin; Jin, Meilin; Chen, Huanchun] Huazhong Agr Univ, State Key Lab Agr Microbiol, Wuhan 430070, Hubei, Peoples R China.
   [Li, Yaoming; Ye, Jing; Cao, Shengbo; Xiao, Shaobo; Zhao, Qian; Jin, Meilin; Chen, Huanchun] Huazhong Agr Univ, Lab Anim Virol, Coll Vet Med, Wuhan, Peoples R China.
   [Liu, Xueqin] Huazhong Agr Univ, Minist Educ, Key Lab Agri Anim Genet & Breeding, Wuhan, Peoples R China.
RP Cao, SB (reprint author), Huazhong Agr Univ, State Key Lab Agr Microbiol, Wuhan 430070, Hubei, Peoples R China.
EM sbcao@mail.hzau.edu.cn
FU National Natural Sciences Foundation of China [30600446]; National Basic
   Research Program (973) of China [2005CB523003, 2005CB523200]; Key
   Project of Science and Technology in the Hubei Province [2006AA205A02]
FX The authors would like to thank Jarred Yasuhara-Bell for his comments on
   the manuscript. This work was supported by National Natural Sciences
   Foundation of China (30600446), National Basic Research Program (973) of
   China (2005CB523003 and 2005CB523200) and a Key Project of Science and
   Technology in the Hubei Province (2006AA205A02).
CR Abe T, 2005, J VIROL, V79, P2847, DOI 10.1128/JVI.79.5.2847-2858.2005
   Abe T, 2003, J IMMUNOL, V171, P1133, DOI 10.4049/jimmunol.171.3.1133
   Aoki H, 1999, VET MICROBIOL, V68, P197, DOI 10.1016/S0378-1135(99)00110-8
   Barsoum J, 1997, HUM GENE THER, V8, P2011, DOI 10.1089/hum.1997.8.17-2011
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Chang GJJ, 2000, J VIROL, V74, P4244, DOI 10.1128/JVI.74.9.4244-4252.2000
   Chia SC, 2001, MICROB PATHOGENESIS, V31, P9, DOI 10.1006/mpat.2001.0442
   Estcourt MJ, 1998, CURR OPIN MICROBIOL, V1, P411, DOI 10.1016/S1369-5274(98)80058-1
   Facciabene A, 2004, J VIROL, V78, P8663, DOI 10.1128/JVI.78.16.8663-8672.2004
   Ghosh S, 2002, MOL THER, V6, P5, DOI 10.1006/mthe.2000.0643
   Gronowski AM, 1999, J VIROL, V73, P9944
   Hennessy S, 1996, LANCET, V347, P1583, DOI 10.1016/S0140-6736(96)91075-2
   Hervas-Stubbs S, 2007, J IMMUNOL, V178, P2361, DOI 10.4049/jimmunol.178.4.2361
   HOFMANN C, 1995, P NATL ACAD SCI USA, V92, P10099, DOI 10.1073/pnas.92.22.10099
   HOKE CH, 1988, NEW ENGL J MED, V319, P608, DOI 10.1056/NEJM198809083191004
   Hu YC, 2005, ACTA PHARMACOL SIN, V26, P405, DOI 10.1111/j.1745-7254.2005.00078.x
   Jiang YB, 2007, VACCINE, V25, P547, DOI 10.1016/j.vaccine.2006.07.032
   Kost TA, 2005, NAT BIOTECHNOL, V23, P567, DOI 10.1038/nbt1095
   KU CC, 1994, J MED VIROL, V44, P122, DOI 10.1002/jmv.1890440204
   Liu ZL, 1997, J INFECT DIS, V176, P1366, DOI 10.1086/517323
   Pieroni L, 2001, HUM GENE THER, V12, P871, DOI 10.1089/104303401750195845
   POLAND JD, 1990, J INFECT DIS, V161, P878, DOI 10.1093/infdis/161.5.878
   ROBERTS S, 2007, MOL THER, V15, P193
   Shoji I, 1997, J GEN VIROL, V78, P2657, DOI 10.1099/0022-1317-78-10-2657
   Strauss R, 2007, MOL THER, V15, P193, DOI 10.1038/sj.mt.6300008
   SUMIYOSHI H, 1987, VIROLOGY, V161, P497, DOI 10.1016/0042-6822(87)90144-9
   Tani H, 2003, J VIROL, V77, P9799, DOI 10.1128/JVI.77.18.9799-9808.2003
   Wang SP, 2007, VACCINE, V25, P8220, DOI 10.1016/j.vaccine.2007.09.069
   Xu GY, 2004, VACCINE, V22, P1846, DOI 10.1016/j.vaccine.2003.09.015
   Yang Dong-Kun, 2005, J Vet Sci, V6, P125
   YASUDA A, 1990, J VIROL, V64, P2788
NR 31
TC 9
Z9 15
U1 4
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1099-498X
EI 1521-2254
J9 J GENE MED
JI J. Gene. Med.
PD FEB
PY 2009
VL 11
IS 2
BP 150
EP 159
DI 10.1002/jgm.1282
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 407SF
UT WOS:000263383900006
PM 19040206
OA Bronze
DA 2018-12-27
ER

PT J
AU Tai, CT
   Chen, SA
AF Tai, Ching-Tai
   Chen, Shih-Ajin
TI RETRACTED: Electrophysiological Mechanisms of Atrial Flutter (Retracted
   article. See vol. 74, pg. I, 2009)
SO JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
LA English
DT Review; Retracted Publication
DE antiarrhythmic drugs; atrial flutter
ID CRISTA TERMINALIS; SLOW CONDUCTION; EXCITABLE GAP; INTRACARDIAC
   ECHOCARDIOGRAPHY; TRICUSPID-VALVE; CIRCUS MOVEMENT; ISTHMUS; ABLATION;
   REENTRY; ACTIVATION
AB Atrial flutter (AFL) is a common arrhythmia in clinical practice. Several experimental models, such as tricuspid regurgitation model, tricuspid ring model, sterile pericarditis model and atrial crush injury model, have provided important information about reentrant circuit and can test the effects of antiarrhythmic drugs. Human AFL has typical and atypical forms. Typical AFL rotates around the tricuspid annulus and uses the crista terminalis and sometimes sinus venosa as the boundary. The tricuspid isthmus is a slow conduction zone and the target of radiofrequency ablation. Atypical AFL may arise from the right or left atrium. Right AFL includes upper loop reentry, free wall reentry and figure-of-8 reentry. Left AFL includes mitral annular AFL, pulmonary vein-related AFL and left septal AFL. Radiofrequency ablation of the isthmus between the boundaries can eliminate these arrhythmias. [J Chin Med Assoc 2009;72(2):60-67]
C1 [Tai, Ching-Tai; Chen, Shih-Ajin] Natl Yang Ming Univ, Div Cardiol, Dept Med, Sch Med,Taipei Vet Gen Hosp, Taipei 112, Taiwan.
RP Tai, CT (reprint author), Natl Yang Ming Univ, Div Cardiol, Dept Med, Sch Med,Taipei Vet Gen Hosp, 201 Sect 2,Shih Pai Rd, Taipei 112, Taiwan.
EM ct.tai@msa.hinet.net
FU National Science Council, Taipei, Taiwan, R.O.C. [NSC 97-2314-B-075-04]
FX This work was supported in part by a grant from the National Science
   Council (NSC 97-2314-B-075-04), Taipei, Taiwan, R.O.C.
CR Arenal A, 1999, CIRCULATION, V99, P2771, DOI 10.1161/01.CIR.99.21.2771
   BOINEAU JP, 1980, AM J CARDIOL, V45, P1167, DOI 10.1016/0002-9149(80)90475-0
   BOYDEN PA, 1981, CIRC RES, V49, P1319, DOI 10.1161/01.RES.49.6.1319
   Cabrera JA, 1998, J CARDIOVASC ELECTR, V9, P1186, DOI 10.1111/j.1540-8167.1998.tb00091.x
   Callans DJ, 1997, J AM COLL CARDIOL, V30, P1793, DOI 10.1016/S0735-1097(97)00383-5
   DELLABELLA P, 1991, AM J CARDIOL, V68, P492
   Feld GK, 1997, J CARDIOVASC ELECTR, V8, P1338, DOI 10.1111/j.1540-8167.1997.tb01030.x
   FELD GK, 1992, J AM COLL CARDIOL, V20, P441, DOI 10.1016/0735-1097(92)90115-4
   FRAME LH, 1986, CIRC RES, V58, P495, DOI 10.1161/01.RES.58.4.495
   Friedman PA, 2000, CIRCULATION, V101, P1568, DOI 10.1161/01.CIR.101.13.1568
   Higa S, 2006, HEART RHYTHM, V3, P1386, DOI 10.1016/j.hrthm.2006.09.006
   Jais P, 2004, CIRCULATION, V110, P2996, DOI 10.1161/01.CIR.0000146917.75041.58
   Jolly WA, 1910, HEART, V2, P177
   Kalman JM, 1996, CIRCULATION, V94, P398, DOI 10.1161/01.CIR.94.3.398
   Lewis T, 1921, HEART-J STUD CIRC, V8, P341
   Marrouche NF, 2004, CIRCULATION, V109, P2440, DOI 10.1161/01.CIR.0000129439.03836.96
   OLGIN JE, 1995, CIRCULATION, V92, P1839, DOI 10.1161/01.CIR.92.7.1839
   OLSHANSKY B, 1990, J AM COLL CARDIOL, V16, P1639, DOI 10.1016/0735-1097(90)90314-F
   PAGE PL, 1986, J AM COLL CARDIOL, V8, P872, DOI 10.1016/S0735-1097(86)80429-6
   ROSENBLUETH A, 1947, AM HEART J, V33, P677, DOI 10.1016/0002-8703(47)90084-7
   SCHERF D, 1947, P SOC EXP BIOL MED, V64, P233
   SPACH MS, 1988, CIRC RES, V62, P811, DOI 10.1161/01.RES.62.4.811
   SPACH MS, 1986, CIRC RES, V58, P356, DOI 10.1161/01.RES.58.3.356
   Tai CT, 1998, J CARDIOVASC ELECTR, V9, P811
   Tai CT, 2004, J AM COLL CARDIOL, V44, P1080, DOI 10.1016/j.jacc.2004.05.057
   Tai CT, 2004, J CARDIOVASC ELECTR, V15, P406, DOI 10.1046/j.1540-8167.2004.03535.x
   Tai CT, 2002, J AM COLL CARDIOL, V40, P746, DOI 10.1016/S0735-1097(02)02036-3
   Tai CT, 1997, CIRCULATION, V96, P2601, DOI 10.1161/01.CIR.96.8.2601
   Tai CT, 2001, PACE, V24, P384, DOI 10.1046/j.1460-9592.2001.t01-1-00384.x
NR 29
TC 2
Z9 2
U1 4
U2 10
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 1726-4901
EI 1728-7731
J9 J CHIN MED ASSOC
JI J. Chin. Med. Assoc.
PD FEB
PY 2009
VL 72
IS 2
BP 60
EP 67
DI 10.1016/S1726-4901(09)70024-3
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 421KI
UT WOS:000264357400002
PM 19251532
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Fang, K
   Chen, SP
   Lin, CW
   Cheng, WC
   Huang, HT
AF Fang, Kang
   Chen, Shih-Ping
   Lin, Chia-Wei
   Cheng, Wan-Chun
   Huang, Hwei-Tien
TI RETRACTED: Ellipticine-induced apoptosis depends on Akt translocation
   and signaling in lung epithelial cancer cells(Retracted article.See
   vol.100,pg.120,2016)
SO LUNG CANCER
LA English
DT Article; Retracted Publication
DE Ellipticine; Akt; Human non-small-cell-lung-cancer cells; Apoptosis
ID MALIGNANT GLIOMA-CELLS; CYCLE ARREST; DNA-DAMAGE; 3-KINASE/AKT PATHWAY;
   TOPOISOMERASE-II; KINASE-B; P53; ANTICANCER; INHIBITOR; INDUCTION
AB Ellipticine and its analogues were reported as topoisomerase II inhibitors and promising antitumor agents. In this work, we showed that the growth of human non-small-cell-lung-cancer (NSCLC) epithelial cells A549 can be inhibited by ellipticine. The inhibitory effect was reverted by PI3K inhibitors. The sub-G, phase cells after ellipticine treatment appeared at the expense of those that accumulated first at S- and G(2)/M phases during the early stage of treatment. We showed that the progression leading to cell death was impaired by wortmannin, which reverted apoptosis by retaining cells at S- and G2/M transition states. The characteristic apoptosis marker p53 activation after treatment appeared first followed by poly(ADPribose)polymerase (PARP) fragmentation. They disappeared upon co-treatment with wortmannin and the apoptotic phenotype reversed. Furthermore, ellipticine regulated endogenous survival signaling by up-regulating phosphorylated Akt that returned to its basal level later. Furthermore, ellipticine induced nucleus translocalization of p53 and Akt and recruitment of autophagosomes. The autophagic-related cell death was interfered by wortmannin and the suppressed growth reverted. The Akt-related cell death also occurred in p53-deficient cells with stable expression of exogenous p53. The work showed that ellipticine-induced cytotoxicity in NSCLC cells was achieved through autophagy and apoptotic death as a result of Akt-modulation. Being a topoisomerase II inhibitor, ellipticine proved a regulator in autophagy-related cell death through corporation of p53 and Akt. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Fang, Kang; Chen, Shih-Ping; Lin, Chia-Wei; Huang, Hwei-Tien] Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan.
   [Cheng, Wan-Chun] Natl Taipei Univ Educ, Dept Nat Sci Educ, Taipei, Taiwan.
RP Fang, K (reprint author), Natl Taiwan Normal Univ, Dept Life Sci, 88 Ting Chou Rd,Sec 4, Taipei, Taiwan.
EM biofv033@scc.ntnu.edu.tw
FU National Taiwan Normal University, Taipei, Taiwan [95A10]
FX This work is supported in part by grants from National Taiwan Normal
   University, Taipei, Taiwan (Grant number 95A10).
CR Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515
   Brognard J, 2001, CANCER RES, V61, P3986
   Chiu CC, 2005, APOPTOSIS, V10, P643, DOI 10.1007/s10495-005-1898-8
   Chiu CC, 2005, CANCER LETT, V223, P249, DOI 10.1016/j.canlet.2004.10.049
   Crowell JA, 2003, J NATL CANCER I, V95, P252, DOI 10.1093/jnci/95.4.252
   DJURIC Z, 1992, CANCER RES, V52, P1515
   Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200
   Fujiwara K, 2007, INT J ONCOL, V31, P753
   Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj/onc/1205181
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Hagg M, 2004, MOL CANCER THER, V3, P489
   KENNEY S, 1995, BIOCHEM PHARMACOL, V49, P23, DOI 10.1016/0006-2952(94)00471-W
   Kingma PS, 1997, J BIOL CHEM, V272, P7488, DOI 10.1074/jbc.272.11.7488
   Kuo PL, 2005, ANTI-CANCER DRUG, V16, P789, DOI 10.1097/01.cad.0000171768.36317.93
   Kuo PL, 2005, CANCER LETT, V223, P293, DOI 10.1016/j.canlet.2004.09.046
   Kuo YC, 2006, LIFE SCI, V78, P2550, DOI 10.1016/j.lfs.2005.10.041
   Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4
   PECQ JBL, 1974, PNAS, V71, P5078
   Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777
   Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1
   SCHWALLER MA, 1995, J BIOL CHEM, V270, P22709, DOI 10.1074/jbc.270.39.22709
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Shi LM, 1998, MOL PHARMACOL, V53, P241
   Simbulan-Rosenthal CM, 1999, MOL CELL BIOCHEM, V193, P137, DOI 10.1023/A:1006988832729
   Sourbier C, 2006, CANCER RES, V66, P5130, DOI 10.1158/0008-5472.CAN-05-1469
   Stiborova M, 2004, CANCER RES, V64, P8374, DOI 10.1158/0008-5472.CAN-04-2202
   Sugikawa E, 1999, ANTICANCER RES, V19, P3099
   SUREAU F, 1993, BIOPHYS J, V65, P1767, DOI 10.1016/S0006-3495(93)81273-6
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   te Poele RH, 2002, CANCER RES, V62, P1876
   Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998
   TEWEY KM, 1984, J BIOL CHEM, V259, P9182
   VanderWeele DJ, 2004, MOL CANCER THER, V3, P1605
   Zhang MC, 2007, BIOCHEM PHARMACOL, V73, P15, DOI 10.1016/j.bcp.2006.07.034
NR 34
TC 25
Z9 27
U1 3
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-5002
EI 1872-8332
J9 LUNG CANCER
JI Lung Cancer
PD FEB
PY 2009
VL 63
IS 2
BP 227
EP 234
DI 10.1016/j.lungcan.2008.05.026
PG 8
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 402NP
UT WOS:000263020700010
PM 18619705
DA 2018-12-27
ER

PT J
AU Thompson, PD
   Venero, CV
AF Thompson, Paul D.
   Venero, Carmelo V.
TI RETRACTED: A History of Medical Reports on the Boston Marathon: 112
   Years and Still Running (Retracted article. See vol 41, pg 1349, 2009)
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Article; Retracted Publication
DE ENDURANCE; EXERCISE; ATHLETE'S HEART; CARDIOMEGALY; TROPONIN
ID KINASE-MB-ISOENZYME; LONG-DISTANCE RUNNERS; SKELETAL-MUSCLE; CARDIAC
   MARKERS; MYOCARDIAL-INFARCTION; PROLONGED EXERCISE; ISCHEMIC COLITIS;
   INJURY; RACE; COMPETITION
AB THOMPSON, P. D., and C. V. VENERO. A History of Medical Reports oil the Boston Marathon: 112 Years and Still Running. Med. Sci. Sports Exerc., Vol. 41, No. 2, pp. 257-264, 2009. Introduction/Methods: We performed a systematic search for medical reports oil the Boston Marathon, run annually since April 19, 1897 and Studied medically since 1899. Results: We identified 66 articles: 25 were related to cardiology; 10, exercise physiology; 8, metabolism; 5, neurology; 4, gastroenterology; 3, hematology; 3, several disciplines; and 8, nephrology, orthopedics, and general topics. The predominance of cardiology articles reflects concerns about the cardiac risks of exercise present in the early 20th century and persistent to this day. The authors and contributors included luminaries from the medical and exercise community including Drs Paul Dudley White, Samuel Levine, Kenneth Cooper, Paul Zoll, Ellsworth Buskirk, and David Costill. The articles identified or confirmed many of the presently accepted principles of marathon medicine. Conclusions: Medical Studies on the Boston Marathon not only provide lessons applicable to managing modem athletes but also demonstrate the interests and concerns of researchers who have used the event to study the physiology of prolonged exercise for more than a century.
C1 [Thompson, Paul D.] Hartford Hosp, Div Cardiol, Henry Low Heart Ctr, Hartford, CT 06102 USA.
RP Thompson, PD (reprint author), Hartford Hosp, Div Cardiol, Henry Low Heart Ctr, 80 Seymour St, Hartford, CT 06102 USA.
EM pthomps@harthosp.org
CR ADNER MM, 1980, JAMA-J AM MED ASSOC, V243, P534, DOI 10.1001/jama.243.6.534
   ADNER MM, 1988, PHYSICIAN SPORTSMED, V16, P99
   ADNER MM, 2002, POINT CARE J NEAR PA, V1, P237
   Almond CSD, 2005, NEW ENGL J MED, V352, P1550, DOI 10.1056/NEJMoa043901
   Behrman RA, 1941, NEW ENGL J MED, V225, P801
   Blake JB, 1903, BOSTON MED SURG J, V148, P0195, DOI 10.1056/NEJM190302191480801
   BOCK AV, 1963, J SPORTS MED PHYS FI, V168, P80
   BUSKIRK ER, 1960, MED SPORTIVA, V14, P493
   CONLAY LA, 1989, J NEURAL TRANSM, V76, P65, DOI 10.1007/BF01244992
   CONLAY LA, 1992, INT J SPORTS MED, V13, pS141, DOI 10.1055/s-2007-1024619
   CONLAY LA, 1986, NEW ENGL J MED, V315, P892
   COSTILL DL, 1971, J APPL PHYSIOL, V31, P834
   COSTILL DL, 1969, MED SCI SPORTS EXERC, V1, P81, DOI DOI 10.1249/00005768-196906000-00005
   CURRENS JH, 1961, NEW ENGL J MED, V265, P988, DOI 10.1056/NEJM196111162652006
   DERDERIAN T, 1995, BOSTON MARATHON 1 CE
   DILL DB, 1965, J NATL CANCER I, V35, P185, DOI 10.1093/jnci/35.1.185
   DOUGLAS PS, 1987, CIRCULATION, V76, P1206, DOI 10.1161/01.CIR.76.6.1206
   Edmondstone WM, 1995, BRIT MED J, V311, P1660, DOI 10.1136/bmj.311.7021.1660
   Ely MR, 2007, MED SCI SPORT EXER, V39, P2029, DOI 10.1249/mss.0b013e318149f2c3
   Ely MR, 2007, MED SCI SPORT EXER, V39, P487, DOI 10.1249/mss.0b013e31802d3aba
   Farkas TA, 2006, J EMERG MED, V31, P79, DOI 10.1016/j.jemermed.2005.09.009
   Fortescue EB, 2007, ANN EMERG MED, V49, P137, DOI 10.1016/j.annemergmed.2006.09.024
   Gilligan DR, 1943, J CLIN INVEST, V22, P859, DOI 10.1172/JCI101460
   Gordon B, 1924, ARCH INTERN MED, V33, P738, DOI 10.1001/archinte.1924.00110300081003
   Gordon B, 1925, AM J ROENTGENOL RADI, V14, P424
   GORDON B, 1930, J MED SOC NEW JERSEY, P672
   GORDON B, 1926, NW MED, V25, P376
   Gordon B., 1925, JAMA-J AM MED ASSOC, V85, P508, DOI [10.1001/jama.1925.02670070028009, DOI 10.1001/JAMA.1925.02670070028009]
   GREEN LH, 1976, ANN INTERN MED, V84, P704, DOI 10.7326/0003-4819-84-6-704
   IRVING RA, 1991, J APPL PHYSIOL, V70, P342
   Isaacs R, 1924, AM J PHYSIOL, V71, P106
   Jessen N, 2005, J APPL PHYSIOL, V99, P330, DOI 10.1152/japplphysiol.00175.2005
   KAVANAGH T, 1974, JAMA-J AM MED ASSOC, V229, P1602, DOI 10.1001/jama.229.12.1602
   KNAPP PC, 1904, J NERV MENT DIS, V31, P94
   Kratz A, 2006, AM J CLIN PATHOL, V125, P296, DOI 10.1309/PRF5-N7P2-XM6E-243H
   Kratz A, 2005, ARCH PATHOL LAB MED, V129, P227
   Kratz A, 2003, ARCH PATHOL LAB MED, V127, P345
   Kratz A, 2002, AM J CLIN PATHOL, V118, P856, DOI 10.1092/BTWQ5YMYVQ67QK9L
   Kyriakos R, 2006, ABDOM IMAGING, V31, P54, DOI 10.1007/s00261-005-0364-y
   Larrabee RC, 1902, J MED RES, V7, P76
   Levine S.A., 1924, JAMA-J AM MED ASSOC, V82, P1778, DOI DOI 10.1001/JAMA.1924.02650480034015
   LEVINE SA, 1951, AM HEART J, V42, P406, DOI 10.1016/0002-8703(51)90134-2
   Lucas W, 1998, AM J GASTROENTEROL, V93, P2231
   MARESH CM, 1989, INT J SPORTS MED, V10, P101, DOI 10.1055/s-2007-1024883
   MCMAHON LF, 1984, ANN INTERN MED, V100, P846, DOI 10.7326/0003-4819-100-6-846
   Melanson SEF, 2006, AM J CLIN PATHOL, V126, P888, DOI 10.1309/1D62H6KRFTVQRJ0A
   Myers K J, 1976, J Am Optom Assoc, V47, P515
   Neilan TG, 2006, EUR HEART J, V27, P1079, DOI 10.1093/eurheartj/ehi813
   Neilan TG, 2006, CIRCULATION, V114, P2325, DOI 10.1161/CIRCULATIONAHA.106.647461
   NEWMARK SR, 1976, J CLIN ENDOCR METAB, V42, P393, DOI 10.1210/jcem-42-2-393
   NOAKES TD, 1985, MED SCI SPORT EXER, V17, P370
   NOBLE BJ, 1979, MED SCI SPORT EXER, V11, P239
   O'Donnell T F Jr, 1977, Ann N Y Acad Sci, V301, P262, DOI 10.1111/j.1749-6632.1977.tb38204.x
   Pedersen BK, 2007, BIOCHEM SOC T, V35, P1295, DOI 10.1042/BST0351295
   POORTMAN.J, 1968, J CLIN INVEST, V47, P386, DOI 10.1172/JCI105735
   Roberts WO, 2007, SPORTS MED, V37, P400, DOI 10.2165/00007256-200737040-00033
   ROSE LI, 1970, J APPL PHYSIOL, V29, P449
   RUBIN CT, 1987, J BIOMECH, V20, P723, DOI 10.1016/0021-9290(87)90038-8
   Saenz AJ, 2006, AM J CLIN PATHOL, V126, P185, DOI 10.1039/D7QUF0HJMCYYYY5A
   Sanchez LD, 2006, J EMERG MED, V30, P321, DOI 10.1016/j.jemermed.2005.05.021
   Shin AY, 2006, PEDIATRICS, V117, P1818, DOI 10.1542/peds.2005-1249
   SIEGEL A J, 1990, Annals of Sports Medicine, V5, P67
   SIEGEL AJ, 1980, YALE J BIOL MED, V53, P275
   SIEGEL AJ, 1983, JAMA-J AM MED ASSOC, V250, P2835, DOI 10.1001/jama.250.20.2835
   Siegel AJ, 2001, AM J CARDIOL, V88, P920, DOI 10.1016/S0002-9149(01)01910-5
   Siegel AJ, 2001, AM J CARDIOL, V88, P918, DOI 10.1016/S0002-9149(01)01909-9
   SIEGEL AJ, 1985, AM J MED, V79, P431, DOI 10.1016/0002-9343(85)90029-4
   SIEGEL AJ, 1979, JAMA-J AM MED ASSOC, V241, P391, DOI 10.1001/jama.241.4.391
   SIEGEL AJ, 1981, JAMA-J AM MED ASSOC, V246, P2049, DOI 10.1001/jama.246.18.2049
   SIEGEL AJ, 1995, CARDIOLOGY, V86, P451, DOI 10.1159/000176922
   Siegel AJ, 1997, CARDIOLOGY, V88, P487, DOI 10.1159/000177396
   Siegel AJ, 2007, AM J MED, V120, DOI 10.1016/j.amjmed.2006.10.027
   Takahashi M, 1996, CLIN BIOCHEM, V29, P301, DOI 10.1016/0009-9120(96)00016-1
   Thijssen DHJ, 2006, AGING CELL, V5, P495, DOI 10.1111/j.1474-9726.2006.00242.x
   THOMAS D, 2000, EXERCISE SPORTS CARD, P43
   Thompson PD, 2006, CIRCULATION, V114, P2306, DOI 10.1161/CIRCULATIONAHA.106.663245
   Thompson PD, 2004, MED SCI SPORT EXER, V36, P363, DOI 10.1249/01.MSS.0000117117.67849.F6
   TRAPASSO LM, 1989, INT J BIOMETEOROL, V33, P233, DOI 10.1007/BF01051083
   WARHOL MJ, 1985, AM J PATHOL, V118, P331
   White PD, 1942, J AMER MED ASSOC, V120, P642, DOI 10.1001/jama.1942.02830430064025
   White PD, 1918, J AMER MED ASSOC, V71, P1047, DOI 10.1001/jama.1918.02600390031009
   WILLETT W, 1980, NEW ENGL J MED, V303, P1159, DOI 10.1056/NEJM198011133032007
   WILLIAMS H, 1899, PHILA MED J, P1233
   WOOD PD, 1976, METABOLISM, V25, P1249, DOI 10.1016/S0026-0495(76)80008-X
NR 84
TC 5
Z9 6
U1 3
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD FEB
PY 2009
VL 41
IS 2
BP 257
EP 264
DI 10.1249/MSS.0b013e3181878067
PG 8
WC Sport Sciences
SC Sport Sciences
GA 396OO
UT WOS:000262601200001
PM 19127202
DA 2018-12-27
ER

PT J
AU Shang, E
   Hasenberg, T
   Magdeburg, R
   Keese, M
   Post, S
   Weiner, R
AF Shang, Edward
   Hasenberg, Till
   Magdeburg, Richard
   Keese, Michael
   Post, Stefan
   Weiner, Rudolf
TI RETRACTED: First Experiences with A Circular Stapled Gastro-Jejunostomy
   by a New Transorally Introducible Stapler System in Laparoscopic
   Roux-en-Y Gastric Bypass (Retracted article. See vol. 22, pg. 1141,
   2012)
SO OBESITY SURGERY
LA English
DT Article; Retracted Publication
DE Laparoscopy; Roux-en-Y gastric bypass; Bariatric surgery;
   Gastrointestinal anastomosis; Computerized circular stapling system
ID BARIATRIC SURGERY; STENOSIS; OBESITY
AB The only effective treatment for patients with morbid obesity is surgery. Laparoscopic bariatric surgery has become quite popular in attempts to decrease the morbidity associated with laparotomy. The aim of this study was to assess the safety and efficiency by using SurgASSISTA (R) for performing the gastrojejunostomy in laparoscopic Roux-en-Y gastric bypass (RYGBP). The variables were compared with the results using the standard laparoscopic circular end-to-end anastomotic stapler (CEEAA (R)).
   After randomization, the gastro-jejuostomy of RYGBP was performed in ten patients by transabdominal introduced circular stapler (group A) and in ten patients by transorally introduced circular stapler (SurgASSISTA (R); group B) via five-port laparoscopy. A prospective 12-month postoperative follow-up including documentation of minor and major complication as well as weight loss and body composition is done every 8 weeks.
   The average body mass index (BMI, 52 kg/m(2)) and the other baseline characteristics were equally distributed in both groups. There was no difference in reduction of BMI, excess weight loss, and fat mass in both groups. The rate of port site wound infection in group A was significantly higher (p = 0.03) when compared to group B. There was no anastomotic leak or stricture postoperatively in both groups.
   Performing of a gastrojejunostomy in RYGBP by SurgASSIST is a safe and feasible method in comparison to conventional circular stapler systems. The advantage of SurgASSIST is the avoidance to introduce the stapler through the abdominal wall and, by this, a possible port site wound infection. Further prospective studies have to be performed to verify the advantages of the SurgASSIST in comparison to conventional circular stapler systems.
C1 [Shang, Edward; Hasenberg, Till; Magdeburg, Richard; Keese, Michael; Post, Stefan] Univ Hosp Mannheim, Dept Surg, D-68135 Mannheim, Germany.
   [Weiner, Rudolf] Krankenhaus Sachsenhausen, Dept Surg, Frankfurt, Germany.
RP Shang, E (reprint author), Univ Hosp Mannheim, Dept Surg, Theodor Kutzer Ufer 1-3, D-68135 Mannheim, Germany.
EM edward.shang@urz.uni-heidelberg.de
CR BALTASAR A, 1980, REV CLIN ESP, V157, P395, DOI 10.1093/milmed/146.2.91
   Buchwald H, 2004, JAMA-J AM MED ASSOC, V292, P1724, DOI 10.1001/jama.292.14.1724
   Buchwald H, 2002, OBES SURG, V12, P705, DOI 10.1381/096089202321019747
   Buchwald H, 2004, OBES SURG, V14, P1157, DOI 10.1381/0960892042387057
   CHAPMAN A, 2002, 31 ASERNIPS
   Chapman AE, 2004, SURGERY, V135, P326, DOI 10.1016/S0039-6060(03)00392-1
   Christou Nicolas V, 2005, Adv Surg, V39, P165, DOI 10.1016/j.yasu.2005.04.005
   de la Torre RA, 1999, OBES SURG, V9, P492, DOI 10.1381/096089299765552800
   DeMaria J, 2002, ANN SURG, V235, P640, DOI 10.1097/00000658-200205000-00005
   DIMATTEO G, 1988, INT SURG, V73, P23
   Fisher BL, 2007, SURG OBES RELAT DIS, V3, P176, DOI 10.1016/j.soard.2006.11.014
   FRANTZIDES CT, 1995, J LAPAROENDOSC SURG, V5, P97, DOI 10.1089/lps.1995.5.97
   Gonzalez R, 2004, OBES SURG, V14, P1299, DOI 10.1381/0960892042583978
   Gould JC, 2006, SURG ENDOSC, V20, P1017, DOI 10.1007/s00464-005-0207-5
   Higa KD, 2000, OBES SURG, V10, P509, DOI 10.1381/096089200321593706
   Higa KD, 2001, J LAPAROENDOSC ADV A, V11, P377, DOI 10.1089/10926420152761905
   HULTL H, 1986, CITED SURG STAPLING
   Kellum JM, 1998, CURR PROB SURG, V35, P796
   LATIMER RG, 1975, AM J SURG, V130, P766, DOI 10.1016/0002-9610(75)90438-9
   LOWDON IMR, 1982, BRIT J SURG, V69, P333, DOI 10.1002/bjs.1800690614
   Nguyen N T, 1999, JSLS, V3, P193
   Nguyen NT, 2004, OBES SURG, V14, P1308, DOI 10.1381/0960892042583879
   PENNINCKX FM, 1984, DIS COLON RECTUM, V27, P714, DOI 10.1007/BF02554594
   ROBERTS PL, 1991, SURG CLIN N AM, V71, P1247
   Schauer PR, 1999, J LAPAROENDOSC ADV A, V9, P101, DOI 10.1089/lap.1999.9.101
   Schauer PR, 2000, ANN SURG, V232, P515, DOI 10.1097/00000658-200010000-00007
   Sjostrom L, 2007, NEW ENGL J MED, V357, P741, DOI 10.1056/NEJMoa066254
   Teixeira JA, 2000, OBES SURG, V10, P240, DOI 10.1381/096089200321643520
   Waage A, 2005, OBES SURG, V15, P782, DOI 10.1381/0960892054222704
   Weiner R, 2003, OBES SURG, V13, P427, DOI 10.1381/096089203765887787
   Wittgrove AC, 1996, OBES SURG, V6, P500, DOI 10.1381/096089296765556412
   WITTGROVE AC, 1994, OBES SURG, V4, P353, DOI 10.1381/096089294765558331
NR 32
TC 9
Z9 9
U1 4
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0960-8923
EI 1708-0428
J9 OBES SURG
JI Obes. Surg.
PD FEB
PY 2009
VL 19
IS 2
BP 230
EP 236
DI 10.1007/s11695-008-9661-1
PG 7
WC Surgery
SC Surgery
GA 397HC
UT WOS:000262652500016
PM 18758872
DA 2018-12-27
ER

PT J
AU Grewal, NS
   Gabbay, JS
   Ashley, RK
   Wasson, KL
   Bradley, JP
   Zuk, PA
AF Grewal, Navanjun S.
   Gabbay, Joubin S.
   Ashley, Rebekah K.
   Wasson, Kristy L.
   Bradley, James P.
   Zuk, Patricia A.
TI RETRACTED: BMP-2 Does Not Influence the Osteogenic Fate of Human
   Adipose-Derived Stem Cells (Retracted article. See vol. 123, pg. 1402,
   2009)
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 52nd Annual Meeting of the Plastic-Surgery-Research-Council
CY JUN 20-23, 2007
CL Stanford, CA
SP Plast Surg Res Council
ID BONE MORPHOGENETIC PROTEIN; RETINOIC ACID; STROMAL CELLS; DEFECT MODEL;
   TISSUE; DIFFERENTIATION; MATRIX
AB Background: Recent studies have shown that bone morphogenetic protein (BMP)-2, a potent osteogenic growth factor, in combination with human adipose-derived stem cells can heal critical-sized bony defects. However, whether BMP-2 induces an osteogenic response in the adipose-derived stem cells remains unknown.
   Methods: In vitro calcium production, osteogenic gene expression, and BMP-2 receptor expression on the adipose-derived stem cell surface were analyzed in BMP-2-stimulated adipose-derived stem cells. The cells (2 x 10(7) cells) maintained in osteogenic medium were treated with an initial pulse of BMP-2 for 48 hours or 7 days or were given continuous BMP-2. To assess the response of these cells to BMP-2 in vivo, they (250,000 cells) were seeded into polylactic-co-glycolic acid (PLGA) collagraft scaffolds treated with 5 mu g of BMP-2 and implanted into critical-sized femoral rat defects (n = 40). Healing was assessed histologically and quantitated by micro-computed tomography.
   Results: In vitro treatment of adipose-derived stem cells with BMP-2 revealed decreased ability of the cells to undergo matrix calcification, demonstrated by decreased calcium production and decreased osteogenic gene expression of transcription factor Cbfa-1 and key extracellular proteins. Flow cytometry demonstrated decreased expression of BMP-2 receptors 1a and 1b in osteogenically differentiated adipose-derived stem cells stimulated with BMP-2. In vivo implantation of adipose-derived stem cell-seeded PLGA did not result in healing of critical-sized femoral defects in rodents, whereas implantation of BMP-2 absorbed PLGA, with or without adipose-derived stem cells, consistently healed these defects.
   Conclusions: The data suggests that osteogenic differentiation of adipose-derived stem cells is marginally affected by the addition of BMP-2. Consequently, stem cells in combination with BMP-2 may not be a viable strategy for the bony healing. (Plast. Reconstr. Surg. 123 (Suppl.): 158S, 2009.)
C1 [Grewal, Navanjun S.; Gabbay, Joubin S.; Ashley, Rebekah K.; Wasson, Kristy L.; Bradley, James P.; Zuk, Patricia A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Plast & Reconstruct Surg, Los Angeles, CA 90095 USA.
RP Bradley, JP (reprint author), 200 UCLA Med Plaza,Suite 465,Box 956960, Los Angeles, CA 90095 USA.
EM bradley.research@gmail.com
CR Ashjian PH, 2003, PLAST RECONSTR SURG, V111, P1922, DOI 10.1097/01.PRS.0000055043.62589.05
   Chen JC, 2007, PLAST RECONSTR SURG, V120, P1503, DOI 10.1097/01.prs.0000282029.99225.b5
   Cowan CM, 2005, TISSUE ENG, V11, P645, DOI 10.1089/ten.2005.11.645
   Diefenderfer DL, 2003, CONNECT TISSUE RES, V44, P305, DOI 10.1080/03008200390181825
   Dragoo JL, 2003, J ORTHOP RES, V21, P622, DOI 10.1016/S0736-0266(02)00238-3
   Dudas JR, 2006, ANN PLAS SURG, V56, P543, DOI 10.1097/01.sap.0000210629.17727.bd
   Erickson GR, 2002, BIOCHEM BIOPH RES CO, V290, P763, DOI 10.1006/bbrc.2001.6270
   Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151
   Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681
   Huang JI, 2002, PLAST RECONSTR SURG, V109, P1033, DOI 10.1097/00006534-200203000-00037
   Jimenez MJG, 2001, J CELL BIOL, V155, P1333, DOI 10.1083/jcb.200106147
   Lee JA, 2003, ANN PLAS SURG, V50, P610, DOI 10.1097/01.SAP.0000069069.23266.35
   Peterson B, 2005, TISSUE ENG, V11, P120, DOI 10.1089/ten.2005.11.120
   Roemer FW, 2005, AM J ROENTGENOL, V184, P1215, DOI 10.2214/ajr.184.4.01841215
   SIFFERT RS, 1951, J EXP MED, V93, P415, DOI 10.1084/jem.93.5.415
   Toriyama K, 2002, TISSUE ENG, V8, P157, DOI 10.1089/107632702753503144
   Vogelin E, 2005, J BONE JOINT SURG AM, V87A, P1323, DOI 10.2106/JBJS.C.00913
   Wan DC, 2006, P NATL ACAD SCI USA, V103, P12335, DOI 10.1073/pnas.0604849103
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   Yamagiwa H, 2001, J BONE MINER METAB, V19, P20, DOI 10.1007/s007740170056
   Yoon E, 2007, TISSUE ENG, V13, P619, DOI 10.1089/ten.2006.0102
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 22
TC 8
Z9 12
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0032-1052
EI 1529-4242
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD FEB
PY 2009
VL 123
IS 2
SU S
BP 158S
EP 165S
DI 10.1097/PRS.0b013e318191c844
PG 8
WC Surgery
SC Surgery
GA 412JR
UT WOS:000263721600019
PM 19182675
DA 2018-12-27
ER

PT J
AU Schwarz, JBK
   Langwieser, N
   Langwieser, NN
   Bek, MJ
   Seidl, S
   Eckstein, HH
   Lu, B
   Schomig, A
   Pavenstadt, H
   Zohlnhofer, D
AF Schwarz, Johannes B. K.
   Langwieser, Nicolas
   Langwieser, Nicole N.
   Bek, Martin J.
   Seidl, Stefan
   Eckstein, Hans-Henning
   Lu, Bao
   Schoemig, Albert
   Pavenstaedt, Hermann
   Zohlnhoefer, Dietlind
TI RETRACTED: Novel Role of the CXC Chemokine Receptor 3 in Inflammatory
   Response to Arterial Injury Involvement of mTORC1 (Retracted article.
   See vol. 108, pg. E14, 2011)
SO CIRCULATION RESEARCH
LA English
DT Article; Retracted Publication
DE intimal hyperplasia; inflammation; apoptosis; chemokines; mTORC1
ID VASCULAR INJURY; DEFICIENT MICE; DIFFERENTIAL EXPRESSION;
   ALLOGRAFT-REJECTION; NEOINTIMA FORMATION; MAMMALIAN TARGET;
   INTERFERON-GAMMA; CELLS; ATHEROSCLEROSIS; RAPAMYCIN
AB Atherosclerosis, restenosis, and posttransplant graft atherosclerosis are characterized by endothelial damage, infiltration of inflammatory cells, and proliferation of smooth muscle cells. The CXCR3-activating chemokines interferon-gamma inducible protein 10 (IP10) and MIG (monokine induced by interferon-gamma) have been implicated in vascular repair and remodeling. The underlying molecular mechanisms, however, remain elusive. Here, we show that wire-mediated arterial injury induced local and systemic expression of IP10 and MIG, resulting in enhanced recruitment of CXCR3(+) leukocytes and hematopoietic progenitor cells. This was accompanied by profound activation of mammalian target of rapamycin complex (mTORC) 1, increased reactive oxygen species production, apoptosis, and intimal hyperplasia. Genetic and pharmacological inactivation of CXCR3 signaling not only suppressed recruitment of inflammatory cells but also abolished mTORC1 activation, reduced reactive oxygen species generation, and blocked apoptosis of vascular cells, resulting in significant reduction of intimal hyperplasia in vivo. In vitro, stimulation of T cells with IP10 directly activated mTORC1 and induced generation of reactive oxygen species and apoptosis in an mTORC1-dependent manner. These results strongly indicate that CXCR3-dependent activation of mTORC1 directly links stimulation of the Th1 immune system with the proliferative response of intimal cells in vascular remodeling. (Circ Res. 2009; 104: 189-200.)
C1 [Schwarz, Johannes B. K.; Langwieser, Nicolas; Langwieser, Nicole N.; Schoemig, Albert; Zohlnhoefer, Dietlind] Tech Univ Munich, Deutsch Herzzentrum, Munich, Germany.
   [Schwarz, Johannes B. K.; Langwieser, Nicolas; Langwieser, Nicole N.; Schoemig, Albert; Zohlnhoefer, Dietlind] Tech Univ Munich, Med Klin 1, Munich, Germany.
   [Bek, Martin J.; Pavenstaedt, Hermann] Univ Clin Muenster, Div Nephrol & Gen Med, Dept Med, Munster, Germany.
   [Seidl, Stefan] Tech Univ Munich, Klinikum Rechts Isar, Inst Pathol, D-8000 Munich, Germany.
   [Eckstein, Hans-Henning] Tech Univ Munich, Klinikum Rechts Isar, Dept Vasc Surg, D-8000 Munich, Germany.
   [Lu, Bao] Childrens Hosp, Ina Sue Perlmutter Lab, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
RP Zohlnhofer, D (reprint author), Charite, Med Klin Kardiol & Pulmol 2, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.
EM d_zohlnhoefer@yahoo.com
FU Deutsche Forschungsgemeinschaft [Zo104/2-1, Zo104/2-2]
FX This study was supported by Deutsche Forschungsgemeinschaft grant
   Zo104/2-1, Zo104/2-2 (to D. Z.).
CR Bek MJ, 2003, J IMMUNOL, V170, P931, DOI 10.4049/jimmunol.170.2.931
   Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129
   Braunersreuther V, 2007, THROMB HAEMOSTASIS, V97, P714
   Castro C, 2004, ATHEROSCLEROSIS, V172, P31, DOI 10.1016/j.atherosclerosis.2003.09.003
   de Obanos MPP, 2007, BBA-MOL CELL RES, V1773, P1681, DOI 10.1016/j.bbamcr.2007.07.005
   Eisen HJ, 2003, NEW ENGL J MED, V349, P847, DOI 10.1056/NEJMoa022171
   Farb A, 2002, CIRCULATION, V105, P2974, DOI 10.1161/01.CIR.0000019071.72887.BD
   Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201
   Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515
   HANSSON GK, 1991, P NATL ACAD SCI USA, V88, P10530, DOI 10.1073/pnas.88.23.10530
   Jiang SG, 2004, P NATL ACAD SCI USA, V101, P16891, DOI 10.1073/pnas.0404398101
   Jinquan T, 2001, J IMMUNOL, V167, P4405, DOI 10.4049/jimmunol.167.8.4405
   Kaur S, 2007, J BIOL CHEM, V282, P1757, DOI 10.1074/jbc.M607365200
   Khurana R, 2004, CIRCULATION, V110, P2436, DOI 10.1161/01.CIR.0000145138.25577.F1
   Legare JF, 2000, AM J PATHOL, V157, P859, DOI 10.1016/S0002-9440(10)64599-3
   Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204
   Mach F, 1999, J CLIN INVEST, V104, P1041, DOI 10.1172/JCI6993
   Miller FJ, 1998, CIRC RES, V82, P1298, DOI 10.1161/01.RES.82.12.1298
   Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071
   Murooka TT, 2008, BLOOD, V111, P4892, DOI 10.1182/blood-2007-11-125039
   Nakaya I, 2007, NEPHRON EXP NEPHROL, V107, pE12, DOI 10.1159/000106505
   Nuhrenberg TG, 2008, CARDIOVASC RES, V77, P580, DOI 10.1093/cvr/cvm076
   Okamoto Y, 2008, CIRC RES, V102, P218, DOI 10.1161/CIRCRESAHA.107.164988
   Remskar M, 2001, CIRC RES, V88, P390
   Romagnani P, 2001, J CLIN INVEST, V107, P53, DOI 10.1172/JCI9775
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Sahara M, 2005, STEM CELLS, V23, P874, DOI 10.1634/stemcells.2005-0012
   Sata M, 2000, J MOL CELL CARDIOL, V32, P2097, DOI 10.1006/jmcc.2000.1238
   Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403
   Schober A, 2003, CIRCULATION, V108, P2491, DOI 10.1161/01.CIR.0000099508.76665.9A
   Tannenbaum CS, 1998, J IMMUNOL, V161, P927
   Van Wanrooij EJA, 2008, ARTERIOSCL THROM VAS, V28, P251, DOI 10.1161/ATVBAHA.107.147827
   Wang YN, 2007, CIRC RES, V101, P560, DOI 10.1161/CIRCRESAHA.107.151068
   Weber C, 2007, THROMB HAEMOSTASIS, V97, P685, DOI 10.1160/TH07-02-0112
   Wendt MK, 2008, GASTROENTEROLOGY, V135, P508, DOI 10.1053/j.gastro.2008.05.033
   Werner N, 2002, ARTERIOSCL THROM VAS, V22, P1567, DOI 10.1161/01.ATV.0000036417.43987.D8
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Xie JH, 2003, J LEUKOCYTE BIOL, V73, P771, DOI 10.1189/jlb.1102573
   Zohlnhofer D, 2004, MOL PHARMACOL, V65, P880, DOI 10.1124/mol.65.4.880
   Zohlnhofer D, 2001, MOL CELL, V7, P1059, DOI 10.1016/S1097-2765(01)00239-8
NR 40
TC 27
Z9 27
U1 4
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD JAN 30
PY 2009
VL 104
IS 2
BP 189
EP U94
DI 10.1161/CIRCRESAHA.108.182683
PG 22
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA 401AC
UT WOS:000262909500010
PM 19059841
OA Bronze
DA 2018-12-27
ER

PT J
AU Juanes, ME
   Elvira, G
   Garcia-Grande, A
   Calero, M
   Gasset, M
AF Juanes, Maria E.
   Elvira, Gema
   Garcia-Grande, Aranzazu
   Calero, Miguel
   Gasset, Maria
TI RETRACTED: Biosynthesis of Prion Protein Nucleocytoplasmic Isoforms by
   Alternative Initiation of Translation (Retracted article. See vol. 292,
   pg. 20044, 2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID ENDOPLASMIC-RETICULUM; SIGNAL SEQUENCE; CYTOSOLIC PRP; TRANSMEMBRANE;
   CELLS; FORM; NEURODEGENERATION; PROLIFERATION; NEUROTOXICITY;
   ACCUMULATION
AB The cellular prion protein PrPC is synthesized as a family of four distinct forms. Of these, (PrP)-Pr-Cyt is a minor member that segregates outside of the secretory route and can generate cytotoxic forms. Using signal sequence mutants, we found that (PrP)-Pr-Cyt is translated from a downstream AUG (coding for Met-8 in human PrP or Met-15 in Syrian hamster PrP). Shortening of the signal sequence dictated the spillage of this isoform into the cytosol, from where it accessed the nucleus or formed insoluble cytosolic aggregates if the proteasome is inhibited. The PrP isoform isolated from the nuclear fractions of cell and brain homogenates was partially SUMO-1-conjugated. Expression of HaPrP(M15) in cells caused an antiproliferative phenotype due to a cell cycle arrest at the G(0)/G(1) phase. The identification of this PrP isoform and its properties provides novel insight into PrPC physiological and pathological functions.
C1 [Juanes, Maria E.; Elvira, Gema; Gasset, Maria] CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain.
   [Garcia-Grande, Aranzazu] Ctr Nacl Invest Oncol, Madrid 28029, Spain.
   [Calero, Miguel] Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid 28220, Spain.
RP Gasset, M (reprint author), CSIC, Inst Quim Fis Rocasolano, Serrano 119, E-28006 Madrid, Spain.
EM mgasset@iqfr.csic.es
RI Gasset, Maria/K-4339-2012; Calero, Miguel/H-5691-2015
OI Gasset, Maria/0000-0001-6436-4055; Calero, Miguel/0000-0001-5366-3324
FU Ministerio de Ciencia e Innovacion [SAF2006-00418, PI050912]; European
   Union [FOOD-CT-2004506579]
FX This work was supported by Grants SAF2006-00418 (to M. G.) and FIS
   PI050912 (to M. C.) from the Ministerio de Ciencia e Innovacion (to M.
   G.) and Grant FOOD-CT-2004506579 (M. G.) from the European Union. The
   costs of publication of this article were defrayed in part by the
   payment of page charges. This article must therefore be hereby marked
   "advertisement" in accordance with 18 U. S. C. Section 1734 solely to
   indicate this fact.
CR Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6
   Caughey B, 2006, NATURE, V443, P803, DOI 10.1038/nature05294
   Chang KJ, 2006, J BIOL CHEM, V281, P7775, DOI 10.1074/jbc.M511265200
   Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433
   Crozet C, 2006, MOL CELL NEUROSCI, V32, P315, DOI 10.1016/j.mcn.2006.05.004
   Derrington E, 2002, CR BIOL, V325, P17, DOI 10.1016/S1631-0691(02)01388-4
   Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200
   GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940
   Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293
   Ghaemmaghami S, 2007, P NATL ACAD SCI USA, V104, P17971, DOI 10.1073/pnas.0708372104
   Gonzalez-Iglesias R, 2002, J MOL BIOL, V319, P527, DOI 10.1016/S0022-2836(02)00341-8
   Hegde RS, 2003, TRENDS NEUROSCI, V26, P337, DOI 10.1016/S0166-2236(03)00143-7
   Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827
   Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3
   Holscher C, 2001, J BIOL CHEM, V276, P13388, DOI 10.1074/jbc.M007331200
   Hosokawa T, 2008, BIOCHEM BIOPH RES CO, V366, P657, DOI 10.1016/j.bbrc.2007.11.163
   Kim SJ, 2001, J BIOL CHEM, V276, P26132, DOI 10.1074/jbc.M101638200
   Levine CG, 2005, MOL BIOL CELL, V16, P279, DOI 10.1091/mbc.E04-06-0508
   Liang J, 2007, FASEB J, V21, P2247, DOI 10.1096/fj.06-7799com
   Lorenz H, 2002, J BIOL CHEM, V277, P8508, DOI 10.1074/jbc.M110197200
   Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725
   Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619
   Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098
   MEHDI H, 1990, GENE, V91, P173, DOI 10.1016/0378-1119(90)90085-6
   Mironov A, 2003, J NEUROSCI, V23, P7183, DOI 10.1523/JNEUROSCI.23-18-07183.2003
   Orsi A, 2006, J BIOL CHEM, V281, P30431, DOI 10.1074/jbc.M605320200
   Ott CM, 2004, BIOCHEMISTRY-US, V43, P11973, DOI 10.1021/bi049156s
   Rambold AS, 2006, MOL BIOL CELL, V17, P3356, DOI 10.1091/mbc.E06-01-0083
   Rane NS, 2004, EMBO J, V23, P4550, DOI 10.1038/sj.emboj.7600462
   Rogers GW, 2004, P NATL ACAD SCI USA, V101, P2794, DOI 10.1073/pnas.0308576101
   Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200
   Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200
   Say YH, 2007, PROTEOMICS, V7, P1059, DOI 10.1002/pmic.200600849
   Schagger H, 2006, NAT PROTOC, V1, P16, DOI 10.1038/nprot.2006.4
   Sorensen V, 2006, BIOESSAYS, V28, P504, DOI 10.1002/bies.20405
   Steele AD, 2006, P NATL ACAD SCI USA, V103, P3416, DOI 10.1073/pnas.0511290103
   Stewart RS, 2003, J BIOL CHEM, V278, P45960, DOI 10.1074/jbc.M307833200
   Touriol C, 2003, BIOL CELL, V95, P169, DOI 10.1016/S0248-4900(03)00033-9
   Wang XH, 2006, J BIOL CHEM, V281, P13559, DOI 10.1074/jbc.M512306200
   Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383
NR 40
TC 20
Z9 22
U1 5
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 30
PY 2009
VL 284
IS 5
BP 2787
EP 2794
DI 10.1074/jbc.M804051200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 397ZL
UT WOS:000262700900021
PM 19059915
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Liu, F
   Sun, WW
   Wang, Y
   Hu, LQ
   Dai, P
   Tian, CF
   Wang, TH
AF Liu, Fen
   Sun, Wei-Wei
   Wang, Ying
   Hu, Li-Qun
   Dai, Ping
   Tian, Chang-Fu
   Wang, Ting-Hua
TI RETRACTED: Effects of electro-acupuncture on NT-4 expression in spinal
   dorsal root ganglion and associated segments of the spinal dorsal horn
   in cats subjected to adjacent dorsal root ganglionectomy (Retracted
   article. See vol. 528, pg. 91, 2012)
SO NEUROSCIENCE LETTERS
LA English
DT Article; Retracted Publication
DE Electro-acupuncture; Neurotrophin-4; Ganglionectomy; Dorsal root
   ganglion; Spinal cord; Cat
ID NEUROTROPHIC FACTOR; MOTOR-NEURONS; CORD-INJURY; ADULT-RAT; IN-VIVO;
   BRAIN; MOTONEURONS; DEATH; BDNF; DIFFERENTIATION
AB It is well known that neuroplasticity occurs in the central nervous system in response to injury. Electroacupuncture (EA) may also promote neuroplasticity. But little is known about the underlying molecular mechanisms for the beneficial effects of EA. This study investigated the effects of EA on neurotrophin-4 (NT-4) expression in L-6 spinal dorsal root ganglion (DRG) and associated segments of the spinal dorsal horn in cats subjected to unilateral removal of L-1-L-5 and L-7-S-2 DRG. NT-4 protein was normally present in the cytoplasm of the L-6 DRG neurons and L-3 and L-6 spinal dorsal horn neurons and glia. Adjacent ganglionectomy leads to a significant decrease in NT-4 expression in the 4 DRG, but no change in the spinal dorsal horn. Following EA treatment a significant increase occurred in the L-6 DRG at 14 days post-operation (dpo) as well as the L-6 cord segment at 7 and 14 dpo. These findings pointed to a possible association between NT-4 expression and EA promoted spinal cord plasticity in adult cats subjected to partial ganglionectomy. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
C1 [Tian, Chang-Fu] Kunming Med Coll, Expt Ctr Med Sci, Kunming 650031, Peoples R China.
   [Liu, Fen; Sun, Wei-Wei; Dai, Ping; Wang, Ting-Hua] Kunming Med Coll, Inst Neurosci, Kunming 650031, Peoples R China.
   [Hu, Li-Qun] Anhui Prov Hosp, Cadres Ward, Hefei 230001, Peoples R China.
   [Sun, Wei-Wei] Kunming Childrens Hosp, Ctr Nerve Electrophysiol, Kunming 650034, Peoples R China.
   [Wang, Ying] Weifang Med Coll, Dept Nursing, Weifang 261042, Peoples R China.
RP Tian, CF (reprint author), Kunming Med Coll, Expt Ctr Med Sci, Kunming 650031, Peoples R China.
EM Tiancf@21cn.com; tinghua-neuron@263.net
FU China National Science Foundation [30260125]; New York-China Medical
   Board [CMB00-722]
FX We thank Prof. Seng-Kee Leong for his invaluable comments for this
   manuscript. This research was supported by a grant from the China
   National Science Foundation (No. 30260125) and the New York-China
   Medical Board (CMB00-722).
CR Blesch A, 2004, MOL CELL NEUROSCI, V27, P190, DOI 10.1016/j.mcn.2004.06.007
   Bregman BS, 1997, EXP NEUROL, V148, P475, DOI 10.1006/exnr.1997.6705
   CARNAHAN J, 1995, MOL NEUROBIOL, V10, P135, DOI 10.1007/BF02740672
   FRIEDMAN B, 1995, J NEUROSCI, V15, P1044
   GAO WQ, 1995, J NEUROSCI, V15, P2656
   GRIESBECK O, 1995, J NEUROSCI RES, V42, P21, DOI 10.1002/jnr.490420104
   Gulino R, 2004, BRAIN RES, V1013, P174, DOI 10.1016/j.brainres.2004.03.055
   Heppenstall PA, 2001, P NATL ACAD SCI USA, V98, P8107, DOI 10.1073/pnas.141015098
   HICKS SP, 1975, AM J ANAT, V143, P1, DOI 10.1002/aja.1001430102
   JIN ZG, 1997, CHIN ACUPUNCT, V8, P489
   KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105
   KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304
   LEONG SK, 1976, EXP BRAIN RES, V26, P235
   LI LX, 1994, J NEUROBIOL, V25, P759, DOI 10.1002/neu.480250702
   Liang XB, 2003, NEUROREPORT, V14, P1177, DOI 10.1097/01.wnr.0000074772.23712.94
   Liang XB, 2002, MOL BRAIN RES, V108, P51, DOI 10.1016/S0169-328X(02)00513-2
   LIU CN, 1958, ARCH NEURO PSYCHIATR, V79, P46, DOI 10.1001/archneurpsyc.1958.02340010064005
   Lobner D, 2004, NEUROCHEM RES, V29, P2303, DOI 10.1007/s11064-004-7040-4
   MCNEILL DL, 1991, EXP NEUROL, V114, P321, DOI 10.1016/0014-4886(91)90158-9
   MEMBERG SP, 1995, MOL CELL NEUROSCI, V6, P323, DOI 10.1006/mcne.1995.1025
   Ming Y, 1999, NEUROSCI LETT, V273, P187, DOI 10.1016/S0304-3940(99)00655-2
   MURRAY M, 1986, J NEUROSCI, V6, P3205
   Qiao XX, 1996, NEUROREPORT, V7, P682, DOI 10.1097/00001756-199601310-00071
   Riley CP, 2004, J MOL HISTOL, V35, P771, DOI 10.1007/s10735-004-0778-9
   Sakuma K, 2002, ACTA NEUROPATHOL, V104, P482, DOI 10.1007/s00401-002-0576-y
   Scarisbrick IA, 1999, J NEUROSCI, V19, P7757
   SCHMALBRUCH H, 1995, BRAIN RES, V700, P254, DOI 10.1016/0006-8993(95)00982-V
   STENERVICTORIN E, 2003, REPROD BIOL ENDOCRIN, V8, P1
   Sun WW, 2008, NEUROCHEM RES, V33, P437, DOI 10.1007/s11064-007-9451-5
   VEJSADA R, 1995, EUR J NEUROSCI, V7, P108, DOI 10.1111/j.1460-9568.1995.tb01025.x
   Wang TTH, 2006, NEUROSCIENCE, V140, P1169, DOI 10.1016/j.neuroscience.2006.03.008
   Wang TH, 2007, NEUROCHEM RES, V32, P1415, DOI 10.1007/s11064-007-9326-9
   Wang TTH, 2005, NEUROSCI LETT, V382, P236, DOI 10.1016/j.neulet.2005.03.020
   Wong AMK, 2003, AM J PHYS MED REHAB, V82, P21, DOI 10.1097/01.PHM.0000043517.06642.D0
   Wu Liangfang, 1993, Journal of West China University of Medical Sciences, V24, P117
   WU YG, 1995, J TRADIT CHIN MED, V2, P14
   XIAO RY, 1989, CHIN J NEUROANAT, V5, P149
NR 37
TC 7
Z9 10
U1 5
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD JAN 30
PY 2009
VL 450
IS 2
BP 158
EP 162
DI 10.1016/j.neulet.2008.09.066
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 406DL
UT WOS:000263275100019
PM 18838104
DA 2018-12-27
ER

PT J
AU Wang, YF
   Gu, YT
   Xu, WB
   Lv, G
AF Wang, Yan-Feng
   Gu, Yan-Ting
   Xu, Wei-Bing
   Lv, Gang
TI RETRACTED: Temporary loss of perivascular aquaporin-4 in white matter
   after the spinal cord ischemic injury of rats (Retracted article. See
   vol. 21, pg. 1, 2010)
SO NEUROREPORT
LA English
DT Article; Retracted Publication
DE aquaporin-4; spinal cord edema; spinal cord ischemia
ID BRAIN EDEMA; AORTIC OCCLUSION; AQP4 EXPRESSION; MICE; STROKE
AB The study was performed to investigate whether the ischemic gray matter and white matter show distinct patterns of aquaporin-4 (AQP4) expression in the reperfusion phase using an in-vivo transient spinal cord ischemia model in rats. We investigated to the time course of AQP4 expression at the blood-spinal cord interface by the quantitative immunogold and western blots methods. The results showed that disruption of AQP4 anchoring at the perivascular membrane did not lead to a net loss of protein. This is the first systematic and extensive study fully showing AQP4 expression dynamics after transient spinal cord ischemia and the findings are of major clinical and experimental interest. NeuroReport 20:145-149 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Wang, Yan-Feng; Lv, Gang] China Med Univ, Affiliated Hosp 1, Dept Orthopaed, Shenyang 110001, Liaoning Prov, Peoples R China.
   [Gu, Yan-Ting] Shenyang Pharmaceut Univ, Dept Physiol, Life Sci & Biol Pharmacopedia Inst, Shenyang, Peoples R China.
   [Xu, Wei-Bing] Dalian Municipal Ctr Hosp, Dept Orthopaed, Da Lian, Liaoning Prov, Peoples R China.
RP Wang, YF (reprint author), China Med Univ, Beier Rd 92, Shenyang 110001, Liaoning Prov, Peoples R China.
EM wyf2007888@yahoo.com.cn
FU Natural Science Foundation of Liaoning Province in China [20052096]; 
   [20050159019];  [20060400292]
FX This study was supported by Natural Science Foundation of Liaoning
   Province in China, no. 20052096; special fund for scientific research of
   doctor-degree subjects in colleges and universities, no. 20050159019,
   special fund for scientific research of postdoctoral subjects in China,
   no.20060400292.
CR Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100
   Chen CH, 2007, NEUROCRIT CARE, V7, P92, DOI 10.1007/s12028-007-0033-9
   COSTON A, 1983, PHYSIOL BEHAV, V30, P967, DOI 10.1016/0031-9384(83)90263-9
   Fryclenlund DS, 2006, P NATL ACAD SCI USA, V103, P13532, DOI 10.1073/pnas.0605796103
   Fujiki M, 2005, BRAIN RES, V1053, P175, DOI 10.1016/j.brainres.2005.06.055
   Leypold BG, 2008, AM J NEURORADIOL, V29, P1012, DOI 10.3174/ajnr.A0962
   Lu H, 2003, CHINESE MED J-PEKING, V116, P1063
   Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256
   MARSALA M, 1994, J CEREBR BLOOD F MET, V14, P526, DOI 10.1038/jcbfm.1994.65
   Meng SZ, 2004, EUR J NEUROSCI, V19, P2261, DOI 10.1111/j.1460-9568.2004.03315.x
   Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198
   Nesic O, 2006, NEUROSCIENCE, V143, P779, DOI 10.1016/j.neuroscience.2006.08.079
   Oshio K, 2004, NEUROSCIENCE, V127, P685, DOI 10.1016/j.neuroscience.2004.03.016
   Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje
   Puwarawuttipanit W, 2006, NEUROSCIENCE, V137, P165, DOI 10.1016/j.neuroscience.2005.08.051
   Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981
   Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014
   Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X
NR 18
TC 10
Z9 11
U1 3
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959-4965
EI 1473-558X
J9 NEUROREPORT
JI Neuroreport
PD JAN 28
PY 2009
VL 20
IS 2
BP 145
EP 149
DI 10.1097/WNR.0b013e32831c6c44
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 406TX
UT WOS:000263318900009
PM 19151597
DA 2018-12-27
ER

PT J
AU Wang, HT
   Yang, W
   Shao, H
   Zhang, JH
   Qi, L
   Liao, AJ
   Li, YC
   Liu, ZG
AF Wang, Hongtao
   Yang, Wei
   Shao, Hui
   Zhang, Jihong
   Qi, Li
   Liao, Aijun
   Li, Yingchun
   Liu, Zhuogang
TI RETRACTED: Complex t(2;21;8)(p12;q22;q22): a variant t(8;21) in a
   patient with acute myeloid leukemia (AML-M2) (Retracted Article. See vol
   192, pg 54, 2009)
SO CANCER GENETICS AND CYTOGENETICS
LA English
DT Article; Retracted Publication
ID ACUTE MYELOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; TRANSLOCATION;
   CHROMOSOMES; MATURATION; TRANSCRIPT; AML1-ETO; FORM; M2
AB Acute myeloid leukemia with maturation (AML-M2 based on the French-American-British classification) is often accompanied by typical chromosomal changes such as t (8;21)(q22;q22). We report it case of a 31-year-old female with a positive RUNX1/CBFA2T1 (alias AML1/ETO) fusion gene and a karyotype with a t(2;21;8)(p12;q22;q22). Although variant translocations involving chromosome region 2p12 have never been reported before, we suppose this translocation may be responsible for the clinical manifestation and prognosis of this case. The role of this complex variant translocation, as well as the possible formation mechanism, prognostic factors, and morphologic changes are discussed. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Wang, Hongtao; Yang, Wei; Shao, Hui; Zhang, Jihong; Qi, Li; Liao, Aijun; Li, Yingchun; Liu, Zhuogang] China Med Univ, Sheng Jing Hosp, Hematol Malignancy Treatment Ctr, Shenyang 110022, Liao Ning, Peoples R China.
RP Yang, W (reprint author), China Med Univ, Sheng Jing Hosp, Hematol Malignancy Treatment Ctr, Shenyang 110022, Liao Ning, Peoples R China.
EM yangw@sj-hospital.org
CR Ahmad F, 2008, CANCER GENET CYTOGEN, V180, P153, DOI 10.1016/j.cancergencyto.2007.10.005
   Albano F, 2005, LEUKEMIA RES, V29, P855, DOI 10.1016/j.leukres.2004.12.018
   Farra C, 2004, CANCER GENET CYTOGEN, V155, P138, DOI 10.1016/j.cancergencyto.2004.03.016
   Ferrara F, 2002, HAEMATOLOGICA, V87, P306
   GALLEGO M, 1994, CANCER GENET CYTOGEN, V75, P139, DOI 10.1016/0165-4608(94)90166-X
   Giles FJ, 1998, CANCER GENET CYTOGEN, V104, P66, DOI 10.1016/S0165-4608(97)00438-X
   Gong Jin-ying, 2006, Zhonghua Xue Ye Xue Za Zhi, V27, P314
   Haferlach T, 1996, LEUKEMIA LYMPHOMA, V23, P227, DOI 10.3109/10428199609054825
   Hsiao HH, 2005, CANCER GENET CYTOGEN, V159, P96, DOI 10.1016/j.cancergencyto.2004.10.003
   Ishida F, 2002, CANCER GENET CYTOGEN, V132, P133, DOI 10.1016/S0165-4608(01)00550-7
   Lee J, 2005, CANCER GENET CYTOGEN, V159, P79, DOI 10.1016/j.cancergenyto.2004.10.002
   Liu Xu-ping, 2006, Zhonghua Nei Ke Za Zhi, V45, P918
   Nakao T, 1997, EUR J HAEMATOL, V59, P126
   Pallisgaard N, 1998, BLOOD, V92, P574
   PASQUALI F, 1981, CANCER GENET CYTOGEN, V3, P335, DOI 10.1016/0165-4608(81)90042-X
   ROWLEY JD, 1973, ANN GENET-PARIS, V16, P109
   SANDBERG AA, 1986, SEMIN HEMATOL, V23, P201
   SHAFFER LG, 2005, INT SYSTEM HUMAN CYT
   Shinagawa A, 1999, CANCER GENET CYTOGEN, V109, P72, DOI 10.1016/S0165-4608(98)00121-6
   Takahashi T, 2004, CANCER GENET CYTOGEN, V155, P152, DOI 10.1016/j.cancergencyto.2004.03.009
   Udayakumar AM, 2008, ARCH MED RES, V39, P252, DOI 10.1016/j.arcmed.2007.09.002
   Vieira L, 2001, CANCER GENET CYTOGEN, V128, P104, DOI 10.1016/S0165-4608(01)00404-6
   Wong KF, 1998, CANCER GENET CYTOGEN, V101, P39, DOI 10.1016/S0165-4608(97)00033-2
   Xue YQ, 2001, LEUKEMIA LYMPHOMA, V42, P533, DOI 10.3109/10428190109064613
   Yoo SJ, 2005, HAEMATOL-HEMATOL J, V90, P1493
NR 25
TC 4
Z9 4
U1 5
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0165-4608
J9 CANCER GENET CYTOGEN
JI Cancer Genet. Cytogenet.
PD JAN 15
PY 2009
VL 188
IS 2
BP 95
EP 98
DI 10.1016/j.cancergencyto.2008.08.007
PG 4
WC Oncology; Genetics & Heredity
SC Oncology; Genetics & Heredity
GA 391SB
UT WOS:000262252000007
PM 19100512
DA 2018-12-27
ER

PT J
AU Augustine, CK
   Yoo, JS
   Potti, A
   Yoshimoto, Y
   Zipfel, PA
   Friedman, HS
   Nevins, JR
   Ali-Osman, F
   Tyler, DS
AF Augustine, Christina K.
   Yoo, Jin Soo
   Potti, Anil
   Yoshimoto, Yasunori
   Zipfel, Patricia A.
   Friedman, Henry S.
   Nevins, Joseph R.
   Ali-Osman, Francis
   Tyler, Douglas S.
TI RETRACTED: Genomic and Molecular Profiling Predicts Response to
   Temozolomide in Melanoma (Retracted Article. See vol 15, pg 3240, 2009)
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID METASTATIC CUTANEOUS MELANOMA; ADVANCED EXTREMITY MELANOMA;
   GENE-EXPRESSION; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE;
   O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; MALIGNANT-MELANOMA; MISMATCH
   REPAIR; PHASE-II; RESISTANCE; CHEMOTHERAPY
AB Purpose: Despite objective response rates of only similar to 13%, temozolomide remains one of the most effective single chemotherapy agents against metastatic melanoma, second only to dacarbazine, the current standard of care for systemic treatment of melanoma. The goal of this study was to identify molecular and/or genetic markers that correlate with, and could be used to predict, response to temozolomide-based treatment regimens and that reflect the intrinsic properties of a patient's tumor.
   Experimental Design: Using a panel of 26 human melanoma-derived cell lines, we determined in vitro temozolomide sensitivity, O(6)-methylguanine-DNA methyltransferase (MGMT) activity, MGMT expression and promoter methylation status, and mismatch repair proficiency, as well as the expression profile of 38,000 genes using an oligonucleotide-based microarray platform.
   Results: The results showed a broad spectrum of temozolomide sensitivity across the panel of cell lines, with IC(50) values ranging from 100 mu mol/L to 1 mmol/L. There was a significant correlation between measured temozolomide sensitivity and a gene expression signature-derived prediction of temozolomide sensitivity (P < 0.005). Notably, MGMT alone showed a significant correlation with temozolomide sensitivity (MGMT activity, P < 0.0001; MGMT expression, P <= 0.0001). The promoter methylation status of the MGMT gene, however, was not consistent with MGMT gene expression or temozolomide sensitivity.
   Conclusions: These results show that melanoma resistance to temozolomide is conferred predominantly by MGMT activity and suggest that MGMT expression could potentially be a useful tool for predicting the response of melanoma patients to temozolomide therapy.
C1 [Augustine, Christina K.; Yoo, Jin Soo; Yoshimoto, Yasunori; Zipfel, Patricia A.; Friedman, Henry S.; Ali-Osman, Francis; Tyler, Douglas S.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
   [Potti, Anil] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   [Nevins, Joseph R.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.
   [Potti, Anil; Nevins, Joseph R.] Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA.
   [Augustine, Christina K.; Yoshimoto, Yasunori; Zipfel, Patricia A.; Tyler, Douglas S.] Durham VA Med Ctr, Durham, NC USA.
RP Augustine, CK (reprint author), Duke Univ, Med Ctr, Dept Surg, Box 3118, Durham, NC 27710 USA.
EM Christi.augustine@duke.edu
FU Durham VA Medical Center Institute for Medical Research; VA Merit
   Review; Institute of Genomic Sciences; Policy at Duke University Medical
   Center
FX Grant support: Durham VA Medical Center Institute for Medical Research
   Grant (C.K. Augustine), VA Merit Review Grant (D.S. Tyler), and the
   Institute of Genomic Sciences and Policy at Duke University Medical
   Center (D.S. Tyler, F. Ali-Osman, H.S. Friedman, and J.R. Nevins).
CR Adams DM, 2008, PEDIATR BLOOD CANCER, V50, P549, DOI 10.1002/pbc.21362
   *AM CANC SOC, 2007, CANC FACTS FIG 2007
   Augustine CK, 2008, CANCER RES, V68, P3777, DOI 10.1158/0008-5472.CAN-07-5949
   Awada A, 2005, BRIT J CANCER, V92, P1855, DOI 10.1038/sj.bjc.6602584
   Berchuck A, 2005, CLIN CANCER RES, V11, P3686, DOI 10.1158/1078-0432.CCR-04-2398
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115
   Boogerd W, 2007, CANCER, V109, P306, DOI 10.1002/cncr.22411
   Buzaid AC, 2004, ONCOLOGY-NY, V18, P1443
   BUZAID AC, 2004, ONCOLOGY HUNTINGT, V18, P57
   DOMORADZKI J, 1984, CARCINOGENESIS, V5, P1641, DOI 10.1093/carcin/5.12.1641
   Drablos F, 2004, DNA REPAIR, V3, P1389, DOI 10.1016/j.dnarep.2004.05.004
   Eggermont AMM, 2004, EUR J CANCER, V40, P1825, DOI 10.1016/j.ejca.2004.04.030
   Esteller M, 1999, CANCER RES, V59, P793
   Friedman HS, 2000, CLIN CANCER RES, V6, P2585
   FRIEDMAN HS, 1995, CANCER RES, V55, P2853
   Friedman HS, 1997, CANCER RES, V57, P2933
   Friedman HS, 1998, J CLIN ONCOL, V16, P3851, DOI 10.1200/JCO.1998.16.12.3851
   Gogas HJ, 2007, CANCER-AM CANCER SOC, V109, P455, DOI 10.1002/cncr.22427
   Grubbs EG, 2004, SURGERY, V136, P210, DOI 10.1016/j.surg.2004.04.021
   GUPTA V, 1995, CANCER CHEMOTH PHARM, V36, P13
   Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102
   HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   HORSPOOL KR, 1990, J MED CHEM, V33, P1393, DOI 10.1021/jm00167a018
   Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9
   Ma S, 2002, MELANOMA RES, V12, P335, DOI 10.1097/00008390-200208000-00005
   Marchesia F, 2007, PHARMACOL RES, V56, P275, DOI 10.1016/j.phrs.2007.08.003
   Middleton MR, 1998, BRIT J CANCER, V78, P1199, DOI 10.1038/bjc.1998.654
   Middleton MR, 2000, INT J CANCER, V88, P469, DOI 10.1002/1097-0215(20001101)88:3<469::AID-IJC21>3.0.CO;2-7
   Middleton MR, 2000, J CLIN ONCOL, V18, P158, DOI 10.1200/JCO.2000.18.1.158
   Paul MJ, 2002, MELANOMA RES, V12, P175, DOI 10.1097/00008390-200204000-00011
   Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563
   Paz MF, 2004, CLIN CANCER RES, V10, P4933, DOI 10.1158/1078-0432.CCR-04-0392
   Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X
   PEGG AE, 1990, CANCER RES, V50, P6119
   Pepponi R, 2003, J PHARMACOL EXP THER, V304, P661, DOI 10.1124/jpet.102.043950
   Pieper RO, 1997, PHARMACOL THERAPEUT, V74, P285, DOI 10.1016/S0163-7258(97)00003-X
   Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491
   Quirt I, 2007, ONCOLOGIST, V12, P1114, DOI 10.1634/theoncologist.12-9-1114
   Ranson M, 2007, J CLIN ONCOL, V25, P2540, DOI 10.1200/JCO.2007.10.8217
   Rietschel P, 2008, J CLIN ONCOL, V26, P2299, DOI 10.1200/JCO.2007.14.5292
   Ross MI, 2006, CLIN CANCER RES, V12, p2312S, DOI 10.1158/1078-0432.CCR-05-2643
   Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454
   Spiro T, 2000, Forum (Genova), V10, P274
   Tentori L, 2003, MOL PHARMACOL, V63, P192, DOI 10.1124/mol.63.1.192
   Trivedi RN, 2005, CANCER RES, V65, P6394, DOI 10.1158/0008-5472.CAN-05-0715
   Ueno T, 2006, MOL CANCER THER, V5, P732, DOI 10.1158/1535-7163.MCT-05-0098
   Ueno T, 2004, AM J SURG, V188, P532, DOI 10.1016/j.amjsurg.2004.07.014
   Yoshimoto Y, 2007, MOL CANCER THER, V6, P1492, DOI 10.1158/1535-7163.MCT-06-0718
NR 50
TC 71
Z9 73
U1 4
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JAN 15
PY 2009
VL 15
IS 2
BP 502
EP 510
DI 10.1158/1078-0432.CCR-08-1916
PG 9
WC Oncology
SC Oncology
GA 397VD
UT WOS:000262689300012
PM 19147755
OA Bronze
DA 2018-12-27
ER

PT J
AU Jablonski, AE
   Humphries, WH
   Payne, CK
AF Jablonski, Amy E.
   Humphries, William H.
   Payne, Christine K.
TI RETRACTED: Pyrenebutyrate-Mediated Delivery of Quantum Dots across the
   Plasma Membrane of Living Cells (Retracted Article. See vol 114, pg
   9946, 2010)
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article; Retracted Publication
ID ARGININE-RICH PEPTIDES; PENETRATING PEPTIDES; LIVE CELLS; NUCLEAR
   DELIVERY; CELLULAR UPTAKE; TRACKING; INTERNALIZATION; NANOCRYSTALS;
   TRANSDUCTION; PROTEINS
AB Quantum dots have been delivered directly across the plasma membrane to the cytosol of living cells using a combination of a cationic peptide, polyarginine, and a hydrophobic counterion, pyrenebutyrate. Quantum dot delivery did not disrupt the plasma membrane and bypassed the barrier of endocytic vesicles. Cellular uptake was independent of temperature but highly dependent oil the surface charge of the quantum dot and the membrane potential of the cell, suggesting a direct translocation across the membrane. This method of delivery can find immediate application for quantum dots and may be broadly applicable to other nanoparticles.
C1 [Payne, Christine K.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA.
   Georgia Inst Technol, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA.
RP Payne, CK (reprint author), Georgia Inst Technol, Sch Chem & Biochem, 901 Atlantic Dr, Atlanta, GA 30332 USA.
EM christine.payne@chemistry.gatech.edu
FU NIH Research Scholar Development Award; Georgia Institute of Technology
FX The authors thank Prof. Christoph Fahrni for helpful discussion and
   Prof. Nils Kroger for use of the Zetasizer. This work was supported by
   an NIH Research Scholar Development Award to C.K.P. and the Georgia
   Institute of Technology.
CR Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x
   AUBIN JE, 1979, J HISTOCHEM CYTOCHEM, V27, P36, DOI 10.1177/27.1.220325
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Busch NA, 2000, MACROMOLECULES, V33, P5932, DOI 10.1021/ma0005724
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Courty S, 2006, NANO LETT, V6, P1491, DOI 10.1021/nl060921t
   Derfus AM, 2004, ADV MATER, V16, P961, DOI 10.1002/adma.200306111
   Derfus AM, 2007, BIOCONJUGATE CHEM, V18, P1391, DOI 10.1021/bc060367e
   Dubertret B, 2002, SCIENCE, V298, P1759, DOI 10.1126/science.1077194
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   El-Sayed A, 2008, J BIOL CHEM, V283, P23450, DOI 10.1074/jbc.M709387200
   Fabre JW, 2006, CURR GENE THER, V6, P459, DOI 10.2174/156652306777934865
   Fischer R, 2005, CHEMBIOCHEM, V6, P2126, DOI 10.1002/cbic.200500044
   Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009
   Harms GS, 2001, BIOPHYS J, V80, P2396, DOI 10.1016/S0006-3495(01)76209-1
   Hess GT, 2007, BBA-MOL CELL RES, V1773, P1583, DOI 10.1016/j.bbamcr.2007.07.009
   Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt.767
   Jaiswal JK, 2004, TRENDS CELL BIOL, V14, P497, DOI 10.1016/j.tcb.2004.07.012
   Jaiswal JK, 2007, NAT CHEM BIOL, V3, P92, DOI 10.1038/nchembio855
   Jones AT, 2007, J CELL MOL MED, V11, P670, DOI 10.1111/j.1582-4934.2007.00062.x
   Kawamura KS, 2006, BIOCHEMISTRY-US, V45, P1116, DOI 10.1021/bi051338e
   Lee J, 2008, PHYS CHEM CHEM PHYS, V10, P1739, DOI 10.1039/b801317a
   Lidke DS, 2004, NAT BIOTECHNOL, V22, P198, DOI 10.1038/nbt929
   Liu W, 2008, J AM CHEM SOC, V130, P1274, DOI 10.1021/ja076069p
   Liu WH, 2007, J AM CHEM SOC, V129, P14530, DOI 10.1021/ja073790m
   Luccardini C, 2007, J BIOMED BIOTECHNOL, DOI 10.1155/2007/68963
   Medintz IL, 2005, NAT MATER, V4, P435, DOI 10.1038/nmat1390
   Melikov K, 2005, CELL MOL LIFE SCI, V62, P2739, DOI 10.1007/s00018-005-5293-y
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Nan XL, 2005, J PHYS CHEM B, V109, P24220, DOI 10.1021/jp056360w
   Nishihara M, 2005, ORG BIOMOL CHEM, V3, P1659, DOI 10.1093/b501472g
   Payne CK, 2007, TRAFFIC, V8, P389, DOI 10.1111/j.1600-0854.2007.00540.x
   Perret F, 2005, J AM CHEM SOC, V127, P1114, DOI 10.1021/ja043633c
   Potocky TB, 2003, J BIOL CHEM, V278, P50188, DOI 10.1074/jbc.M308719200
   Rosenthal SJ, 2002, J AM CHEM SOC, V124, P4586, DOI 10.1021/ja003486s
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Sakai N, 2003, J AM CHEM SOC, V125, P14348, DOI 10.1021/ja0376011
   SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321
   STROBER W, 1997, CURRENT PROTOCOLS IM
   Susumu K, 2007, J BIOMED BIOTECHNOL, DOI 10.1155/2007/90651
   Takeuchi T, 2006, ACS CHEM BIOL, V1, P299, DOI 10.1021/cb600127m
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Zhang Q, 2007, P NATL ACAD SCI USA, V104, P17843, DOI 10.1073/pnas.0706906104
NR 44
TC 14
Z9 14
U1 4
U2 25
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD JAN 15
PY 2009
VL 113
IS 2
BP 405
EP 408
DI 10.1021/jp809956w
PG 4
WC Chemistry, Physical
SC Chemistry
GA 392TF
UT WOS:000262324400003
PM 19099434
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Christiansen, P
   Mazak, JH
AF Christiansen, Per
   Mazak, Ji H.
TI RETRACTED: A primitive Late Pliocene cheetah, and evolution of the
   cheetah lineage (Retracted article. See vol. 109, pg. 15072, 2012)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE Acinonyx; Miracinonyx; Felidae; morphology; systematics
ID ACINONYX-JUBATUS; FELIDAE; CARNIVORA; RADIATION; AMERICAN; PUMA; CAT
AB The cheetah lineage is a group of large, slender, and long-limbed cats with a distinctive skull and dental morphology, of which only the extant cheetah (Acinonyx jubatus) is present today. The lineage is characterized by having abbreviated, tall, and domed crania, and a trenchant dentition with a much reduced, posteriorly placed protocone on the upper carnassial. In this article, we report on a new discovery of a Late Pliocene specimen from China with an estimated age of similar to 2.2-2.5 million years, making it one of the oldest specimens known to date. A cladistic analysis confirmed that it is the most primitive cheetah known, and it shares a number of unambiguous derived cranial traits with the Acinonyx lineage, but has more primitive dentition than previously known cheetahs, demonstrating that the many unusual skull and dental characters hitherto considered characteristic of cheetahs evolved in a gradual fashion. Isolated teeth of primitive cheetahs may not be recognizable as such, but can be confused with, for instance, those of leopards or other similar-sized pantherine cats or pumas. The age and morphology of the new specimen supports an Old World origin of the cheetah lineage, not a New World one, as has been suggested. We name the new species Acinonyx kurteni in honor of the late Bjorn Kurten.
C1 [Christiansen, Per] Zool Museum, DK-2100 Copenhagen O, Denmark.
   [Mazak, Ji H.] Shanghai Sci & Technol Museum, Shanghai 200002, Peoples R China.
RP Christiansen, P (reprint author), Zool Museum, Univ Pk 15, DK-2100 Copenhagen O, Denmark.
EM p2christiansen@snm.ku.dk
FU Carlsberg Foundation
FX We thank the staffs at the Natural History Museum, London; Museum fur
   Naturkunde, Berlin; Museum National d'Histoire Naturelle, Paris;
   Naturmuseum Senckenberg, Frankfurt, Germany; and Naturhistoriska
   riksmuseet, Stockholm. This work was supported by a grant from the
   Carlsberg Foundation (to P. C.).
CR ADAMS DB, 1979, SCIENCE, V205, P1155, DOI 10.1126/science.205.4411.1155
   BAILEY E, 1993, AFRICAN LEOPARD ECOL
   Barnett R, 2005, CURR BIOL, V15, pR589, DOI 10.1016/j.cub.2005.07.052
   Bissett C, 2007, J ZOOL, V271, P310, DOI 10.1111/j.1469-7998.2006.00217.x
   Broomhall LS, 2003, J ZOOL, V261, P119, DOI 10.1017/S0952836903004059
   Caro TM, 1994, CHEETAHS SERENGETI P
   Deng Tao, 2004, Vertebrata Palasiatica, V42, P45
   DIVYABHANUSINH, 2002, END TRAIL CHEETAH IN
   EATON R L, 1970, Zeitschrift fuer Tierpsychologie, V27, P492
   Felsenstein J, 2004, PHYLIP PHYLOGENY INF
   Felsenstein J, 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X
   Geraads D, 1997, GEOBIOS-LYON, V30, P127, DOI 10.1016/S0016-6995(97)80263-X
   Hemmer H., 1965, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V122, P324
   Hemmer H, 2004, NEUES JAHRB GEOL P-A, V233, P197
   Jackson P., 1996, WILD CATS STATUS SUR
   Johnson WE, 2006, SCIENCE, V311, P73, DOI 10.1126/science.1122277
   KURTEN B, 1976, NETH J ZOOL, V26, P502
   KURTEN B, 1968, PLEISTOCENE MAMMALS
   Kurten B, 1980, PLEISTOCENE MAMMALS
   Marcolini Federica, 2000, Bollettino della Societa Paleontologica Italiana, V39, P243
   Mattern MY, 2000, CLADISTICS, V16, P232, DOI 10.1111/j.1096-0031.2000.tb00354.x
   ORR PC, 1969, SANTA BARBARA MUS NA, V2, P1
   PETTER G, 1976, CR ACAD SCI D NAT, V282, P843
   POCOCK RI, 1939, MAMMALIA, V1
   Qiu Z., 2004, PALAEONTOLOGIA SIN C, V191, P1
   Schaub S., 1950, Eclogae Geologicae Helvetiae, V42, P492
   Sokal RR, 1995, BIOMETRY
   SOTNIKOVA MV, 1978, INT GEOL REV, V20, P335
   Sunquist M., 2002, WILD CATS WORLD
   TAYLOR CR, 1973, AM J PHYSIOL, V224, P848
   THENIUS E, 1953, N JAHRB GEOL PALAONT, V3, P225
   TURNER A, 1984, S AFR J SCI, V80, P227
   TURNER A, 1997, BIG CATS THEIR FOSSI
   van Valkenburgh B., 1990, Journal of Vertebrate Paleontology, V10, P434
   Viret J., 1954, NOUV ARCH MUS HIST N, V4, P1
NR 35
TC 16
Z9 17
U1 3
U2 38
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 13
PY 2009
VL 106
IS 2
BP 512
EP 515
DI 10.1073/pnas.0810435106
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 399MM
UT WOS:000262804000030
PM 19114651
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Bereczkei, T
   Hegedus, G
   Hajnal, G
AF Bereczkei, Tamas
   Hegedus, Gabor
   Hajnal, Gabor
TI RETRACTED: Facialmetric similarities mediate mate choice: sexual
   imprinting on opposite-sex parents (Retracted article. See vol. 276, pg.
   1199, 2009)
SO PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
LA English
DT Article; Retracted Publication
DE facial resemblance; sexual imprinting; homogamy
ID GENETIC SIMILARITY; ATTRACTIVENESS JUDGMENTS; ZEBRA FINCH; PREFERENCES;
   WOMEN; RECOGNITION; DIMORPHISM; SELECTION; BRITISH; HUMANS
AB Former studies have suggested that imprinting-like processes influence the shaping of human mate preferences. In this study, we provide more direct evidence for assessing facial resemblance between subjects' partner and subjects' parents. Fourteen facial proportions were measured on 312 adults belonging to 52 families, and the correlations between family members were compared with those of pairs randomly selected from the population. Spouses proved to be assortatively mated in the majority of measured facial proportions. Significant correlations have been found between the young men and their partner's father (but not his mother), especially on facial proportions belonging to the central area of the face. Women also showed resemblance to their partner's mother (but not to their father) in the facial characteristics of their lower face. Replicating our previous studies, facial photographs of participants were also matched by independent judges who ascribed higher resemblance between partners, and subjects and their partners' opposite-sex parents, compared with controls. Our results support the sexual imprinting hypothesis which states that children shape a mental template of their opposite-sex parents and search for a partner who resembles that perceptual schema. The fact that only the facial metrics of opposite-sex parents showed resemblance to the partner's face tends to rule out the role of familiarity in shaping mating preferences. Our findings also reject several other rival hypotheses. The adaptive value of imprinting-related human mating is discussed, and a hypothesis is made of why different facial areas are involved in males' and females' search for resemblance.
C1 [Bereczkei, Tamas; Hegedus, Gabor; Hajnal, Gabor] Univ Pecs, Inst Psychol, H-7624 Pecs, Hungary.
RP Bereczkei, T (reprint author), Univ Pecs, Inst Psychol, H-7624 Pecs, Hungary.
EM btamas@btk.pte.hu
CR Bateson P., 1983, P257
   BATESON P, 1988, ACT 19 C INT ORN, V1, P961
   Baudouin JY, 2004, ACTA PSYCHOL, V117, P313, DOI 10.1016/j.actpsy.2004.07.002
   Bereczkei T, 2004, P ROY SOC B-BIOL SCI, V271, P1129, DOI 10.1098/rspb.2003.2672
   Bereczkei T, 2002, PERS INDIV DIFFER, V33, P677, DOI 10.1016/S0191-8869(01)00182-9
   BERECZKEI T, 1996, ETHOL SOCIOBIOL, V17, P23
   BOLHUIS JJ, 1990, ANIM BEHAV, V40, P472, DOI 10.1016/S0003-3472(05)80527-5
   CUNNINGHAM MR, 2002, EVOLUTIONARY ATTRACT, P193
   IMMELMANN K, 1991, ANIM BEHAV, V42, P83, DOI 10.1016/S0003-3472(05)80608-6
   Jacob S, 2002, NAT GENET, V30, P175, DOI 10.1038/ng830
   JONES D, 1995, CURR ANTHROPOL, V36, P723, DOI 10.1086/204427
   Little AC, 2003, EVOL HUM BEHAV, V24, P43, DOI 10.1016/S1090-5138(02)00119-8
   Little AC, 2002, P ROY SOC B-BIOL SCI, V269, P1095, DOI 10.1098/rspb.2002.1984
   LITTLE AC, 2005, PERSONALITY INDIVIDU, V40, P973, DOI DOI 10.1016/J.PAID.2005.09.016
   Lorenz K, 1965, EVOLUTION MODIFICATI
   Mascie-Taylor C. G., 1988, HUMAN MATING PATTERN, P61
   Mascie-Taylor C. G. N., 1995, HUMAN POPULATIONS DI, P86
   ODA R, 2006, EVOL HUM BEHAV, V26, P441, DOI DOI 10.1016/J.EVOLHUMBEHAV.2005.04.002
   Penton-Voak IS, 2004, EVOL HUM BEHAV, V25, P355, DOI 10.1016/j.evolhumbehav.2004.06.002
   Penton-Voak IS, 1999, CURR PSYCHOL, V18, P104
   Perrett DI, 2002, P ROY SOC B-BIOL SCI, V269, P873, DOI 10.1098/rspb.2002.1971
   Read AF, 1988, HUMAN MATING PATTERN, P115
   Roberts SC, 2005, BIOL LETT-UK, V1, P400, DOI 10.1098/rsbl.2005.0343
   Rushton JP, 2005, PSYCHOL SCI, V16, P555, DOI 10.1111/j.0956-7976.2005.01574.x
   RUSHTON JP, 1989, BEHAV BRAIN SCI, V12, P503, DOI 10.1017/S0140525X00057320
   SCHOONJANS F, 2008, MEDCALC WINDOWS SOFT
   Spence R, 2007, ETHOLOGY, V113, P62, DOI 10.1111/j.1439-0310.2006.01295.x
   ten Cate C, 2006, CURR BIOL, V16, P1128, DOI 10.1016/j.cub.2006.03.068
   Thiessen D, 1997, PERS INDIV DIFFER, V22, P157, DOI 10.1016/S0191-8869(96)00181-X
   Thornhill R, 2006, EVOL HUM BEHAV, V27, P131, DOI 10.1016/j.evolhumbehav.2005.06.001
   VOS DR, 1995, ANIM BEHAV, V50, P645, DOI 10.1016/0003-3472(95)80126-X
   WALKENBACH J, 2004, EXCEL 2003 FORMULAS
   Waynforth D, 2005, EVOL HUM BEHAV, V26, P409, DOI 10.1016/j.evolhumbehav.2005.03.003
   Wedekind C, 1997, P ROY SOC B-BIOL SCI, V264, P1471, DOI 10.1098/rspb.1997.0204
   Wedekind C, 2007, OXFORD HDB EVOLUTION, P315
   WEISFELD GE, 1992, ETHOL SOCIOBIOL, V13, P125, DOI 10.1016/0162-3095(92)90022-V
   Weisfeld GE, 2003, J EXP CHILD PSYCHOL, V85, P279, DOI 10.1016/S0022-0965(03)00061-4
   Wiszewska A, 2007, EVOL HUM BEHAV, V28, P248, DOI 10.1016/j.evolhumbehav.2007.02.006
   Witte K, 2003, ANIM BEHAV, V65, P195, DOI 10.1006/anbe.2002.2009
NR 39
TC 10
Z9 11
U1 3
U2 18
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8452
J9 P R SOC B
JI Proc. R. Soc. B-Biol. Sci.
PD JAN 7
PY 2009
VL 276
IS 1654
BP 91
EP 98
DI 10.1098/rspb.2008.1021
PG 8
WC Biology; Ecology; Evolutionary Biology
SC Life Sciences & Biomedicine - Other Topics; Environmental Sciences &
   Ecology; Evolutionary Biology
GA 388FE
UT WOS:000262004900012
PM 18765339
OA Green Published
DA 2018-12-27
ER

PT J
AU Motiwala, T
   Majumder, S
   Ghoshal, K
   Kutay, H
   Datta, J
   Roy, S
   Lucas, DM
   Jacob, ST
AF Motiwala, Tasneem
   Majumder, Sarmila
   Ghoshal, Kalpana
   Kutay, Huban
   Datta, Jharna
   Roy, Satavisha
   Lucas, David M.
   Jacob, Samson T.
TI RETRACTED: PTPROt Inactivates the Oncogenic Fusion Protein BCR/ABL and
   Suppresses Transformation of K562 Cells (Retracted article. See vol.
   293, pg. 3589, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; RECEPTOR-TYPE-O;
   ABL TYROSINE KINASE; BCR-ABL; PHILADELPHIA-CHROMOSOME; TUMOR-SUPPRESSOR;
   SH3 DOMAIN; PHOSPHATASE; DIFFERENTIATION
AB Chronic myelogenous leukemia is typified by constitutive activation of the c-abl kinase as a result of its fusion to the breakpoint cluster region (BCR). Because the truncated isoform of proteintyrosine phosphatase receptor-type O (PTPROt) is specifically expressed in hematopoietic cells, we tested the possibility that it could potentially dephosphorylate and inactivate the fusion protein bcr/abl. Ectopic expression of PTPROt in the chronic myelogenous leukemia cell line K562 indeed resulted in hypophosphorylation of bcr/abl and reduced phosphorylation of its downstream targets CrkL and Stat5, confirming that PTPROt could inactivate the function of bcr/abl. Furthermore, the expression of catalytically active PTPROt in K562 cells caused reduced proliferation, delayed transition from G(0)/G(1) to S phase, loss of anchorage independent growth, inhibition of ex vivo tumor growth, and increased their susceptibility to apoptosis, affirming that this tyrosine phosphatase can revert the transformation potential of bcr/abl. Additionally, the catalytically inactive PTPROt acted as a trapping mutant that was also able to inhibit anchorage independence and facilitate apoptosis of K562 cells. The inhibitory action of PTPROt on bcr/abl was also confirmed in a murine myeloid cell line overexpressing bcr/abl. PTPROt expression was suppressed in K562 cells and was relieved upon treatment of the cells with 5-azacytidine, aninhibitor of DNA methyltransferase, with concomitant hypomethylation of the PTPRO CpG island. These data demonstrate that suppression of PTPROt by promoter methylation could contribute to the augmented phosphorylation and constitutive activity of its substrate bcr/abl and provide a potentially significant molecular therapeutic target for bcr/abl-positive leukemia.
C1 [Motiwala, Tasneem; Majumder, Sarmila; Ghoshal, Kalpana; Kutay, Huban; Datta, Jharna; Roy, Satavisha; Jacob, Samson T.] Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.
   [Lucas, David M.] Ohio State Univ, Coll Med, Dept Internal Med, Div Hematol Oncol, Columbus, OH 43210 USA.
   [Jacob, Samson T.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
RP Jacob, ST (reprint author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, 646B Tzagournis Med Res Facil,420 W 12th Ave, Columbus, OH 43210 USA.
EM Samson.Jacob@osumc.edu
FU National Institutes of Health [CA122695, CA101956, CA086978]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant CA122695, CA101956, and CA086978. The costs of publication
   of this article were defrayed in part by the payment of page charges.
   This article must therefore be hereby marked "advertisement" in
   accordance with 18 U. S. C. Section 1734 solely to indicate this fact.
CR Aguiar RCT, 1999, BLOOD, V94, P2403
   Amin HM, 2007, J PATHOL, V212, P402, DOI 10.1002/path.2178
   Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780
   Chen LF, 2006, BLOOD, V108, P3428, DOI 10.1182/blood-2006-03-013821
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902
   Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097
   Di Bacco A, 2000, Oncologist, V5, P405, DOI 10.1634/theoncologist.5-5-405
   Donato NJ, 2000, CLIN CANCER RES, V6, P2965
   Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561
   Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083
   Gorre ME, 2002, CURR OPIN HEMATOL, V9, P303, DOI 10.1097/00062752-200207000-00007
   Iervolino A, 2002, MOL CELL BIOL, V22, P2255, DOI 10.1128/MCB.22.7.2255-2266.2002
   Jacob ST, 2005, CANCER GENE THER, V12, P665, DOI 10.1038/sj.cgt.7700828
   Jacquel A, 2003, FASEB J, V17, P2160, DOI 10.1096/fj.03-0322fje
   Ju DS, 2007, CANCER LETT, V252, P75, DOI 10.1016/j.canlet.2006.12.013
   Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529
   Koschmieder S, 2007, BLOOD, V110, P3695, DOI 10.1182/blood-2006-11-058941
   Kurzrock R, 2003, ANN INTERN MED, V138, P819, DOI 10.7326/0003-4819-138-10-200305200-00010
   LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965
   LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094
   Liedtke M, 1998, ONCOGENE, V17, P1889, DOI 10.1038/sj.onc.1202117
   Lim YM, 2000, P NATL ACAD SCI USA, V97, P12233, DOI 10.1073/pnas.210253497
   Lowenberg B, 2003, NEW ENGL J MED, V349, P1399, DOI 10.1056/NEJMp038130
   MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587
   Meyn MA, 2006, J BIOL CHEM, V281, P30907, DOI 10.1074/jbc.M605902200
   Motiwala T, 2004, P NATL ACAD SCI USA, V101, P13844, DOI 10.1073/pnas.0405451101
   Motiwala T, 2003, ONCOGENE, V22, P6319, DOI 10.1038/sj.onc.1206750
   Motiwala T, 2007, CLIN CANCER RES, V13, P3174, DOI 10.1158/1078-0432.CCR-06-1720
   Motiwala T, 2006, PROG NUCLEIC ACID RE, V81, P297, DOI 10.1016/S0079-6603(06)81008-1
   Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015
   Nieborowska-Skorska M, 2002, BLOOD, V99, P4531, DOI 10.1182/blood.V99.12.4531
   Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754
   Peltola KJ, 2004, BLOOD, V103, P3744, DOI 10.1182/blood-2003-09-3126
   Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567
   RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286
   Rhodes J, 2000, EXP HEMATOL, V28, P305, DOI 10.1016/S0301-472X(99)00148-4
   Saglio G, 2004, CELL MOL LIFE SCI, V61, P2897, DOI 10.1007/s00018-004-4271-0
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575
   SEIMIYA H, 1995, ONCOGENE, V10, P1731
   Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464
   Sillaber C, 2000, BLOOD, V95, P2118
   Smith KM, 2003, MOL CELL, V12, P27, DOI 10.1016/S1097-2765(03)00274-0
   Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200
   Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241
   Thomas EK, 2007, CANCER CELL, V12, P467, DOI 10.1016/j.ccr.2007.10.015
   Van Etten RA, 2004, LEUKEMIA RES, V28, pS21, DOI 10.1016/j.leukres.2003.10.005
NR 48
TC 29
Z9 31
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 2
PY 2009
VL 284
IS 1
BP 455
EP 464
DI 10.1074/jbc.M802840200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 387TP
UT WOS:000261974800050
PM 18997174
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Mengistu, AM
   Mayer, J
   Boldt, J
   Rohm, KD
AF Mengistu, A. M.
   Mayer, J.
   Boldt, J.
   Roehm, K. D.
TI RETRACTED: Whole-blood aggregometry: are there any limits with regard to
   platelet counts? (Retracted article. See vol. 55, pg. 903, 2011)
SO ACTA ANAESTHESIOLOGICA SCANDINAVICA
LA English
DT Article; Retracted Publication
ID IN-VITRO; ELECTRICAL AGGREGOMETRY; RICH PLASMA; AGGREGATION; IMPEDANCE;
   HEMATOCRIT; DEVICE
AB Whole-blood aggregometry (WBA) is a promising tool to assess platelet function in its physiological environment. Dilution of whole blood in WBA disregards platelet concentrations that may impact the results, especially in the case of low platelet counts. In a blinded, prospective in vitro study, the influence of platelet concentrations on WBA was assessed.
   Aggregation studies were carried out using whole blood from 10 healthy volunteers adjusted to platelet concentrations of 150, 100, 75, 50 and 25/nl using a plasma-balanced crystalloid solution. Platelet aggregation was measured by a new near-side whole blood aggregometer, activated by adenosin-diphosphate, collagen and thrombin-receptor activating protein. Three different approaches were applied: P1: whole blood diluted by an isotonic saline solution before activation, P2: undiluted whole blood with the single and P3: with the twofold concentration of the stimulating agent.
   Aggregometry in diluted whole blood (P1) decreased significantly from a platelet concentration of 100/nl (P < 0.01). In undiluted whole blood, aggregation declined significantly from concentrations of 75 and 50/nl for P2 and P3 (P < 0.01). No correlation to platelet count occurred in the undiluted approaches until a platelet concentration of 75/nl, whereas correlation in the diluted test run was detected starting from 100/nl.
   This study demonstrates that WBA depends on the platelet count and sensitivity towards low platelet concentrations may be improved by abdication of further dilution and the use of undiluted whole blood.
C1 [Mengistu, A. M.; Mayer, J.; Boldt, J.; Roehm, K. D.] Klinikum Stadt Ludwigshafen, Dept Anaesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Mengistu, AM (reprint author), Klinikum Stadt Ludwigshafen, Dept Anaesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM a.mengistu@gmx.de
CR Boldt J, 2007, ANESTH ANALG, V104, P425, DOI 10.1213/01.ane.0000253484.19070.87
   BORN GVR, 1963, NATURE, V197, P974, DOI 10.1038/197974a0
   Breddin HK, 2005, PLATELETS, V16, P151, DOI 10.1080/09537100400020161
   CARDINAL DC, 1980, J PHARMACOL METHOD, V3, P135, DOI 10.1016/0160-5402(80)90024-8
   Cornell Robert F, 2002, Clin Lab Sci, V15, P30
   Dyszkiewicz-Korpanty AM, 2005, CLIN APPL THROMB-HEM, V11, P25, DOI 10.1177/107602960501100103
   Eugster M, 2005, THROMB HAEMOSTASIS, V94, P1213, DOI 10.1160/TH05-06-0424
   HUTTON RA, 1989, J CLIN PATHOL, V42, P858, DOI 10.1136/jcp.42.8.858
   INGERMANWOJENSKI C, 1983, J LAB CLIN MED, V101, P44
   MACKIE IJ, 1984, J CLIN PATHOL, V37, P874, DOI 10.1136/jcp.37.8.874
   Mani H, 2005, J CLIN PATHOL, V58, P747, DOI 10.1136/jcp.2004.022129
   McKenzie ME, 1999, CARDIOLOGY, V92, P240, DOI 10.1159/000006981
   MULLER MR, 1995, J PHARMACOL TOXICOL, V34, P17, DOI 10.1016/1056-8719(94)00075-F
   REININGER AJ, 1995, THROMB HAEMOSTASIS, V74, P853
   RIESS H, 1986, AM J CLIN PATHOL, V85, P50, DOI 10.1093/ajcp/85.1.50
   ROPERDREWINKO PR, 1981, AM J HEMATOL, V11, P183, DOI 10.1002/ajh.2830110210
   Scharbert G, 2007, ANESTH ANALG, V105, P885, DOI 10.1213/01.ane.0000270265.36079.2e
   Seyfert UT, 2007, PLATELETS, V18, P199, DOI 10.1080/09537100600944277
   SWEENEY JD, 1988, AM J CLIN PATHOL, V89, P655, DOI 10.1093/ajcp/89.5.655
   Toth O, 2006, THROMB HAEMOSTASIS, V96, P781, DOI 10.1160/TH06-05-0242
NR 20
TC 15
Z9 15
U1 2
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-5172
EI 1399-6576
J9 ACTA ANAESTH SCAND
JI Acta Anaesthesiol. Scand.
PD JAN
PY 2009
VL 53
IS 1
BP 72
EP 76
DI 10.1111/j.1399-6576.2008.01829.x
PG 5
WC Anesthesiology
SC Anesthesiology
GA 384YO
UT WOS:000261780300011
PM 19032554
DA 2018-12-27
ER

PT J
AU Jain, SL
   Joseph, JK
   Kuhn, FE
   Reiser, O
AF Jain, Suman L.
   Joseph, Jomy K.
   Kuehn, Fritz E.
   Reiser, Oliver
TI RETRACTED: An Efficient Synthesis of Poly(ethylene glycol)-Supported
   Iron(II) Porphyrin using a Click Reaction and its Application for the
   Catalytic Olefination of Aldehydes (Retracted article. See vol. 353, pg.
   1391, 2011)
SO ADVANCED SYNTHESIS & CATALYSIS
LA English
DT Article; Retracted Publication
DE click chemistry; iron; olefination; poly(ethylene glycol) (PEG);
   porphyrins; supported catalysts
ID SELECTIVE OLEFINATION; RECOVERABLE CATALYSTS; ETHYL DIAZOACETATE;
   POLYSTYRENE RESIN; ORGANIC-SYNTHESIS; TERMINAL ALKYNES; SOLUBLE
   POLYMERS; AZIDE-ALKYNE; CHEMISTRY; IMMOBILIZATION
AB The first successful synthesis of poly(ethylene glycol) (PEG) immobilized iron(II) porphyrin using a copper-catalyzed azide-alkyne [3 + 2] cycloaddition is reported. In contrast to the existing methods for the synthesis of PEG-immobilized metalloporphyrins, the click method offers better catalyst loading under comparatively mild reaction conditions. The prepared complex 5 (PEG-C(51)H(39)FeN(7)O) was found to be an efficient catalyst for the selective olefination of aldehydes with ethyl diazoacetate in the presence of triphenylphosphine and afforded excellent olefin yields with high (E) selectivities. The PEG-supported catalyst 5 was readily recovered by precipitation and filtration and was recycled for up to ten runs without significant loss of activity.
C1 [Joseph, Jomy K.; Kuehn, Fritz E.] Tech Univ Munich, CRC, D-85747 Garching, Germany.
   [Jain, Suman L.; Reiser, Oliver] Univ Regensburg, Inst Organ Chem, D-93053 Regensburg, Germany.
   [Jain, Suman L.; Joseph, Jomy K.] Indian Inst Petr, Chem & Biotechnol Div, Dehra Dun 248005, Uttar Pradesh, India.
RP Kuhn, FE (reprint author), Tech Univ Munich, CRC, Lichtenbergstr 4, D-85747 Garching, Germany.
EM fritz.kuehn@ch.tum.de; oliver.reiser@chemie.uni-regensburg.de
RI Kuhn, Fritz/A-3113-2010; Reiser, Oliver/B-7743-2008
OI Kuhn, Fritz/0000-0002-4156-780X; Reiser, Oliver/0000-0003-1430-573X
FU DST, New Delhi (India); DAAD, Germany; Alexander von Humboldt
   Foundation; Bavarian Elite Network NANOCAT
FX This work was supported by DST, New Delhi (India) and DAAD, Germany; as
   a Project based Personal Exchange Programme (PPP), the Alexander von
   Humboldt Foundation and the Bavarian Elite Network NANOCAT.
CR Bastero A, 2007, J ORG CHEM, V72, P2460, DOI 10.1021/jo0624952
   Benaglia M, 2003, CHEM REV, V103, P3401, DOI 10.1021/cr010440o
   Benaglia M, 2003, ORG BIOMOL CHEM, V1, P454, DOI 10.1039/b210985a
   Bergbreiter DE, 2002, CHEM REV, V102, P3345, DOI 10.1021/cr010343v
   COLLMAN JP, 1993, SCIENCE, V261, P1404, DOI 10.1126/science.8367724
   Dickerson TJ, 2002, CHEM REV, V102, P3325, DOI 10.1021/cr010335e
   Fernandez-Megia E, 2006, MACROMOLECULES, V39, P2113, DOI 10.1021/ma052448w
   Gheorghe A, 2006, SYNLETT, P2767, DOI 10.1055/s-2006-950256
   Gheorghe A, 2006, ADV SYNTH CATAL, V348, P1016, DOI 10.1002/adsc.200606043
   Gissibl A, 2005, ORG LETT, V7, P2325, DOI 10.1021/ol0505252
   Gissibl A, 2007, ORG LETT, V9, P2895, DOI 10.1021/ol071128p
   Gravert DJ, 1997, CHEM REV, V97, P489, DOI 10.1021/cr960064l
   HUISGEN R, 1989, PURE APPL CHEM, V61, P613, DOI 10.1351/pac198961040613
   Jain S, 2008, CHEMSUSCHEM, V1, P534, DOI 10.1002/cssc.200800025
   KALB HC, 2003, DRUG DISCOV TODAY, V8, P1128
   Kolb H. O, 2002, ANGEW CHEM, V114, P2708, DOI DOI 10.1002/1521-3757(20020715)114:14<2708::AID-ANGE2708>3.0.CO;2-0
   Kolb HC, 2003, DRUG DISCOV TODAY, V8, P1128, DOI 10.1016/S1359-6446(03)02933-7
   Kuhn FE, 2004, MINI-REV ORG CHEM, V1, P55, DOI 10.2174/1570193043488971
   Lee MY, 2003, ORGANOMETALLICS, V22, P4905, DOI 10.1021/om034115y
   Liu ST, 2007, TETRAHEDRON, V63, P1821, DOI 10.1016/j.tet.2006.12.029
   Maas G, 2004, CHEM SOC REV, V33, P183, DOI 10.1039/b309046a
   McNamara CA, 2002, CHEM REV, V102, P3275, DOI 10.1021/cr0103571
   MEUNIER B, 1992, CHEM REV, V92, P1411, DOI 10.1021/cr00014a008
   Mirafzal GA, 2002, J AM CHEM SOC, V124, P176, DOI 10.1021/ja016721v
   Muller P, 2003, CHEM REV, V103, P2905, DOI 10.1021/cr020043t
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4
   Ryu EH, 2005, ORG LETT, V7, P1035, DOI 10.1021/ol047468h
   Sakthivel A, 2006, CATAL COMMUN, V7, P302, DOI 10.1016/j.catcom.2005.11.017
   Severac M, 2007, TETRAHEDRON LETT, V48, P6518, DOI 10.1016/j.tetlet.2007.07.049
   Simonneaux G, 2004, J PORPHYR PHTHALOCYA, V8, P1166, DOI 10.1142/S1088424604000507
   Sun W, 2006, TETRAHEDRON LETT, V47, P1993, DOI 10.1016/j.tetlet.2006.01.055
   Sun W, 2005, APPL CATAL A-GEN, V285, P163, DOI 10.1016/j.apcata.2005.02.021
   Syukri S, 2007, TETRAHEDRON LETT, V48, P1613, DOI 10.1016/j.tetlet.2006.12.135
   Tornoe CW, 2002, J ORG CHEM, V67, P3057, DOI 10.1021/jo011148j
   TORNOE CW, 2001, AM PEPT S, P263
   Wang Q, 2003, J AM CHEM SOC, V125, P3192, DOI 10.1021/ja021381e
   Wang XY, 2006, CHEM COMMUN, P3933, DOI 10.1039/b609382e
   Wu P, 2005, CHEM COMMUN, P5775, DOI 10.1039/b512021g
   Xia QH, 2005, CHEM REV, V105, P1603, DOI 10.1021/cr0406458
   Zhang JL, 2006, CHEM-EUR J, V12, P3020, DOI 10.1002/chem.200501510
   Zhang JL, 2002, ORG LETT, V4, P1911, DOI 10.1021/ol0259138
NR 41
TC 17
Z9 17
U1 4
U2 36
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1615-4150
J9 ADV SYNTH CATAL
JI Adv. Synth. Catal.
PD JAN
PY 2009
VL 351
IS 1-2
BP 230
EP 234
DI 10.1002/adsc.200800361
PG 5
WC Chemistry, Applied; Chemistry, Organic
SC Chemistry
GA 404OW
UT WOS:000263163900027
DA 2018-12-27
ER

PT J
AU Jain, N
   Jain, GK
   Iqbal, Z
   Talegaonkar, S
   Ahmad, FJ
   Khar, RK
AF Jain, Nilu
   Jain, Gaurav Kumar
   Iqbal, Zeenat
   Talegaonkar, Sushma
   Ahmad, Farhan Jalees
   Khar, Roop Krishen
TI RETRACTED: An HPTLC Method for the Determination of Minocycline in Human
   Plasma, Saliva, and Gingival Fluid after Single Step Liquid Extraction
   (Retracted article. See vol 25, pg 950, 2009)
SO ANALYTICAL SCIENCES
LA English
DT Article; Retracted Publication
ID CHROMATOGRAPHY; THERAPY
AB A rapid, sensitive and specific high-performance thin-layer chromatographic (HPTLC) method was developed and validated for determination of minocycline in human plasma, saliva, and gingival fluid samples. Densitometric analysis of minocycline was carried out at 345 nm after single step extraction with methanol. The method uses TLC aluminium plates pre-coated with silica gel 60F-254 as a stationary phase and methanol-acetonitrile-isopropyl alcohol-water (5:4:0.5:0.5, v/v/v/v) as mobile phase. In all the three matrices, the calibration curve was linear (r(2) >= 0.9958) in the tested range of 100 - 1200 ng spot(-1) with a limit of quantification of 15.4 ng spot(-1). Drug recovery from plasma, saliva and gingival fluid averaged 97.7%. Intra- and inter-day accuracies, determined at three different concentrations, were 95.08 to 100.6% and the corresponding precision (% CV) values were < 4.61%. In all the three matrices, rapid degradation of drug occurred and the half-life of drug ranged from 9.9 to 16.1 h at 4 degrees C and from 6.3 to 11.5 h at 20 degrees C. Frozen at -20 degrees C, this drug was stable for at least 2 months and can tolerate two freeze-thaw cycles without losses higher than 10%. The method's ability to quantify minocycline with precision, accuracy and sensitivity makes it useful in pharmacokinetic studies.
C1 [Jain, Nilu; Jain, Gaurav Kumar; Iqbal, Zeenat; Talegaonkar, Sushma; Ahmad, Farhan Jalees; Khar, Roop Krishen] Jamia Hamdard, Fac Pharm, Dept Pharmaceut, New Delhi 110062, India.
RP Jain, N (reprint author), Jamia Hamdard, Fac Pharm, Dept Pharmaceut, New Delhi 110062, India.
EM jneelu78@yahoo.com
RI Talegaonkar, Sushama/B-9752-2018
OI Talegaonkar, Sushama/0000-0001-5301-5298; Ahmad,
   Farhan/0000-0002-0740-8573
CR Araujo MVF, 2001, J CHROMATOGR B, V755, P1, DOI 10.1016/S0378-4347(00)00472-2
   BOCKER RH, 1991, J CHROMATOGR-BIOMED, V568, P363, DOI 10.1016/0378-4347(91)80174-B
   Colovic M, 2003, J CHROMATOGR B, V791, P337, DOI 10.1016/S1570-0232(03)00247-2
   FREEMAN CD, 1994, INT J ANTIMICROB AG, V4, P325, DOI 10.1016/0924-8579(94)90034-5
   Greenstein Gary, 2004, Dent Today, V23, P110
   Jain N, 2007, ANAL CHIM ACTA, V599, P302, DOI 10.1016/j.aca.2007.08.020
   KRASSE BO, 1962, ACTA ODONTOL SCAND, V20, P143, DOI 10.3109/00016356209026102
   Mascher HJ, 1998, J CHROMATOGR A, V812, P339, DOI 10.1016/S0021-9673(98)00402-6
   MOORE WEC, 1987, J PERIODONTAL RES, V22, P335, DOI 10.1111/j.1600-0765.1987.tb01595.x
   Orti V, 2000, J CHROMATOGR B, V738, P357, DOI 10.1016/S0378-4347(99)00547-2
   Persson GR, 2006, CLIN ORAL IMPLAN RES, V17, P386, DOI 10.1111/j.1600-0501.2006.01269.x
   SAIVIN S, 1988, CLIN PHARMACOKINET, V15, P355, DOI 10.2165/00003088-198815060-00001
   SLOTS J, 1990, J CLIN PERIODONTOL, V17, P479
   WAERHAUG J, 1978, J PERIODONTOL, V49, P119, DOI 10.1902/jop.1978.49.3.119
   Wilder Rebecca S, 2003, Tex Dent J, V120, P984
   Wrightson WR, 1998, J CHROMATOGR B, V706, P358, DOI 10.1016/S0378-4347(97)00647-6
NR 16
TC 6
Z9 7
U1 4
U2 16
PU JAPAN SOC ANALYTICAL CHEMISTRY
PI TOKYO
PA 26-2 NISHIGOTANDA 1 CHOME SHINAGAWA-KU, TOKYO, 141, JAPAN
SN 0910-6340
EI 1348-2246
J9 ANAL SCI
JI Anal. Sci.
PD JAN
PY 2009
VL 25
IS 1
BP 57
EP 62
DI 10.2116/analsci.25.57
PG 6
WC Chemistry, Analytical
SC Chemistry
GA 396IS
UT WOS:000262586000008
PM 19139573
OA Bronze
DA 2018-12-27
ER

PT J
AU Song, HA
   Dadwal, M
   Lee, Y
   Mick, E
   Chong, HS
AF Song, Hyun A.
   Dadwal, Manita
   Lee, Yeseid
   Mick, Emily
   Chong, Hyun-Soon
TI RETRACTED: Stable Aziridinium Salts as Versatile Intermediates:
   Isolation and Regio- and Stereoselective Ring-Opening and Rearrangement
   (Retracted article. See vol. 49, pg. 9311, 2010)
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article; Retracted Publication
DE aziridinium ions; rearrangement; regioselectivity; strained molecules
ID BETA-AMINO; ION; DERIVATIVES; DIAMINES; CHLORIDE; ESTERS
C1 [Song, Hyun A.; Dadwal, Manita; Lee, Yeseid; Mick, Emily; Chong, Hyun-Soon] IIT, Biol Chem & Phys Sci Dept, Div Chem, Chicago, IL 60616 USA.
RP Chong, HS (reprint author), IIT, Biol Chem & Phys Sci Dept, Div Chem, Chicago, IL 60616 USA.
EM chong@iit.edu
FU U.S. National Institutes of Health [R01A112503-01A2]; Kilpatrick
   fellowship
FX This work was supported in part by a research grant from the U.S.
   National Institutes of Health (R01A112503-01A2). H.A.S. is the recipient
   of the Kilpatrick fellowship 2007-2008.
CR Anderson JC, 2007, ORG BIOMOL CHEM, V5, P2413, DOI 10.1039/b705081j
   Chong HS, 2002, J CHEM SOC PERK T 1, P2080, DOI 10.1039/b204677f
   Chuang TH, 1999, ORG LETT, V1, P1435, DOI 10.1021/ol990256d
   Concellon JM, 2004, ORG LETT, V6, P4499, DOI 10.1021/ol048176j
   Couturier C, 2006, ORG LETT, V8, P2183, DOI 10.1021/ol060700u
   D'hooghe M, 2006, CHEM COMMUN, P1554, DOI 10.1039/b518298k
   D'hooghe M, 2007, J ORG CHEM, V72, P4733, DOI 10.1021/jo0704210
   de Sousa SE, 1998, J CHEM SOC PERK T 1, P1483, DOI 10.1039/a800550h
   Graham MA, 2001, CHEM COMMUN, P966, DOI 10.1039/b102124i
   HUH N, 1992, BIOORG MED CHEM LETT, V2, P1551, DOI 10.1016/S0960-894X(00)80426-6
   JONES GB, 1995, BIOORG MED CHEM LETT, V5, P93, DOI 10.1016/0960-894X(94)00465-R
   Katagiri T, 1999, J ORG CHEM, V64, P7323, DOI 10.1021/jo990207e
   LEONARD NJ, 1965, J ORG CHEM, V30, P821, DOI 10.1021/jo01014a040
   LILLOCCI C, 1988, J ORG CHEM, V53, P1733, DOI 10.1021/jo00243a025
   LIU QY, 1994, J CHEM SOC PERK T 1, P1363, DOI 10.1039/p19940001363
   Lucet D, 1998, ANGEW CHEM INT EDIT, V37, P2581, DOI 10.1002/(SICI)1521-3773(19981016)37:19<2580::AID-ANIE2580>3.0.CO;2-L
   Lucet D., 1998, ANGEW CHEM, V110, P2724
   O'Brien P, 2002, J ORG CHEM, V67, P304, DOI 10.1021/jo010824e
   RINGDAHL B, 1990, J MED CHEM, V33, P281, DOI 10.1021/jm00163a046
   RINK SM, 1993, J AM CHEM SOC, V115, P2551, DOI 10.1021/ja00060a001
   Weber K, 2000, ORG LETT, V2, P647, DOI 10.1021/ol991402i
NR 21
TC 9
Z9 9
U1 2
U2 13
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PY 2009
VL 48
IS 7
BP 1328
EP 1330
DI 10.1002/anie.200805244
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 409FU
UT WOS:000263492400027
PM 19142922
DA 2018-12-27
ER

PT J
AU Solowiej, E
   Solowiej, J
   Kasprzycka-Guttman, T
   Rowinski, W
AF Solowiej, Ewa
   Solowiej, Jaroslaw
   Kasprzycka-Guttman, Teresa
   Rowinski, Wojciech
TI RETRACTED: Application of sulforaphane-does it lead to improvement of
   islet graft survival after warm and/or cold ischemia (Retracted Article)
SO ANNALS OF TRANSPLANTATION
LA English
DT Correction; Retracted Publication
CR Solowiej Ewa, 2004, Ann Transplant, V9, P68
NR 1
TC 0
Z9 0
U1 1
U2 10
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1425-9524
J9 ANN TRANSPL
JI Ann. Transpl.
PD JAN-MAR
PY 2009
VL 14
IS 1
BP 56
EP 56
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 435HD
UT WOS:000265333800010
DA 2018-12-27
ER

PT J
AU Lyvers, M
AF Lyvers, Michael
TI RETRACTED: Instance of misrepresentation: James (2005) (Retracted
   article. See vol. 62, pg. 236, 2010)
SO AUSTRALIAN JOURNAL OF PSYCHOLOGY
LA English
DT Article; Retracted Publication
DE Biochemical correlates of behaviour; neuropsychology and other
   biological issues; psychopharmacology; substance abuse and addiction
ID CAFFEINE
AB James (2005) misrepresented and misinterpreted several aspects of the report by Lyvers, Brooks, and Matica (2004) on cognitive and psychophysiological effects of caffeine. Lyvers et al. did not claim that an alcohol breath test is a test of caffeine levels. The apparent enhancement effect of caffeine on neuropsychological performance, obtained in light users but not heavy users, was unlikely to be accounted for by reversal of withdrawal-induced deficits.
C1 Bond Univ, Dept Psychol, Gold Coast, Qld 4229, Australia.
RP Lyvers, M (reprint author), Bond Univ, Dept Psychol, Gold Coast, Qld 4229, Australia.
EM mlyvers@staff.bond.edu.au
CR James JE, 2005, AUST J PSYCHOL, V57, P197, DOI 10.1080/00049530500125090
   Lyvers M, 2004, AUST J PSYCHOL, V56, P33, DOI 10.1080/00049530410001688119
NR 2
TC 0
Z9 0
U1 2
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-9530
EI 1742-9536
J9 AUST J PSYCHOL
JI Aust. J. Psychol.
PY 2009
VL 61
IS 2
BP 117
EP 118
AR PII 910040007
DI 10.1080/00049530902758621
PG 2
WC Psychology, Multidisciplinary
SC Psychology
GA 441UT
UT WOS:000265796700007
DA 2018-12-27
ER

PT J
AU Parsian, H
   Nouri, M
   Somi, MH
   Rahimipour, A
   Qujeq, D
   Fard, MK
   Agcheli, K
   Majidi, G
AF Parsian, Hadi
   Nouri, Mohammad
   Somi, Mohammad Hossein
   Rahimipour, Ali
   Qujeq, Durdi
   Fard, Mehrdad Kashi
   Agcheli, Karim
   Majidi, Golnar
TI RETRACTED: Relationship between serum hyaluronic acid level and stage of
   liver fibrosis in patients with chronic hepatitis (Retracted article.
   See vol. 22, pg. 259, 2012)
SO BIOCHEMIA MEDICA
LA English
DT Article; Retracted Publication
DE chronic hepatitis; hepatic inflammation grade; hepatic fibrosis stage;
   hyaluronic acid
ID HISTOLOGICAL ACTIVITY; CLINICAL-SIGNIFICANCE; SCORING SYSTEM; C
   PATIENTS; MARKERS; CIRRHOSIS; PROGRESSION; DISEASE; LAMININ; TESTS
AB Background: Liver biopsy is the gold standard for assessing liver disease stage, but it is prone to some complications. Noninvasive methods have been proposed as surrogate markers for liver biopsy. Serum hyaluronic acid (HA) level has been shown to increase with the development of liver fibrosis. The aim of this study was to determine differences in HA concentration between patients with liver fibrosis and healthy individuals without any signs of liver disease, and the optimal cut-off value for discrimination between the two study groups of Iranian population.
   Materials and methods: Serum HA levels in chronic hepatitis patients (N = 62) and controls (N = 20) were compared by ELISA, while the stage of fibrosis was assessed by the modified Knodell score.
   Results: The mean serum HA concentrations was higher in patients (113.4 +/- 59.2ng/mL) than in the control group (46.0 +/- 10.5ng/mL; P < 0.001). Patients with higher stages and grades of liver necroinflammatory injuries had higher serum HA concentrations. Differences in serum HA concentrations were statistically significant in all fibrosis stages as compared to healthy controls (P < 0.05). The cut-off point of serum HA concentration identified (59.5 ng/mL) showed a reasonably good sensitivity (82.3%) and specificity (85%).
   Conclusions: There was a strong correlation between serum HA concentration and the grade of liver necroinflammatory injury. Our findings suggested serum HA concentration increases above the predictive value to be associated with liver fibrosis and could be used as a noninvasive marker to discriminate between patients with liver fibrosis and healthy individuals.
C1 [Parsian, Hadi; Nouri, Mohammad; Rahimipour, Ali] Tabriz Univ Med Sci, Dept Clin Biochem, Tabriz, Iran.
   [Somi, Mohammad Hossein; Majidi, Golnar] Tabriz Univ Med Sci, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran.
   [Qujeq, Durdi] Babol Univ Med Sci, Dept Biochem & Biophys, Babol Sar, Iran.
   [Fard, Mehrdad Kashi] Babol Univ Med Sci, Yahya Nezhad Hosp, Babol Sar, Iran.
   [Agcheli, Karim] Golestan Univ Med Sci, Gastroenterol Res Ctr, Gorgan, Iran.
RP Nouri, M (reprint author), Tabriz Univ Med Sci, Dept Clin Biochem, Daneshgah Ave, Tabriz, Iran.
EM nourimd2@yahoo.com
RI Parsian, Hadi/H-7825-2017
OI Rahimipour, Ali/0000-0002-5577-9619; parsian, Hadi/0000-0002-3965-7566
CR Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   [蔡卫民 Cai Weimin], 2004, [中华肝脏病杂志, Chinese Journal of Hepatology], V12, P219
   Collier JD, 2005, J VIRAL HEPATITIS, V12, P74, DOI 10.1111/j.1365-2893.2005.00598.x
   Fontana RJ, 2002, HEPATOLOGY, V36, pS57, DOI 10.1053/jhep.2002.36800
   Forns X, 2002, HEPATOLOGY, V36, P986, DOI 10.1053/jhep.2002.36128
   Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247
   Geramizadeh Bita, 2008, Saudi J Gastroenterol, V14, P174, DOI 10.4103/1319-3767.43274
   GRESSNER AM, 1990, SEMIN LIVER DIS, V10, P30, DOI 10.1055/s-2008-1040455
   Gressner OA, 2007, CLIN CHIM ACTA, V381, P107, DOI 10.1016/j.cca.2007.02.038
   GUECHOT J, 1995, J HEPATOL, V22, P103
   Halfon Philippe, 2005, Comp Hepatol, V4, P6, DOI 10.1186/1476-5926-4-6
   HUGUET J, 1993, SCAND J CLIN LAB INV, V53, P693, DOI 10.3109/00365519309092573
   ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6
   KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511
   Korner T, 1996, J HEPATOL, V25, P684, DOI 10.1016/S0168-8278(96)80239-X
   Korner T, 2003, J HEPATOL, V39, P947, DOI 10.1016/S0168-8278(03)00431-8
   KUPCOVA V, 2004, PHYSL RES, V53
   Lebensztejn DM, 2007, HEPATO-GASTROENTEROL, V54, P834
   Mason R M, 1981, Prog Clin Biol Res, V54, P87
   MCHUTCHISON JG, 2000, J GASTROEN HEPATOL, V15, P819
   Montazeri G, 2005, BMC GASTROENTEROL, V5, DOI 10.1186/1471-230X-5-32
   Murawaki Y, 1996, J GASTROEN HEPATOL, V11, P459, DOI 10.1111/j.1440-1746.1996.tb00291.x
   Murawaki Y, 2001, J GASTROENTEROL, V36, P399, DOI 10.1007/s005350170084
   Ninomiya T, 1998, J GASTROEN HEPATOL, V13, P68, DOI 10.1111/j.1440-1746.1998.tb00548.x
   Pilette C, 1998, J HEPATOL, V28, P439, DOI 10.1016/S0168-8278(98)80318-8
   Raslich MA, 2007, BIOCHEM MEDICA, V17, P151
   Stickel F, 2003, EUR J GASTROEN HEPAT, V15, P945, DOI 10.1097/01.meg.0000059174.46867.c2
   Tao J, 2003, WORLD J GASTROENTERO, V9, P2497
   Wong CSM, 1998, J GASTROEN HEPATOL, V13, P1218, DOI 10.1046/j.1440-1746.1998.01785.x
   Xie S, 2001, Zhonghua Gan Zang Bing Za Zhi, V9, P334
   Yuschuk ND, 2005, TERAPEVT ARKH, V77, P50
   Zhang YX, 2008, WORLD J GASTROENTERO, V14, P7117, DOI 10.3748/wjg.14.7117
   Zheng M, 2002, WORLD J GASTROENTERO, V8, P1073, DOI 10.3748/wjg.v8.i6.1073
   ZWEIG MH, 1993, CLIN CHEM, V39, P561
NR 34
TC 2
Z9 2
U1 2
U2 8
PU CROATIAN SOC MEDICAL BIOCHEMISTS
PI ZAGREB
PA DOMAGOJEVA 2, ZAGREB, 10000, CROATIA
SN 1330-0962
EI 1846-7482
J9 BIOCHEM MEDICA
JI Biochem. Medica.
PY 2009
VL 19
IS 2
BP 154
EP 165
PG 12
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 460VV
UT WOS:000267220300005
DA 2018-12-27
ER

PT J
AU Bennaceur, K
   Chapman, JA
   Touraine, JL
   Portoukalian, J
AF Bennaceur, Karim
   Chapman, Jessica Alice
   Touraine, Jean-louis
   Portoukalian, Jacques
TI RETRACTED: Immunosuppressive networks in the tumour environment and
   their effect in dendritic cells (Retracted article. See vol. 1835, pg.
   259, 2013)
SO BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
LA English
DT Review; Retracted Publication
DE Tumour escape; Dendritic cell; immune dysfunction; Tumour
   microenvironment
ID ENDOTHELIAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; ANTIGEN-PRESENTING
   FUNCTION; ANTITUMOR IMMUNE-RESPONSES; MYELOID SUPPRESSOR-CELLS; HUMAN
   PERIPHERAL-BLOOD; T-REGULATORY CELLS; BONE-MARROW; IN-VIVO;
   MULTIPLE-MYELOMA
AB The failure of the immune system to provide protection against turnout cells is an important immunological problem. It is now evident that inadequate function of the host immune system is one of the main mechanisms by which tumours escape from immune control, as well as an important factor that limits the success of cancer immunotherapy. In recent years, it has become increasingly clear that defects in dendritic cells have a crucial role in non-responsiveness to tumours. This article focuses on the functional consequences and recently described mechanisms of the dendritic-cell defects in cancer. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Bennaceur, Karim; Touraine, Jean-louis] Univ Lyon 1, Dept Transplantat & Clin Immunol, F-69365 Lyon, France.
   [Touraine, Jean-louis; Portoukalian, Jacques] Univ Lyon 1, Hop Edouard Herriot, Dept R, Lab Dermatol Res,EA 41 69, F-69437 Lyon 03, France.
   [Chapman, Jessica Alice] Univ Manchester, Fac Life Sci, Manchester M13 9PL, Lancs, England.
RP Bennaceur, K (reprint author), Univ Lyon 1, Dept Transplantat & Clin Immunol, F-69365 Lyon, France.
EM bennaceur.karim@yahoo.fr
CR Armstrong TD, 1998, CANCER IMMUNOL IMMUN, V46, P70, DOI 10.1007/s002620050463
   Baetz A, 2004, J BIOL CHEM, V279, P54708, DOI 10.1074/jbc.M410992200
   Bahlis NJ, 2007, BLOOD, V109, P5002, DOI 10.1182/blood-2006-03-012542
   BANCHEREAU SRM, 1998, NATURE, V392, P245
   BEISSERT S, 1995, J IMMUNOL, V154, P1280
   Bell D, 1999, J EXP MED, V190, P1417, DOI 10.1084/jem.190.10.1417
   Bennaceur K, 2006, INT IMMUNOL, V18, P879, DOI 10.1093/intimm/dxl024
   Bergers G, 2000, NAT CELL BIOL, V2, P737
   Birkle S, 2003, BIOCHIMIE, V85, P455, DOI 10.1016/S0300-9084(03)00006-3
   Blanco P, 2001, SCIENCE, V294, P1540, DOI 10.1126/science.1064890
   BLATTMAN GP, 2004, SCIENCE, V283, P1183
   Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476
   Bronte V, 1999, J IMMUNOL, V162, P5728
   CAUX C, 1994, INT IMMUNOL, V6, P1177, DOI 10.1093/intimm/6.8.1177
   Chauveau C, 2005, BLOOD, V106, P1694, DOI 10.1182/blood-2005-02-0494
   Cheng FD, 2003, IMMUNITY, V19, P425, DOI 10.1016/S1074-7613(03)00232-2
   Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141
   Coukos G, 2005, BRIT J CANCER, V92, P1182, DOI 10.1038/sj.bjc.6602476
   Curiel TJ, 2004, CANCER RES, V64, P5535, DOI 10.1158/0008-5472.CAN-04-1272
   Della Bella S, 2003, BRIT J CANCER, V89, P1463, DOI 10.1038/sj.bjc.6601243
   Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t
   Diacovo TG, 2005, J EXP MED, V202, P687, DOI 10.1084/jem.20051035
   DMITRY VB, 2008, CANC RES, V67
   DOLCETTIA IML, 2008, CANC LETT
   Duarte RF, 2000, MED CLIN-BARCELONA, V114, P227, DOI 10.1016/S0025-7753(00)71252-8
   Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037
   Ellis LM, 1996, EUR J CANCER, V32A, P2451, DOI 10.1016/S0959-8049(96)00389-9
   ENK AH, 1993, J IMMUNOL, V151, P2390
   FACCHETTI DWPC, 1989, AM J CLIN PATHOL, V92, P41
   Furumoto K, 2004, J CLIN INVEST, V113, P774, DOI 10.1172/JCI200419762
   Gabrilovich D, 1998, BLOOD, V92, P4150
   Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096
   Gabrilovich DI, 1996, CELL IMMUNOL, V170, P111, DOI 10.1006/cimm.1996.0140
   Gately S, 2004, SEMIN ONCOL, V31, P2, DOI 10.1016/j.semincol.2004.03.040
   Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463
   Ghiringhelli F, 2007, CURR OPIN IMMUNOL, V19, P224, DOI 10.1016/j.coi.2007.02.003
   Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303
   Grabbe S, 2000, IMMUNOL TODAY, V21, P431, DOI 10.1016/S0167-5699(00)01694-7
   GREENBERG CYP, 2002, NATURE REV CANC, V2, P409
   Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101
   Hakomori S, 2003, CURR OPIN HEMATOL, V10, P16, DOI 10.1097/00062752-200301000-00004
   HALLIDAY GM, 1992, IMMUNOLOGY, V77, P13
   Handley ME, 2005, FREE RADICAL BIO MED, V38, P1637, DOI 10.1016/j.freeabbiomed.2005.02.022
   HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0
   Harshyne LA, 2001, J IMMUNOL, V166, P3717, DOI 10.4049/jimmunol.166.6.3717
   Harshyne LA, 2003, J IMMUNOL, V170, P2302, DOI 10.4049/jimmunol.170.5.2302
   HUANG AYC, 1994, CIBA F SYMP, V187, P229
   Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472CAN-05-1299
   Huang J, 2005, CANCER RES, V65, P8461, DOI 10.1158/0008-5472.CAN-05-0654
   Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3
   Jackson SH, 2004, J IMMUNOL, V172, P2307, DOI 10.4049/jimmunol.172.4.2307
   JOHN XZ, 2006, NATURE, V442
   Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x
   Kriehuber E, 2005, BLOOD, V106, P175, DOI 10.1182/blood-2004-08-3072
   KRUGERKRASAGAKES S, 1994, BRIT J CANCER, V70, P1182, DOI 10.1038/bjc.1994.469
   Kukreja A, 2007, BRIT J HAEMATOL, V136, P106, DOI 10.1111/j.1365-2141.2006.06369.x
   Kukreja A, 2006, J EXP MED, V203, P1859, DOI 10.1084/jem.20052136
   Kusmartsev S, 2006, CANCER METAST REV, V25, P323, DOI 10.1007/s10555-006-9002-6
   Ladanyi A, 2007, CANCER IMMUNOL IMMUN, V56, P1459, DOI 10.1007/s00262-007-0286-3
   Langrish CL, 2004, IMMUNOL REV, V202, P96, DOI 10.1111/j.0105-2896.2004.00214.x
   Lee WC, 1998, TRANSPLANTATION, V66, P1810, DOI 10.1097/00007890-199812270-00040
   Lissoni P, 2001, J BIOL REG HOMEOS AG, V15, P140
   Mellor AL, 2003, J IMMUNOL, V171, P1652, DOI 10.4049/jimmunol.171.4.1652
   Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457
   Menetrier-Caux C, 1998, BLOOD, V92, P4778
   Mirza N, 2006, CANCER RES, V66, P9299, DOI 10.1158/0008-5472.CAN-06-1690
   Monti P, 2004, J IMMUNOL, V172, P7341, DOI 10.4049/jimmunol.172.12.7341
   Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514
   Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1
   Nefedova Y, 2005, CANCER RES, V65, P9525, DOI 10.1158/0008-5472.CAN-05-0529
   Nefedova Y, 2004, J IMMUNOL, V172, P464, DOI 10.4049/jimmunol.172.1.464
   NEFEDOVA Y, 2004, J IMMUNOL, V172, P467
   Nosaka T, 2000, INT J HEMATOL, V71, P309
   O'Neill DW, 2004, BLOOD, V104, P2235, DOI 10.1182/blood-2003-12-4392
   Ohm JE, 1999, J IMMUNOL, V163, P3260
   Park SJ, 2004, J IMMUNOL, V173, P3844, DOI 10.4049/jimmunol.173.6.3844
   Peguet-Navarro J, 2003, J IMMUNOL, V170, P3488, DOI 10.4049/jimmunol.170.7.3488
   Pillarisetty VG, 2005, J IMMUNOL, V174, P2612, DOI 10.4049/jimmunol.174.5.2612
   Poindexter NJ, 2004, BREAST CANCER RES, V6, pR408, DOI 10.1186/bcr808
   PORTOUKALIAN J, 1979, EUR J BIOCHEM, V94, P19, DOI 10.1111/j.1432-1033.1979.tb12866.x
   Pries R, 2006, EXPERT REV ANTICANC, V6, P1195, DOI 10.1586/14737140.6.9.1195
   Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609
   Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925
   Ratta M, 2002, BLOOD, V100, P230, DOI 10.1182/blood.V100.1.230
   RISSOAN SP, 1999, SCIENCE, V283, P1183
   Saito H, 1998, BRIT J CANCER, V78, P1573, DOI 10.1038/bjc.1998.725
   Sato K, 2000, J IMMUNOL, V164, P2285, DOI 10.4049/jimmunol.164.5.2285
   Serafini P, 2004, CANCER RES, V64, P6337, DOI 10.1158/0008-5472.CAN-04-0757
   Sharma S, 2003, CLIN CANCER RES, V9, P961
   Sharma S, 1999, J IMMUNOL, V163, P5020
   Shim KS, 1999, CANCER-AM CANCER SOC, V85, P554, DOI 10.1002/(SICI)1097-0142(19990201)85:3<554::AID-CNCR6>3.0.CO;2-X
   Shurin GV, 2001, CANCER RES, V61, P363
   SINHA CV, 2006, CANCER RES, V65, P11743
   Sombroek CC, 2002, J IMMUNOL, V168, P4333, DOI 10.4049/jimmunol.168.9.4333
   Spits H, 2007, IMMUNITY, V26, P11, DOI 10.1016/j.immuni.2007.01.004
   Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241
   Steinbrink K, 1997, J IMMUNOL, V159, P4772
   Steinbrink K, 1999, BLOOD, V93, P1634
   STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415
   STENE MA, 1988, J INVEST DERMATOL, V91, P125, DOI 10.1111/1523-1747.ep12464142
   Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356
   TAS MPR, 1993, CANCER IMMUNOL IMMUN, V36, P108, DOI 10.1007/BF01754410
   Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365-2567.2006.02321.x
   THURNHER M, 1996, INT J CANCER, V67, P1
   Toi M, 1996, CANCER, V77, P1101, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1101::AID-CNCR15>3.0.CO;2-5
   TORIYAMA WD, 1993, J INVEST DERMATOL, V100, pS269
   Troy AJ, 1999, J UROLOGY, V161, P1962, DOI 10.1016/S0022-5347(05)68864-7
   Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336
   Wang IM, 2004, MOL IMMUNOL, V41, P873, DOI 10.1016/j.molimm.2004.04.027
   Wesa AK, 2008, CELL DEATH DIFFER, V15, P51, DOI 10.1038/sj.cdd.4402243
   Wojas K, 2004, FOLIA HISTOCHEM CYTO, V42, P45
   Yamaguchi Y, 1997, STEM CELLS, V15, P144, DOI 10.1002/stem.150144
   Yang L, 2003, J CLIN INVEST, V111, P727, DOI 10.1172/JCI200316492
   Yang RC, 2006, CANCER RES, V66, P6807, DOI 10.1158/0008-5472.CAN-05-3755
   YOUNG MRI, 1991, CANCER IMMUNOL IMMUN, V33, P146, DOI 10.1007/BF01756134
   Zou WP, 2001, NAT MED, V7, P1339, DOI 10.1038/nm1201-1339
   1995, FREE RADIC BIOL MED, V18, P775
NR 117
TC 31
Z9 37
U1 5
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-419X
J9 BBA-REV CANCER
JI Biochim. Biophys. Acta-Rev. Cancer
PD JAN
PY 2009
VL 1795
IS 1
BP 16
EP 24
DI 10.1016/j.bbcan.2008.07.001
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Oncology
SC Biochemistry & Molecular Biology; Biophysics; Oncology
GA 401CY
UT WOS:000262917200002
PM 18675885
DA 2018-12-27
ER

PT J
AU Sun, LM
   Lv, BB
   Cheng, AX
   Wu, XZ
   Lou, HX
AF Sun, Ling Mei
   Lv, Bel Bei
   Cheng, Ai Xia
   Wu, Xiu Zhen
   Lou, Hong Xiang
TI RETRACTED: The Effect of Plagiochin E Alone and in Combination with
   Fluconazole on the Ergosterol Biosynthesis of Candida albicans
   (Retracted Article. See vol 32, pg 1135, 2009)
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article; Retracted Publication
DE Plagiochin E; Candida albicans; real-time polymerase chain reaction; gas
   chromatography-high resolution mass spectrometry; ergosterol
   biosynthesis pathway
ID SACCHAROMYCES-CEREVISIAE; RESISTANCE; ANTIFUNGAL; AZOLES; DRUG;
   ITRACONAZOLE; ACCUMULATION; EXPRESSION; KRUSEI
AB Plagiochin E (PLE), a macrocyclic bis(bibenzyl) isolated from the liverwort Marchantia polymorpha, has been reported to have antifungal activity and resistance reversal effects on Candida albicans. In order to understand the underlying mechanisms, we studied the effects of PLE alone and in combination with fluconazole (FLC) on the ergosterol biosynthetic pathway against both FLC-sensitive and FLC-resistant strains by analyzing the sterol content and the ergosterol pathway gene (ERG) expression. Relative quantitative analysis of different ergosterol precursors was carried out by employing the hyphenated technique of gas chromatography-high resolution mass spectrometry (GC-HR-MS). We observed that for FLC-resistant strain PILE itself can cause the accumulation of lanosterol and the decrease of 14 a-m ethyl fecosterol. When it combined with FLC, a significant decrease was observed in ergosterol formation and corresponding accumulation of 14 alpha-methylated sterols was also found. Real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis revealed that the transcription level of ERG11 was decreased in FLC-resistant strain when exposed to PLE alone or PLE plus FLC. These results suggest that PLE potentiates FLC antifungal activity by interfering with the FLC-targeted ergosterol biosynthesis pathway.
C1 [Sun, Ling Mei; Lv, Bel Bei; Cheng, Ai Xia; Wu, Xiu Zhen; Lou, Hong Xiang] Shandong Univ, Sch Pharmaceut Sci, Jinan 250012, Peoples R China.
RP Lou, HX (reprint author), Shandong Univ, Sch Pharmaceut Sci, 44 W Wenhua Rd, Jinan 250012, Peoples R China.
EM louhongxiang@sdu.edu.cn
FU National Natural Science Foundation of China [30730109, 30672531];
   Special Foundation for State Major Basic Research Program of China
   [2006CB708511]
FX The authors are grateful to Professor Sun ShuJuan of Qianfoshan Hospital
   for kindly provid-ing the C albicans strains and for discussions of the
   manuscript. We would like to thank Zou YongXin for outstanding technical
   assistance. This work was supported by the National Natural Science
   Foundation of China (No. 30730109 and No. 30672531), and Special
   Foundation for State Major Basic Research Program of China (973 program,
   No. 2006CB708511).
CR Bammert GF, 2000, ANTIMICROB AGENTS CH, V44, P1255, DOI 10.1128/AAC.44.5.1255-1265.2000
   Cao YY, 2005, ANTIMICROB AGENTS CH, V49, P584, DOI 10.1128/AAC.49.2.584-589.2005
   Crowley JH, 1998, CURR GENET, V34, P93, DOI 10.1007/s002940050371
   Guo XL, 2008, J APPL MICROBIOL, V104, P831, DOI 10.1111/j.1365-2672.2007.03617.x
   Henry KW, 2000, ANTIMICROB AGENTS CH, V44, P2693, DOI 10.1128/AAC.44.10.2693-2700.2000
   Kelly SL, 1997, FEBS LETT, V400, P80, DOI 10.1016/S0014-5793(96)01360-9
   Kohli A, 2002, ANTIMICROB AGENTS CH, V46, P1046, DOI 10.1128/AAC.46.4.1046-1052.2002
   LENG P, 2007, CHIN PHARM J, V142, P349
   Li LT, 1996, J BIOL CHEM, V271, P16927, DOI 10.1074/jbc.271.28.16927
   Loeffler J, 2003, CLIN INFECT DIS, V36, pS31, DOI 10.1086/344658
   Marichal P, 1999, ANTIMICROB AGENTS CH, V43, P2663, DOI 10.1128/AAC.43.11.2663
   Mysiakina I S, 2007, Mikrobiologiia, V76, P5
   *NAT COMM CLIN LAB, 2002, M27A2 NCCLS
   NES WD, 1993, ARCH BIOCHEM BIOPHYS, V300, P724, DOI 10.1006/abbi.1993.1100
   Niu C, 2006, CHEM BIODIVERS, V3, P34, DOI 10.1002/cbdv.200690004
   Orozco AS, 1998, ANTIMICROB AGENTS CH, V42, P2645, DOI 10.1128/AAC.42.10.2645
   Pasrija R, 2008, ANTIMICROB AGENTS CH, V52, P694, DOI 10.1128/AAC.00861-07
   Sanglard D, 2003, ANTIMICROB AGENTS CH, V47, P2404, DOI 10.1128/AAC.47.8.2404-2412.2003
   Sun SJ, 2005, ANAL BIOCHEM, V336, P39, DOI 10.1016/j.ab.2004.06.038
   Trosken ER, 2006, TOXICOLOGY, V228, P24, DOI 10.1016/j.tox.2006.08.007
   Venkateswarlu K, 1996, ANTIMICROB AGENTS CH, V40, P2443, DOI 10.1128/AAC.40.11.2443
   WANG XD, 2005, J ORGAN DYSFUNCT, V1, P2
NR 22
TC 10
Z9 15
U1 6
U2 15
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD JAN
PY 2009
VL 32
IS 1
BP 36
EP 40
DI 10.1248/bpb.32.36
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 389CY
UT WOS:000262069200006
PM 19122277
OA Bronze
DA 2018-12-27
ER

PT J
AU Meng, FP
   Dong, BX
   Li, HW
   Fan, DM
   Ding, J
AF Meng, Fanping
   Dong, Baoxia
   Li, Hanwei
   Fan, Daiming
   Ding, Jie
TI RETRACTED: RNAi-mediated inhibition of Raf-1 leads to decreased
   angiogenesis and tumor growth in gastric cancer (Retracted article. See
   vol. 8, pg. 1687, 2009)
SO CANCER BIOLOGY & THERAPY
LA English
DT Article; Retracted Publication
DE gastric cancer; Raf-1; siRNAi; angiogenesis; tumorigenesis
ID SHORT-INTERFERING RNAS; MAMMALIAN-CELLS; ENDOTHELIAL-CELLS; EXPRESSION;
   ANGIOPOIETIN-1; IDENTIFICATION; CRITERIA
AB Tumor angiogenesis plays an important role in the malignancy of solid tumors. A number of recent studies including our own have suggested that Raf-1 is involved in this process, and may be critical in regulating gene activation of several angiogenesis factors. RNA interference (RNAi) provides a powerful method for gene silencing in eukaryotic cells, including proliferating mammalian cells. To further define Raf-1 function in angiogenesis and to explore novel approaches to modulate angiogenesis, we employed the small interference RNA technique to knockdown gene expression of Raf-1 in gastric cancer cells and observed the effect of silencing Raf-1 on gastric cancer tumorigenesis and angiogenesis in vitro and in nude mice. We found that the expression of double stranded RNA leads to the efficient and specific inhibition of endogenous Raf-1 protein expression in gastric cancer cell lines as determined by Western blotting. Raf-1 protein is a potential target for gastric cancer biological therapy. Inhibition of Raf-1 with siRNA technique could inhibit growth of the tumor graft and reduce angiogenesis in nude mice, which probably caused by downregulation of pro-angiogenesis molecules, such as VEGF and HIF-1 alpha. Taken together, our findings indicate that specific Raf-1 targeting may have important therapeutic values for cancer therapy, and that individual Raf-1 may be a useful target in developing angiogenic inhibitors.
C1 [Fan, Daiming; Ding, Jie] Fourth Mil Med Univ, Xijing Hosp, Dept Digest Dis, State Key Lab Canc Biol, Xian 710032, Shaanxi Prov, Peoples R China.
   [Meng, Fanping; Li, Hanwei] 302 Hosp PLA, Dept Liver Transplantat Rehab, Beijing, Peoples R China.
   [Dong, Baoxia] Fourth Mil Med Univ, Dept Hematol, Xian 710032, Shaanxi Prov, Peoples R China.
RP Ding, J (reprint author), Fourth Mil Med Univ, Xijing Hosp, Dept Digest Dis, State Key Lab Canc Biol, Xian 710032, Shaanxi Prov, Peoples R China.
EM dingjie@fmmu.edu.cn
FU PLA [01Z08F]
FX This work was supported by a grant from Key Project for "the Tenth
   Five-Year Plan" of PLA, No. 01Z08F.
CR Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015
   An WG, 1998, NATURE, V392, P405
   Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   CONNOLLY DT, 1991, J CELL BIOCHEM, V47, P219, DOI 10.1002/jcb.240470306
   Ehrenreiter K, 2005, J CELL BIOL, V168, P955, DOI 10.1083/jcb.200409162
   Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3
   Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255
   Fan DM, 2005, J GASTROEN HEPATOL, V20, P360, DOI 10.1111/j.1400-1746.2005.03797.x
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305
   Fu YG, 2005, CANCER LETT, V224, P243, DOI 10.1016/j.canlet.2004.11.038
   Fu YG, 2006, CANCER LETT, V243, P246, DOI 10.1016/j.canlet.2005.11.039
   Garcea G, 2005, EUR J CANCER, V41, P2213, DOI 10.1016/j.ejca.2005.04.044
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503
   JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470
   Kerbel RS, 2005, CANCER CELL, V8, P269, DOI 10.1016/j.ccr.2005.09.016
   Leng QX, 2005, CANCER GENE THER, V12, P682, DOI 10.1038/sj.cgt.7700831
   LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q
   Liang SH, 2006, J MOL MED-JMM, V84, P764, DOI 10.1007/s00109-006-0064-2
   LIU DH, 2001, DISI JUNYI DAXUE XUE, V22, P821
   McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908
   Meng FP, 2005, CANCER BIOL THER, V4, P113
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   Park J I, 2000, Arch Facial Plast Surg, V2, P43, DOI 10.1001/archfaci.2.1.43
   Shi Y, 2003, TRENDS GENET, V19, P9, DOI 10.1016/S0168-9525(02)00005-7
   Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599
   Vermeulen PB, 1996, EUR J CANCER, V32A, P2474, DOI 10.1016/S0959-8049(96)00379-6
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang J, 2006, WORLD J GASTROENTERO, V12, P2450, DOI 10.3748/wjg.v12.i15.2450
   Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498
   Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499
NR 33
TC 6
Z9 6
U1 4
U2 13
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD JAN
PY 2009
VL 8
IS 2
BP 174
EP 179
DI 10.4161/cbt.8.2.7208
PG 6
WC Oncology
SC Oncology
GA 395BK
UT WOS:000262496900013
PM 19029826
DA 2018-12-27
ER

PT J
AU Hattori, Y
   Suzuki, K
   Tomizawa, A
   Hirama, N
   Okayasu, T
   Hattori, S
   Satoh, H
   Akimoto, K
   Kasai, K
AF Hattori, Yoshiyuki
   Suzuki, Kunihiro
   Tomizawa, Atsuko
   Hirama, Noriko
   Okayasu, Toshie
   Hattori, Sachiko
   Satoh, Hiroko
   Akimoto, Kazumi
   Kasai, Kikuo
TI RETRACTED: Cilostazol inhibits cytokine-induced nuclear factor-kappa B
   activation via AMP-activated protein kinase activation in vascular
   endothelial cells (Retracted article. See vol. 92, pg. 181, 2011)
SO CARDIOVASCULAR RESEARCH
LA English
DT Article; Retracted Publication
ID INTERMITTENT CLAUDICATION; ADHESION MOLECULE; LESION FORMATION;
   PHOSPHORYLATION; EXPRESSION; ATHEROGENESIS; MECHANISM; TRIAL
AB Cilostazol is a selective inhibitor of phosphodiesterase 3 that increases intracellular cyclic AMP (cAMP) levels and activates protein kinase A, thereby inhibiting platelet aggregation and inducing peripheral vasodilation. We hypothesized that cilostazol may prevent inflammatory cytokine induced-nuclear factor (NF)-kappa B activation by activating AMP-activated protein kinase (AMPK) in vascular endothelial cells.
   Cilostazol was observed to activate AMPK and its downstream target, acetyl-CoA carboxylase, in human umbilical vein endothelial cells (HUVEC). Phosphorylation of AMPK with cilostazol was not affected by co-treatment with an adenylate cyclase inhibitor, SQ 22536, and a cell-permeable cAMP analogue, pCTP-cAMP, did not induce AMPK phosphorylation and had no effect on cilostazol-induced AMPK phosphorylation, suggesting that cilostazol-induced AMPK activation occurs through a signalling pathway independent of cyclic AMP. Cilostazol also dose-dependently inhibited tumour necrosis factor alpha (TNF alpha)-induced NF-kappa B activation and TNF alpha-induced I kappa B kinase activity. Furthermore, cilostazol attenuated the TNF alpha-induced gene expression of various pro-inflammatory and cell adhesion molecules, such as vascular cell adhesion molecule-1, E-selectin, intercellular adhesion molecule-1, monocyte chemoattractant protein-1 (MCP-1), and PECAM-1 in HUVEC. RNA interference of AMPK alpha 1 or the AMPK inhibitor compound C attenuated cilostazol-induced inhibition of NF-kappa B activation by TNF alpha.
   In the light of these findings, we suggest that cilostazol might attenuate the cytokine-induced expression of adhesion molecule genes by inhibiting NF-kappa B following AMPK activation.
C1 [Hattori, Yoshiyuki; Suzuki, Kunihiro; Tomizawa, Atsuko; Hirama, Noriko; Okayasu, Toshie; Hattori, Sachiko; Satoh, Hiroko; Akimoto, Kazumi; Kasai, Kikuo] Dokkyo Univ, Sch Med, Dept Endocrinol & Metab, Mibu, Tochigi 3210293, Japan.
RP Hattori, Y (reprint author), Dokkyo Univ, Sch Med, Dept Endocrinol & Metab, Mibu, Tochigi 3210293, Japan.
EM yhattori@dokkyomed.ac.jp
FU Japan Private School Promotion Foundation
FX This work was supported in part by a grant from Japan Private School
   Promotion Foundation.
CR Beebe HG, 1999, ARCH INTERN MED, V159, P2041, DOI 10.1001/archinte.159.17.2041
   Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788
   Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598
   Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373
   CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440
   Dawson DL, 2000, AM J MED, V109, P523, DOI 10.1016/S0002-9343(00)00569-6
   Giri S, 2004, J NEUROSCI, V24, P479, DOI 10.1523/JNEUROSCI.4288-03.2004
   Goto S, 2005, ATHEROSCLEROSIS SUPP, V6, P3, DOI 10.1016/j.atherosclerosissup.2005.09.002
   Gotoh F, 2000, J Stroke Cerebrovasc Dis, V9, P147, DOI 10.1053/jscd.2000.7216
   Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540
   Hashimoto A, 2006, ATHEROSCLEROSIS, V189, P350, DOI 10.1016/j.atherosclerosis.2006.01.022
   Hattori Y, 2002, HYPERTENSION, V39, P22, DOI 10.1161/hy1201.097300
   Hattori Y, 2006, HYPERTENSION, V47, P1183, DOI 10.1161/01.HYP.0000221429.94591.72
   Hurley RL, 2006, J BIOL CHEM, V281, P36662, DOI 10.1074/jbc.M606676200
   IGAWA T, 1990, THROMB RES, V57, P617, DOI 10.1016/0049-3848(90)90079-R
   Iiyama K, 1999, CIRC RES, V85, P199, DOI 10.1161/01.RES.85.2.199
   Kamata H, 2002, FEBS LETT, V519, P231, DOI 10.1016/S0014-5793(02)02712-6
   Kambayashi J, 2003, CURR PHARM DESIGN, V9, P2289, DOI 10.2174/1381612033453910
   Kwon SU, 2005, STROKE, V36, P782, DOI 10.1161/01.STR.0000157667.06542.b7
   Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044
   Nomura S, 2002, J HUM HYPERTENS, V16, P539, DOI 10.1038/sj.jhh.1001447
   Ochiai M, 1999, AM J CARDIOL, V84, P1074, DOI 10.1016/S0002-9149(99)00501-9
   OCONNELL KA, 1990, J IMMUNOL, V144, P521
   PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103
   Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096
   Pratt CM, 2001, AM J CARDIOL, V87, p28D
NR 26
TC 44
Z9 45
U1 4
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0008-6363
EI 1755-3245
J9 CARDIOVASC RES
JI Cardiovasc. Res.
PD JAN 1
PY 2009
VL 81
IS 1
BP 133
EP 139
DI 10.1093/cvr/cvn226
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 383NA
UT WOS:000261679100020
PM 18703532
OA Bronze
DA 2018-12-27
ER

PT J
AU Lu, YJ
   Wang, ZY
   Ge, L
   Chen, N
   Liu, H
AF Lu, Yujian
   Wang, Zhenyu
   Ge, Liang
   Chen, Ni
   Liu, Heng
TI RETRACTED: The RZZ Complex and the Spindle Assembly Checkpoint
   (Retracted article. See vol. 35, pg. 1, 2010)
SO CELL STRUCTURE AND FUNCTION
LA English
DT Review; Retracted Publication
DE Rod; spindle; kinetochore; sister chromatids; SAC
ID ANAPHASE-PROMOTING COMPLEX; ACCURATE CHROMOSOME SEGREGATION;
   CENTROMERE-ASSOCIATED PROTEIN; MITOTIC CHECKPOINT; CENP-E; ROUGH-DEAL;
   KINETOCHORE LOCALIZATION; AURORA-B; MICROTUBULE ATTACHMENT;
   MAMMALIAN-CELLS
AB The conserved protein Rod is found in various organisms. It is localized on the kinetochores or spindle microtubules during cell division. Rod is required for proper chromosome segregation during both mitosis and meiosis. The effects of rod mutations are similar for both equational and reductional divisions, giving rise to anaphases with lagging chromosomes and/or unequal numbers of chromosomes at the two poles. Recent studies have shown that Rod is a significant component of the mitotic checkpoint. It can form the RZZ complex with Zw10 and Zwilch, which plays an important role in maintaining a functional spindle assembly checkpoint.
C1 [Lu, Yujian; Wang, Zhenyu; Ge, Liang; Chen, Ni; Liu, Heng] Lanzhou Univ, Inst Cell Biol, Sch Life Sci, MOE Key Lab Arid & Grassland Ecol, Lanzhou 730000, Peoples R China.
RP Liu, H (reprint author), Lanzhou Univ, Inst Cell Biol, Sch Life Sci, MOE Key Lab Arid & Grassland Ecol, Lanzhou 730000, Peoples R China.
EM hengliu@lzu.edu.cn
FU National Natural Science Foundation of China [30771091]; Chinese
   Ministry of Education [307024]; Lanzhou University
FX This work was financially supported by grants received under the
   National Natural Science Foundation of China ( No. 30771091), the Key
   Grant Project of Chinese Ministry of Education ( No. 307024) and the
   Plan of Talent Scout of Lanzhou University ( 2004).
CR Albertson R, 2005, TRENDS CELL BIOL, V15, P92, DOI 10.1016/j.tcb.2004.12.008
   AMON A, 1999, CURR OPIN GENE DEV, P969
   Arasaki K, 2006, MOL BIOL CELL, V17, P2780, DOI 10.1091/mbc.E05-10-0973
   Basto R, 2000, NAT CELL BIOL, V2, P939
   Basto R, 2004, CURR BIOL, V14, P56, DOI 10.1016/j.cub.2003.12.025
   Basu J, 1998, CHROMOSOMA, V107, P376, DOI 10.1007/s004120050321
   Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1
   Buffin E, 2005, CURR BIOL, V15, P856, DOI 10.1016/j.cub.2005.03.052
   Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245
   Chan GK, 2005, TRENDS CELL BIOL, V15, P589, DOI 10.1016/j.tcb.2005.09.010
   Chan GKT, 2000, NAT CELL BIOL, V2, P944
   Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941
   Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49
   Chan Gordon K, 2003, Prog Cell Cycle Res, V5, P431
   Cheeseman IM, 2008, MOL BIOL CELL, V19, P587, DOI 10.1091/mbc.E07-10-1051
   Cheeseman IM, 2006, CELL, V127, P983, DOI 10.1016/j.cell.2006.09.039
   Cheeseman IM, 2004, GENE DEV, V18, P2255, DOI 10.1101/gad.1234104
   Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283
   Chen RH, 2002, J CELL BIOL, V158, P487, DOI 10.1083/jcb.200204048
   Chung EN, 2003, NAT CELL BIOL, V5, P748, DOI 10.1038/ncb1022
   Chung EN, 2002, MOL BIOL CELL, V13, P1501, DOI 10.1091/mbc.02-01-0003
   Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6
   DE AA, 2005, CURR BIOL, V15, P214
   Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091
   Dzhindzhev NS, 2005, J CELL SCI, V118, P3781, DOI 10.1242/jcs.02504
   Elledge SJ, 1998, SCIENCE, V279, P999, DOI 10.1126/science.279.5353.999
   Famulski JK, 2007, CURR BIOL, V17, P2143, DOI 10.1016/j.cub.2007.11.037
   Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437
   Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871
   Fraschini R, 2001, EMBO J, V20, P6648, DOI 10.1093/emboj/20.23.6648
   GASSMANN R, 2008, J CELL BIOL, V183, P187
   GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438
   Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193
   Griffis ER, 2007, J CELL BIOL, V177, P1005, DOI 10.1083/jcb.200702062
   Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871
   Hatsuzawa K, 2000, J BIOL CHEM, V275, P13713, DOI 10.1074/jbc.275.18.13713
   Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092
   Hirose H, 2004, EMBO J, V23, P1267, DOI 10.1038/sj.emboj.7600135
   Hoffman DB, 2001, MOL BIOL CELL, V12, P1995, DOI 10.1091/mbc.12.7.1995
   Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233
   Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093
   Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053
   Huang JY, 2002, J CELL SCI, V115, P2847
   Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041
   Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0
   Johnson VL, 2004, J CELL SCI, V117, P1577, DOI 10.1242/jcs.01006
   Jorgensen PM, 1998, MOL CELL BIOL, V18, P468
   Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393
   Kallio MJ, 2002, J CELL BIOL, V158, P841, DOI 10.1083/jcb.200201135
   Karess R, 2005, TRENDS CELL BIOL, V15, P386, DOI 10.1016/j.tcb.2005.05.003
   KARESS RE, 1989, J CELL BIOL, V109, P2951, DOI 10.1083/jcb.109.6.2951
   Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4
   Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045
   King JM, 2000, J CELL BIOL, V151, P739, DOI 10.1083/jcb.151.4.739
   Kops GJPL, 2005, J CELL BIOL, V169, P49, DOI 10.1083/jcb.200411118
   Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307
   Liu ST, 2003, MOL BIOL CELL, V14, P1638, DOI 10.1091/mbc.02-05-0074
   Lu Y, 2008, DIABETES OBES METAB, V10, P109, DOI 10.1111/j.1463-1326.2007.00799.x
   Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X
   Maiato H, 2004, J CELL SCI, V117, P5461, DOI 10.1242/jcs.01536
   Malmanche N, 2006, FEBS LETT, V580, P2888, DOI 10.1016/j.febslet.2006.03.081
   Mao YH, 2005, J CELL BIOL, V170, P873, DOI 10.1083/jcb.200505040
   Millband DN, 2002, MOL CELL BIOL, V22, P2728, DOI 10.1128/MCB.22.8.2728-2742.2002
   Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929
   Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632
   Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187
   Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3
   PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591
   Przewloka MR, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000478
   RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81
   Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9
   Savoian MS, 2000, NAT CELL BIOL, V2, P948
   Scaerou F, 2001, J CELL SCI, V114, P3103
   Scaerou F, 1999, J CELL SCI, V112, P3757
   Shah JV, 2004, CURR BIOL, V14, P942, DOI 10.1016/j.cub.2004.05.046
   Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137
   Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239
   Skoufias DA, 2001, P NATL ACAD SCI USA, V98, P4492, DOI 10.1073/pnas.081076898
   Starr DA, 2000, J CELL SCI, V113, P1939
   Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763
   Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093
   Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3
   Taylor SS, 2001, J CELL SCI, V114, P4385
   Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1
   Topper LM, 2002, CELL CYCLE, V1, P282, DOI 10.4161/cc.1.4.139
   TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4
   Vader G, 2008, BBA-REV CANCER, V1786, P60, DOI 10.1016/j.bbcan.2008.07.003
   Vagnarelli P, 2004, CHROMOSOMA, V113, P211, DOI 10.1007/s00412-004-0307-3
   Vallee RB, 2006, CELL CYCLE, V5, P2447, DOI 10.4161/cc.5.21.3395
   Wang HM, 2004, J BIOL CHEM, V279, P54590, DOI 10.1074/jbc.M407588200
   Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181
   Weaver BAA, 2003, J CELL BIOL, V162, P551, DOI 10.1083/jcb.200303167
   Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0
   Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247
   Williams BC, 2003, MOL BIOL CELL, V14, P1379, DOI 10.1091/mbc.E02-09-0624
   WILLIAMS BC, 1992, J CELL BIOL, V118, P759, DOI 10.1083/jcb.118.4.759
   WILLIAMS BC, 1994, J CELL SCI, V107, P785
   Williams BC, 1996, J CELL BIOL, V134, P1127, DOI 10.1083/jcb.134.5.1127
   Wojcik E, 2001, NAT CELL BIOL, V3, P1001, DOI 10.1038/ncb1101-1001
   Wu HY, 2000, ONCOGENE, V19, P4557, DOI 10.1038/sj.onc.1203803
   Xiao J, 2001, J BIOL CHEM, V276, P6105, DOI 10.1074/jbc.M008893200
   Yamamoto TG, 2008, J CELL BIOL, V183, P187, DOI 10.1083/jcb.200805185
   Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4
   Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039
   Zhang X, 2007, MOL BIOL CELL, V18, P3264, DOI 10.1091/mbc.E07-01-0086
   Zhou J, 2002, J CELL SCI, V115, P3547, DOI 10.1242/jcs.00029
NR 106
TC 9
Z9 9
U1 4
U2 14
PU JAPAN SOC CELL BIOLOGY
PI KYOTO
PA C/O NAKANISHI PRINTING SHIMODACHIURI OGAWA HIGASHI, KAMIGYO-KU, KYOTO,
   602-8048, JAPAN
SN 0386-7196
EI 1347-3700
J9 CELL STRUCT FUNCT
JI Cell Struct. Funct.
PY 2009
VL 34
IS 1
BP 31
EP 45
DI 10.1247/csf.08040
PG 15
WC Cell Biology
SC Cell Biology
GA 469ER
UT WOS:000267879000005
PM 19420794
OA Bronze
DA 2018-12-27
ER

PT J
AU Tao, J
   Sun, Y
   Wang, QG
   Liu, CW
AF Tao, Jie
   Sun, Yuan
   Wang, Qiu-gen
   Liu, Cheng-wen
TI RETRACTED: Induced Endothelial Cells Enhance Osteogenesis and
   Vascularization of Mesenchymal Stem Cells (Retracted Article. See vol
   191, pg 430, 2010)
SO CELLS TISSUES ORGANS
LA English
DT Article; Retracted Publication
DE Vascularization; Mesenchymal stem cells; Endothelial cells; Osteogenesis
ID BONE; ANGIOGENESIS; BLOOD
AB Adequate vascularization remains one of the major challenges in bone tissue engineering. Since the microvascular endothelium is of benefit to osteogenesis and vascularization when in direct contact with bone marrow mesenchymal stem cells (BM-MSCs), we investigated whether endothelial cells induced from BM-MSCs have the same effect on BM-MSCs in vitro and in vivo. BM-MSCs were isolated, characterized and induced into endothelial-like cells (induced endothelial cells, IECs) in endothelial cell growth medium 2. BM-MSCs and IECs were co-cultured with direct contact. In vitro, IECs were evaluated in terms of their characteristics of endothelial cells and their effects on the osteogenic potential of BM-MSCs by cell morphology, immunofluorescent staining, alkaline phosphatase activity and osteocalcin synthesis. In vivo, scaffolds consisting of beta-tricalcium phosphate co-seeded with IECs and BM-MSCs were transplanted into mouse dorsal pockets, and a histological analysis was performed to determine the extent of new bone and blood vessel formation. Isolated BM-MSCs were positive for the markers CD105 and CD29 and negative for hematopoietic markers CD34, CD45 and CD14. They were able to differentiate into adipocytes, osteocytes and chondrocytes in respective media. Immunofluorescent analysis with von Willebrand factor and CD31 staining showed that BM-MSCs could differentiate into endothelial cells. The alkaline phosphatase activity and the osteocalcin content of the co-culture group were obviously higher than those of any other group (p < 0.05). Histologically, newly formed bone and vessels were more evident in the culture group (p < 0.05). Our findings suggest that IECs could efficiently stimulate the in vitro differentiation of osteoblast-like cells and promote osteogenesis in vivo by direct contact with BM-MSCs. Copyright (C) 2009 S. Karger AG, Basel
C1 [Tao, Jie; Wang, Qiu-gen] Shanghai Jiao Tong Univ, Dept Orthoped, Shanghai Peoples Hosp 1, Shanghai 200080, Peoples R China.
   [Sun, Yuan] Shanghai Jiao Tong Univ, Dept Orthoped, Shanghai Peoples Hosp 6, Shanghai 200080, Peoples R China.
   [Liu, Cheng-wen] Branch Shanghai First Peoples Hosp, Dept Orthoped, Shanghai, Peoples R China.
RP Tao, J (reprint author), Shanghai Jiao Tong Univ, Dept Orthoped, Shanghai Peoples Hosp 1, 85 Wujin Rd, Shanghai 200080, Peoples R China.
EM david1979982@163.com
FU Shanghai Baoshan Foundation for Natural Sciences
FX This work was supported by a grant from Shanghai Baoshan Foundation for
   Natural Sciences.
CR Akita S, 2004, TISSUE ENG, V10, P789, DOI 10.1089/1076327041348338
   Bouletreau PJ, 2002, PLAST RECONSTR SURG, V109, P2384, DOI 10.1097/00006534-200206000-00033
   Cancedda R, 2007, BIOMATERIALS, V28, P4240, DOI 10.1016/j.biomaterials.2007.06.023
   Elbjeirami WM, 2006, TISSUE ENG, V12, P381, DOI 10.1089/ten.2006.12.381
   Fuchs S, 2006, CELL TISSUE RES, V326, P79, DOI 10.1007/s00441-006-0222-4
   Furumatsu T, 2003, J BIOCHEM, V133, P633, DOI 10.1093/jb/mvg081
   Geiger F, 2005, J BONE MINER RES, V20, P2028, DOI 10.1359/JBMR.050701
   Kaigler D, 2005, FASEB J, V19, P665, DOI 10.1096/fj.04-2529fje
   Levenberg S, 2005, NAT BIOTECHNOL, V23, P879, DOI 10.1038/nbt1109
   Li WM, 2000, CYTOKINE, V12, P1017, DOI 10.1006/cyto.1999.0678
   Perets A, 2003, J BIOMED MATER RES A, V65A, P489, DOI 10.1002/jbm.a.10542
   Scherberich A, 2007, STEM CELLS, V25, P1823, DOI 10.1634/stemcells.2007-0124
   Sun HC, 2007, BIOMED ENG ONLINE, V6, DOI 10.1186/1475-925X-6-41
   Tremblay PL, 2005, AM J TRANSPLANT, V5, P1002, DOI 10.1111/j.1600-6143.2005.00790.x
   Unger RE, 2007, BIOMATERIALS, V28, P3965, DOI 10.1016/j.biomaterials.2007.05.032
   Villars F, 2002, AM J PHYSIOL-CELL PH, V282, pC775, DOI 10.1152/ajpcell.00310.2001
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
NR 17
TC 20
Z9 22
U1 1
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1422-6405
EI 1422-6421
J9 CELLS TISSUES ORGANS
JI Cells Tissues Organs
PY 2009
VL 190
IS 4
BP 185
EP 193
DI 10.1159/000218139
PG 9
WC Anatomy & Morphology; Cell Biology; Developmental Biology
SC Anatomy & Morphology; Cell Biology; Developmental Biology
GA 494DD
UT WOS:000269788800001
PM 19420896
DA 2018-12-27
ER

PT J
AU Iwamoto, J
   Matsumoto, H
   Takeda, T
AF Iwamoto, Jun
   Matsumoto, Hideo
   Takeda, Tsuyoshi
TI RETRACTED: Efficacy of Menatetrenone (Vitamin K-2) against Non-Vertebral
   and Hip Fractures in Patients with Neurological Diseases Meta-Analysis
   of Three Randomized, Controlled Trials (Retracted article. See vol. 38,
   pg. 479, 2018)
SO CLINICAL DRUG INVESTIGATION
LA English
DT Article; Retracted Publication
ID SERUM UNDERCARBOXYLATED OSTEOCALCIN; BONE-MINERAL DENSITY;
   ELDERLY-WOMEN; POSTMENOPAUSAL WOMEN; PARKINSONS-DISEASE; PREVENTION;
   RISEDRONATE; SUPPLEMENTATION; OSTEOPOROSIS; THERAPY
AB Background and objective: Patients with neurological diseases such as Alzheimer's disease, stroke and Parkinson's disease have been reported to have vitamin K deficiency secondary to malnutrition, which increases the risk of non-vertebral and hip fractures. The purpose of the present study was to clarify the efficacy of menatetrenone (vitamin K,) against non-vertebral and hip fractures in patients with neurological diseases.
   Methods: A literature search was conducted on PubMed from January 1995 to July 2008 to identify randomized controlled trials (RCTs) of use of menatetrenone against non-vertebral and hip fractures in patients with neurological diseases. A meta-analysis of all RCTs meeting these criteria was then performed.
   Results: Three RCTs of patients with Alzheimer's disease (n = 178, mean age 78 years), stroke (n = 99, mean age 66 years) and Parkinson's disease (n = I 10, mean age 72 years) met the criteria for meta-analysis. These RCTs did not include placebo controls but did have non-treatment controls. According to the meta-analysis, the overall relative risks (95% confidence intervals) for non-vertebral and hip fractures with menatetrenone treatment compared with non-treatment were 0.13 (0.05, 0.35) and 0.14 (0.05, 0.43), respectively, in patients with neurological diseases. No severe adverse events were reported with menatetrenone treatment.
   Conclusion: The present meta-analysis of three RCTs suggests that there is efficacy for menatetrenone treatment against non-vertebral and hip fractures among patients with neurological diseases. Further larger placebo-controlled trials are needed to confirm the results of the present study.
C1 [Iwamoto, Jun] Keio Univ, Sch Med, Inst Integrated Sports Med, Shinjuku Ku, Tokyo 1608582, Japan.
RP Iwamoto, J (reprint author), Keio Univ, Sch Med, Inst Integrated Sports Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM jiwamoto@sc.itc.keio.ac.jp
RI Matsumoto, Hideo/A-2304-2014
CR Bischoff-Ferrari HA, 2004, JAMA-J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999
   Bischoff-Ferrari HA, 2005, JAMA-J AM MED ASSOC, V293, P2257, DOI 10.1001/jama.293.18.2257
   Booth SL, 2000, AM J CLIN NUTR, V71, P1201
   Cockayne S, 2006, ARCH INTERN MED, V166, P1256, DOI 10.1001/archinte.166.12.1256
   Deeks JJ, 2005, J CLIN EPIDEMIOL, V58, P882, DOI 10.1016/j.jclinepi.2005.01.016
   Epstein S, 2007, BONE, V41, pS3, DOI 10.1016/j.bone.2007.03.006
   Feskanich D, 1999, AM J CLIN NUTR, V69, P74
   HARA K, 1993, J BONE MINER RES, V8, P535
   HARA K, 1995, BONE, V16, P179, DOI 10.1016/8756-3282(94)00027-W
   HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990
   Higgins J. P., 2005, COCHRANE HDB SYSTEMA
   Ishida Y, 2004, AM J MED, V117, P549, DOI 10.1016/j.amjmed.2004.05.019
   Iwamoto J, 2001, J Orthop Sci, V6, P487, DOI 10.1007/s007760100002
   Iwamoto J, 2008, CURR MED RES OPIN, V24, P1379, DOI 10.1185/030079908X297321 
   Kaneki M, 2001, NUTRITION, V17, P315, DOI 10.1016/S0899-9007(00)00554-2
   Knapen MHJ, 2007, OSTEOPOROSIS INT, V18, P963, DOI 10.1007/s00198-007-0337-9
   Koshihara Y, 1997, J BONE MINER RES, V12, P431, DOI 10.1359/jbmr.1997.12.3.431
   Luukinen H, 2000, J BONE MINER RES, V15, P2473, DOI 10.1359/jbmr.2000.15.12.2473
   Orimo H., 1992, J NEW REMEDIES CLIN, V41, P1249
   ORIMO H, 1992, CLIN EVAL, V20, P45
   Sato Y, 2002, BONE, V31, P114, DOI 10.1016/S8756-3282(02)00783-4
   Sato Y, 2005, ARCH INTERN MED, V165, P1737, DOI 10.1001/archinte.165.15.1737
   Sato Y, 2005, NEUROLOGY, V64, P811, DOI 10.1212/01.WNL.0000152871.65027.76
   Sato Y, 2005, BONE, V36, P61, DOI 10.1016/j.bone.2004.09.018
   Sato Y, 2005, ARCH INTERN MED, V165, P1743, DOI 10.1001/archinte.165.15.1743
   Sato Y, 2002, BONE, V30, P325, DOI 10.1016/S8756-3282(01)00645-7
   Sato Y, 1998, BONE, V23, P291, DOI 10.1016/S8756-3282(98)00108-2
   Sato Y, 2007, NEUROLOGY, V68, P911, DOI 10.1212/01.wnl.0000257089.50476.92
   Sato Y, 2006, MOVEMENT DISORD, V21, P924, DOI 10.1002/mds.20825
   SHEARER MJ, 1995, LANCET, V345, P229, DOI 10.1016/S0140-6736(95)90227-9
   Shiraki M, 2000, J BONE MINER RES, V15, P515, DOI 10.1359/jbmr.2000.15.3.515
   Szulc P, 1996, BONE, V18, P487, DOI 10.1016/8756-3282(96)00037-3
   SZULC P, 1993, J CLIN INVEST, V91, P1769, DOI 10.1172/JCI116387
   Tabb MM, 2003, J BIOL CHEM, V278, P43919, DOI 10.1074/jbc.M303136200
   Vergnaud P, 1997, J CLIN ENDOCR METAB, V82, P719, DOI 10.1210/jc.82.3.719
   VERMEER C, 1995, ANNU REV NUTR, V15, P1, DOI 10.1146/annurev.nutr.15.1.1
   *WHO SCI GROUP, 2003, WHO TECH REP SER, V921, P86
NR 37
TC 15
Z9 15
U1 1
U2 4
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173-2563
EI 1179-1918
J9 CLIN DRUG INVEST
JI Clin. Drug Invest.
PY 2009
VL 29
IS 7
BP 471
EP 479
DI 10.2165/00044011-200929070-00005
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 462UD
UT WOS:000267381300005
PM 19499964
DA 2018-12-27
ER

PT J
AU Liu, J
   Geng, QD
   Kong, XJ
AF Liu, J.
   Geng, Q. D.
   Kong, X. J.
TI RETRACTED: A fast common plane identification algorithm for 3D contact
   problem (Retracted article. See vol. 36, pg. 915, 2009)
SO COMPUTERS AND GEOTECHNICS
LA English
DT Article; Retracted Publication
DE Contact detection; Common plane; Discrete element method (DEM);
   Discontinuous deformation analysis (DDA)
ID DISCRETE ELEMENT MODEL
AB Determining the contact points between interacting blocks and the associated contact normal is a key step and time consuming calculation in the discrete element method (DEM) and the discontinuous deformation analysis (DDA). Common-plane (CP) algorithm is one of the more effective methods for contact detection when dealing with three-dimensional polyhedral or two-dimensional polygonal blocks. in this paper, fast common plane (FCP) identification algorithm proposed by Nezami is extended to a general case for all contact types and the proof of the algorithm is also provided. FCP approach recognizes that a common plane has identifying characteristics, which dramatically reduce the search space for the common plane. In two-dimensions, the CP is found by checking only five possible candidate lines. In three-dimensions, the candidate planes fall within four types related to the geometry of the blocks and their relative positions. The efficiency for CP identification is improved greatly and the veracity can be guaranteed. Numerical experiments reveal the efficiency of the extended FCP algorithm. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Liu, J.; Geng, Q. D.; Kong, X. J.] Dalian Univ Technol, State Key Lab Offshore & Coastal Engn, Dalian 116024, Liaoning Prov, Peoples R China.
RP Liu, J (reprint author), Dalian Univ Technol, State Key Lab Offshore & Coastal Engn, Dalian 116024, Liaoning Prov, Peoples R China.
EM junliu@dlut.edu.cn
FU Program for Changjiang Scholars and Innovative Research Team in
   University [IRT0518]; National Natural Science Foundation of China
   [50679093, 50538080]
FX The research presented here is supported by Program for Changjiang
   Scholars and Innovative Research Team in University (IRT0518) and the
   National Natural Science Foundation of China (Grant Nos: 50679093 and
   50538080). These supports are gratefully acknowledged.
CR BARBOSA RE, 1990, THESIS U ILLINOIS UR
   CHUENG YM, 2006, ASCE, V6, P303
   CUNDALL PA, 1988, INT J ROCK MECH MIN, V25, P107, DOI 10.1016/0148-9062(88)92293-0
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   FENG YT, 2002, DISCRETE ELEMENT MET, P32
   *IT CONS GROUP 1, 1998, 3DEC 3 DIM DIST EL C
   KRISHNASAMY J, 1995, ENG COMPUTATION, V12, P135, DOI 10.1108/02644409510799523
   Lin X, 1997, GEOTECHNIQUE, V47, P319, DOI 10.1680/geot.1997.47.2.319
   Liu J, 2004, ACTA MECH SINICA, V20, P270
   Munjiza A, 1998, INT J NUMER METH ENG, V43, P131, DOI 10.1002/(SICI)1097-0207(19980915)43:1<131::AID-NME447>3.0.CO;2-S
   Nezami EG, 2004, COMPUT GEOTECH, V31, P575, DOI 10.1016/j.compgeo.2004.08.002
   Perkins E, 2001, ENG COMPUTATION, V18, P48, DOI 10.1108/02644400110365770
   SHI GH, 1992, INT J ENG COMPUT, V9, P157
   TING JM, 1993, INT J NUMER ANAL MET, V17, P603, DOI 10.1002/nag.1610170902
   [王建全 WANG Jianquan], 2006, [岩石力学与工程学报, Chinese Journal of Rock Mechanics and Engineering], V25, P2247
   WILLIAMS JR, 1995, ENG COMPUTATION, V12, P185, DOI 10.1108/02644409510799550
NR 16
TC 10
Z9 13
U1 6
U2 24
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0266-352X
EI 1873-7633
J9 COMPUT GEOTECH
JI Comput. Geotech.
PD JAN-MAR
PY 2009
VL 36
IS 1-2
BP 41
EP 51
DI 10.1016/j.compgeo.2008.03.004
PG 11
WC Computer Science, Interdisciplinary Applications; Engineering,
   Geological; Geosciences, Multidisciplinary
SC Computer Science; Engineering; Geology
GA 391RF
UT WOS:000262249700006
DA 2018-12-27
ER

PT J
AU Cucchiara, S
   Iebba, V
   Conte, MP
   Schippa, S
AF Cucchiara, Salvatore
   Iebba, Valerio
   Conte, Maria Pia
   Schippa, Serena
TI RETRACTED: The Microbiota in Inflammatory Bowel Disease in Different Age
   Groups (Retracted article. See vol. 32, pg. 312, 2014)
SO DIGESTIVE DISEASES
LA English
DT Article; Retracted Publication
DE Microbiota; Inflammatory bowel disease; Biodiversity
ID 16S RIBOSOMAL-RNA; GRADIENT GEL-ELECTROPHORESIS; IN-SITU HYBRIDIZATION;
   ILEAL CROHNS-DISEASE; HUMAN FECAL SAMPLES; INTESTINAL MICROFLORA;
   GASTROINTESTINAL-TRACT; BACTERIAL COMMUNITIES; ULCERATIVE-COLITIS;
   PEDIATRIC-PATIENTS
AB Background: Many efforts were made in the past decades to assess the role of gut microbiota in inflammatory bowel diseases (IBD), leading to the hypothesis that an altered microbial composition, other than the presence of a specific pathogen, could be involved in the pathogenesis of the disease. On the other hand, existing differences in gut microbial community between distinct classes of age make sense of an increasing research in microbial shifts in IBD. Methods: Cultural, molecular, metabolomic and metagenomic approaches are trying to define the human gut microbiota in different age groups. Results and Conclusion: An increase in anaerobic bacteria (Bacteroides vulgatus, Streptococcus faecalis) was observed in adult IBD, whereas an increase in aerobic and facultative-anaerobic (Escherichia coli) was found in pediatric IBD. Overall higher bacterial cell counts were observed in IBD, jointly with a general loss of biodiversity and a preponderance of Bacteroidetes and a parallel decrease of Firmicutes phylum : a predominance of potential harmful members of Proteobacteria (E. coli) and low abundance of beneficial species (Faecalibacterium prausnitzii) was also reported in pediatric and adult age groups, respectively. Microbial community of elderly subjects contains a wider range of different species than those of children and adults, both in healthy and IBD status. Copyright (C) 2009 S. Karger AG, Basel
C1 [Cucchiara, Salvatore] Univ Roma La Sapienza, Pediat Gastroenterol & Liver Unit, Dept Pediat, IT-00161 Rome, Italy.
   [Iebba, Valerio; Conte, Maria Pia; Schippa, Serena] Univ Roma La Sapienza, Dept Publ Hlth Sci, Microbiol Unit, IT-00161 Rome, Italy.
RP Cucchiara, S (reprint author), Univ Roma La Sapienza, Pediat Gastroenterol Unit, Head Pediat Inflammatory Bowel Dis Ctr, Viale Regina Elena 324, IT-00161 Rome, Italy.
EM salvatore.cucchiara@uniroma1.it
OI Cucchiara, Salvatore/0000-0002-2939-9698
CR CARTUN RW, 1993, MODERN PATHOL, V6, P212
   Conte MP, 2006, GUT, V55, P1760, DOI 10.1136/gut.2005.078824
   Coppa GV, 2004, J CLIN GASTROENTEROL, V38, pS80, DOI 10.1097/01.mcg.0000128926.14285.25
   Darfeuille-Michaud A, 2004, GASTROENTEROLOGY, V127, P412, DOI 10.1053/j.gastro.2004.04.061
   Dicksved J, 2008, ISME J, V2, P716, DOI 10.1038/ismej.2008.37
   Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591
   Fanaro S, 2003, ACTA PAEDIATR, V92, P48
   Favier CF, 2002, APPL ENVIRON MICROB, V68, P219, DOI 10.1128/AEM.68.1.219-226.2002
   Frank DN, 2008, CURR OPIN GASTROEN, V24, P4, DOI 10.1097/MOG.0b013e3282f2b0e8
   Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104
   Franks AH, 1998, APPL ENVIRON MICROB, V64, P3336
   Garrett WS, 2007, CELL, V131, P33, DOI 10.1016/j.cell.2007.08.017
   Gore C, 2008, J ALLERGY CLIN IMMUN, V121, P135, DOI 10.1016/j.jaci.2007.07.061
   Guigoz Y, 2008, CURR OPIN CLIN NUTR, V11, P13, DOI 10.1097/MCO.0b013e3282f2bfdf
   Harmsen HJM, 2000, J PEDIATR GASTR NUTR, V30, P61, DOI 10.1097/00005176-200001000-00019
   HARTLEY MG, 1992, J MED MICROBIOL, V36, P96, DOI 10.1099/00222615-36-2-96
   Heavey Patricia M., 1999, Microbial Ecology in Health and Disease, V11, P75
   Heilig HGHJ, 2002, APPL ENVIRON MICROB, V68, P114, DOI 10.1128/AEM.68.1.114-123.2002
   Hopkins MJ, 2001, GUT, V48, P198, DOI 10.1136/gut.48.2.198
   KEIGHLEY MRB, 1978, GUT, V19, P1099, DOI 10.1136/gut.19.12.1099
   Khachatryan ZA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003064
   Liu CH, 2008, P NATL ACAD SCI USA, V105, P3951, DOI 10.1073/pnas.0709266105
   Mackie RI, 1999, AM J CLIN NUTR, V69, p1035S, DOI 10.1093/ajcn/69.5.1035s
   Manichanh C, 2006, GUT, V55, P205, DOI 10.1136/gut.2005.073817
   Martinez-Medina M, 2006, INFLAMM BOWEL DIS, V12, P1136, DOI 10.1097/01.mib.0000235828.09305.0c
   MITSUOKA T, 1992, NUTR REV, V50, P438
   Neish AS, 2009, GASTROENTEROLOGY, V136, P65, DOI 10.1053/j.gastro.2008.10.080
   Nieuwenhuis EES, 2008, DIGEST LIVER DIS, V40, P12, DOI 10.1016/j.dld.2007.07.166
   O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731
   Ott SJ, 2004, GUT, V53, P685, DOI 10.1136/gut.2003.025403
   Ouwehand AC, 2001, J ALLERGY CLIN IMMUN, V108, P144, DOI 10.1067/mai.2001.115754
   Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177
   PEACH S, 1978, GUT, V19, P1034, DOI 10.1136/gut.19.11.1034
   Peterson DA, 2008, CELL HOST MICROBE, V3, P417, DOI 10.1016/j.chom.2008.05.001
   Peyrin-Biroulet L, 2007, GASTROENTEROLOGY, V132, P2594, DOI 10.1053/j.gastro.2007.04.027
   Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059
   Satokari RM, 2001, APPL ENVIRON MICROB, V67, P504, DOI 10.1128/AEM.67.2.504-513.2001
   Saunier K, 2002, DIGEST LIVER DIS, V34, pS19, DOI 10.1016/S1590-8658(02)80158-X
   Scanlan PD, 2006, J CLIN MICROBIOL, V44, P3980, DOI 10.1128/JCM.00312-06
   Schippa S, 2009, INFLAMM BOWEL DIS, V15, P661, DOI 10.1002/ibd.20818
   Schwiertz A, 2003, PEDIATR RES, V54, P393, DOI 10.1203/01.PDR.0000078274.74607.7A
   Seksik P, 2003, GUT, V52, P237, DOI 10.1136/gut.52.2.237
   Sepehri S, 2007, INFLAMM BOWEL DIS, V13, P675, DOI 10.1002/ibd.20101
   Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x
   Sokol H, 2006, INFLAMM BOWEL DIS, V12, P106, DOI 10.1097/01.MIB.0000200323.38139.c6
   Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105
   Strober W, 2007, J CLIN INVEST, V117, P514, DOI 10.1172/JCI30587
   Suau A, 1999, APPL ENVIRON MICROB, V65, P4799
   Swidsinski A, 2005, J CLIN MICROBIOL, V43, P3380, DOI 10.1128/JCM.43.7.3380-3389.2005
   Swidsinski A, 2005, WORLD J GASTROENTERO, V11, P1131, DOI 10.3748/wjg.v11.i8.1131
   Tannock GW, 2008, TRENDS MICROBIOL, V16, P488, DOI 10.1016/j.tim.2008.07.005
   Tannock GW, 2002, ENTEROCOCCI: PATHOGENESIS, MOLECULAR BIOLOGY, AND ANTIBIOTIC RESISTANCE, P101
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   VANDEMERWE JP, 1988, SCAND J GASTROENTERO, V23, P1125, DOI 10.3109/00365528809090179
   Vasquez N, 2007, INFLAMM BOWEL DIS, V13, P684, DOI 10.1002/ibd.20084
   Willing B, 2009, INFLAMM BOWEL DIS, V15, P653, DOI 10.1002/ibd.20783
   Young SL, 2004, CLIN DIAGN LAB IMMUN, V11, P686, DOI 10.1128/CDLI.11.4.686-690.2004
   Zoetendal EG, 1998, APPL ENVIRON MICROB, V64, P3854
   Zoetendal EG, 2002, APPL ENVIRON MICROB, V68, P4225, DOI 10.1128/AEM.68.9.4225-4232.2002
NR 59
TC 39
Z9 40
U1 4
U2 20
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0257-2753
EI 1421-9875
J9 DIGEST DIS
JI Dig. Dis.
PY 2009
VL 27
IS 3
BP 252
EP 258
DI 10.1159/000228558
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 501DU
UT WOS:000270360500009
PM 19786749
DA 2018-12-27
ER

PT J
AU Wilson, RL
   Muir, HC
AF Wilson, Rebecca L.
   Muir, Helen C.
TI RETRACTED: The effect of overwing hatch placement on evacuation from
   smaller transport aircraft (Retracted article. See vol. 52, pg. 1321,
   2009)
SO ERGONOMICS
LA English
DT Article; Retracted Publication
DE aircraft emergency evacuation; smaller transport aircraft; overwing Type
   III exits; exit hatch placement
AB Overwing exits are installed on a number of smaller transport aircraft. With a traditional overwing exit, once released, the hatch is not attached to the fuselage and will fall into the cabin. To operate, the hatch has to be brought inwards, manoeuvred and placed in a location where it does not obstruct egress. Accidents and experimental studies have shown that the hatch is not always disposed of into an appropriate location. Evacuation trials from a smaller transport aircraft cabin were conducted. The placement of the exit hatch was manipulated. The results indicated that hatch placement had a significant effect on passenger evacuation rates from a smaller transport aircraft, with the internal placement tested resulting in slower evacuation rates. The study has highlighted the importance of operators disposing of the hatch into a location whereby it does not impede egress. One way to ensure this would be the installation of an automatically disposed hatch.
C1 [Wilson, Rebecca L.; Muir, Helen C.] Cranfield Univ, Dept Syst Engn & Human Factors, Cranfield MK43 0AL, Beds, England.
RP Wilson, RL (reprint author), Cranfield Univ, Dept Syst Engn & Human Factors, Cranfield MK43 0AL, Beds, England.
EM rebecca.wilson@cranfield.ac.uk
OI Grant, Rebecca/0000-0003-1748-1480
CR *AIR ACC INV BRANC, 1988, 888 AIR ACC INV BRAN
   British Psychological Society, 2006, COD ETH COND
   *CAB SAF HARM WORK, 2002, AV RUL ADV COMM OCC
   CHERRY RGW, 2006, ANAL ACCIDENTS RELAT
   COBBETT AM, 2001, 20016 CAA
   COBBETT AM, 1997, 97006 CAA
   *EUR AV SAF AG, 2008, NOT PROP AM NPA NO
   *EUR AV SAF AG, 2003, CS25 EUR AV SAF AG
   *FED AV ADM, 1999, AV RUL ADV COMM OCC
   FENNELL PJ, 1993, 93015 CAA
   *FLIGHT SAF FDN ED, 2001, CABIN CREW SAFETY, V36, P1
   Galea E., 2003, PASSENGER BEHAV, P128
   MCLEAN GA, 2002, DOTFAAAM0213
   MCLEAN GA, 1992, DOTFAAAM9227
   Muir H., 1996, 95006 CAA
   Muir H., 1989, 89019 CAA
   Muir H., 1992, 92005 CAA
   National Transportation Safety Board, 2000, NTSBSS0001
   RASMUSSEN PG, 1989, DOTFAAAM8914
   2002, 200804 NPA EUR AV SA
   2002, UNIFIED SUBMISSION D
NR 21
TC 1
Z9 1
U1 3
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0014-0139
EI 1366-5847
J9 ERGONOMICS
JI Ergonomics
PY 2009
VL 52
IS 8
BP 931
EP 938
AR PII 913246563
DI 10.1080/00140130902759204
PG 8
WC Engineering, Industrial; Ergonomics; Psychology, Applied; Psychology
SC Engineering; Psychology
GA 474IR
UT WOS:000268277500004
PM 19629808
DA 2018-12-27
ER

PT J
AU Jarvis, S
   Harris, D
AF Jarvis, Steve
   Harris, Don
TI RETRACTED: Development of a bespoke human factors taxonomy for gliding
   accident analysis and its revelations about highly inexperienced UK
   glider pilots (Retracted Article. See vol 52, pg 1321, 2009)
SO ERGONOMICS
LA English
DT Article; Retracted Publication
DE gliding; glider pilots; accident; taxonomy; inexperienced; approach
   judgement; final approach
AB Low-hours solo glider pilots have a high risk of accidents compared to more experienced pilots. Numerous taxonomies for causal accident analysis have been produced for powered aviation but none of these is suitable for gliding, so a new taxonomy was required. A human factors taxonomy specifically for glider operations was developed and used to analyse all UK gliding accidents from 2002 to 2006 for their overall causes as well as factors specific to low hours pilots. Fifty-nine categories of pilot-related accident causation emerged, which were formed into progressively larger categories until four overall human factors groups were arrived at: 'judgement'; 'handling'; 'strategy'; 'attention'. 'Handling' accounted for a significantly higher proportion of injuries than other categories. Inexperienced pilots had considerably more accidents in all categories except 'strategy'. Approach control (path judgement, airbrake and speed handling) as well as landing flare misjudgement were chiefly responsible for the high accident rate in early solo glider pilots.
C1 [Jarvis, Steve; Harris, Don] Cranfield Univ, Dept Syst Engn & Human Factors, Sch Engn, Cranfield MK43 0AL, Beds, England.
RP Jarvis, S (reprint author), Cranfield Univ, Dept Syst Engn & Human Factors, Sch Engn, Cranfield MK43 0AL, Beds, England.
EM s.r.jarvis@cranfield.ac.uk
OI Harris, Don/0000-0002-2113-8848
CR BAKER P, 1996, DOTFAAAM963 OFF AV M
   *BRIT GLID ASS, 2007, UK GLID ACC DA UNPUB
   *CIV AV AUTH, 1997, 667 CAP CIV AV AUTH
   FEGGETTER AJ, 1982, ERGONOMICS, V25, P1065, DOI 10.1080/00140138208925065
   GERBERT K, 1986, ERGONOMICS, V29, P1439, DOI 10.1080/00140138608967257
   Glaser B. G., 1967, DISCOVERY GROUNDED T
   Hollnagel E., 1998, COGNITIVE RELIABILIT
   Jarvis S, 2007, AVIAT SPACE ENVIR MD, V78, P1155, DOI 10.3357/ASEM.2128.2007
   Kasarskis P, 2001, 11 INT S AV PSYCH CO
   LENNE M, 2006, HUMAN FACTORS AEROSP, V6, P395
   O'Hare D, 2000, ERGONOMICS, V43, P2001, DOI 10.1080/00140130050201445
   OHARE D, 1994, ERGONOMICS, V37, P1855, DOI 10.1080/00140139408964954
   Partington D., 2002, ESSENTIAL SKILLS MAN, P136
   PIGGOTT D, 1997, GLIDING HDB SOARING
   Reason J, 1990, HUMAN ERROR
   Reason J, 1997, MANAGING RISKS ORG A
   REICHMANN H, 1993, CROSS COUNTRY SOARIN
   Robson C., 2002, REAL WORLD RES
   SHAPPELL S, 2003, DOTFAAAM034 OFF AER
   Shappell S., 2003, HUMAN ERROR GEN AVIA
   SHAPPELL S, 2004, HUMAN ERROR GEN AVIA
   Shappell S.A., 2000, DOTFAAAM007 OFF AV M
   STEWART K, 1994, GLIDER PILOTS MANUAL
   Strauss A., 1990, BASICS QUALITATIVE R
   THOM T, 1997, AIR PILOTS MANUAL, V1
   van Doorn RRA, 2007, AVIAT SPACE ENVIR MD, V78, P26
   WEIGMANN D, 2005, DOTFAAAM0524 OFF AER
   WEIGMANN D, 2001, 11 INT S AV PSYCH CO
   Weigmann DA, 2003, HUMAN ERROR APPROACH
NR 29
TC 3
Z9 3
U1 4
U2 17
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0014-0139
EI 1366-5847
J9 ERGONOMICS
JI Ergonomics
PY 2009
VL 52
IS 8
BP 1009
EP 1018
AR PII 913252724
DI 10.1080/00140130902836259
PG 10
WC Engineering, Industrial; Ergonomics; Psychology, Applied; Psychology
SC Engineering; Psychology
GA 474IR
UT WOS:000268277500011
PM 19629815
DA 2018-12-27
ER

PT J
AU Xia, ZH
   Xu, BQ
   Mugler, I
   Wu, GJ
   Gleixner, G
   Sachse, D
   Zhu, LP
AF Xia, Zhonghuan
   Xu, Baiqing
   Muegler, Ines
   Wu, Guangjian
   Gleixner, Gerd
   Sachse, Dirk
   Zhu, Liping
TI RETRACTED: Paleoclimatic implications of the hydrogen isotopic
   composition of terrigenous n-alkanes from Lake Yamzho, southern Tibetan
   Plateau (Retracted article. See vol. 44, pg. 159, 2010)
SO GEOCHEMICAL JOURNAL
LA English
DT Article; Retracted Publication
DE n-alkanes; lacustrine sediments; delta D; Tibetan Plateau; paleoclimate
ID STABLE ISOTOPES; DELTA-D; LACUSTRINE SEDIMENTS; CLIMATE VARIABILITY;
   SURFACE SEDIMENT; AQUATIC PLANTS; D/H RATIOS; LEAF WAXES; WATER;
   PRECIPITATION
AB The hydrogen isotopic composition (delta D) of leaf water used for biosynthesis of n-alkanes can be modified by climate. Therefore, the delta D call be considered Lis potential paleoclimatic proxy to explore. We compared measured delta D Values of alkalies (n-C-25 to n-C-31) extracted front a short sediment profile spanning the past 50 years with a 7-year resolution from Lake Yamzho, Southern Tibetan Plateau. Climatic control was reconstructed using meteorological records of the nearby Langkazi and Lhasa weather stations. We found that the delta D values of the n-alkanes correlated with the mean annual air temperature and significantly correlated with the mean growing season air temperature. Oil the other hand, the delta D values show poor correlations with both rainfall amount and relative humidity. These results indicate that stable isotope composition of n-alkanes Could be ail excellent proxy for paleotemperature reconstruction.
C1 [Xia, Zhonghuan; Xu, Baiqing; Wu, Guangjian; Zhu, Liping] Chinese Acad Sci, Inst Tibetan Plateau Res, Beijing 100085, Peoples R China.
   [Muegler, Ines; Gleixner, Gerd; Sachse, Dirk] Max Planck Inst Biogeochem, D-07701 Jena, Germany.
RP Xu, BQ (reprint author), Chinese Acad Sci, Inst Tibetan Plateau Res, Beijing 100085, Peoples R China.
EM baiqing@itpcas.ac.cn
RI Gleixner, Gerd/M-8519-2017
OI Gleixner, Gerd/0000-0002-4616-0953
FU National Basic Research Program of China [2005CB422004]; National
   Natural Science Foundation of China [4012 110]
FX Acknowledgments-This project Was funded by the National Basic Research
   Program of China (grant No. 2005CB422004) and the National Natural
   Science Foundation of China (Innovation Research Groups) (grant No. 4012
   110).
CR Allen JRM, 1999, NATURE, V400, P740, DOI 10.1038/23432
   Andersen N, 2001, GEOLOGY, V29, P799, DOI 10.1130/0091-7613(2001)029<0799:LARCVD>2.0.CO;2
   Burgoyne TW, 1998, ANAL CHEM, V70, P5136, DOI 10.1021/ac980248v
   [陈拓 Chen Tuo], 2003, [冰川冻土, Journal of Glaciology and Geocryology], V25, P83
   Chikaraishi Y, 2003, PHYTOCHEMISTRY, V63, P361, DOI 10.1016/S0031-9422(02)00749-5
   CRANWELL P A, 1973, Freshwater Biology, V3, P259, DOI 10.1111/j.1365-2427.1973.tb00921.x
   CRANWELL PA, 1987, ORG GEOCHEM, V11, P513, DOI 10.1016/0146-6380(87)90007-6
   Dansgaard W., 1953, Tellus, V5, P461
   DANSGAARD W, 1964, TELLUS, V16, P436
   Dawson TE, 2002, ANNU REV ECOL SYST, V33, P507, DOI 10.1146/annurev.ecolsys.33.020602.095451
   EHHALT D, 1963, J GEOPHYS RES, V68, P3775, DOI 10.1029/JZ068i013p03775
   Ficken KJ, 2000, ORG GEOCHEM, V31, P745, DOI 10.1016/S0146-6380(00)00081-4
   Fisher E, 2003, ORG GEOCHEM, V34, P105, DOI 10.1016/S0146-6380(02)00145-6
   Gat JR, 1996, ANNU REV EARTH PL SC, V24, P225, DOI 10.1146/annurev.earth.24.1.225
   Glinton GE, 1967, SCIENCE, V156, P1322
   HAN J, 1969, P NATL ACAD SCI USA, V64, P436, DOI 10.1073/pnas.64.2.436
   Hilkert AW, 1999, RAPID COMMUN MASS SP, V13, P1226, DOI 10.1002/(SICI)1097-0231(19990715)13:13<1226::AID-RCM575>3.0.CO;2-9
   Hou JZ, 2007, ORG GEOCHEM, V38, P977, DOI 10.1016/j.orggeochem.2006.12.009
   Huang YS, 2004, J PALEOLIMNOL, V31, P363, DOI 10.1023/B:JOPL.0000021855.80535.13
   Jacob J, 2007, QUATERNARY SCI REV, V26, P1004, DOI 10.1016/j.quascirev.2006.12.004
   Kang SC, 2000, J GLACIOL, V46, P222
   Larcher W, 1995, PHYSL PLANT ECOLOGY
   Li MingCai, 2004, Acta Botanica Boreali-Occidentalia Sinica, V24, P1052
   Li XB, 1999, ACTA SEDIMENTOLOGICA, V17, P325, DOI [10.3969/j.issn.1000-0550.1999.02.027, DOI 10.3969/J.ISSN.1000-0550.1999.02.027]
   Liu WG, 2006, OECOLOGIA, V150, P330, DOI 10.1007/s00442-006-0494-0
   Liu WG, 2005, ORG GEOCHEM, V36, P851, DOI 10.1016/j.orggeochem.2005.01.006
   Makou MC, 2007, ORG GEOCHEM, V38, P1680, DOI 10.1016/j.orggeochem.2007.06.003
   MEYERS PA, 1993, ORG GEOCHEM, V20, P867, DOI 10.1016/0146-6380(93)90100-P
   PENNINGTON W, 1976, FRESHWATER BIOL, V6, P317, DOI 10.1111/j.1365-2427.1976.tb01617.x
   RIELEY G, 1991, ORG GEOCHEM, V17, P901, DOI 10.1016/0146-6380(91)90031-E
   Sachse D, 2004, GEOCHIM COSMOCHIM AC, V68, P4877, DOI 10.1016/j.gca.2004.06.004
   Sauer PE, 2001, GEOCHIM COSMOCHIM AC, V65, P213, DOI 10.1016/S0016-7037(00)00520-2
   Schimmelmann A, 1999, GEOCHIM COSMOCHIM AC, V63, P3751, DOI 10.1016/S0016-7037(99)00221-5
   Shi W G, 1995, J LAKE SCI, V7, P178
   Smith FA, 2006, GEOCHIM COSMOCHIM AC, V70, P1172, DOI 10.1016/j.gca.2005.11.006
   TAN SQ, 2007, TIBETAN J AGR SCI, V29, P31
   Tian L, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002173
   Tian L, 2001, SCI CHINA SER D, V44, P789, DOI 10.1007/BF02907091
   Tian L, 2001, J GEOPHYS RES-ATMOS, V106, P28081, DOI 10.1029/2001JD900186
   TIAN L, 1997, J GLACIOLOGY GEOCRYO, V19, P295
   Tian LD, 2001, J METEOROL SOC JPN, V79, P959, DOI 10.2151/jmsj.79.959
   TIAN LD, 1999, J GLACIOL GEOCRYOL, V21, P357
   [田立德 Tian Lide], 2006, [第四纪研究, Quaternary Sciences], V26, P145
   VISO AC, 1993, PHYTOCHEMISTRY, V34, P381, DOI 10.1016/0031-9422(93)80012-H
   Wan G.J., 1999, QUATERNARY SCI, V19, P73
   Wan Guojiang, 1997, QUATERNARY SCI, V17, P230
   Wang CJ, 2005, J ORTHOP RES, V23, P274, DOI 10.1016/j.orthres.2004.07.004
   WERSHAW RL, 1970, ORG GEOCHEM, V3, P55
   Xia ZH, 2008, GEOCHEM J, V42, P331, DOI 10.2343/geochemj.42.331
   Xie S, 2000, ORG GEOCHEM, V31, P1053, DOI 10.1016/S0146-6380(00)00116-9
   Xie SC, 2004, GEOCHIM COSMOCHIM AC, V68, P2849, DOI 10.1016/j.gca.2003.08.025
   YAKIR D, 1989, GEOCHIM COSMOCHIM AC, V53, P2769, DOI 10.1016/0016-7037(89)90147-6
   Yang H, 2003, ORG GEOCHEM, V34, P413, DOI 10.1016/S0146-6380(02)00212-7
   Zhu LP, 2003, J PALEOLIMNOL, V29, P391, DOI 10.1023/A:1024440516843
NR 54
TC 0
Z9 0
U1 4
U2 32
PU GEOCHEMICAL SOC JAPAN
PI TOKYO
PA 358-5 YAMABUKI-CHO, SHINJUKU-KU, TOKYO, 162-0801, JAPAN
SN 0016-7002
EI 1880-5973
J9 GEOCHEM J
JI Geochem. J.
PY 2009
VL 43
IS 4
BP 275
EP 286
DI 10.2343/geochemj.1.0024
PG 12
WC Geochemistry & Geophysics
SC Geochemistry & Geophysics
GA 490OH
UT WOS:000269509900006
OA Bronze
DA 2018-12-27
ER

PT J
AU Calvino-Casilda, V
   Guerrero-Perez, MO
   Banares, MA
AF Calvino-Casilda, Vanesa
   Olga Guerrero-Perez, M.
   Banares, Miguel A.
TI RETRACTED: Efficient microwave-promoted acrylonitrile sustainable
   synthesis from glycerol (Retracted article. See vol. 18, pg. 6395, 2016)
SO GREEN CHEMISTRY
LA English
DT Article; Retracted Publication
ID V-O CATALYSTS; PROPANE AMMOXIDATION; COMMODITY CHEMICALS; CONVERSION;
   BIOMASS; FUELS
AB Solvent-free microwave-activation, in the liquid phase using an alumina supported V-Sb-O catalyst, affords highly efficient conversion (47%) of glycerol into acrylonitrile under mild conditions, short reaction times and in the absence of any solvent; in addition, it increases selectivity (> 80%) compared to conventional thermal activation.
C1 [Calvino-Casilda, Vanesa; Banares, Miguel A.] CSIC, Inst Catalisis & Petroleoquim, Catalyt Spect Lab, E-28049 Madrid, Spain.
   [Olga Guerrero-Perez, M.] Univ Malaga, Dept Ingn Quim, E-29071 Malaga, Spain.
RP Calvino-Casilda, V (reprint author), CSIC, Inst Catalisis & Petroleoquim, Catalyt Spect Lab, Marie Curie 2, E-28049 Madrid, Spain.
EM vcalvino@icp.csic.es
RI Banares, Miguel A./C-3873-2013
OI Banares, Miguel A./0000-0003-3875-4468; Guerrero-Perez, M.
   Olga/0000-0002-3786-5839
FU Spanish Ministry of Education and Science [CTQ2008-04261/PPQ]; ESF COST
   Action [D36-006-06]
FX This research was funded by Spanish Ministry of Education and Science
   (CTQ2008-04261/PPQ) and ESF COST Action D36-006-06. The authors thank
   also Prof. Martin-Aranda from Department of Inorganic Chemistry and
   Technical Chemistry (UNED, Madrid) for her help with the Microwave
   equipment. Alumina was provided by Girdler-Sud-Chemie.
CR Banares MA, 2002, J RAMAN SPECTROSC, V33, P359, DOI 10.1002/jrs.866
   Behr A, 2008, GREEN CHEM, V10, P13, DOI 10.1039/b710561d
   Chheda JN, 2007, ANGEW CHEM INT EDIT, V46, P7164, DOI 10.1002/anie.200604274
   Fernando S, 2006, ENERG FUEL, V20, P1727, DOI 10.1021/ef060097w
   Guerrero-Perez MO, 2006, TOP CATAL, V41, P43, DOI 10.1007/s11244-006-0093-7
   Guerrero-Perez M. Olga, 2009, Recent Patents on Chemical Engineering, V2, P11, DOI 10.2174/1874478810902010011
   Guerrero-Perez MO, 2002, CHEM COMMUN, P1292, DOI 10.1039/b202556f
   Guerrero-Perez MO, 2002, J CATAL, V206, P339, DOI 10.1006/jcat.2001.3494
   Huber GW, 2006, CHEM REV, V106, P4044, DOI 10.1021/cr068360d
   LOUPY A, 2006, MICROWAVES ORGANIC S
   Luque R, 2008, ENERG ENVIRON SCI, V1, P542, DOI 10.1039/b807094f
   Guerrero-Perez MO, 2008, CHEMSUSCHEM, V1, P511, DOI 10.1002/cssc.200800023
   Pagliaro M, 2008, RSC GREEN CHEM SER, P1
   Pagliaro M, 2009, EUR J LIPID SCI TECH, V111, P788, DOI 10.1002/ejlt.200800210
   Ruppert AM, 2008, CHEM-EUR J, V14, P2016, DOI 10.1002/chem.200701757
   Xiong G, 2005, J CATAL, V230, P317, DOI 10.1016/j.jcat.2004.11.046
   Zheng YG, 2008, CHEM REV, V108, P5253, DOI 10.1021/cr068216s
   Zhou CHC, 2008, CHEM SOC REV, V37, P527, DOI 10.1039/b707343g
NR 18
TC 34
Z9 34
U1 4
U2 36
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9262
EI 1463-9270
J9 GREEN CHEM
JI Green Chem.
PY 2009
VL 11
IS 7
BP 939
EP 941
DI 10.1039/b904689e
PG 3
WC Chemistry, Multidisciplinary; GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY
SC Chemistry; Science & Technology - Other Topics
GA 467GY
UT WOS:000267727800006
DA 2018-12-27
ER

PT J
AU Seyhan, EC
   Altin, S
   Cetinkaya, E
   Sokucu, S
   Gunluoglu, MZ
   Demir, A
   Korkmaz, P
   Issever, H
AF Seyhan, Ekrem Cengiz
   Altin, Sedat
   Cetinkaya, Erdogan
   Sokucu, Sinem
   Gunluoglu, Mehmet Zeki
   Demir, Adalet
   Korkmaz, Pelin
   Issever, Halim
TI RETRACTED: The Importance of Pleural Fluid and Serum NT-proBNP Levels in
   Differentiating Pleural Effusion due to Heart Failure from Other Causes
   of Effusion (Retracted article. See vol. 48, pg. 1783, 2009)
SO INTERNAL MEDICINE
LA English
DT Article; Retracted Publication
DE congestive heart failure; natriuretic peptides; pleural effusion;
   serum-pleural fluid albumin gradients
ID BRAIN NATRIURETIC PEPTIDE; EMERGENCY DIAGNOSIS; ALBUMIN GRADIENT;
   SEPARATION; ACCURACY; CRITERIA
AB Background and Objective Pleural effusion due to congestive heart failure (CHF) typically are transudates. Light's criteria may be insufficient in determining if the pleural effusion is transudative or exudative in patients with CHF. The aim of our study was to assess the diagnostic performance of the amino-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) in pleural fluid and serum for the identification of pleural effusion owing to heart failure.
   Methods The study prospectively evaluated NT-proBNP in serum and pleural fluid from patients with effusion owing to heart failure (n=51) and other causes (n=64). Measurements were made of levels of NT-proBNP by an electrochemiluminiscence immunoassay. The discriminative properties of NT-proBNP levels in identifying pleural effusion due to heart failure were determined by receiver operating characteristic curve (ROC) analysis and compared to the diagnostic value of finding a transudate by Light's criteria and serum-pleural fluid albumin gradients.
   Results Serum and pleural fluid NT-proBNP levels were significantly elevated in patients with pleural effusion owing to heart failure. The area under ROC for the diagnosis of pleural effusion from heart failure was similar for pleural fluid (0.973, 95% CI: 0.914-0.995) and serum (0.968, 95% CI: 0.890-0.989) NT-proBNP.
   Conclusion NT-proBNP levels in either pleural fluid or serum have high diagnostic values and they are easily useable parameters in the diagnosis of heart failure-related pleural effusion.
C1 [Seyhan, Ekrem Cengiz; Altin, Sedat; Cetinkaya, Erdogan; Sokucu, Sinem; Gunluoglu, Mehmet Zeki; Demir, Adalet; Korkmaz, Pelin] Yedikule Chest Dis & Thorac Surg Educ & Res Hosp, Dept Chest Dis, Istanbul, Turkey.
   [Issever, Halim] Istanbul Univ, Fac Med, Dept Biostat, Istanbul, Turkey.
RP Seyhan, EC (reprint author), Yedikule Chest Dis & Thorac Surg Educ & Res Hosp, Dept Chest Dis, Istanbul, Turkey.
EM drekremcs@yahoo.com
CR BARTTER T, 1994, CHEST, V106, P1209, DOI 10.1378/chest.106.4.1209
   BERKOWITZ R, 2004, REV CARDIOVASC MED, V5, P3
   CHAKKO SC, 1989, CHEST, V95, P798, DOI 10.1378/chest.95.4.798
   Eid AA, 2002, CHEST, V122, P1518, DOI 10.1378/chest.122.5.1518
   Gegenhuber A, 2005, CHEST, V128, P1003, DOI 10.1378/chest.128.2.1003
   Harrison A, 2002, ANN EMERG MED, V39, P131, DOI 10.1067/mem.2002.121483
   Kazanegra R, 2001, J CARD FAIL, V7, P21, DOI 10.1054/jcaf.2001.23355
   Kolditz M, 2006, EUR RESPIR J, V28, P144, DOI 10.1183/09031936.06.00113205
   Liao H, 2008, RESPIROLOGY, V13, P53, DOI 10.1111/j.1440-1843.2007.01191.x
   LIGHT RW, 1972, ANN INTERN MED, V77, P507, DOI 10.7326/0003-4819-77-4-507
   Maisel AS, 2002, NEW ENGL J MED, V347, P161, DOI 10.1056/NEJMoa020233
   MAREL M, 1993, CHEST, V104, P1486, DOI 10.1378/chest.104.5.1486
   McCullough Peter A, 2003, Rev Cardiovasc Med, V4, P72
   McDonagh TA, 2004, EUR J HEART FAIL, V6, P269, DOI 10.1016/j.ejheart.2004.01.010
   Mueller T, 2005, HEART, V91, P606, DOI 10.1136/hrt.2004.037762
   Omland T, 1996, HEART, V76, P232, DOI 10.1136/hrt.76.3.232
   Porcel JM, 2004, AM J MED, V116, P417, DOI 10.1016/j.amjmed.2003.11.008
   Porcel JM, 2007, RESPIROLOGY, V12, P654, DOI 10.1111/j.1440-1843.2007.01109.x
   ROMERO S, 1993, CHEST, V104, P399, DOI 10.1378/chest.104.2.399
   Romero-Candeira S, 2001, AM J MED, V110, P681, DOI 10.1016/S0002-9343(01)00726-4
   ROTH BJ, 1990, CHEST, V98, P546, DOI 10.1378/chest.98.3.546
   SHINTO R A, 1988, American Review of Respiratory Disease, V137, P458
   Tomcsanyi J, 2004, EUR J HEART FAIL, V6, P753, DOI 10.1016/j.ejheart.2003.11.017
NR 23
TC 11
Z9 12
U1 3
U2 18
PU JAPAN SOC INTERNAL MEDICINE
PI TOKYO
PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN
SN 0918-2918
EI 1349-7235
J9 INTERNAL MED
JI Intern. Med.
PY 2009
VL 48
IS 5
BP 287
EP 293
DI 10.2169/internalmedicine.48.1607
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 416YT
UT WOS:000264042100007
PM 19252349
OA Bronze
DA 2018-12-27
ER

PT J
AU Shin, DH
AF Shin, Dong Hee
TI RETRACTED: The Evaluation of User Experience of the Virtual World in
   Relation to Extrinsic and Intrinsic Motivation (Retracted article. See
   vol. 29, pg. 438, 2013)
SO INTERNATIONAL JOURNAL OF HUMAN-COMPUTER INTERACTION
LA English
DT Article; Retracted Publication
ID TECHNOLOGY ACCEPTANCE MODEL; INDIVIDUAL-DIFFERENCES; INFORMATION
   TECHNOLOGY; MOBILE INTERNET; FLOW EXPERIENCE; SOCIAL PRESENCE; PERCEIVED
   EASE; ENVIRONMENTS; COMMUNICATION; COMPUTERS
AB This study utilized the Technology Acceptance Model to study user attitude toward Second Life (SL), an emerging virtual environment. The objective is to explain the intrinsic and extrinsic motivational determinants of SL use. For this goal, the study built a model that links various factors to the attitude, intention, and flow in using SL. A survey instrument was utilized to collect data from SL users, and the data from the survey were analyzed statistically to establish the validity of the model by testing the 13 proposed hypotheses. The research identified factors such as synchronicity, empathy, and self-efficacy to be significant associated with users' motivations to use SL. The results of this study show that users' extrinsic and intrinsic motivations are significantly associated with their motivation to use SL. Extrinsically, synchronicity is found to have a significant effect on perceived usefulness. Intrinsically, empathy is identified as a key component for creating a more enjoyable experience. In addition, self-efficacy is found to have a significant effect on both extrinsic and intrinsic motivation. The study provides a more intensive view of virtual reality users and is an important step toward a better understanding of user behavior of advanced virtual reality like virtual actuality.
C1 Sung Kyung Kwan Univ, Dept Interact Sci, Seoul 110745, South Korea.
RP Shin, DH (reprint author), Sung Kyung Kwan Univ, Dept Interact Sci, 53 Myeongnyun Dong 3 Ga, Seoul 110745, South Korea.
CR Agarwal R, 2000, MIS QUART, V24, P665, DOI 10.2307/3250951
   Bagozzi R. P., 1988, J ACAD MARKET SCI, V16, P74, DOI DOI 10.1007/BF02723327
   Bailenson JN, 2005, PSYCHOL SCI, V16, P814, DOI 10.1111/j.1467-9280.2005.01619.x
   Bandura A., 1997, SELF EFFICACY EXERCI
   Batson CD, 1997, J PERS SOC PSYCHOL, V72, P105, DOI 10.1037/0022-3514.72.1.105
   BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238
   Brave S, 2005, INT J HUM-COMPUT ST, V62, P161, DOI 10.1016/j.ijhcs.2004.11.002
   BRIEF AP, 1979, J SOC PSYCHOL, V109, P289, DOI 10.1080/00224545.1979.9924205
   Brown J., 1998, P CHI 98, P376
   Browne M. W., 1993, TESTING STRUCTURAL E, P136, DOI DOI 10.1177/0049124192021002001
   Chen CM, 2000, J AM SOC INFORM SCI, V51, P499, DOI 10.1002/(SICI)1097-4571(2000)51:6<499::AID-ASI2>3.0.CO;2-K
   Cheong JH, 2005, INTERNET RES, V15, P125, DOI 10.1108/10662240510590324
   Chou TJ, 2003, CYBERPSYCHOL BEHAV, V6, P663, DOI 10.1089/109493103322725469
   Chung DH, 2005, CYBERPSYCHOL BEHAV, V8, P538, DOI 10.1089/cpb.2005.8.538
   Compeau D, 1999, MIS QUART, V23, P145, DOI 10.2307/249749
   Cook AJ, 2006, PAIN, V126, P319, DOI 10.1016/j.pain.2006.06.023
   CSIKSZENTMIHALY.M, 1977, BOREDOM ANXIETY
   Curl SS, 1998, DATA BASE ADV INF SY, V29, P50
   Cyr D, 2007, INTERACT COMPUT, V19, P43, DOI 10.1016/j.intcom.2006.07.010
   DAVIS FD, 1989, MIS QUART, V13, P319, DOI 10.2307/249008
   DAVIS FD, 1992, J APPL SOC PSYCHOL, V22, P1111, DOI 10.1111/j.1559-1816.1992.tb00945.x
   DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037//0022-3514.44.1.113
   DECI EL, 1971, J PERS SOC PSYCHOL, V18, P105, DOI 10.1037/h0030644
   EISSELE M, 2006, P IEEE C ROB AUT MEC, P1
   EtezadiAmoli J, 1996, INFORM MANAGE, V30, P65, DOI 10.1016/0378-7206(95)00052-6
   FABRI M, 2005, P 11 EATA INT C NETW, P23
   FETSCHERIN M, 2007, USER ACCEPTANCE VIRT
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   HASSANEIN K, 2006, INT J HUMAN COMPUTER, V64, P1230
   Heijden H, 2004, MIS Q, V23, P695
   Hershberger SL, 2003, STRUCT EQU MODELING, V10, P35, DOI 10.1207/S15328007SEM1001_2
   Hoffman DL, 1996, J MARKETING, V60, P50, DOI 10.2307/1251841
   Hofstede G. H., 2005, CULTURES ORG SOFTWAR
   Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599
   Huang MH, 2003, COMPUT HUM BEHAV, V19, P425, DOI 10.1016/S0747-5632(02)00080-8
   Igbaria M., 1996, Journal of Management Information Systems, V13, P127
   IGBARIA M, 1993, OMEGA-INT J MANAGE S, V21, P73, DOI 10.1016/0305-0483(93)90040-R
   Joreskog K. G., 1996, LISREL 8 USERS REFER
   Kalyanaraman S, 2006, J COMMUN, V56, P110, DOI 10.1111/j.1460-2466.2006.00006.x
   KITCHELL S, 1995, J ACAD MARKET SCI, V23, P195, DOI DOI 10.1177/0092070395233004
   Koufaris M, 2002, INFORM SYST RES, V13, P205, DOI 10.1287/isre.13.2.205.83
   KWON HS, 2000, P HICSS 34 HAW
   LOMBARD M, 2000, 3 INT WORKSH PRES DE
   Marcus A, 2005, P COMP HUM INT 6 AS, V3101/2004, P252
   Moon JW, 2001, INFORM MANAGE, V38, P217, DOI 10.1016/S0378-7206(00)00061-6
   Newhagen JE, 1996, J COMMUN, V46, P4, DOI 10.1111/j.1460-2466.1996.tb01458.x
   Novak TP, 2000, MARKET SCI, V19, P22, DOI 10.1287/mksc.19.1.22.15184
   Nowak KL, 2003, PRESENCE-TELEOP VIRT, V12, P481, DOI 10.1162/105474603322761289
   Nysveen H, 2005, J SERV RES-US, V7, P257, DOI 10.1177/1094670504271151
   Papadopoulou Panagiota, 2007, Virtual Reality, V11, P107, DOI 10.1007/s10055-006-0059-x
   Picard R. W., 1997, AFFECTIVE COMPUTING
   Reeves B., 1996, MEDIA EQUATION
   Reid D, 2004, PRESENCE-TELEOP VIRT, V13, P451, DOI 10.1162/1054746041944777
   Rettie R, 2001, INTERNET RES, V11, P103, DOI 10.1108/10662240110695070
   Schroeder R, 2002, SOCIAL LIFE AVATARS
   SCHWARZER R, 1994, PSYCHOL HEALTH, V9, P161, DOI 10.1080/08870449408407475
   SHIN D, 2007, TECHNOLOGICAL FORECA, V74, P910
   SHIN DH, 2008, CYBERPSYCHOLOGY BEHA, V11, P12
   Shin DH, 2007, INTERACT COMPUT, V19, P472, DOI 10.1016/j.intcom.2007.04.001
   Shin N, 2006, BRIT J EDUC TECHNOL, V37, P705, DOI 10.1111/j.1467-8535.2006.00641.x
   SIEKPE JS, 2005, J ELECTRON COMMER RE, V6, P31
   Straub D, 1997, INFORM MANAGE, V33, P1, DOI 10.1016/S0378-7206(97)00026-8
   Tomarken AJ, 2005, ANNU REV CLIN PSYCHO, V1, P31, DOI 10.1146/annurev.clinpsy.1.102803.144239
   TREVINO LK, 1992, COMMUN RES, V19, P539, DOI 10.1177/009365092019005001
   Twidale MB, 1997, INFORM PROCESS MANAG, V33, P761, DOI 10.1016/S0306-4573(97)00040-X
   Venkatesh V, 2000, MANAGE SCI, V46, P186, DOI 10.1287/mnsc.46.2.186.11926
   Venkatesh V, 1999, ORGAN BEHAV HUM DEC, V79, P1, DOI 10.1006/obhd.1999.2837
   Venkatesh V, 2000, INFORM SYST RES, V11, P342, DOI 10.1287/isre.11.4.342.11872
   Ward LC, 2006, PAIN, V121, P173, DOI 10.1016/j.pain.2006.01.002
NR 69
TC 38
Z9 39
U1 3
U2 37
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1044-7318
J9 INT J HUM-COMPUT INT
JI Int. J. Hum.-Comput. Interact.
PY 2009
VL 25
IS 6
BP 530
EP 553
AR PII 913648834
DI 10.1080/10447310902963951
PG 24
WC Computer Science, Cybernetics; Ergonomics
SC Computer Science; Engineering
GA 533BY
UT WOS:000272798300003
DA 2018-12-27
ER

PT J
AU Yamamoto, K
   Miyagawa, N
   Masaoka, T
   Katori, Y
   Shishido, T
   Imakiire, A
AF Yamamoto, Kengo
   Miyagawa, Naoki
   Masaoka, Toshinori
   Katori, Youichi
   Shishido, Takaaki
   Imakiire, Atsuhiro
TI RETRACTED: Cement Spacer Loaded With Antibiotics for Infected Implants
   of the Hip Joint (Retracted article. See vol. 26, pg. 824, 2011)
SO JOURNAL OF ARTHROPLASTY
LA English
DT Article; Retracted Publication
DE total hip arthroplasty; infected implants; two-stage procedure; cement
   spacer
ID 2-STAGE PROCEDURE; ARTHROPLASTY; REPLACEMENT; GENTAMICIN; REVISION; SITE
AB It is difficult to treat infected implants of the hip joints. Such treatment involves immeasurable physical and psychological suffering of the patients. We used antibiotic-impregnated cement spacers in 17 cases of infection after total hip arthroplasty and bipolar arthroplasty with good clinical results. We thoroughly removed any foreign material and formed an antibiotic-impregnated cement spacer into a similar shape as that of the implants. A cement spacer enables high-concentration antibiotics to act on infected sites. Also, it can prevent leg length discrepancy and atrophy of bones or muscles. Although cement spacers have been reported to have problems regarding shape and strength, we achieved good results with a cement spacer mold in the present study. No recurring infection has been found at a mean follow-up period of 3 years and 2 months.
C1 [Yamamoto, Kengo] Tokyo Med & Dent Univ, Dept Orthoped Surg, Shinjuku Ku, Tokyo 1600023, Japan.
RP Yamamoto, K (reprint author), Tokyo Med & Dent Univ, Dept Orthoped Surg, Shinjuku Ku, 6-7-1 Nishi Shinjuku, Tokyo 1600023, Japan.
CR Callaghan JJ, 1999, CLIN ORTHOP RELAT R, P139
   COVENTRY MB, 1975, ORTHOP CLIN N AM, V6, P991
   DUNCAN CP, 1994, J BONE JOINT SURG AM, V76A, P1742, DOI 10.2106/00004623-199411000-00020
   GARVIN KL, 1995, J BONE JOINT SURG AM, V77, P1576, DOI 10.2106/00004623-199510000-00015
   Hanssen AD, 1998, J BONE JOINT SURG AM, V80A, P910, DOI 10.2106/00004623-199806000-00016
   HIROSE S, 2002, J JOINT SURG, V21, P349
   IVARSSON I, 1994, ACTA ORTHOP SCAND, V65, P7, DOI 10.3109/17453679408993707
   Jackson WO, 2000, CLIN ORTHOP RELAT R, P101
   Koo KH, 2001, J ARTHROPLASTY, V16, P882, DOI 10.1054/arth.2001.24444
   Leunig M, 1998, INT ORTHOP, V22, P209, DOI 10.1007/s002640050244
   Magnan B, 2001, ACTA ORTHOP SCAND, V72, P591, DOI 10.1080/000164701317269003
   Masterson EL, 1997, J BONE JOINT SURG AM, V79A, P1740, DOI 10.2106/00004623-199711000-00017
   NELSON CL, 1993, CLIN ORTHOP RELAT R, V295, P96
   Paprosky W G, 1994, Chir Organi Mov, V79, P285
   PARK JS, 1996, NIHON KOTSU KANSETSU, V10, P39
   RAUT VV, 1995, CLIN ORTHOP RELAT R, V321, P202
   SANZEN L, 1989, J BONE JOINT SURG BR, V71, P638
   SCULCO TP, 1993, AAOS INSTR COURSE LE, V42, P349
   TONEGAWA M, 1998, J MUSCULOSKELET SYST, V11, P1019
   Tsukayama DT, 1996, J BONE JOINT SURG AM, V78A, P512, DOI 10.2106/00004623-199604000-00005
   WYMENGA AB, 1992, ACTA ORTHOP SCAND, V63, P665, DOI 10.1080/17453679209169732
NR 21
TC 21
Z9 22
U1 5
U2 12
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0883-5403
EI 1532-8406
J9 J ARTHROPLASTY
JI J. Arthroplast.
PD JAN
PY 2009
VL 24
IS 1
BP 83
EP 89
DI 10.1016/j.arth.2004.06.032
PG 7
WC Orthopedics
SC Orthopedics
GA 391MF
UT WOS:000262236700014
PM 18534388
DA 2018-12-27
ER

PT J
AU Salam, MA
AF Salam, Mohammad Asif
TI RETRACTED: Corporate Social Responsibility in Purchasing and Supply
   Chain (Retracted article. See vol. 113, pg. 183, 2013)
SO JOURNAL OF BUSINESS ETHICS
LA English
DT Review; Retracted Publication
DE corporate social responsibility; purchasing; supply chain; Thailand
ID ORGANIZATIONAL CULTURE; FINANCIAL PERFORMANCE; INITIAL EVIDENCE;
   BUSINESS; MANAGEMENT; INDUSTRY; VALUES; MODEL; ENVIRONMENT; INFORMANT
AB The purpose of this study is to understand the drivers of social responsibility in purchasing (PSR). This study replicated and extended the range of empirical application of the model developed by Carter and Jennings (Journal of Business Logistics 25(1), 145-186, 2004). Consequently, the present study contributes to the nomological validity of concept of PSR or Purchasing Social Responsibility. The method used is derived from the previous study by Carter and Jennings (journal of Business Logistics 25(1), 145-186, 2004), and the present study extends the application of that method to an Asian environment. The data were obtained from 197 respondents in Thailand. This sample was largely composed of purchasing and supply chain managers. Respondents were asked to indicate how different dimensions of corporate social responsibility (CSR) affect PSR. The findings of the present study suggest that all the six hypothesized paths have been substantiated. Individual values and people-oriented organizational culture are the most powerful predictors of PSR. This article contributes towards filling the gap in understanding the determinants of PSR. This article contributes towards filling the gap in understanding the determinants of PSR in managing supply chains, particularly in an Asian context.
C1 Assumption Univ, Sch Management, ABAC, Bangkok 10240, Thailand.
RP Salam, MA (reprint author), Assumption Univ, Sch Management, ABAC, Box 640,24 Ramkhamhaeng Rd, Bangkok 10240, Thailand.
EM mbamas@yahoo.com
OI Salam, Mohammad Asif/0000-0002-9306-0429
CR Andre R., 1995, J BUSINESS LOGISTICS, V16, P65
   ARMSTRONG JS, 1977, J MARKETING RES, V14, P396, DOI 10.2307/3150783
   Auskalnis R. J., 1999, J SUPPLY CHAIN MANAG, V35, P28, DOI DOI 10.1111/J.1745-493X.1999.TB00053.X
   Bagozzi R.P., 1994, PRINCIPLES MARKETING
   Banerjee SB, 2003, J MARKETING, V67, P106, DOI 10.1509/jmkg.67.2.106.18604
   BARNEY JB, 1986, ACAD MANAGE REV, V11, P656, DOI 10.2307/258317
   Bhattacharya CB, 2004, CALIF MANAGE REV, V47, P9, DOI 10.2307/41166284
   Bowen H. R, 1953, SOCIAL RESPONSIBILIT
   Brown TJ, 1997, J MARKETING, V61, P68, DOI 10.2307/1252190
   Campbell DT, 1955, AM J SOCIOL, V60, P339, DOI 10.1086/221565
   Carroll A., 1991, BUS HORIZONS, V34, P39, DOI [10.1016/0007-6813(91)90005-G, DOI 10.1016/0007-6813(91)90005-G]
   Carroll A. B., 1979, ACAD MANAGE REV, V4, P497, DOI [10.5465/AMR.1979.4498296, DOI 10.5465/AMR.1979.4498296]
   Carter C. R., 2005, International Journal of Physical Distribution & Logistics Management, V35, P177, DOI 10.1108/09600030510594567
   Carter C. R., 2004, Journal of Business Logistics, V25, P145
   Carter C.R., 2001, J SUPPLY CHAIN MANAG, V37, P12, DOI DOI 10.1111/J.1745-493X.2001.TB00102.X
   Carter C. R, 2000, J SUPPLY CHAIN MANAG, V36, P45
   Carter C. R., 2004, J SUPPLY CHAIN MANAG, V40, P4, DOI DOI 10.1111/JSCM.2004.40.ISSUE-4
   Carter C.R., 1998, INT J PURCHASING MAT, V34, P28, DOI DOI 10.1111/J.1745-493X.1998.TB00299.X
   Carter C. R., 2002, J BUSINESS LOGISTICS, V23, P145, DOI DOI 10.1002/J.2158-1592.2002.TB00020.X
   Carter CR, 1998, DECISION SCI, V29, P659, DOI 10.1111/j.1540-5915.1998.tb01358.x
   Carter CR, 2000, J OPER MANAG, V18, P191, DOI 10.1016/S0272-6963(99)00016-9
   Carter CR, 2002, TRANSPORT RES E-LOG, V38, P37, DOI 10.1016/S1366-5545(01)00008-4
   CARTER CR, 2003, J SUPPLY CHAIN MANAG, V39, P38
   CHATMAN JA, 1994, ACAD MANAGE J, V37, P522, DOI 10.2307/256699
   Chonko L.B., 1996, J PERSONAL SELLING S, V16, P35
   CHONKO LB, 1985, J BUS RES, V13, P339, DOI 10.1016/0148-2963(85)90006-2
   COOPER RW, 1997, EUROPEAN J PURCHASIN, V3, P189, DOI DOI 10.1016/S0969-7012(97)00013-0
   CORSI TM, 1988, LOGIST TRANSPORT REV, V24, P153
   Cullen J. B., 1988, ADM SCI Q, V33, P101, DOI [10.2307/2392857, DOI 10.2307/2392857]
   DAVIS K, 1960, CALIF MANAGE REV, V2, P70, DOI 10.2307/41166246
   DAVIS K, 1973, ACAD MANAGE J, V16, P312, DOI 10.2307/255331
   DEAN TJ, 1995, ACAD MANAGE J, V38, P288, DOI 10.2307/256737
   Denison D. R., 1990, CORPORATE CULTURE OR
   DENISON DR, 1995, ORGAN SCI, V6, P204, DOI 10.1287/orsc.6.2.204
   Dillman DA, 2000, MAIL INTERNET SURVEY
   Dollinger M. J., 1991, INT J PURCHASING MAT, V27, P9
   Donaldson T, 1996, HARVARD BUS REV, V74, P48
   DRUMWRIGHT ME, 1994, J MARKETING, V58, P1, DOI 10.2307/1252307
   Dubinsky A. J., 1981, J PURCHASING MATERIA, V17, P9
   Eden D, 2002, ACAD MANAGE J, V45, P841, DOI 10.5465/AMJ.2002.7718946
   Emmelhainz M. A., 1999, J SUPPLY CHAIN MANAG, V35, P51, DOI DOI 10.1111/J.1745-493X.1999.TB00062.X
   Freeman R. E., 1984, STRATEGIC MANAGEMENT
   FROHLICH M, 2003, J OPERATIONS MANAGEM, V21, P373
   FRY LW, 1982, ACAD MANAGE J, V25, P94, DOI 10.2307/256026
   GASKI JF, 1984, J MARKETING, V48, P9, DOI 10.2307/1251326
   Handeman JM, 1999, J MARKETING, V63, P33, DOI 10.2307/1251774
   Handfield R. B., 1997, Journal of Operations Management, V15, P293, DOI 10.1016/S0272-6963(97)00004-1
   HEELER RM, 1972, J MARKETING RES, V9, P361, DOI 10.2307/3149297
   HENDRICK C, 1990, J SOC BEHAV PERS, V5, P41
   HOFSTEDE G, 1990, ADMIN SCI QUART, V35, P286, DOI 10.2307/2393392
   Homburg C, 2000, J MARKETING RES, V37, P449, DOI 10.1509/jmkr.37.4.449.18786
   HUNT SD, 1984, J MARKETING RES, V21, P309, DOI 10.2307/3151607
   Hwang C.-E., 1996, INT J MANAGEMENT, V13, P332
   IBARRA H, 1993, ACAD MANAGE REV, V18, P56, DOI 10.5465/AMR.1993.3997507
   Jennings M.M., 1999, J PUBLIC LAW POLICY, V20, P1
   JOHN G, 1982, J MARKETING RES, V19, P517, DOI 10.2307/3151724
   Kabanoff B, 1996, J ORGAN BEHAV, V17, P201, DOI 10.1002/(SICI)1099-1379(199605)17:3<201::AID-JOB744>3.0.CO;2-9
   KELLY CW, 1979, HUMAN COMMUNICATION, V5, P338, DOI DOI 10.1111/J.1468-2958.1979.TB00646.X
   Kopicki R, 1993, REUSE RECYCLING REVE
   Kotter J. P, 1992, CORPORATE CULTURE PE
   Krause DR, 1998, J OPER MANAG, V17, P39, DOI 10.1016/S0272-6963(98)00030-8
   KUMAR N, 1993, ACAD MANAGE J, V36, P1633, DOI 10.2307/256824
   Lambert D. M., 1990, J BUSINESS LOGISTICS, V11, P5
   Lambert D. M., 1998, FUNDAMENTALS LOGISTI
   Lohr S., 1999, SAMPLING DESIGN ANAL
   LYKKEN DT, 1968, PSYCHOL BULL, V70, P151, DOI 10.1037/h0026141
   Lysons K., 2003, PURCHASING SUPPLY CH
   MAINGAN I, 2002, EUROPEAN MANAGEMENT, V20, P641
   Maloni MJ, 2006, J BUS ETHICS, V68, P35, DOI 10.1007/s10551-006-9038-0
   MARCIL AG, 1992, COLUMBIA J WORLD BUS, V27, P194
   Matsumoto D., 1994, PEOPLE PSYCHOL CULTU
   McLain DL, 1995, ACAD MANAGE J, V38, P1726, DOI 10.2307/256852
   McWilliams A, 2001, ACAD MANAGE REV, V26, P117, DOI 10.5465/AMR.2001.4011987
   MELNYK SA, 1999, ISO 14000 ASSESSING
   Min H, 1997, INT J PURCHASING MAT, V33, P10, DOI DOI 10.1111/J.1745-493X.1997.TB00026.X
   Mintzberg H, 1973, NATURE MANAGERIAL WO
   Murphy P.E., 1995, BUSINESS ETHICS Q, V5, P117, DOI DOI 10.2307/3857275
   Murphy PR, 2002, TRANSPORT J, V41, P23
   Narasimhan R., 1998, ENV SUPPLY CHAIN MAN
   Nunnally JC, 1978, PSYCHOMETRIC THEORY
   OREILLY C, 1989, CALIF MANAGE REV, V31, P9, DOI 10.2307/41166580
   Panapanaan VM, 2003, J BUS ETHICS, V44, P133, DOI 10.1023/A:1023391530903
   Peloza J, 2006, CALIF MANAGE REV, V48, P52, DOI 10.2307/41166338
   Peters T, 1982, SEARCH EXCELLENCE LE
   Popper K. R., 1959, LOGIC SCI DISCOVERY
   PORTER ME, 1991, SCI AM, V264, P168, DOI 10.1038/scientificamerican0491-168
   QUINN JB, 1985, HARVARD BUS REV, V63, P73
   QUINN JB, 1980, STRATEGIES CHANGE
   Roberts PW, 2002, STRATEGIC MANAGE J, V23, P1077, DOI 10.1002/smj.274
   SHERIDAN JE, 1992, ACAD MANAGE J, V35, P1036, DOI 10.2307/256539
   SHRIVASTAVA P, 1995, ACAD MANAGE REV, V20, P936, DOI 10.2307/258961
   SMIRCICH L, 1983, ADMIN SCI QUART, V28, P339, DOI 10.2307/2392246
   Spar DL, 2003, CALIF MANAGE REV, V45, P78, DOI 10.2307/41166177
   STEAD WE, 1990, J BUS ETHICS, V9, P233, DOI 10.1007/BF00382649
   Stock J. R, 1992, REVERSE LOGISTICS
   Stock JR, 1998, DEV IMPLEMENTATION R
   Turner G. B., 1994, INT J PURCHASING MAT, V30, P43
   VONHIPPEL E, 1982, HARVARD BUS REV, V60, P117
   Walton S.V., 1998, J SUPPLY CHAIN MANAG, V34, P2, DOI DOI 10.1111/J.1745-493X.1998.TB00042.X
   WARTICK SL, 1985, ACAD MANAGE REV, V10, P758, DOI 10.2307/258044
   WEBER J, 1993, HUM RELAT, V46, P435, DOI 10.1177/001872679304600402
   WEBSTER FE, 1992, J MARKETING, V56, P1, DOI 10.2307/1251983
   Wiener Y., 1988, ACAD MANAGE REV, V13, P534
   WOOD DJ, 1991, ACAD MANAGE REV, V16, P691, DOI 10.5465/AMR.1991.4279616
   Wu H.J., 1995, INT J PHYS DISTRIB, V25, P20, DOI DOI 10.1108/09600039510083925
NR 105
TC 51
Z9 51
U1 9
U2 69
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-4544
J9 J BUS ETHICS
JI J. Bus. Ethics
PY 2009
VL 85
SU 2
SI SI
BP 355
EP 370
DI 10.1007/s10551-008-9733-0
PG 16
WC Business; Ethics
SC Business & Economics; Social Sciences - Other Topics
GA 452PF
UT WOS:000266552800008
DA 2018-12-27
ER

PT J
AU Barati, K
   Habibi, MH
   Montazerozohori, M
   Shafieyan, H
   Harrington, RW
   Clegg, W
AF Barati, Kazem
   Habibi, Mohammad Hossein
   Montazerozohori, Morteza
   Shafieyan, Hooshang
   Harrington, Ross W.
   Clegg, William
TI RETRACTED: Synthesis, crystal structure and photo-induced isomerization
   of [N,N
   '-bis(4-fluorobenzylidene)ethylenediamine]bromo(triphenylphosphine)coppe
   r(I) complex (Retracted article. See vol. 62, pg. 3701, 2009)
SO JOURNAL OF COORDINATION CHEMISTRY
LA English
DT Article; Retracted Publication
DE Schiff base; Copper(I) complex; Tetrahedral; Photo-induced; Kinetic
   constant
ID NITROGEN; MONONUCLEAR; INVERSION; ZN(II); NI(II); CU(II);
   TRIPHENYLPHOSPHINE; DERIVATIVES; TRIDENTATE; ISOMERISM
AB The crystal structure of [N,N'-bis(4-fluorobenzylidene)ethylenediamine]bromo(triphenylphosphine)copper(I) (C(34)H(29)BrCuF(2)N(2)P) (1), a model compound for photoisomerization reactions which occur in photobiological processes such as vision, has been determined from X-ray diffraction data. The compound crystallizes in the monoclinic space group P2(1/c) with a = 19.1663(18), b = 13.2456(13), c = 11.9120(11)angstrom and alpha = 90 degrees, beta = 90.004(2)degrees and gamma = 90 degrees. The coordination polyhedron around copper(I) in this complex is best described as a distorted tetrahedron. Photochemical investigations in solution of the time resolved spectral changes, recorded before and after irradiation, show the transformation from syn to anti configuration of the C N bond. Spectral profile and K rate constant were evaluated using multivariate curve resolution and non-linear least squares curve fitting by toolbox of MATLAB program using the corresponding absorption spectra-time data.
C1 [Barati, Kazem; Habibi, Mohammad Hossein] Univ Isfahan, Dept Chem, Esfahan 8174673411, Iran.
   [Montazerozohori, Morteza] Univ Yasuj, Dept Chem, Yasuj 75914353, Iran.
   [Shafieyan, Hooshang] KN Toosi Univ Technol, Fac Sci, Tehran, Iran.
   [Harrington, Ross W.; Clegg, William] Newcastle Univ, Sch Nat Sci Chem, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
RP Barati, K (reprint author), Univ Isfahan, Dept Chem, Esfahan 8174673411, Iran.
EM barati111@yahoo.com
RI Harrington, Ross/B-8638-2009; Clegg, William/B-2491-2010
OI Clegg, William/0000-0003-1643-5298; Montazerozohori,
   Morteza/0000-0001-8897-4683
FU EPSRC, UK; Isfahan University Center of Excellence (Catalysts and Fuel
   Cells)
FX The authors thank the EPSRC, UK, and Isfahan University Center of
   Excellence (Catalysts and Fuel Cells) for financial support.
CR Altomare A, 1999, J APPL CRYSTALLOGR, V32, P115, DOI 10.1107/S0021889898007717
   AMIN JH, 1963, TETRAHEDRON LETT, P1585
   BARRON PF, 1988, INORG CHEM, V27, P1829, DOI 10.1021/ic00283a031
   BRANDENBURG K, 2004, DIAMOND 3
   *BRUK AXS, 2001, SMART SAINT
   Bruno IJ, 2002, ACTA CRYSTALLOGR B, V58, P389, DOI 10.1107/S0108768102003324
   Canpolat E, 2005, J COORD CHEM, V58, P1063, DOI 10.1080/00958970500122565
   Chatterjee D, 2004, J COORD CHEM, V57, P175, DOI 10.1080/00958970410001662435
   CHOUDHRY GG, 1987, QUANTUM YIELDS POLYC, P61
   Diewok J, 2003, ANAL CHEM, V75, P641, DOI 10.1021/ac026248j
   GAMPP H, 1985, TALANTA, V32, P95, DOI 10.1016/0039-9140(85)80035-7
   HABIBI MH, 2007, ANAL SCI, V23, P45
   Habibi MH, 2007, ACTA CRYSTALLOGR C, V63, pM592, DOI 10.1107/S0108270107054960
   Habibi MH, 2006, ACTA CRYSTALLOGR E, V62, pM3392, DOI 10.1107/S1600536806048239
   HALL GE, 1971, J AM CHEM SOC, V93, P4778
   Herzfeld R., 1999, SPECTROSC LETT, V31, P57
   Ismail TMA, 2005, J COORD CHEM, V58, P141, DOI 10.1080/0095897042000274733
   IZAWA H, 1969, CAN J CHEMISTRY, V47, P51, DOI 10.1139/v69-007
   Kannan S, 2005, J COORD CHEM, V58, P567, DOI 10.1080/00958970500038910
   KATSUKI T, 1995, COORDIN CHEM REV, V140, P189, DOI 10.1016/0010-8545(94)01124-T
   KESSLER H, 1969, TETRAHEDRON LETT, P427
   KESSLER H, 1968, TETRAHEDRON LETT, P2041
   Kichelbick G., 2003, AUST J CHEM, V56, P323
   LEHN JM, 1968, THEOR CHIM ACTA, V12, P91, DOI 10.1007/BF00527012
   MORIARTY RM, 1970, J AM CHEM SOC, V92, P6360, DOI 10.1021/ja00724a057
   POZIOMEK EJ, 1965, J PHARM SCI, V54, P333, DOI 10.1002/jps.2600540246
   RABAN M, 1971, J AM CHEM SOC, V93, P685, DOI 10.1021/ja00732a022
   Saleh AA, 2005, J COORD CHEM, V58, P255, DOI 10.1080/00958972512331334199
   Sheldrick G. M, 2003, SADABS
   SHELDRICK GM, 2001, SHELXTL VERSION 6
   Tas E, 2004, J COORD CHEM, V57, P677, DOI 10.1080/00958970410001720980
   Tas E, 2002, TRANSIT METAL CHEM, V27, P442, DOI 10.1023/A:1015011517647
   Tauler R, 1995, CHEMOMETR INTELL LAB, V30, P133, DOI 10.1016/0169-7439(95)00047-X
   Temel H, 2004, J COORD CHEM, V57, P723, DOI 10.1080/00958970410001721024
NR 34
TC 2
Z9 2
U1 3
U2 18
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0095-8972
J9 J COORD CHEM
JI J. Coord. Chem.
PY 2009
VL 62
IS 3
BP 417
EP 426
DI 10.1080/00958970802270864
PG 10
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA 386ZP
UT WOS:000261921800008
DA 2018-12-27
ER

PT J
AU Fu, J
   Bian, GX
   Zhao, BJ
   Dong, ZX
   Sun, X
   Chen, F
   Ou, L
   Song, HF
AF Fu, Jie
   Bian, Guangxing
   Zhao, Bijun
   Dong, Zengxiang
   Sun, Xiao
   Chen, Fang
   Ou, Lun
   Song, Haifeng
TI RETRACTED: Enhancing efficacy and mucosa-tropic distribution of an oral
   HIV-PsV DNA vaccine in animal models (Retracted article. See vol. 18,
   pg. 78, 2010)
SO JOURNAL OF DRUG TARGETING
LA English
DT Article; Retracted Publication
DE Mucosal immune; gene delivery vehicles; HIV vaccine; oral
   administration; biodistribution; plasmid DNA; bovine papillomavirus
   pseudovirus
ID PAPILLOMAVIRUS-LIKE PARTICLES; SYSTEMIC IMMUNE-RESPONSES; VIRUS-LIKE
   PARTICLES; PLASMID DNA; DENDRITIC CELLS; REAL-TIME; NEUTRALIZING
   ANTIBODIES; LISTERIA-MONOCYTOGENES; NASAL IMMUNIZATION; QUANTITATIVE PCR
AB A strategy combined the oral delivery route and bovine papillomavirus (BPV) pseudovirus (PsV)-based human immunodeficiency virus (HIV) DNA vaccine, which has been proven to enhance the mucosal immunization compared with the systemic immunization and in general does not induce effective mucosal immune responses. In this study, the immune responses against the BPV expressing HIV gp41 epitopes (ELDKWA, NWFDIT) after oral administration in Cynomolgus monkeys (Macaca fascicularis) were assessed, and the biodistribution of plasmid DNA encapsulated in the papillomavirus-like particles (VLPs) were evaluated in murine models. Results showed that oral immunization with the HIV-PsV DNA vaccine in monkey generated p24 and gp41 epitopes-specific serum IgG. Importantly, these induced antibodies had been shown to neutralize HIV-1 primary strain. In addition, the advantage of VLPs as vehicles delivering genes had been first revealed in biodistribution results. Therefore, orally administered HIV-PsV DNA vaccine was well-tolerated, enhanced the mucosa targeting property of the plasmid DNA, and reduced the nontargeting distribution, which indicate that it would reduce stress associated with systemic vaccination.
C1 [Fu, Jie; Bian, Guangxing; Dong, Zengxiang; Sun, Xiao; Chen, Fang; Ou, Lun; Song, Haifeng] Beijing Inst Radiat Med, Dept Pharmacol & Toxicol, Beijing 100850, Peoples R China.
   [Zhao, Bijun] Fourth Mil Med Univ, XiJing Hosp, Dept Cardiovasc Surg, Xian 710032, Peoples R China.
RP Song, HF (reprint author), Beijing Inst Radiat Med, Dept Pharmacol & Toxicol, 27 Taiping Rd, Beijing 100850, Peoples R China.
EM songhf@vip.163.com
FU National Natural Science Foundation of China [30500625]; National High
   Biotechnology Development Program of China [2003AA2Z347B]
FX This work was supported by grants from the National Natural Science
   Foundation of China (30500625) and the National High Biotechnology
   Development Program of China (2003AA2Z347B).
CR ALTMAN LK, 2008, NY TIMES        0718
   Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316
   Chen XJS, 2000, MOL CELL, V5, P557, DOI 10.1016/S1097-2765(00)80449-9
   Collantes-Fernandez E, 2002, J CLIN MICROBIOL, V40, P1194, DOI 10.1128/JCM.40.4.1194-1998.2002
   Critchfield JW, 2007, J VIROL, V81, P5460, DOI 10.1128/JVI.02535-06
   Dhar AK, 2001, J CLIN MICROBIOL, V39, P2835, DOI 10.1128/JCM.39.8.2835-2845.2001
   Dong XN, 2005, IMMUNOL LETT, V101, P104, DOI 10.1016/j.imlet.2005.04.013
   Fayad R, 2004, J IMMUNOL, V173, P2692, DOI 10.4049/jimmunol.173.4.2692
   *FOOD DRUG ADM CTR, 2007, BIOTECHNOL LAW REPOR, V26, P641
   Fu J, 2009, ANAL SCI, V25, P675, DOI 10.2116/analsci.25.675
   Gravier R, 2007, VACCINE, V25, P6930, DOI 10.1016/j.vaccine.2007.07.001
   Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4
   Honey K, 2008, J CLIN INVEST, V118, P2989, DOI 10.1172/JCI36994
   Huang XG, 2007, VACCINE, V25, P2620, DOI 10.1016/j.vaccine.2006.12.020
   *INT AIDS VACC IN, 2008, IAVI STAT RESP NIAID
   Kaneko H, 2000, VIROLOGY, V267, P8, DOI 10.1006/viro.1999.0093
   Kang KK, 2003, INTERVIROLOGY, V46, P270, DOI 10.1159/000073206
   Kim BM, 2003, ARCH PHARM RES, V26, P493, DOI 10.1007/BF02976869
   Kowalczyk DW, 2001, VACCINE, V19, P3583, DOI 10.1016/S0264-410X(01)00070-6
   LI GH, 1999, CHINESE J VIROL, V4, P305
   Lieberman J, 2002, VACCINE, V20, P2007, DOI 10.1016/S0264-410X(02)00088-9
   Manickan E, 1997, CRIT REV IMMUNOL, V17, P139, DOI 10.1615/CritRevImmunol.v17.i2.20
   Mata M, 2001, VACCINE, V19, P1435, DOI 10.1016/S0264-410X(00)00379-0
   MATHIJS JM, 1988, LANCET, V1, P1111
   MILLER CJ, 1993, LAB INVEST, V68, P129
   Muller M, 1997, VIROLOGY, V234, P93, DOI 10.1006/viro.1997.8591
   Nardelli-Haefliger D, 2005, VACCINE, V23, P3634, DOI 10.1016/j.vaccine.2005.02.019
   NardelliHaefliger D, 1997, INFECT IMMUN, V65, P3328
   *NAT I ALL INF DIS, 2008, AIDS VACC RES SUBC M
   NELSON JA, 1988, LANCET, V1, P259
   Nishikawa M, 1998, J PHARMACOL EXP THER, V287, P408
   Oh YK, 2004, VIROLOGY, V328, P266, DOI 10.1016/j.virol.2004.06.047
   Phillips David M., 1994, Trends in Microbiology, V2, P454, DOI 10.1016/0966-842X(94)90804-4
   POMERANTZ RJ, 1988, ANN INTERN MED, V108, P321, DOI 10.7326/0003-4819-108-3-321
   Sakaue G, 2003, J IMMUNOL, V170, P495, DOI 10.4049/jimmunol.170.1.495
   Sloat BR, 2006, VACCINE, V24, P6405, DOI 10.1016/j.vaccine.2006.06.002
   Slupetzky K, 2001, J GEN VIROL, V82, P2799, DOI 10.1099/0022-1317-82-11-2799
   Straubinger RK, 2000, J CLIN MICROBIOL, V38, P2191
   Trus BL, 1997, NAT STRUCT BIOL, V4, P413, DOI 10.1038/nsb0597-413
   Tuomela M, 2005, VACCINE, V23, P890, DOI 10.1016/j.vaccine.2004.08.004
   Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427
   Villa LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7
   WRIN T, 1995, J VIROL, V69, P39
   Yan MY, 2005, IMMUNOL CELL BIOL, V83, P83, DOI 10.1111/j.1440-1711.2004.01291.x
   Yan MY, 2004, VIROLOGY, V324, P297, DOI 10.1016/j.virol.2004.03.045
   Yang RC, 2004, J VIROL, V78, P11152, DOI 10.1128/JVI.78.20.11152-11160.2004
   Zhang HT, 2004, J VIROL, V78, P10249, DOI 10.1128/JVI.78.19.10249-10257.2004
   Zhang HT, 2004, J VIROL, V78, P8342, DOI 10.1128/jvi.78.15.8342-8348.2004
   Zhao KN, 2000, VIROLOGY, V272, P382, DOI 10.1006/viro.2000.0348
   Zi XY, 2006, EUR J IMMUNOL, V36, P875, DOI 10.1002/eji.200535468
NR 50
TC 2
Z9 2
U1 7
U2 20
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1061-186X
EI 1029-2330
J9 J DRUG TARGET
JI J. Drug Target.
PY 2009
VL 17
IS 10
BP 803
EP 812
DI 10.3109/10611860903089768
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 529ST
UT WOS:000272538300007
PM 19863197
DA 2018-12-27
ER

PT J
AU Field, KS
AF Field, Kenneth S.
TI RETRACTED: Schematic visualisation of ski resort trails (Retracted
   article. See vol. 8, pg. 194, 2012)
SO JOURNAL OF MAPS
LA English
DT Article; Retracted Publication
ID ROUTES
AB Trail maps for winter sports often take the form of highly illustrative landscape paintings, or panorama, overprinted with trails and lifts to allow skiers and snowboarders a mechanism for on-mountain navigation. The character of mountain environments lends itself particularly well to the traditional form of representation which creates aesthetically pleasing maps. These have become the de facto standard for trail mapping in ski resorts. Navigating on mountain is not always easy since conditions, map perspective, orientation and the illustrative form often make reading the map awkward. The map developed here presents an alternative to the traditional trail map by reducing a mountain and its trails to topological primitives. By taking on the style of Harry Beck's famous London Underground schematic map, the network of trails and lifts becomes visible and immediate, thus enhancing a users ability to navigate the mountain. The map illustrates the 176 trails in Breckenridge, Colorado derived from GPS tracklogs and incorporates a range of other contextual datasets. The paper outlines the rationale and design of the map which has been produced entirely using ESRI ArcGIS v9.2 alongside the Network Analyst, Schematics, Spatial Analyst, 3D Analyst, Maplex and ArcScene extensions. It also incorporates a 3D digital panorama of the ski resort rendered across a curved perspective DEM to provide a visual context for the main map.
C1 Kingston Univ, Sch Geog Geol & Environm, Kingston upon Thames KT1 2EE, Surrey, England.
RP Field, KS (reprint author), Kingston Univ, Sch Geog Geol & Environm, Penrhyn Rd, Kingston upon Thames KT1 2EE, Surrey, England.
EM kenneth.field@kingston.ac.uk
CR ANAND S, 2007, P GIS RES UK 15 ANN
   Avelar S., 2006, CARTOGRAPHICA, V41, P217, DOI DOI 10.3138/A477-3202-7876-N514
   Avelar S, 2007, GEOINFORMATICA, V11, P497, DOI 10.1007/s10707-007-0018-z
   Avelar S, 2008, J MAPS, V4, P134, DOI 10.4113/jom.2008.1007
   BARTRAM DJ, 1980, J APPL PSYCHOL, V65, P103, DOI 10.1037//0021-9010.65.1.103
   GARLAND K, 1994, BECKS UNDERGROUND MA
   Morrison A, 1996, CARTOGR J, V33, P93
   PATTERSON T, 2000, CARTOGRAPHIC PERSPEC, V36, P38
   PATTERSON T, 2008, SHADED RELIEF IDEAS
   Tversky B, 1999, LECT NOTES COMPUT SC, V1661, P51
NR 10
TC 2
Z9 2
U1 4
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1744-5647
J9 J MAPS
JI J. Maps
PY 2009
BP 30
EP 36
PG 7
WC Geography; Geography, Physical
SC Geography; Physical Geography
GA 461LE
UT WOS:000267267700004
DA 2018-12-27
ER

PT J
AU Mihaescu, M
   Gutmark, E
   Murugappan, S
   Elluru, R
   Cohen, A
   Willging, JP
AF Mihaescu, Mihai
   Gutmark, Ephraim
   Murugappan, Shanmugam
   Elluru, Ravindhra
   Cohen, Aliza
   Willging, J. Paul
TI RETRACTED: Modeling Flow in a Compromised Pediatric Airway Breathing Air
   and Heliox (Retracted article. See vol. 119, pg. 1256, 2009)
SO LARYNGOSCOPE
LA English
DT Article; Retracted Publication
DE Pediatric airway; subglottic stenosis; computational fluid dynamics;
   heliox
ID COMPUTATIONAL FLUID-DYNAMICS; OXYGEN MIXTURES; TRACHEAL
AB Objectives/Hypothesis: The aim of this study was to perform computer simulations of flow within an accurate model of a pediatric airway with subglottic stenosis. It is believed that the airflow characteristics in a stenotic airway are strongly related to the sensation of dyspnea.
   Methods: Computed tomography images through the respiratory tract of an infant with subglottic stenosis were used to construct the three-dimensional geometry of the airway. By using computational fluid dynamics (CFD) modeling to capture airway flow patterns during inspiration and expiration, we obtained information pertaining to flow velocity, static airway wall pressure, pressure drop across the stenosis, and wall shear stress. These simulations were performed with both air and heliox (helium-oxygen mixture).
   Results: Unlike air, heliox maintained laminar flow through the stenosis. The calculated pressure drop over stenosis was lower for the heliox flow in contrast to the airflow case. This led to an approximately 40% decrease in airway resistance when using heliox and presumably causes a decrease in the level of effort required for breathing.
   Conclusions: CFD simulations offer a quantitative method of evaluating airway flow dynamics in patients with airway abnormalities. CFD modeling illustrated the flow features and quantified flow parameters within a pediatric airway with subglottic stenosis. Simulations with air and heliox conditions mirrored the known clinical benefits of heliox compared with air. We anticipate that computer simulation models will ultimately allow a better understanding of changes in flow caused by specific medical and surgical interventions in patients with conditions associated with dyspnea.
C1 [Mihaescu, Mihai; Gutmark, Ephraim] Univ Cincinnati, Dept Aerosp Engn & Engn Mech, Cincinnati, OH 45221 USA.
   [Gutmark, Ephraim; Murugappan, Shanmugam; Elluru, Ravindhra; Willging, J. Paul] Univ Cincinnati, Coll Med, Dept Otolaryngol Head & Neck Surg, Cincinnati, OH 45221 USA.
   [Elluru, Ravindhra; Cohen, Aliza; Willging, J. Paul] Cincinnati Childrens Hosp, Med Ctr, Div Pediat Otolaryngol, Cincinnati, OH USA.
RP Mihaescu, M (reprint author), Univ Cincinnati, Dept Aerosp Engn & Engn Mech, 310 Rhodes Hall,ML 0070, Cincinnati, OH 45221 USA.
EM Mihai.Mihaescu@uc.edu
OI Gutmark, Ephraim/0000-0001-7816-4257
CR AUGST AD, 2007, AM J PHYSIOL-HEART C, V293, P1031
   Brouns M, 2007, J APPL PHYSIOL, V102, P1178, DOI 10.1152/japplphysiol.01063.2006
   Cebral JR, 2004, IEEE T MED IMAGING, V23, P1021, DOI 10.1109/TMI.2004.828680
   COLLINS JM, 1993, J BIOMECH ENG-T ASME, V115, P299, DOI 10.1115/1.2895490
   Grosz AH, 2001, LARYNGOSCOPE, V111, P1512, DOI 10.1097/00005537-200109000-00004
   Gupta Vineet K, 2005, Pediatr Crit Care Med, V6, P204, DOI 10.1097/01.PCC.0000154946.62733.94
   Kudukis TM, 1997, J PEDIATR-US, V130, P217, DOI 10.1016/S0022-3476(97)70346-9
   Lin CL, 2007, RESP PHYSIOL NEUROBI, V157, P295, DOI 10.1016/j.resp.2007.02.006
   Mihaescu M, 2008, LARYNGOSCOPE, V118, P360, DOI 10.1097/MLG.0b013e31815937c1
   Mihaescu M, 2008, ANN OTO RHINOL LARYN, V117, P303, DOI 10.1177/000348940811700411
   PAPAMOSCHOU D, 1995, RESP PHYSIOL, V99, P183, DOI 10.1016/0034-5687(94)00071-7
   Yang XL, 2006, J BIOMECH, V39, P2743, DOI 10.1016/j.jbiomech.2005.10.009
   Zhao W, 2002, J ACOUST SOC AM, V112, P2134, DOI 10.1121/1.1506693
NR 13
TC 9
Z9 9
U1 3
U2 13
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0023-852X
J9 LARYNGOSCOPE
JI Laryngoscope
PD JAN
PY 2009
VL 119
IS 1
BP 145
EP 151
DI 10.1002/lary.20015
PG 7
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA 396EO
UT WOS:000262575200026
PM 19117302
DA 2018-12-27
ER

PT J
AU Hirano, S
   Kishimoto, Y
   Suehiro, A
   Kanemaru, SI
   Ito, J
AF Hirano, Shigeru
   Kishimoto, Yo
   Suehiro, Atsushi
   Kanemaru, Shin-ichi
   Ito, Juichi
TI RETRACTED: Regeneration of Aged Vocal Fold: First Human Case Treated
   with Fibroblast Growth Factor (Retracted article. See vol. 119, pg.
   1256, 2009)
SO LARYNGOSCOPE
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 129th Meeting of the American-Laryngological-Association
CY MAY 01-02, 2008
CL Orlando, FL
SP Amer Laryngol Assoc
DE Vocal fold atrophy; aged vocal fold; fibroblast growth factor;
   regeneration
ID HYALURONIC-ACID; AGING VOICE; COLLAGEN; FIBERS; TISSUE; MUCOSA
AB Background/Objectives: Aged vocal folds are characterized by atrophy of the mucosa, which caused dysphonia and is difficult to treat. We have revealed a therapeutic potential of basic fibroblast growth factor (bFGF) for tissue regeneration of the aged vocal fold. We report here the first human case that has been treated with bFGF.
   Study Design: Institutional review board-approved clinical human trial.
   Methods: A 63-year-old male with atrophied vocal folds was treated by local injection of 10 mu g of bFGF into the left vocal fold under topical anesthesia. The effects of the injection were examined after 1 to 3 months by videostroboscopy, acoustic, and aerodynamic measurements.
   Results: The atrophy of the vocal fold was improved at 1 week after the injection, and glottic gap disappeared. Aerodynamic and acoustic parameters also showed remarkable improvement. These positive effects were maintained up to 3 months.
   Conclusions: The first case with aged vocal folds treated with bFGF administration was presented. The results are encouraging, suggesting therapeutic effects of bFGF for atrophied vocal folds in human.
C1 [Hirano, Shigeru] Kyoto Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Sakyo Ku, Kyoto 6068507, Japan.
RP Hirano, S (reprint author), Kyoto Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Sakyo Ku, Kyoto 6068507, Japan.
EM hirano@ent.kuhp.kyoto-u.ac.jp
OI Kishimoto, Yo/0000-0002-3583-0165
CR BIEVER D M, 1989, Journal of Voice, V3, P120, DOI 10.1016/S0892-1997(89)80138-9
   Butler JE, 2001, LARYNGOSCOPE, V111, P907, DOI 10.1097/00005537-200105000-00029
   Chan RW, 1999, LARYNGOSCOPE, V109, P1142, DOI 10.1097/00005537-199907000-00026
   Ding H, 2001, J GERONTOL A-BIOL, V56, pB145, DOI 10.1093/gerona/56.4.B145
   EHRLICH HP, 2000, SCARLESS WOUND HEALI, P99
   Gray SD, 1999, LARYNGOSCOPE, V109, P845, DOI 10.1097/00005537-199906000-00001
   Hakuba N, 2003, LARYNGOSCOPE, V113, P1352, DOI 10.1097/00005537-200308000-00016
   HELDIN P, 1989, BIOCHEM J, V258, P919, DOI 10.1042/bj2580919
   HIRANO M, 1989, ACTA OTO-LARYNGOL, V107, P428, DOI 10.3109/00016488909127535
   Hirano M, 2000, ACTA OTO-LARYNGOL, V120, P336
   Hirano S, 2005, ANN OTO RHINOL LARYN, V114, P304, DOI 10.1177/000348940511400409
   Hirano S, 2004, LARYNGOSCOPE, V114, P2161, DOI 10.1097/01.mlg.0000149450.37640.db
   Hom David B, 2002, Facial Plast Surg, V18, P41, DOI 10.1055/s-2002-19826
   Hom DB, 2005, LARYNGOSCOPE, V115, P412, DOI 10.1097/01.mlg.0000157852.01402.12
   Hong HH, 2002, J PERIODONTOL, V73, P145, DOI 10.1902/jop.2002.73.2.145
   PEAK W, 1992, LARYNGOSCOPE, V102, P139
   Ramig LO, 2001, FOLIA PHONIATR LOGO, V53, P252, DOI 10.1159/000052680
   Rumalla VK, 2001, PLAST RECONSTR SURG, V108, P719, DOI 10.1097/00006534-200109010-00019
   Sato K, 2002, ANN OTO RHINOL LARYN, V111, P15, DOI 10.1177/000348940211100103
   Sato K, 1997, ANN OTO RHINOL LARYN, V106, P44, DOI 10.1177/000348949710600109
   SATO K, 1995, ANN OTO RHINOL LARYN, V104, P839, DOI 10.1177/000348949510401102
NR 21
TC 7
Z9 8
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD JAN
PY 2009
VL 119
IS 1
BP 197
EP 202
DI 10.1002/lary.20004
PG 6
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA 396EO
UT WOS:000262575200036
PM 19117294
OA Bronze
DA 2018-12-27
ER

PT J
AU Huang, HW
   Wu, DP
   Fu, JX
   Chen, GH
AF Huang, Haiwen
   Wu, Depei
   Fu, Jinxiang
   Chen, Guanghua
TI RETRACTED: Multiple myeloma cells undergo differentiation upon exposure
   to rosiglitazone and all-trans retinoic acid (Retracted article. See
   vol. 55, pg. 1437, 2014)
SO LEUKEMIA & LYMPHOMA
LA English
DT Article; Retracted Publication
DE Multiple myeloma; rosiglitazone; cell differentiation; PPAR; ATRA;
   CD49e; light chain protein
ID ACTIVATED RECEPTOR-GAMMA; PPAR-GAMMA; INDUCE APOPTOSIS; NUCLEAR
   RECEPTOR; X-RECEPTOR; LIGANDS; CANCER; TROGLITAZONE; EXPRESSION; GROWTH
AB Activation of PPAR by its ligands has shown differentiating effects in solid tumors. However, few reports addressed its role in myeloma cells. Our study demonstrated that exposure to PPAR ligand (rosiglitazone, RGZ) induced proliferation inhibition and cell cycle arrest in myeloma cells. A combination of RGZ with all-trans retinoic acid (ATRA) can enhance the growth inhibition effects of RGZ. Further study shows that RGZ-treated myeloma cells displayed morphological characteristics of cell differentiation, and more evident signs of differentiation were observed when RGZ was combined with ATRA. These changes were confirmed by the detection of CD49e expression and light chain protein secretion. Similar results were also observed when primary CD138+ cells were treated with RGZ and ATRA. Collectively, our study revealed that RGZ can induce cell differentiation in myeloma cells and concomitant treatment with ATRA can enhanced the effects of RGZ.
C1 [Huang, Haiwen; Wu, Depei; Chen, Guanghua] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol,Dept Hematol, Key Lab Thombosis & Hemostasis,Ministry Hlth, Suzhou 215006, Peoples R China.
   [Huang, Haiwen; Fu, Jinxiang] Soochow Univ, Affiliated Hosp 2, Dept Hematol, Suzhou 215004, Peoples R China.
RP Wu, DP (reprint author), Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol,Dept Hematol, Key Lab Thombosis & Hemostasis,Ministry Hlth, 188 Shizi St, Suzhou 215006, Peoples R China.
EM wudepei@medmail.com.cn
FU Hong Kong University
FX This work was supported by Cheung Yu Tung Fellowship of Hong Kong
   University and the authors thank Prof. Raymond Liang and Dr. Anskar
   Leung for technical support in this research. The authors also thank Dr.
   Jayanta Gupta (Cincinnati Children's Hospital Medical Center,
   Cincinnati, OH 45229, USA) for critical review of the manuscript.
CR Chang TH, 2000, CANCER RES, V60, P1129
   CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798
   Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340
   Deeks ED, 2007, DRUGS, V67, P2747, DOI 10.2165/00003495-200767180-00008
   Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649
   Elstner E, 2002, BREAST CANCER RES TR, V74, P155, DOI 10.1023/A:1016114026769
   Eucker J, 2004, ANTI-CANCER DRUG, V15, P955, DOI 10.1097/00001813-200411000-00004
   GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0
   Hisatake J, 2000, CANCER RES, V60, P5494
   Kawa S, 2002, PANCREAS, V24, P1, DOI 10.1097/00006676-200201000-00001
   KAWANO MM, 1993, BLOOD, V82, P564
   Konopleva M, 2004, MOL CANCER THER, V3, P1249
   Laurora S, 2003, J PHARMACOL EXP THER, V305, P932, DOI 10.1124/jpet.103.049098
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0
   Maniratanachote R, 2005, TOXICOL SCI, V83, P293, DOI 10.1093/toxsci/kfi022
   MEHTA J, 2002, MYELOMA, P539
   Motomura W, 2000, CANCER RES, V60, P5558
   Nolte RT, 1998, NATURE, V395, P137
   Padilla J, 2002, CLIN IMMUNOL, V103, P22, DOI 10.1006/clim.2001.5181
   Ray DM, 2004, CLIN IMMUNOL, V113, P203, DOI 10.1016/j.clim.2004.06.011
   Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030
   Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507
   Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237
   Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5
   VANRIET I, 1993, LEUKEMIA LYMPHOMA, V9, P441, DOI 10.3109/10428199309145751
NR 26
TC 5
Z9 5
U1 3
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1042-8194
EI 1029-2403
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PY 2009
VL 50
IS 6
BP 966
EP 973
AR PII 910508337
DI 10.1080/10428190902866724
PG 8
WC Oncology; Hematology
SC Oncology; Hematology
GA 456AS
UT WOS:000266810900018
PM 19373597
DA 2018-12-27
ER

PT J
AU Kouzu-Fujita, M
   Mezaki, Y
   Sawatsubashi, S
   Matsumoto, T
   Yamaoka, I
   Yano, T
   Taketani, Y
   Kitagawa, H
   Kato, S
AF Kouzu-Fujita, Madoka
   Mezaki, Yoshihiro
   Sawatsubashi, Shun
   Matsumoto, Takahiro
   Yamaoka, Ikuko
   Yano, Tetsu
   Taketani, Yuji
   Kitagawa, Hirochika
   Kato, Shigeaki
TI RETRACTED: Coactivation of Estrogen Receptor beta by
   Gonadotropin-Induced Cofactor GIOT-4 (Retracted article. See vol. 34,
   pg. 919, 2014)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID GENE-EXPRESSION; NUCLEAR RECEPTOR; HISTONE METHYLATION; GRANULOSA-CELLS;
   TRANSCRIPTIONAL ACTIVATION; FOLLICLE DEVELOPMENT; BINDING PROTEIN;
   CHROMATIN; ALPHA; COMPLEX
AB Estrogen exerts its diverse effects through two subtypes of estrogen receptors (ER), ER alpha and ER beta. Each subtype has its own distinct function and expression pattern in its target tissues. Little, however, is known about the transcriptional regulatory mechanism of ER beta in the major ER beta-expressing tissues. Using biochemical methods, we identified and described a novel ER beta coactivator. This protein, designated GIOT-4, was biochemically purified from 293F cells. It coactivated ER beta in ovarian granulosa cells. GIOT-4 expression was induced by stimulation with follicle-stimulating hormone (FSH). GIOT-4 recruited an SWI/SNF-type complex in a ligand-independent manner to ER beta as an ER subtype-specific physical bridging factor and induced subsequent histone modifications in the ER beta target gene promoters in a human ovarian granulosa cell line (KGN). Indeed, two ER beta-specific target genes were upregulated by FSH at a specific stage of a normal ovulatory cycle in intact mice. These findings imply the presence of a novel regulatory convergence between the gonadotropin signaling cascade and ER beta-mediated transcription in the ovary.
C1 [Kouzu-Fujita, Madoka; Mezaki, Yoshihiro; Sawatsubashi, Shun; Matsumoto, Takahiro; Yamaoka, Ikuko; Kitagawa, Hirochika; Kato, Shigeaki] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   [Kouzu-Fujita, Madoka; Yano, Tetsu; Taketani, Yuji] Univ Tokyo, Dept Obstet & Gynecol, Bunkyo Ku, Tokyo 1130865, Japan.
   [Sawatsubashi, Shun; Matsumoto, Takahiro; Yamaoka, Ikuko; Kato, Shigeaki] Japan Sci & Technol Agcy, ERATO, Kawaguchi, Saitama 3320012, Japan.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology
FX This work was supported in part by priority area grants from the
   Ministry of Education, Culture, Sports, Science and Technology (to H. K.
   and S. K.).
CR Akatsuka N, 2005, J STEROID BIOCHEM, V96, P45, DOI 10.1016/j.jsbmb.2005.01.027
   Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048
   Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3
   Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009
   Cheung E, 2003, EMBO J, V22, P600, DOI 10.1093/emboj/cdg037
   Chu S, 2000, J CLIN ENDOCR METAB, V85, P1200, DOI 10.1210/jc.85.3.1200
   Couse JF, 2005, ENDOCRINOLOGY, V146, P3247, DOI 10.1210/en.2005-0213
   Craig J, 2007, FRONT BIOSCI-LANDMRK, V12, P3628, DOI 10.2741/2338
   Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611
   Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987
   Drummond AE, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-16
   EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939
   Fitzpatrick SL, 1999, ENDOCRINOLOGY, V140, P2581, DOI 10.1210/en.140.6.2581
   Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4
   Fryer CJ, 1998, NATURE, V393, P88
   Fujiki R, 2005, EMBO J, V24, P3881, DOI 10.1038/sj.emboj.7600853
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   Garcia-Pedrero JM, 2006, J BIOL CHEM, V281, P22656, DOI 10.1074/jbc.M602561200
   GREEN S, 1986, COLD SPRING HARB SYM, V51, P751, DOI 10.1101/SQB.1986.051.01.088
   GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4
   Hess RA, 1997, NATURE, V390, P509, DOI 10.1038/37352
   Hewitt SC, 2003, REPRODUCTION, V125, P143, DOI 10.1530/rep.0.1250143
   HILLIER SG, 1994, MOL CELL ENDOCRINOL, V100, P51, DOI 10.1016/0303-7207(94)90278-X
   Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7
   Kitagawa H, 2007, MOL CELL BIOL, V27, P7486, DOI 10.1128/MCB.00409-07
   Klinge CM, 2004, J MOL ENDOCRINOL, V33, P387, DOI 10.1677/jma.101541
   Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143
   Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200
   Koehler KF, 2005, ENDOCR REV, V26, P465, DOI 10.1210/er.2004-0027
   Korach KS, 1996, RECENT PROG HORM RES, V51, P159
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677
   Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925
   Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Mizutani T, 2001, MOL ENDOCRINOL, V15, P1693, DOI 10.1210/me.15.10.1693
   Naftolin F, 2007, REPROD SCI, V14, P101, DOI 10.1177/1933719107301059
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nilsson S, 2002, CRIT REV BIOCHEM MOL, V37, P1, DOI 10.1080/10409230290771438
   Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606
   Pangas SA, 2004, MOL CELL ENDOCRINOL, V225, P83, DOI 10.1016/j.mce.2004.02.017
   Pepe GJ, 2006, MOL CELL ENDOCRINOL, V247, P41, DOI 10.1016/j.mce.2005.11.045
   Phillips DJ, 2005, DOMEST ANIM ENDOCRIN, V28, P1, DOI 10.1016/j.domaniend.2004.05.006
   Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806
   Sayasith K, 2005, J BIOL CHEM, V280, P28885, DOI 10.1074/jbc.M413434200
   Shiina H, 2006, P NATL ACAD SCI USA, V103, P224, DOI 10.1073/pnas.0506736102
   Silva JM, 2006, REPRODUCTION, V132, P909, DOI 10.1530/REP-06-0058
   Sladek CD, 2004, J NEUROENDOCRINOL, V16, P365, DOI 10.1111/j.0953-8194.2004.01187.x
   Sofi M, 2003, BREAST CANCER RES TR, V79, P399, DOI 10.1023/A:1024038632570
   Song KH, 2006, J BIOL CHEM, V281, P15605, DOI 10.1074/jbc.M505937200
   Stossi F, 2004, ENDOCRINOLOGY, V145, P3473, DOI 10.1210/en.2003-1682
   Takezawa S, 2007, EMBO J, V26, P764, DOI 10.1038/sj.emboj.7601548
   Tateishi Y, 2006, MOL CELL BIOL, V26, P7966, DOI 10.1128/MCB.00713-06
   Trotter KW, 2008, MOL CELL BIOL, V28, P1413, DOI 10.1128/MCB.01301-07
   Trotter Kevin W, 2008, Nucl Recept Signal, V6, pe004, DOI 10.1621/nrs.06004
   Wang YJ, 2003, ENDOCRINOLOGY, V144, P491, DOI 10.1210/en.2002-220734
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Yazawa T, 2003, ENDOCRINOLOGY, V144, P1920, DOI 10.1210/en.2002-221070
   Yokoyama A, 2008, MOL CELL BIOL, V28, P3995, DOI 10.1128/MCB.02030-07
   Zhu Y, 2002, SCIENCE, V295, P505, DOI 10.1126/science.1065250
NR 62
TC 10
Z9 11
U1 3
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD JAN 1
PY 2009
VL 29
IS 1
BP 83
EP 92
DI 10.1128/MCB.00884-08
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 383TW
UT WOS:000261697500006
PM 18981223
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Kunnumakkara, AB
   Nair, AS
   Sung, B
   Pandey, MK
   Aggarwal, BB
AF Kunnumakkara, Ajaikumar B.
   Nair, Asha S.
   Sung, Bokyung
   Pandey, Manoj K.
   Aggarwal, Bharat B.
TI RETRACTED: Boswellic Acid Blocks Signal Transducers and Activators of
   Transcription 3 Signaling, Proliferation, and Survival of Multiple
   Myeloma via the Protein Tyrosine Phosphatase SHP-1 (Retracted article.
   See vol. 16, pg. 1444, 2018)
SO MOLECULAR CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; ACETYL-11-KETO-BETA-BOSWELLIC ACID; HERBAL MEDICINE;
   GENE-EXPRESSION; LEUKEMIA-CELLS; CANCER-CELLS; STAT3; APOPTOSIS;
   INHIBITION; GROWTH
AB Activation of signal transducers and activators of transcription-3 (STAT-3) has been linked with survival, proliferation, chemoresistance, and angiogenesis of tumor cells, including human multiple myeloma (MM). Thus, agents that can suppress STAT3 activation have potential as cancer therapeutics. In our search for such agents, we identified acetyl-11-keto-beta-boswellic acid (AKBA), originally isolated from Boswellia serrata. Our results show that AKBA inhibited constitutive STAT3 activation in human MM cells. AKBA suppressed IL-6-induced STAT3 activation, and the inhibition was reversible. The phosphorylation of both Jak 2 and Src, constituents of the STAT3 pathway, was inhibited by AKBA. Interestingly, treatment of cells with pervanadate suppressed the effect of AKBA to inhibit the phosphorylation of STAT3, thus suggesting the involvement of a protein tyrosine phosphatase. We found that AKBA induced Src homology region 2 domain-containing phosphatase 1 (SHP-1), which may account for its role in dephosphorylation of STAT3. Moreover, deletion of the SHP-1 gene by small interfering RNA abolished the ability of AKBA to inhibit STAT3 activation. The inhibition of STAT3 activation by AKBA led to the suppression of gene products involved in proliferation (cyclin D1), survival (Bcl-2, Bcl-xL, and Mcl-1), and angiogenesis (VEGF). This effect correlated with the inhibition of proliferation and apoptosis in MM cells. Consistent with these results, overexpression of constitutive active STAT3 significantly reduced the AKBA-induced apoptosis. Overall, our results suggest that AKBA is a novel inhibitor of STAT3 activation and has potential in the treatment of cancer. (Mol Cancer Res 2009;7(1):118-28)
C1 [Aggarwal, Bharat B.] Univ Texas MD Anderson Canc Ctr, Cytokine Res Lab, Dept Expt Therapeut, Unit 143, Houston, TX 77030 USA.
RP Aggarwal, BB (reprint author), Univ Texas MD Anderson Canc Ctr, Cytokine Res Lab, Dept Expt Therapeut, Unit 143, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM aggarwal@mdanderson.org
RI Aggarwal, Bharat/G-3388-2013; Kunnumakkara, Ajaikumar/H-8566-2012;
   Pandey, Manoj/K-9706-2015
OI Kunnumakkara, Ajaikumar/0000-0001-9121-6816; Pandey,
   Manoj/0000-0002-2767-2929
FU NIH core grant; Clayton Foundation
FX NIH core grant and Clayton Foundation for Research (B.B. Aggarwal). B.B.
   Aggarwal is a Ransom Home Professor of Cancer Research.
CR Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009
   Aggarwal BB, 2006, ANN NY ACAD SCI, V1091, P151, DOI 10.1196/annals.1378.063
   Anthoni C, 2006, AM J PHYSIOL-GASTR L, V290, pG1131, DOI 10.1152/ajpgi.00562.2005
   Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863
   Bishnoi M, 2005, METHOD FIND EXP CLIN, V27, P465, DOI 10.1358/mf.2005.27.7.920929
   Bishnoi Mahendra, 2006, Indian Journal of Experimental Biology, V44, P128
   Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527
   Brierley MM, 2005, J INTERF CYTOK RES, V25, P733, DOI 10.1089/jir.2005.25.733
   Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5
   Cuaz-Perolin C, 2008, ARTERIOSCL THROM VAS, V28, P272, DOI 10.1161/ATVBAHA.107.155606
   Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074
   Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940
   Glaser T, 1999, BRIT J CANCER, V80, P756, DOI 10.1038/sj.bjc.6690419
   GOLDMANLEIKIN RE, 1989, J LAB CLIN MED, V113, P335
   Gunaje JJ, 2001, BIOCHEM BIOPH RES CO, V288, P252, DOI 10.1006/bbrc.2001.5759
   Han YJ, 2006, BLOOD, V108, P2796, DOI 10.1182/blood-2006-04-017434
   Hoernlein RF, 1999, J PHARMACOL EXP THER, V288, P613
   Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5
   Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086
   Jimeno A, 2006, CRIT REV ONCOL HEMAT, V59, P150, DOI 10.1016/j.critrevonc.2006.01.005
   KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0
   Kim H, 1999, MOL CELL BIOL, V19, P5326
   Kojima H, 2005, P NATL ACAD SCI USA, V102, P4524, DOI 10.1073/pnas.0500679102
   Krieglstein CF, 2001, INT J COLORECTAL DIS, V16, P88, DOI 10.1007/s003840100292
   Liu JJ, 2002, CARCINOGENESIS, V23, P2087, DOI 10.1093/carcin/23.12.2087
   Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575
   MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4
   Oka T, 2002, CANCER RES, V62, P6390
   Park YS, 2002, ADV EXP MED BIOL, V507, P387
   Poeckel D, 2006, MOL PHARMACOL, V70, P1071, DOI 10.1124/mol.106.024836
   Pungle Pratibha, 2003, Indian Journal of Experimental Biology, V41, P1460
   Safayhi H, 1997, J PHARMACOL EXP THER, V281, P460
   SAFAYHI H, 1992, J PHARMACOL EXP THER, V261, P1143
   Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200
   Shao Y, 1998, PLANTA MED, V64, P328, DOI 10.1055/s-2006-957444
   SHARMA ML, 1989, INT J IMMUNOPHARMACO, V11, P647, DOI 10.1016/0192-0561(89)90150-1
   Singh SK, 2007, VASC PHARMACOL, V46, P333, DOI 10.1016/j.vph.2006.09.008
   Sun S, 2002, J GEN VIROL, V83, P1651, DOI 10.1099/0022-1317-83-7-1651
   Syrovets T, 2005, J BIOL CHEM, V280, P6170, DOI 10.1074/jbc.M409477200
   Syrovets T, 2000, MOL PHARMACOL, V58, P71
   Syrovets T, 2005, J IMMUNOL, V174, P498, DOI 10.4049/jimmunol.174.1.498
   Takada Y, 2006, J IMMUNOL, V176, P3127, DOI 10.4049/jimmunol.176.5.3127
   Tanuma N, 2000, J BIOL CHEM, V275, P28216
   Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1
   Weber CC, 2006, PLANTA MED, V72, P507, DOI 10.1055/s-2006-931536
   Wildfeuer A, 1998, ARZNEIMITTEL-FORSCH, V48, P668
   Winking M, 2000, J NEURO-ONCOL, V46, P97, DOI 10.1023/A:1006387010528
   Xia LJ, 2005, MOL CANCER THER, V4, P381
   Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X
   YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555
   Yu ZY, 2002, BIOCHEM J, V367, P97, DOI 10.1042/BJ20020588
NR 51
TC 78
Z9 83
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD JAN
PY 2009
VL 7
IS 1
BP 118
EP 128
DI 10.1158/1541-7786.MCR-08-0154
PG 11
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 400LQ
UT WOS:000262869900012
PM 19147543
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Lee, EH
   Kim, HM
   Lim, SK
   Kim, KS
   Chin, IJ
AF Lee, Eun-Hee
   Kim, Hye-Mi
   Lim, Sang-Kyun
   Kim, Kwang-Sok
   Chin, In-Joo
TI RETRACTED: Electro-Active Polymer Actuator Based on Aligned Cellulose
   Nanofibrous Membrane (Retracted article. See vol. 503, pg. 166, 2009)
SO MOLECULAR CRYSTALS AND LIQUID CRYSTALS
LA English
DT Article; Retracted Publication
DE actuator; cellulose; electro-active paper; electro-active polymer;
   electrospinning
AB We report cellulose-based electro-active paper (EAPap) actuator formed by electrospinning. Cellulose is one of the most abundant natural polymers and has become an attractive smart material. To prepare electrospun nanofibrous cellulose membrane, the LiCl/N,N-dimethylacetamide (DMAc) solvent system was used. The presence of residual LiCl in electrospun membrane was confirmed by elemental analysis using energy dispersive X-ray spectroscopy. To induce orientation, the cellulose membrane was mechanically aligned in simple extension. FE-SEM was used to observe the morphology of the oriented electrospun membranes. The orientation and crystallinity of the cellulose membrane were examined by WAXD. The electro-active characteristic of the electrospun cellulose membrane was measured by the cyclic bending displacement test under different voltages. Aligning of the electrospun membrane was found necessary to render electro-active characteristic.
C1 [Lee, Eun-Hee; Kim, Hye-Mi; Lim, Sang-Kyun; Chin, In-Joo] Inha Univ, Dept Polymer Sci & Engn, Inchon 402751, South Korea.
   [Kim, Kwang-Sok] Small Business Training Inst, Seoul, South Korea.
RP Chin, IJ (reprint author), Inha Univ, Dept Polymer Sci & Engn, 253 Yonghyun Dong, Inchon 402751, South Korea.
EM ichin@inha.ac.kr
FU Korea Research Foundation [KRF-2005-042-D00029]
FX This work was funded by the Korea Research Foundation Grant (MOEHRD)
   (KRF-2005-042-D00029).
CR Anton F., 1934, US Patent, Patent No. [1975504, US1975504]
   Calvert P, 1998, ACTA MATER, V46, P2565, DOI 10.1016/S1359-6454(98)80041-4
   HARRISON SJ, 2000, MATER RES SOC S P, V600, P131
   Huang ZM, 2003, COMPOS SCI TECHNOL, V63, P2223, DOI 10.1016/S0266-3538(03)00178-7
   Je CH, 2004, SENSOR ACTUAT A-PHYS, V112, P107, DOI 10.1016/j.sna.2003.11.005
   Kim J, 2002, SMART MATER STRUCT, V11, P355, DOI 10.1088/0964-1726/11/3/305
   Kim JS, 1999, POLYM ENG SCI, V39, P849, DOI 10.1002/pen.11473
   MACDIARMID AG, 1985, MOL CRYST LIQ CRYST, V121, P187, DOI 10.1080/00268948508074859
   MCCORMICK CL, 1985, MACROMOLECULES, V18, P2394, DOI 10.1021/ma00154a010
   RICHARDS DG, 1994, CELLULOSIC POLYM BLE, P1
   Shahinpoor M, 1998, SMART MATER STRUCT, V7, pR15, DOI 10.1088/0964-1726/7/6/001
   TAYLOR G, 1964, PROC R SOC LON SER-A, V280, P383, DOI 10.1098/rspa.1964.0151
   Teo WE, 2006, NANOTECHNOLOGY, V17, pR89, DOI 10.1088/0957-4484/17/14/R01
   Zhang QM, 1998, SCIENCE, V280, P2101, DOI 10.1126/science.280.5372.2101
   Zong XH, 2003, POLYMER, V44, P4959, DOI 10.1016/S0032-3861(03)00464-6
NR 15
TC 2
Z9 2
U1 4
U2 17
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1542-1406
EI 1563-5287
J9 MOL CRYST LIQ CRYST
JI Mol. Cryst. Liquid Cryst.
PY 2009
VL 499
BP 581
EP 589
AR PII 908938015
DI 10.1080/15421400802619313
PG 9
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA 411KK
UT WOS:000263648300028
DA 2018-12-27
ER

PT J
AU Hu, XY
   Yu, NC
   Fu, L
   Su, W
   Huang, GF
   Wu, YX
   Huang, HJ
   Huang, H
AF Hu, Xiaoyun
   Yu, Nancai
   Fu, Lei
   Su, Wen
   Huang, Guofu
   Wu, Yanxia
   Huang, Hanju
   Huang, Hao
TI RETRACTED: Downregulation of Human Telomerase Reverse Transcriptase
   Through Anti-C-Myc Sirna in Human Colon Cancer Colo 320 Cells (Retracted
   article. See vol. 28, pg. 793, 2009)
SO NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
LA English
DT Article; Retracted Publication
DE c-Myc; hTERT; short hairpin RNA; Colo 320 cells; proliferation
ID CATALYTIC SUBUNIT; RNA INTERFERENCE; HTERT; GENE; EXPRESSION; PROMOTER;
   BINDING; TISSUES
AB The c-Myc and human telomerase reverse transcriptase gene (hTERT) gene are frequently deregulated and overexpressed in malignancy. hTERT activity is induced by c-Myc and strategies designed to inhibit c-Myc expression in cancer cells may have considerable therapeutic value. We designed and used a short hairpin RNA to inhibit c-Myc expression in Colo 320 cells and validated its effect on cell proliferation. In this study, four c-Myc-shRNA expression vectors were constructed and introduced into Colo 320 cells. The effects of c-Myc silencing on tumor cell growth was assessed by soft agar assay and DNA synthesis and MTT experiments. The expressions of c-Myc and hTERT were also assessed by real-time reverse transcription-polymerase chain reaction and Western blot analysis. Upon transient transfection with plasmid encoding shRNA, it was found that expression of c-Myc and hTERT decreased in shRNA-transfected cells. The downregulation of c-Myc and hTERT inhibited cell growth, shortened telomere lengths, and suppressed telomerase activity. In conclusion, our findings demonstrate that shRNA of c-Myc can inhibit the DNA replication in Colo 320 cells effectively and reduce telomere length and telomerase activity; therefore, it could be used as a new potential anticancer tool for therapy of human colon cancer.
C1 [Yu, Nancai; Fu, Lei; Su, Wen; Huang, Guofu; Wu, Yanxia; Huang, Hao] Wuhan 1 Hosp, Ctr Med Expt, Wuhan, Peoples R China.
   [Huang, Hanju; Huang, Hao] Huazhong Univ Sci & Technol, Dept Pathogent Biol, Tongji Med Coll, Wuhan 430074, Peoples R China.
   [Hu, Xiaoyun] Ctr Dis Prevent & Control Hubei Prov, Wuhan, Peoples R China.
   [Hu, Xiaoyun] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Adolescent Hlth & Maternal & Child Hlth Care, Wuhan 430074, Peoples R China.
RP Huang, H (reprint author), Wuhan 1 Hosp, Ctr Med Expt, Wuhan, Peoples R China.
EM whhuanghao10@yahoo.com.cn
FU Foundation for Medicine Scientific Research Project of Wuhan fromwuhan
   Ministry of Health, P. R. China
FX This work is supported by Foundation for Medicine Scientific Research
   Project of Wuhan fromwuhan Ministry of Health, P. R. China.
CR Casillas MA, 2003, GENE, V316, P57, DOI 10.1016/S0378-1119(03)00739-X
   Cerni C, 2000, MUTAT RES-REV MUTAT, V462, P31, DOI 10.1016/S1383-5742(99)00091-5
   Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202
   D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691
   Dasgupta R, 2004, ONCOGENE, V23, P8359, DOI 10.1038/sj.onc.1208028
   de Marval PLM, 2004, MOL CELL BIOL, V24, P7538, DOI 10.1128/MCB.24.17.7538-7547.2004
   Dwyer J, 2007, ANN NY ACAD SCI, V1114, P36, DOI 10.1196/annals.1396.022
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Gunes C, 2000, CANCER RES, V60, P2116
   Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870
   James L, 2002, P NATL ACAD SCI USA, V99, P10429, DOI 10.1073/pnas.162369299
   Janknecht R, 2004, FEBS LETT, V564, P9, DOI 10.1016/S0014-5793(04)0356-4
   Kanzawa T, 2003, INT J ONCOL, V23, P1703
   KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428
   Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200
   Meeker AK, 2004, CURR OPIN ONCOL, V16, P32, DOI 10.1097/00001622-200401000-00007
   Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141
   MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4
   Murphy DJ, 2004, MOL CELL BIOL, V24, P2083, DOI 10.1128/MCB.24.5.2083-2090.2004
   Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261
   Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904
   Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1
   Wright WE, 1996, DEV GENET, V18, P173
   Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198
   Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499
NR 25
TC 6
Z9 6
U1 4
U2 13
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1525-7770
EI 1532-2335
J9 NUCLEOS NUCLEOT NUCL
JI Nucleosides Nucleotides Nucleic Acids
PY 2009
VL 28
IS 1
BP 1
EP 11
AR PII 907247474
DI 10.1080/15257770802581633
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 389QH
UT WOS:000262109100001
PM 19116866
DA 2018-12-27
ER

PT J
AU Granstrom, G
AF Granstrom, Gosta
TI RETRACTED: Middle ear infections (Retracted Article. See vol 51, pg 276,
   2009)
SO PERIODONTOLOGY 2000
LA English
DT Review; Retracted Publication
ID ACUTE OTITIS-MEDIA; PNEUMOCOCCAL CONJUGATE VACCINE; RESISTANT
   STREPTOCOCCUS-PNEUMONIAE; RANDOMIZED CONTROLLED TRIAL;
   PLACEBO-CONTROLLED TRIAL; TYMPANOSTOMY TUBES; GLUE EAR; SECRETORY
   OTITIS; DOUBLE-BLIND; UNITED-STATES
CR ALHO OP, 1995, ARCH OTOLARYNGOL, V121, P432
   Alsarraf R, 1999, ARCH OTOLARYNGOL, V125, P12, DOI 10.1001/archotol.125.1.12
   *AM AC PED COMM IN, 1997, PEDIATRICS, V99, P289
   Anteunis LJC, 1999, AUDIOLOGY, V38, P75
   AROLA M, 1990, PEDIATRICS, V86, P848
   Auinger P, 2003, PEDIATRICS, V112, P514, DOI 10.1542/peds.112.3.514
   Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002
   Bennett KE, 1998, J EPIDEMIOL COMMUN H, V52, P786, DOI 10.1136/jech.52.12.786
   Berman S, 1997, PEDIATRICS, V100, P585, DOI 10.1542/peds.100.4.585
   BLACK NA, 1990, BRIT MED J, V300, P1551, DOI 10.1136/bmj.300.6739.1551
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Bluestone CD, 1996, PEDIATR INFECT DIS J, V15, P281, DOI 10.1097/00006454-199604000-00002
   Bluestone CD, 2002, ANN OTO RHINOL LARYN, V111, P8
   BLUESTONE CD, 1992, PEDIATR INFECT DIS J, V11, pS7, DOI 10.1097/00006454-199208001-00002
   Bluestone CD, 2000, PEDIATR INFECT DIS J, V19, pS37, DOI 10.1097/00006454-200005001-00007
   Bluestone CD, 1999, EVIDENCE BASED OTITI, P85
   BLUESTONE CD, 1999, EVIDENCE BASED OTITI, P137
   Brodsky L, 2001, INT J PEDIATR OTORHI, V58, P59, DOI 10.1016/S0165-5876(00)00467-5
   Brody R, 1999, OTOLARYNG HEAD NECK, V121, P681, DOI 10.1053/hn.1999.v121.a101041
   Brookhouser PE, 1998, PEDIATR INFECT DIS J, V17, P544, DOI 10.1097/00006454-199806000-00033
   CASSELBRANT ML, 1992, PEDIATR INFECT DIS J, V11, P278, DOI 10.1097/00006454-199204000-00004
   Casselbrant ML, 2000, LARYNGOSCOPE, V110, P773, DOI 10.1097/00005537-200005000-00007
   Casselbrant ML, 1999, JAMA-J AM MED ASSOC, V282, P2125, DOI 10.1001/jama.282.22.2125
   CASSELBRANT ML, 1999, EVIDENCE BASED OTITI, P117
   Cates C, 1999, BRIT MED J, V318, P715
   CHALMERS D, 1989, OTITIS MEDIA EFFUSIO
   CHONMAITREE T, 1992, J PEDIATR-US, V120, P856, DOI 10.1016/S0022-3476(05)81950-X
   Chonmaitree T, 1996, ANN OTO RHINOL LARYN, V105, P968
   Chonmaitree T, 2000, PEDIATR INFECT DIS J, V19, pS24, DOI 10.1097/00006454-200005001-00005
   CLEMENTS DA, 1995, ARCH PEDIAT ADOL MED, V149, P1113, DOI 10.1001/archpedi.1995.02170230067009
   Coyte PC, 2001, JAMA-J AM MED ASSOC, V286, P2128, DOI 10.1001/jama.286.17.2128
   Dagan R, 2001, J INFECT DIS, V183, P880, DOI 10.1086/319250
   Damoiseaux RAMJ, 1998, BRIT J GEN PRACT, V48, P1861
   Damoiseaux RAMJ, 2000, BRIT MED J, V320, P350, DOI 10.1136/bmj.320.7231.350
   Del Mar Chris, 2002, Aust Fam Physician, V31, P141
   Dewey C, 2000, INT J PEDIATR OTORHI, V55, P33, DOI 10.1016/S0165-5876(00)00377-3
   DiFranza JR, 1996, PEDIATRICS, V97, P560
   Engel J, 1999, INT J PEDIATR OTORHI, V48, P239, DOI 10.1016/S0165-5876(99)00037-3
   Englund JA, 2000, VACCINE, V19, pS116, DOI 10.1016/S0264-410X(00)00289-9
   Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602
   Faden H, 1998, PEDIATR INFECT DIS J, V17, P1105, DOI 10.1097/00006454-199812000-00002
   FIELLAUNIKOLAJSEN M, 1983, ANN OTO RHINOL LARYN, V92, P172, DOI 10.1177/000348948309200215
   Fireman B, 2003, PEDIATR INFECT DIS J, V22, P10, DOI 10.1097/00006454-200301000-00006
   FLYNN CA, 2002, COCHRANE DB SYST REV, V1
   FORSEN JW, 2000, PEDIAT OTOLARYNGOLOG, P281
   Freid V M, 1998, Vital Health Stat 13, P1
   FRIA TJ, 1985, ARCH OTOLARYNGOL, V111, P10
   GATES GA, 1987, NEW ENGL J MED, V317, P1444, DOI 10.1056/NEJM198712033172305
   Gates GA, 1996, OTOLARYNG HEAD NECK, V114, P525, DOI 10.1016/S0194-5998(96)70243-7
   GEBHART DE, 1981, LARYNGOSCOPE, V91, P849
   GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135
   Ghaffar F, 2002, CLIN INFECT DIS, V34, P1301, DOI 10.1086/340054
   Giebink GS, 1999, MICROB DRUG RESIST, V5, P57, DOI 10.1089/mdr.1999.5.57
   Giebink GS, 2001, NEW ENGL J MED, V345, P1177, DOI 10.1056/NEJMra010462
   Gonzales R, 2001, CLIN INFECT DIS, V33, P757, DOI 10.1086/322627
   GONZALEZ C, 1986, LARYNGOSCOPE, V96, P1330
   GRANSTROM G, 1985, ACTA OTO-LARYNGOL, V100, P405, DOI 10.3109/00016488509126564
   GRANSTROM G, 1987, INT J PEDIATR OTORHI, V13, P181, DOI 10.1016/0165-5876(87)90095-4
   GUM JR, 1992, AM J RESP CELL MOL, V7, P557, DOI 10.1165/ajrcmb/7.6.557
   Hatakka K, 2001, BRIT MED J, V322, P1327, DOI 10.1136/bmj.322.7298.1327
   Hautalahti O, 2007, PEDIATR INFECT DIS J, V26, P423, DOI 10.1097/01.inf.0000259956.21859.dd
   Heikkinen T, 2000, ACTA PAEDIATR, V89, P1316, DOI 10.1080/080352500300002499
   Heikkinen T, 1999, NEW ENGL J MED, V340, P260, DOI 10.1056/NEJM199901283400402
   HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017
   JARLSTEDT J, 1987, EUSTACHIAN TUBE, P137
   Joki-Erkkila VP, 1998, EPIDEMIOL INFECT, V121, P529, DOI 10.1017/S0950268898001575
   Joki-Erkkila VP, 2002, ARCH OTOLARYNGOL, V128, P17, DOI 10.1001/archotol.128.1.17
   KALM O, 1994, INT J PEDIATR OTORHI, V30, P151, DOI 10.1016/0165-5876(94)90198-8
   KALM O, 1991, ARCH OTOLARYNGOL, V117, P1296
   Kelly K M, 1993, Int J Pediatr Otorhinolaryngol, V25, P279
   Kubba H, 2000, CLIN OTOLARYNGOL, V25, P181, DOI 10.1046/j.1365-2273.2000.00350.x
   KURONO Y, 1991, ANN OTO RHINOL LARYN, V100, P455, DOI 10.1177/000348949110000605
   Kvaerner KJ, 1997, ANN OTO RHINOL LARYN, V106, P624, DOI 10.1177/000348949710600802
   Lim DJ, 2000, VACCINE, V19, pS17, DOI 10.1016/S0264-410X(00)00273-5
   LIM DJ, 1994, HDB MUCOSAL IMMUNOLO, P599
   Lin JZ, 2003, JARO, V4, P384, DOI 10.1007/s10162-002-3023-9
   Little P, 2001, BMJ-BRIT MED J, V322, P336, DOI 10.1136/bmj.322.7282.336
   Little P, 1997, BRIT MED J, V315, P350
   Mandel EM, 2002, PEDIATRICS, V110, P1071, DOI 10.1542/peds.110.6.1071
   MANDEL EM, 1992, PEDIATR INFECT DIS J, V11, P270, DOI 10.1097/00006454-199204000-00003
   MANDEL EM, 1989, ARCH OTOLARYNGOL, V115, P1217
   MARCHANT CD, 1984, J PEDIATR-US, V104, P826, DOI 10.1016/S0022-3476(84)80475-8
   Marchisio P, 2002, CLIN INFECT DIS, V35, P168, DOI 10.1086/341028
   Marcy M, 2000, Evid Rep Technol Assess (Summ), P1
   MAW AR, 1983, BRIT MED J, V287, P1586, DOI 10.1136/bmj.287.6405.1586
   MAW R, 1993, BMJ-BRIT MED J, V306, P756, DOI 10.1136/bmj.306.6880.756
   Maw R, 1999, LANCET, V353, P960, DOI 10.1016/S0140-6736(98)05295-7
   MILLER A, 1997, HLTH INFORMATICS J, V3, P10
   NIEMELA M, 1994, PEDIATR INFECT DIS J, V13, P765, DOI 10.1097/00006454-199409000-00002
   Ogra PL, 2002, ANN OTO RHINOL LARYN, V111, P62
   OLLING S, 1990, APMIS, V98, P896, DOI 10.1111/j.1699-0463.1990.tb05012.x
   ONEILL P, 2002, CLIN EVID, V7, P236
   Paradise JL, 1997, PEDIATRICS, V99, P318, DOI 10.1542/peds.99.3.318
   Paradise JL, 2001, NEW ENGL J MED, V344, P1179, DOI 10.1056/NEJM200104193441601
   Paradise JL, 1999, JAMA-J AM MED ASSOC, V282, P945, DOI 10.1001/jama.282.10.945
   PARADISE JL, 1990, JAMA-J AM MED ASSOC, V263, P2066, DOI 10.1001/jama.263.15.2066
   Patel JA, 1996, RECENT ADVANCES IN OTITIS MEDIA, P178
   Pelton SI, 2002, PEDIATRICS, V110, P805, DOI 10.1542/peds.110.4.805
   Pitkaranta A, 1998, PEDIATRICS, V102, P291, DOI 10.1542/peds.102.2.291
   Post J Christopher, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P347, DOI 10.1097/MOO.0b013e3282b97327
   PRELLNER K, 1985, INT J PEDIATR OTORHI, V9, P219, DOI 10.1016/S0165-5876(85)80037-9
   Reidpath DD, 1999, BRIT MED J, V318, P1177
   RENVALL U, 1988, RECENT ADV OTITIS ME, P326
   Roos K, 2001, BRIT MED J, V322, P210, DOI 10.1136/bmj.322.7280.210
   ROOS K, 1990, INT J PEDIATR OTORHI, V20, P219, DOI 10.1016/0165-5876(90)90352-R
   Rosenfeld R, 2003, EVIDENCE BASED OTITI, P180
   Rosenfeld RM, 2000, VACCINE, V19, pS134, DOI 10.1016/S0264-410X(00)00292-9
   ROSENFELD RM, 1994, J PEDIATR-US, V124, P355, DOI 10.1016/S0022-3476(94)70356-6
   Rosenfeld RM, 2000, ARCH OTOLARYNGOL, V126, P585, DOI 10.1001/archotol.126.5.585
   Rosenfeld RM, 2003, EVIDENCE BASED OTITI, P227
   Rovers M, 2002, AM J EPIDEMIOL, V155, P958, DOI 10.1093/aje/155.10.958
   Rovers MM, 1999, EUR J PEDIATR, V158, P1
   Rovers MM, 2004, LANCET, V363, P465, DOI 10.1016/S0140-6736(04)15495-0
   Rovers MM, 1998, CLIN OTOLARYNGOL, V23, P543, DOI 10.1046/j.1365-2273.1998.2360543.x
   Rovers MM, 2001, EAR HEARING, V22, P191, DOI 10.1097/00003446-200106000-00003
   Ruohola A, 2000, J ALLERGY CLIN IMMUN, V106, P467
   SANDERS LAM, 1995, PEDIATR RES, V37, P812, DOI 10.1203/00006450-199506000-00023
   Semaan MT, 2006, OTOLARYNG CLIN N AM, V39, P1143, DOI 10.1016/j.otc.2006.08.003
   SENTURIA BH, 1980, ANN OTO RHINOL LARYN, V89, P3
   STENFORS LE, 1993, ACTA OTO-LARYNGOL, V113, P191, DOI 10.3109/00016489309135791
   Stewart MG, 1999, OTOLARYNG HEAD NECK, V120, P340, DOI 10.1016/S0194-5998(99)70272-X
   STRAETEMANS M, 2004, COCHRANE DB SYST REV, V1
   Takata GS, 2003, PEDIATRICS, V112, P1379, DOI 10.1542/peds.112.6.1379
   Tasker A, 2002, LANCET, V359, P493, DOI 10.1016/S0140-6736(02)07665-1
   TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83
   TEELE DW, 1990, J INFECT DIS, V162, P685, DOI 10.1093/infdis/162.3.685
   THOMAS CL, 2006, COCHRANE DB SYST REV, V19
   TOS M, 1984, AM J OTOL, V5, P459
   *U YORK, 1992, EFF HLTH CARE, V1, P1
   Uhari M, 1996, BRIT MED J, V313, P1180, DOI 10.1136/bmj.313.7066.1180
   Uhari M, 1998, PEDIATRICS, V102, P879, DOI 10.1542/peds.102.4.879
   Uhari M, 1996, CLIN INFECT DIS, V22, P1079, DOI 10.1093/clinids/22.6.1079
   Ukkonen P, 2000, LANCET, V356, P1398, DOI 10.1016/S0140-6736(00)02843-9
   van Kempen MJP, 2000, INT ARCH ALLERGY IMM, V122, P8, DOI 10.1159/000024354
   Van Zuijlen DA, 2001, PEDIATR INFECT DIS J, V20, P140, DOI 10.1097/00006454-200102000-00004
   Veenhoven R, 2004, PEDIATR RES, V55, P159, DOI 10.1203/01.PDR.0000099776.66136.39
   Veenhoven R, 2003, LANCET, V361, P2189, DOI 10.1016/S0140-6736(03)13772-5
   VERNONFEAGANS L, 1999, EVIDENCE BASED OTITI, P353
   Whitley RJ, 2001, PEDIATR INFECT DIS J, V20, P127, DOI 10.1097/00006454-200102000-00002
   Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603
   WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1344, DOI 10.1001/jama.270.11.1344
   Williamson Ian, 2002, Clin Evid, P469
   Winther B, 2002, PEDIATRICS, V109, P826, DOI 10.1542/peds.109.5.826
NR 143
TC 7
Z9 7
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0906-6713
EI 1600-0757
J9 PERIODONTOL 2000
JI Periodontol. 2000
PY 2009
VL 49
BP 179
EP 193
DI 10.1111/j.1600-0757.2008.00281.x
PG 15
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 385UI
UT WOS:000261838700012
PM 19152534
DA 2018-12-27
ER

PT J
AU van den Bos, A
   Stapel, DA
AF van den Bos, Arne
   Stapel, Diederik A.
TI RETRACTED: Why People Stereotype Affects How They Stereotype: The
   Differential Influence of Comprehension Goals and Self-Enhancement Goals
   on Stereotyping (Retracted article. See vol. 38, pg. 1378, 2012)
SO PERSONALITY AND SOCIAL PSYCHOLOGY BULLETIN
LA English
DT Article; Retracted Publication
DE stereotyping; goals; motivation; comprehension; self-enhancement
ID ACTIVATION; ACCESSIBILITY; ESTEEM; JUDGMENT; OTHERS; THREAT
AB In four studies, the authors examined the hypothesis that the way people stereotype is determined by the motives that instigate it. Study 1 measured and demonstrated the effectiveness of a commonly used priming technique to manipulate comprehension and self-enhancement goals. Study 2 demonstrated that why people stereotype determines how they stereotype: When a comprehension goal was salient, positive as well as negative stereotypes were applied, whereas a salient self-enhancement goal led to the application of negative but not positive stereotypes. Study 3 replicated these effects with different stereotypes. Study 4 replicated these effects and gave more insight in the consequences of goal fulfillment on stereotyping. Results indicated the fulfillment of a salient self-enhancement or comprehension goal led to the reduction of stereotyping. These effects were goal specific: Fulfillment of a self-enhancement goal decreased enhancement-driven but not comprehension-driven stereotyping; fulfillment of a comprehension goal decreased comprehension-driven but not enhancement-driven stereotyping.
C1 [van den Bos, Arne] Univ Groningen, NL-9700 AB Groningen, Netherlands.
   [Stapel, Diederik A.] Tilburg Univ, Tilburg, Netherlands.
RP Stapel, DA (reprint author), TIBER, Warandelaan 2,POB 90153, NL-5000 LE Tilburg, Netherlands.
EM d.a.stapel@uvt.nl
CR BANAJI MR, 1993, J PERS SOC PSYCHOL, V65, P272, DOI 10.1037/0022-3514.65.2.272
   BARGH JA, 1997, ADV SOCIAL COGNITION, P93
   Bodenhausen GV, 1998, ADV SOC COG, V11, P1
   Chartrand TL, 2002, SELF AND MOTIVATION: EMERGING PSYCHOLOGICAL PERSPECTIVES, P13, DOI 10.1037/10448-001
   Custers R, 2005, J PERS SOC PSYCHOL, V89, P129, DOI 10.1037/0022-3514.89.2.129
   ESSES VM, 1995, J PERS SOC PSYCHOL, V69, P1052, DOI 10.1037//0022-3514.69.6.1052
   Fein S, 1997, J PERS SOC PSYCHOL, V73, P31, DOI 10.1037/0022-3514.73.1.31
   Fiske ST, 1991, SOCIAL COGNITION
   FISKE ST, 2002, MOTIVATED SOCIAL PER, V9, P233
   Forster J, 2005, J EXP SOC PSYCHOL, V41, P220, DOI 10.1016/j.jesp.2004.06.009
   Gollwitzer P. M., 1996, SOCIAL PSYCHOL HDB B, P361
   HEATHERTON TF, 1991, J PERS SOC PSYCHOL, V60, P895, DOI 10.1037//0022-3514.60.6.895
   Hilton JL, 1996, ANNU REV PSYCHOL, V47, P237, DOI 10.1146/annurev.psych.47.1.237
   KO SJ, 2007, VOICE WORKPLAC UNPUB
   KUNDA Z, 1990, PSYCHOL BULL, V108, P480, DOI 10.1037//0033-2909.108.3.480
   Kunda Z, 2003, PSYCHOL BULL, V129, P522, DOI 10.1037/0033-2909.129.4.522
   Macrae CN, 2000, ANNU REV PSYCHOL, V51, P93, DOI 10.1146/annurev.psych.51.1.93
   MILLER DT, 1999, CULTURAL DIVIDES UND, P213
   Moskowitz GB, 2000, SOC COGNITION, V18, P151, DOI 10.1521/soco.2000.18.2.151
   NEUBERG SL, 1993, J PERS SOC PSYCHOL, V65, P113, DOI 10.1037/0022-3514.65.1.113
   PELHAM BW, 1989, J PERS SOC PSYCHOL, V57, P672, DOI 10.1037//0022-3514.57.4.672
   Pendry LF, 1996, PERS SOC PSYCHOL B, V22, P249, DOI 10.1177/0146167296223003
   Riketta M, 2003, EUR J SOC PSYCHOL, V33, P679, DOI 10.1002/ejsp.179
   Schwinghammer SA, 2006, PERS SOC PSYCHOL B, V32, P27, DOI 10.1177/0146167205277096
   SHAH JY, 2003, MOTIVATED SOCIAL PER, V9, P247
   SINCLAIR L, 1999, J PERS SOC PSYCHOL, V77, P886
   Solomon S., 1991, HDB SOCIAL CLIN PSYC, P21, DOI DOI 10.1521/PREV.90.4.457.23915
   Spencer SJ, 1998, PERS SOC PSYCHOL B, V24, P1139, DOI 10.1177/01461672982411001
   SRULL TK, 1979, J PERS SOC PSYCHOL, V37, P1660, DOI 10.1037//0022-3514.37.10.1660
   STANGOR C, 2000, STEREOTYPES PREJUDIC, P17
   Stapel DA, 1998, J PERS SOC PSYCHOL, V74, P878, DOI 10.1037//0022-3514.74.4.878
   Stapel DA, 2004, SOC COGNITION, V22, P147, DOI 10.1521/soco.22.1.147.30989
   Stapel DA, 1998, J EXP SOC PSYCHOL, V34, P136, DOI 10.1006/jesp.1997.1346
   Stapel DA, 2001, PERS SOC PSYCHOL B, V27, P915, DOI 10.1177/0146167201278001
   Steele CM, 1998, AM PSYCHOL, V53, P680, DOI 10.1037/0003-066X.53.6.680
   Tesser A., 1988, ADV EXPT SOCIAL PSYC, P181, DOI DOI 10.1016/S0065-2601(08)60227-0
   Weary G, 2001, J PERS SOC PSYCHOL, V81, P206, DOI 10.1037//0022-3514.81.2.206
NR 37
TC 5
Z9 5
U1 1
U2 16
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0146-1672
EI 1552-7433
J9 PERS SOC PSYCHOL B
JI Pers. Soc. Psychol. Bull.
PD JAN
PY 2009
VL 35
IS 1
BP 101
EP 113
DI 10.1177/0146167208325773
PG 13
WC Psychology, Social
SC Psychology
GA 387JF
UT WOS:000261947800008
PM 19106080
DA 2018-12-27
ER

PT J
AU Hausser, F
   Voigt, A
AF Hausser, Frank
   Voigt, Axel
TI RETRACTED: Geometric Ginzburg-Landau theory for faceted crystals in one
   dimension: From coarsening to chaos through a driving force (Retracted
   article. See vol. 81, art. no. 039901, 2010)
SO PHYSICAL REVIEW E
LA English
DT Article; Retracted Publication
DE chaos; Ginzburg-Landau theory; numerical analysis; spatiotemporal
   phenomena; surface diffusion; surface dynamics; surface phase
   transformations
ID SURFACE; EQUATION; CURVATURE; DYNAMICS; GROWTH; SCHEME
AB We consider the dynamic behavior in driven phase transitions dominated either by attachment-detachment or by surface diffusion mass transport mechanisms. As the driving force increases, we numerically demonstrate for both cases that the spatiotemporal faceted structure of the surface undergoes a sequential transition from slow coarsening turning to accelerated coarsening followed by fixed length scale structures before finally becoming spatiotemporally chaotic. For the attachment-detachment dominated phase transition problem we compare in the accelerated coarsening regime the simulation results with an intrinsic dynamical system governing the leading-order piecewise-affine dynamic surface (PADS), which can be obtained through a matched asymptotic analysis. The PADS predicts the numerically observed coarsening law for the growth in time of the characteristic morphological length scale LM. In particular we determine the prefactor of the scaling law which allows for quantitative predictions necessary for any use of the theory in preparing patterned surfaces through modifications of the driving force.
C1 [Hausser, Frank] Tech Fachhsch Berlin, Fachbereich Mathemat 2, D-13353 Berlin, Germany.
   [Voigt, Axel] Tech Univ Dresden, Inst Wissensch Rechnen, D-01062 Dresden, Germany.
RP Hausser, F (reprint author), Tech Fachhsch Berlin, Fachbereich Mathemat 2, Luxemburger Str 10, D-13353 Berlin, Germany.
EM hausser@tfh-berlin.de; axel.voigt@tu-dresden.de
FU EU STRP [016447]; NSF DMR [0502737]; DFG SFB [DFG SFB 609 TP C10]
FX We would like to thank S. J. Watson for explaining the asymptotic
   analysis (19) to us and for many helpful discussions. A. V. was
   supported by EU STRP Grant No. 016447 and NSF DMR Grant No. 0502737
   within the project "MagDot" and by DFG SFB Grant No. DFG SFB 609 TP C10.
CR Burger M, 2007, J COMPUT PHYS, V225, P183, DOI 10.1016/j.jcp.2006.11.026
   DICARLO A, 1992, SIAM J APPL MATH, V52, P1111, DOI 10.1137/0152065
   Fried E, 2004, ADV APPL MECH, V40, P1, DOI 10.1016/S0065-2156(04)40001-5
   Golovin AA, 2001, PHYS REV LETT, V86, P1550, DOI 10.1103/PhysRevLett.86.1550
   Golovin AA, 1999, PHYS REV E, V59, P803, DOI 10.1103/PhysRevE.59.803
   Hausser F, 2005, INTERFACE FREE BOUND, V7, P353
   Hausser F, 2006, APPL MATH LETT, V19, P691, DOI 10.1016/j.aml.2005.05.011
   Hausser F, 2005, J CRYST GROWTH, V275, pE47, DOI 10.1016/j.jcrysgro.2004.10.137
   Heffelfinger JR, 1997, SURF SCI, V389, P188, DOI 10.1016/S0039-6028(97)00411-1
   HERRING C, 1951, PHYS REV, V82, P87, DOI 10.1103/PhysRev.82.87
   KNOPPIK D, 1976, J CRYST GROWTH, V34, P332, DOI 10.1016/0022-0248(76)90149-4
   Krug J, 2004, PHYSICA A, V340, P647, DOI 10.1016/j.physa.2004.05.027
   LI B, COMMUN COMP IN PRESS
   LIU F, 1993, PHYS REV B, V48, P5808, DOI 10.1103/PhysRevB.48.5808
   Medhekar NV, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.156102
   Reinecke N, 2000, SURF SCI, V454, P94, DOI 10.1016/S0039-6028(00)00272-7
   Savina TV, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.021606
   Spencer BJ, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.011603
   STEWART J, 1992, PHYS REV A, V46, P6505, DOI 10.1103/PhysRevA.46.6505
   Tersoff J, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.196104
   TORABI S, P R SOC L A IN PRESS
   Watson SJ, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.176103
   Watson SJ, 2003, PHYSICA D, V178, P127, DOI 10.1016/S0167-2789(03)00048-4
   WATSON SW, UNPUB
NR 24
TC 3
Z9 3
U1 4
U2 15
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 2470-0045
EI 2470-0053
J9 PHYS REV E
JI Phys. Rev. E
PD JAN
PY 2009
VL 79
IS 1
AR 011115
DI 10.1103/PhysRevE.79.011115
PN 1
PG 7
WC Physics, Fluids & Plasmas; Physics, Mathematical
SC Physics
GA 401XP
UT WOS:000262976600023
PM 19257009
DA 2018-12-27
ER

PT J
AU Hou, SG
   Yang, YF
   Zhou, JM
AF Hou, Shuguo
   Yang, Yifei
   Zhou, Jian-Min
TI RETRACTED: The multilevel and dynamic interplay between plant and
   pathogen (Retracted article. See vol. 4, pg. 568, 2009)
SO PLANT SIGNALING & BEHAVIOR
LA English
DT Review; Retracted Publication
DE plant-pathogen interactions; arabidopsis; Pseudomonas syringae; type III
   effector; evolution
AB Phytopathogens invade into plant apoplast and proliferate by assimilating nutrition from plant cells. Plants depend on sophisticated defensive strategies to resist this invasion. Therefore, pathogenic disease and plant disease resistance are two opposite phases. Fascinating molecular mechanisms uncovered that interactions between plant and pathogen are multilevel and dynamic processes. On one side, plant immunity system contains multiple layers mainly including the perception of common pathogen-associated molecular patterns (PAMPs) using distinct cell-surface pattern-recognition receptors (PRRs) to activate intracellular signaling pathways for broad-spectrum immunity, and the recognition of pathogen virulence proteins by the specific intracellular disease resistance (R) proteins for cultivar-specific immunity. On the opposite side, the bacterial pathogens employ virulence factors, such as phytotoxin and type III effectors (T3SEs) to interfere with the host immunity in different levels. Meanwhile, natural selection drives plants and pathogens to evolve new strategies to confront with each other constantly. The present review highlights recent insights about Arabidopsis immunity and mechanisms for Pseudomonas syringae to counteract this immunity to give a full understanding of plant-pathogen interactions.
C1 [Hou, Shuguo; Yang, Yifei] Shandong Jianzhu Univ, City & Environm Engn Inst, Fengming Rd 1000, Jinan 250101, Shandong, Peoples R China.
   [Zhou, Jian-Min] Natl Inst Biol Sci, Beijing, Peoples R China.
RP Hou, SG (reprint author), Shandong Jianzhu Univ, City & Environm Engn Inst, Fengming Rd 1000, Jinan 250101, Shandong, Peoples R China.
EM bio-hou@sdjzu.edu.cn
CR Abramovitch RB, 2006, NAT REV MOL CELL BIO, V7, P601, DOI 10.1038/nrm1984
   Agorio A, 2007, PLANT CELL, V19, P3778, DOI 10.1105/tpc.107.054494
   Alfano JR, 2004, ANNU REV PHYTOPATHOL, V42, P385, DOI 10.1146/annurev.phyto.42.040103.110731
   Allegre M, 2007, NEW PHYTOL, V173, P832, DOI 10.1111/j.1469-8137.2006.01959.x
   Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a
   Axtell MJ, 2003, CELL, V112, P369, DOI 10.1016/S0092-8674(03)00036-9
   Azevedo C, 2006, EMBO J, V25, P2007, DOI 10.1038/sj.emboj.7601084
   Belkhadir Y, 2004, CURR OPIN PLANT BIOL, V7, P391, DOI 10.1016/j.pbi.2004.05.009
   Belkhadir Y, 2004, PLANT CELL, V16, P2822, DOI 10.1105/tpc.104.024117
   Bieri S, 2004, PLANT CELL, V16, P3480, DOI 10.1105/tpc.104.026682
   Boter M, 2007, PLANT CELL, V19, P3791, DOI 10.1105/tpc.107.050427
   Boyes DC, 1998, P NATL ACAD SCI USA, V95, P15849, DOI 10.1073/pnas.95.26.15849
   Brader G, 2007, MOL PLANT MICROBE IN, V20, P589, DOI 10.1094/MPMI-20-5-0589
   Brodersen P, 2006, PLANT J, V47, P532, DOI 10.1111/j.1365-313X.2006.02806.x
   Cardinale F, 2000, J BIOL CHEM, V275, P36734, DOI 10.1074/jbc.M007418200
   Century KS, 1997, SCIENCE, V278, P1963, DOI 10.1126/science.278.5345.1963
   Chapman EJ, 2004, GENE DEV, V18, P1179, DOI 10.1101/gad.1201204
   Chinchilla D, 2006, PLANT CELL, V18, P465, DOI 10.1105/tpc.105.036574
   Chinchilla D, 2007, NATURE, V448, P497, DOI 10.1038/nature05999
   Chisholm ST, 2006, CELL, V124, P803, DOI 10.1016/j.cell.2006.02.008
   Coppinger P, 2004, PLANT J, V40, P225, DOI 10.1111/j.1365-313X.2004.02203.x
   Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161
   Day B, 2006, PLANT CELL, V18, P2782, DOI 10.1105/tpc.106.044693
   de Torres M, 2006, PLANT J, V47, P368, DOI 10.1111/j.1365-313X.2006.02798.x
   Desikan R, 2001, PLANT PHYSIOL, V126, P1579, DOI 10.1104/pp.126.4.1579
   Dunoyer P, 2004, PLANT CELL, V16, P1235, DOI 10.1105/tpc.020719
   Fahlgren N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000219
   Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x
   Fu ZQ, 2007, NATURE, V447, P284, DOI 10.1038/nature05737
   Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322
   Goehre V, 2008, CURR BIOL, V18, P1824, DOI 10.1016/j.cub.2008.10.063
   Goel AK, 2008, MOL PLANT MICROBE IN, V21, P361, DOI 10.1094/MPMI-21-3-0361
   Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8
   Grant SR, 2006, ANNU REV MICROBIOL, V60, P425, DOI 10.1146/annurev.micro.60.080805.142251
   Gudesblat GE, 2009, PLANT PHYSIOL, V149, P1017, DOI 10.1104/pp.108.126870
   Hann DR, 2007, PLANT J, V49, P607, DOI 10.1111/j.1365-313X.2006.02981.x
   He P, 2006, CELL, V125, P563, DOI 10.1016/j.cell.2006.02.047
   Heese A, 2007, P NATL ACAD SCI USA, V104, P12217, DOI 10.1073/pnas.0705306104
   Holt BF, 2005, SCIENCE, V309, P929, DOI 10.1126/science.1109977
   Hubert DA, 2003, EMBO J, V22, P5679, DOI 10.1093/emboj/cdg547
   Ichimura K, 2006, J BIOL CHEM, V281, P36969, DOI 10.1074/jbc.M605319200
   Janjusevic R, 2006, SCIENCE, V311, P222, DOI 10.1126/science.1120131
   Jelenska J, 2007, CURR BIOL, V17, P499, DOI 10.1016/j.cub.2007.02.028
   Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286
   Katiyar-Agarwal S, 2007, GENE DEV, V21, P3123, DOI 10.1101/gad.1595107
   Katiyar-Agarwal S, 2006, P NATL ACAD SCI USA, V103, P18002, DOI 10.1073/pnas.0608258103
   Kim HS, 2005, P NATL ACAD SCI USA, V102, P6496, DOI 10.1073/pnas.0500792102
   Li J, 2002, CELL, V110, P213, DOI 10.1016/S0092-8674(02)00812-7
   Ligterink W, 1997, SCIENCE, V276, P2054, DOI 10.1126/science.276.5321.2054
   Livaja M, 2008, IMMUNOBIOLOGY, V213, P161, DOI 10.1016/j.imbio.2007.10.004
   Ma W, 2006, PLOS GENET, V2, P209
   Mackey D, 2003, CELL, V112, P379, DOI 10.1016/S0092-8674(03)00040-0
   Mallory AC, 2006, NAT GENET, V38, pS31, DOI 10.1038/ng1791
   Melotto M, 2006, CELL, V126, P969, DOI 10.1016/j.cell.2006.06.054
   Meszaros T, 2006, PLANT J, V48, P485, DOI 10.1111/j.1365-313X.2006.02888.x
   MITTAL S, 1995, MOL PLANT MICROBE IN, V8, P165, DOI 10.1094/MPMI-8-0165
   Miya A, 2007, P NATL ACAD SCI USA, V104, P19613, DOI 10.1073/pnas.0705147104
   Mucyn TS, 2006, PLANT CELL, V18, P2792, DOI 10.1105/tpc.106.044016
   Nam KH, 2002, CELL, V110, P203, DOI 10.1016/S0092-8674(02)00814-0
   Navarro L, 2006, SCIENCE, V312, P436, DOI 10.1126/science.1126088
   Navarro L, 2004, PLANT PHYSIOL, V135, P1113, DOI 10.1104/pp.103.036749
   Navarro L, 2008, SCIENCE, V321, P964, DOI 10.1126/science.1159505
   Nomura K, 2006, SCIENCE, V313, P220, DOI 10.1126/science.1129523
   Nurnberger T, 2006, TRENDS PLANT SCI, V11, P519, DOI 10.1016/j.tplants.2006.09.005
   Peart JR, 2002, P NATL ACAD SCI USA, V99, P10865, DOI 10.1073/pnas.152330599
   Pedley KF, 2003, ANNU REV PHYTOPATHOL, V41, P215, DOI 10.1146/annurev.phyto.41.121602.143032
   Petersen M, 2000, CELL, V103, P1111, DOI 10.1016/S0092-8674(00)00213-0
   Qi YJ, 2005, FEBS LETT, V579, P5899, DOI 10.1016/j.feblset.2005.08.035
   Qiu JL, 2008, EMBO J, V27, P2214, DOI 10.1038/emboj.2008.147
   Rosebrock TR, 2007, NATURE, V448, P370, DOI 10.1038/nature05966
   Shan LB, 2008, CELL HOST MICROBE, V4, P17, DOI 10.1016/j.chom.2008.05.017
   Shang YL, 2006, P NATL ACAD SCI USA, V103, P19200, DOI 10.1073/pnas.0607279103
   Shirasu K, 2003, TRENDS PLANT SCI, V8, P252, DOI 10.1016/S1360-1385(03)00104-3
   Shirasu K, 1999, CELL, V99, P355, DOI 10.1016/S0092-8674(00)81522-6
   Singer AU, 2004, STRUCTURE, V12, P1669, DOI 10.1016/j.str.2004.06.023
   Stavrinides J, 2006, PLOS PATHOG, V2, P913, DOI 10.1371/journal.ppat.0020104
   Suarez-Rodriguez MC, 2007, PLANT PHYSIOL, V143, P661, DOI 10.1104/pp.106.091389
   Sunkar R, 2007, TRENDS PLANT SCI, V12, P301, DOI 10.1016/j.tplants.2007.05.001
   Takahashi A, 2003, P NATL ACAD SCI USA, V100, P11777, DOI 10.1073/pnas.2033934100
   Tornero P, 2002, PLANT CELL, V14, P1005, DOI 10.1105/tpc.001032
   Underwood W, 2007, PLANT J, V52, P658, DOI 10.1111/j.1365-313X.2007.03262.x
   van der Biezen EA, 1998, CURR BIOL, V8, pR226, DOI 10.1016/S0960-9822(98)70145-9
   van der Hoorn RAL, 2008, PLANT CELL, V20, P2009, DOI 10.1105/tpc.108.060194
   Xiang TT, 2008, CURR BIOL, V18, P74, DOI 10.1016/j.cub.2007.12.020
   Xiao FM, 2007, PLANT J, V52, P595, DOI 10.1111/j.1365-313X.2007.03259.x
   Xing W, 2007, NATURE, V449, P243, DOI 10.1038/nature06109
   Zhang BH, 2006, DEV BIOL, V289, P3, DOI 10.1016/j.ydbio.2005.10.036
   Zhang J, 2007, CELL HOST MICROBE, V1, P175, DOI 10.1016/j.chom.2007.03.006
   Zhang W, 2008, PLANT J, V122, P73
   Zhou HB, 2009, MOL PLANT MICROBE IN, V22, P176, DOI 10.1094/MPMI-22-2-0176
   Zipfel C, 2006, CELL, V125, P749, DOI 10.1016/j.cell.2006.03.037
NR 91
TC 12
Z9 12
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2316
EI 1559-2324
J9 PLANT SIGNAL BEHAV
JI Plant Signal. Behav.
PY 2009
VL 4
IS 4
BP 283
EP 293
DI 10.4161/psb.4.4.8155
PG 11
WC Biochemistry & Molecular Biology; Plant Sciences
SC Biochemistry & Molecular Biology; Plant Sciences
GA V06LR
UT WOS:000213942200005
PM 19794843
OA Green Published
DA 2018-12-27
ER

PT J
AU Stapel, DA
   Noordewier, MK
AF Stapel, Diederik A.
   Noordewier, Marret K.
TI RETRACTED: Stop Making Sense: The Ultimate Fear (Retracted article. See
   vol. 23, pg. 316, 2012)
SO PSYCHOLOGICAL INQUIRY
LA English
DT Editorial Material; Retracted Publication
C1 [Stapel, Diederik A.; Noordewier, Marret K.] Tilburg Univ, TIBER, Dept Social Psychol, NL-5000 LE Tilburg, Netherlands.
RP Stapel, DA (reprint author), Tilburg Univ, TIBER, Dept Social Psychol, POB 90153, NL-5000 LE Tilburg, Netherlands.
EM d.a.stapel@uvt.nl
CR Baumeister R. F, 1991, ESCAPING SELF ALCOHO
   Deci EL, 1985, INTRINSIC MOTIVATION
   Greenberg J., 2004, HDB EXPT EXISTENTIAL
   Greer WL, 1997, AM J HUM GENET, V61, P139, DOI 10.1086/513899
   Kierkegaard S., 1941, SICKNESS DEATH
   LANDAU MJ, HDB UNCERTA IN PRESS
   Leary MR, 2004, PSYCHOL BULL, V130, P478, DOI 10.1037/0033-2909.130.3.478
   Martin LL, 1999, PSYCHOL INQ, V10, P195, DOI 10.1207/S15327965PLI1003_1
   NOORDEWIER MK, 2009, WHAT PEOPLE RE UNPUB
   Proulx T, 2006, PSYCHOL INQ, V17, P309, DOI 10.1080/10478400701366985
   Proulx T, 2009, PSYCHOL SCI, V20, P1125, DOI 10.1111/j.1467-9280.2009.02414.x
   Sartre Jean-Paul, 1939, MUR
   STAPEL DA, 2009, 10 M SOC PERS SOC PS
NR 13
TC 4
Z9 5
U1 2
U2 8
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1047-840X
EI 1532-7965
J9 PSYCHOL INQ
JI Psychol. Inq.
PY 2009
VL 20
IS 4
BP 245
EP 248
AR PII 917479791
DI 10.1080/10478400903448516
PG 4
WC Psychology, Multidisciplinary
SC Psychology
GA 530RZ
UT WOS:000272611300008
DA 2018-12-27
ER

PT J
AU Baum, S
   Bill, A
   Mitchell, WF
AF Baum, Scott
   Bill, Anthea
   Mitchell, William F.
TI RETRACTED: Employability and Labour Under-utilization in
   Non-Metropolitan Labour Markets (Retracted article. See vol. 45, pg.
   282, 2011)
SO REGIONAL STUDIES
LA English
DT Article; Retracted Publication
DE Labour under-utilization; Regional labour markets; Employability
ID SHIFT-SHARE; UNEMPLOYMENT; UNDEREMPLOYMENT; EMPLOYMENT; AUSTRALIA;
   WORKERS; DISADVANTAGE; OPPORTUNITY; FRAMEWORK; OUTCOMES
AB Baum S., Bill A. and Mitchell W. F. Employability and labour under-utilization in non-metropolitan labour markets, Regional Studies. This paper addresses labour under-utilization and considers the factors that are associated with under-utilization risk of individuals embedded in diverse non-metropolitan labour market regions. Taking survey and census data for Australian non-metropolitan regions, this paper applies a broad employability framework that presents the risk of under-utilization as a function of individual characteristics, personal circumstances, and labour market characteristics. The analysis finds that under-utilization is associated with individual characteristics and circumstances plus local labour market conditions. The findings indicate that policy designed to address labour under-utilization needs to focus on the outcomes of a multilevel framework in order to be effective.
C1 [Baum, Scott] Griffith Univ, Urban Res Program, Nathan, Qld 4111, Australia.
   [Bill, Anthea; Mitchell, William F.] Univ Newcastle, Ctr Full Employment & Equ, Callaghan, NSW 2308, Australia.
RP Baum, S (reprint author), Griffith Univ, Urban Res Program, Nathan, Qld 4111, Australia.
EM s.baum@griffith.edu.au; anthea.bill@newcastle.edu.au;
   bill.mitchell@newcastle.edu.au
CR *ACOSS, 2003, 131 ACOSS NSW
   Adams J, 2000, ENVIRON PLANN A, V32, P1841, DOI 10.1068/a3342
   Badinger H, 2002, REG STUD, V36, P977, DOI 10.1080/0034340022000022558
   Baum S, 2005, FAULT LINES EXPOSED: ADVANTAGE AND DISADVANTAGE ACROSS AUSTRALIA'S SETTLEMENT SYSTEM, P1
   Baum S, 2007, PAP REG SCI, V86, P261, DOI 10.1111/j.1435-5957.2007.00117.x
   Beck U, 1992, RISK SOC NEW MODERNI
   Beer A, 2003, DEV AUSTR REGIONS TH
   BEGGS JJ, 1988, EC IMMIGRATION, P143
   BILL A, 2006, 0608 NSW U NEWC CTR
   Brooks C., 1985, STRUCTURE DURATION U, P43
   Brown S, 1997, REG STUD, V31, P351, DOI 10.1080/00343409750132964
   Buck N, 2001, URBAN STUD, V38, P2251, DOI 10.1080/00420980120087153
   CARTER KA, 1982, RURAL SOCIOL, V47, P459
   CASE A, 1991, 3701 NBER
   Caspi A, 1998, AM SOCIOL REV, V63, P424, DOI 10.2307/2657557
   CLOGG CC, 1979, MEASURING UNDEREMPLO
   Dawson J. A., 1982, SHIFT SHARE ANAL BIB
   De Jong GF, 2001, SOC SCI QUART, V82, P117, DOI 10.1111/0038-4941.00011
   DEANDA RM, 1994, HISPANIC J BEHAV SCI, V16, P163, DOI 10.1177/07399863940162006
   DEX S, 1997, 32 DEP ED EMPL
   *DHFETE, 2002, REP TASKF EMPL LONG
   DOOLEY D, 2003, AM J COMMUN PSYCHOL, V32, P1573
   DUJARDIN C, 2006, 23 JOURN MICR APPL U
   Elliott JR, 1999, SOCIOL QUART, V40, P199, DOI 10.1111/j.1533-8525.1999.tb00545.x
   Flynn N, 2003, SOCIOL SPECTRUM, V23, P305, DOI 10.1080/02732170390199575
   Fothergill S, 2001, REG STUD, V35, P241, DOI 10.1080/00343400120039641
   Friedrichs J., 2005, LIFE POVERTY NEIGHBO
   Galster G, 2003, HOUSING STUD, V18, P893, DOI 10.1080/0267303032000135492
   Galster G, 2002, HOUSING STUD, V17, P5, DOI 10.1080/02673030120105848
   GALSTER GC, 1995, HOUS POLICY DEBATE, V6, P7, DOI 10.1080/10511482.1995.9521180
   Goldstein H, 2003, MULTILEVEL STAT MODE
   Gould MI, 1997, ENVIRON PLANN A, V29, P611, DOI 10.1068/a290611
   GREEN A, 1996, NEW INEQUALITIES CHA, P265
   GREEN A, 1998, ARE JOBLESS
   GREGORY R, 1995, 325 AUSTR NAT U CTR
   Harris MN, 1996, ECON REC, V72, P118, DOI 10.1111/j.1475-4932.1996.tb00946.x
   Hauser P. M., 1974, MALAYAN EC REV, V19, P1
   Jargowsky P., 1997, POVERTY PLACE GHETTO
   Jensen L, 1999, RURAL SOCIOL, V64, P417, DOI 10.1111/j.1549-0831.1999.tb00360.x
   Jonas AEG, 1996, REG STUD, V30, P323, DOI 10.1080/00343409612331349688
   LAWSON J, 2002, 200204 RES BANK AUST
   LE AT, 1999, 6293000001 ABS COMM
   Lopez-Bazo E, 2005, REG STUD, V39, P305, DOI 10.1080/00343400500087034
   Maude A, 2004, EUR PLAN STUD, V12, P3, DOI 10.1080/09654310310001635670
   MCCLELLAND A, 1998, YOUNG PEOPLE LABOUR
   McQuaid RW, 2006, ANN REGIONAL SCI, V40, P407, DOI 10.1007/s00168-006-0065-7
   McQuaid RW, 2005, URBAN STUD, V42, P191, DOI 10.1080/0042098042000316092
   McQuaid RW, 2002, ENVIRON PLANN C, V20, P613, DOI 10.1068/c22m
   MITCHELL WF, 2003, 0307 NSW U NEWC CTR
   MITCHELL WF, 2003, FULL EMPLOYMENT IMPE, P121
   Nazara S, 2004, GROWTH CHANGE, V35, P476, DOI 10.1111/j.1468-2257.2004.00258.x
   NOBLE M, 1996, NEW INEQUALITIES CHA, P292
   NORD S, 1989, J REGIONAL SCI, V29, P407, DOI 10.1111/j.1467-9787.1989.tb01386.x
   PECH J, 1999, REPORTS P SPRC, V142
   Reingold DA, 1999, URBAN STUD, V36, P1907, DOI 10.1080/0042098992674
   Sampson RJ, 2002, ANNU REV SOCIOL, V28, P443, DOI 10.1146/annurev.soc.28.110601.141114
   Shapiro Jesse, 2001, 8357 NBER
   SOLTERO J, 1996, INEQUALITY WORKFORCE
   *STAT, 2005, STAT REF MAN K Q
   STEVENS BH, 1980, J REGIONAL SCI, V20, P419, DOI 10.1111/j.1467-9787.1980.tb00660.x
   Stimson R.J., 2002, REGIONAL EC DEV
   Sunley P, 2006, PUTTING WORKFARE PLA
   TRENDLE B, 2002, AUSTRALASIAN J REGIO, V8, P327
   TUROK I, 1998, LOCAL EC, V12, P1
   Turok I, 1999, JOBS GAP BRITAINS CI
   WILKINS R, 2004, 1604 MELB I APPL EC
   Wilson W. J., 1987, TRULY DISADVANTAGED
   WOODEN M, 1993, LABOUR EC PRODUCTIVI, V5, P95
   ZHOU M, 1993, POPUL RES POLICY REV, V12, P139, DOI 10.1007/BF01074562
NR 69
TC 1
Z9 1
U1 5
U2 14
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0034-3404
EI 1360-0591
J9 REG STUD
JI Reg. Stud.
PY 2009
VL 43
IS 8
BP 1091
EP 1103
AR PII 903402510
DI 10.1080/00343400802154565
PG 13
WC Economics; Environmental Studies; Geography
SC Business & Economics; Environmental Sciences & Ecology; Geography
GA 491US
UT WOS:000269606100007
DA 2018-12-27
ER

PT J
AU Meredith, L
   Ducloux, C
   Isel, C
   Marquet, R
   Harrich, D
AF Meredith, Luke
   Ducloux, Celine
   Isel, Catherine
   Marquet, Roland
   Harrich, David
TI RETRACTED: A U5 repressor of reverse transcription is required for
   optimal HIV-1 infectivity and replication (Retracted article. See vol.
   6, pg. O14, 2009)
SO RETROVIROLOGY
LA English
DT Meeting Abstract; Retracted Publication
C1 [Meredith, Luke; Harrich, David] Queensland Inst Med Res, Joint Program Griffith Univ & QIMR, Griffith Med Res Coll, Herston, Qld 4006, Australia.
   [Meredith, Luke; Harrich, David] Queensland Inst Med Res, Herston, Qld 4006, Australia.
   [Meredith, Luke; Harrich, David] Royal Brisbane Hosp PO, Queensland Inst Med Res, Brisbane, Qld 4029, Australia.
   [Ducloux, Celine; Isel, Catherine; Marquet, Roland] Univ Strasbourg, CNRS, IBMC, Architecture & React ARN, F-67084 Strasbourg, France.
RI Isel, Catherine/B-9406-2015
OI Isel, Catherine/0000-0001-7258-869X; Marquet,
   Roland/0000-0002-4209-3976; Isel, Catherine/0000-0002-8014-7525
NR 0
TC 1
Z9 1
U1 5
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PY 2009
VL 6
SU 2
AR O14
DI 10.1186/1742-4690-6-S2-O14
PG 1
WC Virology
SC Virology
GA 498MX
UT WOS:000270146200039
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Pirat, B
   Yildirir, A
   Simsek, V
   Ozin, B
   Muderrisoglu, H
AF Pirat, B.
   Yildirir, A.
   Simsek, V
   Ozin, B.
   Muderrisoglu, H.
TI RETRACTED: WITHDRAWN: The effect of leg lifting on tissue doppler
   parameters in severe coronary artery disease (Retracted Article)
SO SCANDINAVIAN CARDIOVASCULAR JOURNAL
LA English
DT Correction; Retracted Publication
CR PIRAT B, 2008, SCAND CARDIOVASC J, V36, P96
NR 1
TC 0
Z9 0
U1 2
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1401-7431
EI 1651-2006
J9 SCAND CARDIOVASC J
JI Scand. Cardiovasc. J.
PY 2009
VL 43
IS 1
BP 80
EP 80
AR PII 791206476
DI 10.1080/14017430801932840
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 394AH
UT WOS:000262417100014
DA 2018-12-27
ER

PT J
AU Guilleminault, C
   Quo, S
   Huynh, NT
   Li, K
AF Guilleminault, C.
   Quo, S.
   Huynh, N. T.
   Li, K.
TI RETRACTED: Orthodontic expansion treatment and adenotonsillectomy in the
   treatment of obstructive sleep apnea in prepubertal children. (vol 31,
   pg 953, 2008) (Retracted article. See vol 33, pg. 8, 2010)
SO SLEEP
LA English
DT Correction; Retracted Publication
CR Guilleminault C, 2008, SLEEP, V31, P953
NR 1
TC 1
Z9 1
U1 1
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1550-9109
J9 SLEEP
JI Sleep
PD JAN 1
PY 2009
VL 32
IS 1
BP 6
EP 6
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 389FC
UT WOS:000262075600001
DA 2018-12-27
ER

PT J
AU Yuan, M
   Shi, BY
   Li, HZ
   Xia, M
   Han, Y
   Xu, XG
   Zhang, YS
AF Yuan, Ming
   Shi, Bing-Yi
   Li, Han-Zhong
   Xia, Ming
   Han, Yong
   Xu, Xiao-Guang
   Zhang, Yin-Sheng
TI RETRACTED: De novo Urothelial Carcinoma in Kidney Transplantation
   Patients with End-Stage Aristolochic Acid Nephropathy in China
   (Retracted Article. See vol 84, pg 484, 2010)
SO UROLOGIA INTERNATIONALIS
LA English
DT Article; Retracted Publication
DE Kidney transplantation; Urothelial carcinoma; Aristolochic acid
   nephropathy; Chinese herb nephropathy; Herbal medicines
ID INTERSTITIAL RENAL FIBROSIS; HERBS; MALIGNANCY; RECIPIENTS; EXPOSURE;
   FAILURE; BINDING; CANCER; RISK
AB Introduction: Aristolochic acid contained in Chinese herbs has been proved to be nephrotoxic and carcinogenic. Immunosuppression is associated with an increased risk of developing malignancies. What will be the result if these two significant risk factors are concomitantly present in trans planted patients with aristolochic acid nephropathy (AAN)? Patients and Methods: A 2-center cohort of 1,612 renal transplant recipients was studied retrospectively from January 1998 to December 2006. We performed an evaluation of the database and review of the charts and pathology reports of these recipients. Results: Kidney transplantations were performed in 17 patients with AAN. Nine (52.9%) of these recipients developed urothelial carcinoma (UC), compared with a 0.46% prevalence of urinary tract tumors among kidney-transplanted patients in China. Eight cases (88.9%) involved the upper urinary tract ( bilateral, 3 cases, 37.5%; unilateral, 5 cases, 62.5%). All patients underwent surgical treatment. Six patients (75%) had recurrence during the follow-up period. Three patients died within a mean of 20 months after tumor excision. Conclusions: The risk for UC is distinctly increased in patients with AAN after transplantation. Regular screening for early detection of malignancy is mandatory. Copyright (C) 2009 S. Karger AG, Basel
C1 [Yuan, Ming; Shi, Bing-Yi; Han, Yong; Xu, Xiao-Guang] Gen Hosp Chinese PLA, Affiliated Hosp 2, Organ Transplantat Ctr, Dept Urol, Beijing 100091, Peoples R China.
   [Li, Han-Zhong; Xia, Ming; Zhang, Yin-Sheng] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Urol, Beijing 100037, Peoples R China.
   Peking Union Med Coll, Beijing 100021, Peoples R China.
RP Shi, BY (reprint author), Gen Hosp Chinese PLA, Affiliated Hosp 2, Organ Transplantat Ctr, Dept Urol, 17 Heishanhu Rd, Beijing 100091, Peoples R China.
EM shibingyi@medmail.com.cn
CR Arlt VM, 2004, INT J CANCER, V111, P977, DOI 10.1002/ijc.20316
   Arlt VM, 2000, CARCINOGENESIS, V21, P235, DOI 10.1093/carcin/21.2.235
   BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209
   Chang CH, 2001, AM J NEPHROL, V21, P441, DOI 10.1159/000046647
   CHEN W, 2005, J NEPHROL DIAL TRANS
   COSYNS JP, 1994, LANCET, V344, P188, DOI 10.1016/S0140-6736(94)92786-3
   Cosyns JP, 1999, AM J KIDNEY DIS, V33, P1011, DOI 10.1016/S0272-6386(99)70136-8
   Debelle FD, 2002, J AM SOC NEPHROL, V13, P431
   Debelle FD, 2008, KIDNEY INT, V74, P158, DOI 10.1038/ki.2008.129
   Li Wei-hua, 2005, Zhonghua Yi Xue Za Zhi, V85, P2487
   LI XB, 2008, CHIN J UROL
   Li XB, 2008, INT J UROL, V15, P53, DOI 10.1111/j.1442-2042.2007.01932.x
   LIN F, 2004, J WENZHOU MED COLL
   Lord GM, 2001, LANCET, V358, P1515, DOI 10.1016/S0140-6736(01)06576-X
   Nortier JL, 2000, NEW ENGL J MED, V342, P1686, DOI 10.1056/NEJM200006083422301
   Nortier JL, 2003, NEPHROL DIAL TRANSPL, V18, P426, DOI 10.1093/ndt/18.2.426
   [彭明强 Peng Mingqiang], 2005, [中华器官移植杂志, Chinese Journal of Organ Transplantation], V26, P269
   Penn I, 2000, ADV RENAL REPLACE TH, V7, P147, DOI 10.1053/rr.2000.5269
   PENN I, 1977, Urology, V10, P57
   Sheil AGR, 1997, TRANSPLANT P, V29, P825, DOI 10.1016/S0041-1345(96)00151-0
   Stiborova M, 2005, CANCER LETT, V229, P193, DOI 10.1016/j.canlet.2005.06.038
   VANHERWEGHEM JL, 1995, NEPHROL DIAL TRANSPL, V10, P270
   VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2
   YANG TC, 1998, CHUNG HUA I HSUEH TS, V61, P281
NR 24
TC 10
Z9 12
U1 8
U2 15
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0042-1138
J9 UROL INT
JI Urol.Int.
PY 2009
VL 83
IS 2
BP 200
EP 205
DI 10.1159/000230024
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 494DE
UT WOS:000269788900014
PM 19752617
DA 2018-12-27
ER

PT J
AU Adikesavan, AK
   Unni, E
   Jaiswal, AK
AF Adikesavan, Anbu Karani
   Unni, Emmanual
   Jaiswal, Anil K.
TI RETRACTED: Overlapping signal sequences control nuclear localization and
   endoplasmic reticulum retention of GRP58 (Retracted article. See vol.
   50, pg. 826, 2018)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE GRP58; Thioredoxin-like domains; Nuclear import; Endoplasmic reticulum
   retention; Signals regulating subcellular localization
ID ERP57; RETRIEVAL; PROTEINS; CELLS
AB Glucose-regulated GRP58 has shown clinical applications to endoplasmic reticulum (ER) stress and cancer. GRP58 is localized in the cytosol, endoplasmic reticulum (ER) and nucleus. Twenty-four amino acids at the N-terminal hydrophobic region are known to target GRP58 to ER for synthesis at the ER membrane and translocation into the ER lumen. In addition, GRP58 contains putative nuclear localization (494KPKKKKK500) and ER retention (502QEDL505) signals. However, the role of these signals in nuclear import and ER retention of GRP58 remains unknown. Present studies investigated the signals that control nuclear localization and ER retention of GRP58. Deletion/mutation Of nuclear localization signal (NLS) abrogated nuclear import of GRP58. NLS attached to EGFP localized EGFP in the nucleus. However, deletion/mutation of putative ER retention signal alone did not alter ER retention of GRP58. Interestingly, a combined deletion/mutation of NLS and ER retention signals blocked the GRP58 retention in the ER. These results concluded that overlapping NLS and ER retention signal sequences regulate nuclear localization and ER retention of GRP58. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Unni, Emmanual; Jaiswal, Anil K.] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St, Baltimore, MD 21201 USA.
   [Adikesavan, Anbu Karani] Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA.
RP Jaiswal, AK (reprint author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St, Baltimore, MD 21201 USA.
EM ajaiswal@som.umaryland.edu
FU NIH [RO1 CA81057]
FX This work was supported by NIH Grant RO1 CA81057.
CR Adikesavan AK, 2007, MOL CANCER THER, V6, P2719, DOI 10.1158/1535-7163.MCT-07-0160
   Celli CM, 2003, CANCER RES, V63, P6016
   Coppari S, 2002, J CELL BIOCHEM, V85, P325, DOI 10.1002/jcb.10137
   Ellerman DA, 2006, DEV CELL, V10, P831, DOI 10.1016/j.devcel.2006.03.011
   Garbi N, 2006, NAT IMMUNOL, V7, P93, DOI 10.1038/ni1288
   Grillo C, 2006, FREE RADICAL BIO MED, V41, P1113, DOI 10.1016/j.freeadbiomed.2006.06.016
   HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x
   JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317
   Jessop CE, 2007, EMBO J, V26, P28, DOI 10.1038/sj.emboj.7601505
   Kita K, 2006, FEBS LETT, V580, P199, DOI 10.1016/j.febslet.2005.11.074
   Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9
   Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499
   PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7
   Schelhaas M, 2007, CELL, V131, P516, DOI 10.1016/j.cell.2007.09.038
NR 14
TC 9
Z9 9
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 12
PY 2008
VL 377
IS 2
BP 407
EP 412
DI 10.1016/j.bbrc.2008.09.133
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 378DO
UT WOS:000261301600016
PM 18851953
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Martinez, JA
   Francis, GJ
   Liu, WQ
   Pradzinsky, N
   Fine, J
   Wilson, M
   Hanson, LR
   Frey, WH
   Zochodne, D
   Gordon, T
   Toth, C
AF Martinez, J. A.
   Francis, G. J.
   Liu, W. Q.
   Pradzinsky, N.
   Fine, J.
   Wilson, M.
   Hanson, L. R.
   Frey, W. H., II
   Zochodne, D.
   Gordon, T.
   Toth, C.
TI RETRACTED: INTRANASAL DELIVERY OF INSULIN AND A NITRIC OXIDE SYNTHASE
   INHIBITOR IN AN EXPERIMENTAL MODEL OF AMYOTROPHIC LATERAL SCLEROSIS
   (Retracted article. See vol. 275, pg. 549, 2014)
SO NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE amyotrophic lateral sclerosis; insulin; free oxygen radicals; endplate
   innervation; behavior testing; electrophysiology
ID GROWTH-FACTOR-I; MOTOR-NEURON DEGENERATION; TRANSGENIC MOUSE MODEL;
   CENTRAL-NERVOUS-SYSTEM; PROGRAMMED CELL-DEATH; SPINAL-CORD;
   SKELETAL-MUSCLE; RECEPTOR SUBSTRATE-1; NEURITE FORMATION; SENSORY
   NEURONS
AB Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disorder in which motor neurons may be targeted by oxidative and nitrergic stress without sufficient compensation by intrinsic support mechanisms. In this work, we addressed two key tenets of this hypothesis for the pathogenesis of ALS. Using superoxide dismutase (SOD) 1(G93A) mice, we studied the impact of reduction of nitrergic stress within the CNS with the use of a broad spectrum nitric oxide synthase (NOS) inhibitor, NG-nitro-L-arginine methyl ester. A separate cohort of SOD 1(G93A) mice received direct insulin neurotrophic support, ligating receptors expressed upon motor neurons, to attempt protection against neuronal and functional motor dropout. For direct access, we used a novel form of intranasal delivery that provides peak concentration levels in the CNS within 1 h of delivery without systemic side effects at doses which previously rescued retrograde loss of motor axons after axotomy. To identify even minor impacts of these interventions on the outcome, we utilized an intensive program of serial behavioral and electrophysiological testing weekly, combined with endpoint quantitative morphometry and molecular analysis. This intensive evaluation enhanced our knowledge of the time course in SOD1(G93A) mice and impact of the SOD1(G93A) mutation upon motor neurons and their function. Neither intervention had even minimal impact upon slowing progression of disease in SOD1(G93A) mice. Our data argue against significant roles for nitrergic stress in promoting motor neuron loss and the importance of alternative neurotrophic support mechanisms that might support motor neurons and prevent disease progression in SOD1(G93A) mice. (C) 2008 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Martinez, J. A.; Francis, G. J.; Liu, W. Q.; Pradzinsky, N.; Wilson, M.; Zochodne, D.; Toth, C.] Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada.
   [Martinez, J. A.; Francis, G. J.; Liu, W. Q.; Pradzinsky, N.; Wilson, M.; Zochodne, D.; Toth, C.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada.
   [Fine, J.; Hanson, L. R.; Frey, W. H., II] Reg Hosp, HealthPartners Res Fdn, Alzheimers Res Ctr, St Paul, MN USA.
   [Gordon, T.] Univ Alberta, Dept Neurosci, Edmonton, AB, Canada.
RP Toth, C (reprint author), Univ Calgary, Dept Clin Neurosci, Room 155,3330 Hosp Dr,NW, Calgary, AB T2N 4N1, Canada.
EM corytoth@shaw.ca
OI Frey II, William/0000-0002-6373-0794
FU Alberta Heritage Foundation for Medical Research (AHFMR)
FX This study was supported by an operating grant from the Alberta Heritage
   Foundation for Medical Research (AHFMR). C.T. is a Clinical Investigator
   of the Alberta Heritage Foundation for Medical Research and D.Z. is a
   Scientist of the Alberta Heritage Foundation for Medical Research
   (AHFMR).
CR Abou Ezzi S, 2007, J NEUROCHEM, V102, P170, DOI 10.1111/j.1471-4159.2007.04531.x
   Alisky JM, 2000, HUM GENE THER, V11, P2315, DOI 10.1089/104303400750038435
   Anneser JMH, 2001, EXP NEUROL, V171, P418, DOI 10.1006/exnr.2001.7756
   Beck M, 2001, AMYOTROPH LATERAL SC, V2, pS55, DOI 10.1080/146608201300079454
   Boillee S, 2004, TRENDS NEUROSCI, V27, P235, DOI 10.1016/j.tins.2004.03.002
   Borasio GD, 1998, NEUROLOGY, V51, P583, DOI 10.1212/WNL.51.2.583
   Bruss MD, 2005, DIABETES, V54, P41, DOI 10.2337/diabetes.54.1.41
   Carriedo SG, 2000, J NEUROSCI, V20, P240, DOI 10.1523/JNEUROSCI.20-01-00240.2000
   Cassina P, 2008, J NEUROSCI, V28, P4115, DOI 10.1523/JNEUROSCI.5308-07.2008
   Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9
   DHANDA DS, 2005, DRUG DELIV TECHNOL, V5, P64
   Dodge JC, 2008, MOL THER, V16, P1056, DOI 10.1038/mt.2008.60
   EDBLADH M, 1994, BRAIN RES, V641, P76, DOI 10.1016/0006-8993(94)91817-1
   Federici T, 2006, MUSCLE NERVE, V33, P302, DOI 10.1002/mus.20439
   Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004
   FOLLI F, 1994, J NEUROSCI, V14, P6412
   FRANCIS GJ, 2008, DIABETES IN PRESS
   FRANCIS GJ, 2008, BRAIN IN PRESS
   Frandsen U, 2001, J PHYSIOL-LONDON, V531, P257, DOI 10.1111/j.1469-7793.2001.0257j.x
   Frandsen U, 2000, J VASC RES, V37, P297, DOI 10.1159/000025743
   Frey D, 2000, J NEUROSCI, V20, P2534
   GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9
   GRANT GJ, 1992, ANESTH ANALG, V75, P889
   Guegan C, 2003, J CLIN INVEST, V111, P153, DOI 10.1172/JCI200317610
   GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258
   Hegedus J, 2007, NEUROBIOL DIS, V28, P154, DOI 10.1016/j.nbd.2007.07.003
   Hensley K, 2006, ANTIOXID REDOX SIGN, V8, P2075, DOI 10.1089/ars.2006.8.2075
   Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299
   Huang C, 2005, J BIOL CHEM, V280, P19426, DOI 10.1074/jbc.M412317200
   Huang TJ, 2005, MOL CELL NEUROSCI, V28, P42, DOI 10.1016/j.mcn.2004.08.009
   Hyun DH, 2003, J NEUROCHEM, V86, P363, DOI 10.1046/j.1471-4159.2003.01841.x
   Kang BS, 2007, EXP MOL MED, V39, P38, DOI 10.1038/emm.2007.5
   Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137
   Kim HJ, 2007, EXP MOL MED, V39, P574, DOI 10.1038/emm.2007.63
   Lai EC, 1997, NEUROLOGY, V49, P1621, DOI 10.1212/WNL.49.6.1621
   Lepore AC, 2007, BRAIN RES, V1185, P256, DOI 10.1016/j.brainres.2007.09.034
   Liu Xin-Feng, 2004, J Stroke Cerebrovasc Dis, V13, P16, DOI 10.1016/j.jstrokecerebrovasdis.2004.01.005
   Mahadev K, 2004, CELL SIGNAL, V16, P323, DOI 10.1016/j.cellsig.2003.08.002
   Matsumoto A, 2006, J NEUROSCI RES, V83, P119, DOI 10.1002/jnr.20708
   Messi ML, 2007, EXP NEUROL, V207, P52, DOI 10.1016/j.expneurol.2007.05.016
   Pasinelli P, 2006, NAT REV NEUROSCI, V7, P710, DOI 10.1038/nrn1971
   Pun S, 2006, NAT NEUROSCI, V9, P408, DOI 10.1038/nn1653
   RECIOPINTO E, 1988, J NEUROSCI RES, V19, P312, DOI 10.1002/jnr.490190306
   RECIOPINTO E, 1986, J NEUROSCI, V6, P1211
   Reger MA, 2008, NEUROLOGY, V70, P440, DOI 10.1212/01.WNL.0000265401.62434.36
   Reger MA, 2006, NEUROBIOL AGING, V27, P451, DOI 10.1016/j.neurobiolaging.2005.03.016
   ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0
   Sander M, 1999, HYPERTENSION, V33, P937, DOI 10.1161/01.HYP.33.4.937
   Sasaki S, 2001, ACTA NEUROPATHOL, V101, P351
   Shaw BF, 2007, TRENDS BIOCHEM SCI, V32, P78, DOI 10.1016/j.tibs.2006.12.005
   Shefner JM, 2002, MUSCLE NERVE, V25, P39, DOI 10.1002/mus.10000
   Sippel JM, 1999, SLEEP, V22, P786, DOI 10.1093/sleep/22.6.786
   Sugimoto K, 2002, J PERIPHER NERV SYST, V7, P44, DOI 10.1046/j.1529-8027.2002.02005.x
   Tam SL, 2003, J NEUROCYTOL, V32, P961, DOI 10.1023/B:NEUR.0000020635.41233.0f
   Tankersley CG, 2007, J APPL PHYSIOL, V102, P926, DOI 10.1152/japplphysiol.00193.2006
   Tateno M, 2004, HUM MOL GENET, V13, P2183, DOI 10.1093/hmg/ddh246
   Thorne RG, 2004, NEUROSCIENCE, V127, P481, DOI 10.1016/j.neuroscience.2004.05.029
   Toth C, 2006, NEUROSCIENCE, V139, P429, DOI 10.1016/j.neuroscience.2005.11.065
   Toth C, 2006, DIABETOLOGIA, V49, P1081, DOI 10.1007/s00125-006-0169-8
   Toth C, 2004, J NEUROPATH EXP NEUR, V63, P561, DOI 10.1093/jnen/63.6.561
   Trejo JL, 2004, J MOL MED, V82, P156, DOI 10.1007/s00109-003-0499-7
   Veldink JH, 2003, NEUROMUSCULAR DISORD, V13, P737, DOI 10.1016/S0960-8966(03)00104-4
   Vig PJS, 2006, BRAIN RES BULL, V69, P573, DOI 10.1016/j.brainresbull.2006.02.020
   Wengenack TM, 2004, BRAIN RES, V1027, P73, DOI 10.1016/j.brainres.2004.08.054
   White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001
   Wilczak N, 2005, ENDOCR DEV, V9, P160, DOI 10.1159/000085764
   Xu QG, 2004, EXP NEUROL, V188, P43, DOI 10.1016/j.expneurl.2004.03.008
   Zochodne DW, 2001, BRAIN, V124, P2319, DOI 10.1093/brain/124.11.2319
NR 68
TC 17
Z9 17
U1 3
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD DEC 10
PY 2008
VL 157
IS 4
BP 908
EP 925
DI 10.1016/j.neuroscience.2008.08.073
PG 18
WC Neurosciences
SC Neurosciences & Neurology
GA 382JS
UT WOS:000261602700018
PM 18951954
DA 2018-12-27
ER

PT J
AU Garman, KS
   Acharya, CR
   Edelman, E
   Grade, M
   Gaedcke, J
   Sud, S
   Barry, W
   Diehl, AM
   Provenzale, D
   Ginsburg, GS
   Ghadimi, BM
   Ried, T
   Nevins, JR
   Mukherjee, S
   Hsu, D
   Potti, A
AF Garman, Katherine S.
   Acharya, Chaitanya R.
   Edelman, Elena
   Grade, Marian
   Gaedcke, Jochen
   Sud, Shivani
   Barry, William
   Diehl, Anna Mae
   Provenzale, Dawn
   Ginsburg, Geoffrey S.
   Ghadimi, B. Michael
   Ried, Thomas
   Nevins, Joseph R.
   Mukherjee, Sayan
   Hsu, David
   Potti, Anil
TI RETRACTED: A genomic approach to colon cancer risk stratification yields
   biologic insights into therapeutic opportunities (Retracted Article. See
   vol 106, pg 6878, 2009)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE biology; personalized medicine; progression
ID ADVANCED COLORECTAL-CANCER; CELL LUNG-CANCER; HUMAN BREAST; STAGE-II;
   CELECOXIB; FLUOROURACIL; LEUCOVORIN; PREVENTION; PREDICTION; IRINOTECAN
AB Gene expression profiles provide an opportunity to dissect the heterogeneity of solid tumors, including colon cancer, to improve prognosis and predict response to therapies. Bayesian binary regression methods were used to generate a signature of disease recurrence in patients with resected early stage colon cancer validated in an independent cohort. A 50-gene signature was developed that effectively distinguished early stage colon cancer patients with a low or high risk of disease recurrence. RT-PCR analysis of the 50-gene signature validated 9 of the top 10 differentially expressed genes. When applied to two independent validation cohorts of 55 and 73 patients, the 50-gene model accurately predicted recurrence. Standard Kaplan-Meier survival analysis confirmed the prognostic accuracy (P < 0.01, log rank), as did multivariate Cox proportional hazard models. Wetested potential targeted therapeutic options for patients at high risk for disease recurrence and found a clinically important relationship between sensitivity to celecoxib, LY-294002 (PI3kinase inhibitor), retinol, and sulindac in colon cancer cell lines expressing the poor prognostic phenotype (P < 0.01, t test), which performed better than standard chemotherapy (5-FU and oxaliplatin). We present a genomic strategy in early stage colon cancer to identify patients at highest risk of recurrence. An ability to move beyond current staging by refining the estimation of prognosis in early stage colon cancer also has implications for individualized therapy.
C1 [Garman, Katherine S.; Acharya, Chaitanya R.; Edelman, Elena; Sud, Shivani; Barry, William; Ginsburg, Geoffrey S.; Nevins, Joseph R.; Mukherjee, Sayan; Hsu, David; Potti, Anil] Duke Univ, Inst Genome Sci & Policy, Durham, NC 27708 USA.
   [Garman, Katherine S.; Diehl, Anna Mae; Provenzale, Dawn; Hsu, David; Potti, Anil] Duke Univ, Dept Med, Durham, NC 27708 USA.
   [Edelman, Elena; Barry, William; Mukherjee, Sayan] Duke Univ, Dept Stat Sci, Durham, NC 27708 USA.
   [Grade, Marian; Ried, Thomas] NCI, Bethesda, MD 20892 USA.
   [Gaedcke, Jochen; Ghadimi, B. Michael] Univ Gottingen, Univ Med Ctr, Dept Gen & Visceral Surg, D-37073 Gottingen, Germany.
RP Potti, A (reprint author), Duke Univ, Duke Inst Genome Sci & Policy, Box 3382,101 Sci Dr, Durham, NC 27708 USA.
EM anil.potti@duke.edu
FU Emilene Brown Cancer Research Fund; National Institutes of Health;
   National Cancer Institute; Deutsche Forschungsgemeinschaft [KFO 179];
   American Cancer Society; Department of Defense; Jimmy V. Foundation;
   American Association for Cancer Research
FX This work was supported in part by the Emilene Brown Cancer Research
   Fund, the intramural research program of the National Institutes of
   Health, National Cancer Institute, and by the Deutsche
   Forschungsgemeinschaft KFO 179. A. P. receives funding from National
   Cancer Institute, American Cancer Society, Department of Defense, Jimmy
   V. Foundation, and American Association for Cancer Research.
CR Andre T, 2007, J CLIN ONCOL, V25, P3732, DOI 10.1200/JCO.2007.12.2234
   Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652
   Bandres E, 2007, ONCOL REP, V17, P1089
   Barrier A, 2006, J CLIN ONCOL, V24, P4685, DOI 10.1200/JCO.2005.05.0229
   Benito M, 2004, BIOINFORMATICS, V20, P105, DOI 10.1093/bioinformatics/btg385
   Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Del Rio M, 2007, J CLIN ONCOL, V25, P773, DOI 10.1200/JCO.2006.07.4187
   El-Rayes BF, 2008, CANCER CHEMOTH PHARM, V61, P283, DOI 10.1007/s00280-007-0472-1
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Gradilone A, 2008, CURR CANCER DRUG TAR, V8, P414, DOI 10.2174/156800908785133178
   Ho SB, 2004, CLIN CANCER RES, V10, P5777, DOI 10.1158/1078-0432.CCR-03-0507
   Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9
   IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Kohne CH, 2008, ANN ONCOL, V19, P920, DOI 10.1093/annonc/mdm544
   Kuebler JP, 2007, J CLIN ONCOL, V25, P2198, DOI 10.1200/JCO.2006.08.2974
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lin YH, 2007, CLIN CANCER RES, V13, P498, DOI 10.1158/1078-0432.CCR-05-2734
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pittman J, 2004, BIOSTATISTICS, V5, P587, DOI 10.1093/biostatistics/kxh011
   Pittman J, 2004, P NATL ACAD SCI USA, V101, P8431, DOI 10.1073/pnas.0401736101
   Potti A, 2006, NEW ENGL J MED, V355, P570, DOI 10.1056/NEJMoa060467
   Ramaswamy S, 2004, NEW ENGL J MED, V350, P1814, DOI 10.1056/NEJMp048059
   Rosell R, 1997, INT J CANCER, V74, P330, DOI 10.1002/(SICI)1097-0215(19970620)74:3<330::AID-IJC17>3.0.CO;2-F
   Rostom A, 2007, ANN INTERN MED, V146, P376, DOI 10.7326/0003-4819-146-5-200703060-00010
   Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Wang YX, 2004, J CLIN ONCOL, V22, P1564, DOI 10.1200/JCO.2004.08.186
   WOOD DA, 1971, CANCER, V28, P109, DOI 10.1002/1097-0142(197107)28:1<109::AID-CNCR2820280120>3.0.CO;2-C
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
NR 32
TC 66
Z9 67
U1 4
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 9
PY 2008
VL 105
IS 49
BP 19432
EP 19437
DI 10.1073/pnas.0806674105
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 383XB
UT WOS:000261706600073
PM 19050079
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Jang, DO
   Kim, SY
AF Jang, Doo Ok
   Kim, Sang Yoon
TI RETRACTED: Highly Enantioselective Radical Addition to N-Benzoyl
   Hydrazones Using Chiral Ammonium Salts (Retracted article. See vol. 135,
   pg. 12475, 2013)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article; Retracted Publication
ID LEWIS-ACID; C=N BOND; ACYLHYDRAZONES; KETONES; ORGANOCATALYSIS;
   CHEMISTRY; CATALYSIS; AIR
AB In the presence of a protonated cinchonine derivative, radical addition reactions proceeded efficiently, affording addition adducts in high yields with an extremely high enantioselectivity. The chiral ammonium salt was recyclable after a simple aqueous workup. The reaction provides environmentally benign reaction conditions.
C1 [Jang, Doo Ok; Kim, Sang Yoon] Yonsei Univ, Dept Chem, Wonju 220710, South Korea.
RP Jang, DO (reprint author), Yonsei Univ, Dept Chem, Wonju 220710, South Korea.
EM dojang@yonsei.ac.kr
FU Center for Bioactive Molecular Hybrids
FX This work was supported by the Center for Bioactive Molecular Hybrids.
CR Aechtner T, 2004, ANGEW CHEM INT EDIT, V43, P5849, DOI 10.1002/anie.200461222
   Bar G, 2003, CHEM SOC REV, V32, P251, DOI 10.1039/b111414j
   BARTON DHR, 1990, TETRAHEDRON LETT, V31, P4681, DOI 10.1016/S0040-4039(00)97705-0
   Bauer A, 2005, NATURE, V436, P1139, DOI 10.1038/nature03955
   Berkessel A, 2005, ASYMMETRIC ORGANOCATALYSIS: FROM BIOMIMETIC CONCEPTS TO APPLICATIONS IN ASYMMETRIC SYNTHESIS, P1, DOI 10.1002/3527604677
   Bertelsen S, 2007, ANGEW CHEM INT EDIT, V46, P7356, DOI 10.1002/anie.200702834
   Cho DH, 2006, CHEM COMMUN, P5045, DOI 10.1039/b613045c
   Dalko P. I., 2007, ENANTIOSELECTIVE ORG
   de Figueiredo RM, 2007, EUR J ORG CHEM, P2575, DOI 10.1002/ejoc.200700032
   Doyle AG, 2007, CHEM REV, V107, P5713, DOI 10.1021/cr068373r
   Fernandez M, 2003, ORG LETT, V5, P2461, DOI 10.1021/ol034696n
   Friestad GK, 2005, J ORG CHEM, V70, P6330, DOI 10.1021/jo050756m
   Friestad GK, 2003, ANGEW CHEM INT EDIT, V42, P5061, DOI 10.1002/anie.200352104
   Friestad GK, 2001, J AM CHEM SOC, V123, P9922, DOI 10.1021/ja011312k
   Friestad GK, 2006, J ORG CHEM, V71, P7016, DOI 10.1021/jo061158q
   Guerin B, 2001, RADICALS ORGANIC SYN, V1
   He LW, 2005, J ORG CHEM, V70, P8140, DOI 10.1021/jo051334f
   Hein JE, 2005, ORG LETT, V7, P2755, DOI 10.1021/ol050956k
   Hirabayashi R, 2001, J AM CHEM SOC, V123, P9493, DOI 10.1021/ja011125m
   Huang HB, 2006, J AM CHEM SOC, V128, P7170, DOI 10.1021/ja0620890
   List B, 2006, CHEM COMMUN, P819, DOI 10.1039/b514296m
   Liu K, 2007, ORG LETT, V9, P923, DOI 10.1021/ol0701666
   Miyabe H, 2004, SYNLETT, P1140, DOI 10.1055/s-2004-822889
   Mukherjee S, 2007, NATURE, V447, P152, DOI 10.1038/447152a
   Renaud P, 1998, ANGEW CHEM INT EDIT, V37, P2563, DOI 10.1002/(SICI)1521-3773(19981016)37:19<2562::AID-ANIE2562>3.0.CO;2-D
   Renaud P., 2001, RADICALS ORGANIC SYN
   Sibi MP, 2005, J AM CHEM SOC, V127, P2390, DOI 10.1021/ja043371e
   Sibi MP, 2003, CHEM REV, V103, P3263, DOI 10.1021/cr020044l
   Sibi MP, 1999, ACCOUNTS CHEM RES, V32, P163, DOI 10.1021/ar9600547
   Sibi MP, 2007, J AM CHEM SOC, V129, P4124, DOI 10.1021/ja069245n
   Sibl MP, 2005, ORG LETT, V7, P1453, DOI 10.1021/ol047347h
   Tsogoeva SB, 2006, CHEM COMMUN, P1451, DOI 10.1039/b517937h
   Wessig P, 2006, ANGEW CHEM INT EDIT, V45, P2168, DOI 10.1002/anie.200503908
   Yamada KI, 2004, J ORG CHEM, V69, P1531, DOI 10.1021/jo035496s
   Yang D, 2006, ANGEW CHEM INT EDIT, V45, P255, DOI 10.1002/anie.200503056
NR 35
TC 22
Z9 22
U1 4
U2 25
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD DEC 3
PY 2008
VL 130
IS 48
BP 16152
EP +
DI 10.1021/ja807685r
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 406UG
UT WOS:000263319800014
PM 18998683
DA 2018-12-27
ER

PT J
AU Roblin, X
   Biroulet, LP
   Phelip, JM
   Nancey, S
   Flourie, B
AF Roblin, Xavier
   Biroulet, Laurent P.
   Phelip, Jean M.
   Nancey, Stephane
   Flourie, Bernard
TI RETRACTED: A 6-Thioguanine Nucleotide Threshold Level of 400 pmol/8 x
   10(8) Erythrocytes Predicts Azathioprine Refractoriness in Patients With
   Inflammatory Bowel Disease and Normal TPMT Activity (Retracted article.
   See vol. 104, pg. 801, 2009)
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article; Retracted Publication
ID THIOPURINE METHYLTRANSFERASE ACTIVITY; 6-MERCAPTOPURINE METABOLITES;
   5-AMINOSALICYLIC ACID; ULCERATIVE-COLITIS; CROHNS-DISEASE;
   PHARMACOGENETICS; THERAPY; ASSOCIATION; RESISTANCE; 6-MP
AB BACKGROUND A therapeutic level of 6-thioguanine nucleotides (6-TGN) has been reported in inflammatory
   AND AIMS: bowel disease (IBD) patients under azathioprine (AZA). We investigated the threshold value of 6-TGN that may be predictive of AZA refractoriness and its impact on safety profile.
   METHODS: Patients with normal thiopurine methyltransferase (TPMT) activity (7.5-14 U/mL erythrocytes), suffering from steroid-dependent or active IBD despite AZA use for at least 6 months, were prospectively included. Clinical efficacy, adverse events, and thiopurine metabolite levels were recorded at baseline, 1 month after each dose escalation, and thereafter every 3 months.
   RESULTS: Fifty-five patients were included (43 with Crohn's disease, 12 with ulcerative colitis). After a mean follow-up of 12 months, 31 patients (56.3%) did not reach clinical remission despite a gradual increase in AZA dose and 6-TGN level of > 400 pmol/8 x 10(8) erythrocytes, and were considered refractory to AZA (sensitivity 45%, specificity 100%). Adverse events occurred more frequently in these patients than in responders (42% vs 25%, respectively, P = 0.02). Among 55 patients, 15 cases of myelotoxicity associated with elevated levels of total methylated metabolites (14,500 pmol/8 x 10(8) erythrocytes vs 5,230 pmol/8 x 10(8) erythrocytes in patients without myelotoxicity, P = 0.03) were observed. Patients with total methylated metabolites of > 11,100 pmol/8 x 10(8) erythrocytes had an increased risk of developing myelotoxicity (odds ratio [OR] 11.0, 95% confidence interval [CI] 1.1-250, P = 0.05).
   CONCLUSION: A 6-TGN level of > 400 pmol/8 x 10(8) erythrocytes in IBD patients with normal TPMT activity and steroid-dependent or active disease despite an optimal AZA regimen may predict refractoriness to this drug. Furthermore, high levels of methylated derivatives are associated with an increased risk of myelotoxicity.
   (Am J Gastroenterol 2008;103:3115-3122).
C1 [Roblin, Xavier; Phelip, Jean M.] CHU Grenoble, Dept Gastroenterol, F-38000 Grenoble, France.
   [Biroulet, Laurent P.] CHU Nancy, INSERM, U724, Nancy, France.
   [Biroulet, Laurent P.] CHU Nancy, Dept Gastroenterol, Nancy, France.
   [Nancey, Stephane; Flourie, Bernard] CHU Lyon, Dept Gastroenterol, Lyon, France.
RP Roblin, X (reprint author), CHU Grenoble, Dept Gastroenterol, F-38000 Grenoble, France.
CR Ansari A, 2002, ALIMENT PHARM THERAP, V16, P1743, DOI 10.1046/j.0269-2813.2002.01353.x
   ANSARI AR, 2004, GASTROENTEROLOGY S2, V126, pA1293
   Ardizzone S, 2006, GUT, V55, P47, DOI 10.1136/gut.2005.068809
   Belaiche J, 2001, SCAND J GASTROENTERO, V36, P71, DOI 10.1080/00365520150218084
   BEST WR, 1976, GASTROENTEROLOGY, V70, P439
   Cuffari C, 2001, GUT, V48, P642, DOI 10.1136/gut.48.5.642
   Cuffari C, 2004, CLIN GASTROENTEROL H, V2, P410, DOI 10.1053/S1542-3565(04)00127-2
   Dervieux T, 1998, CLIN CHEM, V44, P2511
   Dubinsky MC, 2000, GASTROENTEROLOGY, V118, P705, DOI 10.1016/S0016-5085(00)70140-5
   Dubinsky MC, 2002, GASTROENTEROLOGY, V122, P904, DOI 10.1053/gast.2002.32420
   ELION GB, 1993, ANN NY ACAD SCI, V685, P401, DOI 10.1111/j.1749-6632.1993.tb35897.x
   Farrell RJ, 2000, GASTROENTEROLOGY, V118, P279, DOI 10.1016/S0016-5085(00)70210-1
   Gisbert JP, 2007, DIGEST DIS SCI, V52, P1262, DOI 10.1007/s10620-006-9119-z
   Gisbert JP, 2005, MED CLIN-BARCELONA, V125, P281, DOI 10.1157/13078420
   Giverhaug T, 1997, THER DRUG MONIT, V19, P663, DOI 10.1097/00007691-199712000-00010
   Hindorf U, 2006, GUT, V55, P1423, DOI 10.1136/gut.2005.074930
   LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V
   Lichtenstein GR, 2006, GASTROENTEROLOGY, V130, P940, DOI 10.1016/j.gastro.2006.01.048
   Lindqvist M, 2006, NUCLEOS NUCLEOT NUCL, V25, P1033, DOI 10.1080/15257770600890814
   Lowry PW, 2001, GUT, V49, P665, DOI 10.1136/gut.49.5.665
   MODIGLIANI R, 1990, GASTROENTEROLOGY, V98, P811, DOI 10.1016/0016-5085(90)90002-I
   Osterman MT, 2006, GASTROENTEROLOGY, V130, P1047, DOI 10.1053/j.gastro.2006.01.046
   Rossi AM, 2001, EUR J CLIN PHARMACOL, V57, P51, DOI 10.1007/s002280000246
   Shaye OA, 2007, AM J GASTROENTEROL, V102, P2488, DOI 10.1111/j.1572-0241.2007.01515.x
   SUTHERLAND LR, 1987, GASTROENTEROLOGY, V92, P1894, DOI 10.1016/0016-5085(87)90621-4
   TIDD DM, 1974, CANCER RES, V34, P738
   Tiede I, 2003, J CLIN INVEST, V111, P1133, DOI 10.1172/JCI200316432
   Weinshilboum R, 2001, DRUG METAB DISPOS, V29, P601
   WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651
   Wright S, 2004, GUT, V53, P1123, DOI 10.1136/gut.2003.032896
NR 30
TC 36
Z9 38
U1 5
U2 15
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD DEC
PY 2008
VL 103
IS 12
BP 3115
EP 3122
DI 10.1111/j.1572-0241.2008.01743.x
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 378YN
UT WOS:000261361200024
PM 19086961
DA 2018-12-27
ER

PT J
AU Guo, CF
   Haider, HK
   Wang, C
   Tan, RS
   Shim, WSN
   Wong, P
   Sim, EKW
AF Guo, Changfa
   Haider, Husnain Kh.
   Wang, Chunsheng
   Tan, Ru-San
   Shim, Winston S. N.
   Wong, Philip
   Sim, Eugene K. W.
TI RETRACTED: Myoblast Transplantation for Cardiac Repair: From
   Automyoblast to Allomyoblast Transplantation (Retracted Article. See vol
   88, pg 354, 2009)
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Retracted Publication
ID AUTOLOGOUS SKELETAL MYOBLASTS; CELL TRANSPLANTATION; INTRAMYOCARDIAL
   INJECTION; HEART-FAILURE; IN-VIVO; MUSCLE; SURVIVAL; DIFFERENTIATION;
   DYNAMICS
AB Background. We sought to compare host immune cell kinetics, survival profile of donor skeletal myoblasts, and skeletal myoblast graft efficacy after autologous and allogeneic skeletal myoblast transplantation into a rat model of myocardial infarction.
   Methods. One week after myocardial infarction, 128 animals were divided into four groups: group 1 (n = 24, receiving medium only), group 2 (n = 24, receiving medium and cyclosporine), group 3 (n = 40, autologous skeletal myoblast transplantation), and group 4 (n = 40, allogeneic skeletal myoblast transplantation with cyclosporine treatment). Rats were euthanized 10 minutes, 1 day, and 4, 7, and 28 days later. Host immune cell kinetics were assessed by immunohistochemical studies for macrophages, and CD4+ and CD8+ lymphocytes. Donor skeletal myoblast survival was confirmed by tracking prelabeled signals, and quantified by beta-gal assay. Heart function was evaluated by echocardiography.
   Results. A transient immune cell infiltration was demonstrated in group 3, with macrophage infiltration on day 1 and day 4, CD8+ cell infiltration on day 4 and day 7, and CD4+ cell infiltration on day 4. In group 4, immunocyte infiltration was slightly more severe than that in group 3. Automyoblasts and allomyoblasts showed no significant difference of survival from day 1 to day 7 (p > 0.10); however, on day 28, automyoblasts showed better survival than allomyoblasts (p < 0.05). Transplantation of allomyoblasts increased systolic heart function and limited heart dilation after myocardial injury to a similar degree as automyoblasts (p > 0.10).
   Conclusions. The use of allomyoblasts is feasible and effective for cardiac repair with immunosuppressive treatment as compared with automyoblasts.
C1 [Guo, Changfa] Fudan Univ, Dept Cardiac Surg, Zhongshan Hosp, Shanghai 200032, Peoples R China.
   Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH USA.
   Natl Heart Ctr, Singapore, Singapore.
   Natl Univ Singapore, Dept Surg, Singapore 117597, Singapore.
RP Guo, CF (reprint author), Fudan Univ, Dept Cardiac Surg, Zhongshan Hosp, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
EM drguocf@yahoo.com; sursimkw@nus.edu.sg
OI Tan, Ru San/0000-0003-2086-6517
FU National Medical Research Council [Singapore, R176000077213]; Shanghai
   Leading Academic Discipline [B116]
FX Funding was provided by a National Medical Research Council Grant
   (Singapore, R176000077213). Funding was also supported by Shanghai
   Leading Academic Discipline Project, B116.
CR Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9
   ATOUI A, 2008, ANN THORAC SURG, V86, P237
   Chachques JC, 2004, INT J CARDIOL, V95, pS29, DOI 10.1016/j.ijcard.2004.04.000
   Deasy BM, 2002, STEM CELLS, V20, P50, DOI 10.1634/stemcells.20-1-50
   Guo CF, 2008, ANN THORAC SURG, V86, P1841, DOI 10.1016/j.athoracsur.2008.08.038
   Guo C, 2007, J THORAC CARDIOV SUR, V134, P1332, DOI 10.1016/j.jtcvs.2007.07.025
   Hodgetts SI, 2000, CELL TRANSPLANT, V9, P489, DOI 10.1177/096368970000900406
   Ishida M, 2004, J HEART LUNG TRANSPL, V23, P881, DOI 10.1016/j.healun.2003.08.006
   LAW PK, 2006, J GERIATR CARDIO, V3, P135
   Menasche P, 2001, LANCET, V357, P279, DOI 10.1016/S0140-6736(00)03617-5
   Menasche P, 2008, CIRCULATION, V117, P1189, DOI 10.1161/CIRCULATIONAHA.107.734103
   MORRIS PJ, 1992, TRANSPLANT P, V24, P2865
   Pagani FD, 2003, J AM COLL CARDIOL, V41, P879, DOI 10.1016/S0735-1097(03)00081-0
   Pouzet B, 2001, ANN THORAC SURG, V71, P844, DOI 10.1016/S0003-4975(00)01785-9
   Reinecke H, 2004, CIRC RES, V94, pE56, DOI 10.1161/01.RES.0000125294.04612.81
   Skuk D, 2002, CELL TRANSPLANT, V11, P671, DOI 10.3727/000000002783985378
   Smits PC, 2003, J AM COLL CARDIOL, V42, P2063, DOI 10.1016/j.jacc.2003.06.017
   Smythe GM, 2000, CELL TRANSPLANT, V9, P379, DOI 10.1177/096368970000900309
   Suzuki K, 2000, CIRCULATION, V102, P359
   Suzuki K, 2000, CIRCULATION, V102, P216
   Suzuki K, 2004, FASEB J, V18, P1153, DOI 10.1096/fj.03-1308fje
   Teng CJ, 2006, J THORAC CARDIOV SUR, V132, P628, DOI 10.1016/j.jtcvs.2006.05.034
   VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576
   YABLONKAREUVENI Z, 1990, J CELL BIOL, V111, P1623, DOI 10.1083/jcb.111.4.1623
   Zambrano J, 2007, CIRCULATION, V116, P202
NR 25
TC 5
Z9 7
U1 4
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD DEC
PY 2008
VL 86
IS 6
BP 1841
EP 1848
DI 10.1016/j.athoracsur.2008.08.038
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 373SX
UT WOS:000260994200017
PM 19021990
DA 2018-12-27
ER

PT J
AU Francis, GJ
   Martinez, JA
   Liu, WQ
   Xu, K
   Ayer, A
   Fine, J
   Tuor, UI
   Glazner, G
   Hanson, LR
   Frey, WH
   Toth, C
AF Francis, George J.
   Martinez, Jose A.
   Liu, Wei Q.
   Xu, Kevin
   Ayer, Amit
   Fine, Jared
   Tuor, Ursula I.
   Glazner, Gordon
   Hanson, Leah R.
   Frey, William H., II
   Toth, Cory
TI RETRACTED: Intranasal insulin prevents cognitive decline, cerebral
   atrophy and white matter changes in murine type I diabetic
   encephalopathy (Retracted article. See vol. 137, pg. E83, 2014)
SO BRAIN
LA English
DT Review; Retracted Publication
ID GLYCOGEN-SYNTHASE KINASE-3-BETA; CENTRAL-NERVOUS-SYSTEM; HIPPOCAMPAL
   SYNAPTIC PLASTICITY; BLOOD-BRAIN-BARRIER; SIGNAL-REGULATED KINASE;
   ALZHEIMER-LIKE CHANGES; ADULT SENSORY NEURONS; VASCULAR RISK-FACTORS;
   GROWTH-FACTOR-I; IGF-I
AB Insulin deficiency in type I diabetes may lead to cognitive impairment, cerebral atrophy and white matter abnormalities. We studied the impact of a novel delivery system using intranasal insulin (I-I) in a mouse model of type I diabetes (streptozotocin-induced) for direct targeting of pathological and cognitive deficits while avoiding potential adverse systemic effects. Daily I-I, subcutaneous insulin (S-I) or placebo in separate cohorts of diabetic and non-diabetic CD1 mice were delivered over 8 months of life. Radio-labelled insulin delivery revealed that I-I delivered more rapid and substantial insulin levels within the cerebrum with less systemic insulin detection when compared with S-I. I-I delivery slowed development of cognitive decline within weekly cognitive/behavioural testing, ameliorated monthly magnetic resonance imaging abnormalities, prevented quantitative morphological abnormalities in cerebrum, improved mouse mortality and reversed diabetes-mediated declines in mRNA and protein for phosphoinositide 3-kinase (PI3K)/Akt and for protein levels of the transcription factors cyclic AMP response element binding protein (CREB) and glycogen synthase kinase 3 (GSK-3) within different cerebral regions. Although the murine diabetic brain was not subject to cellular loss, a diabetes-mediated loss of protein and mRNA for the synaptic elements synaptophysin and choline acetyltransferase was prevented with I-I delivery. As a mechanism of delivery, I-I accesses the brain readily and slows the development of diabetes-induced brain changes as compared to S-I delivery. This therapy and delivery mode, available in humans, may be of clinical utility for the prevention of pathological changes in the diabetic human brain.
C1 [Francis, George J.; Martinez, Jose A.; Liu, Wei Q.; Xu, Kevin; Ayer, Amit; Tuor, Ursula I.; Toth, Cory] Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada.
   [Francis, George J.; Martinez, Jose A.; Liu, Wei Q.; Xu, Kevin; Ayer, Amit; Tuor, Ursula I.; Toth, Cory] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada.
   [Fine, Jared; Hanson, Leah R.; Frey, William H., II] Reg Hosp, Alzheimers Res Ctr, HealthPartners Res Fdn, St Paul, MN USA.
   [Glazner, Gordon] Univ Manitoba, Dept Pharmacol & Therapeut, Div Neurodegenerat Disorders, St Boniface Hosp Res Ctr, Winnipeg, MB, Canada.
RP Toth, C (reprint author), Univ Calgary, Dept Clin Neurosci, Room 155,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
EM corytoth@shaw.ca
OI Frey II, William/0000-0002-6373-0794
FU Alberta Heritage Foundation for Medical Research; Canadian Diabetes
   Association
FX This study was supported by an operating grant from the Alberta Heritage
   Foundation for Medical Research and the Canadian Diabetes Association.
   C. T. is a Clinical Investigator of the Alberta Heritage Foundation for
   Medical Research and D. W. Z. is a Scientist of the Alberta Heritage
   Foundation for Medical Research.
CR Abbott MA, 1999, J NEUROSCI, V19, P7300, DOI 10.1523/JNEUROSCI.19-17-07300.1999
   ADAMO M, 1989, MOL NEUROBIOL, V3, P71, DOI 10.1007/BF02935589
   Akisaki T, 2006, DIABETES-METAB RES, V22, P376, DOI 10.1002/dmrr.632
   Awad N, 2004, J CLIN EXP NEUROPSYC, V26, P1044, DOI 10.1080/13803390490514875
   BASKIN DG, 1987, ANNU REV PHYSIOL, V49, P335, DOI 10.1146/annurev.ph.49.030187.002003
   Benedict C, 2004, PSYCHONEUROENDOCRINO, V29, P1326, DOI 10.1016/j.psyneuen.2004.04.003
   BENEDICT C, 2008, J CLIN ENDOCRINOL ME
   Benedict C, 2007, NEUROENDOCRINOLOGY, V86, P136, DOI 10.1159/000106378
   Biessels GJ, 2008, LANCET NEUROL, V7, P184, DOI 10.1016/S1474-4422(08)70021-8
   Biessels GJ, 1998, BRAIN RES, V800, P125, DOI 10.1016/S0006-8993(98)00510-1
   Biessels GJ, 1996, DIABETES, V45, P1259, DOI 10.2337/diabetes.45.9.1259
   Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Bruss MD, 2005, DIABETES, V54, P41, DOI 10.2337/diabetes.54.1.41
   BURDO JR, 2008, NEUROBIOL AGING
   Chen X-Q, 1998, J ALZHEIMERS DIS, V1, P35, DOI DOI 10.1080/10942919809524563
   Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075
   COHEN RA, 1993, CIRCULATION, V87, P67
   Craft S, 2004, LANCET NEUROL, V3, P169, DOI 10.1016/S1474-4422(04)00681-7
   Craft S, 1998, NEUROLOGY, V50, P164, DOI 10.1212/WNL.50.1.164
   CRAWLEY JN, 2000, WHATS WRONG MY MOUSE, P87
   Cui QL, 2007, J NEUROCHEM, V100, P1480, DOI 10.1111/j.1471-4159.2006.04329.x
   de Groot JC, 2000, ANN NEUROL, V47, P145
   DHANDA DS, 2005, DRUG DELIV TECHNOL, V5, P64
   Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661
   Fernyhough P, 2003, J PERIPHER NERV SYST, V8, P227, DOI 10.1111/j.1085-9489.2003.03028.x
   FILE SE, 1975, PSYCHOPHARMACOLOGIA, V44, P47, DOI 10.1007/BF00421183
   Fox MA, 2003, J PEDIATR PSYCHOL, V28, P569, DOI 10.1093/jpepsy/jsg047
   Frederick TJ, 2007, GLIA, V55, P1011, DOI 10.1002/glia.20520
   Freude S, 2005, DIABETES, V54, P3343, DOI 10.2337/diabetes.54.12.3343
   Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x
   GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x
   Haan MN, 2006, NAT CLIN PRACT NEURO, V2, P159, DOI 10.1038/ncpneuro0124
   Hallschmid M, 2008, INT J OBESITY, V32, P275, DOI 10.1038/sj.ijo.0803722
   Hattori Y, 2000, CARDIOVASC RES, V46, P188, DOI 10.1016/S0008-6363(99)00425-3
   HAVRANKOVA J, 1978, NATURE, V272, P827, DOI 10.1038/272827a0
   HAVRANKOVA J, 1978, P NATL ACAD SCI USA, V75, P5737, DOI 10.1073/pnas.75.11.5737
   HEIDENREICH KA, 1983, J BIOL CHEM, V258, P8527
   Hetman M, 2000, J NEUROSCI, V20, P2567
   Ho L, 2004, FASEB J, V18, P902, DOI 10.1096/fj.03-0978fje
   Hoyer S, 2004, EUR J PHARMACOL, V490, P115, DOI 10.1016/j.ejphar.2004.02.049
   Huang C, 2005, J BIOL CHEM, V280, P19426, DOI 10.1074/jbc.M412317200
   Huang TJ, 2005, MOL CELL NEUROSCI, V28, P42, DOI 10.1016/j.mcn.2004.08.009
   Ikram MA, 2008, NEUROBIOL AGING, V29, P882, DOI 10.1016/j.neurobiolaging.2006.12.012
   Jacobson AM, 2007, NEW ENGL J MED, V356, P1842
   Jones DM, 2003, J NEUROCHEM, V86, P1116, DOI 10.1046/j.1471-4159.2003.01925.x
   Kaiyala KJ, 2000, DIABETES, V49, P1525, DOI 10.2337/diabetes.49.9.1525
   Kamal A, 2006, BRAIN RES, V1073, P276, DOI 10.1016/j.brainres.2005.12.070
   Kamal A, 2000, DIABETOLOGIA, V43, P500, DOI 10.1007/s001250051335
   Khafagy ES, 2007, ADV DRUG DELIVER REV, V59, P1521, DOI 10.1016/j.addr.2007.08.019
   Kloppenborg RP, 2008, EUR J PHARMACOL, V585, P97, DOI 10.1016/j.ejphar.2008.02.049
   Knopman D, 2001, NEUROLOGY, V56, P42, DOI 10.1212/WNL.56.1.42
   Kramer L, 1998, DIABETES, V47, P1909, DOI 10.2337/diabetes.47.12.1909
   Last D, 2007, DIABETES CARE, V30, P1193, DOI 10.2337/dc06-2052
   Leinninger GM, 2004, FASEB J, V18, P1544, DOI 10.1096/fj.04-1581fje
   Leroy K, 1999, J CHEM NEUROANAT, V16, P279, DOI 10.1016/S0891-0618(99)00012-5
   Li ZG, 2005, BRAIN RES, V1037, P12, DOI 10.1016/j.brainres.2004.11.063
   Li ZG, 2007, DIABETES, V56, P1817, DOI 10.2337/db07-0171
   Liu Xin-Feng, 2004, J Stroke Cerebrovasc Dis, V13, P16, DOI 10.1016/j.jstrokecerebrovasdis.2004.01.005
   Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4
   Lupien SB, 2006, NEUROBIOL DIS, V21, P487, DOI 10.1016/j.nbd.2005.08.008
   Mahadev K, 2004, CELL SIGNAL, V16, P323, DOI 10.1016/j.cellsig.2003.08.002
   Manschot SM, 2006, DIABETES, V55, P1106, DOI 10.2337/diabetes.55.04.06.db05-1323
   MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8
   MATSUMOTO H, 1990, J NEUROCHEM, V54, P347, DOI 10.1111/j.1471-4159.1990.tb13321.x
   McCarthy AM, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e9
   Miles WR, 1922, ARCH INTERN MED, V30, P767, DOI 10.1001/archinte.1922.00110120086003
   Mooradian AD, 1997, BRAIN RES REV, V23, P210, DOI 10.1016/S0165-0173(97)00003-9
   MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4
   MUNOZ DG, 1993, ARCH NEUROL-CHICAGO, V50, P492, DOI 10.1001/archneur.1993.00540050044013
   Murray AD, 2005, RADIOLOGY, V237, P251, DOI 10.1148/radiol.2371041496
   Musen G, 2006, DIABETES, V55, P326, DOI 10.2337/diabetes.55.02.06.db05-0520
   Northam EA, 2001, DIABETES CARE, V24, P1541, DOI 10.2337/diacare.24.9.1541
   Ogata T, 2004, J NEUROSCI, V24, P6724, DOI 10.1523/JNEUROSCI.5520-03.2004
   Owens DR, 2003, DIABETIC MED, V20, P886, DOI 10.1046/j.1464-5491.2003.01076.x
   Pantoni L, 1997, STROKE, V28, P652, DOI 10.1161/01.STR.28.3.652
   Pantoni L, 2007, CURR OPIN NEUROL, V20, P390, DOI 10.1097/WCO.0b013e328172d661
   Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929
   PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670
   REAVEN GM, 1990, DIABETES CARE, V13, P16, DOI 10.2337/diacare.13.1.16
   Reger MA, 2008, NEUROLOGY, V70, P440, DOI 10.1212/01.WNL.0000265401.62434.36
   Reger MA, 2006, NEUROBIOL AGING, V27, P451, DOI 10.1016/j.neurobiolaging.2005.03.016
   Ross TM, 2004, J NEUROIMMUNOL, V151, P66, DOI 10.1016/j.jneuroim.2004.02.011
   ROTHBLAT LA, 1991, BEHAV BRAIN RES, V42, P25, DOI 10.1016/S0166-4328(05)80036-1
   RYAN CM, 1993, J CLIN EXP NEUROPSYC, V15, P685, DOI 10.1080/01688639308402589
   Ryan CM, 2000, DIABETES METAB RES, V16, P308, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR141>3.0.CO;2-X
   RYAN CM, 1988, DIABETES CARE, V11, P86, DOI 10.2337/diacare.11.1.86
   RYAN CM, 1993, DIABETOLOGIA, V36, P329, DOI 10.1007/BF00400236
   Salkovic-Petrisic M, 2006, J NEUROCHEM, V96, P1005, DOI 10.1111/j.1471-4159.2005.03637.x
   Schmidt R, 2004, DIABETES, V53, P687, DOI 10.2337/diabetes.53.3.687
   Schoenle EJ, 2002, DIABETOLOGIA, V45, P108, DOI 10.1007/s125-002-8250-6
   Schwabe K, 2006, BEHAV BRAIN RES, V168, P150, DOI 10.1016/j.bbr.2005.11.005
   Schwartz AV, 2008, DIABETES CARE, V31, P391, DOI 10.2337/dc07-1152
   Stewart R, 1999, DIABETIC MED, V16, P93, DOI 10.1046/j.1464-5491.1999.00027.x
   Strachan MWJ, 1997, DIABETES CARE, V20, P438, DOI 10.2337/diacare.20.3.438
   Stranahan AM, 2008, NAT NEUROSCI, V11, P309, DOI 10.1038/nn2055
   Thorne RG, 2004, NEUROSCIENCE, V127, P481, DOI 10.1016/j.neuroscience.2004.05.029
   Tomlinson DR, 2008, NAT REV NEUROSCI, V9, P36, DOI 10.1038/nrn2294
   Toth C, 2006, NEUROBIOL DIS, V23, P445, DOI 10.1016/j.nbd.2006.03.015
   Trejo JL, 2008, MOL CELL NEUROSCI, V37, P402, DOI 10.1016/j.mcn.2007.10.016
   Tullberg M, 2004, NEUROLOGY, V63, P246, DOI 10.1212/01.WNL.0000130530.55104.B5
   UNGER J, 1989, NEUROSCIENCE, V31, P143, DOI 10.1016/0306-4522(89)90036-5
   UNGER JW, 1991, PROG NEUROBIOL, V36, P343, DOI 10.1016/0301-0082(91)90015-S
   van Harten B, 2007, EUR NEUROL, V57, P70, DOI 10.1159/000098054
   van Harten B, 2006, DIABETES CARE, V29, P2539, DOI 10.2337/dc-06-1637
   Verdelho A, 2007, J NEUROL NEUROSUR PS, V78, P1325, DOI 10.1136/jnnp.2006.110361
   Viard P, 2004, NAT NEUROSCI, V7, P939, DOI 10.1038/nn1300
   Vig PJS, 2006, BRAIN RES BULL, V69, P573, DOI 10.1016/j.brainresbull.2006.02.020
   Walton M, 1999, J NEUROCHEM, V73, P1836
   Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792
   Weinger K, 2008, DIABETOLOGIA, V51, P417, DOI 10.1007/s00125-007-0904-9
   Wessels AM, 2007, DIABETOLOGIA, V50, P1763, DOI 10.1007/s00125-007-0714-0
   White MF, 1998, CURR TOP MICROBIOL, V228, P179
   Whitman GT, 2001, NEUROLOGY, V57, P990, DOI 10.1212/WNL.57.6.990
   Wickelgren I, 1998, SCIENCE, V280, P517, DOI 10.1126/science.280.5363.517
   Woods SC, 2003, CURR PHARM DESIGN, V9, P795, DOI 10.2174/1381612033455323
   YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324
   Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010
   Yu XR, 2006, ACTA BIOCH BIOPH SIN, V38, P241, DOI 10.1111/j.1745-7270.2006.00152.x
   Zhao LX, 2004, J NEUROSCI, V24, P11120, DOI 10.1523/JNEUROSCI.2860-04.2004
   Zhao WQ, 2008, FASEB J, V22, P246, DOI 10.1096/fj.06-7703com
   Zhao WQ, 1999, J BIOL CHEM, V274, P34893, DOI 10.1074/jbc.274.49.34893
   Zhao WQ, 2004, EUR J PHARMACOL, V490, P71, DOI 10.1016/j.ejphar.2004.02.045
   Zheng WH, 2002, MOL PHARMACOL, V62, P225, DOI 10.1124/mol.62.2.225
NR 124
TC 119
Z9 126
U1 3
U2 26
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD DEC
PY 2008
VL 131
BP 3311
EP 3334
DI 10.1093/brain/awn288
PN 12
PG 24
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 388CA
UT WOS:000261996700022
PM 19015157
OA Bronze
DA 2018-12-27
ER

PT J
AU Zheng, YG
   Chen, XL
   Shen, YC
AF Zheng, Yuguo
   Chen, Xiaolong
   Shen, Yinchu
TI RETRACTED: Commodity Chemicals Derived from Glycerol, an Important
   Biorefinery Feedstock (Retracted Article. See vol 110, pg 1807, 2010)
SO CHEMICAL REVIEWS
LA English
DT Review; Retracted Publication
ID ALPHA-D-GLUCOSYLGLYCEROL; LIQUID-PHASE OXIDATION; ION-EXCHANGE-RESINS;
   SOLVENT-FREE SYSTEM; CHEMOSELECTIVE CATALYTIC-OXIDATION; SUPERCRITICAL
   CARBON-DIOXIDE; PLATINUM-BISMUTH CATALYST; SUPPORTED GOLD CATALYSTS;
   CONJUGATED LINOLEIC-ACID; SELECTIVE OXIDATION
C1 [Zheng, Yuguo; Chen, Xiaolong; Shen, Yinchu] Zhejiang Univ Technol, Inst Bioengn, Hangzhou 310032, Zhejiang, Peoples R China.
RP Zheng, YG (reprint author), Zhejiang Univ Technol, Inst Bioengn, Hangzhou 310032, Zhejiang, Peoples R China.
EM zhengyg@zjut.edu.cn
RI Chen, XiaoLong/G-8581-2012
FU Major Basic Research Development Program of China [2007CB714306]
FX This work was supported by the Major Basic Research Development Program
   of China (no. 2007CB714306).
CR Abbadi A, 1996, APPL CATAL A-GEN, V148, P113, DOI 10.1016/S0926-860X(96)00229-3
   AHN E, 1995, SEPAR SCI TECHNOL, V30, P2021, DOI 10.1080/01496399508010391
   Ancillotti F, 1998, FUEL PROCESS TECHNOL, V57, P163, DOI 10.1016/S0378-3820(98)00081-2
   ANTAL MJ, 1985, J ANAL APPL PYROL, V8, P291, DOI 10.1016/0165-2370(85)80032-2
   Antolin G, 2002, BIORESOURCE TECHNOL, V83, P111, DOI 10.1016/S0960-8524(01)00200-0
   AOKI T, 2000, Patent No. 1059278
   Aresta M, 2006, J MOL CATAL A-CHEM, V257, P149, DOI 10.1016/j.molcata.2006.05.021
   ARNTZ D, 1991, CHEM-ING-TECH, V63, P733, DOI 10.1002/cite.330630714
   Asawanonda P, 1999, INT J DERMATOL, V38, P916, DOI 10.1046/j.1365-4362.1999.00779.x
   BALTZING BL, 1971, J BACTERIOL, V108, P592
   Ban K, 2002, J MOL CATAL B-ENZYM, V17, P157, DOI 10.1016/S1381-1177(02)00023-1
   Barbirato F, 1996, APPL ENVIRON MICROB, V62, P4405
   Barbirato F, 1996, APPL ENVIRON MICROB, V62, P1448
   Barbirato F, 1998, BIOTECHNOL BIOENG, V58, P303, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<303::AID-BIT28>3.0.CO;2-B
   Barrault J., 2005, Lipid Technology, V17, P131
   Barrault J, 2004, CR CHIM, V7, P593, DOI 10.1016/j.crci.2003.12.006
   Barrault J, 1998, CHEM INDUST, V75, P13
   Bauer JE, 2006, J NUTR, V136, p1955S, DOI 10.1093/jn/136.7.1955S
   Bauer R, 2005, BIOPROC BIOSYST ENG, V28, P37, DOI 10.1007/s00449-005-0009-0
   Belafi-Bako K, 2002, BIOCATAL BIOTRANSFOR, V20, P437, DOI 10.1080/1024242021000040855
   Bell JB, 1959, US Patent, Patent No. [2, 915, 529, 2915529]
   BERGER M, 1992, J AM OIL CHEM SOC, V69, P961, DOI 10.1007/BF02541058
   BERGER M, 1992, J AM OIL CHEM SOC, V69, P955, DOI 10.1007/BF02541057
   BERGER M, 1993, FETT WISS TECHNOL, V95, P169, DOI 10.1002/lipi.19930950504
   Bianchi CL, 2005, CATAL TODAY, V102, P203, DOI 10.1016/j.cattod.2005.02.003
   Blanco M, 2004, ANAL CHIM ACTA, V521, P143, DOI 10.1016/j.aca.2004.06.003
   Bornscheuer U.T., 1999, RECENT RES DEV OIL C, V3, P93
   BORNSCHEUER UT, 1995, ENZYME MICROB TECH, V17, P578, DOI 10.1016/0141-0229(94)00096-A
   BORNSCHEUER UT, 1995, J AM OIL CHEM SOC, V72, P193, DOI 10.1007/BF02638899
   Bouaid A, 2005, CATAL TODAY, V106, P193, DOI 10.1016/j.cattod.2005.07.163
   Bournay L, 2005, CATAL TODAY, V106, P190, DOI 10.1016/j.cattod.2005.07.181
   Brown DA, 2001, J PHOTOCH PHOTOBIO B, V63, P148, DOI 10.1016/S1011-1344(01)00212-3
   Buhler W, 2002, J SUPERCRIT FLUID, V22, P37, DOI 10.1016/S0896-8446(01)00105-X
   Canakci M, 2001, T ASAE, V44, P1429
   Cantrell DG, 2005, APPL CATAL A-GEN, V287, P183, DOI 10.1016/j.apcata.2005.03.027
   Cardone M, 2003, BIOMASS BIOENERG, V25, P623, DOI 10.1016/S0961-9534(03)00058-8
   CAROLE TM, 2004, APPL BIOCHEM BIOTECH, V871, P113
   Carrettin S, 2003, PHYS CHEM CHEM PHYS, V5, P1329, DOI 10.1039/b212047j
   Carrettin S, 2004, TOP CATAL, V27, P131, DOI 10.1023/B:TOCA.0000013547.35106.0d
   Carrettin S, 2002, CHEM COMMUN, P696, DOI 10.1039/b201112n
   Cerce T, 2005, IND ENG CHEM RES, V44, P9535, DOI 10.1021/ie050252e
   Chai SH, 2007, GREEN CHEM, V9, P1130, DOI 10.1039/b702200j
   Chai SH, 2007, J CATAL, V250, P342, DOI 10.1016/j.jcat.2007.06.016
   Chaminand J, 2004, GREEN CHEM, V6, P359, DOI 10.1039/b407378a
   CHE TM, 1987, Patent No. 4642394
   CHEN HW, 2004, HUAGONG XIANDAI, V24, P36
   Cheng KK, 2006, BIOTECHNOL LETT, V28, P1817, DOI 10.1007/s10529-006-9158-8
   Chiu CW, 2006, IND ENG CHEM RES, V45, P791, DOI 10.1021/ie050915s
   Cho KH, 2006, ANN NUTR METAB, V50, P467, DOI 10.1159/000095353
   CHOU CC, 2006, Patent No. 2006063242
   Ciriminna R, 2003, ADV SYNTH CATAL, V345, P383, DOI 10.1002/adsc.200390043
   Ciriminna R, 2006, TETRAHEDRON LETT, V47, P6993, DOI 10.1016/j.tetlet.2006.07.123
   Clacens JM, 2002, STUD SURF SCI CATAL, V143, P687
   Clacens JM, 2002, APPL CATAL A-GEN, V227, P181, DOI 10.1016/S0926-860X(01)00920-6
   Claisse O, 2001, J FOOD PROTECT, V64, P833, DOI 10.4315/0362-028X-64.6.833
   Compagno C, 1996, BIOTECHNOL PROGR, V12, P591, DOI 10.1021/bp960043c
   CORBIN DR, 2001, Patent No. 2001025178
   Coteron A, 1998, J AM OIL CHEM SOC, V75, P657, DOI 10.1007/s11746-998-0080-1
   CRANS DC, 1985, J AM CHEM SOC, V107, P7019, DOI 10.1021/ja00310a045
   DALONZO RP, 1982, J AM OIL CHEM SOC, V59, P292, DOI 10.1007/BF02662229
   DANIEL R, 1992, FEMS MICROBIOL LETT, V100, P281, DOI 10.1111/j.1574-6968.1992.tb05716.x
   Dasari MA, 2005, APPL CATAL A-GEN, V281, P225, DOI 10.1016/j.apcata.2004.11.033
   Davis WR, 2000, BIOCHEMISTRY-US, V39, P14279, DOI 10.1021/bi0015764
   DELGADO PJ, 2003, Patent No. 1331260
   Demirbas A, 2003, ENERG SOURCE, V25, P457, DOI 10.1080/00908310390142451
   Demirbas A, 2002, ENERG CONVERS MANAGE, V43, P2349, DOI 10.1016/S0196-8904(01)00170-4
   Demirel S, 2007, APPL CATAL B-ENVIRON, V70, P637, DOI 10.1016/j.apcatb.2005.11.036
   DEMORAES ED, 2006, Patent No. 2006069274
   Deppenmeier U, 2002, APPL MICROBIOL BIOT, V60, P233, DOI 10.1007/s00253-002-1114-5
   DEUTSCHER J, 1986, J BACTERIOL, V166, P829, DOI 10.1128/jb.166.3.829-836.1986
   Diaz I, 2005, MICROPOR MESOPOR MAT, V80, P33, DOI 10.1016/j.micromeso.2004.11.011
   Diaz I, 2003, APPL CATAL A-GEN, V242, P161, DOI 10.1016/S0926-860X(02)00501-X
   Dimitratos N, 2006, J MOL CATAL A-CHEM, V256, P21, DOI 10.1016/j.molcata.2006.04.019
   Dimitratos N, 2006, CATAL LETT, V108, P147, DOI 10.1007/s10562-006-0036-8
   Dimitratos N, 2005, APPL CATAL A-GEN, V291, P210, DOI 10.1016/j.apcata.2005.01.044
   Dimitratos N, 2006, J CATAL, V244, P113, DOI 10.1016/j.jcat.2006.08.019
   Dimitratos N, 2006, APPL CATAL A-GEN, V311, P185, DOI 10.1016/j.apcata.2006.06.026
   DIVO C, 1980, Patent No. 2029821
   Doleyres Y, 2005, APPL MICROBIOL BIOT, V68, P467, DOI 10.1007/s00253-005-1895-4
   Drent E., 1999, [No title captured], Patent No. [Wo 9,905,085, 9905085]
   DRENT E, 2000, Patent No. 6080898
   Drochner A, 2004, CHEM ENG TECHNOL, V27, P1073, DOI 10.1002/ceat.200403225
   Dubois J. L., 2006, [No title captured], Patent No. [2006087083, WO2006087083]
   DUBOIS JL, 2006, Patent No. 2006087084
   Ederer HJ, 1999, J SUPERCRIT FLUID, V15, P191, DOI 10.1016/S0896-8446(99)00013-3
   Encinar JM, 2005, IND ENG CHEM RES, V44, P5491, DOI 10.1021/ie040214f
   Encinar JM, 2002, ENERG FUEL, V16, P443, DOI 10.1021/ef010174h
   Eychenne V, 2000, J SURFACTANTS DETERG, V3, P173, DOI 10.1007/s11743-000-0122-3
   FANSURI H, 2004, DEV CHEM ENG MINER P, V12, P333
   Feng J, 2007, CHEM LETT, V36, P1274, DOI 10.1246/cl.2007.1274
   Feng J, 2007, PROG CHEM, V19, P651
   Fesq H, 2001, DERMATOLOGY, V203, P241, DOI 10.1159/000051757
   Finogenova TV, 2005, APPL BIOCHEM MICRO+, V41, P418, DOI 10.1007/s10438-005-0076-7
   FLECKENSTEIN T, 1994, Patent No. 4302464
   Flickinger BD, 2003, LIPIDS, V38, P129, DOI 10.1007/s11745-003-1042-8
   Fordham P, 1997, STUD SURF SCI CATAL, V108, P429
   Fordham P, 1996, STUD SURF SCI CATAL, V101, P161
   Fordham P, 1997, CATAL LETT, V46, P195, DOI 10.1023/A:1019082905366
   Frondel M, 2007, ENERG POLICY, V35, P1675, DOI 10.1016/j.enpol.2006.04.022
   Furikado I, 2007, GREEN CHEM, V9, P582, DOI 10.1039/b614253b
   Gatgens C, 2007, APPL MICROBIOL BIOT, V76, P553, DOI 10.1007/s00253-007-1003-z
   GALLAGHER JL, 2006, Patent No. 2006110701
   Gallezot P, 1997, CATAL TODAY, V37, P405, DOI 10.1016/S0920-5861(97)00024-2
   GARCIA R, 1995, APPL CATAL A-GEN, V127, P165, DOI 10.1016/0926-860X(95)00048-8
   Ghamgui H, 2006, ENZYME MICROB TECH, V39, P717, DOI 10.1016/j.enzmictec.2005.12.014
   Gilbeau P, 2006, PCT Patent Application, Patent No. [WO2006100311, 2006100311]
   GILBEAU P, 2006, Patent No. 2006106154
   GINOSAR DM, 2000, Patent No. 2000005327
   Grace AN, 2006, ELECTROCHEM COMMUN, V8, P1340, DOI 10.1016/j.elecom.2006.06.007
   GRIMSBY FN, 1986, Patent No. 4620912
   GRYBEK RST, 1975, Patent No. 3884674
   Gupta A, 2001, J MOL MICROB BIOTECH, V3, P445
   GUPTA VP, 1995, Patent No. 5476971
   HAFTENDORN R, 1995, TETRAHEDRON, V51, P1177, DOI 10.1016/0040-4020(94)01013-P
   Hekmat D, 2003, BIOPROC BIOSYST ENG, V26, P109, DOI 10.1007/s00449-003-0338-9
   Henry E. M. T., 2001, Malawi Journal of Science and Technology, V6, P35
   HETTWER J, 2002, J MOL CATAL B-ENZYM, V215, P19
   HIGHSMITH TK, 2004, Patent No. 2004138481
   Hirai T, 2005, ENERG FUEL, V19, P1761, DOI 10.1021/ef050121q
   HOOKER JD, 2005, Patent No. 2005027137
   Hossein N., 2000, US Patent, Patent No. [6,015,440, 6015440]
   HUTCHINGS GJ, 2003, SPEC CHEM MAG, V23, P12
   Ijiri Y, 2006, ATHEROSCLEROSIS SUPP, V7, P436, DOI 10.1016/S1567-5688(06)81758-7
   Ito T, 2005, J BIOSCI BIOENG, V100, P260, DOI 10.1263/jbb.100.260
   Ivy JL, 1998, MED SCI SPORT EXER, V30, P837, DOI 10.1097/00005768-199806000-00010
   Jackson MA, 1997, J AM OIL CHEM SOC, V74, P103, DOI 10.1007/s11746-997-0152-7
   Jamroz ME, 2007, SPECTROCHIM ACTA A, V67, P980, DOI 10.1016/j.saa.2006.09.017
   KANAEV GI, 1986, Patent No. 8405527
   KARABINA E, 1994, SYNTHETIC COMMUN, V24, P3009, DOI 10.1080/00397919408011314
   Karinen RS, 2006, APPL CATAL A-GEN, V306, P128, DOI 10.1016/j.apcata.2006.03.047
   KARRI V, 2006, Patent No. 2006100428
   KATO N, 1986, APPL MICROBIOL BIOT, V23, P180
   Ketchie WC, 2007, J CATAL, V250, P264, DOI 10.1016/j.jcat.2007.06.011
   Ketchie WC, 2007, J CATAL, V250, P94, DOI 10.1016/j.jcat.2007.06.001
   Ketchie WC, 2007, TOP CATAL, V44, P307, DOI 10.1007/s11244-007-0304-x
   KHALIL CN, 2005, Patent No. 2005030911
   Kim HJ, 2006, ANN NUTR METAB, V50, P219, DOI 10.1159/000090765
   Kim JW, 2000, BIOTECHNOL PROGR, V16, P657, DOI 10.1021/bp000037n
   Kimura H, 1996, J POLYM SCI POL CHEM, V34, P3615
   KIMURA H, 1993, APPL CATAL A-GEN, V96, P217, DOI 10.1016/0926-860X(90)80011-3
   KIMURA H, 1993, APPL CATAL A-GEN, V105, P147, DOI 10.1016/0926-860X(93)80245-L
   KIMURA H, 1993, APPL CATAL A-GEN, V95, P143, DOI 10.1016/0926-860X(93)85071-V
   KIMURA H, 1993, J AM OIL CHEM SOC, V70, P1027, DOI 10.1007/BF02543031
   Kimura H, 1996, J POLYM SCI POL CHEM, V34, P3595
   Kimura H, 2001, POLYM ADVAN TECHNOL, V12, P697, DOI 10.1002/pat.91
   Kimura H, 1998, J POLYM SCI POL CHEM, V36, P195, DOI 10.1002/(SICI)1099-0518(19980115)36:1<195::AID-POLA24>3.3.CO;2-1
   Kimura H, 1998, J POLYM SCI POL CHEM, V36, P189, DOI 10.1002/(SICI)1099-0518(19980115)36:1<189::AID-POLA23>3.0.CO;2-E
   KIMURA H, 1995, APPL CATAL A-GEN, V123, P323, DOI 10.1016/0926-860X(95)00008-9
   Kimura S, 2006, INT J VITAM NUTR RES, V76, P75, DOI 10.1024/0300-9831.76.2.75
   Klepacova K, 2006, CHEM PAP, V60, P224, DOI 10.2478/s11696-006-0040-x
   Klepacova K, 2005, APPL CATAL A-GEN, V294, P141, DOI 10.1016/j.apcata.2005.06.027
   Klepacova K, 2003, PET COAL, V45, P54
   Klepacova K, 2007, APPL CATAL A-GEN, V328, P1, DOI 10.1016/j.apcata.2007.03.031
   Komers K, 2002, EUR J LIPID SCI TECH, V104, P728, DOI 10.1002/1438-9312(200211)104:11<728::AID-EJLT728>3.0.CO;2-J
   KOVACS A, 2003, Patent No. 2003040081
   Krafft P, 2005, PCT Patent Application, Patent No. [2005054167, WO2005054167]
   Kristensen JB, 2006, J NUTR, V136, P1800
   Kristensen JB, 2006, EUR J LIPID SCI TECH, V108, P336, DOI 10.1002/ejlt.200500232
   KUMAR R, 2006, CHEM IND DIG, V19, P69
   KUSDIANA D, 2004, APPL BIOCHEM BIOTECH, V781, P113
   Lahr DG, 2005, J CATAL, V232, P386, DOI 10.1016/j.jcat.2005.03.015
   Lahr DG, 2003, IND ENG CHEM RES, V42, P5467, DOI 10.1021/ie030468l
   LAM KT, 1997, Patent No. 9716250
   LAUER A, 1986, Patent No. 2168341
   Lee SY, 2004, MACROMOL BIOSCI, V4, P157, DOI 10.1002/mabi.200300096
   Levinson WE, 2007, ENZYME MICROB TECH, V41, P292, DOI 10.1016/j.enzmictec.2007.02.005
   LI ZY, 1994, J IND MICROBIOL, V13, P238, DOI 10.1007/BF01569755
   Lichtenthaler FW, 2004, CR CHIM, V7, P65, DOI 10.1016/j.crci.2004.02.002
   LILI W, 2006, ANAL CHIM ACTA, V557, P262
   Lin H, 2005, CHINESE J CATAL, V26, P497
   Luthi-Peng Q, 2002, APPL MICROBIOL BIOT, V59, P289, DOI 10.1007/s00253-002-1002-z
   Luthi-Peng Q, 2002, APPL MICROBIOL BIOT, V60, P73, DOI 10.1007/s00253-002-1099-0
   LUXEM FJ, 2004, Patent No. 2004254387
   Macierzanka A, 2004, IND ENG CHEM RES, V43, P7744, DOI 10.1021/ie040077m
   Maki KC, 2002, AM J CLIN NUTR, V76, P1230
   Maris EP, 2007, J CATAL, V251, P281, DOI 10.1016/j.jcat.2007.08.007
   Maris EP, 2007, J CATAL, V249, P328, DOI 10.1016/j.jcat.2007.05.008
   Martinez CE, 2005, APPL BIOCHEM BIOTECH, V125, P63, DOI 10.1385/ABAB:125:1:063
   Matsuyama T, 2006, J PEDIATR ENDOCR MET, V19, P795
   MATTSON FH, 1961, J LIPID RES, V2, P58
   McMorn P, 1999, CATAL LETT, V63, P193, DOI 10.1023/A:1019073122592
   MCNEILL GP, 1991, J AM OIL CHEM SOC, V68, P6, DOI 10.1007/BF02660299
   MCNEILL GP, 1991, Patent No. 445692
   Meguro S, 2006, LIPIDS, V41, P347, DOI 10.1007/s11745-006-5105-7
   Michnick S, 1997, YEAST, V13, P783, DOI 10.1002/(SICI)1097-0061(199707)13:9<783::AID-YEA128>3.0.CO;2-W
   MIRELGUELEN S, 2005, CATAL TODAY, V166, P102
   MONTASSIER C, 1989, B SOC CHIM FR, V148
   MORGANS DJ, 1986, Patent No. 187297
   Morgunov IG, 2004, PROCESS BIOCHEM, V39, P1469, DOI 10.1016/S0032-9592(03)00259-0
   MOROZOV Y, 1996, Patent No. 1225836
   Mu Y, 2006, BIOTECHNOL LETT, V28, P1755, DOI 10.1007/s10529-006-9154-z
   NABE K, 1979, APPL ENVIRON MICROB, V38, P1056
   Nagata J, 2006, NUTRITION, V22, P395, DOI 10.1016/j.nut.2005.08.008
   Nakano H, 2003, J BIOSCI BIOENG, V95, P583, DOI 10.1263/jbb.95.583
   NARAYANA T, 2004, Patent No. 193299
   Navratil M, 2001, PROCESS BIOCHEM, V36, P1045, DOI 10.1016/S0032-9592(00)00298-3
   Nevoigt E, 1996, YEAST, V12, P1331, DOI 10.1002/(SICI)1097-0061(199610)12:13<1331::AID-YEA28>3.3.CO;2-S
   OKU T, 2006, Patent No. 2006088254
   Oku T, 2005, PCT Application NoWO/2005/021697, Patent No. [2005021697, WO/2005/021697;10.03]
   Okutsu M., 2002, US Patent, Patent No. [6,495,703, 6495703, 6 , 495 ,703]
   Ott L, 2006, GREEN CHEM, V8, P214, DOI 10.1039/b506285c
   Papanikolaou S, 2003, J CHEM TECHNOL BIOT, V78, P542, DOI 10.1002/jctb.831
   Papanikolaou S, 2002, J APPL MICROBIOL, V92, P737, DOI 10.1046/j.1365-2672.2002.01577.x
   Parant B, 1999, OCL-OL CORPS GRAS LI, V6, P393
   PAUTOVA LN, 1981, Patent No. 840035
   Pavel K, 2005, US Patent, Patent No. [WO2005/021476, 2005021476]
   PELLY MF, 2004, Patent No. 2004085579
   Petitdemange E, 1995, J IND MICROBIOL, V15, P498, DOI 10.1007/BF01570021
   Plou FJ, 1996, ENZYME MICROB TECH, V18, P66, DOI 10.1016/0141-0229(96)00054-3
   Porta F, 2004, J CATAL, V224, P397, DOI 10.1016/j.jcat.2004.03.009
   Prati L, 1997, STUD SURF SCI CATAL, V110, P509
   Prati L, 2005, APPL CATAL A-GEN, V291, P199, DOI 10.1016/j.apcata.2004.11.050
   RAMAYYA S, 1987, FUEL, V66, P1364, DOI 10.1016/0016-2361(87)90183-9
   Ro YT, 1997, J BACTERIOL, V179, P6041, DOI 10.1128/jb.179.19.6041-6047.1997
   Rokicki G, 2005, GREEN CHEM, V7, P529, DOI 10.1039/b501597a
   Rosu R, 1999, J AM OIL CHEM SOC, V76, P839, DOI 10.1007/s11746-999-0074-7
   Rymowicz W, 2007, J BIOTECHNOL, V131, pS149, DOI 10.1016/j.jbiotec.2007.07.864
   SAINTAMANS S, 1994, BIOTECHNOL LETT, V16, P831, DOI 10.1007/BF00133962
   Saito S, 2006, ANN NUTR METAB, V50, P372, DOI 10.1159/000094302
   Sakthivel A, 2007, J SUPERCRIT FLUID, V42, P219, DOI 10.1016/j.supflu.2007.03.012
   Sauvageot N, 2000, INT J FOOD MICROBIOL, V55, P167, DOI 10.1016/S0168-1605(00)00191-4
   SAWAI T, 1962, J BIOL CHEM, V237, P2047
   Schlaf M, 2001, ANGEW CHEM INT EDIT, V40, P3887, DOI 10.1002/1521-3773(20011015)40:20<3887::AID-ANIE3887>3.0.CO;2-Q
   SCHUTZ H, 1984, SYST APPL MICROBIOL, V5, P169, DOI 10.1016/S0723-2020(84)80018-1
   SHARIFOV GS, 1981, Patent No. 2951770
   SIANO D, 2006, Patent No. 2006111810
   Simonetti DA, 2007, J CATAL, V247, P298, DOI 10.1016/j.jcat.2007.01.022
   Simonetti DA, 2007, GREEN CHEM, V9, P1073, DOI 10.1039/b704476c
   SLININGER PJ, 1985, APPL ENVIRON MICROB, V50, P1444
   SLININGER PJ, 1983, APPL ENVIRON MICROB, V46, P62
   Soares RR, 2006, ANGEW CHEM INT EDIT, V45, P3982, DOI 10.1002/anie.200600212
   SONNTAG NOV, 1982, J AM OIL CHEM SOC, V59, pA795, DOI 10.1007/BF02634442
   SPADLO M, 1994, PRZEM CHEM, V73, P306
   SPADLO M, 1994, Patent No. 163256
   STANKO RT, 1992, AM J CLIN NUTR, V55, P771
   Stavarache C, 2003, CHEM LETT, V32, P716, DOI 10.1246/cl.2003.716
   STEIN YS, 1983, J ANAL APPL PYROL, V4, P283, DOI 10.1016/0165-2370(83)80003-5
   STEVENSON DE, 1993, BIOTECHNOL LETT, V15, P1043, DOI 10.1007/BF00129935
   [索掌怀 Suo Zhanghuai], 2005, [石油化工, Petrochemical Technology], V34, P932
   SVITEL J, 1994, J FERMENT BIOENG, V78, P351, DOI 10.1016/0922-338X(94)90279-8
   Taguchi H, 2000, J AM COLL NUTR, V19, P789, DOI 10.1080/07315724.2000.10718079
   Takenaka F, 2000, BIOSCI BIOTECH BIOCH, V64, P1821, DOI 10.1271/bbb.64.1821
   Takenaka F, 2000, BIOSCI BIOTECH BIOCH, V64, P378, DOI 10.1271/bbb.64.378
   Takenaka F, 2001, BIOSCI BIOTECH BIOCH, V65, P1458, DOI 10.1271/bbb.65.1458
   TALARICO TL, 1990, APPL ENVIRON MICROB, V56, P943
   Tan TW, 2006, APPL BIOCHEM BIOTECH, V128, P109, DOI 10.1385/ABAB:128:2:109
   TEALL R, 2003, Patent No. 2003175182
   Teles J.H., 1994, [No title captured], Patent No. [USP 5359094, 5359094]
   THIPENG Q, 2003, APPL MICROBIOL BIOT, V60, P73
   TONG IT, 1991, APPL ENVIRON MICROB, V57, P3541
   Toraya T, 2000, CELL MOL LIFE SCI, V57, P106, DOI 10.1007/s000180050502
   Torres CF, 2001, J AM OIL CHEM SOC, V78, P1093, DOI 10.1007/s11746-001-0395-8
   Tsukuda E, 2007, CATAL COMMUN, V8, P1349, DOI 10.1016/j.catcom.2006.12.006
   [Удалова О.В. Udalova O.V.], 2005, [Кинетика и катализ, Kinetika i kataliz], V46, P569
   Udalova OV, 2005, KINET CATAL+, V46, P535, DOI 10.1007/s10975-005-0106-8
   Ulmer C., 2002, CHEM-ING-TECH, V74, P674
   Umeda T, 2006, J ANIM PHYSIOL AN N, V90, P208, DOI 10.1111/j.1439-0396.2005.00592.x
   van Well WJM, 2006, J MOL CATAL A-CHEM, V256, P1, DOI 10.1016/j.molcata.2006.04.030
   VANCAUWENBERGE JE, 1990, APPL ENVIRON MICROB, V56, P329
   VEIGADACUNHA M, 1992, APPL ENVIRON MICROB, V58, P2005
   Venancio EC, 2002, ELECTROCHIM ACTA, V47, P1495, DOI 10.1016/S0013-4686(01)00877-5
   Vieville C, 1998, CATAL LETT, V56, P245, DOI 10.1023/A:1019050205502
   Vollenweider S, 2004, APPL MICROBIOL BIOT, V64, P16, DOI 10.1007/s00253-003-1497-y
   Vollenweider S, 2003, J AGR FOOD CHEM, V51, P3287, DOI 10.1021/jf021086d
   WAHNELT S, 1991, FETT WISS TECHNOL, V93, P117, DOI 10.1002/lipi.19910930401
   Wang D, 2006, CHEM COMMUN, P1956, DOI 10.1039/b518069d
   Wang KY, 2003, IND ENG CHEM RES, V42, P2913, DOI 10.1021/ie020754h
   Wang ZX, 2001, BIOTECHNOL ADV, V19, P201, DOI 10.1016/S0734-9750(01)00060-X
   Watanabe M, 2007, BIORESOURCE TECHNOL, V98, P1285, DOI 10.1016/j.biortech.2006.05.007
   Watanabe T, 2005, PROCESS BIOCHEM, V40, P637, DOI 10.1016/j.procbio.2004.01.046
   Watanabe T, 2003, J AM OIL CHEM SOC, V80, P1201, DOI 10.1007/s11746-003-0843-5
   Wei SH, 2007, PREP BIOCHEM BIOTECH, V37, P67, DOI 10.1080/10826060601040954
   Werpy T, 2002, World Organisation Patent, Patent No. [03, 035, 582, 03035582]
   Xu JH, 2001, BIOTECHNOL BIOENG, V73, P493, DOI 10.1002/bit.1084
   Xu YY, 2004, BIOCATAL BIOTRANSFOR, V22, P45, DOI 10.1080/10242420410001661222
   YAMADA K, 1988, AGR BIOL CHEM TOKYO, V52, P711
   YAMANE T, 1994, J AM OIL CHEM SOC, V71, P339, DOI 10.1007/BF02638064
   Yi XD, 2003, CHINESE J CATAL+, V24, P769
   Yoo JW, 2003, STUD SURF SCI CATAL, V146, P757
   ZAPPI M, 2005, Patent No. 2005035693
   Zeng An-Ping, 2002, Adv Biochem Eng Biotechnol, V74, P239
   Zeng AP, 1996, BIOPROCESS ENG, V14, P169
   Zhang BC, 2007, INT J HYDROGEN ENERG, V32, P2367, DOI 10.1016/j.ijhydene.2006.11.003
   ZHANG Z, 2007, HUAXUE YU SHENGWU GO, V24, P1
   Zhao CL, 2006, CATAL TODAY, V118, P332, DOI 10.1016/j.cattod.2006.07.018
   Zhao YN, 2006, BIOCHEM ENG J, V32, P93, DOI 10.1016/j.bej.2006.09.007
   ZHENG Y, 2001, J ZHEJIANG U TECHNOL, V29, P124
   Zheng Y, 2006, Chinese Pat, Patent No. 1821418
   Zimmerman D., 1974, Patent US, Patent No. [3 814 725, 3814725]
NR 289
TC 271
Z9 280
U1 25
U2 223
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0009-2665
EI 1520-6890
J9 CHEM REV
JI Chem. Rev.
PD DEC
PY 2008
VL 108
IS 12
BP 5253
EP 5277
DI 10.1021/cr068216s
PG 25
WC Chemistry, Multidisciplinary
SC Chemistry
GA 384DB
UT WOS:000261723400009
PM 18922037
DA 2018-12-27
ER

PT J
AU Elhoweris, H
AF Elhoweris, Hala
TI RETRACTED: The effect of the child's disability on United Arab Emirates
   in-service teachers' educational decisions regarding gifted and talented
   children (Retracted article. See vol 35, pg 237, 2009)
SO EDUCATIONAL STUDIES
LA English
DT Article; Retracted Publication
DE effect; disabilities; gifted and talented; teachers' decisions
ID LABELS
AB This study investigated the effect of the disability labels: learning disabilities (LD), physical disabilities (PHD) and emotional and behavioural disorder (EBD), oil United Arab Emirates public school general education and special education teachers' willingness to refer and place Students in gifted and talented programmes. A total of 269 elementary school teachers participated in this study. All participants were randomly assigned to one of the four treatment conditions. Results indicated that teachers were significantly influenced by the LD, PHD and EBD labels when making referrals to gifted and talented programmes. Additionally, both groups of teachers were much less willing to place Students with disability labels in gifted and talented programmes.
C1 United Arab Emirates Univ, Dept Special Educ, Abu Dhabi, U Arab Emirates.
RP Elhoweris, H (reprint author), United Arab Emirates Univ, Dept Special Educ, Abu Dhabi, U Arab Emirates.
EM halae@uaeu.ac.ae
CR BALDWIN AY, 1999, MANY FACES GIFTEDNES, P103
   Beckley D., 1998, GIFTED LEARNING DISA
   Bianco M, 2005, LEARN DISABILITY Q, V28, P285, DOI 10.2307/4126967
   BOODOO GM, 1989, GIFTED CHILD QUART, V33, P110, DOI 10.1177/001698628903300303
   Brody LE, 1997, J LEARN DISABIL, V30, P282, DOI 10.1177/002221949703000304
   CLINE S, 2001, GIFTED CHILD TODAY, V24, P16
   Davis G, 2004, ED GIFTED TALENTED
   DUNN LM, 1968, EXCEPT CHILDREN, V35, P5
   Ford D. Y., 1991, ROEPER REV, V13, P27
   GEAR GH, 1978, GIFTED CHILD QUART, V22, P90, DOI 10.1177/001698627802200121
   Good T. L., 1978, LOOKING CLASSROOMS
   GRIMM S, 1998, GIFTED STUDENTS
   Hadaway Nancy, 1992, ROEPER REV, V15, P73, DOI [10.1080/02783199209553467, DOI 10.1080/02783199209553467]
   HALLAHAN DP, 2000, EXCEPTIONAL LEARNERS
   Maker CJ, 1996, GIFTED CHILD QUART, V40, P41, DOI 10.1177/001698629604000106
   MINNER S, 1984, ACAD THER, V20, P225, DOI 10.1177/105345128402000213
   MINNER S, 1990, GIFTED CHILD QUART, V34, P37, DOI 10.1177/001698629003400108
   MINNER S, 1987, ROEPER REV, V9, P247, DOI DOI 10.1080/027831987095
   MORRISON WF, 2000, RECLAIMING CHILDREN, V9, P103
   PATTON JM, 1997, REDUCING DISPROPORTI
   Piirto J., 1999, TALENTED CHILDREN AD
   Silverman L. K, 2003, HDB GIFTED ED, P533
   Swesson K., 1994, GIFTED CHILD TODAY, V17, P24
   TAYLOR RL, 1983, EDUC TRAIN MENT RET, V18, P45
NR 24
TC 2
Z9 2
U1 2
U2 8
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0305-5698
EI 1465-3400
J9 EDUC STUD-UK
JI Educ. Stud.
PD DEC
PY 2008
VL 34
IS 5
BP 557
EP 564
DI 10.1080/03055690802288536
PG 8
WC Education & Educational Research
SC Education & Educational Research
GA 398NG
UT WOS:000262738200011
DA 2018-12-27
ER

PT J
AU Albanito, L
   Lappano, R
   Madeo, A
   Chimento, A
   Prossnitz, ER
   Cappello, AR
   Dolce, V
   Abonante, S
   Pezzi, V
   Maggiolini, M
AF Albanito, Lidia
   Lappano, Rosamaria
   Madeo, Antonio
   Chimento, Adele
   Prossnitz, Eric R.
   Cappello, Anna Rita
   Dolce, Vincenza
   Abonante, Sergio
   Pezzi, Vincenzo
   Maggiolini, Marcello
TI RETRACTED: G-Protein-Coupled Receptor 30 and Estrogen Receptor-alpha Are
   Involved in the Proliferative Effects Induced by Atrazine in Ovarian
   Cancer Cells (Retracted article. See vol. 122, pg. A42, 2014)
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article; Retracted Publication
DE 17 beta-estradiol; atrazine; estrogen receptor; GPR30; ovarian cancer
   cells
ID ADRENOCORTICAL CARCINOMA-CELLS; AROMATASE CYP19 ACTIVITY; GROWTH-FACTOR
   RECEPTOR; S-TRIAZINE HERBICIDES; BREAST-CANCER; NONGENOMIC ACTIONS;
   MEMBRANE-RECEPTOR; C-FOS; G-PROTEIN-COUPLED-RECEPTOR-30 GPR30;
   TESTOSTERONE-METABOLISM
AB BACKGROUND: Atrazine, one of the most common pesticide contaminants, has been shown to up-regulate aromatase activity in certain estrogen-sensitive tumors without binding or activating the estrogen receptor (ER). Recent investigations have demonstrated that the orphan G-protein-coupled receptor 30 (GPR30), which is structurally unrelated to the ER, mediates rapid actions of 17 beta-estradiol and environmental estrogens.
   OBJECTIVES: Given the ability of atrazine to exert estrogen-like activity in cancer cells, we evaluated the potential of atrazine to signal through GPR30 in stimulating biological responses in cancer cells.
   METHODS AND RESULTS: Atrazine did not transactivate the endogenous ER alpha in different cancer cell contexts or chimeric proteins encoding the ER alpha and ER beta hormone-binding domain in gene reporter assays. Moreover, atrazine neither regulated the expression of ER alpha nor stimulated aromatase activity. Interestingly, atrazine induced extracellular signal-regulated kinase (ERK) phosphorylation and the expression of estrogen target genes. Using specific signaling inhibitors and gene silencing, we demonstrated that atrazine stimulated the proliferation of ovarian cancer cells through the GPR30-epidermal growth factor receptor transduction pathway and the involvement of ER alpha.
   CONCLUSIONS: Our results indicate a novel mechanism through which atrazine may exert relevant biological effects in cancer cells. On the basis of the present data, atrazine should be included among the environmental contaminants potentially able to signal via GPR30 in eliciting estrogenic action.
C1 [Albanito, Lidia; Lappano, Rosamaria; Madeo, Antonio; Chimento, Adele; Cappello, Anna Rita; Dolce, Vincenza; Abonante, Sergio; Pezzi, Vincenzo; Maggiolini, Marcello] Univ Calabria, Dept Pharmacobiol, I-87030 Arcavacata Di Rende, CS, Italy.
   [Prossnitz, Eric R.] Univ New Mexico, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA.
   [Prossnitz, Eric R.] Univ New Mexico, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA.
RP Maggiolini, M (reprint author), Univ Calabria, Dept Pharmacobiol, I-87030 Arcavacata Di Rende, CS, Italy.
EM marcellomaggiolini@yahoo.it
RI Prossnitz, Eric/B-4543-2008
OI pezzi, Vincenzo/0000-0003-2311-2286; Lappano,
   Rosamaria/0000-0002-9374-9701; Abonante, Sergio/0000-0003-4686-6961;
   Prossnitz, Eric/0000-0001-9190-8302; Dolce, Vincenza/0000-0003-2966-4866
FU Associazione Italiana per la Ricerca sul Cancro; Ministero
   dell'Universita e Ricerca Scientifica e Tecnologica; Regione Calabria
FX This research was supported by grants from the Associazione Italiana per
   la Ricerca sul Cancro, Ministero dell'Universita e Ricerca Scientifica e
   Tecnologica, and Regione Calabria.
CR Albanito L, 2008, ENDOCRINOLOGY, V149, P3799, DOI 10.1210/en.2008-0117
   Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909
   BABICGOJMERAC T, 1989, J STEROID BIOCHEM, V33, P141, DOI 10.1016/0022-4731(89)90369-5
   Bardin A, 2004, CANCER RES, V64, P5861, DOI 10.1158/0008-5472.CAN-04-0552
   Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775
   BRAWER JR, 1975, AM J ANAT, V144, P57, DOI 10.1002/aja.1001440105
   Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175
   Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x
   Connor K, 1996, FUND APPL TOXICOL, V30, P93, DOI 10.1006/faat.1996.0046
   Cooper RL, 2007, BIRTH DEFECTS RES B, V80, P98, DOI 10.1002/bdrb.20110
   Cooper RL, 2000, TOXICOL SCI, V53, P297, DOI 10.1093/toxsci/53.2.297
   COOPER RL, 1999, TOXICOLOGIST, V42, P60
   Crain DA, 1997, ENVIRON HEALTH PERSP, V105, P528, DOI 10.1289/ehp.97105528
   Cummings AM, 2000, TOXICOL SCI, V58, P135, DOI 10.1093/toxsci/58.1.135
   DONNA A, 1989, SCAND J WORK ENV HEA, V15, P47, DOI 10.5271/sjweh.1882
   Dudek P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001859
   Falkenstein E, 2000, PHARMACOL REV, V52, P513
   Fan WQ, 2007, ENVIRON HEALTH PERSP, V115, P720, DOI 10.1289/ehp.9758
   Fan W, 2007, BIOCHEM BIOPH RES CO, V355, P1012, DOI 10.1016/j.bbrc.2007.02.062
   Fenelon JM, 1998, J ENVIRON QUAL, V27, P884, DOI 10.2134/jeq1998.00472425002700040024x
   Filardo E, 2007, ENDOCRINOLOGY, V148, P3236, DOI 10.1210/en.2006-1605
   Filardo EJ, 2006, CLIN CANCER RES, V12, P6359, DOI 10.1158/1078-0432.CCR-06-0860
   Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649
   Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70
   Friedmann AS, 2002, REPROD TOXICOL, V16, P275, DOI 10.1016/S0890-6238(02)00019-9
   Gammon DW, 2005, PEST MANAG SCI, V61, P331, DOI 10.1002/ps.1000
   GEISINGER KR, 1989, CANCER-AM CANCER SOC, V63, P280, DOI 10.1002/1097-0142(19890115)63:2<280::AID-CNCR2820630213>3.0.CO;2-N
   Keller JM, 2004, MAR ENVIRON RES, V58, P347, DOI 10.1016/j.marenvres.2004.03.080
   Kettles MA, 1997, ENVIRON HEALTH PERSP, V105, P1222, DOI 10.1289/ehp.971051222
   KNIEWALD J, 1979, J STEROID BIOCHEM, V11, P833, DOI 10.1016/0022-4731(79)90018-9
   KNIEWALD J, 1995, J APPL TOXICOL, V15, P215, DOI 10.1002/jat.2550150312
   KNIEWALD J, 1980, PHARM MODULATION STE, P159
   Kolpin DW, 1998, ENVIRON SCI TECHNOL, V32, P558, DOI 10.1021/es970412g
   Lee Y, 1996, P NATL ACAD SCI USA, V93, P15180, DOI 10.1073/pnas.93.26.15180
   Lehmann TP, 2005, ACTA BIOCHIM POL, V52, P485
   LEPHART ED, 1991, METHOD ENZYMOL, V206, P477
   LODE O, 1995, SCI TOTAL ENVIRON, V160-61, P421, DOI 10.1016/0048-9697(95)04375-B
   Loomis AK, 2000, BIOL REPROD, V62, P995, DOI 10.1095/biolreprod62.4.995
   Maggiolini M, 1999, BIOL CHEM, V380, P695, DOI 10.1515/BC.1999.086
   Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200
   Mcelroy JA, 2007, J EXPO SCI ENV EPID, V17, P207, DOI 10.1038/sj.jes.7500511
   Migliaccio A, 2006, ANN NY ACAD SCI, V1089, P194, DOI 10.1196/annals.1386.006
   Miller SM, 2000, ENVIRON SCI TECHNOL, V34, P55, DOI 10.1021/es990486n
   Morinaga H, 2004, ENDOCRINOLOGY, V145, P1860, DOI 10.1210/en.2003-1182
   Muller SR, 1997, ENVIRON SCI TECHNOL, V31, P2104, DOI 10.1021/es9609314
   Nadal A, 2000, P NATL ACAD SCI USA, V97, P11603, DOI 10.1073/pnas.97.21.11603
   Narotsky MG, 2001, REPROD TOXICOL, V15, P61, DOI 10.1016/S0890-6238(00)00111-8
   *NAT CTR BIOT INF, 2008, SEARCH GENBANK
   NEPHEW KP, 1993, ENDOCRINOLOGY, V133, P419, DOI 10.1210/en.133.1.419
   Norman AW, 2004, NAT REV DRUG DISCOV, V3, P27, DOI 10.1038/nrd1283
   PINTER A, 1990, NEOPLASMA, V37, P533
   Revankar CM, 2007, ACS CHEM BIOL, V2, P536, DOI 10.1021/cb700072n
   Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943
   Revelli A, 1998, ENDOCR REV, V19, P3, DOI 10.1210/er.19.1.3
   Roberge M, 2004, TOXICOL LETT, V154, P61, DOI 10.1016/j.toxlet.2004.07.005
   Ruehlmann DO, 1998, FASEB J, V12, P613
   Rusiecki JA, 2004, JNCI-J NATL CANCER I, V96, P1375, DOI 10.1093/jnci/djh264
   Safaei R, 2005, CLIN CANCER RES, V11, P756
   Sanderson JT, 2000, TOXICOL SCI, V54, P121, DOI 10.1093/toxsci/54.1.121
   Sanderson JT, 2002, TOXICOL APPL PHARM, V182, P44, DOI 10.1006/taap.2002.9420
   Sanderson JT, 2001, ENVIRON HEALTH PERSP, V109, P1027, DOI 10.2307/3454957
   Santagati S, 1997, MOL ENDOCRINOL, V11, P938, DOI 10.1210/me.11.7.938
   Sass JB, 2006, INT J OCCUP ENV HEAL, V12, P260
   SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x
   Shafer TJ, 1999, TOXICOLOGY, V142, P57, DOI 10.1016/S0300-483X(99)00133-X
   SIMIC B, 1991, B ENVIRON CONTAM TOX, V46, P92, DOI 10.1007/BF01688260
   Singleton DW, 2003, ENDOCRINOLOGY, V144, P121, DOI 10.1210/en.2002-220625
   Solomon KR, 1996, ENVIRON TOXICOL CHEM, V15, P31, DOI 10.1897/1551-5028(1996)015<0031:ERAOAI>2.3.CO;2
   Spano L, 2004, AQUAT TOXICOL, V66, P369, DOI 10.1016/j.aquatox.2003.10.009
   Stoker TE, 2000, TOXICOL SCI, V58, P50, DOI 10.1093/toxsci/58.1.50
   Stoker TE, 1999, TOXICOL SCI, V52, P68, DOI 10.1093/toxsci/52.1.68
   TENNANT MK, 1994, J TOXICOL ENV HEALTH, V43, P183, DOI 10.1080/15287399409531914
   TENNANT MK, 1994, J TOXICOL ENV HEALTH, V43, P197, DOI 10.1080/15287399409531915
   Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064
   Thomas P, 2000, MAR ENVIRON RES, V50, P127, DOI 10.1016/S0141-1136(00)00114-8
   Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017
   Thurman EM, 2000, ENVIRON SCI TECHNOL, V34, P3079, DOI [10.1021/es000995l, 10.1021/es0009951]
   Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280
   Vivacqua A, 2006, MOL PHARMACOL, V70, P1414, DOI 10.1124/mol.106.026344
   Watson CS, 2007, MOL CELL ENDOCRINOL, V274, P1, DOI 10.1016/j.mce.2007.05.011
   Watson CS, 1999, EXP PHYSIOL, V84, P1013, DOI 10.1111/j.1469-445X.1999.01903.x
   Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605
   WETZEL LT, 1994, J TOXICOL ENV HEALTH, V43, P169, DOI 10.1080/15287399409531913
   Young HA, 2005, J OCCUP ENVIRON MED, V47, P1148, DOI 10.1097/01.jom.0000177044.43959.e8
NR 84
TC 76
Z9 89
U1 3
U2 25
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD DEC
PY 2008
VL 116
IS 12
BP 1648
EP 1655
DI 10.1289/ehp.11297
PG 8
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA 377ZG
UT WOS:000261290300026
PM 19079715
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Trujillo, JJ
   Beltrame, S
   Urso, S
   Aldamiz-Echevarria, G
AF Trujillo, John J.
   Beltrame, Sergio
   Urso, Stefano
   Aldamiz-Echevarria, Gonzalo
TI RETRACTED: latrogenic perforation of the right pulmonary artery
   (Retracted article. See vol 35, pg 1119, 2009)
SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
LA English
DT Editorial Material; Retracted Publication
DE Pulmonary artery; Drainage; latrogenic
C1 [Trujillo, John J.; Beltrame, Sergio; Urso, Stefano; Aldamiz-Echevarria, Gonzalo] Clin Capio, Dept Cardiac Surg, Albacete 02006, Spain.
RP Trujillo, JJ (reprint author), Clin Capio, Dept Cardiac Surg, Plaza Madrono 11, Albacete 02006, Spain.
EM jjto@idcsa.net
NR 0
TC 1
Z9 1
U1 4
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1010-7940
EI 1873-734X
J9 EUR J CARDIO-THORAC
JI Eur. J. Cardio-Thorac. Surg.
PD DEC
PY 2008
VL 34
IS 6
BP 1249
EP 1249
DI 10.1016/j.ejcts.2008.09.017
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 384DN
UT WOS:000261724600021
PM 18951035
OA Bronze
DA 2018-12-27
ER

PT J
AU Tanabe, M
   Kouzmenko, AP
   Ito, S
   Sawatsubashi, S
   Suzuki, E
   Fujiyama, S
   Yamagata, K
   Zhao, Y
   Kimura, S
   Ueda, T
   Murata, T
   Matsukawa, H
   Takeyama, K
   Kato, S
AF Tanabe, Masahiko
   Kouzmenko, Alexander P.
   Ito, Saya
   Sawatsubashi, Shun
   Suzuki, Eriko
   Fujiyama, Sally
   Yamagata, Kaoru
   Zhao, Yue
   Kimura, Shuhei
   Ueda, Takashi
   Murata, Takuya
   Matsukawa, Hiroyuki
   Takeyama, Ken-ichi
   Kato, Shigeaki
TI RETRACTED: Activation of facultatively silenced Drosophila loci
   associates with increased acetylation of histone H2AvD (Retracted
   article. See vol. 18, pg. 1147, 2013)
SO GENES TO CELLS
LA English
DT Article; Retracted Publication
ID GENOME-WIDE; VARIANT H2A.Z; SACCHAROMYCES-CEREVISIAE; CHROMATIN
   MODIFICATIONS; HETEROCHROMATIN; TRANSCRIPTION; EUCHROMATIN;
   MELANOGASTER; NUCLEOSOMES; REPLACEMENT
AB H2A.Z is an evolutionarily highly conserved non-allelic variant of histone H2A. H2A.Z and its homologues have been shown to involve in both chromatin silencing and activation. Although much of our knowledge of H2A.Z biological activity has come from studies on its yeast homologue Htz1, H2A.Z appears to have more complex and diverse functions in higher eukaryotes. To investigate the involvement of H2AvD, a Drosophila homologue of mammalian H2A.Z, in mechanisms of conditional activation of facultatively silenced genes, we generated transgenic Drosophila lines expressing H2AvD fused at the C- or N-terminus with the green fluorescent protein (GFP). Using heat shock-induced gene activation and polytene chromosome puff formation as an in vivo model system, we analyzed effects of H2AvD termini modifications on transcription. We found that N-terminally fused GFP inhibited H2AvD acetylation and impaired heat shock-induced puff formation and hsp70 gene activation. Our data suggest that the N-terminal region of H2AvD plays a pivotal role in transcriptional activation and that induction of transiently silenced Drosophila loci associates with increased acetylation of H2AvD.
C1 [Tanabe, Masahiko; Kouzmenko, Alexander P.; Ito, Saya; Sawatsubashi, Shun; Suzuki, Eriko; Fujiyama, Sally; Yamagata, Kaoru; Zhao, Yue; Kimura, Shuhei; Ueda, Takashi; Murata, Takuya; Matsukawa, Hiroyuki; Takeyama, Ken-ichi; Kato, Shigeaki] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   [Kouzmenko, Alexander P.; Ito, Saya; Sawatsubashi, Shun; Suzuki, Eriko; Fujiyama, Sally; Yamagata, Kaoru; Kato, Shigeaki] Japan Sci & Technol Agcy, ERATO, Kawaguchi, Saitama 3320012, Japan.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
FU Program for Promotion of Basic Research Activities for Innovative
   Biosciences (PROBRAIN); Ministry of Education, Culture, Sports, Science
   and Technology of Japan; Exploratory Research for Advanced Technology
   (ERATO); Japan Science and Technology Agency (JST); Integrative Life
   Science Based on the Study of Biosignaling Mechanisms
FX We thank members of the Department of Nuclear Signaling for constructive
   discussions and technical support, and K. Motoi for manuscript
   preparation. This work was funded in part by the Program for Promotion
   of Basic Research Activities for Innovative Biosciences (PROBRAIN) and
   priority areas from the Ministry of Education, Culture, Sports, Science
   and Technology of Japan (to K. T. and S. K.), and by the Kato Nuclear
   Complex Project grant from the Exploratory Research for Advanced
   Technology (ERATO), Japan Science and Technology Agency (JST) (to S.
   K.), Global COE Program (Integrative Life Science Based on the Study of
   Biosignaling Mechanisms) (to M. T., T. M. and S. K.).
CR Babiarz JE, 2006, GENE DEV, V20, P700, DOI 10.1101/gad.1386306
   Boyne MT, 2006, J PROTEOME RES, V5, P248, DOI 10.1021/pr050269n
   Bruce K, 2005, NUCLEIC ACIDS RES, V33, P5633, DOI [10.1093/nar/gki874, 10.1093/nar.gki874]
   Clarkson MJ, 1999, NATURE, V399, P694, DOI 10.1038/21436
   Clayton AL, 2006, MOL CELL, V23, P289, DOI 10.1016/j.molcel.2006.06.017
   Furuhashi H, 2006, DEVELOPMENT, V133, P4475, DOI 10.1242/dev.02620
   GUILLEMETTE B, 2005, PLOS BIOL, V384, pH2
   Guillemette B, 2006, BIOCHEM CELL BIOL, V84, P528, DOI 10.1139/O06-077
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jin CY, 2007, GENE DEV, V21, P1519, DOI 10.1101/gad.1547707
   Kamakaka RT, 2005, GENE DEV, V19, P295, DOI 10.1101/gad.1272805
   Keogh MC, 2006, GENE DEV, V20, P660, DOI 10.1101/gad.1388106
   Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131
   Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200
   Leach TJ, 2000, J BIOL CHEM, V275, P23267, DOI 10.1074/jbc.M910206199
   Mellor J, 2006, TRENDS GENET, V22, P320, DOI 10.1016/j.tig.2006.03.008
   Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5
   Millar CB, 2006, GENE DEV, V20, P711, DOI 10.1101/gad.1395506
   Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701
   Osley MA, 2006, RES PRO CEL, V41, P47, DOI 10.1007/006
   Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653
   Raisner RM, 2005, CELL, V123, P233, DOI 10.1016/j.cell.2005.10.002
   Raisner RM, 2006, CURR OPIN GENET DEV, V16, P119, DOI 10.1016/j.gde.2006.02.005
   Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4
   Ren QH, 2001, MOL CELL, V7, P1329, DOI 10.1016/S1097-2765(01)00269-6
   Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8
   Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298
   Santisteban MS, 2000, CELL, V103, P411, DOI 10.1016/S0092-8674(00)00133-1
   Sarcinella E, 2007, MOL CELL BIOL, V27, P6457, DOI 10.1128/MCB.00241-07
   Schones DE, 2008, NAT REV GENET, V9, P179, DOI 10.1038/nrg2270
   Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114
   Swaminathan J, 2005, GENE DEV, V19, P65, DOI 10.1101/gad.1259105
   VANDAAL A, 1992, MOL BIOL CELL, V3, P593
   Venkatasubrahmanyam S, 2007, P NATL ACAD SCI USA, V104, P16609, DOI 10.1073/pnas.0700914104
   WU RS, 1982, CELL, V31, P367, DOI 10.1016/0092-8674(82)90130-1
   WU RS, 1981, CELL, V27, P321, DOI 10.1016/0092-8674(81)90415-3
   Zhang HY, 2005, CELL, V123, P219, DOI 10.1016/j.cell.2005.08.036
   Zlatanova J, 2008, STRUCTURE, V16, P166, DOI 10.1016/j.str.2007.12.008
NR 38
TC 7
Z9 7
U1 2
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1356-9597
EI 1365-2443
J9 GENES CELLS
JI Genes Cells
PD DEC
PY 2008
VL 13
IS 12
BP 1279
EP 1288
DI 10.1111/j.1365-2443.2008.01244.x
PG 10
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 379LA
UT WOS:000261396500008
PM 19032341
OA Bronze
DA 2018-12-27
ER

PT J
AU Bahaa, GM
AF Bahaa, G. M.
TI RETRACTED: Boundary control for hyperbolic systems involving
   infinite-order operators with control constraints (Retracted article.
   See vol. 28, pg. 143, 2011)
SO IMA JOURNAL OF MATHEMATICAL CONTROL AND INFORMATION
LA English
DT Article; Retracted Publication
ID VARIABLES; NUMBER; EQUATIONS
AB In this paper, a class of n x n hyperbolic boundary control problems with control constraints is investigated. We first establish the solvability of an n x n system with non-homogeneous mixed Neumann conditions involving hyperbolic operator of infinite order. Also a boundary control problem for this system is considered. The necessary and sufficient conditions for the control to be optimal are obtained. Two mathematical examples for derived optimality conditions are presented.
C1 Beni Suef Univ, Fac Sci, Dept Math, Bani Suwayf, Egypt.
RP Bahaa, GM (reprint author), Beni Suef Univ, Fac Sci, Dept Math, Bani Suwayf, Egypt.
EM bahaa_gm@hotmail.com
OI Bahaa, G/0000-0001-6670-3110
CR Bahaa GM, 2008, IMA J MATH CONTROL I, V25, P49, DOI 10.1093/imamci/dnm003
   Bahaa GM, 2008, IMA J MATH CONTROL I, V25, P37, DOI 10.1093/imamci/dnm002
   Bahaa GM, 2005, IMA J MATH CONTROL I, V22, P364, DOI 10.1093/imamci/dni033
   Bahaa GM, 2007, IMA J MATH CONTROL I, V24, P1, DOI [10.1093/imamci/dn1001, 10.1093/imamci/dnl001]
   Bahaa G. M., 2003, IMA Journal of Mathematical Control and Information, V20, P167, DOI 10.1093/imamci/20.2.167
   Bahaa G. M., 2005, DIFFER EQU CONTROL P, V4, P64
   Bahaa G. M., 2007, AMO ADV MODELING OPT, V9, P37
   BAHAA GM, 2006, DIFFER EQU CONTROL P, V4, P17
   BAHAA GM, 2006, DIFFER EQU CONTROL P, V1, P78
   BAHAA GM, 2008, J MATH CONT IN PRESS, P1
   DUBINSKII IA, 1981, DOKL AKAD NAUK SSSR+, V258, P780
   El-Saify H. A., 2003, Mathematica Slovaca, V53, P291
   El-Saify H. A., 2002, Mathematica Slovaca, V52, P409
   El-Saify H. A., 2001, REV MAT APL, V22, P41
   El-Saify H. A., 2000, ADV MODELLING ANAL, V37, P47
   GALI IM, 1982, J MATH ANAL APPL, V85, P24, DOI 10.1016/0022-247X(82)90023-3
   GALI IM, 1983, J OPTIMIZ THEORY APP, V39, P293, DOI 10.1007/BF00934534
   GALI IM, 1983, FUNCTIONAL DIFFERENT, V3, P99
   Imanuvilov O. Yu., 1998, ESAIM. Control, Optimisation and Calculus of Variations, V3, P97, DOI 10.1051/cocv:1998104
   Kotarski W., 2002, IMA Journal of Mathematical Control and Information, V19, P461, DOI 10.1093/imamci/19.4.461
   Kotarski W, 2005, EUR J CONTROL, V11, P150, DOI 10.3166/ejc.11.150-156
   Kotarski W, 2007, J INFORM OPTIM SCI, V28, P315, DOI 10.1080/02522667.2007.10699746
   KOTARSKI W., 2002, INT J PURE APPL MATH, V1, P241
   KOTARSKI W, 1997, REPORTS SILESIAN U, P1
   LI X, 1995, SYSTEMS CONTROL FDN, P1
   Lions J. L., 1955, EUR SER APPL IND MAT, V1, P1
   Lions J.-L., 1972, NONHOMOGENEOUS BOUND, VI
   Lions JL, 1971, OPTIMAL CONTROL SYST, V170
NR 28
TC 1
Z9 1
U1 3
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0265-0754
EI 1471-6887
J9 IMA J MATH CONTROL I
JI IMA J. Math. Control Inf.
PD DEC
PY 2008
VL 25
IS 4
BP 491
EP 505
DI 10.1093/imamci/dnn005
PG 15
WC Automation & Control Systems; Mathematics, Applied
SC Automation & Control Systems; Mathematics
GA 380JB
UT WOS:000261460900007
DA 2018-12-27
ER

PT J
AU Ebtekar, M
AF Ebtekar, Massoumeh
TI RETRACTED: Air Pollution Induced Asthma and Alterations in Cytokine
   Patterns (Retracted Article)
SO IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY
LA English
DT Correction; Retracted Publication
CR Ebtekar Massoumeh, 2006, Iran J Allergy Asthma Immunol, V5, P47
NR 1
TC 0
Z9 0
U1 1
U2 7
PU IRANIAN SCIENTIFIC SOCIETY MEDICAL ENTOMOLOGY
PI TEHRAN
PA SCHOOL PUBLIC HEALTH & INST HEALTH RESEARCH, TEHRAN UNIV MEDICAL
   SCIENCES, P O BOX  6446-14155, TEHRAN, 00000, IRAN
SN 1735-1502
J9 IRAN J ALLERGY ASTHM
JI Iran. J. Allergy Asthma Immunol.
PD DEC
PY 2008
VL 7
IS 4
BP 243
EP 243
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA 404PJ
UT WOS:000263165200009
DA 2018-12-27
ER

PT J
AU Uflacker, R
   Schonholz, C
   Papamitisakis, N
AF Uflacker, R.
   Schonholz, C.
   Papamitisakis, N.
CA Investigators SENTIS Trial
TI RETRACTED: Interim report of the SENTIS trial: cerebral perfusion
   augmentation via partial aortic occlusion in acute ischemic stroke
   (Retracted Article. See vol 50, pg 569, 2009)
SO JOURNAL OF CARDIOVASCULAR SURGERY
LA English
DT Article; Retracted Publication
DE Brain stem infarctions; Stroke; Perfusion
ID THRESHOLDS; PRESSURE; PENUMBRA
AB Aim. The aim of this paper was to present the interim results of the the Safety and Efficacy of NeuroFlo (TM) Technology in Ischemic Stroke (SENTIS) trial.
   Methods. The SENTIS study is a phase M, multi-center randomized prospective study to evaluate cerebral perfusion augmentation with partial aortic occlusion in acute ischemic stroke. The trial was designed to compare conventional management of stroke patients with stroke patients treated by partial occlusion of the abdominal aorta by the NeuroFlo (TM) device. Follow up was at 24 hours and 90 days.
   Results. Of the 100 patients enrolled, 53 were randomized to treatment and 47 to control. Six patients enrolled to treatment were found to have specific exclusion criteria and were excluded. Therefore, 97 validated patients, 47 treated patients and 47 control patients were included in the analysis. Adverse events were evenly distributed, among the two cohorts of patients with 16 patients or 34% in each group, including fatal and non-fatal adverse events. However, the mortality was significantly lower for the treated population (6.4%) versus the control population (14.9%), with more stroke progression (8.5%) and hemorrhagic transformation of the stroke area (4.3%) in the control population.
   Conclusion. The SENTIS trial was designed to test the hypothesis that the NeuroFlo (TM) system is safe to be used in humans and able to produce cerebral perfusion augmentation, based on imaging and neurological assessment at 24 hours and at 90 days. The preliminary data yielded by the interim analysis showed that the population enrolled in the trial was rather homogeneous regarding age, baseline NIHSS scores, and other risk factors, suggesting that the treated and control cohorts were similar. The analysis also showed that the adverse events were rather comparable between the two groups, suggesting the treatment procedure to be safe enough for continuation of the trial. The NeuroFlo (TM) system so far proved to be safe enough for clinical use and seems to be promising in improving survival in the acute stroke population.
C1 [Uflacker, R.] Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA.
   [Papamitisakis, N.] Med Univ S Carolina, Stroke Ctr, Charleston, SC 29425 USA.
RP Uflacker, R (reprint author), Med Univ S Carolina, Dept Radiol, 171 Ashley Ave, Charleston, SC 29425 USA.
EM uflacker@musc.edu
CR Alexandrov AW, 2008, STROKE, V39, P2760, DOI 10.1161/STROKEAHA.107.512418
   ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723
   Becker KJ, 2005, STROKE, V36, P400, DOI 10.1161/01.STR.0000153056.25397.ff
   *COAX INC, 2005, REP PRIOR INV SUMM
   GOLD JP, 1995, J THORAC CARDIOV SUR, V110, P1302, DOI 10.1016/S0022-5223(95)70053-6
   GROTTA JC, 1985, STROKE, V16, P790, DOI 10.1161/01.STR.16.5.790
   JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773
   Kaufmann AM, 1999, STROKE, V30, P93, DOI 10.1161/01.STR.30.1.93
   Labiche LA, 2003, STROKE, V34, P695, DOI 10.1161/01.STR.0000055940.00316.6B
   Rosen CL, 2000, ACTA NEUROCHIR, V142, P25, DOI 10.1007/s007010050003
   *SOURC AHA, 1999, 1998 HEART STROK STA
   Stead LG, 2008, NEUROCRIT CARE, V8, P259, DOI 10.1007/s12028-007-9010-6
   TOBERTS HC, 2002, STROKE, V33, P1557
NR 13
TC 13
Z9 14
U1 1
U2 8
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0021-9509
EI 1827-191X
J9 J CARDIOVASC SURG
JI J. Cardiovasc. Surg.
PD DEC
PY 2008
VL 49
IS 6
BP 715
EP 721
PG 7
WC Cardiac & Cardiovascular Systems; Surgery; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology; Surgery
GA 402VK
UT WOS:000263041000002
PM 19043384
DA 2018-12-27
ER

PT J
AU Radhakrishnan, S
   Arneson, LN
   Upshaw, JL
   Howe, CL
   Felts, SJ
   Colonna, M
   Leibson, PJ
   Rodriguez, M
   Pease, LR
AF Radhakrishnan, Suresh
   Arneson, Laura N.
   Upshaw, Jadee L.
   Howe, Charles L.
   Felts, Sara J.
   Colonna, Marco
   Leibson, Paul J.
   Rodriguez, Moses
   Pease, Larry R.
TI RETRACTED: TREM-2 Mediated Signaling Induces Antigen Uptake and
   Retention in Mature Myeloid Dendritic Cells (Retracted Article. See vol
   184, pg 6557, 2010)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID PROTEIN-TYROSINE KINASE; CROSS-LINKING; T-CELLS; TRYPTOPHAN CATABOLISM;
   IN-VIVO; VOL. 70; B7-DC; ACTIVATION; FAMILY; PD-L2
AB Myeloid dendritic cells (mDC) activated with a B7-DC-specific cross-linking IgM Ab (B7-DC XAb) take up and retain Ag and interact with T cell compartments to affect a number of biologic changes that together cause strong antitumor responses and blockade of inflammatory airway disease in animal models. The molecular events mediating the initial responses in mDC remain unclear. In this study we show that B7-DC XAb caused rapid phosphorylation of the adaptor protein DAP12 and intracellular kinases Syk and phospholipase G-gamma 1. Pretreatment of mDC with the Syk inhibitor piceatannol blocked B7-DC XAb-induced Ag uptake with a concomitant loss of tumor protection in mice. Vaccination with tumor lysate-pulsed wild-type B7-DC XAb-activated mDC, but not TREM-2 knockout XAb-activated mDC, protected mice from lethal melanoma challenge. Multimolecular caps appeared within minutes of B7-DC XAb binding to either human or mouse mDC, and FRET analysis showed that class II, CD80, CD86, and TREM-2 are recruited in tight association on the cell surface. When TREM-2 expression was reduced in wild-type mDC using short hairpin RNA or by using mDC from TREM-2 knockout mice., in vitro DC failed to take up Ag after B7-DC XAb stimulation. These results directly link TREM-2 signaling with one change in the mDC phenotype that occurs in response to this unique All. The parallel signaling events observed in both human and mouse mDC support the hypothesis that B7-DC cross-linking may be useful as a therapeutic immune modulator in human patients. The Journal of Immunology, 2008, 181: 7863-7872.
C1 [Radhakrishnan, Suresh; Arneson, Laura N.; Upshaw, Jadee L.; Howe, Charles L.; Felts, Sara J.; Leibson, Paul J.; Rodriguez, Moses; Pease, Larry R.] Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA.
   [Howe, Charles L.; Rodriguez, Moses] Mayo Clin, Coll Med, Dept Neurol, Rochester, MN 55905 USA.
   [Colonna, Marco] Washington Univ, Sch Med, Pathol & Immunol Program, St Louis, MO 63110 USA.
RP Pease, LR (reprint author), Mayo Clin, Coll Med, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.
EM pease.larry@mayo.edu
RI Howe, Charles/B-4945-2009
OI Rodriguez, Moses/0000-0001-6328-6497; Colonna,
   Marco/0000-0001-5222-4987; Howe, Charles/0000-0002-3889-8739
FU National Institutes of Health [R01 CA104996-4, R01 HL077296-3, R01
   CA96859]; Ralph Wilson Medical Research Foundation
FX This work was supported by Grants R01 CA104996-4 (to L.R.P.), R01
   HL077296-3 (to L.R.P.), and R01 CA96859 (to L.R.P.) from the National
   Institutes of Health and by a grant from the Ralph Wilson Medical
   Research Foundation.
CR Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Bhatia S, 2005, P NATL ACAD SCI USA, V102, P15569, DOI 10.1073/pnas.0507257102
   Block MS, 2001, J IMMUNOL, V167, P821, DOI 10.4049/jimmunol.167.2.821
   Bouchon A, 2001, J EXP MED, V194, P1111, DOI 10.1084/jem.194.8.1111
   Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000
   Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106
   Daws MR, 2001, EUR J IMMUNOL, V31, P783, DOI 10.1002/1521-4141(200103)31:3<783::AID-IMMU783>3.0.CO;2-U
   Dong HD, 2003, J CLIN INVEST, V111, P363, DOI 10.1172/JCI200316015
   Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611
   Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846
   Heckman KL, 2007, EUR J IMMUNOL, V37, P1827, DOI 10.1002/eji.200637002
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   Jankovic D, 2002, IMMUNITY, V16, P429, DOI 10.1016/S1074-7613(02)00278-9
   Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059
   Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330
   Madsen L, 1999, P NATL ACAD SCI USA, V96, P10338, DOI 10.1073/pnas.96.18.10338
   McVicar DW, 1998, J BIOL CHEM, V273, P32934, DOI 10.1074/jbc.273.49.32934
   Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4
   Nguyen LT, 2002, J EXP MED, V196, P1393, DOI 10.1084/jem.20021466
   Orabona C, 2005, EUR J IMMUNOL, V35, P3111, DOI 10.1002/eji.200535289
   Orabona C, 2004, NAT IMMUNOL, V5, P1134, DOI 10.1038/ni1124
   Pavelko KD, 2008, CANCER RES, V68, P2471, DOI 10.1158/0008-5472.CAN-07-5937
   Radhakrishnan S, 2005, J ALLERGY CLIN IMMUN, V116, P668, DOI 10.1016/j.jaci.2005.04.038
   Radhakrishnan S, 2005, P NATL ACAD SCI USA, V102, P11438, DOI 10.1073/pnas.0501420102
   Radhakrishnan S, 2004, J IMMUNOL, V173, P1360, DOI 10.4049/jimmunol.173.2.1360
   Radhakrishnan S, 2004, CANCER RES, V64, P4965, DOI 10.1158/0008-5472.CAN-03-3025
   Radhakrishnan S, 2003, J IMMUNOL, V170, P1830, DOI 10.4049/jimmunol.170.4.1830
   Radhakrishnan S, 2008, J IMMUNOL, V181, P3137, DOI 10.4049/jimmunol.181.5.3137
   Radhakrishnan S, 2007, J IMMUNOL, V178, P3583, DOI 10.4049/jimmunol.178.6.3583
   Radhakrishnan S, 2007, J IMMUNOL, V178, P1426, DOI 10.4049/jimmunol.178.3.1426
   Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712
   Sedlik C, 2003, J IMMUNOL, V170, P846, DOI 10.4049/jimmunol.170.2.846
   Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611
   TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907
   Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   Tomasello E, 2000, IMMUNITY, V13, P355, DOI 10.1016/S1074-7613(00)00035-2
   Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839
   Turnbull IR, 2007, NAT REV IMMUNOL, V7, P155, DOI 10.1038/nri2014
   Turnbull IR, 2006, J IMMUNOL, V177, P3520, DOI 10.4049/jimmunol.177.6.3520
   Wang SD, 2003, J EXP MED, V197, P1083, DOI 10.1084/jem.20021752
NR 42
TC 14
Z9 14
U1 4
U2 14
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD DEC 1
PY 2008
VL 181
IS 11
BP 7863
EP 7872
DI 10.4049/jimmunol.181.11.7863
PG 10
WC Immunology
SC Immunology
GA 376YX
UT WOS:000261220000049
PM 19017976
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Jackson, MJ
   Whitfield, MD
   Morrell, JS
   Ahmed, W
   Davim, JP
AF Jackson, M. J.
   Whitfield, M. D.
   Morrell, J. S.
   Ahmed, W.
   Davim, J. P.
TI RETRACTED: Initial shear strain development during formation of
   nanostructured metal chips (Retracted article. See vol. 33, pg. 1268,
   2017)
SO MATERIALS SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Plastic shear strain; Chip formation; Nanostructured metals; Machining
AB The interaction between a newly formed metal chip and the rake face of a cutting tool reveal the complicated nature of initial chip formation and plastic shear strains during the first few seconds of intimate contact. The loading placed on the metal chip during the first encounter with the cutting tool manifest themselves as an unpredictable curl that forces the chip to move away from the surface of the rake face and produce uneven plastic shear strains throughout the chip. The variation of the load causes instabilities on the shear plane that is directly observed using a high speed camera. As the variation of load progresses, the chip tends to curl away from the tool with varying radii until the apparently curved shear plane becomes linear. The results of initial chip formation demonstrate a very complex interaction between metal chip and rake face of the tool and the resulting development of the shear plane and its effect on plastic shear strains within the metal chip.
C1 [Jackson, M. J.; Whitfield, M. D.; Morrell, J. S.] Purdue Univ, Coll Technol, Ctr Adv Mfg, W Lafayette, IN 47907 USA.
   [Ahmed, W.] Univ Ulster, Newtownabbey BT37 0QB, Antrim, North Ireland.
   [Davim, J. P.] Univ Aveiro, Dept Mech Engn, MACTRIB, P-3810 Aveiro, Portugal.
RP Jackson, MJ (reprint author), Purdue Univ, Coll Technol, Ctr Adv Mfg, W Lafayette, IN 47907 USA.
EM jacksomj@purdue.edu
RI Group, GAME/B-3464-2014; Davim, Joao Paulo/D-2314-2009; Research Unit,
   TEMA/H-9264-2012
OI Davim, Joao Paulo/0000-0002-5659-3111; Ahmed, Waqar/0000-0003-4152-5172
CR ASKATOV VP, 2005, INT J MECH SCI, V47, P1649
   BOWDEN FP, 2001, FRICTION LUBRICATION, P168
   Brown TL, 2002, J MATER RES, V17, P2484, DOI 10.1557/JMR.2002.0362
   DOYLE ED, 1979, P ROY SOC LOND A MAT, V366, P173, DOI 10.1098/rspa.1979.0046
   Jackson MJ, 2005, J MATER ENG PERFORM, V14, P293, DOI [10.1361/10599490523878, 10.1361/10599490523979]
   Jackson MJ, 2005, P I MECH ENG B-J ENG, V219, P245, DOI 10.1243/095440505X30168
   Jackson MJ, 2005, MATER SCI TECH-LOND, V21, P281, DOI 10.1179/174328405X18610
   Jackson RD, 2006, ECOSYSTEMS, V9, P254, DOI 10.1007/s10021-005-0166-7
   Komanduri R, 2001, PHILOS MAG B, V81, P1989, DOI 10.1080/13642810110069260
   LEE EH, 1951, J APPL MECH-T ASME, V18, P405
   Luo X, 2003, INT J PROD RES, V41, P1449, DOI 10.1080/0020754031000069607
   SHAW MC, 1953, T ASME, V75, P273
   TIMME II, 1880, RESISTANCE METALS WO
   Zorev N. N., 1966, METAL CUTTING MECH
NR 14
TC 3
Z9 3
U1 2
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0267-0836
EI 1743-2847
J9 MATER SCI TECH-LOND
JI Mater. Sci. Technol.
PD DEC
PY 2008
VL 24
IS 12
BP 1452
EP 1461
DI 10.1179/174328407X243014
PG 10
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 384SM
UT WOS:000261764500009
DA 2018-12-27
ER

PT J
AU Lavine, JA
   Raess, PW
   Davis, DB
   Rabaglia, ME
   Presley, BK
   Keller, MP
   Beinfeld, MC
   Kopin, AS
   Newgard, CB
   Attie, AD
AF Lavine, Jeremy A.
   Raess, Philipp W.
   Davis, Dawn Belt
   Rabaglia, Mary E.
   Presley, Brent K.
   Keller, Mark P.
   Beinfeld, Margery C.
   Kopin, Alan S.
   Newgard, Christopher B.
   Attie, Alan D.
TI RETRACTED: Overexpression of Pre-Pro-Cholecystokinin Stimulates
   beta-Cell Proliferation in Mouse and Human Islets with Retention of
   Islet Function (Retracted article. See vol. 24, pg. 472, 2010)
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article; Retracted Publication
ID HEPATOCYTE GROWTH-FACTOR; CYCLIN-DEPENDENT KINASE-4; TRANSCRIPTIONAL
   INDUCTION; DIABETES SUSCEPTIBILITY; PLACENTAL-LACTOGEN;
   INSULIN-SECRETION; SIGNAL TRANSDUCER; DEFICIENT MICE; IN-VIVO; RAT
AB Type 1 and type 2 diabetes result from a deficit in insulin production and beta-cell mass. Methods to expand beta-cell mass are under intensive investigation for the treatment of type 1 and type 2 diabetes. We tested the hypothesis that cholecystokinin (CCK) can promote beta-cell proliferation. We treated isolated mouse and human islets with an adenovirus containing the CCK cDNA (AdCMV-CCK). We measured [H-3] thymidine and BrdU incorporation into DNA and additionally, performed flow cytometry analysis to determine whether CCK overexpression stimulates beta-cell proliferation. We studied islet function by measuring glucose-stimulated insulin secretion and investigated the cell cycle regulation of proliferating beta-cells by quantitative RTPCR and Western blot analysis. Overexpression of CCK stimulated [3H] thymidine incorporation into DNA 5.0-fold and 15.8-fold in mouse and human islets, respectively. AdCMV-CCK treatment also stimulated BrdU incorporation into DNA 10-fold and 21-fold in mouse and human beta-cells, respectively. Glucose-stimulated insulin secretion was unaffected by CCK expression. Analysis of cyclin and cdk mRNA and protein abundance revealed that CCK overexpression increased cyclin A, cyclin B, cyclin E, cdk1, and cdk2 with no change in cyclin D1, cyclin D2, cyclin D3, cdk4, or cdk6 in mouse and human islets. Additionally, AdCMV-CCK treatment of CCK receptor knockout and wild-type mice resulted in equal [3H] thymidine incorporation. CCK is a beta-cell proliferative factor that is effective in both mouse and human islets. CCK triggers beta-cell proliferation without disrupting islet function, up-regulates a distinct set of cell cycle regulators in islets, and signals independently of the CCK receptors.
C1 [Lavine, Jeremy A.; Raess, Philipp W.; Davis, Dawn Belt; Rabaglia, Mary E.; Keller, Mark P.; Attie, Alan D.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.
   [Davis, Dawn Belt] Univ Wisconsin, Dept Med, Madison, WI 53706 USA.
   [Presley, Brent K.; Newgard, Christopher B.] Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27704 USA.
   [Presley, Brent K.; Newgard, Christopher B.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27704 USA.
   [Beinfeld, Margery C.] Tufts Univ, Dept Pharmacol, Medford, MA 02111 USA.
   [Kopin, Alan S.] Tufts Med Ctr, Mol Pharmacol Res Ctr, Medford, MA 02111 USA.
RP Attie, AD (reprint author), 433 Babcock Dr,Room 543A, Madison, WI 53706 USA.
EM adattie@wisc.edu
RI Davis, Dawn/B-1624-2013
OI Raess, Philipp/0000-0002-6841-4993
FU Juvenile Diabetes Research Foundation [17-2007-1026]; National
   Institutes of Health [DK 66539, DK 58037]; National Human Genome
   Research Institute [5T32HG002760]; National Institute on Aging [T32
   AG20013]
FX This work was supported by Juvenile Diabetes Research Foundation Grant
   17-2007-1026 (to A.D.A. and C.B.N.). A.D.A. was additionally supported
   by National Institutes of Health Grants DK 66539 and DK 58037. J.A.L.
   was supported by a National Human Genome Research Institute training
   grant to the Genomic Sciences Training Program (5T32HG002760). P.W.R.
   and D.B.D. were supported by National Institute on Aging training grant
   T32 AG20013.
CR AHREN B, 1983, ACTA ENDOCRINOL-COP, V102, P96, DOI 10.1530/acta.0.1020096
   Beattie GM, 1996, DIABETES, V45, P1223, DOI 10.2337/diabetes.45.9.1223
   Beattie GM, 1997, DIABETES, V46, P244, DOI 10.2337/diabetes.46.2.244
   BECKER TC, 1994, METHOD CELL BIOL, V43, P161
   BEINFELD MC, 1981, BRAIN RES, V212, P51, DOI 10.1016/0006-8993(81)90031-7
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brun T, 2008, HUM MOL GENET, V17, P478, DOI 10.1093/hmg/ddm325
   Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238
   Chen S, 2007, AM J PHYSIOL-ENDOC M, V293, pE1459, DOI 10.1152/ajpendo.00375.2007
   Cozar-Castellano I, 2006, DIABETES, V55, P70, DOI 10.2337/diabetes.55.01.06.db05-0632
   Cozar-Castellano I, 2004, DIABETES, V53, P149, DOI 10.2337/diabetes.53.1.149
   Dufresne M, 2006, PHYSIOL REV, V86, P805, DOI 10.1152/physrev.00014.2005
   Fatrai S, 2006, DIABETES, V55, P318, DOI 10.2337/diabetes.55.02.06.db05-0757
   FEHMANN HC, 1991, BIOCHIM BIOPHYS ACTA, V1091, P356, DOI 10.1016/0167-4889(91)90200-H
   Friedrichsen BN, 2001, MOL ENDOCRINOL, V15, P136, DOI 10.1210/me.15.1.136
   Friedrichsen BN, 2006, J ENDOCRINOL, V188, P481, DOI 10.1677/joe.1.06160
   Friedrichsen BN, 2003, MOL ENDOCRINOL, V17, P945, DOI 10.1210/me.2002.0356
   Fueger PT, 2008, MOL ENDOCRINOL, V22, P1251, DOI 10.1210/me.2007-0500
   Fung TK, 2002, J BIOL CHEM, V277, P35140, DOI 10.1074/jbc.M205503200
   Garcia-Ocana A, 2000, J BIOL CHEM, V275, P1226, DOI 10.1074/jbc.275.2.1226
   Georgia S, 2004, J CLIN INVEST, V114, P963, DOI 10.1172/JC1200422098
   HILDEBRAND P, 1991, J CLIN ENDOCR METAB, V72, P1123, DOI 10.1210/jcem-72-5-1123
   Hohmeier HE, 2005, NAT BIOTECHNOL, V23, P1231, DOI 10.1038/nbt1005-1231
   Julien S, 2004, REGUL PEPTIDES, V121, P73, DOI 10.1016/j.regpep.2004.04.017
   Keller MP, 2008, GENOME RES, V18, P706, DOI 10.1101/gr.074914.107
   Kitagawa K, 2001, J ORG CHEM, V66, P1, DOI 10.1021/jo000895y
   Kopin AS, 1999, J CLIN INVEST, V103, P383, DOI 10.1172/JCI4901
   Kuntz Emmanuelle, 2004, JOP, V5, P464
   Kushner JA, 2005, MOL CELL BIOL, V25, P3752, DOI 10.1128/MCB.25.9.3752-3762.2005
   Lacourse KA, 1999, AM J PHYSIOL-GASTR L, V276, pG1302, DOI 10.1152/ajpgi.1999.276.5.G1302
   Lan H, 2003, DIABETES, V52, P688, DOI 10.2337/diabetes.52.3.688
   Langhans N, 1997, GASTROENTEROLOGY, V112, P280, DOI 10.1016/S0016-5085(97)90000-7
   Path G, 2006, AM J PHYSIOL-ENDOC M, V291, pE1168, DOI 10.1152/ajpendo.00436.2005
   Prentki M, 2006, J CLIN INVEST, V116, P1802, DOI 10.1172/JCI29103
   Rabaglia ME, 2005, AM J PHYSIOL-ENDOC M, V289, pE218, DOI 10.1152/ajpendo.00573.2004
   Rane SG, 1999, NAT GENET, V22, P44
   Rao P, 2005, DIABETES, V54, P1664, DOI 10.2337/diabetes.54.6.1664
   Rulifson IC, 2007, P NATL ACAD SCI USA, V104, P6247, DOI 10.1073/pnas.0701509104
   Ryan EA, 2002, DIABETES, V51, P2148, DOI 10.2337/diabetes.51.7.2148
   Ryan EA, 2001, DIABETES, V50, P710, DOI 10.2337/diabetes.50.4.710
   Ryan EA, 2005, DIABETES, V54, P2060, DOI 10.2337/diabetes.54.7.2060
   Schisler JC, 2008, MOL CELL BIOL, V28, P3465, DOI 10.1128/MCB.01791-07
   Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401
   Vasavada RC, 2000, J BIOL CHEM, V275, P15399, DOI 10.1074/jbc.275.20.15399
   Vasavada RC, 2007, DIABETES, V56, P2732, DOI 10.2337/db07-0461
   Wajchenberg BL, 2007, ENDOCR REV, V28, P187, DOI 10.1210/er.2006-0038
   Weir GC, 2004, DIABETES, V53, pS16, DOI 10.2337/diabetes.53.suppl_3.S16
   Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270
   Zhang XB, 2005, DIABETES, V54, P712, DOI 10.2337/diabetes.54.3.712
NR 49
TC 14
Z9 14
U1 3
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0888-8809
EI 1944-9917
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD DEC
PY 2008
VL 22
IS 12
BP 2716
EP 2728
DI 10.1210/me.2008-0255
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 378EY
UT WOS:000261305200011
PM 18845673
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Marshall, L
   White, RJ
AF Marshall, Lynne
   White, Robert J.
TI RETRACTED: Non-coding RNA production by RNA polymerase III is implicated
   in cancer (Retracted article. See vol. 12, pg. 732, 2012)
SO NATURE REVIEWS CANCER
LA English
DT Article; Retracted Publication
ID TATA-BINDING PROTEIN; TRANSCRIPTION FACTOR; ONCOGENIC TRANSFORMATION;
   DEPENDENT TRANSCRIPTION; ALU RNA; C-MYC; TUMORS; EXPRESSION; TFIIIB;
   SUBUNIT
AB RNA polymerase III (Pol III) makes a variety of small non-coding RNAs, such as tRNA and 5S ribosomal RNA. Increased expression of pol III products is often observed in transformed cells. Much progress has been made in determining how Pol III-dependent transcription is regulated and how it increases in cancers, but the importance of this increase has not been clearly established. New evidence suggests that Pol III output can substantially affect transformation.
C1 [Marshall, Lynne; White, Robert J.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland.
   [Marshall, Lynne; White, Robert J.] Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.
RP White, RJ (reprint author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.
EM r.white@beatson.gla.ac.uk
CR ARRAND JR, 1982, J VIROL, V41, P376
   Borchert GM, 2006, NAT STRUCT MOL BIOL, V13, P1097, DOI 10.1038/nsmb1174
   Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8
   Chen W, 1997, EUR J CANCER, V33, P288, DOI 10.1016/S0959-8049(96)00453-4
   Chesnokov I, 1996, MOL CELL BIOL, V16, P7084
   Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265
   Daly NL, 2005, ONCOGENE, V24, P880, DOI 10.1038/sj.onc.1208031
   Dieci G, 2007, TRENDS GENET, V23, P614, DOI 10.1016/j.tig.2007.09.001
   Felton-Edkins ZA, 2003, EMBO J, V22, P2422, DOI 10.1093/emboj/cdg240
   Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200
   Felton-Edkins ZA, 2006, J BIOL CHEM, V281, P33871, DOI 10.1074/jbc.M600468200
   Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327
   Hirsch HA, 2004, MOL CELL BIOL, V24, P5989, DOI 10.1128/MCB.24.13.5989-5999.2004
   HOEFFLER WK, 1985, CELL, V41, P955, DOI 10.1016/S0092-8674(85)80076-3
   ITTMANN M, 1993, CELL GROWTH DIFFER, V4, P503
   Johnson SAS, 2008, J BIOL CHEM, V283, P19184, DOI 10.1074/jbc.M802872200
   Johnson SS, 2007, MOL CELL, V26, P367, DOI 10.1016/j.molcel.2007.03.021
   Johnson SAS, 2003, MOL CELL BIOL, V23, P3043, DOI 10.1128/MCB.23.9.3043-3051.2003
   Kassavetis GA, 2006, BIOCHEM SOC T, V34, P1082, DOI 10.1042/BST0341082
   Kenneth NS, 2007, P NATL ACAD SCI USA, V104, P14917, DOI 10.1073/pnas.0702909104
   KOHNOE S, 1987, BIOCHIM BIOPHYS ACTA, V909, P107, DOI 10.1016/0167-4781(87)90032-7
   KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315
   Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549
   MANN C, 1992, MOL CELL BIOL, V12, P4314, DOI 10.1128/MCB.12.10.4314
   Mariner PD, 2008, MOL CELL, V29, P499, DOI 10.1016/j.molcel.2007.12.013
   Marshall L, 2008, CELL, V133, P78, DOI 10.1016/j.cell.2008.02.035
   Morton JP, 2007, NUCLEIC ACIDS RES, V35, P3046, DOI 10.1093/nar/gkm208
   Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581
   SCHWARTZ LB, 1974, J BIOL CHEM, V249, P5889
   Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200
   Steiger D, 2008, NAT GENET, V40, P1084, DOI 10.1038/ng.178
   Stein T, 2002, ONCOGENE, V21, P2961, DOI 10.1038/sj/onc/1205372
   Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255
   Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000
   Tang RB, 2005, MOL CARCINOGEN, V42, P93, DOI 10.1002/mc.20057
   Thiel CT, 2005, AM J HUM GENET, V77, P795, DOI 10.1086/497708
   TUGWOOD JD, 1987, J GEN VIROL, V68, P1081, DOI 10.1099/0022-1317-68-4-1081
   WANG HD, 1995, MOL CELL BIOL, V15, P6720
   WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2
   White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547
   White RJ, 2004, EUR J CANCER, V40, P21, DOI 10.1016/j.ejca.2003.09.027
   Willis IM, 2007, TRENDS BIOCHEM SCI, V32, P51, DOI 10.1016/j.tibs.2006.12.001
   Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097
   Woiwode A, 2008, MOL CELL BIOL, V28, P4204, DOI 10.1128/MCB.01912-07
   Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575
   Yee NS, 2007, PLOS BIOL, V5, P2484, DOI 10.1371/journal.pbio.0050312
   ZETTERBE.A, 1965, EXP CELL RES, V40, P1, DOI 10.1016/0014-4827(65)90284-3
NR 47
TC 68
Z9 70
U1 3
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-175X
J9 NAT REV CANCER
JI Nat. Rev. Cancer
PD DEC
PY 2008
VL 8
IS 12
BP 911
EP 914
DI 10.1038/nrc2539
PG 4
WC Oncology
SC Oncology
GA 375QA
UT WOS:000261127200011
PM 18987635
DA 2018-12-27
ER

PT J
AU Liu, D
   Niu, ZX
AF Liu, D.
   Niu, Z. -X.
TI RETRACTED: Construction, Expression and Immunoassay Detection of
   Recombinant Plasmid Encoding Fusion Protein of Roman Chicken Complement
   C3d and Newcastle Disease Virus F gene (Retracted article. See vol. 70,
   pg. 501, 2009)
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID MOLECULAR ADJUVANT C3D; HUMAN LYMPHOCYTES-B; RECEPTOR TYPE-2;
   PROTEOLYTIC CLEAVAGE; DNA VACCINES; HEMAGGLUTININ; ANTIBODIES;
   GLYCOPROTEIN; ENHANCEMENT; ENVELOPE
AB The terminal degradation product (C3d) of mammalian complement component C3 plays an important role in modulation of the adaptive immune response through the interaction with complement receptor type 2 (CR2) on B cells. In this study, the gene fragment coding for the complement protein C3d (chC3d) from Roman chicken was cloned and expressed as a fusion protein for its application in the vaccine study of chicken, and for in vitro experiments. The chC3d fragment strengthened B-cell responses when complexed with antigen. Three potential vaccine construct units were engineered to contain two, four and six copies of chC3d coding gene linked to the F gene of Newcastle disease virus (NDV), an economically important pathogen of chicken that is classified as a list A contagious disease of poultry by the Office International des Epizooties. The cloned chC3d protein and different repeats of C3d proteins in addition to the F gene of NDV were generated separately in Escherichia coli and chicken embryo fibroblast cells with the help of expression vectors. All recombinant proteins were analysed by SDS-PAGE and Western blotting. Analysis of the immunogenicity of different repeats of C3d revealed that chC3d had an enhancing effect on the immunogenicity of antigens, and that six or more repeats of C3d may be necessary for efficient enhancement of antigen-specific immune responses. To date, published research into the adjuvant activities of C3d has been limited to experiments in mice, rabbits and cattle. The adjuvant properties of C3d have not been assessed in poultry using homologous C3d in association with antigens relevant to the target species. The Roman chicken C3d fusion proteins described in this study is the first report and will provide a basis for immunization trials in chicken, studies of receptor binding and cell activation of chicken lymphocytes, and investigations of new types of vaccines, including recombinant vaccines and DNA vaccines for future use against other pathogens in chicken.
C1 [Liu, D.; Niu, Z. -X.] Shandong Agr Univ, Coll Anim Sci & Vet Med, Tai An 271018, Shandong, Peoples R China.
   [Liu, D.] Jinan Anim Husb & Vet Bur, Jinan, Peoples R China.
RP Niu, ZX (reprint author), Shandong Agr Univ, Coll Anim Sci & Vet Med, Tai An 271018, Shandong, Peoples R China.
EM zxniu@sdau.edu.cn
FU Shandong Natural Science Foundation [Y2007D47]
FX This work was supported by Shandong Natural Science Foundation (grant
   number: Y2007D47). While this manuscript was in preparation, the
   sequence of Roman chicken C3d was deposited in GenBank (accession no.
   EU868824).
CR Bergmann-Leitner ES, 2006, CLIN IMMUNOL, V121, P177, DOI 10.1016/j.clim.2006.07.001
   CARTER RH, 1988, J IMMUNOL, V141, P457
   CARTER RH, 1989, J IMMUNOL, V143, P1755
   Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348
   Donnelly J J, 1998, Dev Biol Stand, V95, P43
   ESPARZA I, 1991, EUR J IMMUNOL, V21, P2829, DOI 10.1002/eji.1830211126
   Firth MA, 2006, VET IMMUNOL IMMUNOP, V114, P61, DOI 10.1016/j.vetimm.2006.07.005
   Green TD, 2003, J VIROL, V77, P2046, DOI 10.1128/JVI.77.3.2046-2055.2003
   Green TD, 2001, VACCINE, V20, P242, DOI 10.1016/S0264-410X(01)00266-3
   GRIFFIOEN AW, 1991, INFECT IMMUN, V59, P1839
   Haas KM, 2004, J IMMUNOL, V172, P5833, DOI 10.4049/jimmunol.172.10.5833
   LAMBRIS JD, 1985, P NATL ACAD SCI USA, V82, P4235, DOI 10.1073/pnas.82.12.4235
   Li DJ, 2003, J REPROD IMMUNOL, V60, P129, DOI 10.1016/j.jri.2003.09.001
   LING JY, 2008, CHIN J BIOTECHNOL, V24, P209
   Liu D, 2008, CLIN VACCINE IMMUNOL, V15, P901, DOI 10.1128/CVI.00465-07
   Liu XF, 2003, ARCH VIROL, V148, P1387, DOI 10.1007/s00705-003-0014-z
   [马雪云 MA Xueyun], 2006, [西北农林科技大学学报. 自然科学版, Journal of northwest sci-tech university of agriculture and forestry], V34, P55
   Mayo MA, 2002, ARCH VIROL, V147, P1271, DOI 10.1007/s007050200037
   MILLAR NS, 1988, J GEN VIROL, V69, P613, DOI 10.1099/0022-1317-69-3-613
   Mitchell JA, 2003, VACCINE, V21, P902, DOI 10.1016/S0264-410X(02)00539-X
   NAGAI Y, 1976, VIROLOGY, V72, P494, DOI 10.1016/0042-6822(76)90178-1
   Panshin A, 1998, COMP IMMUNOL MICROB, V21, P51, DOI 10.1016/S0147-9571(97)00016-7
   Robinson HL, 1997, AIDS, V11, pS109
   Robinson HL, 2000, ADV VIRUS RES, V55, P1, DOI 10.1016/S0065-3527(00)55001-5
   Ross TM, 2000, NAT IMMUNOL, V1, P127, DOI 10.1038/77802
   Ross TM, 2001, AIDS RES HUM RETROV, V17, P829, DOI 10.1089/088922201750252025
   SAMBROOK J, 1989, MOL CLONING LAB MANU, P24
   Suradhat S, 2001, VET IMMUNOL IMMUNOP, V83, P79, DOI 10.1016/S0165-2427(01)00369-5
   Test ST, 2001, INFECT IMMUN, V69, P3031, DOI 10.1128/IAI.69.5.3031-3040.2001
   UMINO Y, 1990, J GEN VIROL, V71, P1189, DOI 10.1099/0022-1317-71-5-1189
   Wang LX, 2004, WORLD J GASTROENTERO, V10, P2072, DOI 10.3748/wjg.v10.i14.2072
   Wang LS, 2004, J VIROL, V78, P1616, DOI 10.1128/JVI.78.4.1616-1622.2004
   Watanabe I, 2003, VACCINE, V21, P4532, DOI 10.1016/S0264-410X(03)00510-3
NR 33
TC 4
Z9 4
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-9475
EI 1365-3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD DEC
PY 2008
VL 68
IS 6
BP 598
EP 606
DI 10.1111/j.1365-3083.2008.02177.x
PG 9
WC Immunology
SC Immunology
GA 367CB
UT WOS:000260529000007
PM 19055698
DA 2018-12-27
ER

PT J
AU Nasser, MW
   Datta, J
   Nuovo, G
   Kutay, H
   Motiwala, T
   Majumder, S
   Wang, B
   Suster, S
   Jacob, ST
   Ghoshal, K
AF Nasser, Mohd W.
   Datta, Jharna
   Nuovo, Gerard
   Kutay, Huban
   Motiwala, Tasneem
   Majumder, Sarmila
   Wang, Bo
   Suster, Saul
   Jacob, Samson T.
   Ghoshal, Kalpana
TI RETRACTED: Down-regulation of Micro-RNA-1 (miR-1) in Lung Cancer
   SUPPRESSION OF TUMORIGENIC PROPERTY OF LUNG CANCER CELLS AND THEIR
   SENSITIZATION TO DOXORUBICIN-INDUCED APOPTOSIS BY miR-1 (Retracted
   article. See vol. 293, pg. 12945, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID HUMAN HEPATOCELLULAR CARCINOMAS; TUMOR-SUPPRESSOR; MICRORNA FUNCTION;
   C/EBP-ALPHA; EXPRESSION; SURVIVAL; TARGETS; GROWTH; DEGRADATION; THERAPY
AB Micro-RNAs are similar to 21-25-nucleotide-long noncoding RNAs that regulate gene expression primarily at the post-transcriptional level in animals. Here, we report that micro-RNA-1 (miR-1), abundant in the cardiac and smooth muscles, is expressed in the lung and is down-regulated in human primary lung cancer tissues and cell lines. In situ hybridization demonstrated localization of miR-1 in bronchial epithelial cells. The tumor suppressor C/EBP alpha, frequently suppressed in lung cancer, reactivated miR-1 expression in the lung cancer cells. Repressed miR-1 was also activated in lung cancer cells upon treatment with a histone deacetylase inhibitor. These observations led us to examine the antitumorigenic potential of miR-1 in lung cancer cells. Expression of miR-1 in nonexpressing A549 and H1299 cells reversed their tumorigenic properties, such as growth, replication potential, motility/migration, clonogenic survival, and tumor formation in nude mice. Exogenous miR-1 significantly reduced expression of oncogenic targets, such as MET, a receptor tyrosine kinase, and Pim-1, a Ser/Thr kinase, frequently upregulated in lung cancer. Similarly, the levels of two additional targets, FoxP1, a transcription factor with oncogeneic property, and HDAC4 that represses differentiation-promoting genes, were reduced in miR-1-expressing cells. Conversely, depletion of miR-1 facilitated N417 cell growth with concomitant elevation of these targets. Further, ectopic miR-1 induced apoptosis in A549 cells in response to the potent anticancer drug doxorubicin. Enhanced activation of caspases 3 and 7, cleavage of their substrate PARP-1, and depletion of anti-apoptotic Mcl-1 contributed to the sensitivity of miR-1-expressing cells to doxorubicin. Thus, miR-1 has potential therapeutic application against lung cancers.
C1 [Nasser, Mohd W.; Datta, Jharna; Kutay, Huban; Motiwala, Tasneem; Majumder, Sarmila; Wang, Bo; Jacob, Samson T.; Ghoshal, Kalpana] Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.
   [Nuovo, Gerard; Suster, Saul] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.
   [Majumder, Sarmila; Jacob, Samson T.; Ghoshal, Kalpana] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
RP Jacob, ST (reprint author), 420 W 12th Ave, Columbus, OH 43210 USA.
EM Samson.Jacob@osumc.edu; Kalpana.Ghoshal@osumc.edu
RI Wang, Bo/F-6519-2011
FU National Institutes of Health [CA122695, PO1CA101956]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants CA122695 and PO1CA101956. The costs of publication of this
   article were defrayed in part by the payment of page charges. This
   article must therefore be hereby marked "advertisement" in accordance
   with 18 U. S. C. Section 1734 solely to indicate this fact.
CR Adiseshaiah P, 2007, CANCER RES, V67, P6204, DOI 10.1158/0008-5472.CAN-06-4687
   Bai S, 2007, J BIOL CHEM, V282, P27171, DOI 10.1074/jbc.M700691200
   Banham AH, 2005, CLIN CANCER RES, V11, P1065
   Bhattacharyya SN, 2006, COLD SPRING HARB SYM, V71, P513, DOI 10.1101/sqb.2006.71.038
   Calin GA, 2006, ONCOGENE, V25, P6202, DOI 10.1038/sj.onc.1209910
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800
   Cassel TN, 2003, AM J PHYSIOL-LUNG C, V285, pL773, DOI 10.1152/ajplung.00023.2003
   Chang TC, 2007, ANNU REV GENOM HUM G, V8, P215, DOI 10.1146/annurev.genom.8.080706.092351
   Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725
   Costa DB, 2006, LUNG CANCER, V53, P253, DOI 10.1016/j.lungcan.2006.04.011
   Czabotar PE, 2007, P NATL ACAD SCI USA, V104, P6217, DOI 10.1073/pnas.0701297104
   Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Fiore R, 2008, BBA-GENE REGUL MECH, V1779, P471, DOI 10.1016/j.bbagrm.2007.12.006
   Fulda S, 2004, CURR CANCER DRUG TAR, V4, P569, DOI 10.2174/1568009043332763
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200
   He XY, 2007, CANCER RES, V67, P11099, DOI 10.1158/0008-5472.CAN-07-2672
   Hogan C, 2008, J BIOL CHEM, V283, P18012, DOI 10.1074/jbc.M709695200
   Hu H, 2006, NAT IMMUNOL, V7, P819, DOI 10.1038/ni1358
   Hwang H-W, 2007, Br J Cancer, V96 Suppl, pR40
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Kaposi-Novak P, 2006, J CLIN INVEST, V116, P1582, DOI 10.1172/JCI27236
   Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644
   Koon HB, 2007, EXPERT OPIN THER TAR, V11, P955, DOI 10.1517/14728222.11.7.955
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Kutay H, 2006, J CELL BIOCHEM, V99, P671, DOI 10.1002/jcb.20982
   Laskin JJ, 2005, CANCER INVEST, V23, P427, DOI 10.1081/CNV-200067172
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Martin MM, 2007, J BIOL CHEM, V282, P24262, DOI 10.1074/jbc.M701050200
   Mazzone M, 2006, FASEB J, V20, P1611, DOI 10.1096/fj.06-5947rev
   Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057
   Mishima T, 2007, BRAIN RES, V1131, P37, DOI 10.1016/j.brainres.2006.11.035
   Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634
   Motiwala T, 2004, P NATL ACAD SCI USA, V101, P13844, DOI 10.1073/pnas.0405451101
   Nilsen TW, 2007, TRENDS GENET, V23, P243, DOI 10.1016/j.tig.2007.02.011
   Niwa R, 2007, CURR OPIN GENET DEV, V17, P145, DOI 10.1016/j.gde.2007.02.004
   Nuovo GJ, 2008, METHODS, V44, P39, DOI 10.1016/j.ymeth.2007.10.008
   O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104
   Peltier HJ, 2008, RNA, V14, P844, DOI 10.1261/rna.939908
   Ramalingam SS, 2007, CLIN CANCER RES, V13, P3605, DOI 10.1158/1078-0432.CCR-07-0162
   SCHUG J, 2008, CURRENT PROTOCOLS BI, P21
   Schuster MB, 2006, BBA-REV CANCER, V1766, P88, DOI 10.1016/j.bbcan.2006.02.003
   Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202
   Sevignani C, 2007, P NATL ACAD SCI USA, V104, P8017, DOI 10.1073/pnas.0702177104
   Sokol NS, 2005, GENE DEV, V19, P2343, DOI 10.1101/gad.1356105
   Song LX, 2005, CANCER BIOL THER, V4, P267, DOI 10.4161/cbt.4.3.1496
   Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347
   Tada T, 2006, J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093
   Taganov KD, 2007, IMMUNITY, V26, P133, DOI 10.1016/j.immuni.2007.02.005
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Takimoto CH, 2008, CANCER CHEMOTH PHARM, V61, P535, DOI 10.1007/s00280-007-0639-9
   Van Rooij E, 2007, PHYSIOL GENOMICS, V31, P365, DOI 10.1152/physiolgenomics.00206.2007
   van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103
   Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460
   Weidhaas JB, 2007, CANCER RES, V67, P11111, DOI 10.1158/0008-5472.CAN-07-2858
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488
   Zhang BH, 2007, J CELL PHYSIOL, V210, P279, DOI 10.1002/jcp.20869
   Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817
   Zhao Y, 2007, CELL, V129, P303, DOI 10.1016/j.cell.2007.03.030
NR 66
TC 274
Z9 295
U1 0
U2 17
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 28
PY 2008
VL 283
IS 48
BP 33394
EP 33405
DI 10.1074/jbc.M804788200
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 376KY
UT WOS:000261183700044
PM 18818206
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Conrad, S
   Renninger, M
   Hennenlotter, J
   Wiesner, T
   Just, L
   Bonin, M
   Aicher, W
   Buhring, HJ
   Mattheus, U
   Mack, A
   Wagner, HJ
   Minger, S
   Matzkies, M
   Reppel, M
   Hescheler, J
   Sievert, KD
   Stenzl, A
   Skutella, T
AF Conrad, Sabine
   Renninger, Markus
   Hennenlotter, Joerg
   Wiesner, Tina
   Just, Lothar
   Bonin, Michael
   Aicher, Wilhelm
   Buehring, Hans-Joerg
   Mattheus, Ulrich
   Mack, Andreas
   Wagner, Hans-Joachim
   Minger, Stephen
   Matzkies, Matthias
   Reppel, Michael
   Hescheler, Juergen
   Sievert, Karl-Dietrich
   Stenzl, Arnulf
   Skutella, Thomas
TI RETRACTED: Generation of pluripotent stem cells from adult human testis
   (Retracted article. See vol. 512, pg. 338, 2014)
SO NATURE
LA English
DT Article; Retracted Publication
ID PRIMORDIAL GERM-CELLS; IN-VITRO; DIFFERENTIATION; FIBROBLASTS; CULTURE;
   CARDIOMYOCYTES; DERIVATION; MARKERS
AB Human primordial germ cells and mouse neonatal and adult germline stem cells are pluripotent and show similar properties to embryonic stem cells. Here we report the successful establishment of human adult germline stem cells derived from spermatogonial cells of adult human testis. Cellular and molecular characterization of these cells revealed many similarities to human embryonic stem cells, and the germline stem cells produced teratomas after transplantation into immunodeficient mice. The human adult germline stem cells differentiated into various types of somatic cells of all three germ layers when grown under conditions used to induce the differentiation of human embryonic stem cells. We conclude that the generation of human adult germline stem cells from testicular biopsies may provide simple and non- controversial access to individual cell- based therapy without the ethical and immunological problems associated with human embryonic stem cells.
C1 [Conrad, Sabine; Wiesner, Tina; Just, Lothar; Skutella, Thomas] Inst Anat, Dept Expt Embryol, D-72074 Tubingen, Germany.
   [Mattheus, Ulrich; Mack, Andreas; Wagner, Hans-Joachim] Inst Anat, Dept Cellular Neurobiol, D-72074 Tubingen, Germany.
   [Renninger, Markus; Hennenlotter, Joerg; Sievert, Karl-Dietrich; Stenzl, Arnulf] Univ Clin Tubingen, Dept Urol, D-72076 Tubingen, Germany.
   [Bonin, Michael] Univ Clin Tubingen, Inst Anthropol & Human Genet, Microarray Facil, D-72076 Tubingen, Germany.
   [Aicher, Wilhelm] Univ Clin Tubingen, ZMF Res Labs, D-72072 Tubingen, Germany.
   [Aicher, Wilhelm; Skutella, Thomas] Ctr Regenerat Biol & Med ZRM, D-72076 Tubingen, Germany.
   [Buehring, Hans-Joerg] Univ Clin Tubingen, Dept Internal Med 2, D-72076 Tubingen, Germany.
   [Minger, Stephen] Kings Coll London, Stem Cell Biol Lab, Wolfson Ctr Age Related Dis, London SE1 1UL, England.
   [Matzkies, Matthias; Reppel, Michael; Hescheler, Juergen] Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany.
RP Skutella, T (reprint author), Inst Anat, Dept Expt Embryol, Osterbergstr 3, D-72074 Tubingen, Germany.
EM Thomas.Skutella@regmed.uni-tuebingen.de
OI Aicher, Wilhelm K/0000-0003-2210-6773
FU Department of Urology; Institute of Anatomy; ZRM (University Clinic
   Tubingen)
FX We thank S. Singer, U. Mau-Holzmann and O. Riess for karyotyping the
   human adult GSCs obtained from the patients' biopsies; M. Schenk for
   providing support with ELISA; D. Blaurock for proofreading the
   manuscript; K. Kohler for discussion and encouragement; and P. Bauer for
   conducting the microsatellite analysis. Financial support for this
   research was provided by the Department of Urology, Institute of Anatomy
   and ZRM (University Clinic Tubingen).
CR Alexander D, 2002, BIOL CHEM, V383, P1845, DOI 10.1515/BC.2002.208
   Bibel M, 2004, NAT NEUROSCI, V7, P1003, DOI 10.1038/nn1301
   Bielby RC, 2004, TISSUE ENG, V10, P1518, DOI 10.1089/ten.2004.10.1518
   Blyszczuk P, 2004, INT J DEV BIOL, V48, P1095, DOI 10.1387/ijdb.041904pb
   BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303
   Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367
   de Rooij DG, 2006, P NATL ACAD SCI USA, V103, P7939, DOI 10.1073/pnas.0602432103
   Ginis I, 2004, DEV BIOL, V269, P360, DOI 10.1016/j.ydbio.2003.12.034
   Guan K, 2006, NATURE, V440, P1199, DOI 10.1038/nature04697
   Hamra FK, 2004, DEV BIOL, V269, P393, DOI 10.1016/j.ydbio.2004.01.027
   Kanatsu-Shinohara M, 2004, CELL, V119, P1001, DOI 10.1016/j.cell.2004.11.011
   Kanatsu-Shinohara M, 2007, BIOL REPROD, V76, P55, DOI 10.1095/biolreprod.106.055863
   Kehat I, 2003, METHOD ENZYMOL, V365, P461
   Kubota H, 2006, NAT CLIN PRACT ENDOC, V2, P99, DOI 10.1038/ncpendmet0098
   Kubota H, 2004, BIOL REPROD, V71, P722, DOI 10.1095/biolreprod.104.029207
   Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866
   MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P
   MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6
   Meissner A, 2007, NAT BIOTECHNOL, V25, P1177, DOI 10.1038/nbt1335
   Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]
   Pollard SM, 2006, CEREB CORTEX, V16, pI112, DOI 10.1093/cercor/bbhj167
   RESNICK JL, 1992, NATURE, V359, P550, DOI 10.1038/359550a0
   Ringe J, 2003, MED KLIN, V98, P35
   Schatten G, 2005, NAT METHODS, V2, P455, DOI 10.1038/nmeth0605-455
   Seandel M, 2007, NATURE, V449, P346, DOI 10.1038/nature06129
   Segev H, 2004, STEM CELLS, V22, P265, DOI 10.1634/stemcells.22-3-265
   Shamblott MJ, 2001, P NATL ACAD SCI USA, V98, P113, DOI 10.1073/pnas.021537998
   Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726
   Shinohara T, 1999, P NATL ACAD SCI USA, V96, P5504, DOI 10.1073/pnas.96.10.5504
   STEVENS LC, 1984, CELL DIFFER DEV, V15, P69, DOI 10.1016/0045-6039(84)90054-X
   Stukenborg JB, 2008, J ANDROL, V29, P312, DOI 10.2164/jandrol.107.002857
   Turnpenny L, 2006, STEM CELLS, V24, P212, DOI 10.1634/stemcells.2005-0255
   Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944
   WITTWER CT, 1989, NUCLEIC ACIDS RES, V17, P4353, DOI 10.1093/nar/17.11.4353
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1172482
NR 37
TC 340
Z9 381
U1 4
U2 39
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD NOV 20
PY 2008
VL 456
IS 7220
BP 344
EP U25
DI 10.1038/nature07404
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 374JM
UT WOS:000261039600034
PM 18849962
DA 2018-12-27
ER

PT J
AU Kylmala, T
   Valkonen, A
   Rissanen, K
   Xu, YJ
   Franzen, R
AF Kylmala, Tuula
   Valkonen, Arto
   Rissanen, Kari
   Xu, Youjun
   Franzen, Robert
TI RETRACTED: trans-Tetrakis(pyridine)dichloroiron(II) as catalyst for
   Suzuki cross-coupling in ethanol and water (Retracted article. See vol.
   50, pg. 5692, 2009)
SO TETRAHEDRON LETTERS
LA English
DT Article; Retracted Publication
DE Iron catalysts; Pyridine ligands; Suzuki cross-coupling; Biaryls
ID ARYL BORONIC ACIDS; GRIGNARD-REAGENTS; IRON COMPLEXES; ETHYLENE;
   CHLORIDE; CRYSTAL; HALIDES
AB Aryl bromides can be coupled with phenylboronic acid in moderate to excellent yields using a trans-tetrakis(pyridine)dichloroiron(II) catalyst. The Suzuki-Miyaura reaction can be carried out Under air in ethanol and aqueous ethanol with low catalyst loading. Addition of TBAB dramatically increases the yields in aqueous ethanol or in water, trans-Tetrakis(pyridine)dichloroiron(II) offers an environmental and less expensive method for the synthesis of biaryl compounds. This is the first example of an iron-pyridine catalyst for Suzuki cross-coupling. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Kylmala, Tuula; Franzen, Robert] Tampere Univ Technol, Chem Lab, Dept Chem & Bioengn, FIN-33720 Tampere, Finland.
   [Valkonen, Arto; Rissanen, Kari] Univ Jyvaskyla, Dept Chem, Nanosci Ctr, Jyu 40014, Finland.
   [Xu, Youjun] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Shenyang 110016, Peoples R China.
RP Franzen, R (reprint author), Tampere Univ Technol, Chem Lab, Dept Chem & Bioengn, Korkeakoulunkatu 8, FIN-33720 Tampere, Finland.
EM kari.rissanen@jyu.fi; robert.franzen@tut.fi
RI Franzen, Robert/G-4226-2014; Rissanen, Kari/B-5688-2008
OI Rissanen, Kari/0000-0002-7282-8419
FU Academy of Finland [110043, 122350]
FX We acknowledge the Academy of Finland for financial support [110043
   (R.F.) and 122350 (K.R.)], and thank Noora Kuuloja and Tommi Aronen for
   helpful discussions during the work.
CR Amani V, 2007, POLYHEDRON, V26, P4257, DOI 10.1016/j.poly.2007.05.050
   BAUDISCH O, 1939, INORG SYNTH, V1, P185
   BAUDISCH O, 1939, INORG SYNTH, V1, P184
   Campora J, 2005, ORGANOMETALLICS, V24, P4878, DOI 10.1021/om050645d
   Costas M, 1999, J MOL CATAL A-CHEM, V148, P49, DOI 10.1016/S1381-1169(99)00057-6
   Franzen R, 2005, CAN J CHEM, V83, P266, DOI 10.1139/V05-048
   Furstner A, 2008, J AM CHEM SOC, V130, P8773, DOI 10.1021/ja801466t
   Furstner A, 2002, ANGEW CHEM INT EDIT, V41, P609
   Furstner A, 2005, CHEM LETT, V34, P624, DOI 10.1246/cl.2005.624
   Hassan J, 2002, CHEM REV, V102, P1359, DOI 10.1021/cr000664r
   HOSER A, 1983, ACTA CRYSTALLOGR C, V39, P1039, DOI 10.1107/S0108270183007295
   Jain SL, 2006, INORG CHIM ACTA, V359, P4398, DOI 10.1016/j.ica.2006.06.042
   Kuuloja N, 2008, CENT EUR J CHEM, V6, P390, DOI 10.2478/s11532-008-0044-1
   Kylmala T, 2008, EUR J ORG CHEM, P4019, DOI 10.1002/ejoc.200800119
   LEADBEATER NE, 2005, CHEM COMMUN, P2802
   LONG GJ, 1978, INORG CHEM, V17, P1394, DOI 10.1021/ic50184a002
   Lu G, 2005, TETRAHEDRON LETT, V46, P4255, DOI 10.1016/j.tetlet.2005.04.022
   Nagano T, 2005, ORG LETT, V7, P491, DOI 10.1021/ol047509+
   Rosa GR, 2006, INORG CHIM ACTA, V359, P1947, DOI 10.1016/j.ica.2005.11.031
   Sheloumov AM, 2008, EUR J INORG CHEM, P572, DOI 10.1002/ejic.200700923
   Shoji M, 2007, CHEM PHYS LETT, V446, P228, DOI 10.1016/j.cplett.2007.08.049
   Souane R, 2002, CR CHIM, V5, P43, DOI 10.1016/S1631-0748(02)01329-2
   Volla C. M. R., 2008, ANGEW CHEM INT EDIT, V47, P1305
   Walker SD, 2004, ANGEW CHEM INT EDIT, V43, P1871, DOI 10.1002/anie.200353615
   Zim D, 2002, TETRAHEDRON LETT, V43, P4009, DOI 10.1016/S0040-4039(02)00716-5
NR 25
TC 17
Z9 17
U1 4
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4039
J9 TETRAHEDRON LETT
JI Tetrahedron Lett.
PD NOV 17
PY 2008
VL 49
IS 47
BP 6679
EP 6681
DI 10.1016/j.tetlet.2008.09.059
PG 3
WC Chemistry, Organic
SC Chemistry
GA 373BB
UT WOS:000260944900020
DA 2018-12-27
ER

PT J
AU Shi, SJ
   Li, ZF
   Chen, HT
   Zeng, FD
AF Shi, Shaojun
   Li, Zhongfang
   Chen, Huating
   Zeng, Fandian
TI RETRACTED: Development and validation of an LC-MS method with
   electrospray ionization for quantitation of digoxin in human plasma and
   urine: Application to a pharmacokinetic study (Retracted article. See
   vol. 877, pg. 661, 2009)
SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES
LA English
DT Article; Retracted Publication
DE Digoxin; LC-MS; Electrospray ionization; Human plasma; Urine;
   Pharmacokinetic study
ID TANDEM MASS-SPECTROMETRY; CARDIAC-GLYCOSIDES; ASSAY; CHROMATOGRAPHY
AB A highly sensitive and specific LC-MS method was developed and validated for the quantification of digoxin in human plasma and urine using d5-dihydrodigoxin as internal standard (IS). The assay procedure involved extraction of digoxin and IS from human plasma with chloroform-isopropanol (95:5, v/v). Chromatogrphic separation was achieved on a Spherisorb ODS2 column using a gradient mobile phase with 5 mmol/L ammonium acetate in water with 1% acetic acid and acetonitrile. The mass spectrometer was operated in the selected ion monitoring mode using the respective [M+K](+) ions, m/z 819.4 for digoxin and m/z 826.4 for IS. The method was proved to be accurate and precise at linearity range of 0.12-19.60 ng/mL in plasma with a correlation coefficient (r(2)) of >= 0.9968 and 1.2-196.0 ng/mL in urine. The limit of quantification achieved with this method was 0.12 ng/mL in plasma and 1.2 ng/mL in urine. The intra- and inter-assay precision and accuracy values were found to be within the assay variability limits as per the FDA guidelines. The developed assay method was successfully applied to a pharmacokinetic study in human volunteers following intravenous administration of digoxin. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Shi, Shaojun; Li, Zhongfang; Chen, Huating] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pharm, Wuhan 430022, Peoples R China.
   [Zeng, Fandian] Huazhong Univ Sci & Technol, Tongji Med Coll, Inst Clin Pharmacol, Wuhan 430030, Peoples R China.
RP Shi, SJ (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pharm, 1277 Jiefang Ave, Wuhan 430022, Peoples R China.
EM sjshicn@163.com
CR Barclay Murray, 2003, N Z Med J, V116, pU704
   BEDNARCZYK B, 1988, CLIN CHEM, V34, P393
   Dasgupta A, 2002, AM J CLIN PATHOL, V118, P132
   Dasgupta Amitava, 2006, Toxicol Rev, V25, P273, DOI 10.2165/00139709-200625040-00007
   Feuring M, 2003, J CLIN PHARMACOL, V43, P912, DOI 10.1177/0091270003256113
   Frommherz L, 2008, INT J LEGAL MED, V122, P109, DOI 10.1007/s00414-007-0175-5
   Gurley BJ, 2007, DRUG METAB DISPOS, V35, P240, DOI 10.1124/dmd.106.012708
   Hashimoto Y, 2008, J CHROMATOGR B, V869, P126, DOI 10.1016/j.jchromb.2008.05.026
   Kirby BJ, 2008, BIOMED CHROMATOGR, V22, P712, DOI 10.1002/bmc.988
   Manunta P, 2006, HYPERTENSION, V47, P343, DOI 10.1161/01.HYP.0000202641.29167.c0
   MATZUK MM, 1991, THER DRUG MONIT, V13, P215, DOI 10.1097/00007691-199105000-00005
   MILLER JJ, 1994, CLIN CHEM, V40, P1898
   Mitamura K, 2007, BIOL PHARM BULL, V30, P1653, DOI 10.1248/bpb.30.1653
   Ni JS, 2008, PHARM RES-DORDR, V25, P1572, DOI 10.1007/s11095-008-9555-x
   Smalley J, 2007, J CHROMATOGR B, V854, P260, DOI 10.1016/j.jchromb.2007.04.030
   Tracqui A, 1997, J CHROMATOGR B, V692, P101, DOI 10.1016/S0378-4347(96)00462-8
   Tsutsumi K, 2002, J CLIN PHARMACOL, V42, P1159, DOI 10.1177/009127002237992
   VALDES R, 1985, CLIN CHEM, V31, P1525
   Yao M, 2003, J PHARMACEUT BIOMED, V32, P1189, DOI 10.1016/S0731-7085(03)00050-5
NR 19
TC 4
Z9 5
U1 4
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1570-0232
EI 1873-376X
J9 J CHROMATOGR B
JI J. Chromatogr. B
PD NOV 15
PY 2008
VL 875
IS 2
BP 405
EP 410
DI 10.1016/j.jchromb.2008.09.016
PG 6
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 377TG
UT WOS:000261272900011
PM 18922744
DA 2018-12-27
ER

PT J
AU Hunton, JE
   Mauldin, EG
   Wheeler, PR
AF Hunton, James E.
   Mauldin, Elaine G.
   Wheeler, Patrick R.
TI RETRACTED: Potential Functional and Dysfunctional Effects of Continuous
   Monitoring (Retracted article. See vol. 90, pg. 1709, 2015)
SO ACCOUNTING REVIEW
LA English
DT Article; Retracted Publication
DE continuous monitoring; incentive compensation; earnings management;
   project continuation
ID EARNINGS MANAGEMENT; BONUS SCHEMES; MANAGERIAL; MANIPULATION; AUDIT;
   PLANS
AB The trend toward continuous monitoring of automated business transactions by the internal audit function is growing as organizations seek to improve internal control. In this study, we demonstrate that continuous monitoring and the time horizon over which performance-contingent incentives are based can interact, thereby yielding potential functional and dysfunctional effects on managerial decisions. Seventy-two experienced corporate managers completed a between-participants experiment that randomized monitoring frequency (periodic or continuous) and incentive horizon (short-term or long-term). We found that earnings management of real activities significantly decreased as the frequency of monitoring increased in the presence of a short-term incentive horizon-a functional effect. However, with a long-term incentive horizon, the participants' willingness to change the current level of investment in a risky but viable project significantly dropped as the frequency of monitoring increased, even though additional investment would enhance the likelihood of the project's eventual success-a dysfunctional effect. We also observed that more frequent monitoring significantly decreased the willingness of managers to continue with a risky but viable project regardless of incentive horizon and the effect was significantly pronounced in the presence of a short-term, relative to long-term, incentive horizon-another dysfunctional consequence. Implications of the research findings to theory and practice are discussed.
C1 [Hunton, James E.] Bentley Coll, Waltham, MA 02154 USA.
   [Mauldin, Elaine G.; Wheeler, Patrick R.] Univ Missouri, Columbia, MO 65211 USA.
RP Hunton, JE (reprint author), Bentley Coll, Waltham, MA 02154 USA.
RI alrefaei, hessa/F-1443-2015
OI Mauldin, Elaine/0000-0003-3152-6710
CR *AICPA CICA, 1999, CONT AUD
   ANDERSON GJ, 1991, J APPL ECONOMET, V6, P153, DOI 10.1002/jae.3950060205
   ANDERSON U, 1988, AUDITING-J PRACT TH, V8, P23
   BAIMAN S, 1990, ACCOUNT ORG SOC, V15, P341, DOI 10.1016/0361-3682(90)90023-N
   Bhojraj S, 2005, ACCOUNT REV, V80, P1, DOI 10.2308/accr.2005.80.1.1
   Chou CLY, 2007, DECIS SUPPORT SYST, V42, P2274, DOI 10.1016/j.dss.2006.08.002
   Chow C., 1995, BEHAV RES ACCOUNTING, V7, P1
   Chow C. W., 2000, ABACUS, V36, P160
   CHURCHILL NC, 1982, AUDITING-J PRACT TH, V11, P69
   Coderre D., 2006, GLOBAL TECHNOLOGY AU
   COHEN JK, 1981, MANAGE SCI, V27, P1097
   Dittmann I, 2007, J FINANC, V62, P303, DOI 10.1111/j.1540-6261.2007.01208.x
   EISENHARDT KM, 1989, ACAD MANAGE REV, V14, P57, DOI 10.5465/AMR.1989.4279003
   Fischbacher U, 2007, ACCOUNT REV, V82, P679, DOI 10.2308/accr.2007.82.3.679
   Frederickson JR, 1999, J ACCOUNTING RES, V37, P151, DOI 10.2307/2491401
   GAVER JJ, 1995, J ACCOUNT ECON, V19, P3, DOI 10.1016/0165-4101(94)00358-C
   Groomer S.M., 1989, J INFORM SYSTEMS, V3, P53
   Guidry F, 1999, J ACCOUNT ECON, V26, P113, DOI 10.1016/S0165-4101(98)00037-8
   Healy P. M., 1999, ACCOUNT HORIZ, V13, P365, DOI DOI 10.2308/ACCH.1999.13.4.365
   HEALY PM, 1985, J ACCOUNT ECON, V7, P85, DOI 10.1016/0165-4101(85)90029-1
   HOLTHAUSEN RW, 1995, J ACCOUNT ECON, V19, P29, DOI 10.1016/0165-4101(94)00376-G
   HOSKISSON RE, 1993, ORGAN SCI, V4, P325, DOI 10.1287/orsc.4.2.325
   Hunton J, 2003, TRUST DATA ASSURANCE, P7
   INDJEJIKIAN RJ, 1999, ACCOUNT HORIZ, V13, P147, DOI DOI 10.2308/ACCH.1999.13.2.147
   JENSEN MC, 1976, J FINANC ECON, V3, P305, DOI 10.1016/0304-405X(76)90026-X
   Kadous K, 2004, CONTEMP ACCOUNT RES, V21, P55, DOI 10.1506/R0MH-W9H9-CQJD-1356
   Keppel G, 2007, DESIGN ANAL
   Koch HS, 1981, MIS QUART, V5, P29, DOI 10.2307/249156
   Kogan A., 1999, Journal of Information Systems, V13, P87, DOI 10.2308/jis.1999.13.2.87
   Kogan A., 2006, International Journal of Accounting Information Systems, V7, P137, DOI 10.1016/j.accinf.2005.10.004
   KRELL E, 2006, BUSINESS FINANCE MAR
   Lambert RA, 2001, J ACCOUNT ECON, V32, P3, DOI 10.1016/S0165-4101(01)00037-4
   Ng D, 1979, J ACCOUNTING RES S, V17, P1
   PricewaterhouseCoopers (PwC), 2006, PRICEWATERHOUSECOOPE
   Richardson V. J, 2002, REV QUANT FINANC ACC, V18, P161
   Roychowdhury S, 2006, J ACCOUNT ECON, V42, P335, DOI 10.1016/j.jacceco.2006.01.002
   Shelley MK, 1996, ORGAN BEHAV HUM DEC, V66, P42, DOI 10.1006/obhd.1996.0037
   Tosi HL, 1997, ACAD MANAGE J, V40, P584, DOI 10.2307/257054
   VASARHELYI MA, 1991, AUDITING-J PRACT TH, V10, P110
   WALLER WS, 1994, CONTEMP ACCOUNT RES, V10, P721
   Wiseman RM, 1998, ACAD MANAGE REV, V23, P133, DOI 10.2307/259103
   YATES B, 1998, MANAGE FINANC, V24, P44
NR 42
TC 33
Z9 34
U1 3
U2 29
PU AMER ACCOUNTING ASSOC
PI SARASOTA
PA 5717 BESSIE DR, SARASOTA, FL 34233 USA
SN 0001-4826
EI 1558-7967
J9 ACCOUNT REV
JI Account. Rev.
PD NOV
PY 2008
VL 83
IS 6
BP 1551
EP 1569
DI 10.2308/accr.2008.83.6.1551
PG 19
WC Business, Finance
SC Business & Economics
GA 391NL
UT WOS:000262239900006
DA 2018-12-27
ER

PT J
AU Shah, A
   Mistry, B
   Gibiansky, E
   Gibiansky, L
AF Shah, Ajit
   Mistry, Bipin
   Gibiansky, Ekaterina
   Gibiansky, Leonid
TI RETRACTED: Fospropofol Assay Issues and Impact on Pharmacokinetic and
   Pharmacodynamic Evaluation (Retracted article. See vol. 112, pg. 1058,
   2010)
SO ANESTHESIOLOGY
LA English
DT Letter; Retracted Publication
ID WATER-SOLUBLE PRODRUG; GPI 15715; BOLUS INJECTION; PROPOFOL
C1 [Shah, Ajit] MGI Pharma Inc, Bloomington, MN USA.
RP Shah, A (reprint author), MGI Pharma Inc, Bloomington, MN USA.
EM ajit.shah@mgipharma.com
CR Fechner J, 2005, ANESTH ANALG, V100, P701, DOI 10.1213/01.ANE.0000144772.13372.F4
   Fechner J, 2004, ANESTHESIOLOGY, V101, P626, DOI 10.1097/00000542-200409000-00011
   Fechner J, 2003, ANESTHESIOLOGY, V99, P303, DOI 10.1097/00000542-200308000-00012
   Gibiansky E, 2005, ANESTHESIOLOGY, V103, P718, DOI 10.1097/00000542-200510000-00010
   Schywalsky M, 2003, EUR J ANAESTH, V20, P182, DOI 10.1097/00003643-200303000-00002
   Struys MMRF, 2005, ANESTHESIOLOGY, V103, P730, DOI 10.1097/00000542-200510000-00011
NR 6
TC 13
Z9 13
U1 3
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD NOV
PY 2008
VL 109
IS 5
BP 937
EP 937
DI 10.1097/ALN.0b013e31818aa6e1
PG 1
WC Anesthesiology
SC Anesthesiology
GA 366XL
UT WOS:000260516800035
PM 18946316
OA Bronze
DA 2018-12-27
ER

PT J
AU Gupta, R
   Kumar, A
AF Gupta, Radha
   Kumar, Ashok
TI RETRACTED: Molecular imprinting in sol-gel matrix (Retracted article.
   See vol. 28, pg. 939, 2010)
SO BIOTECHNOLOGY ADVANCES
LA English
DT Review; Retracted Publication
DE Molecular recognition; Molecular imprinting technique; Molecularly
   imprinted polymers; Sol-gel; Templated xerogels; Surface molecular
   imprinting; Bio-imprinting
ID THIN-FILMS; PROTEIN RECOGNITION; PHASE EXTRACTION; INTERNAL ENVIRONMENT;
   SENSOR APPLICATIONS; SELECTIVE DETECTION; BIOMIMETIC SENSORS; POLYMERS;
   SURFACE; SILICA
AB Molecular imprinting is a newly developed methodology which provides molecular assemblies of desired structures and properties and is being increasingly used for several applications such as in separation processes, microreactors, immunoassays and antibody mimics, catalysis, artificial enzymes, biosensor recognition elements and bio- and chemo-sensors. The ambient processing conditions and versatility of the sol-gel process makes sol-gel glassy matrix suitable for molecular imprinting. The progress of sol-gel based molecular imprinted polymers (MIPs) for various applications can be seen from the growing number of publications. The main focus of the review is molecular imprinting in sol-gel matrix and applications of molecular imprinted sol-gel derived materials for the development of sensors. Combining sol-gel process with molecular imprinting enables to procure the sensors with greater sensitivity and selectivity necessary for sensing applications. The merits, problems, challenges and factors affecting molecular imprinting in sol-gel matrix have been discussed. Considerable attention has been drawn on recent developments like use of organically modified silane precursors (ORMOSILS) for the synthesis of hybrid molecular imprinted polymers (HMIPs) and applying surface sol-gel process for molecular imprinting. The development of molecular imprinted sol-gel nanotubes for biochemical separation and bio-imprinting is a new advancement and is under progress. Templated xerogels and molecularly imprinted sol-gel films provide a good platform for various sensor applications. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Gupta, Radha; Kumar, Ashok] Indian Inst Technol, Dept Biol Sci & Bioengn, Kanpur 208016, Uttar Pradesh, India.
RP Kumar, A (reprint author), Indian Inst Technol, Dept Biol Sci & Bioengn, Kanpur 208016, Uttar Pradesh, India.
EM ashokkum@iitk.ac.in
FU DST for providing financial support through Young Scientist Award under
   SERC-Fast track scheme
FX We would like to acknowledge all those researchers who's works are being
   cited here. Radha Gupta would like to thank DST for providing financial
   support through Young Scientist Award under SERC-Fast track scheme.
CR Alexander C, 2003, TETRAHEDRON, V59, P2025, DOI 10.1016/S0040-4020(03)00152-2
   ANDERSSON LI, 1995, P NATL ACAD SCI USA, V92, P4788, DOI 10.1073/pnas.92.11.4788
   Ansell RJ, 1996, CURR OPIN BIOTECH, V7, P89, DOI 10.1016/S0958-1669(96)80101-7
   Arkhireeva A, 2005, CHEM MATER, V17, P875, DOI 10.1021/cm049634l
   Bourget L, 1998, J NON-CRYST SOLIDS, V242, P81, DOI 10.1016/S0022-3093(98)00789-3
   Brinker CJ, 1990, SOL GEL SCI PHYS CHE
   Bukowski RM, 2005, ANAL CHEM, V77, P2670, DOI 10.1021/ac048199b
   Burleigh MC, 2001, CHEM MATER, V13, P2537, DOI 10.1021/cm000894m
   Carlson CA, 2006, ANAL CHEM, V78, P3537, DOI 10.1021/ac051375b
   Chaudhury NK, 2007, DEFENCE SCI J, V57, P241, DOI 10.14429/dsj.57.1765
   CHUNYA L, 2005, ANAL CHIM ACTA, V545, P122
   Ciardelli G, 2006, BIOSENS BIOELECTRON, V21, P2329, DOI 10.1016/j.bios.2005.12.027
   Collinson MM, 1999, CRIT REV ANAL CHEM, V29, P289, DOI 10.1080/10408349891199310
   Cummins W, 2005, ANAL CHIM ACTA, V542, P52, DOI 10.1016/j.aca.2005.01.042
   Dai S, 1997, CHEM MATER, V9, P2521, DOI 10.1021/cm970209k
   Dai S, 1999, ANGEW CHEM INT EDIT, V38, P1235, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1235::AID-ANIE1235>3.0.CO;2-X
   Defreese JL, 2005, CHEM MATER, V17, P6503, DOI 10.1021/cm050730b
   Diaz-Garcia ME, 2005, MICROCHIM ACTA, V149, P19, DOI 10.1007/s00604-004-0274-7
   Dickert FL, 2003, ANAL BIOANAL CHEM, V377, P540, DOI 10.1007/s00216-003-2060-5
   Dickert FL, 2002, ANAL CHEM, V74, P1302, DOI 10.1021/ac010642k
   DICKEY FH, 1949, P NATL ACAD SCI USA, V35, P227, DOI 10.1073/pnas.35.5.227
   Fang GZ, 2005, ANAL CHEM, V77, P1734, DOI 10.1021/ac048570v
   Fireman-Shoresh S, 2005, LANGMUIR, V21, P7842, DOI 10.1021/la050240y
   Fireman-Shoresh S, 2005, J AM CHEM SOC, V127, P2650, DOI 10.1021/ja0454384
   Fireman-Shoresh S, 2003, CHEM MATER, V15, P3607, DOI 10.1021/cm0340734
   Fujiwara M, 2004, ANAL CHEM, V76, P2374, DOI 10.1021/ac035179w
   Gao N, 2007, ELECTROANAL, V19, P1655, DOI 10.1002/elan.200703919
   Gill I, 2001, CHEM MATER, V13, P3404, DOI 10.1021/cm0102483
   Silva RGD, 2006, J CHROMATOGR A, V1114, P216, DOI 10.1016/j.chroma.2006.03.073
   Graham AL, 2002, ANAL CHEM, V74, P458, DOI 10.1021/ac0106142
   Guardia L, 2006, BIOSENS BIOELECTRON, V21, P1822, DOI 10.1016/j.bios.2005.09.016
   Gupta R, 2007, BIOSENS BIOELECTRON, V22, P2387, DOI 10.1016/j.bios.2006.12.025
   Gupta R, 2005, BIOSENS BIOELECTRON, V21, P549, DOI 10.1016/j.bios.2004.12.002
   Gupta R, 2005, BIOSENS BIOELECTRON, V20, P1358, DOI 10.1016/j.bios.2004.05.007
   GUPTA R, 2008, LAB INT, V22, P10
   Gupta R, 2008, BIOMED MATER, V3, DOI 10.1088/1748-6041/3/3/034005
   Gutierrez-Fernandez S, 2001, ELECTROANAL, V13, P1399, DOI 10.1002/1521-4109(200111)13:17<1399::AID-ELAN1399>3.0.CO;2-W
   Han DM, 2005, J CHROMATOGR A, V1100, P131, DOI 10.1016/j.chroma.2005.09.035
   Haupt K, 1999, ANAL COMMUN, V36, P391, DOI 10.1039/a907844d
   Haupt K, 2003, CHEM COMMUN, P171, DOI 10.1039/b207596b
   Haupt K, 2001, ANALYST, V126, P747, DOI 10.1039/b102799a
   Hay JN, 2001, CHEM MATER, V13, P3396, DOI 10.1021/cm011024n
   Hegde ND, 2006, J SOL-GEL SCI TECHN, V38, P55, DOI 10.1007/s10971-006-5348-z
   HENCH LL, 1990, CHEM REV, V90, P33, DOI 10.1021/cr00099a003
   Hunnius M, 1999, MICROPOR MESOPOR MAT, V29, P389, DOI 10.1016/S1387-1811(99)00008-6
   Ichinose I, 1997, CHEM MATER, V9, P1296, DOI 10.1021/cm970008g
   Ichinose I, 1996, CHEM LETT, P831, DOI 10.1246/cl.1996.831
   JANG J, 2002, POLYM PREPR, V43, P582
   Jiang ZY, 2006, J MEMBRANE SCI, V280, P876, DOI 10.1016/j.memsci.2006.03.006
   Jin W, 2002, ANAL CHIM ACTA, V461, P1, DOI 10.1016/S0003-2670(02)00229-5
   Jirage KB, 1997, SCIENCE, V278, P655, DOI 10.1126/science.278.5338.655
   KEMPE M, 1995, J MOL RECOGNIT, V8, P35, DOI 10.1002/jmr.300080106
   KIEFER HC, 1972, P NATL ACAD SCI USA, V69, P2155, DOI 10.1073/pnas.69.8.2155
   Klein JU, 1999, ANGEW CHEM INT EDIT, V38, P2057
   KRIZ D, 1995, ANAL CHIM ACTA, V300, P71, DOI 10.1016/0003-2670(94)00368-V
   Kunitake T, 2004, ANAL CHIM ACTA, V504, P1, DOI 10.1016/S0003-2670(03)00811-0
   Lee K, 2007, ACTA BIOMATER, V3, P515, DOI 10.1016/j.actbio.2007.01.003
   Lee SW, 1998, LANGMUIR, V14, P2857, DOI 10.1021/la9801763
   Leung MKP, 2001, J MATER CHEM, V11, P2985, DOI 10.1039/b103182c
   Li CY, 2005, SENSOR ACTUAT B-CHEM, V107, P411, DOI 10.1016/j.snb.2004.10.037
   Li F, 2008, TALANTA, V74, P1247, DOI 10.1016/j.talanta.2007.08.032
   Lulka MF, 2000, MAT SCI ENG C-BIO S, V11, P101, DOI 10.1016/S0928-4931(00)00129-6
   Malitesta C, 1999, ANAL CHEM, V71, P1366, DOI 10.1021/ac980674g
   Martin CR, 2003, NAT REV DRUG DISCOV, V2, P29, DOI 10.1038/nrd988
   MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961
   Marx S, 2004, ANAL CHEM, V76, P120, DOI 10.1021/ac034531s
   Marx S, 2003, INT J ENVIRON AN CH, V83, P671, DOI 10.1080/0306731021000015029
   Marx S, 2001, CHEM MATER, V13, P3624, DOI 10.1021/cm000983z
   McDonagh C, 2002, J NON-CRYST SOLIDS, V306, P138, DOI 10.1016/S0022-3093(02)01154-7
   Miller SA, 2001, J AM CHEM SOC, V123, P12335, DOI 10.1021/ja011926p
   Mitchell P, 2001, NAT BIOTECHNOL, V19, P717, DOI 10.1038/90754
   MOSBACH K, 1994, TRENDS BIOCHEM SCI, V19, P9, DOI 10.1016/0968-0004(94)90166-X
   Mosbach K, 1996, BIO-TECHNOL, V14, P163, DOI 10.1038/nbt0296-163
   Olwill A, 2004, BIOSENS BIOELECTRON, V20, P1045, DOI 10.1016/j.bios.2004.04.029
   Park JK, 2004, ENZYME MICROB TECH, V35, P688, DOI 10.1016/j.enzmictec.2004.08.023
   Pauling L, 1940, J AM CHEM SOC, V62, P2643, DOI 10.1021/ja01867a018
   Piletsky SA, 2001, TRENDS BIOTECHNOL, V19, P9, DOI 10.1016/S0167-7799(00)01523-7
   Piletsky SA, 2000, MACROMOLECULES, V33, P3092, DOI 10.1021/ma991087f
   Pinel C, 1997, ADV MATER, V9, P582, DOI 10.1002/adma.19970090715
   Rachkov A, 2001, BBA-PROTEIN STRUCT M, V1544, P255, DOI 10.1016/S0167-4838(00)00226-0
   Ramstrom O, 1998, CHIRALITY, V10, P195, DOI 10.1002/(SICI)1520-636X(1998)10:3<195::AID-CHIR1>3.0.CO;2-9
   SANCHEZ C, 1994, NEW J CHEM, V18, P1007
   Sassi Z, 2002, VIB SPECTROSC, V28, P251, DOI 10.1016/S0924-2031(01)00158-8
   SELLERGREN B, 2001, TECH INSTRUM ANAL CH, V23, P5571
   SHEA KJ, 1994, TRENDS POLYM SCI, V2, P166
   Shi HQ, 1999, NATURE, V398, P593
   Shustak G, 2003, ELECTROANAL, V15, P398, DOI 10.1002/elan.200390046
   Skrdla PJ, 2006, J NON-CRYST SOLIDS, V352, P3302, DOI 10.1016/j.jnoncrysol.2006.04.010
   Takeuchi T, 1999, J CHROMATOGR B, V728, P1, DOI 10.1016/S0378-4347(99)00057-2
   Tao ZY, 2006, ANAL CHIM ACTA, V564, P59, DOI 10.1016/j.aca.2006.01.076
   Tripathi VS, 2006, SENSOR ACTUAT B-CHEM, V114, P1071, DOI 10.1016/j.snb.2005.07.037
   VLATAKIS G, 1993, NATURE, V361, P645, DOI 10.1038/361645a0
   Vorotilov KA, 1994, J SOL-GEL SCI TECHN, V2, P559, DOI 10.1007/BF00486309
   Wei HS, 2006, J CHROMATOGR B, V836, P57, DOI 10.1016/j.jchromb.2006.03.047
   Wen JY, 1996, CHEM MATER, V8, P1667, DOI 10.1021/cm9601143
   WHITCOMBE MJ, 1995, J AM CHEM SOC, V117, P7105, DOI 10.1021/ja00132a010
   Wojcik AB, 1994, J SOL-GEL SCI TECHN, V2, P115, DOI 10.1007/BF00486223
   WULFF G, 1995, ANGEW CHEM INT EDIT, V34, P1812, DOI 10.1002/anie.199518121
   Wulff G, 1972, ANGEW CHEM, V84, P364
   Yang HH, 2004, J AM CHEM SOC, V126, P4054, DOI 10.1021/ja0389570
   Yang HH, 2005, J AM CHEM SOC, V127, P1378, DOI 10.1021/ja0467622
   Ye L, 2001, REACT FUNCT POLYM, V48, P149, DOI 10.1016/S1381-5148(01)00050-5
   Yu C, 1997, J ORG CHEM, V62, P4057, DOI 10.1021/jo961784v
   Zhang ZH, 2006, BIOSENS BIOELECTRON, V21, P1244, DOI 10.1016/j.bios.2005.05.009
   Zhang ZH, 2005, ANAL BIOCHEM, V336, P108, DOI 10.1016/j.ab.2004.09.027
   Zheng JY, 2000, J INORG ORGANOMET P, V10, P103, DOI 10.1023/A:1009428010719
NR 106
TC 71
Z9 77
U1 7
U2 146
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0734-9750
EI 1873-1899
J9 BIOTECHNOL ADV
JI Biotechnol. Adv.
PD NOV-DEC
PY 2008
VL 26
IS 6
BP 533
EP 547
DI 10.1016/j.biotechadv.2008.07.002
PG 15
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 367QU
UT WOS:000260568100004
PM 18692561
DA 2018-12-27
ER

PT J
AU Anand, P
   Kunnumakkara, AB
   Harikumar, KB
   Ahn, KS
   Badmaev, V
   Aggarwal, BB
AF Anand, Preetha
   Kunnumakkara, Ajaikumar B.
   Harikumar, Kuzhuvelil B.
   Ahn, Kwang Seok
   Badmaev, Vladimir
   Aggarwal, Bharat B.
TI RETRACTED: Modification of Cysteine Residue in p65 Subunit of Nuclear
   Factor-kappa B (NF-kappa B) by Picroliv Suppresses NF-kappa B-Regulated
   Gene Products and Potentiates Apoptosis (Retracted article. See vol. 78,
   pg. 5187, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID NITROSODIETHYLAMINE-INDUCED HEPATOCARCINOGENESIS; IRIDOID GLYCOSIDE
   FRACTION; TRANSCRIPTION FACTOR; PICRORHIZA-KURROA; ALPHA KINASE;
   CELLULAR INVASION; TYROSINE KINASE; AFLATOXIN B-1; RAT-LIVER; ACTIVATION
AB Picroliv, an iridoid glycoside derived from the plant Picrorhiza kurroa, is used traditionally to treat fever, asthma, hepatitis, and other inflammatory conditions. However, the exact mechanism of its therapeutic action is still unknown. Because nuclear factor-kappa B (NF-kappa B) activation plays a major role in inflammation and carcinogenesis, we postulated that picroliv must interfere with this pathway by inhibiting the activation of NF-kappa B-mediated signal cascade. Electrophoretic mobility shift assay showed that pretreatment with picroliv abrogated tumor necrosis factor (TNF)-induced activation of NF-kappa B. The glycoside also inhibited NF-kappa B activated by carcinogenic and inflammatory agents, such as cigarette smoke condensate, phorbol 12-myristate 13-acetate, okadaic acid, hydrogen peroxide, lipopolysaccharide, and epidermal growth factor. When examined for the mechanism of action, we found that picroliv inhibited activation of I kappa B alpha kinase, leading to inhibition of phosphorylation and degradation of I kappa B alpha. It also inhibited phosphorylation and nuclear translocation of p65. Further studies revealed that picroliv directly inhibits the binding of p65 to DNA, which was reversed by the treatment with reducing agents, suggesting a role for a cysteine residue in interaction with picroliv. Mutation of Cys(38) in p65 to serine abolished this effect of picroliv. NF-kappa B inhibition by picroliv leads to suppression of NF-kappa B-regulated proteins, including those linked with cell survival (inhibitor of apoptosis protein 1, Bcl-2, Bcl-xL, survivin, and TNF receptor-associated factor 2), proliferation (cyclin D1 and cyclooxygenase-2), angiogenesis (vascular endothelial growth factor), and invasion (intercellular adhesion molecule-1 and matrix metalloproteinase-9). Suppression of these proteins enhanced apoptosis induced by TNF. Overall, our results show that picroliv inhibits the NF-kappa B activation pathway, which may explain its anti-inflammatory
C1 [Aggarwal, Bharat B.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Unit 143, Houston, TX 77030 USA.
   [Badmaev, Vladimir] Sabinsa Corp, Piscataway, NJ USA.
RP Aggarwal, BB (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Unit 143, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM aggarwal@mdanderson.org
RI Aggarwal, Bharat/G-3388-2013; Kunnumakkara, Ajaikumar/H-8566-2012; Ahn,
   Kwang Seok/G-4249-2013
OI Kunnumakkara, Ajaikumar/0000-0001-9121-6816; 
FU Clayton Foundation; NIH Cancer Center Support [5P30 CA016672-32]
FX Clayton Foundation and NIH Cancer Center Support grant. 5P30
   CA016672-32. B.B. Aggarwal is the Ransom Horne, Jr., Professor of Cancer
   Research.
CR Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184
   Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003
   ANTARKAR DS, 1980, INDIAN J MED RES, V72, P588
   Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511
   Baruah CC, 1998, PHARMACOL RES, V38, P487, DOI 10.1006/phrs.1998.0397
   CHANDER R, 1992, BIOCHEM PHARMACOL, V44, P180, DOI 10.1016/0006-2952(92)90054-M
   Dannenberg AJ, 2005, J CLIN ONCOL, V23, P254, DOI 10.1200/JCO.2005.09.112
   Ding J, 2007, CANCER SCI, V98, P1323, DOI 10.1111/j.1349-7006.2007.00530.x
   Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200
   FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884
   Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959
   Gaddipati JP, 1999, MOL CELL BIOCHEM, V194, P271, DOI 10.1023/A:1006982028460
   Garcia-Pineres AJ, 2001, J BIOL CHEM, V276, P39713, DOI 10.1074/jbc.M101985200
   Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj/leu/2402482
   Ichikawa H, 2005, J IMMUNOL, V174, P7383, DOI 10.4049/jimmunol.174.11.7383
   Jeena KJ, 1999, CANCER LETT, V136, P11, DOI 10.1016/S0304-3835(98)00294-8
   Jia Q, 1999, J NAT PROD, V62, P901, DOI 10.1021/np980493+
   Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200
   Kunnurnakkara AB, 2007, BLOOD, V109, P5112, DOI 10.1182/blood-2007-01-067256
   Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com
   Liang MC, 2006, BIOCHEM PHARMACOL, V71, P634, DOI 10.1016/j.bcp.2005.11.013
   Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213
   MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557
   MEHROTRA R, 1990, INDIAN J MED RES-B, V92, P133
   Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090
   Rajeshkumar NV, 2003, CANCER LETT, V191, P137, DOI 10.1016/S0304-3835(02)00203-3
   Rajeshkumar NV, 2000, J EXP CLIN CANC RES, V19, P459
   Rajeshkumar NV, 2001, TERATOGEN CARCIN MUT, V21, P303, DOI 10.1002/tcm.1018
   Rastogi R, 2001, PHYTOTHER RES, V15, P307, DOI 10.1002/ptr.722
   Rastogi R, 1996, PLANTA MED, V62, P283, DOI 10.1055/s-2006-957882
   Rastogi R, 2001, PHARMACOL TOXICOL, V88, P53, DOI 10.1034/j.1600-0773.2001.d01-83.x
   Rastogi R, 2000, PLANTA MED, V66, P709, DOI 10.1055/s-2000-9907
   Sandur SK, 2006, J BIOL CHEM, V281, P17023, DOI 10.1074/jbc.M601595200
   Santra A, 1998, Indian J Gastroenterol, V17, P6
   Saraswat Binduja, 1997, Indian Journal of Experimental Biology, V35, P1302
   Seth P, 2003, SHOCK, V19, P169, DOI 10.1097/01.SHK.0000054748.80495.21
   Seth P, 2000, BIOCHEM PHARMACOL, V59, P1315, DOI 10.1016/S0006-2952(00)00268-9
   Sethi G, 2007, ONCOGENE, V26, P7324, DOI 10.1038/sj.onc.1210544
   Shin SR, 2006, CANCER RES, V66, P2570, DOI 10.1158/0008-5472.CAN-05-3056
   Singh AK, 2000, EUR J PHARMACOL, V395, P229, DOI 10.1016/S0014-2999(00)00146-1
   Singh AK, 2007, PLANTA MED, V73, P251, DOI 10.1055/s-2007-967119
   Sinha S, 1998, IMMUNOPHARM IMMUNOT, V20, P579, DOI 10.3109/08923979809031518
   Stathopoulos GT, 2007, P NATL ACAD SCI USA, V104, P18514, DOI 10.1073/pnas.0705316104
   Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200
   Vaidya A B, 1996, J Postgrad Med, V42, P105
   WATANABE H, 1993, J CELL SCI, V104, P991
   Zheng X, 2008, INT J ONCOL, V32, P257
NR 47
TC 46
Z9 48
U1 1
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD NOV 1
PY 2008
VL 68
IS 21
BP 8861
EP 8870
DI 10.1159/0008-5472.CAN-08-1902
PG 10
WC Oncology
SC Oncology
GA 369MP
UT WOS:000260698900028
PM 18974130
DA 2018-12-27
ER

PT J
AU Nakazato, T
   Okudaira, T
   Ishikawa, C
   Nakama, S
   Sawada, S
   Tomita, M
   Uchihara, J
   Taira, N
   Masuda, M
   Tanaka, Y
   Ohshiro, K
   Takasu, N
   Mori, N
AF Nakazato, Tetsuro
   Okudaira, Taeko
   Ishikawa, Chie
   Nakama, Shinji
   Sawada, Shigeki
   Tomita, Mariko
   Uchihara, Jun-nosuke
   Taira, Naoya
   Masuda, Masato
   Tanaka, Yuetsu
   Ohshiro, Kazuiku
   Takasu, Nobuyuki
   Mori, Naoki
TI RETRACTED: Anti-adult T-cell leukemia effects of a novel synthetic
   retinoid, Am80 (Tamibarotene) (Retracted article. See vol. 102, pg. 499,
   2011)
SO CANCER SCIENCE
LA English
DT Article; Retracted Publication
ID VIRUS TYPE-I; ACUTE PROMYELOCYTIC LEUKEMIA; ONCOGENE PRODUCT TAX; HUMAN
   CYCLIN D2; FACTOR-KAPPA-B; MONOCLONAL-ANTIBODY; HTLV-1 TAX; CONSTITUTIVE
   ACTIVATION; APOPTOTIC CELLS; ACID RECEPTORS
AB Clinical trials for treatment of adult T-cell leukemia (ATL) caused by human T-cell leukemia virus type I (HTLV-I) using all-trans-retinoic acid (ATRA) have shown satisfactory therapeutic responses, although efficacies were limited. Recently, many synthetic retinoids have been developed and among them, a novel synthetic retinoid, Am80 (Tamibarotene) is an RAR alpha- and RAR beta-specific retinoid expected to overcome ATRA resistance. The present study examined the inhibitory effects of Am80 on HTLV-I-infected T-cell lines and ATL cells. Am80 had negligible growth inhibition of peripheral blood mononuclear cells but marked growth inhibition of both HTLV-I-infected T-cell lines and ATL cells. Am80 arrested cells in the G1 phase of the cell cycle and induced apoptosis in HTLV-I-infected T-cell lines. It inhibited also the phosphorylation of I kappa B alpha and NF-kappa B-DNA binding, in conjunction with reduction of expression of proteins involved in the G1/S cell cycle transition and apoptosis. Am80 also inhibited the expression of JunD, resulting in suppression of AP-1-DNA binding. Furthermore, severe combined immunodeficient mice with tumors induced by subcutaneous inoculation of HTLV-I-infected T cells, responded to Am80 treatment with partial regression of tumors and no side-effects. These findings demonstrate that Am80 is a potential inhibitor of NF-kappa B and AP-1, and is a potentially useful therapeutic agent against ATL. (Cancer Sci 2008; 99: 2286-2294).
C1 [Nakazato, Tetsuro; Okudaira, Taeko; Ishikawa, Chie; Nakama, Shinji; Sawada, Shigeki; Tomita, Mariko; Mori, Naoki] Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Okinawa 9030215, Japan.
   [Nakazato, Tetsuro; Okudaira, Taeko; Masuda, Masato; Takasu, Nobuyuki] Univ Ryukyus, Fac Med, Div Endocrinol & Metab, Okinawa 9030215, Japan.
   [Ishikawa, Chie] Univ Ryukyus, Fac Med, Div Child Hlth & Welf, Okinawa 9030215, Japan.
   [Nakama, Shinji] Musashino Res Inst Immun, Okinawa 9060106, Japan.
   [Sawada, Shigeki] Univ Ryukyus, Fac Med, Div Oral & Maxillofacial Funct Rehabil, Okinawa 9030215, Japan.
   [Uchihara, Jun-nosuke] Naha City Hosp, Dept Internal Med, Okinawa 9028511, Japan.
   [Taira, Naoya] Heartlife Hosp, Dept Internal Med, Nakagusu Ku, Okinawa 9012492, Japan.
   [Tanaka, Yuetsu] Univ Ryukyus, Fac Med, Div Immunol, Okinawa 9030215, Japan.
   [Ohshiro, Kazuiku] Okinawa Prefectural Nanbu Med Ctr, Dept Internal Med, Okinawa 9011193, Japan.
   [Ohshiro, Kazuiku] Childrens Med Ctr, Okinawa 9011193, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
CR Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036
   Altucci L, 2007, NAT REV DRUG DISCOV, V6, P793, DOI 10.1038/nrd2397
   BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096
   Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090
   Cassinat B, 2001, BLOOD, V98, P2862, DOI 10.1182/blood.V98.9.2862
   Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8
   Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9
   Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj/leu/2402414
   Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978
   Hall WW, 2005, ONCOGENE, V24, P5965, DOI 10.1038/sj.onc.1208975
   HASHIMOTO Y, 1995, J CANCER RES CLIN, V121, P696, DOI 10.1007/BF01218530
   Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198
   Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304
   Ji JD, 2001, J AUTOIMMUN, V17, P215, DOI 10.1006/jaut.2001.0542
   KAGECHIKA H, 1988, J MED CHEM, V31, P2182, DOI 10.1021/jm00119a021
   Kannagi M, 2004, TRENDS MICROBIOL, V12, P346, DOI 10.1016/j.tim.2004.05.005
   Kawakami A, 1999, BLOOD, V94, P3847
   KOEFFLER HP, 1984, BLOOD, V64, P482
   Krueger A, 2006, BLOOD, V107, P3933, DOI 10.1182/blood-2005-06-2567
   Lefebvre P, 2005, VITAM HORM, V70, P199, DOI 10.1016/S0083-6729(05)70007-8
   MAEDA M, 1985, J EXP MED, V162, P2169, DOI 10.1084/jem.162.6.2169
   Maeda Y, 2008, J CANCER RES CLIN, V134, P673, DOI 10.1007/s00432-007-0334-6
   MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7
   Matsumoto K, 1997, J VIROL, V71, P4445
   MIYOSHI I, 1980, GANN, V71, P155
   MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0
   Mori N, 2004, J VIROL, V78, P4582, DOI 10.1128/JVI.78.9.4582-4590.2004
   Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749
   Mori N, 1999, BLOOD, V93, P2360
   Mori N, 2000, BLOOD, V95, P3915
   Nawata H, 2001, LEUKEMIA RES, V25, P323, DOI 10.1016/S0145-2126(00)00126-0
   Okudaira T, 2006, MOL CANCER THER, V5, P704, DOI 10.1158/1535-7163.MCT-05-0434
   Okudaira T, 2007, INT J CANCER, V120, P2251, DOI 10.1002/ijc.22534
   Okuno M, 2004, CURR CANCER DRUG TAR, V4, P285, DOI 10.2174/1568009043333023
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519
   RENSTROM B, 1989, BIOCHIM BIOPHYS ACTA, V998, P69, DOI 10.1016/0167-4838(89)90120-9
   Sanz MA, 2005, BLOOD, V105, P3019, DOI 10.1182/blood-2004-09-3475
   Seth A, 1997, AIDS, V11, P1059
   Suzui M, 2004, MOL CANCER THER, V3, P309
   TAKAHASHI N, 1989, J BIOL CHEM, V264, P5159
   TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x
   Taylor GP, 2005, ONCOGENE, V24, P6047, DOI 10.1038/sj.onc.1208979
   Tobita T, 1997, BLOOD, V90, P967
   Wada M, 2001, J BIOCHEM-TOKYO, V130, P457, DOI 10.1093/oxfordjournals.jbchem.a003006
   Waldele K, 2006, BLOOD, V107, P4491, DOI 10.1182/blood-2005-08-3138
   WATTEL E, 1995, J VIROL, V69, P2863
   Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046/j.1365-2141.2001.02737.x
   YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
   ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0
   Zhang CH, 1996, J IMMUNOL, V157, P3980
NR 54
TC 14
Z9 14
U1 2
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD NOV
PY 2008
VL 99
IS 11
BP 2286
EP 2294
DI 10.1111/j.1349-7006.2008.00917.x
PG 9
WC Oncology
SC Oncology
GA 369YV
UT WOS:000260730700026
PM 18771528
OA Bronze
DA 2018-12-27
ER

PT J
AU Aggarwal, V
   Logani, A
   Shah, N
AF Aggarwal, Vivek
   Logani, Ajay
   Shah, Naseem
TI RETRACTED: The Evaluation of Computed Tomography Scans and Ultrasounds
   in the Differential Diagnosis of Periapical Lesions(Retracted article.
   See vol. 43, pg. 833, 2017)
SO JOURNAL OF ENDODONTICS
LA English
DT Article; Retracted Publication
DE Color-power Doppler flowmetry; computed tomography; periapical lesions;
   ultrasound
ID RADICULAR CYSTS; LESIONS; RADIOGRAPHY; GRANULOMAS
AB Traditionally, the definitive diagnosis of periapical lesion depends on histopathological examination of the tissues, which is impractical in cases planned for nonsurgical treatment. Recently, some authors have used ultrasound with power Doppler and computed tomography in differential diagnosis between a cyst and a granuloma. The aim of this study was to evaluate and compare the use of computed tomography (CT) scan and ultrasound with power Doppler flowmetry in differential diagnosis of periapical lesions. Twelve periapical lesions were imaged with the help of CT scans and ultrasound with color-power Doppler flowmetry. A provisional preoperative diagnosis was made based on history, clinical presentation, and radiographic features. The cases were treated by surgical endodontics. In all 12 cases, the diagnosis with CT scan and ultrasound coincided with the histopathological diagnosis of the lesions. It is proposed that CT scans and ultrasound with power Doppler flowmetry can provide an additional dignostic tool without invasive surgery, where treatment option is nonsurgical. (J Endod 2008;34:1312-1315)
C1 [Aggarwal, Vivek; Logani, Ajay; Shah, Naseem] All India Inst Med Sci, Ctr Dent Educ & Res, Dept Conservat Dent & Endodont, New Delhi, India.
RP Shah, N (reprint author), All India Inst Med Sci, Ctr Dent Educ & Res, Dept Conservat Dent & Endodont, New Delhi, India.
EM naseemys@gmail.com
RI aggarwal, vivek/E-7141-2010
OI aggarwal, vivek/0000-0002-9792-4554
CR Burkes E J Jr, 1975, J Endod, V1, P76, DOI 10.1016/S0099-2399(75)80086-0
   Christoph GD, 1996, AM SOC NEURORADIOL, V96, P1709
   Cotti E, 2003, INT ENDOD J, V36, P556, DOI 10.1046/j.1365-2591.2003.00690.x
   Cotton TP, 2007, J ENDODONT, V33, P1121, DOI 10.1016/j.joen.2007.06.011
   CUNNINGHAM CJ, 1968, ORAL SURG ORAL MED O, V26, P96, DOI 10.1016/0030-4220(68)90228-4
   Estrela C, 2008, J ENDODONT, V34, P273, DOI 10.1016/j.joen.2007.11.023
   FORSBERG A, 1960, DENT RADIOGRAPH PHOT, V33, P84
   GROSSMAN LI, 1950, ROOT CANAL THERAPY
   Gundappa M, 2006, DENTOMAXILLOFAC RAD, V35, P326, DOI 10.1259/dmfr/60326577
   Howell F V, 1968, J South Calif Dent Assoc, V36, P161
   KAFFE I, 1988, J ENDODONT, V14, P330, DOI 10.1016/S0099-2399(88)80193-6
   Klingenbeck-Regn K, 1999, EUR J RADIOL, V31, P110, DOI 10.1016/S0720-048X(99)00086-8
   Low KMT, 2008, J ENDODONT, V34, P557, DOI 10.1016/j.joen.2008.02.022
   MCCALL JO, 1952, CLIN DENT ROENTGENOL
   MORSE DR, 1973, ORAL SURG ORAL MED O, V35, P249, DOI 10.1016/0030-4220(73)90292-2
   MOUYEN F, 1989, ORAL SURG ORAL MED O, V68, P238, DOI 10.1016/0030-4220(89)90200-4
   Nair MK, 2007, J ENDODONT, V33, P1, DOI 10.1016/j.joen.2006.08.013
   Nair PNR, 1998, INT ENDOD J, V31, P155
   SHAH N, 1992, ENDOD DENT TRAUMATOL, V8, P39
   Simon J H, 1980, J Endod, V6, P845, DOI 10.1016/S0099-2399(80)80039-2
   Simon JHS, 2006, J ENDODONT, V32, P833, DOI 10.1016/j.joen.2006.03.008
   TROPE M, 1989, ENDOD DENT TRAUMATOL, V5, P69
NR 22
TC 40
Z9 40
U1 4
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0099-2399
EI 1878-3554
J9 J ENDODONT
JI J. Endod.
PD NOV
PY 2008
VL 34
IS 11
BP 1312
EP 1315
DI 10.1016/j.joen.2008.08.005
PG 4
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 374CZ
UT WOS:000261021400004
PM 18928838
DA 2018-12-27
ER

PT J
AU Rathinam, C
   Lassmann, H
   Mengel, M
   Klein, C
AF Rathinam, Chozhavendan
   Lassmann, Hans
   Mengel, Michael
   Klein, Christoph
TI RETRACTED: Transcription Factor Gfi1 Restricts B Cell-Mediated
   Autoimmunity (Retracted article. See vol. 189, pg. 3777, 2012)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; HEMATOPOIETIC STEM-CELLS; REPRESSOR GFI1;
   MICE LACKING; DISEASE; DIFFERENTIATION; PROTEIN; GENE; PROLIFERATION;
   EXPRESSION
AB The zinc finger transcription factor Gfi1 (growth factor-independent-1) has been involved in various cellular differentiation processes. Gfi1 acts as a transcriptional repressor and splicing control factor upon binding to cognate binding sites in regulatory elements of its target genes. In this study, we report that Gfi1-deficient mice develop autoimmunity. Gfi1-deficient peripheral B cells show a hyperproliferative phenotype leading to expansion of plasma cells, increased levels of nuclear autoantibodies, and Ig deposition in brain and kidneys. Dysregulation of multiple transcription factors and cell cycle control elements may contribute to B cell-dependent autoimmunity. Gfi1 thus emerges as a novel master regulator restricting autoimmunity. The Journal of Immunology, 2008, 181: 6222-6229.
C1 [Rathinam, Chozhavendan; Klein, Christoph] Childrens Hosp, Hannover Med Sch, Dept Pediat Hematol Oncol, D-30625 Hannover, Germany.
   [Lassmann, Hans] Med Univ Vienna, Ctr Brain Res, Vienna, Austria.
   [Mengel, Michael] Hannover Med Sch, Inst Pathol, D-3000 Hannover, Germany.
RP Klein, C (reprint author), Childrens Hosp, Hannover Med Sch, Dept Pediat Hematol Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM klein.christoph@mh-hannover.de
FU Deutsche Forschungsgemeinschaft [110-2, SFB738]; Else Kroner-Fresenius
   Stiftung
FX This work was supported by grants from Deutsche Forschungsgemeinschaft
   (Clinical Research Group 110-2 and SFB738) and the Else Kroner-Fresenius
   Stiftung.
CR Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3
   Brard F, 1999, J EXP MED, V190, P691, DOI 10.1084/jem.190.5.691
   Calame KL, 2001, NAT IMMUNOL, V2, P1103, DOI 10.1038/ni1201-1103
   Duan ZJ, 2005, MOL CELL BIOL, V25, P10338, DOI 10.1128/MCB.25.23.10338-10351.2005
   Duan ZJ, 2003, P NATL ACAD SCI USA, V100, P5932, DOI 10.1073/pnas.1031694100
   Durali D, 2003, BLOOD, V102, P4084, DOI 10.1182/blood-2003-02-0518
   Fairhurst AM, 2006, ADV IMMUNOL, V92, P1, DOI 10.1016/S0065-2776(06)92001-X
   Friedmann D, 1999, J IMMUNOL, V162, P4406
   GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759
   Goodnow CC, 2005, NATURE, V435, P590, DOI 10.1038/nature03724
   Grimaldi C, 2005, J IMMUNOL, V174, P1775, DOI 10.4049/jimmunol.174.4.1775
   Groom JR, 2007, J EXP MED, V204, P1959, DOI 10.1084/jem.20062567
   Hermiston ML, 2005, IMMUNITY, V23, P635, DOI 10.1016/j.immuni.2005.11.001
   Heyd F, 2006, NAT IMMUNOL, V7, P859, DOI 10.1038/ni1361
   Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994
   Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0
   Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831
   Lipsky PE, 2001, NAT IMMUNOL, V2, P764, DOI 10.1038/ni0901-764
   Liu NS, 2003, NAT IMMUNOL, V4, P687, DOI 10.1038/ni941
   Majeti R, 2000, CELL, V103, P1059, DOI 10.1016/S0092-8674(00)00209-9
   Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a
   Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8
   Pao LI, 2007, IMMUNITY, V27, P35, DOI 10.1016/j.immuni.2007.04.016
   Peng SL, 2002, P NATL ACAD SCI USA, V99, P5545, DOI 10.1073/pnas.082114899
   Peng SL, 2008, FRONT BIOSCI-LANDMRK, V13, P4218, DOI 10.2741/3001
   Rathinam C, 2005, IMMUNITY, V22, P717, DOI 10.1016/j.immuni.2005.01.007
   Rathinam C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000306
   Rioux JD, 2005, NATURE, V435, P584, DOI 10.1038/nature03723
   Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7
   Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572
   Shlomchik MJ, 2008, IMMUNITY, V28, P18, DOI 10.1016/j.immuni.2007.12.004
   Shlomchik MJ, 2001, NAT REV IMMUNOL, V1, P147, DOI 10.1038/35100573
   Shroyer NF, 2005, GENE DEV, V19, P2412, DOI 10.1101/gad.1353905
   Tsuda H, 2005, CELL, V122, P633, DOI 10.1016/j.cell.2005.06.012
   Wallis D, 2003, DEVELOPMENT, V130, P221, DOI 10.1242/dev.00190
   William J, 2002, SCIENCE, V297, P2066, DOI 10.1126/science.1073924
   WINFIELD JB, 1977, J CLIN INVEST, V59, P90, DOI 10.1172/JCI108626
   Yucel R, 2004, J BIOL CHEM, V279, P40906, DOI 10.1074/jbc.M400808200
   Yucel R, 2003, J EXP MED, V197, P831, DOI 10.1084/jem.20021417
   Zeng H, 2004, EMBO J, V23, P4116, DOI 10.1038/sj.emboj.7600419
   Zhu JF, 2002, IMMUNITY, V16, P733, DOI 10.1016/S1074-7613(02)00317-5
NR 41
TC 11
Z9 11
U1 3
U2 13
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD NOV 1
PY 2008
VL 181
IS 9
BP 6222
EP 6229
DI 10.4049/jimmunol.181.9.6222
PG 8
WC Immunology
SC Immunology
GA 368YI
UT WOS:000260659000047
PM 18941212
OA Bronze
DA 2018-12-27
ER

PT J
AU Du, SS
   Kaneda, Y
   Yarborough, M
AF Du, Shisen
   Kaneda, Yushi
   Yarborough, Mike
TI RETRACTED: 488 nm ultraviolet light generated by vecsel and V-cavity
   second-harmonic generation using lithium triborate (Retracted article.
   See vol. 51, pg. 583, 2009)
SO MICROWAVE AND OPTICAL TECHNOLOGY LETTERS
LA English
DT Article; Retracted Publication
DE VECSEL; lithimn triborate; second-hormonic generation
ID LASER
AB We report an optically pumped vertical external cavity surface-emitting laser based on InGaAs/GaAs single wavelength continuous output beam at 977 nm. V-Cavity second-harmonic generation was achieved in lithium triborate to produce 480 mW at 488 nm in output beams. There is no significance decrease in second harmonic output power up to 3 h test. (c) 2008 Wiley Periodicals, Inc.
C1 [Du, Shisen; Kaneda, Yushi; Yarborough, Mike] Univ Arizona, Coll Opt Sci, Tucson, AZ 85721 USA.
   [Du, Shisen] Beijing Univ Aeronaut & Astronaut, Sch Instrument Sci & Optoelect Engn, Beijing 100083, Peoples R China.
RP Du, SS (reprint author), Univ Arizona, Coll Opt Sci, Tucson, AZ 85721 USA.
EM sdu@optics.arizona.edu
CR Abram RH, 2004, OPT EXPRESS, V12, P5434, DOI 10.1364/OPEX.12.005434
   GARDNER KS, 2007, THESIS U STRATHCLYDE, P40
   Garnache A, 2002, APPL PHYS LETT, V80, P3892, DOI 10.1063/1.1482143
   MORTON LG, 2006, C LAS EL CLEO
NR 4
TC 2
Z9 2
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0895-2477
EI 1098-2760
J9 MICROW OPT TECHN LET
JI Microw. Opt. Technol. Lett.
PD NOV
PY 2008
VL 50
IS 11
BP 2892
EP 2894
DI 10.1002/mop.23809
PG 3
WC Engineering, Electrical & Electronic; Optics
SC Engineering; Optics
GA 352ZB
UT WOS:000259534800044
DA 2018-12-27
ER

PT J
AU Han, BY
   Hua, PY
   Gu, XM
   Miller-Butterworth, CM
   Zhang, SY
AF Han, B. Y.
   Hua, P. Y.
   Gu, X. M.
   Miller-Butterworth, C. M.
   Zhang, S. Y.
TI RETRACTED: Isolation and characterization of microsatellite loci in the
   western long-fingered bat, Miniopterus magnater (Retracted article. See
   vol. 9, pg. 438, 2009)
SO MOLECULAR ECOLOGY RESOURCES
LA English
DT Article; Retracted Publication
DE genetic diversity; microsatellites; Miniopterus magnater
AB We isolated and characterized 10 microsatellite loci in the western long-fingered bat, Miniopterus magnater. These loci were tested on 48 individuals from Anhui Province of China, and all loci were highly polymorphic. The mean number of observed alleles per locus was 13.6 (range from six to 27). Observed and expected heterozygosity values ranged from 0.364 to 0.957, and from 0.676 to 0.951, respectively. After Bonferroni correction, four loci deviated significantly from Hardy-Weinberg equilibrium. No pairs of loci were in linkage disequilibrium. These polymorphic markers will be used to examine population structure and genetic diversity in this species.
C1 [Han, B. Y.; Hua, P. Y.; Zhang, S. Y.] E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China.
   [Han, B. Y.; Gu, X. M.] Guizhou Normal Univ, Sch Geog & Biol Sci, Guiyang 550001, Peoples R China.
   [Miller-Butterworth, C. M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
RP Zhang, SY (reprint author), E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China.
EM syzhang@bio.ecnu.edu.cn
FU East China Normal University
FX This study was supported by Zijiang scholarship of East China Normal
   University to S. Y. Zhang. We thank Dr Kailiang Hu, Guangjian Zhu and
   Feng Luo for assistance in the field survey.
CR Hua PY, 2007, MOL ECOL NOTES, V7, P486, DOI 10.1111/j.1471-8286.2006.01629.x
   KANDPAL RP, 1994, P NATL ACAD SCI USA, V91, P88, DOI 10.1073/pnas.91.1.88
   Karp A., 1998, MOL TOOLS SCREENING
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573
   Simmons N.B., 2005, MAMMAL SPECIES WORLD
   Van Oosterhout C, 2004, MOL ECOL NOTES, V4, P535, DOI 10.1111/j.1471-8286.2004.00684.x
   WORTHINGTONWILM.J, 1996, BAT RES NEWS, V37, P1
   Zhang Y. Z., 1999, ZOOGEOGRAPHY CHINA
NR 9
TC 3
Z9 3
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-098X
EI 1755-0998
J9 MOL ECOL RESOUR
JI Mol. Ecol. Resour.
PD NOV
PY 2008
VL 8
IS 6
BP 1445
EP 1447
DI 10.1111/j.1471-8286.2007.02008.x
PG 3
WC Biochemistry & Molecular Biology; Ecology; Evolutionary Biology
SC Biochemistry & Molecular Biology; Environmental Sciences & Ecology;
   Evolutionary Biology
GA 367BY
UT WOS:000260528700068
PM 21586071
DA 2018-12-27
ER

PT J
AU Gatta, R
   Mantovani, R
AF Gatta, Raffaella
   Mantovani, Roberto
TI RETRACTED: NF-Y substitutes H2A-H2B on active cell-cycle promoters:
   recruitment of CoREST-KDM1 and fine-tuning of H3 methylations (Retracted
   article. See vol. 41, pg. 9208, 2013)
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article; Retracted Publication
ID RNA-POLYMERASE-II; LSD1 HISTONE DEMETHYLASE; LOCUS-CONTROL REGION;
   TRANSCRIPTION-FACTOR; HUMAN GENOME; SACCHAROMYCES-CEREVISIAE;
   CRYSTAL-STRUCTURE; CHROMATIN REGULATION; DYNAMIC RECRUITMENT;
   GENE-EXPRESSION
AB The CCAAT box is a frequent promoter element, as illustrated by bioinformatic analysis, and it is bound by NF-Y, a trimer with H2A-H2B-like subunits. We developed a MNase I-based ChIP protocol on homogeneous cell populations to study cell-cycle promoters at the single nucleosome level. We analyzed histone methylations and the association of enzymatic activities. Two novel results emerged: (i) H3-H4 are present on core promoters under active conditions, with the expected cohort of 'positive' modifications; H2A-H2B are removed and substituted by NF-Y. Through the use of a dominant negative mutant we show that NF-Y is important for H3K36me3 deposition and for elongation, not recruitment of Pol II; (ii) H3K4 methylations are highly dynamic and H3K4me1 is a crucial positive mark. Functional siRNA inactivation and treatment with Tranylcypromine determined that KDM1 (LSD1) plays a positive role in transcription, specifically of G2/M genes. It requires CoREST, which is recruited on active promoters through direct interactions with NF-Y. These data are the first in vivo indication of a crucial interplay between core histones and 'deviant' histone-fold such as NF-Y, leading to fine-tuning of histone methylations.
C1 [Gatta, Raffaella; Mantovani, Roberto] Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy.
RP Mantovani, R (reprint author), Univ Milan, Dipartimento Sci Biomol & Biotecnol, Via Celoria 26, I-20133 Milan, Italy.
EM mantor@unimi.it
FU AIRC; PRIN-MIUR; CARIPLO-Nobel
FX AIRC, PRIN-MIUR and CARIPLO-Nobel grants ( to R. M.). Funding for open
   access charges: CARIPLO-NOBEL grants to R. M.
CR Adkins MW, 2007, MOL CELL BIOL, V27, P6372, DOI 10.1128/MCB.00981-07
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Benatti P, 2008, NUCLEIC ACIDS RES, V36, P1415, DOI 10.1093/nar/gkm1046
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Bhattacharya A, 2003, CANCER RES, V63, P8167
   Caretti G, 1999, MOL CELL BIOL, V19, P8591
   Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200
   Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023
   Ceribelli M, 2008, MOL CELL BIOL, V28, P2047, DOI 10.1128/MCB.01861-07
   Chau CM, 2008, J VIROL, V82, P3428, DOI 10.1128/JVI.01412-07
   Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003
   Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908
   Cosgrove MS, 2004, NAT STRUCT MOL BIOL, V11, P1037, DOI 10.1038/nsmb851
   Cowger JJM, 2007, ONCOGENE, V26, P3378, DOI 10.1038/sj.onc.1210126
   Donati G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002066
   Donati G, 2006, NUCLEIC ACIDS RES, V34, P3116, DOI 10.1093/nar/gkl304
   Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128
   Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203
   Ferrai C, 2007, J BIOL CHEM, V282, P12537, DOI 10.1074/jbc.M700867200
   Forneris F, 2008, TRENDS BIOCHEM SCI, V33, P181, DOI 10.1016/j.tibs.2008.01.003
   Gangloff YG, 2001, TRENDS BIOCHEM SCI, V26, P250, DOI 10.1016/S0968-0004(00)01741-2
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   Grskovic M, 2007, PLOS GENET, V3, P1524, DOI 10.1371/journal.pgen.0030145
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   Hakimi MA, 2003, J BIOL CHEM, V278, P7234, DOI 10.1074/jbc.M208992200
   Hartlepp KF, 2005, MOL CELL BIOL, V25, P9886, DOI 10.1128/MCB.25.22.9886-9896.2005
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Hu QH, 2006, NUCLEIC ACIDS RES, V34, P6272, DOI 10.1093/nar/gkl801
   Hyland EA, 2005, MOL CELL BIOL, V25, P10060, DOI 10.1128/MCB.25.22.10060-10070.2005
   Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005
   Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017
   Johnson KD, 2003, MOL CELL BIOL, V23, P6484, DOI 10.1128/MCB.23.18.6484-6493.2003
   Joshi AA, 2005, MOL CELL, V20, P971, DOI 10.1016/j.molcel.2005.11.021
   Kabe Y, 2005, MOL CELL BIOL, V25, P512, DOI 10.1128/MCB.25.1.512-522.2005
   Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2
   Keogh MC, 2005, CELL, V123, P593, DOI 10.1016/j.cell.2005.10.025
   Kim J, 2005, MOL CELL, V20, P759, DOI 10.1016/j.molcel.2005.11.012
   Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005
   Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013
   Koch CM, 2007, GENOME RES, V17, P691, DOI 10.1101/gr.5704207
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lee J, 2007, PLOS COMPUT BIOL, V3, P721, DOI 10.1371/journal.pcbi.0030067
   Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004
   Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Liu CL, 2005, PLOS BIOL, V3, P1753, DOI 10.1371/journal.pbio.0030328
   Luger K, 2003, CURR OPIN GENET DEV, V13, P127, DOI 10.1016/S0959-437X(03)00026-1
   Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6
   Masternak K, 2003, NAT IMMUNOL, V4, P132, DOI 10.1038/ni883
   Mavrich TN, 2008, NATURE, V453, P358, DOI 10.1038/nature06929
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Mimasu S, 2008, BIOCHEM BIOPH RES CO, V366, P15, DOI 10.1016/j.bbrc.2007.11.066
   Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015
   Ozsolak F, 2007, NAT BIOTECHNOL, V25, P244, DOI 10.1038/nbt1279
   Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674
   Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026
   Romier C, 2003, J BIOL CHEM, V278, P1336, DOI 10.1074/jbc.M209635200
   Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014
   Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039
   Salsi V, 2003, J BIOL CHEM, V278, P6642, DOI 10.1074/jbc.M210065200
   Schones DE, 2008, CELL, V132, P887, DOI 10.1016/j.cell.2008.02.022
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204
   Scibetta AG, 2007, MOL CELL BIOL, V27, P7220, DOI 10.1128/MCB.00274-07
   Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979
   Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550
   Suzuki Y, 2004, GENOME RES, V14, P1711, DOI 10.1101/gr.2435604
   TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331
   Tu SJ, 2008, NAT STRUCT MOL BIOL, V15, P419, DOI 10.1038/nsmb.1400
   Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671
   Werten S, 2002, J BIOL CHEM, V277, P45502, DOI 10.1074/jbc.M206587200
   Williams LR, 2007, SIGHT SOUND, V17, P93
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Yamagoe S, 2003, MOL CELL BIOL, V23, P1025, DOI 10.1128/MCB.23.3.1025-1033.2003
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Yang MJ, 2006, MOL CELL, V23, P377, DOI 10.1016/j.molcel.2006.07.012
   You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454
   Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178
   Zhu Z, 2005, GENOME RES, V15, P848, DOI 10.1101/gr.3394405
NR 83
TC 29
Z9 30
U1 3
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD NOV
PY 2008
VL 36
IS 20
BP 6592
EP 6607
DI 10.1093/nar/gkn699
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 373NA
UT WOS:000260977500032
PM 18940868
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Singh, U
   Jialal, I
AF Singh, Uma
   Jialal, Ishwarlal
TI RETRACTED: Alpha-lipoic acid supplementation and diabetes (Retracted
   article. See vol. 70, pg. 482, 2012)
SO NUTRITION REVIEWS
LA English
DT Review; Retracted Publication
DE diabetes; diabetic neuropathy; dosage; lipoic acid; oxidative stress
ID CONTROLLED-TRIAL ALADIN; THIOCTIC ACID; OXIDATIVE STRESS; ENDOTHELIAL
   DYSFUNCTION; VASCULAR-DISEASE; GLUCOSE-DISPOSAL; REDOX-REGULATION;
   GLYCEMIC CONTROL; ORAL TREATMENT; BLOOD-FLOW
AB Diabetes is a common metabolic disorder that is usually accompanied by increased production of reactive oxygen species or by impaired antioxidant defenses. Importantly, oxidative stress is particularly relevant to the risk of cardiovascular disease. Alpha-lipoic acid (LA), a naturally occurring dithiol compound, has long been known as an essential cofactor for mitochondrial bioenergetic enzymes. LA is a very important micronutrient with diverse pharmacologic and antioxidant properties. Pharmacologically, LA improves glycemic control and polyneuropathies associated with diabetes mellitus; it also effectively mitigates toxicities associated with heavy metal poisoning. As an antioxidant, LA directly terminates free radicals, chelates transition metal ions, increases cytosolic glutathione and vitamin C levels, and prevents toxicities associated with their loss. These diverse actions suggest that LA acts by multiple mechanisms both physiologically and pharmacologically. Its biosynthesis decreases as people age and is reduced in people with compromised health, thus suggesting a possible therapeutic role for LA in such cases. Reviewed here is the known efficacy of LA with particular reference to types 1 and 2 diabetes. Particular attention is paid to the potential benefits of LA with respect to glycemic control, improved insulin sensitivity, oxidative stress, and neuropathy in diabetic patients. It appears that the major benefit of LA supplementation is in patients with diabetic neuropathy. (C) 2008 International Life Sciences Institute
C1 [Singh, Uma; Jialal, Ishwarlal] Univ Calif Davis, Med Ctr, Dept Pathol & Lab Med, Lab Atherosclerosis & Metab Res, Sacramento, CA 95817 USA.
RP Jialal, I (reprint author), Univ Calif Davis, Med Ctr, Dept Pathol & Lab Med, Lab Atherosclerosis & Metab Res, 4635 2nd Ave,Room 3000,Res Bldg 1, Sacramento, CA 95817 USA.
EM ishwarlal.jialal@ucdmc.ucdavis.edu
FU NIH [K-24 AT 00596]
FX Funding: NIH Grant K-24 AT 00596 (I.J.).
CR Ametov AS, 2003, DIABETES CARE, V26, P770, DOI 10.2337/diacare.26.3.770
   Androne L, 2000, IN VIVO, V14, P327
   Bast A, 2003, BIOFACTORS, V17, P207, DOI 10.1002/biof.5520170120
   Bernkop-Schnurch A, 2004, DRUG DEV IND PHARM, V30, P35, DOI 10.1081/DDC-120027509
   Biewenga GP, 1997, GEN PHARMACOL, V29, P315, DOI 10.1016/S0306-3623(96)00474-0
   Borcea V, 1999, FREE RADICAL BIO MED, V26, P1495, DOI 10.1016/S0891-5849(99)00011-8
   BURKART V, 1993, AGENTS ACTIONS, V38, P60, DOI 10.1007/BF02027215
   Carreau J P, 1979, Methods Enzymol, V62, P152
   Coppey LJ, 2001, DIABETES, V50, P1927, DOI 10.2337/diabetes.50.8.1927
   Doraiswamy PM, 2004, LANCET NEUROL, V3, P431, DOI 10.1016/S1474-4422(04)00809-9
   Estrada DE, 1996, DIABETES, V45, P1798, DOI 10.2337/diabetes.45.12.1798
   Evans Joseph L, 2002, Endocr Pract, V8, P29
   FAUST A, 1994, INT J IMMUNOPHARMACO, V16, P61, DOI 10.1016/0192-0561(94)90119-8
   Forstermann U, 2008, NAT CLIN PRACT CARD, V5, P338, DOI 10.1038/ncpcardio1211
   Foster TS, 2007, DIABETES EDUCATOR, V33, P111, DOI 10.1177/0145721706297450
   Gleiter CH, 1996, EUR J CLIN PHARMACOL, V50, P513, DOI 10.1007/s002280050151
   Gokce N, 2003, J AM COLL CARDIOL, V41, P1769, DOI 10.1016/S0735-1097(03)00333-4
   Haak E, 2000, EXP CLIN ENDOCR DIAB, V108, P168, DOI 10.1055/s-2000-7739
   HAUGAARD N, 1970, BIOCHIM BIOPHYS ACTA, V222, P583, DOI 10.1016/0304-4165(70)90183-2
   Heitzer T, 2001, FREE RADICAL BIO MED, V31, P53, DOI 10.1016/S0891-5849(01)00551-2
   HENDLER S, 2001, PDR NUTR SUPPLEMENTS
   Hermann R, 1996, EUR J PHARM SCI, V4, P167, DOI 10.1016/0928-0987(95)00045-3
   Hermann R, 1998, EUR J PHARM SCI, V6, P27, DOI 10.1016/S0928-0987(97)00065-1
   Hofmann MA, 1998, DIABETES CARE, V21, P1310, DOI 10.2337/diacare.21.8.1310
   JACOB S, 1995, ARZNEIMITTEL-FORSCH, V45-2, P872
   Jacob S, 1999, BIOFACTORS, V10, P169, DOI 10.1002/biof.5520100212
   Jacob S, 1996, EXP CLIN ENDOCR DIAB, V104, P284, DOI 10.1055/s-0029-1211455
   Jin HY, 2007, DIABETIC MED, V24, P1034, DOI 10.1111/j.1464-5491.2007.02179.x
   Jones W, 2002, FREE RADICAL BIO MED, V33, P83, DOI 10.1016/S0891-5849(02)00862-6
   Kamenova Petya, 2006, Hormones (Athens), V5, P251
   Khanna S, 1999, AM J PHYSIOL-REG I, V276, pR1327, DOI 10.1152/ajpregu.1999.276.5.R1327
   Konrad D, 2005, ANTIOXID REDOX SIGN, V7, P1032, DOI 10.1089/ars.2005.7.1032
   Konrad T, 1999, DIABETES CARE, V22, P280, DOI 10.2337/diacare.22.2.280
   Kozlov AV, 1999, ARCH BIOCHEM BIOPHYS, V363, P148, DOI 10.1006/abbi.1998.1064
   Kramer K., 2001, Nutraceuticals in health and disease prevention, P129
   Marangon K, 1999, FREE RADICAL BIO MED, V27, P1114, DOI 10.1016/S0891-5849(99)00155-0
   Meijer JWG, 2008, CLIN NEUROPHYSIOL, V119, P1379, DOI 10.1016/j.clinph.2008.02.003
   Morcos M, 2001, DIABETES RES CLIN PR, V52, P175, DOI 10.1016/S0168-8227(01)00223-6
   PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R
   PICK U, 1995, BIOCHEM BIOPH RES CO, V206, P724, DOI 10.1006/bbrc.1995.1102
   Prasad PD, 1997, PLACENTA, V18, P527, DOI 10.1016/0143-4004(77)90006-6
   Reed LJ, 2001, J BIOL CHEM, V276, P38329, DOI 10.1074/jbc.R100026200
   Reljanovic M, 1999, FREE RADICAL RES, V31, P171, DOI 10.1080/10715769900300721
   Ross Stephanie Maxine, 2006, Holist Nurs Pract, V20, P305
   Ruhnau KJ, 1999, DIABETIC MED, V16, P1040, DOI 10.1046/j.1464-5491.1999.00190.x
   Schalkwijk CG, 2005, CLIN SCI, V109, P143, DOI 10.1042/CS20050025
   SINGH HPP, 1970, BIOCHEM BIOPH RES CO, V41, P555, DOI 10.1016/0006-291X(70)90048-3
   Smith AR, 2004, CURR MED CHEM, V11, P1135, DOI 10.2174/0929867043365387
   Sola S, 2005, CIRCULATION, V111, P343, DOI 10.1161/01.CIR.0000153272.48711.B9
   STEPHENS JW, 2008, ATHEROSCLEROSIS
   Suh JH, 2005, REDOX REP, V10, P52, DOI 10.1179/135100005X21624
   Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101
   Suh JH, 2004, REDOX REP, V9, P57, DOI 10.1179/135100004225003923
   Tang J, 2007, NEUROLOGIST, V13, P164, DOI 10.1097/01.nrl.0000263703.78318.2b
   Tankova Tsvetalina, 2004, Rom J Intern Med, V42, P457
   TEICHERT J, 1992, INT J CLIN PHARM TH, V30, P511
   Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635
   Yadav V, 2005, MULT SCLER J, V11, P159, DOI 10.1191/1352458505ms1143oa
   Yaworsky K, 2000, DIABETOLOGIA, V43, P294, DOI 10.1007/s001250050047
   Zempleni J, 1999, J NUTR BIOCHEM, V10, P128, DOI 10.1016/S0955-2863(98)00095-3
   Ziegler D, 1999, DIABETES CARE, V22, P1296, DOI 10.2337/diacare.22.8.1296
   Ziegler D, 2004, DIABETIC MED, V21, P114, DOI 10.1111/j.1464-5491.2004.01109.x
   Ziegler D, 1997, DIABETES CARE, V20, P369, DOI 10.2337/diacare.20.3.369
   ZIEGLER D, 1995, DIABETOLOGIA, V38, P1425, DOI 10.1007/BF00400603
   Ziegler D, 2006, DIABETES CARE, V29, P2365, DOI 10.2337/dc06-1216
   Ziegler Dan, 2004, Treat Endocrinol, V3, P173, DOI 10.2165/00024677-200403030-00005
NR 66
TC 115
Z9 117
U1 3
U2 18
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0029-6643
EI 1753-4887
J9 NUTR REV
JI Nutr. Rev.
PD NOV
PY 2008
VL 66
IS 11
BP 646
EP 657
DI 10.1111/j.1753-4887.2008.00118.x
PG 12
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 365YT
UT WOS:000260446700005
PM 19019027
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Meijer, J
   Ogink, J
   Roos, E
AF Meijer, J.
   Ogink, J.
   Roos, E.
TI RETRACTED: Effect of the chemokine receptor CXCR7 on proliferation of
   carcinoma cells in vitro and in vivo (Retracted article. See vol. 104,
   pg. 227, 2011)
SO BRITISH JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE tumour growth; chemokines; carcinoma; migration
ID BREAST-CANCER METASTASIS; COLORECTAL-CANCER; COLON-CARCINOMA;
   EXPRESSION; GROWTH; HIV-1; INACTIVATION; CORECEPTOR; ACTIVATION;
   INCREASES
AB The chemokine CXCL12/SDF-1 and its receptor CXCR4 have been implicated in invasion, survival and proliferation of carcinoma cells. Recently, CXCR7 was identified as a second receptor for CXCL12. We observed that CXCL12 promoted proliferation of CT26 colon and KEP1 mammary carcinoma cells, and this was blocked when CXCR7 was downregulated by 'intrakines' or RNAi, but not by CXCR4 inhibitors. The K1R mutant of CXCL12, which acts as a CXCR4 antagonist, also promoted proliferation through CXCR7 and is therefore a selective CXCR7 agonist. The effect of CXCR7 was not due to reduced apoptosis, and CXCR7 mediated chemotaxis of the carcinoma cells towards CXCL12. These results differ from those in a previous report on other carcinoma cells. We conclude that CXCL12 can be a potent growth factor for carcinoma cells by acting on CXCR7. Nevertheless, we observed no effect of complete and stable CXCR7 suppression on the growth of s.c. tumours or lung metastases of KEP1 and CT26 cells. A CXCR7 inhibitor has been reported to reduce growth of other tumours. Our results indicate that this inhibitor may not be applicable to therapy of all carcinomas.
C1 [Meijer, J.; Ogink, J.; Roos, E.] Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands.
RP Roos, E (reprint author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.
EM e.roos@nki.nl
FU Dutch Cancer Society [NKI 2003 - 2856]
FX We thank Tania Maidment for expert technical assistance with animal
   experiments, Dr O van Tellingen for help with the IVIS bioluminescence
   assay system, and Anita Pfauth and Frank van Diepen for FACS sorting. We
   are grateful to Dr IJ Fidler, Dr T Sauerbruch and Dr J Jonkers for
   providing cells. This research was supported by Dutch Cancer Society
   Grant NKI 2003 - 2856.
CR Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200
   Barbero S, 2003, CANCER RES, V63, P1969
   Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144
   Chen JD, 1997, NAT MED, V3, P1110, DOI 10.1038/nm1097-1110
   Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996
   Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013
   Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072
   Goldberg-Bittman L, 2004, IMMUNOL LETT, V92, P171, DOI 10.1016/j.imlet.2003.10.020
   Kaifi JT, 2005, J NATL CANCER I, V97, P1840, DOI 10.1093/jnci/dji431
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Katayama A, 2005, CLIN CANCER RES, V11, P2937, DOI 10.1158/1078-0432.CCR-04-1470
   Kim J, 2005, J CLIN ONCOL, V23, P2744, DOI 10.1200/JCO.2005.07.078
   Meijer J, 2008, CANCER RES, V68, P4701, DOI 10.1158/0008-5472.CAN-08-0482
   Meijer J, 2006, CANCER RES, V66, P9576, DOI 10.1158/0008-5472.CAN-06-1507
   Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104
   Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100
   Saur D, 2005, GASTROENTEROLOGY, V129, P1237, DOI 10.1053/j.gastro.2005.06.056
   Scala S, 2005, CLIN CANCER RES, V11, P1835, DOI 10.1158/1078-0432.CCR-04-1887
   Schimanski CC, 2005, CLIN CANCER RES, V11, P1743, DOI 10.1158/1078-0432.CCR-04-1195
   Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267
   Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650
   Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874
   Sutton A, 2007, MOL CANCER RES, V5, P21, DOI 10.1158/1541-7786/MCR-06-0103
   Tamamura H, 2001, BIOORG MED CHEM LETT, V11, P1897, DOI 10.1016/S0960-894X(01)00323-7
   Yang LH, 2007, CANCER RES, V67, P651, DOI 10.1158/0008-5472.CAN-06-2762
   Zeelenberg IS, 2003, CANCER RES, V63, P3833
   Zeelenberg IS, 2001, J CLIN INVEST, V108, P269, DOI 10.1172/JCI11330
NR 28
TC 50
Z9 63
U1 2
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD OCT 28
PY 2008
VL 99
IS 9
BP 1493
EP 1501
DI 10.1038/sj.bjc.6604727
PG 9
WC Oncology
SC Oncology
GA 366SE
UT WOS:000260502900018
PM 18854833
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Rusli, RH
AF Rusli, Ronnie Higuchi
TI RETRACTED: Role of hydrogen environment induced hydrogen embrittlement
   of Ti-8Al-1Mo-2V alloy (Retracted article. See vol. 556, pg. 985, 2012)
SO MATERIALS SCIENCE AND ENGINEERING A-STRUCTURAL MATERIALS PROPERTIES
   MICROSTRUCTURE AND PROCESSING
LA English
DT Article; Retracted Publication
DE Accoustic emission; Crack propagation; Embrittlement; Fractographic;
   Precracked; Widmanstatten structure
ID ALPHA-BETA TITANIUM; CRACK-GROWTH
AB Structural analysis by mean of metallographic, SEM fractographic and TEM replica technique including acoustics-emission studies have been carried out on Ti-8Al-1Mo-2V alloy specimen tested at room temperature in gaseous hydrogen environment. The result provided evidences of the presence of face centred cubic titanium hydride at the fracture surfaces, with discontinuous nature Of Crack Propagation. The present work confirmed that an essentially continuous path of P phase is necessary for the occurrence of slow crack growth in gaseous hydrogen. Metallographic and fractographic observation leave little doubt that cracks propagates along the alpha-beta interface rather than through stable a phase. (C) 2008 Elsevier B.V. All rights reserved.
C1 Univ Indonesia, Sch Grad Studies, Jakarta 10430, Indonesia.
RP Rusli, RH (reprint author), Univ Indonesia, Sch Grad Studies, Jl Salemba 4, Jakarta 10430, Indonesia.
EM ronnie_rusli@yahoo.com
CR BLACKBURN MJ, 1996, T ASM, V59, P876
   KOCH GH, 1996, INT REPORT STRESS CO
   MEYN DA, 1972, METALL TRANS, V3, P2302, DOI 10.1007/BF02643252
   NELSON HG, 1976, METALL TRANS A, V7, P621, DOI 10.1007/BF02646469
   NELSON HG, 1972, METALL TRANS, V3, P469
   PITTINATO GF, 1970, METALL TRANS, V1, P3241
   WALTER RJ, 1968, D8142 ASM
   WILLIAMS DP, 1973, MET T, V3, P2107
NR 8
TC 4
Z9 6
U1 3
U2 13
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0921-5093
EI 1873-4936
J9 MAT SCI ENG A-STRUCT
JI Mater. Sci. Eng. A-Struct. Mater. Prop. Microstruct. Process.
PD OCT 25
PY 2008
VL 494
IS 1-2
SI SI
BP 143
EP 146
DI 10.1016/j.msea.2008.04.006
PG 4
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Metallurgy & Metallurgical Engineering
SC Science & Technology - Other Topics; Materials Science; Metallurgy &
   Metallurgical Engineering
GA 359JU
UT WOS:000259983700021
DA 2018-12-27
ER

PT J
AU Dudley, JI
   Lekli, I
   Mukherjee, S
   Das, M
   Bertelli, AAA
   Das, DK
AF Dudley, Jocelyn I.
   Lekli, Istvan
   Mukherjee, Subfiendu
   Das, Manika
   Bertelli, Alberto A. A.
   Das, Dipak K.
TI RETRACTED: Does White Wine Qualify for French Paradox? Comparison of the
   Cardioprotective Effects of Red and White Wines and Their Constituents:
   Resveratrol, Tyrosol, and Hydroxytyrosol (Retracted article. See vol.
   60, pg. 2767, 2012)
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article; Retracted Publication
DE White wine; red wine; resveratrol; tyrosol; hydroxytyrosol;
   ischemia/reperfusion; peroxide formation; mitochondrial swelling
ID LOW-DENSITY-LIPOPROTEIN; OLIVE OIL; NITRIC-OXIDE; IN-VIVO;
   PLATELET-AGGREGATION; HEART-MITOCHONDRIA; BAX TRANSLOCATION;
   GENE-TRANSFER; COMPLEX-III; ISCHEMIA
AB It is generally believed that the French paradox is related to the consumption of red wine and not other varieties of wine, including white wine or champagne. Some recent studies have indicated that white wine could also be as cardioprotective as red wine. The present investigation compares the cardioprotective abilities of red wine, white wine, and their principal cardioprotective constituents. Different groups of rats were gavaged with red wine, white wine, resveratrol, tyrosol, and hydroxytyrosol. Red wine and its constituent resveratrol and white wine and its constituents tyrosol and hydroxytyrosol all showed different degrees of cardioprotection as evidenced by their abilities to improve postischemic ventricular performance, reduce myocardial infarct size and cardiomyocyte apoptosis, and reduce peroxide formation. It was discovered in this study that although each of the wines and their components increased the enzymatic activities of the mitochondrial complex (I-IV) and citrate synthase, which play very important roles in oxidative phosphorylation and ATP synthesis, some of the groups were more complex-specific in inducing the activity compared to the other groups. Cardioprotective ability was further confirmed by increased expression of phospho-Akt, Bcl-2, eNOS, NOS, COX-1, COX-2, Trx-1, Trx-2, and HO-1. The results of this study suggest that white wine can provide cardioprotection similar to red wine if it is rich in tyrosol and hydroxytyrosol.
C1 [Dudley, Jocelyn I.; Lekli, Istvan; Mukherjee, Subfiendu; Das, Manika; Das, Dipak K.] Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
   [Bertelli, Alberto A. A.] Univ Milan, Dept Human Anat, Milan, Italy.
RP Das, M (reprint author), Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
EM ddas@neuron.uchc.edu
FU NIH [HL 22559, HL 33889, HL 69910]
FX The study was supported in part by NIH HL 22559, HL 33889, and HL 69910.
CR AMBROSIO G, 1993, J BIOL CHEM, V268, P18532
   Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025
   Bertelli AAE, 2002, ANN NY ACAD SCI, V957, P295, DOI 10.1111/j.1749-6632.2002.tb02929.x
   Briet F, 2001, AM J CLIN NUTR, V73, P975
   Carluccio MA, 2003, ARTERIOSCL THROM VAS, V23, P622, DOI 10.1161/01.ATV.0000062884.69432.A0
   Chen YR, 2007, J BIOL CHEM, V282, P32640, DOI 10.1074/jbc.M702294200
   Clark J. B., 1997, NEUROCHEMISTRY PRACT, P151
   Covas MI, 2003, DRUG EXP CLIN RES, V29, P203
   Cui J, 2002, DRUG EXP CLIN RES, V28, P1
   Cui JH, 2002, ANN NY ACAD SCI, V957, P308, DOI 10.1111/j.1749-6632.2002.tb02931.x
   Das M, 2003, J PHYSIOL-LONDON, V547, P893, DOI 10.1113/jphysiol.2002.035006
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   DEMROW HS, 1995, CIRCULATION, V91, P1182, DOI 10.1161/01.CIR.91.4.1182
   Falchi M, 2006, J AGR FOOD CHEM, V54, P6613, DOI 10.1021/jf061048k
   Fauconneau B, 1997, LIFE SCI, V61, P2103, DOI 10.1016/S0024-3205(97)00883-7
   FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V
   Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5
   GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501
   Gustafsson AB, 2008, CARDIOVASC RES, V77, P334, DOI 10.1093/cvr/cvm005
   Gustafsson AB, 2007, AM J PHYSIOL-CELL PH, V292, pC45, DOI 10.1152/ajpcell.00229.2006
   Hall SS, 2003, SCIENCE, V301, P1165, DOI 10.1126/science.301.5637.1165
   Hattori R, 2002, AM J PHYSIOL-HEART C, V282, pH1988, DOI 10.1152/ajpheart.01012.2001
   Huang JH, 2005, CIRCULATION, V112, P76, DOI 10.1161/CIRCULATIONAHA.105.535740
   Imahashi K, 2004, CIRC RES, V95, P734, DOI 10.1161/01.RES.0000143898.67182.4c
   Javadov S, 2008, CARDIOVASC RES, V77, P416, DOI 10.1093/cvr/cvm039
   JEANDET P, 1995, AM J ENOL VITICULT, V46, P1
   Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004
   Matsui T, 2001, CIRCULATION, V104, P330
   Miao WF, 2000, J MOL CELL CARDIOL, V32, P2397, DOI 10.1006/jmcc.2000.1283
   Mukherjee S, 2008, J AGR FOOD CHEM, V56, P609, DOI 10.1021/jf0728146
   Naderali EK, 2000, CLIN SCI, V98, P537, DOI 10.1042/CS19990303
   PETRONI A, 1995, THROMB RES, V78, P151, DOI 10.1016/0049-3848(95)00043-7
   Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com
   Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200
   RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F
   RENAUD SC, 1992, AM J CLIN NUTR, V55, P1012
   Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7
   ROUSLIN W, 1986, AM J PHYSIOL, V250, pH503
   ROUSLIN W, 1983, AM J PHYSIOL, V244, pH743
   Sherwood S, 2006, BIOCHEM J, V400, P541, DOI 10.1042/BJ20060766
   SIEMANN EH, 1992, AM J ENOL VITICULT, V43, P49
   Thirunavukkarasu M, 2007, FREE RADICAL BIO MED, V43, P720, DOI 10.1016/j.freeradbiomed.2007.05.004
   Tong HY, 2000, CIRC RES, V87, P309, DOI 10.1161/01.RES.87.4.309
   Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200
   Vazquez-Agell M, 2007, J NUTR, V137, P2279
   VEENSTRA J, 1990, THROMB HAEMOSTASIS, V63, P345
   VISIOLI F, 1995, ATHEROSCLEROSIS, V117, P25, DOI 10.1016/0021-9150(95)05546-9
   Zhao X, 2005, CIRCULATION, V111, P2966, DOI 10.1161/CIRCULATIONAHA.104.527226
   Zhu LP, 2001, J MOL CELL CARDIOL, V33, P2135, DOI 10.1006/jmcc.2001.1476
NR 49
TC 68
Z9 72
U1 3
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD OCT 22
PY 2008
VL 56
IS 20
BP 9362
EP 9373
DI 10.1021/jf801791d
PG 12
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
SC Agriculture; Chemistry; Food Science & Technology
GA 361BM
UT WOS:000260102500007
PM 18821770
DA 2018-12-27
ER

PT J
AU Bibi, Z
AF Bibi, Zakia
TI RETRACTED: Role of cytochrome P450 in drug interactions (Retracted
   article. See vol. 11, 2014)
SO NUTRITION & METABOLISM
LA English
DT Review; Retracted Publication
ID HUMAN LIVER-MICROSOMES; DEBRISOQUINE SPARTEINE METABOLISM; SEROTONIN
   REUPTAKE INHIBITORS; ETHANOL OXIDIZING SYSTEM; PROTON-PUMP INHIBITORS;
   GENETIC-POLYMORPHISM; CLINICAL-SIGNIFICANCE; IN-VITRO; PHARMACOKINETIC
   INTERACTIONS; HUMAN HEPATOCYTES
AB Drug-drug interactions have become an important issue in health care. It is now realized that many drug-drug interactions can be explained by alterations in the metabolic enzymes that are present in the liver and other extra-hepatic tissues. Many of the major pharmacokinetic interactions between drugs are due to hepatic cytochrome P450 (P450 or CYP) enzymes being affected by previous administration of other drugs. After coadministration, some drugs act as potent enzyme inducers, whereas others are inhibitors. However, reports of enzyme inhibition are very much more common. Understanding these mechanisms of enzyme inhibition or induction is extremely important in order to give appropriate multiple-drug therapies. In future, it may help to identify individuals at greatest risk of drug interactions and adverse events.
C1 Univ Karachi, Dept Chem, Karachi 75270, Pakistan.
RP Bibi, Z (reprint author), Univ Karachi, Dept Chem, Karachi 75270, Pakistan.
EM araynezs@gmail.com
CR Albengres E, 1998, DRUG SAFETY, V18, P83, DOI 10.2165/00002018-199818020-00001
   Ameer B, 1997, CLIN PHARMACOKINET, V33, P103, DOI 10.2165/00003088-199733020-00003
   ANDERSSON T, 1990, CLIN PHARMACOL THER, V47, P79, DOI 10.1038/clpt.1990.12
   ANDERSSON T, 1991, CLIN PHARMACOKINET, V21, P195, DOI 10.2165/00003088-199121030-00004
   Andersson T, 1996, CLIN PHARMACOKINET, V31, P9, DOI 10.2165/00003088-199631010-00002
   AOYAMA T, 1989, J BIOL CHEM, V264, P10388
   Arayne M Saeed, 2005, Pak J Pharm Sci, V18, P45
   Asai H, 1996, J PHARMACOL EXP THER, V277, P1004
   BACK DJ, 1990, CLIN PHARMACOKINET, V18, P472, DOI 10.2165/00003088-199018060-00004
   Backman JT, 1996, EPILEPSIA, V37, P253, DOI 10.1111/j.1528-1157.1996.tb00021.x
   BAILEY DG, 1989, CLIN INVEST MED, V12, P357
   BAILEY DG, 1993, CLIN PHARMACOL THER, V53, P637, DOI 10.1038/clpt.1993.84
   Baker GB, 1998, NEUROSCI BIOBEHAV R, V22, P325, DOI 10.1016/S0149-7634(97)00018-3
   BERTILSSON L, 1992, CLIN PHARMACOL THER, V51, P388, DOI 10.1038/clpt.1992.38
   BIBI Z, 2008, THESIS KARACHI U
   Borcherding SM, 1996, J FAM PRACTICE, V42, P69
   BRECKENRIDGE A, 1992, BRIT J DERMATOLO S39, V19, P22
   BRIAN WR, 1990, BIOCHEMISTRY-US, V29, P11280, DOI 10.1021/bi00503a018
   BROSEN K, 1989, EUR J CLIN PHARMACOL, V36, P537, DOI 10.1007/BF00637732
   BROSEN K, 1995, CLIN PHARMACOKINET S, V20, P25
   BURGER DM, 1993, ANTIMICROB AGENTS CH, V37, P1426, DOI 10.1128/AAC.37.7.1426
   Campana C, 1996, CLIN PHARMACOKINET, V30, P141, DOI 10.2165/00003088-199630020-00004
   Ciummo P E, 1995, Am Pharm, VNS35, P41
   COMBALBERT J, 1989, DRUG METAB DISPOS, V17, P197
   Cropp JS, 1997, PHARMACOTHERAPY, V17, P917
   Cupp MJ, 1998, AM FAM PHYSICIAN, V57, P107
   Dal Negro R, 1998, CLIN PHARMACOKINET, V35, P135, DOI 10.2165/00003088-199835020-00003
   DESGRANGES C, 1986, CANCER RES, V46, P1094
   DEVANE CL, 1994, J CLIN PSYCHIAT, V55, P38
   DOSSING M, 1983, EUR J CLIN PHARMACOL, V25, P215, DOI 10.1007/BF00543794
   EICHELBAUM M, 1990, PHARMACOL THERAPEUT, V46, P377, DOI 10.1016/0163-7258(90)90025-W
   EICHELBAUM M, 1979, EUR J CLIN PHARMACOL, V16, P183, DOI 10.1007/BF00562059
   Ereshefsky L, 1996, J CLIN PSYCHIAT, V57, P17
   Ereshefsky L, 1996, J CLIN PSYCHIAT, V57, P12
   Ereshefsky L, 1995, Clin Pharmacokinet, V29 Suppl 1, P10
   ERESHEFSKY L, 1995, CLIN PHARM S1, V29, P18
   FINLEY PR, 1994, ANN PHARMACOTHER, V28, P1359, DOI 10.1177/106002809402801207
   Fleishaker JC, 1996, EUR J CLIN PHARMACOL, V50, P139, DOI 10.1007/s002280050082
   Flockhart D A, 1995, Clin Pharmacokinet, V29 Suppl 1, P45
   Fraser AG, 1997, CLIN PHARMACOKINET, V33, P79, DOI 10.2165/00003088-199733020-00001
   Fromm MF, 1997, PAIN, V72, P261, DOI 10.1016/S0304-3959(97)00044-4
   Fromm MF, 1996, HEPATOLOGY, V24, P796
   GAN LSL, 1984, BIOCHEMISTRY-US, V23, P3827, DOI 10.1021/bi00312a006
   GILLAM EMJ, 1995, ARCH BIOCHEM BIOPHYS, V317, P374, DOI 10.1006/abbi.1995.1177
   GILLUM JG, 1993, CLIN PHARMACOKINET, V25, P450, DOI 10.2165/00003088-199325060-00005
   GODIN JRP, 1986, DRUG INTEL CLIN PHAR, V20, P504, DOI 10.1177/106002808602000617
   GONZALEZ FJ, 1991, CLIN PHARMACOL THER, V50, P233, DOI 10.1038/clpt.1991.131
   GRANGE JM, 1994, DRUG SAFETY, V11, P242, DOI 10.2165/00002018-199411040-00003
   GUENGERICH FP, 1991, J MED CHEM, V34, P1838, DOI 10.1021/jm00110a012
   Guengerich FP, 1996, CRIT REV TOXICOL, V26, P551, DOI 10.3109/10408449609037477
   GUENGERICH FP, 1992, FASEB J, V6, P745
   GUENGERICH FP, 1990, CHEM RES TOXICOL, V3, P363, DOI 10.1021/tx00016a015
   GUENGERICH FP, 1997, ADV PHARMACOL, V4, P37
   GUGLER R, 1985, GASTROENTEROLOGY, V89, P1235, DOI 10.1016/0016-5085(85)90638-9
   Gurevitz S L, 1997, J Dent Hyg, V71, P159
   Harder S, 1996, CLIN PHARMACOKINET, V30, P416, DOI 10.2165/00003088-199630060-00002
   Holtbecker N, 1996, DRUG METAB DISPOS, V24, P1121
   HONIG PK, 1992, CLIN PHARMACOL THER, V52, P231, DOI 10.1038/clpt.1992.135
   HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513
   HUKKINEN SK, 1995, CLIN PHARMACOL THER, V58, P127, DOI 10.1016/0009-9236(95)90188-4
   HUMPHRIES TJ, 1991, DIGEST DIS SCI, V36, P1665, DOI 10.1007/BF01296606
   HUNT SN, 1976, CLIN PHARMACOL THER, V19, P546
   Jones TE, 1996, BRIT J CLIN PHARMACO, V42, P642, DOI 10.1111/j.1365-2125.1996.tb00062.x
   Jones TE, 1997, BRIT J CLIN PHARMACO, V44, P499, DOI 10.1046/j.1365-2125.1997.t01-1-00616.x
   Jou MJ, 1997, J PHARM PHARMACOL, V49, P1072, DOI 10.1111/j.2042-7158.1997.tb06044.x
   JUSKO WJ, 1978, J PHARMACOKINETICS B, V40, P67
   KETTER TA, 1995, J CLIN PSYCHOPHARM, V15, P387, DOI 10.1097/00004714-199512000-00002
   KIM RB, 1994, PHARMACOGENETICS, V4, P162
   Kitson KE, 1996, ALCOHOL CLIN EXP RES, V20, pA82, DOI 10.1111/j.1530-0277.1996.tb01752.x
   Kivisto KT, 1995, BRIT J CLIN PHARMACO, V40, P523, DOI 10.1111/j.1365-2125.1995.tb05796.x
   KIVISTO KT, 1994, CLIN PHARMACOKINET, V27, P1, DOI 10.2165/00003088-199427010-00001
   KNODELL RG, 1991, GASTROENTEROLOGY, V101, P1680, DOI 10.1016/0016-5085(91)90408-D
   KOSELJ M, 1994, TRANSPLANT P, V26, P2823
   KRONBACH T, 1988, CLIN PHARMACOL THER, V43, P630, DOI 10.1038/clpt.1988.87
   LEE KH, 1993, EUROPEAN J CLIN PHAR, V93, P45287
   LENNARD MS, 1990, PHARMACOL TOXICOL, V67, P273, DOI 10.1111/j.1600-0773.1990.tb00830.x
   LEVY RH, 1995, EPILEPSIA, V36, pS8, DOI 10.1111/j.1528-1157.1995.tb06007.x
   Li AP, 1997, CHEM-BIOL INTERACT, V107, P17, DOI 10.1016/S0009-2797(97)00071-9
   Lieber C S, 1994, Alcohol Alcohol Suppl, V2, P315
   LIEBER CS, 1994, J TOXICOL-CLIN TOXIC, V32, P631, DOI 10.3109/15563659409017974
   LIEBER CS, 1987, ANN NY ACAD SCI, V492, P11, DOI 10.1111/j.1749-6632.1987.tb48649.x
   LING KHJ, 1995, DRUG METAB DISPOS, V23, P631
   LOWN KS, 1995, CLIN PHARMACOL THER, V57, P16, DOI 10.1016/0009-9236(95)90261-9
   LUCEY MR, 1990, LANCET, V335, P11, DOI 10.1016/0140-6736(90)90137-T
   MAHGOUB A, 1977, LANCET, V2, P584, DOI 10.1016/S0140-6736(77)91430-1
   MARKOWITZ JS, 1995, ANN PHARMACOTHER, V29, P603, DOI 10.1177/106002809502900610
   MATTILA MJ, 1990, ANN MED, V22, P363, DOI 10.3109/07853899009147921
   MAURER PM, 1993, DRUG SAFETY, V8, P30, DOI 10.2165/00002018-199308010-00005
   MAURICE M, 1992, FASEB J, V6, P752
   McLeod HL, 1998, BRIT J CLIN PHARMACO, V45, P539, DOI 10.1046/j.1365-2125.1998.00719.x
   MEYER UA, 1990, PHARMACOL THERAPEUT, V46, P297, DOI 10.1016/0163-7258(90)90096-K
   Meyer UA, 1996, EUR J GASTROEN HEPAT, V8, pS21, DOI 10.1097/00042737-199610001-00005
   Michalets EL, 1998, PHARMACOTHERAPY, V18, P84
   Mignat C, 1997, DRUG SAFETY, V16, P267, DOI 10.2165/00002018-199716040-00004
   Miners JO, 1998, BRIT J CLIN PHARMACO, V45, P525, DOI 10.1046/j.1365-2125.1998.00721.x
   Mitchell PB, 1997, DRUG SAFETY, V17, P390, DOI 10.2165/00002018-199717060-00005
   MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788
   MOREL F, 1990, EUR J BIOCHEM, V191, P437, DOI 10.1111/j.1432-1033.1990.tb19140.x
   Mota CR, 1996, EUR J PEDIATR, V155, P345
   MURPHY R, 1990, ANN INTERN MED, V113, P799, DOI 10.7326/0003-4819-113-10-799
   Murray M, 1997, CLIN EXP PHARMACOL P, V24, P465, DOI 10.1111/j.1440-1681.1997.tb01228.x
   Nahata M, 1996, J ANTIMICROB CHEMOTH, V37, P133, DOI 10.1093/jac/37.suppl_C.133
   NAKAMURA K, 1985, CLIN PHARMACOL THER, V38, P402, DOI 10.1038/clpt.1985.194
   NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1
   NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1
   Nemeroff CB, 1996, AM J PSYCHIAT, V153, P311
   Okuda H, 1997, DRUG METAB DISPOS, V25, P270
   ORTIZDEMONTELLANO PR, 1979, P NATL ACAD SCI USA, V76, P746
   Paterson DL, 1997, CLIN INFECT DIS, V25, P1430, DOI 10.1086/516138
   PELKONEN O, 1986, BRIT J CLIN PHARMACO, V22, P125, DOI 10.1111/j.1365-2125.1986.tb05239.x
   PERITI P, 1992, CLIN PHARMACOKINET, V23, P106, DOI 10.2165/00003088-199223020-00004
   PERROT N, 1989, EUR J CLIN INVEST, V19, P549, DOI 10.1111/j.1365-2362.1989.tb00273.x
   POHJOLASINTONEN S, 1993, EUR J CLIN PHARMACOL, V45, P191, DOI 10.1007/BF00315505
   PRESKORN SH, 1994, J CLIN PSYCHOPHARM, V14, P90
   Rambeck B, 1996, CLIN PHARMACOKINET, V31, P309, DOI 10.2165/00003088-199631040-00006
   RODRIGUES AD, 1995, DRUG METAB DISPOS, V23, P765
   SCHEIN JR, 1995, ANN PHARMACOTHER, V29, P1139, DOI 10.1177/106002809502901113
   SESARDIC D, 1988, BRIT J CLIN PHARMACO, V26, P363, DOI 10.1111/j.1365-2125.1988.tb03393.x
   SHEN WW, 1995, INT J PSYCHIAT MED, V25, P277, DOI 10.2190/29NP-2XPN-X0ME-MQWU
   SLAUGHTER RL, 1995, ANN PHARMACOTHER, V29, P619, DOI 10.1177/106002809502900612
   SOMOGYI A, 1987, CLIN PHARMACOKINET, V12, P321, DOI 10.2165/00003088-198712050-00002
   SOMOGYI A, 1982, CLIN PHARMACOKINET, V7, P23, DOI 10.2165/00003088-198207010-00002
   Song BJ, 1996, ALCOHOL CLIN EXP RES, V20, pA138, DOI 10.1111/j.1530-0277.1996.tb01764.x
   Sproule BA, 1997, CLIN PHARMACOKINET, V33, P454, DOI 10.2165/00003088-199733060-00004
   STAFSTROM CE, 1995, ARCH PEDIAT ADOL MED, V149, P99, DOI 10.1001/archpedi.1995.02170130101025
   Taburet AM, 1996, CLIN PHARMACOKINET, V30, P385, DOI 10.2165/00003088-199630050-00005
   TANAKA E, 1988, BRIT J CLIN PHARMACO, V26, P96, DOI 10.1111/j.1365-2125.1988.tb03370.x
   Unge P, 1997, DRUG SAFETY, V16, P171, DOI 10.2165/00002018-199716030-00003
   VANDEN BOSSCHE H, 1995, PHARMACOL THERAPEUT, V67, P79
   VENKATESAN K, 1992, CLIN PHARMACOKINET, V22, P47, DOI 10.2165/00003088-199222010-00005
   Virani A, 1997, PAIN, V73, P3, DOI 10.1016/S0304-3959(97)00041-9
   von Moltke L L, 1995, Clin Pharmacokinet, V29 Suppl 1, P33
   von Moltke L.L., 1995, CLIN PHARMACOKINET, V29, P43
   vonMoltke LL, 1998, BIOCHEM PHARMACOL, V55, P113, DOI 10.1016/S0006-2952(97)00239-6
   VONROSENSTIEL NA, 1995, DRUG SAFETY, V13, P105, DOI 10.2165/00002018-199513020-00005
   WAGNER F, 1987, BRIT J CLIN PHARMACO, V24, P213, DOI 10.1111/j.1365-2125.1987.tb03164.x
   WALUBO A, 1995, S AFR MED J, V85, P1175
   Watkins VS, 1997, ANN PHARMACOTHER, V31, P349, DOI 10.1177/106002809703100314
   WILKINSON GR, 1989, PHARMACOL THERAPEUT, V43, P53, DOI 10.1016/0163-7258(89)90047-8
   WRIGHTON SA, 1993, ARCH BIOCHEM BIOPHYS, V306, P240, DOI 10.1006/abbi.1993.1506
   Yeates RA, 1997, INT J CLIN PHARM TH, V35, P577
   YUN CH, 1993, DRUG METAB DISPOS, V21, P403
   Zimmermann T, 1996, ARZNEIMITTEL-FORSCH, V46, P213
   Zomorodi K, 1996, BRIT J CLIN PHARMACO, V42, P157, DOI 10.1046/j.1365-2125.1996.03563.x
   ZOMORODI K, 1995, PHARMACEUT RES, V12, P1642, DOI 10.1023/A:1016241000480
NR 146
TC 55
Z9 62
U1 3
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1743-7075
J9 NUTR METAB
JI Nutr. Metab.
PD OCT 18
PY 2008
VL 5
AR 27
DI 10.1186/1743-7075-5-27
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 372AA
UT WOS:000260872600001
PM 18928560
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ahimastos, AA
   Dart, AM
   Kingwell, BA
AF Ahimastos, Anna A.
   Dart, Anthony M.
   Kingwell, Bronwyn A.
TI RETRACTED: Angiotensin II blockade in Marfan's syndrome (Retracted
   article. See vol. 373, pg. 2280, 2015)
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter; Retracted Publication
ID ANEURYSM
C1 [Ahimastos, Anna A.; Dart, Anthony M.; Kingwell, Bronwyn A.] Baker IDI Heart & Diabet Inst, Melbourne, Vic 3004, Australia.
RP Ahimastos, AA (reprint author), Baker IDI Heart & Diabet Inst, Melbourne, Vic 3004, Australia.
RI Dart, Anthony/E-7461-2010
OI Dart, Anthony/0000-0003-1360-3778
CR Ahimastos AA, 2007, JAMA-J AM MED ASSOC, V298, P1539, DOI 10.1001/jama.298.13.1539
   Brooke BS, 2008, NEW ENGL J MED, V358, P2787, DOI 10.1056/NEJMoa0706585
   Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287
   Loeys BL, 2006, NEW ENGL J MED, V355, P788, DOI 10.1056/NEJMoa055695
   Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116
NR 5
TC 10
Z9 10
U1 7
U2 9
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 16
PY 2008
VL 359
IS 16
BP 1732
EP 1732
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 360EY
UT WOS:000260041400017
PM 18927953
DA 2018-12-27
ER

PT J
AU Garedew, A
   Moncada, S
AF Garedew, Assegid
   Moncada, Salvador
TI RETRACTED: Mitochondrial dysfunction and HIF1 alpha stabilization in
   inflammation (Retracted article. See vol. 125, pg. 3254, 2012)
SO JOURNAL OF CELL SCIENCE
LA English
DT Article; Retracted Publication
DE Nitric oxide; Mitochondria; HIF1 alpha; Inflammation; Glycolysis;
   Oxidative phosphorylation
ID HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; NITRIC-OXIDE; OXYGEN-CONSUMPTION;
   OXIDATIVE STRESS; SKELETAL-MUSCLE; COMPLEX-I; NEURODEGENERATIVE
   DISEASES; RESPIRATORY INHIBITION; PERSISTENT INHIBITION; PROTON
   CONDUCTANCE
AB Activation of murine-derived J774.A1 macrophages with interferon. and lipopolysaccharide leads to a progressive mitochondrial defect characterized by inhibition of oxygen consumption and a decrease in the generation of ATP by oxidative phosphorylation. These changes are dependent on the generation of nitric oxide (NO) by an inducible NO synthase that becomes a significant consumer of oxygen. Furthermore, in these activated cells there is a biphasic stabilization of the hypoxia-inducible factor HIF1 alpha, the second phase of which is also dependent on the presence of NO. The mitochondrial defect and stabilization of HIF1 alpha synergize to activate glycolysis, which, at its maximum, generates quantities of ATP greater than those produced by non-activated cells. Nevertheless, the amount of ATP generated is not sufficient to fulfil the energy requirements of the activated cells, probably leading to a progressive energy deficit with the consequent inhibition of cell proliferation and death.
C1 [Garedew, Assegid; Moncada, Salvador] UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England.
RP Moncada, S (reprint author), UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England.
EM s.moncada@ucl.ac.uk
CR Almeida A, 2001, P NATL ACAD SCI USA, V98, P15294, DOI 10.1073/pnas.261560998
   Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602
   Beltran B, 2000, BRIT J PHARMACOL, V129, P953, DOI 10.1038/sj.bjp.0703147
   BERGMEYER HU, 1974, ENZYMATIC ASSAY L LA
   Boushel R, 2007, DIABETOLOGIA, V50, P790, DOI 10.1007/s00125-007-0594-3
   Brand MD, 2005, BIOCHEM J, V392, P353, DOI 10.1042/BJ20050890
   Brand MD, 2005, BIOCHEM SOC T, V33, P897, DOI 10.1042/BST0330897
   Brealey D, 2002, LANCET, V360, P219, DOI 10.1016/S0140-6736(02)09459-X
   BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3
   Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200
   CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2
   Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631
   Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5
   EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083
   Escames G, 2007, FEBS J, V274, P2135, DOI 10.1111/j.1742-4658.2007.05755.x
   Frost MT, 2005, AM J PHYSIOL-REG I, V288, pR394, DOI 10.1152/ajpregu.00504.2004
   Hollis VS, 2003, BBA-BIOENERGETICS, V1607, P191, DOI 10.1016/j.bbabio.2003.09.012
   Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172
   Jung F, 2000, CIRC RES, V86, P319, DOI 10.1161/01.RES.86.3.319
   Kasuno K, 2004, J BIOL CHEM, V279, P2550, DOI 10.1074/jbc.M308197200
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   LEONE AM, 1991, J BIOL CHEM, V266, P23790
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Mateo J, 2003, BIOCHEM J, V376, P537, DOI 10.1042/BJ20031155
   Mogensen M, 2007, DIABETES, V56, P1592, DOI 10.2337/db06-0981
   Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762
   Nicolson GL, 2007, J CELL BIOCHEM, V100, P1352, DOI 10.1002/jcb.21247
   Orsi A, 2000, BIOCHEM J, V346, P407, DOI 10.1042/0264-6021:3460407
   ORSI A, 2000, BIOL NITRIC OXIDE 7
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012
   Parker N, 2008, BIOCHEM J, V412, P131, DOI 10.1042/BJ20080006
   Peyssonnaux C, 2005, J CLIN INVEST, V115, P1806, DOI 10.1172/JCI123865
   Protti A, 2007, CRIT CARE MED, V35, P2150, DOI 10.1097/01.ccm.0000281448.00095.4d
   Quintero M, 2006, CANCER RES, V66, P770, DOI 10.1158/0008-5472.CAN-05-0333
   Rees DD, 1998, BRIT J PHARMACOL, V124, P540, DOI 10.1038/sj.bjp.0701815
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441
   SEMENIUK C, 2007, WETLANDS ECOL CONSER, V1, P1
   SEMENZA GL, 1994, J BIOL CHEM, V269, P23757
   STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543
   TSUKAHARA H, 1994, KIDNEY INT, V45, P598, DOI 10.1038/ki.1994.78
   Whitton PS, 2007, BRIT J PHARMACOL, V150, P963, DOI 10.1038/sj.bjp.0707167
   Yadava N, 2007, J NEUROSCI, V27, P7310, DOI 10.1523/JNEUROSCI.0212-07.2007
NR 43
TC 21
Z9 23
U1 2
U2 11
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD OCT 15
PY 2008
VL 121
IS 20
BP 3468
EP 3475
DI 10.1242/jcs.034660
PG 8
WC Cell Biology
SC Cell Biology
GA 358JD
UT WOS:000259912100019
PM 18827009
OA Other Gold
DA 2018-12-27
ER

PT J
AU Litovchick, A
   Szostak, JW
AF Litovchick, Alexander
   Szostak, Jack W.
TI RETRACTED: Selection of cyclic peptide aptamers to HCV IRES RNA using
   mRNA display (Retracted article. See vol. 106, pg. 7263, 2009)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE hepatitis C internal ribosomal entry site; RNA binding; translation
   initiation; viral mRNA translation
ID HEPATITIS-C VIRUS; RIBOSOME-ENTRY SITE; TRANSLATION INITIATION; MEDIATED
   TRANSLATION; PROTEIN; RECOGNITION; PERSISTENCE; INHIBITORS; MOLECULES;
   LIBRARIES
AB The hepatitis C virus (HCV) is a positive strand RNA flavivirus that is a major causative agent of serious liver disease, making new treatment modalities an urgent priority. Because HCV translation initiation occurs by a mechanism that is fundamentally distinct from that of host mRNAs, it is an attractive target for drug discovery. The translation of HCV mRNA is initiated from an internal ribosomal entry site (IRES), independent of cap and poly(A) recognition and bypassing eIF4F complex formation. We used mRNA display selection technology combined with a simple and robust cyclization procedure to screen a peptide library of >10(13) different sequences and isolate cyclic peptides that bind with high affinity and specificity to HCV IRES RNA. The best peptide binds the IRES with subnanomolar affinity, and a specificity of at least 100-fold relative to binding to several other RNAs of similar length. The peptide specifically inhibits HCV IRES-initiated translation in vitro with no detectable effect on normal cap-dependent translation initiation. An 8-aa cyclic peptide retains most of the activity of the full-length 27-aa bicyclic peptide. These peptides may be useful tools for the study of HCV translation and may have potential for further development as an anti-HCV drug.
C1 [Szostak, Jack W.] Massachusetts Gen Hosp, Howard Hughes Med Inst, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Dept Mol Biol, Simches Res Ctr, Boston, MA 02114 USA.
RP Szostak, JW (reprint author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Ctr Computat & Integrat Biol, 185 Cambridge St, Boston, MA 02114 USA.
EM szostak@molbio.mgh.harvard.edu
FU Howard Hughes Medical Institute
CR Athanassiou Z, 2007, BIOCHEMISTRY-US, V46, P741, DOI 10.1021/bi0619371
   Barrick JE, 2001, P NATL ACAD SCI USA, V98, P12374, DOI 10.1073/pnas.221467798
   BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155
   Dash S, 2005, LIVER INT, V25, P580, DOI 10.1111/j.1478-3231.2005.01082.x
   Davis JH, 2002, P NATL ACAD SCI USA, V99, P11616, DOI 10.1073/pnas.182095699
   Fraser CS, 2007, NAT REV MICROBIOL, V5, P29, DOI 10.1038/nrmicro1558
   Gallego J, 2002, BIOCHEM SOC T, V30, P140, DOI 10.1042/BST0300140
   Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101
   Hughes CA, 2006, ANN PHARMACOTHER, V40, P74, DOI 10.1345/aph.1G263
   Jefferson EA, 2004, BIOORG MED CHEM LETT, V14, P5139, DOI 10.1016/j.bmcl.2004.07.066
   KIM JJ, 2007, Patent No. 20070259844
   Leeper TC, 2005, BIOCHEMISTRY-US, V44, P12362, DOI 10.1021/bi0510532
   Litovchick A, 2003, RNA, V9, P937, DOI 10.1261/rna.2172103
   Liu RH, 2000, METHOD ENZYMOL, V318, P268
   Manns MP, 2007, NAT REV DRUG DISCOV, V6, P991, DOI 10.1038/nrd2411
   Martinez-Salas E, 2008, J GEN VIROL, V89, P611, DOI 10.1099/vir.0.83426-0
   Otto GA, 2004, CELL, V119, P369, DOI 10.1016/j.cell.2004.09.038
   Pavio N, 2003, J BIOSCIENCES, V28, P287, DOI 10.1007/BF02970148
   Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67
   Radkowski M, 2005, HEPATOLOGY, V41, P106, DOI 10.1002/hep.20518
   Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297
   ROGERS GA, 1976, J BIOL CHEM, V251, P5711
   Scott JD, 2007, JAMA-J AM MED ASSOC, V297, P724, DOI 10.1001/jama.297.7.724
   Seebeck FP, 2006, J AM CHEM SOC, V128, P7150, DOI 10.1021/ja060966w
   Seth PP, 2005, J MED CHEM, V48, P7099, DOI 10.1021/jm050815o
   Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802
   Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0
   Spahn CMT, 2001, SCIENCE, V291, P1959, DOI 10.1126/science.1058409
   Timmerman P, 2005, CHEMBIOCHEM, V6, P821, DOI 10.1002/cbic.200400374
   *VGX PHARM INC, 2005, RAND OP LAB PHAS 2 T
   Wohnsland A, 2007, CLIN MICROBIOL REV, V20, P23, DOI 10.1128/CMR.00010-06
NR 31
TC 7
Z9 7
U1 2
U2 14
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 7
PY 2008
VL 105
IS 40
BP 15293
EP 15298
DI 10.1073/pnas.0805837105
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 364UI
UT WOS:000260360500017
PM 18824687
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Shi, RX
   Yin, YS
   Li, J
   Wang, DZ
AF Shi Rui-Xia
   Yin Yan-Sheng
   Li Jia
   Wang Dong-Zhi
TI RETRACTED: Influence of cobalt phase on thermal shock resistance of
   Al2O3-TiC composites evaluated by indentation technique (Retracted
   article. See vol. 61, pg. 560, 2015)
SO MATERIALS RESEARCH BULLETIN
LA English
DT Article; Retracted Publication
DE composites; ceramics; mechanical properties; microstructure
ID GRAIN-SIZE; BEHAVIOR; NANOCOMPOSITES
AB Cobalt-coated Al2O3 and TiC powders were prepared using an electroless method to improve resistance to thermal shock. The mixture of cobalt-coated Al2O3 and TiC powders (about 70 wt.% Al2O3-Co + 30 wt.% TiC-Co) was hot-pressed into an Al2O3-TiC-Co composite. The thermal shock properties of the composite were evaluated by indentation technique and compared with the traditional Al2O3-TiC composite. The composites containing 3.96 vol.% cobalt exhibited better resistance to crack propagation, cyclic thermal shock and higher critical temperature difference (Delta T-c). The calculation of thermal shock resistance parameters (R parameters) shows that the incorporation of cobalt improves the resistance to thermal shock fracture and thermal shock damage. The thermal physic parameters are changed very little but the flexure strength and fracture toughness of the composites are improved greatly by introducing cobalt into Al2O3-TiC (AT) composites. The better thermal shock resistance of the composites should be attributed to the higher flexure strength and fracture toughness. (C) 2007 Elsevier Ltd. All rights reserved.
C1 [Shi Rui-Xia; Li Jia; Wang Dong-Zhi] Univ Jinan, Sch Mat Sci & Engn, Jinan 250022, Shandong, Peoples R China.
   [Shi Rui-Xia; Yin Yan-Sheng] Ocean Univ China, Sch Mat Sci & Engn, Qingdao 266100, Shandong, Peoples R China.
RP Shi, RX (reprint author), Univ Jinan, Sch Mat Sci & Engn, Jinan 250022, Shandong, Peoples R China.
EM mse_shirx@ujn.edu.cn
FU Doctoral Fund of Shandong Province [2006BS04037]; National Nature
   Science Fund of China [50572034]; Primary Program of University of Jinan
   [Y0602]
FX Sponsored by the Doctoral Fund of Shandong Province (Grant No.
   2006BS04037). National Nature Science Fund of China (Grant No.
   50572034). and the Primary Program of University of Jinan (Y0602).
CR AGHAJANIAN MK, 1989, J MATER SCI, V24, P658, DOI 10.1007/BF01107457
   Andersson T, 1998, J EUR CERAM SOC, V18, P2065, DOI 10.1016/S0955-2219(97)00200-8
   Collin M, 2000, ACTA MATER, V48, P1655, DOI 10.1016/S1359-6454(00)00011-2
   Deng JX, 2005, CERAM INT, V31, P249, DOI 10.1016/j.ceramint.2004.05.009
   HASSELMAN PH, 1969, J AM CERAM SOC, V52, P600, DOI 10.1111/j.1151-2916.1969.tb15848.x
   Li M, 2000, J AM CERAM SOC, V83, P967
   Lu JS, 2000, MATER RES BULL, V35, P2387, DOI 10.1016/S0025-5408(00)00454-2
   Maensiri S, 2002, J AM CERAM SOC, V85, P1971, DOI 10.1111/j.1151-2916.2002.tb00390.x
   MANSON SS, 2002, 2933 NCA
   OH ST, 1997, J EUR CERAM SOC, V17, P495
   Sbaizero O, 2000, ACTA MATER, V48, P985, DOI 10.1016/S1359-6454(99)00349-3
   Vollath D, 1997, J EUR CERAM SOC, V17, P1317, DOI 10.1016/S0955-2219(96)00224-5
   You XQ, 2005, CERAM INT, V31, P33, DOI 10.1016/j.ceramint.2004.02.009
   Zhao J, 2002, J MATER PROCESS TECH, V129, P161, DOI 10.1016/S0924-0136(02)00602-7
   ZHOU Y, 1995, CERAMIC MAT, V342, P354
NR 15
TC 5
Z9 5
U1 3
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0025-5408
EI 1873-4227
J9 MATER RES BULL
JI Mater. Res. Bull.
PD OCT 2
PY 2008
VL 43
IS 10
BP 2544
EP 2553
DI 10.1016/j.materresbull.2007.11.001
PG 10
WC Materials Science, Multidisciplinary
SC Materials Science
GA 351JB
UT WOS:000259419500004
DA 2018-12-27
ER

PT J
AU Hunton, JE
   Rose, JM
AF Hunton, James E.
   Rose, Jacob M.
TI RETRACTED: Can directors' self-interests influence accounting choices?
   (Retracted article. See vol. 50, pg. 74, 2016)
SO ACCOUNTING ORGANIZATIONS AND SOCIETY
LA English
DT Article; Retracted Publication
ID AUDIT COMMITTEE; CORPORATE GOVERNANCE; FIRM PERFORMANCE; BOARD;
   RESTATEMENTS; EARNINGS; COMPENSATION; CONSEQUENCES; PERCEPTIONS;
   OWNERSHIP
AB Eighty-eight audit committee members participated in an experiment designed to investigate the effects of audit issue (adjustment versus restatement) and director status (single directorship versus Multiple directorships) on the likelihood of accepting an auditor's recommendation. Results indicate that all participants are less likely to accept an auditor's restatement recommendation than adjustment recommendation. Further, directors holding multiple directorships are less likely to accept art auditor's restatement recommendation than directors with a single directorship. Analysis of post-experiment clinical debriefing items indicates that directors with multiple directorships are less willing to support restatements due to the potential adverse effects of restatements on their reputation capital. (C) 2007 Elsevier Ltd. All rights reserved.
C1 [Rose, Jacob M.] So Illinois Univ, Sch Accountancy, Carbondale, IL 62901 USA.
   [Hunton, James E.] Bentley Coll, Dept Accountancy, Waltham, MA 02452 USA.
RP Rose, JM (reprint author), So Illinois Univ, Sch Accountancy, Carbondale, IL 62901 USA.
EM jakerose@cba.siu.edu
CR Abbott LJ, 2004, AUDITING-J PRACT TH, V23, P69, DOI 10.2308/aud.2004.23.1.69
   Agrawal A, 2005, J LAW ECON, V48, P371, DOI 10.1086/430808
   Beasley MS, 1996, ACCOUNT REV, V71, P443
   Beeler J. D., 2002, ADV ACCOUNTING BEHAV, V5, P21
   Blue Ribbon Committee, 1999, REP REC BLUE RIBB CO
   Box G. E. P., 2005, STAT EXPT DESIGN INN
   BRICKLEY JA, 1994, J FINANC ECON, V35, P371, DOI 10.1016/0304-405X(94)90038-8
   Clement RW, 2000, BRIT J SOC PSYCHOL, V39, P279, DOI 10.1348/014466600164471
   Core JE, 1999, J FINANC ECON, V51, P371, DOI 10.1016/S0304-405X(98)00058-0
   *COUNC I INV, 1998, COR POL POS EXPL NO
   Dechow P., 1996, CONTEMP ACCOUNT RES, V13, P1, DOI DOI 10.1111/J.1911-3846.1996.TB00489.X
   Eli Rosen Robert, 2003, CONN L REV, V35, P1157
   FAMA EF, 1980, J POLIT ECON, V88, P288, DOI 10.1086/260866
   FAMA EF, 1983, J LAW ECON, V26, P301, DOI 10.1086/467037
   Farber DB, 2005, ACCOUNT REV, V80, P539, DOI 10.2308/accr.2005.80.2.539
   Ferris SP, 2003, J FINANC, V58, P1087, DOI 10.1111/1540-6261.00559
   Fich EM, 2006, J FINANC, V61, P689, DOI 10.1111/j.1540-6261.2006.00852.x
   FOSBERG RH, 1989, AKRON BUS ECON REV, V20, P24
   GILSON SC, 1990, J FINANC ECON, V27, P355, DOI 10.1016/0304-405X(90)90060-D
   GREENWALD AG, 1980, AM PSYCHOL, V35, P603, DOI 10.1037//0003-066X.35.7.603
   HAYES R, 2004, BOARD COMMITTEE STRU
   Hribar P, 2004, REV ACC STUD, V9, P337, DOI 10.1023/B:RAST.0000028194.11371.42
   *HUR CONS GROUP, 2004, ANN REV FIN REP MATT
   KAPLAN SN, 1990, J FINANC ECON, V27, P389, DOI 10.1016/0304-405X(90)90061-4
   Keys P. Y., 2005, J FINANC RES, V28, P575, DOI DOI 10.1111/JFIR.2005.28.ISSUE-4
   KINNEY WR, 1989, J ACCOUNT ECON, V11, P71, DOI 10.1016/0165-4101(89)90014-1
   Klein A, 1998, J LAW ECON, V41, P275, DOI 10.1086/467391
   Klein A, 2002, J ACCOUNT ECON, V33, P375, DOI 10.1016/S0165-4101(02)00059-9
   *KORN FERR INT, 1998, 25 ANN BOARD DIR STU
   KRUGLANSKI AW, 1980, PSYCHOL REV, V87, P70, DOI 10.1037/0033-295X.87.1.70
   KUNDA Z, 1990, PSYCHOL BULL, V108, P480, DOI 10.1037//0033-2909.108.3.480
   Linn SC, 2005, J CORP FINANC, V11, P680, DOI 10.1016/j.jcorpfin.2004.11.002
   MacAvoy P., 1999, J APPL CORPORATE FIN, V11, P8, DOI DOI 10.1111/J.1745-6622.1999.TB00510.X
   Mikulincer M, 1999, J PERS SOC PSYCHOL, V76, P1022, DOI 10.1037/0022-3514.76.6.1022
   MYERS J, 2004, P MID YEAR M AUD SEC
   National Association of Corporate Directors, 1996, REP NACD BLUE RIBB C
   *NEW YORK STOCK EX, 2003, 303A06 NEW YORK STOC
   Ng TBP, 2003, ACCOUNT REV, V78, P801, DOI 10.2308/accr.2003.78.3.801
   Palmrose ZV, 2004, CONTEMP ACCOUNT RES, V21, P139, DOI 10.1506/WBF9-Y69X-L4DX-JMV1
   Powers Jr W., 2002, REPORT INVESTIGATION
   PYSZCZYNSKI T, 1987, ADV EXP SOC PSYCHOL, V20, P297, DOI 10.1016/S0065-2601(08)60417-7
   ROSENSTEIN S, 1990, J FINANC ECON, V26, P175, DOI 10.1016/0304-405X(90)90002-H
   Ruvolo AP, 1999, PERS RELATIONSHIP, V6, P57, DOI 10.1111/j.1475-6811.1999.tb00211.x
   SARBANES P, 2002, SARBANESOXLEY ACT 20
   Smith E., 1997, PSYCHODYNAMIC COUNSE, V3, P117
   Srinivasan S, 2005, J ACCOUNTING RES, V43, P291, DOI 10.1111/j.1475-679x.2005.00172.x
   Subrahmanyam V, 1997, FINANC MANAGE, V26, P23, DOI 10.2307/3666211
   *US SEC EXCH COMM, 1999, SEC STAFF ACC B, V99
   *US SEC EXCH COMM, 1999, SEC STAFF ACC B, V101
   WU M, 2002, THESIS NEW YORK U
NR 50
TC 23
Z9 23
U1 2
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0361-3682
EI 1873-6289
J9 ACCOUNT ORG SOC
JI Account. Organ. Soc.
PD OCT-NOV
PY 2008
VL 33
IS 7-8
BP 783
EP 800
DI 10.1016/j.aos.2007.10.001
PG 18
WC Business, Finance
SC Business & Economics
GA 378DN
UT WOS:000261301500006
DA 2018-12-27
ER

PT J
AU Gupta, D
   Jain, R
   Mishra, S
   Kumar, S
   Thulkar, S
   Bhatnagar, S
AF Gupta, Deepak
   Jain, Roopesh
   Mishra, Seema
   Kumar, Santosh
   Thulkar, Sanjay
   Bhatnagar, Sushma
TI RETRACTED: Ultrasonography reinvents the originally described technique
   for ganglion impar neurolysis in perianal cancer pain (Retracted
   article. See vol. 111, pg. 1524, 2010)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID BLOCK
AB Visceral pain in the perineal area associated with malignancies may be effectively treated with neurolysis of the ganglion impar. Since the first description of the technique of accessing the ganglion impar through anococcygeal ligament, many techniques for ganglion impar block have been described. We present a patient diagnosed with carcinoma of the anal canal who was successfully given ultrasound guided ganglion impar block using a Chiba needle inserted through the anococcygeal ligament. In summary, Ultrasound-guided ganglion impar neurolysis is a fast, safe, and cost-effective method, which call be used as a first-line pain relief intervention for good quality of life in patients with perianal cancers.
C1 [Kumar, Santosh; Thulkar, Sanjay] All India Inst Med Sci, Dept Radiol, Rotary Canc Hosp, New Delhi 110029, India.
   [Gupta, Deepak; Jain, Roopesh; Mishra, Seema; Bhatnagar, Sushma] All India Inst Med Sci, Dept Anesthesiol, Rotary Canc Hosp, New Delhi 110029, India.
RP Bhatnagar, S (reprint author), All India Inst Med Sci, Dept Anesthesiol, Room 242,Dr BRA-IRCH,Ansari Nagar, New Delhi 110029, India.
EM Shumob@yahoo.com
CR de Leon-Casasola O A, 2000, Cancer Control, V7, P142
   Foye Patrick M, 2007, Pain Physician, V10, P780
   Foye PM, 2007, REGION ANESTH PAIN M, V32, P269, DOI 10.1016/j.rapm.2006.12.005
   Foye PM, 2006, AM J PHYS MED REHAB, V85, P783, DOI 10.1097/01.phm.0000233174.86070.63
   Munir MA, 2004, CAN J ANAESTH, V51, P915, DOI 10.1007/BF03018890
   Nebab EG, 1997, ANESTHESIOLOGY, V86, P1213, DOI 10.1097/00000542-199705000-00028
   Oh CS, 2004, ANESTHESIOLOGY, V101, P249, DOI 10.1097/00000542-200407000-00039
   PLANCARTE R, 1990, ANESTHESIOLOGY, V73, P236, DOI 10.1097/00000542-199008000-00008
   WEMM K, 1995, REGION ANESTH, V20, P544
NR 9
TC 16
Z9 17
U1 3
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD OCT
PY 2008
VL 107
IS 4
BP 1390
EP 1392
DI 10.1213/ane.0b013e31817f6d2e
PG 3
WC Anesthesiology
SC Anesthesiology
GA 352UE
UT WOS:000259522100053
PM 18806057
DA 2018-12-27
ER

PT J
AU Zhao, Z
   Ma, N
   Pan, LD
   Xu, N
   Sun, K
AF Zhao Zhong
   Ma Nannan
   Pan Lideng
   Xu Ning
   Sun Kang
TI RETRACTED: Direct Adaptive Control Based on Gradient Estimation
   (Retracted article. See vol. 20, pg. 848, 2012)
SO CHINESE JOURNAL OF CHEMICAL ENGINEERING
LA English
DT Article; Retracted Publication
DE direct adaptive control; embedding property; gradient estimation; robust
   convergence; static error; polypropylene process
ID TIME NONLINEAR-SYSTEMS; NEURAL-NETWORKS; NN CONTROL; IDENTIFICATION
AB A control method of direct adaptive control based on gradient estimation is proposed in this article. The dynamic system is embedded in a linear model set. Based on the embedding property of the dynamic system, an adaptive optimal control algorithm is proposed. The robust convergence of the proposed control algorithm has been proved and the static control error with the proposed method is also analyzed. The application results of the proposed method to the industrial polypropylene process have verified its feasibility and effectiveness.
C1 [Zhao Zhong; Ma Nannan; Pan Lideng; Sun Kang] Beijing Univ Chem Technol, Res Inst Automat, Beijing 100029, Peoples R China.
   [Xu Ning; Sun Kang] SINOPEC Corp, Beijing Res Inst Chem Technol, Beijing 100023, Peoples R China.
RP Zhao, Z (reprint author), Beijing Univ Chem Technol, Res Inst Automat, Beijing 100029, Peoples R China.
EM zhaozhong@mail.buct.edu.cn
FU National Natural Science Foundation of China [60774080]; BJNOVA
   [2005B15]
FX Supported by the National Natural Science Foundation of China (60774080)
   and BJNOVA 2005B15.
CR ASTROM KJ, 1992, AUTOMATICA, V28, P1
   CHUI CK, 1990, INTRO WAVELET, P170
   FANG C, 1988, PROCESS IDENTIFICATI, P210
   Ge SS, 2003, AUTOMATICA, V39, P807, DOI 10.1016/S0005-1098(03)00032-3
   Ge SS, 2003, INT J CONTROL, V76, P334, DOI 10.1080/0020717031000073063
   *HON INC, 2000, RPID US GUID
   *HON INC, 2000, PROF LOOP US GUID
   Levin AU, 1996, IEEE T NEURAL NETWOR, V7, P30, DOI 10.1109/72.478390
   LEVIN AU, 1993, IEEE T NEURAL NETWOR, V4, P192, DOI 10.1109/72.207608
   Lewis FL, 1996, IEEE T NEURAL NETWOR, V7, P388, DOI 10.1109/72.485674
   MALLAT SG, 1989, IEEE T PATTERN ANAL, V11, P674, DOI 10.1109/34.192463
   MARSIK J, 1989, AUTOMATICA, V25, P273, DOI 10.1016/0005-1098(89)90081-2
   Narendra K S, 1990, IEEE Trans Neural Netw, V1, P4, DOI 10.1109/72.80202
   Polycarpou MM, 1996, IEEE T AUTOMAT CONTR, V41, P447, DOI 10.1109/9.486648
   Qin SJ, 2003, CONTROL ENG PRACT, V11, P733, DOI 10.1016/S0967-0661(02)00186-7
   RARDIN RL, 1998, OPTIMIZATION OPERATI, P100
   Rugh WJ, 2000, AUTOMATICA, V36, P1401, DOI 10.1016/S0005-1098(00)00058-3
   Spall JC, 1997, IEEE T SYST MAN CY B, V27, P369, DOI 10.1109/3477.584945
   Spall JC, 1998, IEEE T AUTOMAT CONTR, V43, P1198, DOI 10.1109/9.718605
   YESILDIREK A, 1995, AUTOMATICA, V31, P1659, DOI 10.1016/0005-1098(95)00078-B
   Zhao Z, 2000, J CHEM ENG JPN, V33, P823, DOI 10.1252/jcej.33.823
NR 21
TC 2
Z9 2
U1 4
U2 13
PU CHEMICAL INDUSTRY PRESS
PI BEIJING
PA NO. 3 HUIXINLI CHAOYANGQU, BEIJING 100029, PEOPLES R CHINA
SN 1004-9541
EI 2210-321X
J9 CHINESE J CHEM ENG
JI Chin. J. Chem. Eng.
PD OCT
PY 2008
VL 16
IS 5
BP 752
EP 761
DI 10.1016/S1004-9541(08)60151-2
PG 10
WC Engineering, Chemical
SC Engineering
GA 369KY
UT WOS:000260694600014
DA 2018-12-27
ER

PT J
AU Betrouni, N
   Dewalleb, AS
   Puech, P
   Vermandel, M
   Rousseau, J
AF Betrouni, N.
   Dewalleb, A. S.
   Puech, P.
   Vermandel, M.
   Rousseau, J.
TI RETRACTED: 3D delineation of prostate, rectum and bladder on MR images
   (Retracted Article. See vol 33, pg 651, 2009)
SO COMPUTERIZED MEDICAL IMAGING AND GRAPHICS
LA English
DT Article; Retracted Publication
DE 3D image segmentation; Deformable models; Treatment planning; Prostate
   cancer; MRI
ID DEFORMABLE REGISTRATION; SEMINAL-VESICLES; TARGET VOLUME; SEGMENTATION;
   RADIOTHERAPY; REGION; CANCER; DISTRIBUTIONS; VARIABILITY; VALIDATION
AB In radiotherapy planning, target volumes and organs at risk delineation are a tedious and time-consuming task. In this paper we address a method to assist the radiologist in this task. We developed a 3D deformable model for prostate segmentation and used a seeded region growing algorithm for bladder and rectum delineation on MR images. Evaluation of the methods is made by comparison of the results to manual delineation in 24 patients. The following parameters were measured: volume ratio (V-R) (automatic/manual), volume overlap (V-O) (ratio of the volume of intersection to the volume of union, optimal value = 1), and correctly delineated volume (V-C) (percent ratio of the volume of intersection to the manual defined volume, optimal value = 100). For prostate the V-R, V-O and V-C were 1.13 (+/- 0.1), 0.78 (+/- 0.05) and 94.75 (+/- 3.3), respectively. For rectum, the V-R, V-O and V-C were 0.97 (+/- 0.1), 0.78 (+/- 0.06) and 86.52 (+/- 5), respectively. V-R, V-O and V-C were 0.95 (+/- 0.03), 0.88 (+/- 0.03) and 91.29 (+/- 3.1) for bladder, respectively. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Betrouni, N.; Dewalleb, A. S.; Puech, P.; Vermandel, M.; Rousseau, J.] CHRU, INSERM, U703, Med Technol Inst, F-59037 Lille, France.
   [Betrouni, N.; Dewalleb, A. S.; Puech, P.; Vermandel, M.; Rousseau, J.] Univ Lille 2, Fac Med, UPRES EA 1049, Lille, France.
   [Puech, P.] Claude Huriez Hosp, Dept Radiol, Lille, France.
RP Betrouni, N (reprint author), CHRU, INSERM, U703, French Natl Inst Hlth & Med Res, Pavillon Vancostenobel, F-59037 Lille, France.
EM n-betrouni@chru-lille.fr
RI Betrouni, Nacim/M-5591-2018
CR ADAMS R, 1994, IEEE T PATTERN ANAL, V16, P641, DOI 10.1109/34.295913
   BESL PJ, 1992, IEEE T PATTERN ANAL, V14, P239, DOI 10.1109/34.121791
   Betrouni N, 2005, COMPUT MED IMAG GRAP, V29, P43, DOI 10.1016/j.compmedimag.2004.07.007
   Bondiau PY, 2005, INT J RADIAT ONCOL, V61, P289, DOI 10.1016/j.ijrobp.2004.08.055
   BROADHURST RE, 2005, LECT NOTES COMPUTER, V3753, P71
   BUENO G, 2001, P MED IM UND AN MIUA, P36
   Cazzaniga LF, 1998, RADIOTHER ONCOL, V47, P293, DOI 10.1016/S0167-8140(98)00028-0
   Fiorino C, 1998, RADIOTHER ONCOL, V47, P285, DOI 10.1016/S0167-8140(98)00021-8
   Foskey M, 2005, PHYS MED BIOL, V50, P5869, DOI 10.1088/0031-9155/50/24/008
   Freedman D, 2005, IEEE T MED IMAGING, V24, P281, DOI 10.1109/TMI.2004.841228
   KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671
   Lee FKH, 2005, INT J RADIAT ONCOL, V61, P608, DOI 10.1016/j.ijrobp.2004.09.024
   Lu WG, 2004, PHYS MED BIOL, V49, P3067, DOI 10.1088/0031-9155/49/14/003
   Mazonakis M, 2001, BRIT J RADIOL, V74, P243, DOI 10.1259/bjr.74.879.740243
   Mehnert A, 1997, PATTERN RECOGN LETT, V18, P1065, DOI 10.1016/S0167-8655(97)00131-1
   Mohan R, 2005, INT J RADIAT ONCOL, V61, P1258, DOI 10.1016/j.ijrobp.2004.11.033
   Pekar V, 2004, INT J RADIAT ONCOL, V60, P973, DOI 10.1016/j.ijrobp.2004.06.004
   Pizer SM, 2005, MED PHYS, V32, P1335, DOI 10.1118/1.1869872
   Rao M, 2005, INT J RADIAT ONCOL, V61, P954, DOI 10.1016/j.ijrobp.2004.11.014
   Seddon B, 2000, RADIOTHER ONCOL, V56, P73, DOI 10.1016/S0167-8140(00)00191-2
   Shao F, 2003, J ULTRAS MED, V22, P605, DOI 10.7863/jum.2003.22.6.605
   Wang H, 2005, INT J RADIAT ONCOL, V61, P725, DOI 10.1016/j.ijrobp.2004.07.677
NR 22
TC 9
Z9 9
U1 4
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-6111
EI 1879-0771
J9 COMPUT MED IMAG GRAP
JI Comput. Med. Imaging Graph.
PD OCT
PY 2008
VL 32
IS 7
BP 622
EP 630
DI 10.1016/j.compmedimag.2008.07.002
PG 9
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 358DW
UT WOS:000259897900011
PM 18692991
DA 2018-12-27
ER

PT J
AU Wei, ZL
   Cao, YX
   Cong, L
   Zhou, P
   Zhang, ZG
   Li, J
AF Wei, Zhaolian
   Cao, Yunxia
   Cong, Lin
   Zhou, Ping
   Zhang, Zhiguo
   Li, Jun
TI RETRACTED: Effect of metformin pretreatment on pregnancy outcome of in
   vitro matured oocytes retrieved from women with polycystic ovary
   syndrome (Retracted article. See vol. 104, pg. 1048, 2015)
SO FERTILITY AND STERILITY
LA English
DT Article; Retracted Publication
DE metformin; polycystic ovary syndrome; in vitro maturation; pregnancy
ID METABOLIC PROFILES; INDUCED OVULATION; NONOBESE PATIENTS;
   GROWTH-FACTORS; MATURATION; FERTILIZATION; HYPERINSULINEMIA;
   HYPERANDROGENISM; TRIAL; PCOS
AB Objective: To determine the effect of metformin pretreatment on in vitro maturation (IVM) in the patients with clomiphene citrate-resistant polycystic ovary syndrome.
   Design: Prospective randomized study.
   Setting: University affiliated hospital.
   Patient(s): Fifty-six women with clomiphene citrate-resistant polycystic ovary syndrome underwent 70 cycles of IVM treatment.
   Intervention(s): Metformin was administered at a dose of 500 mg twice per day for 12 weeks before IVM treatment.
   Main Outcome Measure(s): The number of immature oocytes, oocyte maturation, fertilization, cleavage, high-quality embryo, and clinical pregnancy rates.
   Result(s): A significantly higher high-quality embryo rate (37.8%) was obtained in the metformin-treated group compared with the control group (24.3%). Accordingly, the clinical pregnancy and implantation rates were significantly higher in the metformin-treated group (38.2% and 15.3%) than the control group (16.7% and 6.2%).
   Conclusion(s): Pretreatment with metformin improves IVM outcome in terms of embryo quality and clinical pregnancy rate as well as implantation rate.
C1 [Wei, Zhaolian; Cao, Yunxia; Cong, Lin; Zhou, Ping; Zhang, Zhiguo] Anhui Med Univ, Affiliated Hosp 1, Reprod Med Ctr, Hefei 230022, Anhui, Peoples R China.
   [Li, Jun] Anhui Med Univ, Pharmacol Coll, Hefei, Peoples R China.
RP Cao, YX (reprint author), Anhui Med Univ, Affiliated Hosp 1, Reprod Med Ctr, Hefei 230022, Anhui, Peoples R China.
EM caoyunxia6@126.com; lijun@ahmu.edu.cn
CR ADASHI EY, 1985, ENDOCR REV, V6, P400, DOI 10.1210/edrv-6-3-400
   Cha KY, 1998, HUM REPROD UPDATE, V4, P103, DOI 10.1093/humupd/4.2.103
   Chian RC, 2004, REPROD BIOMED ONLINE, V8, P148, DOI 10.1016/S1472-6483(10)60511-1
   Child TJ, 2002, OBSTET GYNECOL, V100, P665, DOI 10.1016/S0029-7844(02)02193-2
   Child TJ, 2001, FERTIL STERIL, V76, P936, DOI 10.1016/S0015-0282(01)02853-9
   Fedorcsak P, 2003, GYNECOL ENDOCRINOL, V17, P207, DOI 10.1080/713603249
   FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307
   Genazzani AD, 2004, FERTIL STERIL, V81, P114, DOI 10.1016/j.fertnstert.2003.05.020
   Genazzani AD, 2007, GYNECOL ENDOCRINOL, V23, P146, DOI 10.1080/09513590701214398
   Ibanez L, 2002, J CLIN ENDOCR METAB, V87, P2870, DOI 10.1210/jc.87.6.2870
   Khattab S, 2006, REPROD BIOMED ONLINE, V13, P194, DOI 10.1016/S1472-6483(10)60614-1
   Khorram O, 2006, FERTIL STERIL, V85, P1448, DOI 10.1016/j.fertnstert.2005.10.042
   Kjotrod SB, 2004, HUM REPROD, V19, P1315, DOI 10.1093/humrep/deh248
   Le Du A, 2005, HUM REPROD, V20, P420, DOI 10.1093/humrep/deh603
   Mikkelsen AL, 2001, REPRODUCTION, V122, P587
   NESTLER JE, 1991, J CLIN ENDOCR METAB, V72, P83, DOI 10.1210/jcem-72-1-83
   Nestler JE, 1998, NEW ENGL J MED, V338, P1876, DOI 10.1056/NEJM199806253382603
   Ng EHY, 2001, HUM REPROD, V16, P1625, DOI 10.1093/humrep/16.8.1625
   POLSON DW, 1989, FERTIL STERIL, V51, P30
   Stadtmauer LA, 2001, FERTIL STERIL, V75, P505, DOI 10.1016/S0015-0282(00)01766-0
   Tang T, 2006, HUM REPROD, V21, P1416, DOI 10.1093/humrep/de1025
   Tasdemir Seval, 2004, Archives of Gynecology and Obstetrics, V269, P121, DOI 10.1007/s00404-002-0447-8
   TROUNSON A, 1994, FERTIL STERIL, V62, P353
   VELAZQUEZ EM, 1994, METABOLISM, V43, P647, DOI 10.1016/0026-0495(94)90209-7
NR 24
TC 22
Z9 27
U1 4
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD OCT
PY 2008
VL 90
IS 4
BP 1149
EP 1154
DI 10.1016/j.fertnstert.2007.07.1385
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 358UQ
UT WOS:000259943400032
PM 18022165
DA 2018-12-27
ER

PT J
AU Zhao, S
   Hong, HS
   Zhang, LP
AF Zhao, Sheng
   Hong, Huasheng
   Zhang, Luoping
TI RETRACTED: Linking the concept of ecological footprint and valuation of
   ecosystem services: A case study of economic growth and natural carrying
   capacity (Retracted article. See vol. 16, pg. 368, 2009)
SO INTERNATIONAL JOURNAL OF SUSTAINABLE DEVELOPMENT AND WORLD ECOLOGY
LA English
DT Article; Retracted Publication
DE Ecological footprint; ecosystem services; carrying capacity; GDP;
   steady-state economy
ID SUSTAINABLE DEVELOPMENT; CRITICALITY; INDICATORS; MANAGEMENT
AB Human activities have become so extensive that all ecosystems on the planet have been altered to some extent. The fate of humankind will be determined by how sustainable ecosystems and the renewable resources in them are managed. The implication of this is obvious: humanity must live within nature's carrying capacity. In recent years, humans have recognised that growth of the economy depends on natural capital, and it is important that we now recognise that we are part of an international ecological economics community, so as to better integrate the economy and ecology. However, there are few successful examples of this. The aim of this paper is to show a method for integrated analysis between economic growth and natural carrying capacity by linking the concepts of ecological footprint and valuation of ecosystem services. When applied to China for the period 1987-2003, the empirical evidence suggests that the size of the Chinese economy surpassed the carrying capacity in 1992. Perhaps, we should abandon our high-growth predilection and initiate a transition to a steady-state economy.
C1 [Zhao, Sheng] Zhejiang Ocean Univ, Marine Sci Coll, Zhoushan, Peoples R China.
   [Zhao, Sheng; Hong, Huasheng; Zhang, Luoping] Xiamen Univ, Environm Sci Res Ctr, Xiamen 361005, Peoples R China.
RP Zhao, S (reprint author), Xiamen Univ, Environm Sci Res Ctr, Xiamen 361005, Peoples R China.
EM shzhao@xnw.edu.cn
RI Zhang, LuoPing/G-3430-2010; Hong, HS/G-3347-2010
OI Zhang, LuoPing/0000-0002-0112-1141; 
CR Barrett GW, 2000, BIOSCIENCE, V50, P311, DOI 10.1641/0006-3568(2000)050[0311:IEAE]2.3.CO;2
   CATTON W, 1986, SOC EC SESS 1 NEW DE
   Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0
   Costanza R, 2002, ECOL ECON, V41, P367, DOI 10.1016/S0921-8009(02)00087-3
   COSTANZA R, 1992, CONSERV BIOL, V6, P37, DOI 10.1046/j.1523-1739.1992.610037.x
   Daly H. E., 2003, ECOLOGICAL EC PRINCI
   DALY HE, 1992, REV SOC LINK EC EC S
   De Groot R, 2003, ECOL ECON, V44, P187, DOI 10.1016/S0921-8009(02)00273-2
   de Groot RS, 2002, ECOL ECON, V41, P393, DOI 10.1016/S0921-8009(02)00089-7
   Ekins P., 2003, Ecological Economics, V44, P159, DOI 10.1016/S0921-8009(02)00271-9
   Knaus M, 2006, ENVIRON IMPACT ASSES, V26, P156, DOI 10.1016/j.eiar.2005.04.010
   Lawn P, 2006, ECOL ECON, V56, P440, DOI 10.1016/j.ecolecon.2005.09.024
   Lawn Philip, 2005, SOCIO-ECON REV, V3, P209
   MacDonald DV, 1999, ECOL ECON, V29, P73, DOI 10.1016/S0921-8009(98)00051-2
   MEA (Millennium Ecosystem Assessment), 2003, EC HUM WELL BEING FR
   Pagiola Stefano, 2004, 101 WORLD BANK ENV D
   Rapport DJ, 2000, ECOL ECON, V32, P367
   Rees W, 1996, ENVIRON IMPACT ASSES, V16, P223, DOI 10.1016/S0195-9255(96)00022-4
   Rees W. E., 1990, Ecologist, V20, P18
   Rees W.E., 1992, ENVIRON URBAN, V4, P121, DOI DOI 10.1177/095624789200400212
   Rees WE, 1996, POPUL ENVIRON, V17, P195, DOI 10.1007/BF02208489
   Sutton PC, 2002, ECOL ECON, V41, P509, DOI 10.1016/S0921-8009(02)00097-6
   Turner RK, 2000, ECOL ECON, V35, P7, DOI 10.1016/S0921-8009(00)00164-6
   VICTOR PA, 1991, ECOL ECON, V4, P191
   Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494
   Wackernagel M, 2000, ECOL ECON, V32, P391
   Wackernagel M, 1999, ECOL ECON, V29, P375, DOI 10.1016/S0921-8009(98)90063-5
   Wackernagel M, 2002, P NATL ACAD SCI USA, V99, P9266, DOI 10.1073/pnas.142033699
   Wackernagel M, 1996, OUR ECOLOGICAL FOOTP
   Wackernagel M., 2002, ENV DEV SUSTAINABILI, V2, P21
   *WWF UNEP WORLD CO, 2004, LIV PLAN REP 2004
NR 31
TC 4
Z9 5
U1 6
U2 31
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1350-4509
J9 INT J SUST DEV WORLD
JI Int. J. Sustain. Dev. World Ecol.
PD OCT
PY 2008
VL 15
IS 5
BP 448
EP 456
DI 10.3843/SusDev.15.5:6
PG 9
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Ecology
SC Science & Technology - Other Topics; Environmental Sciences & Ecology
GA 370PG
UT WOS:000260773500006
DA 2018-12-27
ER

PT J
AU Li, ZY
   Fallon, J
   Mandeli, J
   Wetmur, J
   Woo, SLC
AF Li, Zhiyu
   Fallon, John
   Mandeli, John
   Wetmur, James
   Woo, Savio L. C.
TI RETRACTED: A genetically enhanced anaerobic bacterium for oncopathic
   therapy of pancreatic cancer (Retracted article. See vol. 102, pg. 283,
   2010)
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article; Retracted Publication
ID BACILLUS-ANTHRACIS SPORES; NECROSIS-FACTOR-ALPHA;
   CLOSTRIDIUM-PERFRINGENS; TUMOR MICROENVIRONMENT; DELIVERY SYSTEM;
   GENE-TRANSFER; RUBRERYTHRIN; MACROPHAGES; NEUTROPHILS; RESISTANT
AB Background A major obstacle in treatment of solid tumors is the inefficient delivery of therapeutic agents to the hypoxic cores. Hypoxia offers the potential for anaerobic bacteria colonization and tumor destruction by the bacteria, and dormant spores of wild-type Clostridium perfringens (Cp) germinate and proliferate within the hypoxic cores of pancreatic tumors in mice. However, the oncopathic effects of Cp were limited by host inflammatory responses and by Cp's residual tolerance to oxygen, which caused toxic effects in animals.
   Methods Recombinant Cp strains in which superoxide dismutase, a major oxygen tolerance gene, was deleted (Cp/sod(-)) were constructed to enhance its selective growth in tumors. In addition, Panton-Valentine Leukocidin (PVL), an inflammation-suppressing gene from Staphylococcus aureus, was inserted into the Cp/sod(-) genome to enhance its oncopathic potency. The ability of the recombinant Cp strains to kill tumors was investigated in C57/BL6 mice bearing murine PANC02 tumors. Systemic and organ toxic effects were assessed by monitoring serum chemistries and histopathological examination. Statistical tests were two-sided.
   Results Cp/sod(-) showed reduced toxic effects compared with wild-type Cp when spores were administered intravenously into PANC02 tumor-bearing mice. Mice treated with Cp/sod(-)/PVL spores demonstrated a reduction in neutrophils and macrophages in tumors, logarithmically elevated growth of intratumoral bacteria, enhanced tumor necrosis, and substantially prolonged survival without apparent systemic and organ toxic effects, compared with mice treated with both wild-type Cp and Cp/sod(-) spores. Accordingly, 47% of Cp/sod(-)/PVL-treated mice (n = 15) achieved tumor-free survival for over 120 days, whereas all mice treated with Cp/sod(-) or phosphate-buffered saline (n = 10 per group) died within 50 days. The median survival for Cp/sod(-)/PVL-treated mice was 77 days (95% confidence interval [CI] = 45 to 120 days) and for Cp/sod(-)-treated mice was 30 days (95% CI = 23 to 36 days; P < .001).
   Conclusions Cp/sod(-)/PVL provides a prototype for a novel class of oncopathic microbes that may have potential for the safe and effective treatment of pancreatic cancer and other poorly vascularized tumors.
C1 [Li, Zhiyu; Woo, Savio L. C.] Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA.
   [Fallon, John] Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA.
   [Mandeli, John] Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA.
   [Wetmur, James] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.
RP Woo, SLC (reprint author), Mt Sinai Sch Med, Dept Gene & Cell Med, 1 Gustave L Levy Pl,Box 1496, New York, NY 10029 USA.
EM savio.woo@mssm.edu
OI Fallon, John/0000-0002-7677-4868
FU National Institutes of Health [CA-120017]
FX This research was supported by a National Institutes of Health grant
   CA-120017. We wish to thank Ms Marcia Meseck, Dr Tian-gui Huang and Dr
   Lan Wu for helpful discussions, and Ms Yafang Wang and Mr Boxun Xie for
   technical assistance.
CR Block A, 1997, PANCREAS, V15, P25, DOI 10.1097/00006676-199707000-00004
   Briolat V, 2002, J BACTERIOL, V184, P2333, DOI 10.1128/JB.184.9.2333-2343.2002
   Brown JM, 2002, CANCER BIOL THER, V1, P453, DOI 10.4161/cbt.1.5.157
   CAREY R. W., 1967, EUR J CANCER, V3, P37, DOI 10.1016/0014-2964(67)90060-6
   CASPER ES, 1993, EUR J CANCER, V29A, P171, DOI 10.1016/0959-8049(93)90167-E
   Cheong I, 2006, SCIENCE, V314, P1308, DOI 10.1126/science.1130651
   Cote CK, 2006, INFECT IMMUN, V74, P469, DOI 10.1128/IAI.74.1.469-480.2006
   Cote CK, 2004, MICROB PATHOGENESIS, V37, P169, DOI 10.1016/j.micpath.2004.06.013
   Critchley R, 2004, GENE THER, V11, P1224, DOI 10.1038/sj.gt.3302281
   Dang LH, 2001, P NATL ACAD SCI USA, V98, P15155, DOI 10.1073/pnas.251543698
   Dutta A, 2005, PARASITOL INT, V54, P119, DOI 10.1016/j.parint.2005.01.001
   ENGELBART K, 1964, CANCER RES, V24, P239
   EZAKI T, 2000, MOL ECOLOGICAL DETEC, P214
   Forbes NS, 2006, NAT BIOTECHNOL, V24, P1484, DOI 10.1038/nbt1206-1484
   Galan JE, 2005, J EXP MED, V201, P321, DOI 10.1084/jem.20050080
   Geissmann TA, 1999, J BACTERIOL, V181, P7136
   Genestier AL, 2005, J CLIN INVEST, V115, P3117, DOI 10.1172/JCI22684
   GILL CO, 1981, APPL ENVIRON MICROB, V41, P90
   HEPPNER F, 1978, ACTA NEUROCHIR, V42, P123, DOI 10.1007/BF01406639
   Karlin S, 2004, P NATL ACAD SCI USA, V101, P6182, DOI 10.1073/pnas.0401504101
   Kato I, 1981, Nihon Saikingaku Zasshi, V36, P445
   Kondoh S. K., 2003, CANCER SCI, V94, P1021
   Lehmann Y, 1996, J BACTERIOL, V178, P7152, DOI 10.1128/jb.178.24.7152-7158.1996
   Lemmon MJ, 1997, GENE THER, V4, P791, DOI 10.1038/sj.gt.3300468
   Lyke KE, 2004, INFECT IMMUN, V72, P5630, DOI 10.1128/IAI.72.10.5630-5637.2004
   OKUMOTO M, 1985, INT OPHTHALMOL CLIN, V25, P133, DOI 10.1097/00004397-198502520-00015
   Pawelek JM, 1997, CANCER RES, V57, P4537
   Pawelek JM, 2003, LANCET ONCOL, V4, P548, DOI 10.1016/S1470-2045(03)01194-X
   Rooijen N. V., 1996, J IMMUNOL METHODS, V193, P93
   ROUSSEAU D, 2001, BMC MICROBIOL, V1, P1471
   Ryan RM, 2006, BIOESSAYS, V28, P84, DOI 10.1002/bies.20336
   Stephens C D, 1998, Oncol Nurs Forum, V25, P87
   Storniolo AM, 1999, CANCER, V85, P1261, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.3.CO;2-K
   Sun X, 2001, GENE THER, V8, P638, DOI 10.1038/sj.gt.3301388
   Sznol M, 2000, J CLIN INVEST, V105, P1027, DOI 10.1172/JCI9818
   Theys J, 2001, CANCER GENE THER, V8, P294, DOI 10.1038/sj.cgt.7700303
   Theys J., 2003, Current Gene Therapy, V3, P207, DOI 10.2174/1566523034578357
   Vordermark D, 2003, INT J RADIAT ONCOL, V56, P1184, DOI 10.1016/S0360-3016(03)00289-X
   Wan JMF, 2006, INT IMMUNOPHARMACOL, V6, P750, DOI 10.1016/j.intimp.2005.11.008
   WELKOS SL, 1989, MICROB PATHOGENESIS, V7, P15, DOI 10.1016/0882-4010(89)90108-3
   Yazawa K, 2001, BREAST CANCER RES TR, V66, P165, DOI 10.1023/A:1010644217648
NR 41
TC 15
Z9 16
U1 3
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD OCT 1
PY 2008
VL 100
IS 19
BP 1389
EP 1400
DI 10.1093/jnci/djn308
PG 12
WC Oncology
SC Oncology
GA 356HO
UT WOS:000259769500011
PM 18812551
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU De Hert, SG
   Lorsomradee, S
   vanden Eede, H
   Cromheecke, S
   Van der Linden, PJ
AF De Hert, Stefan G.
   Lorsomradee, Suraphong
   vanden Eede, Herve
   Cromheecke, Stefanie
   Van der Linden, Philippe J.
TI RETRACTED: A randomized trial evaluating different modalities of
   levosimendan administration in cardiac surgery patients with myocardial
   dysfunction (Retracted article. See vol. 25, pg. 897, 2011)
SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
LA English
DT Article; Retracted Publication
DE cardiac surgery; levosimendan; milrinone; cardiac bypass
ID CORONARY-ARTERY-BYPASS; OUTPUT HEART-FAILURE; CARDIOPULMONARY BYPASS;
   CALCIUM SENSITIZER; CARDIOPROTECTIVE PROPERTIES; INTRAVENOUS
   LEVOSIMENDAN; VENTRICULAR MYOCARDIUM; ACTIVE METABOLITE; SEVOFLURANE;
   DOBUTAMINE
AB Objective: To evaluate the effects of 2 different administration modalities of levosimendan (start before cardiopulmonary bypass [CPB] and at the end of CPB) compared with a standard treatment with milrinone started at the end of CPB in cardiac surgery patients with a preoperative ejection fraction < 30%.
   Design: A prospective study.
   Setting: A university hospital.
   Participants: Sixty patients undergoing elective cardiac surgery with CPB.
   Interventions: Patients were randomly assigned to 3 different treatment options for weaning from CPB after cardiac surgery. Group A received milrinone, 0.5 mu g/kg/min, after the release of the aortic cross-clamp; group B received levosimendan, 0.1 mu g/kg/min, after the induction of anesthesia; and in group C, levosimendan, 0.1 mu g/kg/min, was started immediately after the release of the aortic cross-clamp. In all patients, additional dobutamine, 5 mu g/kg/min, was initiated after the release of the aortic cross-clamp. Norepinephrine maintained mean arterial pressure constant.
   Measurements and Main Results: Stroke volume after surgery was initially higher than at baseline in all groups and highest in group B. Stroke volume declined 12 hours after surgery in group A but not in groups B and C (p < 0.05 between groups), despite similar filling pressures. Four patients in group A, none in group 13, and 1 in group C died within 30 days of surgery. Postoperative atrial fibrillation was observed in 10 patients in group A, 7 patients in group C, and only 1 in group B (p < 0.01). No differences were observed in postoperative troponin I release among groups.
   Conclusion: In the conditions of the present study, starting the levosimendan treatment before CPB was associated with a higher initial postoperative stroke volume and a lower incidence of postoperative atrial fibrillation, but had no effect on the extent of postoperative troponin I release. (c) 2008 Elsevier Inc. All rights reserved.
C1 [De Hert, Stefan G.] Univ Amsterdam, Acad Med Ctr, Div Cardiothorac & Vasc Anesthesiol, Dept Anesthesiol, NL-1100 AZ Amsterdam, Netherlands.
RP De Hert, SG (reprint author), Univ Amsterdam, Acad Med Ctr, Div Cardiothorac & Vasc Anesthesiol, Dept Anesthesiol, Meibergdreef 9, NL-1100 AZ Amsterdam, Netherlands.
EM s.g.dehert@amc.uva.nl
CR Barisin S, 2004, J CARDIOVASC PHARM, V44, P703, DOI 10.1097/00005344-200412000-00013
   Braun JP, 2006, CRIT CARE, V10, DOI 10.1186/cc3979
   Cromheecke S, 2006, ANESTH ANALG, V103, P289, DOI 10.1213/01.ane.0000226097.22384.f4
   De Hert SG, 2004, ANESTHESIOLOGY, V101, P299, DOI 10.1097/00000542-200408000-00009
   De Hert SG, 2004, ANESTHESIOLOGY, V101, P9, DOI 10.1097/00000542-200407000-00005
   De Hert SG, 2007, ANESTH ANALG, V104, P766, DOI 10.1213/01.ane.0000256863.92050.d3
   De Luca L, 2006, EUR HEART J, V27, P1908, DOI 10.1093/eurheartj/ehi875
   DEHERT SG, 1995, J CARDIOTHOR VASC AN, V9, P264, DOI 10.1016/S1053-0770(05)80319-2
   DESPOTIS GJ, 1994, J THORAC CARDIOV SUR, V107, P271
   Follath F, 2002, LANCET, V360, P196, DOI 10.1016/S0140-6736(02)09455-2
   Guarracino F, 2006, J CARDIOTHOR VASC AN, V20, P477, DOI 10.1053/j.jvca.2006.05.012
   Kersten JR, 2000, ANESTH ANALG, V90, P5, DOI 10.1097/00000539-200001000-00003
   Kivikko M, 2002, J CLIN PHARMACOL, V42, P43, DOI 10.1177/0091270002042001005
   Kivikko M, 2003, CIRCULATION, V107, P81, DOI 10.1161/01.CIR.0000043245.00859.11
   Labriola C, 2004, INT J CLIN PHARM TH, V42, P204
   Landoni G, 2007, J CARDIOTHOR VASC AN, V21, P672, DOI 10.1053/j.jvca.2006.11.017
   Landoni G, 2007, J CARDIOTHOR VASC AN, V21, P502, DOI 10.1053/j.jvca.2007.02.013
   Lilleberg J, 1998, EUR HEART J, V19, P660, DOI 10.1053/euhj.1997.0806
   Morelli A, 2005, INTENS CARE MED, V31, P638, DOI 10.1007/s00134-005-2619-z
   Nashef SAM, 1999, EUR J CARDIO-THORAC, V16, P9, DOI 10.1016/S1010-7940(99)00134-7
   Nijhawan N, 1999, J CARDIOVASC PHARM, V34, P219, DOI 10.1097/00005344-199908000-00007
   Oldner A, 2001, CRIT CARE MED, V29, P2185, DOI 10.1097/00003246-200111000-00022
   Pagel PS, 1996, BRIT J PHARMACOL, V119, P609, DOI 10.1111/j.1476-5381.1996.tb15716.x
   Pollesello P, 2007, J CARDIOVASC PHARM, V50, P257, DOI 10.1097/FJC.0b013e3180986230
   Raja SG, 2006, ANN THORAC SURG, V81, P1536, DOI 10.1016/j.athoracsur.2005.08.073
   Schwarte LA, 2005, CRIT CARE MED, V33, P135, DOI 10.1097/01.CCM.0000150653.89451.6F
   Siirila-Waris K, 2005, J CARDIOTHOR VASC AN, V19, P345, DOI 10.1053/j.jvca.2005.03.012
   Takahashi R, 2000, EUR J PHARMACOL, V400, P103, DOI 10.1016/S0014-2999(00)00385-X
   Takahashi R, 2000, J CARDIOVASC PHARM, V36, P118, DOI 10.1097/00005344-200007000-00016
   Tasouli A, 2007, EUR J CARDIO-THORAC, V32, P629, DOI 10.1016/j.ejcts.2007.07.010
   Toller WG, 2006, ANESTHESIOLOGY, V104, P556, DOI 10.1097/00000542-200603000-00024
   Tritapepe L, 2006, BRIT J ANAESTH, V96, P694, DOI 10.1093/bja/ael082
   Ukkonen H, 2000, CLIN PHARMACOL THER, V68, P522, DOI 10.1067/mcp.2000.110972
   Ukkonen H, 1997, CLIN PHARMACOL THER, V61, P596, DOI 10.1016/S0009-9236(97)90139-9
   Van der Linden P, 2001, CAN J ANAESTH, V48, P894, DOI 10.1007/BF03017357
   Yapic D, 2008, EUR J ANAESTH, V25, P8, DOI 10.1017/S0265021507002736
   Yilmaz MB, 2007, CARDIOVASC DRUG THER, V21, P431, DOI 10.1007/s10557-007-6066-7
   Yokoshiki H, 1997, J PHARMACOL EXP THER, V283, P375
NR 38
TC 44
Z9 48
U1 2
U2 12
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1053-0770
EI 1532-8422
J9 J CARDIOTHOR VASC AN
JI J. Cardiothorac. Vasc. Anesth.
PD OCT
PY 2008
VL 22
IS 5
BP 699
EP 705
DI 10.1053/j.jvca.2008.02.019
PG 7
WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System;
   Peripheral Vascular Disease
SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System
GA 357OM
UT WOS:000259856000009
PM 18922426
DA 2018-12-27
ER

PT J
AU Han, C
   Lim, K
   Xu, LH
   Li, GY
   Wu, T
AF Han, Chang
   Lim, Kyu
   Xu, Lihong
   Li, Guiying
   Wu, Tong
TI RETRACTED: Regulation of Wnt/beta-catenin pathway by cPLA(2)alpha and
   PPAR delta (Retracted article. See vol. 116, pg. 686, 2015)
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE cPLA(2); PPAR-delta; arachidonic acid; beta-catenin; cholangiocarcinoma
ID CYTOSOLIC PHOSPHOLIPASE A(2); PROLIFERATOR-ACTIVATED RECEPTORS; E-2
   SIGNALING PATHWAYS; NUCLEAR-ENVELOPE; ARACHIDONIC-ACID; LIPID MEDIATORS;
   MICE DEFICIENT; COLON-CANCER; CELL-GROWTH; LUNG INJURY
AB Cytosolic phospholipase A(2)alpha (cPLA(2)alpha) is a rate-limiting key enzyme that releases arachidonic acid (AA) from membrane phospholipid for the production of biologically active lipid mediators including prostaglandins, leukotrienes and platelet-activating factor. cPLA(2)alpha is translocated to nuclear envelope in response to intracellular calcium increase and the enzyme is also present inside the cell nucleus; however, the biological function of cPLA(2)alpha in the nucleus remains unknown. Here we show a novel role of cPLA(2)alpha for activation of peroxisome proliferator-activated receptor-delta (PPAR delta) and beta-catenin in the nuclei. Overexpression of cPLA(2)alpha in human cholangiocarcinoma cells induced the binding of PPAR delta beta-catenin and increased their association with the TCF/LEF response element. These effects are inhibited by the cPLA(2)alpha siRNA and inhibitors as well as by siRNA knockdown of PPAR delta. Overexpression of PPAR delta or treatment with the selective PPAR delta ligand, GW501516, also increased beta-catenin binding to TCF/LFF response element and increased its reporter activity. Addition of AA and GW501516 to nuclear extracts induced a comparable degree of beta-catenin binding to TCF/LEF response element. Furthermore, cPLA(2)alpha protein is present in the PPAR delta and beta-catenin binding complex. Thus the close proximity between cPLA(2)alpha and PPAR delta provides a unique advantage for their efficient functional coupling in the nucleus, where AA produced by cPLA(2)alpha becomes immediately available for PPAR delta binding and subsequent beta-catenin activation. These results depict a novel interaction linking cPLA(2)alpha, PPAR delta and Wnt/beta-catenin signaling pathways and provide insight for further understanding the roles of these key molecules in human cells and diseases.
C1 [Han, Chang; Lim, Kyu; Xu, Lihong; Li, Guiying; Wu, Tong] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA.
RP Han, C (reprint author), Univ Pittsburgh, Sch Med, Dept Pathol, MUH E-740,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM changhan@pitt.edu; wut@upmc.edu
FU Cancer Research and Prevention Foundation grant; National Institutes of
   Health [R01 CA102325, 106280]
FX This study was supported by the Cancer Research and Prevention
   Foundation grant (to C.H.) and the National Institutes of Health grants
   R01 CA102325 and 106280 (to T.W.).
CR Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175
   Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635
   Bonventre JV, 2004, TRENDS IMMUNOL, V25, P116, DOI 10.1016/j.it.2004.01.006
   Capper EA, 2001, PROG LIPID RES, V40, P167, DOI 10.1016/S0163-7827(01)00002-9
   Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221
   Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573
   Chinetti-Gbaguidi G, 2005, CURR OPIN PHARMACOL, V5, P177, DOI 10.1016/j.coph.2004.11.004
   CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Desvergne B, 2004, MOL ENDOCRINOL, V18, P1321, DOI 10.1210/me.2004-0088
   Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0
   Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200
   Fitzpatrick FA, 2001, J CLIN INVEST, V107, P1347, DOI 10.1172/JCI13241
   FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0
   Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871
   Ghosh M, 2006, PROG LIPID RES, V45, P487, DOI 10.1016/j.plipres.2006.05.003
   Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200
   Grewal S, 2002, J CELL SCI, V115, P4533, DOI 10.1242/jcs.00148
   Han C, 2004, J BIOL CHEM, V279, P44344, DOI 10.1074/jbc.M404852200
   Han C, 2004, CANCER RES, V64, P1369, DOI 10.1158/0008-5472.CAN-03-1086
   Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5
   He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5
   Hegen M, 2003, J EXP MED, V197, P1297, DOI 10.1084/jem.20030016
   Herbert SP, 2005, MOL BIOL CELL, V16, P3800, DOI 10.1091/mbc.E05-02-0164
   Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163
   Hoppler S, 2007, J CELL SCI, V120, P385, DOI 10.1242/jcs.03363
   Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k
   Kita Y, 2006, BBA-MOL CELL BIOL L, V1761, P1317, DOI 10.1016/j.bbalip.2006.08.001
   Kliewer SA, 2001, RECENT PROG HORM RES, V56, P239, DOI 10.1210/rp.56.1.239
   KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9
   Knouff C, 2004, ENDOCR REV, V25, P899, DOI 10.1210/er.2003-0036
   Leslie CC, 2004, PROSTAG LEUKOTR ESS, V70, P373, DOI 10.1016/j.plefa.2003.12.012
   Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709
   Marusic S, 2005, J EXP MED, V202, P841, DOI 10.1084/jem.20050665
   Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254
   Michalik L, 2006, PHARMACOL REV, V58, P726, DOI 10.1124/pr.58.4.5
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101
   Nagase T, 2000, NAT IMMUNOL, V1, P42
   Nagase T, 2003, AM J PHYSIOL-LUNG C, V284, pL720, DOI 10.1152/ajplung.00396.2002
   Nagase T, 2002, NAT MED, V8, P480, DOI 10.1038/nm0502-480
   Nakatani N, 2000, BIOCHEM J, V352, P311, DOI 10.1042/0264-6021:3520311
   PetersGolden M, 1996, BIOCHEM J, V318, P797, DOI 10.1042/bj3180797
   Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419
   Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   Schaloske RH, 2006, BBA-MOL CELL BIOL L, V1761, P1246, DOI 10.1016/j.bbalip.2006.07.011
   Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749
   Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200
   SHARP JD, 1994, J BIOL CHEM, V269, P23250
   SierraHonigmann R, 1996, LAB INVEST, V74, P684
   Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701
   Tabuchi S, 2003, ACT NEUR S, V86, P169
   Tan NS, 2005, J STEROID BIOCHEM, V93, P99, DOI 10.1016/j.jsbm.2004.12.025
   Tsuboi K, 2002, PROSTAG OTH LIPID M, V68-9, P535, DOI 10.1016/S0090-6980(02)00054-0
   Uozumi N, 1997, NATURE, V390, P618
   VAMCEQ J, 1999, LANCET, V354, P141
   Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011
   Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341
   Wu T, 2002, HEPATOLOGY, V36, P363, DOI 10.1053/jhep.2002.34743
   Xu L, 2008, J BIOL CHEM, V283, P3077, DOI 10.1074/jbc.M705709200
   Xu LH, 2006, J BIOL CHEM, V281, P33982, DOI 10.1074/jbc.M600135200
   Xu LH, 2006, CANCER RES, V66, P11859, DOI 10.1158/0008-5472.CAN-06-1445
NR 64
TC 21
Z9 22
U1 4
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT 1
PY 2008
VL 105
IS 2
BP 534
EP 545
DI 10.1002/jcb.21852
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 356QN
UT WOS:000259792800023
PM 18636547
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Kapoor, M
   Liu, SX
   Shi-Wen, X
   Huh, K
   McCann, M
   Denton, CP
   Woodgett, JR
   Abraham, DJ
   Leask, A
AF Kapoor, Mohit
   Liu, Shangxi
   Shi-Wen, Xu
   Huh, Kun
   McCann, Matthew
   Denton, Christopher P.
   Woodgett, James R.
   Abraham, David J.
   Leask, Andrew
TI RETRACTED: GSK-3 beta in mouse fibroblasts controls wound healing and
   fibrosis through an endothelin-1-dependent mechanism (Retracted article.
   See vol. 118, pg. 3812, 2008)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID HYPERPLASTIC CUTANEOUS WOUNDS; BETA-CATENIN STABILIZATION; ACTIVATION;
   PATHWAY; MATRIX; CCN2
AB Glycogen synthase kinase-3 (GSK-3) is a widely expressed and highly conserved serine/threonine protein kinase encoded by 2 genes, GSK3A and GSK3B. GSK-3 is thought to be involved in tissue repair and fibrogenesis, but its role in these processes is currently unknown. To investigate the function of GSK-3 beta in fibroblasts, we generated mice harboring a fibroblast-specific deletion of Gsk3b and evaluated their wound-healing and fibrogenic responses. We have shown that Gsk3b-conditional-KO mice (Gsk3b-CKO mice) exhibited accelerated wound closure, increased fibrogenesis, and excessive scarring compared with control mice. In addition, Gsk3b-CKO mice showed elevated collagen production, decreased cell apoptosis, elevated levels of profibrotic alpha-SMA, and increased myofibroblast formation during wound healing. In cultured Gsk3b-CKO fibroblasts, adhesion, spreading, migration, and contraction were enhanced. Both Gsk3b-CKO mice and fibroblasts showed elevated expression and production of endothelin-1 (ET-1) compared with control mice and cells. Antagonizing ET-1 reversed the phenotype of Gsk3b-CKO fibroblasts and mice. Thus, GSK-3 beta appears to control the progression of wound healing and fibrosis by modulating ET-1 levels. These results suggest that targeting the GSK-3 beta pathway or ET-1 may be of benefit in controlling tissue repair and fibrogenic responses in vivo.
C1 [Leask, Andrew] Univ Western Ontario, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, Div Oral Biol, London, ON N6A 5C1, Canada.
   [Kapoor, Mohit; Liu, Shangxi; Huh, Kun; McCann, Matthew; Leask, Andrew] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada.
   [Shi-Wen, Xu; Denton, Christopher P.; Abraham, David J.] UCL, Ctr Rheumatol, London, England.
   [Woodgett, James R.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
RP Leask, A (reprint author), Univ Western Ontario, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, Div Oral Biol, Dent Sci Bldg, London, ON N6A 5C1, Canada.
EM Andrew.leask@schulich.uwo.ca
RI Woodgett, Jim/F-1087-2010
OI Woodgett, Jim/0000-0003-3731-5797
FU Canadian Foundation for Innovation; Canadian institutes of Health
   Research; Arthritis Research Campaign; Reynaud's and Scleroderma
   Foundation; Scleroderma Society; Canadian Scleroderma Research Group;
   Canadian Arthritis Network; Ontario Ministry of Research and Innovation
FX This work is supported by grants from the Canadian Foundation for
   Innovation and the Canadian institutes of Health Research, the Arthritis
   Research Campaign, the Reynaud's and Scleroderma Foundation, and the
   Scleroderma Society. A. Leask is a New Investigator of the Arthritis
   Society (Scleroderma Society of Ontario), the recipient of an Early
   Researcher Award, and a member of the Canadian Scleroderma Research
   Group New Emerging Team. M. Kapoor is the recipient of postdoctoral
   fellowships from the Canadian Arthritis Network and the Ontario Ministry
   of Research and Innovation.
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Alman BA, 1997, AM J PATHOL, V151, P329
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Chen SQ, 2007, J CELL COMMUN SIGNAL, V1, P175, DOI 10.1007/s12079-007-0015-x
   Chen YL, 2005, AM J PATHOL, V167, P1699, DOI 10.1016/S0002-9440(10)61252-7
   Cheon S, 2005, LAB INVEST, V85, P416, DOI 10.1038/labinvest.3700237
   Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399
   Clozel M, 2005, ANN MED, V37, P2, DOI 10.1080/07853890410018925
   Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384
   Eckes B, 1999, SPRINGER SEMIN IMMUN, V21, P415, DOI 10.1007/BF00870303
   Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427
   Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574
   Kennedy L, 2007, EXP CELL RES, V313, P952, DOI 10.1016/j.yexcr.2006.12.006
   Kim TH, 2005, ONCOGENE, V24, P597, DOI 10.1038/sj.onc.1208237
   Leask A, 2008, CELL SIGNAL, V20, P1409, DOI 10.1016/j.cellsig.2008.01.006
   Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75
   Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   NEUMAN RE, 1950, J BIOL CHEM, V184, P299
   Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735
   Patel S, 2004, BIOCHEM SOC T, V32, P803, DOI 10.1042/BST0320803
   Ponticos M, 2004, MATRIX BIOL, V22, P619, DOI 10.1016/j.matbio.2003.12.002
   Reddy GK, 1996, CLIN BIOCHEM, V29, P225, DOI 10.1016/0009-9120(96)00003-6
   Shi-Wen X, 2006, J BIOL CHEM, V281, P10715, DOI 10.1074/jbc.M511343200
   Shi-Wen Xu, 2006, Mol Cell Biol, V26, P5518, DOI 10.1128/MCB.00625-06
   Tanabe K, 2008, PLOS BIOL, V6, P307, DOI 10.1371/journal.pbio.0060037
   Xu SW, 2007, MATRIX BIOL, V26, P625, DOI 10.1016/j.matbio.2007.06.003
   Xu SW, 2004, MOL BIOL CELL, V15, P2707, DOI 10.1091/mbc.E03-12-0902
   Zheng B, 2002, AM J PATHOL, V160, P1609, DOI 10.1016/S0002-9440(10)61108-X
NR 29
TC 51
Z9 53
U1 3
U2 11
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD OCT
PY 2008
VL 118
IS 10
BP 3279
EP 3290
DI 10.1172/JCI35381
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 357EH
UT WOS:000259828600011
PM 18802478
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Hollingsworth, JW
   Maruoka, S
   Boon, K
   Garantziotis, S
   Li, ZW
   Tomfohr, J
   Bailey, N
   Potts, EN
   Whitehead, G
   Brass, DM
   Schwartz, DA
AF Hollingsworth, John W.
   Maruoka, Shuichiro
   Boon, Kathy
   Garantziotis, Stavros
   Li, Zhuowei
   Tomfohr, John
   Bailey, Nathaniel
   Potts, Erin N.
   Whitehead, Gregory
   Brass, David M.
   Schwartz, David A.
TI RETRACTED: In utero supplementation with methyl donors enhances allergic
   airway disease in mice (Retracted article. See vol. 126, pg. 2012, 2016)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID FOXP3 GENE-EXPRESSION; HELPER TYPE-1 CELLS; DNA METHYLATION; RUNX3;
   EPIGENETICS; DIFFERENTIATION; INFLAMMATION; CANCER; MOUSE; INHERITANCE
AB Asthma is a complex heritable disease that is increasing in prevalence and severity, particularly in developed countries such as the United States, where 11% of the population is affected. The contribution of environmental and genetic factors to this growing epidemic is currently not well understood. We developed the hypothesis, based on previous literature, that changes in DNA methylation resulting in aberrant gene transcription may enhance the risk of developing allergic airway disease. our findings indicate that in mice, a maternal diet supplemented with methyl donors enhanced the severity of allergic airway disease that was inherited transgenerationally. Using a genomic approach, we discovered 82 gene-associated loci that were differentially methylated after in utero supplementation with a methyl-rich diet. These methylation changes were associated with decreased transcriptional activity and increased disease severity. Runt-related transcription factor 3 (Runx3), a gene known to negatively regulate allergic airway disease, was found to be excessively methylated, and Runx3 mRNA and protein levels were suppressed in progeny exposed in utero to a high-methylation diet. Moreover, treatment with a demethylating agent increased Runx3 gene transcription, further supporting our claim that a methyl-rich diet can affect methylation status and consequent transcriptional regulation. Our findings indicate that dietary factors can modify the heritable risk of allergic airway disease through epigenetic mechanisms during a vulnerable period of fetal development in mice.
C1 [Hollingsworth, John W.; Garantziotis, Stavros; Li, Zhuowei; Potts, Erin N.] Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Dept Med, Durham, NC 27710 USA.
   [Hollingsworth, John W.; Maruoka, Shuichiro; Boon, Kathy; Garantziotis, Stavros; Li, Zhuowei; Tomfohr, John; Bailey, Nathaniel; Brass, David M.; Schwartz, David A.] NHLBI, Environm Lung Dis Lab, Res Triangle Pk, NC USA.
   [Boon, Kathy] NCI, Off Canc Genom, Bethesda, MD 20892 USA.
   [Garantziotis, Stavros; Whitehead, Gregory] Natl Inst Environm Hlth Sci, Lab Resp Biol, Res Triangle Pk, NC USA.
   [Brass, David M.] Duke Univ, Med Ctr, Neonatal Perinatal Res Inst, Durham, NC 27710 USA.
   [Schwartz, David A.] Natl Jewish Hlth, Dept Med, Div Pulm Crit Care, Denver, CO USA.
RP Hollingsworth, JW (reprint author), Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Dept Med, Box 3136, Durham, NC 27710 USA.
EM holli017@mc.duke.edu
RI Garantziotis, Stavros/A-6903-2009
OI Garantziotis, Stavros/0000-0003-4007-375X
FU NIH; National Heart, Lung, and Blood Institute [HL91335]
FX This work was supported in part by the Intramural Research Program of
   the NIH, National Heart, Lung, and Blood Institute (to D.A. Schwartz).
   The authors also receive support through a National Heart, Lung, and
   Blood Institute career development award (HL91335 to J.W.
   Hollingsworth). We thank Richard Del Mastro for his support with the
   global DNA methylation assay and both Maria Sifre and John Whitesides
   for their assistance with flow cytometry. Histology analysis was
   provided by the Pathology Support Group, a division of the Laboratory of
   Experimental Pathology, NIEHS. We appreciate the dedication from both
   Jessica Ramsberger and Sandy Hackney with animal husbandry.
CR Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   *CDCP, 2004, MMWR-MORBID MORTAL W, V53, P145
   Digel W, 2005, CRIT REV ONCOL HEMAT, V55, P1, DOI 10.1016/j.critrevonc.2005.02.002
   Djuretic IM, 2007, NAT IMMUNOL, V8, P145, DOI 10.1038/ni1424
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308
   Ehlers M, 2003, J IMMUNOL, V171, P3594, DOI 10.4049/jimmunol.171.7.3594
   Fainaru O, 2005, P NATL ACAD SCI USA, V102, P10598, DOI 10.1073/pnas.0504787102
   Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fields PE, 2004, IMMUNITY, V21, P865, DOI 10.1016/j.immuni.2004.10.015
   Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hollingsworth JW, 2006, J IMMUNOL, V176, P5856, DOI 10.4049/jimmunol.176.10.5856
   Holt PG, 2000, ALLERGY, V55, P688, DOI 10.1034/j.1398-9995.2000.00118.x
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Jiang YH, 2004, ANNU REV GENOM HUM G, V5, P479, DOI 10.1146/annurev.genom.5.061903.180014
   Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109
   Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X
   Lee GR, 2006, IMMUNITY, V24, P369, DOI 10.1016/j.immuni.2006.03.007
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6
   Lukacs NW, 1996, J LEUKOCYTE BIOL, V60, P573
   Moephuli SR, 1997, P NATL ACAD SCI USA, V94, P543, DOI 10.1073/pnas.94.2.543
   Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490
   Mueller W, 2007, ONCOGENE, V26, P583, DOI 10.1038/sj.onc.1209805
   Naoe Y, 2007, J EXP MED, V204, P1749, DOI 10.1084/jem.20062456
   Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105
   Puig-Kroger A, 2006, J CELL BIOCHEM, V98, P744, DOI 10.1002/jcb.20813
   Rakyan VK, 2003, P NATL ACAD SCI USA, V100, P2538, DOI 10.1073/pnas.0436776100
   Rosenquist TH, 2001, P NUTR SOC, V60, P53
   Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508
   Santangelo S, 2002, J IMMUNOL, V169, P1893, DOI 10.4049/jimmunol.169.4.1893
   Shin HJ, 2005, J IMMUNOL, V175, P7143, DOI 10.4049/jimmunol.175.11.7143
   Skinner MK, 2008, REPROD TOXICOL, V25, P2, DOI 10.1016/j.reprotox.2007.09.001
   Subramaniam MM, 2009, BREAST CANCER RES TR, V113, P113, DOI 10.1007/s10549-008-9917-4
   Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X
   Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003
   WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D
   Wolff GL, 1998, FASEB J, V12, P949
   Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100
NR 41
TC 322
Z9 336
U1 8
U2 65
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD OCT
PY 2008
VL 118
IS 10
BP 3462
EP 3469
DI 10.1172/JCI34378
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 357EH
UT WOS:000259828600027
PM 18802477
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Bellinger, DL
   Lubahn, C
   Lorton, D
AF Bellinger, Denise L.
   Lubahn, Cheri
   Lorton, Dianne
TI RETRACTED: Maternal and early life stress effects on immune function:
   relevance to immunotoxicology (Retracted article. See vol. 8, pg. 399,
   2008)
SO JOURNAL OF IMMUNOTOXICOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 46th Annual Meeting of the Society-of-Toxicology
CY MAR 25-29, 2007
CL Charlotte, NC
SP Soc Toxicol
DE prenatal stress; postnatal stress; immune system; gestation; placenta;
   glucocorticoids; catecholamines; hypothalamic-pituitary-adrenocortical
   axis; sympathetic nervous system
ID PITUITARY-ADRENAL AXIS; LEUKEMIA INHIBITORY FACTOR; T-CELL DEVELOPMENT;
   GLUCOCORTICOID-INDUCED APOPTOSIS; CORTICOTROPIN-RELEASING-FACTOR;
   CENTRAL-NERVOUS-SYSTEM; LONG-TERM ALTERATIONS; TRANS-RETINOIC ACID;
   COMPLETE FOLLOW-UP; PRENATAL STRESS
AB Stress is triggered by a variety of unexpected environmental stimuli, such as aggressive behavior, fear, forced physical activity, sudden environmental changes, social isolation or pathological conditions. Stressful experiences during very early life (particularly, maternal stress during fetal ontogeny) can permanently alter the responsiveness of the nervous system, an effect called programming or imprinting. Programming affects the hypothalamic-pituitary-adrenocortical (HPA) axis, brain neurotransmitter systems, sympathetic nervous system (SNS), and the cognitive abilities of the offspring, which can alter neural regulation of immune function. Prenatal or early life stress may contribute to the malaclaptive immune responses to stress that occur later in life. This review focuses on the effect of maternal and early life stress on immune function in the offspring across life span. It highlights potential mechanisms by which prenatal stress impacts immune functions over life span. The literature discussed in this review suggests that psychosocial stress during pre- and early postnatal life may increase the vulnerability of infants to the effects of immunotoxicants or immune-mediated diseases, with long-term consequences. Neural-immune interactions may provide an indirect route through which immunotoxicants affect the developing immune system. A developmental approach to understanding how immunotoxicants interact with maternal and early life stress-induced changes in immunity is needed, because as the body changes physiologically across life span so do the effects of stress and immunotoxicants. In early and late life, the immune system is more vulnerable to the effects of stress. Stress can mimic the effects of aging and exacerbate age-related changes in immune function. This is important because immune dysregulation in the elderly is more frequently and seriously associated with clinical impairment and death. Aging, exposure to teratogens, and psychological stress interact to increase vulnerability and put the elderly at the greatest risk for disease.
C1 [Bellinger, Denise L.] Loma Linda Univ, Sch Med, Dept Pathol & Human Anat, Loma Linda, CA 92352 USA.
   [Lubahn, Cheri; Lorton, Dianne] Sun Hlth Res Inst, Hoover Arthrit Res Ctr, Sun City, AZ USA.
RP Bellinger, DL (reprint author), Loma Linda Univ, Sch Med, Dept Pathol & Human Anat, Alumni Hall Basic Sci,Rm 325,11021 Campus St, Loma Linda, CA 92352 USA.
EM dbellinger@llu.edu
CR ADER R, 1968, PSYCHOSOM MED, V30, P277, DOI 10.1097/00006842-196805000-00002
   AIRD F, 1993, P NATL ACAD SCI USA, V90, P7104, DOI 10.1073/pnas.90.15.7104
   Ashwell JD, 1996, STEM CELLS, V14, P490, DOI 10.1002/stem.140490
   Aspinall R, 2006, MECH AGEING DEV, V127, P572, DOI 10.1016/j.mad.2006.01.016
   Bakker JM, 1995, J NEUROIMMUNOL, V63, P183, DOI 10.1016/0165-5728(95)00152-2
   Bakker JM, 2001, J NEUROIMMUNOL, V112, P47, DOI 10.1016/S0165-5728(00)00406-9
   Bakker JM, 1998, J NEUROIMMUNOL, V82, P56, DOI 10.1016/S0165-5728(97)00188-4
   BALLOW M, 1986, PEDIATR RES, V20, P899, DOI 10.1203/00006450-198609000-00019
   Barbazanges A, 1996, J NEUROSCI, V16, P3943
   Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235
   BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A
   BATANERO E, 1992, BRAIN BEHAV IMMUN, V6, P249, DOI 10.1016/0889-1591(92)90047-R
   BATE LA, 1985, CAN J ANIM SCI, V65, P87, DOI 10.4141/cjas85-009
   BATE LA, 1985, CAN J ANIM SCI, V65, P77, DOI 10.4141/cjas85-008
   BATE LA, 1991, HISTOL HISTOPATHOL, V6, P207
   Bellinger DL, 2001, NEUROIMMUNOMODULAT, V9, P78, DOI 10.1159/000049010
   BELLINGER DL, 2005, IMMUNOPHARMACOLOGY I, P489
   Benediktsson R, 1997, CLIN ENDOCRINOL, V46, P161, DOI 10.1046/j.1365-2265.1997.1230939.x
   BENOIST C, 1999, FUNDAMENTAL IMMUNOLO, P376
   Berki T, 2002, INT IMMUNOL, V14, P463, DOI 10.1093/intimm/14.5.463
   Blattman JN, 2003, NAT MED, V9, P540, DOI 10.1038/nm866
   Blois SM, 2004, J IMMUNOL, V172, P5893, DOI 10.4049/jimmunol.172.10.5893
   Boisse L, 2004, J NEUROSCI, V24, P4928, DOI 10.1523/JNEUROSCI.1077-04.2004
   Brewer JA, 2002, ENDOCR RES, V28, P545, DOI 10.1081/ERC-120016839
   Brewer JA, 2003, NAT MED, V9, P1318, DOI 10.1038/nm895
   Brewer JA, 2002, J IMMUNOL, V169, P1837, DOI 10.4049/jimmunol.169.4.1837
   Brewer JA, 2002, J IMMUNOL, V169, P1309, DOI 10.4049/jimmunol.169.3.1309
   Brouxhon SM, 1998, BRAIN BEHAV IMMUN, V12, P107, DOI 10.1006/brbi.1998.0520
   CAPITANIO JP, 1991, AIDS, V5, P1103, DOI 10.1097/00002030-199109000-00007
   Carrion VG, 2002, BIOL PSYCHIAT, V51, P575, DOI 10.1016/S0006-3223(01)01310-5
   CASTILLA JA, 1989, J REPROD IMMUNOL, V15, P103, DOI 10.1016/0165-0378(89)90030-2
   Challis JRG, 2000, ENDOCR REV, V21, P514, DOI 10.1210/er.21.5.514
   CHAOUAT G, 1995, J IMMUNOL, V154, P4261
   CHEN CH, 1974, J REPROD FERTIL, V39, P407
   Chen D, 2000, OCCUP ENVIRON MED, V57, P661, DOI 10.1136/oem.57.10.661
   Chen JC, 1997, INT J DEV NEUROSCI, V15, P257, DOI 10.1016/S0736-5748(96)00121-9
   Chen YaoXing, 2000, Journal of China Agricultural University, V5, P113
   Cheng LE, 2002, P NATL ACAD SCI USA, V99, P3001, DOI 10.1073/pnas.052676899
   COE C L, 1989, Brain Behavior and Immunity, V3, P47, DOI 10.1016/0889-1591(89)90005-6
   Coe CL, 2007, PEDIATR RES, V61, P520, DOI 10.1203/pdr.0b013e318045be53
   Coe CL, 2000, HEALTH PSYCHOL, V19, P554, DOI 10.1037//0278-6133.19.6.554
   Coe CL, 1999, BIOL NEONATE, V76, P301, DOI 10.1159/000014172
   Coe CL, 2002, J CLIN ENDOCR METAB, V87, P675, DOI 10.1210/jc.87.2.675
   Coe CL, 1997, DEV PSYCHOBIOL, V30, P1
   COE CL, 1992, PEDIATRICS, V90, P505
   Coe CL, 2000, ANN NY ACAD SCI, V917, P468
   Coe CL, 1996, BRAIN BEHAV IMMUN, V10, P221, DOI 10.1006/brbi.1996.0020
   COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608
   Colomina MT, 2001, TERATOLOGY, V63, P144, DOI 10.1002/tera.1025
   Copper RL, 1996, AM J OBSTET GYNECOL, V175, P1286, DOI 10.1016/S0002-9378(96)70042-X
   Cory-Slechta DA, 2005, NEUROTOXICOLOGY, V26, P491, DOI 10.1016/j.neuro.2004.12.007
   Cory-Slechta DA, 2004, ENVIRON HEALTH PERSP, V112, P717, DOI 10.1289/ehp.6481
   Coussons-Read ME, 2007, BRAIN BEHAV IMMUN, V21, P343, DOI 10.1016/j.bbi.2006.08.006
   Coussons-Read ME, 2005, PSYCHOSOM MED, V67, P625, DOI 10.1097/01.psy.0000170331.74960.ad
   d'Hauterive SP, 2005, NEUROIMMUNOMODULAT, V12, P157, DOI 10.1159/000084848
   DALLMAN MF, 2000, ENCY STRESS, P468
   DEGENNE D, 1988, CLIN IMMUNOL IMMUNOP, V48, P187, DOI 10.1016/0090-1229(88)90082-7
   Dhabhar F, 2001, PSYCHONEUROIMMUNOLOG, V1, P301
   Di Santo JP, 1998, CURR OPIN IMMUNOL, V10, P196, DOI 10.1016/S0952-7915(98)80249-5
   Dietert RR, 2003, TOXICOLOGY, V194, P163, DOI 10.1016/j.tox.2003.07.001
   Dole N, 2003, AM J EPIDEMIOL, V157, P14, DOI 10.1093/aje/kwf176
   Dong YL, 2007, AUTON NEUROSCI-BASIC, V131, P87, DOI 10.1016/j.autneu.2006.08.001
   DUNN AJ, 1995, PSYCHOPHARMACOLOGY 4, P96
   *EUR FDN IMPR LIV, 2001, 3 EUR SURV WORK COND
   FELTEN DL, 1991, PSYCHONEUROIMMUNOLOG, P1
   Fisher DA, 1998, WILLIAMS TXB ENDOCRI, P1273
   Fonseca ESM, 2005, NEUROENDOCRINOLOGY, V81, P322, DOI 10.1159/000088759
   Fonseca ESM, 2002, PHYSIOL BEHAV, V77, P205, DOI 10.1016/S0031-9384(02)00812-0
   Fowden AL, 2006, PHYSIOLOGY, V21, P29, DOI 10.1152/physiol.00050.2005
   Fowden AL, 2004, REPRODUCTION, V127, P515, DOI 10.1530/rep.1.00033
   Franchimont D, 2002, J IMMUNOL, V168, P2212, DOI 10.4049/jimmunol.168.5.2212
   Francis DD, 2002, J NEUROSCI, V22, P7840
   FRIDE E, 1989, PHARMACOL BIOCHEM BE, V32, P425, DOI 10.1016/0091-3057(89)90174-3
   FRIDE E, 1984, DEV PSYCHOBIOL, V17, P651
   Fujioka T, 1999, NEUROSCIENCE, V92, P1079, DOI 10.1016/S0306-4522(99)00073-1
   Gerardin DCC, 2005, PHYSIOL BEHAV, V84, P97, DOI 10.1016/j.physbeh.2004.10.014
   Godfrey DI, 2000, IMMUNOL TODAY, V21, P606, DOI 10.1016/S0167-5699(00)01741-2
   Gotz AA, 2007, J NEUROIMMUNOL, V185, P95, DOI 10.1016/j.jneuroim.2007.01.019
   Gotz AA, 2007, PHYSIOL BEHAV, V90, P108, DOI 10.1016/j.physbeh.2006.09.014
   GOLDMAN AS, 1964, ARCH ENVIRON HEALTH, V8, P648, DOI 10.1080/00039896.1964.10663735
   GOLDMAN AS, 1963, J PHARMACOL EXP THER, V142, P351
   Gonzalez-Ariki S, 1999, J NEUROIMMUNOL, V99, P97, DOI 10.1016/S0165-5728(99)00108-3
   Gonzalez-Ariki S, 1998, BRAIN BEHAV IMMUN, V12, P53, DOI 10.1006/brbi.1997.0509
   GORCZYNSKI RM, 1992, BRAIN BEHAV IMMUN, V6, P87, DOI 10.1016/0889-1591(92)90062-S
   Greenwood JP, 2001, CIRCULATION, V104, P2200, DOI 10.1161/hc4301.098253
   GU W, 1986, J DEV PHYSIOL, V8, P173
   Gunnar MR, 2001, DEV PSYCHOPATHOL, V13, P611, DOI 10.1017/S095457940100311X
   Haghdoost NR, 1997, REPROD TOXICOL, V11, P9, DOI 10.1016/S0890-6238(96)00156-6
   Hamada K, 2003, J IMMUNOL, V170, P1683, DOI 10.4049/jimmunol.170.4.1683
   Hansen D, 2000, LANCET, V356, P875, DOI 10.1016/S0140-6736(00)02676-3
   HARBUZ MS, 1992, J ENDOCRINOL, V134, P327, DOI 10.1677/joe.0.1340327
   HART JL, 1986, AM J PHYSIOL, V251, P1000
   HARTEL A, 1960, SCIENCE, V132, P1483, DOI 10.1126/science.132.3438.1483
   HARVEY PW, 1985, HORM BEHAV, V19, P86, DOI 10.1016/0018-506X(85)90009-1
   Hashimoto M, 2001, PHYSIOL BEHAV, V73, P125, DOI 10.1016/S0031-9384(01)00473-5
   Haussmann MF, 2000, J ANIM SCI, V78, P2399
   Heim C, 2000, JAMA-J AM MED ASSOC, V284, P592, DOI 10.1001/jama.284.5.592
   HENNESSY DP, 1982, J ENDOCRINOL, V95, P71, DOI 10.1677/joe.0.0950071
   HENRY C, 1994, J NEUROENDOCRINOL, V6, P341, DOI 10.1111/j.1365-2826.1994.tb00591.x
   Herold MJ, 2006, CELL MOL LIFE SCI, V63, P60, DOI 10.1007/s00018-005-5390-y
   Hodgson DM, 2001, PEDIATR RES, V50, P750, DOI 10.1203/00006450-200112000-00020
   Holladay SD, 2000, ENVIRON HEALTH PERSP, V108, P463, DOI 10.2307/3454538
   Holsapple MP, 2003, BIRTH DEFECTS RES B, V68, P321, DOI 10.1002/bdrb.10035
   HOLSON RR, 1995, NEUROTOXICOL TERATOL, V17, P393, DOI 10.1016/0892-0362(94)00074-N
   Hougaard KS, 2007, NEUROTOXICOL TERATOL, V29, P425, DOI 10.1016/j.ntt.2007.02.003
   Hougaard KS, 2005, DEV BRAIN RES, V159, P55, DOI 10.1016/j.devbrainres.2005.06.014
   Huizink AC, 2004, PSYCHOL BULL, V130, P115, DOI 10.1037/0033-2909.130.1.115
   Iseki S, 1993, Kokubyo Gakkai Zasshi, V60, P66
   ISHII HIDEO, 1960, GUNMA JOUR MED SCI, V9, P153
   IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316
   Joachim R, 2003, STEROIDS, V68, P931, DOI 10.1016/j.steroids.2003.08.010
   JOHNS A, 1975, CONTRACEPTION, V11, P563, DOI 10.1016/0010-7824(75)90110-9
   JOHNSON EO, 1992, NEUROSCI BIOBEHAV R, V16, P115, DOI 10.1016/S0149-7634(05)80175-7
   Jondal M, 2004, TRENDS IMMUNOL, V25, P595, DOI 10.1016/j.it.2004.09.003
   JONDAL M, 1993, EUR J IMMUNOL, V23, P1246, DOI 10.1002/eji.1830230608
   Kaffman A, 2007, J CHILD PSYCHOL PSYC, V48, P224, DOI 10.1111/j.1469-7610.2007.01730.x
   Kang JS, 2004, CURR OPIN IMMUNOL, V16, P180, DOI 10.1016/j.coi.2004.02.002
   Kapoor A, 2006, J PHYSIOL-LONDON, V572, P31, DOI 10.1113/jphysiol.2006.105254
   Karrow NA, 2006, BRAIN BEHAV IMMUN, V20, P144, DOI 10.1016/j.bbi.2005.05.003
   KASHON ML, 1992, BEHAV NEUROSCI, V106, P555, DOI 10.1037/0735-7044.106.3.555
   Kay G, 1998, PHYSIOL BEHAV, V63, P397, DOI 10.1016/S0031-9384(97)00456-3
   Kehoe P, 2001, DEV BRAIN RES, V132, P23, DOI 10.1016/S0165-3806(01)00292-9
   KELLER EA, 1982, SCIENCE, V215, P1269, DOI 10.1126/science.7058348
   KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3
   KINSLEY C, 1986, PHYSIOL BEHAV, V37, P191, DOI 10.1016/0031-9384(86)90405-1
   KLEIN SL, 1995, DEV PSYCHOBIOL, V28, P321, DOI 10.1002/dev.420280603
   KLEMCKE HG, 1995, BIOL REPROD, V53, P1293, DOI 10.1095/biolreprod53.6.1293
   Klukovits A, 2002, BIOL REPROD, V67, P1013, DOI 10.1095/biolreprod.101.002287
   Kofman O, 2002, NEUROSCI BIOBEHAV R, V26, P457, DOI 10.1016/S0149-7634(02)00015-5
   Kramer BW, 2004, PEDIATR RES, V55, P764, DOI 10.1203/01.PDR.0000120678.72485.19
   Krishnan L, 1996, J IMMUNOL, V156, P653
   Landreth KS, 2002, HUM EXP TOXICOL, V21, P493, DOI 10.1191/0960327102ht287oa
   Langdown ML, 2001, MOL CELL ENDOCRINOL, V185, P109, DOI 10.1016/S0303-7207(01)00629-3
   LARA HE, 1990, ENDOCRINOLOGY, V127, P2199, DOI 10.1210/endo-127-5-2199
   LARA HE, 1990, ENDOCRINOLOGY, V126, P364, DOI 10.1210/endo-126-1-364
   LAUDENSLAGER ML, 1982, BEHAV NEURAL BIOL, V36, P40, DOI 10.1016/S0163-1047(82)90223-0
   Lawlor DA, 2005, CIRCULATION, V112, P1414, DOI 10.1161/CIRCULATIONHA.104.528356
   Lechner O, 2000, EUR J IMMUNOL, V30, P337
   Lechner O, 2001, INT IMMUNOL, V13, P769, DOI 10.1093/intimm/13.6.769
   LEGRAND C, 1986, J REPROD FERTIL, V76, P415
   Lemaire V, 2000, P NATL ACAD SCI USA, V97, P11032, DOI 10.1073/pnas.97.20.11032
   Lesage J, 2004, J ENDOCRINOL, V181, P291, DOI 10.1677/joe.0.1810291
   Lewis MH, 2000, BIOL PSYCHIAT, V47, P119, DOI 10.1016/S0006-3223(99)00238-3
   LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0
   Licinio J, 2000, BRAZ J MED BIOL RES, V33, P1141, DOI 10.1590/S0100-879X2000001000003
   Lin YC, 2004, CLIN EXP ALLERGY, V34, P548, DOI 10.1111/j.1365-2222.2004.1928.x
   Llorente E, 2002, J PHYSIOL BIOCHEM, V58, P143, DOI 10.1159/000064490
   Lobel M, 2000, HEALTH PSYCHOL, V19, P544, DOI 10.1037/0278-6133.19.6.544
   LOBEL M, 1994, J BEHAV MED, V17, P225, DOI 10.1007/BF01857952
   Loizzo A, 2002, BRIT J PHARMACOL, V135, P1219, DOI 10.1038/sj.bjp.0704577
   Longo NS, 1999, MOL IMMUNOL, V36, P979, DOI 10.1016/S0161-5890(99)00134-0
   Lu FWM, 2000, IMMUNITY, V12, P183, DOI 10.1016/S1074-7613(00)80171-5
   LUBACH GR, 1995, BRAIN BEHAV IMMUN, V9, P31, DOI 10.1006/brbi.1995.1004
   Maccari S, 2003, NEUROSCI BIOBEHAV R, V27, P119, DOI 10.1016/S0149-7634(03)00014-9
   MACCARI S, 1995, J NEUROSCI, V15, P110
   MACDONALD E, 1981, MED BIOL, V59, P111
   MACHADONETO R, 1987, J ANIM SCI, V65, P445
   Manni L, 1998, INT J DEV NEUROSCI, V16, P1, DOI 10.1016/S0736-5748(98)00003-3
   MARICHICH ES, 1979, J NUTR, V109, P1045
   Mastorakos G, 2003, ANN NY ACAD SCI, V997, P136, DOI 10.1196/annals.1290.016
   Matthews SG, 2002, TRENDS ENDOCRIN MET, V13, P373, DOI 10.1016/S1043-2760(02)00690-2
   McCarthy LE, 2004, J NEUROIMMUNOL, V153, P91, DOI 10.1016/j.jneuroim.2004.04.006
   McDade TW, 2001, AM J CLIN NUTR, V74, P543
   McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x
   Merlot E, 2008, BRAIN BEHAV IMMUN, V22, P42, DOI 10.1016/j.bbi.2007.05.007
   Miller AH, 1998, CELL IMMUNOL, V186, P45, DOI 10.1006/cimm.1998.1293
   MILLER DB, 1992, VULNERABLE BRAIN ENV, V1, P239
   Minagawa M, 1999, CELL IMMUNOL, V196, P1, DOI 10.1006/cimm.1999.1541
   Mittelstadt PR, 2003, MOL ENDOCRINOL, V17, P1534, DOI 10.1210/me.2002-0429
   Mokler DJ, 2001, NUTR NEUROSCI, V4, P109, DOI 10.1080/1028415X.2001.11747355
   MORALE MC, 1995, ENDOCRINOLOGY, V136, P3949, DOI 10.1210/en.136.9.3949
   MORGAN CD, 1972, AM J OBSTET GYNECOL, V112, P1068
   Morgane PJ, 2002, NEUROSCI BIOBEHAV R, V26, P471, DOI 10.1016/S0149-7634(02)00012-X
   MUGLIA L, 1995, NATURE, V373, P427, DOI 10.1038/373427a0
   MURTHY KK, 1994, EARLY HUM DEV, V36, P1, DOI 10.1016/0378-3782(94)90028-0
   Nachmias M, 1996, CHILD DEV, V67, P508, DOI 10.1111/j.1467-8624.1996.tb01748.x
   Nardone A, 1997, J DAIRY SCI, V80, P838, DOI 10.3168/jds.S0022-0302(97)76005-3
   Neto JP, 2001, NEUROTOXICOL TERATOL, V23, P497, DOI 10.1016/S0892-0362(01)00164-7
   NEVEU PJ, 1994, DEV PSYCHOBIOL, V27, P205, DOI 10.1002/dev.420270403
   Nielsen Naja Rod, 2004, Ugeskr Laeger, V166, P4155
   Nordentoft M, 1996, AM J PUBLIC HEALTH, V86, P347, DOI 10.2105/AJPH.86.3.347
   OHKAWA T, 1991, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V43, P783
   OHKAWA T, 1991, ENDOCRINOL JAPON, V38, P187
   OHKAWA T, 1991, EXP CLIN ENDOCRINOL, V98, P123, DOI 10.1055/s-0029-1211108
   Otte C, 2005, BIOL PSYCHIAT, V57, P27, DOI 10.1016/j.biopsych.2004.10.009
   Otten W, 2004, THERIOGENOLOGY, V61, P1649, DOI 10.1016/j.theriogenology.2003.09.009
   Otten W, 2007, LIVEST SCI, V106, P261, DOI 10.1016/j.livsci.2006.08.012
   Owen D, 2005, NEUROSCI BIOBEHAV R, V29, P209, DOI 10.1016/j.neubiorev.2004.10.004
   Pazirandeh A, 2004, ENDOCRINOLOGY, V145, P2392, DOI 10.1210/en.2003-1660
   Pazirandeh A, 2002, FASEB J, V16, P727, DOI 10.1096/fj.01-0891fje
   Pazirandeh A, 1999, FASEB J, V13, P893
   Pazirandeh A, 2000, BIOCHEM BIOPH RES CO, V276, P189, DOI 10.1006/bbrc.2000.3458
   PERSINGER MA, 1992, PSYCHOL REP, V70, P976, DOI 10.2466/PR0.70.3.976-978
   Pichel JG, 2003, MECH DEVELOP, V120, P349, DOI 10.1016/S0925-4773(02)00449-5
   Pincus-Knackstedt MK, 2006, J IMMUNOL, V177, P8484, DOI 10.4049/jimmunol.177.12.8484
   POLLARD I, 1984, J ENDOCRINOL, V100, P301, DOI 10.1677/joe.0.1000301
   Precht DH, 2007, ACTA OBSTET GYN SCAN, V86, P266, DOI 10.1080/00016340601088406
   Prescott SL, 2005, CLIN EXP ALLERGY, V35, P417, DOI 10.1111/j.1365-2222.2005.02171.x
   PRUETT SB, 1993, J TOXICOL ENV HEALTH, V39, P163, DOI 10.1080/15287399309531744
   Purton JF, 2000, IMMUNITY, V13, P179, DOI 10.1016/S1074-7613(00)00018-2
   Purton JF, 2002, EUR J IMMUNOL, V32, P3546, DOI 10.1002/1521-4141(200212)32:12<3546::AID-IMMU3546>3.0.CO;2-S
   QIAO S, 2008, EXP CELL RES    0628
   RASCO JF, 1994, REPROD TOXICOL, V8, P49, DOI 10.1016/0890-6238(94)90066-3
   RASCO JF, 1995, TERATOLOGY, V51, P57, DOI 10.1002/tera.1420510203
   RASCO JF, 1995, TERATOLOGY, V51, P63, DOI 10.1002/tera.1420510204
   Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6
   Reis FM, 2001, BIOL NEONATE, V79, P150
   Repetti RL, 2002, PSYCHOL BULL, V128, P330, DOI 10.1037//0033-2909.128.2.330
   RESNICK O, 1979, NEUROSCI BIOBEHAV R, V3, P233, DOI 10.1016/0149-7634(79)90011-3
   Reyes TM, 1997, BRAIN RES, V769, P29, DOI 10.1016/S0006-8993(97)00687-2
   Rhees RW, 1999, BRAIN RES BULL, V50, P193, DOI 10.1016/S0361-9230(99)00191-4
   Rich-Edwards JW, 1999, ANN INTERN MED, V130, P278, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00005
   ROBERTSON M, 1993, DEV GENET, V14, P165, DOI 10.1002/dvg.1020140303
   ROBINSON BG, 1989, MOL CELL ENDOCRINOL, V62, P337, DOI 10.1016/0303-7207(89)90022-1
   Saarikoski S, 1974, Acta Physiol Scand Suppl, V421, P1
   Sacedon R, 1999, J NEUROIMMUNOL, V94, P103, DOI 10.1016/S0165-5728(98)00231-8
   Sacedon R, 1999, NEUROIMMUNOMODULAT, V6, P23, DOI 10.1159/000026360
   Sacedon R, 1999, BLOOD, V94, P2819
   Sacedon R, 1999, J NEUROIMMUNOL, V98, P157, DOI 10.1016/S0165-5728(99)00091-0
   Sacedon R, 2000, ANN NY ACAD SCI, V917, P732
   Sanders VM, 2006, BRAIN BEHAV IMMUN, V20, P317, DOI 10.1016/j.bbi.2005.08.005
   SANDLER M, 1963, NATURE, V197, P598, DOI 10.1038/197598a0
   Savino W, 2000, ENDOCR REV, V21, P412, DOI 10.1210/er.21.4.412
   SAVU L, 1985, INT J TISSUE REACT, V7, P443
   SCHLESINGER L, 1995, J NEUROIMMUNOL, V57, P1, DOI 10.1016/0165-5728(94)00151-D
   Schneider ML, 2001, ALCOHOL CLIN EXP RES, V25, P1383
   Schrott LM, 2004, BRAIN BEHAV IMMUN, V18, P515, DOI 10.1016/j.bbi.2003.12.006
   SCOLLAY R, 1983, THYMUS, V5, P245
   Seckl JR, 2007, NAT CLIN PRACT ENDOC, V3, P479, DOI 10.1038/ncpendmet0515
   Seckl JR, 2001, MOL CELL ENDOCRINOL, V185, P61, DOI 10.1016/S0303-7207(01)00633-5
   SECKL R, 2004, EUR J ENDOCRINOL, V151, pU49
   SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223
   Seniz F N, 1993, J Clin Lab Immunol, V40, P181
   Sgoifo A, 2005, NEUROSCI BIOBEHAV R, V29, P1, DOI 10.1016/j.neubiorev.2004.11.002
   Shanks N, 2000, P NATL ACAD SCI USA, V97, P5645, DOI 10.1073/pnas.090571897
   Shannon C, 1998, AM J PRIMATOL, V46, P311, DOI 10.1002/(SICI)1098-2345(1998)46:4<311::AID-AJP3>3.0.CO;2-L
   SHOEMAKER WJ, 1971, SCIENCE, V171, P1017, DOI 10.1126/science.171.3975.1017
   Silva FR, 1999, IMMUNOPHARM IMMUNOT, V21, P247, DOI 10.3109/08923979909052761
   Smith JW, 2004, PSYCHONEUROENDOCRINO, V29, P227, DOI 10.1016/S0306-4530(03)00025-8
   Sobrian SK, 1997, ENVIRON RES, V73, P227, DOI 10.1006/enrs.1997.3734
   SOBRIAN SK, 1992, PHARMACOL BIOCHEM BE, V43, P537, DOI 10.1016/0091-3057(92)90189-M
   SOBRIAN SK, 1988, DEV PSYCHOBIOL, V10, P403
   SODHA RJ, 1984, AM J OBSTET GYNECOL, V148, P474, DOI 10.1016/0002-9378(84)90729-4
   SOTOMOYANO R, 1987, INT J NEUROSCI, V37, P93, DOI 10.3109/00207458708987140
   Spencer SJ, 2006, BRAIN BEHAV IMMUN, V20, P325, DOI 10.1016/j.bbi.2005.08.004
   Staud F, 2006, PLACENTA, V27, P171, DOI 10.1016/j.placenta.2005.01.001
   Stohr T, 1998, PHARMACOL BIOCHEM BE, V59, P799, DOI 10.1016/S0091-3057(97)00541-8
   SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125
   Szyf M, 2005, FRONT NEUROENDOCRIN, V26, P139, DOI 10.1016/j.yfrne.2005.10.002
   TAKAHASHI LK, 1992, BRAIN RES, V574, P131, DOI 10.1016/0006-8993(92)90809-N
   TAKAHASHI LK, 1988, PHYSIOL BEHAV, V42, P323, DOI 10.1016/0031-9384(88)90273-9
   Talwar GP, 1997, AM J REPROD IMMUNOL, V37, P485
   THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0
   Tolosa E, 1998, IMMUNITY, V8, P67, DOI 10.1016/S1074-7613(00)80459-8
   Torchinsky A, 2003, AM J REPROD IMMUNOL, V49, P159, DOI 10.1034/j.1600-0897.2003.01174.x
   Tuchscherer M, 2002, VET IMMUNOL IMMUNOP, V86, P195, DOI 10.1016/S0165-2427(02)00035-1
   Vacchio MS, 2000, SEMIN IMMUNOL, V12, P475, DOI 10.1006/smim.2000.0265
   Vacchio MS, 1997, J EXP MED, V185, P2033, DOI 10.1084/jem.185.11.2033
   Vacchio MS, 1999, J IMMUNOL, V163, P1327
   VACCHIO MS, 1994, J EXP MED, V179, P1835, DOI 10.1084/jem.179.6.1835
   Vallee M, 1997, J NEUROSCI, V17, P2626
   Vanbesien-Mailliot CCA, 2007, PSYCHONEUROENDOCRINO, V32, P114, DOI 10.1016/j.psyneuen.2006.11.005
   Vassiliadou N, 1996, BIOL REPROD, V55, P1017, DOI 10.1095/biolreprod55.5.1017
   Venihaki M, 2000, P NATL ACAD SCI USA, V97, P7336, DOI 10.1073/pnas.97.13.7336
   Virgolini MB, 2006, NEUROTOXICOLOGY, V27, P11, DOI 10.1016/j.neuro.2005.05.012
   von Hertzen LC, 2002, J ALLERGY CLIN IMMUN, V109, P923, DOI 10.1067/mai.2002.124776
   VONHOERSTEN S, 1993, PHYSIOL BEHAV, V54, P931, DOI 10.1016/0031-9384(93)90305-Y
   VONSAAL FS, 1991, PHYSIOL BEHAV, V49, P1073
   Wadhwa PD, 2005, PSYCHONEUROENDOCRINO, V30, P724, DOI 10.1016/j.psyneuen.2005.02.004
   WADHWA PD, 1993, AM J OBSTET GYNECOL, V169, P858, DOI 10.1016/0002-9378(93)90016-C
   Ward IL, 2003, HORM BEHAV, V43, P531, DOI 10.1016/S0018-506X(03)00061-8
   WARD IL, 1972, SCIENCE, V175, P82, DOI 10.1126/science.175.4017.82
   Ware Carol B, 2003, Reprod Biol Endocrinol, V1, P43, DOI 10.1186/1477-7827-1-43
   WARE CB, 1995, DEVELOPMENT, V121, P1283
   Weaver ICG, 2007, J NEUROSCI, V27, P1756, DOI 10.1523/JNEUROSCI.4164-06.2007
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D
   WEINSTOCK M, 1992, BRAIN RES, V595, P195, DOI 10.1016/0006-8993(92)91049-K
   Weinstock M, 1997, NEUROSCI BIOBEHAV R, V21, P1, DOI 10.1016/S0149-7634(96)00014-0
   Weinstock M, 2007, NEUROCHEM RES, V32, P1730, DOI 10.1007/s11064-007-9339-4
   Welberg LAM, 2001, J NEUROENDOCRINOL, V13, P113, DOI 10.1046/j.1365-2826.2001.00601.x
   Wiegers GJ, 1998, TRENDS PHARMACOL SCI, V19, P317, DOI 10.1016/S0165-6147(98)01229-2
   Wiegers GJ, 2001, NEUROENDOCRINOLOGY, V73, P139, DOI 10.1159/000054630
   Wiegers GJ, 2001, EUR J IMMUNOL, V31, P2293, DOI 10.1002/1521-4141(200108)31:8<2293::AID-IMMU2293>3.0.CO;2-I
   Wilckens T, 1997, IMMUNOL TODAY, V18, P418, DOI 10.1016/S0167-5699(97)01111-0
   Williams MT, 1999, NEUROTOXICOL TERATOL, V21, P403, DOI 10.1016/S0892-0362(98)00060-9
   Williams MT, 1999, NEUROTOXICOL TERATOL, V21, P653, DOI 10.1016/S0892-0362(99)00038-0
   Wongweragiat S, 1999, J CLIN PATHOL, V52, P888, DOI 10.1136/jcp.52.12.888
   Worlein JM, 1997, AM J PRIMATOL, V41, P23, DOI 10.1002/(SICI)1098-2345(1997)41:1<23::AID-AJP2>3.3.CO;2-#
   Wust S, 2005, PSYCHONEUROENDOCRINO, V30, P591, DOI 10.1016/j.psyneuen.2005.01.008
   Yano H, 1998, MOL ENDOCRINOL, V12, P1708, DOI 10.1210/me.12.11.1708
   Yorty JL, 2004, BRAIN BEHAV IMMUN, V18, P15, DOI 10.1016/S0889-1591(03)00115-6
   Yorty JL, 2003, J VIROL, V77, P6613, DOI 10.1128/JVI.77.12.6613-6619.2003
   Young JB, 2002, TRENDS ENDOCRIN MET, V13, P381, DOI 10.1016/S1043-2760(02)00661-6
   ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037
   Zaletel-Kragelj L, 2005, CROAT MED J, V46, P137
   ZARROW MX, 1970, NATURE, V226, P1058, DOI 10.1038/2261058a0
NR 297
TC 48
Z9 49
U1 4
U2 29
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1547-691X
EI 1547-6901
J9 J IMMUNOTOXICOL
JI J. Immunotoxicol.
PD OCT-DEC
PY 2008
VL 5
IS 4
BP 419
EP 444
DI 10.1080/15476910802483415
PG 26
WC Toxicology
SC Toxicology
GA 400DN
UT WOS:000262848300009
PM 19404876
OA Bronze
DA 2018-12-27
ER

PT J
AU Jagannathan, J
   Kanter, AS
   Olson, C
   Sherman, JH
   Laws, ER
   Sheehan, JP
AF Jagannathan, Jay
   Kanter, Adam S.
   Olson, Claire
   Sherman, Jonathan H.
   Laws, Edward R., Jr.
   Sheehan, Jason P.
TI RETRACTED: Applications of radiotherapy and radiosurgery in the
   management of pediatric Cushing's disease: a review of the literature
   and our experience (Retracted Article. See vol 103, pg 173, 2011)
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Review; Retracted Publication
DE Cushing's disease; outcomes; radiation; pediatrics; pituitary;
   radiosurgery; surgery
ID GAMMA-KNIFE SURGERY; TERM-FOLLOW-UP; FRACTIONATED STEREOTACTIC
   RADIOTHERAPY; VISUAL-FIELD PRESERVATION; PITUITARY-ADENOMAS;
   RADIATION-THERAPY; CAVERNOUS SINUS; CYBERKNIFE RADIOSURGERY;
   TRANSSPHENOIDAL SURGERY; CONSERVATIVE SURGERY
AB Surgical extirpation of pituitary adenomas is considered the mainstay of therapy in pediatric patients with Cushing's disease. However, a small subset of patients will require adjuvant therapy either due to tumor invasiveness, or disease recurrence. Conventional radiation therapy (or radiotherapy) delivers ionizing radiation to control hormonally active cells in fractionated doses (spread out over time) in order to give normal cells time to recover, while radiosurgery involves focusing a high dose of radiation structures in a single treatment session to the adenoma while generally sparing the normal gland and surrounding of any substantial amount of radiation. This paper reviews the effectiveness of radiation in the treatment of pediatric Cushing's disease.
C1 [Jagannathan, Jay; Olson, Claire; Sherman, Jonathan H.; Sheehan, Jason P.] Univ Virginia, Hlth Sci Ctr, Dept Neurol Surg, Charlottesville, VA 22908 USA.
   [Kanter, Adam S.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA.
   [Laws, Edward R., Jr.] Stanford Univ, Med Ctr, Dept Neurosurg, Stanford, CA 94305 USA.
RP Jagannathan, J (reprint author), Univ Virginia, Hlth Sci Ctr, Dept Neurol Surg, Charlottesville, VA 22908 USA.
EM jj5a@hscmail.mcc.virginia.edu
CR Adler JR, 2006, NEUROSURGERY, V59, P244, DOI 10.1227/01.NEU.0000223512.09115.3E
   Adler JR, 1997, STEREOT FUNCT NEUROS, V69, P124, DOI 10.1159/000099863
   Albright AL, 2005, CHILD NERV SYST, V21, P649, DOI 10.1007/s00381-005-1185-6
   Amendola BE, 2003, MED PEDIATR ONCOL, V41, P123, DOI 10.1002/mpo.10364
   Batista D, 2005, J CLIN ENDOCR METAB, V90, P5134, DOI 10.1210/jc.2005-1778
   Bliss P, 1994, Clin Oncol (R Coll Radiol), V6, P361, DOI 10.1016/S0936-6555(05)80187-6
   BRADA M, 1993, CLIN ENDOCRINOL, V38, P571, DOI 10.1111/j.1365-2265.1993.tb02137.x
   BRADA M, 1992, BRIT MED J, V304, P1343, DOI 10.1136/bmj.304.6838.1343
   Chang SD, 1998, NEUROL MED-CHIR, V38, P780, DOI 10.2176/nmc.38.780
   Chen JCT, 2001, NEUROSURGERY, V48, P1022, DOI 10.1097/00006123-200105000-00011
   Chiou SM, 2001, NEURO-ONCOLOGY, V3, P159, DOI 10.1093/neuonc/3.3.159
   CICCARELLI E, 1989, ACTA ENDOCRINOL-COP, V121, P827, DOI 10.1530/acta.0.1210827
   Ciric I, 1997, NEUROSURGERY, V40, P225, DOI 10.1097/00006123-199702000-00001
   DEGERBLAD M, 1986, ACTA ENDOCRINOL-COP, V112, P310, DOI 10.1530/acta.0.1120310
   Estrada J, 1997, NEW ENGL J MED, V336, P172, DOI 10.1056/NEJM199701163360303
   FLICKINGER JC, 1989, INT J RADIAT ONCOL, V17, P879, DOI 10.1016/0360-3016(89)90082-5
   Franzin Alberto, 2007, Neurosurg Focus, V23, pE10
   FRIEDMAN RB, 1989, J NEUROSURG, V71, P520, DOI 10.3171/jns.1989.71.4.0520
   GRATTANSMITH PJ, 1992, ACTA NEUROL SCAND, V86, P626, DOI 10.1111/j.1600-0404.1992.tb05500.x
   GROSSMAN A, 1984, BRIT MED J, V288, P1105, DOI 10.1136/bmj.288.6424.1105
   HARRIS JR, 1976, RADIOLOGY, V120, P167, DOI 10.1148/120.1.167
   Hasegawa T, 2017, J NEUROSURG, V127, P60, DOI 10.3171/JNS-07/10/0745
   HOWLETT TA, 1989, CLIN ENDOCRINOL, V31, P309, DOI 10.1111/j.1365-2265.1989.tb01255.x
   Hughes NR, 1999, CLIN ENDOCRINOL, V51, P61, DOI 10.1046/j.1365-2265.1999.00738.x
   Jagannathan Jay, 2005, Neurosurg Focus, V18, pE6
   Jagannathan J, 2007, J NEUROSURG, V106, P980, DOI 10.3171/jns.2007.106.6.980
   Jagannathan J, 2006, FRONT HORM RES, V34, P83
   JANNOUN L, 1990, INT J RADIAT ONCOL, V18, P747, DOI 10.1016/0360-3016(90)90393-X
   JENNINGS AS, 1977, NEW ENGL J MED, V297, P957, DOI 10.1056/NEJM197711032971801
   JONES A, 1991, CLIN ENDOCRINOL, V35, P379, DOI 10.1111/j.1365-2265.1991.tb03554.x
   Kajiwara K, 2005, MINIM INVAS NEUROSUR, V48, P91, DOI 10.1055/s-2004-830261
   Kalapurakal JA, 2000, CHILD NERV SYST, V16, P296, DOI 10.1007/s003810050517
   Kalapurakal JA, 2005, CHILD NERV SYST, V21, P808, DOI 10.1007/s00381-005-1188-3
   KANTOR D, 2005, STATA J, V5, P413
   Kim MS, 1999, STEREOT FUNCT NEUROS, V72, P119, DOI 10.1159/000056447
   KJELLBERG RN, 1974, P ROY SOC MED, V67, P32
   Landolt AM, 2000, J CLIN ENDOCR METAB, V85, P1287, DOI 10.1210/jc.85.3.1287
   LEKSELL L, 1951, ACTA CHIR SCAND, V102, P316
   Lienhardt A, 2001, J CLIN ENDOCR METAB, V86, P5711, DOI 10.1210/jc.86.12.5711
   LITTLEY MD, 1990, CLIN ENDOCRINOL, V33, P445, DOI 10.1111/j.1365-2265.1990.tb03883.x
   LITTLEY MD, 1989, Q J MED, V70, P145
   LITTLEY MD, 1990, BAILLIERE CLIN ENDOC, V4, P147, DOI 10.1016/S0950-351X(05)80321-0
   MAGIAKOU MA, 1994, J CLIN ENDOCR METAB, V78, P131, DOI 10.1210/jc.78.1.131
   MAGIAKOU MA, 1994, NEW ENGL J MED, V331, P629, DOI 10.1056/NEJM199409083311002
   MURON T, 1993, ANN MED INTERNE, V144, P9
   ORTH DN, 1971, NEW ENGL J MED, V285, P243, DOI 10.1056/NEJM197107292850501
   Pandey P, 2005, J CLIN NEUROSCI, V12, P124, DOI 10.1016/j.jocn.2004.10.003
   Peace KA, 1997, CLIN ENDOCRINOL, V46, P445, DOI 10.1046/j.1365-2265.1997.1600971.x
   PEGOLO G, 1995, ACTA CYTOL, V39, P887
   Pham CJ, 2004, NEUROSURGERY, V54, P799, DOI 10.1227/01.NEU.0000114261.18723.6A
   POLLOCK BE, 1994, ACT NEUR S, V62, P33
   Purdy JA, 1996, INT J RADIAT ONCOL, V35, P845, DOI 10.1016/0360-3016(96)00223-4
   RAJAN B, 1993, RADIOTHER ONCOL, V26, P1, DOI 10.1016/0167-8140(93)90019-5
   ROSS WM, 1979, CLIN RADIOL, V30, P149, DOI 10.1016/S0009-9260(79)80135-X
   Schulz-Ertner D, 2002, INT J RADIAT ONCOL, V54, P1114, DOI 10.1016/S0360-3016(02)03029-8
   SELMAN WR, 1986, J NEUROSURG, V64, P402, DOI 10.3171/jns.1986.64.3.0402
   Shamisa A, 2001, J NEUROSURG, V94, P816, DOI 10.3171/jns.2001.94.5.0816
   Sheehan JP, 2006, FRONT HORM RES, V34, P185
   Sindou M, 2007, J NEUROSURG, V107, P937, DOI 10.3171/JNS-07/11/0937
   Storr HL, 2003, J CLIN ENDOCR METAB, V88, P34, DOI 10.1210/jc.2002-021032
   THOREN M, 1986, ACTA PAEDIATR SCAND, V75, P388, DOI 10.1111/j.1651-2227.1986.tb10219.x
   TSANG RW, 1993, CANCER-AM CANCER SOC, V72, P2227, DOI 10.1002/1097-0142(19931001)72:7<2227::AID-CNCR2820720727>3.0.CO;2-I
   Turner HE, 1999, CLIN ENDOCRINOL, V51, P281
   Vik-Mo EO, 2007, EUR J ENDOCRINOL, V157, P255, DOI 10.1530/EJE-07-0189
   WEBER A, 1995, CLIN ENDOCRINOL, V43, P19, DOI 10.1111/j.1365-2265.1995.tb01888.x
NR 65
TC 9
Z9 9
U1 3
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD OCT
PY 2008
VL 90
IS 1
BP 117
EP 124
DI 10.1007/s11060-008-9641-2
PG 8
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 341HN
UT WOS:000258704900018
PM 18568291
DA 2018-12-27
ER

PT J
AU Kumar, M
   Chatterji, D
AF Kumar, Manish
   Chatterji, Dipankar
TI RETRACTED: Cyclic di-GMP: a second messenger required for long-term
   survival, but not for biofilm formation, in Mycobacterium smegmatis
   (Retracted article. See vol. 157, pg. 918, 2011)
SO MICROBIOLOGY-SGM
LA English
DT Article; Retracted Publication
ID EAL DOMAIN PROTEIN; PSEUDOMONAS-AERUGINOSA; STRINGENT RESPONSE;
   DIGUANYLIC ACID; ACETOBACTER-XYLINUM; GENE-EXPRESSION; VIBRIO-CHOLERAE;
   CELLULOSE SYNTHESIS; ALLOSTERIC CONTROL; SWARMING MOTILITY
AB Cyclic di-GMP (c-di-GMP) plays an important role in bacterial adaptation to enable survival in changing environments. It orchestrates various pathways involved in biofilm formation, changes in the cell surface, host colonization and virulence. In this article, we report the presence of c-di-GMP in Mycobacterium smegmatis, and its role in the long-term survival of the organism. M. smegmatis has a single bifunctional protein with both GGDEF and EAL domains, which show diguanylate cyclase (DGC) and phosphodiesterase (PDE)-A activity, respectively, in vitro. We named this protein MSDGC-1. Deletion of the gene encoding MSDGC-1 did not affect growth and biofilm formation in M. smegmatis, but long-term survival under conditions of nutritional starvation was affected. Most of the proteins that contain GGDEF and EAL domains have been demonstrated to have either DGC or PDE-A activity. To gain further insight into the regulation of the protein, we cloned the individual domains, and tested their respective activities. MSDGC-1, the full-length protein, is required for activity, as its GGDEF and EAL domains are inactive when separated.
C1 [Kumar, Manish; Chatterji, Dipankar] Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.
RP Chatterji, D (reprint author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.
EM dipankar@mbu.iisc.ernet.in
OI Chatterji, Dipankar/0000-0002-9985-0632
FU DBT, Government of India
FX We thank Professor Urs Jenal, Biozentrum, Switzerland, for providing the
   PleD clone for the c-di-GMP assay. This work was financially supported
   by DBT, Government of India. M. K. acknowledges DBT for the postdoctoral
   fellowship. The authors also would like to thank Binod Kumar Bharati for
   help in a few experiments, Y. S. Prakash for help in HPLC and mass
   spectroscopy, and R. Saraswati for suggestions. Thanks are also given to
   Professor Umesh Varshney and Krishna from the Department of Microbiology
   and Cell Biology, Indian Institute of Science, for valuable suggestions
   during the review of this manuscript, and help in microscopy.
CR Aldridge P, 2003, MOL MICROBIOL, V47, P1695, DOI 10.1046/j.1365-2958.2003.03401.x
   Beyhan S, 2006, J BACTERIOL, V188, P3600, DOI 10.1128/JB.t88.10.3600-3613.2006
   BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055
   Brouillette E, 2005, ANTIMICROB AGENTS CH, V49, P3109, DOI 10.1128/AAC.49.8.3109-3113.2005
   Camilli A, 2006, SCIENCE, V311, P1113, DOI 10.1126/science.1121357
   CASHEL M, 1996, ESCHERICHIA COLI SAL, P1458
   Chan C, 2004, P NATL ACAD SCI USA, V101, P17084, DOI 10.1073/pnas.0406134101
   Chatterji D, 2001, CURR OPIN MICROBIOL, V4, P160, DOI 10.1016/S1369-5274(00)00182-X
   Christen M, 2005, J BIOL CHEM, V280, P30829, DOI 10.1074/jbc.M504429200
   D'Argenio DA, 2002, J BACTERIOL, V184, P6481, DOI 10.1128/JB.184.23.6481-6489.2002
   Dahl JL, 2005, J BACTERIOL, V187, P2439, DOI 10.1128/JB.187.7.2439-2447.2005
   Ferreira RBR, 2008, J BACTERIOL, V190, P851, DOI 10.1128/JB.01462-07
   Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1016/S0378-1097(01)00326-3
   Hall-Stoodley L, 2004, NAT REV MICROBIOL, V2, P95, DOI 10.1038/nrmicro821
   Hickman JW, 2005, P NATL ACAD SCI USA, V102, P14422, DOI 10.1073/pnas.0507170102
   Hisert KB, 2005, MOL MICROBIOL, V56, P1234, DOI 10.1111/j.1365-2958.2005.04632.x
   Huitema E, 2006, CELL, V124, P1025, DOI 10.1016/j.cell.2006.01.019
   Hurley James H, 2003, Sci STKE, V2003, pPE1
   JACOBS WR, 1987, NATURE, V327, P532, DOI 10.1038/327532a0
   Jain V, 2006, J MICROBIOL, V44, P1
   Jain V, 2006, PROTEIN SCI, V15, P1449, DOI 10.1110/ps.062117006
   Jenal U, 2006, ANNU REV GENET, V40, P385, DOI 10.1146/annurev.genet.40.110405.090423
   Karaolis DKR, 2005, ANTIMICROB AGENTS CH, V49, P1029, DOI 10.1128/AAC.49.3.1029-1038.2005
   Kazmierczak BI, 2006, MOL MICROBIOL, V60, P1026, DOI 10.1111/j.1365-2958.2006.05156.x
   Kirillina O, 2004, MOL MICROBIOL, V54, P75, DOI 10.1111/j.1365-2958.2004.04253.x
   Klebensberger J, 2007, ENVIRON MICROBIOL, V9, P2247, DOI 10.1111/j.1462-2920.2007.01339.x
   Kuchma SL, 2007, J BACTERIOL, V189, P8165, DOI 10.1128/JB.00586-07
   Kuchma SL, 2005, J BACTERIOL, V187, P1441, DOI 10.1128/JB.187.4.1441-1454.2005
   Kulesekara H, 2006, P NATL ACAD SCI USA, V103, P2839, DOI 10.1073/pnas.0511090103
   Lestrate P, 2003, INFECT IMMUN, V71, P7053, DOI 10.1128/IAI.71.12.7053-7060.2003
   Mathew R, 2006, MICROBIOL-SGM, V152, P1741, DOI 10.1099/mic.028879-0
   Mendez-Ortiz MM, 2006, J BIOL CHEM, V281, P8090, DOI 10.1074/jbc.M510701200
   Merkel TJ, 1998, INFECT IMMUN, V66, P4367
   Merritt JH, 2007, J BACTERIOL, V189, P8154, DOI 10.1128/JB.00585-07
   Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165
   NYKA W, 1974, INFECT IMMUN, V9, P843
   O'Toole GA, 1999, METHOD ENZYMOL, V310, P91
   Ojha AK, 2000, INFECT IMMUN, V68, P4084, DOI 10.1128/IAI.68.7.4084-4091.2000
   Ojha A, 2007, MOL MICROBIOL, V66, P468, DOI 10.1111/j.1365-2958.2007.05935.x
   Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5
   Paul R, 2004, GENE DEV, V18, P715, DOI 10.1101/gad.289504
   Pei JM, 2001, PROTEINS, V42, P210, DOI 10.1002/1097-0134(20010201)42:2<210::AID-PROT80>3.0.CO;2-8
   Pelicic V, 1997, P NATL ACAD SCI USA, V94, P10955, DOI 10.1073/pnas.94.20.10955
   Primm TP, 2000, J BACTERIOL, V182, P4889, DOI 10.1128/JB.182.17.4889-4898.2000
   Romling U, 2005, MOL MICROBIOL, V57, P629, DOI 10.1111/j.1365-2958.2005.04697.x
   ROSS P, 1987, NATURE, V325, P279, DOI 10.1038/325279a0
   Ryan RP, 2006, P NATL ACAD SCI USA, V103, P6712, DOI 10.1073/pnas.0600345103
   Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005
   Schmidt AJ, 2005, J BACTERIOL, V187, P4774, DOI 10.1128/JB.187.14.4774-4781.2005
   Shenoy AR, 2006, TRENDS MICROBIOL, V14, P543, DOI 10.1016/j.tim.2006.10.005
   Smeulders MJ, 1999, J BACTERIOL, V181, P270
   STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0
   Tal R, 1998, J BACTERIOL, V180, P4416
   Tamayo R, 2005, J BIOL CHEM, V280, P33324, DOI 10.1074/jbc.M506500200
   Tamayo R, 2007, ANNU REV MICROBIOL, V61, P131, DOI 10.1146/annurev.micro.61.080706.093426
   Tarutina M, 2006, J BIOL CHEM, V281, P34751, DOI 10.1074/jbc.M604819200
   Teng R, 2003, FEMS MICROBIOL LETT, V227, P171, DOI 10.1016/S0378-1097(03)00584-6
   Thormann KM, 2006, J BACTERIOL, V188, P2681, DOI 10.1128/JB.188.7.2681-2691.2006
   Tischler AD, 2004, MOL MICROBIOL, V53, P857, DOI 10.1111/j.1365-2958.2004.04155.x
   Tischler AD, 2005, INFECT IMMUN, V73, P5873, DOI 10.1128/IAI.73.9.5873-5882.2005
   Weinhouse H, 1997, FEBS LETT, V416, P207, DOI 10.1016/S0014-5793(97)01202-7
NR 61
TC 44
Z9 46
U1 4
U2 12
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 1350-0872
EI 1465-2080
J9 MICROBIOL-SGM
JI Microbiology-(UK)
PD OCT
PY 2008
VL 154
BP 2942
EP 2955
DI 10.1099/mic.0.2008/017806-0
PN 10
PG 14
WC Microbiology
SC Microbiology
GA 366IN
UT WOS:000260474300006
PM 18832301
OA Bronze
DA 2018-12-27
ER

PT J
AU Riedel, RF
   Porrello, A
   Pontzer, E
   Chenette, EJ
   Hsu, DS
   Balakumaran, B
   Potti, A
   Nevins, J
   Febbo, PG
AF Riedel, Richard F.
   Porrello, Alessandro
   Pontzer, Emily
   Chenette, Emily J.
   Hsu, David S.
   Balakumaran, Bala
   Potti, Anil
   Nevins, Joseph
   Febbo, Phillip G.
TI RETRACTED: A genomic approach to identify molecular pathways associated
   with chemotherapy resistance (Retracted article. See vol. 11, pg. 1214,
   2012)
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 43rd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-05, 2007
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
ID CELL LUNG-CANCER; MULTIPLE-DRUG RESISTANCE; PHASE-III TRIAL; 2ND-LINE
   CHEMOTHERAPY; METHIONINE DEPENDENCE; DOCETAXEL; EXPRESSION; CISPLATIN;
   CHEMOSENSITIVITY; APOPTOSIS
AB Resistance to chemotherapy in cancer is common. As gene expression profiling has been shown to anticipate chemotherapeutic resistance, we sought to identify cellular pathways associated with resistance to facilitate effective combination therapy. Gene set enrichment analysis was used to associate pathways with resistance in two data sets: the NCI-60 cancer cell lines deemed sensitive and resistant to specific chemotherapeutic agents (Adriamycin, cyclophosphamide, docetaxel, etoposide, 5-fluorouracil, paclitaxel, and topotecan) and a series of 40 lung cancer cell lines for which sensitivity to cisplatin and docetaxel was determined. Candidate pathways were further screened in silico using the Connectivity Map. The lead candidate pathway was functionally validated in vitro. Gene set enrichment analysis associated the matrix metalloproteinase, p53, methionine metabolism, and free pathways with cytotoxic resistance in the NCI-60 cell lines across multiple agents, but no gene set was common to all drugs. Analysis of the lung cancer cell lines identified the bcl-2 pathway to be associated with cisplatin resistance and the AKT pathway enriched in cisplatin- and docetaxel-resistant cell lines. Results from Connectivity Map supported an association between phosphatidylinositol 3-kinase/AKT and docetaxel resistance but did not support the association with cisplatin. Targeted inhibition of the phosphatidylinositol 3-kinase/AKT pathway with LY294002, in combination with docetaxel, resulted in a synergistic effect in previously docetaxel-resistant cell lines but not with cisplatin. These results support the use of a genomic approach to identify drug-specific targets associated with the development of chemotherapy resistance and underscore the importance of disease context in identifying these pathways. [Mol Cancer Ther 2008;7(10):3141-9]
C1 [Riedel, Richard F.; Porrello, Alessandro; Pontzer, Emily; Chenette, Emily J.; Hsu, David S.; Balakumaran, Bala; Potti, Anil; Nevins, Joseph; Febbo, Phillip G.] Duke Univ, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA.
   [Riedel, Richard F.; Hsu, David S.; Potti, Anil; Febbo, Phillip G.] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA.
RP Febbo, PG (reprint author), Duke Univ, Duke Inst Genome Sci & Policy, 2175 CIEMAS Bldg, Durham, NC 27710 USA.
EM Phil.febbo@duke.edu
OI Chenette, Emily/0000-0003-0393-395X
CR Bild A, 2005, P NATL ACAD SCI USA, V102, P15278, DOI 10.1073/pnas.0507477102
   Bush JA, 2002, INT J CANCER, V98, P323, DOI 10.1002/ijc.10226
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   DENGLER WA, 1995, ANTI-CANCER DRUG, V6, P522, DOI 10.1097/00001813-199508000-00005
   Desoize B, 2000, CRIT REV ONCOL HEMAT, V36, P193, DOI 10.1016/S1040-8428(00)00086-X
   Di Leo A, 2007, ANN ONCOL, V18, P997, DOI 10.1093/annonc/mdm075
   Donnenberg VS, 2005, J CLIN PHARMACOL, V45, P872, DOI 10.1177/0091270005276905
   ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217
   Fossella FV, 2000, J CLIN ONCOL, V18, P2354, DOI 10.1200/JCO.2000.18.12.2354
   Funato T, 2000, CANCER GENE THER, V7, P495, DOI 10.1038/sj.cgt.7700125
   Han Ji-Youn, 1999, Korean Journal of Internal Medicine, V14, P42
   Hsu DS, 2007, J CLIN ONCOL, V25, P4350, DOI 10.1200/JCO.2007.11.0593
   Kim R, 2004, CANCER, V101, P2491, DOI 10.1002/cncr.20696
   Kosmas C, 2001, CANCER-AM CANCER SOC, V92, P2902, DOI 10.1002/1097-0142(20011201)92:11<2902::AID-CNCR10103>3.0.CO;2-O
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lee JK, 2007, P NATL ACAD SCI USA, V104, P13086, DOI 10.1073/pnas.0610292104
   Li J, 2008, CANCER CHEMOTH PHARM, V61, P525, DOI 10.1007/s00280-007-0499-3
   Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052
   MECHAM JO, 1983, BIOCHEM BIOPH RES CO, V117, P429, DOI 10.1016/0006-291X(83)91218-4
   Mimeault M, 2007, MOL CANCER THER, V6, P967, DOI 10.1158/1535-7163.MCT-06-0648
   Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602
   Mondesire WH, 2004, CLIN CANCER RES, V10, P7031, DOI 10.1158/1078-0432.CCR-04-0361
   MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418
   Nelli F, 2004, J CHEMOTHERAPY, V16, P392, DOI 10.1179/joc.2004.16.4.392
   Pavillard V, 2006, BIOCHEM PHARMACOL, V71, P772, DOI 10.1016/j.bcp.2005.12.014
   Paz-Ares L, 2008, BRIT J CANCER, V98, P1608, DOI 10.1038/sj.bjc.6604372
   Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491
   Schuette W, 2005, J CLIN ONCOL, V23, P8389, DOI 10.1200/JCO.2005.02.3739
   Schwabedissen HEMZ, 2006, DRUG METAB DISPOS, V34, P524, DOI 10.1124/dmd.105.007591
   Sims-Mourtada J, 2007, ONCOGENE, V26, P5674, DOI 10.1038/sj.onc.121035
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Wulfkuhle J, 2004, EUR J CANCER, V40, P2623, DOI 10.1016/j.ejca.2004.05.020
NR 34
TC 53
Z9 53
U1 3
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD OCT
PY 2008
VL 7
IS 10
BP 3141
EP 3149
DI 10.1158/1535-7163.MCT-08-0642
PG 9
WC Oncology
SC Oncology
GA 362MO
UT WOS:000260202000003
PM 18852117
DA 2018-12-27
ER

PT J
AU Kunnumakkara, AB
   Ichikawa, H
   Anand, P
   Mohankumar, CJ
   Hema, PS
   Nair, MS
   Aggarwal, BB
AF Kunnumakkara, Ajaikumar B.
   Ichikawa, Haruyo
   Anand, Preetha
   Mohankumar, Chiramel J.
   Hema, Padmanabhan S.
   Nair, Mangalam S.
   Aggarwal, Bharat B.
TI RETRACTED: Coronarin D, a labdane diterpene, inhibits both constitutive
   and inducible nuclear factor-kappa B pathway activation, leading to
   potentiation of apoptosis, inhibition of invasion, and suppression of
   osteoclastogenesis (Retracted article. See vol. 17, pg. 2074, 2018)
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article; Retracted Publication
ID TUMOR-NECROSIS-FACTOR; HEDYCHIUM-CORONARIUM; TRANSCRIPTION FACTOR;
   ENDOTHELIAL-CELLS; PROSTATE-CANCER; ALPHA KINASE; CYCLIN D1; GROWTH;
   CYCLOOXYGENASE-2; PHOSPHORYLATION
AB Compounds isolated from members of the Zingiberaceae family are traditionally used as a medicine against inflammatory diseases, but little is known about the mechanism. Here, we report the isolation and structural identification of coronarin D [E-labda-8(17),12-diene-15-ol], a labdane-type diterpene, from Hedychium coronarium and delineate its mechanism of action. Because the transcription factor nuclear factor-kappa B (NF-kappa B) is a key mediator of inflammation, apoptosis, invasion, and osteoclastogenesis, we investigated the effect of coronarin D on NF-kappa B activation pathway, NF-kappa B-regulated gene products, and NF-kappa B-regulated cellular responses. The coronarin D inhibited NF-kappa B activation induced by different inflammatory stimuli and carcinogens. This labdane also suppressed constitutive NF-kappa B activity in different cell lines and inhibited I kappa B alpha kinase activation, thus leading to the suppression of I kappa B alpha phosphorylation, degradation, p65 nuclear translocation, and reporter gene transcription. Coronarin D also inhibited the NF-kappa B-regulated gene products involved in cell survival (inhibitor of apoptosis protein 1, Bcl-2, survivin, and tumor necrosis factor receptor-associated factor-2), proliferation (c-myc, cyclin D1, and cyclooxygenase-2), invasion (matrix metalloproteinase-9), and angiogenesis (vascular endothelial growth factor). Suppression of these gene products by the diterpene enhanced apoptosis induced by TNF and chemotherapeutic agents, suppressed TNF-induced cellular invasion, and abrogated receptor activator of NF-kappa B ligand-induced osteoclastogenesis. Coronarin D was found to be more potent than its analogue coronarin D acid. Overall, our results show that coronarin D inhibited NF-kappa B activation pathway, which leads to inhibition of inflammation, invasion, and osteoclastogenesis, as well as potentiation of apoptosis. [Mol Cancer Ther 2008;7(10):3306-17]
C1 [Kunnumakkara, Ajaikumar B.; Ichikawa, Haruyo; Anand, Preetha; Aggarwal, Bharat B.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA.
   [Mohankumar, Chiramel J.; Hema, Padmanabhan S.; Nair, Mangalam S.] Natl Inst Interdisciplinary Sci & Technol, Organ Chem Sect, Thiruvananthapuram, Kerala, India.
RP Aggarwal, BB (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Unit 143,1515 Holcombe Blvd, Houston, TX 77030 USA.
EM aggarwal@mdanderson.org
RI Aggarwal, Bharat/G-3388-2013; Kunnumakkara, Ajaikumar/H-8566-2012; TVM,
   NIIST/E-5132-2012; MSN, Nair/F-9473-2013
OI Kunnumakkara, Ajaikumar/0000-0001-9121-6816; TVM,
   NIIST/0000-0002-5814-466X; 
CR Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184
   Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003
   Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511
   Bharti AC, 2004, BLOOD, V103, P3175, DOI 10.1182/blood-2003-06-2151
   Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj/onc/1205243
   Cammarano MS, 2001, J BIOL CHEM, V276, P25876, DOI 10.1074/jbc.M011345200
   Campbell KJ, 2001, BIOCHEM SOC T, V29, P688
   Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926
   Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585
   DAMAY BG, 1999, J BIOL CHEM, V274, P7724
   DUYAO MP, 1992, J BIOL CHEM, V267, P16288
   Erickson LA, 2000, MODERN PATHOL, V13, P186, DOI 10.1038/modpathol.3880034
   Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200
   Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113
   Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj/leu/2402482
   Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008
   Guttridge DC, 1999, MOL CELL BIOL, V19, P5785
   Hardwick JCH, 2001, ONCOGENE, V20, P819, DOI 10.1038/sj.onc.1204162
   Hurlin PJ, 2004, INT REV CYTOL, V238, P183, DOI 10.1016/S0074-7696(04)38004-6
   Ichikawa H, 2005, J IMMUNOL, V174, P7383, DOI 10.4049/jimmunol.174.11.7383
   ITOKAWA H, 1988, PLANTA MED, P311, DOI 10.1055/s-2006-962442
   ITOKAWA H, 1988, CHEM PHARM BULL, V36, P2682
   ITOKAWA H, 1987, PLANTA MED, V54, P311
   Jackson-Bernitsas DG, 2007, ONCOGENE, V26, P1385, DOI 10.1038/sj.onc.1209945
   Kang S, 2005, CANCER LETT, V217, P11, DOI 10.1016/j.canlet.2004.06.053
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200
   Kong YY, 1999, NATURE, V397, P315
   Kunnurnakkara AB, 2007, BLOOD, V109, P5112, DOI 10.1182/blood-2007-01-067256
   LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933
   Lou H, 2007, J BIOL CHEM, V282, P29470, DOI 10.1074/jbc.M706145200
   Matsuda H, 2002, BIOORGAN MED CHEM, V10, P2527, DOI 10.1016/S0968-0896(02)00121-9
   Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812
   Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664
   MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276
   Morikawa T, 2002, CHEM PHARM BULL, V50, P1045, DOI 10.1248/cpb.50.1045
   Oh S, 2003, BIOORG MED CHEM LETT, V13, P2009, DOI 10.1016/S0960-894X(03)00345-7
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   RIBEIRO RD, 1988, J ETHNOPHARMACOL, V24, P19
   Romano M, 2003, FASEB J, V17, P1986, DOI 10.1096/fj.03-0053rev
   Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641
   Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368
   Sethi G, 2007, ONCOGENE, V26, P7324, DOI 10.1038/sj.onc.1210544
   Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026
   Shrotriya S, 2007, PAK J PHARM SCI, V20, P47
   Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082
   Tai DI, 2000, CANCER, V89, P2274, DOI 10.1002/1097-0142(20001201)89:11<2274::AID-CNCR16>3.3.CO;2-U
   Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200
   Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3
   Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531
   Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680
   Wang WX, 1999, CLIN CANCER RES, V5, P119
   Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735
   Xiao CW, 2001, ENDOCRINOLOGY, V142, P557, DOI 10.1210/en.142.2.557
   Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315
   You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328
   Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8
   1959, WEALTH INDIA DICT IN, V5, P11
NR 58
TC 41
Z9 42
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD OCT
PY 2008
VL 7
IS 10
BP 3306
EP 3317
DI 10.1158/1535-7163.MCT-08-0432
PG 12
WC Oncology
SC Oncology
GA 362MO
UT WOS:000260202000020
PM 18852134
OA Bronze
DA 2018-12-27
ER

PT J
AU Jagannathan, P
   Jagannathan, J
AF Jagannathan, Pavan
   Jagannathan, Jay
TI RETRACTED: Molecular mechanisms of traumatic brain injury in children
   (Retracted article. See vol. 26, pg Nil_0078, 2009)
SO NEUROSURGICAL FOCUS
LA English
DT Article; Retracted Publication
DE management; outcome; pediatric trauma
ID SEVERE HEAD-INJURY; FLUID-PERCUSSION INJURY; D-ASPARTATE ANTAGONISTS;
   LONG-TERM POTENTIATION; DEVELOPING RAT-BRAIN; CEREBRAL-BLOOD-FLOW;
   CEREBROSPINAL-FLUID; APOPTOTIC NEURODEGENERATION; IN-VITRO; INTRACRANIAL
   HYPERTENSION
AB Despite advances in molecular biology and genetics, the precise pathophysiology of traumatic brain injury (TBI) in children is unknown. In this paper the authors review what is currently known about intra- and extracellular responses to pediatric TBI and relate these factors to future investigations. Although hyperemia and vascular congestion have long been thought to be the hallmarks of pediatric TBI, on a cellular level, calcium influx as well as modulation of local neurotransmitters appears to play a major role in its onset. Recent genetic and proteomic research has identified specific neurotrophic factors as well as apoptotic and antiapoptotic genes that appear to control the progression of inflammation and neuronal damage. The search for a therapeutic target will ultimately require a thorough understanding of these factors and their interplay on a proteomic, genomic, and neuromic level.
C1 [Jagannathan, Jay] Univ Virginia Hlth Syst, Dept Neurosurg, Charlottesville, VA 22908 USA.
   [Jagannathan, Pavan] Landon Sch, Bethesda, MD USA.
RP Jagannathan, J (reprint author), Univ Virginia Hlth Syst, Dept Neurosurg, Box 800212, Charlottesville, VA 22908 USA.
EM jj5a@hscmail.mcc.virginia.edu
CR Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873
   ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282
   Adelson P D, 2000, Clin Neurosurg, V47, P319
   Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004
   Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005
   Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168
   Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x
   Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P
   Blitzer R, 2003, J AM ACAD CHILD PSY, V42, P998, DOI 10.1097/01.CHI.0000046894.27264.9D
   Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147
   Clark RSB, 1997, J NEUROSCI, V17, P9172
   Clark RSB, 1999, FASEB J, V13, P813
   Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903
   Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536
   D'Ambrosio R, 1999, J NEUROSCI, V19, P8152
   D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1
   Di X, 2000, ACT NEUR S, V76, P379
   Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8
   Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CMM.0000080493.04978.73
   Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161
   Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513
   Franz G, 2002, J CEREBR BLOOD F MET, V22, P951, DOI 10.1097/00004647-200208000-00006
   Gao WM, 2007, J NEUROTRAUM, V24, P43, DOI 10.1089/neu.2006.0061
   Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950
   Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163
   Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999
   Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704
   Golarai G, 2001, J NEUROSCI, V21, P8523
   Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457
   Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030
   Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401
   Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183
   Hellmich HL, 2007, BRAIN RES, V1127, P119, DOI 10.1016/j.brainres.2006.09.094
   Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504
   Ikonomidou C, 1995, CURR OPIN NEUROL, V8, P487, DOI 10.1097/00019052-199512000-00017
   Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70
   Ikonomidou C, 1996, CRIT REV NEUROBIOL, V10, P239
   Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056
   Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197
   Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500
   Ishimaru MJ, 1999, J COMP NEUROL, V408, P461
   Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600
   Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268
   Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101
   Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082
   Jones PA, 2005, ACT NEUR S, V95, P29
   JOURDAN C, 1993, NEUROCHIRURGIE, V39, P304
   Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001
   Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059
   KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J
   KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889
   Kingham PJ, 2001, J NEUROCHEM, V76, P1475, DOI 10.1046/j.1471-4159.2001.00146.x
   Konrad K, 2003, COGNITIVE BRAIN RES, V16, P425, DOI 10.1016/S0926-6410(03)00057-0
   KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017
   Kwak S, 2006, CURR OPIN NEUROBIOL, V16, P281, DOI 10.1016/j.conb.2006.05.004
   Lau A, 2006, J NEUROSCI, V26, P11540, DOI 10.1523/JNEUROSCI.3507-06.2006
   Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615
   Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400
   Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959
   Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003
   Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001
   Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011
   Ohsumi Y, 2004, SEMIN CELL DEV BIOL, V15, P231, DOI 10.1016/j.semcdb.2003.12.004
   Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7
   Pickard JD, 2005, ACT NEUR S, V95, P459
   Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0
   Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508
   Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6
   Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170
   Crespo ART, 2007, BRAIN INJURY, V21, P441, DOI 10.1080/02699050701311125
   Robertson CL, 2004, DEV BRAIN RES, V151, P141, DOI 10.1016/j.devbrainres.2004.04.007
   Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979
   Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x
   Sitcheran R, 2005, EMBO J, V24, P510, DOI 10.1038/sj.emboj.7600555
   Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617
   Tang YP, 1999, NATURE, V401, P63
   Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F
   TAYLOR CP, 1995, TRENDS PHARMACOL SCI, V16, P309, DOI 10.1016/S0165-6147(00)89060-4
   The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P471
   Walter B, 2004, J NEUROTRAUM, V21, P1076, DOI 10.1089/0897715041651024
   Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490
   Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748
   Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777
   Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001
   Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027
NR 85
TC 2
Z9 2
U1 3
U2 11
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 1092-0684
J9 NEUROSURG FOCUS
JI Neurosurg. Focus
PD OCT
PY 2008
VL 25
IS 4
AR E6
DI 10.3171/FOC.2008.25.10.E6
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 355HX
UT WOS:000259701100006
PM 18828704
OA Bronze
DA 2018-12-27
ER

PT J
AU Spalart, PR
   Coleman, GN
   Johnstone, R
AF Spalart, Philippe R.
   Coleman, Gary N.
   Johnstone, Roderick
TI RETRACTED: Direct numerical simulation of the Ekman layer: A step in
   Reynolds number, and cautious support for a log law with a shifted
   origin (Retracted article. See vol. 21, art. no. 109901, 2009)
SO PHYSICS OF FLUIDS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Workshop on Turbulence Physics and Control
CY SEP 14-15, 2007
CL Stanford Univ, Stanford, CA
HO Stanford Univ
ID TURBULENT BOUNDARY-LAYER; CHANNEL FLOWS; SIMILARITY; PIPE; WALL
AB Results at Ekman Reynolds numbers Re ranging from 1000 to 2828 expand the direct numerical simulation (DNS) contribution to the theory of wall-bounded turbulence. An established spectral method is used, with rules for domain size and grid resolution at each Reynolds number derived from the theory. The Re increase is made possible by better computers and by optimizing the grid in relation to the wall shear-stress direction. The boundary-layer thickness in wall units delta(+) varies here by a factor of about 5.3, and reaches values near 5000, or 22 times the minimum at which turbulence has been sustained. An equivalent channel Reynolds number, based on the pressure gradient in wall units, would reach about Re(tau)=1250. The principal goal of the analysis, the impartial identification of a log law, is summarized in the local "Karman measure" d(ln z(+))/dU(+). The outcome differs from that for Hoyas and Jimenez [Phys. Fluids 18, 011702 (2006)] and for Hu et al. [AIAA J. 44, 1541 (2006)] in channel-flow DNS at similar Reynolds numbers, for reasons unknown: Here, the law of the wall is gradually established up to a z+ around 400, with little statistical scatter. To leading order, it is consistent with the experiments of osterlund et al. [Phys. Fluids 12, 1 (2000)] in boundary layers. With the traditional expression, a logarithmic law is not present, in that the Karman measure drifts from about 0.41 at z(+) approximate to 70 to the 0.37-0.38 range for z(+) approximate to 500, with Re=2828. However, if a virtual origin is introduced with a shift of a(+) = 7.5 wall units, the data support a long logarithmic layer with kappa = 0.38 a good fit to d(ln[z(+) + a(+) ])/dU(+). A determination of the Karman constant from the variation of the skin-friction coefficients with Reynolds numbers also yields values near 0.38. The uncertainty is about +/-0.01. These values are close to the boundary-layer experiments, but well below the accepted range of [0.40,0.41] and the experimental pipe-flow results near 0.42. The virtual-origin concept is also controversial, although nonessential at transportation or atmospheric Reynolds numbers. Yet, this series may reflect some success in verifying the law of the wall and investigating the logarithmic law by DNS, redundantly and with tools more impartial than the visual fit of a straight line to a velocity profile. (C) 2008 American Institute of Physics. [DOI: 10.1063/1.3005858]
C1 [Spalart, Philippe R.] Boeing Commercial Airplane Co, Seattle, WA 98124 USA.
   [Coleman, Gary N.] Univ Southampton, Sch Engn Sci, Southampton SO17 1BJ, Hants, England.
   [Johnstone, Roderick] STFC Daresbury, Warrington WA4 4AD, Cheshire, England.
RP Spalart, PR (reprint author), Boeing Commercial Airplane Co, POB 3707, Seattle, WA 98124 USA.
OI Johnstone, Roderick/0000-0001-7060-3059
CR BARENBLATT GI, 1993, J FLUID MECH, V248, P513, DOI 10.1017/S0022112093000874
   BLACKADAR AK, 1968, J ATMOS SCI, V25, P1015, DOI 10.1175/1520-0469(1968)025<1015:ASINBP>2.0.CO;2
   CHAUHAN K, 2007, 2007532 AIAA
   COLEMAN GN, 1990, J FLUID MECH, V213, P313, DOI 10.1017/S0022112090002348
   Coleman GN, 1999, J ATMOS SCI, V56, P891, DOI 10.1175/1520-0469(1999)056<0891:SSFADN>2.0.CO;2
   CSANADY GT, 1967, J ATMOS SCI, V24, P467, DOI 10.1175/1520-0469(1967)024<0467:OTLOAT>2.0.CO;2
   Hoyas S, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2162185
   Hu ZW, 2006, AIAA J, V44, P1541, DOI 10.2514/1.17638
   McKeon BJ, 2004, J FLUID MECH, V501, P135, DOI 10.1017/S0022112003007304
   Osterlund JM, 2000, PHYS FLUIDS, V12, P1, DOI 10.1063/1.870250
   SPALART PR, 1989, J FLUID MECH, V205, P319, DOI 10.1017/S0022112089002053
   SPALART PR, 1988, J FLUID MECH, V187, P61, DOI 10.1017/S0022112088000345
   SPALART PR, 1991, J COMPUT PHYS, V96, P297, DOI 10.1016/0021-9991(91)90238-G
   Squire H.B., 1948, Philosophical Magazine, V39, P1
   Wosnik M, 2000, J FLUID MECH, V421, P115, DOI 10.1017/S0022112000001385
   Zanoun ES, 2004, PHYS FLUIDS, V16, P3509, DOI 10.1063/1.1778789
NR 16
TC 38
Z9 38
U1 5
U2 16
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 1070-6631
J9 PHYS FLUIDS
JI Phys. Fluids
PD OCT
PY 2008
VL 20
IS 10
AR 101507
DI 10.1063/1.3005858
PG 9
WC Mechanics; Physics, Fluids & Plasmas
SC Mechanics; Physics
GA 367SM
UT WOS:000260572800007
OA Green Published
DA 2018-12-27
ER

PT J
AU Senzaki, H
   Iwamoto, Y
   Ishido, H
   Masutani, S
   Taketazu, M
   Kobayashi, T
   Katogi, T
   Kyo, S
AF Senzaki, Hideaki
   Iwamoto, Yoichi
   Ishido, Hirotaka
   Masutani, Satoshi
   Taketazu, Mio
   Kobayashi, Toshiki
   Katogi, Toshiyuki
   Kyo, Shunei
TI RETRACTED: Ventricular-vascular stiffening in patients with repaired
   coarctation of aorta - Integrated pathophysiology of hypertension
   (Retracted article. See vol. 125, pg. E1020, 2012)
SO CIRCULATION
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 80th Annual Scientific Session of the American-Heart-Association
CY NOV 04-07, 2007
CL Orlando, FL
SP Amer Heart Assoc
DE blood pressure; congenital; hemodynamics; heart defects; patients
ID CONGENITAL HEART-DISEASE; TERM FOLLOW-UP; BLOOD-PRESSURE; SYSTOLIC
   HYPERTENSION; BARORECEPTOR FUNCTION; ELASTIC PROPERTIES; SURGICAL
   REPAIR; ASCENDING AORTA; YOUNG-ADULTS; EXERCISE
AB Background-Despite successful repair, patients with coarctation of the aorta (COA) often show persistent hypertension at rest and/or during exercise. Previous studies indicated that the hypertension is mainly due to abnormalities in the arterial bed and its regulatory systems. We hypothesized that ventricular systolic stiffness also contributes to the hypertensive state in these patients in addition to increased vascular stiffness.
   Methods and Results-The study involved 43 patients with successfully repaired COA and 45 age-matched control subjects. Ventricular systolic stiffness (end systolic elastance) and arterial stiffness (effective arterial elastance) were measured invasively by ventricular pressure-area relationship during varying preload before and after beta-adrenergic stimulation. The mean systolic blood pressure was significantly higher with concomitant increases in both end systolic elastance and effective arterial elastance in patients with COA compared with control subjects (113.2 +/- 16.8 versus 91.0 +/- 9.1 mm Hg, 44.5 +/- 17.0 versus 19.2 +/- 6.7 mm Hg/mL/m(2), and 27.8 +/- 11.4 versus 20.2 +/- 4.8 mm Hg/mL/m(2), respectively; P <0.01 for each). End systolic elastance and effective arterial elastance of patients with COA showed exaggerated responses to beta-adrenergic stimulation, further amplifying blood pressure elevation. Quantification analyses assuming that ventricular systolic stiffness of patients with COA is equal to that of the control revealed that ventricular systolic stiffness accounts for approximately 50% to 70% of the elevated blood pressure in patients with COA. Furthermore, combined ventricular-arterial stiffening amplified systolic pressure sensitivity to increased preload during abdominal compression and limited stroke volume gain/relaxation improvement induced by beta-adrenergic stimulation.
   Conclusions-Increased ventricular systolic stiffness, coupled with increased arterial stiffness, plays important roles in hypertension in patients with repaired COA. Thus, ventricular systolic stiffness is a potentially suitable target for reduction of blood pressure and improvement of prognosis of patients with COA.
C1 [Senzaki, Hideaki; Iwamoto, Yoichi; Ishido, Hirotaka; Masutani, Satoshi; Taketazu, Mio; Kobayashi, Toshiki; Katogi, Toshiyuki; Kyo, Shunei] Saitama Med Sch Hosp, Dept Pediatr Cardiol & Cardiovasc Surg, Saitama, Japan.
RP Senzaki, H (reprint author), Saitama Med Univ, Int Med Ctr, Dept Pediatr Cardiol, Staff Off Bldg 303,1397-1 Yamane, Hidaka, Saitama 3501298, Japan.
EM hsenzaki@saitama-med.ac.jp
OI Senzaki, Hideaki/0000-0002-8289-0953
CR BEEKMAN RH, 1983, AM J CARDIOL, V52, P112, DOI 10.1016/0002-9149(83)90080-2
   BROUWER RMHJ, 1994, J THORAC CARDIOV SUR, V108, P525
   Celermajer DS, 2002, HEART, V88, P113, DOI 10.1136/heart.88.2.113
   Chen CH, 1998, J AM COLL CARDIOL, V32, P1221, DOI 10.1016/S0735-1097(98)00374-X
   Chen CH, 1999, J AM COLL CARDIOL, V33, P1602, DOI 10.1016/S0735-1097(99)00052-2
   COHEN M, 1989, CIRCULATION, V80, P840, DOI 10.1161/01.CIR.80.4.840
   de Divitiis M, 2003, J AM COLL CARDIOL, V41, P2259, DOI 10.1016/S0735-1097(03)00480-7
   De Divitiis M, 2001, CIRCULATION S1, V104, pI
   Diller GP, 2005, CIRCULATION, V112, P828, DOI 10.1161/CIRCULATIONAHA.104.529800
   GARDINER HM, 1994, CIRCULATION, V89, P1745, DOI 10.1161/01.CIR.89.4.1745
   Georgakopoulos D, 1998, AM J PHYSIOL-HEART C, V274, pH1416, DOI 10.1152/ajpheart.1998.274.4.H1416
   GIDDING SS, 1985, CIRCULATION, V71, P495, DOI 10.1161/01.CIR.71.3.495
   Guenthard J, 1996, EUR HEART J, V17, P1572
   Hauser M, 2000, CARDIOL YOUNG, V10, P353
   IGLER FO, 1981, CIRC RES, V48, P365, DOI 10.1161/01.RES.48.3.365
   Instebo A, 2004, EUR J APPL PHYSIOL, V93, P116, DOI 10.1007/s00421-004-1180-8
   ISNER JM, 1987, CIRCULATION, V75, P689, DOI 10.1161/01.CIR.75.4.689
   JAMES FW, 1974, CIRCULATION, V50, P27
   Kass DA, 2005, HYPERTENSION, V46, P185, DOI 10.1161/01.HYP.0000168053.34306.d4
   KELLY RP, 1992, CIRCULATION, V86, P513, DOI 10.1161/01.CIR.86.2.513
   Kim GB, 2004, INT J CARDIOL, V97, P471, DOI 10.1016/j.ijcard.2003.10.020
   KIMBALL TR, 1994, J AM COLL CARDIOL, V24, P194, DOI 10.1016/0735-1097(94)90563-0
   Kobayashi J, 1999, HEART VESSELS, V14, P240, DOI 10.1007/BF01747853
   MERILLON JP, 1985, J CARDIOVASC PHARM, V7, pS36, DOI 10.1097/00005344-198507002-00008
   MOSKOWITZ WB, 1990, AM HEART J, V120, P103, DOI 10.1016/0002-8703(90)90166-U
   Niwa K, 2001, CIRCULATION, V103, P393
   NOZAWA T, 1994, CIRCULATION, V90, P3047, DOI 10.1161/01.CIR.90.6.3047
   O'Sullivan JJ, 2002, HEART, V88, P163, DOI 10.1136/heart.88.2.163
   ONG CM, 1992, AM HEART J, V123, P1594, DOI 10.1016/0002-8703(92)90815-D
   Pacileo G, 2001, AM J CARDIOL, V87, P748, DOI 10.1016/S0002-9149(00)01495-8
   Polson JW, 2006, CIRCULATION, V113, P2844, DOI 10.1161/CIRCULATIONAHA.105.602748
   PRESBITERO P, 1987, BRIT HEART J, V57, P462
   ROSS RD, 1992, AM HEART J, V123, P1293, DOI 10.1016/0002-8703(92)91036-Z
   Schroeder Valerie A, 2004, Pediatr Crit Care Med, V5, P539, DOI 10.1097/01.PCC.0000144730.44552.E3
   SEHESTED J, 1982, BRIT HEART J, V48, P357
   SEHESTED J, 1982, CIRCULATION, V65, P1060, DOI 10.1161/01.CIR.65.6.1060
   Senzaki H, 1999, J AM COLL CARDIOL, V34, P1529, DOI 10.1016/S0735-1097(99)00362-9
   Senzaki H, 2001, CATHETER CARDIO INTE, V53, P392, DOI 10.1002/ccd.1188
   Senzaki H, 2001, J THORAC CARDIOV SUR, V121, P1200, DOI 10.1067/mtc.2001.111376
   SENZAKI H, 2001, J THORAC CARDIOVASC, V22, P535
   Su DF, 2001, CLIN EXP PHARMACOL P, V28, P709, DOI 10.1046/j.1440-1681.2001.03508.x
   SUGA H, 1984, JPN CIRC J, V48, P136, DOI 10.1253/jcj.48.136
   SUNAGAWA K, 1983, AM J PHYSIOL, V245, pH773
   Toro-Salazar OH, 2002, AM J CARDIOL, V89, P541, DOI 10.1016/S0002-9149(01)02293-7
   Vogt M, 2005, CIRCULATION, V111, P3269, DOI 10.1161/CIRCULATIONAHA.104.529792
NR 45
TC 32
Z9 32
U1 3
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD SEP 30
PY 2008
VL 118
IS 14
SU 1
BP S191
EP S198
DI 10.1161/CIRCULATIONAHA.107.757096
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 354OJ
UT WOS:000259648600028
PM 18824754
OA Bronze
DA 2018-12-27
ER

PT J
AU Malhotra, D
   Thimmulappa, R
   Navas-Acien, A
   Sandford, A
   Elliott, M
   Singh, A
   Chen, LN
   Zhuang, XX
   Hogg, J
   Pare, P
   Tuder, RM
   Biswal, S
AF Malhotra, Deepti
   Thimmulappa, Rajesh
   Navas-Acien, Ana
   Sandford, Andrew
   Elliott, Mark
   Singh, Anju
   Chen, Linan
   Zhuang, Xiaoxi
   Hogg, James
   Pare, Peter
   Tuder, Rubin M.
   Biswal, Shyam
TI RETRACTED: Decline in NRF2-regulated antioxidants in chronic obstructive
   pulmonary disease lungs due to loss of its positive regulator, DJ-1
   (Retracted article. See vol. 193, pg. 344, 2016)
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article; Retracted Publication
DE chronic obstructive pulmonary disease; NRF2; DJ-1; oxidative stress;
   antioxidants
ID CHEMOPREVENTIVE AGENT SULFORAPHANE; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE;
   INDUCED INFLAMMATORY RESPONSE; NRF2 ENHANCES SUSCEPTIBILITY;
   TRANSCRIPTION FACTOR NRF2; HEME OXYGENASE-1 GENE; CIGARETTE-SMOKE;
   AIRWAY INFLAMMATION; OXIDATIVE DAMAGE; EPITHELIAL-CELLS
AB Rationale Oxidative stress is a key contributor in chronic obstructive pulmonary disease (COPD) pathogenesis caused by cigarette smoking. NRF2, a redox-sensitive transcription factor, dissociates from its inhibitor, KEAP1, to induce antioxidant expression that inhibits oxidative stress.
   Objectives: To determine the link between severity of COPD, oxidative stress, and NRF2-dependent antioxidant levels in the peripheral lung tissue of patients with COPD.
   Methods: We assessed the expression of NRF2, NRF2-dependent antioxidants, regulators of NRF2 activity, and oxidative damage in non-COPD (smokers and former smokers) and smoker COPD lungs (mild and advanced). Cigarette smoke-exposed human lung epithelial cells (Beas2B) and mice were used to understand the mechanisms.
   Measurements and Main Results: When compared with non-COPD lungs, the COPD patient lungs showed (7) marked decline in NRF2-dependent antioxidants and glutathione levels, (2) increased oxidative stress markers, (3) significant decrease in NRF2 protein with no change in NRF2 mRNA levels, and (4) similar KEAP1 but significantly decreased DJ-1 levels (a protein that stabilizes NRF2 protein by impairing KEAP1-dependent proteasomal degradation of NRF2). Exposure of Bea2B cells to cigarette smoke caused oxidative modification and enhanced proteasomal degradation of DJ-1 protein. Disruption of DJ-1 in mouse lungs, mouse embryonic fibroblasts, and Beas2B cells lowered NRF2 protein stability and impaired antioxidant induction in response to cigarette smoke. Interestingly, targeting KEAP1 by si RNA or the small-molecule activator sulforaphane restored induction of NRF2-dependent antioxidants in DJ-1-disrupted cells in response to cigarette smoke.
   Conclusions: NRF2-dependent antioxidants and DJ-1 expression was negatively associated with severity of COPD. Therapy directed toward enhancing NRF2-regulated antioxidants may be a novel strategy for attenuating the effects of oxidative stress in the pathogenesis of COPD.
C1 [Malhotra, Deepti; Thimmulappa, Rajesh; Navas-Acien, Ana; Singh, Anju; Biswal, Shyam] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA.
   [Sandford, Andrew; Elliott, Mark; Hogg, James; Pare, Peter] Univ British Columbia, Div Resp, Dept Med, Vancouver, BC, Canada.
   [Sandford, Andrew; Elliott, Mark; Hogg, James; Pare, Peter] St Pauls Hosp, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, Vancouver, BC V6Z 1Y6, Canada.
   [Chen, Linan; Zhuang, Xiaoxi] Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA.
   [Tuder, Rubin M.] Univ Colorado, Div Pulm Sci & Crit Care Med, Denver, CO 80202 USA.
   [Tuder, Rubin M.; Biswal, Shyam] Johns Hopkins Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD USA.
   [Biswal, Shyam] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA.
RP Biswal, S (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Room E7624,615 N Wolfe St, Baltimore, MD 21202 USA.
EM sbiswal@jhsph.edu
RI Pare, Peter/C-7425-2011
FU NHLBI NIH HHS [P50 HL084945, R01 HL081205-04, R01HL081205,
   P50HL084948-01, P50HL084945, R01HL66554, R01 HL081205, P50
   HL084945-010004]; NCI NIH HHS [R01 CA140492]; NIEHS NIH HHS
   [P50ES015903]
CR Aleyasin H, 2007, P NATL ACAD SCI USA, V104, P18748, DOI 10.1073/pnas.0709379104
   Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176
   Barnes PJ, 2004, PHARMACOL REV, V56, P515, DOI 10.1124/pr.56.4.2
   Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407
   Bartalesi B, 2005, EUR RESPIR J, V25, P15, DOI 10.1183/09031936.04.00067204
   Bea F, 2003, CIRC RES, V92, P386, DOI 10.1161/01.RES.0000059561.65545.16
   Cho HY, 2006, ANTIOXID REDOX SIGN, V8, P76, DOI 10.1089/ars.2006.8.76
   Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501
   Choi J, 2006, J BIOL CHEM, V281, P10816, DOI 10.1074/jbc.M509079200
   Clements CM, 2006, P NATL ACAD SCI USA, V103, P15091, DOI 10.1073/pnas.0607260103
   Decramer M, 2005, LANCET, V365, P1552, DOI 10.1016/S0140-6736(05)66456-2
   Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899
   Drost EM, 2005, THORAX, V60, P293, DOI 10.1136/thx.2004.027946
   Gong PF, 2002, ANTIOXID REDOX SIGN, V4, P249, DOI 10.1089/152308602753666307
   Guenegou A, 2008, AM J EPIDEMIOL, V167, P139, DOI 10.1093/aje/kwm282
   Harju T, 2002, AM J RESP CRIT CARE, V166, P754, DOI 10.1164/rccm.2112014
   He JQ, 2004, AM J RESP CRIT CARE, V170, P388, DOI 10.1164/rccm.200312-1763OC
   Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138
   Inden M, 2006, NEUROBIOL DIS, V24, P144, DOI 10.1016/j.nbd.2006.06.004
   Ishii Y, 2005, J IMMUNOL, V175, P6968, DOI 10.4049/jimmunol.175.10.6968
   Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467
   Lopez AD, 2006, EUR RESPIR J, V27, P397, DOI 10.1183/09031936.06.00025805
   MacNee W, 2007, CLIN CHEST MED, V28, P479, DOI 10.1016/j.ccm.2007.06.008
   MALHOTRA D, 2008, EXP BIOL M APR 4 9 2
   Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4
   Meulener MC, 2006, P NATL ACAD SCI USA, V103, P12517, DOI 10.1073/pnas.0601891103
   Mudway IS, 2006, FREE RADICAL BIO MED, V40, P1702, DOI 10.1016/j.freeradbiomed.2005.10.050
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003
   Okawa H, 2006, BIOCHEM BIOPH RES CO, V339, P79, DOI 10.1016/j.bbrc.2005.10.185
   Ooe H, 2006, NEUROSCI LETT, V404, P166, DOI 10.1016/j.neulet.2006.05.031
   Ooe H, 2006, NEUROSCI LETT, V406, P165, DOI 10.1016/j.neulet.2006.06.067
   Oudshoorn JH, 2007, J CYST FIBROS, V6, P35, DOI 10.1016/j.jcf.2006.05.005
   Papaiahgari S, 2006, ANTIOXID REDOX SIGN, V8, P43, DOI 10.1089/ars.2006.8.43
   Rahman I, 1996, FREE RADICAL BIO MED, V21, P669, DOI 10.1016/0891-5849(96)00155-4
   Rahman I, 2002, AM J RESP CRIT CARE, V166, P490, DOI 10.1164/rccm.2110101
   Rahman I, 2006, NAT PROTOC, V1, P3159, DOI 10.1038/nprot.2006.378
   Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538
   Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146
   Sandford AJ, 2002, THORAX, V57, P736, DOI 10.1136/thorax.57.8.736
   Shapiro SD, 2005, AM J RESP CELL MOL, V32, P367, DOI 10.1165/rcmb.F296
   Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420
   Singh A, 2006, AM J RESP CELL MOL, V35, P639, DOI 10.1165/rcmb.2005-03225OC
   Thimmulappa RK, 2007, ANTIOXID REDOX SIGN, V9, P1963, DOI 10.1089/ars.2007.1745
   Thimmulappa RK, 2006, BIOCHEM BIOPH RES CO, V351, P883, DOI 10.1016/j.bbrc.2006.10.102
   Thimmulappa RK, 2002, CANCER RES, V62, P5196
   Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1127/JCI25790
   Thompson SA, 1999, TOXICOL LETT, V110, P1, DOI 10.1016/S0378-4274(99)00133-2
   Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960
   Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248
   Walda IC, 2002, EUR J CLIN NUTR, V56, P638, DOI 10.1038/sj.ejcn.1601370
   Yanagisawa D, 2008, J CEREBR BLOOD F MET, V28, P563, DOI 10.1038/sj.jcbfm.9600553
   Yoshida T, 2007, PHYSIOL REV, V87, P1047, DOI 10.1152/physrev.00048.2006
   Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004
NR 54
TC 247
Z9 260
U1 4
U2 15
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD SEP 15
PY 2008
VL 178
IS 6
BP 592
EP 604
DI 10.1164/rccm.200803-380OC
PG 13
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 347RL
UT WOS:000259158600009
PM 18556627
OA Green Published
DA 2018-12-27
ER

PT J
AU Reddy, MA
   Villeneuve, LM
   Wang, M
   Lanting, L
   Natarajan, R
AF Reddy, Marpadga A.
   Villeneuve, Louisa M.
   Wang, Mei
   Lanting, Linda
   Natarajan, Rama
TI RETRACTED: Role of the lysine-specific demethylase 1 in the
   proinflammatory phenotype of vascular smooth muscle cells of diabetic
   mice (Retracted article. See vol. 105, pg. E9, 2009)
SO CIRCULATION RESEARCH
LA English
DT Article; Retracted Publication
DE atherosclerosis; diabetes; histone modifications; inflammation vascular
   smooth muscle cells
ID GLYCATION END-PRODUCTS; FACTOR-KAPPA-B; HISTONE MODIFICATIONS;
   GENE-TRANSCRIPTION; DB/DB MICE; INFLAMMATION; METHYLATION; ACTIVATION;
   GLUCOSE; COMPLICATIONS
AB Insulin resistance and type 2 diabetes are major risk factors for vascular complications. Vascular smooth muscle cells (VSMCs) derived from db/db mice, an established mouse model of type 2 diabetes, displayed enhanced inflammatory gene expression and proatherogenic responses. We examined the hypothesis that aberrant epigenetic chromatin events may the underlying mechanism for this persistent dysfunctional behavior and "memory" of the diabetic cells. Chromatin immunoprecipitation assays showed that levels of histone H3 lysine 4 dimethylation (H3K4me2), a key chromatin mark associated with active gene expression, were significantly elevated at the promoters of the inflammatory genes monocyte chemoattractant protein-1 and interleukin-6 in db/db VSMCs relative to db/+ cells. Tumor necrosis factor-alpha-induced inflammatory gene expression, H3K4me2 levels, and recruitment of RNA polymerase II at the gene promoters were also enhanced in db/db VSMCs, demonstrating the formation of open chromatin poised for transcriptional activation in diabetes. On the other hand, protein levels of lysine-specific demethylase1 (LSD1), which negatively regulates H3K4 methylation and its occupancy at these gene promoters, were significantly reduced in db/db VSMCs. High glucose (25 mmol/L) treatment of human VSMCs also increased inflammatory genes with parallel increases in promoter H3K4me2 levels and reduced LSD1 recruitment. LSD1 gene silencing with small interfering RNAs significantly increased inflammatory gene expression and enhanced VSMC-monocyte binding in nondiabetic VSMCs. In contrast, overexpression of LSD1 in diabetic db/db VSMCs inhibited their enhanced inflammatory gene expression. These results demonstrate novel functional roles for LSD1 and H3K4 methylation in VSMCs and inflammation. Dysregulation of their actions may be a major mechanism for vascular inflammation and metabolic memory associated with diabetic complications.
C1 [Reddy, Marpadga A.; Villeneuve, Louisa M.; Wang, Mei; Lanting, Linda; Natarajan, Rama] Beckman Res Inst City Hope, Dept Diabet, Duarte, CA 91010 USA.
   [Villeneuve, Louisa M.; Natarajan, Rama] Beckman Res Inst City Hope, Grad Sch Biol Sci, Duarte, CA 91010 USA.
RP Natarajan, R (reprint author), Beckman Res Inst City Hope, Dept Diabet, 1500 E Duarte Rd, Duarte, CA 91010 USA.
EM rnatarajan@coh.org
FU NIH National Heart, Lung, and Blood Institute; National Institute of
   Diabetes and Digestive and Kidney Diseases; Myrtle Carr Foundation;
   American Diabetes Association
FX These studies were supported by grants from the NIH (National Heart,
   Lung, and Blood Institute and National Institute of Diabetes and
   Digestive and Kidney Diseases) (to R.N.), a predoctoral fellowship grant
   from the Myrtle Carr Foundation (to L. M. V.), and a Junior Faculty
   Award from the American Diabetes Association (to M. A. R.).
CR Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101
   Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Cai QJ, 2004, ARTERIOSCL THROM VAS, V24, P2263, DOI 10.1161/01.ATV.0000146552.16943.5e
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   Das Evcimen N, 2007, PHARMACOL RES, V55, P498, DOI 10.1016/j.phrs.2007.04.016
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Hatley ME, 2003, J BIOL CHEM, V278, P25369, DOI 10.1074/jbc.M301175200
   Ihnat MA, 2007, DIABETOLOGIA, V50, P1523, DOI 10.1007/s00125-007-0684-2
   Ihnat MA, 2007, DIABETIC MED, V24, P582, DOI 10.1111/j.1464-5491.2007.02138.x
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570
   Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   Li SL, 2006, DIABETES, V55, P2611, DOI 10.2337/db06-0164
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Metzger E, 2007, NAT STRUCT MOL BIOL, V14, P252, DOI 10.1038/nsmb0407-254
   Miao F, 2006, MOL ENDOCRINOL, V20, P1562, DOI 10.1210/me.2005-0365
   Miao F, 2004, J BIOL CHEM, V279, P18091, DOI 10.1074/jbc.M311786200
   NATARAJAN R, 1992, BIOCHEM BIOPH RES CO, V187, P552, DOI 10.1016/S0006-291X(05)81529-3
   Natarajan R, 1996, J CELL PHYSIOL, V169, P391, DOI 10.1002/(SICI)1097-4652(199611)169:2<391::AID-JCP19>3.3.CO;2-Q
   Natarajan R, 2004, ARTERIOSCL THROM VAS, V24, P1542, DOI 10.1161/01.ATV.0000133606.69732.4c
   Nathan DM, 2005, NEW ENGL J MED, V353, P2643
   Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015
   Nishikawa T, 2000, NATURE, V404, P787
   Raines EW, 2005, J LIPID RES, V46, P1081, DOI 10.1194/jlr.R500004-JLR200
   Ramasamy R, 2005, GLYCOBIOLOGY, V15, p16R, DOI 10.1093/glycob/cwi053
   Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1
   Reddy MA, 2006, J BIOL CHEM, V281, P13685, DOI 10.1074/jbc.M511425200
   Sakaguchi T, 2003, J CLIN INVEST, V111, P959, DOI 10.1172/JCI200317115
   Santos-Rosa H, 2005, EUR J CANCER, V41, P2381, DOI 10.1016/j.ejca.2005.08.010
   Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
   Stavropoulos P, 2006, NAT STRUCT MOL BIOL, V13, P626, DOI 10.1038/nsmb1113
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Wen YS, 2006, ENDOCRINOLOGY, V147, P2518, DOI 10.1210/en.2005-0519
   Yasunari K, 1997, CIRC RES, V81, P953
   Yerneni KKV, 1999, DIABETES, V48, P855, DOI 10.2337/diabetes.48.4.855
NR 40
TC 57
Z9 65
U1 3
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD SEP 12
PY 2008
VL 103
IS 6
BP 615
EP 623
DI 10.1161/CIRCRESAHA.108.175190
PG 9
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA 349AZ
UT WOS:000259252500012
PM 18688044
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Wenz, T
   Diaz, F
   Spiegelman, BM
   Moraes, CT
AF Wenz, Tina
   Diaz, Francisca
   Spiegelman, Bruce M.
   Moraes, Carlos T.
TI RETRACTED: Activation of the PPAR/PGC-1 alpha pathway prevents a
   bioenergetic deficit and effectively improves a mitochondrial myopathy
   phenotype (Retracted article. See vol. 24, pg. 889, 2016)
SO CELL METABOLISM
LA English
DT Article; Retracted Publication
ID TRANSCRIPTIONAL COACTIVATOR PGC-1-ALPHA; C-OXIDASE DEFICIENCY;
   GENE-EXPRESSION; RECEPTOR-GAMMA; ERR-ALPHA; MUSCLE; BIOGENESIS; LACKING;
   CELLS; DNA
AB Neuromuscular disorders with defects in the mitochondrial ATP-generating system affect a large number of children and adults worldwide, but remain without treatment. We used a mouse model of mitochondrial myopathy, caused by a cytochrome c oxidase deficiency, to evaluate the effect of induced mitochondrial biogenesis on the course of the disease' Mitochondrial biogenesis was induced either by transgenic expression of peroxisome proliferator-activated receptor gamma (PPAR gamma) coactivator alpha (PGC-1 alpha) in skeletal muscle or by administration of bezafibrate, a PPAR panagonist. Both strategies successfully stimulated residual respiratory capacity in muscle tissue. Mitochondrial proliferation resulted in an enhanced OXPHOS capacity per muscle mass. As a consequence, ATP levels were conserved resulting in a delayed onset of the myopathy and a markedly prolonged life span. Thus, induction of mitochondrial biogenesis through pharmacological or metabolic modulation of the PPAR/PGC-1 alpha pathway promises to be an effective therapeutic approach for mitochondrial disorders.
C1 [Wenz, Tina; Diaz, Francisca; Moraes, Carlos T.] Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Moraes, Carlos T.] Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
   [Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
RP Moraes, CT (reprint author), Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
FU Muscular Dystrophy Association; PHS [NS041777, EY10804]; United
   Mitochondrial Disease Foundation
FX This work was supported by the Muscular Dystrophy Association and PHS
   grants NS041777 and EY10804. T.W. was supported by a fellowship from the
   United Mitochondrial Disease Foundation.
CR Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613
   Barros MH, 2002, FEBS LETT, V516, P119, DOI 10.1016/S0014-5793(02)02514-0
   Bastin J, 2008, J CLIN ENDOCR METAB, V93, P1433, DOI 10.1210/jc.2007-1701
   Calvo JA, 2008, J APPL PHYSIOL, V104, P1304, DOI 10.1152/japplphysiol.01231.2007
   Diaz F, 2008, GUT, V57, P232, DOI 10.1136/gut.2006.119180
   Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   DiMauro S, 2007, BIOSCIENCE REP, V27, P125, DOI 10.1007/s10540-007-9041-4
   Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200
   Handschin C, 2007, GENE DEV, V21, P770, DOI 10.1101/gad.1525107
   Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037
   Hondares E, 2007, BIOCHEM BIOPH RES CO, V354, P1021, DOI 10.1016/j.bbrc.2007.01.092
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Mensink M, 2007, INT J OBESITY, V31, P1302, DOI 10.1038/sj.ijo.0803567
   Miller DL, 2001, ANAT HISTOL EMBRYOL, V30, P253, DOI 10.1046/j.1439-0264.2001.00330.x
   Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101
   Rossmanith W, 2008, J MED GENET, V45, P117, DOI 10.1136/jmg.2007.052076
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Tenenbaum A, 2005, CARDIOVASC DIABETOL, V4, DOI 10.1186/1475-2840-4-14
   Vives-Bauza C, 2007, METHOD CELL BIOL, V80, P155, DOI 10.1016/S0091-679X(06)80007-5
   Wang YL, 2002, J BIOL CHEM, V277, P31781, DOI 10.1074/jbc.M204279200
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
NR 24
TC 233
Z9 237
U1 2
U2 20
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD SEP 3
PY 2008
VL 8
IS 3
BP 249
EP 256
DI 10.1016/j.cmet.2008.07.006
PG 8
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 344PJ
UT WOS:000258939500012
PM 18762025
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Kim, DM
   Lee, GD
   Aum, SH
   Kim, HJ
AF Kim, Dong-Myung
   Lee, Gee-Dong
   Aum, Seung-Hyun
   Kim, Ho-Jun
TI RETRACTED: Preparation of propolis nanofood and application to human
   cancer (Retracted Article. See vol 32, pg 1135, 2009)
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article; Retracted Publication
DE nanoparticle; propolis; nanofood; human cancer cell
ID BIOLOGICAL-PROPERTIES; IMMUNOMODULATORY ACTION; VASCULAR-PERMEABILITY;
   CLINICAL APPLICATION; BRAZILIAN PROPOLIS; POLYMERIC MICELLES; ETHANOL
   EXTRACT; CINNAMIC ACID; ARTEPILLIN-C; CELL-LINE
AB Propolis has well-known antimicrobial activity as well as antioxidant, antitumoral, anti-inflammatory, and regenerative properties, but its effects on the immune response are not well understood. Furthermore, clinical application of this relatively efficacious agent in cancer and other diseases has been limited due to poor aqueous solubility and, consequently, minimal systemic bioavailability. Nanoparticle-based delivery approaches have the potential to render hydrophobic agents like propolis dispersible in aqueous media, thus circumventing the pitfalls of poor solubility. We have synthesized a polymeric nanoparticle-encapsulated formulation of propolis (propolis nanofood) utilizing micellar aggregates of cross-linked and random copolymers of N-isopropylacrylamide (NIPAAM) with N-vinyl-2-pyrrollidone (VP) and poly(ethyleneglycol) monoacrylate (PEG-A). Physicochemical characterization of the polymeric nanoparticles by dynamic laser light scattering and transmission electron microscopy confirms a narrow size distribution in the 50-nm range. Propolis nanofood, unlike free propolis, is readily, dispersed in aqueous media. Propolis nanofood demonstrates comparable ill vitro therapeutic efficacy, to free propolis against a panel of human pancreatic cancer cell lines, as assessed by cell viability and clonogenicity assays in soft agar. Future studies utilizing propolis nanofood are warranted in pre-clinical in vivo.
C1 [Kim, Ho-Jun] Dongguk Univ, Coll Oriental Med, Gyeongju 780714, South Korea.
   [Aum, Seung-Hyun] Tachyon Nanotech Co Ltd, Seoul 139817, South Korea.
   [Lee, Gee-Dong] Daegu Bio Ind Ctr, Taegu 704230, South Korea.
   [Kim, Dong-Myung] Seoul Natl Univ, Nanofood Res Soc, Seoul 151742, South Korea.
RP Kim, HJ (reprint author), Dongguk Univ, Coll Oriental Med, Gyeongju 780714, South Korea.
EM kimklar@duih.org
FU Tachyon Nanotech Co., Ltd [070929-NRS82]
FX This research was supported by a fellowship grant (070929-NRS82) from
   Tachyon Nanotech Co., Ltd. in 2007.
CR Akao Y, 2003, BIOL PHARM BULL, V26, P1057, DOI 10.1248/bpb.26.1057
   AMOROS M, 1992, APIDOLOGIE, V23, P231, DOI 10.1051/apido:19920306
   Bazo AP, 2002, TERATOGEN CARCIN MUT, V22, P183, DOI 10.1002/tcm.10011
   Burdock GA, 1998, FOOD CHEM TOXICOL, V36, P347, DOI 10.1016/S0278-6915(97)00145-2
   Choi YH, 1999, INT J MOL MED, V4, P29
   DAVID DC, 2002, P AN M AM SOC CLIN, V21, P89
   DIMOV V, 1992, VACCINE, V10, P817, DOI 10.1016/0264-410X(92)90043-J
   DIMOV V, 1991, APIDOLOGIE, V22, P155, DOI 10.1051/apido:19910208
   DOBROWOLSKI JW, 1991, J ETHNOPHARMACOL, V35, P77, DOI 10.1016/0378-8741(91)90135-Z
   FELDMANN G, 2006, HEPATOB PANCREAT DIS, V12, P298
   Gradishar WJ, 2006, EXPERT OPIN PHARMACO, V7, P1041, DOI 10.1517/14656566.7.8.1041
   GRANGE JM, 1990, J ROY SOC MED, V83, P159
   GRUNBERGER D, 1988, EXPERIENTIA, V44, P230, DOI 10.1007/BF01941717
   HAUSEN BM, 1987, CONTACT DERMATITIS, V17, P171
   HAUSEN BM, 1987, CONTACT DERMATITIS, V17, P163, DOI 10.1111/j.1600-0536.1987.tb02699.x
   IVANOVSKA N, 1995, APIDOLOGIE, V26, P73, DOI 10.1051/apido:19950201
   Kawano K, 2004, ONCOLOGY-BASEL, V66, P458, DOI 10.1159/000079500
   KIM DM, 2005, ADV DRUG DELIV REV, V47, P221
   Kim Dong-Myong, 2006, Agricultural Chemistry and Biotechnology, V49, P39
   Kimoto T, 2000, PATHOL INT, V50, P679, DOI 10.1046/j.1440-1827.2000.01097.x
   KLEINROK Z, 1978, ARZNEIMITTEL-FORSCH, V28-1, P291
   Kwon GS, 2003, CRIT REV THER DRUG, V20, P357, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i5.20
   Maeda H, 2003, INT IMMUNOPHARMACOL, V3, P319, DOI 10.1016/S1567-5769(02)00271-0
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   MARCUCCI MC, 1995, APIDOLOGIE, V26, P83, DOI 10.1051/apido:19950202
   Matsuno T, 1997, MED SCI RES, V25, P583
   Miyares C, 1988, Acta Gastroenterol Latinoam, V18, P195
   NADA O, 2005, BIOL PHARM BULL, V28, P19
   NAJJIA NM, 2000, CARCINOGENESIS, V5, P921
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   RODRIGO O, 2005, ENVIRON MOL MUTAGEN, V45, P8
   SCHELLER S, 1978, ARZNEIMITTEL-FORSCH, V28-1, P289
   SCHELLER S, 1989, Z NATURFORSCH C, V44, P1063
   SCHELLER S, 1988, PHARMACOL RES, V20, P323, DOI 10.1016/S0031-6989(88)80068-7
   SCHWIEBERT LA, 1996, J ALLERGY, V97, P145
   Shimizu K, 2005, MOL CARCINOGEN, V44, P293, DOI 10.1002/mc.20148
   SHIVA M, 2007, FOOD CHEM, V103, P1097
   Soni S, 2006, J DRUG TARGET, V14, P87, DOI 10.1080/10611860600635608
   Torchilin VP, 2007, PHARM RES-DORDR, V24, P1, DOI 10.1007/s11095-006-9132-0
   Torchilin VP, 2004, CELL MOL LIFE SCI, V61, P2549, DOI 10.1007/s00018-004-4153-5
   Tyagi R, 2005, J DRUG TARGET, V13, P161, DOI 10.1080/10611860500046732
   van Vlerken Lilian E, 2006, Expert Opin Drug Deliv, V3, P205, DOI 10.1517/17425247.3.2.205
NR 42
TC 14
Z9 16
U1 3
U2 43
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD SEP
PY 2008
VL 31
IS 9
BP 1704
EP 1710
DI 10.1248/bpb.31.1704
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 346IJ
UT WOS:000259061700013
PM 18758063
OA Bronze
DA 2018-12-27
ER

PT J
AU Mayer, J
   Boldt, J
   Triem, JG
   Schellhaass, A
   Mengistu, AM
   Suttner, S
AF Mayer, J.
   Boldt, J.
   Triem, J. G.
   Schellhaass, A.
   Mengistu, A. M.
   Suttner, S.
TI RETRACTED: Individual titration of propofol plasma target improves
   anaesthetic stability in patients undergoing major abdominal surgery: a
   comparison with manually controlled infusion (Retracted article. See
   vol. 28, pg. 468, 2011)
SO EUROPEAN JOURNAL OF ANAESTHESIOLOGY
LA English
DT Article; Retracted Publication
DE anaesthesia intravenous; total; target controlled; surgery abdominal;
   propofol; anaesthesia recovery period; infusion pumps
ID EFFECT-SITE; BISPECTRAL INDEX; RECOVERY; EQUILIBRATION; INDUCTION;
   FENTANYL; SEDATION; EFFICACY; SCORE
AB Background and objective: The impact of anaesthesia using target-controlled infusion with propofol on intraoperative stability, recovery and cost compared to manually controlled infusion has been evaluated with inconsistent results. We studied a new device that allows more individual titration of propofol target-controlled infusion by using the effect-site concentration at the loss of eyelash reflex to predict the maintenance infusion rare (FM-TCI). Methods: Fifty-six patients undergoing major abdominal surgery lasting >2 h were randomly assigned to receive either FM-TCI (n = 28) or MCI-controlled (n = 28) anaesthesia. Both groups were Bispectral Index-monitored and thoracic epidural analgesia was established. Anaesthetic stability, incidence of haemodynamic abnormalities, time to extubation, propofol consumption and patient satisfaction were assessed. Results: In the FM-TCI group, a significantly improved anaesthetic stability was achieved (0.43 +/- 0.44 vs. 1.31 +/- 0.78 adjustments of propofol infusion per patient per hour, P = 0.003) and time to extubation was significantly shorter (9.6 +/- 2.1 vs. 15.7 +/- 9.6 min P = 0.011). With FM-TCI, propofol consumption was significantly lower. Haemodynamic stability and patient satisfaction did not differ between the groups. Conclusion: FM-TCI helps to provide more stable anaesthesia conditions requiring less-frequent adjustments of the propofol infusion compared to manually controlled infusion in patients undergoing major abdominal surgery.
C1 [Mayer, J.; Boldt, J.; Triem, J. G.; Schellhaass, A.; Mengistu, A. M.; Suttner, S.] Klinikum Ludwigshafen, Dept Anaesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Mayer, J (reprint author), Klinikum Ludwigshafen, Dept Anaesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM j-mayer@gmx.de
CR Agarwal A, 2004, ANESTH ANALG, V99, P1684, DOI 10.1213/01.ANE.0000136422.70531.5A
   ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K
   ANDACHI YU, 2005, ACTA ANAESTH SCAND, V49, P331
   Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196
   Barakat AR, 2007, ANAESTHESIA, V62, P661, DOI 10.1111/j.1365-2044.2007.05059.x
   Breslin DS, 2004, ANAESTHESIA, V59, P1059, DOI 10.1111/j.1365-2044.2004.03870.x
   Bruhn J, 2005, ANAESTHESIST, V54, P1021, DOI 10.1007/s00101-005-0864-8
   Buchanan FF, 2006, ANESTH ANALG, V102, P291, DOI 10.1213/01.ane.0000181321.55422.C6
   Frolich MA, 2005, BRIT J ANAESTH, V94, P434, DOI 10.1093/bja/aei081
   Hoymork SC, 2003, BRIT J ANAESTH, V91, P773, DOI 10.1093/bja/aeg258
   HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003
   Hunt-Smith J, 1999, ANAESTH INTENS CARE, V27, P260
   Iwakiri H, 2005, ANESTH ANALG, V100, P107, DOI 10.1213/01.ANE.0000139358.15909.EA
   Kazama T, 2002, ANESTHESIOLOGY, V97, P1156, DOI 10.1097/00000542-200211000-00020
   Kurita T, 2004, ANESTHESIOLOGY, V100, P871, DOI 10.1097/00000542-200404000-00017
   Lehmann A, 2002, ANESTH ANALG, V95, P639, DOI 10.1213/01.ANE.0000024203.86693.2E
   Liu N, 2006, EUR J ANAESTH, V23, P465, DOI 10.1017/S0265021506000196
   Lysakowski C, 2006, ANAESTHESIA, V61, P826, DOI 10.1111/j.1365-2044.2006.04747.x
   MARSH B, 1991, BRIT J ANAESTH, V67, P41, DOI 10.1093/bja/67.1.41
   O'Hare RA, 1999, ANESTHESIOLOGY, V91, pU217
   Passot S, 2005, ANESTH ANALG, V100, P1338, DOI 10.1213/01.ANE.0000149542.04833.55
   Passot S, 2002, ANESTH ANALG, V94, P1212, DOI 10.1097/00000539-200205000-00030
   Salmi E, 2004, ANESTH ANALG, V99, P1420, DOI 10.1213/01.ANE.0000135409.81842.31
   Schnider TW, 1999, ANESTHESIOLOGY, V90, P1502, DOI 10.1097/00000542-199906000-00003
   Servin FS, 1998, ANAESTHESIA, V53, P82, DOI 10.1111/j.1365-2044.1998.53s107.x
   Struys M, 1997, ANAESTHESIA, V52, P41, DOI 10.1111/j.1365-2044.1997.002-az001.x
   Struys MMRF, 2007, ANESTHESIOLOGY, V107, P386, DOI 10.1097/01.anes.0000278902.15505.f8
   Sukhani R, 1996, ANESTH ANALG, V83, P975, DOI 10.1097/00000539-199611000-00013
   Triem JG, 2006, ANASTH INTENSIV NOTF, V41, P150, DOI 10.1055/s-2005-921199
   Van Poucke GE, 2004, IEEE T BIO-MED ENG, V51, P1869, DOI 10.1109/TBME.2004.827935
NR 30
TC 6
Z9 13
U1 2
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0265-0215
EI 1365-2346
J9 EUR J ANAESTH
JI Eur. J. Anaesth.
PD SEP
PY 2008
VL 25
IS 9
BP 741
EP 747
DI 10.1017/S0265021508004328
PG 7
WC Anesthesiology
SC Anesthesiology
GA 343VO
UT WOS:000258883600008
PM 18426626
OA Bronze
DA 2018-12-27
ER

PT J
AU Dina, OA
   Khasar, SG
   Alessandri-Haber, N
   Bogen, O
   Chen, XJ
   Green, PG
   Reichling, DB
   Messing, RO
   Levine, JD
AF Dina, Olayinka A.
   Khasar, Sachia G.
   Alessandri-Haber, Nicole
   Bogen, Oliver
   Chen, Xiaojie
   Green, Paul G.
   Reichling, David B.
   Messing, Robert O.
   Levine, Jon D.
TI RETRACTED: Neurotoxic catecholamine metabolite in nociceptors
   contributes to painful peripheral neuropathy (Retracted article. See
   vol. 30, pg. 2235, 2009)
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE catecholaminergic neurons; DOPEGAL; epinephrine; mitochondria;
   norepinephrine; rat
ID PRIMARY SENSORY NEURONS; ROOT GANGLION NEURONS; NOREPINEPHRINE
   TRANSPORTER EXPRESSION; SMALL FIBER NEUROPATHY; MONOAMINE OXIDASE-A;
   PROTEIN-KINASE-C; MECHANICAL HYPERALGESIA; TYROSINE-HYDROXYLASE;
   ALCOHOLIC NEUROPATHY; NEUROGENIC INFLAMMATION
AB The neurotoxic effects of catecholamine metabolites have been implicated in neurodegenerative diseases. As some sensory neurons express tyrosine hydroxylase and monoamine oxidase (MAO), we investigated the potential contribution of catecholamine metabolites to neuropathic pain in a model of alcoholic neuropathy. The presence of catecholamines in sensory neurons is supported by capsaicin-stimulated epinephrine release, an effect enhanced in ethanol-fed rats. mRNA for enzymes in dorsal root ganglia involved in catecholamine uptake and metabolism, dopamine beta-hydroxylase and MAO-A, were decreased by neonatal administration of capsaicin. Ethanol-induced hyperalgesia was attenuated by systemic and local peripheral administration of inhibitors of MAO-A, reduction of norepinephrine transporter (NET) in sensory neurons and a NET inhibitor. Finally, intradermal injection of 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL), a neurotoxic MAO-A catecholamine metabolite, produced robust mechanical hyperalgesia. These observations suggest that catecholamines in nociceptors are metabolized to neurotoxic products by MAO-A, which can cause neuronal dysfunction underlying neuropathic pain.
C1 [Levine, Jon D.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Dina, Olayinka A.; Khasar, Sachia G.; Alessandri-Haber, Nicole; Bogen, Oliver; Chen, Xiaojie; Green, Paul G.; Reichling, David B.; Levine, Jon D.] Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, San Francisco, CA 94143 USA.
   [Dina, Olayinka A.; Khasar, Sachia G.; Alessandri-Haber, Nicole; Bogen, Oliver; Chen, Xiaojie; Green, Paul G.; Reichling, David B.; Levine, Jon D.] Univ Calif San Francisco, UCSF NIH Pain Ctr, San Francisco, CA 94143 USA.
   [Messing, Robert O.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
   [Messing, Robert O.; Levine, Jon D.] Univ Calif San Francisco, Div Neurosci & Biomed Sci, San Francisco, CA 94143 USA.
   [Messing, Robert O.] Ernest Gallo Clin & Res Ctr, Emeryville, CA 94608 USA.
RP Levine, JD (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
EM Jon.Levine@ucsf.edu
RI Alessandri-Haber, Nicole/A-5572-2009; Green, Paul/C-5943-2011; Messing,
   Robert/D-3642-2015
OI Green, Paul/0000-0001-7648-6826; Messing, Robert/0000-0002-5345-4431
FU NIH/NIAAA [R01 AA013875]; Alcoholic Beverage Medical Research Foundation
FX We are grateful to Mr Dennis Mendoza for technical assistance. This
   study was supported by NIH/NIAAA Grant #R01 AA013875 and the Alcoholic
   Beverage Medical Research Foundation.
CR Alessandri-Haber N, 2003, NEURON, V39, P497, DOI 10.1016/S0896-6273(03)00462-8
   Baloh RH, 2008, NEUROSCIENTIST, V14, P12, DOI 10.1177/1073858407307354
   BARON R, 1988, J COMP NEUROL, V275, P460, DOI 10.1002/cne.902750310
   Brain WR, 1969, BRAINS DIS NERVOUS S, P817
   Brumovsky P, 2006, EXP NEUROL, V200, P153, DOI 10.1016/j.expneurol.2006.01.023
   Burke WJ, 1999, BRAIN RES, V816, P633, DOI 10.1016/S0006-8993(98)01211-6
   Burke WJ, 2004, NEUROTOXICOLOGY, V25, P101, DOI 10.1016/S0161-813X(03)00090-1
   Chen XJ, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-5
   Chikuma T, 2007, NEUROCHEM INT, V50, P236, DOI 10.1016/j.neuint.2006.08.010
   Creange A, 2004, REV NEUROL-FRANCE, V160, P363
   Czaja K, 2000, CELLS TISSUES ORGANS, V166, P275, DOI 10.1159/000016741
   Dina OA, 2004, EUR J NEUROSCI, V19, P634, DOI 10.1111/j.1460-9568.2004.03169.x
   Dina OA, 2001, NEUROSCIENCE, V108, P507, DOI 10.1016/S0306-4522(01)00425-0
   Dina OA, 2000, J NEUROSCI, V20, P8614, DOI 10.1523/JNEUROSCI.20-22-08614.2000
   Dina OA, 2008, EUR J NEUROSCI, V27, P83, DOI 10.1111/j.1460-9568.2007.05987.x
   Dina OA, 2006, EUR J NEUROSCI, V24, P197, DOI 10.1111/j.1460-9568.2006.04886.x
   Eisenhofer G, 2004, PHARMACOL REV, V56, P331, DOI 10.1124/pr.56.3.1
   Eisenhofer G, 2001, PHARMACOL THERAPEUT, V91, P35, DOI 10.1016/S0163-7258(01)00144-9
   Fadda F, 1998, PROG NEUROBIOL, V56, P385, DOI 10.1016/S0301-0082(98)00032-X
   Flatmark T, 2000, ACTA PHYSIOL SCAND, V168, P1
   Freeman R, 2005, LANCET, V365, P1259, DOI 10.1016/S0140-6736(05)74815-7
   Freeman R, 2007, NEUROL CLIN, V25, P277, DOI 10.1016/j.ncl.2007.01.001
   GLAZER EJ, 1980, SCIENCE, V208, P1479, DOI 10.1126/science.6155697
   Green PG, 2005, EUR J NEUROSCI, V21, P486, DOI 10.1111/j.1460-9568.2005.03872.x
   Green PG, 1998, ANN NY ACAD SCI, V840, P282, DOI 10.1111/j.1749-6632.1998.tb09568.x
   Grundemann D, 1998, NAT NEUROSCI, V1, P349, DOI 10.1038/1557
   Habecker BA, 2006, J NEUROCHEM, V97, P1044, DOI 10.1111/j.1471-4159.2006.03792.x
   Hara K, 2002, N-S ARCH PHARMACOL, V365, P406, DOI 10.1007/s00210-002-0534-1
   Hoitsma E, 2004, J NEUROL SCI, V227, P119, DOI 10.1016/j.jns.2004.08.012
   Hucho TB, 2006, EUR J NEUROSCI, V24, P527, DOI 10.1111/j.1460-9568.2006.04913.x
   Jahng JW, 1998, DEV BRAIN RES, V107, P241, DOI 10.1016/S0165-3806(98)00013-3
   Jamieson SMF, 2005, CANCER CHEMOTH PHARM, V56, P391, DOI 10.1007/s00280-004-0953-4
   Joseph EK, 2006, PAIN, V121, P105, DOI 10.1016/j.pain.2005.12.010
   Joseph EK, 2004, EUR J NEUROSCI, V20, P2896, DOI 10.1111/j.1460-9568.2004.03750.x
   KATZ DM, 1983, P NATL ACAD SCI-BIOL, V80, P3526, DOI 10.1073/pnas.80.11.3526
   KATZ DM, 1986, J NEUROSCI, V6, P983
   KATZ DM, 1987, FASEB J, V46, P24
   Keller NR, 2004, CIRCULATION, V110, P1191, DOI 10.1161/01.CIR.0000141804.90845.E6
   KERSTENS HMJ, 1995, J HISTOCHEM CYTOCHEM, V43, P347, DOI 10.1177/43.4.7897179
   Khasar SG, 1998, J NEUROSCI, V18, P3043
   Khasar SG, 2002, J PAIN, V3, P369, DOI 10.1054/jpai.2002.126610
   Khasar SG, 2003, EUR J NEUROSCI, V17, P909, DOI 10.1046/j.1460-9568.2003.02503.x
   Kiyono Y, 2008, NUCL MED BIOL, V35, P213, DOI 10.1016/j.nucmedbio.2007.11.006
   Koike H, 2001, NEUROLOGY, V56, P1727, DOI 10.1212/WNL.56.12.1727
   Koike H, 2006, CURR OPIN NEUROL, V19, P481, DOI 10.1097/01.wco.0000245371.89941.eb
   KUMMER W, 1990, CELL TISSUE RES, V261, P595, DOI 10.1007/BF00313540
   Leinninger GM, 2006, NAT CLIN PRACT NEURO, V2, P620, DOI 10.1038/ncpneuro0320
   LIEBER CS, 1989, J NUTR, V119, P2038
   LIEBER CS, 1989, ALCOHOL ALCOHOLISM, V24, P197
   LIEBER CS, 1989, HEPATOLOGY, V10, P501, DOI 10.1002/hep.1840100417
   Liu H, 2008, CELL BIOL TOXICOL, V24, P113, DOI 10.1007/s10565-007-9021-2
   Mao WK, 2005, AM J PHYSIOL-HEART C, V288, pH2381, DOI 10.1152/ajpheart.00904.2004
   Marchitti SA, 2007, PHARMACOL REV, V59, P125, DOI 10.1124/pr.59.2.1
   Mega BT, 2002, N-S ARCH PHARMACOL, V366, P319, DOI 10.1007/s00210-002-0616-0
   Miao FJP, 2000, J PHYSIOL-LONDON, V527, P601, DOI 10.1111/j.1469-7793.2000.00601.x
   MIAO FJP, 1995, J AUTONOM NERV SYST, V56, P115, DOI 10.1016/0165-1838(95)00052-X
   Miao FJP, 2001, J PHYSIOL-LONDON, V532, P811
   Nalk AK, 2006, EUR J PAIN, V10, P573, DOI 10.1016/j.ejpain.2005.08.006
   Paczkowski NJ, 1996, N-S ARCH PHARMACOL, V353, P423
   Patterson-Buckendahl P, 2005, ALCOHOL, V37, P157, DOI 10.1016/j.alcohol.2005.09.007
   Patterson-Buckendahl P, 2004, ANN NY ACAD SCI, V1018, P173, DOI 10.1196/annals.1296.020
   PRICE J, 1983, NATURE, V301, P241, DOI 10.1038/301241a0
   PRICE J, 1985, J NEUROSCI, V5, P2051
   RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409
   Ren ZG, 2003, DEV NEUROSCI-BASEL, V25, P1, DOI 10.1159/000071462
   RIVETT AJ, 1982, J NEUROCHEM, V39, P1009, DOI 10.1111/j.1471-4159.1982.tb11490.x
   Rommelfanger KS, 2007, BIOCHEM PHARMACOL, V74, P177, DOI 10.1016/j.bcp.2007.01.036
   Rusnak M, 2005, EUR J NEUROSCI, V21, P889, DOI 10.1111/j.1460-9568.2005.03913.x
   Schuchardt V, 2000, Ther Umsch, V57, P196, DOI 10.1024/0040-5930.57.4.196
   Shearman LP, 1999, EUR J PHARMACOL, V386, P1, DOI 10.1016/S0014-2999(99)00624-X
   Sieber-Blum M, 2000, MOL CELL BIOCHEM, V212, P61, DOI 10.1023/A:1007100803568
   Siniscalco D, 2007, PHARMACOL RES, V55, P158, DOI 10.1016/j.phrs.2006.11.009
   STUDENT AK, 1977, BIOCHEM PHARMACOL, V26, P2337, DOI 10.1016/0006-2952(77)90437-3
   TAIWO YO, 1989, BRAIN RES, V487, P148, DOI 10.1016/0006-8993(89)90950-5
   Thackeray JT, 2007, J NUCL MED, V48, P1733, DOI 10.2967/jnumed.107.043570
   VEGA JA, 1991, CELL MOL BIOL, V37, P519
   WALDMEIER PC, 1976, N-S ARCH PHARMACOL, V292, P9, DOI 10.1007/BF00506483
   WESTLUND KN, 1993, BRAIN RES, V612, P221, DOI 10.1016/0006-8993(93)91664-E
   WILKINSON CW, 1981, ENDOCRINOLOGY, V109, P162, DOI 10.1210/endo-109-1-162
   Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9
   Zambelis T, 2005, J PERIPHER NERV SYST, V10, P375, DOI 10.1111/j.1085-9489.2005.00050.x
NR 81
TC 18
Z9 19
U1 5
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-816X
EI 1460-9568
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD SEP
PY 2008
VL 28
IS 6
BP 1180
EP 1190
DI 10.1111/j.1460-9568.2008.06425.x
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 348KQ
UT WOS:000259209800014
PM 18783367
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Cardullo, B
   Rohmer, E
AF Cardullo, Bert
   Rohmer, Eric
TI RETRACTED: An Auteur for All Seasons An Interview with Eric Rohmer
   (Retracted article. See vol. 39, pg. 173, 2014)
SO FRENCH FORUM
LA English
DT Editorial Material; Retracted Publication
C1 [Cardullo, Bert] Izmir Univ Econ, Izmir, Turkey.
RP Cardullo, B (reprint author), Izmir Univ Econ, Izmir, Turkey.
NR 0
TC 2
Z9 2
U1 2
U2 6
PU UNIV NEBRASKA PRESS
PI LINCOLN
PA 1111 LINCOLN MALL, LINCOLN, NE 68588-0630 USA
SN 0098-9355
EI 1534-1836
J9 FR FORUM
JI Fr. Forum
PD FAL
PY 2008
VL 33
IS 3
BP 123
EP 136
PG 14
WC Literature, Romance
SC Literature
GA 423SO
UT WOS:000264516200009
DA 2018-12-27
ER

PT J
AU Zhou, YP
AF Zhou, Yi-peng
TI RETRACTED: Fast and Robust Stereo Vision Algorithm for Obstacle
   Detection (Retracted article)
SO JOURNAL OF BIONIC ENGINEERING
LA English
DT Article; Retracted Publication
DE stereo vision; vehicle dynamics; visibility range; image alignment
AB Binocular computer vision is based on bionics, after the calibration through the camera head by double-exposure image synchronization, access to the calculation of two-dimensional image pixels of the three-dimensional depth information. In this paper, a fast and robust stereo vision algorithm is described to perform in-vehicle obstacles detection and characterization. The stereo algorithm which provides a suitable representation of the geometric content of the road scene is described, a ndan in-vehicle embedded system is presented. We present the way in which the algorithm is used, and then report experiments on real situations which show that our solution is accurate, reliable and efficient. In particular, both processes are fast, generic, robust to noise and bad conditions, and work even with partial occlusion.
C1 Northwestern Polytech Univ, Dept Automat, Xian 710068, Peoples R China.
RP Zhou, YP (reprint author), Northwestern Polytech Univ, Dept Automat, Xian 710068, Peoples R China.
EM aws1188@126.com
CR Bertozzi M, 2000, PROCEEDINGS OF THE IEEE INTELLIGENT VEHICLES SYMPOSIUM 2000, P39, DOI 10.1109/IVS.2000.898315
   Franke U, 2000, PROCEEDINGS OF THE IEEE INTELLIGENT VEHICLES SYMPOSIUM 2000, P273, DOI 10.1109/IVS.2000.898354
   Goldbeck J., 1999, Proceedings 199 IEEE/IEEJ/JSAI International Conference on Intelligent Transportation Systems (Cat. No.99TH8383), P74, DOI 10.1109/ITSC.1999.821030
   GRIMSON WEL, 1985, IEEE T PATTERN ANAL, V7, P17, DOI 10.1109/TPAMI.1985.4767615
   GRUYER D, 1999, P 15 C UNC ART INT S, P255
   HANCOCK J, 2000, CMURITR9717
   HATTORI H, 2000, C COMP VIS PATT REC, P177
   Hautiere N, 2006, IEEE T INTELL TRANSP, V7, P201, DOI 10.1109/TITS.2006.874682
   KALINKE T, 1998, P IEEE INT VEH S STU, V1, P143
   LABAYRADE R, 2003, P IEEE INT VEH S COL, P31
   LABAYRADE R, 2003, 1 INT WORKSH IN VEH, P13
   Labayrade R., 2002, P IEEE S INT VEH, V2, P646
   ROJAS JC, 1997, P IEEE C INT TRANSP, P403
   WILLIAMSON TA, 1998, THESIS CARNEGIE MELL
NR 14
TC 2
Z9 2
U1 4
U2 16
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1672-6529
J9 J BIONIC ENG
JI J. Bionic Eng.
PD SEP
PY 2008
VL 5
IS 3
BP 247
EP 252
DI 10.1016/S1672-6529(08)60031-1
PG 6
WC Engineering, Multidisciplinary; Materials Science, Biomaterials;
   Robotics
SC Engineering; Materials Science; Robotics
GA 359GJ
UT WOS:000259974100010
DA 2018-12-27
ER

PT J
AU Radhakrishnan, S
   Cabrera, R
   Schenk, EL
   Nava-Parada, P
   Bell, MP
   Van Keulen, VP
   Marler, RJ
   Felts, SJ
   Pease, LR
AF Radhakrishnan, Suresh
   Cabrera, Rosalyn
   Schenk, Erin L.
   Nava-Parada, Pilar
   Bell, Michael P.
   Van Keulen, Virginia P.
   Marler, Ronald J.
   Felts, Sara J.
   Pease, Larry R.
TI RETRACTED: Reprogrammed FoxP3(+) T regulatory cells become IL-17(+)
   antigen-specific autoimmune effectors in vitro and in vivo (Retracted
   article. See vol. 184, pg. 6556, 2010)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID TRANSCRIPTION FACTOR FOXP3; CROSS-LINKING ANTIBODY; GROWTH-FACTOR-BETA;
   DENDRITIC CELLS; TGF-BETA; IMMUNE DYSREGULATION; CUTTING EDGE;
   ROR-GAMMA; LINEAGE; DIFFERENTIATION
AB Lymphocyte differentiation from naive CD4(+) T cells into mature Th1, Th2, Th17, or T regulatory cell (Treg) phenotypes has been considered end stage in character. In this study, we demonstrate that dendritic cells (DCs) activated with a novel immune modulator B7-DC XAb (DC(XAb)) can reprogram Tregs into T effector cells. Down-regulation of FoxP3 expression after either in vitro or in vivo Treg-DC(XAb) interaction is Ag-specific, IL-6-dependent, and results in the functional reprogramming of the mature T cell phenotype. The reprogrammed Tregs cease to express IL-10 and TGF beta, fail to suppress T cell responses, and gain the ability to produce IFN-gamma, IL-17, and TNF-alpha. The ability of IL-6(+) DC(XAb) and the inability of IL-6(-/-) DC(XAb) vaccines to protect animals from lethal melanoma suggest that exogenously modulated DC can reprogram host Tregs. In support of this hypothesis and as a test for Ag specificity, transfer of DC(XAb) into RIP-OVA mice causes a break in immune tolerance, inducing diabetes. Conversely, adoptive transfer of reprogrammed Tregs but not similarly treated CD25(-) T cells into naive RtP-OVA mice is also sufficient to cause autoimmune diabetes. Yet, treatment of normal mice with B7-DC XAb fails to elicit generalized autoimmunity. The finding that mature Tregs can be reprogrammed into competent effector cells provides new insights into the plasticity of T cell lineage, underscores the importance of DC-T cell interaction in balancing immunity with tolerance, points to Tregs as a reservoir of autoimmune effectors, and defines a new approach for breaking tolerance to self Ags as a strategy for cancer immunotherapy.
C1 [Radhakrishnan, Suresh; Cabrera, Rosalyn; Schenk, Erin L.; Nava-Parada, Pilar; Bell, Michael P.; Van Keulen, Virginia P.; Felts, Sara J.; Pease, Larry R.] Mayo Clin, Dept Immunol, Coll Med, Rochester, MN 55905 USA.
   [Marler, Ronald J.] Mayo Clin, Coll Med, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA.
RP Pease, LR (reprint author), Mayo Clin, Dept Immunol, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.
EM pease.larry@mayo.edu
FU National Institutes of Health [R01 CA 104996, R01 HL077296]
FX This work was funded by Grants R01 CA 104996 and R01 HL077296 from the
   National Institutes of Health (to L.R.P.).
CR Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387
   Bennett CL, 2001, NAT GENET, V27, P20
   Bettelli E, 2006, NATURE, V441, P166
   Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6
   Blocki FA, 2006, FASEB J, V20, P2408, DOI 10.1096/fj.06-6171fje
   BONOMO A, 1995, J IMMUNOL, V154, P6602
   Cabarrocas J, 2006, P NATL ACAD SCI USA, V103, P8453, DOI 10.1073/pnas.0603086103
   Campbell DJ, 2007, NAT REV IMMUNOL, V7, P305, DOI 10.1038/nr2061
   Chang JT, 2007, SCIENCE, V315, P1687, DOI 10.1126/science.1139393
   Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152
   Colombo MP, 2007, NAT REV CANCER, V7, P880, DOI 10.1038/nrc2250
   Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003
   Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149
   Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Gambineri E, 2003, CURR OPIN RHEUMATOL, V15, P430, DOI 10.1097/00002281-200307000-00010
   Gudmundsdottir H, 1999, J IMMUNOL, V162, P5212
   Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254
   Heckman KL, 2007, EUR J IMMUNOL, V37, P1827, DOI 10.1002/eji.200637002
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035
   Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909
   Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923
   Lachman LB, 2001, CANCER GENE THER, V8, P259, DOI 10.1038/sj.cgt.7700300
   Liston A, 2007, CURR OPIN IMMUNOL, V19, P176, DOI 10.1016/j.coi.2007.02.005
   LUCCHINI F, 1992, CANCER LETT, V64, P203, DOI 10.1016/0304-3835(92)90044-V
   Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754
   Miyara M, 2007, TRENDS MOL MED, V13, P108, DOI 10.1016/j.molmed.2007.01.003
   Nava-Parada P, 2007, CANCER RES, V67, P1326, DOI 10.1158/0008-5472.CAN-06-3290
   Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135
   Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261
   Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231
   Pavelko KD, 2008, CANCER RES, V68, P2471, DOI 10.1158/0008-5472.CAN-07-5937
   Radhakrishnan S, 2005, J ALLERGY CLIN IMMUN, V116, P668, DOI 10.1016/j.jaci.2005.04.038
   Radhakrishnan S, 2005, P NATL ACAD SCI USA, V102, P11438, DOI 10.1073/pnas.0501420102
   Radhakrishnan S, 2004, J IMMUNOL, V173, P1360, DOI 10.4049/jimmunol.173.2.1360
   Radhakrishnan S, 2004, CANCER RES, V64, P4965, DOI 10.1158/0008-5472.CAN-03-3025
   Radhakrishnan S, 2003, J IMMUNOL, V170, P1830, DOI 10.4049/jimmunol.170.4.1830
   Radhakrishnan S, 2007, J IMMUNOL, V178, P3583, DOI 10.4049/jimmunol.178.6.3583
   Radhakrishnan S, 2007, J IMMUNOL, V178, P1426, DOI 10.4049/jimmunol.178.3.1426
   Reiner SL, 2007, CELL, V129, P33, DOI 10.1016/j.cell.2007.03.019
   Richter A, 1999, J EXP MED, V190, P1439, DOI 10.1084/jem.190.10.1439
   Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122
   Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821
   Stockinger B, 2007, CURR OPIN IMMUNOL, V19, P281, DOI 10.1016/j.coi.2007.04.005
   Sugimoto N, 2006, INT IMMUNOL, V18, P1197, DOI 10.1093/intimm/dx1060
   Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3
   Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572
   Van Keulen VP, 2006, CLIN EXP IMMUNOL, V143, P314, DOI 10.1111/j.1365-2249.2005.02992.x
   Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001
   Wan YY, 2007, IMMUNOL REV, V220, P199, DOI 10.1111/j.1600-065X.2007.00565.x
   Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557
   Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002
   Xu LL, 2007, J IMMUNOL, V178, P6725, DOI 10.4049/jimmunol.178.11.6725
   Xystrakis E, 2004, BLOOD, V104, P3294, DOI 10.1182/blood-2004-03-1214
   Yamagiwa S, 2001, J IMMUNOL, V166, P7282, DOI 10.4049/jimmunol.166.12.7282
   Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016
   Zheng Y, 2007, NAT IMMUNOL, V8, P457, DOI 10.1038/ni1455
   Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547
NR 60
TC 98
Z9 102
U1 4
U2 15
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD SEP 1
PY 2008
VL 181
IS 5
BP 3137
EP 3147
DI 10.4049/jimmunol.181.5.3137
PG 11
WC Immunology
SC Immunology
GA 352QJ
UT WOS:000259511800022
PM 18713984
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Szepfalusi, Z
AF Szepfalusi, Zsolft
TI RETRACTED: The maturation of the fetal and neonatal immune system
   (Retracted article. See vol. 138, pg. 2548, 2008)
SO JOURNAL OF NUTRITION
LA English
DT Article; Proceedings Paper; Retracted Publication
CT International Symposium on Infant Nutrition
CY SEP 08, 2007
CL Rotterdam, NETHERLANDS
SP Sophia Childrens Hosp, Erasmus Univ, Danone Res
ID BLOOD MONONUCLEAR-CELLS; INTERFERON-GAMMA PRODUCTION; ACELLULAR
   PERTUSSIS-VACCINE; CORD T-LYMPHOCYTES; PERIPHERAL-BLOOD; HUMAN-FETUS;
   ENVIRONMENTAL ALLERGENS; INHALANT ALLERGENS; IFN-GAMMA; DECREASED
   PRODUCTION
AB The prevalence of allergic diseases has risen markedly since the 1960s, particularly in the developed countries of the Western world. These diseases manifest initially during infancy and childhood and are apparently becoming more persistent in successive birth cohorts. The importance of genetic susceptibility in the disease process is widely recognized, and it is further recognized that the ultimate expression of the disease is the result of complex interactions between genetic and environmental factors, with nutrition representing 1 main variable, neither of which have yet been comprehensively characterized. There is increasing evidence that the level of complexity inherent in the pathogenesis of allergic diseases may be even greater than is currently contemplated, as an additional set of crucial factors appear to be involved. Notably, it appears likely that the ultimate effects of the ''gene-environment" interaction within individuals may also be related to the developmental status of the relevant target tissues at the time the interactions occur. Examples of the latter, discussed below, are elements of innate and adaptive immune function and aspects of food allergy and of airway function relevant to atopic asthma.
C1 Med Univ Vienna, Dept Pediat, A-1090 Vienna, Austria.
RP Szepfalusi, Z (reprint author), Med Univ Vienna, Dept Pediat, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM zsolt.szepfalusi@meduniwien.ac.at
CR AASE JM, 1972, NEW ENGL J MED, V286, P1379, DOI 10.1056/NEJM197206292862603
   Adkins B, 1998, J IMMUNOL, V160, P4217
   Adkins B, 1999, IMMUNOL TODAY, V20, P330, DOI 10.1016/S0167-5699(99)01473-5
   ANDERSSON U, 1981, IMMUNOL REV, V57, P5, DOI 10.1111/j.1600-065X.1981.tb00440.x
   Arkwright PD, 2000, CLIN EXP IMMUNOL, V122, P16, DOI 10.1046/j.1365-2249.2000.01338.x
   Arulanandam BP, 1999, EUR J IMMUNOL, V29, P256, DOI 10.1002/(SICI)1521-4141(199901)29:01<256::AID-IMMU256>3.0.CO;2-G
   Ashkar AA, 2000, J EXP MED, V192, P259, DOI 10.1084/jem.192.2.259
   ASMA GEM, 1983, CLIN EXP IMMUNOL, V53, P429
   Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494
   Barrios C, 1996, EUR J IMMUNOL, V26, P1489, DOI 10.1002/eji.1830260713
   BIANCHI DW, 1993, PRENATAL DIAG, V13, P293, DOI 10.1002/pd.1970130408
   Biasucci G, 2008, J NUTR, V138, p1796S
   Bjorksten B, 1996, CLIN EXP ALLERGY, V26, P775, DOI 10.1111/j.1365-2222.1996.tb00607.x
   Boehm G, 2008, J NUTR, V138, p1818S
   Bonney EA, 1997, J IMMUNOL, V158, P40
   BRADLEY LM, 1989, CLIN IMMUNOL IMMUNOP, V51, P426, DOI 10.1016/0090-1229(89)90041-X
   BYRNE JA, 1994, J IMMUNOL, V152, P3098
   Calado RT, 1999, CYTOMETRY, V38, P133, DOI 10.1002/(SICI)1097-0320(19990615)38:3<133::AID-CYTO8>3.0.CO;2-9
   CAMPANA D, 1989, J IMMUNOL, V142, P57
   Chalmers IMH, 1998, BLOOD, V92, P11
   Chheda S, 1996, PEDIATR RES, V40, P475, DOI 10.1203/00006450-199609000-00018
   Chirico G, 2008, J NUTR, V138, p1801S
   CLEMENT LT, 1990, J IMMUNOL, V145, P102
   ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2
   Dastur F D, 1993, J Assoc Physicians India, V41, P94
   de Vries E, 2000, PEDIATR RES, V47, P528, DOI 10.1203/00006450-200004000-00019
   DURANDY A, 1995, J IMMUNOL, V154, P1560
   Early EM, 1996, EUR J IMMUNOL, V26, P2885, DOI 10.1002/eji.1830261212
   Edelbauer M, 2003, INT ARCH ALLERGY IMM, V130, P25, DOI 10.1159/000068373
   Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307
   FICHTELIUS KE, 1968, EXP CELL RES, V49, P87, DOI 10.1016/0014-4827(68)90522-3
   Fievet N, 1996, PARASITE IMMUNOL, V18, P483, DOI 10.1046/j.1365-3024.1996.d01-19.x
   FULEIHAN R, 1994, EUR J IMMUNOL, V24, P1925, DOI 10.1002/eji.1830240832
   Gans HA, 1999, J IMMUNOL, V162, P5569
   Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X
   GERLI R, 1993, CELL IMMUNOL, V148, P32, DOI 10.1006/cimm.1993.1089
   GERLI R, 1986, CLIN IMMUNOL IMMUNOP, V40, P429, DOI 10.1016/0090-1229(86)90187-X
   GILL TJ, 1983, J CLIN INVEST, V72, P987, DOI 10.1172/JCI111071
   Gottrand F, 2008, J NUTR, V138, p1807S
   GRIFFITHSCHU S, 1984, BLOOD, V64, P296
   Guller S, 1999, SEMIN REPROD ENDOCR, V17, P39, DOI 10.1055/s-2007-1016210
   Hammer A, 1999, AM J REPROD IMMUNOL, V41, P41
   HANNET I, 1992, IMMUNOL TODAY, V13, P215, DOI 10.1016/0167-5699(92)90157-3
   Hassan J, 1996, IMMUNOLOGY, V87, P604, DOI 10.1046/j.1365-2567.1996.476587.x
   Hassan J, 1998, EUR J IMMUNOL, V28, P3057, DOI 10.1002/(SICI)1521-4141(199810)28:10<3057::AID-IMMU3057>3.0.CO;2-Z
   HASSAN J, 1993, RES IMMUNOL, V144, P87, DOI 10.1016/0923-2494(93)80064-6
   Hassan J, 2001, J IMMUNOL, V167, P1970, DOI 10.4049/jimmunol.167.4.1970
   HASSAN J, 1995, CLIN EXP IMMUNOL, V102, P192
   HAYNES BF, 1988, J EXP MED, V168, P1061, DOI 10.1084/jem.168.3.1061
   HAYNES BF, 1988, J IMMUNOL, V141, P3776
   HAYWARD AR, 1981, IMMUNOL REV, V57, P39, DOI 10.1111/j.1600-065X.1981.tb00441.x
   HAYWARD AR, 1989, EUR J IMMUNOL, V19, P771, DOI 10.1002/eji.1830190430
   HERZENBERG LA, 1979, P NATL ACAD SCI USA, V76, P1453, DOI 10.1073/pnas.76.3.1453
   HILKENS CMU, 1995, EUR J IMMUNOL, V25, P59, DOI 10.1002/eji.1830250112
   Holgate ST, 1998, CLIN EXP ALLERGY, V28, P97
   Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P1117, DOI 10.1067/mai.2000.105804
   HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x
   Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1
   Holt PG, 2002, EUR RESPIR J, V19, P538, DOI 10.1183/09031936.02.00229302
   HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P85, DOI 10.1111/j.1399-3038.1995.tb00264.x
   HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x
   Howie D, 1998, J IMMUNOL, V161, P5862
   Kabesch M, 2004, J LEUKOCYTE BIOL, V75, P383, DOI 10.1189/jlb.1003468
   King CL, 1998, J IMMUNOL, V160, P3578
   KINGSLEY G, 1988, CLIN EXP IMMUNOL, V73, P40
   Klinge J, 2000, VACCINE, V18, P3134, DOI 10.1016/S0264-410X(00)00096-7
   KONDO N, 1992, ARCH DIS CHILD, V67, P1003, DOI 10.1136/adc.67.8.1003
   KotirantaAinamo A, 1997, PEDIATR RES, V41, P110, DOI 10.1203/00006450-199701000-00017
   Kovarik J, 1999, J IMMUNOL, V162, P1611
   Krishnan L, 1996, J IMMUNOL, V156, P653
   Lafeber HN, 2008, J NUTR, V138, p1813S
   LATTHE M, 1994, EUR J IMMUNOL, V24, P1703, DOI 10.1002/eji.1830240737
   Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1
   Lee SM, 1996, BLOOD, V88, P945
   LEWIS DB, 1991, J CLIN INVEST, V87, P194, DOI 10.1172/JCI114970
   Liao SY, 1996, CLIN EXP ALLERGY, V26, P397, DOI 10.1111/j.1365-2222.1996.tb00555.x
   LO YMD, 1989, LANCET, V2, P1363
   Loibichler C., 2002, Clinical and Experimental Allergy, V32, P1546, DOI 10.1046/j.1365-2222.2002.01479.x
   M'Rabet L, 2008, J NUTR, V138, p1782S
   Ma YF, 2005, J IMMUNOL, V174, P7961, DOI 10.4049/jimmunol.174.12.7961
   Macardle PJ, 1999, HUM IMMUNOL, V60, P127, DOI 10.1016/S0198-8859(98)00107-4
   Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223
   Macaubas C, 2002, CLIN EXP ALLERGY, V32, P97, DOI 10.1046/j.0022-0477.2001.01288.x
   Macaubas C, 2001, INT ARCH ALLERGY IMM, V124, P176, DOI 10.1159/000053703
   MACCARIO R, 1983, J IMMUNOL, V130, P1129
   MARKGRAF R, 1982, CELL TISSUE RES, V225, P387, DOI 10.1007/BF00214691
   MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4
   MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301
   Martinez FD, 1999, LANCET, V354, pS12
   Martinez X, 1997, P NATL ACAD SCI USA, V94, P8726, DOI 10.1073/pnas.94.16.8726
   MCLEOD R, 1990, J LAB CLIN MED, V116, P623
   McVay LD, 1998, J IMMUNOL, V160, P5851
   MCWILLIAM AS, 1994, J EXP MED, V179, P1331, DOI 10.1084/jem.179.4.1331
   MIGLIACCIO G, 1986, J CLIN INVEST, V78, P51, DOI 10.1172/JCI112572
   Miles EA, 1996, CLIN EXP ALLERGY, V26, P780, DOI 10.1111/j.1365-2222.1996.tb00608.x
   Miscia S, 1999, J IMMUNOL, V163, P2416
   Morelli L, 2008, J NUTR, V138, p1791S
   Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191
   NAMIKAWA R, 1986, IMMUNOLOGY, V57, P61
   NELSON DJ, 1994, J EXP MED, V179, P203, DOI 10.1084/jem.179.1.203
   NOVATOSILVA E, 1992, SCAND J IMMUNOL, V35, P429, DOI 10.1111/j.1365-3083.1992.tb02878.x
   Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602
   PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q
   PIASTRA M, 1994, INT ARCH ALLERGY IMM, V104, P358, DOI 10.1159/000236692
   PICCINNI MP, 1995, J IMMUNOL, V155, P128
   PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301, DOI 10.1159/000236541
   PIRENNE H, 1992, PEDIATR RES, V32, P81, DOI 10.1203/00006450-199207000-00016
   Porcu P, 1998, P NATL ACAD SCI USA, V95, P4538, DOI 10.1073/pnas.95.8.4538
   Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6
   Prescott SL, 1998, LANCET, V351, P1489, DOI 10.1016/S0140-6736(05)78871-1
   Prescott SL, 1998, J IMMUNOL, V160, P4730
   Qian JX, 1997, BLOOD, V90, P3106
   Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x
   Roth I, 1996, J EXP MED, V184, P539, DOI 10.1084/jem.184.2.539
   Rowe J, 2000, INFECT IMMUN, V68, P3873, DOI 10.1128/IAI.68.7.3873-3877.2000
   Rowe J, 2001, J INFECT DIS, V184, P80, DOI 10.1086/320996
   ROYO C, 1987, THYMUS, V10, P57
   SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1
   SANJEEVI CB, 1991, ACTA PAEDIATR SCAND, V80, P1134, DOI 10.1111/j.1651-2227.1991.tb11800.x
   Sato K, 2001, J IMMUNOL, V166, P1659, DOI 10.4049/jimmunol.166.3.1659
   SCHONHEGRAD MA, 1991, J EXP MED, V173, P1345, DOI 10.1084/jem.173.6.1345
   Scott ME, 1997, PEDIATR RES, V41, P547, DOI 10.1203/00006450-199704000-00015
   Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77
   SHU U, 1994, J CLIN INVEST, V94, P1352, DOI 10.1172/JCI117469
   Smillie FI, 2001, CLIN EXP ALLERGY, V31, P1194, DOI 10.1046/j.1365-2222.2001.01173.x
   SPENCER J, 1986, CLIN EXP IMMUNOL, V64, P536
   SPLAWSKI JB, 1991, J CLIN INVEST, V88, P967, DOI 10.1172/JCI115400
   Stern D A, 1992, Dev Immunol, V2, P175, DOI 10.1155/1992/64292
   STITES DP, 1974, CELL IMMUNOL, V11, P257, DOI 10.1016/0008-8749(74)90026-4
   Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019
   SzekeresBartho J, 1996, AM J REPROD IMMUNOL, V35, P348
   SzekeresBartho J, 1996, J REPROD IMMUNOL, V31, P81, DOI 10.1016/0165-0378(96)00964-3
   Szepfalusi Z, 2000, PEDIATR RES, V48, P404, DOI 10.1203/00006450-200009000-00024
   Szepfalusi Z, 2000, J ALLERGY CLIN IMMUN, V106, P530
   Szepfalusi Z, 2006, CLIN EXP ALLERGY, V36, P1130, DOI 10.1111/j.1365-2222.2006.02559.x
   Szepfalusi Z, 1997, CLIN EXP ALLERGY, V27, P28, DOI 10.1046/j.1365-2222.1997.d01-417.x
   TAKAHASHI N, 1995, J IMMUNOL, V155, P5213
   TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1
   TAYLOR S, 1985, J IMMUNOL, V134, P1493
   TIMENS W, 1987, IMMUNOLOGY, V60, P603
   van Goudoever JB, 2008, J NUTR, V138, p1829S
   VanDurenSchmidt K, 1997, PEDIATR RES, V41, P128, DOI 10.1203/00006450-199701000-00020
   Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1
   VELLGUTH S, 1985, CELL TISSUE RES, V242, P579, DOI 10.1007/BF00225424
   Visser HKA, 2008, J NUTR, V138, p1768S
   Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187
   WACHTEL S, 1991, HUM REPROD, V6, P1466, DOI 10.1093/oxfordjournals.humrep.a137290
   Wahn HU, 2008, J NUTR, V138, p1770S
   WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x
   WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D
   WELLIVER RC, 1993, PEDIATR PULM, V15, P19, DOI 10.1002/ppul.1950150104
   WHISLER RL, 1995, MECH AGEING DEV, V77, P197, DOI 10.1016/0047-6374(94)01526-R
   Williams TJ, 2000, J ALLERGY CLIN IMMUN, V105, P951, DOI 10.1067/mai.2000.106211
   WILSON CB, 1986, J CLIN INVEST, V77, P860, DOI 10.1172/JCI112383
   Woolcock AJ, 1995, ALLERGY, V50, P935, DOI 10.1111/j.1398-9995.1995.tb02504.x
   WUCHERPFENNIG KW, 1993, J EXP MED, V177, P425, DOI 10.1084/jem.177.2.425
   Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261
   Zola H, 1996, IMMUNOLOGY, V87, P86
   ZOLA H, 1995, PEDIATR RES, V38, P397, DOI 10.1203/00006450-199509000-00021
NR 159
TC 15
Z9 15
U1 5
U2 18
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD SEP
PY 2008
VL 138
IS 9
BP 1773S
EP 1781S
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 342RU
UT WOS:000258802000033
PM 18716186
DA 2018-12-27
ER

PT J
AU Avramova, YR
   Stapel, DA
AF Avramova, Yana R.
   Stapel, Diederik A.
TI RETRACTED: Moods as spotlights: The influence of mood on accessibility
   effects (Retracted article. See vol. 103, pg. 471, 2012)
SO JOURNAL OF PERSONALITY AND SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
DE mood; assimilation; contrast; priming; perceptual focus
ID IMPRESSION-FORMATION; FACIAL EXPRESSIONS; SOCIAL COMPARISONS; 2 FACES;
   JUDGMENTS; CATEGORIZATION; INFORMATION; ACCURACY; CONTRAST; BEHAVIOR
AB Three studies explore the manner in which, one's mood may affect the use and impact of accessible information on judgments. Specifically, the authors demonstrated that positive and negative moods differentially influence the direction of accessibility effects (assimilation, contrast) by determining whether abstract traits or concrete actor-trait links are primed. Study 1 investigated the impact of positive versus negative mood on the judgmental impact of trait-implying behaviors and found that positive moods lead to assimilation and negative moods to contrast. In Study 2, this effect was replicated in a subliminal priming paradigm. In Study 3, it was demonstrated that the type of information activated by trait-implying behaviors is indeed mood dependent, such that abstract trait information is activated in a positive mood, whereas specific actor-trait links are activated in a negative mood.
C1 [Avramova, Yana R.; Stapel, Diederik A.] Tilburg Univ, TIBER, Social Psychol Dept, NL-5000 LE Tilburg, Netherlands.
RP Avramova, YR (reprint author), Tilburg Univ, TIBER, Social Psychol Dept, Warandelaan 2, NL-5000 LE Tilburg, Netherlands.
EM y.r.avramova@uvt.nl
CR Ambady N, 2000, ADV EXP SOC PSYCHOL, V32, P201, DOI 10.1016/S0065-2601(00)80006-4
   ANDERSON MC, 1996, MEMORY, P237, DOI DOI 10.1111/1467-9280.00325
   Bargh JA, 2000, HDB RES METHODS SOCI, P253
   Beukeboom CJ, 2006, J EXP SOC PSYCHOL, V42, P553, DOI 10.1016/j.jesp.2005.09.005
   BLESS H, 1992, J PERS SOC PSYCHOL, V63, P585, DOI 10.1037//0022-3514.63.4.585
   Bless H, 1999, DUAL-PROCESS THEORIES IN SOCIAL PSYCHOLOGY, P423
   Bless H, 2006, AFFECT SOCIAL THINKI, P65, DOI DOI 10.4324/9780203720752
   Clore GL, 2001, HANDBOOK OF AFFECT AND SOCIAL COGNITION, P121
   DELIS DC, 1986, NEUROPSYCHOLOGIA, V24, P205, DOI 10.1016/0028-3932(86)90053-9
   Dijksterhuis A, 1998, J PERS SOC PSYCHOL, V75, P862, DOI 10.1037//0022-3514.75.4.862
   Dimberg U, 2000, PSYCHOL SCI, V11, P86, DOI 10.1111/1467-9280.00221
   EDWARDS JA, 1993, J PERS SOC PSYCHOL, V64, P636, DOI 10.1037/0022-3514.64.4.636
   EICH E, 1989, J EXP PSYCHOL LEARN, V15, P443, DOI 10.1037//0278-7393.15.3.443
   ERBER R, 1991, J EXP SOC PSYCHOL, V27, P480, DOI 10.1016/0022-1031(91)90005-Q
   Fiedler K, 2001, HANDBOOK OF AFFECT AND SOCIAL COGNITION, P163
   Fink GR, 1996, NATURE, V382, P626, DOI 10.1038/382626a0
   Forgas JP, 1998, J PERS SOC PSYCHOL, V75, P318, DOI 10.1037/0022-3514.75.2.318
   FORGAS JP, 1995, PSYCHOL BULL, V117, P39, DOI 10.1037//0033-2909.117.1.39
   Forster J, 2006, J EXP SOC PSYCHOL, V42, P133, DOI 10.1016/j.jesp.2005.02.004
   Forster J, 2005, PSYCHOL SCI, V16, P631, DOI 10.1111/j.1467-9280.2005.01586.x
   Friedman RS, 2003, CREATIVITY RES J, V15, P277, DOI 10.1207/S15326934CRJ152&3_18
   Gasper K, 2002, PSYCHOL SCI, V13, P34, DOI 10.1111/1467-9280.00406
   Gasper K, 2004, COGNITION EMOTION, V18, P405, DOI 10.1080/02699930341000068
   Glaser J, 2007, ASSIMILATION AND CONTRAST IN SOCIAL PSYCHOLOGY, P229
   Innes-Ker A, 2002, J PERS SOC PSYCHOL, V83, P804, DOI 10.1037//0022-3514.83.4.804
   Isen A. M., 1984, HDB SOCIAL COGNITION, V3, P179
   ISEN AM, 1984, J PERS SOC PSYCHOL, V47, P1206, DOI 10.1037//0022-3514.47.6.1206
   KIMCHI R, 1992, PSYCHOL BULL, V112, P24, DOI 10.1037/0033-2909.112.1.24
   Krull DS, 1996, PERS SOC PSYCHOL B, V22, P949, DOI 10.1177/0146167296229008
   Kuhnen U, 2002, J EXP SOC PSYCHOL, V38, P492, DOI 10.1016/S0022-1031(02)00011-2
   LAMB MR, 1990, PERCEPT PSYCHOPHYS, V47, P489, DOI 10.3758/BF03208182
   MACKIE DM, 1989, J PERS SOC PSYCHOL, V57, P27, DOI 10.1037/0022-3514.57.1.27
   Martin L, 2001, THEORIES MOOD COGNIT, P135
   Martin LL, 1998, MOTIV EMOTION, V22, P33, DOI 10.1023/A:1023092508471
   MARTIN LL, 1986, J PERS SOC PSYCHOL, V51, P493, DOI 10.1037/0022-3514.51.3.493
   MURPHY ST, 1993, J PERS SOC PSYCHOL, V64, P723, DOI 10.1037/0022-3514.64.5.723
   NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3
   PARK J, 2000, J PERS SOC PSYCHOL, V6, P1005
   PETTY RE, 1993, J EXP SOC PSYCHOL, V29, P137, DOI 10.1006/jesp.1993.1007
   REYNA VF, 1995, LEARN INDIVID DIFFER, V7, P1, DOI 10.1016/1041-6080(95)90031-4
   Ruys KI, 2006, J PERS SOC PSYCHOL, V90, P399, DOI 10.1037/0022-3514.90.3.399
   Ruys KI, 2008, PSYCHOL SCI, V19, P593, DOI 10.1111/j.1467-9280.2008.02128.x
   SCHWARZ N, 1992, CONSTRUCTION OF SOCIAL JUDGMENTS, P217
   Schwarz N., 1996, SOCIAL PSYCHOL HDB B, P433
   SINCLAIR RC, 1988, ORGAN BEHAV HUM DEC, V42, P22, DOI 10.1016/0749-5978(88)90018-0
   Srull T.K, 1989, MEMORY COGNITION ITS
   Stapel DA, 1998, J PERS SOC PSYCHOL, V74, P878, DOI 10.1037//0022-3514.74.4.878
   Stapel DA, 2004, J PERS SOC PSYCHOL, V87, P860, DOI 10.1037/0022-3514.87.6.860
   Stapel DA, 2004, J PERS SOC PSYCHOL, V87, P468, DOI 10.1037/0022-3514.87.4.468
   Stapel DA, 1996, J PERS SOC PSYCHOL, V70, P437, DOI 10.1037/0022-3514.70.3.437
   Stapel DA, 2007, ASSIMILATION AND CONTRAST IN SOCIAL PSYCHOLOGY, P1
   Stapel DA, 2002, J PERS SOC PSYCHOL, V83, P60, DOI 10.1037//0022-3514.83.1.60
   Stapel DA, 2001, J EXP SOC PSYCHOL, V37, P134, DOI 10.1006/jesp.2000.1440
   STAPEL DA, 2007, J PERS SOC PSYCHOL, V93, P34
   Todorov A, 2005, SCIENCE, V308, P1623, DOI 10.1126/science.1110589
   TROPE Y, 1986, PSYCHOL REV, V93, P239, DOI 10.1037/0033-295X.93.3.239
   Tucker D. M., 1994, HEARTS EYE EMOTIONAL, P167, DOI [10.1016/B978-0-12-410560-7.50014-4, DOI 10.1016/B978-0-12-410560-7.50014-4]
   ULEMAN JS, 1996, ADV EXPT SOCIAL PSYC, V29
   WEGENER DT, 1994, J PERS SOC PSYCHOL, V66, P1034, DOI 10.1037/0022-3514.66.6.1034
   WILSON TD, 1994, PSYCHOL BULL, V116, P117, DOI 10.1037/0033-2909.116.1.117
   Zebrowitz LA, 2002, PERS SOC PSYCHOL B, V28, P238, DOI 10.1177/0146167202282009
   Zebrowitz LA, 2006, SOC COGNITION, V24, P657, DOI 10.1521/soco.2006.24.5.657
NR 62
TC 19
Z9 19
U1 2
U2 18
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-3514
EI 1939-1315
J9 J PERS SOC PSYCHOL
JI J. Pers. Soc. Psychol.
PD SEP
PY 2008
VL 95
IS 3
BP 542
EP 554
DI 10.1037/a0012560
PG 13
WC Psychology, Social
SC Psychology
GA 337TR
UT WOS:000258458900004
PM 18729693
DA 2018-12-27
ER

PT J
AU Niu, YP
   Wu, LM
   Jiang, YL
   Wang, WX
   Li, LD
AF Niu, Yang P.
   Wu, Li M.
   Jiang, Yan L.
   Wang, Wen X.
   Li, Lian D.
TI RETRACTED: beta-escin, a natural triterpenoid saponin from Chinese horse
   chestnut seeds, depresses HL-60 human leukaemia cell proliferation and
   induces apoptosis (Retracted article. See vol. 61, pg. 685, 2009)
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Review; Retracted Publication
ID VENOUS INSUFFICIENCY; CANCER CELLS; GROWTH; INDUCTION; PRODUCTS;
   EXTRACT; AESCIN; MICE
AB beta-Escin, a natural triterpenoid saponin isolated from the seed of the horse chestnut, is known to generate a wide variety of biochemical and pharmacological effects. The purpose of the present study was to examine the apoptotic and antiproliferative activity of beta-escin in HL-60 human acute myeloid leukaemia cells. Anti proliferative activity was examined by soft agar colony assay and the trypan blue exclusion method. Apoptotic activity was evaluated by morphological analysis, annexin V analysis, DNA fragmentation analysis and flow cytometry cell cycle analysis. The results showed that beta-escin caused a significant inhibition of HL-60 cell proliferation in a dose- and time-dependent manner. Morphological evidence of apoptosis, including vacuolization, apoptotic nuclei fragmentation and apoptotic body formation, was observed in cells treated with 30 mu g mL(-1) of beta-escin for 24, 48 and 72 h. A significant increase in the population of annexin V+ and Pl(-) cells (early apoptotic) among the total cells was observed in cells treated with beta-escin (30-50 mu g mL(-1)) for 24 h (P < 0.001). Typical DNA ladders, DNA with a unit length of about 180 bp, were detected in cells treated with beta-escin (30-50 mu g mL(-1)) for 48h by agarose gel electrophoresis. Flow cytometry cell cycle analysis revealed that beta-escin (30-50 mu g mL(-1)) induced G1-5 arrest and led to a significant accumulation of the sub-G1 population in HL-60 cells (P < 0.05). Taken together, the results demonstrate that beta-escin is a potent natural inhibitor of cell proliferation and inducer of apoptosis in HL-60 acute myeloid leukaemia cells. The results indicate that beta-escin may be a useful candidate agent for exploring potential antileukaemic drugs.
C1 [Niu, Yang P.; Wang, Wen X.] Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou 310032, Peoples R China.
   [Niu, Yang P.; Wu, Li M.; Jiang, Yan L.; Li, Lian D.] Zhejiang Univ, Inst Chinese Herbal Med, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China.
RP Wu, LM (reprint author), Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou 310032, Peoples R China.
EM niuyangping@hotmail.com
FU Nature Science Foundation of Zhejiang (ZJNSF); Science and Technology
   Department of Zhejiang (ZJSTD) [Y205636, 2008C23064]
FX The authors would like to thank Professor Jingyu Shao and Dr Haibo He
   for help with the preparation of this paper. The authors would also like
   to thank the Nature Science Foundation of Zhejiang (ZJNSF) and the
   Science and Technology Department of Zhejiang (ZJSTD) for financial
   support in the form of grants (Nos Y205636 and 2008C23064) to Y. P. Niu.
CR ARENDS MJ, 1990, AM J PATHOL, V136, P593
   BERTI F, 1977, PROSTAG OTH LIPID M, V14, P241, DOI 10.1016/0090-6980(77)90169-1
   Diehm C, 1996, LANCET, V347, P292, DOI 10.1016/S0140-6736(96)90467-5
   FACINO RM, 1995, ARCH PHARM, V328, P720, DOI 10.1002/ardp.19953281006
   Gaidi G, 2002, J NAT PROD, V65, P1568, DOI 10.1021/np020105a
   Haddad M, 2004, BIOORGAN MED CHEM, V12, P4725, DOI 10.1016/j.bmc.2004.06.025
   Haridas V, 2001, P NATL ACAD SCI USA, V98, P5821, DOI 10.1073/pnas.101619098
   HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506
   KIKUCHI Y, 1991, ANTI-CANCER DRUG, V2, P63, DOI 10.1097/00001813-199102000-00009
   Lacaille-Dubois MA, 2000, STUD NAT PROD CHEM, V21, P633
   Lee YN, 1996, EUR J CANCER, V32A, P1420, DOI 10.1016/0959-8049(96)00102-5
   Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723
   Matsuda H, 2000, LIFE SCI, V66, P2233, DOI 10.1016/S0024-3205(00)00551-8
   Mujoo K, 2001, CANCER RES, V61, P5486
   MURAKI K, 1992, PFLUG ARCH EUR J PHY, V420, P461, DOI 10.1007/BF00374620
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O
   Niu Yang-Ping, 2001, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V9, P178
   Niu Yang-ping, 2002, Zhongguo Zhong Xi Yi Jie He Za Zhi, V22, P450
   Niu Yang-ping, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P127
   Park JA, 1997, CANCER LETT, V121, P73, DOI 10.1016/S0304-3835(97)00333-9
   Patiolla JMR, 2006, MOL CANCER THER, V5, P1459, DOI 10.1158/1535-7163.MCT-05-0495
   Pearson P J, 1993, Rev Physiol Biochem Pharmacol, V122, P1, DOI 10.1007/BFb0035273
   Pittler MH, 1998, ARCH DERMATOL, V134, P1356, DOI 10.1001/archderm.134.11.1356
   Reddy L, 2003, PHARMACOL THERAPEUT, V99, P1, DOI 10.1016/S0163-7258(03)00042-1
   Sirtori CR, 2001, PHARMACOL RES, V44, P183, DOI 10.1006/phrs.2001.0847
   STONE OJ, 1986, MED HYPOTHESES, V20, P117, DOI 10.1016/0306-9877(86)90093-9
   Suter A, 2006, ADV THER, V23, P179, DOI 10.1007/BF02850359
   TODE T, 1993, J CANCER RES CLIN, V120, P24, DOI 10.1007/BF01200720
   TUTTON PJM, 1980, BRIT J CANCER, V41, P47, DOI 10.1038/bjc.1980.6
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   Yang Xiu-Wei, 2004, Beijing Da Xue Xue Bao Yi Xue Ban, V36, P31
   Yui S, 2001, INT IMMUNOPHARMACOL, V1, P1989, DOI 10.1016/S1567-5769(01)00126-6
NR 32
TC 15
Z9 17
U1 4
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3573
EI 2042-7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD SEP
PY 2008
VL 60
IS 9
BP 1213
EP 1220
DI 10.1211/jpp.60.9.0014
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 344PD
UT WOS:000258938900014
PM 18718126
DA 2018-12-27
ER

PT J
AU Biswas, S
   Rahman, I
AF Biswas, Saibal
   Rahman, Irfan
TI RETRACTED: Modulation of steroid activity in chronic inflammation: A
   novel anti-inflammatory role for curcumin (Retracted Article. See vol
   53, pg 309, 2009)
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Review; Retracted Publication
DE asthma; chronic obstructive pulmonary disease; corticosteroids; historic
   deacetylase; nuclear factor-kappa B
ID NF-KAPPA-B; OBSTRUCTIVE PULMONARY-DISEASE; HISTONE DEACETYLASE ACTIVITY;
   ALVEOLAR EPITHELIAL-CELLS; OXIDATIVE STRESS; GENE-EXPRESSION;
   CHEMOPREVENTIVE AGENT; LIPID-PEROXIDATION; DIFERULOYL-METHANE; CANCER
   CELLS
AB The expression of NF-kappaB (NF-kappa B)-dependent pro-inflammatory genes in response to oxidative stress is regulated by the acetylation-deacetylation status of histones bound to the DNA. It has been suggested that in severe asthma and in chronic obstructive pulmonary disease (COPD) patients, oxidative stress not only activates the NF-kappa B pathway but also alters the historic acetylation and deacetylation balance via post-translational modification of histone deacetylases (HDACs). Corticosteroids have been one of the major modes of therapy against various chronic respiratory diseases such as asthma and COPD. Failure of corticosteroids to ameliorate such disease conditions has been attributed to their inability to either recruit HDAC2 or to the presence of an oxidatively modified HDAC2 in asthmatics and COPD subjects. Naturally occurring polyphenols such as curcumin and resveratrol have been increasingly considered as safer nutraceuticals. Curcumin is a polyphenol present in the spice turmeric, which can directly scavenge free radicals such as superoxide anion and nitric oxide and modulate important signaling pathways mediated via NF-kappa B and mitogen-activated protein kinase pathways. Polyphenols also down-regulate expression of pro-inflammatory mediators, matrix metalloprotemases, adhesion molecules, and growth factor receptor genes and they up-regulate HDAC2 in the lung. Thus, curcumin may be a potential antioxidant and anti-inflammatory therapeutic agent against chronic inflammatory lung diseases.
C1 [Biswas, Saibal; Rahman, Irfan] Univ Rochester, Med Ctr, Dept Environm Med, Lung Biol & Dis Program, Rochester, NY 14642 USA.
RP Rahman, I (reprint author), Univ Rochester, Med Ctr, Dept Environm Med, Lung Biol & Dis Program, Box 850,601 Elmwood Ave, Rochester, NY 14642 USA.
EM irfan_rahman@urmc.rochester.edu
FU NIEHS NIH HHS [ES-01247]
CR Abe Y, 1999, PHARMACOL RES, V39, P41, DOI 10.1006/phrs.1998.0404
   AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004
   Araujo CAC, 2001, MEM I OSWALDO CRUZ, V96, P723, DOI 10.1590/S0074-02762001000500026
   Barnes PJ, 2000, AM J RESP CRIT CARE, V161, P342
   Biswas SK, 2005, ANTIOXID REDOX SIGN, V7, P32, DOI 10.1089/ars.2005.7.32
   Bravo L, 1998, NUTR REV, V56, P317
   Chen HW, 1998, BRIT J PHARMACOL, V124, P1029, DOI 10.1038/sj.bjp.0701914
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Colin DA, 2003, INFECT IMMUN, V71, P3724, DOI 10.1128/IAI.71.7.3724-3729.2003
   Collett GP, 2004, CARCINOGENESIS, V25, P2183, DOI 10.1093/carcin/bgh233
   Deeb D, 2003, MOL CANCER THER, V2, P95
   Duvoix A, 2005, CANCER LETT, V223, P181, DOI 10.1016/j.canlet.2004.09.041
   Eastwood MA, 1999, QJM-MON J ASSOC PHYS, V92, P527, DOI 10.1093/qjmed/92.9.527
   Eigner D, 1999, J ETHNOPHARMACOL, V67, P1, DOI 10.1016/S0378-8741(98)00234-7
   Galati G, 2002, TOXICOLOGY, V177, P91, DOI 10.1016/S0300-483X(02)00198-1
   HOLDER GM, 1978, XENOBIOTICA, V8, P761, DOI 10.3109/00498257809069589
   Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892
   Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899
   Ito K, 2001, FASEB J, V15, pA473
   Jobin C, 1999, J IMMUNOL, V163, P3474
   JOE B, 1994, BBA-MOL CELL RES, V1224, P255, DOI 10.1016/0167-4889(94)90198-8
   Kang JH, 2005, BIOCHEM PHARMACOL, V69, P1205, DOI 10.1016/j.bcp.2005.01.014
   Kelly MR, 2001, MUTAT RES-DNA REPAIR, V485, P309, DOI 10.1016/S0921-8777(01)00066-0
   Kirkham P, 2006, PHARMACOL THERAPEUT, V111, P476, DOI 10.1016/j.pharmthera.2005.10.025
   Knekt P, 2002, AM J CLIN NUTR, V76, P560
   LIU JY, 1993, CARCINOGENESIS, V14, P857, DOI 10.1093/carcin/14.5.857
   Mahakunakorn P, 2003, BIOL PHARM BULL, V26, P725, DOI 10.1248/bpb.26.725
   Marwick JA, 2004, AM J RESP CELL MOL, V31, P633, DOI 10.1165/rcmb.2004-0006OC
   Nakamura Y, 2003, FREE RADICAL BIO MED, V35, P997, DOI 10.1016/S0891-5849(03)00440-4
   Nanji AA, 2003, AM J PHYSIOL-GASTR L, V284, pG321, DOI 10.1152/ajpgi.00230.2002
   O'Byrne KJ, 2001, BRIT J CANCER, V85, P473, DOI 10.1054/bjoc.2001.1943
   O'Byrne KJ, 2000, EUR J CANCER, V36, P151, DOI 10.1016/S0959-8049(99)00241-5
   Okamoto T, 2004, AM J PHYSIOL-LUNG C, V286, pL198, DOI 10.1152/ajplung.00136.2003
   Pan MH, 1999, DRUG METAB DISPOS, V27, P486
   Paterson HM, 2003, J IMMUNOL, V171, P1473, DOI 10.4049/jimmunol.171.3.1473
   Piwocka K, 1999, EXP CELL RES, V249, P299, DOI 10.1006/excr.1999.4480
   Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980
   Rahman I, 2004, BIOCHEM PHARMACOL, V68, P1255, DOI 10.1016/j.bcp.2004.05.042
   Rahman I, 2002, MOL CELL BIOCHEM, V234, P239, DOI 10.1023/A:1015905010086
   RAVINDRANATH V, 1980, TOXICOLOGY, V16, P259, DOI 10.1016/0300-483X(80)90122-5
   REDDY ACP, 1992, MOL CELL BIOCHEM, V111, P117
   Saklatvala J, 2003, BIOCHEM SOC SYMP, V70, P95, DOI 10.1042/bss0700095
   Santus P, 2005, AM J RESP CRIT CARE, V171, P838, DOI 10.1164/rccm.200404-558OC
   SATOSKAR RR, 1986, INT J CLIN PHARM TH, V24, P651
   Shah BH, 1999, BIOCHEM PHARMACOL, V58, P1167, DOI 10.1016/S0006-2952(99)00206-3
   Shishodia S, 2003, CARCINOGENESIS, V24, P1269, DOI 10.1093/carcin/bgg078
   Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450
   SRIVASTAVA KC, 1995, PROSTAG LEUKOTR ESS, V52, P223, DOI 10.1016/0952-3278(95)90040-3
   STARSSER EM, 2005, BIOCHEM PHARMACOL, V70, P552
   Syng-ai C, 2004, MOL CANCER THER, V3, P1101
   Tabak C, 2001, AM J RESP CRIT CARE, V164, P61, DOI 10.1164/ajrccm.164.1.2010025
   Venkatesan N, 2007, ADV EXP MED BIOL, V595, P379
   WAHLSTROM B, 1978, ACTA PHARMACOL TOX, V43, P86
   Walda IC, 2002, EUR J CLIN NUTR, V56, P638, DOI 10.1038/sj.ejcn.1601370
   Yang SR, 2006, AM J PHYSIOL-LUNG C, V291, pL46, DOI 10.1152/ajplung.00241.2005
   Zhang F, 1999, CARCINOGENESIS, V20, P445, DOI 10.1093/carcin/20.3.445
NR 56
TC 34
Z9 38
U1 3
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1613-4125
EI 1613-4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD SEP
PY 2008
VL 52
IS 9
BP 987
EP 994
DI 10.1002/mnfr.200700259
PG 8
WC Food Science & Technology
SC Food Science & Technology
GA 354FO
UT WOS:000259624500002
PM 18327875
DA 2018-12-27
ER

PT J
AU Ling, YH
   Lin, RP
   Perez-Soler, R
AF Ling, Yi-He
   Lin, Ruoping
   Perez-Soler, Roman
TI RETRACTED: Erlotinib induces mitochondrial-mediated apoptosis in human
   H3255 non-small-cell lung cancer cells with epidermal growth factor
   receptor(L858R) mutation through mitochondrial oxidative
   phosphorylation-dependent activation of BAX and BAK (Retracted article.
   See vol. 88, pg. 391, 2015)
SO MOLECULAR PHARMACOLOGY
LA English
DT Article; Retracted Publication
ID TYROSINE KINASE INHIBITOR; BH3-ONLY PROTEINS; EGFR MUTATIONS; BIM;
   GEFITINIB; DEATH; TRANSLOCATION; INDUCTION; LINES; CHEMOTHERAPY
AB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib shows potent antitumor activity in some non small-cell lung cancer (NSCLC) cell lines and is approved by the Food and Drug Administration as second and third line treatment for NSCLC. However, the molecular mechanisms by which erlotinib induces apoptosis remain to be elucidated. Here, we investigated the effect of erlotinib on apoptotic signal pathways in H3255 cells with the EGFR(L858R) mutation. Erlotinib induces apoptosis associated with the activation of caspases in a dose- and time-dependent manner. Erlotinib did not alter the expression of apoptotic receptors FAS and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), although it induced caspase-8 activation and BID cleavage. In addition, cell death caused by erlotinib was not prevented by coincubation with FAS and TRAIL antagonists, ZB-4 monoclonal antibody and TRAIL/Fc recombinant, suggesting that erlotinib-induced apoptosis is not associated with receptor-mediated pathways. Erlotinib induces loss of mitochondrial membrane potential and release of cytochrome c and second mitochondria-derived activator of caspases/direct IAP binding protein with low pI from mitochondria. Furthermore, erlotinib causes BAX translocation to mitochondria, BAX and BAK conformational changes, and oligomerization. Erlotinib did not induce reactive oxygen species generation, and cotreatment with antioxidants did not alter erlotinib-induced activation of BAX and BAK and apoptosis. However, cotreatment with inhibitors of mitochondrial oxidative phosphorylation significantly blocked erlotinib-induced activation of BAX and BAK and cell death. Benzyloxycarbiny-VAD-fluoromethyl ketone had no effect on erlotinib-induced BAX and BAK activation but effectively prevented apoptosis. Overexpression of BCL-2 caused a significant attenuation of erlotinib-induced cell death, but no effect on BAX and BAK activation. Down-regulation of BAX and BAK gene expression with small interfering RNA led to an effective reduction of erlotinib-induced apoptosis. Our data indicate that activation of BAX and BAK plays a critical role in the initiation of erlotinib-induced apoptotic cascades.
C1 [Ling, Yi-He; Lin, Ruoping; Perez-Soler, Roman] Albert Einstein Coll Med, Div Med Oncol, Bronx, NY 10467 USA.
RP Perez-Soler, R (reprint author), Montefiore Med Ctr, Dept Oncol, 111 E 210th St,Hofheimer 100, Bronx, NY 10467 USA.
EM rperezso@montefiore.org
FU National Institutes of Health [CA84119, CA96515]; OSI Pharmaceuticals
FX This work was supported in part by National Institutes of Health grants
   CA84119 and CA96515 and by OSI Pharmaceuticals.
CR Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0
   Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675
   Antignani A, 2006, CURR OPIN CELL BIOL, V18, P685, DOI 10.1016/j.ceb.2006.10.004
   Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315
   Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316
   Dai Q, 2005, CLIN CANCER RES, V11, P1572, DOI 10.1158/1078-0432.CCR-04-0993
   Deng J, 2007, CANCER RES, V67, P11867, DOI 10.1158/0008-5472.CAN-07-1961
   Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1
   Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294
   Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9
   Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878
   HARRIS RC, 1989, J CELL PHYSIOL, V139, P383, DOI 10.1002/jcp.1041390222
   Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2
   Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111
   Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838
   KROEMER G, 1995, FASEB J, V9, P1277
   Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103
   LI H, 1998, CELL, V98, P481
   Ling YH, 2003, J BIOL CHEM, V278, P33714, DOI 10.1074/jbc.M302559200
   Ling YH, 2007, MOL PHARMACOL, V72, P248, DOI 10.1124/mol.107.034827
   Linnett P E, 1979, Methods Enzymol, V55, P472
   Liu BL, 2001, ONCOGENE, V20, P3726, DOI 10.1038/sj.onc.1204490
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004
   Moyer JD, 1997, CANCER RES, V57, P4838
   Noonberg SB, 2000, DRUGS, V59, P753, DOI 10.2165/00003495-200059040-00003
   Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200
   Pollack VA, 1999, J PHARMACOL EXP THER, V291, P739
   Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726
   SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I
   Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753
   Stankiewicz AR, 2005, J BIOL CHEM, V280, P38729, DOI 10.1074/jbc.M509497200
   Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200
   Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7
   Tomiyama A, 2006, J NATL CANCER I, V98, P1462, DOI 10.1093/jnci/djj395
   Tracy S, 2004, CANCER RES, V64, P7241, DOI 10.1158/0008-5472.CAN-04-1905
   Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840
   Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200
   YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Zheng YH, 2005, ONCOGENE, V24, P3339, DOI 10.1038/sj.onc.1208484
NR 43
TC 46
Z9 47
U1 3
U2 15
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
EI 1521-0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD SEP
PY 2008
VL 74
IS 3
BP 793
EP 806
DI 10.1124/mol.107.044396
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 340HU
UT WOS:000258637500026
PM 18524889
OA Bronze
DA 2018-12-27
ER

PT J
AU He, HB
   Shi, MQ
   Yang, XZ
   Zeng, XW
   Wu, LM
   Li, LD
AF He, Haibo
   Shi, Mengqiong
   Yang, Xianzhe
   Zeng, Xiaowei
   Wu, Limao
   Li, Lianda
TI RETRACTED: Comparison of cardioprotective effects using salvianolic acid
   B and benazepril for the treatment of chronic myocardial infarction in
   rats (Retracted Article. See vol 380, pg 95, 2009)
SO NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE angiogenesis; benazepril; blood viscosity; chronic myocardial
   infarction; heart function; infarct size; salvianolic acid B;
   ventricular remodeling
ID ENDOTHELIAL GROWTH-FACTOR; LEFT-VENTRICULAR DYSFUNCTION; IN-VITRO
   ANGIOGENESIS; NAD(P)H OXIDASE; HEART-FAILURE; GENE-EXPRESSION; NADPH
   OXIDASE; UP-REGULATION; MILTIORRHIZA; ISCHEMIA
AB The aim of this study was to compare the cardioprotective effects of salvianolic acid B (Sal B) and the angiotension-converting enzyme inhibitor, benazepril, in rats with chronic myocardial infarction (MI) that resulted from a coronary artery ligation for 4 weeks. The rats were divided into four groups: those undergoing a sham operation; a MI group; a MI+SalB group (100 mg/kg by a gavage, once a day for 4 weeks); a MI+benazepril group (10 mg/kg by a gavage, once a day for 4 weeks). The following parameters were measured: echocardiographic, hemodynamic and hemorheological changes, angiogenesis, infarct size and cardiac remodeling and the messenger ribonucleic acid (mRNA) of vascular endothelium growth factor (VEGF). Rats treated with SalB or benazepril manifested the following: (1) marked improvements in echocardiographic, hemodynamic and hemorheological parameters; (2) significant reduction of infarct size; (3) significantly attenuated heart, kidney and lung hypertrophies, left ventricular (LV) dilatation and fibrosis. The unique effects of SalB were angiogenesis and augmented VEGF expression in the border and remote noninfarcted left ventricular area. These results suggest that both SalB and benazepril exerted beneficial cardioprotective effects in our experimental system, but that the modality of Sal B was different from that of benazepril. The additional beneficial effects of Sal B relative to benazpril, augmenting VEGF expression and promoting angiogenesis, may result in improved myocardial microcirculation.
C1 [He, Haibo; Yang, Xianzhe; Zeng, Xiaowei; Wu, Limao; Li, Lianda] Zhejiang Univ, Inst Chinese Herbal Med, Coll Pharmaceut, Hangzhou 310058, Zhejiang, Peoples R China.
   [Shi, Mengqiong] Ctr Med Sci Anal, Hangzhou, Zhejiang, Peoples R China.
RP Wu, LM (reprint author), Zhejiang Univ, Inst Chinese Herbal Med, Coll Pharmaceut, Zijingang Campus, Hangzhou 310058, Zhejiang, Peoples R China.
EM wulimao@zju.edu.cn
FU National Postdoctor Science Foundation of China [20070411201]; National
   Natural Science Foundation of China [30500661]; National Important Basic
   Development Plan of China [2005CB523405]
FX This study was supported by a project from the National Postdoctor
   Science Foundation of China (No: 20070411201), a common project of
   Chinese Medica Science Foundation of Zhejiang Province, a common project
   from National Natural Science Foundation of China (No: 30500661) and a
   grant of National Important Basic Development Plan of China (also called
   973 project, No: 2005CB523405). Professor Dr. Yuling Ma (Research
   Fellow, School of Pharmacy, University of Reading, GB) provided
   assistance with the composition and English styling of the paper.
CR Chen YH, 2000, ACTA PHARMACOL SIN, V21, P463
   Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jcb.M107711200
   Fan TP, 2006, TRENDS PHARMACOL SCI, V27, P297, DOI 10.1016/j.tips.2006.04.006
   FISHBEIN MC, 1978, AM J PATHOL, V90, P57
   Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608
   Freedman SB, 2001, J MOL CELL CARDIOL, V33, P379, DOI 10.1006/jmcc.2000.1329
   Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494
   He HB, 2007, J PHARM PHARMACOL, V59, P977, DOI 10.1211/jpp.59.7.0010
   Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A
   Ikeda S, 2005, CIRC RES, V96, P467, DOI 10.1161/01.RES.0000158286.51045.16
   Ji XY, 2003, LIFE SCI, V73, P1413, DOI 10.1016/S0024-3205(03)00432-6
   Ji XY, 2000, ACTA PHARMACOL SIN, V21, P1089
   Junker R, 1998, ARTERIOSCL THROM VAS, V18, P870, DOI 10.1161/01.ATV.18.6.870
   Kastrup J, 2005, J AM COLL CARDIOL, V45, P982, DOI 10.1016/j.jacc.2004.12.068
   Lay IS, 2003, PLANTA MED, V69, P26, DOI 10.1055/s-2003-37034
   Lay IS, 2003, J SURG RES, V115, P279, DOI 10.1016/S0022-4804(03)00226-9
   LEE AR, 1987, J NAT PROD, V50, P157, DOI 10.1021/np50050a004
   Lin YL, 2006, J ETHNOPHARMACOL, V105, P215, DOI 10.1016/j.jep.2005.10.021
   Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21
   Morgan EE, 2004, AM J PHYSIOL-HEART C, V287, pH2049, DOI 10.1152/ajpheart.00393.2004
   Na T, 2007, N-S ARCH PHARMACOL, V375, P39, DOI 10.1007/s00210-007-0134-1
   Nagaya N, 2001, CIRCULATION, V104, P1430, DOI 10.1161/hc3601.095575
   NICOSIA RF, 1994, AM J PATHOL, V145, P1023
   Okere IC, 2006, HYPERTENSION, V48, P1116, DOI 10.1161/01.HYP.0000248430.26229.0f
   PEARLMAN JD, 1995, NAT MED, V1, P1085, DOI 10.1038/nm1095-1085
   PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001
   Sasaki H, 2002, J MOL CELL CARDIOL, V34, P335, DOI 10.1006/jmcc.2001.1516
   Sasaki H, 2001, J MOL CELL CARDIOL, V33, P283, DOI 10.1006/jmcc.2000.1299
   SCHOLKENS BA, 1990, CLIN PHYSIOL BIOCH, V8, P33
   Soeki T, 2005, J AM COLL CARDIOL, V45, p420A
   Stanton LW, 2000, CIRC RES, V86, P939, DOI 10.1161/01.RES.86.9.939
   Stauss H M, 1994, J Cardiovasc Risk, V1, P255
   Sumi M, 2007, LIFE SCI, V80, P559, DOI 10.1016/j.lfs.2006.10.020
   Sun J, 2005, LIFE SCI, V76, P2849, DOI 10.1016/lfs.2004.11.016
   Tang MK, 2002, PHYTOMEDICINE, V9, P405, DOI 10.1078/09447110260571634
   Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8
   Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556
   Ushio-Fukai M, 2006, CARDIOVASC RES, V71, P226, DOI 10.1016/j.cardiores.2006.04.015
   Wang XH, 2007, MED RES REV, V27, P133, DOI 10.1002/med.20077
   Wu GF, 2006, AM J PHYSIOL-HEART C, V290, pH248, DOI 10.1152/ajpheart.01225.2004
   Zhang HS, 2006, J MOL CELL CARDIOL, V41, P138, DOI 10.1016/j.yjmcc.2006.03.007
   Zhang SY, 2006, BIOL PHARM BULL, V29, P945, DOI 10.1248/bpb.29.945
   Zhou LM, 2006, J PHARMACEUT BIOMED, V41, P744, DOI 10.1016/j.jpba.2005.12.032
   Zhu YC, 1997, AM J CARDIOL, V80, pA110, DOI 10.1016/S0002-9149(97)00465-7
   ZHU YZ, 1998, ACE INHIBITION TARGE, P1
NR 45
TC 8
Z9 9
U1 2
U2 21
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0028-1298
EI 1432-1912
J9 N-S ARCH PHARMACOL
JI Naunyn-Schmiedebergs Arch. Pharmacol.
PD SEP
PY 2008
VL 378
IS 3
BP 311
EP 322
DI 10.1007/s00210-008-0287-6
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 339KR
UT WOS:000258577000008
PM 18500511
DA 2018-12-27
ER

PT J
AU Li, YK
   Zhang, JY
   Li, LD
AF Li, Yikui
   Zhang, Jinyan
   Li, Lianda
TI RETRACTED: Comparison of the therapeutic effects of different
   compositions of muskone in the treatment of experimental myocardial
   infarct in rats and analgesia in mice (Retracted article. See vol. 23,
   pg. 745, 2009)
SO PHYTOTHERAPY RESEARCH
LA English
DT Article; Retracted Publication
DE muskone; slender Dutchmanspipe root; inula root; acute myocardial
   infarction; analgesia
ID INTERSTITIAL RENAL FIBROSIS; ARISTOLOCHIC ACID; CHINESE HERBS;
   NEPHROPATHY; IDENTIFICATION; CARCINOMA; TUMORS
AB The aim of this study was to compare the therapeutic effects of muskone, a traditional preparation containing slender Dutchmanspipe root (MCS) used to treat angina pectoris and related conditions, muskone containing inula root (MCI) in place of MCS, and muskone (M) without either slender Dutchmanspipe root (S) or inula root (1) on acute myocardial infarct (AMI) in rats and the pain response in mice. The AMI model was established by ligating the left anterior descending coronary artery (LAD). The AMI rats were treated with MCS, MCI, M, S and 1, respectively, before the surgical operation. Plasma endothelin (ET), 6-keto-prostaglandin F-1 alpha(6-keto-PGF(1 alpha)), thromboxane (TXB2) and myocardial apoptosis were detected, the ratio of 6-keto-PGF(1 alpha), level to TXB2 level (6-keto-PGF(2 alpha)/TXB2) was calculated, and the infarct size was determined. In the pain relieving study, the prophylactic treatments with MCS, MCI, M, S, I and aspirin were administered to the mice once a day for 5 days, the response latency and the number of abdominal contractions after the stimulus of intraperitoneal injection of acetic acid were recorded. The results show that MCS, MCI and M significantly ameliorated plasma ET, TYB2, 6-keto-PGF(1 alpha), and 6-keto-PGF(1 alpha)/TXB2 levels, reduced infarct size and opposed myocardial apoptosis. Simultaneously, they also significantly reduced the abdominal contractions and also prolonged the response latency induced by acetic acid in the mice. S and I only showed a degree of relieving pain, but their efficacy was weaker than that of MCS, MCI and M, and they had little cardioprotective effect. In conclusion, MCS, MCI and M had a significant cardioprotective and analgesic effect, and they had similar efficacy. S and I only had a secondary analgesic effect. Removing S from the MCS or replacing S with I did not influence the cardioprotective effect and analgesic effect. Copyright (c) 2008 John Wiley & Sons, Ltd.
C1 [Li, Yikui; Zhang, Jinyan; Li, Lianda] Xiyuan Hosp, China Acad Chinese Med Sci, Beijing, Peoples R China.
RP Li, LD (reprint author), Xiyuan Hosp, China Acad Chinese Med Sci, Beijing, Peoples R China.
EM lilianda1934@163.com
FU Tenth Five-Year Programme of the Science and Technology Foundation of
   China [2004BA721A10]
FX This study was supported by the Tenth Five-Year Programme of the Science
   and Technology Foundation of China for Tackling Key Problems (no.
   2004BA721A10).
CR Arlt VM, 2002, MUTAGENESIS, V17, P265, DOI 10.1093/mutage/17.4.265
   Cosyns JP, 1998, ARCH TOXICOL, V72, P738, DOI 10.1007/s002040050568
   Cosyns JP, 1999, AM J KIDNEY DIS, V33, P1011, DOI 10.1016/S0272-6386(99)70136-8
   Hangaishi M, 2001, BIOCHEM BIOPH RES CO, V285, P1220, DOI 10.1006/bbrc.2001.5319
   HORNG RC, 2007, FOOD CHEM TOXICOL, V45, P396
   Li Wei-hua, 2005, Zhonghua Yi Xue Za Zhi, V85, P2487
   Lord GM, 1999, LANCET, V354, P481, DOI 10.1016/S0140-6736(99)03380-2
   MENGS U, 1982, ARCH TOXICOL, V51, P107, DOI 10.1007/BF00302751
   Nortier JL, 2000, NEW ENGL J MED, V342, P1686, DOI 10.1056/NEJM200006083422301
   Pena JM, 1996, NEPHROL DIAL TRANSPL, V11, P1359, DOI 10.1093/ndt/11.7.1359
   ROBISCH G, 1982, MUTAT RES, V105, P201, DOI 10.1016/0165-7992(82)90031-8
   ROSSIELLO MR, 1993, CANCER LETT, V71, P83, DOI 10.1016/0304-3835(93)90101-E
   SCHMEISER HH, 1986, CARCINOGENESIS, V7, P59, DOI 10.1093/carcin/7.1.59
   SCHMEISER HH, 1990, CANCER RES, V50, P5464
   Stengel B, 1998, NEPHROLOGIE, V19, P15
   VANHAELEN M, 1994, LANCET, V343, P174, DOI 10.1016/S0140-6736(94)90964-4
   VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2
   Wu MJ, 2004, AM J KIDNEY DIS, V43, P1091, DOI 10.1053/j.ajkd.2004.03.016
   Yang CS, 2000, AM J KIDNEY DIS, V35, P313, DOI 10.1016/S0272-6386(00)70343-X
   Yang HY, 2006, J NEPHROL, V19, P111
   ZENG MY, 1995, TRADIT CHIN DRUGS RE, V6, P48
NR 21
TC 6
Z9 7
U1 3
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD SEP
PY 2008
VL 22
IS 9
BP 1219
EP 1223
DI 10.1002/ptr.2444
PG 5
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 354GB
UT WOS:000259625800015
PM 18729258
DA 2018-12-27
ER

PT J
AU Persson, J
   Reuter-Lorenz, PA
AF Persson, Jonas
   Reuter-Lorenz, Patricia A.
TI RETRACTED: Gaining Control Training Executive Function and Far Transfer
   of the Ability to Resolve Interference (Retracted article. See vol. 22,
   pg. 562, 2011)
SO PSYCHOLOGICAL SCIENCE
LA English
DT Article; Retracted Publication
ID PREFRONTAL CORTEX FUNCTION; WORKING-MEMORY; PROACTIVE-INTERFERENCE;
   NEURAL MECHANISMS; TASK; PERFORMANCE
AB Functional brain-imaging data document overlapping sites of activation in prefrontal cortex across memory tasks, suggesting that these tasks may share common executive components. We leveraged this evidence to develop a training regimen and a set of transfer tasks to examine the trainability of a putative executive-control process: interference resolution. Eight days of training on high-interference versions of three different working memory tasks increased the efficiency with which proactive interference was resolved on those particular tasks. Moreover, an improved ability to resolve interference was also transferred to different working memory, semantic memory, and episodic memory tasks, a demonstration of far-transfer effects from process-specific training. Participants trained with noninterference versions of the tasks did not exhibit transfer. We infer that the transfer we demonstrated resulted from increased efficiency of the interference-resolution process. Therefore, this aspect of executive control is plastic and adaptive, and can be improved by training.
C1 [Persson, Jonas; Reuter-Lorenz, Patricia A.] Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA.
   [Persson, Jonas] Stockholm Univ, S-10691 Stockholm, Sweden.
RP Reuter-Lorenz, PA (reprint author), Univ Michigan, Dept Psychol, East Hall,530 Church St, Ann Arbor, MI 48109 USA.
EM parl@umich.edu
OI Persson, Jonas/0000-0001-9143-3730
FU NIA NIH HHS [AG-18286]
CR Badre D, 2005, CEREB CORTEX, V15, P2003, DOI 10.1093/cercor/bhi075
   Barnett SM, 2002, PSYCHOL BULL, V128, P612, DOI 10.1037//0033-2909.128.4.612
   Braver TS, 2006, TRENDS COGN SCI, V10, P529, DOI 10.1016/j.tics.2006.10.006
   D'Esposito M, 1999, P NATL ACAD SCI USA, V96, P7514, DOI 10.1073/pnas.96.13.7514
   Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7
   ERICSSON KA, 1995, PSYCHOL REV, V102, P211, DOI 10.1037/0033-295X.102.2.211
   Green CS, 2003, NATURE, V423, P534, DOI 10.1038/nature01647
   Henson RNA, 2002, NEUROIMAGE, V17, P543, DOI 10.1006/nimg.2002.1229
   Jonides J, 2006, NEUROSCIENCE, V139, P181, DOI 10.1016/j.neuroscience.2005.06.042
   Jonides J, 1998, P NATL ACAD SCI USA, V95, P8410, DOI 10.1073/pnas.95.14.8410
   Kan IP, 2004, COGN AFFECT BEHAV NE, V4, P43, DOI 10.3758/CABN.4.1.43
   Kelly AMC, 2005, CEREB CORTEX, V15, P1089, DOI 10.1093/cercor/bhi005
   Kramer RF, 2003, PSYCHOL LEARN MOTIV, V43, P267
   MCEVOY RE, 1993, J CHILD PSYCHOL PSYC, V34, P563, DOI 10.1111/j.1469-7610.1993.tb01036.x
   Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167
   Moore CD, 2006, J NEUROSCI, V26, P11187, DOI 10.1523/JNEUROSCI.1873-06.2006
   Morice R, 1996, SCHIZOPHRENIA BULL, V22, P125, DOI 10.1093/schbul/22.1.125
   Muraven M, 1999, J SOC PSYCHOL, V139, P446, DOI 10.1080/00224549909598404
   Nelson JK, 2003, P NATL ACAD SCI USA, V100, P11171, DOI 10.1073/pnas.1334125100
   Oberauer K, 2004, J EXP PSYCHOL HUMAN, V30, P689, DOI 10.1037/0096-1523.30.4.689
   Olesen PJ, 2004, NAT NEUROSCI, V7, P75, DOI 10.1038/nn1165
   Persson J, 2004, NEUROIMAGE, V23, P1382, DOI 10.1016/j.neuroimage.2004.08.004
   PERSSON J, 2006, ANN M COGN NEUR SOC
   Persson J, 2007, NEUROPSYCHOLOGIA, V45, P1571, DOI 10.1016/j.neuropsychologia.2006.12.007
   Rainer G, 2000, NEURON, V27, P179, DOI 10.1016/S0896-6273(00)00019-2
   Reuter-Lorenz PA, 2008, CURR DIR PSYCHOL SCI, V17, P177, DOI 10.1111/j.1467-8721.2008.00570.x
   SALOMON G, 1989, EDUC PSYCHOL-US, V24, P113, DOI 10.1207/s15326985ep2402_1
   Sayala S, 2006, CEREB CORTEX, V16, P609, DOI 10.1093/cercor/bhj007
   Schretlen D, 2000, J INT NEUROPSYCH SOC, V6, P52
   Schumacher EH, 2001, PSYCHOL SCI, V12, P101, DOI 10.1111/1467-9280.00318
   Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657
   Thompson-Schill SL, 1997, P NATL ACAD SCI USA, V94, P14792, DOI 10.1073/pnas.94.26.14792
   West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272
NR 33
TC 72
Z9 72
U1 2
U2 20
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0956-7976
EI 1467-9280
J9 PSYCHOL SCI
JI Psychol. Sci.
PD SEP
PY 2008
VL 19
IS 9
BP 881
EP 888
DI 10.1111/j.1467-9280.2008.02172.x
PG 8
WC Psychology, Multidisciplinary
SC Psychology
GA 358YX
UT WOS:000259954500009
PM 18947353
OA Bronze
DA 2018-12-27
ER

PT J
AU Ketlogetswe, C
   Fiszdon, JK
   Seabe, OO
AF Ketlogetswe, Clever
   Fiszdon, Jerzy K.
   Seabe, Omphemetse O.
TI RETRACTED: Solar chimney power generation project - The case for
   Botswana (Retracted article. See vol. 16, pg. 6488, 2012)
SO RENEWABLE & SUSTAINABLE ENERGY REVIEWS
LA English
DT Review; Retracted Publication
DE renewable energy; solar chimney
AB Import of a huge proportion of electrical energy from the Southern African Power Pool, and the geographical location and population distribution of Botswana stimulated the need to consider renewable energy as in alternative to imported power. The paper describes a systematic experimental study oil a mini-solar chimney system. Particular attention is given to measurements of air velocity, temperature and solar radiation. The results for the selected 5 and 6 clear days of October and November, respectively, are presented. These results enable the relationship between average insolation, temperature difference and velocity for selected clear days to be discussed. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Ketlogetswe, Clever; Seabe, Omphemetse O.] Univ Botswana, Dept Mech Engn, Gaborone, Botswana.
   [Fiszdon, Jerzy K.] Minnesota State Univ, Mankato, MN USA.
RP Ketlogetswe, C (reprint author), Univ Botswana, Dept Mech Engn, PO 0061, Gaborone, Botswana.
EM ketloget@mopipi.ub.bw
CR *BPC, 2005, BPC ANN REP
   GUNTHER H, 1931, HUNDERT JAHREN KUNFT
   KOTZE IA, 2000, S AFRICA NATL ELECTR
   *MIN MIN EN WAT RE, 2002, EN AFF DIV ANN REP
   Pasumarthi N, 1998, INT J ENERG RES, V22, P277, DOI 10.1002/(SICI)1099-114X(19980310)22:3<277::AID-ER380>3.0.CO;2-R
   *SADC, 2005, SADC ANN REP
   *SAPP, 2005, SAPP ANN REP
   SCHLAICH J, 1995, SOLAR CHIMNEY
   TOBICH R, 2001, 120020382 ESI
NR 9
TC 21
Z9 21
U1 3
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1364-0321
J9 RENEW SUST ENERG REV
JI Renew. Sust. Energ. Rev.
PD SEP
PY 2008
VL 12
IS 7
BP 2005
EP 2012
DI 10.1016/j.rser.2007.03.009
PG 8
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA 333OY
UT WOS:000258163000014
DA 2018-12-27
ER

PT J
AU Pankratov, EL
AF Pankratov, E. L.
TI RETRACTED: Redistribution of infused and implanted dopants in a
   multilayer structure during annealing of dopant and radiation defects
   for the production of a system of p-n junctions (Retracted article. See
   vol. 42, pg. Nil_413, 2009)
SO SEMICONDUCTOR SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
ID DIFFUSION; SILICON; GROWTH; GAAS
AB It has been recently shown that the inhomogeneity of a multilayer structure leads to increase of sharpness of diffusion-junction rectifiers ( see, for example, Pankratov 2005 Phys. Rev. B 72 075201; Pankratov and Spagnolo 2005 Eur. Phys. J. B 46 15) and implanted-junction rectifiers ( see, for example, Pankratov 2008 Phys. Lett. A 372 1897), which were formed in the multilayer structure. It has also been shown that together with the increase of the sharpness, the homogeneity of the impurity distribution in the doped area increases. In this paper, both the effects ( increase of sharpness of p-n junction and increase of homogeneity of impurity distribution together) have been used for the production of a system of p-n junctions ( such as a bipolar transistor). The annealing time has been optimized for increasing simultaneously the sharpness and the homogeneity.
C1 RAS, Inst Phys Microstruct, Nizhnii Novgorod 603950, Russia.
RP Pankratov, EL (reprint author), RAS, Inst Phys Microstruct, GSP-105, Nizhnii Novgorod 603950, Russia.
EM elp2004@mail.ru
CR Ahlgren T, 1997, PHYS REV B, V56, P4597, DOI 10.1103/PhysRevB.56.4597
   Aleksandrov OV, 2004, SEMICONDUCTORS+, V38, P258, DOI 10.1134/1.1682322
   Bagraev NT, 2005, SEMICONDUCTORS+, V39, P528, DOI 10.1134/1.1923559
   DVURECHENSKY AV, 1982, PULSE ANNEALING SEMI
   FAHEY PM, 1989, REV MOD PHYS, V61, P289, DOI 10.1103/RevModPhys.61.289
   Gotra Z. Yu, 1991, TECHNOLOGY MICROELEC
   Grebene AB, 1983, BIPOLAR MOS ANALOGOU
   Gusev V. G., 1991, ELECTRONICS
   KOROL VM, 2005, SURFACE XRAY SYNCHRO, V1, P105
   Nazmul AM, 2003, J CRYST GROWTH, V251, P303, DOI 10.1016/S0022-0248(02)02274-1
   Pankratov EL, 2008, PHYS LETT A, V372, P1897, DOI 10.1016/j.physleta.2007.10.058
   Pankratov EL, 2007, EUR PHYS J B, V57, P251, DOI [10.1140/epjb/e2007-00173-8, 10.1140/epjb/c2007-00173-8]
   Pankratov EL, 2008, J APPL PHYS, V103, DOI 10.1063/1.2887989
   Pankratov EL, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.075201
   Pankratov EL, 2005, EUR PHYS J B, V46, P15, DOI 10.1140/epjb/e2005-00233-1
   Ryssel H, 1978, ION IMPLANTATION
   SHALIMOVA KV, 1985, PHYS SEMICONDUCTORS
   Sisianu ST, 2002, SEMICONDUCTORS+, V36, P581, DOI 10.1134/1.1478552
   Sokolov Y.D., 1955, APPL MECH, V1, P23
   Zorin EI, 1975, ION DOPING SEMICONDU
NR 20
TC 2
Z9 2
U1 4
U2 11
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0268-1242
EI 1361-6641
J9 SEMICOND SCI TECH
JI Semicond. Sci. Technol.
PD SEP
PY 2008
VL 23
IS 9
AR 095005
DI 10.1088/0268-1242/23/9/095005
PG 9
WC Engineering, Electrical & Electronic; Materials Science,
   Multidisciplinary; Physics, Condensed Matter
SC Engineering; Materials Science; Physics
GA 343SL
UT WOS:000258875200005
DA 2018-12-27
ER

PT J
AU Liu, D
   Niu, ZX
AF Liu, Dong
   Niu, Zhong-Xiang
TI RETRACTED: Immunogenicity of a Chicken Viral Newcastle Disease Virus F
   Gene-C3d Fusion Protein Containing a Chicken Homologue of C3d (Retracted
   Article. See vol 21, pg 495, 2008)
SO VIRAL IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID FOLLICULAR DENDRITIC CELLS; DNA VACCINES; B-CELLS; COMPLEMENT;
   ENHANCEMENT; ANTIBODIES; HEMAGGLUTININ; RESPONSES; ENVELOPE; IMMUNITY
AB The gene fragment coding for Arbor Acres (AA) chicken C3d gene (chC3d) was cloned and expressed as a component of fusion proteins for its potential use as a vaccine for chickens and for in vitro experiments. This fragment of complement protein C3 (C3d) has been shown to strengthen B-cell responses when complexed with antigen. Three potential vaccine constructs were engineered to contain two, four, and six copies of chC3d-P29 coding gene, which was linked to the F gene of Newcastle disease virus (NDV), an economically important pathogen of chicken that is classified as a class A contagious disease of poultry by the Office international des epizooties (OIE). The cloned chC3d protein and different repeats of C3d-P29 proteins contained in the F gene of NDV (C3d-F-P29.n) were generated separately in Escherichia coli and CEF cells with the help of expression vectors. All recombinant proteins were analyzed by SDS-PAGE and Western blotting. The results with different repeats of C3d-F-P29.n revealed that C3d-P29 could enhance immunogenicity. Six or more repeats of C3d-P29 may be necessary for efficient enhancement of antigen-specific immune responses. To date, published research into the adjuvant activities of C3d has been limited to experiments in mice, rabbits, and cattle, and adjuvant properties of C3d have not been assessed in poultry using homologous C3d in association with antigens relevant to the target species. The chicken C3d fusion proteins detailed in this study are the first reports and they provide a basis for immunization trials in chicken, studies of receptor binding and cell activation of chicken lymphocytes, and investigations of new types of vaccines, including genetic recombinant and DNA vaccines for future use against chicken pathogens.
C1 [Liu, Dong] Shandong Agr Univ, Coll Anim Sci & Vet Med, Tai An 271018, Shandong, Peoples R China.
   Jinan Anim Husb & Vet Bur, Jinan, Peoples R China.
RP Liu, D (reprint author), Shandong Agr Univ, Coll Anim Sci & Vet Med, Daizong Rd 61, Tai An 271018, Shandong, Peoples R China.
EM liudong81223@163.com
FU Shandong Natural Science Foundation [Y2007D47]
FX This work was supported by the Shandong Natural Science Foundation
   (grant number Y2007D47). While this manuscript was in preparation, the
   sequence of AA chicken C3d was deposited in the GenBank (Acc. no.
   EF632299, accepted June 27, 2007) by our colleagues Chu X.X., Weng L.X.,
   and Niu Z.Z. We thank them for their significant contributions to this
   work.
CR Aydar Y, 2005, J IMMUNOL, V174, P5358, DOI 10.4049/jimmunol.174.9.5358
   Cherukuri A, 2001, J IMMUNOL, V167, P163, DOI 10.4049/jimmunol.167.1.163
   Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348
   Donnelly J J, 1998, Dev Biol Stand, V95, P43
   ELKE S, 2006, CLIN IMMUNOL, V121, P177
   Firth MA, 2006, VET IMMUNOL IMMUNOP, V114, P61, DOI 10.1016/j.vetimm.2006.07.005
   Green TD, 2003, J VIROL, V77, P2046, DOI 10.1128/JVI.77.3.2046-2055.2003
   Green TD, 2001, VACCINE, V20, P242, DOI 10.1016/S0264-410X(01)00266-3
   Hess MW, 2000, BLOOD, V95, P2617
   Liu XF, 2003, ARCH VIROL, V148, P1387, DOI 10.1007/s00705-003-0014-z
   Lyubchenko T, 2005, J IMMUNOL, V174, P3264, DOI 10.4049/jimmunol.174.6.3264
   [马雪云 MA Xueyun], 2006, [西北农林科技大学学报. 自然科学版, Journal of northwest sci-tech university of agriculture and forestry], V34, P55
   Mitchell JA, 2003, VACCINE, V21, P902, DOI 10.1016/S0264-410X(02)00539-X
   Qin DH, 1998, J IMMUNOL, V161, P4549
   Robinson HL, 1997, AIDS, V11, pS109
   Robinson HL, 2000, ADV VIRUS RES, V55, P1, DOI 10.1016/S0065-3527(00)55001-5
   Ross TM, 2000, NAT IMMUNOL, V1, P127, DOI 10.1038/77802
   Ross TM, 2001, AIDS RES HUM RETROV, V17, P829, DOI 10.1089/088922201750252025
   SAMBROOK J, 1989, MOL CLONING LAB MANU, P24
   Suradhat S, 2001, VET IMMUNOL IMMUNOP, V83, P79, DOI 10.1016/S0165-2427(01)00369-5
NR 20
TC 2
Z9 3
U1 4
U2 14
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0882-8245
J9 VIRAL IMMUNOL
JI Viral Immunol.
PD SEP
PY 2008
VL 21
IS 3
BP 389
EP 398
DI 10.1089/vim.2008.0013
PG 10
WC Immunology; Virology
SC Immunology; Virology
GA 357XM
UT WOS:000259880500016
PM 18788947
DA 2018-12-27
ER

PT J
AU Sullivan, JC
   Kakati, DD
   Carter, E
   Boyd, AK
   Kyriakides, TR
   Agah, A
AF Sullivan, Janson C.
   Kakati, Donny D.
   Carter, Elliot
   Boyd, Amy K.
   Kyriakides, Themis R.
   Agah, Azin
TI RETRACTED: Elevated expression of isopeptide bond cross-links
   contributes to fibrosis in scleroderma and the healing wounds of tight
   skin mice (Retracted article. See vol. 18, pg. 550, 2010)
SO WOUND REPAIR AND REGENERATION
LA English
DT Article; Retracted Publication
ID SYSTEMIC-SCLEROSIS SCLERODERMA; TISSUE GROWTH-FACTOR; MOUSE MODEL;
   FACTOR-BETA; TGF-BETA; COLLAGEN; PATHOGENESIS; TRANSGLUTAMINASE;
   FIBROBLAST; ABNORMALITIES
AB Scleroderma is a chronic disease characterized by excessive tissue fibrosis. Recent studies indicate that cultured dermal fibroblasts isolated from patients produce excessive amounts of collagen and other extracellular matrix components. In this study, we investigated the mechanism(s) of abnormal extracellular matrix accumulation in the scleroderma biopsies and the healing wounds of Tsk1/+ mice. Full-thickness excisional wounds were made in Tsk1/+ and wild-type mice and were subsequently harvested at days 7, 10, and 14 postinjury. The levels of pro-fibrotic cytokine, transforming growth factor were elevated in the wounds of Tsk1/+ mice. Interestingly, the levels of matrix metalloproteinase were significantly reduced in the granulation tissue of Tsk1/+ mice in comparison with wild-type. Furthermore, immunohistochemical analysis of the wounds indicated that the levels of gamma-glutamyl-epsilon-lysine cross-links were elevated in the granulation tissue of Tsk1/+ mice as well as the fibrotic lesions of scleroderma specimens. Collectively, these findings indicate that elevated collagen synthesis and decreased matrix metalloproteinase levels, in combination with increased isopeptide bond cross-links, contribute to abnormal collagen synthesis and assembly in granulation tissue of Tsk1/+ mice and the fibrotic lesions of scleroderma patients.
C1 [Sullivan, Janson C.; Kakati, Donny D.; Boyd, Amy K.; Agah, Azin] Univ S Alabama, Dept Biomed Sci, Mobile, AL 36688 USA.
   [Carter, Elliot] Univ S Alabama, Coll Med, Dept Pathol, Mobile, AL 36688 USA.
   [Kyriakides, Themis R.] Yale Univ, Dept Pathol, New Haven, CT USA.
   [Kyriakides, Themis R.] Yale Univ, Dept Biomed Engn, New Haven, CT USA.
RP Agah, A (reprint author), Univ S Alabama, Dept Biomed Sci, Mobile, AL 36688 USA.
EM aagah@usouthal.edu
FU NIGMS NIH HHS [R01 GM072194-03, R01 GM072194]
CR Agah A, 2005, AM J PATHOL, V167, P81, DOI 10.1016/S0002-9440(10)62955-0
   Atamas SP, 2003, CURR OPIN RHEUMATOL, V15, P772, DOI 10.1097/00002281-200311000-00015
   Baxter RM, 2005, LAB INVEST, V85, P1199, DOI 10.1038/labinvest.3700331
   Bornstein P, 2004, INT J BIOCHEM CELL B, V36, P1115, DOI 10.1016/j.biocel.2004.01.012
   BOTSTEIN GR, 1982, ARTHRITIS RHEUM, V25, P189, DOI 10.1002/art.1780250212
   CHANOKI M, 1995, BRIT J DERMATOL, V133, P710
   Denton CP, 2004, AUTOIMMUN REV, V3, P285, DOI 10.1016/j.autrev.2003.10.003
   Denton CP, 2001, CURR OPIN RHEUMATOL, V13, P505, DOI 10.1097/00002281-200111000-00010
   Derk CT, 2003, AUTOIMMUN REV, V2, P181, DOI 10.1016/S1568-9972(03)00005-3
   Eckert RL, 2005, J INVEST DERMATOL, V124, P481, DOI 10.1111/j.0022-202X.2005.23627.x
   FLEISCHMAJER R, 1991, J INVEST DERMATOL, V97, P638, DOI 10.1111/1523-1747.ep12483132
   Furuse S, 2003, J RHEUMATOL, V30, P1524
   Gayraud B, 2000, J CELL BIOL, V150, P667, DOI 10.1083/jcb.150.3.667
   Haroon ZA, 1999, FASEB J, V13, P1787
   Jimenez SA, 1996, RHEUM DIS CLIN N AM, V22, P647, DOI 10.1016/S0889-857X(05)70294-5
   Jimenez SA, 1999, SPRINGER SEMIN IMMUN, V21, P397
   Jun JB, 2003, CURR OPIN RHEUMATOL, V15, P756, DOI 10.1097/00002281-200311000-00012
   Kaartinen MT, 2002, J BONE MINER RES, V17, P2161, DOI 10.1359/jbmr.2002.17.12.2161
   Kodera T, 2002, P NATL ACAD SCI USA, V99, P3800, DOI 10.1073/pnas.052709999
   Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419
   Kyriakides TR, 2001, AM J PATHOL, V159, P1255, DOI 10.1016/S0002-9440(10)62512-6
   Kyriakides TR, 2001, MOL THER, V3, P842, DOI 10.1006/mthe.2001.0336
   Lakos G, 2004, AM J PATHOL, V165, P203, DOI 10.1016/S0002-9440(10)63289-0
   Leask A, 2004, J INVEST DERMATOL, V122, P1, DOI 10.1046/j.0022-202X.2003.22133.x
   Leask A, 2008, CELL SIGNAL, V20, P1409, DOI 10.1016/j.cellsig.2008.01.006
   LEROY EC, 1988, J RHEUMATOL, V15, P202
   Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014
   Nicholas B, 2003, BIOCHEM J, V371, P413, DOI 10.1042/BJ20021949
   Pablos JL, 2004, CLIN EXP RHEUMATOL, V22, pS81
   Ritchie H, 2000, J BIOL CHEM, V275, P24915, DOI 10.1074/jbc.M002901200
   RUDNICKA L, 1994, J CLIN INVEST, V93, P1709, DOI 10.1172/JCI117154
   Saito S, 1999, Curr Rheumatol Rep, V1, P34, DOI 10.1007/s11926-999-0022-4
   Smith Edwin A., 1992, Current Opinion in Rheumatology, V4, P869
   Uzawa K, 2003, BIOCHEM BIOPH RES CO, V305, P484, DOI 10.1016/S0006-291X(03)00799-X
   VARGA J, 1995, ANN INTERN MED, V122, P60, DOI 10.7326/0003-4819-122-1-199501010-00010
   Wallis DD, 2004, ARTHRITIS RHEUM, V50, P329, DOI 10.1002/art.11437
   Wang HW, 2005, EXP DERMATOL, V14, P295, DOI 10.1111/j.0906-6705.2005.00315.x
   Yamamoto T, 2003, J INVEST DERMATOL, V121, P510, DOI 10.1046/j.1523-1747.2003.12408.x
   Young-Min SA, 2001, ANN RHEUM DIS, V60, P846
   Zhu H, 2004, AUTOIMMUNITY, V37, P51, DOI 10.1080/08916930310001633782
NR 40
TC 4
Z9 4
U1 3
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1067-1927
EI 1524-475X
J9 WOUND REPAIR REGEN
JI Wound Repair Regen.
PD SEP-OCT
PY 2008
VL 16
IS 5
BP 699
EP 705
DI 10.1111/j.1524-475X.2008.00420.x
PG 7
WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery
SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery
GA 348PR
UT WOS:000259222900012
PM 19128265
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Wang, ZW
   Song, W
   Aboukameel, A
   Mohammad, M
   Wang, GP
   Banerjee, S
   Kong, D
   Wang, SM
   Sarkar, FH
   Mohammad, RM
AF Wang, Zhiwei
   Song, Wen
   Aboukameel, Amro
   Mohammad, Mussop
   Wang, Guoping
   Banerjee, Sanjeev
   Kong, Dejuan
   Wang, Shaomeng
   Sarkar, Fazlul H.
   Mohammad, Ramzi M.
TI RETRACTED: TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell
   growth and invasion in pancreatic cancer(Retracted article. See
   vol.139,pg.2146,2016)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE bcl-2; NF-kappa B; pancreatic cancer; invasion; angiogenesis
ID NF-KAPPA-B; MATRIX METALLOPROTEINASE-2; SIGNALING PATHWAY; XENOGRAFT
   MODEL; DOWN-REGULATION; BREAST-CANCER; EXPRESSION; METASTASIS;
   ACTIVATION; MATRIX-METALLOPROTEINASE-9
AB Bcl-2 family of proteins plays critical roles in human cancers, including pancreatic cancer, suggesting that the discovery of specific agents targeting Bcl-2 family proteins would be extremely valuable for pancreatic cancer therapy. We have previously reported the synthesis and characterization of TW-37, which seems to be a negative regulator of Bcl-2. In this investigation, we tested our hypothesis whether TW-37 could be an effective inhibitor of cell growth, invasion and angiogenesis in pancreatic cancer cells. Using multiple cellular and molecular approaches such as MTT assay, apoptosis enzyme-linked immunosorbent assay, realtime reverse transcription-polymerase chain reaction, Western blotting, electrophoretic mobility shift assay for measuring DNA binding activity of NF-kappa B, migration, invasion and angiogenesis assays, we found that TW-37, in nanomolar concentrations, inhibited cell growth in a dose- and time-dependent manner. This was accompanied by increased apoptosis and concomitant attenuation of NF-kappa B, and downregulation of NF-kappa B downstream genes such as MMP-9 and VEGF, resulting in the inhibition of pancreatic cancer cell migration, invasion and angiogenesis in vitro and caused antitumor activity in vivo. From these results, we conclude that TW-37 is a potent inhibitor of progression of pancreatic cancer cells, which could be due to attenuation of Bcl-2 cellular signaling processes. Our findings provide evidence showing that TW-37 could act as a small-molecule Bcl-2 inhibitor on well-characterized pancreatic cancer cells in culture as well as when grown as tumor in a xenograft model. We also suggest that TW-37 could be further developed as a potential therapeutic agent for the treatment of pancreatic cancer. (c) 2008 Wiley-Liss, Inc.
C1 [Song, Wen; Aboukameel, Amro; Mohammad, Mussop; Mohammad, Ramzi M.] Wayne State Univ, Sch Med, Dept Internal Med, Karmanos Canc Inst,Div Hematol & Oncol, Detroit, MI 48201 USA.
   [Wang, Zhiwei; Banerjee, Sanjeev; Kong, Dejuan; Sarkar, Fazlul H.] Wayne State Univ, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48201 USA.
   [Wang, Guoping; Wang, Shaomeng] Univ Michigan, Ctr Comprehens Canc, Dept Internal Med Pharmacol & Med Chem, Ann Arbor, MI 48109 USA.
RP Mohammad, RM (reprint author), Wayne State Univ, Sch Med, Dept Internal Med, Karmanos Canc Inst,Div Hematol & Oncol, 732 HWCRC,4100 John R St, Detroit, MI 48201 USA.
EM Mohammad@karmanos.org
RI Wang, Shaomeng/E-9686-2010; Wang, Zhiwei/A-6809-2011
FU NCI NIH HHS [P30 CA022453, R01CA109389, R01 CA109389, R01 CA101870,
   P30CA22453, 5R01CA101870, U19CA11317]
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Bae IH, 2006, CANCER RES, V66, P4991, DOI 10.1158/0008-5472.CAN-05-4254
   Choi J, 2005, CANCER RES, V65, P5554, DOI 10.1158/0008-5472.CAN-04-4570
   Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8
   Dong Z, 2005, AM J PATHOL, V166, P1173, DOI 10.1016/S0002-9440(10)62337-1
   Garcea G, 2005, EUR J CANCER, V41, P2213, DOI 10.1016/j.ejca.2005.04.044
   Gilmore TD, 2007, CANCER CELL, V12, P95, DOI 10.1016/j.ccr.2007.07.010
   Giovannetti E, 2006, MOL CANCER THER, V5, P1387, DOI 10.1158/1535-7163.MCT-06-0004
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Karl E, 2005, CANCER RES, V65, P5063, DOI 10.1158/0008-5472.CAN-05-0140
   Mohammad RM, 2007, CLIN CANCER RES, V13, P2226, DOI 10.1158/1078-0432.CCR-06-1574
   Mohammad RM, 2006, CANCER-AM CANCER SOC, V106, P1260, DOI 10.1002/cncr.21731
   Mohammad RM, 2005, PANCREAS, V31, P317, DOI 10.1097/01.mpa.0000179731.46210.01
   Mohammad RM, 1998, PANCREAS, V16, P19, DOI 10.1097/00006676-199801000-00004
   MOISSAC D, 1998, J BIOL CHEM, V273, P23946
   Mortenson MM, 2007, J CELL BIOCHEM, V102, P1171, DOI 10.1002/jcb.21343
   Nagakawa Y, 2002, PANCREAS, V24, P169, DOI 10.1097/00006676-200203000-00008
   Neri A, 2006, BREAST CANCER RES TR, V99, P77, DOI 10.1007/s10549-006-9183-2
   OHNO I, 2007, 97 AACR ANN M LOS AN
   Regula KM, 2002, J BIOL CHEM, V277, P38676, DOI 10.1074/jbc.M206175200
   Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.0.CO;2-W
   Sclabas Guido M, 2003, Int J Gastrointest Cancer, V33, P15, DOI 10.1385/IJGC:33:1:15
   Takada Y, 2005, J BIOL CHEM, V280, P17203, DOI 10.1074/jbc.M500077200
   Takada Y, 2004, ONCOGENE, V23, P9247, DOI 10.1038/sj.onc.1208169
   VAN WC, 2007, CLIN CANCER RES, V13, P1076
   Verhaegen M, 2006, CANCER RES, V66, P11348, DOI 10.1158/0008-5472.CAN-06-1748
   Wang GP, 2006, J MED CHEM, V49, P6139, DOI 10.1021/jm060460o
   Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265
   Wang ZW, 2006, CANCER RES, V66, P7653, DOI 10.1158/0008-5472.CAN-06-1019
   Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281
   Xu LP, 2007, MOL CELL BIOCHEM, V295, P153, DOI 10.1007/s11010-006-9285-5
   Zeitlin BD, 2006, CANCER RES, V66, P8698, DOI 10.1158/0008-5472.CAN-05-3691
NR 32
TC 42
Z9 44
U1 2
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD AUG 15
PY 2008
VL 123
IS 4
BP 958
EP 966
DI 10.1002/ijc.23610
PG 9
WC Oncology
SC Oncology
GA 328SL
UT WOS:000257818000030
PM 18528859
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Crawford, AH
   Adjei, OB
   Lenke, LG
AF Crawford, Alvin H.
   Adjei, Oheneba Boachie
   Lenke, Lawrence G.
TI RETRACTED: Untitled - In response (Retracted Article)
SO SPINE
LA English
DT Letter; Retracted Publication
CR Vora VP, 2008, SPINE, V33, P120, DOI 10.1097/BRS.0b013e31815e35fe
NR 1
TC 0
Z9 0
U1 1
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0362-2436
EI 1528-1159
J9 SPINE
JI SPINE
PD AUG 15
PY 2008
VL 33
IS 18
BP 2023
EP 2023
DI 10.1097/BRS.0b013e318182a55f
PG 1
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 339QT
UT WOS:000258592800017
PM 18708937
DA 2018-12-27
ER

PT J
AU Premenko-Lanier, M
   Moseley, NB
   Pruett, ST
   Romagnoli, PA
   Altman, JD
AF Premenko-Lanier, Mary
   Moseley, Nelson B.
   Pruett, Sarah T.
   Romagnoli, Pablo A.
   Altman, John D.
TI RETRACTED: Transient FTY720 treatment promotes immune-mediated clearance
   of a chronic viral infection (Retracted article. See vol. 464, pg. 942,
   2010)
SO NATURE
LA English
DT Article; Retracted Publication
ID SPHINGOSINE 1-PHOSPHATE RECEPTORS; T-CELL RESPONSES; LYMPHOCYTE EGRESS;
   VIRUS-INFECTION; PERSISTENCE; IMMUNOMODULATOR; SPECIFICITY; IMPAIRMENT;
   EXHAUSTION; MICE
AB For a wide variety of microbial pathogens, the outcome of the infection is indeterminate. In some individuals the microbe is cleared, but in others it establishes a chronic infection, and the factors that tip this balance are often unknown. In a widely used model of chronic viral infection, C57BL/6 mice clear the Armstrong strain of lymphocytic choriomeningitis virus (LCMV), but the clone 13 strain persists(1,2). Here we show that the Armstrong strain induces a profound lymphopenia at days 1-3 after infection, but the clone 13 strain does not. If we transiently augment lymphopenia by treating the clone-13-infected mice with the drug FTY720 at days 0-2 after infection, the mice successfully clear the infection by day 30. Clearance does not occur when CD4 T cells are absent at the time of treatment, indicating that the drug is not exerting direct antiviral effects. Notably, FTY720 treatment of an already established persistent infection also leads to viral clearance. In both models, FTY720 treatment preserves or augments LCMV-specific CD4 and CD8 T-cell responses, a result that is counter-intuitive because FTY720 is generally regarded as a new immunosuppressive agent(3). Because FTY720 targets host pathways that are completely evolutionarily conserved, our results may be translatable into new immunotherapies for the treatment of chronic microbial infections in humans.
C1 [Premenko-Lanier, Mary; Moseley, Nelson B.; Romagnoli, Pablo A.; Altman, John D.] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30329 USA.
   [Premenko-Lanier, Mary; Moseley, Nelson B.; Romagnoli, Pablo A.; Altman, John D.] Emory Univ, Dept Microbiol & Immunol, Atlanta, GA 30329 USA.
   [Premenko-Lanier, Mary; Moseley, Nelson B.; Romagnoli, Pablo A.; Altman, John D.] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA.
   [Premenko-Lanier, Mary; Moseley, Nelson B.; Romagnoli, Pablo A.; Altman, John D.] Emory Univ, Sch Med, Atlanta, GA 30329 USA.
   [Pruett, Sarah T.] Yerkes Natl Primate Res Ctr, Div Psychobiol, Atlanta, GA 30329 USA.
RP Altman, JD (reprint author), Emory Univ, Emory Vaccine Ctr, 954 Gatewood Rd, Atlanta, GA 30329 USA.
EM mflanie@emory.edu; jaltman@rmy.emory.edu
RI Pruett, Sarah/C-7433-2009
OI Romagnoli, Pablo/0000-0002-6328-9070
FU NIAID NIH HHS [5F32AI062002, AI042373]
CR AHMED R, 1984, J VIROL, V51, P34
   Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
   Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C220176200
   Brooks DG, 2008, J EXP MED, V205, P533, DOI 10.1084/jem.20071948
   Brooks DG, 2006, NAT MED, V12, P1301, DOI 10.1038/nm1492
   Budde K, 2002, J AM SOC NEPHROL, V13
   CEMBRZYNSKANOWAK M, 1989, ARCH IMMUNOL THER EX, V37, P499
   Chiba K, 2005, PHARMACOL THERAPEUT, V108, P308, DOI 10.1016/j.pharmthera.2005.05.002
   CHISARI FV, 1995, SPRINGER SEMIN IMMUN, V17, P261, DOI 10.1007/BF00196169
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   Folgori A, 2006, GUT, V55, P1012, DOI 10.1136/gut.2005.080077
   Ha SJ, 2008, J EXP MED, V205, P543, DOI 10.1084/jem.20071949
   Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643
   Kunzendorf U, 2004, NEPHROL DIAL TRANSPL, V19, P1677, DOI 10.1093/ndt/gfh295
   MAMALAKI C, 1993, DEV IMMUNOL, V3, P159, DOI 10.1155/1993/98015
   MATLOUBIAN M, 1994, J VIROL, V68, P8056
   Matter M, 2006, J EXP MED, V203, P2145, DOI 10.1084/jcm.20060651
   Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009
   MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0
   Muller S, 2002, J VIROL, V76, P2375, DOI 10.1128/JVI.76.5.2375-2383.2002
   Pinschewer DD, 2000, J IMMUNOL, V164, P5761, DOI 10.4049/jimmunol.164.11.5761
   Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606
   Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003
   Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205
NR 25
TC 20
Z9 20
U1 3
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD AUG 14
PY 2008
VL 454
IS 7206
BP 894
EP U52
DI 10.1038/nature07199
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 336XH
UT WOS:000258398600038
PM 18704087
DA 2018-12-27
ER

PT J
AU Huang, H
   Yu, NC
   Fu, L
   Wei, X
   Su, W
   Huang, GF
   Wu, YX
   Huang, HJ
   Liu, Q
   Xiao, H
AF Huang Hao
   Yu Nancai
   Fu Lei
   Wei Xiong
   Su Wen
   Huang Guofu
   Wu yanxia
   Huang Hanju
   Liu Qian
   Xiao Hong
TI RETRACTED: siRNA directed against c-Myc inhibits proliferation and
   downregulates human telomerase reverse transcriptase in human colon
   cancer Colo 320 cells (Retracted article. See vol 28, artn 101, 2009)
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID CATALYTIC SUBUNIT; RNA INTERFERENCE; HTERT; EXPRESSION; DOMAINS;
   BINDING; TISSUES; GENE; MAD
AB The c-Myc and human telomerase reverse transcriptase gene (hTERT) gene are frequently deregulated and overexpressed in malignancy. hTERT activity is induced by c-Myc and strategies designed to inhibit c-Myc expression in cancer cells may have considerable therapeutic value. We designed and used a short hairpin RNA to inhibit c-Myc expression in Colo 320 cells and validated its effect on cell proliferation. In this study, four c-Myc-shRNA expression vectors were constructed and introduced into Colo 320 cells. The effects of c-Myc silencing on tumor cell growth was assessed by soft agar assay and DNA synthesis experiments. The expressions of c-Myc and hTERT were also assessed by real-time reverse transcription-polymerase chain reaction and Western blot analysis. Upon transient transfection with plasmid encoding shRNA, it was found that expression of c-Myc and hTERT decreased in shRNA-transfected cells. The downregulation of c-Myc and hTERT inhibited cell growth, shortened telomere lengths, and suppressed telomerase activity. In conclusion, our findings demonstrate that shRNA of c-Myc can inhibit the DNA replication in Colo 320 cells effectively and reduce telomere length and telomerase activity, therefore, it could be used as a new potential anticancer tool for therapy of human colon cancer.
C1 [Huang Hao; Yu Nancai; Fu Lei; Su Wen; Huang Guofu; Wu yanxia; Liu Qian; Xiao Hong] Wuhan 1 Hosp, Ctr Med Expt, Wuhan 430022, Peoples R China.
   [Huang Hao; Huang Hanju] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Pathogent Biol, Wuhan 430030, Peoples R China.
   [Wei Xiong] Univ British Columbia, Brain Res Ctr, Vancouver, BC V5Z 1M9, Canada.
RP Xiao, H (reprint author), Wuhan 1 Hosp, Ctr Med Expt, Wuhan 430022, Peoples R China.
EM hao4@163.com; yunancai2000@yahoo.com.cn; wuhanhuanghao10@yahoo.com.cn;
   weixiong0718@yahoo.com; wuhanhuanghao10@yahoo.com.cn;
   hgfmkp@yahoo.com.cn; wuhanhuanghao10@yahoo.com.cn;
   juguangying@yahoo.com.cn; LiuQian9097@yahoo.com.cn;
   wuhanhuanghao10@yahoo.com.cn
FU Foundation for Medicine Scientific Research Project of Wuhan from Wuhan
   Ministry of Health, PR China
FX This work is supported by Foundation for Medicine Scientific Research
   Project of Wuhan from Wuhan Ministry of Health, PR China.
CR Casillas MA, 2003, GENE, V316, P57, DOI 10.1016/S0378-1119(03)00739-X
   Cerezo A, 2002, J CELL SCI, V115, P1305
   Cerni C, 2000, MUTAT RES-REV MUTAT, V462, P31, DOI 10.1016/S1383-5742(99)00091-5
   Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202
   D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691
   Dasgupta R, 2004, ONCOGENE, V23, P8359, DOI 10.1038/sj.onc.1208028
   de Marval PLM, 2004, MOL CELL BIOL, V24, P7538, DOI 10.1128/MCB.24.17.7538-7547.2004
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Gunes C, 2000, CANCER RES, V60, P2116
   Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870
   James L, 2002, P NATL ACAD SCI USA, V99, P10429, DOI 10.1073/pnas.162369299
   Janknecht R, 2004, FEBS LETT, V564, P9, DOI 10.1016/S0014-5793(04)0356-4
   KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428
   Meeker AK, 2004, CURR OPIN ONCOL, V16, P32, DOI 10.1097/00001622-200401000-00007
   Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141
   MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4
   Murphy DJ, 2004, MOL CELL BIOL, V24, P2083, DOI 10.1128/MCB.24.5.2083-2090.2004
   Nikiforov MA, 2003, J BIOL CHEM, V278, P11094, DOI 10.1074/jbc.M212298200
   Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261
   Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904
   Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1
   Wright WE, 1996, DEV GENET, V18, P173
   Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198
   Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499
NR 24
TC 1
Z9 1
U1 3
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD AUG 12
PY 2008
VL 27
AR 27
DI 10.1186/1756-9966-27-27
PG 7
WC Oncology
SC Oncology
GA 408TZ
UT WOS:000263459200001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Kumar, DM
   Simpkins, JW
   Agarwal, N
AF Kumar, D. Maneesh
   Simpkins, James W.
   Agarwal, Neeraj
TI RETRACTED: Estrogens and neuroprotection in retinal diseases (Retracted
   article. See vol. 14, pg. 2204, 2008)
SO MOLECULAR VISION
LA English
DT Article; Retracted Publication
ID HORMONE REPLACEMENT THERAPY; ACTIVATED PROTEIN-KINASE; OPEN-ANGLE
   GLAUCOMA; FEMALE REPRODUCTIVE FACTORS; OXIDATIVE STRESS; GANGLION-CELLS;
   SIGNAL-TRANSDUCTION; MEDICARE BENEFICIARIES; INTRAOCULAR-PRESSURE;
   POSTMENOPAUSAL WOMEN
AB Estrogens play a critical role in the normal growth and development of humans and in recent years our understanding of their effects in the central nervous system (CNS) have been advancing rapidly. It is now known that estrogens influence synaptic plasticity, brain development, and memory. In addition, estrogens have been shown to be neuroprotective in degenerative disorders. The understanding of the influences of estrogens in the retina, as a component of the CNS, has not kept pace with the advances in understanding of the brain. Studies that have addressed the effects of estrogens on the retina, specifically those focusing on glaucoma, are examined here in the hope that estrogen therapy may be a viable option for treating retinal dystrophies and optic neuropathies.
C1 [Kumar, D. Maneesh; Agarwal, Neeraj] UNT Hlth Sci Ctr, Dept Cell Biol, Ft Worth, TX 76107 USA.
   [Kumar, D. Maneesh; Agarwal, Neeraj] UNT Hlth Sci Ctr, Dept Genet, Ft Worth, TX 76107 USA.
RP Agarwal, N (reprint author), UNT Hlth Sci Ctr, Dept Cell Biol, Ft Worth, TX 76107 USA.
EM agarwaln@gmail.com
FU National Glaucoma Program of the American Health Assistance Foundation
   (N. A.) [AG 10485]; National Institute of Aging [AG 2255, AG0204940]
FX This work was partially supported by the National Glaucoma Program of
   the American Health Assistance Foundation (N. A.), grants AG 10485 and
   AG 22550 from the National Institute of Aging (J. W. S.), and a training
   grant, AG020494, from National Institute on Aging (D. M. K.).
CR Abramov Y, 2005, J GLAUCOMA, V14, P271, DOI 10.1097/01.ijg.0000169390.17427.b7
   Amantea D, 2005, PHARMACOL RES, V52, P119, DOI 10.1016/j.phrs.2005.03.002
   Battaglia C, 2004, MENOPAUSE, V11, P69, DOI 10.1097/01.GME.0000079741.18541.92
   Behl C, 2002, J STEROID BIOCHEM, V83, P195, DOI 10.1016/S0960-0760(02)00271-6
   Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846
   Behl C, 1998, RESTOR NEUROL NEUROS, V12, P127
   Blair IA, 2006, CURR DRUG METAB, V7, P853, DOI 10.2174/138920006779010601
   Brann DW, 2007, STEROIDS, V72, P381, DOI 10.1016/j.steroids.2007.02.003
   BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0
   Castagne V, 1999, BRAIN RES, V842, P215, DOI 10.1016/S0006-8993(99)01823-5
   Coca-Prados M, 2003, J STEROID BIOCHEM, V86, P207, DOI 10.1016/j.jsbmb.2003.08.001
   COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3
   Czlonkowska Anna, 2003, Med Sci Monit, V9, pRA247
   Dykens JA, 2004, BIOCHEM PHARMACOL, V68, P1971, DOI 10.1016/j.bcp.2004.06.042
   FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0
   Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8
   Freeman EE, 2005, OPHTHAL EPIDEMIOL, V12, P37, DOI 10.1080/09286580490907779
   FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X
   Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1
   Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200
   HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033
   Hayashi Y, 2007, J NEUROSCI RES, V85, P386, DOI 10.1002/jnr.21127
   Hendrix SL, 2006, CIRCULATION, V113, P2425, DOI 10.1161/CIRCULATIONAHA.105.594077
   HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4
   Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217
   Hulsman CAA, 2001, AM J EPIDEMIOL, V154, P138, DOI 10.1093/aje/154.2.138
   HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2
   Jain SK, 2004, FREE RADICAL BIO MED, V37, P1730, DOI 10.1016/j.freeradbiomed.2004.08.003
   Jain SK, 2004, CYTOKINE, V26, P102, DOI 10.1016/j.cyto.2004.01.002
   JAVITT JC, 1994, ARCH OPHTHALMOL-CHIC, V112, P1025, DOI 10.1001/archopht.1994.01090200031012
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Kaja S, 2003, INVEST OPHTH VIS SCI, V44, P3155, DOI 10.1167/iovs.02-1204
   Kikuchi M, 2000, J NEUROSCI, V20, P5037
   Kilic U, 2006, J NEUROSCI, V26, P12439, DOI 10.1523/JNEUROSCI.0434-06.2006
   Kobayashi K, 1998, INVEST OPHTH VIS SCI, V39, P2105
   Koriyama Y, 2006, ADV EXP MED BIOL, V572, P333
   Kumar DM, 2005, FREE RADICAL BIO MED, V38, P1152, DOI 10.1016/j.freeradbiomed.2004.12.007
   Kumar DM, 2007, J GLAUCOMA, V16, P334
   LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801
   Lee AJ, 2003, BRIT J OPHTHALMOL, V87, P1324, DOI 10.1136/bjo.87.11.1324
   LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0
   Leung H, 2004, MICROVASC RES, V67, P48, DOI 10.1016/j.mvr.2003.10.002
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Lund TD, 2003, NUTR NEUROSCI, V6, P47, DOI 10.1080/1028415021000056050
   Marin R, 2005, CURR NEUROVASC RES, V2, P287, DOI 10.2174/156720205774322629
   MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8
   MCCAY PB, 1989, ANN NY ACAD SCI, V570, P32
   MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203
   Merchenthaler I, 2003, ANN NY ACAD SCI, V1007, P89, DOI 10.1196/annals.1286.009
   Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1
   Munaut C, 2001, BRIT J OPHTHALMOL, V85, P877, DOI 10.1136/bjo.85.7.877
   Nakanishi Y, 2006, EXP EYE RES, V83, P1108, DOI 10.1016/j.exer.2006.05.018
   Nakazawa T, 2005, MOL VIS, V11
   Nakazawa T, 2006, BRAIN RES, V1093, P141, DOI 10.1016/j.brainres.2006.03.084
   Nirmalan PK, 2004, INVEST OPHTH VIS SCI, V45, P4273, DOI 10.1167/iovs.04-0285
   Nonaka A, 2000, INVEST OPHTH VIS SCI, V41, P2689
   Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906
   PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0
   Prokai L, 2003, P NATL ACAD SCI USA, V100, P11741, DOI 10.1073/pnas.2032621100
   Prokai L, 2007, PHARMACOL THERAPEUT, V114, P1, DOI 10.1016/j.pharmthera.2007.01.006
   Prokai-Tatrai K, 2008, STEROIDS, V73, P280, DOI 10.1016/j.steroids.2007.10.011
   Rau SW, 2003, J NEUROSCI, V23, P11420
   ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1
   Sacca SC, 2007, EXP EYE RES, V84, P389, DOI 10.1016/j.exer.2006.10.008
   Sator MO, 1997, MATURITAS, V28, P55, DOI 10.1016/S0378-5122(97)00060-1
   Simpkins JW, 2005, ANN NY ACAD SCI, V1052, P233, DOI 10.1196/annals.1347.019
   Simpkins JW, 2004, STROKE, V35, P2648, DOI 10.1161/01.STR.0000143734.59507.88
   Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724
   Singh M, 2006, EXP BIOL MED, V231, P514
   Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   VANBUSKIRK EM, 1992, AM J OPHTHALMOL, V113, P447, DOI 10.1016/S0002-9394(14)76171-9
   Vina J, 2006, FREE RADICAL RES, V40, P1359, DOI 10.1080/10715760600952851
   Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673
   Wise PM, 2005, ENDOCR REV, V26, P308, DOI 10.1210/er.2004-0014
   WYGNANSKI T, 1995, AM J OPHTHALMOL, V120, P184, DOI 10.1016/S0002-9394(14)72606-6
   Yu XR, 2005, MECH AGEING DEV, V126, P1135, DOI 10.1016/j.mad.2005.05.005
   Yu XR, 2004, J BIOL CHEM, V279, P13086, DOI 10.1074/jbc.M313283200
NR 78
TC 6
Z9 7
U1 0
U2 9
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD AUG 11
PY 2008
VL 14
IS 175-76
BP 1480
EP 1486
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
SC Biochemistry & Molecular Biology; Ophthalmology
GA 344JR
UT WOS:000258923400002
PM 18698377
DA 2018-12-27
ER

PT J
AU Horvath, EM
   Tackett, L
   Elmendorf, JS
AF Horvath, Emily M.
   Tackett, Lixuan
   Elmendorf, Jeffrey S.
TI RETRACTED: A novel membrane-based anti-diabetic action of atorvastatin
   (Retracted article. See vol. 401, pg. 319, 2010)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE atorvastatin; cholesterol; GLUT4; insulin; insulin resistance; plasma
   membrane
ID CHOLESTEROL-DEPENDENT MECHANISM; IMPROVES INSULIN-RESISTANCE; METABOLIC
   SYNDROME; DIABETES-MELLITUS; GLUCOSE-METABOLISM; 3T3-L1 ADIPOCYTES;
   STATINS; PRAVASTATIN; ADIPONECTIN; INHIBITION
AB We recently found that chromium picolinate (CrPic), a nutritional supplement thought to improve insulin sensitivity in individuals with impaired glucose tolerance, enhances insulin action by lowering plasma membrane (PM) cholesterol. Recent in vivo studies suggest that cholesterol-lowering statin drugs benefit insulin sensitivity in insulin-resistant patients, yet a mechanism is unknown. We report here that atorvastatin (ATV) diminished PM cholesterol by 22% (P < 0.05) in 3T3-L1 adipocytes. As documented for CrPic, this small reduction in PM cholesterol enhanced insulin action. Replenishment of cholesterol mitigated the positive effects of ATV on insulin sensitivity. Co-treatment with CrPic and ATV did not amplify the extent of PM cholesterol loss, or insulin sensitivity gain. In addition, analyses of insulin signal transduction suggest a non-signaling basis of both therapies. Our data reveal an unappreciated beneficial non-hepatic effect of statin action and highlight a novel mechanistic similarity between two recently recognized therapies of impaired glucose tolerance. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Horvath, Emily M.; Tackett, Lixuan; Elmendorf, Jeffrey S.] Indiana Univ, Sch Med, Ctr Diabet Res, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA.
   [Elmendorf, Jeffrey S.] Indiana Univ, Sch Med, Ctr Diabet Res, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
RP Elmendorf, JS (reprint author), Indiana Univ, Sch Med, Ctr Diabet Res, Dept Cellular & Integrat Physiol, Bldg Rm 308A, Indianapolis, IN 46202 USA.
EM jelmendo@iupui.edu
FU NCCIH NIH HHS [R01 AT001846, F31-AT003977-01, R01 AT001846-04]
CR Bulcao C, 2007, BRAZ J MED BIOL RES, V40, P229, DOI 10.1590/S0100-879X2006005000042
   CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2
   Chen GL, 2006, MOL ENDOCRINOL, V20, P857, DOI 10.1210/me.2005-0255
   Chen GL, 2004, J BIOL CHEM, V279, P39705, DOI 10.1074/jbc.C400171200
   Chu CH, 2008, J ENDOCRINOL INVEST, V31, P42, DOI 10.1007/BF03345565
   de Luca C, 2008, FEBS LETT, V582, P97, DOI 10.1016/j.febslet.2007.11.057
   DEFRONZO RA, 1985, J CLIN INVEST, V76, P149, DOI 10.1172/JCI111938
   FERRANNINI E, 1985, J CLIN INVEST, V76, P357, DOI 10.1172/JCI111969
   Freeman DJ, 2001, CIRCULATION, V103, P357
   GIBSON SRD, 1997, PHARM RES, V14, pS253
   Guclu F, 2004, BIOMED PHARMACOTHER, V58, P614, DOI 10.1016/j.biopha.2004.09.005
   Horvath EM, 2008, MOL ENDOCRINOL, V22, P937, DOI 10.1210/me.2007-0410
   Hung J, 2008, INT J OBESITY, V32, P772, DOI 10.1038/sj.ijo.0803793
   Huptas S, 2006, AM J CARDIOL, V98, P66, DOI 10.1016/j.amjcard.2006.01.055
   Lee ST, 2008, J NEUROCHEM, V104, P1190, DOI 10.1111/j.1471-4159.2007.05044.x
   Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748
   Liu P, 2004, AM J PHYSIOL-CELL PH, V286, pC317, DOI 10.1152/ajpcell.00073.2003
   Mauser W, 2007, EUR J PHARMACOL, V564, P37, DOI 10.1016/j.ejphar.2007.02.024
   MCCARTHY SKA, 2006, AM J PHYSIOL-CELL PH, V291, pC860
   McTaggart F, 2001, AM J CARDIOL, V87, p28B
   Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074
   Nakata M, 2006, DIABETOLOGIA, V49, P1881, DOI 10.1007/s00125-006-0269-5
   Okada K, 2005, J ATHEROSCLER THROMB, V12, P322, DOI 10.5551/jat.12.322
   Pattar GR, 2006, MUTAT RES-GEN TOX EN, V610, P93, DOI 10.1016/j.mrgentox.2006.06.018
   Pradhan A, 2007, NUTR REV, V65, pS152, DOI 10.1301/nr.2007.dec.S152-S156
   Prasad GVR, 2004, AM J TRANSPLANT, V4, P1897, DOI 10.1111/j.1600-6143.2004.00598.x
   Roudier E, 2006, MOL CANCER THER, V5, P2706, DOI 10.1158/1535-7163.MCT-06-0352
   Sonmez A, 2003, ENDOCRINE, V22, P151, DOI 10.1385/ENDO:22:2:151
   Wong V, 2006, ATHEROSCLEROSIS, V184, P348, DOI 10.1016/j.atherosclerosis.2005.05.009
   Zhang L, 2007, ARTERIOSCL THROM VAS, V27, P2470, DOI 10.1161/ATVBAHA.107.150748
NR 30
TC 12
Z9 12
U1 1
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 8
PY 2008
VL 372
IS 4
BP 639
EP 643
DI 10.1016/j.bbrc.2008.05.095
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 323BR
UT WOS:000257419500024
PM 18514061
OA Green Accepted
DA 2018-12-27
ER

PT J
AU De Domenico, I
   Nemeth, E
   Nelson, JM
   PhillipS, JD
   Ajioka, RS
   Kay, MS
   Kushner, JP
   Ganz, T
   Ward, DM
   Kaplan, J
AF De Domenico, Ivana
   Nemeth, Elizabeta
   Nelson, Jenifer M.
   PhillipS, John D.
   Ajioka, Richard S.
   Kay, Michael S.
   Kushner, James P.
   Ganz, Tomas
   Ward, Diane M.
   Kaplan, Jerry
TI RETRACTED: The hepcidin-binding site on ferroportin is evolutionarily
   conserved (Retracted article. See vol. 19, pg. 1067, 2014)
SO CELL METABOLISM
LA English
DT Article; Retracted Publication
ID IRON OVERLOAD; HEREDITARY HEMOCHROMATOSIS; MASS-SPECTROMETRY; PEPTIDE
   HEPCIDIN; BASS HEPCIDIN; MUTATIONS; SERUM; GENE; INFLAMMATION; SLC11A3
AB Mammalian iron homeostasis is regulated by the interaction of the liver-produced peptide hepcidin and its receptor, the iron transporter ferroportin. Hepcidin binds to ferroportin resulting in degradation of ferroportin and decreased cellular iron export. We identify the hepcidin-binding domain (HBD) on ferroportin and show that a synthetic 19 amino acid peptide corresponding to the HBD recapitulates the characteristics and specificity of hepcidin binding to cell-surface ferroportin. The binding of mammalian hepcidin to ferroportin or the HBD shows an unusual temperature dependency with an increased rate of dissociation at temperatures below 15 degrees C. The increased rate of dissociation is due to temperature-dependent changes in hepcidin structure. In contrast, hepcidin from poikilothermic vertebrates, such as fish or frogs, binds the HBD in a temperature-independent fashion. The affinity of hepcidin for the HBD permits a rapid, sensitive assay of hepcidin from all species and yields insights into the evolution of hepcidin.
C1 [De Domenico, Ivana; Nelson, Jenifer M.; Ward, Diane M.; Kaplan, Jerry] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA.
   [Nemeth, Elizabeta; Ganz, Tomas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
   [De Domenico, Ivana; PhillipS, John D.; Ajioka, Richard S.; Kushner, James P.] Univ Utah, Div Hematol & Bone Marrow Transplant, Salt Lake City, UT 84132 USA.
   [Kay, Michael S.] Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA.
RP Kaplan, J (reprint author), Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA.
EM jerry.kaplan@path.utah.edu
OI Ganz, Tomas/0000-0002-2830-5469
FU NIGMS NIH HHS [GM 082545, P50 GM082545]; NIDDK NIH HHS [DK 070947, R01
   DK070947, SP30DK072437, R01 DK070947-04, P30 DK072437, R01 DK020503]
CR Casale G, 1981, Age Ageing, V10, P119, DOI 10.1093/ageing/10.2.119
   De Domenico I, 2005, P NATL ACAD SCI USA, V102, P8955, DOI 10.1073/pnas.0503804102
   De Domenico I, 2006, HAEMATOL-HEMATOL J, V91, P92
   De Domenico I, 2007, J CLIN INVEST, V117, P1755, DOI 10.1172/JCI32701
   De Domenico I, 2007, MOL BIOL CELL, V18, P2569, DOI 10.1091/mbc.E07-01-0060
   De Domenico I, 2006, HAEMATOL-HEMATOL J, V91, P1092
   Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003
   Drakesmith H, 2005, BLOOD, V106, P1092, DOI 10.1182/blood-2005-02-0561
   ENOCH HG, 1977, J BIOL CHEM, V252, P5656
   Ganz T, 2006, BBA-MOL CELL RES, V1763, P690, DOI 10.1016/j.bbamcr.2006.03.014
   Hetet G, 2003, BLOOD, V102, P1904, DOI 10.1182/blood-2003-02-0439
   Huang FW, 2004, BLOOD, V104, P2176, DOI 10.1182/blood-2004-01-0400
   Huang PH, 2007, MOL IMMUNOL, V44, P1922, DOI 10.1016/j.molimm.2006.09.031
   Hunter HN, 2002, J BIOL CHEM, V277, P37597, DOI 10.1074/jbc.M205305200
   Ilyin G, 2003, FEBS LETT, V542, P22, DOI 10.1016/S0014-5793(03)00329-6
   Kemna E, 2005, BLOOD, V106, P3268, DOI 10.1182/blood-2005-05-1873
   Kemna EHJM, 2007, CLIN CHEM, V53, P620, DOI 10.1373/clinchem.2006.079186
   Lauth X, 2005, J BIOL CHEM, V280, P9272, DOI 10.1074/jbc.M411154200
   Lesbordes-Brion JC, 2006, BLOOD, V108, P1402, DOI 10.1182/blood-2006-02-003376
   Levy JE, 1999, BLOOD, V94, P9
   Liu XB, 2005, BLOOD CELL MOL DIS, V35, P33, DOI 10.1016/j.bcmd.2005.04.005
   Lou DQ, 2004, BLOOD, V103, P2816, DOI 10.1182/blood-2003-07-2524
   Murphy AT, 2007, BLOOD, V110, P1048, DOI 10.1182/blood-2006-11-057471
   Nemeth E, 2006, BLOOD, V107, P328, DOI 10.1182/blood-2005-05-2049
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686
   Njajou OT, 2002, BLOOD CELL MOL DIS, V29, P439, DOI 10.1006/bcmd.2002.0581
   Padhi A, 2007, MOL DIVERS, V11, P119, DOI 10.1007/s11030-007-9066-4
   Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200
   Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200
   Sham RL, 2005, BLOOD CELL MOL DIS, V34, P157, DOI 10.1016/j.bcmd.2004.12.002
   Shi JS, 2006, DEV COMP IMMUNOL, V30, P746, DOI 10.1016/j.dci.2005.10.009
   Shike H, 2002, EUR J BIOCHEM, V269, P2232, DOI 10.1046/j.1432-1033.2002.02881.x
   Tomosugi N, 2006, BLOOD, V108, P1381, DOI 10.1182/blood-2005-10-4043
   Wallace DF, 2007, J HEPATOL, V46, P921, DOI 10.1016/j.jhep.2007.01.033
NR 35
TC 108
Z9 108
U1 5
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD AUG 6
PY 2008
VL 8
IS 2
BP 146
EP 156
DI 10.1016/j.cmet.2008.07.002
PG 11
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 335AH
UT WOS:000258262700007
PM 18680715
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Xing, HY
   Fan, GH
   Zhou, TM
   Li, ST
   Ding, SF
   Sun, HQ
   Dong, HP
AF Xing Hai-Ying
   Fan Guan-Han
   Zhou Tian-Ming
   Li Shu-Ti
   Ding Shao-Feng
   Sun Hui-Qing
   Dong Hai-Ping
TI RETRACTED: Electronic structure and optical properties of GaN by
   Mn-doping (Retracted article. See vol 25, pg 290, 2009)
SO ACTA PHYSICO-CHIMICA SINICA
LA Chinese
DT Article; Retracted Publication
DE Ga1-xMnxN; first-principles; electronic structure; optical property
ID MOLECULAR-BEAM EPITAXY; MAGNETIC SEMICONDUCTORS; ROOM-TEMPERATURE;
   DESIGN; FILMS
AB Electronic structure and optical properties for several Mn doping GaN (Ga1-xMnxN) were calculated using density functional theory. We found that the formation of a 100% spin polarized impurity band in band structure of Ga1-xMnxN which was primarily due to hybridization of Mn 3d and N 2p orbitals. The material was half metallic. So GaxMn1-xN was a highly suitable material for spin injectors. In addition, a peak of absorption due to the transition between e state and t(2) state of Mn2+ ion Could be observed near 1.3 eV. The absorption coefficient increased with the increase of the Mn2+ concentration.
C1 [Xing Hai-Ying; Fan Guan-Han; Zhou Tian-Ming; Li Shu-Ti; Ding Shao-Feng; Sun Hui-Qing; Dong Hai-Ping] S China Normal Univ, Inst Optoelect Mat & Technol, Guangzhou 510631, Guangdong, Peoples R China.
RP Xing, HY (reprint author), S China Normal Univ, Inst Optoelect Mat & Technol, Guangzhou 510631, Guangdong, Peoples R China.
EM hy.xing@yahoo.com.cn; gfan@scnu.edu.cn
CR BOGUSLAWSKI P, 2005, J PHYS REV B, V72
   CHELIKOWSKY JR, 1992, HDB SEMICONDUCTORS
   Crooker SA, 2005, SCIENCE, V309, P2191, DOI 10.1126/science.1116865
   Dietl T, 2000, SCIENCE, V287, P1019, DOI 10.1126/science.287.5455.1019
   Dietl T, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.195205
   Gebicki W, 2001, MAT SCI ENG B-SOLID, V82, P182
   Han B, 2004, APPL PHYS LETT, V84, P5320, DOI 10.1063/1.1766082
   Jungwirth T, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.012402
   Katayama-Yoshida H, 2001, J CRYST GROWTH, V231, P428, DOI 10.1016/S0022-0248(01)01474-9
   Kim JJ, 2003, MAT SCI SEMICON PROC, V6, P503, DOI 10.1016/j.mssp.2003.07.023
   Kocan M, 2006, SEMICOND SCI TECH, V21, P1348, DOI 10.1088/0268-1242/21/9/022
   Korotkov RY, 2001, PHYSICA B, V308, P30, DOI 10.1016/S0921-4526(01)00660-3
   Korotkov RY, 2002, APPL PHYS LETT, V80, P1731, DOI 10.1063/1.1456544
   LIANG CG, 1999, CHINESE J SEMICONDUC, V20, P2
   MONKHORST HJ, 1976, PHYS REV B, V13, P5188, DOI 10.1103/PhysRevB.13.5188
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   PICKETT WE, 1989, COMPUT PHYS REP, V9, P115, DOI 10.1016/0167-7977(89)90002-6
   Pugh SK, 1999, SEMICOND SCI TECH, V14, P23, DOI 10.1088/0268-1242/14/1/003
   Reed MJ, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1881786
   Reed ML, 2001, APPL PHYS LETT, V79, P3473, DOI 10.1063/1.1419231
   Sato K, 2002, SEMICOND SCI TECH, V17, P367, DOI 10.1088/0268-1242/17/4/309
   Sato K, 2001, JPN J APPL PHYS 2, V40, pL485, DOI 10.1143/JJAP.40.L485
   Segall MD, 2002, J PHYS-CONDENS MAT, V14, P2717, DOI 10.1088/0953-8984/14/11/301
   Shen X C, 1992, SPECTRUM OPTICAL PRO, P76
   Sonoda S, 2002, J CRYST GROWTH, V237, P1358, DOI 10.1016/S0022-0248(01)02183-2
   Thaler GT, 2002, APPL PHYS LETT, V80, P3964, DOI 10.1063/1.1481533
   Theodoropoulou N, 2001, APPL PHYS LETT, V78, P3475, DOI 10.1063/1.1376659
   VANDERBILT D, 1990, PHYS REV B, V41, P7892, DOI 10.1103/PhysRevB.41.7892
   VANSCHILFGAARDE M, 2001, PHYS REV B, V63
   VANSCHILFGAARDE M, 2000, PHYS REV B, V63
   Wolos A, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.245202
   Yoder MN, 1996, IEEE T ELECTRON DEV, V43, P1633, DOI 10.1109/16.536807
   Zenneck J, 2007, J APPL PHYS, V101, DOI 10.1063/1.2710342
NR 33
TC 2
Z9 4
U1 5
U2 15
PU PEKING UNIV PRESS
PI BEIJING
PA PEKING UNIV, CHEMISTRY BUILDING, BEIJING 100871, PEOPLES R CHINA
SN 1000-6818
J9 ACTA PHYS-CHIM SIN
JI Acta Phys.-Chim. Sin.
PD AUG
PY 2008
VL 24
IS 8
BP 1432
EP 1438
PG 7
WC Chemistry, Physical
SC Chemistry
GA 347WB
UT WOS:000259171000018
DA 2018-12-27
ER

PT J
AU Kanat-Pektas, M
   Kunt, C
   Gungor, T
   Mollamahmutoglu, L
AF Kanat-Pektas, Mine
   Kunt, Cigdem
   Gungor, Tayfun
   Mollamahmutoglu, Leyla
TI RETRACTED: Perinatal and first year outcomes of spontaneous versus
   assisted twins: a single center experience (Retracted Article. See vol
   282, pg 593, 2010)
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article; Retracted Publication
DE assisted reproductive techniques; behavioural patterns; perinatal
   outcome; psychomotor development; twin gestation
ID IN-VITRO FERTILIZATION; REPRODUCTIVE TECHNIQUES; MULTIPLE GESTATIONS;
   NEONATAL OUTCOMES; FOLLOW-UP; PREGNANCIES; COHORT
AB Objective The aim is to compare naturally conceived twins with twins conceived by assisted reproductive techniques (ART) by means of perinatal outcome, behavioural patterns and psychomotor development.
   Material and methods Three hundred and five spontaneous and 119 assisted twins were compared in aspects of behavioural patterns, mental and psychomotor development, as well as maternal and gestational age, foetal presentation, birth weight, sex, Apgar scores, perinatal complications, delivery route, and admission to neonatal intensive care unit (NICU)
   Results Although the maternal age was higher in assisted twins, the mean gestational age and birth weight of assisted twins were significantly less than those of spontaneous twins. The assisted twins did not differ from the naturally conceived twins in aspects of presentation, Apgar scores, admission to NICU and perinatal complications. However, caesarean section rate and the delivery rate of male foetuses were significantly higher in assisted twins. During the first year of life, retardation in mental and psychomotor development was more pronounced in assisted twins. Also assisted twins experienced behavioural problems and difficulties in parent-child interactions more frequently.
   Conclusions Although twins born to assisted pregnancies had significantly shorter duration of gestation and thus less birth weight, their perinatal outcome was similar to that of spontaneous twins. The mothers of assisted twins may be keener on getting intensive prenatal care, which might in turn help to diminish any possible maternal and foetal risks. However, assisted twins showed significantly retarded psychomotor and mental development and experienced problems with environmental factors more frequently during their first year.
C1 [Kanat-Pektas, Mine] Ertugrul Gazi Mah, TR-06590 Ankara, Turkey.
   [Kanat-Pektas, Mine; Kunt, Cigdem; Gungor, Tayfun; Mollamahmutoglu, Leyla] Dr Zekai Tahir Burak Womens Hlth Educ & Res Hosp, Dept Perinatol, Ankara, Turkey.
RP Kanat-Pektas, M (reprint author), Ertugrul Gazi Mah, Kutlugus Sok 37-14, TR-06590 Ankara, Turkey.
EM minekanat@hotmail.com
OI Gungor, Tayfun/0000-0002-7869-9662
CR Bayley N., 1993, BAYLEY SCALES INFANT
   Bernasko J, 1997, OBSTET GYNECOL, V89, P368, DOI 10.1016/S0029-7844(96)00527-3
   BRADLEY RH, 1984, CHILD DEV, V55, P803, DOI 10.1111/j.1467-8624.1984.tb03817.x
   Conde-Agudelo A, 2000, OBSTET GYNECOL, V95, P899, DOI 10.1016/S0029-7844(99)00640-7
   Daniel Y, 2000, FERTIL STERIL, V74, P683, DOI 10.1016/S0015-0282(00)01491-6
   DEROM C, 1987, LANCET, V1, P1236
   Fitzsimmons BP, 1998, AM J OBSTET GYNECOL, V179, P1162, DOI 10.1016/S0002-9378(98)70125-5
   Goetghebuer T, 2003, TWIN RES, V6, P279, DOI 10.1375/twin.6.4.279
   KESSLER I, 1980, OBSTET GYNECOL, V56, P165
   Lambalk CB, 2001, FERTIL STERIL, V75, P731, DOI 10.1016/S0015-0282(01)01679-X
   Liang Runcai, 2002, Zhonghua Fu Chan Ke Za Zhi, V37, P327
   LIPITZ S, 1993, FERTIL STERIL, V60, P1031
   Minakami H, 1999, J REPROD MED, V44, P595
   Minakami H, 1998, HUM REPROD, V13, P2005, DOI 10.1093/humrep/13.7.2005
   Moise J, 1998, HUM REPROD, V13, P1702, DOI 10.1093/humrep/13.6.1702
   Olivennes F, 1996, FERTIL STERIL, V66, P105, DOI 10.1016/S0015-0282(16)58395-2
   Ostfeld B M, 2000, Twin Res, V3, P234, DOI 10.1375/136905200320565201
   PETERSEN K, 1995, ACTA OBSTET GYN SCAN, V74, P129, DOI 10.3109/00016349509008921
   Sutcliffe AG, 2006, EARLY HUM DEV, V82, P379, DOI 10.1016/j.earlhumdev.2006.03.007
   TAN SL, 1992, AM J OBSTET GYNECOL, V167, P778, DOI 10.1016/S0002-9378(11)91589-0
   YE R, 2000, ZHONGHUA FU CHAN KE, V3, P157
   Zaib-un-Nisa S, 2003, EUR J OBSTET GYN R B, V109, P51, DOI 10.1016/S0301-2115(02)00468-2
NR 22
TC 12
Z9 13
U1 6
U2 16
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD AUG
PY 2008
VL 278
IS 2
BP 143
EP 147
DI 10.1007/s00404-007-0545-8
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 307KR
UT WOS:000256318300008
PM 18193247
DA 2018-12-27
ER

PT J
AU Schulz, PJ
AF Schulz, Peter J.
TI RETRACTED: Comments on 'Strategic Manoeuvring with the Intention of the
   Legislator in the Justification of Judicial Decisions'(Retracted
   article. See vol. 29, pg. 493, 2015)
SO ARGUMENTATION
LA English
DT Editorial Material; Retracted Publication
C1 Univ Lugano CH, Inst Commun & Hlth, Lugano, Switzerland.
RP Schulz, PJ (reprint author), Univ Lugano CH, Inst Commun & Hlth, Lugano, Switzerland.
EM peter.schulz@lu.unisi.ch
OI Schulz, Peter Johannes/0000-0003-4281-489X
CR VERMEULE A, 2006, JUDGING UNCERTAINTY
NR 1
TC 1
Z9 1
U1 1
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-427X
EI 1572-8374
J9 ARGUMENTATION
JI Argumentation
PD AUG
PY 2008
VL 22
IS 3
BP 355
EP 357
DI 10.1007/s10503-008-9092-0
PG 3
WC Communication; Linguistics; Language & Linguistics; Philosophy
SC Communication; Linguistics; Philosophy
GA V17VI
UT WOS:000207964300005
DA 2018-12-27
ER

PT J
AU Mayack, SR
   Wagers, AJ
AF Mayack, Shane R.
   Wagers, Amy J.
TI RETRACTED: Osteolineage niche cells initiate hematopoietic stem cell
   mobilization (Retracted article. See vol. 119, pg. 1793, 2012)
SO BLOOD
LA English
DT Article; Retracted Publication
ID COLONY-STIMULATING FACTOR; ETS TRANSCRIPTION FACTORS; INDUCED OXIDATIVE
   STRESS; MARROW STROMAL CELLS; BONE-MARROW; GENE-EXPRESSION; OSTEOBLAST
   DIFFERENTIATION; PROPHYLACTIC ACTION; PROGENITOR CELLS; MC3T3-E1 CELLS
AB Recent studies have implicated bone-lining osteoblasts as important regulators of hematopoietic stem cell (HSC) self-renewal and differentiation; however, because much of the evidence supporting this notion derives from indirect in vivo experiments, which are unavoidably complicated by the presence of other cell types within the complex bone marrow milieu, the sufficiency of osteoblasts in modulating HSC activity has remained controversial. To address this, we prospectively isolated mouse osteoblasts, using a novel flow cytometry-based approach, and directly tested their activity as HSC niche cells and their role in cyclophosphamide/granulocyte colony-stimulating factor (G-CSF)-induced HSC proliferation and mobilization. We found that osteoblasts expand rapidly after cyclophosphamide/G-CSF treatment and exhibit phenotypic and functional changes that directly influence HSC proliferation and maintenance of reconstituting potential. Effects of mobilization on osteoblast number and function depend on the function of ataxia telangiectasia mutated (ATM), the product of the Atm gene, demonstrating a new role for ATM in stem cell niche activity. These studies demonstrate that signals from osteoblasts can directly initiate and modulate HSC proliferation in the context of mobilization. This work also establishes that direct interaction with osteollneage niche cells, in the absence of additional environmental inputs, is sufficient to modulate stem cell activity.
C1 [Mayack, Shane R.; Wagers, Amy J.] Harvard Univ, Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, Dept Stem Cell & Regenerat Biol, Boston, MA 02215 USA.
   [Mayack, Shane R.; Wagers, Amy J.] Harvard Stem Cell Inst, Boston, MA USA.
RP Wagers, AJ (reprint author), Harvard Univ, Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, Dept Stem Cell & Regenerat Biol, 1 Joslin Pl,Room 620C, Boston, MA 02215 USA.
EM amy.wagers@joslin.harvard.edu
FU NIDDK NIH HHS [T32DK07260-29, T32 DK007260]
CR Adams GB, 2007, NAT BIOTECHNOL, V25, P238, DOI 10.1038/nbt1281
   Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Bakker A, 2003, METH MOLEC MED, V80, P19
   Balduino A, 2005, CELL TISSUE RES, V319, P255, DOI 10.1007/s00441-004-1006-3
   Bhatia AL, 2006, J MED FOOD, V9, P261, DOI 10.1089/jmf.2006.9.261
   Bradford GB, 1997, EXP HEMATOL, V25, P445
   Bruserud O, 2004, HAEMATOLOGICA, V89, P391
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Carlesso N, 1999, BLOOD, V93, P838
   Chen K, 2003, J BIOL CHEM, V278, P39527, DOI 10.1074/jbc.M304423200
   DRIZE N, 1995, EXP HEMATOL, V23, P1180
   FERMOR B, 1995, J BONE MINER RES, V10, P1935
   FLEMING WH, 1993, J CELL BIOL, V122, P897, DOI 10.1083/jcb.122.4.897
   Glimm H, 2000, BLOOD, V96, P4185
   Hadjantonakis AK, 2001, HISTOCHEM CELL BIOL, V115, P49, DOI 10.1007/s004180000233
   Hadjantonakis Anna-Katerina, 2002, BMC Biotechnol, V2, P11, DOI 10.1186/1472-6750-2-11
   Haylock DN, 2006, BRIT J HAEMATOL, V134, P467, DOI 10.1111/j.1365.2141.2006.06218.x
   Heinloth AN, 2003, RADIAT RES, V160, P273, DOI 10.1667/RR3047
   Hishiya A, 2005, BONE, V37, P497, DOI 10.1016/j.bone.2005.05.012
   Hofseth LJ, 2003, P NATL ACAD SCI USA, V100, P143, DOI 10.1073/pnas.0237083100
   Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388
   Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989
   Jonsson KB, 1999, ACTA ORTHOP SCAND, V70, P365, DOI 10.3109/17453679908997826
   Jung Y, 2005, CYTOKINE, V32, P155, DOI 10.1016/j.cyto.2005.09.001
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041
   Kiel MJ, 2006, IMMUNITY, V25, P862, DOI 10.1016/j.immuni.2006.11.003
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Kitching R, 2002, J BONE MINER METAB, V20, P269, DOI 10.1007/s007740200039
   Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007
   Li V, 2004, IN VIVO, V18, P517
   Manda K, 2003, CELL BIOL TOXICOL, V19, P367, DOI 10.1023/B:CBTO.0000013342.17370.16
   Marom R, 2005, J CELL PHYSIOL, V202, P41, DOI 10.1002/jcp.20109
   Morrison SJ, 1997, P NATL ACAD SCI USA, V94, P1908, DOI 10.1073/pnas.94.5.1908
   NEBEN S, 1993, BLOOD, V81, P1960
   Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293
   Papayannopoulou T, 1999, ANN NY ACAD SCI, V872, P187, DOI 10.1111/j.1749-6632.1999.tb08464.x
   Papayannopoulou T., 1999, ANN NY ACAD SCI, V872, P197
   Passegue E, 2005, J EXP MED, V202, P1599, DOI 10.1084/jem.20050967
   POCKWINSE SM, 1992, J CELL BIOCHEM, V49, P310, DOI 10.1002/jcb.240490315
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Raouf A, 2000, ONCOGENE, V19, P1969, DOI 10.1038/sj.onc.1203505
   Raouf A, 2002, MATRIX BIOL, V21, P361, DOI 10.1016/S0945-053X(02)00027-6
   Raouf A, 2002, BONE, V30, P463, DOI 10.1016/S8756-3282(01)00699-8
   Raouf A, 2000, ONCOGENE, V19, P6455, DOI 10.1038/sj.onc.1204037
   Rasheed N, 2006, HUM MOL GENET, V15, P1938, DOI 10.1093/hmg/ddl116
   Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood-2004-01-0272
   Shackelford RE, 2001, J BIOL CHEM, V276, P21951, DOI 10.1074/jbc.M011303200
   Shoelson SE, 2006, CELL METAB, V4, P337, DOI 10.1016/j.cmet.2006.10.009
   SivaKumar V, 2006, DRUG CHEM TOXICOL, V29, P279, DOI 10.1080/01480540600652921
   Stewart K, 1999, J BONE MINER RES, V14, P1345, DOI 10.1359/jbmr.1999.14.8.1345
   Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992
   Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016
   Telford WG, 1999, CYTOMETRY, V37, P314, DOI 10.1002/(SICI)1097-0320(19991201)37:4<314::AID-CYTO9>3.0.CO;2-X
   Vary CPH, 2000, EXP CELL RES, V257, P213, DOI 10.1006/excr.2000.4879
   Visnjic D, 2001, J BONE MINER RES, V16, P2222, DOI 10.1359/jbmr.2001.16.12.2222
   WERGEDAL JE, 1984, P SOC EXP BIOL MED, V176, P60
   Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081
   Wright DE, 2001, BLOOD, V97, P2278, DOI 10.1182/blood.V97.8.2278
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhu J, 2004, BIOESSAYS, V26, P595, DOI 10.1002/bies.20052
NR 62
TC 75
Z9 78
U1 2
U2 12
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD AUG 1
PY 2008
VL 112
IS 3
BP 519
EP 531
DI 10.1182/blood-2008-01-133710
PG 13
WC Hematology
SC Hematology
GA 334YO
UT WOS:000258257900017
PM 18456874
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Makishi, S
   Okudaira, T
   Ishikawa, C
   Sawada, S
   Watanabe, T
   Hirashima, M
   Sunakawa, H
   Mori, N
AF Makishi, Shoko
   Okudaira, Taeko
   Ishikawa, Chie
   Sawada, Shigeki
   Watanabe, Toshiki
   Hirashima, Mitsuomi
   Sunakawa, Hajime
   Mori, Naoki
TI RETRACTED: A modified version of galectin-9 induces cell cycle arrest
   and apoptosis of Burkitt and Hodgkin lymphoma cells (Retracted article.
   See vol. 152, pg. 788, 2011)
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article; Retracted Publication
DE galectin-9; Burkitt lymphoma; Hodgkin lymphoma; NF-kappa B; AP-1
ID NF-KAPPA-B; VIRUS TYPE-I; ONCOGENE PRODUCT TAX; MONOCLONAL-ANTIBODY;
   CONSTITUTIVE ACTIVATION; STERNBERG CELLS; LEUKEMIA-CELLS; INHIBITION;
   DISEASE; PROTEIN
AB The identification of galectin-9 as a ligand for T-cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3), expressed on T-helper type-1 (Th1) cells, has established the Tim-3-galectin-9 pathway as a regulator of Th1 immunity. Whereas there is compelling evidence for the effects of galectin-9 on T-cell fate, limited information is available on the impact of galectin-9 on B lymphocytes. We found that protease-resistant galectin-9, hG9NC(null), but not galectin-1 or -8, prevented cell growth of malignant B cells, such as Burkitt lymphoma (BL) and Hodgkin lymphoma (HL). beta-galactoside binding was essential for galectin-9-induced cell growth suppression. hG9NC(null) induced cell cycle arrest by reducing the expression of cyclin D1, D2, B1, Cdk4, Cdc25C and c-Myc, and apoptosis by reducing the expression of XIAP, c-IAP2 and survivin. Most of the genes that encode these proteins are regulated by nuclear factor-kappa B (NF-kappa B), and constitutive activation of NF-kappa Beta is a common characteristic of both types of malignancies. hG9NC(null) inhibited I kappa B alpha phosphorylation, resulting in suppression of NF-kappa B. AP-1 has also been implicated in the control of cell survival. hG9NC(null) inhibited the expression of JunD, resulting in the suppression of AP-1. Our results suggest that hG9NC(null) is a potentially suitable agent for the management of BL and HL.
C1 [Makishi, Shoko; Okudaira, Taeko; Ishikawa, Chie; Sawada, Shigeki; Mori, Naoki] Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan.
   [Makishi, Shoko; Sawada, Shigeki; Sunakawa, Hajime] Univ Ryukyus, Fac Med, Div Oral & Maxillofacial Funct Rehabil, Nishihara, Okinawa 9030215, Japan.
   [Okudaira, Taeko] Univ Ryukyus, Fac Med, Div Endocrinol & Metab, Nishihara, Okinawa 9030215, Japan.
   [Ishikawa, Chie] Univ Ryukyus, Fac Med, Div Child Hlth & Welf, Nishihara, Okinawa 9030215, Japan.
   [Watanabe, Toshiki] Univ Tokyo, Grad Sch Frontier Sci, Tumor Cell Biol Lab, Tokyo, Japan.
   [Hirashima, Mitsuomi] Kagawa Univ, Fac Med, Dept Immunol & Immunopathol, Miki, Kagawa, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Nishihara, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
CR Arbel-Goren R, 2005, J BIOL CHEM, V280, P19105, DOI 10.1074/jbc.M502060200
   Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849
   Bi S, 2008, J BIOL CHEM, V283, P12248, DOI 10.1074/jbc.M800523200
   Bremer E, 2006, TRENDS MOL MED, V12, P382, DOI 10.1016/j.molmed.2006.06.002
   Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090
   Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8
   Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057
   Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979
   Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215
   Diehl V, 2004, LANCET ONCOL, V5, P19, DOI 10.1016/S1470-2045(03)01320-2
   Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9
   DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727
   Griffin J, 2001, SEMIN ONCOL, V28, P3, DOI 10.1016/S0093-7754(01)90097-1
   Hernandez JD, 2002, GLYCOBIOLOGY, V12, p127R, DOI 10.1093/glycob/cwf081
   Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589
   Hinz M, 1999, MOL CELL BIOL, V19, P2690
   Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198
   Hussain A, 2003, HAEMATOLOGICA, V88, P167
   Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304
   Izban KF, 2001, MODERN PATHOL, V14, P297, DOI 10.1038/modpathol.3880306
   Jazirehi AR, 2005, ONCOGENE, V24, P2121, DOI 10.1038/sj.onc.1208349
   Jazirehi AR, 2005, CANCER RES, V65, P264
   Jost PJ, 2007, BLOOD, V109, P2700, DOI 10.1182/blood-2006-07-025809
   Kawakami H, 2005, INT J CANCER, V115, P967, DOI 10.1002/ijc.20954
   Kimura N, 2007, LEUKEMIA RES, V31, P1529, DOI 10.1016/j.leukres.2007.02.015
   Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762
   Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912
   Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6
   Lu LH, 2007, J BIOCHEM, V141, P157, DOI 10.1093/jb/mvm019
   Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154
   Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976
   Matsushita N, 2000, J BIOL CHEM, V275, P8355, DOI 10.1074/jbc.275.12.8355
   Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a
   Mori N, 1999, BLOOD, V93, P2360
   Mounier N, 2007, BRIT J HAEMATOL, V136, P685, DOI 10.1111/j.1365-2141.2006.06464.x
   Mouzakiti A, 2003, BRIT J HAEMATOL, V122, P61, DOI 10.1046/j.1365-2141.2003.04424.x
   Nguyen PL, 1996, AM J PATHOL, V148, P847
   Nishi N, 2005, FEBS LETT, V579, P2058, DOI 10.1016/j.febslet.2005.02.054
   Okudaira T, 2007, INT J CANCER, V120, P2251, DOI 10.1002/ijc.22534
   Piva R, 2005, BLOOD, V105, P1750, DOI 10.1182/blood-2004-04-1360
   Rabinovich GA, 1999, CELL DEATH DIFFER, V6, P711, DOI 10.1038/sj.cdd.4400535
   Seth A, 1997, AIDS, V11, P1059
   Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595
   Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383
   Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q
   Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211
   Stillman BN, 2006, J IMMUNOL, V176, P778, DOI 10.4049/jimmunol.176.2.778
   Tribulatti MV, 2007, GLYCOBIOLOGY, V17, P1404, DOI 10.1093/glycob/cwm104
   Tureci O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/jbc.272.10.6416
   van den Bosch CA, 2004, LANCET ONCOL, V5, P738, DOI 10.1016/S1470-2045(04)01650-X
   Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429
   Watanabe M, 2007, LAB INVEST, V87, P372, DOI 10.1038/labinvest.3700528
   WeberNordt RM, 1996, BLOOD, V88, P809
   Zhang CH, 1996, J IMMUNOL, V157, P3980
   Zheng B, 2004, CLIN CANCER RES, V10, P3207, DOI 10.1158/1078-0432.CCR-03-0494
   Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271
NR 56
TC 13
Z9 17
U1 3
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD AUG
PY 2008
VL 142
IS 4
BP 583
EP 594
DI 10.1111/j.1365-2141.2008.07229.x
PG 12
WC Hematology
SC Hematology
GA 328KH
UT WOS:000257796800008
PM 18503581
OA Bronze
DA 2018-12-27
ER

PT J
AU Okuyama, H
   Hirono, O
   Tamura, H
   Nishiyama, S
   Takeishi, Y
   Kayama, T
   Kubota, I
AF Okuyama, Hidenobu
   Hirono, Osamu
   Tamura, Harutoshi
   Nishiyama, Satoshi
   Takeishi, Yasuchika
   Kayama, Takamasa
   Kubota, Isao
TI RETRACTED: Impact of aortic arch stiffness on recurrence of stroke in
   patients with acute ischemic stroke (Retracted article. See vol. 72, pg.
   1914, 2008)
SO CIRCULATION JOURNAL
LA English
DT Article; Retracted Publication
DE aorta; atherosclerosis; stroke; transesophageal echocardiography
ID ATRIAL SEPTAL ANEURYSM; MEDIA THICKNESS; RISK-FACTOR; ATHEROMAS;
   DISEASE; ATHEROSCLEROSIS; ECHOCARDIOGRAPHY; POPULATION; MORTALITY;
   EVENTS
AB Background Aortic arch plaques are associated with increased risk of stroke recurrence. The atherosclerotic process also affects aortic stiffness. The purpose of the present study was to evaluate aortic arch stiffness by transesophageal echocardiography (TEE) and its effect on recurrence of stroke.
   Methods and Results TEE was performed in 201 patients with stroke and the aortic stiffness parameter beta was measured as an expression of the elasticity of the aortic arch wall. Patients were followed during a median follow-up period of 459 days with the endpoint as stroke recurrence. There were 21 cases of stroke recurrence (10%) during the follow-up period and the stiffness parameter beta was significantly higher in those cases (16.8 +/- 4.6 vs 12.5 +/- 3.3 [no recurrence], p<0.01). Cox multivariate hazard analysis revealed that stiffness parameter beta was the only independent predictor for stroke recurrence (hazard ratio 1.683, p<0.01). Kaplan-Meier Survival analysis revealed that stiffness parameter beta effectively risk stratified patients for stoke recurrence. Furthermore, in 3 groups based on the value of beta, the 3(rd) tertile had the highest stroke recurrent risk (relative risk 5.473, p<0.01).
   Conclusions The value of beta in the aortic arch, assessed by TEE, may be a sensitive indicator of stroke recurrence.
C1 [Okuyama, Hidenobu; Hirono, Osamu; Tamura, Harutoshi; Nishiyama, Satoshi; Takeishi, Yasuchika; Kubota, Isao] Yamagata Univ, Sch Med, Dept Cardiol, Yamagata 9909585, Japan.
   [Okuyama, Hidenobu; Hirono, Osamu; Tamura, Harutoshi; Nishiyama, Satoshi; Takeishi, Yasuchika; Kubota, Isao] Yamagata Univ, Sch Med, Dept Pulmonol, Yamagata 9909585, Japan.
   [Okuyama, Hidenobu; Hirono, Osamu; Tamura, Harutoshi; Nishiyama, Satoshi; Takeishi, Yasuchika; Kubota, Isao] Yamagata Univ, Sch Med, Dept Nephrol, Yamagata 9909585, Japan.
   [Kayama, Takamasa] Yamagata Univ, Sch Med, Dept Neurosurg, Yamagata 9909585, Japan.
RP Okuyama, H (reprint author), Yamagata Univ, Sch Med, Dept Cardiol Pulmonol & Nephrol, 2-2-2 Iida Nishi, Yamagata 9909585, Japan.
EM hiokuyama-cire@umin.net
CR AMARENCO P, 1994, NEW ENGL J MED, V331, P1474, DOI 10.1056/NEJM199412013312202
   Amarenco P, 1996, NEW ENGL J MED, V334, P1216
   Aschoff Ludwig, 1933, ARTERIOSCLEROSIS SUR, P1
   AVOLIO AP, 1985, CIRCULATION, V71, P202, DOI 10.1161/01.CIR.71.2.202
   Bitigen A, 2007, CIRC J, V71, P727, DOI 10.1253/circj.71.727
   BLANKENHORN DH, 1989, CIRCULATION, V79, P1, DOI 10.1161/01.CIR.79.1.1
   Di Tullio MR, 2000, STROKE, V31, P2623, DOI 10.1161/01.STR.31.11.2623
   Di Tullio MR, 2000, AM HEART J, V139, P329, DOI 10.1016/S0002-8703(00)90243-6
   DiTullio MR, 1996, NEUROLOGY, V46, P1560, DOI 10.1212/WNL.46.6.1560
   Ebrahim S, 1999, STROKE, V30, P841, DOI 10.1161/01.STR.30.4.841
   HANLEY PC, 1985, J AM COLL CARDIOL, V6, P1370, DOI 10.1016/S0735-1097(85)80228-X
   HAYASHI K, 1974, EXP MECH, V14, P440, DOI 10.1007/BF02324024
   HAYASHI K, 1980, J BIOMECH, V13, P175, DOI 10.1016/0021-9290(80)90191-8
   Laurent S, 2001, HYPERTENSION, V37, P1236, DOI 10.1161/01.HYP.37.5.1236
   Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4
   NINDS Working Group, 1990, STROKE, V21, P637
   NISHINO M, 1994, AM HEART J, V127, P336
   O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103
   O'Rourke MF, 2007, J AM COLL CARDIOL, V50, P1, DOI 10.1016/j.jacc.2006.12.050
   Okuyama H, 2006, CIRC J, V70, P971, DOI 10.1253/circj.70.971
   Riley WA, 1997, ULTRASOUND MED BIOL, V23, P157, DOI 10.1016/S0301-5629(96)00211-6
   Rundek T, 1999, STROKE, V30, P2683, DOI 10.1161/01.STR.30.12.2683
   Stefanadis C, 2000, EUR HEART J, V21, P390, DOI 10.1053/euhj.1999.1756
   Sugioka K, 2002, STROKE, V33, P2077, DOI 10.1161/01.STR.0000021410.83049.32
   Tamura H, 2007, CIRC J, V71, P1573, DOI 10.1253/circj.71.1573
   Tanriverdi H, 2006, CIRC J, V70, P737, DOI 10.1253/circj.70.737
   Tomochika Y, 1996, ARTERIOSCL THROM VAS, V16, P955, DOI 10.1161/01.ATV.16.8.955
   TUNICK PA, 1991, ANN INTERN MED, V115, P423, DOI 10.7326/0003-4819-115-6-423
   van Popele NM, 2001, STROKE, V32, P454, DOI 10.1161/01.STR.32.2.454
   WADA T, 1994, ARTERIOSCLER THROMB, V14, P479, DOI 10.1161/01.ATV.14.3.479
   ZABALGOITIAREYES M, 1990, AM J CARDIOL, V66, P761, DOI 10.1016/0002-9149(90)91146-W
NR 31
TC 2
Z9 2
U1 3
U2 7
PU JAPANESE CIRCULATION SOC
PI TOYKO
PA 18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO,
   100-0011, JAPAN
SN 1346-9843
EI 1347-4820
J9 CIRC J
JI Circ. J.
PD AUG
PY 2008
VL 72
IS 8
BP 1296
EP 1302
DI 10.1253/circj.72.1296
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 332AS
UT WOS:000258054600016
PM 18654017
OA Bronze
DA 2018-12-27
ER

PT J
AU Sher, LS
   Cramer, D
AF Sher, Linda S.
   Cramer, Donald
TI RETRACTED: Preclinical bridge to clinical tolerance (Retracted Article)
SO CURRENT OPINION IN ORGAN TRANSPLANTATION
LA English
DT Correction; Retracted Publication
ID SEE
CR Contreras JL, 1998, TRANSPLANTATION, V65, P1159, DOI 10.1097/00007890-199805150-00003
   Thomas JM, 2000, TRANSPLANTATION, V69, P2497, DOI 10.1097/00007890-200006270-00007
   THOMAS JM, 2006, TRANSPLANTATION, P82
   THOMAS JM, 2001, CURR OPIN ORGAN TRAN, V6, P95
   Thomas JM, 2008, TRANSPLANTATION, V85, P920, DOI 10.1097/TP.0b013e318172dbe0
NR 5
TC 0
Z9 0
U1 3
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1087-2418
EI 1531-7013
J9 CURR OPIN ORGAN TRAN
JI Curr. Opin. Organ Transpl.
PD AUG
PY 2008
VL 13
IS 4
BP 452
EP 452
PG 1
WC Transplantation
SC Transplantation
GA 334YU
UT WOS:000258258500021
DA 2018-12-27
ER

PT J
AU Sher, LS
   Cramer, D
AF Sher, Linda S.
   Cramer, Donald
TI RETRACTED: Immunotoxins and tolerance induction in primates (Retracted
   Article)
SO CURRENT OPINION IN ORGAN TRANSPLANTATION
LA English
DT Correction; Retracted Publication
CR Contreras JL, 1998, TRANSPLANTATION, V65, P1159, DOI 10.1097/00007890-199805150-00003
   HUBBARD WJ, 2000, CURR OPIN ORGAN TRAN, V5, P29
   Thomas JM, 2008, TRANSPLANTATION, V85, P920, DOI 10.1097/TP.0b013e318172dbe0
NR 3
TC 0
Z9 0
U1 3
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1087-2418
EI 1531-7013
J9 CURR OPIN ORGAN TRAN
JI Curr. Opin. Organ Transpl.
PD AUG
PY 2008
VL 13
IS 4
BP 452
EP 452
PG 1
WC Transplantation
SC Transplantation
GA 334YU
UT WOS:000258258500020
DA 2018-12-27
ER

PT J
AU Al-Daraji, WI
   Al-Mahmoud, RMW
   Ilyas, M
AF Al-Daraji, Wael Ismail
   Al-Mahmoud, Riham M. W.
   Ilyas, Mohammed
TI RETRACTED: Gastric changes following colchicine therapy in patients with
   FMF (Retracted Article. See vol 54, pg 2772, 2009)
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article; Retracted Publication
DE colchicine; GI effects; FMF; ring mitoses; antrum
ID FAMILIAL-MEDITERRANEAN-FEVER; INDUCED CELL-DEATH;
   GASTROINTESTINAL-TRACT; MOLECULAR DIAGNOSIS; BEHCETS-DISEASE; AA
   AMYLOIDOSIS; MEFV GENE; TAXOL; MUTATION; MALABSORPTION
AB Background Familial Mediterranean fever (FMF) is also called recurrent polyserositis. The salient features of this disease include brief recurrent episodes of peritonitis, pleuritis, and arthritis, which are usually associated with fever. Colchicine is highly effective in the treatment of FMF and in preventing the development of recurrent attacks and amyloidosis, and it is essential to make the correct diagnosis and institute daily therapy with colchicine (0.5-0.6 mg bid). Colchicine is used to treat a variety of conditions but it is known to have gastrointestinal (GI) side effects. In this study, effects of colchicines on the gastrointestinal tract were evaluated in patients with FMF treated with colchicine. Methods Biopsies were reviewed from 43 patients attending Ain Shams University Hospital (Egypt) who were diagnosed with FMF and treated with colchicine. One-hundred and twelve GI biopsies, obtained over a 14-year period, were reviewed. This included biopsies from stomach body (38), stomach antrum (50), and colon (24). In addition, gastric biopsies were reviewed from 17 control patients who did not have FMF and were not on colchicine. Results Three patients known to have FMF and on colchicine therapy showed typical histological features of colchicine (metaphase mitoses, epithelial pseudoproliferation, mucin depletion, and frequent apoptosis). These features were seen only in gastric antral biopsies and not in colonic biopsies. None of the control group showed the characteristic morphological features of colchicine toxicity. Conclusion This is the first report of histological changes seen in the stomach following colchicine therapy. In contrast with previous reports, we did not find any definitive change in the large intestine. Our data show that gastric changes can be encountered in symptomatic patients who have recently had colchicine. If these finding are seen histologically, they merit correlation with the clinical impression and should not be interpreted as toxicity in isolation.
C1 [Al-Daraji, Wael Ismail; Ilyas, Mohammed] Univ Nottingham, Sch Mol Med, Dept Pathol, Nottingham NG7 2UH, England.
   [Al-Mahmoud, Riham M. W.] Ain Shams Univ Hosp, Dept Med, Cairo, Egypt.
RP Al-Daraji, WI (reprint author), Univ Nottingham, Sch Mol Med, Dept Pathol, Nottingham NG7 2UH, England.
EM waldaraji@aol.com
CR Al-Alami JR, 2003, SAUDI MED J, V24, P1055
   ANDREU JM, 1982, BIOCHEMISTRY-US, V21, P534, DOI 10.1021/bi00532a019
   ANILKUMAR TV, 1992, BRIT J CANCER, V65, P552, DOI 10.1038/bjc.1992.113
   Ben-Chetrit E, 1998, SEMIN ARTHRITIS RHEU, V28, P48, DOI 10.1016/S0049-0172(98)80028-0
   Ben-Chetrit E, 2003, J NEPHROL, V16, P431
   Ben-Chetrit E, 2002, CLIN EXP RHEUMATOL, V20, pS25
   Ben-Chetrit E, 2002, J RHEUMATOL, V29, P530
   Ben-Chetrit E, 2001, CLIN EXP RHEUMATOL, V19, pS1
   Ben-Chetrit E, 2000, HUM MUTAT, V15, P385, DOI 10.1002/(SICI)1098-1004(200004)15:4<385::AID-HUMU22>3.0.CO;2-A
   Booth DR, 2000, QJM-INT J MED, V93, P217, DOI 10.1093/qjmed/93.4.217
   Booth DR, 1998, QJM-INT J MED, V91, P603, DOI 10.1093/qjmed/91.9.603
   Booth DR, 2001, QJM-INT J MED, V94, P527, DOI 10.1093/qjmed/94.10.527
   Cazeneuve C, 2000, AM J HUM GENET, V67, P1136, DOI 10.1016/S0002-9297(07)62944-9
   Cazeneuve C, 2003, ARTHRITIS RHEUM-US, V48, P2324, DOI 10.1002/art.11102
   Chen XG, 2000, P SOC EXP BIOL MED, V224, P32, DOI 10.1046/j.1525-1373.2000.22362.x
   Debernardis D, 1997, CANCER RES, V57, P870
   Dode C, 2002, NEPHROL DIAL TRANSPL, V17, P1212, DOI 10.1093/ndt/17.7.1212
   Haldar S, 1996, CANCER RES, V56, P1253
   HART J, 1993, DIGEST DIS SCI, V38, P2017, DOI 10.1007/BF01297078
   HRUBAN RH, 1989, CANCER, V63, P1944, DOI 10.1002/1097-0142(19890515)63:10<1944::AID-CNCR2820631013>3.0.CO;2-#
   Iacobuzio-Donahue CA, 2001, AM J SURG PATHOL, V25, P1067, DOI 10.1097/00000478-200108000-00012
   Livneh A, 1999, AMYLOID, V6, P1, DOI 10.3109/13506129908993281
   Livneh A, 2001, EUR J HUM GENET, V9, P191, DOI 10.1038/sj.ejhg.5200608
   Parfitt JR, 2007, HUM PATHOL, V38, P527, DOI 10.1016/j.humpath.2007.01.014
   RACE TF, 1970, AM J MED SCI, V259, P32, DOI 10.1097/00000441-197001000-00005
   Settin A, 2007, J GASTROINTEST LIVER, V16, P141
   STEMMERMANN GN, 1971, HUM PATHOL, V2, P321, DOI 10.1016/S0046-8177(71)80040-0
   STERN N, 1997, SCHWEIZ RUNDSCH MED, V86, P952
   TISHLER RB, 1995, CANCER RES, V55, P6021
   Torres K, 1998, CANCER RES, V58, P3620
   WEBB DI, 1968, NEW ENGL J MED, V279, P845, DOI 10.1056/NEJM196810172791602
   WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588
NR 32
TC 7
Z9 7
U1 3
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD AUG
PY 2008
VL 53
IS 8
BP 2079
EP 2082
DI 10.1007/s10620-007-0132-7
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 321SY
UT WOS:000257328000011
PM 18080195
DA 2018-12-27
ER

PT J
AU Chen, MY
   Cai, JT
   Du, Q
   Wang, LJ
   Chen, JM
   Shao, LM
AF Chen, Miao-Yan
   Cai, Jian-Ting
   Du, Qin
   Wang, Liang-Jing
   Chen, Jia-Min
   Shao, Li-Ming
TI RETRACTED: Reliable experimental model of hepatic veno-occluslive
   disease caused by monocrotaline (Retracted article. See vol 8, pg 396,
   2009)
SO HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL
LA English
DT Article; Retracted Publication
DE hepatic veno-occlusive disease; monocrotaline; proliferating cell
   nuclear antigen
ID SINUSOIDAL-OBSTRUCTION SYNDROME; VENOOCCLUSIVE DISEASE; GEMTUZUMAB
   OZOGAMICIN; LIVER; TRANSPLANTATION; HYPERTENSION
AB BACKGROUND: Hepatic veno-occlusive disease (HVOD) is a severe complication of chemotherapy before hematopoietic stem cell transplantation and dietary ingestion of pyrrolizidine alkaloids. Many experimental models were established to study its mechanisms or therapy, but few are ideal. This work aimed at evaluating a rat model of HVOD induced by monocrotaline to help advance research into this disease.
   METHODS: Thirty-two male rats were randomly classified into 5 groups, and PBS or monocrotaline was administered (100 mg/kg or 160 mg/kg). They were sacrificed on day 7 (groups A, B and D) or day 10 (groups C and E). Blood samples were collected to determine liver enzyme concentrations. The weight of the liver and body and the amount of ascites were measured. Histopathological changes of liver tissue on light microscopy were assessed by a modified Deleve scoring system. The positivity of proliferating cell nuclear antigen (PCNA) was estimated.
   RESULTS: The rats that were treated with 160 mg/kg monocrotaline presented with severe clinical symptoms (including two deaths) and the histopathological picture of HVOD. On the other hand, the rats that were fed with 100 mg/kg monocrotaline had milder and reversible manifestations. Comparison of the rats sacrificed on day 10 with those sacrificed on day 7 showed that the positivity of PCNA increased, especially that of hepatocytes.
   CONCLUSIONS: Monocrotaline induces acute, dose-dependent HVOD in rats. The model is potentially reversible with a tow dose, but reliable and irreversible with a higher dose. The modified scoring system seems to be more accurate than the traditional one in reflecting the histopathology of HVOD. The enhancement of PCNA positivity may be associated with hepatic tissue undergoing recovery.
C1 [Chen, Miao-Yan; Cai, Jian-Ting; Du, Qin; Wang, Liang-Jing; Chen, Jia-Min; Shao, Li-Ming] Zhejiang Univ, Sch Med, Dept Gastroenterol & Hepatol, Affiliated Hosp 2, Hangzhou 310009, Peoples R China.
RP Cai, JT (reprint author), Zhejiang Univ, Sch Med, Dept Gastroenterol & Hepatol, Affiliated Hosp 2, Hangzhou 310009, Peoples R China.
EM jianting_cai@sina.com
CR Borowska Halina, 2004, Folia Morphol (Warsz), V63, P91
   Chen MY, 2007, EUR J INTERN MED, V18, P609, DOI 10.1016/j.ejim.2007.03.006
   Chojkier M, 2003, J HEPATOL, V39, P437, DOI 10.1016/S0168-8278(03)00231-9
   Czauderna P, 2000, EUR J PEDIATR SURG, V10, P300, DOI 10.1055/s-2008-1072380
   Dai Hui-Fen, 2006, Hepatobiliary Pancreat Dis Int, V5, P406
   DeLeve LD, 1999, HEPATOLOGY, V29, P1779, DOI 10.1002/hep.510290615
   DeLeve LD, 2002, SEMIN LIVER DIS, V22, P27, DOI 10.1055/s-2002-23204
   EPSTEIN RB, 1992, TRANSPLANTATION, V54, P12, DOI 10.1097/00007890-199207000-00002
   GAO XS, 2006, CHIN J PRACT MED, V5, P391
   Kolettis Theofilos, 2007, Hellenic J Cardiol, V48, P206
   Maruyama H, 2007, CIRC J, V71, P138, DOI 10.1253/circj.71.138
   Mckoy JM, 2007, LEUKEMIA RES, V31, P599, DOI 10.1016/j.leukres.2006.07.005
   O'Boyle KR, 2003, MED ONCOL, V20, P379, DOI 10.1385/MO:20:4:379
   Perazzo J, 1999, HEPATO-GASTROENTEROL, V46, P432
   SHULMAN HM, 1987, AM J PATHOL, V126, P114
   SHULMAN HM, 1994, HEPATOLOGY, V19, P1171, DOI 10.1016/0270-9139(94)90864-8
   Smith LH, 2006, BLOOD, V107, P132, DOI 10.1182/blood-2005-07-2681
   Wadleigh M, 2003, CURR OPIN HEMATOL, V10, P451, DOI 10.1097/00062752-200311000-00010
   Wadleigh M, 2003, BLOOD, V102, P1578, DOI 10.1182/blood-2003-01-0255
NR 19
TC 10
Z9 12
U1 64
U2 74
PU ZHEJIANG UNIV SCH MEDICINE
PI HANGZHOU
PA FIRST AFFILIATED HOSPITAL, 79 QINGCHUN RD, HANGZHOU, 310003, PEOPLES R
   CHINA
SN 1499-3872
EI 2352-9377
J9 HEPATOB PANCREAT DIS
JI Hepatob. Pancreatic. Dis. Int.
PD AUG
PY 2008
VL 7
IS 4
BP 395
EP 400
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 335TA
UT WOS:000258312300008
PM 18693175
DA 2018-12-27
ER

PT J
AU Kikuno, N
   Shiina, H
   Urakami, S
   Kawamoto, K
   Hirata, H
   Tanaka, Y
   Majid, S
   Igawa, M
   Dahiya, R
AF Kikuno, Nobuyuki
   Shiina, Hiroaki
   Urakami, Shinji
   Kawamoto, Ken
   Hirata, Hiroshi
   Tanaka, Yuichiro
   Majid, Shahana
   Igawa, Mikio
   Dahiya, Rajvir
TI RETRACTED: Genistein mediated histone acetylation and demethylation
   activates tumor suppressor genes in prostate cancer cells (Retracted
   article. See vol. 141, pg. 1492, 2017)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE genistein; prostate cancer; tumor suppressor gene
ID NF-KAPPA-B; SIGNALING PATHWAY; FACULTATIVE HETEROCHROMATIN;
   PROTEIN-KINASE; EXPRESSION; SIRT1; METHYLATION; APOPTOSIS;
   TRANSCRIPTION; CYLD
AB Genistein is a phytoestrogen that has been reported to suppress the AKT signaling pathway in several malignancies. However, the molecular mechanism of genistein action is not known. We tested the hypothesis that genistein activates expression of several aberrantly silenced tumor suppressor genes (TSGs) that have unmethylated promoters such as PTEN, CYLD, p53 and FOX03a. We report here that genistein activates TSGs through remodeling of the heterochromatic domains at promoters in prostate cancer cells by modulating histone H3-Lysine 9 (H3-K9) methylation and deacetylation. Genistein activation involved demethylation and acetylation of H3-K9 at the PTEN and the CYLD promoter, while acetylation of H3-K9 at the p53 and the FOX03a promoter occurred through reduction of endogenous SIRT1 activity. There was a decrease of SIRT1 expression and accumulation of SIRT1 in the cytoplasm from the nucleus. Increased expression of these TSGs was also reciprocally related to attenuation of phosphorylated-AKT and NF-kappa B binding activity in prostate cancer cells. This is the first report describing a novel epigenetic pathway that activates TSGs by modulating either histone H3-Lysine 9 (H3-K9) methylation or deacetylation at gene promoters leading to inhibition of the AKT signaling pathway. These findings strengthen the understanding of how genistein may be chemoprotective in prostate cancer. (C) 2008 Wiley-Liss, Inc.
C1 [Dahiya, Rajvir] Vet Affairs Med Ctr, Dept Urol, Urol Res Ctr 112F, San Francisco, CA 94121 USA.
   [Kikuno, Nobuyuki; Kawamoto, Ken; Hirata, Hiroshi; Tanaka, Yuichiro; Majid, Shahana; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94121 USA.
   [Shiina, Hiroaki; Urakami, Shinji; Igawa, Mikio] Shimane Univ, Sch Med, Dept Urol, Izumo, Shimane, Japan.
RP Dahiya, R (reprint author), Vet Affairs Med Ctr, Dept Urol, Urol Res Ctr 112F, 4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
FU NCI NIH HHS [R01CA111470]; NIDDK NIH HHS [T32DK007790]
CR Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9
   Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753
   Badia E, 2000, CANCER RES, V60, P4130
   Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006
   Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787
   Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200
   BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811
   Buck SW, 2004, J LEUKOCYTE BIOL, V75, P939, DOI 10.1189/jlb.0903424
   Cao F, 2006, BIOMED ENVIRON SCI, V19, P35
   Chen F, 2004, CANCER RES, V64, P8135, DOI 10.1158/0008-5472.CAN-04-2096
   Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2
   Day JK, 2002, J NUTR, V132, p2419S, DOI 10.1093/jn/132.8.2419S
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000
   Fu MF, 2006, MOL CELL BIOL, V26, P8122, DOI 10.1128/MCB.00289-06
   Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1
   Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0
   Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200
   HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5
   Jono H, 2004, J BIOL CHEM, V279, P36171, DOI 10.1074/jbc.M406638200
   Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802
   Koyama Y, 2000, BLOOD, V96, P1490
   Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383
   Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103
   Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010
   Li YW, 2005, CANCER RES, V65, P6934, DOI 10.1158/0008-5472.CAN-04-4604
   Li YW, 2002, CLIN CANCER RES, V8, P2369
   Lim CS, 2006, MED HYPOTHESES, V67, P341, DOI 10.1016/j.mehy.2006.01.050
   Lu T, 2004, P NATL ACAD SCI USA, V101, P7112, DOI 10.1073/pnas.0402048101
   Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4
   Lynch RL, 2005, MOL CANCER RES, V3, P163, DOI 10.1158/1541-7786.MCR-04-0163
   Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843
   Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033
   Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6
   Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353
   Nakashima H, 2006, CANCER RES, V66, P7041, DOI 10.1158/0008-5472.CAN-05-4588
   Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6
   Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Reiley W, 2004, J BIOL CHEM, V279, P55161, DOI 10.1074/jbc.M411049200
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Smirnoff P, 1999, ONCOL RES, V11, P255
   Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803
   Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809
   ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K
   Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246
   Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Zava DT, 1997, NUTR CANCER, V27, P31, DOI 10.1080/01635589709514498
   Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041
NR 55
TC 157
Z9 165
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD AUG 1
PY 2008
VL 123
IS 3
BP 552
EP 560
DI 10.1002/ijc.23590
PG 9
WC Oncology
SC Oncology
GA 319NY
UT WOS:000257171900008
PM 18431742
DA 2018-12-27
ER

PT J
AU Kuklo, TR
   Groth, AT
   Anderson, RC
   Frisch, HM
   Islinger, RB
AF Kuklo, T. R.
   Groth, A. T.
   Anderson, R. C.
   Frisch, H. M.
   Islinger, R. B.
TI RETRACTED: Recombinant human bone morphogenetic protein-2 for grade III
   open segmental tibial fractures from combat injuries in Iraq (Retracted
   Article. See vol 91B, pg 285, 2009)
SO JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME
LA English
DT Article; Retracted Publication
ID SPINAL-FUSION; EXTERNAL FIXATION; WAR WOUNDS; GULF-WAR; MANAGEMENT;
   COLLAGEN; RHBMP-2; CANINE; MODEL; UNION
AB This is a retrospective consecutive case series of 138 Gustillo-Anderson type IIIB and IIIC segmental tibial fractures treated at Walter Reed Army Medical Center in soldiers injured in Iraq between March 2003 and March 2005. Five patients with a head injury and four who were lost to follow-up were excluded. The patients were treated definitively with either a ringed external fixator or a reamed intramedullary nail, evaluated in terms of supplementary bone grafting with either autogenous bone (group 1, 67 patients) or recombinant human bone morphogenetic protein-2 at 1.50 mg/ml applied to an absorbable collagen sponge (group 2, 62 patients).
   The mechanism of injury, defect size and classification, associated injuries, presence of infection, preliminary treatment/fixation, number of procedures before definitive management, time to and details of definitive management, subsequent infection, re-operation, smoking history and other complications were noted. Radiographs were assessed for union, delayed union or nonunion by an independent investigator.
   All the patients were male. Their mean age was 26.6 years (20 to 42) and the mean follow-up was for 15.6 months (12 to 32). Group 2 had a slightly higher profile of concomitant injuries and a slightly worse fracture classification, but these were not significant.
   The rate of union was 76% (51 of 67) for group 1 and 92% for group 2 (57 of 62; p = 0.015). There was also a higher rate of subsequent infection in group 1 (14.9%) compared with group 2 (3.2%; p = 0.001) and a higher rate of re-operation (28%) in group 1 (p = 0.003). There were no observed hypersensitivity reactions to the recombinant human bone morphogenetic protein-2 implant.
C1 [Kuklo, T. R.; Groth, A. T.; Anderson, R. C.; Frisch, H. M.; Islinger, R. B.] Walter Reed Army Med Ctr, Washington, DC 20307 USA.
RP Kuklo, TR (reprint author), One Barnes Jewish Hosp Pl, Suite 11300 W Pavil, St Louis, MO 63110 USA.
EM kuklot@wustl.edu
CR Alberts KA, 1999, INJURY, V30, P519, DOI 10.1016/S0020-1383(99)00143-6
   BAJEC J, 1993, INJURY, V24, P517, DOI 10.1016/0020-1383(93)90026-3
   Bartlett C S, 2000, J Am Acad Orthop Surg, V8, P21
   BATINICA J, 1995, MIL MED, V160, P124
   BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001
   BONE LB, 1994, J ORTHOP TRAUMA, V8, P45, DOI 10.1097/00005131-199402000-00010
   Bosse MJ, 2001, J BONE JOINT SURG AM, V83A, P3, DOI 10.2106/00004623-200101000-00002
   BOWYER GW, 1995, ANN ROY COLL SURG, V77, P131
   BURKLE FM, 1994, ANN EMERG MED, V23, P755, DOI 10.1016/S0196-0644(94)70311-6
   CAUDLE RJ, 1987, J BONE JOINT SURG AM, V69A, P801, DOI 10.2106/00004623-198769060-00002
   Covey DC, 2000, J ORTHOP TRAUMA, V14, P278, DOI 10.1097/00005131-200005000-00010
   David SM, 1999, SPINE, V24, P1973, DOI 10.1097/00007632-199910010-00002
   EDWARDS CC, 1988, CLIN ORTHOP RELAT R, P98
   Fischgrund JS, 1997, J SPINAL DISORD, V10, P467
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623-200212000-00001
   Groenveld HHJ, 1999, J CLIN PERIODONTOL, V26, P841, DOI 10.1034/j.1600-051X.1997.00841.x
   GUSTILO RB, 1984, J TRAUMA, V24, P742, DOI 10.1097/00005373-198408000-00009
   GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004
   HANSEN ST, 1987, J BONE JOINT SURG AM, V69A, P799, DOI 10.2106/00004623-198769060-00001
   Hecht BP, 1999, SPINE, V24, P629, DOI 10.1097/00007632-199904010-00004
   Hollinger JO, 1998, J BIOMED MATER RES, V43, P356, DOI 10.1002/(SICI)1097-4636(199824)43:4<356::AID-JBM3>3.0.CO;2-7
   Howell TH, 1997, INT J PERIODONT REST, V17, P125
   HYDER PR, 1992, J PERIODONTOL, V63, P182, DOI 10.1902/jop.1992.63.3.182
   Islinger RB, 2000, MIL MED, V165, P463
   JACKSON DS, 1983, ANN ROY COLL SURG, V65, P281
   Jevtic M, 1996, J TRAUMA, V40, pS173, DOI 10.1097/00005373-199603001-00038
   Lange RH, 1989, CLIN ORTHOP RELAT R, V243, P92
   Naique SB, 2006, J BONE JOINT SURG BR, V88B, P351, DOI 10.1302/0301-620X.88B3.17120
   RIEMER BL, 1995, J ORTHOP TRAUMA, V9, P66, DOI 10.1097/00005131-199502000-00011
   Rowley DI, 1996, J BONE JOINT SURG BR, V78B, P706
   SANDERS R, 1994, J ORTHOP TRAUMA, V8, P504, DOI 10.1097/00005131-199412000-00008
   Shepherd LE, 1998, CLIN ORTHOP RELAT R, P90
   SINGER RW, 1995, CLIN ORTHOP RELAT R, V315, P114
   STEGEMANN P, 1995, J ORTHOP TRAUMA, V9, P117, DOI 10.1097/00005131-199504000-00005
   SUGURDSSON TJ, 1996, INT J PERIODONT REST, V16, P524
   Tarnuzzer Roy W., 1996, Wound Repair and Regeneration, V4, P321, DOI 10.1046/j.1524-475X.1996.40307.x
   TORNETTA P, 1994, J BONE JOINT SURG BR, V76B, P13
   Uhorchak JM, 1995, TECH ORTHOP, V10, P176
   Uludag H, 1999, ANN NY ACAD SCI, V875, P369, DOI 10.1111/j.1749-6632.1999.tb08519.x
NR 39
TC 20
Z9 20
U1 2
U2 9
PU BRITISH EDITORIAL SOC BONE JOINT SURGERY
PI LONDON
PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND
SN 0301-620X
EI 2044-5377
J9 J BONE JOINT SURG BR
JI J. Bone Joint Surg.-Br. Vol.
PD AUG
PY 2008
VL 90B
IS 8
BP 1068
EP 1072
DI 10.1302/0301-620X.90B8.20349
PG 5
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 332QK
UT WOS:000258098000016
PM 18669965
OA Bronze
DA 2018-12-27
ER

PT J
AU Khanna, N
   Inkster, T
AF Khanna, N.
   Inkster, T.
TI RETRACTED: Meticillin-resistant Staphylococcus aureus hepatic abscess
   treated with tigecycline (Retracted Article. See vol 61, pg 1072, 2008)
SO JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article; Retracted Publication
ID VANCOMYCIN; PNEUMONIA
AB Pyogenic liver abscesses are uncommon in clinical practice and are usually polymicrobial in nature, with members of the Enterobacteriacae family often implicated. This report describes the use of tigecycline to treat a liver abscess caused by meticillin-resistant Staphylococcus aureus, which was refractory to therapy with standard antimicrobials.
C1 [Khanna, N.; Inkster, T.] Univ Glasgow, Western Infirm, Dept Microbiol, Glasgow G11 6NT, Lanark, Scotland.
RP Khanna, N (reprint author), Univ Glasgow, Western Infirm, Dept Microbiol, Dumbarton Rd, Glasgow G11 6NT, Lanark, Scotland.
EM niti12@hotmail.com
CR Chi Chih-Yu, 2004, J Microbiol Immunol Infect, V37, P124
   JOHANNSEN EC, 2000, PRINCIPLES PRACTICE, pCH69
   LEVISON MA, 1991, AM J SURG, V161, P593
   MANACO M, 2007, INT J LAB HEM, V29, P474
   Munoz-Price LS, 2006, SCAND J INFECT DIS, V38, P1081, DOI 10.1080/00365540600833135
   Pea F, 2008, CLIN PHARMACOKINET, V47, P147, DOI 10.2165/00003088-200847030-00001
   Saner FH, 2006, LIVER TRANSPLANT, V12, P1689, DOI 10.1002/lt.20885
   Smith BM, 2007, SURGERY, V141, P110, DOI 10.1016/j.surg.2006.05.010
   Soriano A, 2008, CLIN INFECT DIS, V46, P193, DOI 10.1086/524667
   Tan NWH, 2005, ANN ACAD MED SINGAP, V34, P558
NR 10
TC 11
Z9 11
U1 3
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0021-9746
EI 1472-4146
J9 J CLIN PATHOL
JI J. Clin. Pathol.
PD AUG
PY 2008
VL 61
IS 8
BP 967
EP 968
DI 10.1136/jcp.2008.056689
PG 2
WC Pathology
SC Pathology
GA 331BC
UT WOS:000257986700018
PM 18495793
DA 2018-12-27
ER

PT J
AU Zou, SM
   Jiang, XY
AF Zou, S. M.
   Jiang, X. Y.
TI RETRACTED: Gene duplication and functional evolution of Hox genes in
   fishes (Retracted article. See vol. 77, pg. 778, 2010)
SO JOURNAL OF FISH BIOLOGY
LA English
DT Review; Retracted Publication
DE evolution; gene duplication; gene function; Hox clusters; teleosts
ID VERTEBRATE GENOME EVOLUTION; RAY-FINNED FISH; CONSERVED REGULATORY
   ELEMENTS; TROUT ONCORHYNCHUS-MYKISS; BLUNT SNOUT BREAM;
   MEGALOBRAMA-AMBLYCEPHALA; CLUSTER DUPLICATIONS; MOLECULAR EVOLUTION;
   NONCODING SEQUENCES; TELEOST FISHES
AB With their power to shape animal morphology, few genes have captured the imagination of biologists as much as the evolutionarily conserved members of the Hox clusters. Hox genes encode transcription factors that play a key role in specifying the body plan in metazoans and are therefore essential in explaining patterns of evolutionary diversity. While each Hox cluster contains the same genes among the different mammalian species, this does not happen in ray-finned fish, in which both the number and organization of Hox genes and even Hox clusters are variable. Teleost fishes provide the first unambiguous support for ancient whole-genome duplication (third round) in an animal lineage. The number of genes differs in each cluster as a result of increased freedom to mutate after duplication. This has also allowed them to diverge and to adopt novel developmental roles. In this review, the authors have firstly focused on broadly outlining the duplication of Hox genes in fishes and discussing how comparative genomics is elucidating the molecular changes associated with the evolution of Hox genes expression and developmental function in the teleost fishes. Additional related research aspects, such as imaging of roles of microRNAs, chromatin regulation and evolutionary findings are also discussed. (C) 2008 The Authors Journal compilation (C) 2008 The Fisheries Society of the British Isles.
C1 [Zou, S. M.; Jiang, X. Y.] Shanghai Fisheries Univ, Minist Agr, Key Lab Aquat Genet Resources & Aquacultural Ecos, Shanghai 200090, Peoples R China.
RP Zou, SM (reprint author), Shanghai Fisheries Univ, Minist Agr, Key Lab Aquat Genet Resources & Aquacultural Ecos, Jungong Rd 334, Shanghai 200090, Peoples R China.
EM smzou@shfu.edu.cn
CR Aboobaker AA, 2003, CURR BIOL, V13, P37, DOI 10.1016/S0960-9822(02)01399-4
   Allendorf F.W., 1984, P1
   ALLENDORF FW, 1978, NATURE, V272, P76, DOI 10.1038/272076a0
   Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711
   Amores A, 2004, GENOME RES, V14, P1, DOI 10.1101/gr.1717804
   Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104
   APARICIO S, 1995, P NATL ACAD SCI USA, V92, P1684, DOI 10.1073/pnas.92.5.1684
   Arthur W, 2002, NATURE, V415, P757
   Bailey WJ, 1997, MOL BIOL EVOL, V14, P843, DOI 10.1093/oxfordjournals.molbev.a025825
   Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119
   Bernardi G, 1995, ANNU REV GENET, V29, P445, DOI 10.1146/annurev.ge.29.120195.002305
   Boffelli D, 2004, NAT REV GENET, V5, P456, DOI 10.1038/nrg1350
   Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6
   Bruce AEE, 2001, EVOL DEV, V3, P127, DOI 10.1046/j.1525-142x.2001.003003127.x
   Brunet FG, 2006, MOL BIOL EVOL, V23, P1808, DOI 10.1093/molbev/mls049
   Carroll SB, 2000, CELL, V101, P577, DOI 10.1016/S0092-8674(00)80868-5
   CARROLL SB, 2001, DNA DIVERSITY MOL GE
   Chiu CH, 2000, MOL PHYLOGENET EVOL, V17, P305, DOI 10.1006/mpev.2000.0837
   Chiu CH, 2004, GENOME RES, V14, P11, DOI 10.1101/gr.1712904
   Chiu CH, 2002, P NATL ACAD SCI USA, V99, P5492, DOI 10.1073/pnas.052709899
   Cho SJ, 2006, DEV GENES EVOL, V216, P347, DOI 10.1007/s00427-006-0058-7
   Christoffels A, 2004, MOL BIOL EVOL, V21, P1146, DOI 10.1093/molbev/msh114
   Corredor-Adamez M, 2005, EVOL DEV, V7, P362, DOI 10.1111/j.1525-142X.2005.05042.x
   Crow KD, 2006, MOL BIOL EVOL, V23, P121, DOI 10.1093/molbev/msj020
   Daftary GS, 2006, ENDOCR REV, V27, P331, DOI 10.1210/er.2005-0018
   Dehal P, 2005, PLOS BIOL, V3, P1700, DOI 10.1371/journal.pbio.0030314
   di Roseto GD, 2002, GENE, V295, P311, DOI 10.1016/S0378-1119(02)00734-5
   Duboule D, 2007, DEVELOPMENT, V134, P2549, DOI 10.1242/dev.001065
   Edelman GM, 2000, P NATL ACAD SCI USA, V97, P3038, DOI 10.1073/pnas.040569897
   Fares MA, 2003, MOL BIOL EVOL, V20, P2104, DOI 10.1093/molbev/msg222
   FERRIS SD, 1977, NATURE, V265, P258, DOI 10.1038/265258a0
   Fisher RA, 1935, AM NAT, V69, P446, DOI 10.1086/280618
   Force A, 2002, J EXP ZOOL, V294, P30, DOI 10.1002/jez.10091
   Force A, 1999, GENETICS, V151, P1531
   Fried C, 2003, J EXP ZOOL PART B, V299B, P18, DOI 10.1002/jez.b.00037
   GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0
   GEHRING WJ, 1993, GENE, V135, P215, DOI 10.1016/0378-1119(93)90068-E
   Geraudie J, 2003, DEV GENES EVOL, V213, P182, DOI 10.1007/s00427-003-0307-y
   Gomez-Skarmeta JL, 2006, DEV DYNAM, V235, P870, DOI 10.1002/dvdy.20659
   Halanych KM, 2001, AM ZOOL, V41, P629, DOI 10.1668/0003-1569(2001)041[0629:ABROMP]2.0.CO;2
   Haldane JBS, 1933, AM NAT, V67, P5, DOI 10.1086/280465
   Hale ME, 2004, J NEUROSCI, V24, P3070, DOI 10.1523/JNEUROSCI.5624-03.2004
   Hardison RC, 2000, TRENDS GENET, V16, P369, DOI 10.1016/S0168-9525(00)02081-3
   Hoegg S, 2005, TRENDS GENET, V21, P421, DOI 10.1016/j.tig.2005.06.004
   Hoegg S, 2004, J MOL EVOL, V59, P190, DOI 10.1007/s00239-004-2613-z
   Holland PWH, 1997, CURR BIOL, V7, pR570, DOI 10.1016/S0960-9822(06)00284-3
   Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034
   HUGHES AL, 1999, ADAPTIVE EVOLUTION G
   Hughes CL, 2002, EVOL DEV, V4, P459, DOI 10.1046/j.1525-142X.2002.02034.x
   Hurley IA, 2007, P ROY SOC B-BIOL SCI, V274, P489, DOI 10.1098/rspb.2006.3749
   Iimura T, 2007, DEV GROWTH DIFFER, V49, P265, DOI 10.1111/j.1440-169x.2007.00928.x
   Irvine SQ, 2002, J EXP ZOOL, V294, P47, DOI 10.1002/jez.10090
   Jaillon O, 2004, NATURE, V431, P946, DOI 10.1038/nature03025
   Jozefowicz Chris, 2003, Journal of Structural and Functional Genomics, V3, P185, DOI 10.1023/A:1022690723661
   KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426
   Kasahara M, 2007, NATURE, V447, P714, DOI 10.1038/nature05846
   Kim CB, 2000, P NATL ACAD SCI USA, V97, P1655, DOI 10.1073/pnas.030539697
   Koh EGL, 2003, P NATL ACAD SCI USA, V100, P1084, DOI 10.1073/pnas.0237317100
   KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9
   Kurosawa G, 2006, GENE, V370, P75, DOI 10.1016/j.gene.2005.11.015
   Le Comber SC, 2004, BIOL J LINN SOC, V82, P431
   Ledje C, 2002, J EXP ZOOL, V294, P107, DOI 10.1002/jez.10152
   Lee AP, 2006, P NATL ACAD SCI USA, V103, P6994, DOI 10.1073/pnas.0601492103
   Lemons D, 2006, SCIENCE, V313, P1918, DOI 10.1126/science.1132040
   Lewis EB, 2003, CURR BIOL, V13, pR587, DOI 10.1016/S0960-9822(03)00520-7
   Long S, 2001, EVOL DEV, V3, P302, DOI 10.1046/j.1525-142X.2001.01036.x
   Longhurst TJ, 1999, J EXP ZOOL, V285, P140, DOI 10.1002/(SICI)1097-010X(19990815)285:2<140::AID-JEZ6>3.0.CO;2-V
   Lufkin T, 1996, CURR OPIN GENET DEV, V6, P575, DOI 10.1016/S0959-437X(96)80086-4
   Luo J, 2007, J EXP ZOOL PART B, V308B, P250, DOI 10.1002/jez.b.21144
   Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151
   Lynch M, 2000, GENETICS, V154, P459
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Malaga-Trillo E, 2001, AM ZOOL, V41, P676, DOI 10.1668/0003-1569(2001)041[0676:GDAAEO]2.0.CO;2
   Mannaert A, 2006, MOL PHYLOGENET EVOL, V38, P449, DOI 10.1016/j.ympev.2005.08.012
   Mannervik M, 1999, BIOESSAYS, V21, P267, DOI 10.1002/(SICI)1521-1878(199904)21:4<267::AID-BIES1>3.0.CO;2-C
   Mansfield JH, 2004, NAT GENET, V36, P1079, DOI 10.1038/ng1421
   McClintock JM, 2002, DEVELOPMENT, V129, P2339
   McClintock JM, 2001, DEVELOPMENT, V128, P2471
   MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N
   Messler W, 1997, NATURE, V385, P151, DOI 10.1038/385151a0
   Meyer A, 1998, NATURE, V391, P225, DOI 10.1038/34530
   Meyer A, 2005, BIOESSAYS, V27, P937, DOI 10.1002/bies.20293
   Moghadam HK, 2005, J MOL EVOL, V61, P804, DOI 10.1007/s00239-004-0230-5
   Moghadam HK, 2005, J MOL EVOL, V61, P636, DOI 10.1007/s00239-004-0338-7
   Muller F, 2002, BIOESSAYS, V24, P564, DOI 10.1002/bies.10096
   Nelson J. S., 2006, FISHES WORLD
   Ohno S., 1970, EVOLUTION GENE DUPLI
   Otto SP, 2000, ANNU REV GENET, V34, P401, DOI 10.1146/annurev.genet.34.1.401
   PABIC PL, 2007, DEV GENES EVOL, V217, P749
   Pearson JC, 2005, NAT REV GENET, V6, P893, DOI 10.1038/nrg1726
   Postlethwait JH, 2000, GENOME RES, V10, P1890, DOI 10.1101/gr.164800
   Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345
   Powers TP, 2004, CURR GENOMICS, V5, P459, DOI 10.2174/1389202043349048
   Powers TP, 2004, CURR BIOL, V14, pR183, DOI 10.1016/j.cub.2004.02.015
   Pradel J, 1998, INT J DEV BIOL, V42, P417
   Prince VE, 2002, NAT REV GENET, V3, P827, DOI 10.1038/nrg928
   Prohaska SJ, 2004, THEOR BIOSCI, V123, P89, DOI 10.1016/j.thbio.2004.03.004
   Raff RA, 2000, NAT REV GENET, V1, P74, DOI 10.1038/35049594
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rohrschneider MR, 2007, DEV BIOL, V309, P358, DOI 10.1016/j.ydbio.2007.06.012
   RUDDLE FH, 1994, ANNU REV GENET, V28, P423, DOI 10.1146/annurev.ge.28.120194.002231
   Santini S, 2005, GENE, V346, P51, DOI 10.1016/j.gene.2004.10.027
   Santini S, 2003, GENOME RES, V13, P1111, DOI 10.1101/gr.700503
   Scannell DR, 2006, NATURE, V440, P341, DOI 10.1038/nature04562
   Scemama JL, 2006, GENE EXPR PATTERNS, V6, P843, DOI 10.1016/j.modgep.2006.02.004
   Seo HC, 2004, NATURE, V431, P67, DOI 10.1038/nature02709
   Sharman AC, 1998, INT J DEV BIOL, V42, P617
   Shin JT, 2005, NUCLEIC ACIDS RES, V33, P5437, DOI 10.1093/nar/gki853
   SORDINO P, 1995, NATURE, V375, P678, DOI 10.1038/375678a0
   Sordino P, 1996, MECH DEVELOP, V59, P165, DOI 10.1016/0925-4773(96)00587-4
   Spagnuolo A, 2003, GENE, V309, P71, DOI 10.1016/S0378-1119(03)00488-8
   Stadler PF, 2004, MOL PHYLOGENET EVOL, V32, P686, DOI 10.1016/j.ympev.2004.03.015
   Steinke D, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-20
   Tanzer A, 2005, J EXP ZOOL PART B, V304B, P75, DOI 10.1002/jez.b.21021
   Tautz D, 2000, CURR OPIN GENET DEV, V10, P575, DOI 10.1016/S0959-437X(00)00130-1
   Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303
   THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D
   Thummel R, 2004, DEV BIOL, V274, P318, DOI 10.1016/j.ydbio.2004.07.018
   vanderHoeven F, 1996, MECH DEVELOP, V54, P9, DOI 10.1016/0925-4773(95)00455-6
   Venkatesh B, 2007, PLOS BIOL, V5, P932, DOI 10.1371/journal.pbio.0050101
   Venkatesh B, 2006, SCIENCE, V314, P1892, DOI 10.1126/science.1130708
   VonAllmen G, 1996, NATURE, V380, P116, DOI 10.1038/380116a0
   Wagner GP, 2005, J MOL EVOL, V60, P665, DOI 10.1007/s00239-004-0252-z
   Wagner GP, 2003, P NATL ACAD SCI USA, V100, P14603, DOI 10.1073/pnas.2536656100
   WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048
   Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519
   Wolfe KH, 2001, NAT REV GENET, V2, P333, DOI 10.1038/35072009
   Woltering JM, 2006, NAT GENET, V38, P601, DOI 10.1038/ng0606-601
   Woods IG, 2005, GENOME RES, V15, P1307, DOI 10.1101/gr.4134305
   Woolfe A, 2005, PLOS BIOL, V3, P116, DOI 10.1371/journal.pbio.0030007
   Yang L, 2004, MOL BIOL EVOL, V21, P1264, DOI 10.1093/molbev/msh121
   Yang ZH, 2005, P NATL ACAD SCI USA, V102, P3179, DOI 10.1073/pnas.0500371102
   Yang ZH, 1998, MOL BIOL EVOL, V15, P568, DOI 10.1093/oxfordjournals.molbev.a025957
   Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434
   Zakany J, 2007, CURR OPIN GENET DEV, V17, P359, DOI 10.1016/j.gde.2007.05.011
   Zardoya R, 1996, P NATL ACAD SCI USA, V93, P13036, DOI 10.1073/pnas.93.23.13036
   Zhang JZ, 2003, TRENDS ECOL EVOL, V18, P292, DOI 10.1016/S0169-5347(03)00033-8
   Zhang JZ, 1996, GENETICS, V142, P295
   Zhao YX, 2001, DEVELOPMENT, V128, P3197
   Zou SM, 2007, GENE, V400, P60, DOI 10.1016/j.gene.2007.05.021
   Zou SM, 2007, AQUACULTURE, V270, P574, DOI 10.1016/j.aquaculture.2007.05.015
   Zou SM, 2004, AQUACULTURE, V238, P155, DOI 10.1016/j.aquaculture.2004.05.020
NR 142
TC 4
Z9 4
U1 3
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-1112
EI 1095-8649
J9 J FISH BIOL
JI J. Fish Biol.
PD AUG
PY 2008
VL 73
IS 2
BP 329
EP 354
DI 10.1111/j.1095-8649.2008.01852.x
PG 26
WC Fisheries; Marine & Freshwater Biology
SC Fisheries; Marine & Freshwater Biology
GA 332HH
UT WOS:000258073600001
PM 20646134
DA 2018-12-27
ER

PT J
AU Derradj, M
   Kaci, S
AF Derradj, Mohamed
   Kaci, Salah
TI RETRACTED: Numerical study of compact shear (Mode II) type test specimen
   geometry (Retracted article. See vol. 42, pg. 539, 2009)
SO MATERIALS AND STRUCTURES
LA English
DT Article; Retracted Publication
DE shear test specimen; concrete; size effect
AB The Iosipescu shear test specimen geometry has been investigated by a number of research workers in recent years with conflicting results. The paper describes a numerical study of a compact shear test specimen, based on the Iosipescu geometry, which is proposed to investigate size effects in shear failure. A range of geometries has been studied and the extreme cases are reported. Results are presented for the largest absolute principal stresses together with a detailed study of the stresses between and around the roots of the two notches introduced in the test specimens. The results for the largest absolute principal stresses show that tensile stresses are created at the roots of the two notches. These tensile stresses may result in Mode I failure and probably account for the Mode I or mixed mode fracture observed in tests using the Iosipescu geometry. The results for the distribution of stresses between the roots of the two notches show that deep notches increase the likelihood of shear fracture prior to tensile failure. Shallow notches give a stress distribution similar to that developed in the indirect tensile test and hence tensile failure is likely to precede shear failure in such cases. Further numerical and experimental work is proposed.
C1 [Derradj, Mohamed; Kaci, Salah] Univ Mouloud Mammeri, Lab Modelisat Expt & Numer Mat & Struct Genie Civ, Tizi Ouzou 15000, Peoples R China.
RP Derradj, M (reprint author), Univ Mouloud Mammeri, Lab Modelisat Expt & Numer Mat & Struct Genie Civ, BP 17 RP, Tizi Ouzou 15000, Peoples R China.
EM derradj@yahoo.fr
CR Aliabadi MH, 2002, ENG FRACT MECH, V69, P267, DOI 10.1016/S0013-7944(01)00089-3
   BARR B, 1987, SEM RILEM INT C HOUS
   BARR B, 1986, P 3 INT S DEV FRC CO
   Barr B., 1987, FIBER REINFORCED CON, P27
   Bazant Z.P., 1985, P 2 S INT NONN MUN S
   CARPINTERI A, 1987, INTERACTION TENSILE
   INGRAFFEA ARM, 1985, P SEM SPNS JAP SOC P
   Liu K, 1985, INT J CEMENT COMPOSI, V7, P93, DOI [10.1016/0262-5075(85)90064-8, DOI 10.1016/0262-5075(85)90064-8]
   SWARTZ SE, 1987, 191 KANS STAT U COLL
NR 9
TC 4
Z9 4
U1 3
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1359-5997
J9 MATER STRUCT
JI Mater. Struct.
PD AUG
PY 2008
VL 41
IS 7
BP 1203
EP 1210
DI 10.1617/s11527-007-9318-x
PG 8
WC Construction & Building Technology; Engineering, Civil; Materials
   Science, Multidisciplinary
SC Construction & Building Technology; Engineering; Materials Science
GA 320CR
UT WOS:000257211800002
DA 2018-12-27
ER

PT J
AU Postma, DS
   Kerstjens, HAM
   ten Hacken, NHT
AF Postma, Dirkje S.
   Kerstjens, Huib A. M.
   ten Hacken, Nick H. T.
TI RETRACTED: Inhaled corticosteroids and long-acting beta-agonists in
   adult asthma: a winning combination in all? (Retracted Article. See vol
   380, pg 97, 2009)
SO NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
LA English
DT Review; Retracted Publication
DE asthma; beta-2-agonist; inhaled corticosteroids; hyperresponsiveness
ID MILD PERSISTENT ASTHMA; RANDOMIZED CONTROLLED TRIAL; DOUBLE-BLIND TRIAL;
   SINGLE INHALER; AIRWAY INFLAMMATION; RELIEVER THERAPY;
   SALMETEROL/FLUTICASONE PROPIONATE; BUDESONIDE/FORMOTEROL MAINTENANCE;
   FLUTICASONE PROPIONATE/SALMETEROL; BRONCHIAL HYPERRESPONSIVENESS
AB In the recent years, considerable insight has been gained in to the optimal management of adult asthma. Most adult patients with asthma have mild intermittent and persistent disease, and it is acknowledged that many patients do not reach full control of all symptoms and signs of asthma. Those with mild persistent asthma are usually not well controlled without inhaled corticosteroids (ICS). Studies have provided firm evidence that these patients can be well controlled when receiving ICS, especially when disease is of recent onset. This treatment should be given on a daily basis at a low dose and when providing a good response should be maintained to prevent severe exacerbations and disease deterioration. Intermittent ICS treatment at the time of an exacerbation has also been suggested as a strategy for mild persistent asthma, but it is less effective than low-dose regular treatment for most outcomes. Adding a long-acting beta-agonist (LABA) to ICS appears to be unnecessary in most of these patients for optimising control of their asthma. Patients with moderate persistent asthma can be regarded as those who are not ideally controlled on low-dose ICS alone. The combination of an ICS and LABA is preferred in these patients, irrespective of the brand of medicine, and this combination is better than doubling or even quadrupling the dose of ICS to achieve better asthma control and reduce exacerbation risks. An ICS/LABA combination in a single inhaler represents a safe, effective and convenient treatment option for the management of patients with asthma unstable on inhaled steroids alone. Ideally, once asthma is under full control, the dose of inhaled steroids should be reduced, which is possible in many patients. The duration of treatment before initiating this dose reduction has, however, not been fully established. One of the combinations available to treat asthma (budesonide and formoterol) has also been assessed as both maintenance and rescue therapy with a further reduction in the risk for a severe exacerbation. Clinical effectiveness in the real world now has to be established, since this approach likely improves compliance with regular maintenance therapy.
C1 [Postma, Dirkje S.; Kerstjens, Huib A. M.; ten Hacken, Nick H. T.] Univ Groningen, Dept Pulmonol, Univ Med Ctr, NL-9713 GZ Groningen, Netherlands.
RP Postma, DS (reprint author), Univ Groningen, Dept Pulmonol, Univ Med Ctr, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM d.s.postma@int.umcg.nl
CR Aalbers R, 2004, CURR MED RES OPIN, V20, P225, DOI 10.1185/030079903125002928
   Adams NP, 2006, RESP MED, V100, P1297, DOI 10.1016/j.rmed.2006.04.015
   Barnes PJ, 2006, EUR J PHARMACOL, V533, P2, DOI 10.1016/j.ejphar.2005.12.052
   Barnes PJ, 2001, ALLERGY, V56, P928, DOI 10.1034/j.1398-9995.2001.00001.x
   Barnes PJ, 1996, BRIT J CLIN PHARMACO, V42, P3, DOI 10.1046/j.1365-2125.1996.03721.x
   Bateman ED, 2006, J ALLERGY CLIN IMMUN, V117, P563, DOI 10.1016/j.jaci.2005.11.036
   Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI [10.1164/rccm.200401-033OC, 10.1164/rccm.2408006]
   Bateman ED, 2007, J ASTHMA, V44, P667, DOI 10.1080/02770900701554821
   Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429
   Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552
   Bousquet J, 2007, RESP MED, V101, P2437, DOI 10.1016/j.rmed.2007.07.014
   CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034
   Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271
   Douma WR, 2002, CHEST, V121, P151, DOI 10.1378/chest.121.1.151
   FitzGerald J Mark, 2003, Can Respir J, V10, P427
   FitzGerald JM, 2005, CLIN THER, V27, P393, DOI 10.1016/j.clinthera.2005.03.006
   Fujimoto K, 2006, INTERNAL MED, V45, P843, DOI 10.2169/internalmedicine.45.1749
   Gibson PG, 2007, J ALLERGY CLIN IMMUN, V119, P344, DOI 10.1016/j.jaci.2006.10.043
   *GLOB IN ASTHM, 2004, NIH PUBL
   Green RH, 2006, EUR RESPIR J, V27, P1144, DOI 10.1183/09031936.06.00102605
   Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5
   Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875
   GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3
   Ind PW, 2004, RESP MED, V98, P464, DOI 10.1016/j.rmed.2003.07.010
   KERSTJENS HAM, 1993, EUR RESPIR J, V6, P868
   KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003
   KERSTJENS HAM, 1995, AM J RESP CRIT CARE, V151, P360, DOI 10.1164/ajrccm.151.2.7842192
   Kips JC, 2000, AM J RESP CRIT CARE, V161, P996, DOI 10.1164/ajrccm.161.3.9812056
   Koopmans JG, 2005, J ALLERGY CLIN IMMUN, V116, P1007, DOI 10.1016/j.jaci.2005.08.016
   Kuna P, 2007, INT J CLIN PRACT, V61, P725, DOI 10.1111/j.1742-1241.2007.01338.x
   Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703
   Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583
   Lemiere Catherine, 2004, Can Respir J, V11 Suppl A, p9A
   Li X, 1999, AM J RESP CRIT CARE, V160, P1493, DOI 10.1164/ajrccm.160.5.9811052
   Lundborg M, 2006, CURR MED RES OPIN, V22, P809, DOI 10.1185/030079906X100212
   Maneechotesuwan K, 2005, CHEST, V128, P1936, DOI 10.1378/chest.128.4.1936
   Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035
   Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x
   Miller-Larsson A, 2006, CURR PHARM DESIGN, V12, P3261, DOI 10.2174/138161206778194187
   Nelson Harold S, 2006, Prim Care Respir J, V15, P271, DOI 10.1016/j.pcrj.2006.08.006
   Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P1088, DOI 10.1067/mai.2000.110920
   Nelson HS, 2003, J ALLERGY CLIN IMMUN, V112, P29, DOI 10.1067/mai.2003.1558
   Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15
   *NHLBI, 2002, GLOB IN ASTHM GLOB S
   O'Byrne PM, 2006, LANCET, V368, P794, DOI 10.1016/S0140-6736(06)69289-1
   O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102
   O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC
   Oppenheimer J, 2008, CURR OPIN PULM MED, V14, P64, DOI 10.1097/MCP.0b013e3282f1980b
   Panettieri Reynold A Jr, 2004, Proc Am Thorac Soc, V1, P231, DOI 10.1513/pats.200402-021MS
   Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001
   Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7
   Pedersen SE, 2007, J ALLERGY CLIN IMMUN, V120, P1036, DOI 10.1016/j.jaci.2007.07.016
   Pohl WR, 2006, RESP MED, V100, P551, DOI 10.1016/j.rmed.2005.05.019
   Price DB, 2007, RESP RES, V8, DOI 10.1187/1465-9921-8-46
   Rabe KF, 2006, CHEST, V129, P246, DOI 10.1378/chest.129.2.246
   Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2
   Reid DW, 2003, EUR RESPIR J, V21, P994, DOI 10.1183/09031936.03.00109702
   Ringdal N, 1998, RESP MED, V92, P1017, DOI 10.1016/S0954-6111(98)90348-1
   Ringdal N, 2003, RESP MED, V97, P234, DOI 10.1053/rmed.2003.1436
   Salpeter SR, 2006, ANN INTERN MED, V144, P904, DOI 10.7326/0003-4819-144-12-200606200-00126
   Scicchitano R, 2004, CURR MED RES OPIN, V20, P1403, DOI 10.1085/030079904x2051
   Shrewsbury S, 2000, BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368
   Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100
   ten Hacken NHT, 1998, EUR RESPIR J, V12, P546, DOI 10.1183/09031936.98.12030546
   van den Boom P. P. G., 1998, LEJEUNIA, V158, P1
   Vogelmeier C, 2005, EUR RESPIR J, V26, P819, DOI 10.1183/09031936.05.00028305
   Wallin A, 2003, J ALLERGY CLIN IMMUN, V112, P72, DOI 10.1067/mai.2003.1518
   Woodcock Ashley A, 2007, Prim Care Respir J, V16, P155, DOI 10.3132/pcrj.2007.00043
   Zetterstrom O, 2001, EUR RESPIR J, V18, P262, DOI 10.1183/09031936.01.00065801
NR 69
TC 15
Z9 15
U1 3
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0028-1298
EI 1432-1912
J9 N-S ARCH PHARMACOL
JI Naunyn-Schmiedebergs Arch. Pharmacol.
PD AUG
PY 2008
VL 378
IS 2
BP 203
EP 215
DI 10.1007/s00210-008-0302-y
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 324BB
UT WOS:000257491500005
PM 18500509
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Joly, JF
   Stapel, DA
   Lindenberg, SM
AF Joly, Janneke F.
   Stapel, Diederik A.
   Lindenberg, Siegwart M.
TI RETRACTED: Silence and table manners: When environments activate norms
   (Retracted article. See vol. 38, pg. 1378, 2012)
SO PERSONALITY AND SOCIAL PSYCHOLOGY BULLETIN
LA English
DT Article; Retracted Publication
DE norms; situationist perspective; social influence; priming; environment
ID SOCIAL NORMS; BEHAVIOR
AB Two studies tested the conditions under which an environment (e. g., library, restaurant) raises the relevance of environment-specific social norms (e. g., being quiet, using table manners). As hypothesized, the relevance of such norms is raised when environments are goal relevant ("I am going there later") and when they are humanized with people or the remnants of their presence (e. g., a glass of wine on a table). Two studies show that goal-relevant environments and humanized environments raise the perceived importance of norms (Study 1) and the intention to conform to norms (Study 2). Interestingly, in both studies, these effects reach beyond norms related to the environments used in the studies.
C1 [Joly, Janneke F.; Lindenberg, Siegwart M.] Univ Groningen, Interuniv Ctr Social Sci Theory & Methodol, Dept Social & Behav Sci, NL-9700 AB Groningen, Netherlands.
RP Stapel, DA (reprint author), Tilburg Univ, Tilburg Inst Behav Econ Res, Dept Cognit Social Psychol, POB 90153, NL-5000 LE Tilburg, Netherlands.
EM d.a.stapel@uvt.nl
CR Aarts H, 2003, J PERS SOC PSYCHOL, V84, P18, DOI 10.1037/0022-3514.84.1.18
   AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Ajzen I, 1980, UNDERSTANDING ATTITU
   Brauer M, 2005, J APPL SOC PSYCHOL, V35, P1519, DOI 10.1111/j.1559-1816.2005.tb02182.x
   Cialdini R.B., 1998, HDB SOCIAL PSYCHOL, P151, DOI DOI 10.2307/2654253
   CIALDINI RB, 1990, J PERS SOC PSYCHOL, V58, P1015, DOI 10.1037//0022-3514.58.6.1015
   COLLINS AM, 1975, PSYCHOL REV, V82, P407, DOI 10.1037/0033-295X.82.6.407
   DEUTSCH MORTON, 1955, JOUR ABNORMAL AND SOCIAL PSYCHOL, V51-31, P629, DOI 10.1037/h0046408
   HARVEY MD, 1981, J PERS SOC PSYCHOL, V41, P866, DOI 10.1037/0022-3514.41.5.866
   JOLY JF, 2007, BEING THERE NORMATIV
   Kay AC, 2004, ORGAN BEHAV HUM DEC, V95, P83, DOI 10.1016/j.obhdp.2004.06.003
   LATANE B, 1970, UNRESPONSIVE BYSTAND, P19
   Ludwig TD, 1997, J APPL PSYCHOL, V82, P253, DOI 10.1037/0021-9010.82.2.253
   Marques J. M., 1994, EUROPEAN REV SOCIAL, V5, P37, DOI DOI 10.1080/14792779543000011
   Maxwell S., 1989, DESIGNING EXPT ANAL
   Nisbett R. E., 1991, PERSON SITUATION PER
   PEPITONE A, 1976, J PERS SOC PSYCHOL, V34, P641
   Sherif M., 1965, PSYCHOL SOCIAL NORMS
NR 18
TC 11
Z9 12
U1 2
U2 23
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0146-1672
EI 1552-7433
J9 PERS SOC PSYCHOL B
JI Pers. Soc. Psychol. Bull.
PD AUG
PY 2008
VL 34
IS 8
BP 1047
EP 1056
DI 10.1177/0146167208318401
PG 10
WC Psychology, Social
SC Psychology
GA 327GV
UT WOS:000257718500003
PM 18493030
DA 2018-12-27
ER

PT J
AU He, HB
   Liu, QJ
   Shi, MQ
   Zeng, XW
   Yang, J
   Wu, LM
   Li, LD
AF He, Haibo
   Liu, Qiuju
   Shi, Mengqiong
   Zeng, Xiaowei
   Yang, Jun
   Wu, Limao
   Li, Lianda
TI RETRACTED: Cardioprotective effects of hydroxysafflor yellow A on
   diabetic cardiac insufficiency attributed to up-regulation of the
   expression of intracellular calcium handling proteins of sarcoplasmic
   reticulum in rats (Retracted article. See vol. 23, pg. 746, 2009)
SO PHYTOTHERAPY RESEARCH
LA English
DT Article; Retracted Publication
DE hydroxysafflor yellow A; diabetic cardiomyopathy; calcium handling
   proteins; endothelin system; reactive oxygen species pathway
ID HEART-FAILURE; OXIDATIVE STRESS; NITRIC-OXIDE; CONTRACTILE DYSFUNCTION;
   RYANODINE RECEPTOR; CARDIOMYOPATHY; ENDOTHELIN; RELEASE; PATHWAY;
   OVEREXPRESSION
AB Depressed sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA2a) and Ca2+-release channels (ryanodine receptor RyR2) are involved in diabetic cardiomyopathy, however, the implication of intracellular calcium handling proteins in SR is undefined. It was hypothesized that the down-regulation of the intracellular calcium handling proteins of SR is closely related to an up-regulated endothelin (ET) system. Hydroxysafflor yellow A (HSYA) is expected to ameliorate cardiac insufficiency which is mediated by the depressed intracellular calcium handling system in diabetic rat heart. Diabetes was produced in male rats 8 weeks after an injection of streptozotocin (60 mg/kg i.p.) and HSYA was administered (100 mg/kg) by gavage in the last 4 weeks. Hemodynamic and echo cardiographic changes, cardiac calcium handling proteins, serum biochemistry, ET system and redox were measured. The compromised cardiac function in diabetic rats was accompanied by a significant down-regulation of the expression of RyR2, FKBP12.6 as well as SERCA2a and PLB. These were closely linked with oxidative stress, an increased ET-1 and up-regulation of ECE, PropreET-1 and iNOS mRNA in diabetic cardiomyopathy. After a 4 week treatment with HSYA, all abnormalities were reversed significantly. In conclusion, diabetic cardiomyopathy was correlated with an abnormal expression of calcium handing proteins in SR and an activated ET-ROS (reactive oxygen species) system in the diabetic affected myocardium. HSYA significantly improved the cardiac function and down-regulated the ET system and ROS pathway, resulting in a reversal of the abnormalities of expression of calcium handing proteins and the cardiac performance in diabetic cardiomyopathy. Copyright (C) 2008 John Wiley & Sons, Ltd.
C1 [He, Haibo; Zeng, Xiaowei; Yang, Jun; Wu, Limao] Zhejiang Univ, Coll Pharmaceut Sci, Inst Chinese Herbal Med, Hangzhou 310058, Zhejiang, Peoples R China.
   [Liu, Qiuju] Ezhou Third People Hosp, Ezhou, Hubei, Peoples R China.
   [Shi, Mengqiong] Ctr Med Sci Anal, Hangzhou, Zhejiang, Peoples R China.
RP Wu, LM (reprint author), Zhejiang Univ, Coll Pharmaceut Sci, Inst Chinese Herbal Med, Zijingang Campus, Hangzhou 310058, Zhejiang, Peoples R China.
EM wulimao@zju.edu.cn
FU National Natural Science Foundation of China [30500661]; National
   Important Basic Development Plan of China [2005CB523405]; Key Projects
   of Zhejiang Province [2004C13022]
FX The authors thank Dr Yuling Ma, University of Reading, UK, a visiting
   Professor in our Department, for providing assistance with the
   composition and English styling of the paper.; This project was
   supported by the National Natural Science Foundation of China (No:
   30500661), the National Important Basic Development Plan of China (also
   called 973 project. No: 2005CB523405) and the Technology Foundation for
   Key Projects of Zhejiang Province (No: 2004C13022).
CR AN XO, 1990, TRADIT HERB DRUGS, V21, P188
   Belke DD, 2004, CURR HYPERTENS REP, V6, P424, DOI 10.1007/s11906-004-0035-3
   Cardillo C, 2002, CIRCULATION, V106, P1783, DOI 10.1161/01.CIR.0000032260.01569.64
   Chen YM, 2006, ACTA MECH SOLIDA SIN, V19, P26, DOI 10.1007/s10338-006-0604-x
   Choi KM, 2002, AM J PHYSIOL-HEART C, V283, pH1398, DOI 10.1152/ajpheart.00313.2002
   Dixon LJ, 2005, AM J HYPERTENS, V18, P839, DOI 10.1016/j.amjhyper.2005.01.004
   El-Omar MM, 2003, EUR J HEART FAIL, V5, P229, DOI 10.1016/S1388-9842(03)00010-2
   Farhangkhoee H, 2003, J MOL CELL CARDIOL, V35, P1439, DOI 10.1016/j.yjmcc.2003.09.007
   Ferri C, 1999, CLIN SCI, V96, P261, DOI 10.1042/CS19980190
   He HB, 2007, J PHARM PHARMACOL, V59, P977, DOI 10.1211/jpp.59.7.0010
   He HB, 2006, ACTA PHARMACOL SIN, V27, P1213, DOI 10.1111/j.1745-7254.2006.00373.x
   He HB, 2008, J PHARM PHARMACOL, V60, P115, DOI 10.1211/jpp.60.1.0015
   JIN M, 2006, CHIN TRAD HERBAL DRU, V16, P665
   Jin Ming, 2004, Zhongguo Zhong Yao Za Zhi, V29, P447
   Joffe II, 1999, J AM COLL CARDIOL, V34, P2111, DOI 10.1016/S0735-1097(99)00436-2
   Liu F, 1992, Yao Xue Xue Bao, V27, P785
   Marks AR, 2003, CIRCULATION, V107, P1456, DOI 10.1161/01.CIR.0000059745.95643.83
   Marra G, 2002, DIABETES CARE, V25, P370, DOI 10.2337/diacare.25.2.370
   MESELHY MR, 1993, CHEM PHARM BULL, V41, P1796
   Morgan EE, 2004, AM J PHYSIOL-HEART C, V287, pH2049, DOI 10.1152/ajpheart.00393.2004
   Netticadan T, 2001, DIABETES, V50, P2133, DOI 10.2337/diabetes.50.9.2133
   Penckofer Sue, 2002, J Cardiovasc Nurs, V16, P68
   PU Y, 2005, CHIN HERBAL MED, V35, P374
   SHAN HL, 2004, CHIN J CLIN REHABIL, V25, P243
   Shannon TR, 2003, CIRC RES, V93, P592, DOI 10.1161/01.RES.0000093399.11734.B3
   SONG Y, 2005, J CHIN PHARM SCI, V14, P181
   Suarez J, 2004, AM J PHYSIOL-HEART C, V286, pH68, DOI 10.1152/ajpheart.00245.2003
   [田京伟 Tian Jingwei], 2003, [中草药, Chinese Traditional and Herbal Drugs], V34, P741
   Trost SU, 2002, DIABETES, V51, P1166, DOI 10.2337/diabetes.51.4.1166
   Vasanji Z, 2004, MOL CELL BIOCHEM, V261, P245, DOI 10.1023/B:MCBI.0000028762.97754.26
   Verma S, 2002, J THORAC CARDIOV SUR, V123, P1120, DOI 10.1067/mtc.2002.121973
   Vetter R, 2002, FASEB J, V16, P1657, DOI 10.1096/fj.01-1019fje
   WANG YP, 1995, J THORAC CARDIOVASC, V11, P176
   Wehrens XHT, 2005, ANNU REV PHYSIOL, V67, P69, DOI 10.1146/annurev.physiol.67.040403.114521
   Wehrens XHT, 2005, P NATL ACAD SCI USA, V102, P9607, DOI 10.1073/pnas.0500353102
   Wehrens XHT, 2004, NAT REV DRUG DISCOV, V3, P565, DOI 10.1038/nrd1440
   Wei XB, 2005, NEUROSCI LETT, V386, P58, DOI 10.1016/j.neulet.2005.05.069
   XIAO WY, 2006, P CLIN MED J, V15, P646
   XU CH, 2005, CHIN J CLIN REHABIL, V43, P93
   Xu FP, 2004, CIRCULATION, V110, P1269, DOI 10.1161/01.CIR.0000140766.52771.6D
   Yano M, 2003, CIRCULATION, V107, P477, DOI 10.1161/01.CIR.0000044917.74408.BE
   Yaras N, 2005, DIABETES, V54, P3082, DOI 10.2337/diabetes.54.11.3082
   Zang Bao-xia, 2002, Yaoxue Xuebao, V37, P696
   [郑为超 Zheng Weichao], 2005, [中国药理学通报, Chinese Pharmacological Bulletin], V21, P978
   Zhong Y, 2001, AM J PHYSIOL-HEART C, V281, pH1137
NR 45
TC 9
Z9 14
U1 4
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD AUG
PY 2008
VL 22
IS 8
BP 1107
EP 1114
DI 10.1002/ptr.2468
PG 8
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 345IH
UT WOS:000258989300020
PM 18570267
DA 2018-12-27
ER

EF